

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

PUREWICK CORPORATION,	)	
	)	
Plaintiff/Counterclaim Defendant,	)	
	)	C.A. No. 22-102-MN
v.	)	
	)	<b>REDACTED-PUBLIC VERSION</b>
SAGE PRODUCTS, LLC,	)	<b>(Filed February 23, 2024)</b>
	)	
Defendant/Counterclaim Plaintiff.	)	
	)	

**PROPOSED JOINT FINAL PRETRIAL ORDER**

John W. Shaw (No. 3362)  
Andrew E. Russell (No. 5382)  
SHAW KELLER LLP  
I.M. Pei Building  
1105 North Market Street, 12th Floor  
Wilmington, DE 19801  
(302) 298-0700  
jshaw@shawkeller.com  
arussell@shawkeller.com  
*Attorneys for Plaintiff*

Anne Shea Gaza (No. 4093)  
Samantha G. Wilson (No. 5816)  
YOUNG CONAWAY STARGATT  
& TAYLOR, LLP  
Rodney Square  
1000 North King Street  
Wilmington, DE 19801  
(302) 571-6600  
agaza@ycst.com  
swilson@ycst.com  
*Attorneys for Defendant*

## **TABLE OF CONTENTS**

I.	NATURE OF THE CASE .....	2
II.	FEDERAL JURISDICTION .....	4
III.	UNCONTESTED FACTS .....	4
IV.	ISSUES OF FACT THAT REMAIN TO BE LITIGATED .....	4
V.	ISSUES OF LAW THAT REMAIN TO BE LITIGATED .....	5
VI.	EXHIBITS .....	5
VII.	WITNESSES.....	7
A.	PureWick’s Witness List.....	7
B.	Sage’s Witness List .....	8
VIII.	THE PARTIES’ STATEMENTS OF INTENDED PROOFS.....	8
A.	PureWick’s Statement of Intended Proof.....	8
B.	Sage’s Statement of Intended Proof.....	10
IX.	AMENDMENTS OF THE PLEADINGS .....	15
X.	CERTIFICATION OF GOOD-FAITH SETTLEMENT EFFORTS.....	16
XI.	MOTIONS IN LIMINE .....	16
XII.	OTHER MATTERS.....	16
A.	Sage Proposal for Stay of Proceedings Pending Appeal.....	16
B.	Bench Trial on Sage’s Equitable Defenses .....	17
C.	Trial Time.....	17
D.	Live Witnesses .....	19
E.	Identification of Exhibits and Demonstratives.....	20
F.	Identification of Deposition Testimony and Exhibits.....	21
G.	Objections to Expert Testimony.....	23
H.	Exhibits and Demonstratives for Opening Statements and Closing Statements.....	23
I.	Set-up of Electronic Equipment.....	24
J.	Notice of Intention to Rest.....	24
K.	Sealing Courtroom, Transcripts, and Other Matters .....	24
L.	Jury Notebooks.....	25



1. This Final Pretrial Order contains all of the materials required pursuant to this Court's Standing Order and Local Rule 16.3(c). Where the parties have competing proposals or statements, such language is preceded by bolded text.

## **I. NATURE OF THE CASE**

2. This matter comes before the Court at a final pretrial conference held pursuant to Rule 16 of the Federal Rules of Civil Procedure and Local Rule 16.3(c). The parties are Plaintiff PureWick Corporation ("PureWick" or "Plaintiff") and Defendant Sage Products, LLC ("Sage" or "Defendant").

3. This is an action for patent infringement. PureWick filed suit against Sage on January 26, 2022, accusing Sage of infringing U.S. Patent Nos. 10,226,376 ("the '376 patent) and 10,390,989 ("the '989 patent") (collectively the "Patents-in-Suit"). D.I. 1.

4. The Patents-in-Suit are directed to external urine collection devices. PureWick alleged in its Complaint that Sage infringes the '376 and '989 patents by making, using, offering for sale, selling, and/or importing into the United States the PrimaFit<sup>®</sup> 2.0 product.

5. Sage filed its Answer and Defenses to PureWick's Complaint on May 9, 2022. D.I. 8. Sage's Answer denied infringement and asserts the following affirmative defenses: failure to state a claim; lack of direct, induced, and contributory infringement; lack of willful infringement; invalidity; prosecution history estoppel; principles of equity, including waiver, estoppel, unclean hands, and/or acquiescence; unenforceability based on inequitable conduct; right to seek damages limited or barred by 35 U.S.C. § 287; damages barred by 35 U.S.C. § 288; no injunctive relief; and no damages suffered by PureWick; and Sage entitled to an award of attorneys' fees pursuant to 35 U.S.C. § 285. *Id.* Sage demanded a jury trial.

6. On June 17, 2022, PureWick filed a motion for judgment on the pleadings with respect to Sage's invalidity and unenforceability defenses. D.I. 12, 13.

7. On February 2, 2021, the Court held a claim construction hearing in *PureWick Corp. v. Sage Products, LLC*, C.A. No. 19-1508 (MN) (“PureWick I”). On February 17, 2021, the Court entered a claim construction order in PureWick I, which included limitations of the ‘376 and ‘989 patents. On February 12, 2023, the Court held a claim construction hearing in the present litigation on an additional claim limitation, and on March 30, 2023, the Court issued a claim construction order. D.I. 131. Fact discovery closed March 31, 2023. (*See* 2/22/23 Order granting motion to extend discovery.)

8. On March 30, 2023, the Court granted-in-part and denied-in-part PureWick’s motion for Judgment on the Pleadings. D.I. 134. The Court granted the motion as to Sage’s invalidity defenses based on anticipation and obviousness, and as to Sage’s unenforceability defense based on unclean hands. The Court denied the motion with respect to Sage’s inequitable conduct defense. Sage’s defenses based on waiver, acquiescence, and equitable estoppel were also allowed to proceed.

9. On July 28, 2023, the parties filed Daubert motions, motions to exclude or strike portions of expert reports, and letters requesting leave to file summary judgment motions. The requests for summary judgment include a request by Sage for case-dispositive summary judgment of (a) noninfringement of the ‘376 and ‘989 patents and (b) invalidity of the ‘376 and ‘989 patents for indefiniteness, and a request by PureWick for summary judgment that (a) the PureWick product practices the claims of the ‘376 and ‘989 patents, and (b) that the asserted claims are not invalid for lack of written description or indefiniteness. Those requests are still pending.

10. A pretrial conference is scheduled to be held on February 20, 2024 at 2:00 p.m. The Court ordered a five day jury trial to begin on February 26, 2024 at 9:30 a.m.

## **II. FEDERAL JURISDICTION**

11. This Court has federal-question jurisdiction over this action because it arises under the patent laws of the United States, 35 U.S.C. § 1 et seq.

12. This Court has original jurisdiction over the subject matter of both PureWick's claims and Sage's defenses pursuant to 28 U.S.C. §§ 1331, 1338, and the patent laws of the United States, including 35 U.S.C. § 271 et seq.

13. No party contests personal or subject matter jurisdiction for purposes of this action.

14. No party contests venue for purposes of this action in this District pursuant to 28 U.S.C. §§ 1391 and 1400(b).

## **III. UNCONTESTED FACTS**

15. The parties respectfully submit a Joint Statement of Undisputed Facts as **Schedule A1**. A party, with the consent of the Court, may read any or all of the undisputed facts to the jury.

## **IV. ISSUES OF FACT THAT REMAIN TO BE LITIGATED**

16. PureWick's Statement of Issues of Fact that Remain to be Litigated is attached as **Schedule B1**.

17. Sage's Statement of Issues of Fact that Remain to be Litigated is attached as **Schedule B2**.

18. The parties reserve the right to modify or supplement their statements as needed to fairly reflect the Court's rulings on motions, any other subsequent orders of the Court, or by agreement of the parties. If the Court determines that any issue identified in a party's statement of issues of fact that remain to be litigated is instead more properly considered an issue of law that remains to be litigated, it should be so considered.

**V. ISSUES OF LAW THAT REMAIN TO BE LITIGATED**

19. PureWick's Statement of the Issues of Law that Remain to be Litigated is set forth in **Schedule C1**.

20. Sage's Statement of the Issues of Law that Remain to be Litigated is set forth in **Schedule C2**.

**VI. EXHIBITS**

21. PureWick's list of trial exhibits that it may offer at trial, including Sage's objections, is attached as **Schedule D1**. PureWick's list of discovery responses that it may seek to read into the record at trial, subject to objections, is attached as **Schedule D4**.

22. Sage's list of trial exhibits that it may offer at trial, including PureWick's objections, is attached as **Schedule D2**. Sage's list of discovery responses that it may seek to read into the record at trial, subject to objections, is attached as **Schedule D5**.

23. Joint trial exhibits will be marked with "JTX" numbers. The parties' joint list of trial exhibits they may offer at trial is attached as **Schedule D3**.

24. The parties shall provide a completed AO Form 187 exhibit list to the Court on the first day of trial.

25. Each party reserves the right to offer an exhibit designated by the other party, even if not introduced by the designating party. If the non-designating party offers into evidence an exhibit designated but not introduced by the designating party, the designating party reserves its right to object to the introduction into evidence of that exhibit, depending on the use for which it is being offered. The pretrial order contains the maximum universe of exhibits to be used by any party (other than solely for impeachment). The exhibit lists shall not be supplemented without approval of all parties or leave of the Court, on good cause shown.

26. The parties agree that exhibits to be used solely for impeachment need not be included on the lists of trial exhibits.

27. The listing of a document on a party's exhibit list is not an admission that such document is relevant or admissible when offered by the opposing party. Each party reserves the right to object to the relevance or admissibility of any evidence offered by the other party, at the time such evidence is offered, in view of the specific context in which such evidence is offered. Moreover, the parties have included certain exhibits on their lists that it may seek to introduce in rebuttal to the other parties' claims or defenses (such as infringement, inequitable conduct, etc.) including non-jury defenses. By including a document on its exhibit list, neither party concedes that the exhibit is relevant to the issues that are to be decided including by the jury.

28. Any trial exhibit that was produced in discovery by a party or third party that on its face appears to have been authored by an employee, officer, or agent of the party or third party producing such document, shall be deemed a true and correct copy of a document maintained in that party's files as of the date of the party's document collection under Federal Rule of Evidence 901, subject to the right of the party against whom such a document is offered to adduce evidence to the contrary.

29. The parties acknowledge that certain anticipated trial exhibits may not be feasible to show to a witness and/or to provide the jury in paper form, including, but not limited to, voluminous spreadsheets, videos, and product samples. Such exhibits may be initially presented to a sponsoring witness via a computer display prior to a party seeking their admission and publication to the jury, and such exhibits will be provided to the jury on a laptop or USB drive.

30. With regard to voluminous spreadsheets, to facilitate review of such exhibits by the jury, the parties agree that they may under Federal Rule of Evidence 1006 create a summary of the

portions of such trial exhibits shown to the jury, which shall be given the same trial exhibit number, with the suffix “A”, although the parties must agree in advance to such a summary.

## **VII. WITNESSES**

31. Below is an identification of the witnesses whose testimony each party may present at trial. The inclusion of a witness on this list does not require a party to call that witness to testify, and does not imply or establish that the party has the power to compel the live testimony of that witness or make that witness available to the opposing party. The parties expressly reserve the right to call any witness identified by the other party at any point before or during trial.

32. As discussed below, deposition designations are attached hereto including for witnesses that the other party has not indicated will be live at trial. The parties reserve the right to call any witness for purposes of rebuttal, impeachment, or authentication of a document.

### **A. PureWick’s Witness List**

33. PureWick’s witness list is attached as **Schedule E1**.

34. The deposition testimony that PureWick may offer into evidence is identified in **Schedule E2a**. PureWick further reserves the right to rely on Sage’s designations or to rely on PureWick’s initial designations as counter-designations. Sage’s objections to PureWick’s designations and Sage’s counter-designations are attached as **Schedule E2b**. PureWick’s objections and counter-counter designations to Sage’s counter-designations are attached as **Schedule E2c**. Sage’s objections to PureWick’s counter-counter-designations are attached as **Schedule E2d**.

35. PureWick reserves the right to amend its disclosures and designations of witnesses in view of events at trial or based on circumstances that may evolve prior to the commencement of trial, including, but not limited to, evidentiary rulings or other rulings by the Court.

**B. Sage's Witness List**

36. Sage's witness list is attached as **Schedule E3**.

37. The deposition and trial testimony that Sage may offer into evidence including a list of designations, counter designations, and counter-counter designations as well as objections are identified in **Schedule E4**. Sage designations are attached as **Schedule E4a**. Sage further reserves the right to rely on PureWick's designations and all additional Sage designations reflected in Schedule E2. Sage reserves the right to rely on its initial designations as counter designations. PureWick's objections to Sage's designations and PureWick's counter-designations are attached as **Schedule E4b**. Sage's objections to PureWick's counter-designations are attached as **Schedule E4c**. Sage's counter-counter designations are attached as **Schedule E4d**. PureWick's objections to Sage's counter-counter designations are attached as **Schedule E4e**.

38. Sage reserves the right to amend its disclosures and designations of witnesses in view of events at trial or based on circumstances that may evolve prior to the commencement of trial, including, but not limited to, evidentiary rulings or other rulings by the Court.

**VIII. THE PARTIES' STATEMENTS OF INTENDED PROOFS**

Below are the parties' respective statements of intended proofs provided by each respective party. Each party does not agree with the other party's statements and positions.

**A. PureWick's Statement of Intended Proof**

39. By way of summary, PureWick intends to prove the following at trial. As noted in PureWick's Statement of Issues of Fact that Remain to be Litigated (Schedule B1), PureWick contends that facts and issues that were already decided at the parties' prior trial in *PureWick Corp. v. Sage Products LLC*, C.A. No. 19-1508-MN (D. Del.), are subject to collateral estoppel and should not be relitigated at this trial.

40. PureWick intends to prove that Sage has directly infringed claims 1, 5, 9, and 10 of the '376 patent and claims 1-6 of the '989 patent by making, using, offering for sale, selling, and/or importing the PrimaFit 2.0 product.

41. PureWick intends to prove that Sage has indirectly infringed claims 1, 5, 9, and 10 of the '376 patent and claims 1-6 of the '989 patent by inducing or contributing to the direct infringement by others.

42. PureWick intends to prove that Sage's infringement of the '376 and '989 patents was willful.

43. PureWick intends to prove that damages should be awarded to PureWick due to Sage's infringement of the '376 and '989 patents. In particular, PureWick intends to prove that Sage's infringement of the '376 and '989 patents has caused PureWick to lose sales of PureWick's Female External Catheter (FEC) product and that PureWick is entitled to recover lost profits for a portion of Sage's allegedly infringing sales of the PrimaFit 2.0 product. In addition, PureWick intends to prove that it is entitled to a reasonable royalty for any of Sage's acts of infringement of the '376 and '989 patents for which PureWick is not awarded lost profits.

44. PureWick should be awarded its costs and reasonable attorneys' fees under at least 35 U.S.C. § 285; and PureWick is entitled to permanent injunctive relief enjoining Sage from further infringement of any of the Patents-in-Suit. To the extent that a permanent injunction is not entered, PureWick may alternatively seek an ongoing royalty.

45. PureWick intends to rebut Sage's allegations that the asserted claims of the Patents-in-Suit are invalid for lack of written description or indefiniteness.

46. PureWick intends to rebut Sage's allegations that the Patents-in-Suit are unenforceable based on estoppel, acquiescence, waiver, or unclean hands based on inequitable



conduct.<sup>1</sup> In rebutting Sage’s inequitable conduct defense, PureWick may seek to prove that the patents-in-suit are entitled to an earlier priority date. Sage has contended that because the Court did not instruct the jury concerning the priority date in *PureWick I* that the priority dates for the patents-in-suit were somehow decided in the prior case. As explained in PureWick’s opposition to Sage’s *Daubert* motion (D.I. 177), however, the priority dates were not adjudicated in *PureWick I* because Sage accepted judgment as a matter of law on Sage’s prior use or sale defense. As a result, there was no need for the jury to determine the priority dates as there was no invalidity defense presented to the jury that depended upon the priority dates of the patents.

**B. Sage’s Statement of Intended Proof**

47. By way of summary, Sage intends to prove the following at trial.

1. Noninfringement of The ‘376 and ‘989 Patents

48. Sage intends to prove that PureWick cannot carry its burden of proving that Sage’s PrimaFit 2.0 product infringes Claims 1, 5, 9, and 10 of the ‘376 patent (“the Asserted ‘376 Patent Claims”) and Claims 1-6 of the ‘989 patent (“the Asserted ‘989 Patent Claims”) under the Court’s claim constructions.<sup>2</sup> It is noted that PureWick only asserts literal infringement. PureWick cannot carry its burden of proving that Sage infringes the ‘376 and ‘989 patents by making, using, offering for sale, selling, and/or importing into the United States the PrimaFit® 2.0 product.

49. Sage intends to prove that PureWick has not carried its burden of establishing that Sage indirectly infringes the Asserted ‘376 Patent Claims and Asserted ‘989 Patent Claims. Knowledge of the patent-in-suit and knowledge of infringement is required for indirect

---

<sup>1</sup> As the parties indicate below, these equitable defenses asserted by Sage are to be decided by the Court, not the jury.

<sup>2</sup> For each of the patents-in-suit, Sage preserves its objections to the Court’s Claim Construction.

infringement claims. Sage did not have the requisite specific intent to infringe or knowledge of infringement of the ‘376 or ‘989 patents required for inducement of infringement or contributory infringement. Sage does not offer to sell or sell within the United States or import into the United States any component knowing that it is especially made or especially adapted for use in infringement of the ‘376 or ‘989 patents. No third party directly infringes the ‘376 patent or ‘989 patents via use of a PrimaFit 2.0 product.

2. Invalidity of the ‘376 and ‘989 Patents Under 35 U.S.C. §112 (Written Description and Indefiniteness)

50. Sage intends to prove that the claims of the ‘376 and ‘989 patents are invalid under 35 U.S.C. § 112 for lack of written description relating to the term “fluid reservoir...”.

51. Sage intends to prove that the claims of the ‘376 and ‘989 patents are invalid under 35 U.S.C. § 112 for indefiniteness relating to the term “fluid reservoir...”.

3. Lack of Willfulness of PureWick’s ‘376 and ‘989 Patents

52. Sage intends to prove that PureWick cannot carry its burden of establishing, by a preponderance of the evidence, that any infringement of the Asserted ‘376 and ‘989 Patent Claims by Sage was willful. There is no evidence that Sage has willfully infringed PureWick’s ‘376 and ‘989 patents. Among other things, the PrimaFit 2.0 was independently developed by Sage, is a non-infringing alternative made known to PureWick, and is significantly different than PureWick’s product. Sage has a good faith belief that its activities regarding the PrimaFit 2.0 would not infringe any valid patent rights under the ‘376 and ‘989 patents and none of the evidence identified by PureWick constitutes willful infringement as a matter of law.

4. Unenforceability of The ‘376 and ‘989 Patents Due To Waiver, Equitable Estoppel, and Acquiescence Relating to PrimaFit 2.0 (To Be Decided By The Court)

53. Sage asserts an affirmative defense of unenforceability of the ‘376 and ‘989 patents due to waiver, equitable estoppel, and acquiescence.<sup>3</sup> Sage intends to prove that although PureWick knew of the PrimaFit 2.0, and PureWick led Sage through its acts and inactions to believe that PureWick did not believe that the PrimaFit 2.0 infringed any PureWick patents. Sage intends to prove, by a preponderance of the evidence, that the ‘376 and ‘989 patents are unenforceable under principles of equity including equitable estoppel as a result of the misleading conduct of PureWick relating to the PrimaFit 2.0 product. Sage intends to prove, by clear and convincing evidence, that the ‘376 and ‘989 patents are unenforceable under principles of equity including waiver due to the conduct of PureWick relating to the PrimaFit 2.0 product. Sage intends to prove, by a preponderance of the evidence, that the ‘376 and ‘989 patents are unenforceable due to principles of equity including acquiescence as a result of the misleading conduct of PureWick relating to the PrimaFit 2.0 product. Additionally, there was spoliation of evidence and PureWick failed to preserve what PureWick described as a legacy PureWick server which contained critical information relating to Sage’s defenses, including its prior art defense relating to the on-sale bar and information relating to the valuation of the patents.

5. Unenforceability of The ‘376 and ‘989 Patents Due To Inequitable Conduct (To Be Decided By The Court)

54. Sage intends to prove, by a preponderance of the evidence, that the ‘376 and ‘989 patents are unenforceable due to inequitable conduct in the procurement of the patents. At least one of the individuals who owed a duty of candor and good faith to the Patent Office relating to the prosecution of the ‘376 and ‘989 patents, including attorneys who prosecuted the ‘376 and ‘989 patents and Camille and Ray Newton, named inventors of the ‘376 and ‘989 patents, intentionally

---

<sup>3</sup> Sage reserves its rights as to the Court’s ruling on unclean hands.

withheld material prior art from the Patent Office and made misleading and/or false statements to the Patent Office during prosecution of the patents with an intent to deceive the Patent Office. This withheld material prior art related to PureWick products publicly used, publicly disclosed, and/or on-sale during the period between 2013 and 2016 including certain of the PureWick products (e.g., curved, tapered, and spun plastic products disclosed, used, sold, and/or offered for sale, including sales and offers to sale to Kate Pawlik and others). Moreover, the Newtons were also aware of public use of their products as well as marketing efforts and public disclosures to the Connect Foundation.

55. Additionally, PureWick represented to the Patent Office during prosecution of the ‘989 patent that there were no relevant references or public disclosures during the intervening period between the ‘989 application filing date and the asserted priority date even though numerous individuals were aware of relevant and highly material information. These statements were false and misleading and material to patentability, and the most reasonable inference is that they were made with an intent to deceive the Patent Office.

56. Moreover, this inequitable conduct during the prosecution of the ‘989 patent also renders the ‘376 patent, which claims priority to the ‘989 patent, unenforceable including under the doctrine of infectious unenforceability. In addition, no individual involved in the prosecution of the ‘376 patent advised the Patent Office of the false and misleading statements during the prosecution of the ‘989 patent.

57. Additionally, as discussed, there was spoliation of evidence and PureWick failed to preserve what PureWick described as a legacy PureWick server which contained critical information relating to Sage’s defenses, including its inequitable conduct defense.

58. PureWick asserts above that it “may seek to prove” an earlier priority date. However, contrary to PureWick’s claim, the priority date was in fact already determined in *PureWick I* and, of course, was not relevant only to the issue of “prior use or sale” invalidity. Importantly, as explained elsewhere (D.I. 157), in *PureWick I*, the parties hotly contested the patents’ effective filing dates throughout the lawsuit including in expert reports, summary judgment, the pretrial order, and trial. (See PW1, D.I. 204 at 17-21; PW1, D.I. 286 at pp. 14; PW1, D.I. 282, Sch. B, p. 3.) Because the issue was not resolved on summary judgment, Sage presented jury instructions with varying priority dates for the jury to determine and questioned the inventors on the priority date. (PW1, D.I. 285 at 45-47.) Ultimately, PureWick did not establish an earlier priority date at trial, and the effective filing dates of the patents was determined to be their respective filing dates including for instructions on invalidity. (See, e.g., PW1, D.I. 314, p. 26; PW1, D.I. 330, Trial Tr. at 1086-1087, 1081 (Court: “[W]e took out the effective filing date instruction and...anywhere it [the jury instructions] said effective filing date and changed that to filing date.”).) Sage has filed a motion to exclude PureWick’s experts from asserting an earlier priority date. (See D.I. 157 at 18-19.)

#### 6. Remedies

59. Sage intends to prove that PureWick cannot carry its burden of proving that it is entitled to damages or remedies, as Sage does not infringe any valid claim of the ‘376 and ‘989 patents. Notwithstanding the foregoing, Sage intends to prove that PureWick is not entitled to more than a reasonable royalty, as adduced by the evidence of record, based upon sales of the PrimaFit 2.0 product.

60. Sage intends to prove that PureWick has not carried its burden of establishing, by a preponderance of the evidence, that PureWick is entitled to lost profits for any infringement of the ‘376 and ‘989 patents by the Sage PrimaFit 2.0. PureWick is not entitled to lost profits due to

its failure to prove the absence of noninfringing alternatives. Sage has identified numerous noninfringing alternatives including numerous products on the market as well as design option changes to the PrimaFit 2.0 product. Moreover, PureWick failed to appropriately apportion lost profit damages and reasonable royalty damages to account for the alleged value of the patented invention.

61. Even if PureWick were entitled to damages, PureWick failed to provide notice under 35 U.S.C. §287 and otherwise failed to establish marking of patented products, and PureWick is only entitled to damages after the date PureWick filed its complaint, if at all.

62. Sage intends to prove that PureWick cannot carry its burden of establishing that PureWick is entitled to a permanent injunction or that this is an exceptional case.

63. Sage intends to prove that PureWick's egregious conduct, including its maintenance of legally meritless infringement allegations against Sage, justifies a finding of exceptional case pursuant to 35 U.S.C. § 285, entitling Sage to recover its attorney fees, expenses and costs. These issues are not appropriate for determination until final judgment is entered.

7. Response to PureWick Statement About Collateral Estoppel

64. As noted in Sage's Statement of Issues of Fact that Remain to be Litigated (Schedule B2) as well as Paragraph 8 above, the scope of collateral estoppel requested by PureWick has already been ruled on by the Court. (D.I. 134.) Sage disagrees with PureWick's characterizations of decided issues subject to collateral estoppel and Sage does not believe this pretrial order is an appropriate time or location to seek reconsideration or new argument on the issue.

**IX. AMENDMENTS OF THE PLEADINGS**

65. Neither party intends to request an amendment to its pleadings at the present time.

## **X. CERTIFICATION OF GOOD-FAITH SETTLEMENT EFFORTS**

66. The parties hereby certify that they have engaged in a good-faith effort to explore resolution of the controversy by settlement.

## **XI. MOTIONS IN LIMINE**

PureWick's contested motions *in limine*, Sage's oppositions, and PureWick's replies are attached as **Schedules F1 to F3**.

67. Sage's contested motions *in limine*, PureWick's oppositions, and Sage's replies are attached as **Schedules F4 to F6**.

## **XII. OTHER MATTERS**

### **A. Sage Proposal for Stay of Proceedings Pending Appeal**

68. [Sage's Position: As set forth in its January 17, 2024 letter to the Court and other submissions (D.I. 201 and D.I. 19), Sage believes a stay of these proceedings pending appeal in *PureWick I* is warranted. In the *PureWick I* matter, the Court entered Final Judgment on October 27, 2023, and Sage filed a Notice of Appeal to the Federal Circuit on November 20, 2023. Sage's opening brief is presently due on March 22, 2024. The case would be simplified if further proceedings in this matter were stayed pending the appeal. The Court and parties would have the benefit of the Federal Circuit's guidance on matters including claim construction and avoid potentially litigating or re-litigating a host of issues, including ones that could be rendered moot. A ruling on that appeal is likely to narrow the issues for trial in this present lawsuit. Further, Sage

has ceased manufacture of the accused PrimaFit 2.0 device (D.I. 190), and PureWick would not be prejudiced by a stay.<sup>4,5]</sup>

69. **[PureWick's Position:** For the reasons set forth in PureWick's January 18, 2024 letter (D.I. 202), Sage's untimely request for reconsideration of the Court's prior order denying Sage's motion to stay this case should be denied. PureWick also objects to Sage's suggestion that some unidentified aspects of this case, apart from Sage's equitable defenses, should be bifurcated.]

#### **B. Bench Trial on Sage's Equitable Defenses**

70. Sage's equitable defenses, including its defenses of equitable estoppel, waiver, acquiescence, and unclean hands based on inequitable conduct should be tried separately to the Court **[PureWick Proposal:** and not be presented, or alluded to, in front of the jury.] **[Sage Proposal:** There are facts that relate to both equitable defenses as well as, e.g., infringement, lack of willfulness, and damages, and will be presented to the jury.]

71. **[PureWick Proposal:** PureWick proposes that any live testimony relating to these defenses be presented to the Court after the jury has been sent home for the day.] **[Sage Proposal:** Sage proposes that Sage's equitable defenses be tried separately to the Court in a separate two-day bench trial following the completion of the jury trial (if still needed).]

#### **C. Trial Time**

72. The Court has scheduled a five day jury trial. (11/8/23 Order.) For the jury trial, both parties propose one (1) hour for closing arguments.

---

<sup>4</sup> Given the potential for simplification and the timing of the submission of the pretrial order, Sage contacted the Court on January 17, 2024 to request guidance on the issue of a potential stay. This would also potentially avoid unnecessary pre-trial activity as well.

<sup>5</sup> Even if this case were to proceed, Sage has sought exclusion of certain evidence relating to the first case and other issues. *See, e.g.*, D.I. 155, 157; pending motions in limine. Depending on the Court's rulings on various motions, it may become appropriate to bifurcate aspects of the trial.



73. **[PureWick's Proposal:** PureWick proposes that each side be allotted nine (9) hours for opening, presenting its case, and dealing with evidentiary issues, and one additional hour for closing arguments, for a total of ten (10) hours. The parties were given 12 hours per side (including closings) in the prior trial, which involved three asserted patents, two accused products and a defense of invalidity based on prior art. This case involves only two asserted patents, one accused product, and no defense of invalidity based on prior art. Accordingly, PureWick believes the case can be tried in less time. And PureWick's time proposal will provide more time to address Sage's equitable defenses during the same week after the jury has been sent home for the day.]

74. **[Sage's Proposal:** For the jury trial, Sage believes based on PureWick's current allegations, Sage needs 20 hours to fairly defend the issues in the case. The timing will depend on the Court's rulings on Sage's *Daubert* and other motions. Thus, for the jury trial, Sage proposes it be allotted twenty (20) hours for opening, presenting its case, and dealing with evidentiary issues, and one additional hour for closing arguments, for a total of twenty-one (21) hours. More specifically, this time is needed given that PureWick has indicated that it intends to retry the prior case, designating significant portions of the prior trial transcript for inclusion and more than 13 hours of deposition transcripts from the prior case relating solely to the prior accused product. Additionally, PureWick is asserting almost 50% more patent claims in this case compared to *PureWick I*. (See *PureWick I*, D.I. 286 at ¶¶43-44.)

75. As discussed in Section B above, Sage proposes a two day bench trial for its equitable defenses, if needed, at some time following the jury trial. For the bench trial, Sage proposes each side being allotted seven (7) hours for opening, presenting its case, and dealing with evidentiary issues, and an additional 45 minutes for each side's closing arguments.]

**D. Live Witnesses**

76. The parties shall discuss the schedule of live witnesses to be called and a proposed schedule for witnesses at 3:00 pm three days in advance of trial.

77. A party shall provide reasonable notice if for any reason it does not intend to call a witness that it had previously indicated would appear live. In that event, the other party may designate and offer deposition testimony from such witness (subject to the Federal Rules of Evidence). Counter-designations and objections may also be provided. In the event that such designations cannot be completed by the times agreed to below, the parties shall work in good faith to set deadlines for the disclosure of such designations, counter-designations, counter-counter-designations, and objections.

78. Each party will identify the final live trial witnesses in the order that the party expects to call them by 7:00 pm two (2) calendar days before the witnesses are to be called.

79. Before they testify, fact witnesses shall be barred from hearing the testimony of other witnesses. Expert witnesses are not excluded from the courtroom for either fact or expert testimony.

80. An offering party may discuss with a witness his or her testimony while on direct examination, including during adjournments in the trial, breaks during the trial day and overnight. An offering party may not discuss with a witness his or her testimony while the witness is tendered for cross-examination, including during adjournments in the trial, breaks during the trial day and overnight. Once cross-examination of a witness is concluded and the witness is passed for re-direct examination, the offering party may discuss with the witness his or her testimony on re-direct examination.

**E. Identification of Exhibits and Demonstratives**

81. The parties agree that the offering party shall provide the other side with a list of any exhibits that will be used with a given witness and copies of any demonstratives to be used with a given witness by 7:00 p.m. two (2) calendar days before the witness is to be called. The other party shall identify any objections to such exhibits or demonstratives by 7:00 p.m. the following day. The parties shall then meet and confer regarding all objections by 8:00 p.m. the day objections are provided. To the extent the objections are not resolved by the meet and confer, the party calling the witness will e-mail the Court's judicial administrator by 7:00 a.m. on the day the witness is to testify, the exhibit is to be offered, or the demonstrative will be used, and inform the Court whether the exhibit or demonstrative is expected to be used before lunch or after lunch so that the Court can determine whether and when to hear the objection.

82. When exchanging trial demonstratives, the party seeking to use a demonstrative exhibit will provide a color representation of the demonstrative exhibit to the other side in PDF format. However, for demonstrative exhibits that cannot be placed in PDF form such as video or animations, the party seeking to use the demonstrative exhibit will provide it to the other side in its native form via a downloadable link and provide it in a form such that the other side may view it.

83. PureWick's demonstrative exhibits will be identified by numbers prefixed with "PDX." Sage's demonstratives will be identified by numbers prefixed with "SDX."

84. Demonstratives are to be used for illustrative purposes only and generally will not be entered into evidence. Following the conclusion of trial, demonstratives shown to the jury may be lodged with the Court. The parties do not waive any objection to the admissibility of evidence cited or referenced in any demonstrative exhibit.

85. The parties agree that any changes to the demonstratives made after being provided to the opposing party will only be to style/formatting, not the substance of the demonstrative, unless made in response to an objection in order to resolve that objection. If a party's demonstrative otherwise changes after being provided to the opposing party, the party intending to use the demonstrative exhibit must promptly and in good faith inform the opposing party of that change.

86. The provisions regarding the exchange of demonstrative exhibits does not apply to demonstratives created during testimony, demonstratives to be used for cross examination, or to the enlargement, highlighting, ballooning, excerpting, etc. of trial exhibits or testimony, none of which need to be provided to the opposing party in advance of their use.

87. Legible photocopies of documents may be offered and received in evidence in lieu of originals thereof, subject to all foundational requirements and other objections that might be made to the admissibility of originals.

88. Any exhibit, once admitted, may be used by any party. No party shall comment or argue to the jury that the other side had a document on its exhibit list but did not introduce it into evidence. The parties stipulate to the authenticity of patents, patent applications, and their respective certified file histories.

89. The parties agree that any description of a document listed on an exhibit list is provided for convenience only and shall not be used as an admission or otherwise as evidence regarding the document or its contents.

**F. Identification of Deposition Testimony and Exhibits**

90. For any witness whose testimony the parties intend to present at trial by deposition, the party offering a witness will identify those portions of the transcript to be played or read to the jury by 7:00 p.m. [**PureWick's Proposal:** four (4); **Sage's Proposal:** three (3)] calendar days before the designations are to be played or read to the jury. By [**PureWick's Proposal:** 5:00 pm;

**Sage's Proposal:** 8:00 p.m.] three days before the witness is put to the stand by deposition, the responsive party will identify any objections and counter-designations that will be presented to the jury and identify any objections to the testimony. By 9:00 pm three days before the witness is put to the stand by deposition, the party offering the witness will identify any counter-counter designations and objections to the counter designations. The parties shall meet-and-confer by 10:00 p.m. three (3) calendar days before the designations are to be played or read to the jury to narrow their disputes and identify any remaining objections to be presented to the Court. If there are objections that remain to be resolved, the party calling the witness by deposition shall, no later than 48 hours before the deposition designations are to be played or read, submit, on behalf of all parties a cover letter and a copy of the entire deposition testimony of the witness at issue, clearly highlighting the designations, counter-designations, and pending objections. If there is a particular witness where a party, after hearing testimony, wishes to add additional deposition testimony, the parties shall confer over the addition of such testimony and separately identify it in the letter to the Court.

91. By 9:00 pm the night before the witness is put on the stand by deposition, the party offering the witness will provide a copy of the video or transcript containing both parties' designations. All irrelevant and redundant material, including colloquy between counsel and objections, will be eliminated when the deposition is read or viewed at trial.

92. A designation and any corresponding counter-designations will be read or played by video in chronological order at the same time.

93. Any party may use testimony that is designated by another party to the same effect as if it had initially designated the testimony as its own, subject to all objections.

94. The parties may offer some or all of the deposition testimony set forth herein at trial. No party shall comment or argue to the jury that the other side designated deposition testimony in the pre-trial order but did not introduce it into evidence.

95. Any deposition testimony may be used at trial for the purpose of impeachment and cross examination, subject to objections, regardless of whether a party identified that testimony on its list of deposition designations if the testimony is otherwise competent for such purpose.

96. For those witnesses whose depositions or prior trial testimony will be played or read, the parties shall be permitted to make brief transition statements to introduce the witnesses by name, position or title, and/or the company to which he or she is associated, the time for which shall be charged to the party offering the witness's testimony, unless otherwise agreed to by the parties. However, counsel shall not be permitted to argue or comment on the evidence during transition statements.

**G. Objections to Expert Testimony**

97. Any objections to expert testimony as outside the scope of prior expert disclosures shall be taken up at trial when such testimony is sought to be introduced.

**H. Exhibits and Demonstratives for Opening Statements and Closing Statements**

98. The parties shall identify any exhibits and demonstrative exhibits expected to be used during their opening statement by 5:00 p.m. on the day before the first day of trial. The other party shall identify any objections to demonstrative exhibits and any objections to the admissibility of the exhibits sought to be used during opening statements by 7:00 p.m. that evening. The parties shall then meet and confer by 9:00 p.m. that evening regarding all objections and, to the extent the objections are not resolved by the meet and confer, they will e-mail the Court's judicial administrator by 7:00 a.m. on the day opening statements are to be made so that the Court can determine whether and when to hear the objection.

99. The parties agree that demonstrative exhibits to be used for closing arguments will be exchanged on the day of closing arguments prior to the reading of jury instructions. Any objections to demonstratives to be used for closing arguments will be provided to the Court after the reading of jury instructions and prior to the closing arguments. The notice provisions in this section do not apply to demonstrative exhibits created in the courtroom, or to the enlargement, highlighting, ballooning, excerpting, etc. of trial exhibits or testimony.

**I. Set-up of Electronic Equipment**

100. The parties request that the Court grant them access to the Courtroom on Friday, February 23, 2024, the business day before trial begins, to allow them to set up electronic and computer devices to be used during the trial.

**J. Notice of Intention to Rest**

101. By 7:00 p.m. the night before a party intends to rest its case, the resting party shall give the other party notice of its intention to rest.

**K. Sealing Courtroom, Transcripts, and Other Matters**

102. The parties request that the trial be open to the public and not sealed unless a party requests that a particularly sensitive portion be sealed and not open. If a party makes such a request, subject to the Court's approval, and for good cause shown, the courtroom will be cleared of those individuals not qualified under the Protective Order entered in this case, except that each party may include three corporate representatives, who are not fact witnesses, who may remain in the courtroom throughout the entirety of the trial.

103. Transcripts of any sealed testimony, and exhibits entered while the courtroom is sealed, shall remain under seal until thirty (30) calendar days after the conclusion of the trial. The parties may designate, by page and line designations, the portions of the transcript they seek to remain under seal and the exhibits they seek to remain under seal, subject to Court approval.

104. [Sage's Proposal: Counsel table shall only include attorneys of record and an employee representative of a party and shall not include third parties.]<sup>6,7</sup>

**L. Jury Notebooks**

105. Subject to the Court's permission, the parties shall be allowed to provide a joint jury notebook to each of the jurors, which shall contain only the patents-in-suit and blank notebook paper. The jury will be permitted to bring these notebooks and handwritten notes into the deliberation room.

/s/ Andrew E. Russell

John W. Shaw (No. 3362)  
 Andrew E. Russell (No. 5382)  
 SHAW KELLER LLP  
 I.M. Pei Building  
 1105 North Market Street, 12th Floor  
 Wilmington, DE 19801  
 (302) 298-0700  
 jshaw@shawkeller.com  
 arussell@shawkeller.com  
*Attorneys for Plaintiff*

/s/ Anne Shea Gaza

Anne Shea Gaza (No. 4093)  
 Samantha G. Wilson (No. 5816)  
 YOUNG CONAWAY STARGATT  
 & TAYLOR, LLP  
 Rodney Square  
 1000 North King Street  
 Wilmington, DE 19801  
 (302) 571-6600  
 agaza@ycst.com  
 swilson@ycst.com  
*Attorneys for Defendant*

Dated: February 13, 2024

---

<sup>6</sup> **PureWick's Position:** Sage's new proposal, which was not in the Joint Pre-Trial Order from *PureWick I*, appears designed to prevent Camille Newton, the founder of PureWick who is no longer an employee, from sitting at counsel table. Dr. Newton was permitted to sit at counsel table during the *PureWick I* trial after she finished her testimony and there is no reason Dr. Newton should be precluded from sitting at counsel table at this trial.

<sup>7</sup> **Sage's Position:** Dr. Newton is neither a party nor an attorney representing a party. Importantly, PureWick has treated her as a third party and non-party throughout this case, requiring Sage to subpoena her under Rule 45 and resisting subpoenas for her documents. Magistrate Judge Hall ultimately required PureWick to produce her documents and make her available. (D.I. 67; 1/6/23 Hearing Tr. at 24-26.) PureWick cites no authority to support why it should be allowed to treat Dr. Newton as a non-party this entire proceeding except for trial or why a non-party should be seated at trial counsel's table as if *she* were the aggrieved party. Doing so serves no purpose other than to elicit inappropriate sympathy and/or to give the prejudicial misimpression to the jury that the parties are a large corporation (Sage) versus an individual (Dr. Newton). Courts in this district regularly reject similar transparent attempts at invoking irrelevant sympathy. (*See* Schedule F6 at 1-2, citing authority.)



IT IS HEREBY ORDERED, this day of \_\_\_\_\_, 2024, that this Final Pretrial Order shall control the subsequent course of the action, unless modified by the Court to prevent manifest injustice.

---

Honorable Maryellen Noreika  
U.S. District Court Judge

**CERTIFICATE OF SERVICE**

I hereby certify that on February 13, 2024, this document was served on the persons listed below in the manner indicated:

**BY EMAIL**

Anne Shea Gaza  
Samantha G. Wilson  
YOUNG CONAWAY STARGATT  
& TAYLOR, LLP  
Rodney Square  
1000 North King Street  
Wilmington, DE 19801  
(302) 571-6727  
agaza@ycst.com  
swilson@ycst.com

Robert A. Surrette  
Sandra A. Frantzen  
Deborah A. Loughton  
Christopher M. Scharff  
Ryan J. Pianetto  
Gene Volchenko  
Robert A. Surrette  
Madeline P. Paradkar  
Sarine R. Hagopian  
Michael J. Weil  
MCANDREWS, HELD & MALLOY, LTD  
500 West Madison Street  
Chicago, IL 60661  
(312) 775-8000  
bsurrette@mcandrews-ip.com  
sfrantzen@mcandrews-ip.com  
dlaughton@mcandrews-ip.com  
cscharff@mcandrews-ip.com  
rpianetto@mcandrews-ip.com  
gvolchenko@mcandrews-ip.com  
bsurrette@mcandrews-ip.com  
mparadkar@mcandrews-ip.com  
shagopian@mcandrews-ip.com  
mweil@mcandrews-ip.com

/s/ Andrew E. Russell

John W. Shaw (No. 3362)  
Andrew E. Russell (No. 5382)  
SHAW KELLER LLP  
I.M. Pei Building  
1105 North Market Street, 12th Floor  
Wilmington, DE 19801  
(302) 298-0700  
jshaw@shawkeller.com  
arussell@shawkeller.com  
*Attorneys for Plaintiff*

**SCHEDULE A1: JOINT STATEMENT OF UNDISPUTED FACTS**

The parties respectfully submit this Joint Statement of Undisputed Facts. By agreeing to this Joint Statement, neither party admits that any stated fact is relevant to any material issue of dispute.

1. PureWick is a corporation organized under the laws of the State of Delaware.
2. Sage is a corporation organized under the laws of the State of Delaware.
3. U.S. Patent No. 10,390,989 (“the 989 patent”) is entitled “Apparatus And Methods For Receiving Discharged Urine.” The 989 patent was issued by the United States Patent and Trademark Office on August 27, 2019, from U.S. Application No. 15/260,103. The 989 patent was filed on September 8, 2016. Joint Trial Exhibit JTX-2 is a true and correct copy of the 989 patent. Defendant’s Trial Exhibit DTX-24 is a true and correct copy of the file history of the 989 patent.
4. Robert A. Sanchez, Camille R. Newton, Joseph M. Forehand, and Raymond J. Newton are named inventors on the face of the 989 patent.
5. Defendant’s Trial Exhibit DTX-38 is a true and correct copy of a September 26, 2018, Office Action from the U.S. Patent Office in U.S. Application No. 15/260,103, the application from which the 989 patent issued. Claims 9 through 14 of that application correspond to issued Claims 1 through 6 of the 989 Patent.
6. Defendant’s Trial Exhibit DTX-40 is a true and correct copy of a December 20, 2018, Amendment and Response submitted by PureWick in U.S. Application No. 15/260,103, the application from which the 989 patent issued.
7. Defendant’s Trial Exhibit DTX-43 is a true and correct copy of a February 14, 2019, Office Action from the U.S. Patent Office in U.S. Application No. 15/260,103, the application from which the 989 patent issued.

8. Defendant's Trial Exhibit DTX-44 is a true and correct copy of a May 13, 2019, Office Action Response and Amendment B from U.S. Application No. 15/260,103, the application from which the 989 patent issued.

9. U.S. Patent No. 10,226,376 ("the 376 patent") is entitled "Apparatus And Methods For Receiving Discharged Urine." The 376 patent was issued by the United States Patent and Trademark Office on March 12, 2019, from U.S. Application No. 15/611,587, filed June 1, 2017. Joint Trial Exhibit JTX-1 is a true and correct copy of the 376 patent. Defendant's Trial Exhibit DTX-26 is a true and correct copy of the file history of the 376 patent.

10. Robert A. Sanchez, Camille R. Newton, Joseph M. Forehand, and Raymond J. Newton are named inventors on the face of the 376 patent

11. Defendant's Trial Exhibit DTX-641, which bears bates number SAGE00029359-91, is a true and correct copy of a Sage financial document including spreadsheets and is an authentic business record of Sage Products within the meaning of Federal Rule of Evidence 803(6).

12. Defendant's Trial Exhibit DTX-737, which bears bates number SAGE00040648, is a true and correct copy of a Sage document and is an authentic business record of Sage Products within the meaning of Federal Rule of Evidence 803(6).

13. Defendant's Trial Exhibit DTX-60, which bears bates number PureWick\_0064463, is a true and correct copy of a PureWick financial spreadsheet and is an authentic business record of PureWick Corporation within the meaning of Federal Rule of Evidence 803(6).

14. Defendant's Trial Exhibit DTX-1011, which bears bates number BDPureWick\_00002070, is a true and correct copy of a PureWick document and is an authentic business record of PureWick Corporation within the meaning of Federal Rule of Evidence 803(6).

15. Defendant's Trial Exhibit DTX-1057, which bears bates number BDPureWick\_00002936, is a true and correct copy of a PureWick financial spreadsheet and is an authentic business record of PureWick Corporation within the meaning of Federal Rule of Evidence 803(6).

16. Defendant's Trial Exhibit DTX-2568, which bears bates number STRSAGE00025468, is a true and correct copy of a Sage financial spreadsheet and is an authentic business record of Sage Products within the meaning of Federal Rule of Evidence 803(6).

17. Defendant's Trial Exhibit DTX-2569, which bears bates number STRSAGE00025469, is a true and correct copy of a Sage financial spreadsheet and is an authentic business record of Sage Products within the meaning of Federal Rule of Evidence 803(6).

18. PureWick Trial Exhibit PTX-586, which bears bates number BDPureWick\_00002198, is a true and correct copy of a PureWick financial spreadsheet and is an authentic business record of PureWick Corporation within the meaning of Federal Rule of Evidence 803(6).

19. PureWick Trial Exhibit PTX-587, which bears bates number BDPureWick\_00002201, is a true and correct copy of a PureWick financial document and is an authentic business record of PureWick Corporation within the meaning of Federal Rule of Evidence 803(6).

20. Defendant's Trial Exhibit DTX-758, which bears bates number PureWick\_0030253, is a true and correct copy of a PureWick financial document and is an authentic business record of PureWick Corporation within the meaning of Federal Rule of Evidence 803(6).

21. PureWick Trial Exhibit PTX-547, which bears bates number STRSAGE00023084, is a true and correct copy of a Sage financial spreadsheet and is an authentic business record of Sage Products LLC within the meaning of Federal Rule of Evidence 803(6).

22. PureWick Trial Exhibit PTX-544, which bears bates number STRSAGE00000141, is a true and correct copy of a Sage financial spreadsheet and is an authentic business record of Sage Products LLC within the meaning of Federal Rule of Evidence 803(6).

23. PureWick Trial Exhibit PTX-547, which bears bates number STRSAGE00023164, is a true and correct copy of a Sage financial spreadsheet and is an authentic business record of Sage Products LLC within the meaning of Federal Rule of Evidence 803(6).

24. PureWick Trial Exhibit PTX-757, which bears bates number STRSAGE\_EXP\_000006, is a true and correct copy of a Sage financial spreadsheet and is an authentic business record of Sage Products LLC within the meaning of Federal Rule of Evidence 803(6).

25. Sage's Trial Exhibit DTX-1057, which bears bates number BDPureWick\_00002936, is a true and correct copy of a PureWick financial spreadsheet and is an authentic business record of PureWick Corporation within the meaning of Federal Rule of Evidence 803(6).

26. Documents produced to a party to this action by another party or a third party in response to compulsory process (e.g., subpoena) shall be deemed authentic for the purposes of this lawsuit only, absent good cause.

27. Sage's Trial Exhibit DTX-61 is a true and correct copy of a PureWick financial spreadsheet and is an authentic business record of PureWick Corp. within the meaning of Federal Rule of Evidence 803(6).

28. Sage's Trial Exhibit DTX-62 is a true and correct copy of a PureWick financial spreadsheet and is an authentic business record of PureWick Corp. within the meaning of Federal Rule of Evidence 803(6).

29. Sage's Trial Exhibit DTX-1411 is a true and correct copy of a PureWick financial spreadsheet and is an authentic business record of PureWick Corp. within the meaning of Federal Rule of Evidence 803(6).

30. Sage's Trial Exhibit DTX-1412 is a true and correct copy of a PureWick financial spreadsheet and is an authentic business record of PureWick Corp. within the meaning of Federal Rule of Evidence 803(6).

31. Sage's Trial Exhibit DTX-298 is a true and correct copy of the Agreement and Plan of Merger by and among C.R. Bard, Inc., Candle Acquisition Corp., PureWick Corporation and The Securityholder Representative, dated June 16, 2017.

32. Sage's Trial Exhibit DTX-496 is a true and correct copy of a PureWick sales spreadsheet and is an authentic business record of PureWick Corp. within the meaning of Federal Rule of Evidence 803(6).

33. Sage's Trial Exhibit DTX-758 is a true and correct copy of a PureWick financial spreadsheet and is an authentic business record of PureWick Corp. within the meaning of Federal Rule of Evidence 803(6).

34. Documents produced by Connect Foundation bearing "CF" Bates Labels are authentic business records of Connect Foundation within the meaning of Federal Rule of Evidence 803(6). Each of Defendant Trial Exhibits 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, and 520 are a business record of Connect Foundation.

35. Documents produced by Omni Medical Systems, Inc. bearing “OMNI” Bates Labels are authentic business records of Omni Medical Systems, Inc. within the meaning of Federal Rule of Evidence 803(6). Each of Defendant Trial Exhibits 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, and 438 are a business record of Omni Medical Systems.

36. Documents produced by Medline Industries bearing “MEDLINE” Bates Labels are authentic business records of Medline Industries within the meaning of Federal Rule of Evidence 803(6). DTX-3003 is the Declaration of Jason Jost which describes Medline Industries’ business records. Each of Defendant Trial Exhibits DTX-1260 and DTX-2941 through DTX-2950 are a business record of Medline Industries.

37. Documents produced by Deloitte Corporate Finance bearing “DCF” Bates Labels are authentic business records of Deloitte Corporate Finance within the meaning of Federal Rule of Evidence 803(6). DTX-3004 is the Declaration of Emily Schmidt which describes Deloitte Corporate Finance business records. Each of Defendant Trial Exhibits DTX-2579 through DTX-2607 are a business record of Deloitte Corporate Finance.

38. Documents produced by First Quality Enterprises, Inc. bearing “FQE” Bates Labels are authentic business records of First Quality Enterprises, Inc. within the meaning of Federal Rule of Evidence 803(6). DTX-3002 is the Declaration of Dominick Glenn Vicari which describes First Quality Enterprises, Inc.’s business records. Each of Defendant Trial Exhibits DTX-2610 through DTX-2935, are a business record of First Quality Enterprises.

39. Documents produced by Molnlycke Health Care US, LLC bearing “MOLN” Bates Labels are authentic business records of Molnlycke Health Care US, LLC within the meaning of Federal Rule of Evidence 803(6). DTX-3001 is the Declaration of Anders Hestner which describes



Molnlycke Health Care US's business records. Defendant Trial Exhibit DTX-2970 is a business record of Molnlycke Health Care US.

40. Documents produced by Tri-City Medical Center bearing "TRICITY" Bates Labels are authentic business records of Tri-City Medical Center within the meaning of Federal Rule of Evidence 803(6). DTX-3000 is the Declaration of Patricia Guerra which describes Tri-City Medical Center's business records. Each of Defendant Trial Exhibits DTX-2960 through 2969 are a business record of TriCity Medical Center.

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

PUREWICK CORPORATION,	)	
	)	
Plaintiff/Counterclaim Defendant,	)	
	)	C.A. No. 22-102-MN
v.	)	
	)	
SAGE PRODUCTS, LLC,	)	
	)	
Defendant/Counterclaim Plaintiff.	)	
	)	

**PLAINTIFF’S STATEMENT OF ISSUES OF FACT TO BE LITIGATED**

Plaintiff identifies the following issues of fact that remain to be litigated. This statement is based on the claims Plaintiff expects to present as well as its understanding of the claims or defenses that Defendant is likely to present. If Defendant pursues additional claims or defenses, or raises additional issues, Plaintiff reserves the right to supplement this statement. If an issue identified herein is more properly considered an issue of law, it should be so considered. If an issue of law is more properly considered an issue of fact, that issue is incorporated into this statement.

Plaintiff reserves the right to revise this statement as necessary in light of the Court's pretrial orders, including evidentiary rulings, or in the event that any new allegations arise for which Defendant's submissions did not fairly put Plaintiff on notice. By including an issue of fact here, Plaintiff does not assume the burden of proof or production with regard to the issues that are Defendant's burdens to prove. Nor does Plaintiff concede that any genuine factual dispute exists as to any of the issues listed below. As noted below, PureWick contends that certain facts that were established in the parties' prior litigation should be deemed established in this case because of collateral estoppel.

# **I. FACTS SUBJECT TO COLLATERAL ESTOPPEL**

PureWick contends that Sage is collaterally estopped from relitigating certain issues that were determined in *PureWick Corp. v. Sage Products, LLC*, C.A. No. 19-cv-1508-MN (D. Del.) ("*PureWick I*"). "Collateral estoppel (also known as issue preclusion) is a doctrine that operates to preclude a party from relitigating an issue that has previously been decided." *Biogen Int'l GmbH v. Amneal Pharms. LLC*, 487 F. Supp. 3d 254, 258 (D. Del. 2020). "Under Third Circuit law, collateral estoppel applies when: (1) the identical issue was previously adjudicated, (2) that issue was actually litigated, (3) the previous determination was necessary to the decision and (4) the party being precluded from relitigating the issue was fully represented in the prior action." *Id.*

Moreover, collateral estoppel also bars re-litigation of facts essential to a judgment, even when the claim asserted is different. *C.I.R. v. Sunnen*, 333 U.S. 591, 601 (1948) (“where a question of fact essential to the judgment is actually litigated and determined in the first tax proceeding, the parties are bound by that determination in a subsequent proceeding even though the cause of action is different”) (citation omitted); *S. Pac. R. Co. et al. v. U.S.*, 168 U.S. 1, 48-49 (1897) (citing cases).

PureWick contends that issues decided in PureWick I, and facts that were essential to the judgment in *PureWick I*, including at least the ones listed below, have been conclusively determined for purposes of the present case and, therefore, Sage should be precluded from re-litigating these facts and issues.

1. Whether PureWick Corporation is the owner by assignment of all right, title and interest in the ‘376 and ‘989 patents.
2. Whether PureWick’s product practices the claims of the ‘376 and ‘989 patents. *See PureWick I*, D.I. 368 at 25; *see also* D.I. 153.
3. Whether the fabric used in PrimaFit 2.0 is a “wicking material” as claimed in ‘376 patent, claim 9.
4. Whether Sage had knowledge of the ‘376 Patent as of the day it issued. *See* D.I. 368 at 18.
5. Whether Sage had knowledge of the ‘989 Patent as of the day it issued. *See* D.I. 368 at 18.
6. Whether there is demand for the patented product as called for by *Panduit* factor 1. *See* D.I. 345 at 27-28; D.I. 368 at 22-24.
7. Whether the inventions claimed in the asserted claims were sold more than one year prior to the earliest filing date of the ‘376 and ‘989 patents. *See Purewick I*, D.I. 381 at ¶6;

*Purewick I*, D.I. 310 at p. 609; *Purewick I*, D.I. 312 at 2-7; *PureWick I*, D.I. 326, pp. 121-129, 180-187; *PureWick I*, D.I. 327, pp. 297-303. [Note: This is only relevant only to Sage's inequitable conduct defense].

8. Whether the inventions claimed in the asserted claims were in public use more than one year prior to the earliest filing date of the '376 and '989 patents. *See Purewick I*, D.I. 381 at ¶6; *Purewick I*, D.I. 310 at p. 609; *Purewick I*, D.I. 312 at 2-7; *PureWick I*, D.I. 326, pp. 121-129, 180-187; *PureWick I*, D.I. 327, pp. 297-303. [Note: This is only relevant only to Sage's inequitable conduct defense].

9. Whether PureWick's testing of prototype devices constituted experimental use that does not constitute a prior public use. *See Purewick I*, D.I. 381 at ¶6; *Purewick I*, D.I. 310 at p. 609; *Purewick I*, D.I. 312 at 2-7; *PureWick I*, D.I. 326, pp. 121-129, 180-187; *PureWick I*, D.I. 327, pp. 297-303. [Note: This is only relevant only to Sage's inequitable conduct defense].

## **II. INFRINGEMENT OF THE '376 PATENT**

10. Whether Plaintiff has proven by a preponderance of the evidence that Defendant directly infringes claims 1, 5, 9, and 10 of the '376 patent.

11. Whether Plaintiff has proven by a preponderance of the evidence that Defendant is liable for indirect infringement by actively inducing infringement of claims 1, 5, 9, and 10 of the '376 patent pursuant to 35 U.S.C. § 271(b).

12. Whether Plaintiff has proven by a preponderance of the evidence that Defendant is liable for indirect infringement by way of contributory infringement of claims 1, 5, 9, and 10 of the '376 patent pursuant to 35 U.S.C. § 271(c).

13. Whether Plaintiff has proven by a preponderance of the evidence that Defendant's infringement of the '376 patent has been willful.

### **III. INFRINGEMENT OF THE '989 PATENT**

14. Whether Plaintiff has proven by a preponderance of the evidence that Defendant directly infringes claims 1-6 of the '989 patent.

15. Whether Plaintiff has proven by a preponderance of the evidence that Defendant is liable for indirect infringement by actively inducing infringement of claims 1-6 of the '989 patent pursuant to 35 U.S.C. § 271(b).

16. Whether Plaintiff has proven by a preponderance of the evidence that Defendant is liable for indirect infringement by way of contributory infringement of claims 1-6 of the '989 patent pursuant to 35 U.S.C. § 271(c).

17. Whether Plaintiff has proven by a preponderance of the evidence that Defendant's infringement of the '989 patent has been willful.

### **IV. VALIDITY – WRITTEN DESCRIPTION**

18. Whether Defendant has proven by clear and convincing evidence that any of the asserted claims of the Patents-in-Suit are invalid pursuant to 35 U.S.C. §112 for lack of adequate written description.

### **V. DAMAGES**

19. The amount of damages that Plaintiff has proven by a preponderance of the evidence that it should be awarded due to Defendant's infringement of the Patents-in-Suit.

20. Whether Plaintiff is entitled to an ongoing enhanced royalty to compensate Plaintiff for Defendant's future infringement and, if so, the amount of any ongoing enhanced royalty.

21. Whether Plaintiff is entitled to costs and, if so, the dollar amount of such costs.

22. Whether Plaintiff is entitled to a finding that the case is exceptional pursuant to 35 U.S.C. § 285 and whether Plaintiff is entitled to an award of attorneys' fees.

23. Whether Plaintiff is entitled to enhanced damages due to Defendant's willful infringement under 35 U.S.C. § 284 and, if so, the level of enhancement.

**SCHEDULE B2:**  
**SAGE’S STATEMENT OF FACTS REMAINING TO BE**  
**LITIGATED RELATING TO THE ‘376 AND ‘989 PATENTS**

Pursuant to Local Rule 16.3(c)(4), Defendant’s Sage Products, LLC (“Sage”) submits the following issues of fact that remain to be litigated relating to the ‘376 and ‘989 patents. Certain issues cannot be determined until the entire case is completed.

Sage’s identification of the issues of fact that remain to be litigated is based on Sage’s current understanding of the arguments that PureWick is likely to advance based upon the pleadings and discovery in this action to date. To the extent that PureWick attempts to introduce different or additional facts, Sage reserves the right to contest those facts, and to present any and all rebuttal evidence in response to those facts.

To the extent that Sage’s Statement of Issues of Law That Remain to be Litigated in Schedule C2 contains issues of fact, those issues are incorporated herein by reference. Moreover, if any issue of fact identified below is more properly considered an issue of law, then such statement should be considered part of Defendant’s Statement of Issues of Law that Remain to Be Litigated. Additionally, Sage incorporates by reference the parties’ Joint Statement of Undisputed Facts in Schedule A, as well as the parties’ Joint Statement of Undisputed Facts submitted in *PureWick v. Sage*, C.A. No. 19-1508-MN (“PureWick I”) (attached herewith).

**I. INFRINGEMENT OF THE ‘376 PATENT**

1. Whether Plaintiff can prove by a preponderance of the evidence that Sage literally infringes, or has infringed, Claims 1, 5, 9, and 10 of the ‘376 patent (“the Asserted ‘376 Patent Claims”) by making, using, selling, and/or offering to sell the PrimaFit 2.0 product.<sup>1,2</sup>

---

<sup>1</sup> Sage preserves its objections to the Court’s Claim Construction in both PureWick I and the current lawsuit, and its related arguments as set forth in the Markman briefs.

<sup>2</sup> PureWick does not allege equivalents infringement for the ‘376 or ‘989 patents.



2. To the extent Plaintiff has proven acts of direct infringement, whether Plaintiff can prove by a preponderance of the evidence that Sage induces, or has induced, infringement of the Asserted ‘376 Patent Claims.

3. To the extent Plaintiff has proven acts of direct infringement, whether Plaintiff can prove by a preponderance of the evidence that Sage contributorily infringes, or has contributorily infringed, the Asserted ‘376 Patent Claims.

4. Whether Plaintiff can prove by a preponderance of the evidence that any infringement by Sage of the ‘376 patent was willful.

## **II. INFRINGEMENT OF THE ‘989 PATENT**

5. Whether Plaintiff can prove by a preponderance of the evidence that Sage literally infringes, or has infringed, Claims 1-6 of the ‘989 patent (“the Asserted ‘989 Patent Claims”) by performing all of the steps of the methods of the ‘989 patent claims.

6. For alleged direct infringement by third parties, whether Plaintiff has proven that a single party performs all steps of the claimed method.

7. To the extent Plaintiff has proven acts of direct infringement, whether Plaintiff can prove by a preponderance of the evidence that Sage induces, or has induced, infringement of the Asserted ‘989 Patent Claims.

8. To the extent Plaintiff has proven acts of direct infringement, whether Plaintiff can prove by a preponderance of the evidence that Sage contributorily infringes, or has contributorily infringed, the Asserted ‘989 Patent Claims.

9. Whether Plaintiff can prove by a preponderance of the evidence that any infringement by Sage of the ‘989 patent was willful.

### **III. INVALIDITY OF THE ‘376 AND ‘989 PATENTS<sup>3</sup>**

10. Whether Sage can prove by clear and convincing evidence that claims 1, 5, 9, and 10 of the ‘376 and claims 1-6 of the ‘989 patent are invalid under 35 U.S.C. § 112 for lack of written description relating to the term “reservoir”.

11. Whether Sage can prove by clear and convincing evidence that claims 1, 5, 9, and 10 of the ‘376 patent and claims 1-6 of the ‘989 patent are invalid under 35 U.S.C. § 112 for indefiniteness relating to the term “reservoir.” Indefiniteness is a question of law subject to a determination of underlying facts. Sage has requested leave to file summary judgment on indefiniteness.

### **IV. UNENFORCEABILITY OF THE ‘376 AND ‘989 PATENTS DUE TO WAIVER (TO BE DECIDED BY THE COURT)**

12. Whether Sage can prove by clear and convincing evidence that the ‘376 and ‘989 patents are unenforceable under principles of equity including waiver due to the conduct of PureWick relating to the PrimaFit 2.0 product.

### **V. UNENFORCEABILITY OF THE ‘376 AND ‘989 PATENTS DUE TO EQUITABLE ESTOPPEL (TO BE DECIDED BY THE COURT)**

13. Whether Sage can prove by clear and convincing evidence that the ‘376 and ‘989 patents are unenforceable under principles of equity including equitable estoppel as a result of the misleading conduct of PureWick relating to the PrimaFit 2.0 product.

### **VI. UNENFORCEABILITY OF THE ‘376 AND ‘989 PATENTS DUE TO ACQUIESCENCE (TO BE DECIDED BY THE COURT)**

---

<sup>3</sup> Sage was precluded from asserting invalidity under 35 U.S.C. §§102 or 103 and its unclean hands defense. (D.I. 134). Sage reserves all its right to appeal.

14. Whether Sage can prove by clear and convincing evidence that the ‘376 and ‘989 patents are unenforceable under principles of equity including acquiescence as a result of the misleading conduct of PureWick relating to the PrimaFit 2.0 product.

**VII. UNENFORCEABILITY OF THE ‘376 AND ‘989 PATENTS DUE TO INEQUITABLE CONDUCT (TO BE DECIDED BY THE COURT)**

15. Whether Sage can prove by a preponderance of the evidence, that the ‘376 and ‘989 patents are unenforceable due to inequitable conduct in the procurement of the patents based on allegations, including as discussed in the Pretrial Order, that at least one of the individuals who owed a duty of candor and good faith to the Patent Office relating to the prosecution of the ‘376 and ‘989 patents, including attorneys who prosecuted the ‘376 and ‘989 patents and Camille and Ray Newton, named inventors of the ‘376 and ‘989 patents, intentionally withheld material prior art from the Patent Office and/or made false or misleading statements to the Patent Office during prosecution of the patents with an intent to deceive the Patent Office. This includes failure to disclose material prior art PureWick products.

16. Whether the inequitable conduct during the prosecution of the ‘989 patent also renders the ‘376 patent, which claims priority to the ‘989 patent, unenforceable including under the doctrine of infectious unenforceability.

**VIII. REMEDIES FOR PUREWICK’S CLAIMS**

The following issues only apply if Sage is found liable for infringing a valid claim of the ‘376 or ‘989 patents and equitable defenses do not apply.

17. The amount of damages to which PureWick is entitled, including the amount of reasonable royalties, if any, to compensate PureWick for any alleged infringement by the PrimaFit 2.0, and the amount of prejudgment or post-judgment interest, if any.

18. Whether PureWick can prove by a preponderance of the evidence that it is entitled to lost profits damages, including whether it can prove by a preponderance of the evidence: demand for the patented product, absence of acceptable non-infringing substitutes, manufacturing and marketing capability to exploit the demand, and the amount of profit that PureWick would have made.

19. Whether PureWick can prove by a preponderance of the evidence that it is entitled to pre-suit damages, including compliance with 35 U.S.C. § 287 for the 376 and 989 patents.

20. Whether PureWick can prove by a preponderance of the evidence that it is entitled to an ongoing royalty in view of Sage ceasing manufacture of the accused PrimaFit 2.0 device.

21. (For the Court) Whether PureWick can prove enhanced damages due to willful infringement are warranted.

22. (For the Court) Whether PureWick can prove that the case is exceptional pursuant to 35 U.S.C. §285 and whether an award of attorneys' fees to PureWick is warranted.

23. (For the Court) Whether PureWick can prove an award of its costs is warranted.

#### **IX. REMEDIES FOR SAGE'S DEFENSES**

24. (For the Court) Whether Sage can prove that the case is exceptional pursuant to 35 U.S.C. §285 and whether an award of attorneys' fees to Sage is warranted.

25. (For the Court) Whether Sage can prove an award of its costs is warranted.

26. (For the Court) Whether Sage can prove other remedies are appropriate including equitable remedies described above.

#### **X. RESPONSE TO PUREWICK'S COLLATERAL ESTOPPEL ARGUMENTS**

Days before the Pretrial Order was due (and after all final exchanges had been scheduled between the parties), PureWick surprisingly added a section about "Collateral Estoppel" to its

Schedule B1 (Header I) of the pretrial order raising eight new items (and even later adding an additional ninth item). PureWick's improper new collateral estoppel contentions are inappropriate for a pretrial order, not part of any motion by PureWick, and should be rejected out of hand for multiple reasons.

First, PureWick already filed a Rule 12(c) motion addressing the issue of collateral estoppel based on the *PureWick I* litigation and the Court already ruled on it. (*See* D.I. 12, D.I. 13, D.I. 19, D.I. 134.) PureWick's Rule 12(c) motion argued that collateral estoppel precluded Sage's defenses of (a) invalidity under Sections 102/103, (b) invalidity under Section 112, (c) unenforceability based on unclean hands; (d) unenforceability based on equitable estoppel, waiver, acquiescence, and inequitable conduct. (D.I. 13; D.I. 19.) In ruling on PureWick's 12(c) motion, the Court already decided the scope of collateral estoppel from the *PureWick I* lawsuit finding collateral estoppel on items (a) and (c) but not items (b) and (d). (D.I. 134). Importantly, the eight items in PureWick's "collateral estoppel" argument were either never included in its Rule 12(c) motion or the Court ruled against PureWick on the issue. The Court's ruling on PureWick's motion is what governs the issue of collateral estoppel in this case—not PureWick's untimely submission in a pretrial document effectively seeking judgment on the pleadings again.

It is too late for PureWick to now raise new issues subject to Rule 12(c). Fed. R. Civ. P. 12 explicitly prevents parties from "piecemeal" litigation of Rule 12 issues and states "a party that makes a motion under this rule may not make another motion under this rule raising a defense or objection that was available to the party but omitted from its earlier motion." PureWick had the opportunity to raise all of the issues for which it believed Sage was estopped in the present litigation as part of its Rule 12 motion. New issues raised by PureWick in its Schedule B1 are thus waived. *See* Fed. Rule Civ. P. 12(g); Notes of Advisory Committee on Rules-1966 Amendment

(“[I]f the defendant moves before answer to dismiss the complaint for failure to state a claim, he is barred from making a further motion presenting the defense..., if that defense was available to him when he made his original motion. Amended subdivision (g) is to the same effect. This required consolidation of defenses and objections in a Rule 12 motion is salutary in that it works against piecemeal consideration of a case.”).

Additionally, PureWick’s new assertions are procedurally improper and a pretrial order is not the appropriate mechanism to address such issues. PureWick has not filed another Rule 12 motion (despite its request falling under that Rule). PureWick’s attempt to circumvent the required motion and briefing procedures is improper.

In any case, PureWick’s nine collateral estoppel arguments are wrong on the merits. “Issue preclusion, of narrower scope than res judicata [claim preclusion], requires that the identical issue was decided on the merits between the same parties.” *Allen v. McCurry*, 449 U.S. 90, 94 (1980). The party seeking to invoke issue preclusion or collateral estoppel bears the burden of showing: “(1) the identical issue was previously adjudicated, (2) that issue was actually litigated, (3) the previous determination was necessary to the decision and (4) the party being precluded from relitigating the issue was fully represented in the prior action.” *Jean Alexander Cosmetics, Inc. v. L’Oreal USA, Inc.*, 458 F3d 244, 249 (3d Cir. 2006). “Issue preclusion [ ] applies only to issues actually litigated in the prior action, not issues that could have been litigated.” *ViaTech Techs., Inc. v. Microsoft Corp.*, No. 17-570-RGA, 2019 WL 3241131, \*5 (D. Del. July 18, 2019). Indeed, the party seeking to apply issue preclusion must prove “the issue was actually decided in a decision that was final, valid, and on the merits.” *Novartis Pharm. Corp. v. Abbott Labs.*, 375 F.3d 1328, 1333 (Fed. Cir. 2004) (quoting *Hawksbill Sea Turtle v. FEMA*, 126 F.3d 461, 475 (3d Cir. 1997)) (collateral estoppel did not apply because plaintiff could not prove that application of the court’s

claim construction was necessary to support the jury verdict). Here, none of PureWick’s newly-raised issues are subject to issue preclusion for the following reasons:

- *PureWick Issue 1*: Regardless of whether or not PureWick sufficiently proved, and the jury determined, that PureWick was the owner by assignment of the ‘376 and ‘989 patents *during the damages period in PureWick I*, that does not mean that it can automatically be assumed that PureWick is still the owner of the patents and has been the owner at all times during the *different* damages period in this lawsuit. Because the issues are not identical, there is no collateral estoppel and PureWick cannot avoid having to meet its burden of proof.

- *PureWick Issue 2*: The jury never determined whether “PureWick’s product practices the claims of the ‘376 and ‘989 patents”—whatever “PureWick product” means. The jury was never asked this question nor was that determination necessary to the judgment or in determining any issue in *PureWick I*. (See D.I. 164 at 1.) Additionally, in *PureWick I*, PureWick claimed to have had “hundreds” of “PureWick products”—many of which it claimed did *not* practice the invention. (*Id.* at 2; *see also* Schedule F5 (Sage’s Reply ISO Motion in Limine #2 at 2.) And further yet, the identical issue of whether “PureWick’s product” *as sold during the current damages period in this case* (which post-dates the damages period in the first case) practices the claims of the ‘376 and ‘989 patent was never litigated in *PureWick I*.

- *PureWick Issue 3*: The identical issue of whether the fabric *used in PrimaFit 2.0* is a “wicking material” as claimed in dependent claim 9 of the ‘376 patent was not litigated in *PureWick I*. Only infringement of the *PrimaFit 1.0* was litigated or decided in the prior litigation. Nor was it ever litigated in *PureWick I* that *PrimaFit 2.0* uses the same fabric in the same way as the *PrimaFit 1.0*. That is presently disputed as the materials are configured differently.

- *PureWick Issues 4 and 5*: The date of first knowledge of the patents-in-suit was not

“determined” in the prior lawsuit. The jury was never asked that question. (*PureWick I*, D.I. 316.) Moreover, the damages period in *PureWick I* started after PureWick filed the *PureWick I* lawsuit. (*PureWick I*, D.I. 314 at 51).

- *PureWick Issue 6*: The identical issue of whether there is “demand for the patented product” during the damages period in this lawsuit (*see supra*) was never litigated in *PureWick I*. *See Kalman v. Berlyn Corp.*, 914 F.2d 1473, 1484 (Fed. Cir. 1990) (proving entitlement to lost profits requires proving, among other things, “a demand for the patented product during the period of infringing sales”). The market in this case is different as there are numerous new market entrants.

27. *PureWick Issues 7, 8, and 9*: PureWick concedes the alleged established “facts” about “prior use” and “sale” in the present case relate “only to Sage’s inequitable conduct defense.”<sup>4</sup> The Court already found that Sage is not collaterally estopped from arguing inequitable conduct in this lawsuit (D.I. 134 at 14), and the parties have been actively litigating inequitable conduct the entire discovery period in this case including obtaining substantial new subpoenaed evidence on the issue. PureWick cannot reargue the issue now. Additionally, a determination regarding prior art *invalidity* in *PureWick I* is not determinative of whether PureWick failed to disclose material art to the PTO including its impact on *unpatentability* in this case. In *PureWick I*, the parties litigated *invalidity* (analyzed under the clear-and-convincing standard), whereas inequitable conduct addresses *unpatentability* (analyzed under the lower preponderance-of-the-evidence standard and a broader claim construction standard). (*Compare PureWick I*, D.I. 314 at 10 with Schedule C2 at 18); *see B & B Hardware, Inc. v. Hargis Indus., Inc.*, 575 U.S. 138, 154 (2015) (“[I]ssues are not identical if the second action involves application of a different legal

---

<sup>4</sup> PureWick ignores multiple other aspects of the defense.



standard, even though the factual setting of both suits may be the same.”). In any case, Sage’s inequitable conduct claim is not based on the same facts as the prior case.<sup>5</sup> Indeed, there is significant new evidence that was never produced in the prior case including newly-produced public communications, offers for sale and sales, newly revealed prior art products, etc., making collateral estoppel further inapplicable.

---

<sup>5</sup> As set forth in Sage’s response to PureWick’s JMOL on invalidity, the scope of the prior use defense was limited to particular devices with pictures. (*PureWick I*, D.I. 325 at 2.). PureWick’s failure to disclose to the PTO extended far beyond that and also relies on the inventors’ changed trial testimony about the “hundreds” of varying products that were made available.

## **Attachment to Schedule B, Statement of Undisputed Facts from PureWick 1**

**SCHEDULE A: JOINT STATEMENT OF UNDISPUTED FACTS**  
*PureWick Corporation v. Sage Products, LLC* (C.A. No. 19-1508-MN)

The parties respectfully submit this Joint Statement of Undisputed Facts. By agreeing to this Joint Statement, neither party admits that any stated fact is relevant to any material issue of dispute.

1. PureWick is a corporation organized under the laws of the State of Delaware.
2. Sage is a corporation organized under the laws of the State of Delaware.
3. U.S. Patent No. 10,390,989 (“the 989 patent”) is entitled “Apparatus And Methods For Receiving Discharged Urine.” The 989 patent was issued by the United States Patent and Trademark Office on August 27, 2019, from U.S. Application No. 15/260,103. The 989 patent was filed on September 8, 2016. Defendant’s Trial Exhibit DTX002 is a true and correct copy of the 989 patent. Defendant’s Trial Exhibit DTX024 is a true and correct copy of the file history of the 989 patent.
4. Robert A. Sanchez, Camille R. Newton, Joseph M. Forehand, and Raymond J. Newton are named inventors on the face of the 989 patent.
5. Defendant’s Trial Exhibit DTX38 is a true and correct copy of a September 26, 2018, Office Action from the U.S. Patent Office in U.S. Application No. 15/260,103, the application from which the 989 patent issued. Claims 9 through 14 of that application correspond to issued Claims 1 through 6 of the 989 Patent.
6. Defendant’s Trial Exhibit DTX40 is a true and correct copy of a December 20, 2018, Amendment and Response submitted by PureWick in U.S. Application No. 15/260,103, the application from which the 989 patent issued.

7. Defendant's Trial Exhibit DTX43 is a true and correct copy of a February 14, 2019, Office Action from the U.S. Patent Office in U.S. Application No. 15/260,103, the application from which the 989 patent issued.

8. Defendant's Trial Exhibit DTX44 is a true and correct copy of a May 13, 2019, Office Action Response and Amendment B from U.S. Application No. 15/260,103, the application from which the 989 patent issued.

9. U.S. Patent No. 10,226,376 ("the 376 patent") is entitled "Apparatus And Methods For Receiving Discharged Urine." The 376 patent was issued by the United States Patent and Trademark Office on March 12, 2019, from U.S. Application No. 15/611,587, filed June 1, 2017. Defendant's Trial Exhibit DTX003 is a true and correct copy of the 376 patent. Defendant's Trial Exhibit DTX026 is a true and correct copy of the file history of the 376 patent.

10. Robert A. Sanchez, Camille R. Newton, Joseph M. Forehand, and Raymond J. Newton are named inventors on the face of the 376 patent.

11. U.S. Patent No. 10,376,407 is entitled "Using Wicking Material To Collect Urine From A Male For Transport." The 407 patent was issued by the United States Patent and Trademark Office on August 13, 2019 from U.S. Application No. 15/1238,427, filed August 16, 2016. Defendant's Trial Exhibit DTX004 is a true and correct copy of the 407 patent. Defendant's Trial Exhibit DTX051 is a true and correct copy of the file history of the 407 patent.

12. Raymond John Newton is the named inventor on the face of the 407 patent.

13. Defendant's Trial Exhibit DTX900 is Sage's PrimaFit External Urine Management System.

14. Defendant's Trial Exhibit DTX901 is Sage's PrimoFit External Urine Management System.

15. Defendant's Trial Exhibit DTX902 is the current version of the PureWick Female External Catheter.

16. Defendant's Trial Exhibit DTX001 is a true and correct copy of U.S. Pat. No. 8,287,508 ("Sanchez 508"). Sanchez 508 issued on October 16, 2012, from U.S. Application No. 12/840,475, filed on July 21, 2010.

17. Defendant's Trial Exhibit DTX006 is a true and correct copy of U.S. Patent App. No. 2006/0015080 ("Mahnensmith"). Mahnensmith published on January 19, 2006.

18. Defendant's Trial Exhibit DTX007 is a true and correct copy of U.S. Pat. No. 4,747,166 ("Kuntz 166"). Kuntz 166 issued on May 31, 1988.

19. Defendant's Trial Exhibit DTX008 is a true and correct copy of U.S. Patent No. 7,220,250 ("Suzuki"). Suzuki issued on May 22, 2007.

20. Defendant's Trial Exhibit DTX009 is a true and correct copy of U.S. Patent No. 3,349,768 ("Keane"). Keane issued on October 31, 1967.

21. Defendant's Trial Exhibit DTX010 is a true and correct copy of U.S. Patent No. 4,425,130 ("DesMarais"). DesMarias issued on January 10, 1984.

22. Defendant's Trial Exhibit DTX011 is a true and correct copy of U.S. Pat. No. 5,674,212 ("Osborn"). Osborn issued on October 7, 1997.

23. Defendant's Trial Exhibit DTX012 is a true and correct copy of International Publication No. WO 2007/042823 ("Van Den Heuvel"). Van Den Heuvel published on April 19, 2007.

24. Defendant's Trial Exhibit DTX013 is a true and correct copy of WO2007/042823 ("Wolff"). Wolff published on October 5, 2000.

25. Defendant's Trial Exhibit DTX014 is a true and correct copy of U.S. Patent No. 4,886,508 ("Washington"). Washington issued on December 12, 1989.

26. Defendant's Trial Exhibit DTX015 is a true and correct copy of European Publication No. EP EP0613355A1 ("Kuntz EP355"). Kuntz EP355 was published on September 7, 1994.

27. Defendant's Trial Exhibit DTX016 is a true and correct copy of U.S. Patent No. 7,135,012 ("Harvie 012"). Harvie 012 issued on November 14, 2006.

28. Defendant's Trial Exhibit DTX017 is a true and correct copy of the original language and certified translation of JP2001/276107A ("Ishii"). Ishii was published on October 9, 2001.

29. Defendant's Trial Exhibit DTX018 is a true and correct copy of U.S. Pat. No. 3,613,123 ("Langstrom"). Langstrom issued October 19, 1971.

30. Defendant's Trial Exhibit DTX019 is a true and correct copy of U.S. Patent No. 1,742,080 ("Jones"). Jones issued December 31, 1929.

31. Defendant's Trial Exhibit DTX020 is a true and correct copy of U.S. Patent No. 3,520,300 ("Flower"). Flower issued July 14, 1970.

32. Defendant's Trial Exhibit 021 is a true and correct copy of U.S. Pat. Pub. No. 2007/0191804 ("Coley"). Coley was published on August 16, 2007.

33. Defendant's Trial Exhibit DTX029 is a true and correct copy of U.S. Patent No. 4,804,377 ("Hanifl"). Hanifl issued on February 14, 1989.

34. Defendant's Trial Exhibit DTX30 is a true and correct copy of U.S. Patent No. 4,882,794 ("Stewart"). Stewart issued on November 28, 1989.

35. Defendant's Trial Exhibit DTX32 is a true and correct copy of U.S. Patent Pub. No. 2004/0254547 ("Okabe"). Okabe published on December 16, 2004.

36. PureWick Trial Exhibit 172 is a true and correct copy of a PureWick financial spreadsheet and is an authentic business record of PureWick Corp. within the meaning of Federal Rule of Evidence 803(6).

37. PureWick Trial Exhibit 173 is a true and correct copy of a PureWick financial spreadsheet and is an authentic business record of PureWick Corp. within the meaning of Federal Rule of Evidence 803(6).

38. PureWick Trial Exhibit 175 is a true and correct copy of a PureWick financial spreadsheet and is an authentic business record of PureWick Corp. within the meaning of Federal Rule of Evidence 803(6).

39. PureWick Trial Exhibit 176 is a true and correct copy of a PureWick financial spreadsheet and is an authentic business record of PureWick Corp. within the meaning of Federal Rule of Evidence 803(6).

40. PureWick Trial Exhibit 295 is a true and correct copy of a PureWick financial spreadsheet and is an authentic business record of PureWick Corp. within the meaning of Federal Rule of Evidence 803(6).

41. PureWick Trial Exhibit 794 is a true and correct copy of a PureWick financial spreadsheet and is an authentic business record of PureWick Corp. within the meaning of Federal Rule of Evidence 803(6).

42. PureWick Trial Exhibit 795 is a true and correct copy of a PureWick financial spreadsheet and is an authentic business record of PureWick Corp. within the meaning of Federal Rule of Evidence 803(6).

43. PureWick Trial Exhibit 796 is a true and correct copy of a PureWick financial spreadsheet and is an authentic business record of PureWick Corp. within the meaning of Federal Rule of Evidence 803(6).

44. PureWick Trial Exhibit 797 is a true and correct copy of a PureWick financial spreadsheet and is an authentic business record of PureWick Corp. within the meaning of Federal Rule of Evidence 803(6).

45. Defendant Trial Exhibit DTX199 is a true and correct copy of a Sage Products financial spreadsheet from 2017 to 2020 and is an authentic business record of Sage Products LLC within the meaning of Federal Rule of Evidence 803(6).

46. Defendant Trial Exhibit DTX298 is a true and correct copy of the Agreement and Plan of Merger by and among C.R. Bard, Inc., Candle Acquisition Corp., PureWick Corporation and The Securityholder Representative, dated June 16, 2017.

47. Defendant Trial Exhibit DTX496 is a true and correct copy of a PureWick sales spreadsheet and is an authentic business record of PureWick Corp. within the meaning of Federal Rule of Evidence 803(6).

48. Defendant Trial Exhibit DTX751a is a true and correct copy of a Sage Products financial spreadsheet from November 2017 through February 7, 2021 and is an authentic business record of Sage Products LLC within the meaning of Federal Rule of Evidence 803(6).

49. Defendant Trial Exhibit DTX751b is a true and correct copy of a Sage Products financial spreadsheet from November 2017 through November 2021 and is an authentic business record of Sage Products LLC within the meaning of Federal Rule of Evidence 803(6).



50. Defendant Trial Exhibit DTX751c is a true and correct copy of a Sage Products financial spreadsheet from January 2020 through December 2021 and is an authentic business record of Sage Products LLC within the meaning of Federal Rule of Evidence 803(6).

51. Defendant Trial Exhibit DTX752 is a true and correct copy of a Sage Products financial spreadsheet from 2017 through March 2021 and is an authentic business record of Sage Products LLC within the meaning of Federal Rule of Evidence 803(6).

52. Defendant Trial Exhibit DTX758 is a true and correct copy of a PureWick financial spreadsheet from and is an authentic business record of PureWick Corp. within the meaning of Federal Rule of Evidence 803(6).

53. Documents produced to a party to this action by another party or a third party in response to compulsory process (e.g., subpoena) shall be deemed authentic for the purposes of this lawsuit only, absent good cause.

54. Documents produced by Connect Foundation bearing “CF” Bates Labels are authentic business records of Connect Foundation within the meaning of Federal Rule of Evidence 803(6). Each of Defendant Trial Exhibits 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, and 520 are a business record of Connect Foundation.

55. Documents produced by Omni Medical Systems, Inc. bearing “OMNI” Bates Labels are authentic business records of Omni Medical Systems, Inc. within the meaning of Federal Rule of Evidence 803(6). Each of Defendant Trial Exhibits 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, and 438 are a business record of Omni Medical Systems.

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

PUREWICK CORPORATION,	)	
	)	
Plaintiff/Counterclaim Defendant,	)	
	)	C.A. No. 22-102-MN
v.	)	
	)	
SAGE PRODUCTS, LLC,	)	
	)	
Defendant/Counterclaim Plaintiff.	)	
	)	

**PLAINTIFF'S STATEMENT OF ISSUES  
OF LAW THAT REMAIN TO BE LITIGATED**

Plaintiff identifies the following issues of law that remain to be litigated, with citations to authorities relied upon. This statement is based on the arguments Plaintiff expects to make as well as its understanding of the arguments that Defendant is likely to make. If Defendant seeks to introduce different legal arguments, Plaintiff reserves the right to supplement this statement. If an issue identified herein is more properly considered an issue of fact, it should be so considered. If an issue of fact is more properly considered an issue of law, that issue is incorporated into this statement. The authorities cited herein are not exhaustive; Plaintiff may rely on authority not cited in this statement.

The issues of law identified herein do not include any outstanding issues of law with respect to the parties' proposed jury instructions. Plaintiff will present those legal issues, if necessary, in its proposed instructions to the Court.

Plaintiff reserves the right to revise Plaintiff's statement of issues of law as necessary in light of the Court's pretrial orders, including evidentiary rulings, or in the event that any new allegations arise for which Defendant's submissions did not fairly put Plaintiff on notice.

## **I. DAMAGES**

### **A. Lost Profits**

1. Whether Plaintiff is entitled to an award of its lost profits due to Defendant's infringement of the '376 and/or '989 patents.

Relevant Authority: 35 U.S.C. § 284. For lost profits, "the patentee must show a reasonable probability that, 'but for' the infringement, it would have made the sales that were made by the infringer." *WL. Gore & Assocs., Inc. v. C.R. Bard, Inc.*, 198 F. Supp. 3d 366, 374 (D. Del. 2016) (citing *Rite-Hite Corp. v. Kelley Co.*, 56 F.3d 1538, 1545 (Fed. Cir. 1995)). Two recognized frameworks for showing but-for causation are the two-supplier test and the *Panduit* test. *See Micro Chem., Inc. v. Lextron, Inc.*, 318 F.3d 1119, 1122 (Fed. Cir. 2003).

“There is no particular required method to prove but for causation” in patent cases. *Mentor Graphics Corp. v. EVE-USA, Inc.*, 851 F.3d 1275, 1284 (Fed. Cir. 2017). “One useful, but non-exclusive method to establish the patentee’s entitlement to lost profits is the Panduit test first articulated by the Sixth Circuit” in *Panduit Corp. v. Stahl Brothers Fibre Works, Inc.*, 575 F.2d 1152 (6th Cir. 1978). *Mentor Graphics*, 851 F.3d at 1284 (internal quotation marks and citation omitted).

The *Panduit* test requires the patent owner to prove: (1) demand for the patented product; (2) absence of acceptable, non-infringing alternatives; (3) manufacturing and marketing capability to exploit demand; and (4) the amount of the profit it would have made. *Panduit*, 575 F.2d at 1156.

“The first factor—demand for the patented product—considers demand for the product as a whole.” *Mentor Graphics*, 851 F.3d at 1285 (citing *DePuy Spine, Inc. v. Medtronic Sofamor Danek, Inc.*, 567 F.3d 1314, 1330–31 (Fed. Cir. 2009)). “This factor does not require any allocation of consumer demand among the various limitations recited in a patent claim.” *DePuy*, 567 F.3d at 1330.

“The second factor—the absence of non-infringing alternatives—considers demand for particular limitations or features of the claimed invention.” *Mentor Graphics*, 851 F.3d at 1285 (citing *DePuy*, 567 F.3d at 1331).

“[I]f purchasers are motivated to purchase because of particular features available only from the patented product, products without such features—even if otherwise competing in the marketplace—would not be acceptable noninfringing substitutes.” *Standard Havens Prods., Inc. v. Gencor Indus., Inc.*, 953 F.2d 1360, 1373 (Fed. Cir. 1991). Similarly, “products lacking the advantages of the patented invention ‘can hardly be termed a substitute acceptable

to the customer who wants those advantages.’” *Presidio Components, Inc. v. Am. Tech. Ceramics Corp.*, 702 F.3d 1351, 1361 (Fed. Cir. 2012) (quoting *TWM Mfg. Co. v. Dura Corp.*, 789 F.2d 895, 901-02 (Fed. Cir. 1986)); *see also Radio Steel & Mfg. Co. v. MTD Prods., Inc.*, 788 F.2d 1554, 1556 (Fed. Cir. 1986) (affirming district court’s finding of no acceptable, noninfringing alternatives where “[t]he various [proposed alternative] wheelbarrows to which [infringer] refers incorporate only some, but not all, of the elements of the patent.”). This is especially true where the “proposed non-infringing substitutes are not adequate substitutes in the same market” and/or the market is moving away from the proposed non-infringing substitute to the infringing design. *Presidio*, 702 F.3d at 1361.

“[T]he patent holder does not need to negate all possibilities that a purchaser might have bought a different product or might have foregone the purchase altogether” in order to satisfy the second Panduit factor. *State Indus., Inc. v. Mor-Flo Indus., Inc.*, 883 F.2d 1573, 1577 (Fed. Cir. 1989) (quoting *Paper Converting Mach. Co. v. Magna–Graphics Corp.*, 745 F.2d 11, 21 (Fed. Cir. 1984)); *see also Izumi Prods. Co. v. Koninklijke Philips Elecs. N.V.*, 315 F. Supp.2d 589, 613 (D. Del. 2004) (“A patentee need not negate every possibility that a purchaser might have bought a product other than its own.”).

As an alternative to demonstrating the absence of acceptable, noninfringing alternatives under the second *Panduit* element, a patentee can use a market share approach where the patentee recovers lost profits on the percentage of infringing sales equal to its market share. *See, e.g., Procter & Gamble Co. v. Paragon Trade Brands, Inc.*, 989 F.Supp. 547, 601 (D. Del. 1997) (“The Federal Circuit has held that a patent owner may satisfy the second prong of the Panduit test by proving its share of the market in lieu of proof of the absence of acceptable substitutes. . . . Under this approach, a patentee recovers lost profits on

the percentage of infringing sales equal to its market share.”) (citations removed); *Sonos, Inc. v. D & M Holdings Inc.*, 297 F.Supp.3d 501, 518 (D. Del. 2017) (“The market share approach allows a patentee to ‘satisfy the second Panduit element by substituting proof of its market share for proof of the absence of acceptable alternatives’ and it ‘allows a patentee to recover lost profits, despite the presence of acceptable, noninfringing substitutes, because it nevertheless can prove with reasonable probability sales it would have made “but for” the infringement.’”) (quoting *BIC Leisure Prods., Inc. v. Windsurfing Int’l, Inc.*, 1 F.3d 1214, 1219 (Fed. Cir. 1993)).

## **B. Reasonable Royalty**

2. Whether Plaintiff is entitled to an award of a reasonable royalty due to Defendant’s infringement of the ’376 and/or ’989 patents.

Relevant Authority: 35 U.S.C. § 284. Under 35 U.S.C. § 284, the Court “shall award the claimant damages adequate to compensate for the infringement, but in no event less than a reasonable royalty for the use made of the invention by the infringer, together with interest and costs as fixed by the court.” 35 U.S.C. § 284. While the patent statute provides a floor of “a reasonable royalty for the use made of the invention by the infringer,” 35 U.S.C. § 284, it provides no method for defining a “reasonable” royalty, an exercise that “is not an exact science.” *Summit 6, LLC v. Samsung Elecs. Co.*, 802 F.3d 1283, 1296 (Fed. Cir. 2015).

Determining a “reasonable royalty” under Section 284 involves imagining a “hypothetical negotiation” between a willing licensor and a willing licensee at the time the alleged infringement began. *LaserDynamics, Inc. v. Quanta Comput., Inc.*, 694 F.3d 51, 75 (Fed. Cir. 2012); *Wang Labs., Inc. v. Toshiba Corp.*, 993 F.2d 858, 870 (Fed. Cir. 1993). “[T]he hypothetical negotiation framework . . . seeks to discern the value of the patented technology to the parties in the marketplace when infringement began.” *LaserDynamics*, 694

F.3d at 76. This framework “presume[s] that the parties had full knowledge of the facts and circumstances surrounding the infringement at [the] time [of the hypothetical negotiation].” *Id.* “The hypothetical negotiation also assumes that the asserted patent claims are valid and infringed.” *Lucent Techs., Inc. v. Gateway, Inc.*, 580 F.3d 1301, 1325 (Fed. Cir. 2009). “[T]he basic question posed in a hypothetical negotiation is: if, on the eve of infringement, a willing licensor and licensee had entered into an agreement instead of allowing infringement of the patent to take place, what would that agreement be?” *LaserDynamics*, 694 F.3d at 76.

The fifteen factors recited in *Georgia-Pacific Corp. v. U.S. Plywood Corp.*, 318 F.Supp. 1116, 1120 (S.D.N.Y. 1970), *modified*, 446 F.2d 295 (2d Cir. 1971), may assist in the determination of what constitutes a reasonable royalty. *See LaserDynamics*, 694 F.3d at 76.

The Georgia-Pacific factors include:

(1) royalties the patentee has received for licensing the patent to others; (2) rates paid by the licensee for the use of comparable patents; (3) the nature and scope of the license (exclusive or nonexclusive, restricted or nonrestricted by territory or product type); (4) any established policies or marketing programs by the licensor to maintain its patent monopoly by not licensing others to use the invention or granting licenses under special conditions to maintain the monopoly; (5) the commercial relationship between the licensor and licensee, such as whether they are competitors; (6) the effect of selling the patented specialty in promoting sales of other products of the licensee; (7) the duration of the patent and license term; (8) the established profitability of the product made under the patent, including its commercial success and current popularity; (9) the utility and advantages of the patent property over old modes or devices; (10) the nature of the patented invention and the benefits to those who have used the invention; (11) the extent to which the infringer has used the invention and the value of that use; (12) the portion of profit or of the selling price that may be customary in that particular business to allow for use of the invention or analogous inventions; (13) the portion of the realizable profit that should be credited to the invention as opposed to its non-patented elements; (14) the opinion testimony of qualified experts; and (15) the results of a hypothetical negotiation between the licensor and licensee.

*i4i Ltd. P'ship v. Microsoft Corp.*, 598 F.3d 831, 853 (Fed. Cir. 2010) (quoting *Georgia-Pacific*, 318 F.Supp. at 1120).

While the Federal Circuit has approved the use of the Georgia-Pacific factors in numerous decisions, and district courts have repeatedly applied the analysis, the factors are not exclusive, and some or all of the factors may be relevant to a particular case, depending on the facts of the case. *See, e.g., Minks v. Polaris Indus., Inc.*, 546 F.3d 1364, 1372 (Fed. Cir. 2008); *Dow Chemical Co. v. Mee Indus., Inc.*, 341 F.3d 1370, 1382 (Fed. Cir. 2003); *Rite-Hite Corp.*, 56 F.3d at 1555; *Energy Transp. Grp., Inc. v. Sonic Innovations, Inc.*, No. 05-cv-00422, 2011 WL 2222066, \*21 n.29 (D. Del. June 7, 2011).

Where the accused product includes both an allegedly patented feature and unpatented or conventional features, “damages awarded for patent infringement ‘must reflect the value attributable to the infringing features of the product, and no more.’” *CSIRO v. Cisco Sys., Inc.*, 809 F.3d 1295, 1301 (Fed. Cir. 2015) (quoting *Ericsson, Inc. v. D-Link Sys., Inc.*, 773 F.3d 1201, 1226 (Fed. Cir. 2014)); *see also Exmark Mfg. Co., Inc. v. Briggs & Stratton Power Prods. Grp., LLC*, 879 F.3d 1332, 1347-48 (Fed. Cir. 2018). Such apportionment can be applied to the royalty rate or the royalty base, or a combination of both. *Exmark Mfg.*, 879 F.3d at 1348.

### **C. Enhanced Damages**

3. Whether Plaintiff should be awarded enhanced damages for Defendant’s patent infringement.

Relevant Authority: 35 U.S.C. § 284; *Halo Elecs., Inc. v. Pulse Elecs., Inc.*, 579 U.S. 93, 101-102 (2016); *Whitserve, LLC v. Comput. Packages, Inc.*, 694 F.3d 10, 37 (Fed. Cir. 2012); *Jurgens v. CBK, Ltd.*, 80 F.3d 1566, 1570 (Fed. Cir. 1996).



**D. Attorneys' Fees**

4. Whether Plaintiff should be awarded its attorneys' fees in this case under 35 U.S.C. § 285.

Relevant Authority: 35 U.S.C. § 285; *Octane Fitness, LLC v. ICON Health & Fitness, Inc.*, 572 U.S. 545, 552-555 (2014).

**E. Pre-judgment and Post-Judgment Interest**

5. Whether Plaintiff is entitled to prejudgment and post-judgment interest.

Relevant Authority: 35 U.S.C. § 284; *GM Corp. v. Devex Corp.*, 461 U.S. 648, 655 (1983) (“[P]rejudgment interest should ordinarily be awarded.”). “Generally, prejudgment interest should be awarded from the date of infringement to the date of judgment.” *Nickson Indus. v. Rol Mfg. Co.*, 847 F.2d 795, 800 (Fed. Cir. 1988); *Ironworks Patents, LLC v. Apple, Inc.*, 255 F. Supp. 3d 513, 533 (D. Del. 2017).

Post-judgment “[i]nterest shall be allowed on any money judgment in a civil case recovered in a district court” and “[s]uch interest shall be calculated from the date of the entry of the judgment, at a rate equal to the weekly average 1-year constant maturity Treasury yield, as published by the Board of Governors of the Federal Reserve System, for the calendar week preceding the date of the judgment.” 28 U.S.C. § 1961(a).

**F. Permanent Injunctive Relief**

6. Whether Plaintiff should be granted permanent injunctive relief against Defendant enjoining it from further infringement based on the accused products and any products that are not colorably different.

Relevant Authority: 35 U.S.C. § 283; *eBay, Inc. v. MercExchange LLC*, 547 U.S. 388, 392-93 (2006); *Apple Inc. v. Samsung Elecs. Co.*, 809 F.3d 633, 647 (Fed. Cir. 2015); *Trebro Mfg., Inc. v. Firefly Equip., LLC*, 748 F.3d 1159, 1171 (Fed. Cir. 2014); *Ferring*

*Pharma., Inc. v. Watson Pharm., Inc.*, 765 F.3d 205 (3d Cir. 2014); *Presidio*, 702 F.3d at 1363; *Evonik Degussa GmbH v. Materia, Inc.*, No. 09-636 (NLH/JS), 2017 WL 3434156, \*3 (D. Del. Aug. 10, 2017).

**G. Ongoing Royalty**

7. Whether, if a permanent injunction is not awarded, Plaintiff should be awarded an ongoing royalty for Defendants’ future sales of the accused products and any products that are not colorably different.

Relevant Authority: “Under some circumstances, awarding an ongoing royalty for patent infringement in lieu of an injunction may be appropriate.” *Paice LLC v. Toyota Motor Corp.*, 504 F.3d 1293, 1314 (Fed. Cir. 2007); *see also Bard Peripheral Vascular, Inc. v. W.L. Gore & Assocs.*, 670 F.3d 1171, 1192 (Fed. Cir. 2012), *vacated in part on rehearing en banc on other grounds*, 476 Fed.Appx. 747 (Fed. Cir. 2012) (“The award of an ongoing royalty instead of a permanent injunction to compensate for future infringement is appropriate in some cases.”); *Arctic Cat, Inc. v. Bombardier Recreational Prods., Inc.*, 876 F.3d 1350, 1370 (Fed. Cir. 2017) (affirming award of ongoing royalties).

**II. VALIDITY – INDEFINITENESS**

8. Whether Defendant has proven by clear and convincing evidence that any of the asserted claims of the Patents-in-Suit are invalid as indefinite.

Relevant Authority: A patent’s specification must “conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.” 35 U.S.C. § 112, ¶ 2. “The Supreme Court has explained that a patent claim is indefinite if, in view of the patent specification and prosecution history, it ‘fail[s] to inform, with reasonable certainty, those skilled in the art about the scope of the invention.’” *ESCO Grp. LLC v. Deere & Co.*, No. CV 20-1679-WCB, 2023 WL 4199413, at \*10 (D. Del. June

22, 2023) (citing *Nautilus, Inc. v. Biosig Instruments, Inc.*, 572 U.S. 898, 901 (2014)). “[I]ndefiniteness is a question of law that is decided by the court, frequently at the claim construction stage of a case.” *Id.*

The “reasonable certainty” standard for assessing definiteness

reflects a “delicate balance” between “the inherent limitations of language” and providing “clear notice of what is claimed.” It “mandates clarity, while recognizing that absolute precision is unattainable.” It also accommodates the fact that “[s]ome modicum of uncertainty ... is the ‘price of ensuring the appropriate incentives for innovation.’” Consistent with these principles, we have explained that “a patentee need not define his invention with mathematical precision in order to comply with the definiteness requirement.” Instead, “[t]he degree of precision necessary for adequate claims is a function of the nature of the subject matter.”

*Guangdong Alison Hi-Tech Co. v. Int’l Trade Com’n*, 936 F.3d 1353, 1359 (Fed. Cir. 2019) (citations omitted).

“The absence of a precise boundary for [a structural feature] does not make that term indefinite and the patents invalid.” *ESCO Grp. LLC*, 2023 WL 4199413, at \*13.

### **III. UNENFORCEABILITY**

9. Whether Defendant has proven by clear and convincing evidence that any of the Patents-in-Suit are unenforceable based on equitable estoppel, waiver or acquiescence.

Relevant Authority: A claim for equitable estoppel requires proof that: “(1) the patentee, through misleading conduct leads the alleged infringer to reasonably infer that the patentee does not intend to enforce its patent against the alleged infringer; (2) the alleged infringer relies on that conduct; and (3) due to its reliance, the alleged infringer will be materially prejudiced if the patentee is allowed to proceed with its claim.” *Ecolab, Inc. v. Envirochem, Inc.*, 264 F.3d 1358, 1371 (Fed. Cir. 2001); *see also Ferring B.V. v. Allergan, Inc.*, 980 F.3d 841, 853 (Fed. Cir. 2020). “Even if all three elements of equitable estoppel are established, the court must consider any other evidence or facts ‘respecting the equities of the parties in exercising its discretion and deciding

whether to allow the defense of equitable estoppel to bar the suit.” *A.C. Aukerman Co. v. R.L. Chaides Constr. Co.*, 960 F.2d 1020, 1043 (Fed. Cir. 1992) (en banc), *abrogated on other grounds* by *SCA Hygiene Prods. Aktiebolag v. First Quality Baby Prods., LLC*, 580 U.S. 328 (2017).

Silence alone “will not create an estoppel unless there was a clear duty to speak or somehow the patentee’s continued silence reenforces the defendant’s inference from the plaintiff’s known acquiescence that the defendant will be unmolested.” *SCA Hygiene Prods. v. First Quality Baby Prods.*, 767 F.3d 1339, 1349 (Fed. Cir. 2014), *upheld on rehearing*, 807 F.3d 1311, 1333 (Fed. Cir. 2015); *Zimmer Tech., Inc. v. Howmedica Osteonics Corp.*, 453 F. Supp. 2d 1030, 1055 (N.D. Ind. 2006) (“Unless the facts demonstrate misleading conduct by the patentee other than communication followed by a period of silence alone, the patentee must have ‘threatened immediate or vigorous enforcement of its patent rights’ for the communication to be misleading.”).

A claim for implied license by acquiescence “requires proof that (1) the patentee, through statements or conduct, gave an affirmative grant of consent or permission to make, use, or sell to the alleged infringer...The first element requires the patentee to communicate that ‘the accused infringer will not be disturbed by the plaintiff patentee in the activities in which the former is currently engaged.’” *Winbond Elecs. Corp. v. International Trade Com’n*, 262 F.3d 1363, 1374 (Fed. Cir. 2001) (emphasis in original).

A defense of waiver requires a showing of: (1) an existing right; (2) knowledge of the right; (3) and an actual intention to relinquish the right. *Sun Microsystems, Inc. v. Versata Enterprises, Inc.*, 630 F. Supp. 2d 395, 409 (D. Del. 2009).

10. Whether Defendant has proven by clear and convincing evidence that any of the Patents-in-Suit are unenforceable based on inequitable conduct.

Relevant Authority: “Inequitable conduct is an equitable defense to patent infringement that, if proved, bars enforcement of a patent. . . . Inequitable conduct has two separate requirements: materiality and intent.” *Regeneron Pharm., Inc. v. Merus N.V.*, 864 F.3d 1343, 1350 (Fed. Cir. 2017) (internal citations and quotations omitted).

“Intent and materiality are separate requirements. A district court should not use a ‘sliding scale,’ where a weak showing of intent may be found sufficient based on a strong showing of materiality, and vice versa.” *Therasense, Inc. v. Becton, Dickinson and Co.*, 649 F.3d 1276, 1290 (Fed. Cir. 2011) (internal citation omitted).

“The burden of proving inequitable conduct lies with the accused infringer. To successfully prove inequitable conduct, the accused infringer must present ‘evidence that the applicant (1) made an affirmative misrepresentation of material fact, failed to disclose material information, or submitted false material information, and (2) intended to deceive the [PTO].’ Further, at least a threshold level of each element—i.e., both materiality and intent to deceive—must be proven by clear and convincing evidence. And even if this elevated evidentiary burden is met as to both elements, the district court must still balance the equities to determine whether the applicant’s conduct before the PTO was egregious enough to warrant holding the entire patent unenforceable. Thus, even if a threshold level of both materiality and intent to deceive are proven by clear and convincing evidence, the court may still decline to render the patent unenforceable.” *Star Scientific, Inc. v. R.J. Reynolds Tobacco Co.*, 537 F.3d 1357, 1365 (Fed. Cir. 2008) (citations omitted).

#### **A. Materiality**

“[T]he materiality required to establish inequitable conduct is but-for materiality. A prior art reference is but-for material if the PTO would not have allowed a claim had it been aware of

the undisclosed prior art. In determining the materiality of a reference, the court applies the preponderance of the evidence standard and gives claims their broadest reasonable construction.” *Regeneron Pharm.*, 864 F.3d at 1350 (internal citations and quotations omitted).

“A reference is not but-for material, however, if it is merely cumulative. A reference is cumulative when it teaches no more than what a reasonable examiner would consider to be taught by the prior art already before the PTO.” *Id.* (internal citations and quotations omitted); *see also Larson Mfg. Co. of South Dakota, Inc. v. Aluminart Products Ltd.*, 559 F.3d 1317, 1327 (Fed. Cir. 2009) (“[A] withheld otherwise material reference is not material if it is merely cumulative to, or less relevant than, information already considered by the examiner.”).

The Federal Circuit requires that a declaration be “unmistakably false”—not simply “false” or “misleading”—in order for the but-for standard of materiality to be relaxed and the declaration presumed material. *Therasense*, 649 F.3d at 1292–93. This is an important distinction—an affidavit can be alleged to be incorrect for a variety of reasons, including because it is ambiguous or susceptible to multiple interpretations; however, the Federal Circuit held that only “unmistakably false” affidavits are per se material. *Id.*

Moreover, the Federal Circuit came to this conclusion only after considering a trilogy of Supreme Court cases, each involving “‘deliberately planned and carefully executed scheme[s]’ to defraud the PTO and the courts.” *Id.* at 1287 (quoting *Hazel–Atlas Glass Co. v. Hartford–Empire Co.*, 322 U.S. 238, 245 (1944)).

Even where “information ideally would have been disclosed to the PTO, it is nevertheless a non-material omission [where] it can be rendered irrelevant in light of subsequent argument or explanation by the patentee.” *Novo Nordisk A/S v. Caraco Pharm. Labs., Ltd.*, 719 F.3d 1346, 1358–59 (Fed. Cir. 2013) (internal citations and quotations omitted) (rejecting “the district court’s

[but-for] materiality finding as clearly erroneous” because (1) “any reasonable examiner would have understood that Dr. Sturis’s rat study was conducted on animals, and therefore could not definitively prove synergy in humans,” (2) “Dr. Sturis’s declaration . . . was generally consistent with his trial testimony,” and (3) “Dr. Sturis’s decision to omit his original test protocol from the Declaration . . . is not a case where a declarant hid adverse test results from the PTO in favor of more promising data selected post hoc” and “even after taking the omitted test protocol into account, the court specifically found that Dr. Sturis’s conclusions . . . had not been shown to be false”).

The Federal Circuit has explained that there is a narrow exception to the but-for materiality standard for “cases of affirmative egregious misconduct.” *Therasense*, 649 F.3d at 1292. An example of such egregious misconduct is “the filing of an unmistakably false affidavit.” *Id.* at 1293. In creating this narrow exception, the Federal Circuit explained that the exception “incorporates elements of the early unclean hands cases before the Supreme Court, which dealt with ‘deliberately planned and carefully executed scheme[s]’ to defraud the PTO and the courts.” *Id.* at 1292 (quoting *Hazel–Atlas*, 322 U.S. at 245). The “cases before the Supreme Court” referred to by the Federal Circuit are illustrative of what constitutes an “unmistakably false affidavit.” *Id.* In *Keystone Driller Co. v. General Excavator Co.*, the patentee became aware of a potentially invalidating prior public use, paid the prior user to sign a false affidavit stating that his use was an abandoned experiment and paid the affiant to suppress evidence regarding the fraudulent scheme. 290 U.S. 240, 243 (1933). Similarly, in *Hazel–Atlas*, the patentee’s attorneys wrote an article praising the invention and then had a third-party expert present the ghost-written article as his own. 322 U.S. at 240-41. Finally, in *Precision Instruments Mfg. Co. v. Automotive Maintenance Mach.*

Co., the patentee perjured himself by submitting a declaration in a patent interference proceeding that contained fabricated conception and reduction to practice dates. 324 U.S. 806, 809-10 (1945).

## **B. Intent**

The Federal Circuit has held that it is never appropriate to infer intent from materiality. *Therasense*, 649 F.3d at 1290. “[A] district court may not infer intent solely from materiality. Instead, a court must weigh the evidence of intent to deceive independent of its analysis of materiality. Proving that the applicant knew of a reference, should have known of its materiality, and decided not to submit it to the PTO does not prove specific intent to deceive.” *Therasense*, 649 F.3d at 1290 (citations omitted). “Thus, the fact that information later found material was not disclosed cannot, by itself, satisfy the deceptive intent element of inequitable conduct.” *Star Sci.*, 537 F.3d at 1366.

“To prevail on a claim of inequitable conduct, the accused infringer must prove that the patentee acted with the specific intent to deceive the PTO. A finding that the misrepresentation or omission amounts to gross negligence or negligence under a ‘should have known’ standard does not satisfy this intent requirement. In a case involving nondisclosure of information, clear and convincing evidence must show that the applicant made a deliberate decision to withhold a known material reference. In other words, the accused infringer must prove by clear and convincing evidence that the applicant knew of the reference, knew that it was material, and made a deliberate decision to withhold it.” *Therasense*, 649 F.3d at 1290 (citations and quotations omitted) (noting that “[t]his requirement of knowledge and deliberate action has origins in the trio of Supreme Court cases that set in motion the development of the inequitable conduct doctrine” wherein “the patentee acted knowingly and deliberately with the purpose of defrauding the PTO and the courts”).



“Because direct evidence of deceptive intent is rare, a district court may infer intent from indirect and circumstantial evidence. However, to meet the clear and convincing evidence standard, the specific intent to deceive must be the single most reasonable inference able to be drawn from the evidence. Indeed, the evidence must be sufficient to require a finding of deceitful intent in the light of all the circumstances. Hence, when there are multiple reasonable inferences that may be drawn, intent to deceive cannot be found.” *Therasense*, 649 F.3d at 1290–91 (citations omitted); *see also American Calcar, Inc. v. American Honda Motor Co., Inc.*, 651 F.3d 1318, 1334-36 (Fed. Cir. 2011) (“While deceptive intent can be inferred from indirect and circumstantial evidence, that ‘inference must not only be based on sufficient evidence and be reasonable in light of that evidence, but it must also be the single most reasonable inference able to be drawn from the evidence to meet the clear and convincing standard.’”); *Sunoco Partners Mktg. & Terminals L.P. v. U.S. Venture, Inc.*, 339 F. Supp. 3d 803, 844 (N.D. Ill. 2018), *aff’d in part, vacated in part, rev’d in part on other grounds*, 32 F.4th 1161 (Fed. Cir. 2022) (holding that “no reasonable jury viewing all of this evidence could conclude that it compels only the inference of specific intent to deceive” because, *inter alia*, “no reasonable jury could conclude there is clear and convincing evidence foreclosing the possibility that [one inventor] did not disclose the Altoona system because he did not remember it, and that [the other inventor] did not disclose the system because it was not something he associated with the automated technology at issue in the patent applications”).

**SCHEDULE C2:**  
**SAGE’S STATEMENT OF ISSUES OF LAW THAT REMAIN TO BE LITIGATED**  
**RELATING TO THE ‘376 AND ‘989 PATENTS**

Pursuant to Local Rule 16.3(c)(5), Defendant Sage submits the following Statement of Issues of Law that Remain to be Litigated Relating to the ‘376 and ‘989 patents. Certain issues cannot be determined until the entire case is completed.

This Statement is based on Sage’s current understanding of the arguments PureWick is likely to advance in this case, based upon the pleadings and discovery in the action to date. To the extent that PureWick attempts to introduce different or additional facts or legal theories, Sage reserves the right to rely on other legal authorities to counter those facts or theories.

To the extent that Defendant’s Issues of Fact that Remain to Be Litigated in **Schedule B2** contain issues of law, those issues are incorporated by reference. Moreover, if any issue of law identified below is more properly considered an issue of fact, then such statement should be considered part of Defendant’s Issues of Fact that Remain to Be Litigated in **Schedule B2**. Sage reserves the right to rely on additional authority, including authority cited by PureWick in its Statement of Issues of Law that Remain to be Litigated (**Schedule C1**).

## TABLE OF CONTENTS

I.	INFRINGEMENT OF THE ‘376 AND ‘989 PATENTS.....	4
A.	Direct Infringement: Literal Infringement.....	4
1.	Issues.....	4
2.	Legal Standards.....	4
B.	Indirect Infringement: Induced Infringement And Contributory Infringement.....	6
1.	Issues.....	6
2.	Legal Standard For Inducement Of Infringement.....	6
3.	Legal Standard For Contributory Infringement .....	8
C.	Willful Infringement .....	9
II.	INVALIDITY UNDER SECTION 112.....	11
A.	Issues.....	11
B.	Legal Standards.....	11
III.	UNENFORCEABILITY OF THE ‘376 AND ‘989 PATENTS DUE TO WAIVER, EQUITABLE ESTOPPEL, AND ACQUIESCENCE (TO BE DECIDED BY COURT).....	14
IV.	UNENFORCEABILITY DUE TO INEQUITABLE CONDUCT (TO BE DECIDED BY COURT).....	16
A.	In General.....	16
B.	Materiality And Intent.....	17
C.	Timing of Analysis .....	19
D.	Scope of the Prior Art And Relevance Of Art To Unpatentability.....	20
E.	Anticipation And Obviousness .....	23
V.	DAMAGES FOR PATENT INFRINGEMENT.....	27
A.	Issues.....	27
B.	Legal Standards.....	27
1.	Damages Must Be Apportioned To The Patented Feature .....	27
2.	Lost Profits.....	28
3.	Reasonable Royalty .....	29
4.	Ongoing Royalty.....	32
5.	Notice Under 35 U.S.C. § 287 And Limitations On Damages .....	32
VI.	OTHER REMEDIES .....	33

A. Enhanced Damages Under 35 U.S.C. § 284 (To Be Decided By Court) .....33

B. Exceptional Case Under 35 U.S.C. § 285 Including Attorneys’ Fees (To Be Decided By Court).....35

C. Permanent Injunction (To Be Decided By Court) .....35

D. Pre-Judgment and Post-Judgment Interest.....36

## **I. INFRINGEMENT OF THE ‘376 AND ‘989 PATENTS**

### **A. Direct Infringement: Literal Infringement**

#### **1. Issues**

Sage contends that the following are issues of fact though literal infringement includes issues of law as set forth below (including claim construction): (i) whether Sage literally infringes, or has infringed, Claims 1, 5, 9, and 10 of the ‘376 patent (“the Asserted ‘376 Patent Claims”) by making, using, selling, and/or offering to sell the PrimaFit product; and (ii) whether Sage literally infringes, or has infringed, by using the methods in Claims 1-6 of the ‘989 patent (“the Asserted ‘989 Patent Claims”).

#### **2. Legal Standards**

Section 271(a) of the Patent Act, which sets forth the acts that constitute direct infringement of a patent, provides that:

Except as otherwise provided in this title, whoever without authority makes, uses, offers to sell, or sells any patented invention, within the United States or imports into the United States any patented invention during the term of the patent therefor, infringes the patent.

The patent owner bears the burden of proving infringement by a preponderance of the evidence. *See Ferring B.V. v. Watson Labs., Inc.-Fla.*, 764 F.3d 1401, 1408 (Fed. Cir. 2014). Infringement is a question of fact. *Id.* at 1408.

A determination of infringement under 35 U.S.C. § 271(a) requires a two-step analysis. “The first step is determining the meaning and scope of the patent claims asserted to be infringed.” *Markman v. Westview Instruments, Inc.*, 52 F.3d 967, 976 (Fed. Cir. 1995) (*en banc*), *aff’d*, 517 U.S. 370 (1996). “[T]he construction of a patent, including terms of art within its claim,’ is not for a jury but ‘exclusively’ for ‘the court’ to determine.” *Teva Pharm. USA, Inc. v. Sandoz, Inc.*, 135 S.Ct. 831,835 (2015) (quoting *Markman* 517 U.S. at 372). In the second step, the accused device must be compared to the claim language as properly interpreted. *See Markman*, 52 F.3d at

976; *Tanabe Seiyaku Co. v. U.S. Int’l Trade Comm’n*, 109 F.3d 726, 731 (Fed. Cir. 1997).

With regard to claim construction (Step 1), the Court construed disputed claim terms in *PureWick I* implicitly and explicitly, including in its February 17, 2021 Memorandum Opinion on Claim Construction. D.I. 128. The Court additionally construed the term “fluid reservoir”/ “reservoir” in its March 30, 2023 Memorandum Order in the present litigation. D.I. 131.<sup>1</sup>

With regard to Step 2, “[t]o show infringement of a patent, a patentee must supply sufficient evidence to prove that the accused product or process contains,...literally..., every limitation of the properly construed claim.” *Seal-Flex, Inc. v. Athletic Track & Court Constr.*, 172 F.3d 836, 842 (Fed. Cir. 1999). “[A] dependent claim, by nature, incorporates all the limitations of the claim to which it refers.” *Jeneric/Pentron, Inc. v. Dillon Co.*, 205 F.3d 1377, 1383 (Fed. Cir. 2000). Consequently, it is “a fundamental principle of patent law that ‘dependent claims cannot be found infringed unless the claims from which they depend have been found to have been infringed.’” *Id.* (quoting *Wahpeton Canvas Co. v. Frontier, Inc.*, 870 F.2d 1546, 1553 (Fed. Cir. 1998)).

An accused product literally infringes when it contains each and every limitation of the asserted claim. *Trebro Mfg. v. FireFly Equip., LLC*, 748 F.3d 1159, 1166 (Fed. Cir. 2014). If the patentee fails to prove that a claim limitation is literally present in the accused product, then there can be no finding of literal infringement of that claim. *V-Formation, Inc. v. Benetton Group SpA*, 401 F.3d 1307, 1312 (Fed. Cir. 2005) (finding no literal infringement where the accused devices did not include one of the limitations of the asserted claims); *Telemac Cellular Corp. v. Topp Telecom, Inc.*, 247 F.3d 1316, 1330 (Fed. Cir. 2001) (noting that “[a]ny deviation from the claim precludes such a finding” of literal infringement).

PureWick does not allege infringement under the doctrine of equivalents.

---

<sup>1</sup> Sage reserves its objections to the Court’s claim construction rulings.

## **B. Indirect Infringement: Induced Infringement And Contributory Infringement**

### **1. Issues**

PureWick alleges contributory and inducement of infringement of the Asserted Claims of the ‘376 and ‘989 patents, which are issues of fact but may include legal issues as discussed herein.

### **2. Legal Standard For Inducement Of Infringement**

35 U.S.C. § 271(b), which sets forth the acts that constitute direct infringement of a patent, provides that: “Whoever actively induces infringement of a patent shall be liable as an infringer.” Direct infringement is a predicate for a finding of induced infringement. *Limelight Networks, Inc. v. Akamai Techs., Inc.*, 572 U.S. 915, 921, (2014). Further “a method’s steps have not all been performed as claimed by the patent unless they are all attributable to the same defendant, either because the defendant actually performed those steps or because he directed or controlled others who performed them.” *Id.* at 921-22. “Where more than one actor is involved in practicing the steps, a court must determine whether the acts of one are attributable to the other such that a single entity is responsible for the infringement,” and an entity “is responsible for others’ performance of method steps in two sets of circumstances: (1) where that entity directs or controls others’ performance, and (2) where the actors form a joint enterprise.” *Akamai Techs., Inc. v. Limelight Networks, Inc.*, 797 F.3d 1020, 1022–23 (Fed. Cir. 2015) (en banc). “To prove inducement of infringement, the patentee must ‘show that the accused inducer took an affirmative act to encourage infringement with the knowledge that the induced acts constitute patent infringement.’” *Info-Hold v. Muzak LLC*, 783 F.3d 1365, 1372 (Fed. Cir. 2015) (citation omitted). “The mere existence of direct infringement . . . , while necessary to find liability for induced infringement, is not sufficient for inducement.” *Takeda Pharm. U.S.A., Inc. v. West-Ward Pharm. Corp.*, 785 F.3d 625, 630-31 (Fed. Cir. 2015).

Knowledge of the patent-in-suit is a requirement to establish indirect infringement. *Global-*

*Tech Appliances, Inc. v. SEB S.A.*, 563 U.S. 754, 763-64 (2011). “To prevail on a claim for indirect infringement, a plaintiff must first demonstrate direct infringement, and then establish that the ‘defendant possessed the requisite knowledge or intent to be held vicariously liable.’” *Monec Holding AG v. Motorola Mobility, Inc.*, 897 F. Supp. 2d 225, 229 (D. Del. 2012) (citations omitted). That requires, for both induced infringement and contributory infringement, allegations that “the defendant [knew] of the patent, and [knew] that the defendant’s actions [have] either induc[ed] or contribut[ed] to another’s direct infringement.” *Chalumeau Power Sys. LLC v. Alcatel-Lucent*, No. CIV.A. 11-1175-RGA, 2012 WL 6968938, at \*1 (D. Del. July 18, 2012) (citing *Global-Tech Appliances, Inc. v. SEB S.A.*, 563 U.S. 754, 763-64 (2011)) (emphasis added). For the knowledge requirement, “actual, and not constructive knowledge [is] required.” *Id.* “[M]ere knowledge of possible infringement by others does not amount to inducement; specific intent and action to induce infringement must be proven.” *Takeda Pharm*, 785 F.3d at 631.

It is well-established that selling a product and instructing a third party to use a product in a way that a plaintiff alleges constitutes infringement does not amount to knowledge of infringement or specific intent to infringe a particular patent. *See, e.g., Global-Tech*, 563 U.S. at 765 (distinguishing between knowledge of acts that constitute infringement and knowledge that such acts are infringing); *DSU Medical Corp. v. JMS Co., Ltd.*, 471 F.3d 1293, 1306 (Fed. Cir. 2006) (“inducement requires evidence of culpable conduct, . . . not merely that the inducer had knowledge of the direct infringer’s activities”). “Inducement can be found where there is ‘[e]vidence of active steps taken to encourage direct infringement,’ which can in turn be found in ‘advertising an infringing use or instructing how to engage in an infringing use.’” *Takeda*, 785 F.3d at 630-31 (citation omitted). “But such instructions need to evidence ‘intent to encourage infringement.’” *Id.* at 631 (citation omitted). “The question is not just whether instructions



‘describ[e] the infringing mode,’ . . . but whether the ‘instructions teach an infringing use of the device such that [the court is] willing to infer from those instructions an affirmative intent to infringe the patent[.]’” *Id.* (citations omitted). “Merely ‘describ[ing]’ . . . an infringing mode is not the same as ‘recommend[ing],’ . . . ‘encourag[ing],’ . . . or ‘promot[ing]’ . . . an infringing use, or suggesting that an infringing use ‘should’ be performed . . . .” *Id.* (citations omitted).

### 3. Legal Standard For Contributory Infringement

35 U.S.C. § 271(c), which sets forth the acts that constitute direct infringement of a patent, provides that:

Whoever offers to sell or sells within the United States or imports into the United States a component of a patented machine, manufacture, combination or composition, or a material or apparatus for use in practicing a patented process, constituting a material part of the invention, knowing the same to be especially made or especially adapted for use in an infringement of such patent, and not a staple article or commodity of commerce suitable for substantial noninfringing use, shall be liable as a contributory infringer.

To establish liability for contributory infringement, a patentee must prove the following four elements: “1) that there is direct infringement, 2) that the accused infringer had knowledge of the patent, 3) that the component has no substantial noninfringing uses, and 4) that the component is a material part of the invention.” *See Fujitsu Ltd. v. Netgear Inc.*, 620 F.3d 1321, 1326 (Fed. Cir. 2010).

As discussed above, knowledge of the patent-in-suit is a requirement to establish indirect infringement. *Global-Tech* 563 U.S. at 763-64. Further, contributory infringement requires the defendant to know that the defendant’s actions contribute to infringement. “Both induced infringement and contributory infringement require the defendant to . . . know that the defendant’s actions are either inducing or contributing to another’s direct infringement.” *Chalumeau*, 2012 WL 6968938, at \*1 (citing *Global-Tech*, 563 U.S. at 763-64); *Monec*, 897 F. Supp. 2d at 229 (“To prevail on a claim for indirect infringement, a plaintiff must first demonstrate direct infringement,

and then establish that the ‘defendant possessed the requisite knowledge or intent to be held vicariously liable.’” (citations omitted)).

Contributory infringement requires proof of direct infringement (discussed above) and also requires that the accused product have “no use except through practice of the patented method.” *Alloc, Inc. v. Int’l Trade Comm’n*, 342 F.3d 1361, 1374 (Fed. Cir. 2003); *see also Sony Corp. of Am. v. Universal City Studios, Inc.*, 464 U.S. 417, 441 (1984) (“Unless a commodity has no use except through practice of the patented method, the patentee has no right to claim that its distribution constitutes contributory infringement.” (citation and internal quotation marks omitted)). “[A] violator of § 271(c) must know ‘that the combination for which his component was especially designed was both patented and infringing.’” *Global-Tech*, 563 U.S. at 763 (quoting *Aro Mfg. Co. v. Covertible Top Replacement Co.*, 377 U.S. 476, 488 (1964)).

### **C. Willful Infringement**

The issues in this case relate to whether PureWick can prove by a preponderance of the evidence that any infringement by Sage relating to the ‘376 and ‘989 patent was willful. Willfulness involves issues of fact; nevertheless, a holding of no willfulness can be determined as a matter of law if no fact finder could reasonably find willful infringement.

Willful infringement is an issue of fact for the jury. *WBIP, LLC v. Kohler Co.*, 829 F.3d 1317, 1341 (Fed. Cir. 2016). The patentee has the burden to prove willfulness by a preponderance of the evidence. *Halo Elecs., Inc. v. Pulse Elecs., Inc.*, 136 S. Ct. 1923, 1934 (2016). To show willfulness, a patentee must prove “that an accused infringer acted with a specific intent to infringe.” *Vehicle IP, LLC v. AT&T Mobility LLC*, 227 F. Supp. 3d 319, 330 (D. Del. 2017); *see also Stickle v. Heublein, Inc.*, 716 F.2d 1550, 1565 (Fed. Cir. 1983) (“[M]ore is necessary to support a finding of ‘willfulness’ than that the infringing acts were not inadvertent. The court must determine that the infringer acted in disregard of the patent, that is, that the infringer had no

reasonable basis for believing it had a right to do the acts.”). Conduct that is “willful, wanton, malicious, bad faith, deliberate, consciously wrongful, [or] flagrant” may constitute willful infringement and justify the award of enhanced damages. *Halo*, 136 S. Ct. at 1932. “The subjective willfulness of a patent infringer, intentional or knowing, may warrant enhanced damages, without regard to whether his infringement was objectively reckless.” *Id.* at 1933.

“Knowledge of the patent alleged to be willfully infringed continues to be a prerequisite to enhanced damages.” *WBIP*, 829 F.3d at 1341 (Fed. Cir. 2016). Mere awareness of an asserted patent does not constitute willful misconduct. *See Intellectual Ventures I, LLC v. Symantec Corp.*, 234 F. Supp. 3d 601, 611-12 (D. Del. 2017) (granting summary judgment of no willful infringement where plaintiff “identifie[d] no evidence of behavior beyond typical infringement”); *Vehicle IP LLC*, 227 F. Supp. 3d at 331 (granting summary judgment of no willfulness where the patentee “[did] not identify other evidence, beyond pre-suit knowledge of the patent, that could show that [the accused infringer’s] infringement was ‘egregious,’ ‘deliberate,’ [or] ‘wanton’”). Moreover, knowledge of related patents is not evidence of willful infringement of the asserted patent. *Monec*, 897 F. Supp. 2d at 232, 236.

Evidence of competitive activity is not willful infringement. In *Monec*, 897 F. Supp. 2d at 232, the plaintiff alleged willful infringement and attempted to impute knowledge of the reexamined patent-in-suit based on the defendant’s knowledge of the original, pre-reexamination patent. The court dismissed plaintiff’s willfulness claims and noted that there is “no authority for imposing a duty on Defendants to indefinitely track a particular patent in anticipation of a potential infringement lawsuit.” *Id.* at 233; *see Diamond Grading Techs. Inc. v. Am. Gem Soc’y*, No. 2:14-CV-1161-RWS-RSP, 2016 WL 3902482, at \*2 (E.D. Tex. Mar. 30, 2016) (“The existence of the [reissue] ‘RE963 Patent and the scope of the ‘RE963 Patent’s claims are not facts that can be

ascertained merely from notice of the original ‘673 Patent.”); *Virginia Innovation Scis., Inc. v. Samsung Elecs. Co.*, 983 F. Supp. 2d 700, 710 (E.D. Va. 2013) (holding that “knowledge of the ‘492 patent would not plausibly entail knowledge of the patents which claim priority to the ‘492 patent”). *Monec* specifically states that “a plaintiff fails to sufficiently plead knowledge of the patent-in-suit . . . when the factual allegations merely support the conclusion that the parties have patents in the same field.” 897 F. Supp. 2d at 230, 232-33, 236.

## II. INVALIDITY UNDER SECTION 112

### A. Issues

Sage asserts that the Asserted Claims of the ‘376 and ‘989 patents are invalid for failing to comply with the written description and definiteness requirements of 35 U.S.C. § 112 based on the term “reservoir”. Though written description under 35 U.S.C. § 112 is a question of fact, it may be determined as a matter of law when there are no underlying fact disputes. Definiteness under 35 U.S.C. § 112 is a legal inquiry with underlying factual questions. Sage has filed a request to move for summary judgment on indefiniteness.

### B. Legal Standards

**Written Description Requirement.** 35 U.S.C. § 112 requires that “[t]he specification shall contain a written description of the invention.” To adequately disclose an invention, the patent must include a written description that “conveys to those skilled in the art that the inventor had possession of the claimed subject matter as of the filing date.” *Ariad Pharm., Inc. v. Eli Lilly & Co.*, 598 F.3d 1336, 1351 (Fed Cir. 2010). To satisfy this requirement, a patent specification must describe the invention “sufficiently to convey to a person of skill in the art that the patentee had possession of the claimed invention at the time of the application, i.e., that the patentee invented what is claimed.” *LizardTech, Inc. v. Earth Res. Mapping, Inc.*, 424 F.3d 1336, 1345 (Fed. Cir. 2005); *Vas-Cath Inc. v. Mahurkar*, 935 F.2d 1555, 1562-64 (Fed. Cir. 1991) (a patent applicant

must “convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the ‘written description’ inquiry, whatever is now claimed.”). “The purpose of the written description requirement is to ensure that the scope of the right to exclude, as set forth in the claims, does not overreach the scope of the inventor’s contribution to the field of art as described in the patent specification.” *In re Katz Interactive Call Processing Patent Litig.*, 639 F.3d 1303, 1319 (Fed. Cir. 2011) (quoting *Reiffin v. Microsoft Corp.*, 214 F.3d 1342, 1345 (Fed. Cir. 2000)).

Whether a patent claim satisfies the written description requirement is a question of fact. *Ariad Pharm.*, 598 F.3d at 1351. In determining whether a specification contains an adequate written description, “one must make an ‘objective inquiry into the four corners of the specification from the perspective of a person of ordinary skill in the art.’” *Boston Sci. Corp. v. Johnson & Johnson*, 647 F.3d 1353, 1366 (Fed. Cir. 2011) (citing *Ariad*, 598 F.3d at 1351). In particular, the written description must “clearly allow persons of ordinary skill in the art to recognize that [the inventor] invented what is claimed.” *Ariad*, 598 F.3d at 1351 (citation omitted)). “A broad claim is invalid [for lack of adequate written description] when the entirety of the specification clearly indicates that the invention is of a much narrower scope.” *Carnegie Mellon Univ. v. Hoffmann-La Roche Inc.*, 541 F.3d 1115, 1127 (Fed. Cir. 2008).

A patent may fail to satisfy the written description requirement where the specification repeatedly and only describes an invention with a particular feature and the patentee omits that feature from the claims. *See, e.g., Gentry Gallery, Inc. v. Berkline Corp.*, 134 F.3d 1473, 1479-80 (Fed. Cir. 1998); *ICU Med., Inc. v. Alaris Med. Sys., Inc.*, 558 F.3d 1368, 1377-79 (Fed. Cir. 2009) (affirming summary judgment of invalidity under § 112 where specification only described medical valves with spikes yet claims eliminated “spike” element to cover medical valves generically);

*Lizardtech*, 424 F.3d at 1343-46 (affirming summary judgment of invalidity where claim covered “all ways” of creating a seamless array but “[t]he specification provides only a single way” and “[t]here is no evidence that the specification contemplates a more generic way”). Moreover, claims may not “merely recite a description of the problem to be solved while claiming all solutions to it.” *Ariad Pharm.*, 598 F.3d at 1350, 1353.

**Indefiniteness.** Definiteness is a question of law based on underlying fact determinations. *Green Edge Enters., LLC v. Rubber Mulch Etc., LLC*, 620 F.3d 1287, 1299 (Fed. Cir. 2010). “[A] patent is invalid for indefiniteness if its claims, read in light of the specification delineating the patent, and the prosecution history, fail to inform, with reasonable certainty, those skilled in the art about the scope of the invention.” *Nautilus, Inc. v. Biosig Instruments, Inc.*, 572 U.S. 898, 901 (2014).

“In assessing definiteness, claims are to be read [by a person of ordinary skill] in light of the patent’s specification and prosecution history.” *Id.* at 908. “Definiteness is measured from the viewpoint of a person skilled in [the] art at the time the patent was filed.” *Id.* (internal citations omitted). Consequently, to be valid under the definiteness requirement, “the claims, when read in light of the specification and the prosecution history, must provide objective boundaries” such that those skilled in the art are informed about the scope of the invention with “reasonable certainty.” *See Interval Licensing LLC v. AOL, Inc.*, 766 F.3d 1364, 1371 (Fed. Cir. 2014).

Here, Sage alleges that the term “fluid reservoir at a first end,” which appears in the independent claims of the asserted patents, is indefinite and lacks written description, rendering all the claims invalid. If independent claims contain a term that is indefinite or lack written description support, then claims that depend from them are also invalid “because they incorporate the elements of” the independent claims. *Ibormeith IP, LLC v. Mercedes-Benz USA, LLC*, 732

F.3d 1376, 1378 (Fed. Cir. 2013); *LizardTech, Inc. v. Earth Res. Mapping, Inc.*, 424 F.3d 1336, 1346-47 (Fed. Cir. 2005) (dependent claims found invalid where limitation in the parent independent claim lacked written description).

### **III. UNENFORCEABILITY OF THE ‘376 AND ‘989 PATENTS DUE TO WAIVER, EQUITABLE ESTOPPEL, AND ACQUIESCENCE (TO BE DECIDED BY COURT)**

The issues of waiver, equitable estoppel, and acquiescence are equitable matters for the Court. Sage asserts that the ‘376 and ‘989 patents are unenforceable because of the actions and inactions of PureWick with regard to the accused PrimaFit 2.0 product. Further, Sage has suffered prejudice as a result of PureWick’s actions and inactions. Furthermore, Sage has been prejudiced by PureWick’s spoliation of documents and failure to preserve documents including its legacy PureWick server or adequately investigate its loss, which has significantly hampered Sage’s ability to proceed with its claims and defenses. Sage would be materially prejudiced if PureWick was permitted to proceed with its charge of infringement.

Waiver can occur when the patentee’s conduct is “inconsistent with an intent to enforce its rights as to induce a reasonable belief that such right has been relinquished.” *Core Wireless Licensing S.A.R.L. v. Apple Inc.*, 899 F.3d 1356, 1365 (Fed. Cir. 2018). “Waiver can be inferred from conduct or silence.” *Arctic Cat*, 2001 WL 1628634, at \*3 (denying motion to dismiss waiver counterclaim); *see also Mars, Inc. v. TruRX LLC*, Case No. 6:13-CV-526, 2016 WL 4055676, at \*2 (E.D. Tex. April 29, 2016).

Equitable estoppel requires a party to “prove, by a preponderance of the evidence, three elements: ‘(1) The [patentee], who usually must have knowledge of the true facts, communicates something in a misleading way, either by words, conduct or silence. (2) The [accused infringer] relies upon that communication. (3) And the [accused infringer] would be harmed materially if the [patentee] is later permitted to assert any claim inconsistent with his earlier conduct.’”

*Vanderlande Indus. Nederland BV v. I.T.C.*, 366 F.3d 1311, 1324 (Fed. Cir. 2004) (quoting *A.C. Aukerman Co.* 960 F.2d at 1041). *A.C. Aukerman*, 960 F.2d at 1045; *see also Hynix*, 2006 WL 1867724, at \*3 (“Equitable estoppel is an equitable remedy. . . . An absolute requirement that an infringer have knowledge of the patent and patentee regardless of the underlying factual situation would in some cases defeat the purpose of the protection provided by equitable estoppel.”). It is also well-established that “intentionally misleading silence” can serve as the basis for estoppel without a communication. *See, e.g., Aukerman*, 960 F.2d at 1043. As one court noted, “[a] patentee who, with knowledge of the alleged infringing activity, does nothing over a period of years other than mislead a purported infringer . . . to believe that there was and is no problem, lying in wait . . . has engaged in affirmatively misleading silence of the worse order.” *Stryker Corp. v. Zimmer, Inc.*, 741 F. Supp. 509, 514-15 (D.N.J. 1990). Moreover, there is no requirement of knowledge of the patent. *See Hynix Semiconductor Inc. v. Rambus*, No. 00-20905, 2006 WL 1867724, at \*3 (N.D. Cal. July 6, 2006) (knowledge would “defeat the purpose of the protection provided by equitable estoppel”). “Where equitable estoppel is established, all relief on a claim may be barred.” *A.C. Aukerman Co. v. R.L. Chaides Const. Co.*, 960 F.2d 1020, 1041 (Fed. Cir. 1992) (*en banc*).

“Acquiescence” can be shown through statements or conduct from which consent or permission can be implied. *See, e.g., Klaassen v. Allegro Dev. Corp.*, 106 A.3d 1035, 1047 (Del. 2014) (outlining elements of acquiescence including “acts in a manner inconsistent with the subsequent repudiation . . .”); *Weyerhaeuser Co. v. Domtar Corp.*, 204 F. Supp. 3d 731, 740, 743-45 (D. Del. 2016) (granting summary judgment of acquiescence and waiver in favor of defendant where plaintiff took a course of action inconsistent with the rights it was currently asserting against defendant); *cf., Maung Ng We v. Merrill Lynch*, No. 99-9687, 2000 WL 1159835, at \*8 (S.D.N.Y. Aug. 14, 2000) (“‘Acquiesce’ means to ‘give an implied consent to a transaction, to the accrual of



a right, or to any act, by one's mere silence, or without express assent or acknowledgment," citing Black's Law Dictionary (1990).)

#### **IV. UNENFORCEABILITY DUE TO INEQUITABLE CONDUCT (TO BE DECIDED BY COURT)**

##### **A. In General**

Sage intends to prove, by a preponderance of the evidence, that the '376 and '989 patents are unenforceable due to inequitable conduct in the procurement of the patents. At least one of the individuals who owed a duty of candor and good faith to the Patent Office relating to the prosecution of the '376 and '989 patents, including attorneys who prosecuted the '376 and '989 patents and Camille and Ray Newton, named inventors of the '376 and '989 patents, intentionally withheld material prior art from the Patent Office and made misleading and/or false statements to the Patent Office during prosecution of the patents with an intent to deceive the Patent Office. This withheld material prior art related to PureWick products publicly used, publicly disclosed, and/or on-sale during the period between March 2014 and August 2016 including certain of the PureWick products. Moreover, the Newtons were also aware of public use of their products as well as marketing efforts and disclosures to the Connect Foundation. The most reasonable inference is that this information was withheld with an intent to deceive the Patent Office.

Additionally, PureWick's attorney represented to the Patent Office during prosecution of the '989 patent that there were no relevant references or public disclosures during the intervening period between the '989 application filing date and the asserted priority date even though numerous individuals were aware of relevant and highly material information. These statements were false and misleading and material to patentability, and the most reasonable inference is that they were made with an intent to deceive the Patent Office.

Moreover, this inequitable conduct during the prosecution of the ‘989 patent also renders the ‘376 patent, which claims priority to the ‘989 patent, unenforceable including under the doctrine of infectious unenforceability. In addition, no individual involved in the prosecution of the ‘376 patent advised the Patent Office of the false and misleading statements during the prosecution of the ‘989 patent.

Additionally, as described above, there was a spoliation of evidence and PureWick failed to preserve what PureWick described as a legacy PureWick server which contained critical information relating to Sage’s defenses, including its inequitable conduct defenses.

“Inequitable conduct is an equitable defense to patent infringement that, if proved, bars enforcement of a patent.” *U.S. Water Servs., Inc. v. Novozymes A/S*, 843 F.3d 1345, 1352 (Fed. Cir. 2016) (internal quotation marks and citation omitted). “A finding of inequitable conduct as to any single claim renders the entire patent unenforceable[.]” *Id.* (internal quotation marks and citation omitted). To prove inequitable conduct, the challenger must show “that the patent applicant (1) misrepresented or omitted information material to patentability, and (2) did so with specific intent to mislead or deceive the PTO.” *United Cannabis Corp. v. Pure Hemp Collective Inc.*, 66 F.4th 1362, 1368 (Fed. Cir. 2023); *Therasense, Inc. v. Becton, Dickinson & Co.*, 649 F.3d 1276, 1290 (Fed. Cir. 2011). The party asserting inequitable conduct has the burden of proving the defense by clear and convincing evidence. *See id.*

## **B. Materiality And Intent**

**Materiality.** “As a general matter, the materiality required to establish inequitable conduct is but-for materiality. When an applicant fails to disclose prior art to the PTO, that prior art is but-for material if the PTO would not have allowed a claim had it been aware of the undisclosed prior art.” *Therasense*, 649 F.3d at 1291. “A prior art reference may constitute material information, even where the reference is not sufficient to invalidate the claim in district court, if the disclosure

of the reference would have blocked the issuance of a patent *under the PTO's evidentiary standards*,” i.e., the broadest reasonable construction. *Belcher*, 11 F.4th at 1352; *Aventis*, 675 F.3d at 1334 (quoting *Therasense*, 649 F.3d at 1292). Thus, “prior art is but-for material information if the PTO would not have allowed a claim had it been aware of the undisclosed prior art.” *Belcher*, 11 F.4th at 1352.

Information is not material when it is “merely cumulative of references that were already before the examiner.” *Mentor H/S, Inc. v. Medical Device Alliance, Inc.*, 244 F.3d 1365, 1378 (Fed. Cir. 2001). A reference is not cumulative if it contains information or features not found in the prior art of record. *See LaBounty Mfg. v. United States ITC*, 958 F.2d 1066, 1076 (Fed. Cir. 1992) (stating that “MS 107 could not possibility be cumulative with respect to a feature not found in any disclosed prior art”); *Semiconductor Energy Lab. Co. v. Samsung Elecs. Co.*, 204 F.3d 1368, 1374 (Fed. Cir. 2000) (affirming that a reference was not cumulative because it “contained a more complete combination of the elements claimed in the '636 patent than anything else before the PTO”). Information also is not cumulative when an argument made during prosecution could not have been made had that information been disclosed. *See Bruno Indep. Living Aids, Inc. v. Acorn Mobility Servs. Ltd.*, 394 F.3d 1348, 1353 (Fed. Cir. 2005) (finding prior art was not cumulative because “[h]ad the examiner known about the Wecolator ... Bruno could not have touted the front offset swivel as a point of novelty”).

Importantly, “the standard for establishing but-for materiality in the inequitable conduct context only requires a preponderance of the evidence, ‘giv[ing] claims their broadest reasonable construction.’” *Aventis Pharma S.A. v. Hospira, Inc.*, 675 F.3d 1324, 1334 (Fed. Cir. 2012).

But “[a]lthough but-for materiality generally must be proved to satisfy the materiality prong of inequitable conduct, [the Federal Circuit] recognizes an exception in cases of affirmative

egregious misconduct. ... When the patentee has engaged in affirmative acts of egregious misconduct, such as the filing of an unmistakably false affidavit, the misconduct is material.” *Therasense*, 649 F.3d at 1292.

**Intent.** “Inequitable conduct requires clear and convincing evidence of a specific intent to deceive the PTO and that the specific intent to deceive must be the single most reasonable inference able to be drawn from the evidence.” *Belcher Pharms., LLC v. Hospira, Inc.*, 11 F.4th 1345, 1353 (Fed. Cir. 2021). A court, however, “may infer intent from indirect and circumstantial evidence” because “direct evidence of deceptive intent is rare.” *Therasense*, 649 F.3d at 1290. In assessing deceptive intent, “post hoc rationales” for, e.g., withholding the prior art are to be rejected. *Belcher*, 11 F.4th at 1353. The Court may infer deceptive intent from witness “testimony in light of the other evidence.” *Id.* The evidence must be sufficient to “require a finding of deceitful intent in light of all of the circumstances.” *See id.*

### C. Timing of Analysis

For determining inequitable conduct, the relevant inquiry involves asking what the Patent Office would have done *during prosecution of the patents* had it been aware of withheld information. “Determining but-for materiality requires that the court place itself in the shoes of a patent examiner and determine whether, had the reference(s) been before the examiner at the time, the claims of the patent would have still issued.” *Regeneron Pharms., Inc. v. Merus N.V.*, 864 F.3d 1343, 1351 (Fed. Cir. 2017); *Cal. Inst. of Tech. v. Broadcom Ltd.*, 25 F.4th 976, 991 (Fed. Cir. 2022); *see also Capella Photonics, Inc. v. Infinera Corporation*, 2021 WL 765084, \*3–\*5 (E.D. Tex. 2021) (inequitable conduct requires that “the patentee or their associate knew of the reference and its materiality at the time of application”). Thus, information post-dating prosecution of the patents that the Examiner could not have considered is not relevant to the inequitable conduct analysis.

#### **D. Scope of the Prior Art And Relevance Of Art To Unpatentability**

Whether or not withheld information constitutes prior art may depend on the priority date of the challenged claims. The priority dates of the ‘376 and ‘989 patents were determined in the PureWick I litigation to be their respective filing dates. (*See, e.g.*, PW1, D.I. 314, p. 26; PW1, D.I. 330, Trial Tr. at 1086-1087, 1081 (Court: “[W]e took out the effective filing date instruction and...anywhere it said effective filing date and changed that to filing date.”).)

Prior art is material if it renders the claims unpatentable, for example, the prior art anticipates claims or renders them obvious. In the context of analyzing inequitable conduct, the “court must ... determine the broadest reasonable construction of the claims that the PTO would have applied during prosecution.” *Regeneron Pharms., Inc. v. Merus N.V.*, 864 F.3d 1343, 1351 (Fed. Cir. 2017).

35 U.S.C. §§ 102 (post-AIA) define the scope of prior art and are useful for understanding whether the Patent Office would have found a reference or information relevant to anticipation and obviousness. Those sections include for example:

(a) Novelty; Prior Art.—A person shall be entitled to a patent unless—

(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention; ....

“If the invention was known to or used by others in this country before the date of the patentee’s invention, the later inventor has not contributed to the store of knowledge, and has no entitlement to a patent.” *Woodland Tr. v. Flowertree Nursery, Inc.*, 148 F.3d 1368, 1370 (Fed. Cir. 1998). “[I]n order to invalidate a patent based on prior knowledge or use, that knowledge or use must have been available to the public.” *Id.* Specifically, products described in a printed publication, in public use, sold, or otherwise available to the public before the effective filing date may invalidate a patent under 35 U.S.C. § 102(a)(1) and 103. That provision “bars a person from receiving a patent

on an invention that was, ‘in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.’” *Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc.*, 139 S. Ct. 628, 630 (2019) (quoting 35 U.S.C. § 102(a)(1)).

“Public use” includes “any use of [the claimed] invention by a person other than the inventor who is under no limitation, restriction or obligation of secrecy to the inventor.” *Baxter Int’l, Inc. v. COBE Labs., Inc.*, 88 F.3d 1054, 1058 (Fed. Cir. 1996) (alteration in original) (citation omitted). The bar is triggered when, before the critical date, the invention “is in public use and ready for patenting.” *Barry v. Medtronic, Inc.*, 914 F.3d 1310, 1320-21 (Fed. Cir. 2019). “An invention is ‘ready for patenting’ when prior to the critical date: (1) the invention is reduced to practice; or (2) the invention is depicted in drawings or de-scribed in writings of sufficient nature to enable a [POSITA] to practice the invention.” *Hamilton Beach Brands, Inc. v. Sunbeam Prods.*, 726 F.3d 1370, 1375 (Fed. Cir. 2013) (citation omitted).

Section 102 “may bar patentability by anticipation if the device used in public includes every limitation of the later claimed invention, or by obviousness if the differences between the claimed invention and the device used would have been obvious to one of ordinary skill in the art.” *Netscape Commc’ns Corp. v. Konrad*, 295 F.3d 1315, 1321 (Fed. Cir. 2002). With respect to the on-sale bar, “the question is not whether the sale, even a third party sale, ‘discloses’ the invention at the time of the sale, but whether the sale relates to a device that embodies the invention.” *J.A. LaPorte, Inc. v. Norfolk Dredging Co.*, 787 F.2d 1577, 1583 (Fed. Cir. 1986). “Public use” includes “any use of [the claimed] invention by a person other than the inventor who is under no limitation, restriction or obligation of secrecy to the inventor.” *Baxter Int’l, Inc. v. COBE Labs., Inc.*, 88 F.3d 1054, 1058 (Fed. Cir. 1996) (alteration in original) (citation omitted).

“‘It would materially retard the progress of science and the useful arts’ to allow an inventor to ‘sell his invention publicly’ and later ‘take out a patent’ and ‘exclude the public from any farther use than what should be derived under it.’” *Helsinn*, 139 S. Ct. at 632–33 (quoting *Pennock v. Dialogue*, 2 Pet. 1, 19, 7 L.Ed. 327 (1829)); *Dippin’ Dots, Inc. v. Mosey*, 476 F.3d 1337, 1344 (Fed. Cir. 2007) (“The public sale of goods produced by a process more than one year before a patent is filed places that process in the § 102(b) prior art.”). The concealment of sales information “can be particularly egregious because, unlike the applicant’s failure to disclose, for example, a material patent reference, the examiner has no way of securing the information on his own.” *Id.*

“[A] sale or offer of sale need not make an invention available to the public to constitute invalidating prior art.” *Helsinn*, 139 S. Ct. at 630 (“[W]e determine that the reenactment of the phrase ‘on sale’ in the AIA did not alter [the meaning of ‘on sale’]. Accordingly, a commercial sale to a third party who is required to keep the invention confidential may place the invention ‘on sale’ under the AIA.”). Whether the claimed invention was the subject of an offer for sale is an inquiry based on “contract law principles.” *Linear Tech. Corp. v. Micrel, Inc.*, 275 F.3d 1040, 1048 (Fed. Cir. 2001).

One consideration is whether the use or sale “occurred “primarily for purposes of experimentation.” *Sunoco Partners & Mktg. Terminals L.P. v. U.S. Venture, Inc.*, 32 F.4th 1161, 1168 (Fed. Cir. 2022). But “there is no experimental use unless claimed features or overall workability are being tested for purposes of the filing of a patent application.” *Clock Spring, L.P. v. Wrapmaster, Inc.*, 560 F.3d 1317, 1327. The *Allen* factors help assess the experimental nature of a use. *See Allen Eng’g Corp. v. Bartell Indus., Inc.*, 299 F.3d 1336, 1352–53 (Fed. Cir. 2002). These factors include: “(1) the necessity for public testing, (2) the amount of control over the experiment retained by the inventor, (3) the nature of the invention, (4) the length of the test period,

(5) whether payment was made, (6) whether there was a secrecy obligation, (7) whether records of the experiment were kept, (8) who conducted the experiment, . . . (9) the degree of commercial exploitation during testing[,] . . . (10) whether the invention reasonably requires evaluation under actual conditions of use, (11) whether testing was systematically performed, (12) whether the inventor continually monitored the invention during testing, and (13) the nature of contacts made with potential customers.” *Id.* (citation omitted). Lack of control over the invention during the alleged experiment, “while not always dispositive, may be so.” *Clock Spring, L.P. v. Wrapmaster, Inc.*, 560 F.3d 1317, 1327 (Fed. Cir. 2009). For example, if “the patentee did not have control over the alleged testing, which was performed by its customer,” such a lack of control is “dispositive.” *Id.*; *see also Dippin’ Dots, Inc. v. Mosey*, 476 F.3d 1337, 1344 (Fed. Cir. 2007), citing *In re Smith*, 714 F.2d 1127, 1135 (Fed. Cir. 1983) (“The experimental use exception . . . does not include market testing where the inventor is attempting to gauge consumer demand for his claimed invention.”).

#### **E. Anticipation And Obviousness**

**Anticipation.** “Claimed subject matter is ‘anticipated’ when it is not new; that is, when it was previously known.” *Sanofi-Synthelabo v. Apotex, Inc.*, 550 F.3d 1075, 1082 (Fed. Cir. 2008). Anticipation requires that “every element and limitation of the claim was previously described in a single prior art reference, either expressly or inherently, so as to place a person of ordinary skill in possession of the invention.” *Id.* at 1082.

“Determining whether claims are anticipated involves a two-step analysis.” *KSwiss Inc. v. Glide N Lock GmbH*, 567 F. App’x 906, 909 (Fed. Cir. 2014) (quoting *In re Montgomery*, 677 F.3d 1375, 1379 (Fed. Cir. 2012)). “The first step involves construction of the claims of the patent at issue,” and “[t]he second step . . . involves comparing the claims to the prior art.” *Id.* (quoting *Montgomery*, 677 F.3d at 1379). In the context of analyzing inequitable conduct, the “court must



... determine the broadest reasonable construction of the claims that the PTO would have applied during prosecution.” *Regeneron Pharms., Inc. v. Merus N.V.*, 864 F.3d 1343, 1351 (Fed. Cir. 2017). The ultimate determination of anticipation is a question of fact. *See In re Gleave*, 560 F.3d 1331, 1334-35 (Fed. Cir. 2009).

A prior art reference is anticipatory under § 102 if it “disclose[s] each and every element of the claimed invention,” either “explicitly or inherently.” *Id.* at 1334. “While those elements must be arranged or combined in the same way as in the claim, the reference need not satisfy an *ipsisssimis verbis* test.” *Id.* (quotation marks and internal citations omitted). “As long as the reference discloses all of the claim limitations and enables the ‘subject matter that falls within the scope of the claims at issue,’ the reference anticipates—no ‘actual creation or reduction to practice’ is required.” *Id.* (quoting *Schering Corp. v. Geneva Pharm., Inc.*, 339 F.3d 1373, 1380-81 (Fed. Cir. 2003)).

“[A] prior art reference may anticipate without disclosing a feature of the claimed invention if that missing characteristic is necessarily present, or inherent, in the single anticipating reference.” *Schering*, 339 F.3d at 1377; *In re Cruciferous Sprout Litig.*, 301 F.3d 1343, 1352 (Fed. Cir. 2002). “In general, a limitation or the entire invention is inherent and in the public domain if it is the ‘natural result flowing from’ the explicit disclosure of the prior art.” *Perricone v. Medicis Pharm. Corp.*, 432 F.3d 1368, 1377 (Fed. Cir. 2005) (quoting *Schering Corp.*, 339 F.3d at 1379).

**Obviousness.** A patent is invalid as obvious “if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains.” 35 U.S.C. § 103. “[O]bviousness is a matter of law based on findings of underlying fact.” *Sanofi-Synthelabo*, 550 F.3d at 1085. Those underlying findings of fact

include: (1) the scope and content of the prior art; (2) the level of ordinary skill in the art; (3) the differences between the claimed invention and the prior art; and (4) objective evidence of non-obviousness. *Graham v. John Deere Co.*, 383 U.S. 1, 17-18 (1966).

Obviousness can be established by noting that “there existed at the time of invention a known problem for which there was an obvious solution encompassed by the patent’s claims.” *KSR Int’l Co. v. Teleflex Inc.*, 550 U.S. 398, 420 (2007). “In determining whether the subject matter of a patent claim is obvious, neither the particular motivation nor the avowed purpose of the patentee controls. What matters is the objective reach of the claim.” *Id.* at 419. Thus, “any need or problem known in the field of endeavor at the time of invention and addressed by the patent can provide a reason for combining the elements in the manner claimed.” *Id.* at 420.

“The combination of familiar elements according to known methods is likely to be obvious when it does no more than yield predictable results.” *Id.* at 416. A critical issue is whether the “improvement is more than the predictable use of prior art elements according to their established functions.” *Id.* at 417. “Common sense teaches ... that familiar items may have obvious uses beyond their primary purposes, and in many cases a person of ordinary skill will be able to fit the teachings of multiple patents together like pieces of a puzzle.” *Id.* at 420; *see also Leapfrog Enters. v. Fisher-Price, Inc.*, 485 F.3d 1157, 1161-1162 (Fed. Cir. 2007). But conclusory assertions or generalizations will not support a finding of obviousness. *K/S Himpp v. Hear-Wear Techs.*, 751 F.3d 1362, 1365-66 (Fed. Cir. 2014) (no obviousness where “an important structural limitation...is not evidently and indisputably within the common knowledge of those skilled in the art”); *Arendi SARL v. Apple Inc.*, 832 F.3d 1355, 1366 (Fed. Cir. 2016) (rejecting expert testimony that it was common sense to add a claim element where “a key limitation...was missing from the prior art reference”); *Shire LLC v. Amneal Pharms.*, 802 F.3d 1301, 1308-09 (Fed. Cir. 2015) (affirming

summary judgment of no invalidity where prior art did not disclose limitation).

A single prior art reference can render a claim obvious. *See B.F. Goodrich Co. v. Aircraft Braking Sys. Corp.*, 72 F.3d 1577, 1582-83 (Fed. Cir. 1996); *In re O'Farrell*, 853 F.2d 894, 902 (Fed. Cir. 1988). If a prior art reference anticipates a claim, it necessarily also renders that claim obvious. *See In re McDaniel*, 293 F.3d 1379, 1385 (Fed. Cir. 2002) (noting that “‘anticipation is the epitome of obviousness’”) (quoting *Connell v. Sears Roebuck & Co.*, 722 F.2d 1542, 1548 (Fed. Cir. 1983)).

Obviousness is judged from the perspective of a person of ordinary skill in the art at the time the alleged invention was made. *Takeda Chern. Indus. v. Alphapharm Pty., Ltd.*, 492 F.3d 1350, 1355 (Fed. Cir. 2007). A person of ordinary skill is a hypothetical person who is “presumed to be aware of all the pertinent prior art.” *Std. Oil Co. v. Am. Cyanamid Co.*, 774 F.2d 448, 454 (Fed. Cir. 1985).

The question of obviousness requires consideration of objective indicia of nonobviousness. *See KSR*, 550 U.S. at 406 (quoting *Graham*, 383 U.S. at 17-18). In the case of inequitable conduct, the objective indicia evidence must be available or known to the Patent Office. “Objective evidence of nonobviousness can include copying, long felt but unsolved need, failure of others, commercial success, unexpected results created by the claimed invention, unexpected properties of the claimed invention, licenses showing industry respect for the invention, and skepticism of skilled artisans before the invention.” *Power Integrations, Inc. v. Fairchild Semiconductor Int’l, Inc.*, 711 F.3d 1348, 1368 (Fed. Cir. 2013). Objective evidence of non-obviousness requires proof of a “nexus” with the claims and must be commensurate in scope with the claims. *Wyers v. Master Lock*, 616 F.3d 1231, 1246 (Fed. Cir. 2010); *Asyst Techs. Inc. v. Emtrak Inc.*, 544 F.3d 1310, 1316 (Fed. Cir. 2008). The patentee has the burden of production to show the required nexus between

the objective indicia and the claimed invention. *Prometheus Laboratories, Inc. v. Roxane Laboratories, Inc.*, 805 F.3d 1092, 1101-02 (Fed. Cir. 2015).

## **V. DAMAGES FOR PATENT INFRINGEMENT**

### **A. Issues**

Assuming liability is found, PureWick must show the amount of damages to which it is entitled (after the date of notice pursuant to 35 U.S.C. § 287) to compensate for alleged infringement of the ‘376 and ‘989 patents attributable to the patented invention. Here, PureWick seeks damages prior to the date of the lawsuit filing and must establish compliance with 35 U.S.C. § 287.

For the ‘376 and ‘989 patents, PureWick seeks lost profits on sales of the PrimaFit 2.0 product. The availability of lost profits is a question of law. An issue here is whether PureWick can establish the absence of acceptable, non-infringing alternatives, whether PureWick can prove demand for its PureWick product, whether PureWick can prove the amount of lost profit damages for sales of the PrimaFit products, and whether PureWick appropriately apportioned its lost profits claim. For any PrimaFit sales for which lost profits are not awarded, PureWick seeks a reasonable royalty.

PureWick alternatively seeks a reasonable royalty for all sales of the PrimaFit 2.0. Although the amount of a reasonable royalty is a fact question, there are several legal issues involved in the damages analysis.

### **B. Legal Standards**

#### **1. Damages Must Be Apportioned To The Patented Feature**

A patentee is generally entitled to “those damages attributable to the infringing features.” *Virnetx, Inc. v. Cisco Systems, Inc.*, 767 F.3d 1308, 1326 (Fed. Cir. 2014); *see also Power Integrations v. Fairchild Semiconductor*, 904 F.3d 965, 977 (Fed. Cir. 2018) (“A patentee is only

entitled to a reasonable royalty attributable to the infringing features.”). “When the accused infringing products have both patented and unpatented features, measuring [damages] requires a determination of the value added by such features. Indeed, apportionment is required even for non-royalty forms of damages.” *Ericsson, Inc. v. D-Link Sys., Inc.*, 773 F.3d 1201, 1226 (Fed. Cir. 2014). Proper apportionment is a question of fact for the jury. *Yodlee, Inc. v. Plaid Technologies Inc.*, 2017 WL 466358, at \*2 (D. Del. Jan. 27, 2017)

When a patent claim recites conventional features of a device along with patented features, “the patent owner must apportion or separate the damages between the patented improvement and the conventional components of the multicomponent product.... This ensures that [patentee] is compensated for the patented improvement... rather than the entire [device].... [W]hen a patent covers the infringing product as a whole, and the claims recite both conventional elements and unconventional elements, the court must determine how to account for the relative value of the patentee’s invention in comparison to the value of the conventional elements recited in the claim, standing alone.” *Exmark Mfg. Co. Inc. v. Briggs & Stratton Power Prod. Grp., LLC*, 879 F.3d 1332, 1348 (Fed. Cir. 2018).

## 2. Lost Profits

The availability of lost profits damages under 35 U.S.C. § 284 is a question of law. *See Rite-Hite Corp. v. Kelley Co.*, 56 F.3d 1538, 1544 (Fed. Cir. 1995) (*en banc*). “To recover lost profits, the patentee bears the burden of proof to show a reasonable probability that, ‘but for’ infringement, it would have made the sales that were made by the infringer.” *Presidio Components, Inc. v. Am. Tech. Ceramics Corp.*, 875 F.3d 1369, 1380 (Fed. Cir. 2017); *see also BIC Leisure Prods. v. Windsurfing Int’l*, 1 F.3d 1214, 1218 (Fed. Cir. 1993) (“An award of lost profits may not be speculative. Rather the patent owner must show a reasonable probability that, absent the infringement, it would have made the infringer’s sales.”).

In general, under the *Panduit* test, a patent owner must prove causation in fact by showing the so-called *Panduit* factors: “(1) demand for the patented product; (2) absence of acceptable non-infringing substitutes; (3) manufacturing and marketing capability to exploit the demand; and (4) the amount of the profit [the patent owner] would have made.” *Rite-Hite Corp.*, 56 F.3d at 1545. The “but for” test requires the patentee to establish “an absence of acceptable, noninfringing alternatives” by proving “that the potential alternative was not acceptable to potential customers or was not available at the time.” *Presidio*, 875 F.3d at 1380; *Grain Processing Corp. v. Am. Maize-Prod. Co.*, 185 F.3d 1341, 1352-53 (Fed. Cir. 1999) (“[M]arket sales of an acceptable noninfringing substitute often suffice alone to defeat a case for lost profits”).

“[I]f there is a noninfringing alternative which any given purchaser would have found acceptable and bought, then the patentee cannot obtain lost profits for that particular sale.” *Mentor Graphics Corp. v. EVE-USA, Inc.*, 851 F.3d 1275, 1286 (Fed. Cir. 2017). “For example, if the customer would have bought the infringing product without the patented feature or with a different, non-infringing alternative to the patented feature, then the patentee cannot establish entitlement to lost profits for that particular sale. And this determination is made on a customer-by-customer basis.” *Id.* For acceptability, the “correct inquiry...is whether a non-infringing alternative would be acceptable compared to the patent owner’s product, not whether it is a substitute for the infringing product.” *Presidio*, 875 F.3d at 1380. Even if there is a two supplier market, courts must still consider whether there is “another available, noninfringing substitute” because “customers may have selected the infringer’s available, noninfringing alternative over the patented invention.” *Micro Chem., Inc. v. Lextron*, 318 F.3d 1119, 1125 (Fed. Cir. 2003).

### **3. Reasonable Royalty**

“A patentee is entitled to no less than a reasonable royalty on an infringer’s sales for which the patentee has not established entitlement to lost profits.” *Rite-Hite*, 56 F.3d at 1554. In

determining a reasonable royalty, “the trial court must carefully tie proof of damages to the claimed invention’s footprint in the market place” *ResQNet.com, Inc. v. Lansa, Inc.*, 594 F.3d 860, 869 (Fed. Cir. 2010). “Any evidence unrelated to the claimed invention does not support compensation for infringement but punishes beyond the reach of the statute.” *Id.*

The amount of damages based on a reasonable royalty rate is an issue of fact for the jury. *Micro Chem., Inc. v. Lextron, Inc.*, 317 F.3d 1387, 1394 (Fed. Cir. 2003). “The burden of proving damages falls on the patentee.” *Lucent Techs., Inc. v. Gateway, Inc.*, 580 F.3d 1301, 1324 (Fed. Cir. 2009). Any evidence offered to support a reasonable royalty “must be tied to the relevant facts and circumstances of the particular case at issue and the hypothetical negotiations that would have taken place in light of those facts and circumstances at the relevant time.” *Uniloc USA, Inc. v. Microsoft Corp.*, 632 F.3d 1292, at 1318 (Fed. Cir. 2011) (finding that an expert’s “use of the 25% rule of thumb ... was arbitrary, unreliable, and irrelevant” and “fails to pass muster under Daubert”); *see also Garretson v. Clark*, 111 U.S. 120, 121 (1884) (“[T]he patentee ... must in every case give evidence tending to separate or apportion the defendant’s profits and the patentee’s damages between the patented feature and the unpatented features, and such evidence must be reliable and tangible, not conjectural or speculative.”); *VirnetX, Inc. v. Cisco Sys.*, 767 F.3d 1308, 1333 (Fed. Cir. 2014); *Uniloc USA, Inc.*, 632 F.3d at 1318 (“[A reasonable royalty] must be tied to the relevant facts and circumstances of the particular case at issue and the hypothetical negotiations that would have taken place in light of those facts and circumstances at the relevant time.”); *Robocast, Inc. v. Microsoft Corp.*, No. 10-1055-RGA, 2014 U.S. Dist. LEXIS 10745, at \*9 (D. Del. Jan. 29, 2014) (“[I]n a world where damages must be tied to the facts of the case,” generic damages theories are “non-starters.”). The common approach to determining a reasonable royalty is to consider the outcome of a hypothetical arms-length negotiation between a willing

licensor and licensee just before infringement began. *See Lucent Techs.*, 580 F.3d at 1324-25. In other words, the reasonable royalty is “the royalty upon which the parties would have agreed had they successfully negotiated an agreement just before infringement began.” *Id.* at 1324.

Courts consider a variety of factors in determining the reasonable royalty that the parties would have agreed to in the “hypothetical negotiation,” outlined in *Georgia-Pacific Corp. v. United States Plywood Corp.*, 318 F. Supp. 1116 (S.D.N.Y. 1970). These include the following:

1. The royalties received by the patentee for the licensing of the patent in suit, proving or tending to prove an established royalty.
2. The rates paid by the licensee for the use of other patents comparable to the patent in suit.
3. The nature and scope of the license, as exclusive or non-exclusive; or as restricted or non-restricted in terms of territory or with respect to whom the manufactured product may be sold.
4. The licensor’s established policy and marketing program to maintain his patent monopoly by not licensing others to use the invention or by granting licenses under special conditions designed to preserve that monopoly.
5. The commercial relationship between the licensor and licensee, such as, whether they are competitors in the same territory in the same line of business; or whether they are inventor and promotor.
6. The effect of selling the patented specialty in promoting sales of other products of the licensee; the existing value of the invention to the licensor as a generator of sales of his non-patented items; and the extent of such derivative or convoyed sales.
7. The duration of the patent and the term of the license.
8. The established profitability of the product made under the patent; its commercial success; and its current popularity.
9. The utility and advantages of the patent property over the old modes of devices, if any, that had been used for working out similar results.
10. The nature of the patented invention; the character of the commercial embodiment of it as owned and produced by the licensor; and the benefits to those who have used the invention.
11. The extent to which the infringer has made use of the invention; and any evidence



probative of the value of that use.

12. The portion of the profit or of the selling price that may be customary in the particular business or in comparable businesses to allow for the use of the invention or analogous inventions.
13. The portion of the realizable profit that should be credited to the invention as distinguished from non-patented elements, the manufacturing process, business risks, or significant features or improvements added by the infringer.
14. The opinion testimony of qualified experts.
15. The amount that a licensor (such as the patentee) and a licensee (such as the infringer) would have agreed upon (at the time the infringement began) if both had been reasonably and voluntarily trying to reach an agreement; that is, the amount which a prudent licensee—who desired, as a business proposition, to obtain a license to manufacture and sell a particular article embodying the patented invention—would have been willing to pay as a royalty and yet be able to make a reasonable profit and which amount would have been acceptable by a prudent patentee who was willing to grant a license.

*Georgia-Pacific*, 318 F. Supp. at 1120. Factor 15 of the *Georgia-Pacific* factors generally represents the hypothetical negotiation analysis as a whole and subsumes many of the other 14 factors. The Federal Circuit has approved the use of the *Georgia-Pacific* factors in numerous decisions. *See, e.g., Minks v. Polaris Indus., Inc.*, 546 F.3d 1364, 1372 (Fed. Cir. 2008).

#### **4. Ongoing Royalty**

PureWick alleges an ongoing royalty is appropriate under certain circumstances. The Court may “exercise its discretion to conclude that no forward-looking relief is appropriate in the circumstances.” *Whitserve, LLC v. Computer Packages, Inc.*, 694 F. 3d 10, 18 (Fed. Cir. 2012). Here, Sage has already informed PureWick that the accused PrimaFit 2.0 is no longer manufactured for sale. (D.I. 190).

#### **5. Notice Under 35 U.S.C. § 287 And Limitations On Damages**

35 U.S.C. § 287(a) provides that “a patentee is entitled to damages from the time when it either began marking its product in compliance with section 287(a), constructive notice, or when it actually notified the accused infringer of its infringement, whichever was earlier.” *Maxwell v. J.*

*Baker, Inc.*, 86 F.3d 1098, 1111 (Fed. Cir. 1996) (citation omitted).

Allegedly infringing products sold before a patentee marks their product, or otherwise provided notice of its patent by filing of a lawsuit, are authorized sales that are “sold free of liability for infringement.” *Fonar Corp. v. General Elec. Co.*, 107 F.3d 1543, 1555 (Fed. Cir. 1997); *ePlus, Inc. v. Lawson Software, Inc.*, 700 F.3d 509, 522 (Fed. Cir. 2012). “[P]ost-notice use of a product sold under circumstances that do not subject the seller to liability does not constitute direct infringement.” *Tesco Corp. v. Weatherford Int’l Inc.*, 722 F. Supp. 2d 755, 776 (S.D. Tex. 2010); *Leapfrog Enter. v. Fisher-Price*, No. 03-CV-927-GMS, 2005 WL 1331216, \*5 (D. Del. June 6, 2005) (continued use of a product sold pre-notice was not infringement “because the machine was sold under circumstances that did not subject its seller to damages”); *In re TransData, Inc. Smart Meters Patent Litigation*, No. 12-ML-2309, 2015 WL 5098310 (W.D. Okla. Aug. 28, 2015) (granting summary judgment of no damages on products sold before notice, rejecting argument that damages may be recovered based on continued use after notice). Whether the patentee provided notice of the patent is a question for the jury. *Funai Elec. Co. v. Daewoo Elecs. Corp.*, 616 F.3d 1357, 1373 (Fed. Cir. 2010).

## **VI. OTHER REMEDIES**

### **A. Enhanced Damages Under 35 U.S.C. § 284 (To Be Decided By Court)**

PureWick seeks enhanced damages under 35 U.S.C. § 284, in which “the court may increase the damages up to three times the amount found or assessed.” 35 U.S.C. § 284. As the Supreme Court stated in *Halo*, awards of enhanced damages due to “willful misconduct” are “generally reserved for egregious cases of culpable behavior,” for example, “the ‘wanton and malicious pirate’ who intentionally infringes another’s patent - with no doubts about its validity or any notion of a defense - for no purpose other than to steal the patentee’s business.” *Halo*, 136 S. Ct. at 1932.

A finding of willful infringement does not require that damages be enhanced. *See Halo*, 136 S. Ct. at 1933 (“[N]one of this is to say that enhanced damages must follow a finding of egregious misconduct.”); *WBIP, LLC v. Kohler Co.*, 829 F.3d 1317, 1341 n.13 (Fed. Cir. 2016) (“[T]his is not to say that a jury verdict of willful infringement ought to result in enhanced damages.”). Rather, willfulness is one factor the Court may consider when deciding whether to exercise its discretion to award enhanced damages pursuant to 35 U.S.C. § 284. *See Halo*, 136 S. Ct. at 1931-1932 (Section 284 “contains no explicit limit or condition” on a district court’s discretion except that enhanced damages are “reserved for egregious cases of culpable behavior”).

The question for the Court to consider when deciding whether to enhance damages is whether the circumstances of the case present an “egregious case[] of culpable behavior.” *See Halo*, 136 S. Ct. at 1932; *see also Trustees of Boston Univ. v. Everlight Elecs. Co.*, 212 F. Supp. 3d 254, 257 (D. Mass. 2016) (“[T]he touchstone for awarding enhanced damages after *Halo* is egregiousness.”); *Sociedad Espanola de Electromedicina y Calidad, S.A. v. Blue Ridge X-Ray Co.*, 226 F. Supp. 3d 520, 531 (W.D.N.C. 2016) (“enhanced damages are designed to punish ‘egregious infringement behavior’ and should not be imposed in the run-of-the-mill case”).

The *Read* court identified numerous factors that are relevant to the enhancement inquiry. 970 F.2d at 827. These factors include: (1) whether the infringer deliberately copied the ideas or design of another; (2) whether the infringer, when he knew of the other’s patent protection, investigated the scope of the patent and formed a good-faith belief that it was invalid or that it was not infringed; (3) the infringer’s behavior as a party to the litigation; (4) the infringer’s size and financial condition; (5) the closeness of the case; (6) the duration of the infringer’s misconduct; (7) the infringer’s remedial action; (8) the infringer’s motivation for harm; and (9) whether the infringer tried to conceal its misconduct. *Id.* at 827.

**B. Exceptional Case Under 35 U.S.C. § 285 Including Attorneys’ Fees (To Be Decided By Court)**

Sage asserts that the case is exceptional under 35 U.S.C. § 285 entitling it to attorneys’ fees under 35 U.S.C. § 285. 35 U.S.C. § 285 provides that “[t]he court in exceptional cases may award reasonable attorney fees to the prevailing party.” An “‘exceptional’ case is simply one that stands out from others with respect to the substantive strength of a party’s litigating position ... or the unreasonable manner in which the case was litigated,” to be determined at the district court’s discretion under the totality of the circumstances based on a preponderance of the evidence. *Octane Fitness, LLC v. ICON Health & Fitness, Inc.*, 134 S. Ct. 1749, 1756, 1758 (2014). Whether a case is exceptional is not appropriate for review until after the entirety of the case is complete. *See, e.g., DH Tech., Inc. v. Synergystex Int’l, Inc.*, 154 F.3d 1333, 1344 (Fed. Cir. 1998) (“Because the case is not yet complete, any analysis of exceptional case status would be premature.”).

**C. Permanent Injunction (To Be Decided By Court)**

PureWick seeks to permanently enjoin the Sage from continuing to make, use, sell, offer for sale, import, or distribute the accused products. However, as Sage has advised PureWick and the Court, the accused PrimaFit 2.0 product is no longer manufactured for sale. D.I. 190; *See XpertUniverse v. Cisco Sys.*, No. 09-157-RGA, 2013 WL 6118447, at \*12 (D. Del. Nov. 20, 2013) (where accused product was no longer manufactured there was no prospective harm or need for injunction).

Regardless, a defendant may be harmed by an injunction even if it no longer sells the adjudicated product because “an injunction may create harmful uncertainty as to what products [PureWick] may assert are covered.” *Xpert*, 2013 WL 6118447, at \*13; to obtain a permanent injunction, a patent holder must show “(1) that it has suffered an irreparable injury; (2) that remedies available at law . . . are inadequate to compensate for that injury; (3) that, considering

the balance of hardships between the plaintiff and defendant, a remedy in equity is warranted; and (4) that the public interest would not be disserved by a permanent injunction.” *eBay Inc. v. MercExchange, L.L.C.*, 547 U.S. 388, 391 (2006). “An injunction should not be granted lightly . . . because it is a ‘drastic and extraordinary remedy.’” *Riverbed Tech., Inc. v. Silver Peak Sys., Inc.*, C.A. No. 11-484-RGA, 2014 WL 4695765, at \*3 (D. Del. Sept. 12, 2014) (quoting *Monsanto Co. v. Geertson Seed Farms*, 561 U.S. 139, 165 (2010)). “Indeed, if the plaintiff’s injury can be adequately redressed with a less severe remedy, ‘recourse to the additional and extraordinary relief of an injunction’ is not warranted.” *Id.* (quoting *Monsanto*, 561 U.S. at 166); *see also id.* at \*14 (denying request for injunctive relief despite three of the four *eBay* factors weighing in favor of an injunction, finding that “the final three factors do not outweigh the absence of irreparable harm”). Likewise, a patentee’s general “assertion that the public interest favors a strong patent system . . . is insufficient to compel an injunction.” *XpertUniverse, Inc. v. Cisco Sys., Inc.*, C.A. No. 09-157-RGA, 2013 WL 6118447, at \*13 (D. Del. Nov. 20, 2013) (citing *ActiveVideo Networks, Inc. v. Verizon Commc’ns, Inc.*, 694 F.3d 1312, 1341 (Fed. Cir. 2012)).

#### **D. Pre-Judgment and Post-Judgment Interest**

In the PureWick I litigation, the parties did not include these topics as part of the Joint Pre-Trial Order, instead briefing it as a requested relief in post-judgment motions. Sage proposes the same should it be necessary.

*With regard to prejudgment interest*, a court can “limit prejudgment interest, or...deny it altogether,” where “the patent owner has been responsible for undue delay in prosecuting the lawsuit.” *Gen. Motors v. Devex*, 461 U.S. 648, 657 (1983). Here, PureWick delayed for years in filing suit, which warrants denial. *Crystal Semiconductor v. TriTech Microelecs.* 246 F.3d 1336, 1362 (Fed. Cir. 2001) (no prejudgment interest for 2-year delay). Moreover, while courts have

awarded the prime rate, many have found the Treasury bill rate compounded annually (see 28 U.S.C. § 1961) adequately compensates. *Sun Ship, v. Matson Nav.*, 785 F.2d 59, 63 (3d Cir. 1986); *Symbol Techs., Inc. v. Proxim*, No. 01-801-SLR, 2004 WL 1770290, at \*10 (D. Del. July 28, 2004); *Verinata Health, v. Ariosa Diags.*, No. 12-cv-05501-SI, 2018 WL 4849681, at \*2 (N.D. Cal. Oct. 4, 2018). That rate is appropriate if a plaintiff fails to show it “borrowed money at a higher rate...or...a causal connection between any borrowing and the loss of the use of the money awarded.” *Laitram v. NEC*, 115 F.3d 947, 955 (Fed. Cir. 1997).

***With regard to post-judgment interest***, its availability at the statutorily-mandated rate depends on post-trial briefing and appeals.

PTX No.	Title	Date	Beg. Bates No.	End Bates No.	Depo. Ex. No.	Objections
PTX-001	WITHDRAWN					
PTX-002	B. Blabas lab notebook of meetings, general notes and projects at Sage	11/14/2016	SAGE00026067	SAGE00026138	Blabas Ex. 7, Blabas Ex. 7 (2023)	DAUB, Duplicative, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-003	Notes from B. Blabas re PureWick product and testing re same	11/18/2016	SAGE00026582	SAGE00026588	Blabas Ex. 8	DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-004	Power presentation of Sage NPD Process: PrimaFit Product Launch	N/A	SAGE00033788	SAGE00033788	Blabas Ex. 9	DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-005	Segue Prototyping - B. Blabas	N/A	SAGE00025072	SAGE00025072	Blabas Ex. 10, Blabas Ex.	DAUB, MIL1, 401, 402, 403, 801, 802
PTX-006	B. Blabas notes of testing PureWick products with Ryan Alvarez	N/A	SAGE00026449	SAGE00026453	Blabas Ex. 11	DAUB, MIL1, 106, 401, 402, 403, 801, 802, 901
PTX-007	B. Blabas lab notebook reagrding project Segue	N/A	SAGE00026139	SAGE00026201	Blabas Ex. 14	DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802
PTX-008	PrimaFit External Urine Management System for females sample (S400)	N/A	SAGE00040003	SAGE00040003	Blabas Ex. 21	DAUB, MIL1, 401, 402, 403, 801, 802
PTX-009	Sage Urine Management System - Launch Guide October 2017	10/00/2017	SAGE00025676	SAGE00025676	Paskal Ex. 27	DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-010	Sage customer/hospital trials	N/A	SAGE00025688	SAGE00025688	Paskal Ex. 28	DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-011	Stryker - 2020 NASM PrimaFit Workshop presentation	N/A	SAGE00039889	SAGE00039889	Paskal Ex. 31	DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-012	Partial outline of a presentation regarding product information and basic understading of the device	N/A	SAGE00025671	SAGE00025675	Paskal Ex. 32	DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-013	Email from K. Paskal re 2021 PrimaFit revenue	10/20/2020	SAGE00040648	SAGE00040648	Paskal Ex. 33	DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-014	PrimaFit 2.0 Internal presentation	N/A	SAGE00040769	SAGE00040772	Paskal Ex. 34	DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-015	PrimaFit 2.0 Summary including financial metrics	N/A	SAGE00040419	SAGE00040419	Paskal Ex. 36	106, 401, 402, 403, 602, 801, 802, 901
PTX-016	PrimaFit 2.0 Project Summary (Financial Summary)	N/A	SAGE00040450	SAGE00040462	Paskal Ex. 51	401, 402, 403, 602, 801, 802, 901
PTX-017	PureWick San Diego Hospital Experiences	N/A	SAGE00023796	SAGE00023797	Sexton Ex. 55	DAUB, MIL1, MIL2, 401, 402, 403, 602, 801, 802, 901
PTX-018	Stryker - PrimaFit 2.0 project team update/presentation	N/A	SAGE00037128	SAGE00037136	Sexton Ex. 73	106, 401, 402, 403, 602, 801, 802, 901
PTX-019	Sage PrimaFit 2.0 schematic	3/5/2020	SAGE00034755	SAGE00034761	Sexton Ex. 74	401, 402, 403, 602, 801, 802
PTX-020	Sage Products, Mutual Confidentiality Agreement between Sage Products, LLC and PureWick	7/5/2016	SAGE00028280	SAGE00028282	Alexander Ex. 4	DAUB, MIL1, MIL2, 401, 402, 403, 602, 901
PTX-021	Email from K. Sexton to G. Davis, et al. re PureWick	6/17/2016	SAGE00035166	SAGE00035166	Alexander Ex. 6; Bobay Ex. 2	Duplicative, MIL2, MIL3, 401, 402, 403, 602, 801, 802
PTX-022	Sage PrimaFit NPD process timeline	N/A	SAGE00035988	SAGE00035988	Alexander Ex. 18	DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-023	Email from J. Bobay to D. Bolt re Financials follow-up	7/29/2016	PUREWICK_0063740	PUREWICK_0063742	Bobay Ex. 8	DAUB, MIL1, MIL2, 106, 401, 402, 403, 801, 802, 901
PTX-024	Email from J. Bobay to D. Bolt, et al. re PureWick External Female Catheter	7/29/2016	PUREWICK_0064060	PUREWICK_0064062	Bobay Ex. 9	DAUB, MIL1, MIL2, 106, 401, 402, 403, 801, 802, 901
PTX-025	Email from J. Bobay to C. Newton, et al. re Follow-Up Discussion	6/8/2016	PUREWICK_0063743	PreWick_0063744	Bobay Ex. 10	DAUB, MIL2, 106, 401, 402, 403, 801, 802, 901
PTX-026	Email from J. Bobay to M. Jackson and C. Newton re Due Diligence and Trials	8/4/2016	PUREWICK_0063734	PUREWICK_0063737	Bobay Ex. 11	DAUB, MIL1, MIL2, 106, 401, 402, 403, 801, 802, 901
PTX-027	Email from M. Jackson to J. Bobay re PureWick Silicone Wick	9/15/2016	PUREWICK_0063879	PUREWICK_0063880	Bobay Ex. 14	DAUB, MIL1, MIL2, 106, 401, 402, 403, 801, 802, 901
PTX-028	Email from S. Talbot to J. Bobay, et al. re PureWick - materials for discussion of patent portfolio 9/21 2 PM CT	9/19/2016	PUREWICK_0063790	PUREWICK_0063887	Bobay Ex. 15	DAUB, MIL2, MIL3, 106, 401, 402, 403, 801, 802, 901
PTX-029	MDDI - 10 Finalists Chosen For Dare-to-Dream Medtech Design Challenge (PureWick)	10/17/2016	PUREWICK_0021742	PUREWICK_0021743	Forehand Ex. 111	401, 402, 403, 602, 801, 802, 901
PTX-030	Photograph of various devices	N/A	PUREWICK_0019770	PUREWICK_0019770	Forehand Ex. 114	401, 402, 403, 901
PTX-031	Photograph of various devices	N/A	PUREWICK_0019767	PUREWICK_0019767	Forehand Ex. 115	401, 402, 403, 901
PTX-032	Agreement and Plan of Merger by and Among C.R. Bard, Inc., Candle Acquisition Corp., PureWick Corporation, and the Securityholder Representative (Execution Copy)	6/16/2017	PUREWICK_0020343	PUREWICK_0020446	Burn Ex. 298	DAUB, Duplicative, MIL2, 401, 402, 403, 602, 801, 802, 901
PTX-033	Photograph of prototype	N/A	PUREWICK_0030276	PUREWICK_0030277	R. Newton Ex. 320	401, 402, 403, 602, 901
PTX-034	Email from R. Newton to M. Jackson, J. Forehand, F. Phillips, and C. Newton re PureWick test BD - Female External Catheter Head to Head Evaluations presentation	5/20/2014	NEWTON_0001141	NEWTON_0001143	R. Newton Ex. 332	106, 401, 402, 403, 602, 801, 802, 901
PTX-035	Measuring Safety, Effectiveness and Ease of Use of PureWick in the Management of Urinary Inconvenience in Bedbound Women: Case Studies by C. Newton, E. Call, and K. Chan	6/5/2018	PUREWICK_0035383	PUREWICK_0035397	PW II Skelton 18	DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-036	Excel of PureWick user results of products	1/8/2016	PUREWICK_0014315	PUREWICK_0014325		401, 402, 403, 602, 801, 802, 901
PTX-037	Stryker - PrimaFit 1.5 Redesign Project Status Update presentation	N/A	PUREWICK_0017094	PUREWICK_0017094		DAUB, MIL2, 401, 402, 403, 602, 801, 802, 901
PTX-038	Photograph of PrimaFit 2.0 front	N/A	SAGE00030401	SAGE00030401		DAUB, MIL1, 106, 401, 402, 403, 801, 802, 901
PTX-039	Photograph of PrimaFit 2.0 back	N/A	SAGE00030402	SAGE00030402		DAUB, Duplicative, 401, 402, 403, 901
PTX-040	Isthmus - PrimaFit 2.0 Functional Specification	8/3/2020	SAGE00030411	SAGE00030463		DAUB, 401, 402, 403, 602, 801, 802, 901
PTX-041	NPD to PE Knowledge Transfer Summary Report for PrimaFit	N/A	SAGE00034173	SAGE00034183	Cole Ex. 61	DAUB, Duplicative, MIL1, 401, 402, 403, 801, 802
PTX-042	Project PrimaFit 2.0 notes	2/26/2019	SAGE00037268	SAGE00037268		106, 401, 402, 403, 602, 801, 802, 901
PTX-043	Tri Medical Center - Patient Care Services Policy Manual for PureWick Female Urinary	N/A	PUREWICK_0014456	PUREWICK_0014458		401, 402, 403, 602, 801, 802, 901
PTX-044	PureWick, Inc. questionnaire	N/A	PUREWICK_0016253	PUREWICK_0016262		401, 402, 403, 801, 802, 901
PTX-045	PureWick Inc. - Urinary Incontinence Manament for Women Simple, Safe, Successful Executive	N/A	PUREWICK_0020909	PUREWICK_0020912		401, 402, 403, 801, 802, 901
PTX-046	Project Candle update	9/13/2016	SAGE00028354	SAGE00028360		DAUB, MIL1, MIL2, 401, 402, 403, 602, 801, 802, 901
PTX-047	Purewick Selected as a Winner of CONNECT'S 28th Annual Most Innovative New Product	12/2/2015	PUREWICK_0017511	PUREWICK_0017512		401, 402, 403, 801, 802, 901
PTX-048	History of Product Design	N/A	PUREWICK_0020181	PUREWICK_0020186		DAUB, MIL3, 401, 402, 403, 801, 802, 901
PTX-049	PureWick Inc. Successful Incontinence Management for Women - Business Plan	3/20/2016	PUREWICK_0025947	PUREWICK_0025947		Duplicative, 401, 402, 403, 602, 801, 802, 901
PTX-050	Excel of user results in 2013 and 2014	N/A	SAGE00040001	SAGE00040001		Duplicative, MIL3, 401, 402, 403, 801, 802, 901
PTX-051	Sample of PrimaFit Device	N/A	SAGE00040002	SAGE00040002		DAUB, MIL1, 401, 402, 403, 801, 802
PTX-052	Sample of PrimaFit Device	N/A	SAGE00040002	SAGE00040002		DAUB, MIL1, 401, 402, 403, 801, 802
PTX-053	Email from K. Pawlik to C. Newton, et al. re PureWick DD	12/26/2015	NEWTON_0002851	NEWTON_0002892		401, 402, 403, 602, 801, 802, 901
PTX-054	PureWick Inc. Successful Incontinence Management for Women	N/A	PUREWICK_0030864	PUREWICK_0030864		Duplicative, 401, 402, 403, 801, 802, 901
PTX-055	PureWick News and Updates	N/A	PUREWICK_0030864	PUREWICK_0030864		401, 402, 403, 801, 802, 901
PTX-056	Photo of PureWick prototypes	N/A	PUREWICK_0019766	PUREWICK_0019766		DAUB, MIL3, 401, 402, 403, 801, 802, 901
PTX-057	PureWick invention story video	N/A	SANCHEZ000006	SANCHEZ000006		DAUB, MIL3, 401, 402, 403, 801, 802, 901
PTX-058	U.S. Patent No. 10,226,376	3/12/2019	PUREWICK_0001884	PUREWICK_0001940		
PTX-059	U.S. Patent No. 10,390,989	8/27/2019	PUREWICK_0001941	PUREWICK_0001982		
PTX-060	File History No. 10,226,376 - App. No. 15611587	3/12/2019	PUREWICK_0000124	PUREWICK_0000823		106
PTX-061	File History No. 10,390,989 - App. No. 15260103	8/27/2019	PUREWICK_0000824	PUREWICK_0001876		106
PTX-062	File History of App. No. 14/625,469	2/18/2015	PUREWICK_0001983	PUREWICK_0002111		DAUB, MIL3, 401, 402, 403
PTX-063	File History of App. No. 61/955,537	3/19/2014	PUREWICK_0002112	PUREWICK_0002184		DAUB, MIL3, 401, 402, 403
PTX-064	U.S. Patent Application Publication No. US2017/0348139 - 968 application	12/7/2017	PUREWICK_0007227	PUREWICK_0007231		DAUB, MIL3, 401, 402, 403
PTX-065	U.S. Patent Application Publication No. US2017/0252202 - 591 application	9/7/2017	PUREWICK_0013403	PUREWICK_0013407		DAUB, MIL3, 401, 402, 403
PTX-066	File History of App. No. 62/084,078	11/25/2014	PUREWICK_0006789	PUREWICK_0006853		DAUB, MIL3, 401, 402, 403
PTX-067	File History of App. No. 15/171,968	6/2/2016	PUREWICK_0004384	PUREWICK_0006175		DAUB, MIL1, MIL3, 106, 401, 402, 403, 801, 802, 901
PTX-068	File History of App. No. 14/952,591	11/25/2015	PUREWICK_0002442	PUREWICK_0004383		DAUB, MIL1, MIL3, 106, 401, 402, 403, 801, 802, 901
PTX-069	File History of PCT/US2016/49274	8/26/2016	PUREWICK_0002185	PUREWICK_0002313		DAUB, MIL3, 401, 402, 403
PTX-070	Email from K. Sexton to B. Blabas and R. Alvarez re Project Segue Recap	11/29/2016	SAGE00026445	SAGE00026445	Blabas Ex. 5	DAUB, MIL1, 106, 401, 402, 403, 801, 802
PTX-071	Project Segue Design Review for Field Evaluations - B. Blabas	7/18/2017	SAGE00025099	SAGE00025100	Blabas Ex. 12	DAUB, MIL1, 106, 401, 402, 403, 801, 802
PTX-072	B. Blabas lab notebook reagrding project Segue	N/A	SAGE00026372	SAGE00026413	Blabas Ex. 13	DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-073	Project Charter for PrimaFit 2.0	10/15/2019	SAGE00034065	SAGE00034067	Blabas Ex. 15; Sexton Ex.	106, 401, 402, 403, 602, 801, 802
PTX-074	PrimaFit schematic	7/31/2017	SAGE00028150	SAGE00028152	Blabas Ex. 16	DAUB, MIL1, 401, 402, 403, 801, 802
PTX-075	Project Segue Manufacturing presentation by B. Blabas	8/3/2017	SAGE00024614	SAGE00024614	Blabas Ex. 17	DAUB, MIL1, 106, 401, 402, 403, 801, 802, 901
PTX-076	Sage Products - SDCU Standard Operating Procedure - PrimaFit (UM1) operating procedure	12/2/2019	SAGE00000478	SAGE00000487	Blabas Ex. 18	DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802
PTX-077	Sage Schematic of Sage Female External Urine Collection Device	10/18/2017	SAGE00000149	SAGE00000151	Blabas Ex. 19	DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-078	Sage Material Specification Doc. No. R60006-Spec	10/12/2017	SAGE00000241	SAGE00000241	Blabas Ex. 20	DAUB, MIL1, 106, 401, 402, 403, 801, 802
PTX-079	Sage PrimaFit External Urine Management System for Females instructions for use	N/A	N/A	N/A	Blabas Ex. 23	DAUB, MIL1, 401, 402, 403, 801, 802



PTX No.	Title	Date	Beg. Bates No.	End Bates No.	Depo. Ex. No.	Objections
PTX-081	Email from K. Buckstaff to G. Ward, et al., re Sage Urinary Management System	10/23/2017	SAGE00037788	SAGE00037789	Paskal Ex. 25	DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-082	Stryker 2021 Urinary Management Annual Marketing Plan	N/A	SAGE00040693	SAGE00040729	Paskal Ex. 26	DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-083	Stryker - Sage Female ECD Sell Test Account Management	9/5/2017	SAGE00027300	SAGE00027301	Paskal Ex. 29	DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-084	Email from K. Haefner to K. Shamblin, et al. re Adventist Female Catheter Trials	10/5/2017	SAGE00037614	SAGE00037615	Paskal Ex. 30	DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-085	Excel of MKT projections from 2018 thru 2022	11/29/2018	SAGE00027583	SAGE00027583	Paskal Ex. 37	DAUB, MIL1, 106, 401, 402, 403, 801, 802, 901
PTX-086	Market projections for PrimaFit	1/8/2019	N/A	N/A	Paskal Ex. 38	DAUB, MIL1, 106, 401, 402, 403, 801, 802, 901
PTX-087	Excel of PrimaFit 2.0 showing demand	5/1/2020	SAGE00027671	SAGE00027671	Paskal Ex. 39	401, 402, 403, 602, 801, 802, 901
PTX-088	Excel of PureWick Sales Model	N/A	SAGE00028298	SAGE00028298	Paskal Ex. 40	DAUB, MIL2, 401, 402, 403, 801, 802, 901
PTX-089	Email from D. Cervenka to K. Gundlach, et al. re Female External Catheter PrimaFit 5400SP	2/20/2019	SAGE00039208	SAGE00039209	Paskal Ex. 46	DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-090	Email from K. Buckstaff to D. Cervenka to External Female Catheter - Implementation Planning	11/19/2020	SAGE00040788	SAGE00040791	Paskal Ex. 47	DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-091	List of hospitals that purchased PureWick wicks	N/A	SAGE00028291	SAGE00028291	Sexton Ex. 56	DAUB, MIL2, 106, 401, 402, 403, 801, 802, 901
PTX-092	PureWick Steps to Successful Hospital Implementation	N/A	SAGE00028896	SAGE00028897	Sexton Ex. 57	DAUB, MIL2, 401, 402, 403, 801, 802, 901
PTX-093	PureWick Management presentation	N/A	SAGE00028915	SAGE00028945	Sexton Ex. 58	DAUB, MIL2, 401, 402, 403, 801, 802, 901
PTX-094	PureWick Trial of product to understand the caregiver and patient usage, and overall acceptance to its protocol.	8/23/2016	SAGE00023798	SAGE00023798	Sexton Ex. 59	DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-095	Field Evaluation data for Project Segue	3/27/2017	SAGE00023810	SAGE00023810	Sexton Ex. 61	DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-096	Email from T. Boersma to K. Sexton, et al., re Project candle - Segway	7/12/2017	SAGE00035249	SAGE00035258	Sexton Ex. 62	DAUB, MIL1, MIL2, 106, 401, 402, 403, 602, 801, 802, 901
PTX-097	Bard PureWick External Female Catheter Trial 2017 Product Evaluation	N/A	SAGE00035536	SAGE00035537	Sexton Ex. 63; Alexander Ex. 19	DAUB, MIL1, MIL2, 106, 401, 402, 403, 602, 801, 802, 901
PTX-098	Sage Female ECD Sell Test Plan - To determine positioning and price point for Sage Female ECD	N/A	SAGE00023973	SAGE00023973	Sexton Ex. 65	DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-099	SLT Meeting PrimaFit Status Update	7/16/2018	SAGE00028998	SAGE00028998	Sexton Ex. 69; Thompson Ex. 11	DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-100	Sage Product Line Market Shares with GHX Data	3/18/2019	SAGE00029393	SAGE00029491	Sexton Ex. 70	DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-101	Market Inclusion List: PrimaFit® in 2019. Source: GHX market share intelligence trending report.	7/15/2019	SAGE00029704	SAGE00029704	Sexton Ex. 71	DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-102	Excel of Sage Net Sales 12 Month History for Product Class 60	N/A	SAGE00000488	SAGE00000488	Thompson Ex. 2	DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-103	Excel of Prima and Primo Lifetime Eaches by Account	7/27/2020	SAGE00027258	SAGE00027258	Thompson Ex. 3; Thompson Ex. 5	DAUB, MIL1, 106, 401, 402, 403, 801, 802, 901
PTX-104	Excel of PrimoFit and PrimaFit product Net Sales, Net Cases, and Standard Cost	N/A	SAGE00043464	SAGE00043464	Thompson Ex. 6	DAUB, MIL1, 106, 401, 402, 403, 801, 802, 901
PTX-105	Defendant's Fourth Supplemental Objections and Responses to Plaintiff's Interrogatories (Nos. Sage Project Segue information	3/16/2021	N/A	N/A	Thompson Ex. 9	MIL1, 401, 402, 403, 801, 802
PTX-106	Stryker - Sage portfolio Update	N/A	SAGE00029359	SAGE00029391	Thompson Ex. 10; Sexton Ex. 70, PW II Ulreich Ex. 87	DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-107	Excel associated with Sage costs for research of a new product	9/23/2019	SAGE00036528	SAGE00036590	Thompson Ex. 12; Ulreich	401, 402, 403, 801, 802
PTX-108	Excel of Sage Net Sales 12 Month History for Product Class 60	N/A	SAGE00029003	SAGE00029003	Thompson Ex. 13	DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-109	Capital Expenditure Request for PrimaFit 2.0	5/18/2020	SAGE00040435	SAGE00040447	Ulreich Ex. 2	401, 402, 403, 602, 801, 802, 901
PTX-110	Email from S. Jirafe to D. Ulreich copying K. Sexton re PrimFit 2.0 Design and Marketing	4/9/2020	SAGE00037157	SAGE00037158	Ulreich Ex. 3, Jirafe Ex. 65	401, 402, 403, 801, 802
PTX-111	Stryker - Sage Key Projects Review	9/21/2020	SAGE00034839	SAGE00034917	Ulreich Ex. 5	401, 402, 403, 801, 802
PTX-112	Stryker - Project Overview PrimaFit 2.0	7/14/2019	SAGE00030464	SAGE00030464	Ulreich Ex. 6	DAUB, MIL1, 106, 401, 402, 403, 801, 802, 901, Mistake
PTX-113	PrimaFit 2.0 Design Drawing	7/10/2019	SAGE00030403	SAGE00030408	Ulreich Ex. 7, PW II Ulreich	401, 402, 403, 801, 802
PTX-114	Stryker PrimaFit Design Drawing	4/1/2019	SAGE00000131	SAGE00000134	Ulreich Ex. 8	DAUB, MIL1, 401, 402, 403, 901
PTX-115	Photo of PrimaFit 2.0 components	N/A	SAGE00030410	SAGE00030410	Ulreich Ex. 9	DAUB, MIL1, 401, 402, 403, 602, 901
PTX-116	Photo of PrimaFit components	N/A	SAGE00030409	SAGE00030409	Ulreich Ex. 10	DAUB, MIL1, 401, 402, 403, 602, 901
PTX-117	Photo of front of PrimaFit 2.0	N/A	N/A	N/A	Ulreich Ex. 11	401, 402, 403
PTX-118	Photo of back of PrimaFit 2.0	N/A	N/A	N/A	Ulreich Ex. 12	401, 402, 403
PTX-119	Email from P. Polanco to D. Ulreich, et al. re PrimaFit 2.0 New Product Code or Existing Product Code RA Perspective	1/31/2020	SAGE00037025	SAGE00037026	Ulreich Ex. 13, Polanco Ex. 2	DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802
PTX-120	New Product Development Technical Report - PrimFit 2.0 Catch and Retention Testing	7/15/2019	SAGE00034072	SAGE00034089	Ulreich Ex. 14	106, 401, 402, 403, 801, 802, 901
PTX-121	Email from P. Polanco to D. Ulreich, et al. re PrimaFit 2.0 conversation about biocompatibility	6/19/2019	SAGE00036204	SAGE00036204	Ulreich Ex. 16	401, 402, 403, 801, 802
PTX-122	PureWick Inc. Cost Benefits information with Post-It note	N/A	SAGE00027147	SAGE00027149	Alexander Ex. 5	DAUB, MIL2, MIL3, 401, 402, 403, 602, 801, 802, 901
PTX-123	PureWick Acquisition Opportunity steps	6/16/2016	SAGE00026019	SAGE00026019	Alexander Ex. 7	DAUB, Duplicative, MIL2, MIL3, 106, 401, 402, 403, 602, 801, 802
PTX-124	Email from T. Keaty to J. Layer re Purewick	7/6/2016	SAGE00026037	SAGE00026037	Alexander Ex. 8	DAUB, MIL2, MIL3, 401, 402, 403, 602, 801, 802
PTX-125	PureWick In-Person Meeting	7/28/2016	SAGE00025842	SAGE00025843	Alexander Ex. 9	DAUB, MIL2, MIL3, 401, 402, 403, 602, 801, 802
PTX-126	Handwritten notes re PureWick call	10/19/2016	SAGE00026029	SAGE00026029	Alexander Ex. 10	DAUB, MIL1, MIL2, 106, 401, 402, 403, 602, 801, 802, 901
PTX-127	PureWick San Diego Hospital Experiences	N/A	SAGE00027131	SAGE00027132	Alexander Ex. 11	DAUB, Duplicative, MIL2, MIL3, 106, 401, 402, 403, 602, 801, 802
PTX-128	Email from J. Layer to B. Sleboda, et al. re Project Candle Model	10/18/2016	SAGE00028590	SAGE00028590	Alexander Ex. 12	MIL2, 106, 401, 402, 403, 602, 801, 802
PTX-129	Email from S. Talbot to J. Bobay, et al. re PureWick - materials for discussion of patent portfolio 9/21 with attachments	9/19/2016	SAGE00043475	SAGE00043475	Alexander Ex. 13	DAUB, MIL2, MIL3, 106, 401, 402, 403, 602, 801, 802
PTX-130	US Patent No. 10,390,989	8/27/2019	N/A	N/A	Alexander Ex. 14	dupe
PTX-131	PureWick Patent Portfolio Urinary Drainage - Female	9/13/2016	SAGE00043551	SAGE00043551	Alexander Ex. 15	DAUB, MIL2, 401, 402, 403, 602, 801, 802
PTX-132	Stryker NPD Limited Launch Design Approval Form for project 85	8/20/2019	SAGE00028163	SAGE00028192	Alexander Ex. 16	DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-133	Email from G. Davis to K. Sexton re Project Segue update	1/17/2017	SAGE00026657	SAGE00026657	Alexander Ex. 17	DAUB, MIL1, MIL2, 401, 402, 403, 602, 801, 802
PTX-134	Email from K. Sexton and R. Alvarez, et al. re Segue Project Weekly Update	5/1/2017	SAGE00026429	SAGE00026429	Alexander Ex. 20	DAUB, MIL1, 401, 402, 403, 602, 801, 802
PTX-135	Email from K. Sexton to J. Allen, et al. re IFU	9/21/2017	SAGE00027413	SAGE00027414	Alexander Ex. 21, Cole Ex. 22	DAUB, MIL1, 401, 402, 403, 801, 802
PTX-136	Market Intelligence: Field Summary	10/23/2018	SAGE00033812	SAGE00033813	Alexander Ex. 22	DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-137	Email from M. Solcan to K. Sexton re MetroHealth PrimaFit 2.0	2/14/2020	SAGE00037056	SAGE00037056	Alexander Ex. 23; Sexton	DAUB, MIL1, 401, 402, 403, 602, 801, 802
PTX-138	Email from J. Bobay to C. Newton and H. Haynes re Mutual CA with attachment of Mutual Confidentiality Agreement between Sage Products, LLC and PureWick Inc.	7/6/2017	PUREWICK_0063999	PUREWICK_0064004	Bobay Ex. 3	DAUB, MIL2, 106, 401, 402, 403, 602, 801, 802, 901
PTX-139	Email from C. Newton to J. Bobay re: management presentation	7/6/2016	PUREWICK_0064153	PUREWICK_0064154	Bobay Ex. 4	DAUB, MIL2, 106, 401, 402, 403, 801, 802, 901
PTX-140	PureWick management presentation	N/A	PUREWICK_0064155	PUREWICK_0064155	Bobay Ex. 5	DAUB, MIL1, MIL2, MIL3, 401, 402, 403, 801, 802, 901
PTX-141	Email from C. Zbierski to J. Bobay and K. Sexton re Research questions	7/20/2016	SAGE00035197	SAGE00035199	Bobay Ex. 7	Duplicative, MIL1, MIL2, 401, 402, 403, 602, 801, 802, 901
PTX-142	PureWick Field Work Plan by J. Bobay	8/8/2016	SAGE00028247	SAGE00028248	Bobay Ex. 12	DAUB, MIL2, 401, 402, 403, 801, 802
PTX-143	Email from J. Bobay to M. Jackson, et al. re Purewick	8/26/2016	PUREWICK_0064066	PUREWICK_0064066	Bobay Ex. 13	DAUB, MIL2, 106, 401, 402, 403, 801, 802, 901
PTX-144	Email from M. Stankovic to J. Bobay re YTD/MTD sales by account with attachment re Hospital Sales Excel	9/21/2016	PUREWICK_0019593	PUREWICK_0019595	Bobay Ex. 16	DAUB, MIL1, MIL2, 106, 401, 402, 403, 602, 801, 802, 901
PTX-145	Excel sheet summarizing hospital product sales	N/A	PUREWICK_0019596	PUREWICK_0019596	Bobay Ex. 17	DAUB, MIL2, 401, 402, 403, 801, 802, 901
PTX-146	Email from M. Stankovic to J. Bobay re PureWick	10/11/2016	PUREWICK_0026669	PUREWICK_0026672	Bobay Ex. 18	DAUB, MIL1, MIL2, MIL3, 106, 401, 402, 403, 602, 801, 802, 901
PTX-147	Email from C. Terry to J. Bobay, et al. re Candle - Weekly Update	10/14/2016	SAGE00028569	SAGE00028570	Bobay Ex. 22	DAUB, MIL1, MIL2, 401, 402, 403, 602, 801, 802, 901
PTX-148	Email from B. Sleboda to J. Layer, et al. re Project Candel Model	10/18/2016	SAGE00028588	SAGE00028588	Bobay Ex. 23	DAUB, Duplicative (live witness), MIL1, MIL2, 106, 401, 402, 403, 602, 801, 802, 901
PTX-149	Excel evaluation model of Project Candle	N/A	SAGE00028589	SAGE00028589	Bobay Ex. 24	DAUB, MIL2, 401, 402, 403, 801, 802, 901
PTX-150	Email from J. Bobay to C. Newton re PureWick - Market pie chart	10/27/2016	PUREWICK_0064055	PUREWICK_0064057	Bobay Ex. 25	DAUB, MIL2, 106, 401, 402, 403, 801, 802, 901
PTX-151	Email from J. Layer to J. Bobay re: Sales through November	12/3/2016	SAGE00028692	SAGE00028693	Bobay Ex. 26	DAUB, MIL1, MIL2, 106, 401, 402, 403, 602, 801, 802, 901



PTX No.	Title	Date	Beg. Bates No.	End Bates No.	Depo. Ex. No.	Objections
PTX-152	Email from J. Bobay to J. Layer re GP Indication of Interest	N/A	SAGE00025975	SAGE00025977	Bobay Ex. 27	DAUB, MIL1, MIL2, 106, 401, 402, 403, 602, 801, 802, 901
PTX-153	Email from G. Davis to R. Alvarez, et al. re Project Segue update with hand written notes	1/17/2017	SAGE00027437	SAGE00027437	Bobay Ex. 28	DAUB, MIL1, MIL2, 401, 402, 403, 602, 801, 802, 901
PTX-154	Fifth Supplemental Responses to Sage Products' First Set of Interrogatories (Nos. 1-11) to	3/18/2021	N/A	N/A	Zani Ex. 55	DAUB, MIL1, MIL2, 401, 402, 403, 602, 801, 802
PTX-155	Excel of PureWick product sales	N/A	PUREWICK_0064470	PUREWICK_0064470	Zani Ex. 57	106, 401, 402, 403, 602, 801, 802, 901
PTX-156	Excel of Act units - PureWick products	N/A	PUREWICK_0064471	PUREWICK_0064471	Zani Ex. 58	401, 402, 403, 602, 801, 802, 901
PTX-157	Excel of PureWick cost of the product codes	N/A	PUREWICK_0033347	PUREWICK_0033347	Zani Ex. 59	106, 401, 402, 403, 602, 801, 802, 901
PTX-158	P&L Statement for PureWick for 2018 and 2017	N/A	PUREWICK_0064463	PureWick_0064463	Zani Ex. 60	401, 402, 403, 601, 802, 901
PTX-159	BMD Legal to Mgmt P&L Walkacross - P12, 2019, YTD (REDACTED)	6/15/2020	PUREWICK_0064464	PUREWICK_0064465	Zani Ex. 61	106, 401, 402, 403, 601, 802, 901
PTX-160	BMD Legal to Mgmt P&L Walkacross - P12, 2020, YTD (REDACTED)	10/7/2020	PUREWICK_0064466	PUREWICK_0064467	Zani Ex. 62	106, 401, 402, 403, 601, 802, 901
PTX-161	Project Candle Preliminary Management Discussion Pack	01/00/2017	PUREWICK_0017843	PUREWICK_0017883	Zani Ex. 63	
PTX-162	Bard - Memo from S. Skelton re Project Candle Market Research Summary	8/6/2017	PUREWICK_0027822	PUREWICK_0027832	Zani Ex. 70, D's Depo Ex. 70	DAUB, MIL2, 106, 401, 402, 403, 601, 802, 901
PTX-163	Email from N. Austerman to P. Zani, et al re PureWick NRL with attachments Compiled Purewick Latex Free Accounts and images.	10/4/2018	PUREWICK_0034364	PUREWICK_0034365	Zani Ex. 83	DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-164	Email from P. Zani to C. Aszmus, et al. re Sage vs Us	10/12/2017	PUREWICK_0034486	PUREWICK_0034486	Zani Ex. 88	DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-165	Due Diligence Report Project PureWick	3/15/2017	PUREWICK_0059418	PUREWICK_0059429	Gohde Ex. 125	106, 401, 402, 403, 602, 801, 802, 901
PTX-166	PureWick Sales Assumptions 2018-2032	N/A	PUREWICK_0064469	PureWick_0064469	Gohde Ex. 131	106, 401, 402, 403, 602, 801, 802, 901
PTX-167	What is Missing From Your Cauti Prevention Bundle?	N/A	PUREWICK_0033396	PureWick_0033401	Gohde Ex. 151	401, 402, 403, 602, 801, 802, 901
PTX-168	Sales: Monthly Wick Sales graph	N/A	PUREWICK_0024830	PUREWICK_0024830	Gohde Ex. 154	106, 401, 402, 403, 602, 801, 802, 901
PTX-169	Excel of PureWick products total quarterly sales 2016-2017	N/A	PUREWICK_0024837	PUREWICK_0024837	Gohde Ex. 156	106, 401, 402, 403, 602, 801, 802, 901
PTX-170	Corporate Quality Assurance Manual - Revision 07-Transfer Phase IV Post-Commercialization	N/A	PUREWICK_0056306	PUREWICK_0056312	Mann Ex. 250	106, 401, 402, 403, 602, 801, 802, 901
PTX-171	BD - PureWick Capacity Review presentation	11/21/2018	PUREWICK_0042808	PUREWICK_0042808	Mann Ex. 256	106, 401, 402, 403, 602, 801, 802, 901
PTX-172	BD - PureWick and DryDoc Capacity Update presentation	N/A	PUREWICK_0042809	PUREWICK_0042809	Mann Ex. 257	106, 401, 402, 403, 602, 801, 802, 901
PTX-173	BD - UCC Capacity Planning presentation	4/24/2020	PUREWICK_0042811	PUREWICK_0042811	Mann Ex. 259	106, 401, 402, 403, 602, 801, 802, 901
PTX-174	U.S. Patent Application Publication 2016/0367226	12/22/2016	SAGE00001019	SAGE00001025	Forehand Ex. 94	DAUB, MIL3, 401, 402, 403
PTX-175	Disclosure Schedules to the Agreement and Plan of Merger by and Among C.R. Bard, Inc., Candle Acquisition Corp., PureWick Corporation, and the Securityholder Representative	6/16/2017	PUREWICK_0015323	PUREWICK_0015361	Burn Ex. 290	
PTX-176	C.R. Bard, Inc. Valuation of Certain Assets and Liabilities of PureWick, Inc. as of May 10, 2017	5/10/2017	PUREWICK_0064638	PUREWICK_0064654	Burn Ex. 301	DAUB, MIL2, 401, 402, 403, 601, 802
PTX-177	PureWick Inc. Successful Incontinence Management for Women production description	N/A	PUREWICK_0014538	PUREWICK_0014539	R. Newton Ex. 311	401, 402, 403, 601, 802, 901
PTX-178	Wick Photograph	N/A	PUREWICK_0030281	PUREWICK_0030282	R. Newton Ex. 312	401, 402, 403, 602, 901
PTX-179	Photograph of PureWick device (WICK# 301-15)	N/A	PUREWICK_0030279	PUREWICK_0030279	R. Newton Ex. 313	401, 402, 403, 602, 901
PTX-180	Photograph of PureWick Blue Tape Wick (Item #625)	N/A	PUREWICK_0035495	PUREWICK_0035495	R. Newton Ex. 314	401, 402, 403, 602, 901
PTX-181	Photograph of PureWick Blue Tape Wick (Item #625)	N/A	PUREWICK_0030294	PUREWICK_0030294	R. Newton Ex. 317	401, 402, 403, 602, 901
PTX-182	Email from B. Sanchez to Dr. Newton re Urine collector with attachments of photos	8/4/2009	NEWTON_0005496	NEWTON_0005496	R. Newton Ex. 322	DAUB, MIL3, 401, 402, 403, 601, 802
PTX-183	Email Chain with Kate Pawlik re DD	8/1/2015	Newton_0002687	Newton_0002687	R. Newton Ex. 344	106, 401, 402, 403, 602, 801, 802, 901
PTX-184	Averch, T. Catheter-Associated Urinary Tract Infections: Definitions and Significance in the Urologic Patient. <i>American Urological Association. 2014</i>	N/A	N/A	N/A		106, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-185	PureWick External Catheter for Women In-Service Training Guide	N/A	PUREWICK_0014327	PUREWICK_0014337		106, 401, 402, 403, 602, 801, 802, 901
PTX-186	External Catheter System Provides Effective Incontinence Management for Women Information	N/A	PUREWICK_0014362	PUREWICK_0014362		106, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-187	Bard BMD - Clinical Evaluation Report of PureWick Female External Catheter (FEC) and Dry	9/8/2017	PUREWICK_0028073	PUREWICK_0028327		106, 401, 402, 403, 602, 801, 802, 901
PTX-188	Zavodnick J, Harley C, Zabriskie K, et al. Effect of a Female External Urinary Catheter on Incidence of Catheter-Associated Urinary Tract Infection. <i>Cureus. 2020 12(10).</i>	10/23/2020	PUREWICK_EXP_0000034	PUREWICK_EXP_0000040		106, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-189	Hooton, T., et al. Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in Adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases	2/4/2010	PUREWICK_EXP_0000090	PUREWICK_EXP_0000128		106, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-190	An APIC Guide (2008) Guide to the Elimination of Catheter-Associated Urinary Tract Infections	N/A	SAGE00023918	SAGE00023959		401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-191	HICPAC - Guideline for Prevention of Catheter-Associated Urinary Tract Infections (2009)	2/15/2017	SAGE00024621	SAGE00024681		106, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-192	APIC Implementation Guide - Guide to Preventing Catheter-Associated Urinary Tract Infections	N/A	SAGE00024686	SAGE00024772		106, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-193	Lo, E., et al. Strategies to Prevent Catheter-Associated Urinary Tract Infections in Acute Care Hospitals: 2014 Update. <i>Infection Control and Hospital Epidemiology. 2014. 35(5).</i>	4/10/2014	SAGE00024773	SAGE00024789		106, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-194	Stryker - Sage MYM PrimaFit presentation	12/19/2021	SAGE00027576	SAGE00027576		DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-195	Sage Products - New product Development Report: PrimaFit In-House Volunteer Position Assessment Report	8/27/2019	SAGE00028125	SAGE00028130		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-196	Photo of 20th Most Innovative New Product Awards PureWick, Inc. for Pharmaceuticals and	N/A	NEWTON_0008146	NEWTON_0008146		401, 402, 403, 602, 801, 802, 901
PTX-197	Project Candle and Foley Alternative VOC (Navicent Health, Macon, GA)	6/27/2016	PUREWICK_0014266	PUREWICK_0014269		106, 401, 402, 403, 602, 801, 802, 901
PTX-198	Project Candle VOC (Norfolk General, Sentara Systems Norfolk, VA)	10/10/2016	PUREWICK_0014272	PUREWICK_0014274		106, 401, 402, 403, 602, 801, 802, 901
PTX-199	Email from S. Patel to V. Behrend re Dear Sheila, question on PureWick use	1/17/2017	PUREWICK_0015944	PUREWICK_0015946		106, 401, 402, 403, 602, 801, 802, 901
PTX-200	External Catheter System Provides Effective Incontinence for Women Product Information	N/A	PUREWICK_0020710	PUREWICK_0020710		106, 401, 402, 403, 602, 702, 703, 801, 802, 901, 1006
PTX-201	Bard Monthly Deep Dive Critical Care Marketing	10/00/2020	PUREWICK_0064274		Pw II Gohde Ex. 32	106, 401, 402, 403, 602, 801, 802, 901
PTX-202	Conference Program Abstracts - April 19-21, 2017 Millenium Knickerbocker Hotel, Chicago	N/A	PUREWICK_EXP_0000517	PUREWICK_EXP_0000592		106, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-203	External Catheters and Reducing Adverse Effects in the Female Inpatient - E. Glover, et al. Northwestern College Department of Nursing, Northwestern College informational chart	N/A	PUREWICK_EXP_0000625	PUREWICK_EXP_0000625		MIL3, 106, 401, 402, 403, 602, 702, 703, 801, 802, 901, 1006
PTX-204	Encouraging the Use of PureWicks - K. Kessler, University of New Hampshire informational chart	N/A	PUREWICK_EXP_0000627	PUREWICK_EXP_0000627		106, 401, 402, 403, 602, 702, 703, 801, 802, 901, 1006
PTX-205	Memorial Sloan Kettering Cancer Center & Hunter-Bellevue School of Nursing, informational chart regarding An Alternative to the Indwelling Foley Catheter in Incontinent Female	N/A	PUREWICK_EXP_0001274	PUREWICK_EXP_0001274		106, 401, 402, 403, 602, 702, 703, 801, 802, 901, 1006
PTX-206	Wound Management and Prevention, <i>Innovation in Products for People with Incontinence</i>	07/00/2017	PUREWICK_EXP_0001275	PUREWICK_EXP_0001278		106, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-207	PureWick Acquisition Opportunity report prepared by G. Davis	6/16/2016	SAGE00025928	SAGE00025928		DAUB, Duplicative, MIL1, MIL2, MIL3, 106, 401, 402, 403, 602, 801, 802, 901
PTX-208	Email from P. Nelson to C. Golden, et al. re Kaiser Meeting Highlights and next steps	8/8/2017	SAGE00026049	SAGE00026050		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-209	Survey Results from 5 Hospitals Using PureWick External Catheter for Women - Hospital Staff Agree on PureWick Benefits chart		PUREWICK_0014379	PUREWICK_0014379		106, 401, 402, 403, 602, 702, 703, 801, 802, 901, 1006
PTX-210	Ltr from P. Curry to C. Newton re Preliminary Proposal to Acquire all of the Issued and Outstanding Shares of Capital Stock of PureWick Inc. ("PureWick")	11/24/2016	PUREWICK_0015039	PUREWICK_0015041		106, 401, 402, 403, 602, 801, 802, 901
PTX-211	Agreement and Plan of Merger by and among C.R. Bard, Inc., Candle Acquisition Corp., PureWick Corporation and The Securityholder Representative	6/16/2017	PUREWICK_0015111	PUREWICK_0015214		Duplicative, 106, 401, 402, 403, 602, 801, 802, 901
PTX-212	PureWick: Wick Sales January 1-Nov 8	N/A	PUREWICK_0020448	PUREWICK_0020448		106, 401, 402, 403, 602, 801, 802, 901
PTX-213	PureWick: 2016 Sales by Quarter	N/A	PUREWICK_0020452	PUREWICK_0020452		106, 401, 402, 403, 602, 801, 802, 901
PTX-214	Sales: Monthly Wick Sales graph	N/A	PUREWICK_0024824	PUREWICK_0024824		106, 401, 402, 403, 602, 801, 802, 901
PTX-215	Sales: Total Monthly Sales	N/A	PUREWICK_0024836	PUREWICK_0024836		106, 401, 402, 403, 602, 801, 802, 901
PTX-216	PureWick External Catheter for Women - Instructions for Use	N/A	PUREWICK_0027201	PUREWICK_0027202		106, 401, 402, 403, 601, 802, 901
PTX-217	Purewick (PW) Voice of Customer: Houston	11/27/2018	PUREWICK_0027928	PUREWICK_0027934		106, 401, 402, 403, 602, 801, 802, 901
PTX-218	Innovation in Reducing CAUTI's, Pressure Ulcer Prevention & Infection Prevention, Tri-City Medical Center informational chart	N/A	PUREWICK_0032110	PUREWICK_0032110		106, 401, 402, 403, 602, 702, 703, 801, 802, 901, 1006
PTX-219	PureWick External Female Catheter presentation	N/A	PUREWICK_0032158	PUREWICK_0032180		106, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-220	Excel file of PureWick sales, carryover, and accounts	N/A	PUREWICK_0034750	PUREWICK_0034750		106, 401, 402, 403, 602, 801, 802, 901
PTX-221	Email from R. Hanson to J. Gohde re Where are you at re NPJ Project prioritization?	3/19/2018	PUREWICK_0034771	PUREWICK_0034773		106, 401, 402, 403, 602, 801, 802, 901
PTX-222	Corporate Quality Assurance Manual - Transfer Phase II Process Characterization/Gap Closure	N/A	PUREWICK_0042850	PUREWICK_0042864		106, 401, 402, 403, 602, 801, 802, 901
PTX-223	PureWick Corporation Corporate Tax Returns	12/31/2016	PUREWICK_0064473	PUREWICK_0064520		106, 401, 402, 403, 602, 801, 802, 901
PTX-224	PureWick 2017 Federal Form 1120 Tax returns	12/18/2018	PUREWICK_0064521	PUREWICK_0064548		106, 401, 402, 403, 602, 801, 802, 901
PTX-225	PureWick 2017 Federal Form 1120 Tax returns	N/A	PUREWICK_0064549	PUREWICK_0064569		106, 401, 402, 403, 602, 801, 802, 901
PTX-226	PureWick 2018 Federal Form 1120 Tax returns	N/A	PUREWICK_0064570	PUREWICK_0064598		106, 401, 402, 403, 602, 801, 802, 901
PTX-227	Draft copy of letter to PureWick Corporation from Oliva, Goddard & Wright Certified Sage Female External Continence Device product information	1/15/2018	PUREWICK_0064599	PUREWICK_0064636		106, 401, 402, 403, 602, 801, 802, 901
PTX-228	Sage Female External Continence Device product information	N/A	SAGE00023853	SAGE00023853		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-229	Sage Female External Continence Device Key Features and Benefits presentation	N/A	SAGE00023856	SAGE00023856		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-230	Excel of MKT projections from 2018 thru 2022	1/8/2019	SAGE00027593	SAGE00027593		DAUB, MIL1, 106, 401, 402, 403, 601, 802, 901
PTX-231	Sage Net Sales History of 12 Months	N/A	SAGE00028948	SAGE00028948		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-232	Sage NPJ Process: PrimaFit Product Launch presentation slides	N/A	SAGE00028988	SAGE00028988		DAUB, Duplicative (live witness), MIL1, 106, 401, 402, 403, 602, 801, 802, 901

PTX No.	Title	Date	Beg. Bates No.	End Bates No.	Depo. Ex. No.	Objections
PTX-233	Stryker - PrimaFit Status Update	10/22/2018	SAGE00029005	SAGE00029005		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-234	Stryker - Sage PrimaFit Capacity	1/10/2019	SAGE00029012	SAGE00029012		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-235	Excel of Prima and Primo SS Net Dollars	N/A	SAGE00030398	SAGE00030398		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-236	Email from B. Ohalloran to K. Paskal et al. re PrimFit 2.0 forecast	9/13/2019	SAGE00036472	SAGE00036472		106, 401, 402, 403, 602, 801, 802, 901
PTX-237	Email from K. Paskal to D. Ulreich and K. Sexton re PrimaFit 2.0 forecast	10/9/2019	SAGE00036668	SAGE00036669		106, 401, 402, 403, 602, 801, 802, 901
PTX-238	Stryker - PrimaFit 2.0 project update	N/A	SAGE00036679	SAGE00036679		DAUB, 106, 401, 402, 403, 602, 801, 802, 901
PTX-239	Sage - Project Segue presentation	N/A	SAGE00037635	SAGE00037679		Duplicative, 106, 401, 402, 403, 602, 801, 802, 901
PTX-240	Email from K. Buckstaff to E. Farrell re Comparison	5/14/2018	SAGE00038681	SAGE00038682		106, 401, 402, 403, 602, 801, 802, 901
PTX-241	PrimaFit External Urine Management System for Females	12/31/2021	SAGE00038877	SAGE00038877		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-242	Email from K. Paskal to M. Laumann and N. Alexander re Female External Catheter Update	5/22/2019	SAGE00039400	SAGE00039402		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-243	Email from B. Pickett to G. Schiming and K. Paskal re PrimaFit 2.0	1/13/2020	SAGE00039931	SAGE00039932		106, 401, 402, 403, 602, 801, 802, 901
PTX-244	Excel of Sage products Monthly Income Statement March 2021	N/A	SAGE00043555	SAGE00043555		DAUB, MIL1, 401, 402, 403, 801, 802, 901
PTX-245	Amendment to Invention Agreement between Rober Snachez and Camille Newton	5/30/2013	SANCHEZ001176	SANCHEZ001176		DAUB, MIL3, 401, 402, 403, 801, 802, 901
PTX-246	Invention Agreement between Robert Sanchez and Camille Newton	5/31/2010	SANCHEZ001201	SANCHEZ001203		DAUB, MIL3, 401, 402, 403, 801, 802, 901
PTX-247	PureWick External Female Catheter Non-Invasive, No nurse required, Up to 100% urine capture	N/A	PUREWICK_0014338	PUREWICK_0014360		106, 401, 402, 403, 602, 801, 802, 901
PTX-248	PureWick External Catheter for Women informational guide	N/A	PUREWICK_0014361	PUREWICK_0014361		106, 401, 402, 403, 602, 801, 802, 901
PTX-249	PureWick External Catheter for Women instructions for use	N/A	PUREWICK_0014365	PUREWICK_0014366		106, 401, 402, 403, 602, 801, 802, 901
PTX-250	Innovation in Reducing CAUTI's informational chart for Pressure Ulcer Prevention & Infection Prevention, Tri-City Medical Center	N/A	PUREWICK_0014368	PUREWICK_0014368	Eckert Ex. 92	106, 401, 402, 403, 602, 702, 703, 801, 802, 901, 1006
PTX-251	PureWick User Guide - External Catheter System for Women	N/A	PUREWICK_0014369	PUREWICK_0014376		106, 401, 402, 403, 602, 801, 802, 901
PTX-252	Beeson, T. and Davis, C. Urinary Management with an External Female Collection Device. <i>J. Wound, Ostomy and Continence Nurses Society</i> . 2018. 45(2): 187-189.	N/A	PUREWICK_0014380	PUREWICK_0014382		106, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-253	Bard Medical brochure letter re PureWick Female External Catheter	N/A	PUREWICK_0014387	PUREWICK_0014387		106, 401, 402, 403, 602, 801, 802, 901
PTX-254	Purewick female external catheter informational brochure	N/A	PUREWICK_0014392	PUREWICK_0014392		106, 401, 402, 403, 602, 801, 802, 901
PTX-255	Bard information guide on Purewick female external catheter	N/A	PUREWICK_0014394	PUREWICK_0014394		106, 401, 402, 403, 602, 801, 802, 901
PTX-256	Bard - The ins and out of the Purewick female external catheter brochure	N/A	PUREWICK_0014395	PUREWICK_0014395		106, 401, 402, 403, 602, 801, 802, 901
PTX-257	Whidbey Health presentation	N/A	PUREWICK_0014479	PUREWICK_0014493		106, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-258	Email from P. Zani to S. Skelton and M. Freeman re PureWick Trial Update	10/6/2017	PUREWICK_0014518	PUREWICK_0014520		106, 401, 402, 403, 602, 801, 802, 901
PTX-259	PureWick schematic of shell	7/14/2017	PUREWICK_0014540	PUREWICK_0014540		106, 401, 402, 403, 602, 801, 802, 901
PTX-260	PureWick schematic of Final Assembly	7/17/2017	PUREWICK_0014544	PUREWICK_0014544	Mann Ex. 65	106, 401, 402, 403, 602, 801, 802, 901
PTX-261	PureWick schematic of Lumen Assembly	3/15/2018	PUREWICK_0014545	PUREWICK_0014545		106, 401, 402, 403, 602, 801, 802, 901
PTX-262	PureWick schematic Sleeve Assembly	3/15/2018	PUREWICK_0014547	PUREWICK_0014547		106, 401, 402, 403, 602, 801, 802, 901
PTX-263	Bard Purewick female external catheter instructions for use	N/A	PUREWICK_0014568	PUREWICK_0014569	Morgan Ex. 52	106, 401, 402, 403, 602, 801, 802, 901
PTX-264	PureWick Management presentation	N/A	PUREWICK_0014675	PUREWICK_0014706		DAUB, Duplicative, MIL2, 401, 402, 403, 801, 802, 901
PTX-265	PureWick - Successful Incontinence Management for Women information brochure	N/A	PUREWICK_0014907	PUREWICK_0014908		Duplicative, 106, 401, 402, 403, 602, 801, 802, 901
PTX-266	Cutting CAUTI at MCNH information chart	N/A	PUREWICK_0015910	PUREWICK_0015910		106, 401, 402, 403, 602, 702, 703, 801, 802, 901, 1006
PTX-267	Deloitte - PureWick, Inc. Summary Fact Sheet	07/00/2016	PUREWICK_0017753	PUREWICK_0017753		106, 401, 402, 403, 602, 801, 802, 901
PTX-268	Deloitte - Purewick, Inc. Executive Summary	N/A	PUREWICK_0017754	PUREWICK_0017769		106, 401, 402, 403, 602, 801, 802, 901
PTX-269	Patent Assignment Cover Sheet for Application Nos. 62414963, 62485578, 1561187, and	6/00/2017	PUREWICK_0018021	PUREWICK_0018030		106, 401, 402, 403, 602, 801, 802, 901
PTX-270	Patent Assignment for US 15/260,103 and PCT/US16/049274	N/A	PUREWICK_0018158	PUREWICK_0018165		106, 401, 402, 403, 602, 801, 802, 901
PTX-271	Purewick 625 Wick, SH Item Number 100008 Biocompatibility Review	10/20/2016	PUREWICK_0019912	PUREWICK_0019966		106, 401, 402, 403, 602, 801, 802, 901
PTX-272	Failure Mode and Effect Analysis for R2P2	12/29/2016	PUREWICK_0027440	PUREWICK_0027446		106, 401, 402, 403, 602, 801, 802, 901
PTX-273	Wick Assembly Instructions - Cutting Station	9/1/2016	PUREWICK_0027448	PUREWICK_0027449	Mann Ex. 66	106, 401, 402, 403, 602, 801, 802, 901
PTX-274	Heaven International Healthcare Co., Ltd. Technical Datasheet for (Compression) Tubular	N/A	PUREWICK_0027489	PUREWICK_0027489		106, 401, 402, 403, 602, 801, 802, 901
PTX-275	Purewick External Catheter for Women Instructions for Use sheet and Frequently Asked	N/A	PUREWICK_0027530	PUREWICK_0027531		106, 401, 402, 403, 602, 801, 802, 901
PTX-276	Bard Design Impact Evaluation Tree - PureWick Latex Free	N/A	PUREWICK_0027626	PUREWICK_0027631		106, 401, 402, 403, 602, 801, 802, 901
PTX-277	EHS Product Impact Assessment Evaluation	N/A	PUREWICK_0027645	PUREWICK_0027655		106, 401, 402, 403, 602, 801, 802, 901
PTX-278	Bard Design Impact Evaluation Tree - PureWick Latex Free	N/A	PUREWICK_0027656	PUREWICK_0027661		106, 401, 402, 403, 602, 801, 802, 901
PTX-279	Subassembly Instructions	3/28/2017	PUREWICK_0027839	PUREWICK_0027840		106, 401, 402, 403, 602, 801, 802, 901
PTX-280	Manufacturing Plan - Purewick and Associated Drydock	N/A	PUREWICK_0027842	PUREWICK_0027846		106, 401, 402, 403, 602, 801, 802, 901
PTX-281	PureWick Compression Bandage Preparation Manufacturing Procedure	N/A	PUREWICK_0027847	PUREWICK_0027849		106, 401, 402, 403, 602, 801, 802, 901
PTX-282	Wick Assembly, PureWick Manufacturing Procedure	N/A	PUREWICK_0027850	PUREWICK_0027861		106, 401, 402, 403, 602, 801, 802, 901
PTX-283	Bard BMD - Clinical Evaluation Report - PureWick Female Catheter (FEC) and DryDoc and	9/19/2018	PUREWICK_0028328	PUREWICK_0028647		106, 401, 402, 403, 602, 801, 802, 901
PTX-284	Bard - Bill of Material Request Form	N/A	PUREWICK_0030484	PUREWICK_0030484		106, 401, 402, 403, 602, 801, 802, 901
PTX-285	Bard - Bill of Material Request Form	N/A	PUREWICK_0030491	PUREWICK_0030491		106, 401, 402, 403, 602, 801, 802, 901
PTX-286	Bard - Data Control Evaluation Template - Wicking Test Post Heat	4/26/2018	PUREWICK_0032257	PUREWICK_0032257		106, 401, 402, 403, 602, 801, 802, 901
PTX-287	BD Urology & Critical Care Memo from L. Sweeney to PureWick Latex Free Project File(6294) re	4/5/2018	PUREWICK_0032465	PUREWICK_0032465		106, 401, 402, 403, 602, 801, 802, 901
PTX-288	Wick Assembly Instructions	N/A	PUREWICK_0032527	PUREWICK_0032528		106, 401, 402, 403, 602, 801, 802, 901
PTX-289	PureWick schematic of Final Assembly	7/23/2020	PUREWICK_0032593	PUREWICK_0032594		106, 401, 402, 403, 602, 801, 802, 901
PTX-290	Bard Pad-nonwoven Raw Material Specification	N/A	PUREWICK_0032595	PUREWICK_0032597		106, 401, 402, 403, 602, 801, 802, 901
PTX-291	Purewick Compression Bandage Preparation Manufacturing Procedure	N/A	PUREWICK_0032600	PUREWICK_0032603		106, 401, 402, 403, 602, 801, 802, 901
PTX-292	PureWick Tube, Cut	8/24/2017	PUREWICK_0032608	PUREWICK_0032610		106, 401, 402, 403, 602, 801, 802, 901
PTX-293	Wick Assembly, PureWick Manufacturing Procedure	N/A	PUREWICK_0032637	PUREWICK_0032647		106, 401, 402, 403, 602, 801, 802, 901
PTX-294	Compression Bandage, PureWick Raw Material Specification	N/A	PUREWICK_0032665	PUREWICK_0032667		106, 401, 402, 403, 602, 801, 802, 901
PTX-295	Washed Compression Bandage, PureWick Subassembly Specification	N/A	PUREWICK_0032676	PUREWICK_0032678		106, 401, 402, 403, 602, 801, 802, 901
PTX-296	Compression Bandage, PureWick Raw Material Specification	N/A	PUREWICK_0032754	PUREWICK_0032756		106, 401, 402, 403, 602, 801, 802, 901
PTX-297	Bard BMD Clinical Evaluation Report	9/19/2018	PUREWICK_0033027	PUREWICK_0033346		106, 401, 402, 403, 602, 801, 802, 901
PTX-298	PureWick Functionality presentation	N/A	PUREWICK_0038876	PUREWICK_0038876		106, 401, 402, 403, 602, 801, 802, 901
PTX-299	Compression Sleeve Washing and QC Instructions	N/A	PUREWICK_0045530	PUREWICK_0045531		106, 401, 402, 403, 602, 801, 802, 901
PTX-300	Email from J. Subieta to M. Drobniak, et al. re Bandage supply issue/update/actions	9/19/2017	PUREWICK_0046424	PUREWICK_0046427		106, 401, 402, 403, 602, 801, 802, 901
PTX-301	Due Diligence Report - Research & Development Project Candle (DRAFT)	N/A	PUREWICK_0062956	PUREWICK_0062972		106, 401, 402, 403, 602, 801, 802, 901
PTX-302	Patent Assignment Abstract of Patent 6287506 from USPTO website	N/A	PUREWICK_0063087	PUREWICK_0063130		DAUB, 106, 401, 402, 403, 602, 801, 802, 901
PTX-303	Definition of "Wicking" from the TextileGlossary.com website	N/A	PUREWICK_EXP_0000160	PUREWICK_EXP_0000163		Duplicative, 106, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-304	Kissa E., <i>Wetting and Wicking</i> . <i>Textile Res. J.</i> , 66(10), 660-668 (1996).	N/A	PUREWICK_EXP_0000164	PUREWICK_EXP_0000173		106, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-305	Avallone E., Baumeister III T., and Sadeh A., <i>Marks' Standard Handbook for Mechanical Engineers</i> , McGraw Hill (2007).	N/A	PUREWICK_EXP_0000174	PUREWICK_EXP_0000178		106, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-306	Chatterjee, A and Singh, P., <i>Studies on Wicking Behaviour of Polyester</i> , Hindavi Publishing Corporation Journal of Textiles (2014).	2/24/2014	PUREWICK_EXP_0000179	PUREWICK_EXP_0000192		106, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-307	Priyalatha, S. and Raja, D., A Multi Directional Wicking Instrument to Measure Wicking Characteristics of Fabrics Under Dynamic Movements, <i>J. Inst. Eng. India Ser. E</i> , 99(2): 209-218	N/A	PUREWICK_EXP_0000193	PUREWICK_EXP_0000206		106, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-308	Traubel, H., <i>Hydrophilic Polymers</i> , New Materials Permeable to Water Vapor, Springer-Verlag Berlin Heidelberg (1999).	N/A	PUREWICK_EXP_0000429	PUREWICK_EXP_0000448		106, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-309	Compression Bandage Test Form	N/A	PUREWICK_EXP_0000467	PUREWICK_EXP_0000467		106, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-310	Female External Urine Management System Protocol	N/A	SAGE000000002	SAGE000000005		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-311	Stryker PrimaFit External Urine Mangement System for Females video	N/A	SAGE000000007	SAGE000000007		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-312	Stryker PrimaFit External Urine Mangement System for Females video	N/A	SAGE000000009	SAGE000000009		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-313	Stryker - What's New? - MYM Marketing materials	N/A	SAGE000000010	SAGE000000079		DAUB, Duplicative, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-314	Addressing the risk of the CAUTI without the catheter presentation	N/A	SAGE000000080	SAGE000000080		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-315	Stryker - Incontinence-associated dermatitis (IAD) infomational brochure	N/A	SAGE000000089	SAGE000000090		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-316	Stryker - Sage PrimaFit External Urine Management System for Females information brochure	N/A	SAGE000000093	SAGE000000093		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-317	Stryker - Stop Catheters Where They Start information brochure	N/A	SAGE000000105	SAGE000000105		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901, 1006

PTX No.	Title	Date	Beg. Bates No.	End Bates No.	Depo. Ex. No.	Objections
PTX-318	Stryker - Helping reduce your risk of IAD and CAUTI - Sage PrimaFit External Urine Management System for Female information guide	N/A	SAGE00000106	SAGE00000106		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901, 1006
PTX-319	Stryker - Sage PrimaFit External Urine Management System for Females information guide	N/A	SAGE00000108	SAGE00000108		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-320	Stryker - Sage PrimaFit External Urine Management System for Females Address the #1 CAUTI risk factor, the indwelling catheter information guide	N/A	SAGE00000109	SAGE00000109		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901, 1006
PTX-321	Sage PrimaFit female catheter demo video	N/A	SAGE00000115	SAGE00000115		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-322	Stryker PrimaFit schematic	7/31/2017	SAGE00000128	SAGE00000130		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-323	Sage PrimaFit schematic	3/15/2019	SAGE00000135	SAGE00000138		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-324	Sage PrimaFit schematic	5/2/2018	SAGE00000143	SAGE00000145		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-325	Sage PrimaFit schematic	3/6/2018	SAGE00000146	SAGE00000148		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-326	Stryker - Tube Port Subassembly w/Flexlink schematic	6/5/2019	SAGE00000206	SAGE00000207		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-327	Sage Material Specification, Component, Tape, Double-sided, Square, 1/2 inch x 1/2 inch	12/26/2018	SAGE00000218	SAGE00000218		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-328	Sage Assembly - Flexible Link Open schematic	10/24/2018	SAGE00000222	SAGE00000222		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-329	Stryker - Flexible Link, Single schematic	7/8/2019	SAGE00000225	SAGE00000225		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-330	Sage Material Specification for Flexible Link Assembly, 11, Cedarberg, 5400	5/8/2018	SAGE00000227	SAGE00000227		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-331	Sage Fabric Batting, Converted for 5400	9/5/2017	SAGE00000236	SAGE00000236		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-332	Sage Material Specification for Roll Stock for 5400	10/12/2017	SAGE00000237	SAGE00000237		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-333	Sage Absorbent Sleeve, Assembly schematic	5/17/2019	SAGE00000238	SAGE00000238		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-334	Sage Absorbent Fabric, Converted schematic	10/10/2017	SAGE00000240	SAGE00000240		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-335	Sage Foam Absorbent Sleeve, Back schematic	4/15/2019	SAGE00000242	SAGE00000242		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-336	Sage Fluid Reservoir, Cap for 5400 schematic	11/13/2018	SAGE00000244	SAGE00000244		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-337	Sage Foam, Adhesive Strip, Bottom schematic	7/12/2019	SAGE00000247	SAGE00000247		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-338	Sage Assembly, Bowtie Anchor schematic	9/28/2017	SAGE00000250	SAGE00000250		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-339	Sage Products - SDCU Work Instructions for PrimaFit (Female Urine Mgmt. System)	5/6/2019	SAGE00000352	SAGE00000354		DAUB, Duplicative, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-340	Sage Products - SDCU Work Instructions for PrimaFit (Female Urine Mgmt. System)	6/14/2018	SAGE00000375	SAGE00000382		DAUB, Duplicative, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-341	Sage Products - SDCU Standard Operating Procedure - PrimaFit (UM1) operating procedure	5/6/2019	SAGE00000454	SAGE00000467		DAUB, Duplicative, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-342	Stryker - Sage Female External Urine Collection Device - Sales and Marketing Primer Binder presentation	2/00/2018	SAGE00023112	SAGE00023112		DAUB, Duplicative, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-343	Stryker - Regulatory Profile Summary: Medical Device Project Segue	10/4/2017	SAGE00023171	SAGE00023181		DAUB, MIL1, 401, 402, 403, 801, 802, 901
PTX-344	PrimaFit Claims (US)	5/10/2016	SAGE00023335	SAGE00023419		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-345	Photograph of prototype	N/A	SAGE00023550	SAGE00023550		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-346	Photograph of prototype	N/A	SAGE00023551	SAGE00023551		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-347	Photograph of prototype	N/A	SAGE00023657	SAGE00023657		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-348	Centegra Health Systems - External Female catheter Trial	N/A	SAGE00023799	SAGE00023799		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-349	Patient Care Services Policy Manual re Female Catheter implementation and policy	10/26/2016	SAGE00023828	SAGE00023831		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-350	Sage - Project Segue: Key Features and Benefits presentation	N/A	SAGE00023848	SAGE00023848		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-351	Stryker - Regulatory Profile Summary: Medical Device Project Segue (with comments)	10/4/2017	SAGE00024050	SAGE00024060		DAUB, Duplicative, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-352	Project Segue Design Review for Field Evaluations by B. Blabas	7/18/2017	SAGE00024526	SAGE00024527		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-353	Sage Female External Continence Device Key Features and Benefits presentation	N/A	SAGE00024796	SAGE00024796		DAUB, Duplicative, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-354	Email from J. Prestipino to B. Blabas re Sage Fabric	8/18/2017	SAGE00024806	SAGE00024807		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-355	Segue Fabric Wicking Rate Data	N/A	SAGE00024819	SAGE00024819		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-356	Stryker - New Product Preview Segue	N/A	SAGE00024862	SAGE00024862		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-357	Stryker - New Product Preview Segue	N/A	SAGE00024873	SAGE00024873		DAUB, Duplicative, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-358	Excel of Sage Products - Component (Fabric or Fiber) Specification Worksheet	9/15/2017	SAGE00024949	SAGE00024949		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-359	Product Segue Fabric Summary Statement - Brett Blabas, NPD Concept I Engineer	10/6/2017	SAGE00024973	SAGE00024973	PW II Blabas Ex. 172	DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-360	Sage Products - Work Instructions for 5400	N/A	SAGE00025037	SAGE00025043		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-361	PrimaFit (Segue) Claims Supportive Evidence (with comments)	11/17/2017	SAGE00025067	SAGE00025070		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-362	Segue Fabric Biocompatibility - B. Blabas	6/7/2017	SAGE00025094	SAGE00025095		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-363	Product Overview presentation	N/A	SAGE00025129	SAGE00025129		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-364	Sage - PrimaFit External Urine Management System for Females	N/A	SAGE00025613	SAGE00025613		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-365	Sage - K. Buckstaff (Senior Marketing Associate) presentation re Sage Urine Management System presentation	N/A	SAGE00025670	SAGE00025670		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-366	Sage - New Product - The Sage Female External Urine Collection Device presentation	N/A	SAGE00025704	SAGE00025704		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-367	Segue and PureWick Testing	1/19/2017	SAGE00026462	SAGE00026462		DAUB, MIL1, 106, 401, 402, 403, 801, 802, 901
PTX-368	Initial Project - Segue Testing Results by B. Blabas	1/23/2017	SAGE00026463	SAGE00026463		DAUB, MIL1, 106, 401, 402, 403, 801, 802, 901
PTX-369	Project Segue: Market Definition	3/27/2017	SAGE00026464	SAGE00026465		DAUB, MIL1, 401, 402, 403, 801, 802, 901
PTX-370	Lab Testing Results for fabric	N/A	SAGE00026589	SAGE00026590		DAUB, MIL1, 106, 401, 402, 403, 801, 802, 901
PTX-371	Sage - Segue presentation	N/A	SAGE00027234	SAGE00027234		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-372	Product Overview presentation	N/A	SAGE00027254	SAGE00027254		DAUB, Duplicative, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-373	Sage Female ECD Highlights from field evaluations	8/30/2017	SAGE00027531	SAGE00027532		DAUB, Duplicative, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-374	Sage PrimaFit presentation	N/A	SAGE00027609	SAGE00027609		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-375	NPD Limited Launch Design Approval Form	6/14/2019	SAGE00028085	SAGE00028088		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901

PTX No.	Title	Date	Beg. Bates No.	End Bates No.	Depo. Ex. No.	Objections
PTX-376	Sage - New Product Development Protocol - PrimaFit In-House Volunteer Assessment	7/25/2019	SAGE00028097	SAGE00028100		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-377	Excel of product issues and possible solutions	N/A	SAGE00028145	SAGE00028145		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-378	Sage - New Product Development Protocol - PrimaFit In-House Volunteer Assessment	7/31/2019	SAGE00028153	SAGE00028162	PW II Blas Ex. 170	DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 1006
PTX-379	Stryker - CAUTI 101 presentation (DRAFT)	12/12/2017	SAGE00028973	SAGE00028973		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-380	Stryker - Project Status Review Segue Upgrade	N/A	SAGE00028993	SAGE00028993		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-381	Stryker - Sage Portfolio Update presentation	4/19/2019	SAGE00029013	SAGE00029048		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-382	PrimaFit External Urine Management for the Female Anatomy package label	N/A	SAGE00030399	SAGE00030400		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-383	Female External Urine Collection Device (localized adhesive)-Limited launch Process-NonFilling Justification Summary	6/29/2019	SAGE00033914	SAGE00033915		DAUB, MIL1, 106, 401, 402, 403, 801, 802, 901
PTX-384	NPD to PE Knowledge Transfer Summary Report for PrimaFit	N/A	SAGE00034149	SAGE00034160		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-385	Sage Products - PrimaFit NPD process Timeline	N/A	SAGE00035988	SAGE00035988		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-386	Kindred Healthcare - PrimaFit Female Urinary Incontinence Management	12/20/2016	SAGE00038211	SAGE00038211		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-387	Sage Product PrimaFit External Urine Management System for Females information brochure	N/A	SAGE00038710	SAGE00038710		DAUB, Duplicative, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-388	Email from E. Ryba to K. Buckstaff re Beyond the bundle - CAUTI Prevention	8/14/2018	SAGE00038829	SAGE00038832		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-389	Stryker - Sage PrimaFit External Urine Management System for Females	N/A	SAGE00039812	SAGE00039816		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-390	Homestead Hospital policy document re Female External Urine Management System	06/00/2018	SAGE00040233	SAGE00040235		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-391	Photograph of catheter (back)	N/A	SAGE00040838	SAGE00040838		401, 402, 403, 602, 901
PTX-392	Photograph of catheter (front)	N/A	SAGE00040839	SAGE00040839		401, 402, 403, 602, 901
PTX-393	Photograph of Fusion Quiet Power Pump	N/A	NEWTON_0005498	NEWTON_0005498		DAUB, MIL3, 401, 402, 403, 801, 802
PTX-394	NHC Pulaski fax to M. Jackson from P. Clayton re Copy of PureWick questionnaire	1/29/2016	PUREWICK_0015924	PUREWICK_0015927		401, 402, 403, 801, 802, 901
PTX-395	Tri-City Medical Center - Innovation in Reducing CAUTIs informational chart	N/A	PUREWICK_0016010	PUREWICK_0016010		DAUB, Duplicative, MIL2, 106, 401, 402, 403, 602, 703, 801, 802, 901, 1006
PTX-396	PureWick Incontinence Relief for Women presentation	N/A	PUREWICK_0017984	PUREWICK_0017990		DAUB, MIL3, 401, 402, 403, 801, 802, 901
PTX-397	Multiple emails regarding hospital quotes	N/A	PUREWICK_0021757	PUREWICK_0021889		MIL2, 401, 402, 403, 801, 802, 901
PTX-398	PureWick 625 Wick, SH - Item Number 100008 Biocompatibility Review	10/10/2016	PUREWICK_0027352	PUREWICK_0027406		Duplicative, 401, 402, 403, 801, 802, 901
PTX-399	Photograph of prototype	N/A	PUREWICK_0030265	PUREWICK_0030265		MIL3, 401, 402, 403, 602, 901
PTX-400	Photograph of extruded wick prototype	N/A	PUREWICK_0030275	PUREWICK_0030275		MIL3, 106, 401, 402, 403, 602, 901
PTX-401	Stryker - Case Studies - Sage PrimaFit - External Urine Management System for Females	N/A	SAGE00000008	SAGE00000008		DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-402	Executive Summary: Sage Female External Continence Device	N/A	SAGE00024810	SAGE00024811		DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-403	Sage Products - PrimaFit External Urine Management System for Females	N/A	SAGE00025612	SAGE00025612		DAUB, MIL1, 401, 402, 403, 801, 802, 901
PTX-404	PureWick product benefits	7/8/2016	SAGE00025925	SAGE00025927		DAUB, MIL1, MIL2, MIL3, 401, 402, 403, 602, 801, 802, 901
PTX-405	Project Candle VOC Summary	N/A	PUREWICK_0014255	PUREWICK_0014258		401, 402, 403, 602, 801, 802, 901
PTX-406	Bard Medical Division Memo to PureWick VOC Folder from J. Gohde re VOC on the PureWick	4/25/2016	PUREWICK_0014279	PUREWICK_0014250		401, 402, 403, 602, 801, 802, 901
PTX-407	BD Challenges with Urine Output Management	N/A	PUREWICK_0014418	PUREWICK_0014418		401, 402, 403, 602, 801, 802, 901
PTX-408	PureWick schematic of shell	2/20/2018	PUREWICK_0014541	PUREWICK_0014542		106, 401, 402, 403, 602, 801, 802, 901
PTX-409	Memorial Sloan Kettering Cancer Center - An Alternative to the Indwelling Foley Catheter in Incontinence Female Patients brochure	N/A	PUREWICK_0014567	PUREWICK_0014567		DAUB, 106, 401, 402, 403, 702, 703, 801, 802, 901
PTX-410	UC Davis Medical Center - The CAUTI's Stop Here: A Quality Improvement Project in an Emergency Department brochure	N/A	PUREWICK_0014572	PUREWICK_0014572		106, 401, 402, 403, 602, 702, 703, 801, 802, 901, 1006
PTX-411	PureWick Agreement and Plan of Merger by and among C.R. bard, Inc., Candle Acquisition Corp., PureWick Corporation, and Camille Newton	6/21/2017	PUREWICK_0015362	PUREWICK_0015893		DAUB, MIL2, 106, 401, 402, 403, 602, 801, 802, 901
PTX-412	Photograph of Camille Newton	N/A	PUREWICK_0016012	PUREWICK_0016012		MIL3, 106, 401, 402, 403, 602, 801, 802, 901
PTX-413	The Simon Foundation for Continence abstract submission form - Innovating for Continence: The engineering Challenge 2017	N/A	PUREWICK_0016147	PUREWICK_0016148		106, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-414	PureWick External Catheter for Women Instructions for Use	N/A	PUREWICK_0017585	PUREWICK_0017586		401, 402, 403, 602, 801, 802, 901
PTX-415	Email from M. Jackson to B. Szabad and L. Hennessey re Tri-City product order	2/24/2016	PUREWICK_0017646	PUREWICK_0017647		106, 401, 402, 403, 602, 801, 802, 901
PTX-416	Sales: Monthly Wick Sales table	N/A	PUREWICK_0017657	PUREWICK_0017657		Duplicative, 106, 401, 402, 403, 602, 801, 802, 901
PTX-417	Sales: Total Quarterly Sales table	N/A	PUREWICK_0017664	PUREWICK_0017664		106, 401, 402, 403, 602, 801, 802, 901
PTX-418	Email from J. Pasquariello to M. Jackson, et al. re Is there any chance I can get more	5/25/2016	PUREWICK_0017688	PUREWICK_0017691		106, 401, 402, 403, 602, 801, 802, 901
PTX-419	Email from S. Floyd to C. Newton re PureWick	4/12/2016	PUREWICK_0017712	PUREWICK_0017712		106, 401, 402, 403, 602, 801, 802, 901
PTX-420	Email from C. Newton to J. Batts re PureWick Steps to successful implementation and	5/15/2016	PUREWICK_0017714	PUREWICK_0017715		106, 401, 402, 403, 602, 801, 802, 901
PTX-421	Ltr to C. Newton from L. Baer re Purewick product	5/25/2016	PUREWICK_0017716	PUREWICK_0017716		106, 401, 402, 403, 602, 801, 802, 901
PTX-422	Email from A. Maffin to J. Hennessey re PureWick instructions and Eval	5/5/2016	PUREWICK_0017718	PUREWICK_0017720		106, 401, 402, 403, 602, 801, 802, 901
PTX-423	Photograph of catheter	N/A	PUREWICK_0017891	PUREWICK_0017891		106, 401, 402, 403, 602, 901
PTX-424	Photograph of 28th Annual Most Innovative New Product Awards to PureWick	N/A	PUREWICK_0017975	PUREWICK_0017975		401, 402, 403, 602, 801, 802, 901
PTX-425	Photograph of 28th Annual Most Innovative New Product Awards to PureWick	N/A	PUREWICK_0018868	PUREWICK_0018868		106, 401, 402, 403, 602, 801, 802, 901
PTX-426	Email from M. Stankovic to J. Bobay re PureWick follow up information	10/12/2016	PUREWICK_0019574	PUREWICK_0015575		DAUB, MIL2, 106, 401, 402, 403, 602, 801, 802, 901
PTX-427	Email from M. Stankovic to J. Bobay, et al. re YTD/MTD sales by account with attachment PureWick August Wick sales	9/20/2016	PUREWICK_0019587	PUREWICK_0019589		DAUB, MIL2, 106, 401, 402, 403, 602, 801, 802, 901
PTX-428	Email from SM. Stankovic to J. Bobay, et al. re YTD/MTD sales by account with attachment re hospital sales	9/20/2016	PUREWICK_0019590	PUREWICK_0019592		DAUB, MIL2, 106, 401, 402, 403, 602, 801, 802, 901
PTX-429	Email from M. Stankovic to J. Bobay re Purewick - Patents with attachments re applications	9/21/2016	PUREWICK_0019597	PUREWICK_0019646		DAUB, MIL2, MIL3, 106, 401, 402, 403, 602, 801, 802, 901
PTX-430	Sage Products Mutual Confidentiality Agreement between Sage Products, LLC and PureWick Inc.	7/5/2016	PUREWICK_0019670	PUREWICK_0019672		DAUB, MIL2, 106, 401, 402, 403, 602, 801, 802, 901
PTX-431	Photograph of prototype	N/A	PUREWICK_0019753	PUREWICK_0019753		106, 401, 402, 403, 602, 901
PTX-432	Photograph of prototype	N/A	PUREWICK_0019756	PUREWICK_0019756		MIL3, 106, 401, 402, 403, 602, 901
PTX-433	Photograph of prototypes	N/A	PUREWICK_0019757	PUREWICK_0019757		MIL3, 106, 401, 402, 403, 602, 901
PTX-434	Photograph of prototypes	N/A	PUREWICK_0019764	PUREWICK_0019764		106, 401, 402, 403, 602, 901
PTX-435	Photograph of prototype	N/A	PUREWICK_0019773	PUREWICK_0019773		106, 401, 402, 403, 602, 901
PTX-436	Photograph of prototypes	N/A	PUREWICK_0019774	PUREWICK_0019774		106, 401, 402, 403, 602, 901
PTX-437	Photograph of PureWick device	N/A	PUREWICK_0019775	PUREWICK_0019775		106, 401, 402, 403, 602, 801, 802, 901
PTX-438	Photograph of prototypes	N/A	PUREWICK_0019781	PUREWICK_0019781		106, 401, 402, 403, 602, 901
PTX-439	Photograph of prototypes	N/A	PUREWICK_0019790	PUREWICK_0019790		106, 401, 402, 403, 602, 901
PTX-440	Heaven International Healthcare - Technical Datasheet	N/A	PUREWICK_0019993	PUREWICK_0019993		401, 402, 403, 602, 801, 802, 901
PTX-441	PureWick Inc. Successful Incontinence Management for Women	N/A	PUREWICK_0022136	PUREWICK_0022137		Duplicative, 401, 402, 403, 602, 801, 802, 901
PTX-442	Invention Agreement between Robert Sanchez and Camille Newton regarding a liquid	5/31/2010	PUREWICK_0023587	PUREWICK_0023589		MIL3, 106, 401, 402, 403, 602, 801, 802, 901
PTX-443	Photograph of Camille Newton with award at Athena, San Diego	N/A	PUREWICK_0024648	PUREWICK_0024648		MIL3, 106, 401, 402, 403, 602, 801, 802, 901
PTX-444	Photograph of prototype	N/A	PUREWICK_0024660	PUREWICK_0024660		106, 401, 402, 403, 602, 901
PTX-445	Photograph of prototype	N/A	PUREWICK_0024665	PUREWICK_0024665		106, 401, 402, 403, 602, 901
PTX-446	Photograph of prototype	N/A	PUREWICK_0024667	PUREWICK_0024667		106, 401, 402, 403, 602, 901
PTX-447	Photograph of PureWick FEC	N/A	PUREWICK_0024782	PUREWICK_0024782		401, 402, 403, 602, 901
PTX-448	PureWick - External Female Catheter presentation	N/A	PUREWICK_0025092	PUREWICK_0025113		106, 401, 402, 403, 602, 801, 802, 901
PTX-449	Scimals Non-Disclosure Agreement between SCIMLAS and PureWick	5/12/2014	PUREWICK_0026794	PUREWICK_0026797		106, 401, 402, 403, 602, 801, 802, 901
PTX-450	BD Acute Urology Monthly Meeting	N/A	PUREWICK_0042812	PUREWICK_0042812		401, 402, 403, 602, 801, 802, 901
PTX-451	BD Monthly Deep Dive Presentation	N/A	PUREWICK_0064264	PUREWICK_0064264		401, 402, 403, 602, 801, 802, 901
PTX-452	Sage Product Line Market Shares with GHX Data presentation	4/18/2019	SAGE00029452	SAGE00029514		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-453	Sage Product Line Market Shares with GHX Data presentation	5/15/2019	SAGE00029515	SAGE00029577		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-454	Sage Product Line Market Shares with GHX Data presentation	6/18/2019	SAGE00029578	SAGE00029640		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-455	Sage Product Line Market Shares with GHX Data presentation	7/15/2019	SAGE00029641	SAGE00029703		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901



PTX No.	Title	Date	Beg. Bates No.	End Bates No.	Depo. Ex. No.	Objections
PTX-456	Sage Product Line Market Shares with GHX Data presentation	9/24/2019	SAGE00029715	SAGE00029777		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-457	Sage Product Line Market Shares with GHX Data presentation	10/21/2019	SAGE00029780	SAGE00029842		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-458	Sage Product Line Market Shares with GHX Data presentation	11/19/2019	SAGE00029845	SAGE00029911		DAUB, Duplicative, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-459	Sage Product Line Market Shares with GHX Data presentation	12/19/2019	SAGE00029914	SAGE00029980		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-460	Sage Product Line Market Shares with GHX Data presentation	1/18/2020	SAGE00029983	SAGE00030049		DAUB, Duplicative, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-461	Sage Product Line Market Shares with GHX Data presentation	3/15/2020	SAGE00030121	SAGE00030187		DAUB, Duplicative, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-462	Sage Product Line Market Shares with GHX Data presentation	4/17/2020	SAGE00030190	SAGE00030256		DAUB, Duplicative, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-463	Sage Product Line Market Shares with GHX Data presentation	5/15/2020	SAGE00030259	SAGE00030325		DAUB, Duplicative, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-464	Sage Product Line Market Shares with GHX Data presentation	6/12/2020	SAGE00030328	SAGE00030394		DAUB, Duplicative, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-465	Photograph of Camille Newton and Robert Sanchez	N/A	NEWTON_0005228	NEWTON_0005228		MIL3, 106, 401, 402, 403, 602, 801, 802, 901
PTX-466	Sample of PrimaFit 1.0 Device	N/A	SAGE00040000	SAGE00040000		DAUB, MIL1, 401, 402, 403, 801, 802
PTX-467	Email from C. Newton to R. Newton re Recorded email of urine suction device	8/3/2009	NEWTON_0000001	NEWTON_0000001		MIL3, 401, 402, 403, 801, 802, 901
PTX-468	Photo of Dry Dock	N/A	NEWTON_0000079	NEWTON_0000079		401, 402, 403, 602, 901
PTX-469	Photo of prototypes and award for the 28th Annual Most Innovative new product	N/A	NEWTON_0005320	NEWTON_0005320		106, 401, 402, 403, 602, 801, 802, 901
PTX-470	Email from B. Jackson to A. Silver, et al. re Positive Lead Comments	7/20/2018	NEWTON_0007577	NEWTON_0007582		106, 401, 402, 403, 602, 801, 802, 901
PTX-471	Email from B. Sanchez to C. Newton re PureWick update	8/13/2016	NEWTON_0008136	NEWTON_0008137		DAUB, MIL3, 401, 402, 403, 801, 802
PTX-472	Purewick External Female Catheter Non-Invasive, no nurse required, Up to 100% Urine	N/A	PUREWICK_0027511	PUREWICK_0027529		106, 401, 402, 403, 602, 801, 802, 901
PTX-473	Excel file of Wick sales and DryDoc sales	N/A	PUREWICK_0030708	PUREWICK_0030708		106, 401, 402, 403, 602, 801, 802, 901
PTX-474	PureWick shell schematic	2/20/2018	PUREWICK_0032559	PUREWICK_0032560		Duplicative, 106, 401, 402, 403, 602, 801, 802, 901
PTX-475	PrimFit marketing video	N/A	SAGE00005311	SAGE00005311		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-476	Sage Excel of net sales, net cases and standard cost for products 5400 and 5452		SAGE00043612	SAGE00043612		DAUB, MIL1, 106, 401, 402, 403, 801, 802, 901
PTX-477	Sage Excel of net sales, net cases and standard cost for products 5404		SAGE00043613	SAGE00043613		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-478	PuerWick conversions from 2017-2021		PUREWICK_0064695	PureWick_0064695		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-479	Physical samples of PureWick FEC Devices	N/A	N/A	N/A		401, 402, 403, 901
PTX-480	Sample of PrimaFit 2.0 Device	N/A	STRSAGE00050006	STRSAGE0005006		401, 402, 403
PTX-481	Sample of PrimaFit 2.0 Device	N/A	STRSAGE00050007	STRSAGE0005007		401, 402, 403
PTX-482	Sample of PrimaFit 2.0 Device	N/A	STRSAGE00050008	STRSAGE0005008		401, 402, 403
PTX-483	Sample of PrimaFit 2.0 Device	N/A	STRSAGE00050009	STRSAGE0005009		401, 402, 403
PTX-484	Sample of PrimaFit 2.0 Device	N/A	STRSAGE00050010	STRSAGE0005010		401, 402, 403
PTX-485	Opening Expert Report of Dr. John Collins Regarding Infringement	5/19/2023	N/A	N/A		DAUB, MIL1, MIL2, MIL3, 401, 402, 403, 702, 703, 801, 802, 901, 1006
PTX-486	Exhibit A to Opening Expert Report of Dr. John Collins Regarding Infringement - Materials	N/A	N/A	N/A		401, 402, 403
PTX-487	Exhibit B to Opening Expert Report of Dr. John Collins Regarding Infringement - Curriculum	N/A	N/A	N/A		401, 402, 403, 801, 802, 901
PTX-488	Exhibit C to Opening Expert Report of Dr. John Collins Regarding Infringement - Prior cases in which Dr. Collins submitted testimony or reports as an expert witness in the last 4 years as of	N/A	N/A	N/A		DAUB, MIL1, 401, 402, 403, 801, 802, 901
PTX-489	Exhibit D to Opening Expert Report of Dr. John Collins Regarding Infringement - U.S. Patent No. 10,226,376 Sage PrimaFit Device and Claims	N/A	N/A	N/A		DAUB, 401, 402, 403, 702, 703, 801, 802, 901
PTX-490	Exhibit E to Opening Expert Report of Dr. John Collins Regarding Infringement - U.S. Patent No. 10,390,989 Sage PrimaFit Device and Claims	N/A	N/A	N/A		DAUB, MIL1, 401, 402, 403, 702, 703, 801, 802, 901
PTX-491	Exhibit F to Opening Expert Report of Dr. John Collins Regarding Infringement - PrimaFit 1.0 U.S. Patent No. 10,226,376 Sage PrimaFit Device and Claim Chart	N/A	N/A	N/A		DAUB, MIL1, 401, 402, 403, 702, 703, 801, 802, 901
PTX-492	Exhibit G to Opening Expert Report of Dr. John Collins Regarding Infringement - PrimaFit 1.0 U.S. Patent No. 10,390,989 Sage PrimaFit Device and Claims	N/A	N/A	N/A		DAUB, MIL1, 401, 402, 403, 702, 703, 801, 802, 901
PTX-493	Exhibit H to Opening Expert Report of Dr. John Collins Regarding Infringement - U.S. Patent No.	N/A	N/A	N/A		401, 402, 403, 702, 703, 801, 802, 901
PTX-494	Exhibit I to Opening Expert Report of Dr. John Collins Regarding Infringement - U.S. Patent No.	N/A	N/A	N/A		401, 402, 403, 702, 703, 801, 802, 901
PTX-495	Exhibit J to Opening Expert Report of Dr. John Collins Regarding Infringement - Photographs of	N/A	N/A	N/A		DAUB, 106, 401, 402, 403, 801, 802
PTX-496	Exhibit K to Opening Expert Report of Dr. John Collins Regarding Infringement - PrimaFit Fluid Path Visualization Protocol	N/A	N/A	N/A		DAUB, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-497	Exhibit L to Opening Expert Report of Dr. John Collins Regarding Infringement - Flowpath Visualization Images	N/A	N/A	N/A		DAUB, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-498	Exhibit M to Opening Expert Report of Dr. John Collins Regarding Infringement - Flowpath Visualization X-ray Videos	N/A	N/A	N/A		DAUB, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-499	Exhibit N to Opening Expert Report of Dr. John Collins Regarding Infringement - CT Images					DAUB, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-500	Exhibit O to Opening Expert Report of Dr. John Collins Regarding Infringement - CT Video	N/A	N/A	N/A		DAUB, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-501	Exhibit P to Opening Expert Report of Dr. John Collins Regarding Infringement - Photographs of Opening Expert Report of Dr. Edward Yun	N/A	N/A	N/A		401, 402, 403, 801, 802, 901
PTX-502	Exhibit A to Opening Expert Report of Dr. Edward Yun - Materials Considered List	N/A	N/A	N/A		DAUB, 401, 402, 403, 702, 703, 801, 802, 901
PTX-503	Exhibit B to Opening Expert Report of Dr. Edward Yun - Curriculum Vitae of Edward Yun	N/A	N/A	N/A		401, 402, 403
PTX-504	Exhibit C to Opening Expert Report of Dr. Edward Yun - List of Prior Trial and Deposition	N/A	N/A	N/A		401, 402, 403, 801, 802
PTX-505	Expert Report of Lauren R. Kinder with Appendices and Exhibits	5/19/2023	N/A	N/A		DAUB, MIL1, 401, 402, 403, 801, 802, 901
PTX-506	Rebuttal Expert Report of Arrigo D. Jezzi Regarding Validity	6/16/2023	N/A	N/A		DAUB, MIL1, MIL2, MIL3, 106, 401, 402, 403, 602, 702, 703, 801, 802, 901, 1006
PTX-507	Exhibit A to Rebuttal Expert Report of Arrigo D. Jezzi - Curriculum Vitae of Arrigo D. Jezzi	N/A	N/A	N/A		401, 402, 403, 801, 802, 901, 1006
PTX-508	Exhibit B to Rebuttal Expert Report of Arrigo D. Jezzi - Materials Considered List	N/A	N/A	N/A		401, 402, 403, 801, 802, 901
PTX-509	Rebuttal Expert Report of Dr. John Collins Regarding Validity	6/16/2023	N/A	N/A		401, 402, 403
PTX-510	Exhibit A to Rebuttal Expert Report of Dr. John Collins - Curriculum Vitae of Arrigo D. Jezzi	N/A	N/A	N/A		DAUB, 401, 402, 403, 702, 703, 801, 802, 1006
PTX-511	Exhibit B to Rebuttal Expert Report of Dr. John Collins - Materials Considered List	N/A	N/A	N/A		401, 402, 403, 801, 802, 901, Error
PTX-512	Reply Expert Report of Dr. John Collins Regarding Infringement	6/30/2023	N/A	N/A		401, 402, 403
PTX-513	Exhibit A-1 to Opening Expert Report of Dr. John Collins Regarding Infringement - Materials	N/A	N/A	N/A		DAUB, MIL1, MIL2, MIL3, 106, 401, 402, 403, 602, 702, 703, 801, 802, 901, 1006
PTX-514	Exhibit B to Opening Expert Report of Dr. John Collins Regarding Infringement - Curriculum	N/A	N/A	N/A		MIL3, 401, 402, 403
PTX-515	Exhibit Q to Opening Expert Report of Dr. John Collins Regarding Infringement - PrimaFit 2.0 Rotational Video	N/A	N/A	N/A		401, 402, 403, 801, 802, 901
PTX-516	Exhibit R to Opening Expert Report of Dr. John Collins Regarding Infringement - PrimaFit 2.0 Top Down Video	N/A	N/A	N/A		DAUB, 106, 401, 402, 403, 602, 702, 703, 801, 802, 901, 1006
PTX-517	Exhibit S to Opening Expert Report of Dr. John Collins Regarding Infringement - PrimaFit 2.0 Frontal Plane Video	N/A	N/A	N/A		DAUB, 106, 401, 402, 403, 602, 702, 703, 801, 802, 901, 1006
PTX-518	Reply Expert Report of Lauren B. Kinder with Appendices and Exhibits	6/30/2023	N/A	N/A		DAUB, 106, 401, 402, 403, 602, 702, 703, 801, 802, 901, 1006
PTX-519	Reply Expert Report of Dr. Edward Yun	6/30/2023	N/A	N/A		DAUB, MIL1, MIL2, 106, 401, 402, 403, 602, 702, 703, 801, 802, 901, 1006
PTX-520	Exhibit A to Reply Expert Report of Dr. Edward Yun - Curriculum Vitae of Dr. Edward Yun	N/A	N/A	N/A		DAUB, MIL1, MIL2, 106, 401, 402, 403, 602, 702, 703, 801, 802, 901, 1006
PTX-521	Attachment A to Reply Expert Report of Dr. Edward Yun - Warren 2021	N/A	N/A	N/A		401, 402, 403, 801, 802, 901
PTX-522	Attachment B to Reply Expert Report of Dr. Edward Yun - Rearigh 2021	N/A	N/A	N/A		401, 402, 403, 702, 703, 801, 802, 901
PTX-523	Attachment C to Reply Expert Report of Dr. Edward Yun - Rose 2021	N/A	N/A	N/A		401, 402, 403, 702, 703, 801, 802, 901
PTX-524	Attachment D to Reply Expert Report of Dr. Edward Yun - NSHN Cauti Presentation	N/A	N/A	N/A		401, 402, 403, 702, 703, 801, 802, 901
PTX-525	Exhibit D to Reply Expert Report of Dr. Edward Yun - Materials Considered List	N/A	N/A	N/A		DAUB, MIL1, MIL2, MIL3, 106, 401, 402, 403, 602, 702, 703, 801, 802, 901, 1006
PTX-526	Email from J. Lukasavage to S. Cherny et al., titled "FW: PrimaFit 2.0"	10/8/2021	BDPUREWICK_00002929	BDPureWick_00002930	S. Skelton Ex. 2	106, 401, 402, 403, 602, 801, 802, 901
PTX-527	BD - Purewick Family VSM - March 2021 Update	N/A	BDPUREWICK_00002888	BDPureWick_00002928	S. Skelton Ex. 13	106, 401, 402, 403, 602, 801, 802, 901
PTX-528	Project Charter re: PrimaFit 2.0	10/17/2019	STRSAGE00021947	STRSAGE00021950	P. Polanco Ex. 1	106, 401, 402, 403, 602, 801, 802, 901
PTX-529	Email from P. Polanco to D. Ulreich et al., titled "RE: Question on testing during limited launch"	11/6/2020	SAGE00034943	SAGE00034946	P. Polanco Ex. 3	401, 402, 403, 602, 801, 802
PTX-530	FDA, CFR - Code of Federal Regulations Title 21, Part 820 - Quality System Regulation, Sec.	11/29/2022	N/A	N/A	P. Polanco Ex. 4	401, 402, 403, 702, 703, 801, 802, 901
PTX-531	New Product Development Technical Report re: Sage Products, Selective Adhesive Device	N/A	STRSAGE00024512	STRSAGE00024514	P. Polanco Ex. 5, Allen Ex. 5	DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-532	Securement Equivalency, PrimaFit 2.0, Doc No. TP21-0122, Complaint Data					DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901

PTX No.	Title	Date	Beg. Bates No.	End Bates No.	Depo. Ex. No.	Objections
PTX-533	Email from P. Polanco to D. Ulreich et al., titled "Should we consider a longer use for PrimaFit 2.0?" with attachment "Purewick maudeExcelReport 2017 to July 2020.xls"	7/24/2020	SAGE00037355	SAGE00037355	P. Polanco Ex. 7	106, 401, 402, 403, 801, 802
PTX-534	Email from A. Alakhramsing to Z. Vandology et al., titled "RE."	11/04/2021	STRSAGE00025352	STRSAGE00025355	A. Alakhramsing Ex. 11	401, 402, 403, 602, 801, 802, 901
PTX-535	Email from K. Paskal to A. Alakhramsing, titled "PrimaFit 2.0 Information"	10/20/2020	SAGE00040650	SAGE00040650	A. Alakhramsing Ex. 12	106, 401, 402, 403, 602, 801, 802, 901
PTX-536	Sage Urine Management, Addressing the risk factors for CAUTI (FastTrack 1) PowerPoint	N/A	STRSAGE00021235	STRSAGE00021235	A. Alakhramsing Ex. 14	106, 401, 402, 403, 602, 801, 802
PTX-537	B. Galenik, PrimaFit External Urine Management for the Female Anatomy PowerPoint	N/A	STRSAGE00021238	STRSAGE00021238	A. Alakhramsing Ex. 15	106, 401, 402, 403, 602, 801, 802, 901
PTX-538	PrimaFit 2.0 update (Design and Automation) PowerPoint Presentation	N/A	STRSAGE00022042	STRSAGE00022042	A. Alakhramsing Ex. 16	401, 402, 403, 602, 801, 802
PTX-539	B. Letzter et al., Sage's 2023 Annual Marketing Plan, Urine Management PowerPoint		STRSAGE00022937	STRSAGE00022937	A. Alakhramsing Ex. 17	401, 402, 403, 602, 801, 802, 901
PTX-540	Marketing business review PowerPoint Presentation	N/A	STRSAGE00022991	STRSAGE00022991	A. Alakhramsing Ex. 18	401, 402, 403, 602, 801, 802, 901
	PrimoFit scorecard PowerPoint Presentation	N/A	STRSAGE00022995	STRSAGE00022995	A. Alakhramsing Ex. 19	
PTX-541						DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-542	PrimaFit 2.0, Financial Model, Executive Summary, CER #1934-5740	N/A	STRSAGE00023025	STRSAGE00023037	A. Alakhramsing Ex. 20	401, 402, 403, 602, 801, 802
PTX-543	Sage Products 2023-2027 Outlook Spreadsheet, REDACTED		STRSAGE00022309	STRSAGE00022365	A. Alakhramsing Ex. 21	401, 402, 403, 602, 801, 802
PTX-544	PrimaFit SS Net Sales and Cases		STRSAGE00000141	STRSAGE00000141	A. Alakhramsing Ex. 22	106, 401, 402, 403, 602, 801, 802
PTX-545	PrimaFit 2.0 Open PO Template	N/A	STRSAGE00023038	STRSAGE00023038	A. Alakhramsing Ex. 23	401, 402, 403, 602, 801, 802, 901
PTX-546	PrimaFit Sales 2018-2021		STRSAGE00023084	STRSAGE00023084	A. Alakhramsing Ex. 24	106, 401, 402, 403, 801, 802, 901
PTX-547	PrimaFit Eaches by Account	12/1/2021	STRSAGE00023164	STRSAGE00023164	A. Alakhramsing Ex. 25	401, 402, 403, 602, 801, 802
PTX-548	PrimaFit 2.0 Supply-Demand	10/28/2019	STRSAGE00024812	STRSAGE00024812	A. Alakhramsing Ex. 26	106, 401, 402, 403, 801, 802, 901, 1006
PTX-549	PrimaFit Capacity Analysis	1/26/2021	STRSAGE00023081	STRSAGE00023081	A. Alakhramsing Ex. 27	106, 401, 402, 403, 801, 802, 901
PTX-550	J. Allen, Director, New Product Regulatory Affairs at Stryker Medical Cary, Regulatory Profile Sage PrimaFit* External Urine Management for the Female Anatomy Brochure (2021)	10/23/2017	SAGE00023240	SAGE00023252	J. Allen Ex. 30	DAUB, MIL1, 401, 402, 403, 602, 801, 802
PTX-551	Project Charter re: PrimaFit 2.0 (July 2019)	7/24/2019	STRSAGE00000004	STRSAGE00000004	E. Farrell Ex. 36	401, 402, 403, 602, 801, 802, 901
PTX-552	Sage PrimaFit* External Urine Management for the Female Anatomy Instructions for Use		STRSAGE00000001	STRSAGE00000001	E. Farrell Ex. 37	401, 402, 403, 602, 801, 802, 901
PTX-553	Email from E. Farrell to A. Cole et al., titled "RE: PrimaFit IFU Update - Project Request Form	11/1/2021	STRSAGE00025338	STRSAGE00025339	E. Farrell Ex. 42	401, 402, 403, 801, 802, 901
PTX-554	Providence Holy Cross Medical Center, Trial Result Summary - External Urine Management Systems for Male and Female Anatomy	N/A	STRSAGE00021320	STRSAGE00021320	E. Farrell Ex. 43	401, 402, 403, 602, 801, 802, 901
PTX-555	Current Practice Survey, CPS Urinary Management	5/30/2022	STRSAGE00021301	STRSAGE00021303	E. Farrell Ex. 44	DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-556	B. Letzter et al., PrimaFit* External Management for the Female Anatomy, National Sales		STRSAGE00021237	STRSAGE00021237	E. Farrell Ex. 45	401, 402, 403, 602, 801, 802, 901
PTX-557	Email from E. Farrell to B. Pickett et al., titled "RE: Product Code Check"	2/27/2019	SAGE00039242	SAGE00039247	E. Farrell Ex. 46	401, 402, 403, 602, 801, 802, 901
PTX-558						DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-559	PrimaFit Risk Management Plan	2/25/2021	STRSAGE00021384	STRSAGE00021384	E. Farrell Ex. 49	
PTX-560	Email from K. Sexton to N. McHugh et al., titled "Re: Medline versette"	5/28/2021	STRSAGE00025178	STRSAGE00025184	E. Farrell Ex. 50	DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-561	RMB Review, 5400-Sage Female External Urine Management System, PrimaFit 2.0	2/25/2021	STRSAGE00023106	STRSAGE00023106	A. Cole Ex. 51	401, 402, 403, 602, 801, 802
PTX-562	Sage PrimaFit* External Urine Management for the Female Anatomy Brochure (2022)		STRSAGE00000003	STRSAGE00000003	A. Cole Ex. 52	401, 402, 403, 801, 802
PTX-563	New Product Development Technical Report re: Sage Products, 5400 Instructions for Use Verification of Effectiveness Justification, PrimaFit 2.0, Doc. No. TP21-0126	N/A	STRSAGE00024488	STRSAGE00024489	A. Cole Ex. 53	DAUB, MIL1, 106, 401, 402, 403, 801, 802
PTX-564	Email from C. Olsen to A. Cole, titled "FW: Reminder about NYU Winthrop issue" with attachment "Sage Products - CFM clarification for Urine Management devices, v1.docx"	5/26/2021	STRSAGE00025139	STRSAGE00025142	A. Cole Ex. 54	DAUB, MIL1, 401, 402, 403, 801, 802
PTX-565	Project Overview, PrimaFit 2.0	N/A	STRSAGE00022113	STRSAGE00022113	A. Cole Ex. 55	401, 402, 403, 801, 802
PTX-566	Schematics re: PrimaFit 2.0, 5400 Rev H (D. Ulreich)	6/23/2021	STRSAGE00000028	STRSAGE00000028	A. Cole Ex. 56	401, 402, 403, 801, 802
PTX-567	Material Specification re: Sage Products, PrimaFit 2.0 Wicking Fabric, Doc. No. NPD2107-SPEC	7/10/2020	STRSAGE00023814	STRSAGE00023814	A. Cole Ex. 57	401, 402, 403, 801, 802
PTX-568	Biocompatibility Evaluation re: Sage Products, PrimaFit 2.0 Biocompatibility Evaluation, Doc.	N/A	STRSAGE00023866	STRSAGE00023875	A. Cole Ex. 58	401, 402, 403, 801, 802
PTX-569	PrimaFit 2.0, Limited Launch Testing	5/7/2019	STRSAGE00021455	STRSAGE00021455	A. Cole Ex. 59	DAUB, Duplicative, MIL1, 106, 401, 402, 403, 801, 802
PTX-570	PrimaFit 2.0 Weekly	5/9/2019	STRSAGE00021457	STRSAGE00021457	A. Cole Ex. 60, Ulreich Ex. 7	DAUB, MIL1, 401, 402, 403, 801, 802
PTX-571	UD and PureWick Loss Spreadsheet	N/A	BDPUREWICK_00002070	BDPUREWICK_00002070	J. Gohde Ex. 11 (PM)	401, 402, 403, 801, 802, 901
PTX-572	Boehringer CareDry® System Brochure	N/A	STRSAGE00024743	STRSAGE00024744	J. Gohde Ex. 28 (PM)	
PTX-573 / PTX-573A	BD - US Acute Care Marketing Plan, FY 23, REDACTED (September 2023)		BDPUREWICK_00001709	BDPUREWick_0001817	J. Gohde Ex. 33	401, 402, 403, 602, 801, 802, 901
PTX-574	BD - Project Raptor, Securing at-risk customers and converting competitive losses across the	N/A	BDPUREWICK_00002030	BDPUREWick_00002059	J. Gohde Ex. 34	401, 402, 403, 602, 801, 802, 901
PTX-575	K. Grupp et al., BD - US PureWick Strategy PowerPoint Presentation		BDPUREWICK_00007641	BDPUREWick_00007641	reproduced version of Gohde	401, 402, 403, 602, 801, 802, 901
PTX-576 / PTX-576A	K. Grupp et al., BD - US PureWick Strategy PowerPoint Presentation	8/10/2022	BDPUREWICK_00002071	BDPUREWick_00002132	J. Gohde Ex. 36	401, 402, 403, 602, 801, 802, 901
PTX-577	Email from K. Paskal to F. Plank, titled "FW: PrimaFit 2.0 Design Freeze Update (Skype Meeting)	2/18/2020	SAGE00040262	SAGE00040263	S. Jirafe Ex. 64	401, 402, 403, 602, 801, 802, 901
PTX-578	Email from C. Schmidt to S. Jirafe et al., titled "FW: PrimaFit Automation"	2/9/2021	STRSAGE00024946	STRSAGE00024948	S. Jirafe Ex. 66	DAUB, MIL1, 401, 402, 403, 602, 801, 802
PTX-579	Product Capacity Ramp re: PrimaFit 2.0	N/A	STRSAGE00025375	STRSAGE00025375	S. Jirafe Ex. 68	401, 402, 403, 602, 801, 802, 901
PTX-580	Email from Z. Vandology to B. Smith et al., titled "PrimaFit 2.0 Transition Update"	11/4/2021	STRSAGE00025340	STRSAGE00025342	S. Jirafe Ex. 69	DAUB, MIL1, 401, 402, 403, 602, 801, 802
PTX-581	Capital Committee, Early Spend Request Sage Project PrimaFit 2.0 PowerPoint Presentation	2/9/2023	SAGE00021955	SAGE00021955	S. Jirafe Ex. 70	401, 402, 403, 602, 801, 802, 901
PTX-582	Email from S. Jirafe to A. Cole et al., titled "RE: Updated Project Charter - PrimaFit 2.0 (2019-10)	10/9/2019	STRSAGE00024803	STRSAGE00024804	S. Jirafe Ex. 71	401, 402, 403, 602, 801, 802, 901
PTX-583	Schematics re: PrimaFit 2.0, 5400-2 Rev NEW (D. Ulreich)	6/23/2021	STRSAGE00000034	STRSAGE00000034	S. Jirafe Ex. 72	401, 402, 403, 602, 801, 802
PTX-584	Sage PrimaFit* External Urine Management for the Female Anatomy (2022)		BDPUREWICK_00000873	BDPUREWick_00000873	R. Morgan Ex. 55	Duplicative, 401, 402, 403, 602, 801, 802, 901
PTX-585	Email from N. Austreman to COV-VMD Critical Care Sales and Marketing et al., titled "Sage PureWick Sales, 2020 - 2023	10/8/2021	BDPUREWICK_00001165	BDPUREWick_00001165	R. Morgan Ex. 56	401, 402, 403, 602, 801, 802, 901
PTX-586	PureWick Income Statement, FY 2020 - FY 2022		BDPUREWICK_00002198	BDPUREWick_00002198	R. Morgan Ex. 58	401, 402, 403, 801, 802
PTX-587	PureWick Costs 2023 Update	N/A	BDPUREWICK_00002202	BDPUREWick_00002202	R. Morgan Ex. 59	401, 402, 403, 602, 801, 802, 901
PTX-588	PureWick Capacity Calculation	6/1/2023	BDPUREWICK_00006047	BDPUREWick_00006047	R. Morgan Ex. 60	401, 402, 403, 602, 801, 802, 901
PTX-589	Due Diligence Reports, Project Candle, REDACTED	4/7/2017	BDPUREWICK_00007079	BDPUREWick_00007155	G. Mann Ex. 63	401, 402, 403, 602, 801, 802, 901
PTX-590	Eckert et al., Reducing the Risk of Indwelling Catheter-Associated Urinary Tract Infection in Female Patients by Implementing an Alternative Femal External Urinary Collection Device, A		SAGE00039997	SAGE00040000	B. Jackson Ex. 74	401, 402, 403, 602, 801, 802, 901
PTX-591	PureWick Corporation Successful Incontinence Management for Women, Business Plan	1/18/2014	PUREWICK_0020880	PureWick_0020904	L. Eckert Ex. 88	106, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-592	Email from K. Pawlik to D. Newton et al., titled "Re: Wicks 6A" with attachments "June 11.jpg; June 11th.jpg; June 11 12.jpg; June 12th.jpg; June 12.jpg; June 13.jpg; June	8/1/2015	Pawlik_009544	Pawlik_009544	M. Jackson Ex. 97	MIL3, 401, 402, 403, 602, 801, 802, 901
PTX-593	Email from K. Pawlik to R. Newton et al., titled "Re: Wicks #1-4"	8/1/2015	Pawlik_009495	Pawlik_009495	K. Pawlik Ex. 167	401, 402, 403, 602, 801, 802, 901
PTX-594	Consulting Agreement between C.R. Bard, Inc. and Dr. C. Newton	11/1/2019	BDPUREWICK_00001177	BDPUREWick_00001184	K. Pawlik Ex. 175	401, 402, 403, 602, 801, 802, 901
PTX-595	Consulting Agreement nunc pro tunc between C.R. Bard, Inc. and Dr. C. Newton	11/1/2021	BDPUREWICK_00001379	BDPUREWick_00001386	B. Burn Ex. 211	106, 401, 402, 403, 602, 801, 802, 901
PTX-596	Project Candle, C.R. Bard, Inc. Acquisition Committee Memo, Proposal to Acquire PureWick	4/10/2017	BDPUREWICK_00007476	BDPUREWick_00007488	B. Burn Ex. 215	106, 401, 402, 403, 602, 801, 802, 901
PTX-597	Email from A. Cole to A. Cole et al., titled "PrimaFit 2.0 Brainstorming Kickoff"	2/22/2019	SAGE00033816	SAGE00033816	B. Burn Ex. 234	MIL3, 106, 401, 402, 403, 602, 801, 802, 901
PTX-598	Email from B. Blasbas to D. Ulreich et al., titled "UFP Technologies"	3/19/2019	SAGE00033821	SAGE00033821	D. Ulreich Ex. 73	401, 402, 403, 801, 802
PTX-599	PrimaFit 2.0, Limited Launch Plan	5/7/2019	STRSAGE00021487	STRSAGE00021496	D. Ulreich Ex. 74	401, 402, 403, 801, 802
PTX-600	Schematics re: PrimaFit 2.0, 700-116 Rev NEW (DRAFT)	7/29/2019	STRSAGE00021777	STRSAGE00021785	D. Ulreich Ex. 75	106, 401, 402, 403, 801, 802, 901
PTX-601	Email from D. Ulreich to B. Blasbas, titled "RE: PrimaFit 2.0"	10/7/2019	SAGE00034039	SAGE00034039	D. Ulreich Ex. 76	401, 402, 403, 801, 802
PTX-602	Email from D. Ulreich to E. Jozwiak et al., titled "RE: PrimaFit 2.0 ECO 21-00003/PrimaFit 2.0	2/5/2021	STRSAGE00024959	STRSAGE00024960	D. Ulreich Ex. 78	401, 402, 403, 801, 802
PTX-603	Schematics re: PrimaFit 2.0, 5400-2 Rev NEW	6/23/2021	STRSAGE00022109	STRSAGE00022109	D. Ulreich Ex. 79	401, 402, 403, 801, 802
PTX-604	Schematics re: PrimaFit 2.0, 5400-2 Rev NEW	6/23/2021	STRSAGE00022109	STRSAGE00022109	D. Ulreich Ex. 80	401, 402, 403, 801, 802
PTX-605	Schematics re: PrimaFit 2.0, 5400-2 Rev A	6/23/2021	STRSAGE00000035	STRSAGE00000035	D. Ulreich Ex. 81	401, 402, 403, 801, 802
PTX-606	Schematics re: PrimaFit 2.0, 5400-2 Rev A	6/23/2021	STRSAGE00022294	STRSAGE00022294	D. Ulreich Ex. 82	401, 402, 403, 801, 802
PTX-607	Schematics re: PrimaFit 2.0, 5400 Rev 1	8/8/2017	SAGE00033694	SAGE00033694	D. Ulreich Ex. 84	401, 402, 403, 801, 802
PTX-608	Email from A. Cole to B. Blasbas, titled "Low cost version"				D. Ulreich Ex. 86	401, 402, 403, 801, 802
PTX-609	Email from C. Newton to R. Newton, titled "Wicks 1" with attachments "IMG_0391.JPG; ATT00002.txt; IMG_0390.JPG; ATT00004.txt; IMG_0385.JPG; ATT00006.txt; IMG_0384.JPG; ATT00002.txt; IMG_0382.JPG; ATT00004.txt; IMG_0381.JPG; ATT00006.txt"	10/24/2014	PWNewton_0002093	PWNewton_0002103	DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901	106, 401, 402, 403, 602, 801, 802, 901
PTX-610	Email from C. Newton to R. Newton, titled "Wicks 2" with attachments "IMG_0383.JPG; ATT00002.txt; IMG_0382.JPG; ATT00004.txt; IMG_0381.JPG; ATT00006.txt"	10/24/2014	PWNewton_0002104	PWNewton_0002110	R. Newton Ex. 266	106, 401, 402, 403, 602, 801, 802, 901
PTX-611	Email from D. Newton to K. Pawlik et al., titled "Re: Woohoo!"	8/5/2015	PWNewton_0003729	PWNewton_0003730	R. Newton Ex. 267	106, 401, 402, 403, 602, 801, 802, 901
PTX-612	Email from D. Newton to K. Pawlik et al., titled "Re: PureWick"	9/16/2015	PWNewton_0002972	PWNewton_0002976	R. Newton Ex. 290	401, 402, 403, 602, 801, 802, 901
PTX-613	Case Studies (09/13/14 - 10/19/15) re: PureWick's DryDoc and Wicks	1/9/2018	PUREWICK_0017078	PureWick_0017084	R. Newton Ex. 298	401, 402, 403, 602, 801, 802, 901
	Email from C. Newton to S. Skelton et al., titled "[External] photos - individual shots" with attachments "5 inch straight PureWick.JPG; 6 inch rigid curve PureWick.JPG; 6 inch rigid taper PureWick.JPG; 6 inch flex curve PureWick.JPG; 6 inch soft flex tape shell PureWick.JPG; 6 inch PureWick History of Prototypes PowerPoint Presentation		PWNewton_0004746	PWNewton_0004746	R. Newton Ex. 304	401, 402, 403, 602, 801, 802, 901
PTX-614					R. Newton Ex. 309	
PTX-615						MIL3, 401, 402, 403, 602, 801, 802
PTX-616	A. Cole et al., Segue Design Review, Review design path to launch PowerPoint Presentation	7/12/2017	SAGE00025835	SAGE00025839	R. Newton Ex. 310	MIL3, 401, 402, 403, 602, 801, 802, 901
PTX-617	Project Segue	N/A	SAGE00035465	SAGE00035509	B. Blasbas Ex. 155	DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-618	Email from B. Blasbas to A. Cole, titled, "Declined: PrimaFit 2.0 Status Meeting"	3/3/2019	SAGE00033819	SAGE00033819	DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901	DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-619	Email from C. Adam to C. Adam et al., titled "Review PrimaFit 2.0 Concepts"	4/11/2019	SAGE00036125	SAGE00036125	B. Blasbas Ex. 158	DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-620	Email from B. O'Halloran to B. Blasbas et al., titled "RE: PrimaFit 2.0 DWG Review"	7/18/2019	SAGE00033935	SAGE00033935	B. Blasbas Ex. 165	401, 402, 403, 801, 802
PTX-621	Email from B. O'Halloran to B. Blasbas et al., titled "RE: PrimaFit 2.0"	7/31/2019	SAGE00036325	SAGE00036325	B. Blasbas Ex. 166	401, 402, 403, 602, 801, 802
PTX-622						

PTX No.	Title	Date	Beg. Bates No.	End Bates No.	Depo. Ex. No.	Objections
PTX-625	Massachusetts General Hospital, Trial Results Summary, Sage #5400 PrimaFit™ External Urine Management System for Females		STRSAGE00021324	STRSAGE00021324	M. Karlovsky Ex. 148	DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-626	Email from D. Wargo to R. Morgan et al., titled "RE: UMPC - PureWick Female PWF030F"	9/22/2022	BDPUREWICK_00002199	BDPureWick_00002200	M. Karlovsky Ex. 150	401, 402, 403, 602, 801, 802, 901
PTX-627	Sage Internal Document re: PrimaFit™ Competitive Intelligence, Consume Medical		STRSAGE00023012	STRSAGE00023013	V. Thomas Ex. 130	401, 402, 403, 801, 802
PTX-628	Sage Internal Document re: PrimaFit™ Competitive Intelligence, Boehringer Laboratories		STRSAGE00023009	STRSAGE00023011	V. Thomas Ex. 131	401, 402, 403, 801, 802
PTX-629	New Look: Sage PrimaFit™ External Urine Management for the Female Anatomy Brochure (2021)		STRSAGE00000005	STRSAGE00000005	V. Thomas Ex. 138	DAUB, Duplicative, MIL1, 401, 402, 403, 602, 801, 802
PTX-630	PrimaFit 700-116, Limited Launch, Liquid Retention and Catch Percentage Testing	8/27/2019	STRSAGE00021793	STRSAGE00021795	Y. David Ex. 105	106, 401, 402, 403, 602, 801, 802, 901
PTX-631	T.D. Averch, et al. "Catheter-Associated Urinary Tract Infections: Definitions and Significance in the Urologic Patient", American Urological Association (2014)	00/00/2014	PUREWICK_EXP_0000013	PureWick_EXP_0000029		106, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-632	T. Beeson and C. Davis, "Urinary Management With an External Female Collection Device," J Wound Ostomy Continence Nurs. 45(2):187-189 (2018)	03/00/2018	BDPUREWICK_EXP_00000003	BDPureWick_EXP_00000005		106, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-633	Boehringer CareDry® System website printout	00/00/2019	BDPUREWICK_EXP_00000006	BDPureWick_EXP_00000008		106, 401, 402, 403, 801, 802, 901
PTX-634	L.E. Fisher, et al. "Biomaterial modification of urinary catheters with antimicrobials to give CrossMark long-term broadspectrum antibiofilm activity," J. of Controlled Release 202:57-64	1/30/2015	BDPUREWICK_EXP_00000020	BDPureWick_EXP_00000027		106, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-635	Consume QiVi website printout		BDPUREWICK_EXP_00000032	BDPureWick_EXP_00000035		106, 401, 402, 403, 801, 802, 901
PTX-636	Medline Versette Female External Catheter website printout		BDPUREWICK_EXP_00000041	BDPureWick_EXP_00000041		106, 401, 402, 403, 801, 802, 901
PTX-637	WITHDRAWN					
PTX-638	Email from S. Skelton to J. Gohde re Alternative Drainage Monthly - September	9/30/2017	PUREWICK_0034238	PureWick_0034242		DAUB, MIL1, 401, 402, 403, 801, 802, 901
PTX-639	Memo from P. Zani to R. Hanson re June 2017 Results	6/30/2017	PUREWICK_0051867	PureWick_0051873		
PTX-640	Memo from P. Zani to R. Hanson re February 2017 Results	3/6/2017	PUREWICK_0057041	PureWick_0057047		DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-641	WITHDRAWN					401, 402, 403, 801, 802, 901
PTX-642	WITHDRAWN					
PTX-643	WITHDRAWN					
PTX-644	WITHDRAWN					
PTX-645	WITHDRAWN					
PTX-646	EP2180907	5/5/2010	SAGE00043345	SAGE00043369		DAUB, 401, 402, 403, 602, 801, 802, 901
PTX-647	WITHDRAWN					
PTX-648	PrimaFit use image		STRSAGE00000002	STRSAGE00000002		Duplicative, 401, 402, 403, 602, 801, 802
PTX-649	WO 00/57784	10/5/2000	STRSAGE00005761	STRSAGE00005788		DAUB, 401, 402, 403, 801, 802
PTX-650	WO 2007/042823	4/19/2007	STRSAGE00006022	STRSAGE00006037		DAUB, 401, 402, 403, 801, 802
PTX-651	WO 2009/052496	4/23/2009	STRSAGE00006057	STRSAGE00006076		DAUB, 401, 402, 403, 801, 802
PTX-652	M. Macaulay, et al. "A Noninvasive Continence Management System Development and Evaluation of a Novel Toileting Device for Women," J Wound Ostomy Continence Nurs.	00/00/2007	STRSAGE00020513	STRSAGE00020520		DAUB, 401, 402, 403, 702, 703, 801, 802, 901
PTX-653	Urine Management Enhancements Launch		STRSAGE00021282	STRSAGE00021282		
PTX-654	Medline Versette Competitive Video	N/A	STRSAGE00023017	STRSAGE00023017		DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-655	Boehringer CareDry™ System Instructions		STRSAGE00024741	STRSAGE00024742		401, 402, 403, 801, 802
PTX-656	QIVI Instructions for Use		STRSAGE00024750	STRSAGE00024751		401, 402, 403, 801, 802
PTX-657	WITHDRAWN					
PTX-658	WITHDRAWN					
PTX-659	WITHDRAWN					
PTX-660	WITHDRAWN					
PTX-661	WITHDRAWN					
PTX-662	WITHDRAWN					
PTX-663	WITHDRAWN					
PTX-664	Schematic		STRSAGE00024754	STRSAGE00024754		401, 402, 403
PTX-665	Medline Versette™ external catheter brochure		MEDLINE002	MEDLINE002		401, 402, 403, 801, 802
PTX-666	Medline Versette™ external catheter instructions for use		MEDLINE003	MEDLINE003		401, 402, 403, 801, 802
PTX-667	Medline Versette™ external catheter Best Practice Guidance		MEDLINE004	MEDLINE004		401, 402, 403, 801, 802
PTX-668	WITHDRAWN					
PTX-669	WITHDRAWN					
PTX-670	Email from J. Gohde to R. Hanson et al. re NTI Report	5/24/2019	PUREWICK_0033617	PureWick_0033617		401, 402, 403, 801, 802, 901
PTX-671	Sage Accounts	9/14/2018	PUREWICK_0034331	PureWick_0034331		401, 402, 403, 801, 802, 901
PTX-672	Tri-City Medical Center Notes	10/21/2016	PUREWICK_0059075	PureWick_0059075		106, 401, 402, 403, 801, 802, 901
PTX-673	WITHDRAWN					
PTX-674	Project Segue Launch Meeting Project Overview PrimaFit 2.0	9/22/2017	SAGE00023981	SAGE00023981	Blabas Ex. 154 (2023)	DAUB, MIL1, 401, 402, 403, 801, 802
PTX-675	Material Risk Assessment of Stryker's PrimaFit 2.0 Device		STRSAGE00022093	STRSAGE00022093		DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-676			STRSAGE00024167	STRSAGE00024167		DAUB, Duplicative, MIL1, 401, 402, 403, 602, 801, 802
PTX-677	Email from M. Jackson to K. Pawlik et al. re PureWick	2/4/2016	Pawlik_002059	Pawlik_002059		401, 402, 403, 602, 801, 802, 901
PTX-678	EP 0613355	1/22/1997	N/A	N/A		
PTX-679	U.S. Patent No. 4,747,166	5/31/1988	N/A	N/A		
PTX-680	U.S. Patent No. 3,349,768	10/31/1967	N/A	N/A		
PTX-681	U.S. Patent ApJ.S. Patent Appl. Pub. No. US 2008/0287894 A1	11/20/2008	N/A	N/A		
PTX-682	U.S. Patent No. 7,135,012	11/14/2006	SAGE00001798	SAGE00001819		
PTX-683	U.S. Patent Application No. 2006/0015080	1/19/2006	N/A	N/A		
PTX-684	WO2007/042823		N/A	N/A		
PTX-685	U.S. Patent No. 4,886,508	12/12/1989	PureWick_0020456	PureWick_0020468		
PTX-686	PureWick Slides for MIP	9/23/2015	PureWick_0021008	PureWick_0021014		106, 401, 402, 403, 602, 801, 802, 901
PTX-687	Emails From K. Pawlik to R. Newton et al re Wicks #1-4	8/12/2015	Pawlik_009493	Pawlik_009494		401, 402, 403, 602, 801, 802, 901
PTX-688	Emails From C. Newton to K. Pawlik et al re PureWick Results DD	11/19/2015	Newton_0002766	Newton_002779		401, 402, 403, 602, 801, 802, 901
PTX-689	Emails From C. Newton to K. Pawlik et al re Wicks 6A	7/31/2015	Newton_0002661	Newton_0002666		401, 402, 403, 602, 801, 802, 901
PTX-690	WITHDRAWN					
PTX-691	10 Finalists Chosen for Dare-to-Dream Medtech Design Challenge (PureWick)	11/10/2014	PUREWICK_0018134	PureWick_0018136		DAUB, MIL3, 106, 401, 402, 403, 602, 801, 802, 901
PTX-692	Prototype Photograph		PUREWICK_0019761	PUREWICK_0019761		DAUB, MIL3, 401, 402, 403, 602, 901
PTX-693	Prototype Photograph		PUREWICK_0019785	PUREWICK_0019785		401, 402, 403, 901
PTX-694	La Vona Coath Test Results	12/22/2014	PUREWICK_0025873	PUREWICK_0025873		106, 401, 402, 403, 602, 801, 802, 901
PTX-695	Urine Capture Device Survey	9/16/2014	PUREWICK_0025880	PUREWICK_0025881		106, 401, 402, 403, 602, 801, 802, 901
PTX-696	PureWick Corporation Informed Consent for Product Evaluation	8/26/2013	PUREWICK_0025897	PUREWICK_0025898		106, 401, 402, 403, 602, 801, 802, 901
PTX-697	PureWick Corporation Informed Consent for Product Evaluation	9/14/2013	PUREWICK_0025899	PUREWICK_0025900		106, 401, 402, 403, 602, 801, 802, 901
PTX-698	PureWick Corporation Informed Consent for Product Evaluation	9/19/2013	PUREWICK_0025903	PUREWICK_0025904		106, 401, 402, 403, 602, 801, 802, 901
PTX-699	PureWick Corporation Informed Consent for Product Evaluation	11/20/2013	PUREWICK_0025905	PUREWICK_0025906		106, 401, 402, 403, 602, 801, 802, 901
PTX-700	Prototype Photograph		PUREWICK_0030278	PUREWICK_0030278		MIL3, 401, 402, 403, 602, 901
PTX-701	Simon Foundation Poster 4-20-17.pdf	7/12/2017	PUREWICK_0032109	PUREWICK_0032109		106, 401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-702	DRG Market Data		BDPUREWICK_00001708	BDPUREWICK_00001708		106, 401, 402, 403, 602, 801, 802, 901
PTX-703	The Simon Foundation for Continence First Place Prize		Newton_0008150	Newton_0008150		401, 402, 403, 602, 801, 802, 901
PTX-704	Prototype Photograph		PWNewton_0002094	PWNewton_0002094		106, 401, 402, 403, 901
PTX-705	MIP Intro Video		CONNECT_0000040	CONNECT_0000040		MIL3, 401, 402, 403, 801, 802, 901
PTX-706	WITHDRAWN					
PTX-707	Global External Urine Management Products Market Analysis (2022 – 2028) dated July 2022		BDPureWick_00001818	BDPureWick_00002029		106, 401, 402, 403, 602, 801, 802, 901
PTX-708	UCC FY23 ASR PureWick Path to 500M	3/17/2022	BDPUREWICK_00002060	BDPureWick_00002069		401, 402, 403, 801, 802, 901
PTX-709	Purewick Sales Sep 2021 to Dec 2022.xlsx		BDPureWick_00002931	BDPureWick_00002931 (native, excel)		401, 402, 403, 602, 801, 802, 901
PTX-710	WITHDRAWN					
PTX-711	PureWick Functional Analysis Presentation dated September 5, 2019	9/5/2019	PureWick_0064472	PureWick_0064472 (native, ppt)		401, 402, 403, 801, 802
PTX-712	PrimaFit Competency Skills Checklist	2/14/2018	SAGE00000110	SAGE00000110		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-713	CNS impact through innovation and implementation of PrimaFit External Urine Management System for Females		SAGE00000111	SAGE00000112		
PTX-714	Email thread between Kieling Todd, Morris Kenneth and Cary Area West Team dated October	10/13/2017	SAGE00027411	SAGE00027412		DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-715	PrimaFit Mid-Year Meeting 2021 Presentation		STRSAGE00021234	STRSAGE00021234 (native, ppt)		DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-716	Urine Management Fast Track II	10/4/2022	STRSAGE00021236	STRSAGE00021236		401, 402, 403, 801, 802, 901
PTX-717	Marquette General Hospital Trial Results Summary		STRSAGE00021321	STRSAGE00021323		DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-718	CAUTI Reduction Initiative, Baptist Hospital of Miami		STRSAGE00021333	STRSAGE00021333		DAUB, MIL1, 401, 402, 403, 602, 801, 802
PTX-719	PrimaFit 2.0 Limited Launch Process Non-Filing Justification Summary		STRSAGE00021684	STRSAGE00021685		401, 402, 403, 602, 801, 802, 901
PTX-720	Annual Marketing Plan for Urine Management		STRSAGE00022938	STRSAGE00022990		401, 402, 403, 801, 802
PTX-721	2021 Urine Management Annual Marketing Plan		STRSAGE00022993	STRSAGE00022993 (native, ppt)		DAUB, MIL1, 401, 402, 403, 801, 802
PTX-722	Test Site Account List	6/17/2019	STRSAGE00025396	STRSAGE00025396		401, 402, 403, 801, 802
PTX-723	WITHDRAWN					

PTX No.	Title	Date	Beg. Bates No.	End Bates No.	Depo. Ex. No.	Objections
PTX-724	WITHDRAWN					
PTX-725	First Female External Catheter: A Founders' Story of Turning Unmet Needs into a Standard of Care ( <a href="https://www.aacn.org/conferences-and-events/events-calendar/national-events/event-sessions/national-teaching-institute---2018/srt901/first-female-external-catheter-a-founders-CONNECT">https://www.aacn.org/conferences-and-events/events-calendar/national-events/event-sessions/national-teaching-institute---2018/srt901/first-female-external-catheter-a-founders-CONNECT</a> Announces Winners of 2015 Most Innovative New Product Awards ( <a href="https://connect.org/connect-announces-the-winners-of-the-most-innovative-new-product-BD-PureWick-Urine-Collection-System">https://connect.org/connect-announces-the-winners-of-the-most-innovative-new-product-BD - PureWick Urine Collection System</a> ( <a href="https://www.mddionline.com/general/-hospital/medical-design-excellence-awards-2021-finalists-gastrointestinal-and-">https://www.mddionline.com/general/-hospital/medical-design-excellence-awards-2021-finalists-gastrointestinal-and-</a>	4/3/2023	N/A	N/A		MIL3, 401, 402, 403, 602, 801, 802, 901
PTX-726	BD - PureWick Urine Collection System ( <a href="https://www.mddionline.com/general/-hospital/medical-design-excellence-awards-2021-finalists-gastrointestinal-and-">https://www.mddionline.com/general/-hospital/medical-design-excellence-awards-2021-finalists-gastrointestinal-and-</a>	4/13/2021	N/A	N/A		MIL3, 106, 401, 402, 403, 602, 801, 802, 901
PTX-727	The Gallen Foundation Announces Nominations are Now Open for the 2022 Prix Gallen USA Awards ( <a href="https://www.pnewswire.com/news-releases/the-gallen-foundation-announces-nominations-are-now-open-for-the-2022-prix-gallen-usa-awards-301469570.html">https://www.pnewswire.com/news-releases/the-gallen-foundation-announces-nominations-are-now-open-for-the-2022-prix-gallen-usa-awards-301469570.html</a> , viewed on	1/27/2022	N/A	N/A		DAUB, MIL3, 106, 401, 402, 403, 602, 801, 802, 901
PTX-728	C.R. Bard, Inc. Form 10-Q for the quarterly period ended September 30, 2017	9/30/2017	N/A	N/A		401, 402, 403, 602, 801, 802, 901
PTX-729	BD Completes Bard Acquisition, Creating New Global Health Care Leader. ( <a href="https://news.bd.com/2017-12-29-BD-Completes-Bard-Acquisition-Creating-New-Global-Sage-An-essential-partner-for-healthcare-facilities.">https://news.bd.com/2017-12-29-BD-Completes-Bard-Acquisition-Creating-New-Global-Sage: An essential partner for healthcare facilities. (<a href="https://sageproductsglobal.com/company-A-History-of-Innovation">https://sageproductsglobal.com/company-A-History-of-Innovation</a> (<a href="https://sageproductsglobal.com/history/">https://sageproductsglobal.com/history/</a>, viewed on April 3, 2023.)</a>	12/29/2017	N/A	N/A		401, 402, 403, 602, 801, 802, 901
PTX-730	Sage: An essential partner for healthcare facilities. ( <a href="https://sageproductsglobal.com/company-A-History-of-Innovation">https://sageproductsglobal.com/company-A-History-of-Innovation</a> ( <a href="https://sageproductsglobal.com/history/">https://sageproductsglobal.com/history/</a> , viewed on April 3, 2023.)	N/A	N/A	N/A		401, 402, 403, 602, 801, 802, 901
PTX-731	A History of Innovation ( <a href="https://sageproductsglobal.com/history/">https://sageproductsglobal.com/history/</a> , viewed on April 3, 2023.)	N/A	N/A	N/A		401, 402, 403, 602, 801, 802, 901
PTX-732	Stryker Announces Definitive Agreement to Acquire Sage Products, LLC from Madison Dearborn Partners for \$2.775 Billion ( <a href="https://investors.stryker.com/press-releases/news-details/2016/Stryker-Announces-Definitive-Agreement-to-Acquire-Sage-Products-LLC-from-Stryker-completes-acquisition-of-Sage-Products-LLC">https://investors.stryker.com/press-releases/news-details/2016/Stryker-Announces-Definitive-Agreement-to-Acquire-Sage-Products-LLC-from-Stryker-completes-acquisition-of-Sage-Products, LLC</a> ( <a href="https://sageproducts.com/press-room/stryker-sage-acquisition-announcement/">https://sageproducts.com/press-room/stryker-sage-acquisition-announcement/</a> , viewed on April 3, 2023.)	2/1/2016	N/A	N/A		401, 402, 403, 602, 801, 802, 901
PTX-733	Stryker completes acquisition of Sage Products, LLC ( <a href="https://sageproducts.com/press-room/stryker-sage-acquisition-announcement/">https://sageproducts.com/press-room/stryker-sage-acquisition-announcement/</a> , viewed on April 3, 2023.)	4/1/2016	N/A	N/A		401, 402, 403, 602, 801, 802, 901
PTX-734	Sage PrimaFit Product Information Brochure (2021)	N/A	N/A	N/A		401, 402, 403, 602, 801, 802, 901
PTX-735	Plaintiff's Complaint dated August 12, 2019 (PureWick Corporation v. Sage Products, LLC, 19-1509-MN)	8/12/2019	N/A	N/A		401, 402, 403, 602, 801, 802, 901
PTX-736	Verdict Form dated April 1, 2022 (PureWick Corporation v. Sage Products, LLC, 19-1509-MN)	4/1/2022	N/A	N/A		DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-737	Sage PrimaFit: External Urine Management for the Female Anatomy ( <a href="https://sageproducts.com/primafit-external-urine-management-system-for-females/">https://sageproducts.com/primafit-external-urine-management-system-for-females/</a> , viewed	N/A	N/A	N/A		DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-738	What are Different Types of Female External Catheters? ( <a href="https://www.consuremedical.com/what-are-different-types-of-female-external-catheters/">https://www.consuremedical.com/what-are-different-types-of-female-external-catheters/</a> ,	N/A	N/A	N/A		401, 402, 403, 602, 801, 802, 901
PTX-739	PureWick Female External Catheter, Critical Care, US ( <a href="https://www.bd.com/en-us/products-and-solutions/products/product-families/purewick-female-external-">https://www.bd.com/en-us/products-and-solutions/products/product-families/purewick-female-external-</a>	N/A	N/A	N/A		401, 402, 403, 602, 801, 802, 901
PTX-740	PrimaFit Product Brochure ( <a href="https://www.bd.com/en-us/products-and-solutions/products/product-page.PWF030F">https://www.bd.com/en-us/products-and-solutions/products/product-page.PWF030F</a> overview, viewed on April 27, 2023.)	N/A	N/A	N/A		401, 402, 403, 602, 801, 802, 901
PTX-741	WITHDRAWN					Duplicative, 401, 402, 403, 602, 801, 802, 901
PTX-742	WITHDRAWN					
PTX-743	WITHDRAWN					
PTX-744	WITHDRAWN					
PTX-745	WITHDRAWN					
PTX-746	Non-invasive continence management system, Brunel University London ( <a href="http://people.brunel.ac.uk/~bsraew/NICMS/project.htm">http://people.brunel.ac.uk/~bsraew/NICMS/project.htm</a> , viewed on May 19, 2023.)	N/A	N/A	N/A		401, 402, 403, 602, 801, 802, 901
PTX-747	Research, development and demonstration of a novel non-invasive continence management system (NICMS): Fact Sheet, European Commission CORDIS	01/01/2003 - 06/30/2006	N/A	N/A		401, 402, 403, 602, 801, 802, 901
PTX-748	Wellcare Smart External Urine Collection System, WellCare Medical ( <a href="https://www.wellcaredmedtech.com/?products">https://www.wellcaredmedtech.com/?products</a> , 19/28.html, viewed on May 19, 2023.)	N/A	N/A	N/A		401, 402, 403, 602, 801, 802, 901
PTX-749	An Alternative to the Indwelling Foley Catheter in Incontinent Female Patients poster (February 2018) ( <a href="http://www.nacns.org/wp-content/uploads/2018/02/Poster-58-Tran.pdf">http://www.nacns.org/wp-content/uploads/2018/02/Poster-58-Tran.pdf</a> ,	N/A	N/A	N/A		401, 402, 403, 602, 801, 802, 901
PTX-750	Bladder Catheterization (2023) ( <a href="https://www.mdsave.com/procedures/bladder-catheterization/d78bfa6d#:~:text=On%20MDSave%2C%20the%20cost%20of,more%20about%2">https://www.mdsave.com/procedures/bladder-catheterization/d78bfa6d#:~:text=On%20MDSave%2C%20the%20cost%20of,more%20about%2</a>	N/A	N/A	N/A		401, 402, 403, 602, 801, 802, 901
PTX-751	Avoid Foley Catheters to Improve ED Patients' Comfort, Reduce Costs ( <a href="https://www.acepnow.com/article/avoid-foley-catheters-improve-ed-patients-comfort-">https://www.acepnow.com/article/avoid-foley-catheters-improve-ed-patients-comfort-</a>	2/12/2014	N/A	N/A		401, 402, 403, 602, 801, 802, 901
PTX-752	Sage PrimaFit External Urine Management for the Female Anatomy (2021) ( <a href="https://sageproducts.com/wp-content/uploads/Sage-PrimaFit-Brochure.pdf">https://sageproducts.com/wp-content/uploads/Sage-PrimaFit-Brochure.pdf</a> , viewed on May	N/A	N/A	N/A		401, 402, 403, 602, 801, 802, 901
PTX-753	Profitability and Royalty Rates Across Industries: Some Preliminary Evidence (March 2019) ( <a href="https://www.researchgate.net/publication/228210498_Profitability_and_Royalty_Rates_Across_Industries_Some_Preliminary_Evidence">https://www.researchgate.net/publication/228210498_Profitability_and_Royalty_Rates_Across_Industries_Some_Preliminary_Evidence</a> , viewed on May 19, 2023.)	N/A	N/A	N/A		401, 402, 403, 602, 801, 802, 901
PTX-754	Appropriate Use and Prompt Removal of Indwelling Urinary Catheters ( <a href="https://www.cdc.gov/infectioncontrol/pdf/strive/CAUTI102-508.pdf">https://www.cdc.gov/infectioncontrol/pdf/strive/CAUTI102-508.pdf</a> , viewed on May 4, 2023.)	N/A	N/A	N/A		401, 402, 403, 602, 801, 802, 901
PTX-755	Vaidyanathan, S., et al. (2002). Prevention of pressure sore caused by indwelling urinary catheters. Spinal Cord, 40, 489, <a href="https://doi.org/10.1038/sj.sc.3101356">https://doi.org/10.1038/sj.sc.3101356</a>	8/21/2022	N/A	N/A		401, 402, 403, 602, 801, 802, 901
PTX-756	Intermittent Urinary Catheters ( <a href="https://extranet.ahsnet.ca/teams/policydocuments/1/klink/et-klink-ckv-intermittent-urinarycatheters-indications-and-planning.pdf">https://extranet.ahsnet.ca/teams/policydocuments/1/klink/et-klink-ckv-intermittent-urinarycatheters-indications-and-planning.pdf</a> , viewed on May 5, 2023.)	6/28/2019	N/A	N/A		401, 402, 403, 602, 801, 802, 901
PTX-757	PrimaFit SS Net Sales and Cases		STRSAGE_EXP_000006	STRSAGE_EXP_000006		401, 402, 403, 801, 802
PTX-758	OMNI Medical Brochure		COOLEY_0001422	COOLEY_0001432		401, 402, 403, 801, 802, 901
PTX-759	WITHDRAWN					
PTX-760	Tri-City Medical Center PureWick Female Urinary Incontinence Management	N/A	TRICITY_0000001	TRICITY_0000025		401, 402, 403, 801, 802
PTX-761	Guideline for Prevention of CAUTI 2009 CDC	N/A	PUREWICK_EXP_0000363	PureWick_EXP_0000423		106, 401, 402, 403, 602, 801, 802, 901
PTX-762	PrimaFit Patient Education Card	N/A	BDPUREWICK_EXP_00000030	BDPureWick_EXP_00000031		401, 402, 403, 602, 801, 802, 901
PTX-763	PrimaFit Competency Skill Checklist	N/A	BDPUREWICK_EXP_00000038	BDPureWick_EXP_00000039		401, 402, 403, 602, 801, 802, 901
PTX-764	Sage PrimaFit Training Video	N/A	BDPUREWICK_EXP_00000040	BDPureWick_EXP_00000040 (native, video)		401, 402, 403, 602, 801, 802, 901
PTX-765	Age, gender, and Voided Volume Dependency of Peak Urinary Flow Rate and Uroflowmetry Nor	N/A	BDPUREWICK_EXP_00000044	BDPureWick_EXP_00000049		401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-766	3B Scientific Catheterization Simulator P93	N/A	BDPUREWICK_EXP_00000056	BDPureWick_EXP_00000067		401, 402, 403, 801, 802
PTX-767	Inman et al article re The Impact of Temperature and Urinary Constituents on Urine Viscosity	N/A	BDPUREWICK_EXP_00000073	BDPureWick_EXP_00000078		401, 402, 403, 602, 702, 703, 801, 802, 901
PTX-768	Incontinence-associated Dermatitis Sell Sheet Sage	4/14/2020	SAGE00021410	SAGE00021411		DAUB, MIL1, 401, 402, 403, 801, 802
PTX-769	PrimaFit 2.0 Bowtie Label Art	10/4/2017	STRSAGE00000007	STRSAGE00000007		401, 402, 403, 801, 802
PTX-770	PrimaFit 2.0 Rev C Flex Link	6/20/2022	STRSAGE00000008	STRSAGE00000008		401, 402, 403, 801, 802
PTX-771	PrimaFit 2.0 Suction Connector	6/20/2022	STRSAGE00000009	STRSAGE00000009		401, 402, 403, 801, 802
PTX-772	PrimaFit 2.0 Flexible Tubing	6/20/2022	STRSAGE00000010	STRSAGE00000010		401, 402, 403, 801, 802
PTX-773	PrimaFit 2.0 Foam Backer	6/20/2022	STRSAGE00000012	STRSAGE00000012		401, 402, 403, 801, 802
PTX-774	PrimaFit 2.0 Bottom Barrier	6/20/2022	STRSAGE00000013	STRSAGE00000013		401, 402, 403, 801, 802
PTX-775	PrimaFit 2.0 Inner Foam	6/20/2022	STRSAGE00000014	STRSAGE00000014		401, 402, 403, 801, 802
PTX-776	Van Den Heuvel Article	N/A	STRSAGE00020521	STRSAGE00020530		DAUB, 401, 402, 403, 801, 802, 901
PTX-777	PrimaFit 2.0 Design Review	4/15/2020	STRSAGE00022047	STRSAGE00022047 (native, ppt)		401, 402, 403, 801, 802, 901
PTX-778	PrimaFit 2.0 Biocompatibility PowerPoint	7/2/2020	STRSAGE00022095	STRSAGE00022095 (native, ppt)		DAUB, MIL1, 401, 402, 403, 801, 802, 901
PTX-779	PrimaFit 2.0 Selective Adhesive Roll Stock	1/19/2021	STRSAGE00022141	STRSAGE00022141		401, 402, 403, 801, 802, 901
PTX-780	Short Term Care Facility PrimaFit 2.0 Evaluation	8/20/2021	STRSAGE00023001	STRSAGE00023003		401, 402, 403, 801, 802, 901
PTX-781	PrimaFit 2.0 Change Request Plan	9/9/2021	STRSAGE00023048	STRSAGE00023056		401, 402, 403, 801, 802, 901
PTX-782	PrimaFit 2.0 Foam Backer Updates	9/9/2021	STRSAGE00023823	STRSAGE00023823		401, 402, 403, 801, 802, 901
PTX-783	PrimaFit 2.0 Wicking Fabric Material Specification Rev. 002	2/7/2020	STRSAGE00023824	STRSAGE00023824		401, 402, 403, 801, 802, 901
PTX-784	PrimaFit 2.0 Inner Foam Rev. 001	2/4/2020	STRSAGE00023825	STRSAGE00023825		401, 402, 403, 801, 802, 901
PTX-785	PrimaFit 2.0 Test Plan	5/7/2020	STRSAGE00024251	STRSAGE00024251 (native, excel)		401, 402, 403, 801, 802, 901
PTX-786	Sage Letter to NYU Winthrop Hospital System	5/26/2021	STRSAGE00025143	STRSAGE00025143		106, 401, 402, 403, 801, 802, 901
PTX-787	Email from K. Sexton to J. Gordon et al re PrimaFit 2.0	7/29/2021	STRSAGE00025236	STRSAGE00025236		401, 402, 403, 801, 802, 901
PTX-788	RMB Review PowerPoint	8/19/2021	STRSAGE00025251	STRSAGE00025251 (native, ppt)		Duplicative, 401, 402, 403, 801, 802, 901
PTX-789	Email from A. Kueffner to A. Cole et al re PrimaFit 2.0 Timeline	9/3/2021	STRSAGE00025258	STRSAGE00025259		401, 402, 403, 801, 802, 901
PTX-790	Email from J. Layer to Z. Vandelogt re PrimaFit 2.0 Transition Update	11/4/2021	STRSAGE00025368	STRSAGE00025371		401, 402, 403, 801, 802, 901
PTX-791	PrimaFit 2.0 Design Drawing Revision I	2/6/2023	STRSAGE00025407	STRSAGE00025407		401, 402, 403, 801, 802
PTX-792	CAUTI PREVENTION Brigham and Women's Hospital	N/A	SAGE00039610	SAGE00039626		DAUB, MIL1, 401, 402, 403, 801, 802, 901
PTX-793	PrimaFit 2.0 Bag Design Drawing		STRSAGE000000045	STRSAGE000000048		401, 402, 403, 801, 802, 901
PTX-794	PrimaFit 2.0 Project Overview		STRSAGE00021536	STRSAGE00021536 (native, ppt)		401, 402, 403, 801, 802, 901
PTX-795	NPJ Limited Launch Design Approval Form	2/26/2019	STRSAGE00021556	STRSAGE00021561		401, 402, 403, 801, 802, 901
PTX-796	PrimaFit 2.0 Catch and Retention Testing	7/15/2019	STRSAGE00021597	STRSAGE00021614		DAUB, MIL1, 106, 401, 402, 403, 602, 801, 802, 901
PTX-797	PrimaFit 2.0 Limited Launch Process Non-Filing Justification Summary		STRSAGE00021676	STRSAGE00021677		106, 401, 402, 403, 801, 802, 901
PTX-798	PrimaFit 2.0 Limited Launch Plan	11/12/2019	STRSAGE00021952	STRSAGE00021953		401, 402, 403, 801, 802, 901
PTX-799	PrimaFit 2.0 Design Update	4/16/2020	STRSAGE00022048	STRSAGE00022048 (native, ppt)		401, 402, 403, 801, 802, 901
PTX-800	PrimaFit 700-116 Limited Launch Liquid Retention and Catch Percentage Testing	9/10/2019	STRSAGE00022115	STRSAGE00022118		DAUB, MIL1, 106, 401, 402, 403, 801, 802, 901
PTX-801	PrimaFit 2.0 Foam Backer Material Specification (with redline edits)		STRSAGE00022304	STRSAGE00022304		106, 401, 402, 403, 801, 802, 901
PTX-802	PrimaFit At Home		STRSAGE00023083	STRSAGE00023083 (native, ppt)		DAUB, MIL1, 401, 402, 403, 602, 801, 802, 901
PTX-803	Uroflowmetry Simulator	1/22/2020	STRSAGE00023117	STRSAGE00023120		DAUB, MIL1, 401, 402, 403, 801, 802, 901
PTX-804	Change Request Plan Form PrimaFit 2.0		STRSAGE00023612	STRSAGE00023617		401, 402, 403, 602, 801, 802, 901
PTX-805	PrimaFit 2.0 Manufacturing - Process Failure Mode and Effects Analysis		STRSAGE00023631	STRSAGE00023631 (native, excel)		401, 402, 403, 602, 801, 802, 901
PTX-806	Liquid Diversion/Retention Test Report, PrimaFit 2.0 (with redline edits)		STRSAGE00024283	STRSAGE00024288		DAUB, MIL1, 401, 402, 403, 801, 802, 901
PTX-807	Selective Adhesive Device Securement Equivalency, PrimaFit 2.0		STRSAGE00024298	STRSAGE00024300		DAUB, MIL1, 401, 402, 403, 801, 802, 901



PTX No.	Title	Date	Beg. Bates No.	End Bates No.	Depo. Ex. No.	Objections
PTX-808	Material Integrity, PrimaFit 2.0		STRSAGE00024303	STRSAGE00024305		401, 402, 403, 801, 802, 901
PTX-809	Liquid Diversion/Retention Test, PrimaFit 2.0		STRSAGE00024405	STRSAGE00024414		DAUB, MILI, 401, 402, 403, 801, 802, 901
PTX-810	Tapered End Material and Weld Softness, PrimaFit 2.0		STRSAGE00024429	STRSAGE00024466		DAUB, MILI, 401, 402, 403, 801, 802, 901
PTX-811	Liquid Diversion/Retention Test Report, PrimaFit 2.0	8/18/2021	STRSAGE00024473	STRSAGE00024482		DAUB, MILI, 106, 401, 402, 403, 801, 802, 901
PTX-812	Fabric Surface Area, PrimaFit 2.0		STRSAGE00024486	STRSAGE00024487		DAUB, MILI, 401, 402, 403, 801, 802, 901
PTX-813	Cheyenne Regional Medical Center - PrimaFit 2.0 Product Evaluation Results	11/16/2022	STRSAGE00024730	STRSAGE00024732		401, 402, 403, 801, 802, 901
PTX-814	Risk Management Board Notes		STRSAGE00024969	STRSAGE00024970		106, 401, 402, 403, 801, 802, 901
PTX-815	Email from C. Schmidt to S. Jirafe et al., titled "RE: PrimaFit 2.0 Updates	9/7/2021	STRSAGE00025264	STRSAGE00025265		401, 402, 403, 801, 802, 901
PTX-816	WITHDRAWN					
PTX-817	WITHDRAWN					
PTX-818	PrimaFit 2.0 Foam Backer Material Specification	6/5/2022	STRSAGE00023832	STRSAGE00023832		401, 402, 403, 801, 802
PTX-819	PrimaFit 2.0 Bottom Barrier	2/4/2020	STRSAGE00023833	STRSAGE00023833		401, 402, 403, 801, 802
PTX-820	PrimaFit 2.0 Selective Adhesive Roll Stock	3/18/2022	STRSAGE00022290	STRSAGE00022290		401, 402, 403, 801, 802
PTX-821	PrimaFit 2.0 Wicking Fabric Material Specification	6/20/2022	STRSAGE00000011	STRSAGE00000011		401, 402, 403, 801, 802
PTX-822	PrimaFit 2.0 Bag with Instructions Design Transfer	3/8/2021	STRSAGE00023855	STRSAGE00023855		401, 402, 403, 801, 802
PTX-823	PrimaFit 2.0 Defects Acceptance	10/5/2021	STRSAGE00023643	STRSAGE00023645		106, 401, 402, 403, 801, 802, 901
PTX-824	PrimaFit 2.0 Defects	10/5/2021	STRSAGE00023646	STRSAGE00023648		106, 401, 402, 403, 801, 802, 901
PTX-825	PrimaFit 2.0 Tapered End Material and Weld Softness Updated	8/16/2021	STRSAGE00024339	STRSAGE00024341		401, 402, 403, 801, 802, 901
PTX-826	TM0301194 Volume Recovery for PureWick	11/9/2017	PureWick_0037856	PureWick_0037859		401, 402, 403, 801, 802, 901
PTX-827	5400 PrimaFit 2.0 Bag	N/A	STRSAGE00000041	STRSAGE00000044		401, 402, 403, 801, 802, 901
PTX-828	WITHDRAWN					
PTX-829	Sage PrimoFit Launch Workshop	N/A	SAGE00028962	SAGE00028962		DAUB, MILI, 401, 402, 403, 801, 802, 901
PTX-830	PureWick Historical Sales Since October 2017	N/A	PureWick_0030220	PureWick_0030220		106, 401, 402, 403, 801, 802, 901
PTX-831	PrimaFit 2.0 Automated Assembly Operating Procedure	4/5/2022	STRSAGE00000119	STRSAGE00000140		401, 402, 403, 801, 802, 901
PTX-832	PureWick Healthy Patient White Paper	10/31/2019	BDPureWick_00013401	BDPureWick_00013404		401, 402, 403, 602, 702, 703, 801, 802, 901, 1006
PTX-833	CAUTI Reduction Working Group LA	10/31/2019	BDPureWick_00013426	BDPureWick_00013426		401, 402, 403, 602, 801, 802, 901
PTX-834	CAUTI Reduction Working Group New Orleans	10/31/2019	BDPureWick_00013442	BDPureWick_00013442		401, 402, 403, 602, 801, 802, 901
PTX-835	Top Value Fabrics 103444	6/6/2019	STRSAGE00023329	STRSAGE00023329		401, 402, 403, 801, 802, 901
PTX-836	PrimaFit 2.0 Updates	9/9/2021	STRSAGE00023580	STRSAGE00023588		DAUB, MILI, 401, 402, 403, 801, 802, 901
PTX-837	Dr Description	4/1/2022	STRSAGE00023635	STRSAGE00023635		106, 401, 402, 403, 801, 802, 901
PTX-838	NW Bentonville PrimaFit Evaluation Summary	11/16/2022	STRSAGE00024733	STRSAGE00024734		401, 402, 403, 801, 802, 901
PTX-839	PrimaFit 2.0 Status Update	4/8/2019	STRSAGE00021438	STRSAGE00021438		DAUB, MILI, 401, 402, 403, 801, 802, 901
PTX-840	PrimaFit 2.0 Rev 001	10/15/2019	STRSAGE00021918	STRSAGE00021918		401, 402, 403, 801, 802, 901
PTX-841	PrimaFit 2.0 700-116-2	3/16/2020	STRSAGE00023034	STRSAGE00023040		401, 402, 403, 801
PTX-842	DRG Market Share Data	8/26/2021	STRSAGE00022366	STRSAGE00022366		401, 402, 403, 801, 802, 901
PTX-843	PrimaFit 2.0 Schedule Delay	4/12/2021	STRSAGE00023060	STRSAGE00023060		401, 402, 403, 801, 802, 901
PTX-844	PrimaFit 2.0 RMB	N/A	STRSAGE00025253	STRSAGE00025255		106, 401, 402, 403, 801, 802, 901
PTX-845	PrimaFit 2.0 Finished Good	N/A	STRSAGE00025233	STRSAGE00025235		401, 402, 403, 801, 802, 901
PTX-846	Email from K. Sexton to A. Cole re Medline Versette	5/28/2021	STRSAGE00025192	STRSAGE00025198		401, 402, 403, 801, 802
PTX-847	Sage Prima and Primo Cost Analysis and Forecasts	N/A	STRSAGE00021956	STRSAGE00021956		401, 402, 403, 801, 802, 901
PTX-848	2021 Urine Management Annual Marketing Plan	00/00/2021	STRSAGE00022993	STRSAGE00022993		DAUB, MILI, 401, 402, 403, 801, 802, 901, dupe
PTX-849	Urine Management Competitive Intelligence for PrimaFit PrimoFit - BD Bard	12/1/2020	STRSAGE00023014	STRSAGE00023016		DAUB, MILI, 401, 402, 403, 801, 802, 901
PTX-850	State of the Business for NEW! PrimaFit 5400	00/00/2021	STRSAGE00023058	STRSAGE00023058		401, 402, 403, 801, 802
PTX-851	Transition Plan from PrimaFit 1.0 to 2.0	5/5/2021	STRSAGE00023061	STRSAGE00023061		106, 401, 402, 403, 801, 802, 901
PTX-852	PrimaFit 2018 Forecast	10/9/2019	STRSAGE00023080	STRSAGE00023080		DAUB, MILI, 401, 402, 403, 801, 802, 901
PTX-853	PrimaFit 2.0 Demand Changes	1/6/2022	STRSAGE00023088	STRSAGE00023088		401, 402, 403, 801, 802, 901
PTX-854	PrimaFit 2.0 presentation	11/6/2020	STRSAGE00023107	STRSAGE00023110		401, 402, 403, 801, 802, 901
PTX-855	Project CANDLÉ: Disruptive Solution for Female Urine Output Management	8/22/2016	PureWick_0062973	PureWick_0062995		DAUB, MILI, 401, 402, 403, 801, 802, 901
PTX-856	Segue Market Assessment 2017	00/00/2017	SAGE00023855	SAGE00023855		DAUB, MILI, 401, 402, 403, 801, 802, 901
PTX-857	Sage Female ECD Highlights from Field Evaluation	00/00/2017	SAGE00023969	SAGE00023969		DAUB, MILI, 401, 402, 403, 801, 802, 901
PTX-858	Innovation in Reducing CAUTI's Poster	4/23/2017	PureWick_0016009	PureWick_0016009		106, 401, 402, 403, 702, 703, 801, 802, 901
PTX-859	Image of C. Newton winning award	N/A	PureWick_0016011	PureWick_0016011		MIL3, 401, 402, 403, 801, 802, 901
PTX-860	Email from L. King to T. Morton re PureWick	5/26/2016	PureWick_0017717	PureWick_0017717		106, 401, 402, 403, 801, 802, 901
PTX-861	Email from M. Leaton to J. Pasquariello re is there any chance I can get more	5/25/2016	PureWick_0019687	PureWick_0019695		106, 401, 402, 403, 801, 802, 901
PTX-862	Lessons from Successful Implementation of the PureWick External Female Catheter at Tri-City	N/A	PureWick_0020700	PureWick_0020700		106, 401, 402, 403, 702, 703, 801, 802, 901
PTX-863	Centegra Woodstock - IMC Product Evaluation Results	10/2/2017	SAGE00024018	SAGE00024019		DAUB, MILI, 401, 402, 403, 801, 802, 901
PTX-864	Email from P. Nelson to C. Golden, et al. re Kaiser Meeting Highlights and next steps	8/8/2017	SAGE00026049	SAGE00026050		DAUB, MILI, 106, 401, 402, 403, 602, 801, 802, 901, Dupe
PTX-865	Hospitals: Trials and Customers	N/A	PureWick_0024833	PureWick_0024833		106, 401, 402, 403, 801, 802, 901
PTX-866	Summary of Customers in 2016 and 2017	N/A	PureWick_0026958	PureWick_0026958		401, 402, 403, 801, 802, 901
PTX-867	PureWick Conversions	N/A	PureWick_0030212	PureWick_0030212		401, 402, 403, 801, 802, 901
PTX-868	PureWick Sales 2017 to 2018	N/A	PureWick_0030215	PureWick_0030215		401, 402, 403, 801, 802, 901
PTX-869	PureWick Account Sales	N/A	PureWick_0030216	PureWick_0030216		401, 402, 403, 801, 802, 901
PTX-870	PureWick Account Sales 2017 to 2019	N/A	PureWick_0030217	PureWick_0030217		401, 402, 403, 801, 802, 901
PTX-871	PureWick Sales Trend	N/A	PureWick_0030221	PureWick_0030221		401, 402, 403, 801, 802, 901
PTX-872	Market Inclusion List: PrimaFit	7/26/2022	STRSAGE00022436	STRSAGE00022436		401, 402, 403, 801, 802, 901
PTX-873	Market Inclusion List: PrimaFit	3/18/2022	STRSAGE00022506	STRSAGE00022506		401, 402, 403, 801, 802, 901
PTX-874	Market Inclusion List: PrimaFit	5/16/2022	STRSAGE00022572	STRSAGE00022572		401, 402, 403, 801, 802, 901
PTX-875	Market Inclusion List: PrimaFit	11/29/2021	STRSAGE00022642	STRSAGE00022642		401, 402, 403, 801, 802, 901
PTX-876	Market Inclusion List: PrimaFit	12/22/2021	STRSAGE00022773	STRSAGE00022773		401, 402, 403, 801, 802, 901
PTX-877	Market Inclusion List: PrimaFit	1/24/2022	STRSAGE00022774	STRSAGE00022774		401, 402, 403, 801, 802, 901
PTX-878	Market Inclusion List: PrimaFit	4/22/2022	STRSAGE00022909	STRSAGE00022909		401, 402, 403, 801, 802, 901
PTX-879	PureWick 2.0 Healthy Volunteer Study	9/2/2021	BDPureWick_00001004	BDPureWick_00001036		401, 402, 403, 801, 802, 901
PTX-880	Excel with list of key accounts and summary	N/A	PureWick_0030211	PureWick_0030211		401, 402, 403, 801, 802, 901
PTX-881	Article titled "Urinary Tract Infection (Catheter-Associated Urinary Tract Infection [CAUTI] and Non-Catheter-Associated Urinary Tract Infection [UTI] and Other Urinary System Infection [USI])	01/00/2017	SAGE00027307	SAGE00027324		401, 402, 403, 602, 801, 802, 901
PTX-882	Strategies to Decrease Urinary Catheter Utilization	N/A	PureWick_0014573	PureWick_0014624		401, 402, 403, 801, 802, 901
PTX-883	Project Pipeline	7/15/2014	SAGE00025962	SAGE00025963		401, 402, 403, 801, 802, 901
PTX-884	Sage Female External Collection Device Sale and Marketing Primer Binder	02/00/2018	SAGE00023974	SAGE00023974		DAUB, MILI, 401, 402, 403, 801, 802, 901
PTX-885	Risk Management Board Minutes PrimaFit 2.0	N/A	STRSAGE00023090	STRSAGE00023094		401, 402, 403, 801, 802, 901
PTX-886	PrimaFit IFU Update, Skin Assessment Justification	11/30/2022	STRSAGE00024252	STRSAGE00024252		401, 402, 403, 801, 802, 901
PTX-887	PrimaFit Risk Management Plan	N/A	STRSAGE00025252	STRSAGE00025252		DAUB, MILI, 401, 402, 403, 801, 802, 901
PTX-888	CAUTI reports with PrimaFit use	N/A	STRSAGE00021331	STRSAGE00021331		DAUB, MILI, 401, 402, 403, 801, 802, 901, 1006
PTX-889	Northwest Georgia Medical Center - S3E PrimaFit Product Evaluation Results	2/25/2022	STRSAGE00024656	STRSAGE00024658		401, 402, 403, 801, 802, 901
PTX-890	Conemaugh Memorial Medical Center Main Campus PrimaFit Product Evaluation Results	3/24/2022	STRSAGE00024662	STRSAGE00024664		401, 402, 403, 801, 802, 901
PTX-891	Citizens Medical Center PrimaFit Product Evaluation Results	4/19/2022	STRSAGE00024669	STRSAGE00024671		401, 402, 403, 801, 802, 901
PTX-892	Samaritan Medical Center PrimaFit Product Evaluation Results	4/25/2022	STRSAGE00024672	STRSAGE00024673		401, 402, 403, 801, 802, 901
PTX-893	C.W. Bill Young VA Medical Center PrimaFit Product Evaluation Results	5/16/2022	STRSAGE00024679	STRSAGE00024680		401, 402, 403, 801, 802, 901
PTX-894	University Medical Center - All units PrimaFit Product Evaluation Results	8/29/2022	STRSAGE00024708	STRSAGE00024713		401, 402, 403, 801, 802, 901
PTX-895	University Medical Center - All units PrimaFit Product Evaluation Results	8/29/2022	STRSAGE00024714	STRSAGE00024715		401, 402, 403, 801, 802, 901
PTX-896	PrimaFit Project Request	N/A	STRSAGE00025333	STRSAGE00025333		401, 402, 403, 801, 802
PTX-897	PrimaFit 2.0 NPQ Limited Launch Design Approval Form	N/A	STRSAGE00021562	STRSAGE00021566		401, 402, 403, 801, 802, 901
PTX-898	CPS Urinary Management survey	2/16/2022	STRSAGE00021298	STRSAGE00021300		401, 402, 403, 801, 802, 901
PTX-899	CPS Urinary Management survey	6/2/2022	STRSAGE00021304	STRSAGE00021307		401, 402, 403, 801, 802
PTX-900	CPS Urinary Management survey	9/14/2022	STRSAGE00021308	STRSAGE00021310		401, 402, 403, 801, 802, 901
PTX-901	CPS Urinary Management survey	9/23/2022	STRSAGE00021311	STRSAGE00021313		401, 402, 403, 801, 802, 901
PTX-902	CPS Urinary Management survey	6/8/2022	STRSAGE00021314	STRSAGE00021316		401, 402, 403, 801, 802, 901
PTX-903	CPS Urinary Management survey	9/28/2022	STRSAGE00021317	STRSAGE00021319		401, 402, 403, 801, 802, 901
PTX-904	Pennsylvania Hospital PrimaFit vs. Current Practice survey	N/A	STRSAGE00021326	STRSAGE00021326		401, 402, 403, 801, 802, 901
PTX-905	Capital Health Regional PrimaFit vs. Current Practice survey	N/A	STRSAGE00021327	STRSAGE00021327		401, 402, 403, 801, 802, 901
PTX-906	Limited Launch Opportunities: PrimaFit 2.0	N/A	STRSAGE00023004	STRSAGE00023004		401, 402, 403, 801, 802
PTX-907	PrimaFit claims	12/10/2021	STRSAGE00023082	STRSAGE00023082		401, 402, 403, 801, 802, 901
PTX-908	Sage sales representative list	12/1/2022	STRSAGE00024735	STRSAGE00024735		401, 402, 403, 801, 802, 901
PTX-909	North Central 2019-2023 PureWick Sales Data	N/A	BDPureWick_00002172	BDPureWick_00002172		401, 402, 403, 801, 802, 901
PTX-910	Project Candle C.R. Bard, Inc. Acquisition Committee Memo Proposal to Acquire PureWick, Inc.	N/A	BDPureWick_00006458	BDPureWick_00006470		401, 402, 403, 801, 802, 901
PTX-911	Email from H. Fletcher to K. Sexton re Inova Fairfax	12/17/2019	SAGE00036921	SAGE00036921		401, 402, 403, 801, 802
PTX-912	Project CANDLÉ: Disruptive Solution for Female Urine Output Management Acquisition	4/10/2017	BDPureWick_00006905	BDPureWick_00006927		401, 402, 403, 801, 802, 901
PTX-913	U.S. Pat. No. 4,804,377 (Hanifi)	2/14/1989	SAGE00022070	SAGE00022074		DAUB, MILI, 401, 402, 403, 801, 802
PTX-914	Project Segue presentation	N/A	SAGE00025715	SAGE00025715		DAUB, MILI, 401, 402, 403, 801, 802, 901
PTX-915	Sage NPQ Innovation presentation	6/19/2019	SAGE00036854	SAGE00036854		DAUB, 401, 402, 403, 602, 801,

PTX No.	Title	Date	Beg. Bates No.	End Bates No.	Depo. Ex. No.	Objections
PTX-918	PrimaFit packaging schematic	N/A	STRSAGE00000016	STRSAGE00000017		401, 402, 403, 801, 802
PTX-919	Hot Melt Pillow (HM-0978)	3/31/2021	STRSAGE00000018	STRSAGE00000018		401, 402, 403, 801, 802
PTX-920	PrimaFit 2.0 Suction Connector	1/14/2021	STRSAGE00000019	STRSAGE00000019		401, 402, 403, 801, 802
PTX-921	PrimaFit 2.0 Flexible Tubing document	5/18/2021	STRSAGE00000021	STRSAGE00000021		401, 402, 403, 801, 802
PTX-922	U.S. Pat. Pub. No. 2017/0266031 (Sanchez)	9/21/2017	STRSAGE00000281	STRSAGE00000236		DAUB, MIL1, MIL3, 401, 402, 403, 801, 802
PTX-923	U.S. Pat. Pub. No. 2018/0028349 (Newton)	2/1/2018	STRSAGE00002382	STRSAGE00002404		DAUB, MIL1, MIL3, 401, 402, 403, 801, 802
PTX-924	PrimaFit assembly schematic	5/2/2018	STRSAGE00002144	STRSAGE00002147		DAUB, MIL1, 401, 402, 403, 801, 802, 901
PTX-925	Project: PrimaFit 2.0 Required/Desired	N/A	STRSAGE00002143	STRSAGE00002143		401, 402, 403, 801, 802, 901
PTX-926	PrimaFit 2.0 Phase Exit presentation	6/28/2019	STRSAGE00002152	STRSAGE00002152		106, 401, 402, 403, 801, 802, 901
PTX-927	PrimaFit 2.0 NPD Limited Launch Design Approval Form	7/31/2019	STRSAGE00002167	STRSAGE00002167		106, 401, 402, 403, 801, 802, 901
PTX-928	PrimaFit 2.0 Female External Urine Collection Device -Limited Launch Process-Non-Filing	8/1/2019	STRSAGE00002168			401, 402, 403, 602, 801, 802, 901
PTX-929	PrimaFit 2.0 NPD Limited Launch Design Approval Form	9/5/2019	STRSAGE00002185	STRSAGE00002186		106, 401, 402, 403, 801, 802, 901
PTX-930	PrimaFit 2.0 NPD Limited Launch Design Approval Form	9/10/2019	STRSAGE00002185	STRSAGE00002189		401, 402, 403, 801, 802
PTX-931	Change Request Form CRP# 20-0398	6/25/2021	STRSAGE00002303	STRSAGE00002304		106, 401, 402, 403, 801, 802, 901
PTX-932	Email from E. Jazwiak to D. Ulreich re Equivalent 6EO Material from Alternative Vendor	3/1/2021	STRSAGE00002503	STRSAGE00002503		401, 402, 403, 801, 802, 901
PTX-933	U.S. Pat. No. 10,857,025 (Davis)	12/8/2020	PureWick_EXP_0001504	PureWick_EXP_0001558		
PTX-934	Bard and Stryker Sales percentages	00/00/2021	STRSAGE00002996	STRSAGE00002996		DAUB, MIL1, 106, 401, 402, 403, 801, 802, 901
PTX-935	Maude Report	4/4/2023				401, 402, 403, 801, 802, 901, untimely and never disclosed during any phase of discovery, unidentified exhibit
PTX-936	PureWick Sales	N/A	BDPureWick_00015408	BDPureWick_00015408		401, 402, 403, 801, 802, 901
PTX-937	PureWick Costs	N/A	BDPureWick_00015409	BDPureWick_00015409		401, 402, 403, 801, 802, 901
PTX-938	PureWick Unit Sales	N/A	BDPureWick_00015410	BDPureWick_00015410		401, 402, 403, 801, 802, 901
PTX-939	PureWick P&L	N/A	BDPureWick_00015411	BDPureWick_00015411		401, 402, 403, 801, 802, 901
PTX-940	Project Candle: Disruptive Solution for Female Incontinence Management Board of Directors Meeting	4/19/2017	BDPureWick_00003098	BDPureWick_00003113		MIL1, MIL3, 401, 402, 403, 602, 801, 802, 901
PTX-941	2021 Prix Gallien Award	00/00/2021	PWNNewton_0000895	PWNNewton_0000895		401, 402, 403, 801, 802, 901, untimely and never disclosed during any phase of discovery
PTX-942	PureWick Physical Sample		BDPureWick_00002931	BDPureWick_00002931		401, 402, 403, 901
PTX-943	PureWick Physical Sample		BDPureWick_00002932	BDPureWick_00002932		DAUB, 401, 402, 403, 901
PTX-944	PureWick Physical Sample		BDPureWick_00002933	BDPureWick_00002933		401, 402, 403, 901
PTX-945	PureWick Physical Sample		BDPureWick_00002934	BDPureWick_00002934		401, 402, 403, 901
PTX-946	PureWick Physical Sample		BDPureWick_00002935	BDPureWick_00002935		401, 402, 403, 901
PTX-947	D. Kirsh, "The 24 best medical device innovations of 2022." Medical Design & Outsourcing (Aug. Supplemental Expert Report of Lauren R. Kindler with Appendices and Exhibits	8/12/2022	N/A	N/A		401, 402, 403, 801, 802, 901, untimely and never disclosed during any phase of discovery, unidentified exhibit
PTX-948		2/5/2024	N/A	N/A		DAUB, 401, 402, 403, 602, 702, 703, 801, 802, 901, 1006
PTX-949	Opening Expert Report of Dr. John Collins Regarding Infringement	5/21/2021				DAUB, MIL1, MIL2, MIL3, 401, 402, 403, 702, 703, 801, 802, 901, 1006, untimely
PTX-950	Exhibit A to Opening Expert Report of Dr. John Collins Regarding Infringement	5/21/2021				DAUB, MIL1, MIL2, MIL3, 401, 402, 403, 702, 703, 801, 802, 901, 1006, untimely
PTX-951	Exhibit B to Opening Expert Report of Dr. John Collins Regarding Infringement	5/21/2021				DAUB, MIL1, MIL2, MIL3, 401, 402, 403, 702, 703, 801, 802, 901, 1006, untimely
PTX-952	Exhibit C to Opening Expert Report of Dr. John Collins Regarding Infringement	5/21/2021				DAUB, MIL1, MIL2, MIL3, 401, 402, 403, 702, 703, 801, 802, 901, 1006, untimely
PTX-953	Exhibit D to Opening Expert Report of Dr. John Collins Regarding Infringement	5/21/2021				DAUB, MIL1, MIL2, MIL3, 401, 402, 403, 702, 703, 801, 802, 901, 1006, untimely
PTX-954	Exhibit E to Opening Expert Report of Dr. John Collins Regarding Infringement	5/21/2021				DAUB, MIL1, MIL2, MIL3, 401, 402, 403, 702, 703, 801, 802, 901, 1006, untimely
PTX-955	Exhibit F to Opening Expert Report of Dr. John Collins Regarding Infringement	5/21/2021				DAUB, MIL1, MIL2, MIL3, 401, 402, 403, 702, 703, 801, 802, 901, 1006, untimely
PTX-956	Exhibit G to Opening Expert Report of Dr. John Collins Regarding Infringement	5/21/2021				DAUB, MIL1, MIL2, MIL3, 401, 402, 403, 702, 703, 801, 802, 901, 1006, untimely
PTX-957	Exhibit H to Opening Expert Report of Dr. John Collins Regarding Infringement	5/21/2021				DAUB, MIL1, MIL2, MIL3, 401, 402, 403, 702, 703, 801, 802, 901, 1006, untimely
PTX-958	Exhibit I to Opening Expert Report of Dr. John Collins Regarding Infringement	5/21/2021				DAUB, MIL1, MIL2, MIL3, 401, 402, 403, 702, 703, 801, 802, 901, 1006, untimely
PTX-959	Exhibit J to Opening Expert Report of Dr. John Collins Regarding Infringement	5/21/2021				DAUB, MIL1, MIL2, MIL3, 401, 402, 403, 702, 703, 801, 802, 901, 1006, untimely
PTX-960	Exhibit K to Opening Expert Report of Dr. John Collins Regarding Infringement	5/21/2021				DAUB, MIL1, MIL2, MIL3, 401, 402, 403, 702, 703, 801, 802, 901, 1006, untimely
PTX-961	Exhibit L to Opening Expert Report of Dr. John Collins Regarding Infringement	5/21/2021				DAUB, MIL1, MIL2, MIL3, 401, 402, 403, 702, 703, 801, 802, 901, 1006, untimely
PTX-962	Exhibit M to Opening Expert Report of Dr. John Collins Regarding Infringement	5/21/2021				DAUB, MIL1, MIL2, MIL3, 401, 402, 403, 702, 703, 801, 802, 901, 1006, untimely
PTX-963	Reply Expert Report of Dr. John Collins Regarding Infringement	7/23/2021				DAUB, MIL1, MIL2, MIL3, 401, 402, 403, 702, 703, 801, 802, 901, 1006, untimely

## Sage Preliminary Exhibit List

DX	DESCRIPTION	PW1 DDX	PW1 DTX	PW2 DDX	PW2 PDX	PROD BEG	PROD END*	PL. OBJ
1	US 8,287,508 to Sanchez	1	1			PUREWICK_0001877	PUREWICK_0001883	
2	US 10,390,989	2	2			PUREWICK_0001941	PUREWICK_0001982	
3	US 10,226,376	3	3			PUREWICK_0001884	PUREWICK_0001940	
4	US 10,376,407	4	4			PureWick_0007220	PureWick_0007226	402, 403
5	WO 2017/209779	5	5			STRSAGE00006557	STRSAGE00006625	402, 403, H, 901, NP
6	US 2006/0015080 to Mahnensmith		6			SAGE00006308	SAGE00006316	402, 403, H, 901, NP
7	US 4,747,166 to Kuntz	007; 039	7	330		STRSAGE00002800	STRSAGE00002808	402, 403, H, 901, NP
8	7,220,250	8	8			SAGE00002332	SAGE00002351	402, 403, H, 901, NP
9	US 3,349,768	625	9			SAGE00003221	SAGE00003228	402, 403, H, 901, NP
10	4,425,130		10			SAGE00022052	SAGE00022062	402, 403, H, 901, NP
11	5,674,212		11			SAGE00022885	SAGE00022926	402, 403, H, 901, NP
12	WO2007/042823 A2	630	12			SAGE00006956	SAGE00006971	402, 403, H, 901, NP
13	WO 2000/057784		13			SAGE00021296	SAGE00021323	402, 403, H, 901, NP
14	US 4,886,508	631	14			SAGE00001240	SAGE00001252	402, 403, H, 901, NP
15	EP 0613355		15			SAGE00009400	SAGE00009415	402, 403, H, 901, NP
16	US 7,135,012 to Harvie	426; 626	016; 426			SAGE00001798	SAGE00001819	402, 403, H, 901, NP
17	JP2001/276107A (with translation)	627	17			SAGE00040840	SAGE00040858	402, 403, H, 901
18	3,613,123		18			SAGE00023070	SAGE00023076	402, 403, H, 901, NP
19	1,742,080		19			SAGE00009395	SAGE00009399	402, 403, H, 901, NP
20	3,520,300		20			SAGE00006662	SAGE00006665	402, 403, H, 901, NP
21	2007/0191804		21			SAGE00006083	SAGE00006091	402, 403, H, 901, NP
22	US 2004/0006321		22			SAGE00021623	SAGE00021669	402, 403, H, 901, NP
23	Certified FH 8,287,508 (12-840,475)	203	23			PUREWICK_0000001	PUREWICK_0000123	
24	Certified File History for 10,390,989	24	24			PUREWICK_0000824	PUREWICK_0001876	
24A	Excerpts of Certified File History for 10,390,989							Incom, 402, 403, NP
25	8/15/2017 - Power of Atty from 10,390,989 FH		25					Incom, 402, 403, NP
26	Certified File History for 10,226,376	26	26		110	PUREWICK_0000124	PUREWICK_0000823	
26A	Excerpts Certified File History for 10,226,376							Incom, 402, 403, NP
27	7/26/2017 Power of Attorney from 10,226,376 FH		27					
28	PCT/2016/049274 File History	028; 215	28			PureWick_0002185	PureWick_0002313	
29	4,804,377		29			SAGE00022070	SAGE00022074	402, 403, H, 901, NP
30	4,882,794		30			SAGE00009416	SAGE00009423	402, 403, H, 901, NP
31	8,353,074		31			SAGE00009036	SAGE00009048	402, 403, H, 901, NP

## Sage Preliminary Exhibit List

32	US 2004/0254547		32		SAGE00000621	SAGE00000631	402, 403, H, 901, NP
33	4,352,356		33		SAGE00041286	SAGE00041292	402, 403, H, 901, NP
34	Macaulay et al, Noninvasive Continence Mgmt System, Journal of Wound Ostomy and Continence Nursing 2007 34(6) 641-648		34		SAGE00040893	SAGE00040902	H, Incom, 901, 402, 403
35	AMXDmax brochure		35				H, 402, 403, 901
36	Nov. 10, 2014, 10 Finalists Chosen for Dare-to-Dream Medtech Design Challenge		36				
37	09/23/2016 PureWick PowerPoint presentation		37				
38	9/26/2018 Office Action from 10,390,989 FH		38				402, 403, H, 901, INCOM
39	4,692,160		39		SAGE00008614	SAGE00008634	402, 403, H, 901, NP
40	12/20/2018 Amendment and Response from 10,390,989 FH	40	40				402, 403, H, 901, INCOM
41	Dorsey Privilege Log	41	41				NE, H, 402, 403
42	Information Disclosure Statement (IDS) from 10,390,989 FH	42	42				Incom, 402, 403, NP
43	2/14/2019 Office Action from 10,390,989 FH	43	43				402, 403, H, 901, INCOM
44	5/13/2019 Amendment B & Response from 10,390,989 FH	44	44				402, 403, H, 901, INCOM
45	06/06/2019 Information Disclosure Statement (IDS) from 10,390,989 FH	45					Incom, 402, 403, NP
46	06/01/2017 Information Disclosure Statement (IDS) from 10,226,376 FH	46					Incom, 402, 403, NP
47	08/31/2017 Information Disclosure Statement (IDS) from 10,226,376 FH	47					Incom, 402, 403, NP
48	11/02/2017 Information Disclosure Statement (IDS) from 10,226,376 FH	48					Incom, 402, 403, NP
49	03/21/2018 Information Disclosure Statement (IDS) from 10,226,376 FH	49					Incom, 402, 403, NP
50	10/09/2018 Information Disclosure Statement by Applicant from 10,226,376 FH	50					Incom, 402, 403, NP
53	First 30(b)(6) Notice to PureWick (PureWick I)	53	53				NE, H
54	Second 30(b)(6) Notice to PureWick (PureWick I)	54	54				NE, H
56	PureWick Financial Spreadsheet	56	56		PureWick_0030212	PureWick_0030212	
57	PureWick Financial Spreadsheet	57	57		PureWick_0064470	PureWick_0064470	
58	PureWick Financial Spreadsheet	58	58		PureWick_0064471	PureWick_0064471	
59	PureWick Financial Spreadsheet	059; 245	59		PureWick_0033347	PureWick_0033347	
60	PureWick Financial Spreadsheet	60	60		PureWick_0064463	PureWick_0064463	
61	PureWick Financial Spreadsheet	61	061; 762		PureWick_0064464	PureWick_0064465	
62	PureWick Financial Spreadsheet	62	062; 763		PureWick_0064466	PureWick_0064467	
63	PureWick Financial Spreadsheet	63	63		PureWick_0017843	PureWick_0017883	
66	4/2017 BD Email Chain re: PureWick	66	66		PureWick_0054269	PureWick_0054270	H, 901, 402, 403

## Sage Preliminary Exhibit List

67	2016-2017 Bard Project Candle VOC Summary	67	67		124	PureWick_0051892	PureWick_0051895	H, 901, 402, 403
68	2/2/2017 Bard Due Diligence Report	068; 150	68			PureWick_0057447	PureWick_0057458	
69	4/19/2017 Letter re: PureWick Recall	069; 266	069; 266			PureWick_0017920	PureWick_0017924	H, 901, 402, 403
70	8/6/2017 Memo re: Market Research Summary	70	70			PureWick_0027822	PureWick_0027832	H, 901, 402, 403
74	9/2017 Bard Email Chain re: Sage Trial	74	74			PureWick_0044275	PureWick_0044277	
75	10/2017 Bard Email Chain re: Camille Newton	75	75			PureWick_0054639	PureWick_0054641	H, 901, 402, 403
76	10/2/2017 PureWick Memo	76	76			PureWick_0034736	PureWick_0034737	H, 901, 402, 403
78	1/3/2018 Email Chain	78	78			PureWick_0048352	PureWick_0048353	H, 402, 403
79	1/2018 Email Chain	79	79			PureWick_0048383	PureWick_0048386	H, 402, 403
83	10/4/2018 Bard Email	83	83			PureWick_0034364	PureWick_0034365	H, 901, 402, 403
84	Bard Memo	84	84			PureWick_0033905	PureWick_0033907	H, 901, 402, 403
85	11/2017 Email Chain	85	85			PureWick_0034307	PureWick_0034308	H, 901, 402, 403
87	12/2017 Email Chain	87	87			PureWick_0034565	PureWick_0034566	H, 901, 402, 403
88	10/12/2017 Bard Email re: Sage Customized Fit	88	88			PureWick_0034486	PureWick_0034487	
89	11/27/2018 PureWick Memo re: PureWick Feedback	89	089; 576		123; 149	PureWick_0027928	PureWick_0027934	H, 901, 402, 403
90	11/27/2017 Email Chain	090; 226	090; 226			PureWick_0034404	PureWick_0034404	H, 402, 403
92	Subpoena to Joseph Forehand	92	92					H, NE, 402, 403
93	Subpoena to Joseph Forehand	93	93					H, NE, 402, 403
94	US 2016/0367226 14/625,469 Publication	94	94			SAGE00001019	SAGE00001025	H, 901, 402, 403
95	US 2017/0252202 14/952,591 Publication	95	95			PureWick_0013403	PureWick_0013407	H, 901, 402, 403
96	US 2017/0348139 15/171,968 Publication	96	96			PureWick_0007227	PureWick_0007231	H, 901, 402, 403
97	62/082,279 - FH	97	97			PureWick_0006730	PureWick_0006788	H, 901, 402, 403, Incom
99	Calendar	99	99			JF0000001	JF0000057	H, 901, 402, 403
100	PureWick Document	100	100			PureWick_0020942	PureWick_0020948	H, 901, 402, 403
102	1/18/2014 Email and Attachment	102	102			Newton_0000184		
103	Business Plan	103	103	97		PureWick_0020880	PureWick_0020904	H, 901, 402, 403
104	1/20/2014 Email Chain	104	104			Newton_0000275	Newton_0000275	H, 901, 402, 403, Incom
105	1/2014 Email Chain and Attachment	105	105			Newton_0000892		H, 901, 402, 403, Incom
106	2/22/2014 Email with Attachment	106	106			Newton_0000346		H, 901, 402, 403, Incom
109	5/1/2014 PureWick Document re: Connect	109	109			PureWick_0020298	PureWick_0020298	H, 901, 402, 403
111	2014 Medtech Website Announcement	111				PureWick_0021742	PureWick_0021743	402, 403, H, 901, NP

## Sage Preliminary Exhibit List

112	Photograph of Tapered Wicks	112				PureWick_0019764	PureWick_0019764	402, 403, H, 901, NP
113	6/12/2015 Letter re: Hilltop Testing	113	113	322		PureWick_0015968	PureWick_0015968	
114	Physicals Photograph July 2015	114	114			PureWick_0019770	PureWick_0019770	
115	Physicals Photograph July 2015	115	115; 457			PureWick_0019767	PureWick_0019767	
116	Connect Application	116	116			PureWick_0020995	PureWick_0020999	H, 402, 403, 901
117	8/16/2015 Connect Press Release	117	117					H, 402, 403, 901
120	5/2016 Specification Drawing	120	120			PureWick_0017645	PureWick_0017645	H, 402, 403, 901
122	PureWick SCIMALS Report	122; 299	122			PureWick_0020725	PureWick_0020751	H, 402, 403, 901
123	2015 PureWick Business Plan	123	123			PureWick_0020752	PureWick_0020774	
124	3/20/2016 PureWick Document	124	124; 757			PureWick_0020788	PureWick_0020810	
125	3/15/2017 Bard Due Diligence Report	125	125			PureWick_0059418	PureWick_0059429	
127	PowerPoint	127	127			PureWick_0062973	PureWick_0062995	
132	03/19/2018 BD Email Chain	132				PureWick_0034771	PureWick_0034773	402, 403, H, 901, NP
133	PowerPoint	133; 234	133; 234			PureWick_0042421	PureWick_0042442	H, 402, 403
135	Bard Memo; Product Opportunity Appraisal	135; 242	135; 242			PureWick_0042774	PureWick_0042790	
136	10/9/18 Bard Memo	136	136			PureWick_0042771	PureWick_0042773	H, 402, 403, 901
139	9/2017 Email Chain	139	139			PureWick_0034171	PureWick_0034172	H, 402, 403, 901
140	9/2017 Email Chain	140	140			PureWick_0030337	PureWick_0030341	H, 402, 403, 901
141	9/7/2017 Email Chain re: Sage PrimaFit	141	141	14		PureWick_0034137	PureWick_0034137	H, 402, 403, 901
142	9/14/2018 PureWick Document re: Sage Accounts	142; 640	142; 640; 597			PureWick_0034331	PureWick_0034331	H, 402, 403, 901
143	1/2018 Email Chain	143	143			PureWick_0034413	PureWick_0034415	H, 402, 403, 901, INCOM
144	1/25/2019 Email Chain re: Sage	144	144			PureWick_0034716	PureWick_0034717	H, 402, 403, 901
145	10/16/2017 Bard Email with Attachments	145; 280	145; 280			PureWick_0034515		H, 402, 403, 901, INCOM
146	2/2018 Email Chain	146	146			PureWick_0034155	PureWick_0034156	H, 402, 403
147	June 2018 BD PowerPoint re: PrimaFit Evaluations	147	147	18	151	PureWick_0035383	PureWick_0035397	H, 402, 403
150	Bard Brochure	151	150			PureWick_0033396	PureWick_0033401	
151	Purewick Document	152	151			PureWick_0014379	PureWick_0014379	
153	Sales Document	153	153			PureWick_0020452	PureWick_0020452	
154	Sales Document	154	154			PureWick_0024830	PureWick_0024830	
155	Sales Document	155	155			PureWick_0024833	PureWick_0024833	
156	Sales Document	156	156			PureWick_0024837	PureWick_0024837	
157	Sales Document	157	157			PureWick_0026958	PureWick_0026958	H, 901, 402, 403
158	5/15/2020 Letter to Cherney		158					H, 901, 402, 403
159	9/23/2019 Powerpoint		159; 658			SAGE00036528	SAGE00036590	
160	PrimaFit 1.0 BOM Rev F		160; 172			SAGE00000128	SAGE00000130	



## Sage Preliminary Exhibit List

161	PrimaFit 1.0 Absorbent Fabric Specification		161; 179			SAGE00000240	SAGE00000240	
162	PrimaFit 1.0 Operating Procedure		162; 185			SAGE00000478	SAGE00000487	
163	PrimaFit 1.0 Absorbent Sleeve, Assembly		163; 178			SAGE00000238	SAGE00000238	
164	Photographs of PrimaFit 1.0		164					H, 402, 403, 901, NP
165	PrimaFit 1.0 Brochure		165			SAGE00000093	SAGE00000093	
166	Sage Marketing Material		166			SAGE00000095	SAGE00000104	
167	Sage Marketing Material		167			SAGE00000105	SAGE00000105	
168	Sage Marketing Material		168			SAGE00000106	SAGE00000107	
169	Sage PrimaFit 1.0 Video		169			SAGE00000009	SAGE00000009	402, 403
170	Sage PrimaFit 1.0 Video		170			SAGE00032908	SAGE00032908	
171	Sage PrimaFit 1.0 Powerpoint		171; 570			SAGE00000109	SAGE00000109	H
173	PrimaFit 1.0 BOM Rev E		173			SAGE00000131	SAGE00000134	
174	PrimaFit 1.0 BOM Rev D		174			SAGE00000135	SAGE00000138	
175	PrimaFit 1.0 Tube Port Subassembly w/Flexlink		175			SAGE00000206	SAGE00000207	
176	PrimaFit 1.0 Fabric Batting Specification		176			SAGE00000236	SAGE00000236	
177	PrimaFit 1.0 Fabric Batting Roll Stock		177			SAGE00000237	SAGE00000237	
181	PrimaFit 1.0 Absorbent Sleeve Specification Rev A		181			SAGE00000242	SAGE00000242	
182	PrimaFit 1.0 Cap Rev New		182			SAGE00000244	SAGE00000244	
183	PrimaFit 2.0 Adhesive Strip (Bottom) Rev A		183			SAGE00000247	SAGE00000247	
184	PrimaFit 1.0 Bowtie Specification Rev A		184			SAGE00000250	SAGE00000250	
186	PrimaFit 1.0 Instructions for Use		186			SAGE00000108	SAGE00000108	
187	Sage Powerpoint - Segue Prototyping		187		156	SAGE00025072	SAGE00025072	
192	Sage Document		192			SAGE00025637	SAGE00025637	H, 402, 403
193	October 2017 Sage Launch Powerpoint		193			SAGE00025676	SAGE00025676	
194	Sage Slide		194			SAGE00025795	SAGE00025795	H, 402, 403, 901
195	9/27/2017 Email Chain		195			SAGE00025975	SAGE00025977	H, 402, 403
196	10/16/2017 Email Chain re: PureWick Problems		196; 582			SAGE00027411	SAGE00027412	H, 402, 403, 901
197	Sage Spreadsheet		197			SAGE00028143	SAGE00028143	H, 403
198	8/8/2016 Memo re: PureWick Feedback		198			SAGE00028247	SAGE00028248	H
200	Updated Subpoena to Edward Callan	200	200					NE, 402, 403, H
201	Notice of Subpoena to Edward Callan	201	201					NE, 402, 403, H
202	File for patent Application Number 12/840,475		202					402, 403, H
204	File for Patent Application Numbers 61/955,537 and 14/625,469		204					402, 403, H
208	DTX 208 - File for Application 62/084,078	208						402, 403, H
209	File for Application Number 14/952,951		209			CALLAN 0000000326	CALLAN 0000000345	402, 403, H
210	File for Application 15/171,968	210	210					402, 403, H
211	File for 14/947,759	211	211					402, 403, H
214	Callan Privilege Log	214	214					NE, 402, 403, H
217	File for 15/238,427	217	217					402, 403, H
243	09/2018 Email Chain	243	243			PureWick_0034436	PureWick_0034438	402, 403, H
244	PureWick Powerpoint re: Sagentia	149; 244	149			PureWick_0064472	PureWick_0064472	H, 402, 403
248	2018 PureWick Product Transfer to Malaysia	248	248			PureWick_0030451	PureWick_0030476	
249	9/20/2017 Bard Document	249	249			PureWick_0055998	PureWick_0056003	
250	Bard Document	250	250			PureWick_0056306	PureWick_0056312	

## Sage Preliminary Exhibit List

251	Bard Document		251		PureWick_0030395	PureWick_0030401	
252	Bard Document	252	252		PureWick_0056985	PureWick_0056995	402, 403, H
253	Bard Document	253	253		PureWick_0052266	PureWick_0052275	402, 403, H
254	2/10/2017 Bard Document	254	254		PureWick_0052283	PureWick_0052322	
255	08/2017 Email Chain re: PureWick Manufacturing in Malaysia	255	255		PureWick_0054197	PureWick_0054198	
256	BD PowerPoint	256	256		PureWick_0042808	PureWick_0042808	
257	BD PowerPoint	257	257		PureWick_0042809	PureWick_0042809	
258	BD PowerPoint	258	258		PureWick_0042810	PureWick_0042810	
259	BD PowerPoint	259	259		PureWick_0042811	PureWick_0042811	
260	9/2017 Email Chain	260	260		PureWick_0044006	PureWick_0044007	H, 403, 901
261	9/2017 Email Chain	261	261		PureWick_0046970	PureWick_0046972	H, 403, 901
262	FDA Registration	262	262				H, 901
267	3/16/2017 Report of Correction re: Latex	267	267		PureWick_0017898	PureWick_0017910	H, 402, 403
268	5/9/2017 Letter	268	268		PureWick_0017925	PureWick_0017925	H, 402, 403
269	5/9/2017 Letter	269	269		PureWick_0017944	PureWick_0017945	H, 402, 403
272	9/28/2017 Letter from O'Farrell	272	272				H, NE, 402, 403, 901
273	4/28/2017 Letter to O'Farrell	273	273				H, NE, 402, 403, 901
274	Sixth Supplemental Responses To Sage Products First Set Of Interrogatories (Nos. 1-11) To Purewick Corporation	274	274				H, 402, 403, NE
276	6/29/2017 Email	276	276		PureWick_0035203	PureWick_0035204	H, 402, 403, 901
278	9/15/2017 Email with Attachment	278	278		PureWick_0052657	PureWick_0052658	H, 402, 403, 901
286	3/18/2014 Agreement	286; 345	286; 345		PureWick_0020273	PureWick_0020275	H, 402, 403, 901
287	2014 Bard-PureWick Agreement	287; 345.1	287		PureWick_0020276	PureWick_0020278	H, 402, 403, 901
288	2/28/2014 Notes re: Bard	288; 338	288; 338	71	PureWick_0020286	PureWick_0020286	H, 402, 403, 901
290	6/16/2017 Disclosures Schedules to the Agreement and Plan of Merger	290	290	139	PureWick_0015323	PureWick_0015361	
291	December 2016 Proposal Letter		291		PureWick_0020200	PureWick_0020203	
294	Bard Document	294	294		PureWick_0062956	PureWick_0062972	H, 402, 403, 901
295	Manufacturing Agreement	295	295		PureWick_0064663	PureWick_0064677	H, 402, 403, 901
297	C.R. BARD, Inc. Form 10-Q	297	297				
298	Agreement and Plan of Merger - Bard/PureWick	298	298		PureWick_0020343	PureWick_0020446	
300	7/11/2017 Memo	300	300		PureWick_0064655	PureWick_0064662	
301	7/8/2017 Document	301	301		PureWick_0064638	PureWick_0064654	
304	12/2018 Email Chain	304	304		PureWick_0034556	PureWick_0034558	H, 402, 403
305	5/31/2010 Assignment	305	305		PureWick_0023587	PureWick_0023589	
306	5/31/2013 Email with attachment	324; 306	306; 324		Newton_0007621	Newton_0007621	H, 403, 901, Error
307	5/31/2013 Email Attachment - Amendment to Assignment	307	307		Newton_0007622	Newton_0007622	
308	PureWick's First Supplemental Response to Interrogs (Nos. 1-11)	308	308				H, 402, 403, NE
310	Amended Subpoena to Ray Newton	310	310				H, 402, 403, NE
311	2015 PureWick Brochure	311	311		PureWick_0014538	PureWick_0014539	
312	Physicals Photograph - Spun fiber, White Vinyl Cap	312	312				
313	Physicals Photograph - Spun fiber, Black Vinyl Cap Wick #6B	313	313	125	PureWick_0030279	PureWick_0030279	
314	Physicals Photograph - spun fiber, white Sump	314	314				402, 403, 901



## Sage Preliminary Exhibit List

315	Photograph of PureWick product - spun fiber, white sump	315	315					402, 403, 901
316	Physicals Photograph - spun fiber, Blue/Brown	316	316					
317	Physicals Photograph - spun fiber, blue foam (Item 625)	317	317					
318	Photographs of PureWick devices	318	318					
319	05/28/2015 PureWick Real Success Stories	319	319; 492			PureWick_0017091	PureWick_0017092	H, 402, 403
320	Physicals photograph - Tapered	320	320			PureWick_0030276	PureWick_0030277	
321	Physicals photograph - Tapered	321	321			PureWick_0030278	PureWick_0030278	
322	8/4/09 Email with Attachments	322	322			Newton_0005496		
323	5/31/10 Assignment	323	323			PureWick_0024000	PureWick_0024000	
325	01/2017 History of Product Design	325	325			PureWick_0020181	PureWick_0020186	H, 402, 403, 901
328	2016 Email Chain	328	328			Newton_0001831	Newton_0001835	H, 402, 403, 901
329	8/23/2013 Email re: User Guide and Consent Form	329	329			Newton_0006003		H, 402, 403, 901
330	8/23/2013 Email re: PureWick Device Use	330	330			Newton_0001874	Newton_0001874	H, 402, 403, 901
331	9/6/2013 Email re: Silver Oak PureWick Device Use	331	331			Newton_0007641		H, 402, 403, 901
332	5/20/2014 Email re: PureWick Device Use Log	332	332			Newton_0001141	Newton_0001142	H, 402, 403, 901
333	10/16/2014 Email re: MIDD Online Competition Questions	333	333			Newton_0001624	Newton_0001627	H, 402, 403, 901
334	11/2014 Email Chain re: MDDI Challenge	334	334			Newton_0002565	Newton_0002567	H, 402, 403, 901
335	12/2013 Email Chain re: Connect Springboard	335	335			Newton_0000865	Newton_0000868	H, 402, 403, 901
337	1/27/2014 Email re: PureWick Connect Show with powerpoint	337	337	326		Newton_0004039	Newton_0004040	402, 403, 901
339	3/10/2014 Email and Attachment re: Bard	339	339			Newton_0001023		H, 402, 403, 901
340	1/22/2015 Email to Connect with Powerpoint	340	340	280		Newton_0004457	Newton_0004458	H, 402, 403, 901
341	1/2015 Email Chain and Attachment	341	341					H, 402, 901
343	6/1/2015 Email Chain re: Selling PureWick for Connect Application	343	343			Newton_0002629	Newton_0002631	H, 402, 403, 901
344	2015 Email Chain with Photographs Attachments	344	344; 488					H, 402, 403, 901
346	3/2014 Email Chain re: Connect Visit	346	346			Newton_0001021	Newton_0001022	H, 901
347	4/29/16 PureWick-Bard Agreement	347	347			PureWick_0020279	PureWick_0020282	H, 402, 403, 901
348	PureWick Development History Notes	348	348			PureWick_0020187	PureWick_0020191	H, 402, 403, 901
351	US 4,747,166 Kuntz Patent Highlighted	351	351			PureWick_0023861	PureWick_0023869	402, 403, H
352	US 7,220,250 Suzuki Patent Highlighted	352	352			PureWick_0023882	PureWick_0023895	402, 403, H
353	5/5/2014 Email Chain re: Prior Art Patent	353	353			Newton_0005013	Newton_0005014	H, 402, 403, 901
354	US 7,699,831 to Bengtson	354	354			COOLEY_0001668	COOLEY_0001681	402, 403, H
355	US 4,886,508 to Washington	355	355			PureWick_0020456	PureWick_0020468	
356	Physicals photographs	356	356			PureWick_0020469	PureWick_0020470	402, 403
357	12/1/2014 Email re: PureWick Video on Youtube	357	357			Newton_0005049	Newton_0005049	H, 402, 403, 901
358	Photographs - Tuck	358	358			Newton_0008245	Newton_0008246	
359	Photographs - Tuck	359	359			PureWick_0024728	PureWick_0024728	
360	Updated Subpoena to Ruby Dy	360	360					NE, H
361	Updated Subpoena to Hilltop	361	361					NE, H
364	11/2014 PureWick Results for PP	364				PureWick_0025877	PureWick_0025877	H, 402, 403
365	12/2014 PureWick Results for PP	365				PureWick_0025876	PureWick_0025876	H, 402, 403

## Sage Preliminary Exhibit List

366	12/2014 PureWick Results for LC	366				PureWick_0025872	PureWick_0025872	H, 402, 403
368	PureWick Physicals photograph - Dated	368	368					901, 402, 403
369	6/2015 Email Chain to Ruby Dy with Attachments	369	369			Newton_0004475		H, 402, 403, 901
370	6/6/2015 Email to Ruby Dy Attaching Letter for Signature	370	370			Newton_0006131		H, 402, 403, 901
371	Hilltop Document	371	371			PureWick_0017088	PureWick_0017088	H, 402, 403, 901
372	Camille Newton Subpoena	372	372					NE, H
373	8/4/2009 Email	373	373			SANCHEZ000574	SANCHEZ000574	H, 402, 403, 901
374	8/17/2009 Email	374	374			SANCHEZ000395	SANCHEZ000395	H, 402, 403, 901
375	2010 Camille Newton - Sanchez Invention Agreement	375	375			SANCHEZ001201	SANCHEZ001203	H, 402, 403, 901
376	8/11/2011 Email Chain re: Covidien Agreement and Response	376	376			Newton_0001856		H, 402, 403, 901
377	Consent Form for LC (Hilltop Country Estates)	377	377			PureWick_0025897	PureWick_0025898	H, 402, 403, 901
378	8/29/2013 Email re: PureWick Results for LC and PP (Hilltop)	378	378			Newton_0007640	Newton_0007640	H, 402, 403, 901
379	2/2014 Email Chain to Connect attaching Business Plan and Powerpoint	379	379			Newton_0004041		H, 402, 403, 901
380	5/31/2014 Email to Scripps	380	380			Newton_0002037	Newton_0002037	H, 402, 403, 901
381	10/8/2014 Email to Basil Leaf Tech	381	381			Newton_0006073	Newton_0006073	H, 402, 403, 901
382	9/2014 Email Chain	382	382			Newton_0005511	Newton_0005514	H, 402, 403, 901
383	PureWick Video 11/25/2014	383	383			PureWick_0022302	PureWick_0022302	
384	PureWick Case Studies 9/13/2014-10/19/2015	384	384; 467			PureWick_0016023	PureWick_0016029	H
385	Camille Newton Handwritten Notebook	385	385			Newton_0008152	Newton_0008222	H, 402, 403
386	9/2014 Email Chain	386	386			Newton_0001618	Newton_0001618	H, 402, 403
387	11/10/2014 Dare-to-Dream Medtech Post	387	387			PureWick_0018134	PureWick_0018136	H, 402, 403
388	4/2014 Email Chain with Bard Attaching Agreement	388	388			Newton_0004089		H, 402, 403
389	6/2014 Email Chain re: Bard Discussion	389	389			Newton_0001147	Newton_0001148	H, 402, 403
390	2015 Email Chain and Attachments to Pawlik	390	390			Newton_0006136	Newton_0006142	H, 402, 403
391	5/23/2015 Email and Attachment re: Biomed Ventures	391	391			Newton_0005109	Newton_0005111	H, 402, 403
392	2015 Email Chain with Bruce Steel	392	392			PureWick_0017770	PureWick_0017776	H, 402, 403
393	7/17/2015 PureWick PureWick Order Form	393	393			PureWick_0023812	PureWick_0023812	H, 402, 403
396	09/2015 Questions About PureWick	396	396	299		PureWick_0021017	PureWick_0021018	H, 402, 403
397	09/2015 PureWick PowerPoint for Connect	397	397			PureWick_0017984	PureWick_0017990	H, 402, 403
398	5/13/2016 Email	398	398			PureWick_0047784	PureWick_0047784	H, 402, 403
399	6/22/2016 Due Diligence Requests	293; 399	399			PureWick_0026621	PureWick_0026625	H, 402, 403
400	PureWick Document	400	400			PureWick_0026792	PureWick_0026793	H, 402, 403
401	7/2016 Email Chain	401	401			PureWick_0050026	PureWick_0050028	H, 402, 403
402	8/2016 Email Chain	402	402			PureWick_0063734	PureWick_0063737	H, 402, 403
403	10/11/2016 Email with attachment	403	403			PureWick_0064150	PureWick_0064151	H, 402, 403
403	10/11/2016 Email Attachment (Sage Document)		596			PureWick_0064152	PureWick_0064152	H, 901, 402, 403
404	3/2016 Email Chain re: PureWick leaking	404	404			Newton_0006384	Newton_0006409	H, 402, 403
405	11/24/2016 Bard Offer to PureWick	405	405			PureWick_0015039	PureWick_0015041	H, 901
406	2016 Email Chain	406	406			PureWick_0064102	PureWick_0064104	H, 901
408	7/20 Email Chain	408	408			Newton_0000856	Newton_0000858	H, 402, 403, 901

## Sage Preliminary Exhibit List

409	Camille Newton Consulting Agreement	409	409		PureWick_0015067	PureWick_0015075	H, 402, 403
410	2016 White Paper	410	410		PureWick_0051687	PureWick_0051697	H, 402, 403, 901
411	10/2014 Email Chain with attachment	411	411		Newton_0006074		H, 402, 403, 901
414	Notice of Subpoena Omni Med. Sys	414	414				NE, H, 402, 403
415	Subpoena to OMNI Medical Systems, Inc.	415	415				NE, H, 402, 403
416	Omni brochure	416	416		SAGE00040993	SAGE00041024	H, 402, 403
417	10/20/06 Letter	417	417		OMNI_0000112	OMNI_0000112	H, 402, 403, 901
418	FDA Document	418	418		OMNI_0000114	OMNI_0000114	H, 402, 403, 901
419	2007 Contract	419	419		OMNI_0000089	OMNI_0000111	H, 402, 403, 901
420	2007 Contract	420	420		OMNI_0000148	OMNI_0000158	H, 402, 403, 901
421	Contract	421	421		OMNI_0000001	OMNI_0000018	H, 402, 403, 901
422	2008 Contract	422	422		OMNI_0000019	OMNI_0000059	H, 402, 403, 901
423	2009 Contract	423	423		OMNI_0000117	OMNI_0000143	H, 402, 403, 901
424	3/18/2013 Memorandum	424	424		OMNI_0000062	OMNI_0000065	H, 402, 403
425	3/18/2013 Memorandum	425	425		OMNI_0000159	OMNI_0000168	H, 402, 403
427	Omni Power Point	427	427		OMNI_0000217	OMNI_0000247	H, 402, 403, 901
428	OMNI Memorandum	428	428		OMNI_0000060	OMNI_0000061	H, 402, 403
429	Specification Document	429	429		OMNI_0000169	OMNI_0000206	H, 402, 403, 901
430	Timeline Document	430	430		OMNI_0000209	OMNI_0000209	H, 402, 403, 901
431	AMXDmax User & Maintenance Guide	431	431		OMNI_0000379	OMNI_0000388	H, 402, 403, 901
432	2010 Engineering Change Proposal	432	432		OMNI_0000066	OMNI_0000067	H, 402, 403, 901
433	2009 Order Form	433	433		OMNI_0000146	OMNI_0000146	H, 402, 403, 901
434	2009 Contract Award	434	434		OMNI_0000068	OMNI_0000087	H, 402, 403, 901
435	2007 FDA Letter	435	435		OMNI_0000207	OMNI_0000208	H, 402, 403, 901
436	4/30/2009 Order	436	436		OMNI_0000088	OMNI_0000088	H, 402, 403, 901
437	Letter	437	437		OMNI_0000147	OMNI_0000147	H, 402, 403, 901
438	2011 Price List	438	438		OMNI_0000144	OMNI_0000145	H, 402, 403, 901
439	Omni Document - URINCare	439			OMNI_0000210	OMNI_0000214	H, 402, 403, 901
440	Omni Document - URINCare	440			OMNI_0000215	OMNI_0000216	H, 402, 403
441	8/4/2009 Email and Attachments	441	441		SANCHEZ001207	SANCHEZ001207	H, 402, 403, 901
442	Notes	442	442		SANCHEZ001209	SANCHEZ001209	H, 402, 403, 901
443	Notes	443	443		SANCHEZ001210	SANCHEZ001210	H, 402, 403, 901
444	8/2009 Email Chain	444	444		SANCHEZ001009	SANCHEZ001010	H, 402, 403, 901
445	1/25/2010 Notes	445	445		SANCHEZ001204	SANCHEZ001204	H, 402, 403, 901

## Sage Preliminary Exhibit List

446	5/31/2010 Notes	446	446			SANCHEZ001176	SANCHEZ001176	
447	7/20/2010 Notes	447	447			SANCHEZ001198	SANCHEZ001200	H, 402, 403, 901
448	Notes	448	448			SANCHEZ001195	SANCHEZ001197	H, 402, 403, 901
449	10/15/2014 Email	449	449			SANCHEZ000991	SANCHEZ000991	H, 402, 403, 901
450	9/4/2016 Email	450	450			SANCHEZ000354	SANCHEZ000355	H, 402, 403, 901
451	11/2017 Email Chain with attachments	451	451			SANCHEZ000372		H, 402, 403, 901
452	11/2017 Email Chain to Sanchez	452	452			SANCHEZ001043	SANCHEZ001054	H, 402, 403, 901
460	6/29/2015 PureWick How to Use Video		460	123		PureWick_0026618	PureWick_0026618	
461	5/6/2016 Email Chain		461			Biomed_0000047	Biomed_0000049	H, 402, 403, 901
462	5/25/2016 Email		462			Biomed_0000011	Biomed_0000014	H, 402, 403, 901
463	07/2015 Connect Application		463			PureWick_0017977	PureWick_0017981	H, 402, 403, 901
464	09/2014 PureWick Use Results (NW)		464			PureWick_0025880	PureWick_0025881	H, 402, 403, 901
465	PureWick Consent Form (NW)		465			PureWick_0025924	PureWick_0025925	H, 402, 403, 901
466	09/13/2014-12/24/2014 Case Studies		466			PureWick_0016017	PureWick_0016022	H, 402, 403, 901
468	09/13/2014-10/12/2014 Case Studies		468			PureWick_0016030	PureWick_0016031	H, 402, 403, 901
469	04/2014 PureWick Connect Show Powerpoint		469			PureWick_0019175	PureWick_0019200	H, 402, 403, 901
470	03/2014 PureWick Connect Show Powerpoint		470			PureWick_0019068	PureWick_0019107	H, 402, 403, 901
471	9/23/2015 Press Release re: Connect		471			PureWick_0021911	PureWick_0021912	H, 402, 403, 901
472	11/15/2015 PureWick Newsletter re: Connect		472			PureWick_0026861	PureWick_0026862	H, 402, 403, 901
473	4/9/2014 PureWick Email re: Connect Show with Powerpoint		473			Newton_0000424		Error, H, 402, 403, 901
474	4/11/2014 Email with Powerpoint		474			Newton_0000430		Error, H, 402, 403, 901
475	4/12/2014 Email with Powerpoint		475			Newton_0000432		Error, H, 402, 403, 901
476	4/13/2014 Email with Powerpoint		476			Newton_0000434		Error, H, 402, 403, 901
477	4/22/2014 Email		477			Newton_0000439	Newton_0000440	H, 402, 403, 901
478	1/16/15 Email		478			Newton_0000629	Newton_0000629	H, 402, 403, 901
480	4/2014/2014 Email with Powerpoint		480			Newton_0004093		Error, H, 402, 403, 901
481	4/16/2014 Email with Powerpoint		481			Newton_0004095		Error, H, 402, 403, 901
482	1/20/2015 Email with Powerpoint		482			Newton_0004455		Error, H, 402, 403, 901

## Sage Preliminary Exhibit List

483	4/16/2014 Email with Powerpoint		483			Newton_0006007		Error, H, 402, 403, 901
484	4/22/2014 Email		484			Newton_0006009	Newton_0006010	H, 402, 403, 901
485	12/5/2013 Email with attachments		485			Newton_0007668		Error, H, 402, 403, 901
486	6/2015 Email Chain with attachment		486			Newton_0002632		Error, H, 402, 403, 901
487	7/2015 Email Chain		487			Newton_0002661	Newton_0002666	H
490	5/21/2015 Letter		490			PureWick_0023808	PureWick_0023808	H, 402, 403, 901
491	Photograph		491			PureWick_0019761	PureWick_0019761	
496	2015+ PureWick Sales Sheet		496			PureWick_0027004	PureWick_0027004	H, 402, 403, 901
500	Subpoena to Connect Foundation	500	500					NE, H, 402, 403
501	Notice of Subpoena to Connect Foundation	501	501					NE, H, 402, 403
502	2/23/14 Connect Springboard Client Agreement with PureWick	502	502			CONNECT_0000100	CONNECT_0000100	H, 402, 403, 901
503	July 2015 PureWick Application to Connect for Most Innovative New product	503	503			CONNECT_0000055	CONNECT_0000058	H, 402, 403, 901
504	July 2015 PureWick Application to Connect for MIP Award	336; 504	336; 504			CONNECT_0000059	CONNECT_0000062	H, 402, 403, 901
505	PureWick Executive Summary for Connect	505	505			CONNECT_0000051	CONNECT_0000052	H, 402, 403, 901
506	PureWick Executive Summary for Connect	506	506			CONNECT_0000053	CONNECT_0000054	H, 402, 403, 901
507	PureWick Executive Summary for Connect	507	507			CONNECT_0000038	CONNECT_0000039	H, 402, 403, 901
508	01/27/15 PureWick Slideshow for Connect	508	508			CONNECT_0000067	CONNECT_0000083	H, 402, 403, 901
509	PureWick Show for Connect	509	509			CONNECT_0000084	CONNECT_0000099	H, 402, 403, 901
510	PowerPoint	510	510			CONNECT_0000008	CONNECT_0000037	H, 402, 403, 901
511	PureWick Executive Summary	511	511			CONNECT_0000063	CONNECT_0000066	H, 402, 403, 901
512	PureWick Executive Summary	512	512			CONNECT_0000110	CONNECT_0000112	H, 402, 403, 901
513	PureWick Executive Summary	513	513			CONNECT_0000107	CONNECT_0000109	H, 402, 403, 901
514	July 2015 PureWick Application Form for Most Innovative New Product Award	514	514			CONNECT_0000041	CONNECT_0000045	H, 402, 403, 901
515	July 2015 PureWick Application to Connect for Most Innovative New Product Award	342; 515	342; 515	327		CONNECT_0000046	CONNECT_0000050	H
516	PureWick Executive Summary	516	516			CONNECT_0000101	CONNECT_0000103	H, 402, 403, 901
517	09/2015 PureWick Executive Summary	517	517			CONNECT_0000104	CONNECT_0000106	H, 402, 403, 901
518	PureWick PowerPoint to Connect	518	518			CONNECT_0000001	CONNECT_0000007	H, 402, 403, 901
519	Connect Video	519	519			CONNECT_0000040	CONNECT_0000040	
520	Connect Video	520	520			CONNECT_0000113	CONNECT_0000113	H, 402, 403, 901
521	Newman Opening Invalidity Report		521					H, Exp, NE, 402, 403
522	Newman CV		522					H, 901, 402, 403

## Sage Preliminary Exhibit List

523	Newman, The Urinary Incontinence Sourcebook (1997)		523					H, 901, 402, 403
0523b	Excerpted Newman book							H, NP, Incom, 901, 402, 403
524	Responsive Expert Report of Dr. Diane Newman		524					H, Exp, NE, 402, 403
525	Clinical Application of Urologic Catheters, Devices and Products		525					H, 901, 402, 403
0525a	Absorbent Product for Incontinence, Chapter 6 (Dianne Newman et al.)		525a					H, Incom, 901, 402, 403
526	Reply Expert Report of Dr. Diane Newman		526					H, Exp, NE, 402, 403
532	Photographs of PrimaFit 1.0		532A					H, EXP, NE, NP, 901, 402, 403
533	Photographs of PrimaFit 1.0 Prototypes		532D					402, 403, NE, NP, 901
536	Expert Report of Robert Sterne		536					H, 901, EXP, NE, 402, 403
537	Sterne CV		537					H, 901, EXP, 402, 403
538	Reply Expert Report of Erika Lietzan		538					H, 901, EXP, NE, 402, 403
539	Lietzan CV		539					H, 901, EXP, 402, 403
542	Appendix B		542					H, 901, EXP, NE, 402, 403
543	2021 06 25 Jezzi Rebuttal Report							H, 901, EXP, NE, 402, 403, Unt
559	6,888,044		559					402, 403, H, 901
560	US 2004/0127872		560					402, 403, H, 901
561	7,766,887		561					402, 403, H, 901
562	7,358,282		562					402, 403, H, 901
563	GB 2,062,472		563			SAGE00022063	SAGE00022069	402, 403, H, 901
564	5,147,345		564					402, 403, H, 901
565	3,382,090		565					402, 403, H, 901
566	6,918,899		566					402, 403, H, 901
567	Wired, New Relief for Pilots? It Depends		567			SAGE00021397	SAGE00021398	402, 403, H, 901
568	How do Pilots Spell Relief: AMXD		568			SAGE00043457	SAGE00043459	402, 403, H, 901
569	"A Solution For An Awkward But Serious Subject"		569			SAGE00043454	SAGE00043456	402, 403, H, 901

## Sage Preliminary Exhibit List

571	8/17/17 PureWick Memo	603	571; 603			PureWick_0014230	PureWick_0014236	H, 402, 403
572	10/21/2016 PureWick Memo	604	572; 604			PureWick_0014237	PureWick_0014238	H, 402, 403
573	8/26/2016 Email	605	573; 605	356		PureWick_0014259	PureWick_0014259	H, 402, 403
574	10/20/2016 Memo	606	574; 606			PureWick_0014272	PureWick_0014274	H, 403
575/ 1008	6/29/2017 Email with Attachment re: PureWick Feedback	607	575; 607	8		PureWick_0014310		H, 402, 403
577	10/21/2016 Memo re: PureWick Feedback		577		125; 146	PureWick_0059075	PureWick_0059076	H, 403
578	10/20/2016 Bard Document re: VOC for PureWick		578			PureWick_0059080	PureWick_0059082	H, 402, 403
580	7/12/2017 Email		580			SAGE00035249	SAGE00035258	H, 402, 403
581	2/28/2017 Memo		581			PureWick_0014144	PureWick_0014145	H, 402, 403
584	Sage Document		584			SAGE00028163	SAGE00028192	402, 403
585	8/11/11 Email		585			Newton_0001858	Newton_0001858	H, 402, 403, 901
594	2019 BD Survey		594			PureWick_0027935	PureWick_0027982	H, Incom, 402, 403, 901
595	2019 PureWick 2.0 Survey Data Presentation		595			PureWick_0027983	PureWick_0027983	H, 402, 403
602	Sage Marketing Sheet Comfort Shield - Incontinence-associated dermatitis (IAD)	602	602			SAGE00000089	SAGE00000090	402, 403
639	PureWick Key Accounts With Minimal Or No PW	639	639			PureWick_0030211	PureWick_0030211	H, 402, 403
641	Sage CER for Project Segue	641	641		87	SAGE00029359	SAGE00029391	
650	US Dept. of Health and Human Services - Urinary Track Infection in Adults		650			SAGE00026997	SAGE00027004	402, 403, H, 901
651	4/19/19 PowerPoint re: PrimaFit 2.0		651			SAGE00029013	SAGE00029048	Incom, H, 402, 403
652	NPD2135 700-116-2 Instructions for Use		652			SAGE00030399	SAGE00030400	H, 403
656	PowerPoint re: Evolution of Project Segue		656; 659		161	SAGE00033788	SAGE00033788	
662	07/2017 Project Segue Design Review for Field Evaluations					SAGE00025099	SAGE00025100	
664	Lab Notebook					SAGE00026067	SAGE00026138	
665	Lab Notebook					SAGE00026139	SAGE00026201	
693	Technical Drawing		693			SAGE00021475	SAGE00021475	H, 402, 403
700	10,857,025		700	700		SAGE00040936	SAGE00040990	H, 402, 403
701	D882,768		701	701		SAGE00043465	SAGE00043474	H, 402, 403
702	11,000,401		702			SAGE00043559	SAGE00043611	H, 402, 403
703	US 17/013,822		703					H, 402, 403, NP
704	US 16/276,191		704					H, 402, 403, NP
719	11/29/2016 Email re: Project Segue		719			SAGE00026445	SAGE00026445	403
720	Sage MicroClimate Body Pad Marketing		720					H, 402, 403, 901, NP
721	07/2019 PrimaFit 2.0 Project Overview		721			SAGE00030464	SAGE00030464	
722	PrimaFit 2.0 Physical / Photographs		722			SAGE00030401	SAGE00030402	402, 403
723	PrimaFit 2.0 Technical Drawing Rev B		723		77	SAGE00030403	SAGE00030408	
724	Photograph of PrimaFit 1.0 and 2.0		724			SAGE00030409	SAGE00030410	
725	PrimaFit 2.0 Project Charter				001; 013	STRSAGE00021947	STRSAGE00021950	
726	08/2020 PrimaFit 2.0 Functional Specification (Isthmus)		726			SAGE00030411	SAGE00030463	
727	Project Charter for PrimaFit 2.0		727		136	SAGE00030465	SAGE00030467	403
728	PrimaFit 2.0 Technical Drawing Rev New		728			SAGE00034755	SAGE00034761	



## Sage Preliminary Exhibit List

729	12/17/2019 Email re: PrimaFit 2.0	729			SAGE00036921	SAGE00036921	402, 403
730	1/2/2020 Email Chain with Attachment re: PrimaFit 2.0	730			SAGE00036975		H, 402, 403
731	4/9/2020 Email re: PrimaFit 2.0	731		65	SAGE00037157	SAGE00037158	403
732	02/2019 Sage Document re: PrimaFit 2.0	732			SAGE00037268	SAGE00037268	403
733	PrimaFit Evaluations	733			SAGE00037942	SAGE00037956	H, 402, 403, 901
734	PrimaFit 2.0 CER	734		41	SAGE00040435	SAGE00040447	403
735	Photograph of PrimaFit 2.0 Physical	735			SAGE00040838	SAGE00040838	402, 403
737	10/20/2020 Email re: PrimaFit 2.0 COGS, ASP, Margin	737			SAGE00040648	SAGE00040648	402, 403
738	11/2020 PrimaFit 2.0 Presentation	738			SAGE00040769	SAGE00040772	402, 403
739	PrimaFit 2.0 Powerpoint	739			SAGE00040419	SAGE00040419	402, 403
740	PrimaFit 2.0 CER	740			SAGE00040450	SAGE00040462	403
741	PrimaFit 2.0 Powerpoint	741			SAGE00037128	SAGE00037136	402, 403
742	PrimaFit 2.0 Cost Reduction Roadmap	742			SAGE00034013	SAGE00034017	H, 402, 403
744	04/2014 Sage NPD Document	744			SAGE00023081	SAGE00023081	H, 402, 403
745	05/2016 Sage Project Mountain Dew Timeline	745			SAGE00027235	SAGE00027235	H, 402, 403
746	07/2014 Sage Vacuum Assisted External Urinary Collection Device Document	746			SAGE00023094	SAGE00023094	H, 402, 403
747	2014 Sage Mini Vacuum Pump Document	747			SAGE00024070	SAGE00024070	H, 402, 403, 901
748	4/2014 Sage NPD Document	748			SAGE00023083	SAGE00023092	H, 402, 403
749	6/2014 Sage External Urinary Collection Device Documents	749			SAGE00026948	SAGE00026948	H, 402, 403, 901
750	2014 Sage Non-Invasive Urinary Collection Device Document	750			SAGE00026949	SAGE00026950	H, 402, 403
753	10/18/2016 Email with Attachment re: PureWick Valuation	753			SAGE00028588	SAGE00028588	403
754	PureWick Valuation Attachment	754			SAGE00028589	SAGE00028589	403
755	PowerPoint	755			SAGE00028998	SAGE00028998	403
756	Sage Spreadsheet	756			SAGE00029003	SAGE00029003	403
758	Financial Spreadsheet	758			PureWick_0030253	PureWick_0030253	H, 402, 403
759	10/27/2016 Email with attachments	759			PureWick_0064055		H, Error, 403
760	7/29/2016 Email	760			PureWick_0064060	PureWick_0064062	H
761	PureWick Document	761			PureWick_0014327	PureWick_0014337	
764	October 2016 Memorandum	764			SAGE00024400	SAGE00024400	H, 402, 403, 901
765	Sage PowerPoint	765			SAGE00025671	SAGE00025675	403
766	Spreadsheet	766			SAGE00000488	SAGE00000488	403
767	Spreadsheet	767			SAGE00021490	SAGE00021490	H, 402, 403
769	Report	769			PureWick_0017753	PureWick_0017753	H
770	6/23/2017 PureWick Email re: Latex	770			PureWick_0049279	PureWick_0049280	H, 402, 403
771	Sage Competitive Analysis (PureWick vs PrimaFit)	771			SAGE00027574	SAGE00027574	H, 402, 403
772	PowerPoint	772		158	SAGE00035465	SAGE00035509	
773	5/2018 Email Chain with Attachment	773			SAGE00038681		Err, 402, 403
774	Financial Document	774			SAGE00033918	SAGE00033918	H, 402, 403
780	Sage Document	780			SAGE00026209	SAGE00026210	H, 402, 403
800	Sage's Fourth Supplemental Objections and Responses to Plaintiff's Interrogatories (Nos. 1-6, 8, and 10) (PureWick I)	800					NE, H, 402, 403, Exp
801	Sage's Third Supplemental Objections and Responses to Plaintiff's First Set of Interrogatories Nos. 4-6 and 9 (PureWick I)	801					NE, H, 402, 403, Exp
802	2021 04 15 - Sage's Responses to Plaintiff's Third Set of Interrogatories (Nos. 13-23) (PureWick I)	802					NE, H, 402, 403, Exp



## Sage Preliminary Exhibit List

803	PureWick's Seventh Response to Interrogatories (Nos. 1-11) (PureWick I)		803					NE, H, 402, 403, Exp
804	PureWick's Responses to Sage's Third Set of Interrogatories Nos. 14-16 (PureWick I)		804					NE, H, 402, 403, Exp
807	Sage's Privilege logs		807					NE, H, 402, 403
808	2020 03 23 - Sage's Responses to Plaintiff's First Set of Interrogatories (No. 1-6) (PW1)							NE, H, 402, 403, Exp
809	2020 08 03 - Sage's First Supp. Responses Interrogs Nos. 1-12 (PureWick I)							NE, H, 402, 403, Exp
810	2020 09 22 - Sage Second Supplemental Responses to Interrog 1, 5, and 6 (PureWick I)							NE, H, 402, 403, Exp
812	02/10/2020 - Sage's Initial Disclosures							H, 402, 403, NE, Exp, Unt
813	10/23/2020 Sage's Supplemental Initial Disclosures (PW1)							H, 402, 403, NE, Exp, Unt
814	Sage Document		814					H, 402, 403
815	Sage Document		815					H, 402, 403
816	Sage Document		816					H, 402, 403
818	Final Written Decision		818			PWNNewton_0001763	PWNNewton_0001828	H, 402, 403, NE, Exp
819	Federal Appeals Court Opinion For IPR2020-01426 Affirming Finding of Invalidity							H, 402, 403, NE, Exp
820	IPR2020-01426 - Petition		820					H, 402, 403, NE, Exp
821	IPR2020-01426 - Declaration of Dr. Diane Newman		821					H, 402, 403, NE, Exp
822	IPR2020-01426 - Second Declaration of Dr. Diane Newman		822					H, 402, 403, NE, Exp
823	IPR2020-01426 - Institution Decision		823			PWNNewton_0001205	PWNNewton_0001243	H, 402, 403, NE, Exp
824	IPR2020-01426 - Petitioner's Reply		824					H, 402, 403, NE, Exp
825	<a href="https://sageproductsglobal.com/company-profile-3/">https://sageproductsglobal.com/company-profile-3/</a>		825					H, 402, 403, NE, NP, 901
826	<a href="https://sageproductsglobal.com/history/">https://sageproductsglobal.com/history/</a>		826					H, 402, 403, NE, NP, 901
827	<a href="https://investors.stryker.com/press-releases/news-details/2016/Stryker-Announces-Definitive-Agreement-to-Acquire-Sage-Products-LLC-from-Madison-Dearborn-Partners-for-2775-Billion/default.aspx">https://investors.stryker.com/press-releases/news-details/2016/Stryker-Announces-Definitive-Agreement-to-Acquire-Sage-Products-LLC-from-Madison-Dearborn-Partners-for-2775-Billion/default.aspx</a>		827					H, 402, 403, NE, NP, 901
828	<a href="https://www.urologyhealth.org/urology-a-z/u/urinary-incontinence">https://www.urologyhealth.org/urology-a-z/u/urinary-incontinence</a>		828					H, 402, 403, NE, NP, 901
829	<a href="https://www.merckmanuals.com/home/special-subjects/hospital-care/incontinence-due-to-hospitalization">https://www.merckmanuals.com/home/special-subjects/hospital-care/incontinence-due-to-hospitalization</a>		829					H, 402, 403, NE, NP, 901

## Sage Preliminary Exhibit List

830	<a href="https://www.cancertherapyadvisor.com/home/decision-support-in-medicine/hospital-medicine/foley-catheters/">https://www.cancertherapyadvisor.com/home/decision-support-in-medicine/hospital-medicine/foley-catheters/</a>	830					H, 402, 403, NE, NP, 901
831	<a href="https://www.healthline.com/health/intermittent-catheterization#conditions">https://www.healthline.com/health/intermittent-catheterization#conditions</a>	831					H, 402, 403, NE, NP, 901
832	<a href="https://wellnessbriefs.com/blog/2016/09/22/absorbent-adult-diapers-features-and-benefits/">https://wellnessbriefs.com/blog/2016/09/22/absorbent-adult-diapers-features-and-benefits/</a>	832					H, 402, 403, NE, NP, 901
833	<a href="https://share.upmc.com/2017/06/adult-diaper-facts/">https://share.upmc.com/2017/06/adult-diaper-facts/</a>	833					H, 402, 403, NE, NP, 901
834	<a href="https://www.webmd.com/men/guide/urinary-incontinence-products-for-men">https://www.webmd.com/men/guide/urinary-incontinence-products-for-men</a>	834					H, 402, 403, NE, NP, 901
835	<a href="https://www.stryker.com/content/dam/stryker/sage/products/primafit/resources/Sage-PrimaFit-Brochure.pdf">https://www.stryker.com/content/dam/stryker/sage/products/primafit/resources/Sage-PrimaFit-Brochure.pdf</a>	835					H, 402, 403, NE, NP, 901
836	<a href="https://www.stryker.com/content/dam/stryker/sage/products/primofit/resources/Sage-PrimoFit-Brochure.pdf">https://www.stryker.com/content/dam/stryker/sage/products/primofit/resources/Sage-PrimoFit-Brochure.pdf</a>	836					H, 402, 403, NE, NP, 901
837	<a href="https://www.hollister.com/-/media/files/pdfs-for-download/continence-care/hol_ccbl_male-female-urinarypouch-product-information_921839.ashx">https://www.hollister.com/-/media/files/pdfs-for-download/continence-care/hol_ccbl_male-female-urinarypouch-product-information_921839.ashx</a>	837					H, 402, 403, NE, NP, 901
838	<a href="https://www.hollister.com/-/media/files/pdfs-for-download/continencecare/care-tips-for-male-urinary-pouch-922091-812.ashx">https://www.hollister.com/-/media/files/pdfs-for-download/continencecare/care-tips-for-male-urinary-pouch-922091-812.ashx</a>	838					H, 402, 403, NE, NP, 901
839	<a href="https://www.hollister.com/-/media/files/pdfs-for-download/continence-care/care-tips-for-female-urinary-pouch-922092-812.ashx">https://www.hollister.com/-/media/files/pdfs-for-download/continence-care/care-tips-for-female-urinary-pouch-922092-812.ashx</a>	839					H, 402, 403, NE, NP, 901
840	<a href="https://activkare.com/collections/mens-acticuf">https://activkare.com/collections/mens-acticuf</a>	840					H, 402, 403, NE, NP, 901
841	<a href="https://activkare.myshopify.com/pages/acticuf">https://activkare.myshopify.com/pages/acticuf</a>	841					H, 402, 403, NE, NP, 901
842	<a href="https://www.tillacare.com/">https://www.tillacare.com/</a>	842					H, 402, 403, NE, NP, 901
843	<a href="https://thetinklebelle.com/">https://thetinklebelle.com/</a>	843					H, 402, 403, NE, NP, 901
844	<a href="https://www.mayoclinic.org/diseases-conditions/urinary-incontinence/in-depth/urinary-incontinence-surgery/art-20046858">https://www.mayoclinic.org/diseases-conditions/urinary-incontinence/in-depth/urinary-incontinence-surgery/art-20046858</a>	844					H, 402, 403, NE, NP, 901
845	<a href="https://www.everydayhealth.com/incontinence/biofeedback-treatment.aspx">https://www.everydayhealth.com/incontinence/biofeedback-treatment.aspx</a>	845					H, 402, 403, NE, NP, 901
846	<a href="https://www.aafp.org/afp/2005/0115/p315.html">https://www.aafp.org/afp/2005/0115/p315.html</a>	846					H, 402, 403, NE, NP, 901
847	<a href="https://www.stryker.com/us/en/sage/products/sage-primafit.html">https://www.stryker.com/us/en/sage/products/sage-primafit.html</a>	847					H, 402, 403, NE, NP, 901
848	<a href="https://www.stryker.com/us/en/sage/products/sage-primofit.html">https://www.stryker.com/us/en/sage/products/sage-primofit.html</a>	848					H, 402, 403, NE, NP, 901
849	<a href="https://homecare.stryker.com/store/p/58-Microclimate-Body-Pad-Large-Size-Full-Body.aspx">https://homecare.stryker.com/store/p/58-Microclimate-Body-Pad-Large-Size-Full-Body.aspx</a>	849					H, 402, 403, NE, NP, 901

## Sage Preliminary Exhibit List

851	PrimaFit 1.0 BOM Rev A		851		SAGE00000146	SAGE00000148	
852	PrimaFit 1.0 BOM Rev New		852		SAGE00000149	SAGE00000151	
853	PrimaFit 1.0 SOP		853		SAGE00000358	SAGE00000365	H, 403
854	PrimaFit 1.0 Fabric Batting Roll Stock Specification		854		SAGE00024946	SAGE00024946	403
855	PrimaFit 1.0 Fabric Absorbent Roll Stock		855		SAGE00024948	SAGE00024948	403
856	2017 PrimaFit 1.0 Document		856		SAGE00025046	SAGE00025046	H, 402, 403
857	PrimaFit 1.0 Fabric Biocompatibility		857		SAGE00025094	SAGE00025095	
858	PrimaFit 1.0 testing		858		SAGE00025096	SAGE00025096	
859	PrimaFit Capital Spend		859		SAGE00030397	SAGE00030397	H, 402, 403
875	2/3/2021 Quinn Email to McAndrews		875				H, 402, 403, NE
876	1/14/2021 McAndrews Email to Quinn		876				H, 402, 403, NE
877	2/12/2021 McAndrews Email to Quinn		877				H, 402, 403, NE
890	<a href="https://www.hcd.com/need-medical-supplies/foley-catheter/">https://www.hcd.com/need-medical-supplies/foley-catheter/</a>		890				H, 402, 403, NE, NP, 901
891	<a href="https://www.nice.org.uk/guidance/cg139/ifp/c-hapter/long-term-use-of-urinary-catheters">https://www.nice.org.uk/guidance/cg139/ifp/c-hapter/long-term-use-of-urinary-catheters</a>		891				H, 402, 403, NE, NP, 901
892	<a href="https://www.nhs.uk/conditions/urinary-catheters/living-with/">https://www.nhs.uk/conditions/urinary-catheters/living-with/</a>		892				H, 402, 403, NE, NP, 901
893	<a href="https://www.bls.gov/ooh/arcture-and-engineering/biomedical-engineers.htm#tab-5">https://www.bls.gov/ooh/arcture-and-engineering/biomedical-engineers.htm#tab-5</a>		893				H, 402, 403, NE, NP, 901
894	<a href="https://www.aha.org/statistics/fast-facts-us-hospitals">https://www.aha.org/statistics/fast-facts-us-hospitals</a>		894				H, 402, 403, NE, NP, 901
895	<a href="https://www.stryker.com/us/en/about/patents/medical-patents.html">https://www.stryker.com/us/en/about/patents/medical-patents.html</a>		895				H, 402, 403, NE, NP, 901
900	PrimaFit 2.0 Physicals						402, 403, NP, 901
900a-j	PrimaFit 2.0 Physicals				STRSAGE00050001	STRSAGE00050010	
900k-n	PrimaFit 2.0 Physicals				STRSAGE_EXP_000001	STRSAGE_EXP_000004	402, 403, NP, 901
900o	PrimaFit 2.0 Physical				SAGE00030401	SAGE00030401	402, 403, 901
901	Sage Non-Infringing Alternative Physicals						402, 403, NP, Unt, 901
901a	Sage Non-Infringing Alternative Physical				STRSAGE00024752	STRSAGE00024752	402, 403, NP, 901
901b	Sage Non-Infringing Alternative Physical				STRSAGE00024753	STRSAGE00024753	402, 403, NP, 901
902	Current Sage PrimaFit Product Physicals				STRSAGE0005011	STRSAGE0005014	402, 403, NP, Unt, 901
903	Photographs of Sage Prototypes		903	903			H, 402, 403, NP, 901
904	Medline Versette Physicals						402, 403, NP, Unt, 901
904a	Medline Versette Physical				STRSAGE00024736	STRSAGE00024736	402, 403, 901
905	Boehringer CareDry Physicals						402, 403, NP, Unt, 901

## Sage Preliminary Exhibit List

0905a	Boehringer CareDry Physical					STRSAGE00024737	STRSAGE00024737	402, 403, 901
906	Photographs of PureWick pre-August 2016 products		906					H, 402, 403, NP, 901
907	PureWick FEC Physicals							
0907a-e	PureWick FEC Physicals					BDPureWick_00002931	BDPureWick_00002935	
0907f	PureWick Physicals Produced in PureWick I							
908	Sage Microclimate Body Pad Physicals		904					H, 402, 403, NP, 901
909	PrimaFit 1.0 Physicals							
910	3b Scientific Catheterization Trainer Physical							
911	Manikin (Female) Physical							H, 402, 403, NP, Unt, 901
912	PrimaFit 2.0 Components Physicals							H, 402, 403, NP, 901
913	Newman, The Urinary Incontinence Sourcebook (1997)							H, 402, 403, NP, 901
914	PureWick prior device Bates-labelled physicals in PureWick's possession							402, 403, 901, Err
0914a	Exhibits reserved for PureWick devices							NE
0914b	PureWick Device Physical					PureWick_0030280	PureWick_0030280	402, 403, 901
0914c	PureWick Device Physical	312	312			PureWick_0030281	PureWick_0030281	402, 403
0914d	PureWick Device Physical	316	316			PureWick_0030284	PureWick_0030284	402, 403
0914e	PureWick Device Physical	317	317	128		PureWick_0030294	PureWick_0030294	402, 403
0914f	PureWick Device Physical	314	314			PureWick_0035495	PureWick_0035495	402, 403
0914g	PureWick Device Physical					PureWick_0030282	PureWick_0030282	402, 403, 901
916	Consure Medical Qivi Female Physicals							402, 403, 901, NP, NE, Unt
950	Photographs of PrimaFit 2.0					STRSAGE00050001A-D	STRSAGE00050001A-D	H, 402, 403, 901
951	Photographs of PrimaFit 2.0					STRSAGE00050002A-D	STRSAGE00050002A-D	H, 402, 403, 901
952	Photographs of PrimaFit 2.0					STRSAGE00050003A-D	STRSAGE00050003A-D	H, 402, 403, 901
953	Photographs of PrimaFit 2.0					STRSAGE00050004A-D	STRSAGE00050004A-D	H, 402, 403, 901
954	Photographs of PrimaFit 2.0					STRSAGE00050005A-D	STRSAGE00050005A-D	H, 402, 403, 901
955	Photographs of PrimaFit 2.0					STRSAGE00050006A-D	STRSAGE00050006A-D	H, 402, 403, 901
956	Photographs of PrimaFit 2.0					STRSAGE00050007A-D	STRSAGE00050007A-D	H, 402, 403, 901
957	Photographs of PrimaFit 2.0					STRSAGE00050008A-D	STRSAGE00050008A-D	H, 402, 403, 901
958	Photographs of PrimaFit 2.0					STRSAGE00050009A-D	STRSAGE00050009A-D	H, 402, 403, 901
959	Photographs of PrimaFit 2.0					STRSAGE00050010A-D	STRSAGE00050010A-D	H, 402, 403, 901
960	Photographs of PrimaFit 2.0					STRSAGE_EXP_000001A	STRSAGE_EXP_000001A	H, 402, 403, 901
961	Photographs of PrimaFit 2.0					STRSAGE_EXP_000002A	STRSAGE_EXP_000002A	H, 402, 403, 901

## Sage Preliminary Exhibit List

962	Photographs of PrimaFit 2.0					STRSAGE_EXP_000003A	STRSAGE_EXP_000003A	H, 402, 403, 901
963	Photographs of PrimaFit 2.0					STRSAGE_EXP_000004A	STRSAGE_EXP_000004A	H, 402, 403, 901
964	Photographs of PrimaFit 2.0					SAGE00030402	SAGE00030402	H, 402, 403, 901
965	Photographs of NonInfringing Alternatives					STRSAGE00024752A-C	STRSAGE00024752A-C	H, 402, 403, 901
966	Photographs of NonInfringing Alternatives					STRSAGE00024753A-C	STRSAGE00024753A-C	H, 402, 403, 901
967	Photographs of Medline Versette					STRSAGE00024736A-G	STRSAGE00024736A-G	H, 402, 403, 901
968	Photographs of Boehringer CareDry					STRSAGE00024737A-E	STRSAGE00024737A-E	H, 402, 403, 901
970	Photographs of Current Sage PrimaFit Product					STRSAGE0005011A	STRSAGE0005011B	H, 402, 403, 901, Unt
971	Photographs of Current Sage PrimaFit Product					STRSAGE0005012A	STRSAGE0005012B	H, 402, 403, 901, Unt
972	Photographs of Current Sage PrimaFit Product					STRSAGE0005013A	STRSAGE0005013B	H, 402, 403, 901, Unt
973	Photographs of Current Sage PrimaFit Product					STRSAGE0005014A	STRSAGE0005014B	H, 402, 403, 901, Unt
1002	10/08/2021 BD Email re: Sage PrimaFit			002; 035; 219	35	BDPureWick_00002929	BDPureWick_00002930	H, 402, 403, 901
1003	03/25/2016 Newton Email to Bard			3		PureWick_0051320	PureWick_0051322	H, 402, 403
1004	09/30/2016 Bard Email			4		PureWick_0051874	PureWick_0051875	H, 402, 403
1005	10/06/16 Bard Email re: Candle			5		PureWick_0051888	PureWick_0051888	H, 402, 403
1006	01/27/2017 Bard Email			6		PureWick_0052112	PureWick_0052113	H, 402, 403, 901
1007	03/09/2017 Bard Email re: Project Candle			7		PureWick_0059288	PureWick_0059289	H, 402, 403
1009	05/24/2019 BD Email with Attachment			9		PureWick_0034475		H, 402, 403
1010 / 1010A	MAUDE FDA Complaint Report for PureWick			10		BDPureWick_00001706	BDPureWick_00001706	H, 402, 403, 901
1011	PureWick Account Spreadsheet			11	145	BDPureWick_00002070	BDPureWick_00002070	H, 901
1012	08/18/2017 BD Email			12		PureWick_0043875	PureWick_0043880	H, 402, 403, 901
1013	2021 PureWick Presentation			13		BDPureWick_00002888	BDPureWick_00002928	H, 402, 403, 901
1015	09/29/2017 BD Email re: Sage Product			15		PureWick_0034220	PureWick_0034223	H, 402, 403, 901
1016	10/05/2018 BD Email			16		PureWick_0034374	PureWick_0034375	H, 402, 403, 901
1017	03/23/2018 BD Email			17		PureWick_0034401	PureWick_0034403	H, 402, 403, 901
1019	06/07/2018 BD Email			19		PureWick_0035423	PureWick_0035425	H, 402, 403, 901
1020	11/13/2017 BD Email			20		PureWick_0034309	PureWick_0034311	H, 402, 403, 901
1021	08/26/2017 Bard Email re: Sage	137		21		PureWick_0033405	PureWick_0033405	H, 402, 403, 901
1022	06/05/2018 BD Email			22		PureWick_0035378	PureWick_0035379	H, 402, 403, 901
1023	08/24/2020 BD email re: Sage Intel			23		BDPureWick_00002196	BDPureWick_00002197	H, 402, 403, 901
1024	03/17/2021 BD Email			24		BDPureWick_00001555	BDPureWick_00001557	H, 402, 403, 901, PRIV



## Sage Preliminary Exhibit List

1076	Project Candle Acquisition Committee Review Presentation			76		BDPureWick_00007303	BDPureWick_00007325	402, 403, 901
1077	Project Candle Acquisition Committee Memo			77		BDPureWick_00007326	BDPureWick_00007338	402, 403, 901
1078	Project Candle Model			78		BDPureWick_00007339	BDPureWick_00007360	402, 403, 901
1079	Project Candle Model			079; 085		BDPureWick_00007397	BDPureWick_00007397	402, 403, 901
1080	02/14/2017 BD Email re: Project Candle with attachment			80		BDPureWick_00005584		H, 402, 403, 901
1081	11/10/2016 Bard email re: Candle P&L			81		BDPureWick_00004637	BDPureWick_00004637	H, 402, 403, 901
1082	Candle - P&L			82		BDPureWick_00004638	BDPureWick_00004639	402, 403, 901
1083	Candle - P&L			83		BDPureWick_00004640	BDPureWick_00004641	402, 403, 901
1084	Bard Document - Project Candle			84		BDPureWick_00004481	BDPureWick_00004521	402, 403, 901
1088	2019 Eckert Article - J. Wound Ostomy Continence Nurs.			88		SAGE00039997	SAGE00040000.1	402, 403
1089	04/07/2019 Eckert Email with Presentation			89		Newton_0005808		H, 402, 403, 901
1090	2017 Bard Powerpoint			90		PureWick_0026558	PureWick_0026587	402, 403, 901
1091	Lorena Eckert Consulting Agreement with PureWick			91		BDPureWick_00005884	BDPureWick_00005886	H, 402, 403, 901
1093	11/17/2015 Eckert Email			93		Newton_0007722	Newton_0007722	H, 402, 403, 901
1094	2015 PureWick Chain Email with Eckert re: PW254-15			94		Newton_0006158	Newton_0006159	402, 403
1095	Subpoena to Lorena Eckert			95				402, NE
1096	Subpoena to Michael Jackson			96				402, NE
1098	09/03/2015 PureWick Email with attachment			98		Newton_0000807	Newton_0000808	H, 402, 403, 901
1099	01/13/2023 Email re: Call with Bard			99		MJackson_000001	MJackson_000002	402, 403, 901
1100	11/10/2022 Email re: Call with Bard			100		MJackson_000003	MJackson_000004	402, 403, 901
1101	09/12/2022 Email re: Call with Bard			101		MJackson_000005	MJackson_000006	402, 403, 901
1102	08/30/2022 Email re: Call with Bard			102		MJackson_000007	MJackson_000008	402, 403, 901
1103	10/13/2022 Email re: Call with Bard			103		MJackson_000009	MJackson_000010	402, 403, 901
1104	11/28/2022 Email re: Call with Bard			104		MJackson_000011	MJackson_000012	402, 403, 901
1105	PureWick Royalty Statement (Q3 2022)			105		MJackson_000013	MJackson_000020	402, 403, 901
1106	11/28/2022 Email re: Call with Bard			106		MJackson_000021	MJackson_000021	402, 403, 901
1107	04/24/2013 PureWick Email			107		Newton_0007615	Newton_0007615	H, 402, 403, 901
1108	06/10/2013 PureWick Email			108		Newton_0000072	Newton_0000072	H, 402, 403, 901
1109	06/24/2013 PureWick Email			109		Newton_0000074	Newton_0000076	H, 402, 403, 901
1110	10/26/2013 PureWick Email			110		Newton_0000109	Newton_0000110	H, 402, 403, 901
1111	PureWick Document re: Funding			111		PureWick_0022266	PureWick_0022266	402, 403, 901
1112	02/10/2015 PureWick Email			112		Newton_0000765	Newton_0000765	402, 403, 901



## Sage Preliminary Exhibit List

1113	08/28/2014 PureWick Email			113		Newton_0001610	Newton_0001610	402, 901
1114	12/17/2014 PureWick Email			114		Newton_0000573	Newton_0000573	402, 901
1115	December 2014 PureWick Sales Brochure			115		Newton_0000574	Newton_0000575	402, 901
1117	09/23/2015 PureWick Connect Press Release			117		PureWick_0017982	PureWick_0017983	
1118	12/25/2015 PureWick FDA Registration			118		PureWick_0063073	PureWick_0063075	402, 403, 901
1119	11/17/2015 PureWick Email to Pawlik			119		Pawlik_004480	Pawlik_004494	H, 402, 403, 901
1121	09/15/2015 PureWick Email attaching Sales Brochure PW254-15			121		Newton_0000809		402, 901
1122	PureWick Word Document with Emails from 2015			122		PureWick_0017799	PureWick_0017802	402, 403, 901
1124	11/19/2015 PureWick Email			124		Newton_0002766	Newton_0002779	901
1126	03/31/2016 PureWick Email to Pawlik			126; 192		Pawlik_001263	Pawlik_001263	H, 901
1127	05/01/2016 Pawlik Email to PureWick			127; 201		Pawlik_005505	Pawlik_005525	H, 901
1129	07/07/2016 PureWick Email to Pawlik			129		Pawlik_000170	Pawlik_000178	H, 901
1130	11/2016 PureWick Hospital Brochure			130		PureWick_0022264	PureWick_0022265	
1131	02/23/2016 PureWick Email to Pawlik			131		Pawlik_001797	Pawlik_001804	H, 901
1132	02/25/2016 PureWick Email to Pawlik			132		Pawlik_001778	Pawlik_001787	H, 901
1133	12/01/2015 PureWick Email Chain to Pawlik			133; 189		Pawlik_004315	Pawlik_004335	H, 901
1134	02/04/2016 PureWick Email to Pawlik			134		Pawlik_002059	Pawlik_002090	H, 901
1137	07/07/2016 First Quality Email to PureWick			137		FQE0000175	FQE0000175	402, 403, 901
1140	02/23/2021 Newton Email re: Distribution Schedule (Q4 2020) attachment			140; 240		PWNewton_0000615		402, 403, 901
1141	Consulting Agreement - Mike Jackson			141		PureWick_0018785	PureWick_0018799	402, 403
1143	11/18/2022 Subpoena to Pawlik			143				402, NE
1144	5/21/2015 Letter	459		144; 319		PureWick_0015966	PureWick_0015966	402, 403
1145	05/04/2015 Pawlik Email Chain Attaching Photograph			145		PWNewton_0003389		H, 901
1146	05/05/2015 Pawlik Email Chain to PureWick			146		Pawlik_009600	Pawlik_009601	402, 403, H, 901
1147	5/5/2015 PureWick Email Chain to Pawlik			147; 261; 329		PWNewton_0003719	PWNewton_0003720	H, 901
1148	06/02/2015 Pawlik Email to PureWick attaching product review letter			148		Pawlik_009580	Pawlik_009581	H, 402, 403, 901
1149	06/02/2015 PureWick Email Chain to Pawlik re: letter			149		PWNewton_0003722	PWNewton_0003722	H, 402, 403, 901
1150	06/02/2015 Pawlik Email Chain to PureWick			150		Pawlik_009579	Pawlik_009579	H, 402, 403, 901
1151	05/13/2015 PureWick Email to Pawlik re: video			151		Pawlik_004716	Pawlik_004716	H, 402, 403, 901
1152	5/21/2015 Pawlik Email to PureWick Attaching Photograph			152		Pawlik_009594		H, 402, 403, 901
1153	05/21/2015 Pawlik Email to PureWick Attaching Photograph			153		Pawlik_009597		H, 402, 403, 901
1154	5/21/2015 Pawlik Email to PureWick Attaching Photograph			154		Pawlik_009588		H, 402, 403, 901
1155	05/21/2015 Pawlik Email to PureWick Attaching Photograph			155		Pawlik_009591		H, 402, 403, 901
1156	05/21/2015 Pawlik Email chain to PureWick			156		Pawlik_009584	Pawlik_009585	H, 402, 403, 901
1157	05/22/2015 PureWick Email Chain to Pawlik			157				H, 402, 403, 901, NP



## Sage Preliminary Exhibit List

1158	5/29/2015 Duffy Agreement			158				H, 402, 403, 901, NP
1159	5/29/2015 Duffy Agreement			159				H, 402, 403, 901, NP
1160	05/27/2015 PureWick Email Chain to Pawlik			160	PWNewton_0003721	PWNewton_0003721		H, 901
1161	06/23/2015 Pawlik Email to PureWick			161	Pawlik_009578	Pawlik_009578		H, 901
1162	07/27/2015 Pawlik Email Chain to PureWick			162	Pawlik_009570	Pawlik_009572		H, 901
1163	07/28/2015 Pawlik Chain Email			163	PWNewton_0002300	PWNewton_0002303		H, 901
1164	07/31/2015 PureWick Email Chain to Pawlik			164	Pawlik_004688	Pawlik_004693		H, 901
1165	07/2015 Pawlik Email Chain with Photograph			165	Pawlik_009551	Pawlik_009556		H, 901
1166	07/2015 Pawlik Email Chain with June Photograph			166	Pawlik_009545	Pawlik_009550		H, 901
1167	07/2015 Pawlik Email Chain to PureWick Attaching June Photographs			167	Pawlik_009524	Pawlik_009544		H, 901
1168	7/26/2015 PureWick First Sales Order	395	395	168	PureWick_0023811	PureWick_0023811		H, 402, 403, 901
1169	08/02/2015 PureWick Email Chain to Pawlik re: Videotaping			169	PWNewton_0002309	PWNewton_0002309		H, 901
1170	08/03/2015 Pawlik Email Chain to PureWick			170	Pawlik_009507	Pawlik_009508		H, 901
1171	08/14/2015 Pawlik Email to PureWick Attaching Photograph			171	Pawlik_009505			H, 901
1172	08/05/2015 PureWick Email to Pawlik			172	Pawlik_004675	Pawlik_004676		H, 901
1173	08/06/2015 Pawlik Email Chain to PureWick			173	Pawlik_009497	Pawlik_009499		H, 901
1174	08/11/2015 Pawlik Email			174	PWNewton_0002314	PWNewton_0002314		H, 901
1175	08/11/2015 Pawlik Email Chain to PureWick			175	Pawlik_009495	Pawlik_009495		
1176	08/13/2015 Pawlik Email			176	PWNewton_0002318	PWNewton_0002318		H, 901
1177	08/17/2015 Pawlik Chain Email			177	PWNewton_0002320	PWNewton_0002321		H, 901
1178	08/20/2015 Pawlik Chain Email			178	PWNewton_0002335	PWNewton_0002339		H, 901
1179	08/26/2015 Pawlik Chain Email			179	PWNewton_0002435	PWNewton_0002482		H, 901
1180	08/30/2015 Pawlik Chain Email			180	PWNewton_0002683	PWNewton_0002735		H, 901
1181	09/01/2015 Pawlik Chain Email			181	PWNewton_0002791	PWNewton_0002845		H, 901
1182	09/03/2015 PureWick Chain Email to Pawlik			182	PWNewton_0003757	PWNewton_0003812		H, 901
1183	09/05/2015 PureWick Email Chain to Pawlik			183	Pawlik_004671	Pawlik_004671		H, 901
1184	09/15/2015 PureWick Email Chain to Pawlik			184	Pawlik_004637	Pawlik_004640		H, 901
1185	09/15/2015 PureWick Invoice to Kate Pawlik			185	PureWick_0063669	PureWick_0063669		H, 402, 403, 901
1186	09/17/2015 Pawlik Email Chain			186	PWNewton_0002977	PWNewton_0002982		H, 901
1187	10/31/2015 PureWick Email Chain to Pawlik			187	Newton_0002713	Newton_0002735		H, 901
1188	11/06/2015 Pawlik Email Chain to PureWick			188	Pawlik_009419	Pawlik_009423		H, 901
1190	12/17/2015 PureWick Email to Pawlik			190	Pawlik_003824	Pawlik_003860		H, 901
1191	01/30/2016 Pawlik Email to PureWick Attaching Photographs			191	Pawlik_006960			H, 402, 403, 901
1193	02/04/2016 PureWick Email to Pawlik			193	Newton_0003234	Newton_0003265		H, 901
1194	08/08/2016 PureWick Email to Pawlik			194	Pawlik_001840	Pawlik_001841		H, 901
1195	03/21/2016 Pawlik Email to PureWick			195	Pawlik_006152	Pawlik_006174		H, 901
1196	04/05/2016 PureWick Email to Pawlik			196	Pawlik_001160	Pawlik_001162		H, 901
1197	04/11/2016 Pawlik Email to PureWick Attaching Photographs			197	Pawlik_005790			H, 402, 403, 901

## Sage Preliminary Exhibit List

1198	04/15/2016 Pawlik Email to PureWick Attaching Photograph			198		Pawlik_005732		H, 402, 403, 901
1199	04/22/2016 PureWick Email to Pawlik			199		Pawlik_000981	Pawlik_000996	H, 901
1200	04/11/2016 PureWick Email Attaching Photographs			200		Newton_0006412		H, 901
1202	05/19/2016 PureWick Email to Pawlik			202		Pawlik_000434	Pawlik_000438	H, 901
1203	05/23/2016 PureWick Email to Pawlik			203		Pawlik_000409	Pawlik_000415	H, 901
1204	06/15/2016 Pawlik Email to PureWick			204, 205		Pawlik_004939	Pawlik_004943	H, 901
1206	07/04/2016 PureWick Email Attaching Photograph			206		Newton_0006600		H, 901
1207	07/04/2016 Pawlik Email to PureWick Attaching Photograph			207		Pawlik_004913		H, 901
1208	07/10/2016 Pawlik Email Chain to PureWick			208		Pawlik_004868	Pawlik_004877	H, 901
1209	08/08/2016 PureWick Email to Pawlik			209		Pawlik_000008	Pawlik_000026	H, 901
1210	04/20/2016 PureWick Email to Pawlik			210		Pawlik_001011	Pawlik_001025	H, 901
1211	11/01/2019 Camille Newton Consulting Agreement			211		BDPureWick_00001177	BDPureWick_00001184	402, 403, 901
1212	02/01/2022 Email re: Camille Newton Consulting Agreement			212		BDPureWick_00001197	BDPureWick_00001199	H, 402, 403, 901
1213	03/02/2022 BD Email re: Camille Newton Consulting Agreement			213		BDPureWick_00001373	BDPureWick_00001373	H, 402, 403, 901
1214	02/28/2022 Camille Newton Consulting Agreement Signature			214		BDPureWick_00001374	BDPureWick_00001378	402, 403, 901
1215	11/01/2022 Camille Newton Consulting Agreement			215		BDPureWick_00001379	BDPureWick_00001386	402, 403, 901
1220	07/27/2022 BD Email			220		BDPureWick_00001611	BDPureWick_00001612	H, 402, 403, 901
1221	07/27/2022 BD Email re: Medline Versette			221		BDPureWick_00001494	BDPureWick_00001494	H, 402, 403, 901
1223	08/10/2022 BD Powerpoint - US PureWick Strategy			223		BDPureWick_00007641	BDPureWick_00007641	H, 901
1224	BD Review of Sage PrimaFit IFU			224		BDPureWick_00007655	BDPureWick_00007655	H, 402, 403, 901
1225	MAUDE FDA Complaint Report for PureWick and individual entries thereon			225		STRSAGE00024635	STRSAGE00024635	402, 403, 901
1226	MAUDE FDA Complaint Report for PureWick and individual entries thereon			038; 226		STRSAGE00024636	STRSAGE00024636	402, 403, 901
1227	MAUDE FDA Complaint Report for PureWick and individual entries thereon			227		STRSAGE00024637	STRSAGE00024637	402, 403, 901
1228	MAUDE FDA Complaint Report for PureWick and individual entries thereon			228		STRSAGE00024539	STRSAGE00024634	402, 403, 901
1229	11/18/2022 BD Email re: PureWick Female Catheter Concerns			229		BDPureWick_00002188	BDPureWick_00002188	H, 402, 403, 901
1230	11/18/2022 BD Email re: PureWick Issue at St. Mary's			230		BDPureWick_00002186	BDPureWick_00002187	H, 402, 403, 901
1231	11/18/2022 BD Email re: External Catheters			231		BDPureWick_00002182	BDPureWick_00002182	H, 402, 403, 901
1233	04/07/2017 Project Candle Due Diligence Report			233		BDPureWick_00007399	BDPureWick_00007475	H, 402, 403, 901
1234	04/10/2017 Project Candle Acquisition Committee Memo			234		BDPureWick_00007476	BDPureWick_00007488	H, 402, 403, 901
1235	04/07/2017 Project Candle Model			235		BDPureWick_00007489	BDPureWick_00007489	H, 402, 403, 901
1236	04/07/2017 Bard Document - Project Candle			236		BDPureWick_00007490	BDPureWick_00007512	H, 402, 403, 901
1237	04/05/2023 Deposition Subpoena to Camille Newton			237				402, NE
1239	12/24/2016 PureWick/Bard Preliminary Proposal			239		PureWick_0015055	PureWick_0015058	402, 403, 901

## Sage Preliminary Exhibit List

1242	09/03/2021 BD Email with Attachment re Milestone			242		PWNewton_0000242		402, 403, 901
1243	04/12/2021 PureWick Email			142; 243; 254		PWNewton_0001362	PWNewton_0001363	H, 402, 403, 901
1244	Consulting Agreement Dated 11/1/2019 between Bard and Camille Newton			244		PWNewton_0004267	PWNewton_0004274	H, 402, 403
1245	01/26/2022 BD Email re: Consulting Agreement			245		PWNewton_0001545	PWNewton_0001545.0002	H, 402, 403
1246	02/28/2022 BD Email re: Consulting Agreement			246		PWNewton_0001536	PWNewton_0001536.0002	H, 402, 403
1247	11/01/2021 Camille Newton Consulting Agreement			247		BDPureWick_00001245	BDPureWick_00001252	H, 402, 403
1248	08/12/2021 Jackson Email Re: PureWick Update			248		PWNewton_0000063	PWNewton_0000064	H, 402, 403, 901
1249	11/18/2021 BD Email			249		PWNewton_0000220	PWNewton_0000221	H, 402, 403, 901
1250	11/18/2021 Newton Email to BD with Attachments			250		PWNewton_0000872	PWNewton_0000880	H, 402, 403, 901
1251	10/15/2020 PureWick Email to BD Re: New FECs			251		PWNewton_0004214	PWNewton_0004214	H, 402, 403, 901
1252	05/25/2021 BD Email re: New PrimaFit Device			252		PWNewton_0004251	PWNewton_0004255	H, 402, 403, 901
1253	05/28/2021 Newton Email to BD with Attachment			253		PWNewton_0000328		402, 403, 901
1255	01/13/2022 Forehand Email			255		PWNewton_0001547	PWNewton_0001548	402, 403, 901
1256	08/10/2022 Newton Email			256		PWNewton_0001650	PWNewton_0001651	402, 403, 901
1257	08/16/2022 BD Email			257		PWNewton_0001555	PWNewton_0001556	H, 402, 403, 901
1258	01/14/2022 Newton Email			258		PWNewton_0001703	PWNewton_0001704	H, 402, 403, 901
1259	09/07/2016 First Quality Email re: Intellectual Property			259		FQE0000775	FQE0000777	H, 402, 403, 901
1260	02/08/2017 Email with Medline			138; 260		MEDLINE0043	MEDLINE0044	H, 402, 403, 901
1265	04/28/2023 Deposition Subpoena to Ray Newton			265				402, NE
1266	10/24/2014 Connor Newton Email Attaching Photographs			266		PWNewton_0002093		402, 403, 901
1267	10/24/2014 Connor Newton Email Attaching Photographs			267		PWNewton_0002104		402, 403, 901
1268	11/11/2014 Amazon Email to Ray Newton			268		PWNewton_0002111	PWNewton_0002112	402, 403, 901
1269	11/11/2014 Amazon Email to Ray Newton			269		PWNewton_0002113	PWNewton_0002114	402, 403, 901
1270	11/13/2014 Camille Newton Attaching Photographs			270		PWNewton_0002115		402, 403, 901
1271	11/13/2014 PureWick Email Attaching Photograph			271		PWNewton_0002118		402, 403, 901
1272	11/13/2014 PureWick Email Attaching Photograph			272		PWNewton_0002121		402, 403, 901
1273	11/15/2014 PureWick Email to Cowley			273; 328		PWNewton_0003251	PWNewton_0003254	H, 402, 403, 901
1274	12/04/2014 Amazon Email to Ray Newton			274		PWNewton_0002124	PWNewton_0002125	H, 402, 403, 901
1275	01/11/2015 PureWick Email re: Brochure attachment			275		Newton_0001666	Newton_0001668	402, 403, 901
1276	Photograph of DryDock and Wick			276		PureWick_0024658	PureWick_0024658	402, 403, 901

## Sage Preliminary Exhibit List

1278	01/11/2015 Photograph of Wick			278		PureWick_0024731	PureWick_0024731	402, 403, 901
1279	Photograph of Wick			279				402, 403, 901, NP
1281	02/03/2015 PureWick Email with Connect Attaching Executive Summary			281		Newton_0002573		402, 403, 901
1282	02/04/2015 PureWick Email to Connect with Attachments			282		Newton_0000711		402, 403, 901
1283	05/11/2015 PureWick Email Chain			283		Newton_0002624	Newton_0002626	H, 402, 403, 901
1284	05/26/2015 Amazon Email to Ray Newton			284		PWNewton_0002139	PWNewton_0002140	402, 403, 901
1285	05/08/2015 PureWick User Guide			285		PureWick_0022190	PureWick_0022191	402, 403
1286	07/07/2015 PureWick Email			286		Newton_0001813	Newton_0001813	H, 402, 403, 901
1287	06/29/2015 PureWick How To Use Video			287		PureWick_0014648	PureWick_0014648	402, 403
1288	07/21/2015 PureWick Assembly Video			288		PureWick_0022332	PureWick_0022332	402, 403, 901
1289	Screenshots of Assembly Video			289				402, 403, 901
1290	8/5/2015 PureWick Email to Pawlik			290		PWNewton_0003729	PWNewton_0003730	H, 901
1291	August 2015 PureWick Operations Plan	118		291		PureWick_0020968	PureWick_0020975	H, 402, 403, 901
1292	08/24/2015 PureWick Photograph - DryDocks			292		PureWick_0018912	PureWick_0018912	402, 403, 901
1293	08/27/2015 Professional Photos of PureWick Wicks			293		PureWick_0018895	PureWick_0018895	402, 403, 901
1294	9/11/2015 Professional Photos of PureWick Wick and DryDock			294				402, 403, 901
1295	08/2015 PureWick Instruction Manual	412	412	120; 295		PureWick_0022152	PureWick_0022158	H, 402, 403
1296	09/11/2015 and 01/13/2016 Connor Newton Emails to Ray Newton Attaching Photographs			296				402, 403, 901, NP
1297	09/01/2015 PureWick Price List			297		PureWick_0019017	PureWick_0019018	402, 403, 901
1298	09/16/2015 PureWick Email to Pawlik			298		PWNewton_0002972	PWNewton_0002976	H, 901
1300	11/15/2015 PureWick Newsletter with Connect Blog			300		PureWick_0017991	PureWick_0017992	
1301	03/18/2023 PureWick's Eighth Supplemental Responses to Sage's Interrogatories (Nos. 5, 6, and 16)			301				402, NE
1302	PureWick Whitepaper			302; 321		PureWick_0016149	PureWick_0016158	
1303	PureWick Case Studies Table by User			303		PureWick_0025865	PureWick_0025865	901
1304	09/13/2014-10/19/2015 PureWick Case Studies			304		PureWick_0017078	PureWick_0017084	901; on our exhibit list
1305	08/03/2015-10/28/2015 PureWick Side-Sleeper User Results			305		PureWick_0025939	PureWick_0025939	901
1306	8/4/2015 PureWick Email to Pawlik			306		PWNewton_0002313	PWNewton_0002313	H, 901
1307	08/05/2015 PureWick Email to Pawlik			307		Pawlik_004673	Pawlik_004674	H, 901
1308	08/11/2015 Pawlik Email to PureWick with Attachments			308		Pawlik_004672	Pawlik_004672	H, 901
1309	01/09/2018 Newton Email to Bard with attachments			309		PureWick_0048702	PureWick_0048708	H, 901
1310	PureWick Development History Document			310		PWNewton_004746.1	PWNewton_004746.1	H, 402, 403, 901
1311	PureWick Photograph of Booth at Nashville			311		PureWick_0022282	PureWick_0022282	402, 403, 901
1312	08/19/2016 Pawlik Email to PureWick			312		Pawlik_004721	Pawlik_004721	H, 901
1313	03/17/2019 PureWick Email re: Milestone Payment with attachments			313		Newton_0008252		402, 403, 901

## Sage Preliminary Exhibit List

1314	12/07/2022 Subpoena to Ray Newton			314				402, NE
1318	11/10/2014 Medtech Design Challenge			318				402, 403, 901, NP
1320	5/5/15 PureWick Email to Pawlik re: Letter			320		Pawlik_004717	Pawlik_004718	H, 402, 403, 901
1324	12/30/2015 PureWick Email to Pawlik			324		Pawlik_003388	Pawlik_003412	H, 901
1325	03/18/2023 PureWick's Eighth Supplemental Responses to Sage's Interrogatories			325				402, NE
1331	US 8,287,508 to Sanchez			331		STRSAGE00004666	STRSAGE00004672	H, 402, 403, 901, DUP
1332	Photograph of Wick			332		Pawlik_009530	Pawlik_009530	402, 403, 901
1334	Sage PrimaFit 2.0 Instructions for Use			334	42	STRSAGE00000001	STRSAGE00000001	
1337	Website - Engineering Systems Inc.			337				402, 403, NP
1338	Manual for 3B Scientific Catheterization Trainer			338				402, 403, NP
1339	Collins Opening Report Ex. L - Photographs of Experiment			339				901
1348	2023 Sage Annual Marketing Plan			345; 348	017; 035; 133	STRSAGE00022910	STRSAGE00022937	
1350	October 2021 Sage Annual Marketing Plan			350		STRSAGE00022938	STRSAGE00022990	
1354	Diane Newman Responsive Report			354				
1355	What is New May Not Always Be Best (Resnick)			355				402, 403, NP
1357	A Single Institution Pre-/Post Comparison After Introduction of an External Urinary Collection Device for Female Medical Patients (Jasperse et al.)			357				402, 403, NP
1359	2020 BD Email attaching Critical Care Slide Deck			359		BDPureWick_00013216	BDPureWick_00013216	H, 402, 403
1360	Critical Care ASR Deck			360		BDPureWick_00013217	BDPureWick_00013217	H, 402, 403, 901
1361	Ascension Health Resource and Supply Management Group LLC Purchase Agreement			361		BDPureWick_00014981	BDPureWick_00015057	H, 402, 403, 901
1362	2017 Bard email regarding National Accounts Monthly Report			362		BDPureWick_00013531	BDPureWick_00013531	H, 402, 403
1363	PureWick National Accounts Monthly Report (August 2017)			363		BDPureWick_00013532	BDPureWick_00013534	H, 402, 403
1364	Amendment to Purchase Agreement between Bard and HealthTrust Purchasing Group, L.P. (2019)			364		BDPureWick_00014786	BDPureWick_00014788	H, 402, 403, 901
1365	Bid for Product Supplier Agreement for Urinary Catheters and Devices between Vizient Supply and Bard			365		BDPureWick_00015322	BDPureWick_00015407	H, 402, 403, 901
1366	06/05/2020 BD Email Chain with image			366		BDPureWick_00013229	BDPureWick_00013231	H, 402, 403
1367	BD GPO Contract List			367		BDPureWick_00015111	BDPureWick_00015111	H, 402, 403, 901
1368	2017 Amendment to Agreement between Vizient Supply and Bard			368		BDPureWick_00015250	BDPureWick_00015256	H, 402, 403, 901
1369	Bard Purchasing Agreement with Healthtrust			369		BDPureWick_00014789	BDPureWick_00014875	H, 402, 403, 901
1370	Amendment to Purchase Agreement between Ascension Health Resource and Supply Management Group and Bard			370		BDPureWick_00015091	BDPureWick_00015092	H, 402, 403, 901
1371	2018 Bard Email regarding PureWick at Vizient			371		PureWick_0034409	PureWick_0034410	H, 402, 403

## Sage Preliminary Exhibit List

1372	Bard National Accounts Monthly Report (March 2018)			372		BDPureWick_00013615	BDPureWick_00013617	H, 402, 403
1373	Bard National Accounts Monthly Report (April 2018)			373		BDPureWick_00013618	BDPureWick_00013621	H, 402, 403
1374	Bard National Accounts Monthly Report (July 2017)			374		BDPureWick_00013511	BDPureWick_00013515	H, 402, 403
1375	Bard National Accounts Monthly Report (August 2017)			375		BDPureWick_00013519	BDPureWick_00013523	H, 402, 403
1376	Bard National Accounts Monthly Report (September 2017)			376		BDPureWick_00013524	BDPureWick_00013528	H, 402, 403
1377	11/06/2017 Bard Memo			377		BDPureWick_00013454	BDPureWick_00013459	H, 402, 403
1378	Bard National Accounts Monthly Report (December 2017)			378		BDPureWick_00013464	BDPureWick_00013468	H, 402, 403
1380	2017 Bard Email re: GPO Contract Update			380		PureWick_0034405	PureWick_0034408	H, 402, 403
1381	Bard National Accounts Monthly Report (January 2018)			381		BDPureWick_00013500	BDPureWick_00013502	H, 402, 403
1382	Bard National Accounts Monthly Report (February 2018)			382		BDPureWick_00013589	BDPureWick_00013591	H, 402, 403
1383	Bard National Accounts Monthly Report (May 2018)			383		BDPureWick_00013684	BDPureWick_00013687	H, 402, 403
1384	Bard National Accounts Monthly Report (June 2018)			384		BDPureWick_00013738	BDPureWick_00013741	H, 402, 403
1385	Bard National Accounts Monthly Report (July 2018)			385		BDPureWick_00013750	BDPureWick_00013753	H, 402, 403
1386	Bard National Accounts Monthly Report (August 2018)			386		BDPureWick_00013806	BDPureWick_00013808	H, 402, 403
1387	Bard National Accounts Monthly Report (September 2018)			387		BDPureWick_00013779	BDPureWick_00013781	H, 402, 403
1388	Bard National Accounts Monthly Report (October 2018)			388		BDPureWick_00013844	BDPureWick_00013846	H, 402, 403
1389	Bard National Accounts Monthly Report (November 2018)			389		BDPureWick_00013849	BDPureWick_00013851	H, 402, 403
1390	Bard National Accounts Monthly Report (December 2018)			390		BDPureWick_00013855	BDPureWick_00013860	H, 402, 403
1391	BD National Accounts Monthly Report (January 2019)			391		BDPureWick_00013864	BDPureWick_00013867	H, 402, 403
1392	BD National Accounts Monthly Report (February 2019)			392		BDPureWick_00013870	BDPureWick_00013873	H, 402, 403
1393	BD National Accounts Monthly Report (March 2019)			393		BDPureWick_00013884	BDPureWick_00013887	H, 402, 403
1394	BD Acute Urology Sales Update: May 2019			394		BDPureWick_00014665	BDPureWick_00014669	H, 402, 403
1396	2020 BD Email re: US Commercial Recovery Tracking			396		BDPureWick_00013232	BDPureWick_00013232	H, 402, 403
1397	2018 BD Email re: Acute Urology Monthly Report			397		PureWick_0033870	PureWick_0033871	H, 402, 403
1398	08/13/2019 BD Email re: Monthly Report			398		PureWick_0033524	PureWick_0033524	H, 402, 403
1399	07/26/2019 BD Email re: June Monthly Recap/Questions			399		BDPureWick_00013157	BDPureWick_00013159	H, 402, 403
1400	A Single Institution Pre-/Post Comparison After Introduction of an External Urinary Collection Device for Female Medical Patients (Jasperse et al.)			400				402, 403, NP, DUP
1401	What is New May Not Always Be Best (Resnick)			401				402, 403, NP, DUP
1402	BD Presentation (2020) - Female Non-Invasive Market Update			402		BDPureWick_00013194	BDPureWick_00013194	H, 402, 403, 901
1403	05/24/2019 BD Email with attachment re: Boehringer CareConnect			403		BDPureWick_00013168	BDPureWick_00013172	H, 402, 403
1404	08/21/2019 BD Email re: PureWick Strategy			404		BDPureWick_00013190	BDPureWick_00013191	H, 402, 403



## Sage Preliminary Exhibit List

1410	11/2013 PureWick Use Results for LH				PureWick_0025882	PureWick_0025884	402, 403, 901
1411	PureWick Historical Sales				PureWick_0030220	PureWick_0030220	901
1412	PureWick Year-Over-Year Trending				PureWick_0064694	PureWick_0064694	NP
1413	06/30/2016 PureWick Email Chain to Pawlik				Pawlik_000199	Pawlik_000203	901, H
1414	Measuring Safety, Effectiveness and Ease of Use of PureWick in the Management of Urinary Incontinence in Bedbound Women: Case Studies (Newton, Call, Chan)				SAGE00041041	SAGE00041051	901
1416	PureWick Connect Springboard Company Advertising sheet				SAGE00041052	SAGE00041052	402, 403, 901, H
1420	01/30/2016 Pawlik Email to PureWick				Pawlik_006901	Pawlik_006928	H, 402, 403, 901
1421	11/13/2014 PureWick Email to Cowley				PWNewton_0003249	PWNewton_0003250	H, 402, 403, 901
1422	02/27/2020 PureWick Email to Eckert re: Pressure Injuries				PWNewton_0004191	PWNewton_0004192	H, 402, 403, 901
1600	Sage Patient Cleansing Brochure			600			NP
1601	Photograph of FlexLink			601			NP
1602	PureWick Sales Brochure PW254-15				PureWick_0014907	PureWick_0014908	901
1646	PrimaFit 2.0 Make v. Buy Presentation				STRSAGE00023071		H, 402, 403, 901, Unt
1647	PrimaFit 2.0 Review Presentation				STRSAGE00021412	STRSAGE00021412	H, 402, 403, 901, Unt
1648	PrimaFit 2.0 Status Update				STRSAGE00021438	STRSAGE00021438	H, 402, 403, 901, Unt
1649	Testing Plan 05 31 2019				STRSAGE00021459	STRSAGE00021460	H, 901, Unt
1650	PrimaFit 2.0 Testing Plan 02-20-2020				STRSAGE00022023	STRSAGE00022024	H, 901, Unt
1651	Purchase Requisition Form for Engineering Trials				STRSAGE00023020	STRSAGE00023020	402, 403, 901, Unt
1652	Purchase Requisition Form for Engineering Trials				STRSAGE00023021	STRSAGE00023021	402, 403, 901, Unt
1653	Purchase Requisition Form for Engineering Trials				STRSAGE00023022	STRSAGE00023022	402, 403, 901, Unt
1654	PrimaFit 2.0 Change Request Plan Form (CRP# 20-0398)				STRSAGE00023048	STRSAGE00023056	H, 901, Unt
1655	Photograph - PrimaFit 2.0 Manufacturing Facility				STRSAGE00023057	STRSAGE00023057	H, 402, 403, 901, Unt
1656	Friday huddle PrimaFit 2.0				STRSAGE00023058	STRSAGE00023058	H, 402, 403, 901, Unt
1657	PrimaFit 2.0 Team Picture				STRSAGE00023062	STRSAGE00023062	402, 403, 901, Unt
1658	PrimaFit 2.0 Lean Lighthouse Report Out Presentation				STRSAGE00023079	STRSAGE00023079	H, 901, Unt
1659	PrimaFit 2.0 Recognition Spotlight Presentation				STRSAGE00023086	STRSAGE00023086	H, 402, 403, 901, Unt
1660	PrimaFit 2.0 Team Photograph				STRSAGE00023114	STRSAGE00023114	402, 403, 901, Unt
1661	Walker Downey & Associates Material Risk Assessment of PrimaFit 2.0 Device			121; 147	STRSAGE00023497	STRSAGE00023540	901, Unt
1662	Visual Inspection of PrimaFit 2.0				STRSAGE00023727	STRSAGE00023749	901, Unt
1663	PrimaFit 2.0 New Product Development Technical Report - Soft Tapered End Material and Weld Softness				STRSAGE00024339	STRSAGE00024341	901, Unt

## Sage Preliminary Exhibit List

1664	07/24/2019 Sage Email Chain with attachment re: PrimaFit 2.0 charter meeting					STRSAGE00024764	STRSAGE00024766	901, Unt
1665	Sage PrimaFit 2.0 Cost Reduction Roadmap					STRSAGE00024793	STRSAGE00024797	402, 403, 901, Unt
1666	03/20/2020 Sage Email Chain re: PrimaFit 2.0 Manufacturing Options					STRSAGE00024821	STRSAGE00024823	402, 403, 901, Unt
1667	04/03/2020 Sage Email Re: PrimaFit 2.0 Highlights					STRSAGE00024827	STRSAGE00024827	901, Unt
1668	05/27/2020 Sage Email Chain with Attachments re: Adhesives Research					STRSAGE00024851	STRSAGE00024866	402, 403, 901, Unt
1670	10/21/2020 Sage Email Chain re: PrimaFit 2.0 build pics					STRSAGE00024899	STRSAGE00024902	402, 403, 901, Unt
1671	02/20/2021 Sage Email Chain with Attachments re: PrimaFit 2.0 Purchase Requisitions					STRSAGE00024949	STRSAGE00024961	901, Unt
1672	02/25/2021 Sage Email with attachment re: PrimaFit 2.0 Risk Management Board Notes					STRSAGE00024968	STRSAGE00024970	402, 403, 901, Unt
1673	04/20/2021 Sage Email chain re: Seam Change Review					STRSAGE00025121	STRSAGE00025122	402, 403, 901, Unt
1674	05/27/2021 Sage Email re: PrimaFit 2.0 FAT Update					STRSAGE00025165	STRSAGE00025165	402, 403, 901, Unt
1676	09/03/2021 Sage email chain re: PrimaFit 2.0 Timeline					STRSAGE00025258	STRSAGE00025259	901, Unt
1677	09/08/2021 Sage email re: PrimaFit 2.0 Production					STRSAGE00025273	STRSAGE00025274	402, 403, 901, Unt
1678	Executive Summary: Sage Female External Continence Device (PrimaFit 1.0)					SAGE00024810	SAGE00024811	901, Unt
1687	09/20/2019 PrimaFit 2.0 Planning Exit					SAGE00036478	SAGE00036478	402, 403, 901, Unt
1688	Sage NPD Fast Track Presentation (2019)					SAGE00036854	SAGE00036854	901, Unt
1689	01/08/2020 Sage email chain re: PrimaFit 2.0 - market feedback					SAGE00036998	SAGE00036999	901, Unt
1691	01/27/2020 Sage Email re: PrimaFit 2.0 ESR					SAGE00037023	SAGE00037023	901, Unt
1692	PrimaFit 2.0 Update					SAGE00037398	SAGE00037399	402, 403, 901, Unt
1693	10/31/2019 PrimaFit 2.0 Monthly Project Review					SAGE00039754	SAGE00039754	H, 402, 403, 901, Unt
1694	Penguin Team Project Update (11/01/2019)					SAGE00039756	SAGE00039760	H, 402, 403, 901, Unt
1695	Penguin Team Project Update (11/15/2019)					SAGE00039777	SAGE00039780	H, 402, 403, 901, Unt
1696	Penguin Team Project Update (11/26/2019)					SAGE00039801	SAGE00039804	H, 402, 403, 901, Unt
1698	Penguin Team Project Update (01/22/2020)					SAGE00040050	SAGE00040053	H, 402, 403, 901, Unt
1699	Penguin Team Project Update (02/18/2020)					SAGE00040257	SAGE00040260	H, 402, 403, 901, Unt
1700	PrimaFit 2.0 Placement Guide					STRSAGE00000002	STRSAGE00000002	
1701	PrimaFit 2.0 Poster			52		STRSAGE00000003	STRSAGE00000003	
1702	PrimaFit 2.0 Poster			138		STRSAGE00000005	STRSAGE00000005	
1703	PrimaFit 2.0 Overshipper insert					STRSAGE00000006	STRSAGE00000006	402, H, 901
1704	PrimaFit 2.0 Specification for bow tie label					STRSAGE00000007	STRSAGE00000007	
1705	PrimaFit 2.0 Specification for FlexLink					STRSAGE00000008	STRSAGE00000008	



## Sage Preliminary Exhibit List

1706	PrimaFit 2.0 Suction Connector Specification					STRSAGE00000009	STRSAGE00000009	
1707	PrimaFit 2.0 tube					STRSAGE00000010	STRSAGE00000010	
1708	PrimaFit 2.0 Fabric					STRSAGE00000011	STRSAGE00000011	
1709	PrimaFit 2.0 Foam Backer					STRSAGE00000012	STRSAGE00000012	
1710	PrimaFit 2.0 Bottom Barrier					STRSAGE00000013	STRSAGE00000013	
1711	PrimaFit 2.0 Inner Foam					STRSAGE00000014	STRSAGE00000014	
1712	PrimaFit 2.0 Selective Adhesive					STRSAGE00000015	STRSAGE00000015	
1713	PrimaFit 2.0 Overshipper Artwork					STRSAGE00000016	STRSAGE00000017	
1714	PrimaFit 2.0 Hot Melt					STRSAGE00000018	STRSAGE00000018	
1715	PrimaFit 2.0 Suction Connector Rev A					STRSAGE00000019	STRSAGE00000019	
1716	PrimaFit 2.0 Suction Connection Rev NEW					STRSAGE00000020	STRSAGE00000020	402, 403, H, 901
1717	PrimaFit 2.0 Tube Rev 000					STRSAGE00000021	STRSAGE00000021	
1718	PrimaFit 2.0 Tube Rev 002					STRSAGE00000022	STRSAGE00000022	402, 403, H, 901
1719	PrimaFit 2.0 BOM Rev H				056; 085	STRSAGE00000023	STRSAGE00000028	
1720	PrimaFit 2.0 BOM Rev NEW				72	STRSAGE00000029	STRSAGE00000034	
1721	PrimaFit 2.0 BOM Rev A				84	STRSAGE00000035	STRSAGE00000040	
1722	PrimaFit 2.0 BOM Rev I			344		STRSAGE00025402	STRSAGE00025407	
1723	PrimaFit 2.0 Bag					STRSAGE00000045	STRSAGE00000048	
1724	Work Instructions Rev 13					STRSAGE00000049	STRSAGE00000050	402, 403, H, 901
1725	SOP Operating Instructions					STRSAGE00000051	STRSAGE00000072	402, 403, H, 901
1726	PrimaFit 2.0 WI Rev 000					STRSAGE00000073	STRSAGE00000076	402, 403, H, 901
1727	SOP Rev 000 Final					STRSAGE00000077	STRSAGE00000096	402, 403, H, 901
1728	SOP Rev 001 Final					STRSAGE00000097	STRSAGE00000118	402, 403, H, 901
1729	SOP Rev 002 Final					STRSAGE00000119	STRSAGE00000140	
1730	PowerPoint - PrimaFit Mid Year Meeting 2021					STRSAGE00021234	STRSAGE00021234	
1731; 2010	Sage Manufacturing Video					STRSAGE_EXP_000005		
1732	PowerPoint - PrimaFit				55	STRSAGE00022113	STRSAGE00022113	
1733	Sage Video - Manufacturing					STRSAGE00022149	STRSAGE00022149	H, 901, Incom
1734	Sage Video - Manufacturing					STRSAGE00022150	STRSAGE00022150	H, 901, Incom
1735	Sage Video - Manufacturing					STRSAGE00022151	STRSAGE00022151	H, 901, Incom
1736	Sage Video - Manufacturing					STRSAGE00022152	STRSAGE00022152	H, 901, Incom
1737	Sage Video - Manufacturing					STRSAGE00022153	STRSAGE00022153	H, 901, Incom
1738	Sage Video - Manufacturing					STRSAGE00022154	STRSAGE00022154	H, 901, Incom
1739	Sage Video - Manufacturing					STRSAGE00022155	STRSAGE00022155	H, 901, Incom
1740	Sage Video - Manufacturing					STRSAGE00022156	STRSAGE00022156	H, 901, Incom
1741	Sage Video - Manufacturing					STRSAGE00022157	STRSAGE00022157	H, 901, Incom
1742	Sage Video - Manufacturing					STRSAGE00022158	STRSAGE00022158	H, 901, Incom
1743	Sage Document - Product Evaluation					STRSAGE00022999	STRSAGE00023000	402, 403, H, 901
1744	Sage Document - Product Evaluation				120	STRSAGE00023001	STRSAGE00023003	

## Sage Preliminary Exhibit List

1745	Providence Holy Cross Trial Result Summary				44	STRSAGE00021320	STRSAGE00021320	
1746	Sage Document - Product Evaluation					STRSAGE00023023	STRSAGE00023024	402, 403, H, 901
1748	PrimaFit 2.0 Video					BDPureWick_EXP_00000040	BDPureWick_EXP_00000040	
1749	Sage Manufacturing Videos							NP
1750	PrimaFit 2.0 Bag					STRSAGE000000041	STRSAGE000000044	
1800	US 2004-025454 to Okabe					STRSAGE000000462	STRSAGE000000472	402, 403
1801	US 2006-0015080 to Mahnensmith					STRSAGE000000607	STRSAGE000000615	402, 403
1802	US 2007-0191804 to Coley					STRSAGE000000802	STRSAGE000000810	402, 403
1803	US 3,349,768 to Keane					STRSAGE000002627	STRSAGE000002634	402, 403
1804	US 3,520,300 to Flower					STRSAGE000002649	STRSAGE000002652	402, 403
1805	US 4,886,508 to Washington					STRSAGE000002901	STRSAGE000002913	402, 403
1806	US 8,303,554 to Tsai					STRSAGE000004673	STRSAGE000004684	402, 403
1807	EP0613355 to Kuntz					STRSAGE000005142	STRSAGE000005157	402, 403
1808	JP4039641B2 to Mizuguchi					STRSAGE000005486	STRSAGE000005495	402, 403
1809	PCTUS2016049274 - International Search Report & Opinion					STRSAGE00020551	STRSAGE00020562	402, 403
1814	US 2004-0128749					STRSAGE00000429	STRSAGE00000436	402, 403
1815	US 2008-0287894 to Van Den Heuvel					STRSAGE00000898	STRSAGE00000904	402, 403
1816	US 2009-0264840A1 to Virginio					STRSAGE00000918	STRSAGE00000941	402, 403
1817	2013-0006206 to Wada					STRSAGE00001385	STRSAGE00001397	402, 403
1818	US 4,610,675 to Triunfol					STRSAGE000002746	STRSAGE000002750	402, 403
1819	US 4,886,509 to Mattson					STRSAGE000002914	STRSAGE000002924	402, 403
1820	US 5,002,541 to Conkling					STRSAGE000002958	STRSAGE000002966	402, 403
1821	US 5,678,564 to Lawrence					STRSAGE000003179	STRSAGE000003200	402, 403
1822	US 5,911,222 to Lawrence					STRSAGE000003294	STRSAGE000003315	402, 403
1823	US 6,569,133 to Cheng					STRSAGE000003601	STRSAGE000003625	402, 403
1824	US 6,702,793 to Sweetser					STRSAGE000003645	STRSAGE000003650	402, 403
1825	US 6,706,027 to Harvie					STRSAGE000003651	STRSAGE000003663	402, 403
1826	US 6,740,066 to Wolff					STRSAGE000003670	STRSAGE000003685	402, 403
1827	US 6,888,044 to Fell					STRSAGE000003779	STRSAGE000003802	402, 403
1828	US 7,220,250 to Suzuki					STRSAGE000004069	STRSAGE000004088	402, 403
1829	US 7,695,460 to Wada					STRSAGE000004241	STRSAGE000004265	402, 403
1830	US 7,749,205 to Tazoe					STRSAGE000004377	STRSAGE000004390	402, 403
1831	US 7,939,706 to Okabe					STRSAGE000004482	STRSAGE000004493	402, 403
1832	US 8,241,262 to Mahnensmith					STRSAGE000004643	STRSAGE000004651	402, 403
1835	GB2148126A to Cottenden					STRSAGE000005227	STRSAGE000005231	402, 403
1836	JP2001276107A to Ishii (English translation & certification)					STRSAGE000005338	STRSAGE000005356	402, 403
1840	JPH11113946A to Chiku w Translation (English translation & certification)					SAGE00040859	SAGE00040880	402, 403
1842	WO2000-057784A1 to Wolff					STRSAGE000005761	STRSAGE000005788	402, 403
1843	WO2007042823 to Van Den Heuvel					STRSAGE000006022	STRSAGE000006037	402, 403
1844	WO2009-052496 to Tsai					STRSAGE000006057	STRSAGE000006076	402, 403
1846	Macaulay et al, A Noninvasive Continence Management System					SAGE000005312	SAGE000005319	H, 402, 403, 901
1847	Research and Development Work Relating to Assistive Technology 2005-2006, Brunel University (Nov 2006)					SAGE000006092	SAGE000006131	H, 402, 403, 901
1848	AMXDmax Presentation					SAGE00021349	SAGE00021368	
1849	Information Disclosure Statement in Sage Application					SAGE00033501	SAGE00033633	402, 403
1850	EP0032138A2 to Ozenne - English translation & certification					SAGE00040912	SAGE00040935	402, 403
1852	AMXDmax Development History: US Air Force and Omni 2002-2014					SAGE00040991	SAGE00040992	H, 402, 403, 901
1853	URINCare Incontinence Management System, Patient Starter Kit					SAGE00041053	SAGE00041062	H, 402, 403, 901
1854	Agenda, April 11-13, 2013, Innovating for Continence Conference					SAGE00041255	SAGE00041262	H, 402, 403, 901

## Sage Preliminary Exhibit List

1855	Omni Development Document - Omni's Proren Bladder Management System					SAGE00043339	SAGE00043340	H, 402, 403, 901
1856	PureWick Instructions for Use					PureWick_0017585	PureWick_0017586	
1857	10/20/06 Omni FDA 510k					OMNI_0000113	OMNI_0000113	402, 403
1858	Omni Device Listing					OMNI_0000115	OMNI_0000116	402, 403
1859	US 6,706,027 to Harvie					OMNI_0000248	OMNI_0000260	402, 403
1860	US 6,918,899 to Harvie					OMNI_0000261	OMNI_0000278	402, 403
1861	US 7,131,964 to Harvie					OMNI_0000279	OMNI_0000306	402, 403
1862	US 7,135,012 to Harvie					OMNI_0000307	OMNI_0000328	402, 403
1863	US 7,141,043 to Harvie					OMNI_0000329	OMNI_0000354	402, 403
1864	US 7,335,189 To Harvie					OMNI_0000355	OMNI_0000378	402, 403
1865	Omni Medical AMXDmax brochure (Formerly PTX-637)					PureWick_0018524		H, 402, 403
1866	Omni AMXDmax brochure (Formerly PTX642)					SAGE00021394		H, 402, 403
1867	AMXDmax® Female Starter Kit – Disposable, Size 1, Omni Defense Tech (2021) ( <a href="https://www.omni-defense.com/female-amxdmax-starter-kit-size-1">https://www.omni-defense.com/female-amxdmax-starter-kit-size-1</a> , viewed on May 19, 2023.) (Formerly PTX744)							H, 402, 403, 901, NP
1900	Sage Urine Management Powerpoint				14	STRSAGE00021235	STRSAGE00021235	
1901	PrimaFit PowerPoint - Making healthcare better (2022)				15	STRSAGE00021238	STRSAGE00021238	
1902	09/2019 NPD Limited Launch Design Approval Form PrimaFit 2.0					STRSAGE00021885	STRSAGE00021894	
1903	Boehringer CareDry, CareDry Claims				131	STRSAGE00023009	STRSAGE00023011	901
1904	Consure Medical Qivi, Qivi Claims				130	STRSAGE00023012	STRSAGE00023013	901
1905	Medline Versette Video					STRSAGE00023017	STRSAGE00023017	901
1906	Medline Versette video					STRSAGE00024738	STRSAGE00024738	H, 403, 901
1907	Medline Versette Best Practice Guidance					STRSAGE00024739	STRSAGE00024739	H, 403, 901
1908	2021 Medline Versette Indication for Use					STRSAGE00024740	STRSAGE00024740	H, 403, 901
1909	Boehringer Caredry System In Service - Video					STRSAGE00024745	STRSAGE00024745	H, 403, 901
1910	CareDry System Product Demo					STRSAGE00024746	STRSAGE00024746	H, 403, 901
1911	Boehringer Caredry Regulatory Classification for CareDry System					STRSAGE00024747	STRSAGE00024747	H, 403, 901
1912	Consure Medical Qivi Video					STRSAGE00024748	STRSAGE00024748	H, 402, 403, 901
1913	Qivi Truly External Female Urine Mgmt Device by Consure - video					STRSAGE00024749	STRSAGE00024749	H, 402, 403, 901
1914	Consure Medical Qivi Instructions for Use					STRSAGE00024750	STRSAGE00024751	H, 402, 403, 901
1915	Sage Blunt End Noninfringing Alternative					STRSAGE00024754	STRSAGE00024754	
1916	02/18/2021 Sage Email re: Medline Versette					STRSAGE00024962	STRSAGE00024964	H, 403, 901
1917	02/18/2021 Sage Email re: Medline Versette with attached video					STRSAGE00024965		H, 403, 901
1918	05/28/2021 Sage Email re: Medline Versette					STRSAGE00025166	STRSAGE00025171	H, 403, 901
1919	05/28/2021 Sage Email re: Medline Versette					STRSAGE00025172	STRSAGE00025177	H, 403, 901
1920	Wellcare Device Document					STRSAGE00025398	STRSAGE00025398	H, 403, 901
1921	WellCare Smart External Urine Collection System					STRSAGE00025399	STRSAGE00025399	H, 403, 901
1922	Wellcare Website					STRSAGE00025400	STRSAGE00025400	H, 403, 901
1923	Wellcare Device images					STRSAGE00025401	STRSAGE00025401	H, 403, 901
1924	Qivi Female External Urine Management Marketing Information							H, 403, 901, Unt, NP
1925	Medline Versette Instructions for Use					BDPureWick_00001554	BDPureWick_00001554	H, 403, 901







## Sage Preliminary Exhibit List

2147	Sage website Microclimate Body pads <a href="https://www.stryker.com/us/en/sage/products/sage-m--microclimate-body-pads.html">https://www.stryker.com/us/en/sage/products/sage-m--microclimate-body-pads.html</a>							H, 402, 403, 901, NP
2150	10/28/2022 Letter from Sage's Counsel							H, 402, 403, 901, NP
2151	11/07/2022 Letter from Sage's Counsel							H, 402, 403, 901, NP
2152	11/28/2022 Email from Sage's Counsel							H, 402, 403, 901, NP
2200	PowerPoint - UCC FY23 ASR PureWick					BDPureWick_00002060	BDPureWick_00002069	901
2201	11/18/2022 BD Email re: External Catheters					BDPureWick_00002173	BDPureWick_00002175	H, 402, 403, 901
2202	11/18/2022 BD Email re: Urology Contract					BDPureWick_00002176	BDPureWick_00002178	H, 402, 403, 901
2203	09/06/2022 BD Email re: Urology Contract					BDPureWick_00002179	BDPureWick_00002181	H, 402, 403, 901
2204	11/18/2022 BD Email re: External Catheters					BDPureWick_00002183	BDPureWick_00002183	H, 402, 403, 901
2205	11/18/2022 BD Email re: Feedback					BDPureWick_00002184	BDPureWick_00002185	H, 402, 403, 901
2206	02/10/2020 BD Idea Product Opportunity Appraisal Document					BDPureWick_00007647	BDPureWick_00007654	402, 403, 901
2207	2021 BD Powerpoint - HVS Debrief					BDPureWick_00007656	BDPureWick_00007656	402, 403, 901
2208	2022 BD Powerpoint - Rise H&H					BDPureWick_00013063	BDPureWick_00013063	402, 403, 901
2209	02/2020 BD Powerpoint - PureWick 2.0					BDPureWick_00013065	BDPureWick_00013065	402, 403, 901
2210	2021 BD Powerpoint - PureWick 2.0					BDPureWick_00013073	BDPureWick_00013073	402, 403, 901
2211	01/04/2022 BD Product Opportunity Appraisal					BDPureWick_00013084	BDPureWick_00013100	402, 403, 901
2212	2021 BD Powerpoint - PureWick 2.0 Concept Lab Testing Summary					BDPureWick_00013125	BDPureWick_00013125	402, 403, 901
2213	Beeson, Urinary Management with an External Female Collection Device					BDPureWick_EXP_00000003	BDPureWick_EXP_00000005	901
2214	Project Candle - User Visits (Bard Attendees)					PureWick_0014246	PureWick_0014247	402, 403, 901
2215	2017 PureWick Instructions and FAQs					PureWick_0014365	PureWick_0014366	901
2216	05/24/2019 BD Email re: PureWick Problems				118	PureWick_0033617	PureWick_0033620	H, 402, 403, 901
2217	01/09/2019 BD Email with Attachment re: Sage Accounts					PureWick_0034330	PureWick_0034330	H, 402, 403, 901
2218	09/2023 BD Powerpoint - US Acute Care Marketing PPlan					BDPureWick_00007687	BDPureWick_00007687	402, 403, 901
2219	08/28/2017 Bard Email with attachments re: PureWick Complaints					PureWick_0054254		901
2226	PureWick Platform Update					PureWick_0064350	PureWick_0064352	H, 402, 403, 901
2227	06/2017-07/2017 Bard Email Chain with Attachment re: Critical Care Monthly Report					PureWick_0051865	PureWick_0051866	402, 403, 901, Unt
2228	Bard Memo re: June 2017 Results					PureWick_0051867	PureWick_0051873	901, Unt
2229	2020 BD Presentation - Critical Care BD-UCC					BDPureWick_00013217	BDPureWick_00013217	402, 403, 901, Unt
2230	Amendment to Agreement between HealthTrust Purchasing Group and Bard (2023)					BDPureWick_00014032	BDPureWick_00014034	H, 402, 403, 901, Unt



## Sage Preliminary Exhibit List

2231	Group Purchasing Agreement - Med/Surg - Premier Healthcare Alliance and Bard					BDPureWick_00014035	BDPureWick_00014077	H, 402, 403, 901, Unt
2232	Group Purchasing Agreement - Med/Surg - Premier Healthcare Alliance and Bard					BDPureWick_00014078	BDPureWick_00014142	H, 402, 403, 901, Unt
2233	Group Purchasing Agreement - Med/Surg - Premier Healthcare Alliance and Bard					BDPureWick_00014143	BDPureWick_00014307	H, 402, 403, 901, Unt
2234	Master Products Agreement between Ascension Health Resource and Supply Management Group and Bard (2020)					BDPureWick_00014308	BDPureWick_00014391	H, 402, 403, 901, Unt
2235	Bid for Product Supplier Agreement for Urinary Catheters and Devices between Vizient Supply and Bard (2022)					BDPureWick_00014392	BDPureWick_00014443	H, 402, 403, 901, Unt
2240	12/22/2017 Bard Email Chain with Attachments					PureWick_0034593	PureWick_0034609	H, 402, 403, 901
2241	04/7/2020 BD Email re: PureWick 2.0 with attachment					BDPureWick_00013153	BDPureWick_00013155	H, 402, 403, 901
2242	03/31/2020 BD Email re: Key Accounts with Minimal Sales with attachment					BDPureWick_00013162	BDPureWick_00013164	H, 402, 403, 901
2243	05/17/2019 BD Email Chain mail re: Competitive Activity					BDPureWick_00013223	BDPureWick_00013224	H, 402, 403, 901
2244	06/05/2020 BD Email Chain					BDPureWick_00013229	BDPureWick_00013230	H, 402, 403, 901
2245	Bard Medical Chart re: Contract					BDPureWick_00013231	BDPureWick_00013231	402, 403, 901
2246	02/25/2020 BD Email with Attachment re: PureWick users					BDPureWick_00013262	BDPureWick_00013263	H, 402, 403, 901
2247	07/12/2019 BD Email attaching 2019 BD Acute Urology Sales Update					BDPureWick_00013276	BDPureWick_00013280	H, 402, 403, 901
2248	11/06/2017 Bard Memo					BDPureWick_00013454	BDPureWick_00013459	H, 402, 403, 901
2297	02/2021 Sage Risk Management Board Minutes					STRSAGE00023090	STRSAGE00023094	
2298	Sage Change Request Plan Form					STRSAGE00023039	STRSAGE00023047	
2299	11/2020 PrimaFit 2.0 Update (Design and Automation)					STRSAGE00022119	STRSAGE00022119	H, 901
2300	PrimaFit 2.0 Sell Sheet				036; 137	STRSAGE00000004	STRSAGE00000004	
2301	10/2020 Sage Powerpoint - Urine Management Enhancements Launch PrimaFit 1.5, PrimaFit 2.0					STRSAGE00021282	STRSAGE00021282	
2302	Sage Powerpoint - Project Overview PrimaFit 2.0					STRSAGE00022093	STRSAGE00022093	
2303	07/2020 Sage Powerpoint - Biocompatibility PrimaFit 2.0					STRSAGE00022095	STRSAGE00022095	
2304	2022 Sage Category Market Shares with DRG Data					STRSAGE00022840	STRSAGE00022908	H, 403, 901
2305	2021 Urine Management Annual Marketing Plan					STRSAGE00022993	STRSAGE00022993	H, 403, 901
2306	Selective Adhesive Device Securement, PrimaFit 2.0					STRSAGE00024298	STRSAGE00024300	
2308	02/2021 RMB Review PrimaFit 2.0				51	STRSAGE00023106	STRSAGE00023106	
2310	PrimaFit 2.0 Biocompatibility Evaluation				58	STRSAGE00023866	STRSAGE00023875	
2311	Sage Project Pipeline (2014) - Non-Invasive Urine Collection for the Bedridden Patient					SAGE00025962	SAGE00025962	H, 402, 403, 901, Unt
2312	09/2015 AMXDmax In-Flight Bladder Relief Leaflet					SAGE00041025	SAGE00041028	H, 402, 403, 901
2316	Harvie et al, Development of Omni's Proren Bladder Management Systems					SAGE00041063	SAGE00041064	H, 402, 403, 901



## Sage Preliminary Exhibit List

2317	7/21/2016 AMXDMax Supply Kit (Female)					SAGE00041065	SAGE00041065	H, 402, 403, 901
2318	7/21/2016 AMXDMax Supply Kit (Male)					SAGE00041066	SAGE00041066	H, 402, 403, 901
2319	AMXDMax User and Maintenance Guide					SAGE00041067	SAGE00041118	H, 402, 403, 901
2320	Simon Foundation for Continence's Innovating for Continence Series (2015) Materials					SAGE00041119	SAGE00041127	H, 402, 403, 901
2327	Simon Foundation for Continence's Innovating for Continence Series (2015) - Photos					SAGE00041128	SAGE00041144	H, 402, 403, 901
2328	Simon Foundation for Continence's Innovating for Continence Series (2015) - 2015 Press Releases					SAGE00041145	SAGE00041145	H, 402, 403, 901
2329	Agenda, April 15-17, 2015, Innovating for Continence Conference					SAGE00041146	SAGE00041153	H, 402, 403, 901
2330	Simon Foundation for Continence's Innovating for Continence Series (2015) - Sponsors					SAGE00041154	SAGE00041154	H, 402, 403, 901
2331	Simon Foundation for Continence's Innovating for Continence Series (2015) -					SAGE00041155	SAGE00041156	H, 402, 403, 901
2332	Simon Foundation for Continence's Innovating for Continence Series (2015) - Pre-conference Workshops					SAGE00041157	SAGE00041166	H, 402, 403, 901
2333	Simon Foundation for Continence's Innovating for Continence Series (2015) - Conference Program Abstracts					SAGE00041167	SAGE00041210	H, 402, 403, 901
2334	Simon Foundation for Continence's Innovating for Continence Series (2015) - Abstracts					SAGE00041211	SAGE00041254	H, 402, 403, 901
2335	AMXDmax In-Flight Bladder Relief - Female Pad IFP-15-2-2					SAGE00041263	SAGE00041264	H, 402, 403, 901
2336	11/17/2006 AMXD Department of the Air Force Memorandum					SAGE00041265	SAGE00041272	H, 402, 403, 901
2337	AMXD-Advanced Mission Extender Device Collection Unite Flier					SAGE00041273	SAGE00041273	H, 402, 403, 901
2338	AMXDMax Introductory Manual					SAGE00041274	SAGE00041277	H, 402, 403, 901
2339	Beeson Abstract - Standardizing Urinary Catheter Care and Maintenance in the Intensive Care Unit					SAGE00043341	SAGE00043341	H, 402, 403, 901
2340	Dublynn Abstract - Female External Catheter Use: A New Bundle Element to Reduce CAUTI					SAGE00043342	SAGE00043343	H, 402, 403, 901
2342	EP2180907 to Weig					SAGE00043345	SAGE00043369	402, 403
2343	JP3087938B2 to Kiuchi					SAGE00043370	SAGE00043388	402, 403
2344	JP3123547 to Saito					SAGE00043389	SAGE00043407	402, 403
2345	JP3132659 to Yanagihara					SAGE00043408	SAGE00043413	402, 403
2346	JP3198994 to Watanabe					SAGE00043414	SAGE00043426	402, 403
2348	JP2015092945 to Uchida					SAGE00043439	SAGE00043447	402, 403
2349	JPH0460220 to Sasaki					SAGE00043448	SAGE00043453	402, 403
2371	01/25/2022 Bard Email re: Camille Newton Consulting Agreement					BDPureWick_00001174		402, 403, 901
2372	07/28/2019 BD Email Attaching Monthly Report					PureWick_0033348		403, 901
2373	07/11/2019 BD Email attaching Monthly Report					PureWick_0033365		403, 901
2374	07/08/2019 Bard Email Attaching Monthly Report					PureWick_0033455		403, 901
2375	Bard Spreadsheet - Grow Urological Drainage					PureWick_0064267	PureWick_0064267	402, 403, 901

## Sage Preliminary Exhibit List

2376	PureWick Platform Update					PureWick_0064390	PureWick_0064392	402, 403, 901
2377	PureWick Platform Update					PureWick_0064393	PureWick_0064397	402, 403, 901
2378	PureWick Platform Update					PureWick_0064398	PureWick_0064403	402, 403, 901
2379	PureWick Platform Update					PureWick_0064404	PureWick_0064409	402, 403, 901
2380	05/2022 BD Powerpoint - UCC FY23 ASR PureWick Path					BDPureWick_00007689	BDPureWick_00007689	402, 403, 901
2381	04/2021 BD Powerpoint - PureWick 2.0					BDPureWick_00013060	BDPureWick_00013060	402, 403, 901
2382	05/2022 BD Powerpoint- PureWick 2.0 & Rise Concept Evaluation Strategy					BDPureWick_00013061	BDPureWick_00013061	402, 403, 901
2383	02/2021 BD Powerpoint - PureWick 2.0					BDPureWick_00013062	BDPureWick_00013062	402, 403, 901
2384	01/2022 BD Powerpoint - PureWick 2.0					BDPureWick_00013064	BDPureWick_00013064	402, 403, 901
2385	03/2022 BD Powerpoint - PureWick 2.0					BDPureWick_00013066	BDPureWick_00013066	402, 403, H, 901
2386	09/2021 BD Powerpoint - PureWick 2.0					BDPureWick_00013067	BDPureWick_00013067	402, 403, H, 901
2387	02/2022 BD Powerpoint - PureWick 2.0 & Rise Capture Collision					BDPureWick_00013068	BDPureWick_00013068	402, 403, H, 901
2388	06/2022 BD Powerpoint - Rise H&H					BDPureWick_00013072	BDPureWick_00013072	402, 403, H, 901
2389	05/2022 BD Powerpoint - Rise H&H					BDPureWick_00013074	BDPureWick_00013074	402, 403, H, 901
2390	10/2020 BD Powerpoint - PureWick 2.0					BDPureWick_00013078	BDPureWick_00013078	402, 403, H, 901
2391	01/2020 BD Powerpoint - PureWick 2.0					BDPureWick_00013079	BDPureWick_00013079	402, 403, H, 901
2392	06/2021 BD Powerpoint - PureWick 2.0					BDPureWick_00013080	BDPureWick_00013080	402, 403, H, 901
2393	05/2022 BD Powerpoint - Rise H&H					BDPureWick_00013082	BDPureWick_00013082	402, 403, H, 901
2394	06/2022 BD Powerpoint - Rise H&H Kick Off					BDPureWick_00013083	BDPureWick_00013083	402, 403, H, 901
2395	BD Powerpoint - PureWick 2.0 Healthy Volunteer Study Design Review					BDPureWick_00013102	BDPureWick_00013102	402, 403, H, 901
2396	BD Powerpoint - PureWick 2.0 Technical Design Review 1A					BDPureWick_00013119	BDPureWick_00013119	402, 403, H, 901
2397	03/2021 BD Powerpoint - PureWick 2.0 Extended Team Update					BDPureWick_00013126	BDPureWick_00013126	402, 403, H, 901
2398	06/2023 BD Powerpoint - PureWick 2.0 High-Level Concepts					BDPureWick_00013128	BDPureWick_00013128	402, 403, H, 901
2399	04/2022 BD Powerpoint - Rise v. PureWick 2.0					BDPureWick_00013139	BDPureWick_00013139	402, 403, H, 901
2400	PureWick Management Presentation					SAGE00025844	SAGE00025875	402, 403, H, 901
2401	PureWick White Paper					SAGE00026758	SAGE00026768	402, 403, H, 901
2402	07/07/2017 BD Email to PureWick Attaching Operations Dashboard					BDPureWick_00003996	BDPureWick_00003997	402, 403, H
2404	PureWick Poster Presentation					PureWick_0014362	PureWick_0014362	H, 901
2405	PureWick User Instruction Video					PureWick_0014708	PureWick_0014708	H, 402, 403, 901
2406	03/2015-04/2015 PureWick Use Results					PureWick_0017093	PureWick_0017093	H, 402, 403, 901
2407	08/2016 PureWick Slides					PureWick_0017160	PureWick_0017178	H, 402, 403, 901

## Sage Preliminary Exhibit List

2408	Photograph of Wick					PureWick_0019753	PureWick_0019753	H, 402, 403, 901
2409	Photograph of Wicks					PureWick_0019757	PureWick_0019757	H, 901
2410	Photograph of Wicks				111	PureWick_0019766	PureWick_0019766	H, 901
2411	Photograph of Tapered Wick					PureWick_0019785	PureWick_0019785	H, 901
2412	01/11/2015 PureWick Brochure					PureWick_0022063	PureWick_0022064	H, 402, 403, 901
2413	12/18/2014 PureWick Brochure					PureWick_0022073	PureWick_0022074	H, 402, 403, 901
2414	03/04/2013 PureWick Brochure					PureWick_0022121	PureWick_0022125	H, 402, 403, 901
2415	11/9/2012 PureWick Brochure					PureWick_0022140	PureWick_0022141	H, 402, 403, 901
2416	07/16/2015 PureWick Instruction Manual Rev B					PureWick_0022145	PureWick_0022151	H, 402, 403, 901
2417	09/11/2015 PureWick Instruction Manual					PureWick_0022159	PureWick_0022165	H, 402, 403, 901
2418	PureWick Demonstration Video					PureWick_0022292	PureWick_0022292	H, 402, 403, 901
2419	2/2/2015 PureWick Easy to Use Video					PureWick_0022303	PureWick_0022303	H, 402, 403, 901
2420	2/1/2015 PureWick Easy to Use Video					PureWick_0022304	PureWick_0022304	H, 402, 403, 901
2421	7/21/2015 PureWick Assembly Video					PureWick_0022333	PureWick_0022333	H, 402, 403, 901
2422	PureWick Wick Development History					PureWick_0023740	PureWick_0023742	H, 402, 403, 901
2423	10/28/2015 PureWick Document re: Design Evolution					PureWick_0023743	PureWick_0023743	H, 402, 403, 901
2425	5/21/2014 PureWick Document re: Potential Licensees/Buyers for PureWick					PureWick_0023845	PureWick_0023847	H, 402, 403, 901
2426	07/26/2016 PureWick Management Presentation					PureWick_0025031	PureWick_0025062	H, 402, 403, 901
2427	12/2014 PureWick Results for LC					PureWick_0025873	PureWick_0025873	H, 901
2428	12/2014 PureWick Results for PP					PureWick_0025875	PureWick_0025875	H, 402, 403, 901
2429	PureWick Results for PP					PureWick_0025878	PureWick_0025878	H, 402, 403, 901
2430	Purewick Informed Consent - Douglas					PureWick_0025899	PureWick_0025900	H, 901
2431	Purewick Informed Consent - Douglas					PureWick_0025901	PureWick_0025901	H, 402, 403, 901
2432	Purewick Informed Consent - Hyman					PureWick_0025903	PureWick_0025904	H, 901
2433	Purewick Informed Consent - MacGregor					PureWick_0025905	PureWick_0025906	H, 901
2434	Purewick Informed Consent - Clark					PureWick_0025909	PureWick_0025910	H, 402, 403, 901
2435	Purewick Informed Consent - Hornke					PureWick_0025911	PureWick_0025912	H, 402, 403, 901
2436	Purewick Informed Consent - Wadoski					PureWick_0025913	PureWick_0025914	H, 402, 403, 901
2437	Purewick Informed Consent - Jenkins Prior					PureWick_0025915	PureWick_0025917	H, 402, 403, 901
2438	Purewick Informed Consent - PP from Hilltop					PureWick_0025920	PureWick_0025921	H, 402, 403, 901
2439	PureWick Use Results 04/2013 to 02/2014					PureWick_0025945	PureWick_0025946	H, 402, 403, 901
2440	PureWick Use Results 03/2013 to 02/2015					PureWick_0025947	PureWick_0025947	H, 901
2441	PureWick Manufacturing Video					PureWick_0046098	PureWick_0046098	H, 402, 403, 901
2442	PureWick Manufacturing Video					PureWick_0046124	PureWick_0046124	H, 402, 403, 901
2443	PureWick Manufacturing Video					PureWick_0046142	PureWick_0046142	H, 402, 403, 901

## Sage Preliminary Exhibit List

2444	PureWick Manufacturing Video					PureWick_0046143	PureWick_0046143	H, 402, 403, 901
2445	PureWick Manufacturing Video					PureWick_0049732	PureWick_0049732	H, 402, 403, 901
2446	Response to Subpoena to Informa Markets					INFORMA_0000001	INFORMA_0000002	H, 402, 403, 901, NE, NP
2447	MD+DI Dare-To-Dream Document					INFORMA_0000003	INFORMA_0000007	H, 402, 403, 901
2448	MD+DI Dare-To-Dream Document					INFORMA_0000008	INFORMA_0000015	H, 402, 403, 901
2449	Video - PureWick Device					SAGE00043556	SAGE00043556	H, 402, 403, 901
2450	Video - PureWick Device					SAGE00043557	SAGE00043557	H, 402, 403, 901
2451	Video - PureWick Device					SAGE00043558	SAGE00043558	H, 402, 403, 901
2452	9/23/2015 PureWick presentation from File History					PureWick_0000303		402, 403, H, 901
2454	12/23/2016 Bard Preliminary Proposal to Acquire PureWick					PureWick_0023747	PureWick_0023750	H, 402, 403, 901
2455	10/24/2016 Bard Email Attaching Tri-City Notes					PureWick_0059073	PureWick_0059073	H, 402, 403, 901
2456	10/21/2016 Bard Email re: Tri-City Attaching Notes					PureWick_0059074	PureWick_0059074	H, 402, 403, 901
2457	10/21/2016 Bard Email with Attachments re Project Candle VOC					PureWick_0059077		H, 402, 403, 901
2458	07/11/2016 Bard Email Attaching Project Candle Notes and presentation					PureWick_0059657	PureWick_0059665	H, 402, 403, 901
2460	2018 Ins and Outs of PureWick					PureWick_0014395	PureWick_0014395	H, 901
2461	PureWick Executive Summary					PureWick_0023767	PureWick_0023782	H, 402, 403, 901
2462	09/18/2017 Bard Clinical Evaluation Report for PureWick					PureWick_0028073	PureWick_0028327	H, 901
2500	Dr. Yadin David Responsive Report							H, 402, 403, Exp, 901, NE
2501	Dr. Yadin David CV							H, 402, 403, Exp, 901, NE
2502	Dr. Yadin David Responsive Report Materials Considered							H, 402, 403, Exp, 901, NE
2503	PrimaFit 2.0 images (Attachment B)							H, 402, 403, Exp, 901, NE
2504	PrimaFit 2.0 images (Attachment C)							H, 402, 403, Exp, 901, NE
2505	PrimaFit 2.0 Images (Attachment D)							H, 402, 403, Exp, 901, NE
2506	PrimaFit 2.0 CT video (Attachment E1)							H, 402, 403, Exp, 901, NE
2507	PrimaFit 2.0 CT video (Attachment E2)							H, 402, 403, Exp, 901, NE
2508	PrimaFit 2.0 CT video (Attachment E3)							H, 402, 403, Exp, 901, NE

## Sage Preliminary Exhibit List

2509	3B Scientific Catheterization Trainer Manual							H, 402, 403, Exp, 901, NE
2510	PrimaFit 2.0 Automated Manufacturing Video							H, 402, 403, Exp, 901, NE
2511	PureWick photographs (Attachment H)							H, 402, 403, Exp, 901, NE
2512	Tube retraction (Attachment I)							H, 402, 403, Exp, 901, NE
2513	Manikin physical / Photographs of Manikin (Attachment J)							H, 402, 403, Exp, 901, NE
2514	3b Catheterization Trainer physical / photographs of trainer (Attachment K)							H, 402, 403, Exp, 901, NE
2515	Dr. Yadin David Reply Report							H, 402, 403, Exp, 901, NE
2516	Dr. Yadin David Reply Report Materials considered Attachment A3							H, 402, 403, Exp, 901, NE
2517	Dr. Karlovsky Responsive Report							H, 402, 403, Exp, 901, NE
2518	Dr. Karlovsky CV							H, 402, 403, Exp, 901, NE
2519	Dr. Karlovsky Materials Considered (Attachment B)							H, 402, 403, Exp, 901, NE
2520	PureWick Female External Catheter from www.bd.com							H, 402, 403, Exp, 901, NE
2521	MAUDE REPORT (Attachment E)							H, 402, 403, Exp, 901, NE
2522	FDA Recall (Attachment F)							H, 402, 403, Exp, 901, NE
2523	Dr. Diane Newman Opening Report							H, 402, 403, Exp, 901, NE
2524	Dr. Diane Newman CV							H, 402, 403, Exp, 901, NE
2525	Dr. Diane Newman Opening Report Materials Considered							H, 402, 403, Exp, 901, NE
2527	Dr. Diane Newman Responsive Report							H, 402, 403, Exp, 901, NE
2528	Dr. Diane Newman Responsive Report Materials Considered (attachment A)							H, 402, 403, Exp, 901, NE
2529	Clinical Application of Urologic Catheters, Devices, and Products							H, 402, 403, Exp, 901, NE

## Sage Preliminary Exhibit List

2530	Sage Microclimante Body Pad (Stryker Home Care) Attachment C							H, 402, 403, Exp, 901, NE
2531	Amazon.com customer reviews							H, 402, 403, Exp, 901, NE
2532	Newman, The Urinary Incontinence Sourcebook (1997)							H, 402, 403, Exp, 901, NE
2533	UR24 Technology (Attachment F)							H, 402, 403, Exp, 901, NE
2534	Omni Medical, Improved Economic Costs and Effect Methods and Outcomes of Managing Urinary Incontinence with URINCare							H, 402, 403, Exp, 901, NE
2535	Omni Female System							H, 402, 403, Exp, 901, NE
2536	Plante et al, CLinical Evaluation of the URINCare System							H, 402, 403, Exp, 901, NE
2537	Liberator Medical Supply Inc., Complaints							H, 402, 403, Exp, 901, NE
2538	Lem et al, Effect of external urinary collection device implementation on female surgical patients							H, 402, 403, Exp, 901, NE
2539	Medline Versette Female External Catheter							H, 402, 403, Exp, 901, NE
2540	Medline Versette Video							H, 402, 403, Exp, 901, NE
2541	Medline Versette							H, 402, 403, Exp, 901, NE
2542	QIVI FEC Female External							H, 402, 403, Exp, 901, NE
2543	Consure Medical information							H, 402, 403, Exp, 901, NE
2544	CareDry System							H, 402, 403, Exp, 901, NE
2545	Dr. Diane Newman Reply Report							H, 402, 403, Exp, 901, NE
2546	Dr. Diane Newman Reply Report Materials Considered Attachment A							H, 402, 403, Exp, 901, NE
2547	Vincent Thomas Responsive Expert Report and Schedules							H, 402, 403, Exp, 901, NE
2548	Vince Thomas Appendix A							H, 402, 403, Exp, 901, NE
2549	Vince Thomas Appendix B							H, 402, 403, Exp, 901, NE

## Sage Preliminary Exhibit List

2550	Vince Thomas Schedule 1.0							H, 402, 403, Exp, 901, NE
2551	Vince Thomas Schedule 2.0							H, 402, 403, Exp, 901, NE
2552	Vince Thomas Schedule 2.1							H, 402, 403, Exp, 901, NE
2553	Vince Thomas Schedule 3.1							H, 402, 403, Exp, 901, NE
2554	Vince Thomas Schedule 3.2							H, 402, 403, Exp, 901, NE
2555	Vince Thomas Schedule 4.0							H, 402, 403, Exp, 901, NE
2556	Vince Thomas Schedule 4.1							H, 402, 403, Exp, 901, NE
2557	Vince Thomas Schedule 5.0							H, 402, 403, Exp, 901, NE
2558	Vince Thomas Schedule 5.1							H, 402, 403, Exp, 901, NE
2559	Vince Thomas Schedule 6.0							H, 402, 403, Exp, 901, NE
2560	Vince Thomas Schedule 7.0.							H, 402, 403, Exp, 901, NE
2561	Vince Thomas Schedule 7.1							H, 402, 403, Exp, 901, NE
2562	Vince Thomas Schedule 8.0							H, 402, 403, Exp, 901, NE
2563	Vince Thomas Schedule 8.1							H, 402, 403, Exp, 901, NE
2564	Vince Thomas Schedule 8.2							H, 402, 403, Exp, 901, NE
2565	Sage Sales				022; 040	STRSAGE00000141	STRSAGE00000141	H, 901
2566	Sage Sales							H, 901
2567	PrimaFit Sales (Eaches)				25	STRSAGE00023164	STRSAGE00023164	H, 901
2568	Sage Sales					STRSAGE00025468	STRSAGE00025468	H, 901
2569	Sage Sales					STRSAGE00025469	STRSAGE00025469	H, 901
2570	Images from Dr. Diane Newman's Expert Reports							H, 402, 403, Exp, 901, NE
2571	Images from Dr. Yadin David's Expert Reports							H, 402, 403, Exp, 901, NE
2573	Lem et al, Effect of External Urinary Collection Device Implementation on female surgical patients (2022)					STRSAGE_EXP_000007		H, 403, Exp, 901, NE
2574	Vincent Thomas Supplemental Expert Report and Schedules and Appendices							Exp, 901, NE

## Sage Preliminary Exhibit List

2575	Supplemental Statement of Diane Newman (December 28, 2023)							H, 402, 403, Exp, 901, NE
2576	PureWick Sales Sep 2021 to Nov 2023					BDPureWick_00015408		
2577	PureWick P&L - 2023 -PWF Allocated					BDPureWick_00015411		
2579	05/2016 PureWick Target Companies List					DCF00000008	DCF00000008	H, 402, 403, Exp, 901, NE
2580	07/2016 PureWick Acquisition Status					DCF00000020	DCF00000020	H, 402, 403, Exp, 901, NE
2581	07/19/2016 Deloitte Email to Medline re: Acquiring PureWick with attachments					DCF00004270	DCF00004275	H, 402, 403, Exp, 901, NE
2582	07/19/2016 Deloitte Email to Cardinal re: Acquiring PureWick with attachments					DCF00004276	DCF00004281	H, 402, 403, Exp, 901, NE
2583	07/19/2016 Deloitte Email to 3M re: Acquiring PureWick with attachments					DCF00004282		H, 402, 403, Exp, 901, NE
2584	07/19/2016 Deloitte Email to Johnson & Johnson re: Acquiring PureWick with attachments					DCF00004288	DCF00004293	H, 402, 403, Exp, 901, NE
2585	07/19/2016 Deloitte Email to Tidi re: Acquiring PureWick with attachments					DCF00004294	DCF00004299	H, 402, 403, Exp, 901, NE
2586	07/19/2016 Deloitte Email to Hartmann re: Acquiring PureWick with attachments					DCF00004302	DCF00004307	H, 402, 403, Exp, 901, NE
2587	07/26/2016 Deloitte Email to B. Braun re: Acquiring PureWick with attachments					DCF00004669	DCF00004674	H, 402, 403, Exp, 901, NE
2588	07/26/2016 Deloitte Email to BD re: Acquiring PureWick with attachments					DCF00004675	DCF00004680	H, 402, 403, Exp, 901, NE
2589	07/26/2016 Deloitte Email to Convatec re: Acquiring PureWick with attachments					DCF00004688	DCF00004693	H, 402, 403, Exp, 901, NE
2590	12/20/2016 Preliminary Proposal to Acquire PureWick to Bard					DCF00000088	DCF00000091	H, 402, 403, Exp, 901, NE
2591	06/07/2016 Deloitte Email with Attachment to PureWick					DCF00000618	DCF00000631	H, 402, 403, Exp, 901, NE
2593	07/19/2016 Johnson & Johnson Email Chain with Deloitte with attachments					DCF00004313	DCF00004319	H, 402, 403, Exp, 901, NE
2594	08/1/2016 Deloitte Email Chain re: 3m					DCF00005571	DCF00005572	H, 402, 403, Exp, 901, NE
2596	08/24/2016 Deloitte Email re: PureWick Patent Work					DCF00005725	DCF00005729	H, 402, 403, Exp, 901, NE
2597	08/24/2016 Deloitte Email re: PureWick Patent Work					DCF00005735	DCF00005739	H, 402, 403, Exp, 901, NE
2598	08/24/2016 Deloitte Email re: First Quality, Bard, Sage					DCF00005756	DCF00005756	H, 402, 403, Exp, 901, NE
2599	11/24/2016 PureWick Email to Deloitte re: Bard					DCF00007814	DCF00007815	H, 402, 403, Exp, 901, NE



## Sage Preliminary Exhibit List

2600	2016 Deloitte email with Newton attaching PureWick Whitepaper 1-16-15 Final					DCF00000778	DCF00000788	H, 402, 403, Exp, 901, NE
2602	07/07/2016 Newton email to Deloitte with attachments re: Molnlycke					DCF00003984	DCF00003995	H, 402, 403, Exp, 901, NE
2605	10/07/2016 Camille Newton Email chain with PureWick trial result attachment					DCF00006754	DCF00006757	H, 402, 403, Exp, 901, NE
2607	08/05/2016 PureWick email chain re Bard					DCF00008569	DCF00008572	H, 402, 403, Exp, 901, NE
2610	07/29/2016 PureWick Email re: Market with attachment					FQE0000001	FQE0000011	H, 402, 403, Exp, 901, NE
2614	08/24/2017 First Quality Email re: PureWick					FQE0000025	FQE0000026	H, 402, 403, Exp, 901, NE
2615	03/04/2016 First Quality Email re: PureWick					FQE0000027	FQE0000028	H, 402, 403, Exp, 901, NE
2616	05/12/2016 First Quality Email re: PureWick					FQE0000029	FQE0000030	H, 402, 403, Exp, 901, NE
2620	06/06/2016 First Quality Email chain re: PureWick					FQE0000034	FQE0000037	H, 402, 403, Exp, 901, NE
2636	06/16/2016 meeting with PureWick					FQE0000053	FQE0000053	H, 402, 403, Exp, 901, NE
2638	06/21/2016 First Quality Email re PureWick					FQE0000055	FQE0000055	H, 402, 403, Exp, 901, NE
2645	06/30/2016 First Quality Email re: PureWick Samples					FQE0000063	FQE0000064	H, 402, 403, Exp, 901, NE
2648	07/24/2016 First Quality Email re: PureWick Visit					FQE0000069	FQE0000070	H, 402, 403, Exp, 901, NE
2649	07/25/2016 First Quality Email re: PureWick					FQE0000071	FQE0000072	H, 402, 403, Exp, 901, NE
2653	08/02/2016 First Quality Email re: PureWick with attachment					FQE0000076	FQE0000082	H, 402, 403, Exp, 901, NE
2656	08/02/2016 First Quality Email re: PureWick with Notes					FQE0000084	FQE0000087	H, 402, 403, Exp, 901, NE
2658	08/10/2016 First Quality Email re: PureWick with Notes					FQE0000088	FQE0000092	H, 402, 403, Exp, 901, NE
2660	08/10/2016 First Quality re: PureWick with Notes					FQE0000093	FQE0000097	H, 402, 403, Exp, 901, NE
2662	08/17/2016 First Quality Email re: PureWick product and IP					FQE0000098	FQE0000099	H, 402, 403, Exp, 901, NE
2670	04/27/2022 First Quality Email re: PureWick					FQE0000118	FQE0000119	H, 402, 403, Exp, 901, NE

## Sage Preliminary Exhibit List

2671	06/21/2016 First Quality Email with Management presentation attachment					FQE0000120	FQE0000151	H, 402, 403, Exp, 901, NE
2680	06/24/2016 First Quality email re: PureWick meeting					FQE0000159	FQE0000159	H, 402, 403, Exp, 901, NE
2687	07/01/2016 First Quality email re Purewick visit					FQE0000168	FQE0000168	H, 402, 403, Exp, 901, NE
2688	07/01/2016 First Quality Email chain re: PureWick visit					FQE0000169	FQE0000169	H, 402, 403, Exp, 901, NE
2693	07/07/2016 Email chain with Mike Jackson re: PureWick visit					FQE0000176	FQE0000177	H, 402, 403, Exp, 901, NE
2694	07/14/2016 First Quality Email re: PureWick					FQE0000178	FQE0000179	H, 402, 403, Exp, 901, NE
2696	07/2016 email correspondence with PureWick with attachments					FQE0000182	FQE0000186	H, 402, 403, Exp, 901, NE
2723	08/16/2016 First Quality email to Deloitte re: PureWick					FQE0000237	FQE0000238	H, 402, 403, Exp, 901, NE
2724	08/17/2016 First Quality Email re: PureWick IP					FQE0000239	FQE0000241	H, 402, 403, Exp, 901, NE
2725	PureWick Sales Overview					FQE0000242	FQE0000243	H, 402, 403, Exp, 901, NE
2727	08/30/2016 First Quality Email re: PureWick and its Intellectual Property					FQE0000245	FQE0000246	H, 402, 403, Exp, 901, NE
2728	09/02/2016 First Quality email chair re: PureWick IP					FQE0000247	FQE0000248	H, 402, 403, Exp, 901, NE
2729	09/02/2016 First Quality email chain re: PureWick IP					FQE0000249	FQE0000250	H, 402, 403, Exp, 901, NE
2730	09/02/2016 First Quality Email re: PureWick IP					FQE0000251	FQE0000252	H, 402, 403, Exp, 901, NE
2731	09/07/2016 First Quality email re: PureWick					FQE0000253	FQE0000253	H, 402, 403, Exp, 901, NE
2734	10/20/2016 First Quality email chain re PureWick IP					FQE0000258	FQE0000258	H, 402, 403, Exp, 901, NE
2746	10/04/2016 Deloitte email to First Quality re: IP follow up					FQE0000270	FQE0000270	H, 402, 403, Exp, 901, NE
2754	11/22/2016 Deloitte voicemail re First Quality with attachment					FQE0000282	FQE0000283	H, 402, 403, Exp, 901, NE
2757	11/23/2016 First Quality email re: Term Sheet from PureWick					FQE0000285	FQE0000285	H, 402, 403, Exp, 901, NE
2761	12/9/2016 Email chain re PureWick					FQE0000290	FQE0000290	H, 402, 403, Exp, 901, NE

## Sage Preliminary Exhibit List

2764	12/20/2016 First Quality email with Doug Bolt (Deloitte) Voicemail					FQE0000294	FQE0000295	H, 402, 403, Exp, 901, NE
2768	Executive Summary					FQE0000298	FQE0000299	H, 402, 403, Exp, 901, NE
2769	PureWick Management Presentation 06.14.2016					FQE0000300	FQE0000330	H, 402, 403, Exp, 901, NE
2779	06/16/2016 First Quality email re: PureWick with attachments incl PureWick Business Plan 08/04/2015					FQE0000342	FQE0000413	H, 402, 403, Exp, 901, NE
2784	06/21/2016 First Quality email attaching PureWick presentation					FQE0000415	FQE0000446	H, 402, 403, Exp, 901, NE
2811	07/07/2016 email to M. Jackson re: PureWick visit					FQE0000481	FQE0000482	H, 402, 403, Exp, 901, NE
2816	PureWick visit					FQE0000488	FQE0000488	H, 402, 403, Exp, 901, NE
2817	07/14/2016 Forehand Email to First Quality re: manufacturing with attachments					FQE0000489	FQE0000493	H, 402, 403, Exp, 901, NE
2823	07/14/2016 First Quality email re purewick visit					FQE0000495	FQE0000496	H, 402, 403, Exp, 901, NE
2831	07/19/2016 First Quality Email re: PureWick Meeting with attachment					FQE0000506	FQE0000509	H, 402, 403, Exp, 901, NE
2833	07/18/2016 Email re: PureWick with attachments					FQE0000510	FQE0000514	H, 402, 403, Exp, 901, NE
2837	07/08/2016 First Quality email re: PureWick Intellectual Property					FQE0000515	FQE0000516	H, 402, 403, Exp, 901, NE
2838	07/19/2016 First Quality email re: IP					FQE0000517	FQE0000518	H, 402, 403, Exp, 901, NE
2839	07/20/2016 Deloitte Email to First Quality re: PureWick Intellectual Property with attachments					FQE0000519	FQE0000617	H, 402, 403, Exp, 901, NE
2864	07/20/2016 First Quality email re: PureWick IP with attachments					FQE0000618	FQE0000716	H, 402, 403, Exp, 901, NE
2889	07/21/2016 Deloitte Email to First Quality re: Intellectual Property with attachments					FQE0000717	FQE0000731	H, 402, 403, Exp, 901, NE
2895	08/22/2016 First Quality Email o Deloitte re: Intellectual Property					FQE0000732	FQE0000733	H, 402, 403, Exp, 901, NE
2898	08/23/2016 Deloitte Email to First Quality re: Intellectual Property					FQE0000739	FQE0000741	H, 402, 403, Exp, 901, NE
2912	09/08/2016 Deloitte Email to First Quality re: Meeting					FQE0000778	FQE0000781	H, 402, 403, Exp, 901, NE
2913	09/08/2016 PureWick follow up request re: IP					FQE0000782		H, 402, 403, Exp, 901, NE

## Sage Preliminary Exhibit List

2917	09/12/2016 email re: meeting with PureWick IP counsel					FQE0000800	FQE0000805	H, 402, 403, Exp, 901, NE
2918	09/12/2016 First Quality Meeting Invitation re: "Patent Discussion"					FQE0000806	FQE0000806	H, 402, 403, Exp, 901, NE
2919	09/13/2016 Talbot Email to First Quality re: Intellectual Property including attachment of Omnibus specification and Portfolio Family Tree chart					FQE0000807	FQE0000883	H, 402, 403, Exp, 901, NE
2923	09/14/2016 First Quality Email to Talbot re: patent portfolio					FQE0000884	FQE0000885	H, 402, 403, Exp, 901, NE
2924	09/14/2016 Talbot email to First Quality					FQE0000886	FQE0000887	H, 402, 403, Exp, 901, NE
2925	09/14/2016 First Quality Email to Talbot					FQE0000888	FQE0000890	H, 402, 403, Exp, 901, NE
2927	09/12/2016 meeting re: Patent Discussion					FQE0000894	FQE0000894	H, 402, 403, Exp, 901, NE
2928	Meeting Dial in					FQE0000895	FQE0000895	H, 402, 403, Exp, 901, NE
2929	09/19/2016 Email re: follow up discussion of patent portfolio					FQE0000896	FQE0000897	H, 402, 403, Exp, 901, NE
2934	09/23/2016 First Quality Meeting Invite re: PureWick IP					FQE0000907	FQE0000907	H, 402, 403, Exp, 901, NE
2935	09/21/2016 First Quality Meeting Invite re PureWick IP					FQE0000908	FQE0000908	H, 402, 403, Exp, 901, NE
2941	Medline Versette Marketing					MEDLINE002	MEDLINE002	H, 403, Exp, 901, NE
2942	Medline Versette Instructions					MEDLINE003	MEDLINE003	H, 403, Exp, 901, NE
2943	Medline Versette Best Practice Guidance					MEDLINE004	MEDLINE004	H, 403, Exp, 901, NE
2944	07/20/2016 Email to Medline re: New Acquisition Opportunity					MEDLINE0045	MEDLINE0046	H, 403, Exp, 901, NE
2945	07/27/2016 Deloitte Email Chain to Medline					MEDLINE0047	MEDLINE0048	H, 403, Exp, 901, NE
2946	US 11,504,265					MEDLINE113	MEDLINE130	H, 403, Exp, 901, NE
2950	Medline Versette Instructions					MEDLINE001	MEDLINE001	H, 403, Exp, 901, NE
2960	Tri-City Medical PureWick Policy Document					TRICITY_0000001	TRICITY_0000002	H, 403, Exp, 901, NE
2961	Tri-City Hospital Versette options					TRICITY_0000003	TRICITY_0000003	H, 403, Exp, 901, NE





## Sage Preliminary Exhibit List

3125	2022 12 16 - Sage's Supplemental Initial Rule 26(a)(1) Disclosures							H, 402, 403, 901, NE
3990	Rob Hanson Exhibits TBD							NE
3991	Any exhibit Sage identified in all of its deposition designations							NE

\*Attachments to be included

# **SCHEDULE D3**



JTX	PTX	DTX	Title	Date	Beg. Bates No.	End Bates No.
JTX-001	PTX-059	DX-3	U.S. Patent No. 10,226,376	3/12/2019	PUREWICK_0001884	PUREWICK_0001940
JTX-002	PTX-060	DX-2	U.S. Patent No. 10,390,989	8/27/2019	PUREWICK_0001941	PUREWICK_0001982

**SCHEDULE D4: PLAINTIFF'S DESIGNATION OF DISCOVERY RESPONSES**

PureWick identifies the following discovery responses provided by Sage that PureWick may seek to read into evidence at trial:

- Defendant's March 16, 2021 Supplemental Response to Plaintiff's Interrogatory Nos. 2, 7 and 8, served in C.A. No. 19-1508-MN;
- Defendants' April 15, 2021 Responses to Plaintiff's Request For Admission Nos. 14-15, 20-29, and 37-40, served in C.A. No. 19-1508-MN;
- Defendant's March 31, 2023 Supplemental Responses to Plaintiff's Interrogatory Nos. 2, 7, and 8, served in C.A. No. 22-102-MN;
- Defendants' January 13, 2023 Responses to Plaintiff's Request For Admission Nos. 1, 5-12, 15, and 17, served in C.A. No. 22-102-MN.

**SCHEDULE D5: SAGE'S DESIGNATION OF DISCOVERY RESPONSES**

Sage identifies the following discovery responses provided by PureWick that Sage may seek to read into evidence at trial:

- PureWick's Eighth Supplemental Responses to Sage's Interrogatories (Nos. 5, 6, and 16), served in C.A. No. 22-102-MN (March 18, 2023);
- PureWick's Supplemental Responses to Sage's First Set of Interrogatories (Nos. 1-6), served in C.A. No. 22-102-MN (December 15, 2022);
- PureWick's Responses to Sage's First Set of Interrogatories (No. 1-6), served in C.A. No. 22-102-MN (September 15, 2022);
- PureWick's Responses to Sage's Second Set of Interrogatories (Nos. 7-8), served in C.A. No. 22-102-MN (January 5, 2023);
- PureWick's Supplemental Responses to Sage Products' Interrogatories (Nos. 1, 2-4, 5, and 7), served in C.A. No. 22-102-MN (March 28, 2023);
- PureWick's Third Suppl Response to Interrog No. 4, served in C.A. No. 22-102-MN (April 19, 2023);
- PureWick's Sixth Supplemental Responses To Sage Products First Set Of Interrogatories (Nos. 1-11), served in C.A. No. 19-1508-MN (April 1, 2021);
- PureWick's First Supplemental Response to Interrogs (Nos. 1-11), served in C.A. No. 19-1508-MN (April 24, 2020);
- PureWick's Seventh Response to Interrogatories (Nos. 1-11), served in C.A. No. 19-1508-MN (April 16, 2021);
- PureWick's Responses to Sage's Third Set of Interrogatories Nos. 14-16, served in C.A. No. 19-1508-MN (November 2, 2020);
- Any other responses listed on Sage's exhibit list.

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

PUREWICK CORPORATION,	)	
	)	
Plaintiff/Counterclaim Defendant,	)	
	)	C.A. No. 22-102-MN
v.	)	
	)	
SAGE PRODUCTS, LLC,	)	
	)	
Defendant/Counterclaim Plaintiff.	)	
	)	

**PLAINTIFF’S TRIAL WITNESS LIST**

Pursuant to Local Rule 16.3 and Federal Rule of Civil Procedure 16(a)(3)(A)(i) and (ii), Plaintiff provides below an identification of the witnesses whose testimony it may present at trial. The inclusion of a witness on this list does not require Plaintiff to call that witness to testify, and does not imply or establish that Plaintiff has the power to compel the live testimony of that witness or make that witness available to the opposing party.

Plaintiff expressly reserves the right to call any witness identified by Defendant at any point before or during trial, whether or not listed on Plaintiff’s list below, live or by deposition designations. Plaintiff also expressly reserves the right to call any witness live or by deposition designations (or to offer additional deposition designations from witnesses identified herein) for purposes of rebuttal, impeachment, or authentication of a document or as required by any of the Court’s pretrial or trial rulings. Plaintiff also reserves its right to change or modify this list as permitted by the Federal Rules of Civil Procedure, Local Rules, or Orders of the Court.

**I. PLAINTIFF’S WILL CALL WITNESSES**

Plaintiff expects to call the following witnesses live at trial:

- 1. Dr. John Collins**
- 2. Lauren Kindler**

3. Dr. Camille Newton

4. Dr. Edward Yun

## **II. PLAINTIFF'S MAY CALL WITNESSES**

Plaintiff may call the following witnesses at trial, live or by deposition:

1. Arun Alakhramsing (by deposition or live)
2. Nick Alexander (by deposition)
3. Jennifer Allen (by deposition or live)
4. Brett Blabas (by deposition, live, or by video)
5. Brian Burn (live)
6. Adam Cole (by deposition or live)
7. Lorena Eckert (by deposition)
8. Eric Farrell (deposition or live)
9. John Gohde (live)
10. Robert Hanson (live)
11. Arrigo D. Jezzi (live)
12. Sameer Jirafe (by deposition or live)
13. Gregory Mann (live)
14. Rick Morgan (by deposition or live)
15. Raymond Newton (live)
16. Kate Pawlik (by deposition)
17. Patricia Polanco (by deposition or live)
18. Robert Sanchez (by deposition)
19. Daniel Ulreich (by deposition)

# SCHEDULE E2a

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

PUREWICK CORPORATION,	)	
	)	
Plaintiff,	)	
	)	C.A. No. 22-102-MN
v.	)	
	)	<b>CONFIDENTIAL –</b>
SAGE PRODUCTS, LLC,	)	<b>FILED UNDER SEAL</b>
	)	
Defendant.	)	
	)	

**PUREWICK CORPORATION’S DEPOSITION DESIGNATIONS**

DESCRIPTION	OBJECTIONS
FEDERAL RULES OF EVIDENCE 401/402 (IRRELEVANT)	402
FEDERAL RULE OF EVIDENCE 403 (UNDULY PREJUDICIAL, CONFUSING, MISLEADING, DELAY, AND/OR WASTE OF TIME)	403
FEDERAL RULE OF EVIDENCE 408 (COMPROMISE OFFERS AND NEGOTIATIONS)	408
FEDERAL RULE OF EVIDENCE 501 (PRIVILEGE)	P
FEDERAL RULE OF EVIDENCE 602 (LACK OF PERSONAL KNOWLEDGE OR COMPETENCY)	602
FEDERAL RULE OF EVIDENCE 611(C) (LEADING)	611
IMPROPER LAY OPINION / IMPROPER EXPERT TESTIMONY BY NON-EXPERT	701
IMPROPER TESTIMONY BY EXPERT WITNESS	702/703
FEDERAL RULE OF EVIDENCE 802 (HEARSAY)	H
LACKS FOUNDATION	F
CALLS FOR SPECULATION	Spec
FEDERAL RULE OF EVIDENCE 611(B) (BEYOND SCOPE OF DESIGNATIONS)	BSD
NOT TESTIMONY – INCLUDES ATTORNEY OBJECTIONS AND/OR DISCUSSIONS BETWEEN ATTORNEYS	NT
DESIGNATION INCOMPLETE / INCOMPREHENSIBLE / INCOMPLETE QUESTION / ANSWER	I
BEYOND SCOPE OF 30(B)(6) NOTICE / QUESTIONS	S
VAGUE AND AMBIGUOUS	V
ARGUMENTATIVE	Arg
IMPROPER / INCOMPLETE HYPOTHETICAL	Hyp
COMPOUND	C
MISCHARACTERIZATION	M
CALLS FOR LEGAL CONCLUSION	LC
ASSUMES FACTS NOT IN EVIDENCE	AF
NON-RESPONSIVE	NR
NARRATIVE	Nar
FOREIGN LANGUAGE	LANG
NOT EVIDENCE	NE
LATE DISCLOSED	LATE DISCLOSED
DUPLICATE	DUP



**PureWick's Designation of Deposition Testimony of Arun Alakhramsing, January 31, 2023**

<b>PureWick's Designated Testimony (Page/line)</b>
10:11-19
23:24-24:25
25:3-27:3
27:8-18
28:9-29:2
29:13-30:4
32:4-7
32:15-33:19
36:3-5
37:6-7
37:9-14
37:18-38:4
41:17-42:13
42:16-17
42:19-20
42:22-23
46:8-10
46:12-20
48:17-24
50:17-21
52:12-22
52:24-53:14
54:9-13
54:16-18
60:17-21
60:25-61:3

<b>PureWick's Designated Testimony (Page/line)</b>
61:6
97:9-11
97:14-19
103:19-22
153:7-23
154:12-13
154:16-23
155:13-15
155:18
193:17-194:2
194:6-10
194:14-15
195:18-20
195:22-24
201:22-202:4
218:17-219:6
232:21-233:12
234:5-7
246:16-247:8
247:11-13
247:16-20

**PureWick's Designation of Deposition Testimony of Nick Alexander, April 13, 2021**

<b>PureWick's Designated Testimony (Page/line)</b>
10:4-10:10
25:4-25:6
25:21-25:25
26:2-26:6
26:9-26:11
56:7-56:12
56:19-56:25
57:2-57:9
58:5-58:11
58:14-58:15
61:14-61:16
61:18-61:25
62:2-62:6
63:8-63:10
64:2-64:3
64:5-64:5
64:9-64:10
64:11-64:14
64:17-64:25
69:22-69:25
70:2-70:5
70:7-70:7
70:10-70:14
70:17-70:20
71:15-71:17
71:19-71:22

<b>PureWick's Designated Testimony (Page/line)</b>
72:2-72:7
72:10-72:11
73:6-73:15
73:18-73:20
73:23-73:25
74:4-74:6
74:9-74:14
74:17-74:23
75:2-75:17
75:20-75:25
76:2-76:2
76:5-76:7
76:10-76:10
77:6-77:7
77:11-77:11
79:18-79:19
79:22-79:25
81:2-81:24
82:5-82:10
82:16-82:17
82:20-82:25
83:2-83:16
84:2-84:18
84:21-84:21
87:8-87:12
87:15-87:16
88:10-88:25
89:2-89:8

<b>PureWick's Designated Testimony (Page/line)</b>
89:20-89:25
90:2-90:2
90:21-90:25
91:2-91:12
91:21-91:22
91:25-91:25
92:2-92:24
94:6-94:16
95:17-95:21
95:24-95:25
96:2-96:5
96:8-96:8
119:19-119:25
120:2-120:13
120:16-120:24
121:5-121:11
121:13-121:23
122:15-122:21
123:6-123:12
123:15-123:18
123:21-123:24
124:19-124:22
125:13-125:25
126:2-126:6
126:8-126:11
126:13-126:20
126:23-126:25
127:3-127:8

<b>PureWick's Designated Testimony (Page/line)</b>
127:10-127:16
127:18-127:22
127:25-127:25
128:2-128:5
128:9-128:19
128:23-128:25
129:2-129:6
130:3-130:23
131:3-131:3
131:6-131:9
131:16-131:21
132:7-132:9
132:11-132:12
132:18-132:25
133:2-133:3
133:5-133:9
133:12-133:16
133:19-133:23
134:18-134:20
134:25-134:25
135:2-135:6
135:10-135:16
135:19-135:22
136:9-136:15
146:6-146:8
146:9-146:13
146:16-146:18
154:8-154:9

<b>PureWick's Designated Testimony (Page/line)</b>
154:13-154:21
154:25-154:25
155:2-155:3
237:10-237:14
237:17-237:23
238:3-238:9
238:12-238:12
238:18-238:20
238:24-238:25

**PureWick's Designation of Deposition Testimony of Jennifer Allen, February 1, 2023**

<b>PureWick's Designated Testimony (Page/line)</b>
6:24-7:2
24:8-21
24:22-25:2
25:4-9
29:2-7
37:25-39:18
47:15-16
47:23-48:2



**PureWick's Designation of Deposition Testimony of Brett Blabas, February 23, 2021**

<b>PureWick's Designated Testimony (Page/line)</b>
6:20-6:25
7:2-7:2
8:9-8:12
13:23-13:24
14:3-14:11
14:14-14:23
30:15-30:19
32:7-32:15
32:19-32:22
36:19-36:25
37:2-37:9
37:12-37:13
37:14-37:15
37:18-37:19
37:20-37:21
37:24-37:25
38:2-38:4
38:8-38:11
40:10-40:12
40:16-40:24
41:3-41:6
43:18-43:24
49:15-49:19
49:22-49:23
57:7-57:9
57:12-57:21

<b>PureWick's Designated Testimony (Page/line)</b>
69:22-69:23
72:8-72:15
74:14-74:22
74:25-74:25
75:2-75:2
75:21-75:22
75:25-75:25
76:2-76:3
89:10-89:11
89:14-89:16
89:19-89:19
89:20-89:25
90:2-90:2
90:5-90:11
90:13-90:15
90:20-90:22
90:25-90:25
91:2-91:2
91:8-91:9
91:11-91:12
91:13-91:14
91:17-91:18
93:14-93:17
93:21-93:25
94:2-94:3
94:6-94:7
95:20-95:25
96:2-96:2

<b>PureWick's Designated Testimony (Page/line)</b>
97:13-97:24
118:17-118:25
119:2-119:5
119:6-119:8
119:11-119:11
122:17-122:25
123:2-123:2
123:3-123:6
123:9-123:23
124:6-124:13
125:23-125:25
126:2-126:5
126:10-126:25
127:2-127:4
127:7-127:12
128:13-128:16
128:19-128:20
132:25-132:25
133:2-133:2
133:5-133:16
133:19-133:24
134:20-134:24
134:25-134:25
135:2-135:14
136:21-136:25
137:2-137:10
137:13-137:19
137:22-137:22

<b>PureWick's Designated Testimony (Page/line)</b>
143:8-143:13
143:20-143:25
144:2-144:8
144:11-144:25
145:2-145:2
145:5-145:12
145:16-145:18
145:21-145:22
146:15-146:21
146:24-146:25
147:2-147:5
147:8-147:12
147:13-147:22
147:25-147:25
148:2-148:2
152:2-152:7
153:19-153:22
154:9-154:25
155:6-155:24
156:3-156:7
156:8-156:12
156:16-156:21
156:24-156:25
157:2-157:5
157:15-157:18
157:23-157:25
158:2-158:5
158:8-158:10

<b>PureWick's Designated Testimony (Page/line)</b>
158:11-158:12
158:15-158:20
158:22-158:25
159:2-159:14
159:15-159:16
159:20-159:25
160:2-160:5
160:6-160:10
160:19-160:24
161:25-161:25
162:2-162:7
163:9-163:16
163:20-163:24
164:3-164:4
164:20-164:25
165:2-165:4
165:5-165:17
166:17-166:22
167:2-167:4
170:12-170:15
171:2-171:6
172:8-172:15
172:20-172:25
173:2-173:3
173:4-173:12
173:15-173:17
174:8-174:12
174:13-174:16

<b>PureWick's Designated Testimony (Page/line)</b>
174:20-174:25
175:2-175:3
176:8-176:11
176:14-176:17
176:18-176:25
177:2-177:3
177:4-177:8
177:11-177:14
177:15-177:17
177:21-177:25
178:2-178:5
178:20-178:24
181:12-181:23
181:24-181:25
182:4-182:8
187:2-187:9
190:3-190:11
191:6-191:13
191:17-191:20
192:23-192:25
193:2-193:4
196:17-196:23
200:19-200:25
205:22-205:25
206:2-206:6
208:16-208:22
212:6-212:12
212:13-212:18

<b>PureWick's Designated Testimony (Page/line)</b>
213:17-213:19
213:22-213:24
215:25-215:25
216:2-216:10
217:9-217:15
220:4-220:10
224:21-224:25
225:2-225:3
230:12-230:18
231:22-231:25
232:2-232:4
233:6-233:12
236:11-236:17
238:5-238:10
238:13-238:17
241:2-241:11
242:14-242:15
242:18-242:18
242:25-242:25
243:2-243:5
243:8-243:11
243:14-243:17
245:2-245:4
245:20-245:22
247:2-247:12
247:25-247:25
248:2-248:7
248:10-248:11

<b>PureWick's Designated Testimony (Page/line)</b>
248:23-248:25
249:2-249:6
252:20-252:22
252:25-252:25
253:2-253:2
255:3-255:5
255:10-255:10
258:8-258:14
258:15-258:20
260:13-260:25
248:23-248:25
249:2-249:6
252:20-252:22
252:25-252:25
253:2-253:2
255:3-255:5
255:10-255:10
258:8-258:14
258:15-258:20
260:13-260:25
261:2-261:2
261:21-261:25
262:2-262:4
262:7-262:11
262:14-262:16
263:7-263:13
263:14-263:18
263:21-263:25



<b>PureWick's Designated Testimony (Page/line)</b>
264:5-264:11
264:16-264:25
265:3-265:4
266:17-266:25
267:2-267:3
267:7-267:11
268:5-268:15
268:16-268:25
269:2-269:6
269:9-269:13
269:14-269:17
269:21-269:25
270:2-270:4
274:19-274:25
276:2-276:10
276:13-276:22
277:10-277:21
277:24-277:25
278:2-278:8
278:12-278:13
278:21-278:25
279:2-279:4
279:9-279:14
279:15-279:20
282:21-282:25
283:2-283:4
283:9-283:13
287:3-287:14

<b>PureWick's Designated Testimony (Page/line)</b>
287:19-287:25
288:2-288:4
288:5-288:10
288:11-288:11
288:15-288:20
288:24-288:25
289:2-289:3
289:4-289:20
289:24-289:25
290:2-290:10
290:11-290:16
290:17-290:18
290:21-290:25
291:2-291:8
291:12-291:25
292:15-292:18
292:19-292:25
293:7-293:14
294:3-294:5
294:8-294:11
297:6-297:12
297:15-297:21
297:24-297:25
298:2-298:11
298:14-298:18
298:21-298:24
301:13-301:19
302:7-302:10

<b>PureWick's Designated Testimony (Page/line)</b>
302:16-302:23
303:2-303:3
303:18-303:21
304:3-304:12
304:23-304:25
305:2-305:6
308:12-308:17
308:23-308:25
309:2-309:13
309:18-309:25
310:2-310:3
310:6-310:6
310:9-310:13
310:16-310:25
311:2-311:4
319:15-319:16
319:22-319:25
320:2-320:7
325:7-325:24
326:3-326:11
326:14-326:17

**PureWick's Designation of Deposition Testimony of Brett Blabas, August 31, 2023**

<b>PureWick's Designated Testimony (Page/line)</b>
5:6-22
19:14-16
19:20
19:22-20:1
20:2-3
20:6-7
20:9-12
23:15-17
23:20
32:21-33:4
33:17-20
34:3-14
35:3
36:2-10
39:19-40:1
40:5
40:12-17
40:22-41:13
42:20-22
43:6-9
43:18-44:4
44:5-11
44:15-18
53:10-14
53:19-54:3
54:17-18

<b>PureWick's Designated Testimony (Page/line)</b>
54:22-24
59:24-60:15
169:7-13
169:17-19
171:6-8
171:11-18
171:20-22
172:1-2
174:24-175:4
175:8-11
178:20-179:3
179:8-13
183:6-7
183:12-16
183:20-22
183:24-184:16
185:4-6
185:11-14
185:19-20
185:22-186:19
186:20-21
186:24-187:1
188:5-16
194:5-7
194:15-196:8
197:10-21
197:24-198:1
198:3-7

<b>PureWick's Designated Testimony (Page/line)</b>
200:6-8
200:13-20
203:20-22
204:3
204:9-205:4
205:10-14
210:1-6
210:15-16
210:19-22
212:13-21
216:3-15
216:23-217:2
217:6-9
217:11-24
230:7-9
230:14-231:2

**PureWick's Designation of Deposition Testimony of Jason Bobay, April 23, 2021**

<b>PureWick's Designated Testimony (Page/line)</b>
7:3-9
14:7-9
15:22-16:2
25:20-24
30:16-23
33:8-13
36:9-20
36:24-37:8
37:11-14
37:18
39:10-15
39:19-23
40:4-18
42:9-18
43:3-7
43:25-44:4
44:8-9
46:20-47:7
47:15-17
49:20-50:3
64:22-65:4
71:15-18
71:20-24
72:3
72:7-15
72:18-73:4

<b>PureWick's Designated Testimony (Page/line)</b>
73:7-17
78:10-16
79:4-6
79:17-20
79:23-80:4
80:7-12
84:11-18
88:4-9
89:4-5
89:8-90:2
103:11-104:3
104:7-10
105:17-107:10
107:13
146:23-147:6
157:8-13
170:3-10



**PureWick's Designation of Deposition Testimony of Adam Cole, February 8, 2023**

<b>PureWick's Designated Testimony (Page/line)</b>
9:8-9:13
11:5-11:11
11:22-11:23
12:2-12:5
12:9-12:12
13:3-13:8
13:10-13:13
13:15-13:16
16:15-16:22
16:23-16:25
17:2-17:4
24:3-24:10
24:15-24:20
24:22-24:23
29:4-29:5
29:8-29:11
29:24-30:2
30:5-30:6
32:11-32:20
33:4-33:5
33:8-33:10
33:12-33:13
33:15-33:17
33:19-33:20
33:22-33:25
34:3-34:10

<b>PureWick's Designated Testimony (Page/line)</b>
36:4-36:7
40:18-40:20
40:23-41:8
41:10-41:11
41:14-41:15
45:20-45:22
45:25-46:5
46:19-46:21
47:3-47:5
47:8-47:12
49:20-49:21
49:23-50:8
50:10-50:11
50:14-50:15
51:16-51:22
51:23-52:8
52:17-52:24
53:18-53:19
53:21-53:23
57:19-57:20
57:23-57:24
60:7-60:25
61:19-61:23
62:11-62:13
62:18-62:20
62:22-62:23
63:3-63:6
63:8-63:11

<b>PureWick's Designated Testimony (Page/line)</b>
63:15-63:16
63:18-63:19
63:22-63:24
64:3-64:4
64:8-64:10
64:12-64:13
64:16-64:19
65:9-65:10
65:12-65:16
66:8-66:9
66:12-66:13
66:15-66:18
67:15-67:16
67:19-67:22
68:24-69:2
69:5-69:8
71:9-71:11
71:13-71:15
72:4-72:6
72:9-72:12
72:20-73:9
73:13-73:13
73:23-73:25
74:2-74:3
74:7-74:9
74:17-74:21
76:10-76:12
76:15-76:18

<b>PureWick's Designated Testimony (Page/line)</b>
77:17-77:24
79:3-79:4
79:7-79:7
79:9-79:16
83:8-83:11
83:14-83:19
84:17-84:19
84:22-85:5
85:7-85:8
85:11-85:17
86:23-87:10
87:11-87:16
87:19-87:25
88:2-88:2
88:5-88:6
88:8-88:10
88:13-88:16
89:14-89:14
89:17-89:18
89:22-89:23
89:25-90:3
90:6-90:11
90:13-90:14
90:17-90:21
90:23-91:8
91:23-91:25
92:2-92:4
92:5-92:7

<b>PureWick's Designated Testimony (Page/line)</b>
92:10-92:15
93:5-93:9
93:10-93:15
93:16-93:24
93:25-94:4
94:5-94:9
94:12-94:14
94:16-94:24
94:25-95:5
95:6-95:11
95:12-95:14
95:17-95:22
95:24-96:2
96:3-96:5
96:8-96:12
96:14-96:17
97:8-97:10
97:12-97:17
98:12-98:19
98:20-99:5
99:10-99:15
101:10-101:13
101:17-101:20
102:9-102:19
102:23-103:3
103:5-103:6
103:7-103:9
103:16-103:20

<b>PureWick's Designated Testimony (Page/line)</b>
103:21-104:2
105:8-105:10
105:11-105:14
105:17-105:21
105:23-106:2
106:5-106:11
106:13-106:15
106:19-106:23
107:17-107:19
107:22-108:2
111:16-111:17
111:20-111:22
111:24-111:25
112:4-112:8
112:20-112:25
113:2-113:4
113:7-113:11
114:6-114:9
114:12-114:19
114:20-115:5
115:9-115:14
115:16-115:18
116:2-116:8
116:9-116:10
116:13-116:14
116:19-116:20
116:23-116:25
117:11-117:24

<b>PureWick's Designated Testimony (Page/line)</b>
117:25-118:7
124:14-124:17
124:20-125:3
125:5-125:7
125:10-125:17
130:5-130:8
130:12-130:17
130:19-130:24
131:4-131:9
131:12-131:24
132:4-132:6
132:24-133:4
133:5-133:8
134:10-134:15
135:4-135:6
135:8-135:9
135:11-135:15
135:16-135:20
136:6-136:8
136:10-136:10
136:12-136:15
136:16-136:24
137:16-137:20
138:21-139:2
142:13-142:16
143:7-143:9
144:12-144:15
144:22-145:5

<b>PureWick's Designated Testimony (Page/line)</b>
147:5-147:8
147:11-147:14
148:17-148:18
148:21-148:23
148:25-149:3
149:5-149:6
149:8-149:10
150:10-150:12
150:15-150:20
152:3-152:5
152:6-152:8
152:10-152:12
152:14-152:16
152:17-152:19
152:20-152:22
153:6-153:7
153:9-153:15
153:17-153:20
153:22-153:24
154:3-154:6
154:16-154:20
154:21-154:22
161:3-161:6
161:9-161:12
163:12-163:14
163:17-163:20
163:22-164:2
164:5-164:11



<b>PureWick's Designated Testimony (Page/line)</b>
164:13-164:16
164:18-164:20
164:22-164:25
165:4-165:7
165:9-165:12
165:14-165:20
165:22-165:25
166:3-166:7
166:9-166:11
166:12-166:13
166:15-166:17
166:19-166:21
166:23-166:24
167:3-167:8
169:21-170:15
171:11-171:12
171:14-171:17
173:6-173:10
173:12-173:14
173:16-173:19
174:21-174:22
174:25-175:5
175:7-175:11
176:12-176:23
176:24-177:2
177:6-177:13
177:15-177:23
177:24-177:25

<b>PureWick's Designated Testimony (Page/line)</b>
178:3-178:5
178:7-178:11
178:12-178:15
179:15-179:16
179:18-179:19
179:21-179:22
179:25-180:4
181:5-181:9
182:5-182:11
182:17-182:21
183:6-183:8
183:11-183:12
183:14-183:17
188:23-189:4
189:11-189:19
190:11-190:17
190:20-190:20
190:22-190:23
190:25-191:2
191:15-191:16
191:18-191:19
192:8-192:9
192:12-192:13
192:15-192:16
192:18-192:19
193:21-193:23
194:2-194:3
194:5-194:9

<b>PureWick's Designated Testimony (Page/line)</b>
195:9-195:10
195:11-195:19
196:3-196:4
196:7-196:9
197:9-197:24
198:3-198:8
199:21-199:23
200:2-200:3
200:25-201:4
201:5-201:7
201:8-201:11
201:12-201:18
203:3-203:7
203:11-203:11
205:4-205:6
205:9-205:9
206:2-206:13
206:18-206:18
206:20-206:23
206:24-206:25
207:2-207:2
207:5-207:6
207:22-207:23
208:2-208:5
208:7-208:10
208:15-208:17
208:20-208:21
209:22-210:4

<b>PureWick's Designated Testimony (Page/line)</b>
213:6-213:11
213:20-214:3
218:12-218:13
218:16-218:19
218:21-218:23
219:2-219:9
219:11-219:14
219:18-219:22
219:24-220:6
220:12-220:13
220:16-220:18
220:18-220:18
220:18-220:18
220:20-220:23
221:2-221:5
221:7-221:16
222:2-222:7
222:9-222:11
222:13-222:14
222:16-222:23
222:25-223:3
223:6-223:10
226:9-226:17
227:6-227:10
227:17-227:23
227:25-228:3
228:5-228:6
228:8-228:11

<b>PureWick's Designated Testimony (Page/line)</b>
228:13-228:23
228:25-229:5
229:7-229:13
229:21-229:23
230:2-230:3
230:5-230:11
230:13-230:15
230:21-230:23
230:25-231:4
231:6-231:8
231:11-231:13
232:6-232:8
232:10-232:13
233:24-233:25
234:4-234:5
234:16-234:18
234:21-234:21
235:8-235:18
235:19-236:8
236:10-236:21
237:3-237:7
237:8-237:9
237:19-237:20
237:22-237:24
237:25-238:22
238:24-239:14
239:15-240:2
240:8-240:11

<b>PureWick's Designated Testimony (Page/line)</b>
240:12-240:14
240:15-240:16
240:19-240:20
240:22-240:24
241:2-241:3
241:5-241:7
241:10-241:12
241:14-241:16
241:18-241:20
241:22-241:24
242:4-242:6
242:8-242:9
242:15-242:15
242:17-242:19
243:4-243:5
243:10-243:12
243:17-244:10
244:11-244:14
244:20-244:24
245:3-245:4
245:7-245:10
245:12-245:14
245:17-245:20
245:22-245:23
246:2-246:25
247:2-247:2
247:4-247:7
247:10-247:12

<b>PureWick's Designated Testimony (Page/line)</b>
247:14-247:15
247:17-247:20
247:23-248:3
249:11-249:18
250:10-250:12
250:14-250:16
251:6-251:9
251:11-251:12
251:25-252:3
252:5-252:7
253:7-253:14
253:18-253:22
254:11-254:14
254:15-254:18
254:24-255:9
255:21-255:25
256:2-256:3
256:6-256:10
256:12-256:13
256:15-256:19
256:20-256:24
257:16-257:20
257:21-257:22
257:25-258:7
258:9-258:11
258:14-258:16
258:18-258:19
258:22-258:24

<b>PureWick's Designated Testimony (Page/line)</b>
259:3-259:5
259:10-259:12
259:14-259:17
259:21-259:24
260:3-260:8
260:11-260:20
260:22-260:25
261:4-261:6
261:8-261:11
261:16-261:20
261:21-262:3
262:20-262:22
262:25-263:7
263:9-263:13
263:16-263:18
263:20-263:23
264:2-264:5
264:7-264:12
264:16-264:19
266:5-266:7
266:10-266:11
267:15-267:17
267:18-267:19
267:20-267:21
267:22-267:22
267:25-268:2
268:6-268:8
268:11-268:14



<b>PureWick's Designated Testimony (Page/line)</b>
268:16-268:23
270:10-270:12
270:15-270:16
271:3-271:7
271:8-271:12
272:8-272:11
272:13-272:16
272:18-272:20
273:12-273:16
273:25-274:2
274:4-274:13
274:16-274:17
274:19-274:23
275:13-275:14
275:17-275:19
276:5-276:13
276:24-277:3
277:7-277:18
277:21-277:25
278:2-278:8
278:9-278:11
278:14-278:15
278:17-278:19
278:22-278:25
281:4-281:5
281:7-281:8
281:9-281:13
282:2-282:5

<b>PureWick's Designated Testimony (Page/line)</b>
282:6-282:6
282:9-282:11
282:25-283:4
283:5-283:8
283:9-283:10
283:13-283:15
283:20-283:21
283:24-284:3
284:5-284:6
284:9-284:10
285:9-285:10
285:13-285:17
286:3-286:4
286:7-286:11
286:13-286:14
286:18-286:23
288:16-288:16
288:17-288:19
288:22-288:24
289:3-289:8
289:14-289:18
290:18-290:22
290:23-290:24
291:3-291:3
291:5-291:6
291:9-291:10
291:19-292:3
292:12-292:15

<b>PureWick's Designated Testimony (Page/line)</b>
292:16-292:21
292:22-292:25
293:2-293:3
293:7-293:9
293:11-293:15
293:17-293:18
293:20-294:3
294:6-294:7
294:9-294:16
294:17-294:19
294:22-294:24
295:3-295:8
295:9-295:14
295:15-295:16
295:19-295:20
296:7-296:17
296:24-297:2
297:8-297:15
298:9-298:19

**PureWick's Designation of Deposition Testimony of Lorena Eckert, March 14, 2023**

<b>PureWick's Designated Testimony (Page/line)</b>
4:7-13
137:17-19
137:22-138:5
139:22-23
140:4-9

**PureWick's Designation of Deposition Testimony of Eric Farrell, February 2, 2023**

<b>PureWick's Designated Testimony (Page/line)</b>
8:4-15
20:18-21:20
21:23-22:18
22:20-24:16
24:20-25:10
25:14-26:2
27:11-13
27:15-28:8
28:12-18
28:20-24
29:2-17
29:20-30:9
30:11-14
30:16-31:6
31:8-18
32:2-10
43:8-16
43:18-23
48:17-50:12
55:8-23
55:25-56:4
59:8-14
59:20-60:23
61:14-17
61:19-62:7
64:10-16

<b>PureWick's Designated Testimony (Page/line)</b>
64:18-23
64:25-65:9
65:15-66:21
67:6-8
67:10-21
69:23-24
70:2-6
70:9-71:13
71:16-72:9
72:11-24
73:3-15
74:5-75:12
75:14-19
76:2-11
76:13-77:2
77:9-16
77:19-78:14
79:22-80:9
80:11-81:22
81:24-82:8
82:22-83:9
84:2-8
84:10-11
86:23-87:5
89:9-90:4
90:6-91:10
91:13
91:15-22

<b>PureWick's Designated Testimony (Page/line)</b>
94:8-9
94:12-18
94:21-95:2
95:8-14
95:21-96:2
96:11-13
96:18-23
97:2-5
97:19-21
98:14-19
98:21-99:9
103:6-10
103:13-17
105:8-15
107:24-108:9
108:22-109:17
109:20-110:7
110:10-15
110:20-24
112:3-8
114:22-24
115:3-8
115:11-116:7
116:10-11
118:3-6
118:9
121:12-13
121:15-122:5

<b>PureWick's Designated Testimony (Page/line)</b>
122:7-18
124:2-6
124:9-12
124:15-19
124:22-23
125:4-5
125:8-12
125:15-23
126:2-6
126:17-19
126:22-127:12
127:5-8
127:11-16
127:19-21
128:6-129:2
139:5-8
139:11-18
140:23-141:5
141:8-11
141:15-17
141:23-143:12
143:15-17
144:4-6
144:9-12
144:15-16
145:23-146:5
148:20-149:3
149:15-17



<b>PureWick's Designated Testimony (Page/line)</b>
149:20-22
150:22-151:2
151:6-11
151:14
152:17-21
153:15-24
154:2-6
154:9-13
160:6-13
166:19-167:17
179:5-6
179:8-16
179:19-180:4
181:14-182:4
182:23-25
183:3-4
183:11-184:11
184:14-18
184:20
189:7-12
197:2-10
198:4-16
200:21-201:20
201:23
202:10-17
202:19-203:10
203:13-15
203:18-21

<b>PureWick's Designated Testimony (Page/line)</b>
209:21-25
210:4
214:20-216:6
220:3-13
220:16-221:3
221:6-9
221:10-14
228:13-15
228:17
231:2-233:4
233:6-18
233:20-23
234:2-8
235:5-9
235:11-21
235:24-236:8

**PureWick's Designation of Deposition Testimony of Sameer Jirafe, February 10, 2023**

<b>PureWick's Designated Testimony (Page/line)</b>
9:6-9
20:8-16
22:14-18
22:20-21
23:17-19
23:22-25
24:3-4
24:6-7
24:24-25
25:15-18
26:13-19
26:21-27:6
27:8
29:2-5
30:2-8
30:10-14
30:16-31:3
32:8-10
32:13-14
33:11-14
34:4-8
34:11-18
34:21-23
35:4-8
35:17-23
35:25-36:4

<b>PureWick's Designated Testimony (Page/line)</b>
36:7-13
36:15-22
36:25-37:12
37:14-19
37:21-38:12
38:15-21
38:24-25
53:9-15
85:7-8
85:11-86:14
87:6-7
87:9-17
87:20-88:3
88:6-12
88:15-20
89:8-10
89:13-19
89:22-23
127:13-18
127:24-128:13
128:16-18
133:20-24
134:2-7
134:9-11

**PureWick's Designation of Deposition Testimony of Richard Morgan, February 10, 2023**

<b>PureWick's Designated Testimony (Page/line)</b>
4:23-5:2
8:7-9:21
10:4-8
15:4-11
15:13-17:4
17:6-12
17:15-19
17:21-19:7
19:9-22
19:24-20:5
20:8
22:24-24:11
24:13-17
25:2-18
32:23-33:1
33:4-14
33:16-22
33:24-34:21
35:20-24
36:2-38:1
114:19-24
115:3-14
115:16-116:1
116:3-4
145:11-146:5
148:17-150:23

PureWick's Designated Testimony (Page/line)
150:24-151:19

**PureWick's Designation of Deposition Testimony of Kelsey Paskal, March 10, 2021**

<b>PureWick's Designated Testimony (Page/line)</b>
7:15-20
22:2-21
22:24-23:2
23:11-20
24:2-10
24:13-14
25:3-5
25:8-23
26:24-27:7
27:10-19
28:18-29:3
26:6-9
29:16-25
30:2-3
31:2-5
31:9-14
31:18-25
32:4-12
32:15-22
33:23-34:13
34:16-18
40:8-10
40:13-16
41:10-12
41:15-18
42:2-8

<b>PureWick's Designated Testimony (Page/line)</b>
42:12-20
42:24-43:3
43:24-44:3
44:6-8
45:6-12
45:23-46:7
48:15-21
49:6-20
49:23-24
50:23-51:4
51:7-11
56:18-22
57:12-58:2
58:5-8
60:5-9
60:12-14
60:23-61:7
61:17-19
61:22-62:5
62:9-12
63:15-18
63:22-64:7
64:10-14
68:12-15
68:18-19
89:23-90:6
90:19-25
99:20-100:10



<b>PureWick's Designated Testimony (Page/line)</b>
100:13-18
100:21-25
101:22-102:2
102:5-7
135:10-11
135:15-20
135:23-136:3
136:12-15
136:19-24
137:3-4
137:18-19
137:22-138:5
159:4-7
159:12-18
161:3-5
161:9-10
163:18-164:18
164:25-165:7
166:3-13
167:2-8
168:10-12
168:15-17
168:20-22
218:25-219:14
223:6-10
223:13-14
226:15-227:3
227:8-10

<b>PureWick's Designated Testimony (Page/line)</b>
227:14-228:2
228:14-17

**PureWick's Designation of Deposition Testimony of Kate Pawlik, March 17, 2023**

<b>PureWick's Designated Testimony (Page/line)</b>
4:21:5-2
20:17-19
20:23-24
21:18-19
21:22-24
22:1
22:3-5
22:8-9
22:17-24
46:6-8
46:12-13
225:7-14
225:15-18
225:22-23

**PureWick's Designation of Deposition Testimony of Patricia Polanco, January 27, 2023**

<b>PureWick's Designated Testimony (Page/line)</b>
7:8-10
21:15-24
22:2-3
23:15-25:14
33:5-19
38:4-16
38:18-22
56:17-18
56:20-21
58:23-59:3
59:12-18
59:24-60:4
61:6-14
65:18-66:16
66:22-67:2
70:4-16
78:18-79:12
79:15-18

**PureWick's Designation of Deposition Testimony of Robert Sanchez, April 21, 2021**

<b>PureWick's Designated Testimony (Page/line)</b>
9:3-6
17:24-18:10
18:19-19:25
22:23-23:4
26:2-7
26:10-16
26:18-27:12
39:2-12
116:6-9
116:12-18
116:20-21
117:25-118:3
118:5-6
148:4-16
153:7-8
153:10-24
154:1-9
154:11-19
154:21-25
155:2-16
155:18-156:1

**PureWick's Designation of Deposition Testimony of Kristin Sexton, March 12, 2021**

<b>PureWick's Designated Testimony (Page/line)</b>
6:17-7:9
15:20-16:6
18:16-24
25:14-17
25:24-25
26:3-4
26:11-16
27:3-7
96:22-97:10
97:12-13
98:12-13
98:18-22
99:7-19
102:17-103:4
104:14-105:23
106:3-8
108:5-6
108:10-22
110:10-18
110:22-25
113:19-114:4
114:8-115:2
115:6-16
115:20-21
117:8-18
117:21-22

<b>PureWick's Designated Testimony (Page/line)</b>
118:7-11
119:2-7
119:14-20
120:3-6
120:9-21
120:25-121:2
156:11-157:18
184:23-25
185:4-25
186:5-16
186:19-21
209:19-23
210:4-21
211:24-212:21
213:10
213:14-15
235:4-5
235:9-15
235:20-23
239:7-8
239:11-17
239:20-21
245:4-8
246:25-247:19
247:24-25
248:7-10
248:14-249:6
249:10-12

<b>PureWick's Designated Testimony (Page/line)</b>
249:15-250:12
250:16-251:12
251:17-21
252:3-6
252:7-8
252:11-13
252:16
252:19-20
252:23-25
253:4-5
253:14-15
253:19-254:9
254:17-18
254:22
256:15-16
256:19-257:20
263:6-9
263:24-264:2
267:19-20
267:23-268:6
269:16-20
269:25-270:7
270:16-18
270:23-24
276:18-25
278:7-14
279:9-11
279:14-15



PureWick's Designated Testimony (Page/line)
295:24-296:3

**PureWick's Designation of Deposition Testimony of Dan Ulreich April 8, 2021**

<b>PureWick's Designated Testimony (Page/line)</b>
5:13-19
20:13-19
20:22
22:20-24
23:8-10
23:13-25
24:6-10
24:13-25
25:4-6
25:7-10
26:11-20
26:23-24
27:10-17
27:18-22
27:25-28:5
28:8-9
29:24-30:17
30:20-21
30:25-31:9
31:19-25
32:4-7
33:8-21
33:24-34:5
34:8-12
35:25-36:12
36:15-17

<b>PureWick's Designated Testimony (Page/line)</b>
37:3-9
40:5-18
42:24-43:13
43:16-25
44:18-45:3
45:6-8
46:18-47:6
47:20-48:8
48:11-22
51:17-21
51:22-52:11
52:14-23
53:2-4
55:15-20
55:24-56:6
56:9-11
57:9-14
57:17-58:10
58:14-22
59:2-3
59:19-60:6
60:9-14
60:18-19
62:5-10
62:14-16
64:2-7
64:24-65:10
65:21-25

<b>PureWick's Designated Testimony (Page/line)</b>
66:5-9
60:8-24
71:16-23
72:8-14
72:17-25
73:25-74:8
74:12-15
74:24-75:6
75:9-19
75:22-76:5
76:8-9
79:17-19
79:22-23
80:25-81:5
81:9-24
82:3-11
82:20-24
83:3-9
83:12-13
83:19-22
83:25-84:6
84:10-20
85:7-12
86:18-87:6
87:9-15
87:19-88:3
88:7-10
89:17-21

<b>PureWick's Designated Testimony (Page/line)</b>
89:24-90:8
90:11-16
92:10-93:9
93:15-17
93:20-25
100:2-23
101:3-10
101:14-20
101:24-102:4
102:7-12
105:15-19
102:22-103:4
103:7-15
103:18-104:2
106:14-20
106:23-107:9
107:12-21
107:24-108:4
108:7-8
108:11-23
109:2-4
109:13-16
109:19-22
111:6-8
111:11-12
111:20-24
112:3-6
112:14-16

<b>PureWick's Designated Testimony (Page/line)</b>
112:19-24
113:3-4
115:12-116:2
118:5-12
118:15-19
118:22-119:5
119:8-13
119:16-22
119:25-120:15
120:18-20
121:16-20
121:23-122:11
122:22-123:4
123:20-124:6
132:13-17
132:22-133:4
133:7-20
133:23-134:2
134:20-24
135:3-25
136:5-15
137:24-138:12
140:11-15
140:18-24
141:3-8
141:11-14
141:17-23
142:2-10

<b>PureWick's Designated Testimony (Page/line)</b>
142:18-21
142:24-143:8
143:20-23
144:2-8
144:11-14
144:17
145:3-9
145:12-14
145:18-21
145:24-146:6
146:10-13
146:24-147:5
147:9-14
147:18
148:5-10
148:13-22
155:14-21
155:24-156:2
157:11-15
157:19-22
159:7-15
160:4-8
160:11-16
160:18-21
161:6-14
161:18-21
161:25-162:2
162:11-14

<b>PureWick's Designated Testimony (Page/line)</b>
162:16-21
162:25-163:11
163:22-164:2
164:7-14
164:19-23
165:12-15
165:18-19
166:15-22
167:4-14
167:19-21
170:20-22
174:2-6
174:9-10
175:4-6
175:9-11
152:22-176:2
176:6-8
176:17-177:10
181:18-22
182:2-3
182:13-18
182:22-23
183:7-8
183:11-24
184:3-7
184:10-11
184:16-19
184:22-24



<b>PureWick's Designated Testimony (Page/line)</b>
185:13-17
185:21-186:2
186:6-7
188:10-12
188:15-189:3
189:6-16
189:19-23
190:2-4
192:20-193:5
193:8-9
194:9-13
194:16-18
195:3-7
195:11-15
195:19-24
196:4-9
196:13-24
197:3-4
197:13-19
197:23-25
198:12-17
198:20-199:2
199:5-10
199:14-16
199:19-21
199:25-200:7
200:11-12
201:15-22

<b>PureWick's Designated Testimony (Page/line)</b>
201:25-202:7
202:10-21
202:24-203:3
203:6-9
203:12
204:25-205:11
205:14-22
208:20-209:9
209:12-19
210:3-5
210:8-15
210:18-211:5
211:8-10
213:2-6
213:10-12
213:16-19
213:23-214:7
221:5-14
221:17-21
225:2-5
225:10-18
225:21
226:4-6
226:9-10
227:14-20
227:23-228:7
228:10

**PureWick's Designation of Deposition Testimony of Dan Ulreich, April 13, 2023**

<b>PureWick's Designated Testimony (Page/line)</b>
5:3-7
9:3-5
9:11-12
10:5-8
10:23-24
11:3-6
11:8-10
11:13-14
11:16-24
14:15-17
14:21-23
15:1-5
15:8-10
15:12-14
15:18
15:20-23
16:13-16
18:15-18
19:9-10
19:13-15
19:17-22
23:4-10
26:8-11
26:14-16
29:11-13
29:18-21

<b>PureWick's Designated Testimony (Page/line)</b>
30:8-10
30:12-14
30:17
30:19-31:4
37:12-16
47:19-23
47:24-48:1
48:4-5
48:7-8
50:12-14
50:19
50:21-24
51:4
51:6-9
60:24-61:5
61:10
61:21-24
62:4-5
62:7-11
62:22-63:5
63:10-15
63:16-18
63:21-22
63:24-64:7
64:14-18
80:8-11
80:19-20
80:24

<b>PureWick's Designated Testimony (Page/line)</b>
81:2-9
81:10-13
82:9-18
97:21-98:1
98:16-22
99:2
99:4-9
105:8-13
105:22-106:12
112:18-24
113:11-21
114:9-10
114:12-115:3
125:10-12
125:17-21
126:3-6
126:16-127:3
127:7-9
127:11-20
128:3-16
128:19-23
129:1-7
129:8-11
129:14-16
129:18-20
129:23-24
130:2-5
130:8-12

<b>PureWick's Designated Testimony (Page/line)</b>
131:5-6
131:11-14
131:20-132:18
132:21-23
133:1-3
133:6-7
133:9-13
133:16-18
133:20-134:4
134:5-10
134:11-14
134:18-21
134:23-135:3
135:7-9
135:11-15
135:18-21
135:23-136:6
136:11-14
142:23-143:4
143:7-12
143:18-144:1
144:4-6
144:8-10
144:13-14
144:16-22
145:4-9
145:12-13
145:15-146:1

<b>PureWick's Designated Testimony (Page/line)</b>
146:4-12
146:15-16
146:18-147:7
147:10-12
147:14-15
147:19-21
147:23-148:6
148:23-24
149:4-6
149:8-15
149:19-150:1
150:5-6
150:8-13
150:17-19
150:21-151:7
151:10-11
151:13-18
151:21-23
152:1-3
152:6-7
152:9-11
152:15-17
152:19-20
152:23-24
153:2-9
153:13-15
153:17-19
153:22-23

<b>PureWick's Designated Testimony (Page/line)</b>
154:1-3
154:7-9
154:11-13
154:17
154:20
154:22-24
155:5-9
155:14-15
155:17-23
156:5-7
156:11-13
156:23-157:3
157:6-7
157:9-11
157:15-18
160:4-7
160:12-18
160:23-161:2
161:11-15
161:18-20
162:5-8
162:11-13
162:15-18
162:22-163:6
163:9-12
166:20-24
167:5-9
167:12-14



<b>PureWick's Designated Testimony (Page/line)</b>
167:16-24
168:4-5
169:1-4
169:8-10
169:12-15
169:18
170:16-21
171:1-4
171:6-7
171:11-15
172:2-7
172:11-14
175:24-176:3
176:7-10
182:12-14
182:18-19
182:21-24

**PureWick's Designation of Trial Testimony of Camille Newton, March 28, 2022**

<b>PureWick's Designated Testimony (Page/line)</b>
160:5-160:19
161:7-163:25
164:3-164:9
164:10-165:12
165:13-167:20
167:21-167:21
168:3-168:4
168:13-170:3
170:4-170:4
170:10-170:12
170:20-173:12
173:20-177:25
178:9-178:14
178:22-179:21
180:7-183:6
183:25-185:14
186:17-186:24
187:8-188:13
190:5-190:9
190:17-191:7
191:17-192:4
192:12-194:6
194:14-195:1
195:5-195:11
195:19-196:21
196:25-197:13

<b>PureWick's Designated Testimony (Page/line)</b>
197:17-198:19
199:2-201:5
201:21-202:15
202:22-203:13
203:18-205:19
206:2-207:9
207:16-208:4
208:11-208:14
208:21-209:7
209:15-209:23
210:5-212:12
212:20-214:11
214:19-215:19
216:2-216:19
217:5-217:6
217:8-218:6
218:14-219:6
219:9-221:25
222:7-224:17

**PureWick's Designation of Trial Testimony of John Gohde, March 29, 2022**

<b>PureWick's Designated Testimony (Page/line)</b>
344:11-347:5
347:6-347:13
348:4-348:18
349:2-349:12
349:13-350:14
350:15-352:10
352:16-352:22
353:13-353:25
354:1-354:5
354:17-356:7
364:13-365:4
365:9-366:18
367:11-367:24
368:17-369:5

**PureWick's Designation of Trial Testimony of Raymond Newton, March 29, 2022**

<b>PureWick's Designated Testimony (Page/line)</b>
287:21-287:24
289:3-289:17
289:18-291:11
291:12-291:15
291:16-291:17
292:3-294:22
294:23-295:2
295:10-296:20
296:22-298:2
298:3-299:23
299:24-300:2
300:10-300:21
300:24-302:15
302:16-302:18
303:2-304:3
304:4-304:6
304:15-305:6
305:9-305:14
308:13-308:24
319:23-320:11

**PureWick's Designation of Trial Testimony of Brett Blabas, March 30, 2022**

<b>PureWick's Designated Testimony (Page/line)</b>
587:20-588:7
588:14-588:19
589:22-589:25
590:1-590:22
601:24-602:4
602:16-603:3
605:5-605:9
608:14-608:24
609:3-609:4
609:10-609:18
611:5-611:20
612:2-613:6
613:11-613:13
614:8-614:13
614:17-614:22
614:23-615:7
615:8-615:25
616:1-616:3
616:15-616:25
617:1-617:25
618:1-618:7
618:10-618:16
619:3-619:12
620:11-620:25
621:1-621:22
622:6-622:19

<b>PureWick's Designated Testimony (Page/line)</b>
623:2-623:11
623:12-623:23
624:5-624:13
625:16-625:19

**PureWick's Designation of Trial Testimony of Kelsey Paskal, March 30, 2022**

<b>PureWick's Designated Testimony (Page/line)</b>
667:12-667:15
667:20-669:1
691:9-693:14



**PureWick's Designation of Trial Testimony of Nick Alexander, March 31, 2022**

<b>PureWick's Designated Testimony (Page/line)</b>
877:19-879:2
881:16-882:6
883:24-884:1
887:10-887:20
887:21-887:25
888:1-888:8
888:13-889:6

## **SCHEDULE E2b**

**Sage's Objections To PureWick's Initial  
Designations and Sage's Counter and  
Contingent Designations**

**Sage's Objections to PureWick's Designations**

<b><u>Number</u></b>	<b><u>Objection</u></b>
1	Irrelevant
2	Lacks foundation / lacks personal knowledge
3	Calls for Speculation
4	Hearsay
5	Vague and Ambiguous
6	Asked and Answered
7	Argumentative
8	Hypothetical
9	Privilege
10	Leading
11	Compound
12	Mischaracterization
13	Best Evidence
14	Calls for Legal Conclusion
15	Assumes facts not in evidence
16	Non-responsive
17	Rule 403
18	Outside scope of 30(b)(6)
19	Not testimony / Not responding to a question
20	Opinion / Expert opinion testimony by non-expert / Rule 701
21	Rule 702
22	Calls for a narrative
23	Improper and/or irrelevant reference to PrimaFit 1.0
24	Vague, improper, and/or irrelevant reference to a PureWick product
25	Violation of Court Order prohibiting duplicative testimony
MIL1	Objectionable as set forth in Sage's Motion in Limine No. 1
MIL2	Objectionable as set forth in Sage's Motion in Limine No. 2
MIL3	Objectionable as set forth in Sage's Motion in Limine No. 3
CONT	Testimony relates to contingent designations including designations subject to outstanding motions
DAUB	Addresses issues raised in Sage's <i>Daubert</i> motions/motions to strike
Outside Scope	Outside scope of designation

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Alakhramsing, Sailindra 2023-01-31	10	11	10	19	
Alakhramsing, Sailindra 2023-01-31	23	24	24	25	
Alakhramsing, Sailindra 2023-01-31	25	3	27	3	
Alakhramsing, Sailindra 2023-01-31	27	8	27	18	1, 5
Alakhramsing, Sailindra 2023-01-31	28	9	29	2	1, 5
Alakhramsing, Sailindra 2023-01-31	29	13	30	4	1, 5
Alakhramsing, Sailindra 2023-01-31	32	4	32	7	1, 5
Alakhramsing, Sailindra 2023-01-31	32	15	33	19	1, 5
Alakhramsing, Sailindra 2023-01-31	36	3	36	5	1, 5
Alakhramsing, Sailindra 2023-01-31	37	6	37	7	1, 5
Alakhramsing, Sailindra 2023-01-31	37	9	37	14	1, 5
Alakhramsing, Sailindra 2023-01-31	37	18	38	4	1, 5
Alakhramsing, Sailindra 2023-01-31	41	17	42	13	1, 13, 18, Outside Scope
Alakhramsing, Sailindra 2023-01-31	42	16	42	17	1, 13, 18, Outside Scope
Alakhramsing, Sailindra 2023-01-31	42	19	42	20	1, 13, 18, Outside Scope
Alakhramsing, Sailindra 2023-01-31	42	22	42	23	1, 13, 18, Outside Scope
Alakhramsing, Sailindra 2023-01-31	46	8	46	10	1, 2, 5, 13, 18, Outside Scope
Alakhramsing, Sailindra 2023-01-31	46	12	46	20	1, 2, 5, 13, 18, Outside Scope
Alakhramsing, Sailindra 2023-01-31	48	17	48	24	1, 2, 5, 13, 18, Outside Scope
Alakhramsing, Sailindra 2023-01-31	50	17	50	21	
Alakhramsing, Sailindra 2023-01-31	52	12	52	22	
Alakhramsing, Sailindra 2023-01-31	52	24	53	14	
Alakhramsing, Sailindra 2023-01-31	54	9	54	13	1, 13, 18, Outside Scope
Alakhramsing, Sailindra 2023-01-31	54	16	54	18	1, 13, 18, Outside Scope
Alakhramsing, Sailindra 2023-01-31	60	17	60	21	1, 5, 13, 18, Outside Scope
Alakhramsing, Sailindra 2023-01-31	60	25	61	3	1, 5, 13, 18, Outside Scope
Alakhramsing, Sailindra 2023-01-31	61	6	61	6	1, 5, 13, 18, Outside Scope
Alakhramsing, Sailindra 2023-01-31	97	9	97	11	1, 2, 3, 4, 12, 13, 15, 18, Outside Scope
Alakhramsing, Sailindra 2023-01-31	97	14	97	19	1, 2, 3, 4, 12, 13, 15, 18, Outside Scope
Alakhramsing, Sailindra 2023-01-31	103	19	103	22	1, 2, 3, 5, 18
Alakhramsing, Sailindra 2023-01-31	153	7	153	23	1, 2, 18
Alakhramsing, Sailindra 2023-01-31	154	12	154	13	1, 3, 5, 13, 14, 18,
Alakhramsing, Sailindra 2023-01-31	154	16	154	23	1, 3, 5, 13, 14, 18
Alakhramsing, Sailindra 2023-01-31	155	13	155	15	1, 2, 3, 13, 18
Alakhramsing, Sailindra 2023-01-31	155	18	155	18	1, 2, 3, 13, 18
Alakhramsing, Sailindra 2023-01-31	193	17	194	2	1, 13, 18
Alakhramsing, Sailindra 2023-01-31	194	6	194	10	1, 5, 13, 18
Alakhramsing, Sailindra 2023-01-31	194	14	194	15	1, 5, 13, 18
Alakhramsing, Sailindra 2023-01-31	195	18	195	20	1, 5, 13, 18
Alakhramsing, Sailindra 2023-01-31	195	22	195	24	1, 5, 13, 18
Alakhramsing, Sailindra 2023-01-31	201	22	202	4	1, 5, 12, 13, 15, 18
Alakhramsing, Sailindra 2023-01-31	218	17	219	6	
Alakhramsing, Sailindra 2023-01-31	232	21	233	12	1, 12, 13, 15
Alakhramsing, Sailindra 2023-01-31	234	5	234	7	1, 5, 13, 14
Alakhramsing, Sailindra 2023-01-31	246	16	247	8	13
Alakhramsing, Sailindra 2023-01-31	247	11	247	13	13
Alakhramsing, Sailindra 2023-01-31	247	16	247	20	12, 13, 15

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initial	Issues
Alakhramsing, Sailindra 2023-01-31	37	4	37	5	36:3-5	Sage Counter Designations
Alakhramsing, Sailindra 2023-01-31	38	5	38	7	37:12-38:4	Sage Counter Designations
Alakhramsing, Sailindra 2023-01-31	38	11	38	13	37:12-38:4	Sage Counter Designations
Alakhramsing, Sailindra 2023-01-31	61	8	61	10	60:17-61:6	Sage Counter Designations
Alakhramsing, Sailindra 2023-01-31	61	13	61	14	60:17-61:6	Sage Counter Designations
Alakhramsing, Sailindra 2023-01-31	103	9	103	11	103:19-22	Sage Counter Designations
Alakhramsing, Sailindra 2023-01-31	103	14	103	17	103:19-22	Sage Counter Designations
Alakhramsing, Sailindra 2023-01-31	197	12	197	15	194:6-194:15; 195:18-24	Sage Counter Designations
Alakhramsing, Sailindra 2023-01-31	197	19	197	21	194:6-194:15; 195:18-24	Sage Counter Designations
Alakhramsing, Sailindra 2023-01-31	249	9	249	10	232:21-233:12; 246:16-247:20	Sage Counter Designations
Alakhramsing, Sailindra 2023-01-31	249	13	249	15	232:21-233:12; 246:16-247:20	Sage Counter Designations
Alakhramsing, Sailindra 2023-01-31	249	16	249	18	232:21-233:12; 246:16-247:20	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
19-1508 - Vol 04, Alexander, Nick	877	19	879	2	1, 4, 17; Entirety of transcript to the extent it is being used inconsistently with Sage's MILs/DAUB
19-1508 - Vol 04, Alexander, Nick	881	16	882	6	1, 4, 17, MIL2
19-1508 - Vol 04, Alexander, Nick	883	24	884	1	1, 4, 17, MIL2
19-1508 - Vol 04, Alexander, Nick	887	10	887	20	1, 4, 17, 23, MIL1
19-1508 - Vol 04, Alexander, Nick	887	21	887	25	1, 4, 17, MIL1, MIL2
19-1508 - Vol 04, Alexander, Nick	888	1	888	8	1, 4, 17, 23, MIL1, MIL2
19-1508 - Vol 04, Alexander, Nick	888	13	889	6	1, 4, 17, MIL2

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
19-1508 - Vol 04, Alexander, Nick	879	10	881	15	e.g., pp. 877-878	Sage Counter Designations
19-1508 - Vol 04, Alexander, Nick	882	7	883	23	e.g., 881:16-882:6	Sage Contingent
19-1508 - Vol 04, Alexander, Nick	884	2	886	19	e.g., 881:16-882:6, 883:24-884:1	Sage Contingent

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Alexander, Nick 2021-04-13	10	4	10	10	Entirety of transcript to the extent it is being used inconsistently with Sage's MILs/DAUB
Alexander, Nick 2021-04-13	25	4	25	6	
Alexander, Nick 2021-04-13	25	21	25	25	
Alexander, Nick 2021-04-13	26	2	26	6	
Alexander, Nick 2021-04-13	26	9	26	11	
Alexander, Nick 2021-04-13	56	7	56	12	1, 2, 3, 4, 15, 17, MIL1
Alexander, Nick 2021-04-13	56	19	56	25	1, 2, 3, 4, 15, 17, MIL1
Alexander, Nick 2021-04-13	57	2	57	9	1, 2, 3, 4, 15, 17, MIL1
Alexander, Nick 2021-04-13	58	5	58	11	1, 3, 5, 17
Alexander, Nick 2021-04-13	58	14	58	15	continued
Alexander, Nick 2021-04-13	61	14	61	16	
Alexander, Nick 2021-04-13	61	18	61	25	
Alexander, Nick 2021-04-13	62	2	62	6	
Alexander, Nick 2021-04-13	63	8	63	10	1, 2, 3, 4, 17, 19, MIL2
Alexander, Nick 2021-04-13	64	2	64	3	1, 2, 3, 4, 17, MIL2
Alexander, Nick 2021-04-13	64	5	64	5	1, 2, 3, 4, 17, MIL2
Alexander, Nick 2021-04-13	64	9	64	10	
Alexander, Nick 2021-04-13	64	11	64	14	1, 5, 17, MIL2
Alexander, Nick 2021-04-13	64	17	64	25	1, 5, 17, MIL2
Alexander, Nick 2021-04-13	69	22	69	25	1, 2, 3, 17, 18, MIL2
Alexander, Nick 2021-04-13	70	2	70	5	1, 2, 3, 17, 18, MIL2
Alexander, Nick 2021-04-13	70	7	70	7	1, 2, 3, 17, 18, MIL2
Alexander, Nick 2021-04-13	70	10	70	14	1, 2, 3, 17, 18, MIL2, MIL3
Alexander, Nick 2021-04-13	70	17	70	20	1, 2, 3, 17, 18, MIL2, MIL3
Alexander, Nick 2021-04-13	71	15	71	17	1, 2, 3, 17, 18, MIL2, MIL3
Alexander, Nick 2021-04-13	71	19	71	22	1, 2, 3, 17, MIL2, MIL3
Alexander, Nick 2021-04-13	71	25	71	25	1, 2, 3, 17, MIL2, MIL3
Alexander, Nick 2021-04-13	72	2	72	7	1, 2, 3, 17, MIL2, MIL3
Alexander, Nick 2021-04-13	72	10	72	11	1, 2, 3, 17, MIL2, MIL3
Alexander, Nick 2021-04-13	73	6	73	15	1, 2, 3, 4, 17, 24, MIL2
Alexander, Nick 2021-04-13	73	18	73	20	1, 2, 3, 4, 17, MIL2
Alexander, Nick 2021-04-13	73	23	73	25	1, 2, 3, 4, 17, MIL2
Alexander, Nick 2021-04-13	74	4	74	6	1, 2, 3, 4, 17, MIL2
Alexander, Nick 2021-04-13	74	9	74	14	1, 2, 3, 4, 17, MIL2
Alexander, Nick 2021-04-13	74	17	74	23	1, 2, 3, 4, 17, MIL2
Alexander, Nick 2021-04-13	75	2	75	17	1, 2, 3, 5, 8, 17
Alexander, Nick 2021-04-13	75	20	75	25	1, 2, 3, 5, 8, 17
Alexander, Nick 2021-04-13	76	2	76	2	1, 17, MIL2, MIL1, Daub
Alexander, Nick 2021-04-13	76	5	76	7	1, 17, MIL2, MIL1, Daub
Alexander, Nick 2021-04-13	76	10	76	10	1, 17, MIL2, MIL1, Daub
Alexander, Nick 2021-04-13	77	6	77	7	1, 2, 4, 17, 18, 24, MIL2, MIL3
Alexander, Nick 2021-04-13	77	11	77	11	continued
Alexander, Nick 2021-04-13	79	18	79	19	1, 17, MIL2
Alexander, Nick 2021-04-13	79	22	79	25	1, 17, MIL2
Alexander, Nick 2021-04-13	81	2	81	24	1, 17, MIL2
Alexander, Nick 2021-04-13	82	5	82	10	1, 17, MIL2
Alexander, Nick 2021-04-13	82	16	82	17	1, 17, MIL2
Alexander, Nick 2021-04-13	82	20	82	25	1, 17, 24, MIL2



Alexander, Nick 2021-04-13	83	2	83	16	1, 4, 17, MIL2, MIL3
Alexander, Nick 2021-04-13	84	2	84	18	1, 2, 3, 17, MIL2, MIL3
Alexander, Nick 2021-04-13	84	21	84	21	cont
Alexander, Nick 2021-04-13	87	8	87	12	1, 5, 17
Alexander, Nick 2021-04-13	87	15	87	16	continued
Alexander, Nick 2021-04-13	88	10	88	25	1, 4, 17, MIL2, MIL3
Alexander, Nick 2021-04-13	89	2	89	8	continued, 12, 15
Alexander, Nick 2021-04-13	89	20	89	25	1, 5, 17, 24, MIL2, MIL3
Alexander, Nick 2021-04-13	90	2	90	2	continued
Alexander, Nick 2021-04-13	90	21	90	25	1, 4, 17, MIL2, MIL3
Alexander, Nick 2021-04-13	91	2	91	12	1, 4, 17, MIL2, MIL3
Alexander, Nick 2021-04-13	91	21	91	22	1, 2, 3, 17, MIL2
Alexander, Nick 2021-04-13	91	25	91	25	cont
Alexander, Nick 2021-04-13	92	2	92	24	1, 2, 3, 17, MIL2, MIL3
Alexander, Nick 2021-04-13	94	6	94	16	1, 17, MIL2
Alexander, Nick 2021-04-13	95	17	95	21	1, 17, MIL2, MIL3
Alexander, Nick 2021-04-13	95	24	95	25	continued
Alexander, Nick 2021-04-13	96	2	96	5	continued
Alexander, Nick 2021-04-13	96	8	96	8	continued
Alexander, Nick 2021-04-13	119	19	119	25	1, 17, MIL3 (unasserted patents)
Alexander, Nick 2021-04-13	120	2	120	13	1, 17, MIL3 (unasserted patents)
Alexander, Nick 2021-04-13	120	16	120	24	1, 17, MIL2, MIL3
Alexander, Nick 2021-04-13	121	5	121	11	1, 17, MIL3 (unasserted patents)
Alexander, Nick 2021-04-13	121	13	121	23	1, 17, MIL3
Alexander, Nick 2021-04-13	122	15	122	21	1, 17, MIL3
Alexander, Nick 2021-04-13	123	6	123	12	1, 17, MIL2
Alexander, Nick 2021-04-13	123	15	123	18	1, 17, MIL2, MIL3
Alexander, Nick 2021-04-13	123	21	123	24	continued
Alexander, Nick 2021-04-13	124	19	124	22	1, 4, 17, MIL2
Alexander, Nick 2021-04-13	125	13	125	25	1, 4, 17, MIL2
Alexander, Nick 2021-04-13	126	2	126	6	1, 4, 17, MIL2
Alexander, Nick 2021-04-13	126	8	126	11	1, 4, 17, MIL2
Alexander, Nick 2021-04-13	126	13	126	20	1, 4, 17, MIL2
Alexander, Nick 2021-04-13	126	23	126	25	1, 4, 17, MIL2
Alexander, Nick 2021-04-13	127	3	127	8	1, 4, 17, MIL2
Alexander, Nick 2021-04-13	127	10	127	16	1, 4, 17, MIL2
Alexander, Nick 2021-04-13	127	18	127	22	1, 4, 17, MIL2
Alexander, Nick 2021-04-13	127	25	127	25	1, 4, 17, MIL2
Alexander, Nick 2021-04-13	128	2	128	5	1, 3, 17, MIL2
Alexander, Nick 2021-04-13	128	9	128	19	1, 2, 3, 4, 17, MIL2
Alexander, Nick 2021-04-13	128	23	128	25	1, 2, 3, 4, 17, MIL2
Alexander, Nick 2021-04-13	129	2	129	6	
Alexander, Nick 2021-04-13	130	3	130	23	
Alexander, Nick 2021-04-13	131	3	131	3	
Alexander, Nick 2021-04-13	131	6	131	9	1, 2, 3, 4, 15, 17, MIL2
Alexander, Nick 2021-04-13	131	16	131	21	1, 2, 3, 4, 15, 17, MIL2
Alexander, Nick 2021-04-13	132	7	132	9	1, 4, 17, MIL2
Alexander, Nick 2021-04-13	132	11	132	12	continued
Alexander, Nick 2021-04-13	132	18	132	25	1, 2, 3, 4, 15, 17, MIL2
Alexander, Nick 2021-04-13	133	2	133	3	1, 2, 3, 4, 15, 17, MIL2
Alexander, Nick 2021-04-13	133	5	133	9	1, 2, 3, 4, 12, 15, 17, MIL2

Alexander, Nick 2021-04-13	133	12	133	16	1, 2, 3, 4, 12, 15, 17, MIL2
Alexander, Nick 2021-04-13	133	19	133	23	1, 2, 3, 4, 12, 15, 17, MIL2
Alexander, Nick 2021-04-13	134	18	134	20	1, 2, 3, 4, 15, 17, MIL2
Alexander, Nick 2021-04-13	134	25	134	25	continued
Alexander, Nick 2021-04-13	135	2	135	6	1, 2, 3, 4, 15, 17, MIL2
Alexander, Nick 2021-04-13	135	10	135	16	1, 2, 3, 15, 17, MIL2
Alexander, Nick 2021-04-13	135	19	135	22	1, 2, 3, 15, 17, MIL2
Alexander, Nick 2021-04-13	136	9	136	15	1, 2, 3, 5, 15, 17, MIL2
Alexander, Nick 2021-04-13	146	6	146	8	1, 12, 15, 17, 23, MIL1, DAUB
Alexander, Nick 2021-04-13	146	9	146	13	1, 12, 15, 17, 23, MIL1, DAUB
Alexander, Nick 2021-04-13	146	16	146	18	continued
Alexander, Nick 2021-04-13	154	8	154	9	1, 2, 3, 18
Alexander, Nick 2021-04-13	154	13	154	21	continued
Alexander, Nick 2021-04-13	154	25	154	25	continued
Alexander, Nick 2021-04-13	155	2	155	3	continued
Alexander, Nick 2021-04-13	237	10	237	14	1, 2, 3, 12, 15, 17, MIL2
Alexander, Nick 2021-04-13	237	17	237	23	continued
Alexander, Nick 2021-04-13	238	3	238	9	continued
Alexander, Nick 2021-04-13	238	12	238	12	continued
Alexander, Nick 2021-04-13	238	18	238	20	1, 2, 3, 12, 15, 17, MIL2
Alexander, Nick 2021-04-13	238	24	238	25	continued

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Alexander, Nick 2021-04-13	27	5	27	9	26:9-11	Sage Counter Designations
Alexander, Nick 2021-04-13	57	23	58	4	56-57	Sage Contingent
Alexander, Nick 2021-04-13	60	19	61	8	56-60	Sage Contingent
Alexander, Nick 2021-04-13	63	18	63	20	63	Sage Contingent
Alexander, Nick 2021-04-13	83	17	83	19	83	Sage Contingent
Alexander, Nick 2021-04-13	86	22	87	7	87	Sage Counter Designations
Alexander, Nick 2021-04-13	89	14	89	16	88	Sage Contingent
Alexander, Nick 2021-04-13	90	3	90	13	89-90	Sage Contingent
Alexander, Nick 2021-04-13	91	13	91	20	91	Sage Contingent
Alexander, Nick 2021-04-13	96	9	96	13	95-96	Sage Contingent
Alexander, Nick 2021-04-13	96	19	96	25	95-96	Sage Contingent
Alexander, Nick 2021-04-13	97	10	97	15	95-96	Sage Contingent
Alexander, Nick 2021-04-13	100	7	100	8	95-96	Sage Contingent
Alexander, Nick 2021-04-13	100	13	100	13	95-96	Sage Contingent
Alexander, Nick 2021-04-13	101	4	101	19	95-96	Sage Contingent
Alexander, Nick 2021-04-13	101	20	101	24	95-96	Sage Contingent
Alexander, Nick 2021-04-13	106	5	106	8	95-96	Sage Contingent
Alexander, Nick 2021-04-13	106	11	107	14	95-96	Sage Contingent
Alexander, Nick 2021-04-13	131	22	131	24	131	Sage Contingent
Alexander, Nick 2021-04-13	132	13	132	17	132	Sage Contingent
Alexander, Nick 2021-04-13	135	23	136	8	135-136	Sage Contingent
Alexander, Nick 2021-04-13	167	9	167	23	95-96	Sage Contingent
Alexander, Nick 2021-04-13	217	15	217	17		Sage Counter Designations
Alexander, Nick 2021-04-13	217	21	218	7		Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Allen, Jennifer 2023-02-01	6	24	7	2	Entirety of transcript to the extent it is being used inconsistently with Sage's MILs/DAUB
Allen, Jennifer 2023-02-01	24	8	24	21	1, 17, 23, DAUB, MIL1
Allen, Jennifer 2023-02-01	24	22	25	2	1, 17, DAUB, MIL1
Allen, Jennifer 2023-02-01	25	4	25	9	
Allen, Jennifer 2023-02-01	29	2	29	7	1, 17, 23, MIL1, DAUB
Allen, Jennifer 2023-02-01	37	25	39	18	1, 2, 3, 4, 17, 23, MIL1, DAUB
Allen, Jennifer 2023-02-01	47	15	47	16	1, 2, 3, 9, 12, 15, 17, 18
Allen, Jennifer 2023-02-01	47	23	48	2	continued

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Allen, Jennifer 2023-02-01	11	9	11	18		Sage Counter Designations
Allen, Jennifer 2023-02-01	11	24	12	2		Sage Counter Designations
Allen, Jennifer 2023-02-01	20	6	20	11	6	Sage Counter Designations
Allen, Jennifer 2023-02-01	21	23	22	3	e.g. 47	Sage Counter Designations
Allen, Jennifer 2023-02-01	22	12	22	18	e.g., 47	Sage Counter Designations
Allen, Jennifer 2023-02-01	23	8	23	19	e.g., 47	Sage Counter Designations
Allen, Jennifer 2023-02-01	29	8	29	12	6	Sage Counter Designations
Allen, Jennifer 2023-02-01	31	19	32	7	20, 24	Sage Counter Designations
Allen, Jennifer 2023-02-01	32	11	32	15	20, 24	Sage Counter Designations
Allen, Jennifer 2023-02-01	32	24	33	6		Sage Counter Designations
Allen, Jennifer 2023-02-01	39	24	40	2	37-39	Sage Contingent
Allen, Jennifer 2023-02-01	50	24	51	2	47	Sage Counter Designations
Allen, Jennifer 2023-02-01	54	22	55	4	47	Sage Counter Designations
Allen, Jennifer 2023-02-01	55	5	55	10	47	Sage Counter Designations
Allen, Jennifer 2023-02-01	59	9	59	12	47	Sage Counter Designations
Allen, Jennifer 2023-02-01	59	13	59	20	47	Sage Counter Designations
Allen, Jennifer 2023-02-01	67	14	67	22	47	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
19-1508 - Vol 03, Blabas, Brett	587	20	588	7	1, 17, 23, MIL1, DAUB; Objection to entirety of Blabas transcript to the extent it is being used inconsistently with Sage's MILs or Daubert
19-1508 - Vol 03, Blabas, Brett	588	14	588	19	1, 17, 23, MIL1, DAUB
19-1508 - Vol 03, Blabas, Brett	589	22	589	25	
19-1508 - Vol 03, Blabas, Brett	590	1	590	22	
19-1508 - Vol 03, Blabas, Brett	601	24	602	4	1, 17, 23, MIL1, DAUB
19-1508 - Vol 03, Blabas, Brett	602	16	603	3	1, 17, 23, MIL1, DAUB
19-1508 - Vol 03, Blabas, Brett	605	5	605	9	1, 17, 23, MIL1, DAUB
19-1508 - Vol 03, Blabas, Brett	608	14	608	24	1, 17, 23, 24, MIL1
19-1508 - Vol 03, Blabas, Brett	609	3	609	4	1, 17, 23, 24, MIL1, DAUB
19-1508 - Vol 03, Blabas, Brett	609	10	609	18	1, 17, 23, MIL1, MIL2, DAUB
19-1508 - Vol 03, Blabas, Brett	611	5	611	20	1, 17, 23, MIL1, DAUB
19-1508 - Vol 03, Blabas, Brett	612	2	613	6	1, 13, 17, 23, 24, MIL1, MIL2, DAUB
19-1508 - Vol 03, Blabas, Brett	613	11	613	13	1, 17, 23, MIL1, DAUB
19-1508 - Vol 03, Blabas, Brett	614	8	614	13	1, 17, 23, MIL1, DAUB
19-1508 - Vol 03, Blabas, Brett	614	17	614	22	1, 17, 23, MIL1, DAUB
19-1508 - Vol 03, Blabas, Brett	614	23	615	7	1, 17, 23, MIL1, DAUB
19-1508 - Vol 03, Blabas, Brett	615	8	615	25	1, 4, 17, 23, 24, MIL1, MIL2, DAUB
19-1508 - Vol 03, Blabas, Brett	616	1	616	3	1, 17, 23, 24, MIL1, MIL2, DAUB
19-1508 - Vol 03, Blabas, Brett	616	15	616	25	1, 4, 17, 23, 24, MIL1, MIL2, DAUB
19-1508 - Vol 03, Blabas, Brett	617	1	617	25	1, 4, 17, 23, 24, MIL1, MIL2, DAUB
19-1508 - Vol 03, Blabas, Brett	618	1	618	7	1, 17, 23, 24, MIL1, MIL2, DAUB
19-1508 - Vol 03, Blabas, Brett	618	10	618	16	1, 17, 23, MIL1, MIL2, DAUB
19-1508 - Vol 03, Blabas, Brett	619	3	619	12	1, 17, 23, 24, MIL1, MIL2, DAUB
19-1508 - Vol 03, Blabas, Brett	620	11	620	25	1, 4, 17, 23, MIL1, DAUB
19-1508 - Vol 03, Blabas, Brett	621	1	621	22	1, 4, 17, 23, MIL1, DAUB
19-1508 - Vol 03, Blabas, Brett	622	6	622	19	1, 2, 17, 23, MIL1, DAUB
19-1508 - Vol 03, Blabas, Brett	623	2	623	11	1, 4, 17, 23, MIL1, DAUB
19-1508 - Vol 03, Blabas, Brett	623	12	623	23	1, 2, 4, 17, 23, MIL1, DAUB
19-1508 - Vol 03, Blabas, Brett	624	5	624	13	1, 2, 4, 17, 23, MIL1, DAUB
19-1508 - Vol 03, Blabas, Brett	625	16	625	19	1, 17, 23, 24, MIL1, MIL2, DAUB

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
19-1508 - Vol 03, Blabas, Brett	581	4	581	16	**Sage's counterdesignations are applicable to numerous PureWick designations across multiple witnesses and topic areas. Identification of page numbers are exemplary.	Sage Contingent
19-1508 - Vol 03, Blabas, Brett	581	17	582	2		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	582	6	582	13		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	583	2	583	7		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	583	10	583	18		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	583	19	583	25		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	584	12	584	19		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	584	25	585	8		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	585	9	585	13		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	585	14	586	1		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	586	2	586	3		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	586	4	586	17		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	586	18	587	2		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	587	10	587	14		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	588	20	589	7		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	589	8	589	17		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	589	18	589	21		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	590	23	591	11		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	591	12	591	17		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	591	18	592	1		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	592	3	592	11		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	592	14	592	22		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	592	23	593	9		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	593	10	593	24		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	594	1	594	10		Sage Contingent
	594	11	594	17		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	594	24	595	2		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	595	3	595	11		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	595	12	595	12		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	595	14	595	25		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	596	1	596	13		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	597	7	597	15		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	597	22	598	5		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	598	6	598	19		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	598	20	599	1		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	599	2	599	16		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	600	6	600	10		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	600	11	600	23		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	600	24	601	7		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	603	4	603	14		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	603	15	603	24		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	604	7	604	17		Sage Contingent

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
19-1508 - Vol 03, Blabas, Brett	605	10	605	23		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	605	24	606	12		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	606	13	606	17		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	606	18	606	22		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	606	23	607	9		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	607	10	607	20		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	607	24	608	9		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	608	10	608	13		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	608	25	609	2	607-608	Sage Contingent
19-1508 - Vol 03, Blabas, Brett	609	5	609	9		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	609	19	610	6	608-609	Sage Contingent
19-1508 - Vol 03, Blabas, Brett	610	10	610	19		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	613	7	613	10		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	614	4	614	7		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	616	10	616	14	614-616	Sage Contingent
19-1508 - Vol 03, Blabas, Brett	618	8	618	9	612-618	Sage Contingent
19-1508 - Vol 03, Blabas, Brett	620	1	620	3	e.g. 618-620	Sage Contingent
19-1508 - Vol 03, Blabas, Brett	622	20	623	1	e.g., 620-622	Sage Contingent
19-1508 - Vol 03, Blabas, Brett	624	23	625	2		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	626	18	626	24		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	633	18	633	25		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	634	1	634	11		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	634	12	634	23		Sage Contingent
19-1508 - Vol 03, Blabas, Brett	635	11	635	13		Sage Contingent



Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Blabas, Brett 2021-02-23	6	20	6	25	Objection to entirety of transcript to the extent it is being used inconsistently with Sage's MILs or Daubert
Blabas, Brett 2021-02-23	7	2	7	2	
Blabas, Brett 2021-02-23	8	9	8	12	
Blabas, Brett 2021-02-23	13	23	13	24	1, 5, 12, 15, 17, 24, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	14	3	14	11	continued
Blabas, Brett 2021-02-23	14	14	14	23	continued
Blabas, Brett 2021-02-23	30	15	30	19	
Blabas, Brett 2021-02-23	32	7	32	15	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	32	19	32	22	continued
Blabas, Brett 2021-02-23	36	19	36	25	1, 5, 12, 15, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	37	2	37	9	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	37	12	37	13	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	37	14	37	15	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	37	18	37	19	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	37	20	37	21	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	37	24	37	25	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	38	2	38	4	1, 2, 3, 5, 17, 23, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	38	8	38	11	1, 2, 3, 5, 17, 23, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	40	10	40	12	1, 2, 3, 5, 17, MIL1, DAUB
Blabas, Brett 2021-02-23	40	16	40	24	1, 2, 3, 5, 17, 23, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	41	3	41	6	1, 2, 3, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	43	18	43	24	1, 5, 17, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	49	15	49	19	1, 4, 5, 12, 15, 17, 23, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	49	22	49	23	continued
Blabas, Brett 2021-02-23	57	7	57	9	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	57	12	57	21	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	69	22	69	23	1, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	72	8	72	15	1, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	74	14	74	22	1, 4, 12, 15, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	74	25	74	25	continued
Blabas, Brett 2021-02-23	75	2	75	2	continued
Blabas, Brett 2021-02-23	75	21	75	22	1, 3, 5, 17, 23, 24, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	75	25	75	25	continued
Blabas, Brett 2021-02-23	76	2	76	3	continued
Blabas, Brett 2021-02-23	89	10	89	11	1, 2, 3, 5, 17, 23, 24, MIL1, MIL2, MIL3, DAUB
Blabas, Brett 2021-02-23	89	14	89	16	1, 2, 3, 5, 17, 23, 24, MIL1, MIL2, MIL3, DAUB
Blabas, Brett 2021-02-23	89	19	89	19	continued
Blabas, Brett 2021-02-23	89	20	89	25	1, 2, 3, 5, 17, 23, 24, MIL1, MIL2, MIL3, DAUB
Blabas, Brett 2021-02-23	90	2	90	2	continued
Blabas, Brett 2021-02-23	90	5	90	11	1, 2, 3, 5, 17, 23, 24, MIL1, MIL2, MIL3, DAUB
Blabas, Brett 2021-02-23	90	13	90	15	continued
Blabas, Brett 2021-02-23	90	20	90	22	1, 2, 3, 5, 17, 23, 24, MIL1, MIL2, MIL3, DAUB
Blabas, Brett 2021-02-23	90	25	90	25	continued
Blabas, Brett 2021-02-23	91	2	91	2	continued
Blabas, Brett 2021-02-23	91	8	91	9	1, 2, 3, 5, 17, 23, 24, MIL1, MIL2, MIL3, DAUB
Blabas, Brett 2021-02-23	91	11	91	12	continued
Blabas, Brett 2021-02-23	91	13	91	14	1, 2, 3, 5, 17, 23, 24, MIL1, MIL2, MIL3, DAUB
Blabas, Brett 2021-02-23	91	17	91	18	continued
Blabas, Brett 2021-02-23	93	14	93	17	1, 2, 3, 3, 5, 17, 23, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	93	21	93	25	1, 2, 3, 3, 5, 17, 23, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	94	2	94	3	1, 2, 3, 3, 5, 17, 23, 24, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	94	6	94	7	1, 2, 3, 3, 5, 17, 23, 24, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	95	20	95	25	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	96	2	96	2	continued
Blabas, Brett 2021-02-23	97	13	97	24	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	118	17	118	25	1, 4, 12, 15, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	119	2	119	5	1, 4, 17, 23, 24, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	119	6	119	8	1, 3, 4, 5, 17, 23, 24, MIL1, MIL2, DAUB

Blabas, Brett 2021-02-23	119	11	119	11	continued
Blabas, Brett 2021-02-23	122	17	122	25	1, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	123	2	123	2	continued
Blabas, Brett 2021-02-23	123	3	123	6	1, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	123	9	123	23	1, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	124	6	124	13	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	125	23	125	25	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	126	2	126	5	continued
Blabas, Brett 2021-02-23	126	10	126	25	1, 3, 4, 5, 17, 23, 24, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	127	2	127	4	1, 3, 5, 17, 23, 24, MIL1, DAUB
Blabas, Brett 2021-02-23	127	7	127	12	continued
Blabas, Brett 2021-02-23	128	13	128	16	1, 3, 5, 17, 23, 24, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	128	19	128	20	continued
Blabas, Brett 2021-02-23	132	25	132	25	1, 5, 12, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	133	2	133	2	continued
Blabas, Brett 2021-02-23	133	5	133	16	1, 5, 12, 15, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	133	19	133	24	continued
Blabas, Brett 2021-02-23	134	20	134	24	1, 5, 12, 15, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	134	25	134	25	continued
Blabas, Brett 2021-02-23	135	2	135	14	continued
Blabas, Brett 2021-02-23	136	21	136	25	1, 3, 4, 5, 12, 17, 23, 24, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	137	2	137	10	continued
Blabas, Brett 2021-02-23	137	13	137	19	continued
Blabas, Brett 2021-02-23	137	22	137	22	continued
Blabas, Brett 2021-02-23	143	8	143	13	1, 4, 17, 23, DAUB, MIL1, MIL2
Blabas, Brett 2021-02-23	143	20	143	25	1, 4, 17, 23, DAUB, MIL1, MIL2
Blabas, Brett 2021-02-23	144	2	144	8	continued
Blabas, Brett 2021-02-23	144	11	144	25	1, 4, 5, 15, 17, 23, 24, DAUB, MIL1, MIL2
Blabas, Brett 2021-02-23	145	2	145	2	continued
Blabas, Brett 2021-02-23	145	5	145	12	1, 4, 5, 15, 17, 23, 24, DAUB, MIL1, MIL2
Blabas, Brett 2021-02-23	145	16	145	18	1, 4, 5, 15, 17, 23, 24, DAUB, MIL1, MIL2
Blabas, Brett 2021-02-23	145	21	145	22	continued
Blabas, Brett 2021-02-23	146	15	146	21	1, 4, 5, 15, 17, 23, 24, DAUB, MIL1, MIL2
Blabas, Brett 2021-02-23	146	24	146	25	continued
Blabas, Brett 2021-02-23	147	2	147	5	1, 4, 5, 15, 17, 23, 24, DAUB, MIL1, MIL2
Blabas, Brett 2021-02-23	147	8	147	12	1, 4, 5, 15, 17, 23, 24, DAUB, MIL1, MIL2
Blabas, Brett 2021-02-23	147	13	147	22	1, 4, 5, 15, 17, 23, 24, DAUB, MIL1, MIL2
Blabas, Brett 2021-02-23	147	25	147	25	continued
Blabas, Brett 2021-02-23	148	2	148	2	continued
Blabas, Brett 2021-02-23	152	2	152	7	1, 2, 3, 4, 17, 23, DAUB, MIL1
Blabas, Brett 2021-02-23	153	19	153	22	1, 2, 3, 4, 17, 23, DAUB, MIL1
Blabas, Brett 2021-02-23	154	9	154	25	1, 2, 3, 4, 12, 15, 17, 23, DAUB, MIL1
Blabas, Brett 2021-02-23	155	6	155	24	1, 2, 3, 4, 17, 23, DAUB, MIL1
Blabas, Brett 2021-02-23	156	3	156	7	continued
Blabas, Brett 2021-02-23	156	8	156	12	1, 2, 3, 4, 17, 23, DAUB, MIL1
Blabas, Brett 2021-02-23	156	16	156	21	1, 2, 3, 4, 17, 23, DAUB, MIL1
Blabas, Brett 2021-02-23	156	24	156	25	continued
Blabas, Brett 2021-02-23	157	2	157	5	1, 5, 17, 23, DAUB, MIL1
Blabas, Brett 2021-02-23	157	15	157	18	1, 2, 3, 4, 17, 23, DAUB, MIL1
Blabas, Brett 2021-02-23	157	23	157	25	continued
Blabas, Brett 2021-02-23	158	2	158	5	1, 2, 3, 4, 17, 23, DAUB, MIL1
Blabas, Brett 2021-02-23	158	8	158	10	continued
Blabas, Brett 2021-02-23	158	11	158	12	1, 5, 17, 23, DAUB, MIL1
Blabas, Brett 2021-02-23	158	15	158	20	1, 5, 17, 23, DAUB, MIL1
Blabas, Brett 2021-02-23	158	22	158	25	1, 5, 17, 23, DAUB, MIL1
Blabas, Brett 2021-02-23	159	2	159	14	1, 5, 17, 23, DAUB, MIL1
Blabas, Brett 2021-02-23	159	15	159	16	1, 5, 17, 23, DAUB, MIL1
Blabas, Brett 2021-02-23	159	20	159	25	continued
Blabas, Brett 2021-02-23	160	2	160	5	continued
Blabas, Brett 2021-02-23	160	6	160	10	1, 4, 17, 23, MIL1, DAUB

Blabas, Brett 2021-02-23	160	19	160	24	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	161	25	161	25	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	162	2	162	7	continued
Blabas, Brett 2021-02-23	163	9	163	16	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	163	20	163	24	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	164	3	164	4	continued
Blabas, Brett 2021-02-23	164	20	164	25	1, 4, 17, 23, 24, MIL1, DAUB
Blabas, Brett 2021-02-23	165	2	165	4	continued
Blabas, Brett 2021-02-23	165	5	165	17	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	166	17	166	22	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	167	2	167	4	continued
Blabas, Brett 2021-02-23	170	12	170	15	1, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	171	2	171	6	1, 17, 19, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	172	8	172	15	1, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	172	20	172	25	1, 3, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	173	2	173	3	continued
Blabas, Brett 2021-02-23	173	4	173	12	1, 3, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	173	15	173	17	continued
Blabas, Brett 2021-02-23	174	8	174	12	1, 3, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	174	13	174	16	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	174	20	174	25	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	175	2	175	3	continued
Blabas, Brett 2021-02-23	176	8	176	11	1, 3, 4, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	176	14	176	17	continued
Blabas, Brett 2021-02-23	176	18	176	25	1, 3, 4, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	177	2	177	3	continued
Blabas, Brett 2021-02-23	177	4	177	8	1, 3, 4, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	177	11	177	14	continued
Blabas, Brett 2021-02-23	177	15	177	17	1, 3, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	177	21	177	25	continued
Blabas, Brett 2021-02-23	178	2	178	5	continued
Blabas, Brett 2021-02-23	178	20	178	24	1, 3, 4, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	181	12	181	23	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	181	24	181	25	1, 3, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	182	4	182	8	continued
Blabas, Brett 2021-02-23	187	2	187	9	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	190	3	190	11	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	191	6	191	13	1, 3, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	191	17	191	20	continued
Blabas, Brett 2021-02-23	192	23	192	25	1, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	193	2	193	4	1, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	196	17	196	23	1, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	200	19	200	25	1, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	205	22	205	25	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	206	2	206	6	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	208	16	208	22	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	212	6	212	12	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	212	13	212	18	1, 3, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	213	17	213	19	1, 3, 4, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	213	22	213	24	continued
Blabas, Brett 2021-02-23	215	25	215	25	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	216	2	216	10	continued
Blabas, Brett 2021-02-23	217	9	217	15	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	220	4	220	10	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	224	21	224	25	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	225	2	225	3	continued
Blabas, Brett 2021-02-23	230	12	230	18	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	231	22	231	25	1, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	232	2	232	4	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	233	6	233	12	1, 5, 17, 23, MIL1, DAUB

Blabas, Brett 2021-02-23	236	11	236	17	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	238	5	238	10	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	238	13	238	17	continued
Blabas, Brett 2021-02-23	241	2	241	11	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	242	14	242	15	1, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	242	18	242	18	continued
Blabas, Brett 2021-02-23	242	25	242	25	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	243	2	243	5	continued
Blabas, Brett 2021-02-23	243	8	243	11	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	243	14	243	17	continued
Blabas, Brett 2021-02-23	245	2	245	4	1, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	245	20	245	22	1, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	247	2	247	12	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	247	25	247	25	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	248	2	248	7	continued
Blabas, Brett 2021-02-23	248	10	248	11	continued
Blabas, Brett 2021-02-23	248	23	248	25	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	249	2	249	6	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	252	20	252	22	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	252	25	252	25	continued
Blabas, Brett 2021-02-23	253	2	253	2	continued
Blabas, Brett 2021-02-23	255	3	255	5	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	255	10	255	10	continued
Blabas, Brett 2021-02-23	258	8	258	14	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	258	15	258	20	1, 4, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	260	13	260	25	1, 4, 5, 17, 23, 24, MIL1, DAUB
Blabas, Brett 2021-02-23	261	2	261	2	continued
Blabas, Brett 2021-02-23	261	21	261	25	1, 2, 3, 4, 5, 17, 23, 24, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	262	2	262	4	continued
Blabas, Brett 2021-02-23	262	7	262	11	1, 2, 3, 4, 5, 17, 23, 24, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	262	14	262	16	continued
Blabas, Brett 2021-02-23	263	7	263	13	1, 4, 5, 17, 23, 24, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	263	14	263	18	1, 2, 3, 4, 5, 17, 23, 24, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	263	21	263	25	1, 2, 3, 4, 5, 17, 23, 24, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	264	5	264	11	1, 2, 3, 4, 5, 17, 23, 24, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	264	16	264	25	1, 2, 3, 4, 5, 12, 17, 23, 24, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	265	3	265	4	continued
Blabas, Brett 2021-02-23	266	17	266	25	1, 4, 12, 17, 23, 24, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	267	2	267	3	1, 4, 12, 17, 23, 24, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	267	7	267	11	continued
Blabas, Brett 2021-02-23	268	5	268	15	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	268	16	268	25	1, 4, 17, 23, 24, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	269	2	269	6	1, 4, 17, 23, 24, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	269	9	269	13	1, 4, 17, 23, 24, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	269	14	269	17	1, 4, 17, 23, 24, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	269	21	269	25	1, 4, 17, 23, 24, MIL1, MIL2, DAUB
Blabas, Brett 2021-02-23	270	2	270	4	continued
Blabas, Brett 2021-02-23	274	19	274	25	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	276	2	276	10	1, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	276	13	276	22	continued
Blabas, Brett 2021-02-23	277	10	277	21	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	277	24	277	25	continued
Blabas, Brett 2021-02-23	278	2	278	8	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	278	12	278	13	continued
Blabas, Brett 2021-02-23	278	21	278	25	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	279	2	279	4	continued
Blabas, Brett 2021-02-23	279	9	279	14	1, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	279	15	279	20	1, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	282	21	282	25	1, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	283	2	283	4	continued

Blabas, Brett 2021-02-23	283	9	283	13	1, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	287	3	287	14	1, 4, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	287	19	287	25	continued
Blabas, Brett 2021-02-23	288	2	288	4	continued
Blabas, Brett 2021-02-23	288	5	288	10	1, 2, 3, 4, 5, 17
Blabas, Brett 2021-02-23	288	11	288	11	1, 2, 3, 4, 5, 17
Blabas, Brett 2021-02-23	288	15	288	20	2, 3, 5
Blabas, Brett 2021-02-23	288	24	288	25	continued.
Blabas, Brett 2021-02-23	289	2	289	3	continued
Blabas, Brett 2021-02-23	289	4	289	20	1, 2, 3, 4, 17, 18
Blabas, Brett 2021-02-23	289	24	289	25	continued
Blabas, Brett 2021-02-23	290	2	290	10	continued
Blabas, Brett 2021-02-23	290	11	290	16	1, 17
Blabas, Brett 2021-02-23	290	17	290	18	1, 2, 3, 4, 17
Blabas, Brett 2021-02-23	290	21	290	25	continued
Blabas, Brett 2021-02-23	291	2	291	8	1, 2, 3, 4, 17
Blabas, Brett 2021-02-23	291	12	291	25	1, 2, 3, 17
Blabas, Brett 2021-02-23	292	15	292	18	
Blabas, Brett 2021-02-23	292	19	292	25	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	293	7	293	14	1, 12, 15, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	294	3	294	5	1, 2, 5, 12, 15, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	294	8	294	11	continued
Blabas, Brett 2021-02-23	297	6	297	12	1, 5, 12, 15, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	297	15	297	21	1, 5, 12, 15, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	297	24	297	25	continued
Blabas, Brett 2021-02-23	298	2	298	11	1, 5, 12, 15, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	298	14	298	18	1, 5, 12, 15, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	298	21	298	24	1, 5, 12, 15, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	301	13	301	19	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	302	7	302	10	1, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	302	16	302	23	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	303	2	303	3	continued
Blabas, Brett 2021-02-23	303	18	303	21	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	304	3	304	12	1, 4, 12, 15, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	304	23	304	25	1, 5, 12, 15, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	305	2	305	6	continued
Blabas, Brett 2021-02-23	308	12	308	17	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	308	23	308	25	1, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	309	2	309	13	1, 4, 12, 15, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	309	18	309	25	1, 5, 12, 15, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	310	2	310	3	continued
Blabas, Brett 2021-02-23	310	6	310	6	continued
Blabas, Brett 2021-02-23	310	9	310	13	1, 5, 12, 15, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	310	16	310	25	1, 5, 12, 15, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	311	2	311	4	1, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	319	15	319	16	1, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	319	22	319	25	1, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	320	2	320	7	1, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	325	7	325	24	1, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	326	3	326	11	1, 3, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2021-02-23	326	14	326	17	continued

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
					**Many of Sage's counterdesignations are applicable to numerous PureWick designations across multiple witnesses and topic areas. Identification of page numbers are exemplary.	
Blabas, Brett 2021-02-23	27	13	27	21		Sage Counter Designations
Blabas, Brett 2021-02-23	28	23	29	11	8	Sage Counter Designations
Blabas, Brett 2021-02-23	29	21	30	10	8	Sage Counter Designations
Blabas, Brett 2021-02-23	31	14	31	18	28-29	Sage Counter Designations
Blabas, Brett 2021-02-23	33	18	33	22	8	Sage Counter Designations
Blabas, Brett 2021-02-23	34	23	35	3	8	Sage Counter Designations
Blabas, Brett 2021-02-23	41	16	41	24	eg 38-41	Sage Contingent
Blabas, Brett 2021-02-23	49	24	50	13	e.g., 49	Sage Contingent
Blabas, Brett 2021-02-23	50	14	50	15	continued	Sage Contingent
Blabas, Brett 2021-02-23	50	16	50	21	49	Sage Contingent
Blabas, Brett 2021-02-23	50	25	51	7	continued	Sage Contingent
Blabas, Brett 2021-02-23	57	22	57	25	57	Sage Contingent
Blabas, Brett 2021-02-23	58	4	58	5	57	Sage Contingent
Blabas, Brett 2021-02-23	68	3	68	13	passim	Sage Contingent
Blabas, Brett 2021-02-23	68	25	69	12	passim	Sage Contingent
Blabas, Brett 2021-02-23	73	22	74	7	72-73	Sage Contingent
Blabas, Brett 2021-02-23	75	3	75	8	74-75	Sage Contingent
Blabas, Brett 2021-02-23	75	9	75	20	74-75	Sage Contingent
Blabas, Brett 2021-02-23	76	22	77	6	74-75	Sage Contingent
Blabas, Brett 2021-02-23	77	7	77	21	74-75	Sage Contingent
Blabas, Brett 2021-02-23	77	22	78	5	74-75	Sage Contingent
Blabas, Brett 2021-02-23	80	22	81	3	74-75	Sage Contingent
Blabas, Brett 2021-02-23	86	2	86	8	74-75	Sage Contingent
Blabas, Brett 2021-02-23	88	6	88	21	74-75	Sage Contingent
Blabas, Brett 2021-02-23	88	22	88	22	continued	Sage Contingent
	91	19	92	2	91	Sage Contingent
Blabas, Brett 2021-02-23	92	3	92	5	e.g., 91-92	Sage Contingent
Blabas, Brett 2021-02-23	92	10	92	17	e.g. 91-92	Sage Contingent
Blabas, Brett 2021-02-23	92	18	92	19	e.g. 91-92	Sage Contingent
Blabas, Brett 2021-02-23	92	23	93	4	e.g. 91-92	Sage Contingent
Blabas, Brett 2021-02-23	112	9	112	19	passim	Sage Contingent
Blabas, Brett 2021-02-23	113	12	113	18	e.g., 74-75	Sage Contingent
Blabas, Brett 2021-02-23	114	18	115	5	e.g., 74-75	Sage Contingent
Blabas, Brett 2021-02-23	119	21	120	9	eg 118-119	Sage Contingent
Blabas, Brett 2021-02-23	120	10	120	23	e.g. 118-119	Sage Contingent
Blabas, Brett 2021-02-23	127	13	127	21	75, 126-127	Sage Contingent
Blabas, Brett 2021-02-23	128	21	129	2	128-129	Sage Contingent
Blabas, Brett 2021-02-23	137	23	138	7	e.g. 136-137	Sage Contingent
Blabas, Brett 2021-02-23	138	17	138	24	136-137	Sage Contingent
Blabas, Brett 2021-02-23	148	3	148	11	e.g., 147-148	Sage Contingent
Blabas, Brett 2021-02-23	148	21	149	7	e.g., 147-148	Sage Contingent
Blabas, Brett 2021-02-23	149	8	149	12	e.g., 147-148	Sage Contingent
Blabas, Brett 2021-02-23	149	18	149	25	e.g., 147-148	Sage Contingent
Blabas, Brett 2021-02-23	150	2	150	14	e.g., 147-148	Sage Contingent



Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Blabas, Brett 2021-02-23	157	6	157	14	e.g., 157	Sage Contingent
Blabas, Brett 2021-02-23	175	15	175	18	173-175	Sage Contingent
Blabas, Brett 2021-02-23	179	21	180	10	e.g. 177-178	Sage Contingent
Blabas, Brett 2021-02-23	180	11	180	23	e.g. 177-178	Sage Contingent
Blabas, Brett 2021-02-23	180	24	181	11	e.g., 177-178	Sage Contingent
Blabas, Brett 2021-02-23	182	9	182	13	e.g., 180-181	Sage Contingent
Blabas, Brett 2021-02-23	183	6	183	20	e.g., 180-181	Sage Contingent
Blabas, Brett 2021-02-23	184	10	184	17	e.g., 180-181	Sage Contingent
Blabas, Brett 2021-02-23	185	17	185	25	e.g., 180-181	Sage Contingent
Blabas, Brett 2021-02-23	186	2	186	15	e.g., 180-181	Sage Contingent
Blabas, Brett 2021-02-23	187	17	187	20	e.g., 187	Sage Contingent
Blabas, Brett 2021-02-23	188	2	188	9	e.g., 187	Sage Contingent
Blabas, Brett 2021-02-23	190	12	190	16	e.g. 190	Sage Contingent
Blabas, Brett 2021-02-23	192	12	192	22	190-191	Sage Contingent
Blabas, Brett 2021-02-23	194	3	194	14	192-193	Sage Contingent
Blabas, Brett 2021-02-23	197	5	197	9	196	Sage Contingent
Blabas, Brett 2021-02-23	197	21	198	6	196	Sage Contingent
Blabas, Brett 2021-02-23	201	17	202	7	200	Sage Contingent
Blabas, Brett 2021-02-23	202	8	202	11	200	Sage Contingent
Blabas, Brett 2021-02-23	205	8	205	21	200	Sage Contingent
Blabas, Brett 2021-02-23	206	19	207	6	205-206	Sage Contingent
Blabas, Brett 2021-02-23	207	7	207	17	205-206	Sage Contingent
Blabas, Brett 2021-02-23	209	2	209	6	208	Sage Contingent
Blabas, Brett 2021-02-23	209	16	209	25	208	Sage Contingent
Blabas, Brett 2021-02-23	212	19	212	23	212	Sage Contingent
Blabas, Brett 2021-02-23	215	11	215	20	213	Sage Contingent
Blabas, Brett 2021-02-23	216	15	216	25	215-216	Sage Contingent
Blabas, Brett 2021-02-23	217	20	217	24	217	Sage Contingent
Blabas, Brett 2021-02-23	218	5	218	16	217	Sage Contingent
Blabas, Brett 2021-02-23	219	10	219	21	217	Sage Contingent
Blabas, Brett 2021-02-23	220	17	220	23	220	Sage Contingent
Blabas, Brett 2021-02-23	222	23	223	14	220	Sage Contingent
Blabas, Brett 2021-02-23	223	15	223	15	220	Sage Contingent
Blabas, Brett 2021-02-23	224	4	224	13	220	Sage Contingent
Blabas, Brett 2021-02-23	225	8	225	10	224	Sage Contingent
Blabas, Brett 2021-02-23	226	2	226	13	224	Sage Contingent
Blabas, Brett 2021-02-23	226	20	227	6	224	Sage Contingent
Blabas, Brett 2021-02-23	231	8	231	21	e.g., 230	Sage Contingent
Blabas, Brett 2021-02-23	232	8	232	12	231-232	Sage Contingent
Blabas, Brett 2021-02-23	233	18	233	22	233	Sage Contingent
Blabas, Brett 2021-02-23	234	21	235	7	233	Sage Contingent
Blabas, Brett 2021-02-23	237	8	237	16	236	Sage Contingent
Blabas, Brett 2021-02-23	238	21	238	23	238	Sage Contingent
Blabas, Brett 2021-02-23	239	22	240	7	e.g., 238	Sage Contingent
Blabas, Brett 2021-02-23	240	8	240	16	e.g., 238	Sage Contingent
Blabas, Brett 2021-02-23	240	17	240	25	e.g., 238	Sage Contingent
Blabas, Brett 2021-02-23	241	15	241	17	241	Sage Contingent
Blabas, Brett 2021-02-23	241	21	242	6	e.g., 241	Sage Contingent
Blabas, Brett 2021-02-23	243	18	243	22	e.g., 242-243	Sage Contingent
Blabas, Brett 2021-02-23	244	17	244	25	e.g., 242-243	Sage Contingent
Blabas, Brett 2021-02-23	261	3	261	9	e.g., 260-261	Sage Contingent

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Blabas, Brett 2021-02-23	261	10	261	20	e.g., 260-261	Sage Contingent
Blabas, Brett 2021-02-23	262	17	262	20	260-262	Sage Contingent
Blabas, Brett 2021-02-23	262	23	263	6	260-262	Sage Contingent
Blabas, Brett 2021-02-23	267	12	268	2	e.g., 264-266	Sage Contingent
Blabas, Brett 2021-02-23	268	3	268	4	continued	Sage Contingent
Blabas, Brett 2021-02-23	276	23	277	9	276	Sage Contingent
Blabas, Brett 2021-02-23	283	14	283	21	283	Sage Contingent
Blabas, Brett 2021-02-23	283	22	284	9	283	Sage Contingent
Blabas, Brett 2021-02-23	284	10	284	17	283	Sage Contingent
Blabas, Brett 2021-02-23	292	7	292	14	289-290	Sage Contingent
Blabas, Brett 2021-02-23	293	15	293	20	292-293	Sage Contingent
Blabas, Brett 2021-02-23	294	19	295	2	292-293	Sage Contingent
Blabas, Brett 2021-02-23	295	18	296	2	e.g., 292-293	Sage Contingent
Blabas, Brett 2021-02-23	296	17	297	5	e.g., 292-293	Sage Contingent
Blabas, Brett 2021-02-23	299	22	300	9	292-298	Sage Contingent
Blabas, Brett 2021-02-23	303	4	303	10	301-303	Sage Contingent
Blabas, Brett 2021-02-23	304	17	304	22	303-304	Sage Contingent
Blabas, Brett 2021-02-23	305	13	305	20	302-305	Sage Contingent
Blabas, Brett 2021-02-23	305	21	305	24	302-305	Sage Contingent
Blabas, Brett 2021-02-23	312	12	312	17	311	Sage Contingent
Blabas, Brett 2021-02-23	314	7	314	13	311	Sage Contingent
Blabas, Brett 2021-02-23	320	8	320	18	319-320	Sage Contingent
Blabas, Brett 2021-02-23	321	3	321	18	319-320	Sage Contingent
Blabas, Brett 2021-02-23	321	19	321	19	319-320	Sage Contingent



Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Blabas, Brett 2023-08-31	5	6	5	22	Objection to entirety of transcript to the extent it is being used inconsistently with Sage's MILs or Daubert
Blabas, Brett 2023-08-31	19	14	19	16	1, 2, 3, 17, 23, MIL1, DAUB
Blabas, Brett 2023-08-31	19	20	19	20	continued
Blabas, Brett 2023-08-31	19	22	20	1	1, 2, 3, 17, 23, MIL1, DAUB
Blabas, Brett 2023-08-31	20	2	20	3	1, 17
Blabas, Brett 2023-08-31	20	6	20	7	continued
Blabas, Brett 2023-08-31	20	9	20	12	1, 2, 3, 17, 23, MIL1, DAUB
Blabas, Brett 2023-08-31	23	15	23	17	1, 2, 3, 17, 23, MIL1, DAUB
Blabas, Brett 2023-08-31	23	20	23	20	continued
Blabas, Brett 2023-08-31	32	21	33	4	1, 2, 3, 17, 23, 25, MIL1, DAUB
Blabas, Brett 2023-08-31	33	17	33	20	1, 2, 3, 17, 23, 25, MIL1, DAUB
Blabas, Brett 2023-08-31	34	3	34	14	1, 2, 3, 17, 23, 25, MIL1, DAUB
Blabas, Brett 2023-08-31	35	3	35	3	
Blabas, Brett 2023-08-31	36	2	36	10	1, 2, 3, 17, 23, MIL1, DAUB
Blabas, Brett 2023-08-31	39	19	40	1	1, 2, 3, 17, 23, 25, MIL1, DAUB
Blabas, Brett 2023-08-31	40	5	40	5	1, 2, 3, 17, 23, MIL1, DAUB
Blabas, Brett 2023-08-31	40	12	40	17	19, 1, 17, 23, MIL1, DAUB
Blabas, Brett 2023-08-31	40	22	41	13	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2023-08-31	42	20	42	22	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2023-08-31	43	6	43	9	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2023-08-31	43	18	44	4	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2023-08-31	44	5	44	11	1, 2, 3, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2023-08-31	44	15	44	18	continued
Blabas, Brett 2023-08-31	53	10	53	14	1, 4, 17, 23, 25, MIL1, DAUB
Blabas, Brett 2023-08-31	53	19	54	3	1, 4, 17, 23, 25, MIL1, DAUB
Blabas, Brett 2023-08-31	54	17	54	18	1, 4, 17, 23, 25, MIL1, DAUB
Blabas, Brett 2023-08-31	54	22	54	24	continued
Blabas, Brett 2023-08-31	59	24	60	15	1, 4, 17, 23, MIL1, DAUB
Blabas, Brett 2023-08-31	169	7	169	13	1, 2, 3, 4, 17
Blabas, Brett 2023-08-31	169	17	169	19	continued
Blabas, Brett 2023-08-31	171	6	171	8	1, 2, 3, 5, 17
Blabas, Brett 2023-08-31	171	11	171	18	continued
Blabas, Brett 2023-08-31	171	20	171	22	1, 2, 3, 5, 17
Blabas, Brett 2023-08-31	172	1	172	2	continued
Blabas, Brett 2023-08-31	174	24	175	4	1, 2, 3, 5, 17
Blabas, Brett 2023-08-31	175	8	175	11	continued
Blabas, Brett 2023-08-31	178	20	179	3	1, 2, 3, 4, 17
Blabas, Brett 2023-08-31	179	8	179	13	1, 4, 17
Blabas, Brett 2023-08-31	183	6	183	7	1, 2, 3, 4, 17
Blabas, Brett 2023-08-31	183	12	183	16	continued
Blabas, Brett 2023-08-31	183	20	183	22	continued
Blabas, Brett 2023-08-31	183	24	184	16	1, 2, 3, 4, 5, 17, 23, MIL1, DAUB
Blabas, Brett 2023-08-31	185	4	185	6	1, 2, 3, 4, 17
Blabas, Brett 2023-08-31	185	11	185	14	1, 2, 3, 4, 17
Blabas, Brett 2023-08-31	185	19	185	20	continued
Blabas, Brett 2023-08-31	185	22	186	19	1, 2, 3, 4, 5, 17
Blabas, Brett 2023-08-31	186	20	186	21	
Blabas, Brett 2023-08-31	186	24	187	1	
Blabas, Brett 2023-08-31	188	5	188	16	1, 3, 5, 17
Blabas, Brett 2023-08-31	194	5	194	7	1, 2, 3, 4, 17
Blabas, Brett 2023-08-31	194	15	196	8	1, 4, 5, 17
Blabas, Brett 2023-08-31	197	10	197	21	1, 3, 4, 5, 17

Blabas, Brett 2023-08-31	197	24	198	1	continued
Blabas, Brett 2023-08-31	198	3	198	7	1, 17
Blabas, Brett 2023-08-31	200	6	200	8	1, 3, 4, 5, 17
Blabas, Brett 2023-08-31	200	13	200	20	1, 3, 4, 17
Blabas, Brett 2023-08-31	203	20	203	22	1, 4, 5, 17
Blabas, Brett 2023-08-31	204	3	204	3	1, 17
Blabas, Brett 2023-08-31	204	9	205	4	1, 2, 3, 4, 5, 17
Blabas, Brett 2023-08-31	205	10	205	14	1, 4, 17
Blabas, Brett 2023-08-31	210	1	210	6	1, 2, 3, 4, 17
Blabas, Brett 2023-08-31	210	15	210	16	1, 17, MIL1, DAUB
Blabas, Brett 2023-08-31	210	19	210	22	1, 17, MIL1, DAUB
Blabas, Brett 2023-08-31	212	13	212	21	1, 4, 17
Blabas, Brett 2023-08-31	216	3	216	15	1, 4, 5, 17
Blabas, Brett 2023-08-31	216	23	217	2	1, 4, 5, 17
Blabas, Brett 2023-08-31	217	6	217	9	continued
Blabas, Brett 2023-08-31	217	11	217	24	1, 17
Blabas, Brett 2023-08-31	230	7	230	9	1, 4, 5, 17
Blabas, Brett 2023-08-31	230	14	231	2	1, 2, 3, 4, 5, 17

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Blabas, Brett 2023-08-31	20	16	20	21	**Many of Sage's counterdesignations are applicable to numerous PureWick designations across multiple witnesses and topic areas. Identification of page numbers are exemplary.	Sage Counter Designations
Blabas, Brett 2023-08-31	24	10	24	12		Sage Counter Designations
Blabas, Brett 2023-08-31	29	16	29	20		Sage Counter Designations
Blabas, Brett 2023-08-31	29	21	29	23		Sage Counter Designations
Blabas, Brett 2023-08-31	29	24	29	24		Sage Counter Designations
Blabas, Brett 2023-08-31	30	6	30	7		Sage Counter Designations
Blabas, Brett 2023-08-31	31	4	31	9		Sage Counter Designations
Blabas, Brett 2023-08-31	31	16	32	1		Sage Counter Designations
Blabas, Brett 2023-08-31	32	2	32	4		Sage Counter Designations
Blabas, Brett 2023-08-31	35	9	35	11	33-34	Sage Contingent
Blabas, Brett 2023-08-31	35	18	35	22	33-34	Sage Contingent
Blabas, Brett 2023-08-31	42	5	42	12	39-40	Sage Contingent
Blabas, Brett 2023-08-31	42	14	42	19	39-40	Sage Contingent
Blabas, Brett 2023-08-31	53	5	53	9		Sage Contingent
Blabas, Brett 2023-08-31	56	3	56	13		Sage Contingent
Blabas, Brett 2023-08-31	86	18	86	23		Sage Contingent
Blabas, Brett 2023-08-31	87	14	87	22		Sage Contingent
Blabas, Brett 2023-08-31	87	23	88	2		Sage Contingent
Blabas, Brett 2023-08-31	89	17	89	22		Sage Contingent
Blabas, Brett 2023-08-31	94	18	95	3		Sage Contingent
Blabas, Brett 2023-08-31	102	10	102	18		Sage Contingent
Blabas, Brett 2023-08-31	106	5	106	10		Sage Contingent
Blabas, Brett 2023-08-31	106	18	106	21		Sage Contingent
Blabas, Brett 2023-08-31	107	5	107	14		Sage Contingent
Blabas, Brett 2023-08-31	153	3	153	7		Sage Contingent
	154	23	155	7		Sage Counter Designations
Blabas, Brett 2023-08-31	170	17	171	4	169	Sage Contingent
Blabas, Brett 2023-08-31	173	17	173	24		Sage Contingent
Blabas, Brett 2023-08-31	174	20	174	23	e.g., 174-175	Sage Counter Designations
Blabas, Brett 2023-08-31	175	23	176	5	e.g., 174-177	Sage Counter Designations
Blabas, Brett 2023-08-31	177	14	177	18	e.g., 174-177	Sage Counter Designations
Blabas, Brett 2023-08-31	180	1	180	6	179	Sage Counter Designations
Blabas, Brett 2023-08-31	180	17	180	24	178-179	Sage Counter Designations
Blabas, Brett 2023-08-31	181	13	181	23	178-179	Sage Counter Designations
Blabas, Brett 2023-08-31	181	24	182	4	178-179	Sage Counter Designations
Blabas, Brett 2023-08-31	184	17	184	20	183	Sage Contingent; Sage Counter Designations
Blabas, Brett 2023-08-31	187	13	187	15	185-186	Sage Counter Designations
Blabas, Brett 2023-08-31	188	17	188	21		Sage Counter Designations
Blabas, Brett 2023-08-31	188	24	188	24		Sage Counter Designations
Blabas, Brett 2023-08-31	190	12	190	17		Sage Counter Designations
Blabas, Brett 2023-08-31	190	18	191	7	Exhibit 76	Sage Contingent
Blabas, Brett 2023-08-31	191	14	191	19	Exhibit 76	Sage Contingent
Blabas, Brett 2023-08-31	193	16	194	4		Sage Counter Designations
Blabas, Brett 2023-08-31	196	9	196	10	194-196	Sage Counter Designations
Blabas, Brett 2023-08-31	196	14	196	16	194-196	Sage Counter Designations
Blabas, Brett 2023-08-31	196	18	196	23	194-196	Sage Counter Designations
Blabas, Brett 2023-08-31	200	21	200	22	200-203	Sage Contingent

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Blabas, Brett 2023-08-31	202	9	202	16	200	Sage Contingent
Blabas, Brett 2023-08-31	203	9	203	15	200	Sage Contingent
Blabas, Brett 2023-08-31	205	15	205	22	203-204	Sage Contingent
Blabas, Brett 2023-08-31	210	7	210	13	203-210	Sage Contingent
Blabas, Brett 2023-08-31	211	9	211	17	203-210	Sage Contingent
Blabas, Brett 2023-08-31	211	22	211	23	continued	Sage Contingent
Blabas, Brett 2023-08-31	212	1	212	11	203-212	Sage Contingent
Blabas, Brett 2023-08-31	214	20	215	6	203-215	Sage Contingent
Blabas, Brett 2023-08-31	215	8	215	15	203-215	Sage Contingent
Blabas, Brett 2023-08-31	222	18	222	24		Sage Counter Designations
Blabas, Brett 2023-08-31	228	21	229	11		Sage Contingent
Blabas, Brett 2023-08-31	231	3	231	4		Sage Counter Designations
Blabas, Brett 2023-08-31	231	11	231	15		Sage Counter Designations
Blabas, Brett 2023-08-31	232	15	232	20		Sage Counter Designations
Blabas, Brett 2023-08-31	273	23	274	2		Sage Counter Designations
Blabas, Brett 2023-08-31	274	3	274	8		Sage Counter Designations
Blabas, Brett 2023-08-31	274	9	274	13		Sage Counter Designations
Blabas, Brett 2023-08-31	274	16	275	3		Sage Counter Designations
Blabas, Brett 2023-08-31	275	4	275	7	see PW1 transcript designations	Sage Contingent
Blabas, Brett 2023-08-31	275	11	275	17		Sage Contingent
Blabas, Brett 2023-08-31	275	19	276	7		Sage Contingent
Blabas, Brett 2023-08-31	276	11	276	18		Sage Contingent
Blabas, Brett 2023-08-31	276	20	276	21		Sage Contingent
Blabas, Brett 2023-08-31	276	24	277	3		Sage Contingent
Blabas, Brett 2023-08-31	277	6	277	15		Sage Contingent
Blabas, Brett 2023-08-31	279	18	279	22		Sage Contingent
Blabas, Brett 2023-08-31	280	2	280	13		Sage Contingent
Blabas, Brett 2023-08-31	280	14	280	16		Sage Contingent
Blabas, Brett 2023-08-31	280	21	280	24		Sage Contingent
Blabas, Brett 2023-08-31	281	5	281	11		Sage Contingent
Blabas, Brett 2023-08-31	281	15	281	22		Sage Contingent
Blabas, Brett 2023-08-31	282	1	282	2		Sage Contingent
Blabas, Brett 2023-08-31	282	4	282	8		Sage Contingent
Blabas, Brett 2023-08-31	282	11	282	13		Sage Contingent
Blabas, Brett 2023-08-31	282	16	284	8		Sage Contingent
Blabas, Brett 2023-08-31	284	10	284	12		Sage Contingent
Blabas, Brett 2023-08-31	284	16	285	2		Sage Contingent
Blabas, Brett 2023-08-31	285	3	285	20		Sage Contingent
Blabas, Brett 2023-08-31	285	21	285	22		Sage Contingent
Blabas, Brett 2023-08-31	286	17	287	5		Sage Contingent
Blabas, Brett 2023-08-31	287	6	287	15		Sage Contingent
Blabas, Brett 2023-08-31	287	23	288	1		Sage Contingent
Blabas, Brett 2023-08-31	288	5	288	10		Sage Contingent
Blabas, Brett 2023-08-31	288	12	289	2		Sage Contingent
Blabas, Brett 2023-08-31	289	3	289	17		Sage Contingent
Blabas, Brett 2023-08-31	289	18	289	19		Sage Contingent
Blabas, Brett 2023-08-31	289	23	290	7		Sage Contingent
Blabas, Brett 2023-08-31	290	8	290	19		Sage Contingent
Blabas, Brett 2023-08-31	291	1	291	4		Sage Contingent
Blabas, Brett 2023-08-31	291	8	291	9		Sage Contingent
Blabas, Brett 2023-08-31	291	17	292	6		Sage Contingent
Blabas, Brett 2023-08-31	292	7	292	12		Sage Contingent
Blabas, Brett 2023-08-31	292	15	292	22		Sage Contingent
Blabas, Brett 2023-08-31	292	24	293	1		Sage Contingent

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Blabas, Brett 2023-08-31	293	11	293	20		Sage Contingent
Blabas, Brett 2023-08-31	294	15	295	1		Sage Contingent
Blabas, Brett 2023-08-31	295	13	295	20		Sage Contingent
Blabas, Brett 2023-08-31	295	21	296	8		Sage Contingent
Blabas, Brett 2023-08-31	296	9	296	10		Sage Contingent
Blabas, Brett 2023-08-31	296	14	296	23		Sage Contingent
Blabas, Brett 2023-08-31	297	1	297	6		Sage Counter Designations
Blabas, Brett 2023-08-31	297	7	297	8		Sage Counter Designations
Blabas, Brett 2023-08-31	297	12	297	17		Sage Counter Designations
Blabas, Brett 2023-08-31	297	20	297	24		Sage Counter Designations
Blabas, Brett 2023-08-31	298	4	298	7		Sage Counter Designations
Blabas, Brett 2023-08-31	298	8	298	13		Sage Counter Designations
Blabas, Brett 2023-08-31	298	16	298	19		Sage Counter Designations
Blabas, Brett 2023-08-31	298	22	299	2		Sage Counter Designations
Blabas, Brett 2023-08-31	300	14	300	17		Sage Counter Designations
Blabas, Brett 2023-08-31	302	1	302	3		Sage Counter Designations
Blabas, Brett 2023-08-31	302	20	302	23		Sage Counter Designations
Blabas, Brett 2023-08-31	303	13	303	17		Sage Counter Designations
Blabas, Brett 2023-08-31	303	20	303	20		Sage Counter Designations
Blabas, Brett 2023-08-31	304	1	304	3		Sage Counter Designations
Blabas, Brett 2023-08-31	304	6	304	6		Sage Counter Designations
Blabas, Brett 2023-08-31	304	11	304	14	Exhibit 170	Sage Contingent
Blabas, Brett 2023-08-31	304	17	304	19		Sage Contingent
Blabas, Brett 2023-08-31	304	23	304	24		Sage Contingent
Blabas, Brett 2023-08-31	305	2	305	5		Sage Contingent
Blabas, Brett 2023-08-31	305	8	305	14		Sage Contingent
Blabas, Brett 2023-08-31	305	17	305	18		Sage Contingent
Blabas, Brett 2023-08-31	305	21	306	1		Sage Contingent
Blabas, Brett 2023-08-31	306	4	306	7		Sage Counter Designations
Blabas, Brett 2023-08-31	306	11	306	16		Sage Counter Designations
Blabas, Brett 2023-08-31	306	24	307	5		Sage Counter Designations
Blabas, Brett 2023-08-31	307	10	307	13		Sage Counter Designations
Blabas, Brett 2023-08-31	307	16	307	19		Sage Contingent
Blabas, Brett 2023-08-31	307	22	308	1		Sage Counter Designations
Blabas, Brett 2023-08-31	309	4	309	7		Sage Contingent
Blabas, Brett 2023-08-31	309	23	310	10		Sage Contingent
Blabas, Brett 2023-08-31	310	16	310	18		Sage Contingent
Blabas, Brett 2023-08-31	310	22	311	10		Sage Contingent
Blabas, Brett 2023-08-31	311	18	311	20		Sage Contingent
Blabas, Brett 2023-08-31	311	24	312	8		Sage Contingent
Blabas, Brett 2023-08-31	312	10	312	19		Sage Contingent
Blabas, Brett 2023-08-31	312	23	313	11		Sage Contingent
Blabas, Brett 2023-08-31	313	12	313	23		Sage Contingent
Blabas, Brett 2023-08-31	314	6	314	9		Sage Contingent
Blabas, Brett 2023-08-31	314	16	314	19		Sage Contingent
Blabas, Brett 2023-08-31	314	23	315	2		Sage Contingent
Blabas, Brett 2023-08-31	315	15	315	16		Sage Contingent
Blabas, Brett 2023-08-31	315	24	316	1		Sage Contingent
Blabas, Brett 2023-08-31	316	14	316	24		Sage Contingent
Blabas, Brett 2023-08-31	317	12	317	15		Sage Contingent
Blabas, Brett 2023-08-31	317	19	317	23		Sage Contingent
Blabas, Brett 2023-08-31	317	24	318	5		Sage Contingent
Blabas, Brett 2023-08-31	318	9	318	23		Sage Contingent
Blabas, Brett 2023-08-31	318	24	319	4		Sage Contingent
Blabas, Brett 2023-08-31	319	18	319	19		Sage Contingent

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Blabas, Brett 2023-08-31	319	23	320	8		Sage Contingent
Blabas, Brett 2023-08-31	320	9	320	11		Sage Contingent
Blabas, Brett 2023-08-31	320	14	320	17		Sage Contingent
Blabas, Brett 2023-08-31	320	20	321	2		Sage Contingent
Blabas, Brett 2023-08-31	321	3	321	6		Sage Contingent
Blabas, Brett 2023-08-31	321	9	321	12		Sage Contingent
Blabas, Brett 2023-08-31	321	15	321	23		Sage Contingent
Blabas, Brett 2023-08-31	322	1	322	3		Sage Contingent
Blabas, Brett 2023-08-31	323	3	323	11		Sage Contingent
Blabas, Brett 2023-08-31	323	12	323	18		Sage Contingent
Blabas, Brett 2023-08-31	324	2	324	7		Sage Contingent
Blabas, Brett 2023-08-31	324	10	324	11		Sage Contingent
Blabas, Brett 2023-08-31	324	14	324	14		Sage Contingent
Blabas, Brett 2023-08-31	324	18	324	20		Sage Contingent
Blabas, Brett 2023-08-31	324	23	325	4		Sage Contingent
Blabas, Brett 2023-08-31	325	7	325	7		Sage Contingent
Blabas, Brett 2023-08-31	325	22	326	1		Sage Contingent
Blabas, Brett 2023-08-31	326	4	326	14		Sage Contingent
Blabas, Brett 2023-08-31	326	19	327	1		Sage Contingent
Blabas, Brett 2023-08-31	327	4	327	6		Sage Contingent
Blabas, Brett 2023-08-31	327	9	327	9		Sage Contingent
Blabas, Brett 2023-08-31	328	8	328	10		Sage Contingent
Blabas, Brett 2023-08-31	328	13	328	16		Sage Contingent
Blabas, Brett 2023-08-31	329	23	329	24		Sage Contingent
Blabas, Brett 2023-08-31	330	3	330	4		Sage Contingent
Blabas, Brett 2023-08-31	330	6	330	7		Sage Contingent
Blabas, Brett 2023-08-31	330	10	330	14		Sage Contingent
Blabas, Brett 2023-08-31	330	17	330	20		Sage Contingent
Blabas, Brett 2023-08-31	330	23	331	3		Sage Contingent
Blabas, Brett 2023-08-31	331	6	331	6		Sage Contingent
Blabas, Brett 2023-08-31	331	14	331	16		Sage Contingent
Blabas, Brett 2023-08-31	331	19	331	23		Sage Contingent
Blabas, Brett 2023-08-31	334	5	334	8		Sage Contingent
Blabas, Brett 2023-08-31	335	4	335	12		Sage Contingent
Blabas, Brett 2023-08-31	336	14	336	17		Sage Contingent
Blabas, Brett 2023-08-31	336	21	336	24		Sage Contingent
Blabas, Brett 2023-08-31	337	20	337	21		Sage Contingent
Blabas, Brett 2023-08-31	337	24	338	7		Sage Contingent
Blabas, Brett 2023-08-31	338	8	338	14		Sage Contingent

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Bobay, Jason 2021-04-23	7	3	7	9	Entirety of transcript to the extent it is being used inconsistently with Sage's MILs/DAUB
Bobay, Jason 2021-04-23	14	7	14	9	
Bobay, Jason 2021-04-23	15	22	16	2	
Bobay, Jason 2021-04-23	25	20	25	24	1, 17, MIL2
Bobay, Jason 2021-04-23	30	16	30	23	1, 17, MIL2
Bobay, Jason 2021-04-23	33	8	33	13	1, 2, 3, 5, 17, MIL1, MIL2
Bobay, Jason 2021-04-23	36	9	36	20	1, 2, 4, 17, MIL1, MIL2
Bobay, Jason 2021-04-23	36	24	37	8	1, 2, 4, 17, 24, MIL1, MIL2, MIL3
Bobay, Jason 2021-04-23	37	11	37	14	1, 2, 3, 4, 17, MIL1, MIL2
Bobay, Jason 2021-04-23	37	18	37	18	continued
Bobay, Jason 2021-04-23	39	10	39	15	1, 2, 3, 4, 17, 24, MIL1, MIL2, MIL3
Bobay, Jason 2021-04-23	39	19	39	23	1, 2, 3, 4, 17, 24, MIL1, MIL2, MIL3
Bobay, Jason 2021-04-23	40	4	40	18	1, 2, 3, 17, MIL1, MIL2, MIL3
Bobay, Jason 2021-04-23	42	9	42	18	1, 2, 3, 4, 5, 17, 24, MIL1, MIL2, MIL3
Bobay, Jason 2021-04-23	43	3	43	7	1, 17, MIL1, MIL2, MIL3
Bobay, Jason 2021-04-23	43	25	44	4	1, 4, 5, 12, 17, 24, MIL1, MIL2, MIL3
Bobay, Jason 2021-04-23	44	8	44	9	continued
Bobay, Jason 2021-04-23	46	20	46	25	1, 2, 3, 17, MIL2
Bobay, Jason 2021-04-23	47	2	47	7	continued
Bobay, Jason 2021-04-23	47	15	47	17	1, 2, 3, 15, 17, MIL2
Bobay, Jason 2021-04-23	49	20	49	25	1, 17, MIL2
Bobay, Jason 2021-04-23	50	2	50	3	continued
Bobay, Jason 2021-04-23	64	22	64	25	1, 2, 3, 4, 17, MIL1, MIL2
Bobay, Jason 2021-04-23	65	2	65	4	1, 2, 3, 4, 17, MIL1, MIL2
Bobay, Jason 2021-04-23	71	15	71	18	1, 2, 3, 4, 17, 24, MIL1, MIL2, MIL3
Bobay, Jason 2021-04-23	71	20	71	24	1, 17, MIL2
Bobay, Jason 2021-04-23	72	3	72	3	continued
Bobay, Jason 2021-04-23	72	7	72	15	1, 2, 3, 4, 17, MIL2
Bobay, Jason 2021-04-23	72	18	73	4	1, 2, 3, 4, 17, 24, MIL1, MIL2
Bobay, Jason 2021-04-23	73	7	73	17	1, 2, 3, 4, 5, 17, 24, MIL1, MIL2
Bobay, Jason 2021-04-23	78	10	78	16	1, 2, 3, 4, 17, 24, MIL1, MIL2
Bobay, Jason 2021-04-23	79	4	79	6	1, 3, 17, 24, MIL1, MIL2
Bobay, Jason 2021-04-23	79	17	79	20	1, 4, 17, 24, MIL1, MIL2
Bobay, Jason 2021-04-23	79	23	79	25	1, 3, 5, 17, 24, MIL1, MIL2
Bobay, Jason 2021-04-23	80	2	80	4	continued
Bobay, Jason 2021-04-23	80	7	80	12	1, 3, 5, 17, 24, MIL1, MIL2
Bobay, Jason 2021-04-23	84	11	84	18	1, 4, 17, MIL2
Bobay, Jason 2021-04-23	88	4	88	9	1, 2, 4, 17, 24, MIL1, MIL2
Bobay, Jason 2021-04-23	89	4	89	5	1, 2, 4, 17, 24, MIL1, MIL2
Bobay, Jason 2021-04-23	89	8	90	2	1, 2, 4, 17, 24, MIL1, MIL2
Bobay, Jason 2021-04-23	103	11	104	3	1, 2, 3, 4, 5, 17, 24, MIL1, MIL2
Bobay, Jason 2021-04-23	104	7	104	10	continued
Bobay, Jason 2021-04-23	105	17	107	10	1, 2, 3, 4, 5, 17, DAUB, MIL1, MIL2, MIL3
Bobay, Jason 2021-04-23	107	13	107	13	continued
Bobay, Jason 2021-04-23	146	23	146	25	1, 17, MIL2
Bobay, Jason 2021-04-23	147	2	147	6	continued
Bobay, Jason 2021-04-23	157	8	157	13	1, 17, MIL2
Bobay, Jason 2021-04-23	170	3	170	10	1, 17, 24, MIL2



Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Bobay, Jason 2021-04-23	14	22	15	25	14	Sage Counter Designations
Bobay, Jason 2021-04-23	17	9	17	25	14, 15	Sage Counter Designations
Bobay, Jason 2021-04-23	18	2	18	25	14, 15	Sage Counter Designations
Bobay, Jason 2021-04-23	20	2	21	11	14, 15	Sage Counter Designations
Bobay, Jason 2021-04-23	21	21	21	25	14, 15	Sage Counter Designations
Bobay, Jason 2021-04-23	22	2	22	8	14, 15	Sage Counter Designations
Bobay, Jason 2021-04-23	32	10	32	13	30	Sage Contingent
Bobay, Jason 2021-04-23	32	19	32	21	30	Sage Contingent
Bobay, Jason 2021-04-23	48	22	49	7	47	Sage Contingent
Bobay, Jason 2021-04-23	49	8	49	19	47	Sage Contingent
Bobay, Jason 2021-04-23	75	4	75	12	72-73	Sage Contingent
Bobay, Jason 2021-04-23	76	14	76	16	75	Sage Contingent
Bobay, Jason 2021-04-23	76	19	77	6	75	Sage Contingent
Bobay, Jason 2021-04-23	81	14	82	12	79-80	Sage Contingent
Bobay, Jason 2021-04-23	82	21	82	23	**Many of Sage's counterdesignations are applicable to numerous PureWick designations across multiple witnesses and topic areas. Identification of page numbers are exemplary.	Sage Contingent
Bobay, Jason 2021-04-23	83	3	83	14		Sage Contingent
Bobay, Jason 2021-04-23	86	9	86	25		Sage Counter Designations
Bobay, Jason 2021-04-23	87	2	87	2		Sage Counter Designations
Bobay, Jason 2021-04-23	90	3	90	8	88-89	Sage Contingent
Bobay, Jason 2021-04-23	90	17	90	19	88-89	Sage Contingent
Bobay, Jason 2021-04-23	92	20	92	22		Sage Counter Designations
Bobay, Jason 2021-04-23	94	5	94	8		Sage Counter Designations
Bobay, Jason 2021-04-23	94	12	94	25		Sage Counter Designations
Bobay, Jason 2021-04-23	95	2	95	25		Sage Counter Designations
Bobay, Jason 2021-04-23	96	2	96	25		Sage Counter Designations
	100	17	100	25		Sage Counter Designations
Bobay, Jason 2021-04-23	101	2	101	25		Sage Counter Designations
Bobay, Jason 2021-04-23	102	2	102	11		Sage Counter Designations
Bobay, Jason 2021-04-23	109	8	109	11	105-107	Sage Contingent
Bobay, Jason 2021-04-23	109	14	109	15	continued	Sage Contingent
Bobay, Jason 2021-04-23	112	3	112	7	105-107	Sage Contingent
Bobay, Jason 2021-04-23	128	16	128	20		Sage Contingent
Bobay, Jason 2021-04-23	130	2	130	4		Sage Counter Designations
Bobay, Jason 2021-04-23	131	11	131	19		Sage Counter Designations
Bobay, Jason 2021-04-23	132	9	132	11		Sage Counter Designations
Bobay, Jason 2021-04-23	132	15	132	25		Sage Counter Designations
Bobay, Jason 2021-04-23	133	2	133	25		Sage Counter Designations
Bobay, Jason 2021-04-23	134	2	134	20		Sage Counter Designations
Bobay, Jason 2021-04-23	148	2	148	12	146-147	Sage Counter Designations
Bobay, Jason 2021-04-23	152	23	153	3	146-147	Sage Counter Designations
Bobay, Jason 2021-04-23	153	5	153	6	146-147	Sage Counter Designations
Bobay, Jason 2021-04-23	154	19	154	25	146-147	Sage Counter Designations
Bobay, Jason 2021-04-23	155	2	155	25	146-147	Sage Counter Designations
Bobay, Jason 2021-04-23	156	2	156	6	146-147	Sage Counter Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Bobay, Jason 2021-04-23	156	15	156	18	146-147	Sage Counter Designations
Bobay, Jason 2021-04-23	161	9	161	25		Sage Counter Designations
Bobay, Jason 2021-04-23	162	2	162	14		Sage Counter Designations
Bobay, Jason 2021-04-23	163	17	163	20		Sage Counter Designations
Bobay, Jason 2021-04-23	164	18	164	22		Sage Counter Designations
Bobay, Jason 2021-04-23	164	25	164	25		Sage Counter Designations
Bobay, Jason 2021-04-23	165	2	165	11		Sage Counter Designations
Bobay, Jason 2021-04-23	165	16	165	25		Sage Counter Designations
Bobay, Jason 2021-04-23	166	3	166	12		Sage Counter Designations
Bobay, Jason 2021-04-23	167	6	167	12		Sage Counter Designations
Bobay, Jason 2021-04-23	167	16	167	17		Sage Counter Designations
Bobay, Jason 2021-04-23	170	13	170	18	169-170	Sage Contingent
Bobay, Jason 2021-04-23	171	25	172	7	169-170	Sage Contingent
Bobay, Jason 2021-04-23	176	23	177	8		Sage Contingent
Bobay, Jason 2021-04-23	180	4	180	11		Sage Contingent
Bobay, Jason 2021-04-23	182	16	182	25		Sage Contingent
Bobay, Jason 2021-04-23	183	2	183	25		Sage Counter Designations
Bobay, Jason 2021-04-23	184	2	184	25		Sage Counter Designations
Bobay, Jason 2021-04-23	185	2	185	5		Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Cole, Adam 2023-02-08	9	8	9	13	
Cole, Adam 2023-02-08	11	5	11	11	
Cole, Adam 2023-02-08	11	22	11	23	1, 2, 4, 5, 17, MIL1, DAUB
Cole, Adam 2023-02-08	12	2	12	5	1, 2, 4, 5, 17, MIL1, DAUB
Cole, Adam 2023-02-08	12	9	12	12	1, 2, 4, 5, 17, MIL1, DAUB
Cole, Adam 2023-02-08	13	3	13	8	1, 2, 4, 5, 17, MIL1, DAUB
Cole, Adam 2023-02-08	13	10	13	13	1, 2, 4, 5, 17, MIL1, DAUB
Cole, Adam 2023-02-08	13	15	13	16	1, 2, 4, 5, 17, MIL1, DAUB
Cole, Adam 2023-02-08	16	15	16	22	1, 4, 18
Cole, Adam 2023-02-08	16	23	16	25	1, 2, 3, 4, 17, 18
Cole, Adam 2023-02-08	17	2	17	4	1, 2, 3, 4, 17, 18
Cole, Adam 2023-02-08	24	3	24	10	1, 3, 4, 18
Cole, Adam 2023-02-08	24	15	24	20	1, 3, 4, 18
Cole, Adam 2023-02-08	24	22	24	23	1, 3, 4, 18
Cole, Adam 2023-02-08	29	4	29	5	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	29	8	29	11	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	29	24	30	2	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	30	5	30	6	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	32	11	32	20	1, 3, 17, 18
Cole, Adam 2023-02-08	33	4	33	5	1, 2, 5, 17, 18
Cole, Adam 2023-02-08	33	8	33	10	
Cole, Adam 2023-02-08	33	12	33	13	1, 2, 3, 5, 17, 18, 23, MIL1, DAUB,
Cole, Adam 2023-02-08	33	15	33	17	
Cole, Adam 2023-02-08	33	19	33	20	1, 2, 3, 5, 17, 18, MIL1, DAUB
Cole, Adam 2023-02-08	33	22	33	25	
Cole, Adam 2023-02-08	34	3	34	10	1, 2, 3, 5, 17, 18, MIL1, DAUB
Cole, Adam 2023-02-08	36	4	36	7	1, 5, 17, 18
Cole, Adam 2023-02-08	40	18	40	20	1, 2, 3, 5, 17, 18, 23
Cole, Adam 2023-02-08	40	23	41	8	1, 2, 3, 5, 17, 18
Cole, Adam 2023-02-08	41	10	41	11	1, 2, 3, 5, 17, 18, 23
Cole, Adam 2023-02-08	41	14	41	15	1, 2, 3, 5, 17, 18, 23
Cole, Adam 2023-02-08	45	20	45	22	1, 2, 3, 4, 5, 17, 18, 23
Cole, Adam 2023-02-08	45	25	46	5	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	46	19	46	21	1, 2, 4, 5, 18
Cole, Adam 2023-02-08	47	3	47	5	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	47	8	47	12	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	49	20	49	21	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	49	23	50	8	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	50	10	50	11	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	50	14	50	15	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	51	16	51	22	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	51	23	52	8	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	52	17	52	24	1, 4, 17, 18
Cole, Adam 2023-02-08	53	18	53	19	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	53	21	53	23	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	57	19	57	20	1, 2, 3, 4, 5, 15, 17, 18
Cole, Adam 2023-02-08	57	23	57	24	1, 2, 3, 4, 5, 15, 17, 18
Cole, Adam 2023-02-08	60	7	60	25	1, 2, 4, 18
Cole, Adam 2023-02-08	61	19	61	23	1, 2, 4, 12, 17, 18
Cole, Adam 2023-02-08	62	11	62	13	1, 2, 4, 12, 18
Cole, Adam 2023-02-08	62	18	62	20	1, 2, 4, 12, 18

Cole, Adam 2023-02-08	62	22	62	23	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	63	3	63	6	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	63	8	63	11	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	63	15	63	16	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	63	18	63	19	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	63	22	63	24	
Cole, Adam 2023-02-08	64	3	64	4	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	64	8	64	10	
Cole, Adam 2023-02-08	64	12	64	13	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	64	16	64	19	
Cole, Adam 2023-02-08	65	9	65	10	
Cole, Adam 2023-02-08	65	12	65	16	
Cole, Adam 2023-02-08	66	8	66	9	
Cole, Adam 2023-02-08	66	12	66	13	
Cole, Adam 2023-02-08	66	15	66	18	
Cole, Adam 2023-02-08	67	15	67	16	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	67	19	67	22	
Cole, Adam 2023-02-08	68	24	69	2	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	69	5	69	8	
Cole, Adam 2023-02-08	71	9	71	11	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	71	13	71	15	
Cole, Adam 2023-02-08	72	4	72	6	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	72	9	72	12	
Cole, Adam 2023-02-08	72	20	73	9	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	73	13	73	13	
Cole, Adam 2023-02-08	73	23	73	25	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	74	2	74	3	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	74	7	74	9	
Cole, Adam 2023-02-08	74	17	74	21	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	76	10	76	12	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	76	15	76	18	
Cole, Adam 2023-02-08	77	17	77	24	1, 4, 5, 18
Cole, Adam 2023-02-08	79	3	79	4	1, 4, 5, 18
Cole, Adam 2023-02-08	79	7	79	7	
Cole, Adam 2023-02-08	79	9	79	16	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	83	8	83	11	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	83	14	83	19	
Cole, Adam 2023-02-08	84	17	84	19	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	84	22	85	5	
Cole, Adam 2023-02-08	85	7	85	8	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	85	11	85	17	
Cole, Adam 2023-02-08	86	23	87	10	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	87	11	87	16	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	87	19	87	25	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	88	2	88	2	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	88	5	88	6	
Cole, Adam 2023-02-08	88	8	88	10	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	88	13	88	16	
Cole, Adam 2023-02-08	89	14	89	14	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	89	17	89	18	
Cole, Adam 2023-02-08	89	22	89	23	
Cole, Adam 2023-02-08	89	25	90	3	1, 4, 5, 17, 18

Cole, Adam 2023-02-08	90	6	90	11	
Cole, Adam 2023-02-08	90	13	90	14	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	90	17	90	21	
Cole, Adam 2023-02-08	90	23	91	8	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	91	23	91	25	1, 17, 18
Cole, Adam 2023-02-08	92	2	92	4	1, 5, 17, 18
Cole, Adam 2023-02-08	92	5	92	7	1, 2, 3, 4, 5, 6, 17, 18
Cole, Adam 2023-02-08	92	10	92	15	
Cole, Adam 2023-02-08	93	5	93	9	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	93	10	93	15	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	93	16	93	24	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	93	25	94	4	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	94	5	94	9	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	94	12	94	14	
Cole, Adam 2023-02-08	94	16	94	24	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	94	25	95	5	1, 4, 17
Cole, Adam 2023-02-08	95	6	95	11	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	95	12	95	14	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	95	17	95	22	
Cole, Adam 2023-02-08	95	24	96	2	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	96	3	96	5	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	96	8	96	12	
Cole, Adam 2023-02-08	96	14	96	17	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	97	8	97	10	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	97	12	97	17	
Cole, Adam 2023-02-08	98	12	98	19	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	98	20	99	5	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	99	10	99	15	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	101	10	101	13	1, 2, 3, 4, 5, 6, 7, 17, 18
Cole, Adam 2023-02-08	101	17	101	20	
Cole, Adam 2023-02-08	102	9	102	19	1, 4, 5
Cole, Adam 2023-02-08	102	23	103	3	
Cole, Adam 2023-02-08	103	5	103	6	1, 4, 5
Cole, Adam 2023-02-08	103	7	103	9	
Cole, Adam 2023-02-08	103	16	103	20	1, 4, 17
Cole, Adam 2023-02-08	103	21	104	2	1, 4, 17
Cole, Adam 2023-02-08	105	8	105	10	1, 4, 17, 18
Cole, Adam 2023-02-08	105	11	105	14	1, 4, 17, 18
Cole, Adam 2023-02-08	105	17	105	21	1, 4, 17, 18
Cole, Adam 2023-02-08	105	23	106	2	1, 4, 17, 18
Cole, Adam 2023-02-08	106	5	106	11	
Cole, Adam 2023-02-08	106	13	106	15	1, 4, 5, 6, 17, 18
Cole, Adam 2023-02-08	106	19	106	23	
Cole, Adam 2023-02-08	107	17	107	19	1, 4, 17, 18
Cole, Adam 2023-02-08	107	22	108	2	
Cole, Adam 2023-02-08	111	16	111	17	1, 4, 5, 7, 17, 18
Cole, Adam 2023-02-08	111	20	111	22	
Cole, Adam 2023-02-08	111	24	111	25	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	112	4	112	8	
Cole, Adam 2023-02-08	112	20	112	25	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	113	2	113	4	1, 4, 5, 7, 17, 18
Cole, Adam 2023-02-08	113	7	113	11	

Cole, Adam 2023-02-08	114	6	114	9	1, 4, 5, 6, 7, 17, 18
Cole, Adam 2023-02-08	114	12	114	19	
Cole, Adam 2023-02-08	114	20	115	5	
Cole, Adam 2023-02-08	115	9	115	14	1, 5, 8, 17, 18, 20
Cole, Adam 2023-02-08	115	16	115	18	
Cole, Adam 2023-02-08	116	2	116	8	1, 2, 18
Cole, Adam 2023-02-08	116	9	116	10	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	116	13	116	14	
Cole, Adam 2023-02-08	116	19	116	20	1, 4, 5, 6, 17, 18
Cole, Adam 2023-02-08	116	23	116	25	
Cole, Adam 2023-02-08	117	11	117	24	1, 4, 17, 18
Cole, Adam 2023-02-08	117	25	118	7	
Cole, Adam 2023-02-08	124	14	124	17	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	124	20	125	3	
Cole, Adam 2023-02-08	125	5	125	7	
Cole, Adam 2023-02-08	125	10	125	17	
Cole, Adam 2023-02-08	130	5	130	8	1, 4, 5, 12, 17, 18
Cole, Adam 2023-02-08	130	12	130	17	
Cole, Adam 2023-02-08	130	19	130	24	1, 4, 5, 6, 7, 12, 17, 18
Cole, Adam 2023-02-08	131	4	131	9	
Cole, Adam 2023-02-08	131	12	131	24	
Cole, Adam 2023-02-08	132	4	132	6	1, 4, 18
Cole, Adam 2023-02-08	132	24	133	4	
Cole, Adam 2023-02-08	133	5	133	8	
Cole, Adam 2023-02-08	134	10	134	15	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	135	4	135	6	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	135	8	135	9	
Cole, Adam 2023-02-08	135	11	135	15	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	135	16	135	20	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	136	6	136	8	1, 4, 17
Cole, Adam 2023-02-08	136	10	136	10	
Cole, Adam 2023-02-08	136	12	136	15	
Cole, Adam 2023-02-08	136	16	136	24	
Cole, Adam 2023-02-08	137	16	137	20	1, 2, 4, 5, 17, 18
Cole, Adam 2023-02-08	138	21	139	2	1, 4, 5
Cole, Adam 2023-02-08	142	13	142	16	
Cole, Adam 2023-02-08	143	7	143	9	1, 4, 5, 12, 17, 18
Cole, Adam 2023-02-08	144	12	144	15	
Cole, Adam 2023-02-08	144	22	145	5	1, 4, 15, 17, 18
Cole, Adam 2023-02-08	147	5	147	8	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	147	11	147	14	1, 4, 18
Cole, Adam 2023-02-08	148	17	148	18	1, 4, 5, 6, 17, 18
Cole, Adam 2023-02-08	148	21	148	23	
Cole, Adam 2023-02-08	148	25	149	3	1, 4, 5, 6, 17, 18
Cole, Adam 2023-02-08	149	5	149	6	
Cole, Adam 2023-02-08	149	8	149	10	1, 4, 5, 6, 12, 17, 18
Cole, Adam 2023-02-08	150	10	150	12	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	150	15	150	20	
Cole, Adam 2023-02-08	152	3	152	5	1, 4, 18
Cole, Adam 2023-02-08	152	6	152	8	1, 4, 5, 12, 14, 17, 18
Cole, Adam 2023-02-08	152	10	152	12	
Cole, Adam 2023-02-08	152	14	152	16	1, 3, 4, 5, 17, 18

Cole, Adam 2023-02-08	152	17	152	19	1, 4, 18
Cole, Adam 2023-02-08	152	20	152	22	1, 4, 18
Cole, Adam 2023-02-08	153	6	153	7	1, 4, 18
Cole, Adam 2023-02-08	153	9	153	15	
Cole, Adam 2023-02-08	153	17	153	20	1, 4, 18
Cole, Adam 2023-02-08	153	22	153	24	
Cole, Adam 2023-02-08	154	3	154	6	1, 4, 18
Cole, Adam 2023-02-08	154	16	154	20	1, 4, 18
Cole, Adam 2023-02-08	154	21	154	22	1, 4, 5, 18
Cole, Adam 2023-02-08	161	3	161	6	1, 2, 3, 4, 5, 6, 7, 12, 17, 18
Cole, Adam 2023-02-08	161	9	161	12	
Cole, Adam 2023-02-08	163	12	163	14	1, 2, 3, 4, 5, 6, 8, 12, 14, 17, 18, 20
Cole, Adam 2023-02-08	163	17	163	20	
Cole, Adam 2023-02-08	163	22	164	2	1, 2, 3, 4, 5, 6, 8, 12, 14, 17, 18, 20
Cole, Adam 2023-02-08	164	5	164	11	
Cole, Adam 2023-02-08	164	13	164	16	1, 2, 3, 4, 5, 6, 8, 12, 14, 17, 18, 20
Cole, Adam 2023-02-08	164	18	164	20	
Cole, Adam 2023-02-08	164	22	164	25	1, 4, 5, 6, 8, 12, 14, 17, 18, 20
Cole, Adam 2023-02-08	165	4	165	7	
Cole, Adam 2023-02-08	165	9	165	12	1, 4, 5, 6, 8, 12, 14, 17, 18, 20
Cole, Adam 2023-02-08	165	14	165	20	
Cole, Adam 2023-02-08	165	22	165	25	1, 4, 5, 6, 8, 12, 14, 17, 18, 20
Cole, Adam 2023-02-08	166	3	166	7	
Cole, Adam 2023-02-08	166	9	166	11	1, 4, 5, 17
Cole, Adam 2023-02-08	166	12	166	13	1, 4, 5, 17
Cole, Adam 2023-02-08	166	15	166	17	
Cole, Adam 2023-02-08	166	19	166	21	1, 4, 5, 17
Cole, Adam 2023-02-08	166	23	166	24	
Cole, Adam 2023-02-08	167	3	167	8	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	169	21	170	15	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	171	11	171	12	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	171	14	171	17	
Cole, Adam 2023-02-08	173	6	173	10	1, 4, 5, 14, 17, 18
Cole, Adam 2023-02-08	173	12	173	14	
Cole, Adam 2023-02-08	173	16	173	19	1, 2, 3, 4, 5, 14, 17, 18
Cole, Adam 2023-02-08	174	21	174	22	1, 2, 3, 4, 5, 14, 17, 18
Cole, Adam 2023-02-08	174	25	175	5	
Cole, Adam 2023-02-08	175	7	175	11	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	176	12	176	23	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	176	24	177	2	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	177	6	177	13	
Cole, Adam 2023-02-08	177	15	177	23	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	177	24	177	25	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	178	3	178	5	
Cole, Adam 2023-02-08	178	7	178	11	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	178	12	178	15	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	179	15	179	16	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	179	18	179	19	
Cole, Adam 2023-02-08	179	21	179	22	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	179	25	180	4	
Cole, Adam 2023-02-08	181	5	181	9	
Cole, Adam 2023-02-08	182	5	182	11	1, 4, 17

Cole, Adam 2023-02-08	182	17	182	21	
Cole, Adam 2023-02-08	183	6	183	8	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	183	11	183	12	
Cole, Adam 2023-02-08	183	14	183	17	1, 4, 5, 17
Cole, Adam 2023-02-08	188	23	189	4	
Cole, Adam 2023-02-08	189	11	189	19	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	190	11	190	17	1, 4, 5, 12, 17, 18
Cole, Adam 2023-02-08	190	20	190	20	
Cole, Adam 2023-02-08	190	22	190	23	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	190	25	191	2	
Cole, Adam 2023-02-08	191	15	191	16	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	191	18	191	19	
Cole, Adam 2023-02-08	192	8	192	9	1, 2, 3, 4, 5, 6, 17, 18
Cole, Adam 2023-02-08	192	12	192	13	
Cole, Adam 2023-02-08	192	15	192	16	1, 4, 5, 6, 17, 18
Cole, Adam 2023-02-08	192	18	192	19	
Cole, Adam 2023-02-08	193	21	193	23	1, 4, 5, 6, 17, 18
Cole, Adam 2023-02-08	194	2	194	3	
Cole, Adam 2023-02-08	194	5	194	9	1, 4, 5, 6, 17, 18
Cole, Adam 2023-02-08	194	19	194	20	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	194	23	195	2	
Cole, Adam 2023-02-08	195	4	195	5	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	195	9	195	10	
Cole, Adam 2023-02-08	195	11	195	19	
Cole, Adam 2023-02-08	196	3	196	4	1, 4, 17, 18
Cole, Adam 2023-02-08	196	7	196	9	
Cole, Adam 2023-02-08	197	9	197	24	1, 4, 5, 6, 12, 17, 18
Cole, Adam 2023-02-08	198	3	198	8	
Cole, Adam 2023-02-08	199	21	199	23	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	200	2	200	3	
Cole, Adam 2023-02-08	200	25	201	4	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	201	5	201	7	1, 3, 4, 17, 18
Cole, Adam 2023-02-08	201	8	201	11	1, 4, 17, 18
Cole, Adam 2023-02-08	201	12	201	18	
Cole, Adam 2023-02-08	203	3	203	7	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	203	11	203	11	
Cole, Adam 2023-02-08	205	4	205	6	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	205	9	205	9	
Cole, Adam 2023-02-08	206	2	206	13	1, 17, 18
Cole, Adam 2023-02-08	206	18	206	18	
Cole, Adam 2023-02-08	206	20	206	23	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	206	24	206	25	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	207	2	207	2	
Cole, Adam 2023-02-08	207	5	207	6	
Cole, Adam 2023-02-08	207	22	207	23	1, 2, 3, 4, 5, 12, 17, 18
Cole, Adam 2023-02-08	208	2	208	5	
Cole, Adam 2023-02-08	208	7	208	10	1, 4, 5, 12, 17, 18
Cole, Adam 2023-02-08	208	15	208	17	1, 4, 5, 12, 17, 18
Cole, Adam 2023-02-08	208	20	208	21	
Cole, Adam 2023-02-08	209	22	210	4	1, 4, 17
Cole, Adam 2023-02-08	213	6	213	11	1, 4, 17
Cole, Adam 2023-02-08	213	20	214	3	1, 2, 3, 4, 17, 18

Cole, Adam 2023-02-08	218	12	218	13	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	218	16	218	19	
Cole, Adam 2023-02-08	218	21	218	23	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	219	2	219	9	
Cole, Adam 2023-02-08	219	11	219	14	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	219	18	219	22	
Cole, Adam 2023-02-08	219	24	220	6	1, 4, 17
Cole, Adam 2023-02-08	220	12	220	13	1, 4, 17, 18
Cole, Adam 2023-02-08	220	16	220	18	
Cole, Adam 2023-02-08	220	18	220	18	
Cole, Adam 2023-02-08	220	18	220	18	
Cole, Adam 2023-02-08	220	20	220	23	1, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	221	2	221	5	
Cole, Adam 2023-02-08	221	7	221	16	1, 4, 17, 18
Cole, Adam 2023-02-08	222	2	222	7	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	222	9	222	11	
Cole, Adam 2023-02-08	222	13	222	14	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	222	16	222	23	
Cole, Adam 2023-02-08	222	25	223	3	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	223	6	223	10	
Cole, Adam 2023-02-08	226	9	226	17	1, 4, 5, 6, 17, 18
Cole, Adam 2023-02-08	227	6	227	10	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	227	17	227	23	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	227	25	228	3	
Cole, Adam 2023-02-08	228	5	228	6	1, 4, 5, 7, 12, 17, 18
Cole, Adam 2023-02-08	228	8	228	11	
Cole, Adam 2023-02-08	228	13	228	23	1, 4, 17, 18
Cole, Adam 2023-02-08	228	25	229	5	
Cole, Adam 2023-02-08	229	7	229	13	1, 4, 17, 18
Cole, Adam 2023-02-08	229	21	229	23	1, 4, 17, 18
Cole, Adam 2023-02-08	230	2	230	3	
Cole, Adam 2023-02-08	230	5	230	11	1, 4, 17, 18
Cole, Adam 2023-02-08	230	13	230	15	
Cole, Adam 2023-02-08	230	21	230	23	1, 4, 17, 18
Cole, Adam 2023-02-08	230	25	231	4	
Cole, Adam 2023-02-08	231	6	231	8	1, 4, 5, 12, 17, 18
Cole, Adam 2023-02-08	231	11	231	13	
Cole, Adam 2023-02-08	232	6	232	8	1, 2, 3, 4, 5, 12, 17, 18, 20
Cole, Adam 2023-02-08	232	10	232	13	
Cole, Adam 2023-02-08	233	24	233	25	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	234	4	234	5	
Cole, Adam 2023-02-08	234	16	234	18	1, 4, 15, 17, 18
Cole, Adam 2023-02-08	234	21	234	21	
Cole, Adam 2023-02-08	235	8	235	18	1, 4, 17, 18
Cole, Adam 2023-02-08	235	19	236	8	
Cole, Adam 2023-02-08	236	10	236	21	1, 2, 3, 4, 5, 9, 12, 15, 17, 18, 23, MIL1, DAUB
Cole, Adam 2023-02-08	237	3	237	7	1, 4, 5, 9, 17, 18
Cole, Adam 2023-02-08	237	8	237	9	1, 4, 5, 9, 12, 15, 17, 18
Cole, Adam 2023-02-08	237	19	237	20	
Cole, Adam 2023-02-08	237	22	237	24	1, 2, 3, 4, 5, 9, 12, 15, 17, 18, 23, MIL1, DAUB
Cole, Adam 2023-02-08	237	25	238	22	1, 2, 3, 4, 5, 9, 12, 15, 17, 18, 23, MIL1, DAUB
Cole, Adam 2023-02-08	238	24	239	14	1, 2, 3, 4, 5, 9, 12, 15, 17, 18, 23, MIL1, DAUB



Cole, Adam 2023-02-08	239	15	240	2	1, 2, 3, 4, 5, 9, 12, 15, 17, 18, 23, MIL1, DAUB
Cole, Adam 2023-02-08	240	8	240	11	1, 4, 5, 17, 18, 24
Cole, Adam 2023-02-08	240	12	240	14	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	240	15	240	16	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	240	19	240	20	
Cole, Adam 2023-02-08	240	22	240	24	1, 4, 5, 9, 17, 18, MIL1, DAUB
Cole, Adam 2023-02-08	241	2	241	3	
Cole, Adam 2023-02-08	241	5	241	7	1, 4, 5, 9, 17, 18
Cole, Adam 2023-02-08	241	10	241	12	
Cole, Adam 2023-02-08	241	14	241	16	1, 2, 3, 4, 5, 9, 17, 18
Cole, Adam 2023-02-08	241	18	241	20	
Cole, Adam 2023-02-08	241	22	241	24	1, 2, 3, 4, 5, 9, 17, 18
Cole, Adam 2023-02-08	242	4	242	6	
Cole, Adam 2023-02-08	242	8	242	9	1, 2, 3, 4, 5, 12, 17, 18
Cole, Adam 2023-02-08	242	15	242	15	
Cole, Adam 2023-02-08	242	17	242	19	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	243	4	243	5	1, 4, 5, 12, 17, 18
Cole, Adam 2023-02-08	243	10	243	12	
Cole, Adam 2023-02-08	243	17	244	10	1, 2, 3, 4, 5, 9, 17, 18, MIL1, DAUB
Cole, Adam 2023-02-08	244	11	244	14	1, 2, 3, 4, 5, 9, 17, 18
Cole, Adam 2023-02-08	244	20	244	24	
Cole, Adam 2023-02-08	245	3	245	4	
Cole, Adam 2023-02-08	245	7	245	10	
Cole, Adam 2023-02-08	245	12	245	14	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	245	17	245	20	
Cole, Adam 2023-02-08	245	22	245	23	
Cole, Adam 2023-02-08	246	2	246	25	
Cole, Adam 2023-02-08	247	2	247	2	
Cole, Adam 2023-02-08	247	4	247	7	
Cole, Adam 2023-02-08	247	10	247	12	
Cole, Adam 2023-02-08	247	14	247	15	
Cole, Adam 2023-02-08	247	17	247	20	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	247	23	248	3	
Cole, Adam 2023-02-08	249	11	249	18	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	250	10	250	12	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	250	14	250	16	
Cole, Adam 2023-02-08	251	6	251	9	1, 2, 4, 5, 6, 12, 17, 18
Cole, Adam 2023-02-08	251	11	251	12	
Cole, Adam 2023-02-08	251	25	252	3	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	252	5	252	7	
Cole, Adam 2023-02-08	253	7	253	14	1, 4, 17, 18
Cole, Adam 2023-02-08	253	18	253	22	1, 4, 17, 18
Cole, Adam 2023-02-08	254	11	254	14	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	254	15	254	18	1, 4, 17
Cole, Adam 2023-02-08	254	24	255	9	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	255	21	255	25	1, 4, 5, 12, 17, 18
Cole, Adam 2023-02-08	256	2	256	3	1, 4, 5, 12, 17, 18
Cole, Adam 2023-02-08	256	6	256	10	
Cole, Adam 2023-02-08	256	12	256	13	1, 4, 5, 12, 17, 18
Cole, Adam 2023-02-08	256	15	256	19	
Cole, Adam 2023-02-08	256	20	256	24	
Cole, Adam 2023-02-08	257	16	257	20	1, 4, 5, 17, 18

Cole, Adam 2023-02-08	257	21	257	22	1, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	257	25	258	7	
Cole, Adam 2023-02-08	258	9	258	11	1, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	258	14	258	16	
Cole, Adam 2023-02-08	258	18	258	19	1, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	258	22	258	24	
Cole, Adam 2023-02-08	259	3	259	5	1, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	259	10	259	12	
Cole, Adam 2023-02-08	259	14	259	17	1, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	259	21	259	24	
Cole, Adam 2023-02-08	260	3	260	8	1, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	260	11	260	20	
Cole, Adam 2023-02-08	260	22	260	25	1, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	261	4	261	6	
Cole, Adam 2023-02-08	261	8	261	11	1, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	261	16	261	20	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	261	21	262	3	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	262	20	262	22	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	262	25	263	7	
Cole, Adam 2023-02-08	263	9	263	13	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	263	16	263	18	
Cole, Adam 2023-02-08	263	20	263	23	1, 2, 3, 4, 5, 12, 17, 18
Cole, Adam 2023-02-08	264	2	264	5	
Cole, Adam 2023-02-08	264	7	264	12	1, 2, 3, 4, 5, 7, 12, 17, 18
Cole, Adam 2023-02-08	264	16	264	19	
Cole, Adam 2023-02-08	266	5	266	7	1, 2, 3, 4, 5, 7, 17, 18
Cole, Adam 2023-02-08	266	10	266	11	
Cole, Adam 2023-02-08	267	15	267	17	1, 4, 17
Cole, Adam 2023-02-08	267	18	267	19	1, 4, 17
Cole, Adam 2023-02-08	267	20	267	21	1, 4, 5, 14, 17, 18
Cole, Adam 2023-02-08	267	22	267	22	
Cole, Adam 2023-02-08	267	25	268	2	
Cole, Adam 2023-02-08	268	6	268	8	1, 2, 3, 4, 5, 14, 17, 18
Cole, Adam 2023-02-08	268	11	268	14	
Cole, Adam 2023-02-08	268	16	268	23	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	270	10	270	12	1, 4, 5, 12, 17, 18
Cole, Adam 2023-02-08	270	15	270	16	
Cole, Adam 2023-02-08	271	3	271	7	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	271	8	271	12	
Cole, Adam 2023-02-08	272	8	272	11	1, 4, 5, 12, 17, 18
Cole, Adam 2023-02-08	272	13	272	16	1, 4, 5, 12, 17, 18
Cole, Adam 2023-02-08	272	18	272	20	
Cole, Adam 2023-02-08	273	12	273	16	1, 4, 5, 9, 12, 17, 18
Cole, Adam 2023-02-08	273	25	274	2	
Cole, Adam 2023-02-08	274	4	274	13	1, 4, 17, 18
Cole, Adam 2023-02-08	274	16	274	17	
Cole, Adam 2023-02-08	274	19	274	23	1, 4, 17, 18
Cole, Adam 2023-02-08	275	13	275	14	
Cole, Adam 2023-02-08	275	17	275	19	
Cole, Adam 2023-02-08	276	5	276	13	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	276	24	277	3	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	277	7	277	18	1, 4, 5, 17, 18

Cole, Adam 2023-02-08	277	21	277	25	1, 4, 5, 17
Cole, Adam 2023-02-08	278	2	278	8	1, 4, 5, 17
Cole, Adam 2023-02-08	278	9	278	11	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	278	14	278	15	
Cole, Adam 2023-02-08	278	17	278	19	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	278	22	278	25	
Cole, Adam 2023-02-08	281	4	281	5	1, 4, 5, 6, 17, 18, 23, 24, MIL1, DAUB
Cole, Adam 2023-02-08	281	7	281	8	
Cole, Adam 2023-02-08	281	9	281	13	
Cole, Adam 2023-02-08	282	2	282	5	1, 2, 3, 4, 5, 6, 17, 18
Cole, Adam 2023-02-08	282	6	282	6	1, 2, 3, 4, 5, 6, 17, 18
Cole, Adam 2023-02-08	282	9	282	11	
Cole, Adam 2023-02-08	282	25	283	4	1, 2, 3, 4, 5, 6, 7, 12, 17, 18
Cole, Adam 2023-02-08	283	5	283	8	1, 2, 3, 4, 5, 6, 7, 12, 17, 18
Cole, Adam 2023-02-08	283	9	283	10	1, 2, 3, 4, 5, 6, 7, 12, 17, 18
Cole, Adam 2023-02-08	283	13	283	15	
Cole, Adam 2023-02-08	283	20	283	21	1, 2, 3, 4, 5, 6, 7, 12, 17, 18
Cole, Adam 2023-02-08	283	24	284	3	
Cole, Adam 2023-02-08	284	5	284	6	
Cole, Adam 2023-02-08	284	9	284	10	1, 2, 3, 4, 5, 6, 7, 12, 17, 18
Cole, Adam 2023-02-08	285	9	285	10	1, 2, 3, 4, 5, 6, 7, 12, 17, 18
Cole, Adam 2023-02-08	285	13	285	17	
Cole, Adam 2023-02-08	286	3	286	4	1, 2, 3, 4, 5, 6, 7, 12, 17, 18
Cole, Adam 2023-02-08	286	7	286	11	
Cole, Adam 2023-02-08	286	13	286	14	1, 2, 3, 4, 5, 6, 7, 12, 17, 18
Cole, Adam 2023-02-08	286	18	286	23	
Cole, Adam 2023-02-08	288	16	288	16	1, 2, 3, 4, 5, 6, 7, 12, 17, 18, MIL1, DAUB, 23
Cole, Adam 2023-02-08	288	17	288	19	1, 2, 3, 4, 5, 6, 7, 12, 17, 18, MIL1, DAUB, 23
Cole, Adam 2023-02-08	288	22	288	24	
Cole, Adam 2023-02-08	289	3	289	8	
Cole, Adam 2023-02-08	289	14	289	18	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	290	18	290	22	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	290	23	290	24	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	291	3	291	3	
Cole, Adam 2023-02-08	291	5	291	6	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	291	9	291	10	
Cole, Adam 2023-02-08	291	19	292	3	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	292	12	292	15	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	292	16	292	21	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	292	22	292	25	1, 4, 5, 17, 18
Cole, Adam 2023-02-08	293	2	293	3	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	293	7	293	9	
Cole, Adam 2023-02-08	293	11	293	15	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	293	17	293	18	
Cole, Adam 2023-02-08	293	20	294	3	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	294	6	294	7	
Cole, Adam 2023-02-08	294	9	294	16	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	294	17	294	19	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	294	22	294	24	
Cole, Adam 2023-02-08	295	3	295	8	1, 4, 17, 18
Cole, Adam 2023-02-08	295	9	295	14	
Cole, Adam 2023-02-08	295	15	295	16	1, 2, 3, 4, 5, 17, 18

Cole, Adam 2023-02-08	295	19	295	20	
Cole, Adam 2023-02-08	296	7	296	17	1, 2, 3, 4, 5, 17, 18
Cole, Adam 2023-02-08	296	24	297	2	
Cole, Adam 2023-02-08	297	8	297	15	1, 4, 17, 18
Cole, Adam 2023-02-08	298	9	298	19	1, 4, 17, 18

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Cole, Adam 2023-02-08	30	8	30	9	29:4-11; 29:24-30:6	Sage Counter Designations
Cole, Adam 2023-02-08	30	11	30	17	29:4-11; 29:24-30:6	Sage Counter Designations
Cole, Adam 2023-02-08	36	17	36	19	36:4-7	Sage Contingent
Cole, Adam 2023-02-08	36	22	36	25	36:4-7	Sage Contingent
Cole, Adam 2023-02-08	37	3	37	15	36:4-7	Sage Contingent
Cole, Adam 2023-02-08	38	23	38	24	36:4-7	Sage Contingent
Cole, Adam 2023-02-08	39	5	39	9	36:4-7	Sage Contingent
Cole, Adam 2023-02-08	39	19	39	20	36:4-7	Sage Contingent
Cole, Adam 2023-02-08	40	2	40	15	36:4-7	Sage Contingent
Cole, Adam 2023-02-08	41	17	41	24	36:4-7	Sage Contingent
Cole, Adam 2023-02-08	42	1	42	7	36:4-7	Sage Contingent
Cole, Adam 2023-02-08	46	22	47	2		Sage Counter Designations
Cole, Adam 2023-02-08	51	10	51	12	51:16-52:7	Sage Counter Designations
Cole, Adam 2023-02-08	52	9	52	16	52:17-24	Sage Counter Designations
Cole, Adam 2023-02-08	52	25	53	4	52:17-24; 226:9-17	Sage Counter Designations
Cole, Adam 2023-02-08	53	6	53	7	52:17-24; 226:9-17	Sage Counter Designations
Cole, Adam 2023-02-08	53	9	53	17	53:18-23; 226:9-17	Sage Counter Designations
Cole, Adam 2023-02-08	53	25	54	2	53:18-23	Sage Counter Designations
Cole, Adam 2023-02-08	54	4	55	3	53:18-23	Sage Counter Designations
Cole, Adam 2023-02-08	55	4	55	17	53:18-23	Sage Counter Designations
Cole, Adam 2023-02-08	55	20	56	2	53:18-23	Sage Counter Designations
Cole, Adam 2023-02-08	56	7	56	8	53:18-23	Sage Counter Designations
Cole, Adam 2023-02-08	56	11	56	22	53:18-23	Sage Counter Designations
Cole, Adam 2023-02-08	68	9	68	11	67:15-22	Sage Counter Designations
Cole, Adam 2023-02-08	68	14	68	22	67:15-22	Sage Counter Designations
	74	22	74	24	73:23-74:3	Sage Counter Designations
Cole, Adam 2023-02-08	75	3	75	7	73:23-74:3	Sage Counter Designations
Cole, Adam 2023-02-08	80	21	80	23	83:8-19	Sage Counter Designations
Cole, Adam 2023-02-08	81	2	81	7	83:8-19	Sage Counter Designations
Cole, Adam 2023-02-08	83	21	83	21	83:8-19	Sage Counter Designations
Cole, Adam 2023-02-08	83	24	83	25		Sage Counter Designations
Cole, Adam 2023-02-08	84	3	84	5	83:8-19	Sage Counter Designations
Cole, Adam 2023-02-08	84	9	84	15	83:8-19	Sage Counter Designations
Cole, Adam 2023-02-08	85	19	85	21	84:17-85:17	Sage Counter Designations
Cole, Adam 2023-02-08	85	25	86	6	84:17-85:17	Sage Counter Designations
Cole, Adam 2023-02-08	91	9	91	12	90:23-91:8	Sage Counter Designations
Cole, Adam 2023-02-08	91	15	91	21	90:23-91:12	Sage Counter Designations
Cole, Adam 2023-02-08	96	18	96	21	93:5-96:17	Sage Counter Designations
Cole, Adam 2023-02-08	96	23	97	4	93:5-96:17	Sage Counter Designations
Cole, Adam 2023-02-08	99	16	99	19	99:10-15	Sage Counter Designations
Cole, Adam 2023-02-08	99	23	100	3	99:10-15	Sage Counter Designations
Cole, Adam 2023-02-08	100	4	100	5	99:10-15	Sage Counter Designations
Cole, Adam 2023-02-08	100	8	100	9	99:10-15	Sage Counter Designations
Cole, Adam 2023-02-08	100	11	100	12	99:10-15	Sage Counter Designations
Cole, Adam 2023-02-08	100	16	100	21	99:10-15	Sage Counter Designations
Cole, Adam 2023-02-08	107	6	107	8	105:8-106:23	Sage Counter Designations
Cole, Adam 2023-02-08	107	10	107	15	105:8-106:23	Sage Counter Designations
Cole, Adam 2023-02-08	108	4	108	5	105:8-106:23	Sage Counter Designations
Cole, Adam 2023-02-08	108	7	108	11	105:8-106:23	Sage Counter Designations
Cole, Adam 2023-02-08	108	13	108	16	105:8-106:23	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Cole, Adam 2023-02-08	108	19	108	25	105:8-106:23	Sage Counter Designations
Cole, Adam 2023-02-08	111	7	111	8	111:16-22	Sage Counter Designations
Cole, Adam 2023-02-08	111	11	111	14	111:16-22	Sage Counter Designations
Cole, Adam 2023-02-08	117	3	117	4	116:9-25	Sage Counter Designations
Cole, Adam 2023-02-08	117	6	117	10	116:9-25	Sage Counter Designations
Cole, Adam 2023-02-08	118	8	118	10	117:11-24	Sage Counter Designations
Cole, Adam 2023-02-08	118	17	118	18	117:11-24	Sage Counter Designations
Cole, Adam 2023-02-08	125	19	125	21	125:10-17	Sage Counter Designations
Cole, Adam 2023-02-08	126	1	126	12	125:10-17	Sage Counter Designations
Cole, Adam 2023-02-08	134	25	135	1	134:10-15	Sage Counter Designations
Cole, Adam 2023-02-08	140	7	140	22	138:21-139:2	Sage Counter Designations
Cole, Adam 2023-02-08	140	23	140	25	138:21-139:2	Sage Counter Designations
Cole, Adam 2023-02-08	141	3	141	9	138:21-139:2	Sage Counter Designations
Cole, Adam 2023-02-08	141	17	141	21	138:21-139:2	Sage Counter Designations
Cole, Adam 2023-02-08	143	21	143	22	144:12-15	Sage Counter Designations
Cole, Adam 2023-02-08	144	2	144	4	144:12-15	Sage Counter Designations
Cole, Adam 2023-02-08	149	11	149	16	147:5-14	Sage Counter Designations
Cole, Adam 2023-02-08	156	20	157	5	153:6-7	Sage Counter Designations
Cole, Adam 2023-02-08	157	14	157	15	153:6-7	Sage Counter Designations
Cole, Adam 2023-02-08	157	17	157	24	153:6-7	Sage Counter Designations
Cole, Adam 2023-02-08	158	3	158	4	153:6-7	Sage Counter Designations
Cole, Adam 2023-02-08	158	6	158	11	153:6-7	Sage Counter Designations
Cole, Adam 2023-02-08	158	13	158	15	153:6-7	Sage Counter Designations
Cole, Adam 2023-02-08	159	2	159	3	153:6-7	Sage Counter Designations
Cole, Adam 2023-02-08	160	3	160	7	153:6-7	Sage Counter Designations
Cole, Adam 2023-02-08	160	10	160	15	153:6-7	Sage Counter Designations
Cole, Adam 2023-02-08	162	3	162	5	163:12-165:7	Sage Counter Designations
Cole, Adam 2023-02-08	162	7	162	8	163:12-165:7	Sage Counter Designations
Cole, Adam 2023-02-08	162	10	162	12	163:12-165:7	Sage Counter Designations
Cole, Adam 2023-02-08	162	14	162	20	163:12-165:7	Sage Counter Designations
Cole, Adam 2023-02-08	162	22	162	24	163:12-165:7	Sage Counter Designations
Cole, Adam 2023-02-08	163	3	163	5	163:12-165:7	Sage Counter Designations
Cole, Adam 2023-02-08	163	8	163	10	163:12-165:7	Sage Counter Designations
Cole, Adam 2023-02-08	191	4	191	5	190:22-191:2	Sage Counter Designations
Cole, Adam 2023-02-08	191	8	191	13	190:22-191:2	Sage Counter Designations
Cole, Adam 2023-02-08	191	21	191	22	191:15-19	Sage Counter Designations
Cole, Adam 2023-02-08	191	25	192	6	191:15-19	Sage Counter Designations
Cole, Adam 2023-02-08	194	10	194	12	194:5-9	Sage Counter Designations
Cole, Adam 2023-02-08	194	14	194	17	194:5-9	Sage Counter Designations
Cole, Adam 2023-02-08	198	10	198	14	197:9-198:8	Sage Counter Designations
Cole, Adam 2023-02-08	198	20	199	5	197:9-198:8	Sage Counter Designations
Cole, Adam 2023-02-08	209	4	209	5	e.g., 208:15-21	Sage Counter Designations
Cole, Adam 2023-02-08	209	8	209	10	e.g., 208:15-21	Sage Counter Designations
Cole, Adam 2023-02-08	210	5	211	5	e.g., 208:15-21; 209:22-210:5	Sage Contingent
Cole, Adam 2023-02-08	211	6	211	10	e.g., 208:15-21; 209:22-210:5	Sage Contingent
Cole, Adam 2023-02-08	212	16	212	18	e.g., 208:15-21; 209:22-210:5	Sage Contingent
Cole, Adam 2023-02-08	212	20	213	5	e.g., 208:15-21; 209:22-210:5	Sage Contingent
Cole, Adam 2023-02-08	221	20	221	25	221:7-16	Sage Counter Designations
Cole, Adam 2023-02-08	226	18	227	2	226:9-17; 52:17-24	Sage Counter Designations
Cole, Adam 2023-02-08	227	11	227	16	227:6-10	Sage Counter Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Cole, Adam 2023-02-08	248	5	248	7	245:3-248:1	Sage Counter Designations
Cole, Adam 2023-02-08	248	10	248	12	245:3-248:1	Sage Counter Designations
Cole, Adam 2023-02-08	248	14	248	14	245:3-248:1	Sage Counter Designations
Cole, Adam 2023-02-08	248	17	248	20	245:3-248:1	Sage Counter Designations
Cole, Adam 2023-02-08	248	21	248	23	245:3-248:1	Sage Counter Designations
Cole, Adam 2023-02-08	248	25	249	9	245:3-248:1	Sage Counter Designations
Cole, Adam 2023-02-08	249	19	249	21	248:11-18	Sage Counter Designations
Cole, Adam 2023-02-08	249	24	250	9	248:11-18	Sage Counter Designations
Cole, Adam 2023-02-08	250	18	250	19	251:6-12	Sage Counter Designations
Cole, Adam 2023-02-08	250	23	250	23	251:6-12	Sage Counter Designations
Cole, Adam 2023-02-08	250	25	251	4	251:6-12	Sage Counter Designations
Cole, Adam 2023-02-08	251	14	251	23		Sage Counter Designations
Cole, Adam 2023-02-08	251	25	252	3	1, 2, 3, 4, 5, 17, 18	Sage Counter Designations
Cole, Adam 2023-02-08	255	10	255	12	254:11-18; 255:2-9	Sage Counter Designations
Cole, Adam 2023-02-08	255	15	255	19	254:11-18; 255:2-9	Sage Counter Designations
Cole, Adam 2023-02-08	257	7	257	9	257:16:00	Sage Counter Designations
Cole, Adam 2023-02-08	261	12	261	15	261:8-11	Sage Counter Designations
Cole, Adam 2023-02-08	264	21	264	25	264:2-19	Sage Counter Designations
Cole, Adam 2023-02-08	265	2	265	4	264:2-19	Sage Counter Designations
Cole, Adam 2023-02-08	265	9	265	10	264:2-19	Sage Counter Designations
Cole, Adam 2023-02-08	265	13	265	15	264:2-19	Sage Counter Designations
Cole, Adam 2023-02-08	268	24	268	25	270:10-16	Sage Counter Designations
Cole, Adam 2023-02-08	269	3	269	6	270:10-16	Sage Counter Designations
Cole, Adam 2023-02-08	269	8	269	16	270:10-16	Sage Counter Designations
Cole, Adam 2023-02-08	269	18	269	20	270:10-16	Sage Counter Designations
Cole, Adam 2023-02-08	269	24	270	8	270:10-16	Sage Counter Designations
Cole, Adam 2023-02-08	271	13	272	4	272:8-20	Sage Counter Designations
Cole, Adam 2023-02-08	274	24	275	2	275:13-19	Sage Counter Designations
Cole, Adam 2023-02-08	275	4	275	11	275:13-19	Sage Counter Designations
Cole, Adam 2023-02-08	275	21	276	4	276:5-13	Sage Counter Designations
Cole, Adam 2023-02-08	279	3	279	4	277:3-278:8	Sage Counter Designations
Cole, Adam 2023-02-08	279	7	279	10	277:3-278:8	Sage Counter Designations
Cole, Adam 2023-02-08	279	12	279	14	277:3-278:8	Sage Counter Designations
Cole, Adam 2023-02-08	279	17	279	19	277:3-278:8	Sage Counter Designations
Cole, Adam 2023-02-08	281	23	281	25	281:4-13; 282:2-11	Sage Counter Designations
Cole, Adam 2023-02-08	284	12	284	13	284:5-10	Sage Counter Designations
Cole, Adam 2023-02-08	284	16	284	20	284:5-10	Sage Counter Designations
Cole, Adam 2023-02-08	284	22	284	24	284:5-10	Sage Counter Designations
Cole, Adam 2023-02-08	285	3	285	7	284:5-10	Sage Counter Designations
Cole, Adam 2023-02-08	288	3	288	5	288:16-24	Sage Counter Designations
Cole, Adam 2023-02-08	288	9	288	14	288:16-24	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Eckert, Lorena 2023-03-14	4	7	4	13	
Eckert, Lorena 2023-03-14	137	17	137	19	1, 2, 3, 17
Eckert, Lorena 2023-03-14	137	22	138	5	1, 2, 3, 17
Eckert, Lorena 2023-03-14	139	22	139	23	1, 2, 3, 17
Eckert, Lorena 2023-03-14	140	4	140	9	1, 2, 3, 17



Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Eckert, Lorena 2023-03-14	16	8	16	11	4:7-13	Sage Counter Designations
Eckert, Lorena 2023-03-14	18	3	18	13	4:7-13	Sage Counter Designations
Eckert, Lorena 2023-03-14	18	15	18	22	4:7-13	Sage Counter Designations
Eckert, Lorena 2023-03-14	19	11	19	19	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-9	Sage Counter Designations
Eckert, Lorena 2023-03-14	19	23	20	2	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-9	Sage Counter Designations
Eckert, Lorena 2023-03-14	20	9	20	18	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-9	Sage Counter Designations
Eckert, Lorena 2023-03-14	21	8	21	22	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-9	Sage Counter Designations
Eckert, Lorena 2023-03-14	25	24	26	2	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-9	Sage Counter Designations
Eckert, Lorena 2023-03-14	26	13	26	22	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-9	Sage Counter Designations
Eckert, Lorena 2023-03-14	27	10	27	20	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-9	Sage Counter Designations
Eckert, Lorena 2023-03-14	28	12	29	4	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-9	Sage Counter Designations
Eckert, Lorena 2023-03-14	29	7	29	10	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-9	Sage Counter Designations
Eckert, Lorena 2023-03-14	29	12	29	16	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-9	Sage Counter Designations
Eckert, Lorena 2023-03-14	29	20	29	24	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-9	Sage Counter Designations
Eckert, Lorena 2023-03-14	31	19	31	22	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-10	Sage Counter Designations
Eckert, Lorena 2023-03-14	31	24	32	7	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-11	Sage Counter Designations
Eckert, Lorena 2023-03-14	35	21	35	24	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-12	Sage Counter Designations
Eckert, Lorena 2023-03-14	36	1	36	3	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-13	Sage Counter Designations
Eckert, Lorena 2023-03-14	40	3	41	2	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-14	Sage Counter Designations
Eckert, Lorena 2023-03-14	41	15	42	4	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-15	Sage Counter Designations
Eckert, Lorena 2023-03-14	43	1	43	13	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-16	Sage Counter Designations
Eckert, Lorena 2023-03-14	55	10	55	13	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-17	Sage Counter Designations
Eckert, Lorena 2023-03-14	55	19	56	6	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-18	Sage Counter Designations
Eckert, Lorena 2023-03-14	56	21	57	4	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-19	Sage Counter Designations
Eckert, Lorena 2023-03-14	57	20	57	22	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-20	Sage Counter Designations
	58	14	58	20	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-21	Sage Counter Designations
Eckert, Lorena 2023-03-14	60	20	60	22	139:22-23, 140:4-9	Sage Counter Designations
Eckert, Lorena 2023-03-14	61	6	61	8	139:22-23, 140:4-9	Sage Counter Designations
Eckert, Lorena 2023-03-14	62	15	62	21	139:22-23, 140:4-9	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Eckert, Lorena 2023-03-14	62	22	63	3	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-22	Sage Counter Designations
Eckert, Lorena 2023-03-14	63	9	63	14	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-23	Sage Counter Designations
Eckert, Lorena 2023-03-14	63	21	64	12	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-24	Sage Counter Designations
Eckert, Lorena 2023-03-14	64	15	64	16	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-25	Sage Counter Designations
Eckert, Lorena 2023-03-14	65	4	65	10	139:22-23, 140:4-9	Sage Counter Designations
Eckert, Lorena 2023-03-14	72	14	72	18	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-26	Sage Counter Designations
Eckert, Lorena 2023-03-14	72	21	72	22	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-27	Sage Counter Designations
Eckert, Lorena 2023-03-14	73	5	73	8	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-28	Sage Counter Designations
Eckert, Lorena 2023-03-14	75	12	75	18	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-29	Sage Counter Designations
Eckert, Lorena 2023-03-14	76	2	76	5	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-30	Sage Counter Designations
Eckert, Lorena 2023-03-14	84	5	84	8	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-31	Sage Counter Designations
Eckert, Lorena 2023-03-14	100	18	100	19	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-9	Sage Counter Designations
Eckert, Lorena 2023-03-14	101	1	101	9	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-9	Sage Counter Designations
Eckert, Lorena 2023-03-14	101	21	102	1	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-9	Sage Counter Designations
Eckert, Lorena 2023-03-14	102	7	102	21	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-9	Sage Counter Designations
Eckert, Lorena 2023-03-14	103	1	103	2	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-9	Sage Counter Designations
Eckert, Lorena 2023-03-14	103	4	103	5	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-31	Sage Counter Designations
Eckert, Lorena 2023-03-14	103	8	103	13	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-31	Sage Counter Designations
Eckert, Lorena 2023-03-14	103	15	103	18	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-31	Sage Counter Designations
Eckert, Lorena 2023-03-14	103	22	103	22	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-31	Sage Counter Designations
Eckert, Lorena 2023-03-14	113	24	114	6	4:7-13	Sage Counter Designations
Eckert, Lorena 2023-03-14	118	2	118	12	4:7-13	Sage Counter Designations
Eckert, Lorena 2023-03-14	120	1	120	6	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-31	Sage Counter Designations
Eckert, Lorena 2023-03-14	120	23	121	11	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-32	Sage Counter Designations
Eckert, Lorena 2023-03-14	121	14	121	18	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-33	Sage Counter Designations
Eckert, Lorena 2023-03-14	121	20	122	3	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-34	Sage Counter Designations
Eckert, Lorena 2023-03-14	122	6	122	12	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-35	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Eckert, Lorena 2023-03-14	122	16	122	21	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-36	Sage Counter Designations
Eckert, Lorena 2023-03-14	125	10	125	20	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-37	Sage Counter Designations
Eckert, Lorena 2023-03-14	127	3	127	10	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-38	Sage Counter Designations
Eckert, Lorena 2023-03-14	127	13	127	14	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-39	Sage Counter Designations
Eckert, Lorena 2023-03-14	127	16	127	19	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-40	Sage Counter Designations
Eckert, Lorena 2023-03-14	127	23	128	2	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-41	Sage Counter Designations
Eckert, Lorena 2023-03-14	128	5	128	5	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-42	Sage Counter Designations
Eckert, Lorena 2023-03-14	128	7	128	23	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-43	Sage Counter Designations
Eckert, Lorena 2023-03-14	129	2	129	7	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-44	Sage Counter Designations
Eckert, Lorena 2023-03-14	129	9	129	13	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-45	Sage Counter Designations
Eckert, Lorena 2023-03-14	129	15	129	18	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-46	Sage Counter Designations
Eckert, Lorena 2023-03-14	129	22	130	2	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-47	Sage Counter Designations
Eckert, Lorena 2023-03-14	130	4	130	11	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-48	Sage Counter Designations
Eckert, Lorena 2023-03-14	135	1	135	15	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-49	Sage Counter Designations
Eckert, Lorena 2023-03-14	136	4	136	7	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-50	Sage Counter Designations
Eckert, Lorena 2023-03-14	144	19	144	23	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-51	Sage Counter Designations
Eckert, Lorena 2023-03-14	145	10	145	12	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-52	Sage Counter Designations
Eckert, Lorena 2023-03-14	147	6	147	8	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-53	Sage Counter Designations
Eckert, Lorena 2023-03-14	147	20	147	23	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-54	Sage Counter Designations
Eckert, Lorena 2023-03-14	150	18	151	6	4:7-13; 137:17-19; 137:22-138:5; 138:22-23; 144:4-55	Sage Counter Designations
Eckert, Lorena 2023-03-14	151	19	151	19	4:7-13	Sage Counter Designations
Eckert, Lorena 2023-03-14	151	21	151	21	4:7-13	Sage Counter Designations
Eckert, Lorena 2023-03-14	151	24	153	3	4:7-13	Sage Counter Designations
Eckert, Lorena 2023-03-14	153	5	153	14	4:7-13	Sage Counter Designations
Eckert, Lorena 2023-03-14	153	17	153	17	4:7-13	Sage Counter Designations
Eckert, Lorena 2023-03-14	153	20	153	23	4:7-13	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Farrell, Eric 2023-02-02	8	4	8	15	
Farrell, Eric 2023-02-02	20	18	21	20	1,13, 17, 18
Farrell, Eric 2023-02-02	21	23	22	18	1,13, 17, 18
Farrell, Eric 2023-02-02	22	20	24	16	1, 5, 13, 17, 18
Farrell, Eric 2023-02-02	24	20	25	10	1, 5, 13, 17, 18
Farrell, Eric 2023-02-02	25	14	26	2	1, 5, 13, 17, 18
Farrell, Eric 2023-02-02	27	10	29	15	1, 2, 3, 5, 11, 13, 17, 18
Farrell, Eric 2023-02-02	27	11	27	13	1, 2, 5, 13, 17, 18
Farrell, Eric 2023-02-02	27	15	28	8	1, 2, 5, 13, 17, 18
Farrell, Eric 2023-02-02	28	12	28	18	1, 2, 5, 13, 17, 18
Farrell, Eric 2023-02-02	28	20	28	24	1, 2, 5, 11, 13, 17, 18
Farrell, Eric 2023-02-02	29	2	29	17	1, 2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	29	20	30	9	1, 2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	30	11	30	14	1, 2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	30	16	31	6	1, 2, 3, 4, 5, 13, 17, 18
Farrell, Eric 2023-02-02	31	8	31	18	1, 2, 3, 4, 5, 13, 17, 18, 23, MIL1
Farrell, Eric 2023-02-02	32	2	32	10	1, 2, 3, 4, 5, 13, 17, 18, 23, MIL1
Farrell, Eric 2023-02-02	43	8	43	16	1, 2, 4, 5, 13, 17, 18
Farrell, Eric 2023-02-02	43	18	43	23	1, 2, 4, 5, 13, 17, 18
Farrell, Eric 2023-02-02	48	17	50	12	1, 2, 5, 13, 17, 18
Farrell, Eric 2023-02-02	55	8	55	23	2, 5
Farrell, Eric 2023-02-02	55	25	56	4	2, 5
Farrell, Eric 2023-02-02	59	8	59	14	1, 2, 3, 4, 5, 13, 17, 18
Farrell, Eric 2023-02-02	59	20	60	23	1, 2, 3, 4, 5, 13, 17, 18, 23, MIL1
Farrell, Eric 2023-02-02	61	14	61	17	1, 2, 3, 4, 5, 13, 17, 18
Farrell, Eric 2023-02-02	61	19	62	7	1, 2, 3, 4, 5, 13, 17, 18
Farrell, Eric 2023-02-02	64	10	64	16	1, 2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	64	18	64	23	1, 2, 3, 5, 12, 13, 17, 18
Farrell, Eric 2023-02-02	64	25	65	9	1, 2, 3, 5, 6, 7, 13, 17, 18
Farrell, Eric 2023-02-02	65	15	66	21	1, 2, 5, 6, 17, 18
Farrell, Eric 2023-02-02	67	6	67	8	1, 2, 3, 4, 5, 6, 13, 17, 18
Farrell, Eric 2023-02-02	67	10	67	21	1, 2, 3, 4, 5, 6, 13, 17, 18
Farrell, Eric 2023-02-02	69	23	69	24	1, 2, 3, 4, 5, 6, 13, 17, 18
Farrell, Eric 2023-02-02	70	2	70	6	1, 2, 3, 4, 5, 6, 7, 13, 17, 18
Farrell, Eric 2023-02-02	70	9	71	13	1, 2, 3, 4, 5, 6, 7, 8, 13, 15, 17, 18
Farrell, Eric 2023-02-02	71	16	72	9	1, 2, 3, 4, 5, 6, 7, 8, 13, 15, 17, 18
Farrell, Eric 2023-02-02	72	11	72	24	1, 2, 3, 4, 5, 6, 7, 8, 13, 15, 17, 18
Farrell, Eric 2023-02-02	73	3	73	15	1, 2, 3, 4, 5, 6, 7, 8, 13, 15, 17, 18
Farrell, Eric 2023-02-02	74	5	75	12	1, 2, 3, 4, 5, 13, 17, 18
Farrell, Eric 2023-02-02	75	14	75	19	1, 2, 3, 4, 5, 13, 17, 18
Farrell, Eric 2023-02-02	76	2	76	11	1, 2, 5, 13, 15, 17, 18
Farrell, Eric 2023-02-02	76	13	77	2	1, 2, 3, 5, 13, 15, 17, 18
Farrell, Eric 2023-02-02	77	9	77	16	1, 2, 3, 5, 13, 15, 17, 18
Farrell, Eric 2023-02-02	77	19	78	14	1, 2, 3, 5, 13, 15, 17, 18
Farrell, Eric 2023-02-02	79	22	80	9	1, 2, 5,
Farrell, Eric 2023-02-02	80	11	81	22	1, 2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	81	24	82	8	1, 2, 3, 4, 5, 13, 15, 17, 18
Farrell, Eric 2023-02-02	82	22	83	9	1, 2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	83	11	83	12	1, 2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	84	2	84	8	1, 2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	84	10	84	11	1, 2, 3, 5, 13, 17, 18

Farrell, Eric 2023-02-02	86	23	87	5	1, 5, 13, 16, 17, 18
Farrell, Eric 2023-02-02	89	9	90	4	1, 2, 5, 6, 7, 13, 17, 18
Farrell, Eric 2023-02-02	90	6	91	10	1, 2, 3, 4, 5, 13, 17, 18
Farrell, Eric 2023-02-02	91	13	91	13	1, 2, 3, 4, 5, 13, 17, 18
Farrell, Eric 2023-02-02	91	15	91	22	1, 2, 13, 15, 17, 18
Farrell, Eric 2023-02-02	94	8	94	9	1, 2, 3, 5, 12, 13, 15, 17, 18
Farrell, Eric 2023-02-02	94	8	94	23	1, 2, 5, 12, 13, 15, 17, 18
Farrell, Eric 2023-02-02	94	12	94	18	1, 2, 5, 12, 13, 15, 17, 18
Farrell, Eric 2023-02-02	94	21	95	2	1, 2, 3, 5, 9, 12, 13, 15, 17, 18
Farrell, Eric 2023-02-02	95	8	95	14	1, 2, 5, 9, 12, 13, 15, 17, 18
Farrell, Eric 2023-02-02	95	21	96	2	1, 2, 3, 5, 9, 12, 13, 15, 16, 17, 18, 19
Farrell, Eric 2023-02-02	96	11	96	13	1, 2, 3, 5, 6, 9, 12, 13, 15, 17, 18
Farrell, Eric 2023-02-02	96	18	96	23	1, 2, 3, 5, 6, 9, 12, 13, 15, 17, 18
Farrell, Eric 2023-02-02	97	2	97	5	1, 2, 3, 5, 6, 9, 12, 13, 15, 18
Farrell, Eric 2023-02-02	97	19	97	21	1, 2, 3, 5, 9, 13, 17, 18
Farrell, Eric 2023-02-02	98	14	98	19	1, 2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	98	21	99	9	1, 2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	103	6	103	10	1, 2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	103	13	103	17	1, 2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	105	8	105	15	1, 2, 5, 13, 17, 18
Farrell, Eric 2023-02-02	107	24	108	9	1, 2, 15, 17
Farrell, Eric 2023-02-02	108	22	109	17	1, 2, 5, 13, 17, 18
Farrell, Eric 2023-02-02	109	20	110	7	1, 2, 5, 13, 17, 18
Farrell, Eric 2023-02-02	110	10	110	15	1, 2, 5, 13, 17, 18
Farrell, Eric 2023-02-02	111	20	111	24	1, 2, 5, 13, 17, 18
Farrell, Eric 2023-02-02	112	3	112	8	1, 2, 5, 13, 17, 18
Farrell, Eric 2023-02-02	114	22	114	24	1, 2, 5, 15, 17, 18
Farrell, Eric 2023-02-02	115	3	115	8	1, 2, 5, 15, 17, 18
Farrell, Eric 2023-02-02	115	11	116	7	1, 2, 3, 5, 15, 17, 18
Farrell, Eric 2023-02-02	116	10	116	11	1, 2, 3, 5, 15, 17, 18
Farrell, Eric 2023-02-02	118	3	118	6	1, 2, 3, 5, 15, 17, 18
Farrell, Eric 2023-02-02	118	9	118	9	1, 2, 3, 5, 15, 17, 18
Farrell, Eric 2023-02-02	121	12	121	13	1, 2, 5, 17, 18
Farrell, Eric 2023-02-02	121	15	122	5	1, 2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	122	7	122	18	1, 2, 3, 5, 6, 13, 17, 18
Farrell, Eric 2023-02-02	124	2	124	6	2, 13, 17, 18
Farrell, Eric 2023-02-02	124	9	124	12	2, 13, 17, 18
Farrell, Eric 2023-02-02	124	15	124	19	2, 3, 13, 17, 18
Farrell, Eric 2023-02-02	124	22	124	23	2, 3, 13, 17, 18
Farrell, Eric 2023-02-02	125	4	125	5	1, 2, 3, 13, 17, 18, 23, MIL1
Farrell, Eric 2023-02-02	125	8	125	12	1, 2, 3, 13, 17, 18, 23, MIL1
Farrell, Eric 2023-02-02	125	15	125	23	1, 2, 3, 13, 14, 15, 17, 18, 23, MIL1
Farrell, Eric 2023-02-02	126	2	126	6	1, 2, 3, 13, 14, 15, 17, 18, 23, MIL1
Farrell, Eric 2023-02-02	126	17	126	19	2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	126	22	127	2	2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	127	5	127	8	1, 2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	127	11	127	16	1, 2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	127	19	127	21	1, 2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	128	6	129	2	1, 2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	139	5	139	8	1, 2, 3, 5, 13, 15, 17, 18
Farrell, Eric 2023-02-02	139	11	139	18	1, 2, 3, 5, 13, 15, 17, 18
Farrell, Eric 2023-02-02	140	23	141	5	1, 2, 3, 5, 13, 15, 17, 18, 23, MIL1

Farrell, Eric 2023-02-02	141	8	141	11	1, 2, 3, 5, 13, 15, 17, 18, 23, MIL1
Farrell, Eric 2023-02-02	141	15	141	17	1, 2, 3, 5, 13, 15, 17, 18
Farrell, Eric 2023-02-02	141	23	143	12	1, 2, 3, 5, 13, 14, 15, 17, 18
Farrell, Eric 2023-02-02	143	15	143	17	1, 2, 3, 5, 13, 14, 17, 18
Farrell, Eric 2023-02-02	144	4	144	6	1, 2, 3, 5, 13, 14, 17, 18
Farrell, Eric 2023-02-02	144	9	144	12	1, 2, 3, 5, 12, 13, 14, 17, 18
Farrell, Eric 2023-02-02	144	15	144	16	1, 2, 3, 5, 12, 13, 14, 17, 18
Farrell, Eric 2023-02-02	145	23	146	5	1, 2, 3, 5, 13, 17
Farrell, Eric 2023-02-02	148	20	149	3	1, 2, 3, 5, 12, 13, 17, 18
Farrell, Eric 2023-02-02	149	15	149	17	1, 2, 3, 5, 6, 12, 13, 17, 18
Farrell, Eric 2023-02-02	149	20	149	22	1, 2, 3, 5, 6, 12, 13, 17, 18
Farrell, Eric 2023-02-02	150	22	151	2	1, 2, 3, 5, 6, 7, 12, 13, 17, 18
Farrell, Eric 2023-02-02	151	6	151	11	1, 2, 3, 5, 6, 7, 12, 13, 17, 18
Farrell, Eric 2023-02-02	151	14	151	14	1, 2, 3, 5, 6, 7, 12, 13, 17, 18
Farrell, Eric 2023-02-02	152	17	152	21	1, 2, 17, 18
Farrell, Eric 2023-02-02	153	15	153	24	1, 2, 5, 13, 17, 18
Farrell, Eric 2023-02-02	154	2	154	6	1, 2, 5, 6, 13, 17, 18
Farrell, Eric 2023-02-02	154	9	154	13	1, 2, 5, 6, 13, 17, 18
Farrell, Eric 2023-02-02	160	6	160	13	1, 2, 13, 17, 18
Farrell, Eric 2023-02-02	166	19	167	17	1, 2, 13, 17, 18
Farrell, Eric 2023-02-02	179	5	179	6	1, 2, 3, 4, 5, 13, 17, 18
Farrell, Eric 2023-02-02	179	8	179	16	1, 2, 3, 4, 5, 13, 17, 18
Farrell, Eric 2023-02-02	179	19	180	4	1, 2, 3, 4, 5, 13, 17, 18
Farrell, Eric 2023-02-02	181	14	182	4	2, 3, 5, 13, 17
Farrell, Eric 2023-02-02	182	23	182	25	1, 2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	183	3	183	4	1, 2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	183	11	184	11	1, 2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	184	14	184	18	1, 2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	184	20	184	20	1, 2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	189	7	189	12	1, 2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	197	2	197	10	2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	198	4	198	16	2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	200	21	201	20	1, 2, 3, 5, 13, 17, 18, 23, MIL1
Farrell, Eric 2023-02-02	201	23	201	23	1, 2, 3, 5, 13, 17, 18, 23, MIL1
Farrell, Eric 2023-02-02	202	10	202	17	1, 2, 13, 17, 18, 23, MIL1
Farrell, Eric 2023-02-02	202	19	203	10	1, 2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	203	13	203	15	1, 2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	203	18	203	21	1, 2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	209	21	209	25	1, 2, 13, 17, 18
Farrell, Eric 2023-02-02	210	4	210	4	1, 2, 13, 17, 18
Farrell, Eric 2023-02-02	214	20	216	6	2
Farrell, Eric 2023-02-02	220	3	220	13	1, 2, 5, 13, 17, 18
Farrell, Eric 2023-02-02	220	16	221	3	1, 2, 5, 13, 17, 18
Farrell, Eric 2023-02-02	221	6	221	9	1, 2, 5, 13, 17, 18
Farrell, Eric 2023-02-02	221	10	221	14	1, 2, 3, 5, 13, 17, 18
Farrell, Eric 2023-02-02	228	13	228	15	1, 2, 3, 5, 6, 13, 17, 18
Farrell, Eric 2023-02-02	228	17	228	17	1, 2, 3, 5, 6, 13, 17, 18
Farrell, Eric 2023-02-02	231	2	233	4	1, 2, 3, 4, 5, 13, 17, 18
Farrell, Eric 2023-02-02	233	6	233	18	1, 2, 3, 4, 5, 13, 17, 18
Farrell, Eric 2023-02-02	233	20	233	23	1, 2, 3, 4, 5, 13, 17, 18
Farrell, Eric 2023-02-02	234	2	234	8	1, 2, 3, 4, 5, 13, 17, 18
Farrell, Eric 2023-02-02	235	5	235	9	1, 2, 5, 6, 13, 17, 18

Farrell, Eric 2023-02-02	235	11	235	21	1, 2, 5, 6, 13, 17, 18
Farrell, Eric 2023-02-02	235	24	236	8	1, 2, 5, 6, 13, 17, 18, 19

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Farrell, Eric 2023-02-02	44	3	44	10	43:8-23	Sage Counter Designations
Farrell, Eric 2023-02-02	62	8	62	9	61:14-62:7	Sage Counter Designations
Farrell, Eric 2023-02-02	62	14	62	21	61:14-62:7	Sage Counter Designations
Farrell, Eric 2023-02-02	62	24	63	5	61:14-62:7	Sage Counter Designations
Farrell, Eric 2023-02-02	104	25	105	3	105:8-15	Sage Counter Designations
Farrell, Eric 2023-02-02	105	5	105	7	105:8-15	Sage Counter Designations
Farrell, Eric 2023-02-02	111	10	111	12	111:20-112:8	Sage Counter Designations
Farrell, Eric 2023-02-02	111	14	111	18	112:20-112:8	Sage Counter Designations
Farrell, Eric 2023-02-02	197	11	197	19	197:2-10; 198:4-16	Sage Counter Designations
Farrell, Eric 2023-02-02	197	22	198	3	197:2-10; 198:4-16	Sage Counter Designations
Farrell, Eric 2023-02-02	239	6	239	14	89:9-90:4; 90:6-91:10	Sage Counter Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Gohde, John 2021-03-26	4	11	4	14	Gohde counter designations to trial testimony	Sage Counter Designations
Gohde, John 2021-03-26	32	20	33	1	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Counter Designations
Gohde, John 2021-03-26	33	23	34	1	Counter to Gohde Trial Tr. at 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	34	5	34	6	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	35	12	35	15	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	35	18	35	18	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	35	20	35	22	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	36	4	36	11	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	37	9	37	17	Counter to Gohde Trial Tr. at 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	38	24	39	6	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	39	10	39	19	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	41	3	41	8	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	41	10	41	13	Counter to Gohde Trial T. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	42	2	42	2	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	43	11	43	21	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	43	22	44	2	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	45	24	46	9	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	46	12	46	13	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	46	20	47	8	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	47	17	47	19	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	51	12	51	17	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	58	3	58	18	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	60	14	60	19	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	60	24	60	24	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	61	7	61	21	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
	61	22	62	10	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	62	14	62	14	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	63	17	63	19	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	63	23	64	1	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	64	22	65	10	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	68	23	68	24	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	70	6	70	9	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	70	10	70	14	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	71	12	72	13	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	73	15	73	21	Counter to Gohde 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	73	24	74	16	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	107	20	108	7	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	141	22	142	3	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	142	5	142	9	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	142	10	142	14	Counter to Gohde 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	142	15	142	20	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	142	21	143	2	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	143	4	143	16	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	143	17	143	24	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	144	1	144	13	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	144	17	144	19	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	145	1	145	6	Counter to Gohde 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	145	1	145	6	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	145	7	145	23	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	146	7	146	12	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Gohde, John 2021-03-26	146	16	146	22	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	147	3	148	1	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	148	19	148	24	Counter to Gohde 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	149	1	149	5	Counter to Gohde 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	150	13	150	18	Counter to Gohde 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	151	1	151	7	Counter to Gohde 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	151	11	151	21	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	153	12	153	17	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	153	19	154	12	Counter to Gohde 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	154	13	154	21	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	155	11	156	1	Counter to Gohde 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	156	4	156	5	Counter to Gohde 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	156	9	156	14	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	163	8	163	13	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	164	5	164	16	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	167	2	167	19	Counter to Gohde Trial Tr. at 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	167	20	168	9	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	168	22	169	4	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	175	10	175	14	Counter to Gohde Trial Tr. at 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	175	17	175	20	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	175	22	177	3	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	177	4	177	18	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	177	20	178	2	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	178	5	178	6	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	178	18	179	17	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Gohde, John 2021-03-26	179	18	179	23	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	180	2	180	6	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	180	8	180	10	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	180	18	181	6	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	181	12	181	22	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	183	23	184	16	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	184	17	185	1	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	185	2	185	7	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	185	10	185	16	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	185	17	186	3	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	186	16	186	24	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	187	12	187	15	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	187	18	187	21	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	189	14	189	20	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	190	11	190	15	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	190	16	190	22	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	191	21	192	1	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	193	7	193	10	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	193	13	193	16	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	194	4	194	5	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	194	7	194	13	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	194	16	194	24	Counter to Gohde Trial Tr. 344-354, 376-369	Sage Contingent
Gohde, John 2021-03-26	195	3	195	12	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	196	13	197	6	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	197	9	197	12	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Gohde, John 2021-03-26	207	16	207	21	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	210	11	210	15	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	210	17	210	22	Counter to Gohde Trial Tr. 344-354, 376-369	Sage Contingent
Gohde, John 2021-03-26	210	23	210	24	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	211	10	211	14	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	214	7	214	10	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	214	12	214	14	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	215	20	215	23	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	216	3	216	11	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent
Gohde, John 2021-03-26	216	14	216	14	Counter to Gohde Trial Tr. 344-354, 367-369	Sage Contingent

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
19-1508 - Vol 02, Gohde, John	344	11	347	5	4, 1, 2, 5, 17, 24, MIL1
19-1508 - Vol 02, Gohde, John	347	6	347	13	4, 1, 2, 5, 17, 24, MIL1
19-1508 - Vol 02, Gohde, John	348	4	348	18	4, 1, 2, 5, 17, 24, MIL1
19-1508 - Vol 02, Gohde, John	349	2	349	12	4, 1, 2, 5, 17, 24, MIL1
19-1508 - Vol 02, Gohde, John	349	13	350	14	4, 1, 2, 5, 17, 24, MIL1
19-1508 - Vol 02, Gohde, John	350	15	352	10	4, 1, 2, 5, 17, 24, MIL1
19-1508 - Vol 02, Gohde, John	352	16	352	22	4, 1, 2, 5, 17, 24, MIL1
19-1508 - Vol 02, Gohde, John	353	13	353	25	4, 1, 2, 5, 17, 24, MIL1
19-1508 - Vol 02, Gohde, John	354	1	354	5	4, 1, 2, 5, 17, 24, MIL1
19-1508 - Vol 02, Gohde, John	354	17	356	7	4, 1, 2, 5, 17, MIL1
19-1508 - Vol 02, Gohde, John	364	13	365	4	4, 1, 2, 5, 17, 24, MIL1
19-1508 - Vol 02, Gohde, John	365	9	366	18	4, 1, 2, 5, 17, 23, 24, MIL1
19-1508 - Vol 02, Gohde, John	367	11	367	24	4, 1, 2, 5, 17, 23, MIL1
19-1508 - Vol 02, Gohde, John	368	17	369	5	4, 1, 2, 5, 17, 23, MIL1

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
19-1508 - Vol 02, Gohde, John	359	13	359	20	Counter to pp. 344-354	Sage Counter Designations
19-1508 - Vol 02, Gohde, John	369	16	371	19	Counter to pp. 344-354	Sage Counter Designations
19-1508 - Vol 02, Gohde, John	371	23	373	24	Counter to pp. 344-354	Sage Counter Designations
19-1508 - Vol 02, Gohde, John	374	3	375	19	Counter to pp. 344-354	Sage Counter Designations
19-1508 - Vol 02, Gohde, John	375	24	376	10	Counter to pp. 344-354	Sage Counter Designations
19-1508 - Vol 02, Gohde, John	376	14	377	4	Counter to pp. 344-354	Sage Counter Designations
19-1508 - Vol 02, Gohde, John	377	8	378	11	Counter to pp. 344-354	Sage Counter Designations
19-1508 - Vol 02, Gohde, John	378	15	379	4	Counter to pp. 344-354	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Jirafe, Sameer 2023-02-10	9	6	9	9	
Jirafe, Sameer 2023-02-10	20	8	20	16	
Jirafe, Sameer 2023-02-10	22	14	22	18	1, 5, 17
Jirafe, Sameer 2023-02-10	22	20	22	21	
Jirafe, Sameer 2023-02-10	23	17	23	19	1, 5, 17
Jirafe, Sameer 2023-02-10	23	22	23	25	
Jirafe, Sameer 2023-02-10	24	3	24	4	1, 5, 17
Jirafe, Sameer 2023-02-10	24	6	24	7	
Jirafe, Sameer 2023-02-10	24	24	24	25	1, 5, 6, 17, Incomplete
Jirafe, Sameer 2023-02-10	25	15	25	18	1, 5, 6, 17, Incomplete
Jirafe, Sameer 2023-02-10	26	13	26	19	1, 5, 17, 23, MIL1
Jirafe, Sameer 2023-02-10	26	21	27	6	1, 5, 17, 23, MIL1
Jirafe, Sameer 2023-02-10	27	8	27	8	
Jirafe, Sameer 2023-02-10	29	2	29	5	
Jirafe, Sameer 2023-02-10	30	2	30	8	1, 17
Jirafe, Sameer 2023-02-10	30	10	30	14	1, 17
Jirafe, Sameer 2023-02-10	30	16	31	3	1, 5, 17
Jirafe, Sameer 2023-02-10	32	8	32	10	1, 5, 17
Jirafe, Sameer 2023-02-10	32	13	32	14	
Jirafe, Sameer 2023-02-10	33	11	33	14	1, 5, 6, 12, 17
Jirafe, Sameer 2023-02-10	33	17	33	24	1, 5, 6, 12, 17
Jirafe, Sameer 2023-02-10	34	4	34	8	1, 3, 5, 6, 12, 17, 18
Jirafe, Sameer 2023-02-10	34	11	34	18	1, 3, 5, 6, 12, 17, 18
Jirafe, Sameer 2023-02-10	34	21	34	23	
Jirafe, Sameer 2023-02-10	35	4	35	8	1, 17
Jirafe, Sameer 2023-02-10	35	17	35	23	1, 2, 3, 5, 17, incomplete
Jirafe, Sameer 2023-02-10	35	25	36	4	1, 5, 6, 17, incomplete
Jirafe, Sameer 2023-02-10	36	7	36	13	1, 2, 3, 5, 17
Jirafe, Sameer 2023-02-10	36	15	36	22	1, 5, 6, 17, incomplete
Jirafe, Sameer 2023-02-10	36	25	37	12	1, 2, 3, 5, 17
Jirafe, Sameer 2023-02-10	37	14	37	19	
Jirafe, Sameer 2023-02-10	37	21	38	12	1, 2, 3, 5, 17
Jirafe, Sameer 2023-02-10	38	15	38	21	1, 2, 3, 5, 17, incomplete
Jirafe, Sameer 2023-02-10	38	24	38	25	
Jirafe, Sameer 2023-02-10	53	9	53	15	1, 5, 17
Jirafe, Sameer 2023-02-10	53	18	53	19	
Jirafe, Sameer 2023-02-10	85	7	85	8	1, 5, 6, 17
Jirafe, Sameer 2023-02-10	85	11	86	14	1, 5, 6, 17
Jirafe, Sameer 2023-02-10	87	6	87	7	1, 5, 6, 17
Jirafe, Sameer 2023-02-10	87	9	87	17	1, 5, 6, 17
Jirafe, Sameer 2023-02-10	87	20	88	3	1, 5, 6, 12, 17
Jirafe, Sameer 2023-02-10	88	6	88	12	1, 5, 6, 12, 17
Jirafe, Sameer 2023-02-10	88	15	88	20	
Jirafe, Sameer 2023-02-10	89	8	89	10	1, 5, 6, 17
Jirafe, Sameer 2023-02-10	89	13	89	19	1, 5, 6, 17
Jirafe, Sameer 2023-02-10	89	22	89	23	
Jirafe, Sameer 2023-02-10	127	13	127	18	1, 17
Jirafe, Sameer 2023-02-10	127	24	128	13	1, 5, 6, 17
Jirafe, Sameer 2023-02-10	128	16	128	18	
Jirafe, Sameer 2023-02-10	133	20	133	24	1, 5, 17
Jirafe, Sameer 2023-02-10	134	2	134	7	1, 5, 17
Jirafe, Sameer 2023-02-10	134	9	134	11	



Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Jirafe, Sameer 2023-02-10	22	23	22	24	e.g., 22:14-21; 23:17-24:7	Sage Counter Designations
Jirafe, Sameer 2023-02-10	23	2	23	2	e.g., 22:14-21; 23:17-24:7	Sage Counter Designations
Jirafe, Sameer 2023-02-10	23	4	23	8	e.g., 22:14-21; 23:17-24:7	Sage Counter Designations
Jirafe, Sameer 2023-02-10	23	10	23	15	e.g., 22:14-21; 23:17-24:7	Sage Counter Designations
Jirafe, Sameer 2023-02-10	24	10	24	13	e.g., 22:14-21; 23:17-24:7	Sage Counter Designations
Jirafe, Sameer 2023-02-10	25	2	25	14	e.g., 22:14-21; 23:17-24:7; 24:24	Sage Counter Designations
Jirafe, Sameer 2023-02-10	31	4	31	11	e.g., 30:2-31:3	Sage Counter Designations
Jirafe, Sameer 2023-02-10	31	13	31	14	e.g., 30:2-31:3	Sage Counter Designations
Jirafe, Sameer 2023-02-10	31	17	31	20	e.g., 30:2-31:3	Sage Counter Designations
Jirafe, Sameer 2023-02-10	32	16	33	9	e.g., 32:8-14; 33:111-24	Sage Counter Designations
Jirafe, Sameer 2023-02-10	39	3	39	8	35:17-38:25	Sage Counter Designations
Jirafe, Sameer 2023-02-10	40	8	40	11	35:17-38:25	Sage Counter Designations
Jirafe, Sameer 2023-02-10	40	19	41	9	35:17-38:25	Sage Counter Designations
Jirafe, Sameer 2023-02-10	41	11	41	14	35:17-38:25	Sage Counter Designations
Jirafe, Sameer 2023-02-10	41	15	41	20	35:17-38:25	Sage Counter Designations
Jirafe, Sameer 2023-02-10	43	7	43	13	35:17-38:25	Sage Contingent
Jirafe, Sameer 2023-02-10	84	6	84	13	e.g., 85:7-86:14	Sage Counter Designations
Jirafe, Sameer 2023-02-10	88	22	89	6	e.g., 85:7-86:14; 87:6-88:20	Sage Counter Designations
Jirafe, Sameer 2023-02-10	134	13	135	8	e.g., 133:20-134:11	Sage Counter Designations
Jirafe, Sameer 2023-02-10	142	23	143	4	e.g., 22:14-21; 23:17-24:7	Sage Counter Designations
Jirafe, Sameer 2023-02-10	146	4	147	17	e.g., 127:13-128:18	Sage Counter Designations
Jirafe, Sameer 2023-02-10	189	15	189	22	e.g., 29:2-5; 30:2-31:2	Sage Counter Designations
Jirafe, Sameer 2023-02-10	210	5	210	22	e.g., 22:14-21; 23:17-24:7; 85:7-8	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Morgan, Richard 2023-02-10	4	23	5	2	4
Morgan, Richard 2023-02-10	8	7	9	21	4
Morgan, Richard 2023-02-10	10	4	10	8	4, 1
Morgan, Richard 2023-02-10	15	4	15	11	4, 5
Morgan, Richard 2023-02-10	15	4	15	23	4, 5
Morgan, Richard 2023-02-10	15	13	17	4	4
Morgan, Richard 2023-02-10	17	6	17	12	4, 5
Morgan, Richard 2023-02-10	17	15	17	19	4, 5
Morgan, Richard 2023-02-10	17	21	19	7	4, 3, 5
Morgan, Richard 2023-02-10	19	9	19	22	4, 3
Morgan, Richard 2023-02-10	19	24	20	5	4, 3
Morgan, Richard 2023-02-10	20	8	20	8	4, 3
Morgan, Richard 2023-02-10	22	24	24	11	4
Morgan, Richard 2023-02-10	24	13	24	17	4
Morgan, Richard 2023-02-10	25	2	25	18	4, 1, 3, 5
Morgan, Richard 2023-02-10	32	23	33	1	4
Morgan, Richard 2023-02-10	33	4	33	14	4, 3, 2, 5
Morgan, Richard 2023-02-10	33	16	33	22	4
Morgan, Richard 2023-02-10	33	24	34	21	4
Morgan, Richard 2023-02-10	35	20	35	24	4, 2, 3, 5
Morgan, Richard 2023-02-10	36	2	38	1	4, 2, 3, 5
Morgan, Richard 2023-02-10	114	19	114	24	4
Morgan, Richard 2023-02-10	115	3	115	14	4, 2, 3, 5
Morgan, Richard 2023-02-10	115	16	116	1	4, 2, 3, 5
Morgan, Richard 2023-02-10	116	3	116	4	4
Morgan, Richard 2023-02-10	145	11	146	5	4
Morgan, Richard 2023-02-10	148	17	150	23	4
Morgan, Richard 2023-02-10	150	17	150	23	4
Morgan, Richard 2023-02-10	150	24	151	19	4

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Morgan, Richard 2023-02-10	10	9	10	14	Counter to p. 10	Sage Counter Designations
Morgan, Richard 2023-02-10	13	3	13	14	Counter to pp. 8-10	Sage Counter Designations
Morgan, Richard 2023-02-10	13	20	13	24	Counter to pp. 8-10	Sage Counter Designations
Morgan, Richard 2023-02-10	16	1	17	4	Counter to pp. 15-16	Sage Counter Designations
Morgan, Richard 2023-02-10	20	10	20	23	Counter to pp. 17-20	Sage Counter Designations
Morgan, Richard 2023-02-10	22	16	22	19	Counter to pp. 17-20	Sage Counter Designations
Morgan, Richard 2023-02-10	22	21	22	22	Counter to pp. 17-20	Sage Counter Designations
Morgan, Richard 2023-02-10	27	20	27	23	Counter to 24, 36-37	Sage Counter Designations
Morgan, Richard 2023-02-10	28	2	28	13	Counter to 24, 36-37	Sage Counter Designations
Morgan, Richard 2023-02-10	30	2	30	12	Counter to pp. 32-34	Sage Counter Designations
Morgan, Richard 2023-02-10	30	18	31	1	Counter to pp. 32-34.	Sage Counter Designations
Morgan, Richard 2023-02-10	31	19	32	4	Counter to pp. 32-34	Sage Counter Designations
Morgan, Richard 2023-02-10	32	7	32	22	Counter to pp. 32-34	Sage Counter Designations
Morgan, Richard 2023-02-10	35	5	35	13	Counter to p. 34	Sage Counter Designations
Morgan, Richard 2023-02-10	35	15	35	16	Counter to p. 34	Sage Counter Designations
Morgan, Richard 2023-02-10	38	2	38	5	Counter to 24, 36-37	Sage Counter Designations
Morgan, Richard 2023-02-10	38	8	38	20	Counter to 24, 33, 36-37	Sage Counter Designations
Morgan, Richard 2023-02-10	39	6	39	9	Counter to 24, 33, 36-37	Sage Counter Designations
Morgan, Richard 2023-02-10	40	15	41	1	Counter to 24, 33, 36-37	Sage Counter Designations
Morgan, Richard 2023-02-10	41	4	41	7	Counter to 24,33, 36-37	Sage Counter Designations
Morgan, Richard 2023-02-10	41	9	41	11	Counter to 24, 33, 36-37	Sage Counter Designations
Morgan, Richard 2023-02-10	41	13	41	13	Counter to 24, 33, 36-37	Sage Counter Designations
Morgan, Richard 2023-02-10	41	20	42	10	Counter to 24, 33, 36-37	Sage Counter Designations
Morgan, Richard 2023-02-10	42	12	42	12	Counter to 24, 33, 36-37	Sage Counter Designations
Morgan, Richard 2023-02-10	42	21	43	3	Counter to 24, 33, 36-37	Sage Counter Designations
	43	6	43	11	Counter to 24, 33, 36-37	Sage Counter Designations
Morgan, Richard 2023-02-10	43	13	43	16	Counter to 24, 33, 36-37	Sage Counter Designations
Morgan, Richard 2023-02-10	43	19	43	22	Counter to 24, 33, 36-37	Sage Counter Designations
Morgan, Richard 2023-02-10	44	5	44	12	Counter to 24, 33, 36-37	Sage Counter Designations
Morgan, Richard 2023-02-10	44	15	44	16	Counter to 24, 33, 36-37	Sage Counter Designations
Morgan, Richard 2023-02-10	45	13	45	21	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	45	24	46	2	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	46	4	46	5	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	46	7	46	15	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	46	20	46	21	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	48	20	49	3	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	49	5	49	14	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	50	5	50	11	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	51	11	52	2	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	52	6	53	3	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	53	11	53	15	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	68	14	68	21	Counter to pp. 24, 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	93	15	94	1	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	94	12	94	24	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	95	3	95	16	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	95	19	95	20	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	96	19	96	21	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	96	24	97	2	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	102	2	102	18	Counter to pp. 18-20	Sage Counter Designations
Morgan, Richard 2023-02-10	102	19	103	18	Counter to pp. 18-21	Sage Counter Designations
Morgan, Richard 2023-02-10	104	8	104	22	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	105	1	105	5	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	105	18	106	11	Counter to pp. 15, 114-115	Sage Counter Designations
Morgan, Richard 2023-02-10	106	15	106	19	Counter to pp. 15, 114-115	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Morgan, Richard 2023-02-10	106	21	108	6	Counter to pp. 15, 18-21	Sage Counter Designations
Morgan, Richard 2023-02-10	113	13	114	18	Counter to 15, 114-115	Sage Counter Designations
Morgan, Richard 2023-02-10	116	6	116	15	Counter to pp. 114-115	Sage Counter Designations
Morgan, Richard 2023-02-10	116	18	116	18	Counter to pp. 114-115	Sage Counter Designations
Morgan, Richard 2023-02-10	117	14	117	22	Counter to pp. 114-115	Sage Counter Designations
Morgan, Richard 2023-02-10	118	1	118	3	Counter to pp. 114-115	Sage Counter Designations
Morgan, Richard 2023-02-10	118	5	118	7	Counter to pp. 114-115	Sage Counter Designations
Morgan, Richard 2023-02-10	118	10	118	10	Counter to pp. 114-115	Sage Counter Designations
Morgan, Richard 2023-02-10	118	12	118	14	Counter to pp. 114-115	Sage Counter Designations
Morgan, Richard 2023-02-10	118	17	118	18	Counter to pp. 114-115	Sage Counter Designations
Morgan, Richard 2023-02-10	119	3	119	21	Counter to pp. 18, 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	119	24	120	3	Counter to pp. 18, 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	120	5	121	12	Counter to pp. 18, 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	121	15	121	20	Counter to pp. 18, 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	122	18	123	6	Counter to pp. 18, 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	123	9	123	12	Counter to pp. 18, 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	124	9	124	11	Counter to pp. 15, 18, 114-115	Sage Counter Designations
Morgan, Richard 2023-02-10	124	14	124	22	Counter to pp. 15, 18, 114-115	Sage Counter Designations
Morgan, Richard 2023-02-10	125	3	126	5	Counter to pp. 15, 18, 114-115	Sage Counter Designations
Morgan, Richard 2023-02-10	131	8	131	16	Counter to pp. 15, 18, 114-115	Sage Counter Designations
Morgan, Richard 2023-02-10	131	19	131	20	Counter to pp. 15, 18, 114-115	Sage Counter Designations
Morgan, Richard 2023-02-10	133	1	133	3	Counter to pp. 15, 114-115	Sage Counter Designations
Morgan, Richard 2023-02-10	133	24	134	10	Counter to pp. 15, 114-115	Sage Counter Designations
Morgan, Richard 2023-02-10	135	12	136	16	Counter to pp. 15, 114-115	Sage Counter Designations
Morgan, Richard 2023-02-10	140	23	141	1	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	142	5	142	6	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	143	9	143	11	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	143	18	143	19	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	143	21	144	1	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	144	5	144	6	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	144	11	144	12	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	144	18	144	21	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	145	5	145	9	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	146	10	147	14	Counter to pp. 31-37	Sage Counter Designations
Morgan, Richard 2023-02-10	148	3	148	15	Counter to pp. 31-37	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
19-1508 - Vol 01, Newton, Camille	160	5	160	19	1, 4, 17
19-1508 - Vol 01, Newton, Camille	161	7	163	25	1, 4, 16, 17
19-1508 - Vol 01, Newton, Camille	164	3	164	9	1, 4, 17
19-1508 - Vol 01, Newton, Camille	164	10	165	12	1, 4, 16, 17
19-1508 - Vol 01, Newton, Camille	165	13	167	20	1, 2, 3, 4, 16, 17, MIL3
19-1508 - Vol 01, Newton, Camille	167	21	167	21	1, 4, 17
19-1508 - Vol 01, Newton, Camille	168	3	168	4	1, 4, 17, MIL3
19-1508 - Vol 01, Newton, Camille	168	13	170	3	1, 2, 4, 17, MIL3
19-1508 - Vol 01, Newton, Camille	170	4	170	4	1, 4, 17, MIL3
19-1508 - Vol 01, Newton, Camille	170	10	170	12	1, 4, 17, MIL3
19-1508 - Vol 01, Newton, Camille	170	20	173	12	1, 2, 3, 4, 5, 17, MIL3
19-1508 - Vol 01, Newton, Camille	173	20	177	25	1, 2, 3, 4, 5, 12, 14, 17, 20, MIL3
19-1508 - Vol 01, Newton, Camille	178	9	178	14	1, 4, 17
19-1508 - Vol 01, Newton, Camille	178	22	179	21	1, 2, 3, 4, 5, 12, 14, 17, 20
19-1508 - Vol 01, Newton, Camille	180	7	183	6	1, 2, 3, 4, 5, 12, 14, 17, 20
19-1508 - Vol 01, Newton, Camille	183	25	185	14	1, 2, 3, 4, 5, 12, 14, 17, 20
19-1508 - Vol 01, Newton, Camille	186	17	186	24	1, 4, 17
19-1508 - Vol 01, Newton, Camille	187	8	188	13	1, 4, 17
19-1508 - Vol 01, Newton, Camille	190	5	190	9	1, 2, 3, 4, 5, 17
19-1508 - Vol 01, Newton, Camille	190	17	191	7	1, 2, 3, 4, 5, 17
19-1508 - Vol 01, Newton, Camille	191	17	192	4	1, 2, 3, 4, 5, 17, 24
19-1508 - Vol 01, Newton, Camille	192	12	194	6	1, 2, 3, 4, 5, 17, 24
19-1508 - Vol 01, Newton, Camille	194	14	195	1	1, 2, 3, 4, 5, 17, 24
19-1508 - Vol 01, Newton, Camille	195	5	195	11	1, 2, 3, 4, 5, 17, 24
19-1508 - Vol 01, Newton, Camille	195	19	196	21	1, 2, 3, 4, 5, 17
19-1508 - Vol 01, Newton, Camille	196	25	197	13	1, 4, 17
19-1508 - Vol 01, Newton, Camille	197	17	198	19	1, 2, 3, 4, 5, 17, 20
19-1508 - Vol 01, Newton, Camille	199	2	201	5	1, 2, 3, 4, 5, 17, 20, 24
19-1508 - Vol 01, Newton, Camille	201	21	202	15	1, 2, 3, 4, 5, 17, 20, 24
19-1508 - Vol 01, Newton, Camille	202	22	203	13	1, 2, 3, 4, 5, 12, 13, 16, 17, 20, 24
19-1508 - Vol 01, Newton, Camille	203	18	205	19	1, 2, 3, 4, 5, 12, 13, 16, 17, 20, 24
19-1508 - Vol 01, Newton, Camille	206	2	207	9	1, 2, 3, 4, 5, 17, 24
19-1508 - Vol 01, Newton, Camille	207	16	208	4	1, 4, 17
19-1508 - Vol 01, Newton, Camille	208	11	208	14	1, 4, 17
19-1508 - Vol 01, Newton, Camille	208	21	209	7	1, 2, 3, 5, 4, 17
19-1508 - Vol 01, Newton, Camille	209	15	209	23	1, 2, 3, 4, 17
19-1508 - Vol 01, Newton, Camille	210	5	212	12	1, 2, 3, 4, 5, 12, 16, 17, 24, MIL1, MIL2
19-1508 - Vol 01, Newton, Camille	212	20	214	11	1, 2, 3, 4, 5, 12, 16, 17, 24, MIL1, MIL2
19-1508 - Vol 01, Newton, Camille	214	19	215	19	1, 2, 3, 4, 5, 12, 16, 17, MIL1, MIL2
19-1508 - Vol 01, Newton, Camille	216	2	216	19	1, 2, 3, 4, 5, 12, 16, 17, MIL1, MIL2
19-1508 - Vol 01, Newton, Camille	217	5	217	6	1, 2, 3, 4, 5, 12, 16, 17, MIL1, MIL2
19-1508 - Vol 01, Newton, Camille	217	8	218	6	1, 2, 3, 4, 5, 12, 16, 17, MIL1, MIL2
19-1508 - Vol 01, Newton, Camille	218	14	219	6	1, 2, 3, 4, 5, 12, 16, 17, MIL1, MIL2
19-1508 - Vol 01, Newton, Camille	219	9	221	25	1, 2, 3, 4, 5, 12, 16, 17, MIL1, MIL2
19-1508 - Vol 01, Newton, Camille	222	7	224	17	1, 2, 3, 4, 5, 12, 16, 17, MIL1, MIL2, MIL3

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
19-1508 - Vol 01, Newton, Camille	185	15	185	22	e.g., 183:25-185:14	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	186	5	186	16	e.g., 183:25-185:14	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	188	14	190	4	e.g., 183:25-186:14; 187:8-188:13	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	190	10	190	16	190:5-9	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	224	24	225	8	e.g., 173:20-177:25; 178:22-179:21; 187:8-188:13	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	225	15	225	19	e.g., 207:16-208:4; 208:11-14; 208:21-209:7; 209:15-23	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	226	2	226	25	e.g., 192:12-194:6; 194:14-196:21; 199:2-207:9; 196:25-198:19; 199:2-207:9	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	227	1	227	20	e.g., 192:12-194:6; 194:14-196:21; 199:2-207:9; 196:25-198:19; 199:2-207:9	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	229	20	229	24	e.g., 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	229	25	230	7	e.g., 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	230	8	230	8	e.g., 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	230	15	231	8	e.g., 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	231	20	232	5	e.g., 173:20-177:25; 178:22-179:21; 187:8-188:13	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	232	9	232	25	e.g., 173:20-177:25; 178:22-179:21; 187:8-188:13	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	233	1	233	14	e.g., 173:20-177:25; 178:22-179:21; 187:8-188:13	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	234	20	235	12	e.g., 173:20-177:25; 178:22-179:21; 187:8-188:13	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	235	23	236	12	e.g., 173:20-177:25; 178:22-179:21; 187:8-188:13	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	236	13	237	7	e.g., 173:20-177:25; 178:22-179:21; 187:8-188:13	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	238	12	238	14	e.g., 160:5-19, 161:7-165:12; 196:25-198:19; 199:2-207:9	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	238	17	239	7	e.g., 160:5-19, 161:7-165:12; 196:25-198:19; 199:2-207:9	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	239	25	240	7	e.g., 160:5-19, 161:7-165:12; 196:25-198:19; 199:2-207:9	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	240	24	241	6	e.g., 160:5-19, 161:7-165:12; 165:13-167:21; 167:21-177:25; 196:25-198:19; 199:2-207:9	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	241	7	241	11	e.g., 192:12-194:6; 194:14-196:21; 199:2-207:9	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	241	15	241	20	e.g., 192:12-194:6; 194:14-196:21; 199:2-207:9	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	241	21	242	14	e.g., 192:12-194:6; 194:14-196:21; 199:2-207:9	Sage Counter Designations
	242	18	243	6	e.g., 192:12-194:6; 194:14-196:21; 199:2-207:9	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	243	7	243	10	e.g., 192:12-194:6; 194:14-196:21; 199:2-207:9	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	243	18	243	24	e.g., 192:12-194:6; 194:14-196:21; 199:2-207:9	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
19-1508 - Vol 01, Newton, Camille	244	15	244	21	e.g., 192:12-194:6; 194:14-196:21; 199:2-207:9	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	244	22	245	1	e.g., 192:12-194:6; 194:14-196:21; 199:2-207:9	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	245	17	246	5	e.g., 192:12-194:6; 194:14-196:21; 199:2-207:9	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	246	6	246	19	e.g., 192:12-194:6; 194:14-196:21; 199:2-207:9	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	246	20	247	4	e.g., 192:12-194:6; 194:14-196:21; 199:2-207:9	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	247	12	247	16	e.g., 192:12-194:6; 194:14-196:21; 199:2-207:9	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	247	20	247	22	e.g., 192:12-194:6; 194:14-196:21; 199:2-207:9	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	248	8	248	12	e.g., 196:25-198:19; 199:2-207:9	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	248	17	248	18	e.g., 196:25-198:19; 199:2-207:9	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	248	20	249	5	e.g., 196:25-198:19; 199:2-207:9	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	249	6	249	14	e.g., 196:25-198:19; 199:2-207:9	Sage Counter Designations
19-1508 - Vol 01, Newton, Camille	249	15	249	20	e.g., 196:25-198:19; 199:2-207:9	Sage Counter Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
19-1508 - Vol 02, Newton, Camille	258	10	258	13	e.g., 178:9-185:22; 186:17-24; 199:2-201:5; 210:5-224:17;	Sage Counter Designations
19-1508 - Vol 02, Newton, Camille	258	14	259	12	e.g., 196:25-198:19; 199:2-207:9; 210:5-224:17	Sage Counter Designations
19-1508 - Vol 02, Newton, Camille	260	1	261	2	e.g., 196:25-198:19; 199:2-207:9; 210:5-224:17;	Sage Counter Designations
19-1508 - Vol 02, Newton, Camille	261	5	261	9	e.g., 196:25-198:19; 199:2-207:9; 210:5-224:17;	Sage Counter Designations
19-1508 - Vol 02, Newton, Camille	261	21	262	2	e.g., 196:25-198:19; 199:2-207:9; 210:5-224:17;	Sage Counter Designations
19-1508 - Vol 02, Newton, Camille	262	3	262	19	e.g., 196:25-198:19; 199:2-207:9; 210:5-224:17;	Sage Counter Designations
19-1508 - Vol 02, Newton, Camille	263	14	263	25	e.g., 196:25-198:19; 199:2-207:9; 210:5-224:17;	Sage Counter Designations
19-1508 - Vol 02, Newton, Camille	264	12	264	16	e.g., 196:25-198:19; 199:2-207:9; 210:5-224:17;	Sage Counter Designations
19-1508 - Vol 02, Newton, Camille	266	25	267	16	e.g., 165:13-167:21; 167:21-177:25; 207:16-208:4; 208:11-14; 208:21-209:7; 209:15-23	Sage Counter Designations
19-1508 - Vol 02, Newton, Camille	267	17	268	1	e.g., 165:13-167:21; 167:21-177:25; 207:16-208:4; 208:11-14; 208:21-209:7; 209:15-23	Sage Counter Designations
19-1508 - Vol 02, Newton, Camille	268	2	268	18	e.g., 165:13-167:21; 167:21-177:25; 207:16-208:4; 208:11-14; 208:21-209:7; 209:15-23	Sage Counter Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Camille 2021-04-15	10	14	10	16	e.g., Camille Newton Trial Tr. 160:1-167:12	Sage Counter Designations
Newton, Camille 2021-04-15	15	25	16	9	e.g., Camille Newton Trial Tr. 160:1-167:12	Sage Counter Designations
Newton, Camille 2021-04-15	16	10	16	18	e.g., Camille Newton Trial Tr. 160:1-167:12	Sage Counter Designations
Newton, Camille 2021-04-15	16	21	17	2	e.g., Camille Newton Trial Tr. 160:1-167:12	Sage Counter Designations
Newton, Camille 2021-04-15	17	3	17	16	e.g., Camille Newton Trial Tr. 160:1-167:12	Sage Counter Designations
Newton, Camille 2021-04-15	17	17	17	22	e.g., Camille Newton Trial Tr. 160:1-167:12	Sage Counter Designations
Newton, Camille 2021-04-15	18	8	18	14	e.g., Camille Newton Trial Tr. 160:1-167:12	Sage Counter Designations
Newton, Camille 2021-04-15	26	18	26	25	e.g., Camille Newton Trial Tr. 160:1-167:12	Sage Counter Designations
Newton, Camille 2021-04-15	27	5	27	17	e.g., Camille Newton Trial Tr. 160:1-167:12	Sage Contingent
Newton, Camille 2021-04-15	29	2	29	19	e.g., Camille Newton Trial Tr. 160:1-167:12	Sage Counter Designations
Newton, Camille 2021-04-15	30	2	30	11	e.g., Camille Newton Trial Tr. 160:1-167:12;196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2021-04-15	31	5	31	8	e.g., C. Newton Trial Tr. 196:25-198:19; 199:2-207:9; 165:13-167:21; 167:21-177:25	Sage Counter Designations
Newton, Camille 2021-04-15	31	24	32	7	e.g., C. Newton Trial Tr. 196:25-198:19; 199:2-207:9; 165:13-167:21; 167:21-177:25	Sage Counter Designations
Newton, Camille 2021-04-15	33	19	33	24	e.g., C. Newton Trial Tr. 196:25-198:19; 199:2-207:9; 165:13-167:21; 167:21-177:25	Sage Counter Designations
Newton, Camille 2021-04-15	33	25	34	7	e.g., C. Newton Trial Tr. 196:25-198:19; 199:2-207:9; 165:13-167:21; 167:21-177:25	Sage Counter Designations
Newton, Camille 2021-04-15	34	15	34	23	e.g., C. Newton Trial Tr. 196:25-198:19; 199:2-207:9; 165:13-167:21; 167:21-177:25	Sage Counter Designations
Newton, Camille 2021-04-15	35	1	35	1	e.g., C. Newton Trial Tr. 196:25-198:19; 199:2-207:9; 165:13-167:21; 167:21-177:25	Sage Counter Designations
Newton, Camille 2021-04-15	40	11	40	14	e.g., C. Newton Trial Tr. 196:25-198:19; 199:2-207:9; 165:13-167:21; 167:21-177:25	Sage Counter Designations
Newton, Camille 2021-04-15	40	17	40	18	e.g., C. Newton Trial Tr. 196:25-198:19; 199:2-207:9; 165:13-167:21; 167:21-177:25	Sage Counter Designations
Newton, Camille 2021-04-15	48	1	48	7	e.g., C. Newton Trial Tr. 196:25-198:19; 199:2-207:9; 165:13-167:21; 167:21-177:25	Sage Counter Designations
Newton, Camille 2021-04-15	51	13	51	17	e.g., C. Newton Trial Tr. 196:25-198:19; 199:2-207:9; 165:13-167:21; 167:21-177:25	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Camille 2021-04-15	52	11	52	13	e.g., C. Newton Trial Tr. 196:25-198:19; 199:2-207:9; 165:13-167:21; 167:21-177:25	Sage Counter Designations
Newton, Camille 2021-04-15	52	15	52	16	e.g., C. Newton Trial Tr. 196:25-198:19; 199:2-207:9; 165:13-167:21; 167:21-177:25	Sage Counter Designations
Newton, Camille 2021-04-15	55	13	55	15	e.g., C. Newton Trial Tr. 196:25-198:19; 199:2-207:9; 165:13-167:21; 167:21-177:25; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	55	18	55	21	e.g., C. Newton Trial Tr. 196:25-198:19; 199:2-207:9; 165:13-167:21; 167:21-177:25; 173:20-177:25; 178:22-179:21	Sage Counter Designations
	65	18	66	4	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	66	6	66	6	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	66	25	67	10	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	67	13	67	21	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	68	14	68	18	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	68	20	68	21	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	70	13	70	15	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	70	22	70	22	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	70	24	70	25	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	71	2	71	7	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	72	14	72	18	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	74	24	75	1	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Camille 2021-04-15	75	3	75	10	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	75	11	75	11	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	75	13	75	13	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	75	15	75	21	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	75	23	76	4	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	77	3	77	12	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	77	22	77	24	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	78	1	78	17	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	78	18	79	3	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	79	5	79	15	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	79	17	79	24	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	81	1	81	13	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	81	25	82	4	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	83	7	83	10	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	83	12	83	13	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	97	16	97	17	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	101	18	101	25	e.g., Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Camille 2021-04-15	102	1	102	1	e.g., Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Camille 2021-04-15	102	3	102	7	e.g., Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Camille 2021-04-15	103	4	103	11	e.g., Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Camille 2021-04-15	103	13	103	15	e.g., Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Camille 2021-04-15	103	25	104	2	e.g., Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Camille 2021-04-15	104	5	104	6	e.g., Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Camille 2021-04-15	104	12	104	14	e.g., Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Camille 2021-04-15	106	7	106	16	e.g., Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Camille 2021-04-15	107	13	107	14	e.g., Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Camille 2021-04-15	107	16	107	16	e.g., Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Camille 2021-04-15	108	5	108	15	e.g., Camille Newton Trial Tr. 192:12-194:6; 194:14-196:21; 199:2-207:9; Eckert Designations	Sage Counter Designations
Newton, Camille 2021-04-15	108	16	108	18	e.g., Camille Newton Trial Tr. 192:12-194:6; 194:14-196:21; 199:2-207:9; Eckert Designations	Sage Counter Designations
Newton, Camille 2021-04-15	108	19	108	22	e.g., Camille Newton Trial Tr. 192:12-194:6; 194:14-196:21; 199:2-207:9; Eckert Designations	Sage Counter Designations
Newton, Camille 2021-04-15	109	10	109	12	e.g., Camille Newton Trial Tr. 192:12-194:6; 194:14-196:21; 199:2-207:9; Eckert Designations; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	109	14	109	16	e.g., Camille Newton Trial Tr. 192:12-194:6; 194:14-196:21; 199:2-207:9; Eckert Designations; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	109	19	109	24	e.g., Camille Newton Trial Tr. 192:12-194:6; 194:14-196:21; 199:2-207:9; Eckert Designations; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	110	14	111	1	e.g., Camille Newton Trial Tr. 192:12-194:6; 194:14-196:21; 199:2-207:9; Eckert Designations; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	112	9	112	18	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Camille 2021-04-15	112	24	112	24	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2021-04-15	113	4	113	6	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2021-04-15	113	19	113	21	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2021-04-15	113	24	114	4	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2021-04-15	114	5	114	6	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2021-04-15	114	9	114	10	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2021-04-15	114	17	114	19	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2021-04-15	115	13	115	15	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2021-04-15	115	19	115	24	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2021-04-15	116	24	117	2	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2021-04-15	117	5	117	10	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2021-04-15	117	13	117	14	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2021-04-15	117	16	117	19	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2021-04-15	117	22	118	1	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2021-04-15	118	3	118	5	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2021-04-15	121	2	121	2	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	121	3	121	9	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	121	12	121	13	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	121	25	122	1	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Camille 2021-04-15	122	4	122	4	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	122	19	122	22	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	122	24	123	4	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	123	5	123	7	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	123	9	123	9	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	123	11	123	13	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	123	15	123	16	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	132	19	133	13	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	133	15	133	15	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	134	10	134	18	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	135	9	135	14	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	135	16	135	16	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	135	18	135	20	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	135	23	136	9	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	136	18	136	20	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	137	4	137	9	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	137	19	138	4	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	138	22	138	24	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	139	2	139	4	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	139	10	140	3	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	140	4	140	18	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	144	21	145	1	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	145	11	145	13	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	145	21	145	23	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	146	4	146	14	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	146	15	147	2	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Camille 2021-04-15	147	15	147	24	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	148	12	148	21	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	149	8	149	11	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	149	15	149	17	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	149	20	149	24	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	156	13	157	2	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	157	7	157	9	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	157	11	157	25	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	159	14	159	16	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	160	11	160	11	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	160	25	161	2	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	161	5	161	5	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	161	7	161	9	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	161	12	161	17	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	161	20	162	2	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	163	8	163	14	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	163	16	163	18	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	163	20	163	21	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	164	6	164	17	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	165	1	165	3	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	165	6	165	13	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	165	15	165	17	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	165	20	165	20	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	165	25	166	11	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	166	16	166	18	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	167	7	167	10	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Camille 2021-04-15	167	13	167	14	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	167	16	167	16	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	167	20	167	24	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	168	2	168	7	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	170	10	170	12	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	170	15	171	5	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	172	6	172	8	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	172	11	172	14	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	172	17	173	1	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	173	14	173	17	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	173	20	173	24	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	174	4	174	6	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	174	7	174	8	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	174	16	174	21	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	174	22	175	6	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	175	7	175	10	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	175	13	175	14	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	177	24	177	25	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	178	15	178	19	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	178	20	178	22	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	178	24	178	25	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	179	10	179	12	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	179	14	179	15	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	179	17	179	21	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	179	23	180	1	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	180	12	181	4	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Camille 2021-04-15	181	5	181	14	Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	183	25	184	15	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	184	16	184	18	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Camille 2021-04-15	184	22	184	25	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	185	12	185	13	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	185	16	185	19	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	185	24	186	4	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	188	9	188	11	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	188	13	188	14	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	190	5	190	13	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	190	14	190	16	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	190	19	190	20	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	191	16	191	18	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	191	21	191	21	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5; 173:20-177:25; 178:22-179:21	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Camille 2021-04-15	192	14	192	19	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	192	20	192	21	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	192	23	192	24	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	193	14	193	14	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	194	5	194	7	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	194	10	194	14	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	195	8	195	10	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	195	15	195	24	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	196	1	196	7	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	196	9	196	10	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	196	12	197	3	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	197	20	198	1	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	198	9	198	14	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	200	12	200	22	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	200	25	201	2	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Camille 2021-04-15	201	10	201	25	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	202	3	202	8	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	202	8	202	13	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	202	16	202	18	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	203	10	203	12	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	203	25	204	3	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	205	21	206	7	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	206	9	206	19	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	207	8	207	13	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	207	14	207	17	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	207	22	208	5	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	208	9	208	19	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	208	25	209	4	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	211	3	211	7	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	212	12	212	12	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	212	19	213	11	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	213	12	213	20	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Camille 2021-04-15	213	22	214	5	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	214	7	214	13	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	214	15	214	16	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	215	2	215	3	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	215	8	215	12	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	215	22	216	1	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	216	2	216	4	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	216	6	216	6	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	216	8	216	10	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	216	16	216	19	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	216	21	217	6	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	217	7	217	8	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	217	10	217	10	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	217	12	217	13	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	217	15	217	16	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	217	18	217	21	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	217	24	218	11	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Camille 2021-04-15	218	13	218	18	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Camille 2021-04-15	218	20	218	20	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Camille 2021-04-15	218	21	218	24	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24	Sage Counter Designations
Newton, Camille 2021-04-15	219	19	220	9	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24	Sage Counter Designations
Newton, Camille 2021-04-15	220	10	220	15	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24	Sage Counter Designations
Newton, Camille 2021-04-15	220	18	220	25	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24	Sage Counter Designations
Newton, Camille 2021-04-15	221	2	221	13	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24	Sage Counter Designations
Newton, Camille 2021-04-15	221	14	222	3	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24	Sage Counter Designations
Newton, Camille 2021-04-15	222	4	222	10	e.g., Camille Newton Trial Tr. 187:8-188:13; 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24	Sage Counter Designations
Newton, Camille 2021-04-15	222	22	222	25	e.g., Camille Newton Trial Tr. 192:12-194:6; 194:14-196:21; 199:2-207:9; Eckert Designations	Sage Counter Designations
Newton, Camille 2021-04-15	223	2	223	3	e.g., Camille Newton Trial Tr. 192:12-194:6; 194:14-196:21; 199:2-207:9; Eckert Designations	Sage Counter Designations
Newton, Camille 2021-04-15	224	16	224	22	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 210:5-224:17	Sage Counter Designations
Newton, Camille 2021-04-15	224	25	225	6	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 210:5-224:17	Sage Counter Designations
Newton, Camille 2021-04-15	225	8	225	16	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 210:5-224:17	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Camille 2021-04-15	225	25	226	3	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 210:5-224:17	Sage Counter Designations
Newton, Camille 2021-04-15	226	5	226	6	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 210:5-224:17	Sage Counter Designations
Newton, Camille 2021-04-15	226	9	226	14	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 210:5-224:17	Sage Counter Designations
Newton, Camille 2021-04-15	226	17	226	23	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 210:5-224:17	Sage Counter Designations
Newton, Camille 2021-04-15	227	1	227	8	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 210:5-224:17	Sage Counter Designations
Newton, Camille 2021-04-15	227	11	227	13	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 210:5-224:17	Sage Counter Designations
Newton, Camille 2021-04-15	227	24	228	2	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 210:5-224:17	Sage Counter Designations
Newton, Camille 2021-04-15	228	5	228	6	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 210:5-224:17	Sage Counter Designations
Newton, Camille 2021-04-15	228	23	228	25	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 210:5-224:17; 207:16-208:4; 208:11-14; 208:21-209:7; 209:15-23	Sage Counter Designations
Newton, Camille 2021-04-15	229	3	229	7	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 210:5-224:17; 207:16-208:4; 208:11-14; 208:21-209:7; 209:15-23	Sage Counter Designations
Newton, Camille 2021-04-15	229	24	230	1	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 210:5-224:17; 207:16-208:4; 208:11-14; 208:21-209:7; 209:15-23	Sage Counter Designations
Newton, Camille 2021-04-15	234	9	234	19	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 210:5-224:17; 207:16-208:4; 208:11-14; 208:21-209:7; 209:15-23	Sage Counter Designations
Newton, Camille 2021-04-15	234	22	234	23	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 210:5-224:17; 207:16-208:4; 208:11-14; 208:21-209:7; 209:15-23	Sage Counter Designations
Newton, Camille 2021-04-15	236	21	236	23	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Camille 2021-04-15	236	25	236	25	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2021-04-15	239	8	239	10	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9; 210:5-224:17	Sage Counter Designations
Newton, Camille 2021-04-15	239	13	239	17	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9; 210:5-224:17	Sage Counter Designations
Newton, Camille 2021-04-15	239	19	239	21	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9; 210:5-224:17	Sage Counter Designations
Newton, Camille 2021-04-15	242	16	242	24	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5; 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2021-04-15	243	2	243	9	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5; 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2021-04-15	243	13	243	20	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5; 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2021-04-15	248	11	248	12	e.g., Camille Newton Trial Tr. 210:5-224:17; 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2021-04-15	248	13	248	13	e.g., Camille Newton Trial Tr. 210:5-224:17; 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2021-04-15	249	10	249	12	e.g., Camille Newton Trial Tr. 210:5-224:17; 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2021-04-15	249	15	249	16	e.g., Camille Newton Trial Tr. 210:5-224:17; 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2021-04-15	250	8	250	11	e.g., Camille Newton Trial Tr. 160:1-167:12; 210:5-224:17; 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2021-04-15	250	14	250	15	e.g., Camille Newton Trial Tr. 160:1-167:12; 210:5-224:17; 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2021-04-15	260	11	260	15	e.g., Camille Newton Trial Tr. 160:1-167:12; 210:5-224:17; 160:5-19, 161:7-165:12	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Camille 2021-04-15	260	18	261	1	e.g., Camille Newton Trial Tr. 160:1-167:12; 210:5-224:17; 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2021-04-15	261	4	261	7	e.g., Camille Newton Trial Tr. 160:1-167:12; 210:5-224:17; 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2021-04-15	261	10	261	13	e.g., Camille Newton Trial Tr. 160:1-167:12; 210:5-224:17; 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2021-04-15	261	15	261	16	e.g., Camille Newton Trial Tr. 160:1-167:12; 210:5-224:17; 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2021-04-15	275	20	276	2	e.g., Camille Newton Trial Tr. 160:1-167:12; 210:5-224:17; 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2021-04-15	276	22	277	1	e.g., Camille Newton Trial Tr. 160:1-167:12; 210:5-224:17; 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2021-04-15	278	11	278	13	e.g., Camille Newton Trial Tr. 160:1-167:12; 210:5-224:17; 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2021-04-15	278	15	278	16	e.g., Camille Newton Trial Tr. 160:1-167:12; 210:5-224:17; 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2021-04-15	279	7	279	11	e.g., Camille Newton Trial Tr. 160:1-167:12; 210:5-224:17; 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2021-04-15	281	9	281	24	e.g., Camille Newton Trial Tr. 160:1-167:12; 210:5-224:17; 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2021-04-15	282	11	282	17	e.g., Camille Newton Trial Tr. 160:1-167:12; 210:5-224:17; 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2021-04-15	283	3	283	9	e.g., Camille Newton Trial Tr. 160:1-167:12; 210:5-224:17; 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2021-04-15	283	19	283	20	e.g., Camille Newton Trial Tr. 160:1-167:12; 210:5-224:17; 160:5-19, 161:7-165:12	Sage Counter Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Camille 2021-04-15	283	22	283	22	e.g., Camille Newton Trial Tr. 160:1-167:12; 210:5-224:17; 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2021-04-15	285	10	285	15	e.g., Camille Newton Trial Tr. 160:1-167:12; 210:5-224:17; 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2021-04-15	285	21	286	10	e.g., Camille Newton Trial Tr. 160:1-167:12; 210:5-224:17; 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2021-04-15	286	15	286	20	e.g., Camille Newton Trial Tr. 160:1-167:12; 210:5-224:17; 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2021-04-15	292	16	292	23	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2- 201:5	Sage Counter Designations
Newton, Camille 2021-04-15	292	24	292	25	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2- 201:5	Sage Counter Designations
Newton, Camille 2021-04-15	293	2	293	3	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2- 201:5	Sage Counter Designations
Newton, Camille 2021-04-15	296	15	296	18	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2021-04-15	297	20	297	24	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2021-04-15	298	3	298	8	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2021-04-15	298	17	298	22	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2021-04-15	298	24	298	25	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Camille 2023-04-06	4	16	4	20	e.g., Camille Newton Trial Tr. 160:1-167:12	Sage Counter Designations
Newton, Camille 2023-04-06	11	24	12	5	e.g., Camille Newton Trial Tr. 160:1-167:12	Sage Counter Designations
Newton, Camille 2023-04-06	13	17	14	4	e.g., Camille Newton Trial Tr. 160:1-167:12	Sage Counter Designations
Newton, Camille 2023-04-06	14	5	14	15	e.g., Camille Newton Trial Tr. 160:1-167:12	Sage Counter Designations
Newton, Camille 2023-04-06	14	22	14	22	e.g., Camille Newton Trial Tr. 160:1-167:12	Sage Counter Designations
Newton, Camille 2023-04-06	15	1	15	13	e.g., Camille Newton Trial Tr. 160:1-167:12	Sage Counter Designations
Newton, Camille 2023-04-06	15	16	15	16	e.g., Camille Newton Trial Tr. 160:1-167:12	Sage Counter Designations
Newton, Camille 2023-04-06	15	18	16	1	e.g., Camille Newton Trial Tr. 160:1-167:12	Sage Counter Designations
Newton, Camille 2023-04-06	16	4	16	4	e.g., Camille Newton Trial Tr. 160:1-167:12	Sage Counter Designations
Newton, Camille 2023-04-06	16	9	16	18	e.g., Camille Newton Trial Tr. 160:1-167:12	Sage Counter Designations
Newton, Camille 2023-04-06	16	21	16	21	e.g., Camille Newton Trial Tr. 160:1-167:12	Sage Counter Designations
Newton, Camille 2023-04-06	17	1	17	8	e.g., Camille Newton Trial Tr. 160:1-167:12	Sage Counter Designations
Newton, Camille 2023-04-06	17	11	17	11	e.g., Camille Newton Trial Tr. 160:1-167:12	Sage Counter Designations
Newton, Camille 2023-04-06	18	22	19	4	e.g., Camille Newton Trial Tr. 160:1-167:12	Sage Counter Designations
Newton, Camille 2023-04-06	19	7	19	7	e.g., Camille Newton Trial Tr. 160:1-167:12	Sage Counter Designations
Newton, Camille 2023-04-06	20	15	20	16	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2023-04-06	21	20	21	23	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2023-04-06	30	6	30	10	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2023-04-06	31	17	31	21	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2023-04-06	32	13	32	16	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2023-04-06	33	16	33	18	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:15; Ray Newton Trial Tr. pp. 287, 288-289, 308; Eckert Designations	Sage Counter Designations
Newton, Camille 2023-04-06	33	21	33	21	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:15; Ray Newton Trial Tr. pp. 287, 288-289, 308; Eckert Designations	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Camille 2023-04-06	34	6	34	10	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:15; Ray Newton Trial Tr. pp. 287, 288-289, 308; Eckert Designations	Sage Counter Designations
Newton, Camille 2023-04-06	34	17	34	19	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:15; Ray Newton Trial Tr. pp. 287, 288-289, 308; Eckert Designations	Sage Counter Designations
Newton, Camille 2023-04-06	34	20	34	23	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:15; Ray Newton Trial Tr. pp. 287, 288-289, 308; Eckert Designations	Sage Counter Designations
	35	2	35	2	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:15; Ray Newton Trial Tr. pp. 287, 288-289, 308; Eckert Designations	Sage Counter Designations
Newton, Camille 2023-04-06	36	22	37	1	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:15; Ray Newton Trial Tr. pp. 287, 288-289, 308; Eckert Designations	Sage Counter Designations
Newton, Camille 2023-04-06	37	5	37	8	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:15; Ray Newton Trial Tr. pp. 287, 288-289, 308; Eckert Designations	Sage Counter Designations
Newton, Camille 2023-04-06	37	16	37	19	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:15; Ray Newton Trial Tr. pp. 287, 288-289, 308; Eckert Designations	Sage Counter Designations
Newton, Camille 2023-04-06	38	11	38	15	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:15; Ray Newton Trial Tr. pp. 287, 288-289, 308; Eckert Designations	Sage Counter Designations
Newton, Camille 2023-04-06	38	19	38	22	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:15; Ray Newton Trial Tr. pp. 287, 288-289, 308; Eckert Designations	Sage Counter Designations
Newton, Camille 2023-04-06	40	2	40	6	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:15; Ray Newton Trial Tr. pp. 287, 288-289, 308; Eckert Designations	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Camille 2023-04-06	40	12	40	18	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:15; Ray Newton Trial Tr. pp. 287, 288-289, 308; Eckert Designations	Sage Counter Designations
Newton, Camille 2023-04-06	40	19	40	19	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:15; Ray Newton Trial Tr. pp. 287, 288-289, 308; Eckert Designations	Sage Counter Designations
Newton, Camille 2023-04-06	41	4	41	6	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:15; Ray Newton Trial Tr. pp. 287, 288-289, 308; Eckert Designations	Sage Counter Designations
Newton, Camille 2023-04-06	42	1	42	4	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2023-04-06	43	8	43	11	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2023-04-06	44	23	45	1	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2023-04-06	45	5	45	5	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2023-04-06	45	10	45	13	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2023-04-06	46	1	46	5	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2023-04-06	48	16	48	19	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2023-04-06	50	8	50	12	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2023-04-06	51	23	52	2	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2023-04-06	52	9	52	15	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2023-04-06	52	16	52	20	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2023-04-06	52	24	52	24	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2023-04-06	56	19	56	20	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2023-04-06	57	4	57	4	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2023-04-06	63	4	63	7	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	63	23	64	1	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	67	14	67	17	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Camille 2023-04-06	68	8	68	11	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	69	15	69	20	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	69	21	69	22	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	70	3	70	3	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	71	22	72	1	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	72	5	72	8	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	72	22	73	1	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	73	19	73	24	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	74	1	74	2	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	74	5	74	7	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	76	20	76	22	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	77	2	77	4	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	77	6	77	7	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	77	21	77	24	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	78	11	78	14	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	78	15	78	24	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	81	12	81	15	e.g., Camille Newton Trial Tr. 210:5-224:17	Sage Counter Designations
Newton, Camille 2023-04-06	81	19	81	22	e.g., Camille Newton Trial Tr. 210:5-224:17	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Camille 2023-04-06	83	4	83	7	e.g., Camille Newton Trial Tr. 210:5-224:17	Sage Counter Designations
Newton, Camille 2023-04-06	83	13	83	13	e.g., Camille Newton Trial Tr. 210:5-224:17	Sage Counter Designations
Newton, Camille 2023-04-06	84	4	84	5	e.g., Camille Newton Trial Tr. 210:5-224:17	Sage Counter Designations
Newton, Camille 2023-04-06	84	18	84	18	e.g., Camille Newton Trial Tr. 210:5-224:17	Sage Counter Designations
Newton, Camille 2023-04-06	84	20	84	21	e.g., Camille Newton Trial Tr. 210:5-224:17	Sage Counter Designations
Newton, Camille 2023-04-06	86	13	86	13	e.g., Camille Newton Trial Tr. 210:5-224:17	Sage Counter Designations
Newton, Camille 2023-04-06	88	15	88	18	e.g., Camille Newton Trial Tr. 210:5-224:17	Sage Counter Designations
Newton, Camille 2023-04-06	89	21	89	22	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2023-04-06	90	1	90	3	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12; 207:16-208:4; 208:11-14; 208:21-209:7; 209:15-23	Sage Counter Designations
Newton, Camille 2023-04-06	90	20	90	23	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12; 207:16-208:4; 208:11-14; 208:21-209:7; 209:15-23	Sage Counter Designations
Newton, Camille 2023-04-06	91	14	91	17	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12; 207:16-208:4; 208:11-14; 208:21-209:7; 209:15-23	Sage Counter Designations
Newton, Camille 2023-04-06	92	1	92	2	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12; 207:16-208:4; 208:11-14; 208:21-209:7; 209:15-23	Sage Counter Designations
Newton, Camille 2023-04-06	92	5	92	11	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12; 207:16-208:4; 208:11-14; 208:21-209:7; 209:15-23	Sage Counter Designations
Newton, Camille 2023-04-06	92	18	92	21	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12; 207:16-208:4; 208:11-14; 208:21-209:7; 209:15-23	Sage Counter Designations
Newton, Camille 2023-04-06	93	4	93	4	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12; 207:16-208:4; 208:11-14; 208:21-209:7; 209:15-23	Sage Counter Designations
Newton, Camille 2023-04-06	96	9	96	12	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12; 207:16-208:4; 208:11-14; 208:21-209:7; 209:15-23	Sage Counter Designations
Newton, Camille 2023-04-06	96	16	96	19	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12; 207:16-208:4; 208:11-14; 208:21-209:7; 209:15-23	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Camille 2023-04-06	99	5	99	8	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12; 207:16-208:4; 208:11-14; 208:21-209:7; 209:15-23	Sage Counter Designations
Newton, Camille 2023-04-06	99	12	99	20	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12; 207:16-208:4; 208:11-14; 208:21-209:7; 209:15-23	Sage Counter Designations
Newton, Camille 2023-04-06	101	8	101	11	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12; 207:16-208:4; 208:11-14; 208:21-209:7; 209:15-23	Sage Counter Designations
Newton, Camille 2023-04-06	101	15	101	23	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12; 207:16-208:4; 208:11-14; 208:21-209:7; 209:15-23	Sage Counter Designations
Newton, Camille 2023-04-06	101	24	102	2	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12; 207:16-208:4; 208:11-14; 208:21-209:7; 209:15-23	Sage Counter Designations
Newton, Camille 2023-04-06	102	9	102	10	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12; 207:16-208:4; 208:11-14; 208:21-209:7; 209:15-23	Sage Counter Designations
Newton, Camille 2023-04-06	102	12	102	13	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12; 207:16-208:4; 208:11-14; 208:21-209:7; 209:15-23	Sage Counter Designations
Newton, Camille 2023-04-06	102	17	102	19	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12; 207:16-208:4; 208:11-14; 208:21-209:7; 209:15-23	Sage Counter Designations
Newton, Camille 2023-04-06	102	21	102	22	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	103	1	103	1	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	103	4	103	7	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	104	1	104	4	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	104	5	104	7	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	104	11	104	15	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	104	19	104	21	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Camille 2023-04-06	105	7	105	9	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	105	12	105	14	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	105	16	105	18	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	105	22	106	2	e.g., Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Camille 2023-04-06	109	5	109	9	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2023-04-06	109	13	109	18	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2023-04-06	109	19	109	21	e.g., Camille Newton Trial Tr. 160:5-19, 161:7-165:12	Sage Counter Designations
Newton, Camille 2023-04-06	110	9	110	11	e.g., Camille Newton Trial Tr. 210:5-224:17; 207-209	Sage Counter Designations
Newton, Camille 2023-04-06	110	21	111	4	e.g., Camille Newton Trial Tr. 210:5-224:17; 207-209	Sage Counter Designations
Newton, Camille 2023-04-06	111	8	111	11	e.g., Camille Newton Trial Tr. 210:5-224:17; 207-209	Sage Counter Designations
Newton, Camille 2023-04-06	111	16	111	19	e.g., Camille Newton Trial Tr. 210:5-224:17; 207-209	Sage Counter Designations
Newton, Camille 2023-04-06	111	20	111	24	e.g., Camille Newton Trial Tr. 210:5-224:17; 207-209	Sage Counter Designations
Newton, Camille 2023-04-06	112	5	112	8	e.g., Camille Newton Trial Tr. 210:5-224:17; 207-209	Sage Counter Designations
Newton, Camille 2023-04-06	113	6	113	12	e.g., Camille Newton Trial Tr. 210:5-224:17; 207-209	Sage Counter Designations
Newton, Camille 2023-04-06	113	13	113	17	e.g., Camille Newton Trial Tr. 210:5-224:17; 207-209	Sage Counter Designations
Newton, Camille 2023-04-06	113	18	113	24	e.g., Camille Newton Trial Tr. 210:5-224:17; 207-209	Sage Counter Designations
Newton, Camille 2023-04-06	114	24	115	2	e.g., Camille Newton Trial Tr. 210:5-224:17	Sage Counter Designations
Newton, Camille 2023-04-06	115	6	115	9	e.g., Camille Newton Trial Tr. 210:5-224:17	Sage Counter Designations
Newton, Camille 2023-04-06	115	13	115	17	e.g., Camille Newton Trial Tr. 210:5-224:17	Sage Counter Designations
Newton, Camille 2023-04-06	115	21	115	24	e.g., Camille Newton Trial Tr. 210:5-224:17	Sage Counter Designations
Newton, Camille 2023-04-06	116	11	116	12	e.g., Camille Newton Trial Tr. 210:5-224:17	Sage Counter Designations
Newton, Camille 2023-04-06	116	15	116	15	e.g., Camille Newton Trial Tr. 210:5-224:17	Sage Counter Designations
Newton, Camille 2023-04-06	117	1	117	5	e.g., Camille Newton Trial Tr. 210:5-224:17	Sage Counter Designations
Newton, Camille 2023-04-06	118	3	118	7	e.g., Camille Newton Trial Tr. 210:5-224:17	Sage Counter Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Camille 2023-04-06	125	14	125	15	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Camille 2023-04-06	125	18	125	19	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Camille 2023-04-06	126	22	127	2	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Camille 2023-04-06	127	6	127	10	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Camille 2023-04-06	128	9	128	12	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Camille 2023-04-06	128	16	128	19	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Camille 2023-04-06	129	3	129	7	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Camille 2023-04-06	129	10	129	13	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Camille 2023-04-06	130	18	131	2	e.g., Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Camille 2023-04-06	131	24	132	6	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 207-209	Sage Counter Designations
Newton, Camille 2023-04-06	132	22	132	23	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 207-209	Sage Counter Designations
Newton, Camille 2023-04-06	133	3	133	4	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 207-209	Sage Counter Designations
Newton, Camille 2023-04-06	133	24	134	2	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 207-209	Sage Counter Designations
Newton, Camille 2023-04-06	134	5	134	5	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 207-209	Sage Counter Designations
Newton, Camille 2023-04-06	134	8	134	22	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 207-209	Sage Counter Designations
Newton, Camille 2023-04-06	134	23	135	1	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 207-209	Sage Counter Designations
Newton, Camille 2023-04-06	135	4	135	5	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 207-209	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Camille 2023-04-06	136	15	136	23	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Camille 2023-04-06	137	3	137	7	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Camille 2023-04-06	137	11	137	18	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Camille 2023-04-06	138	1	138	6	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Camille 2023-04-06	141	16	141	22	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Camille 2023-04-06	142	1	142	1	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Camille 2023-04-06	144	4	144	11	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:9-185:22; 186:17-24; 199:2-201:5; 207- 209	Sage Counter Designations
Newton, Camille 2023-04-06	144	12	144	14	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:9-185:22; 186:17-24; 199:2-201:5; 207- 209	Sage Counter Designations
Newton, Camille 2023-04-06	144	20	144	22	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:9-185:22; 186:17-24; 199:2-201:5; 207- 209	Sage Counter Designations
Newton, Camille 2023-04-06	144	24	145	2	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:9-185:22; 186:17-24; 199:2-201:5; 207- 209	Sage Counter Designations
Newton, Camille 2023-04-06	145	8	145	13	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:9-185:22; 186:17-24; 199:2-201:5; 207- 209	Sage Counter Designations
Newton, Camille 2023-04-06	145	16	145	18	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:9-185:22; 186:17-24; 199:2-201:5; 207- 209	Sage Counter Designations
Newton, Camille 2023-04-06	145	20	145	22	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:9-185:22; 186:17-24; 199:2-201:5; 207- 209	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Camille 2023-04-06	146	2	146	7	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:9-185:22; 186:17-24; 199:2-201:5; 207- 209	Sage Counter Designations
Newton, Camille 2023-04-06	146	12	146	12	e.g., Camille Newton Trial Tr. 173:20-177:25; 178:9-185:22; 186:17-24; 199:2-201:5; 207- 209	Sage Counter Designations
Newton, Camille 2023-04-06	147	8	147	13	e.g., Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Camille 2023-04-06	147	18	147	24	e.g., Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
19-1508 - Vol 02, Newton, Raymond	287	21	287	24	4
19-1508 - Vol 02, Newton, Raymond	289	3	289	17	1, 4, 5, 17
19-1508 - Vol 02, Newton, Raymond	289	18	291	11	1, 4, 3, 5, 17
19-1508 - Vol 02, Newton, Raymond	291	12	291	15	1, 4, 3, 5, 17
19-1508 - Vol 02, Newton, Raymond	291	16	291	17	1, 4, 5, 17
19-1508 - Vol 02, Newton, Raymond	292	3	294	22	1, 4, 3, 5, 17
19-1508 - Vol 02, Newton, Raymond	294	23	295	2	1, 4, 5, 17
19-1508 - Vol 02, Newton, Raymond	295	10	296	20	1, 4, 3, 5, 17
19-1508 - Vol 02, Newton, Raymond	296	22	298	2	1, 4, 3, 5, 17
19-1508 - Vol 02, Newton, Raymond	298	3	299	23	1, 4, 3, 5, 17
19-1508 - Vol 02, Newton, Raymond	299	24	300	2	1, 4, 3, 5, 17
19-1508 - Vol 02, Newton, Raymond	300	10	300	21	1, 4, 3, 5, 17
19-1508 - Vol 02, Newton, Raymond	300	24	302	15	1, 4, 3, 5, 17
19-1508 - Vol 02, Newton, Raymond	302	16	302	18	1, 17
19-1508 - Vol 02, Newton, Raymond	303	2	304	3	1, 4, 3, 5, 17
19-1508 - Vol 02, Newton, Raymond	304	4	304	6	1, 17
19-1508 - Vol 02, Newton, Raymond	304	15	305	6	1, 4, 3, 5, 17, DAUB
19-1508 - Vol 02, Newton, Raymond	305	9	305	14	1, 4, 3, 5, 17, DAUB
19-1508 - Vol 02, Newton, Raymond	308	13	308	24	1, 4, 5, 17, MIL3
19-1508 - Vol 02, Newton, Raymond	319	23	320	11	1, 3, 4, 5, 17

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
19-1508 - Vol 02, Newton, Raymond	288	17	289	2	289:3-20	Sage Counter Designations
19-1508 - Vol 02, Newton, Raymond	309	7	310	7	e.g., pp. 287, 288-289, 308	Sage Counter Designations
19-1508 - Vol 02, Newton, Raymond	310	16	311	22	e.g., pp. 289-299	Sage Counter Designations
19-1508 - Vol 02, Newton, Raymond	311	23	312	14	289:21-300:2	Sage Contingent
19-1508 - Vol 02, Newton, Raymond	312	15	312	20	e.g., pp. 289-299	Sage Counter Designations
19-1508 - Vol 02, Newton, Raymond	313	3	314	23	e.g., pp. 289-299	Sage Counter Designations
19-1508 - Vol 02, Newton, Raymond	315	13	315	16	e.g., pp. 289-299	Sage Counter Designations
19-1508 - Vol 02, Newton, Raymond	317	8	317	10	e.g., pp. 289-299, 317	Sage Counter Designations
19-1508 - Vol 02, Newton, Raymond	317	11	317	15	e.g., pp. 289-299, 304-305	Sage Counter Designations
19-1508 - Vol 02, Newton, Raymond	317	18	317	20	e.g., pp. 289-299, 304-305	Sage Counter Designations
19-1508 - Vol 02, Newton, Raymond	319	20	319	22	e.g., pp. 289-99; 320-321	Sage Counter Designations
19-1508 - Vol 02, Newton, Raymond	320	12	320	20	e.g., pp. 289-299;304-305; 320-321; C. Newton Tr. Designations	Sage Counter Designations
19-1508 - Vol 02, Newton, Raymond	321	1	321	15	e.g., pp. 289-299; Newton Designations (e.g., 187:8-188:13)	Sage Counter Designations
19-1508 - Vol 02, Newton, Raymond	322	10	322	16	e.g., pp. 289-299; Newton Designations (e.g., 187:8-188:13)	Sage Counter Designations
19-1508 - Vol 02, Newton, Raymond	323	11	323	15	e.g., pp. 289-299; Newton Designations (e.g., 187:8-188:13)	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Ray 2021-04-13	9	15	9	18	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2021-04-13	21	4	21	11	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2021-04-13	35	19	35	20	e.g., Ray Newton Trial Tr. pp. 299-302, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	35	22	36	3	e.g., Ray Newton Trial Tr. pp. 299-302, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	36	10	36	18	e.g., Ray Newton Trial Tr. pp. 299-302, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	37	12	38	6	e.g., Ray Newton Trial Tr. e.g., pp. 289-302, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	38	8	38	14	e.g., Ray Newton Trial Tr. e.g., pp. 289-302, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	38	17	38	23	e.g., Ray Newton Trial Tr. e.g., pp. 289-302, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	38	25	39	4	e.g., Ray Newton Trial Tr. e.g., pp. 289-302, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	39	14	40	14	e.g., Ray Newton Trial Tr. e.g., pp. 289-302, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	43	5	43	13	e.g., Ray Newton Trial Tr. e.g., pp. 289-302, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	43	15	44	12	e.g., Ray Newton Trial Tr. e.g., pp. 289-302, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	44	15	44	23	e.g., Ray Newton Trial Tr. e.g., pp. 289-302, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	44	25	45	2	e.g., Ray Newton Trial Tr. e.g., pp. 289-302, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	45	4	45	11	e.g., Ray Newton Trial Tr. e.g., pp. 289-302, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	45	22	45	23	e.g., Ray Newton Trial Tr. e.g., pp. 289-302, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	45	25	46	7	e.g., Ray Newton Trial Tr. e.g., pp. 289-302, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	46	10	46	11	e.g., Ray Newton Trial Tr. e.g., pp. 289-302, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	46	21	46	22	e.g., Ray Newton Trial Tr. e.g., pp. 289-302, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	46	25	47	13	e.g., Ray Newton Trial Tr. e.g., pp. 289-302, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	91	24	96	1	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2021-04-13	96	5	97	16	e.g., Ray Newton Trial Tr. e.g., pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2021-04-13	97	23	98	1	e.g., Ray Newton Trial Tr. e.g., pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2021-04-13	98	5	98	17	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	98	24	99	10	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
	101	1	101	3	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	105	20	106	19	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	109	6	110	10	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	148	15	148	17	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2021-04-13	153	22	154	7	e.g., Ray Newton Trial Tr. pp. 289-302, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	154	10	155	10	e.g., Ray Newton Trial Tr. pp. 289-302, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	155	13	155	16	e.g., Ray Newton Trial Tr. pp. 289-302, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	160	12	160	16	e.g., Ray Newton Trial Tr. pp. 289-302, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	160	19	160	23	e.g., Ray Newton Trial Tr. pp. 289-302, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	161	18	161	25	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	162	3	162	4	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	162	7	162	9	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	162	12	162	15	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	162	17	162	19	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	163	2	163	11	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	163	12	163	14	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	163	17	163	21	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	163	23	163	24	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	164	1	164	3	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	164	5	164	8	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	164	12	164	14	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	164	25	165	11	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	165	13	165	13	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	165	16	165	21	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	165	22	166	5	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Ray 2021-04-13	167	4	168	8	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	168	10	168	17	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	168	21	168	23	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	169	3	169	4	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	169	7	169	9	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	199	6	199	9	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	199	12	199	19	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	199	23	199	25	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	200	2	200	4	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	200	7	200	11	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	200	14	200	21	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320; Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Ray 2021-04-13	201	15	201	18	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320; Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Ray 2021-04-13	201	21	201	25	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320; Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Ray 2021-04-13	202	3	202	3	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320; Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Ray 2021-04-13	202	16	202	18	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320; Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Ray 2021-04-13	202	22	202	23	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320; Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Ray 2021-04-13	203	1	203	5	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320; Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Ray 2021-04-13	203	11	203	13	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320; Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Ray 2021-04-13	203	16	203	23	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320; Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Ray 2021-04-13	204	1	204	1	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320; Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Ray 2021-04-13	204	3	204	5	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320; Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Ray 2021-04-13	204	7	204	7	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320; Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Ray 2021-04-13	204	9	204	11	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320; Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Ray 2021-04-13	204	14	204	17	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320; Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Ray 2021-04-13	204	19	204	22	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320; Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Ray 2021-04-13	204	25	205	4	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320; Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Ray 2021-04-13	205	7	205	8	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320; Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Ray 2021-04-13	205	10	205	11	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320; Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Ray 2021-04-13	205	14	205	20	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320; Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Ray 2021-04-13	207	17	207	19	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Ray 2021-04-13	207	22	207	23	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	208	3	208	10	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320; Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Ray 2021-04-13	208	12	208	13	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320; Camille Newton Trial Tr. 187:8-188:13	Sage Counter Designations
Newton, Ray 2021-04-13	209	11	209	12	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	209	15	209	20	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	209	22	210	1	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	210	21	210	23	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	211	1	211	6	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	211	9	211	9	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	212	23	213	4	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	213	7	213	7	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	213	17	213	18	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	213	21	213	25	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	214	3	214	4	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	218	5	218	7	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Contingent
Newton, Ray 2021-04-13	218	10	218	10	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Contingent
Newton, Ray 2021-04-13	218	12	218	15	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Contingent
Newton, Ray 2021-04-13	219	19	219	20	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320; Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Ray 2021-04-13	219	23	219	24	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320; Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Ray 2021-04-13	220	2	220	3	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320; Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Ray 2021-04-13	220	5	220	10	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320; Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Ray 2021-04-13	220	12	220	13	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320; Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Ray 2021-04-13	220	17	220	18	e.g., Ray Newton Trial Tr. e.g., pp. 299-304, 319-320; Camille Newton Trial Tr. 196:25-198:19; 199:2-207:9	Sage Counter Designations
Newton, Ray 2021-04-13	220	21	220	23	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2021-04-13	248	4	248	5	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Contingent
Newton, Ray 2021-04-13	248	8	248	12	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Contingent
Newton, Ray 2021-04-13	248	15	248	19	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Contingent
Newton, Ray 2021-04-13	251	4	251	11	e.g., Ray Newton Trial Tr. e.g., pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2021-04-13	251	16	252	2	e.g., Ray Newton Trial Tr. e.g., pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2021-04-13	252	6	252	7	e.g., Ray Newton Trial Tr. e.g., pp. 287, 288-289, 308; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Ray 2021-04-13	252	10	252	14	e.g., Ray Newton Trial Tr. e.g., pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2021-04-13	252	17	252	19	e.g., Ray Newton Trial Tr. e.g., pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2021-04-13	254	1	254	3	e.g., Ray Newton Trial Tr. e.g., pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2021-04-13	254	6	254	10	e.g., Ray Newton Trial Tr. e.g., pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2021-04-13	254	13	254	13	e.g., Ray Newton Trial Tr. e.g., pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2021-04-13	256	23	257	3	e.g., Ray Newton Trial Tr. e.g., pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2021-04-13	257	13	257	19	e.g., Ray Newton Trial Tr. e.g., pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2021-04-13	259	16	259	17	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 299-302, 308, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	259	19	260	24	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 299-302, 308, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	261	3	261	5	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 299-302, 308, 319-320	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Ray 2021-04-13	262	7	262	25	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 299-302, 308, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	263	19	263	22	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 299-302, 308, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	264	8	264	24	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 299-302, 308, 319-320	Sage Counter Designations
Newton, Ray 2021-04-13	265	1	265	2	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 299-302, 308, 319-320	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Ray 2023-05-03	4	19	4	22	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2023-05-03	62	4	62	21	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Ray 2023-05-03	64	22	65	1	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:21	Sage Counter Designations
Newton, Ray 2023-05-03	65	7	65	13	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	65	21	66	13	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	66	18	66	23	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	67	3	67	7	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	67	16	67	18	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	67	21	67	22	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	68	1	68	4	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	68	7	68	9	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Ray 2023-05-03	68	13	68	14	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	69	21	69	23	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	70	3	70	3	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	70	5	70	8	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	70	11	70	11	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	95	3	95	5	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	95	12	95	16	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	95	19	95	22	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	96	2	96	8	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	97	7	97	11	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Ray 2023-05-03	97	14	97	14	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	98	4	98	5	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	98	10	98	13	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	100	9	100	10	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
	100	14	100	14	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	100	16	100	18	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	100	23	100	24	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	101	1	101	3	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	101	13	102	4	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	103	18	103	22	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Ray 2023-05-03	105	3	105	5	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	105	9	105	11	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	106	2	106	7	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	106	12	106	13	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	106	15	106	17	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	106	20	106	23	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	107	14	107	23	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	108	1	108	3	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	108	6	108	7	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	108	10	108	10	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Ray 2023-05-03	108	12	108	13	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	108	16	108	16	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	108	18	108	18	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	108	22	108	23	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	109	19	109	20	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	110	1	111	15	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	112	8	112	11	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	112	14	112	15	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	112	17	112	20	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	113	21	113	23	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Ray 2023-05-03	114	2	114	5	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	115	12	115	15	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	115	18	115	18	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	115	20	115	21	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	115	24	116	1	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	116	3	116	9	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	121	22	121	24	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	122	5	122	8	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	123	1	123	3	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	123	6	123	6	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Ray 2023-05-03	123	8	123	9	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	123	12	123	13	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	123	15	123	18	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	124	15	124	17	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	124	21	124	23	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	132	22	132	24	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	133	5	133	8	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	133	11	133	12	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	133	18	133	23	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	134	7	134	8	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Ray 2023-05-03	134	12	134	15	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	134	23	134	24	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	135	5	135	6	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	135	11	135	14	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	135	17	135	19	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	135	23	135	23	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	136	1	136	3	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	136	8	136	10	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	136	14	136	16	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	137	2	137	3	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Ray 2023-05-03	137	10	137	11	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	137	14	137	16	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	138	10	138	12	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	138	16	138	16	e.g., Ray Newton Trial Tr. pp. 289-299; Camille Newton Trial Tr. e.g., 173:20-177:25; 178:22-179:22; 187:8-188:13	Sage Counter Designations
Newton, Ray 2023-05-03	146	3	146	3	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	146	5	146	6	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	146	11	146	14	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	146	21	146	22	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	147	2	147	2		Sage Counter Designations
Newton, Ray 2023-05-03	147	11	147	12		Sage Counter Designations
Newton, Ray 2023-05-03	147	16	147	17		Sage Counter Designations
Newton, Ray 2023-05-03	160	2	160	3	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Ray 2023-05-03	160	8	160	13	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	160	22	160	22	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	161	1	161	2	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	161	21	161	24	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	162	24	163	3	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	163	6	163	7	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	163	19	164	4	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	164	7	164	7	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Ray 2023-05-03	164	17	164	19	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	164	22	164	22	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	164	24	165	2	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	165	5	165	5	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	168	17	168	19	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	168	23	168	24	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	170	3	170	9	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	170	17	170	20	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Ray 2023-05-03	171	2	171	7	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	171	11	171	14	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	171	16	171	21	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	174	16	174	21	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	175	1	175	2	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	176	5	176	7	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	176	12	176	20	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	177	1	177	2	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Ray 2023-05-03	177	16	177	21	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	178	4	178	6	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	178	10	178	11	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	178	16	178	16	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	178	18	178	21	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	179	1	179	2	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	179	9	179	12	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	179	16	179	23	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Ray 2023-05-03	180	3	180	8	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	180	12	180	12	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	180	14	180	17	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	181	1	181	4	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	182	6	182	9	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	184	4	184	7	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	185	14	185	17	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	186	23	187	10	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Ray 2023-05-03	187	15	187	18	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 173:20-177:25; 178:22-179:21; 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	193	2	193	3	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2023-05-03	193	13	193	18	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2023-05-03	194	7	194	9	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2023-05-03	194	13	194	14	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2023-05-03	198	3	198	9	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2023-05-03	205	12	205	14	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2023-05-03	205	19	205	22	e.g., Ray Newton Trial Tr. pp. 289-302; 319-320; Camille Newton Trial Tr. 178:9-185:22; 186:17-24; 199:2-201:5	Sage Counter Designations
Newton, Ray 2023-05-03	205	23	206	2	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2023-05-03	206	7	206	7	e.g., Ray Newton Trial Tr. pp. 289-299	Sage Counter Designations
Newton, Ray 2023-05-03	206	15	206	23	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2023-05-03	207	2	207	4	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2023-05-03	207	9	207	9	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2023-05-03	207	11	207	11	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2023-05-03	207	13	207	15	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2023-05-03	207	18	207	18	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2023-05-03	207	20	207	21	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2023-05-03	207	24	208	1	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2023-05-03	208	5	208	9	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2023-05-03	208	11	208	13	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2023-05-03	208	16	208	16	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2023-05-03	208	18	208	21	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 308	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Newton, Ray 2023-05-03	208	24	208	24	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2023-05-03	209	9	209	10	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2023-05-03	209	15	209	22	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2023-05-03	209	23	210	2	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2023-05-03	210	6	210	7	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2023-05-03	210	9	210	11	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2023-05-03	210	14	210	14	e.g., Ray Newton Trial Tr. pp. 287, 288-289, 308	Sage Counter Designations
Newton, Ray 2023-05-03	221	9	221	11	e.g., Ray Newton Trial Tr. pp 299-302, 319-320	Sage Counter Designations
Newton, Ray 2023-05-03	221	16	221	18	e.g., Ray Newton Trial Tr. pp 299-302, 319-320	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Paskal, Kelsey 2021-03-10	7	15	7	20	Entirety of transcript to the extent it is being used inconsistently with Sage's MILs/DAUB
Paskal, Kelsey 2021-03-10	22	2	22	21	
Paskal, Kelsey 2021-03-10	22	24	23	2	
Paskal, Kelsey 2021-03-10	23	11	23	20	
Paskal, Kelsey 2021-03-10	24	2	24	10	
Paskal, Kelsey 2021-03-10	24	13	24	14	
Paskal, Kelsey 2021-03-10	25	3	25	5	
Paskal, Kelsey 2021-03-10	25	8	25	23	
Paskal, Kelsey 2021-03-10	26	24	27	7	1, 5, 17, MIL 1
Paskal, Kelsey 2021-03-10	27	10	27	19	1, 5, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	28	18	29	3	1, 5, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	29	6	29	9	1, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	29	16	29	25	1, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	30	2	30	3	1, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	31	2	31	5	1, 11,17, 22, 23, MIL 1
Paskal, Kelsey 2021-03-10	31	9	31	14	1, 11, 17, 22, 23, MIL 1
Paskal, Kelsey 2021-03-10	31	18	31	25	1, 5, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	32	4	32	12	1, 5, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	32	15	32	22	1, 5, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	33	23	34	13	1, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	34	16	34	18	1, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	40	8	40	10	1, 5, 17, MIL 1
Paskal, Kelsey 2021-03-10	40	13	40	16	1, 5, 17, MIL 1
Paskal, Kelsey 2021-03-10	41	10	41	12	1, 5, 17, MIL 1
Paskal, Kelsey 2021-03-10	41	15	41	18	1, 5, 17, MIL 1, Outside Scope
Paskal, Kelsey 2021-03-10	42	2	42	8	1, 5, 17, 22, 23, MIL 1
Paskal, Kelsey 2021-03-10	42	12	42	20	1, 5,17, 20, 23, MIL 1
Paskal, Kelsey 2021-03-10	42	24	43	3	1, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	43	24	44	3	1, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	44	6	44	8	1, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	45	6	45	12	1, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	45	23	46	7	1, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	48	15	48	21	1, 5, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	49	6	49	20	1, 5, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	49	23	49	24	1, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	50	23	51	4	1, 5, 6, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	51	7	51	11	1, 5, 6, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	56	18	56	22	1, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	57	12	58	2	1, 5, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	58	5	58	8	1, 5, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	60	5	60	9	1, 5, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	60	12	60	14	1, 5, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	60	23	61	7	1, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	61	17	61	19	1, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	61	22	62	5	1, 5, 15, 17, 23, MIL 1, Outside Scope
Paskal, Kelsey 2021-03-10	62	9	62	12	1, 5, 15, 17, 23, MIL, Outside Scope
Paskal, Kelsey 2021-03-10	63	15	63	18	1, 5, 12, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	63	22	64	7	1, 5, 12, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	64	10	64	14	1, 5, 12, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	68	12	68	15	1, 5, 6, 17, 23, MIL 1

Paskal, Kelsey 2021-03-10	68	18	68	19	1, 5, 6, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	89	23	90	6	1, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	90	19	90	25	1, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	99	20	100	10	1, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	100	13	100	18	1, 5, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	100	21	100	25	1, 5, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	101	22	102	2	1, 5, 12, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	102	5	102	7	1, 5, 12, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	135	10	135	11	1, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	135	15	135	20	1, 5, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	135	23	136	3	1, 5, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	136	12	136	15	1, 5, 11, 17, 23, MIL, Outside Scope
Paskal, Kelsey 2021-03-10	136	19	136	24	1, 5, 11, 17, 23, MIL, Outside Scope
Paskal, Kelsey 2021-03-10	137	3	137	4	1, 5, 17, 23, MIL, Outside Scope
Paskal, Kelsey 2021-03-10	137	18	137	19	1, 5, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	137	22	138	5	1, 5, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	159	4	159	7	1, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	159	12	159	18	1, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	161	3	161	5	1, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	161	9	161	10	1, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	163	18	164	18	1, 17, 23, MIL 1
Paskal, Kelsey 2021-03-10	164	25	165	7	1, MIL 1
Paskal, Kelsey 2021-03-10	166	3	166	13	1, 2, 17, MIL 1
Paskal, Kelsey 2021-03-10	167	2	167	8	1, 2, 17, MIL 1
Paskal, Kelsey 2021-03-10	168	10	168	12	1, 17
Paskal, Kelsey 2021-03-10	168	15	168	17	1, 17
Paskal, Kelsey 2021-03-10	168	20	168	22	1, 17
Paskal, Kelsey 2021-03-10	218	25	219	14	1, 17, MIL 1
Paskal, Kelsey 2021-03-10	223	6	223	10	1, 5, 17, MIL 1, Outside Scope
Paskal, Kelsey 2021-03-10	223	13	223	14	1, 5, 17, MIL, Outside Scope
Paskal, Kelsey 2021-03-10	226	15	227	3	1, 2, 17, MIL 1, Outside scope
Paskal, Kelsey 2021-03-10	227	8	227	10	1, 2, 5, 17, MIL 1, Outside Scope
Paskal, Kelsey 2021-03-10	227	14	228	2	1, 2, 5, 17, MIL 1, Outside Scope
Paskal, Kelsey 2021-03-10	228	14	228	17	1, 2, 5, 17, MIL 1, Outside Scope

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Paskal, Kelsey 2021-03-10	27	20	27	23	pp. 25-27	Sage Contingent
Paskal, Kelsey 2021-03-10	28	2	28	4	pp. 25-27	Sage Contingent
Paskal, Kelsey 2021-03-10	28	5	28	9	pp. 25-27	Sage Contingent
Paskal, Kelsey 2021-03-10	36	12	36	18	pp. 25-27	Sage Contingent
Paskal, Kelsey 2021-03-10	43	4	43	6	pp. 42-43	Sage Contingent
Paskal, Kelsey 2021-03-10	43	9	43	15	pp. 42-43	Sage Contingent
Paskal, Kelsey 2021-03-10	44	9	44	12	pp. 40-44	Sage Contingent
Paskal, Kelsey 2021-03-10	44	16	45	5	pp. 40-44	Sage Contingent
Paskal, Kelsey 2021-03-10	49	25	50	3	p. 49	Sage Contingent
Paskal, Kelsey 2021-03-10	50	6	50	18	p. 49	Sage Contingent
Paskal, Kelsey 2021-03-10	50	21	50	22	p. 49	Sage Contingent
Paskal, Kelsey 2021-03-10	54	24	55	3	p. 49	Sage Contingent
Paskal, Kelsey 2021-03-10	55	6	55	11	p. 49	Sage Contingent
Paskal, Kelsey 2021-03-10	62	13	62	17	p. 62	Sage Contingent
Paskal, Kelsey 2021-03-10	62	20	62	22	p. 62	Sage Contingent
Paskal, Kelsey 2021-03-10	64	23	65	3	p. 64	Sage Contingent
Paskal, Kelsey 2021-03-10	65	9	65	15	p. 64	Sage Contingent
Paskal, Kelsey 2021-03-10	65	18	65	21	p. 64	Sage Contingent
Paskal, Kelsey 2021-03-10	66	16	66	20	pp. 62-64	Sage Contingent
Paskal, Kelsey 2021-03-10	66	23	67	3	pp. 62-64	Sage Contingent
Paskal, Kelsey 2021-03-10	67	12	67	13	pp. 62-64	Sage Contingent
Paskal, Kelsey 2021-03-10	67	16	67	21	pp. 62-64	Sage Contingent
Paskal, Kelsey 2021-03-10	91	22	91	25	p. 90	Sage Contingent
Paskal, Kelsey 2021-03-10	92	4	92	6	p. 90	Sage Contingent
Paskal, Kelsey 2021-03-10	92	14	92	16	p. 90	Sage Contingent
	92	20	92	23	p. 90	Sage Contingent
Paskal, Kelsey 2021-03-10	99	5	99	7	pp. 40-42, 62-64 and Gohde Trial Testimony at 344-354.	Sage Contingent
Paskal, Kelsey 2021-03-10	99	11	99	19	pp. 40-42, 62-64 and Gohde Trial Testimony at 344-354	Sage Contingent
Paskal, Kelsey 2021-03-10	101	2	101	21	pp. 101-102	Sage Contingent
Paskal, Kelsey 2021-03-10	164	19	164	19	p. 164	Sage Contingent
Paskal, Kelsey 2021-03-10	164	23	164	24	p. 164	Sage Contingent
Paskal, Kelsey 2021-03-10	165	18	165	19	p. 164	Sage Contingent
Paskal, Kelsey 2021-03-10	165	23	166	2	p. 164	Sage Contingent
Paskal, Kelsey 2021-03-10	166	14	166	20	p. 166	Sage Contingent
Paskal, Kelsey 2021-03-10	166	24	166	25	p. 166	Sage Contingent
Paskal, Kelsey 2021-03-10	227	4	227	7	pp. 226, 227	Sage Contingent
Paskal, Kelsey 2021-03-10	228	18	228	21	pp. 227-228	Sage Contingent
Paskal, Kelsey 2021-03-10	228	25	229	3	pp. 227-228	Sage Contingent

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
19-1508 - Vol 03, Paskal, Kelsey	667	12	667	15	Entirety of transcript to the extent it is being used inconsistently with Sage's MILs/DAUB
19-1508 - Vol 03, Paskal, Kelsey	667	20	669	1	1, 4, 17, 23, MIL1
19-1508 - Vol 03, Paskal, Kelsey	691	9	693	14	1, 4, 5, 17, 23, MIL1



Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
19-1508 - Vol 03, Paskal, Kelsey	669	2	669	24	667:20-669:1	Sage Counter Designations
19-1508 - Vol 03, Paskal, Kelsey	670	1	670	23	Counter to Gohde Trial Tr. 344-354	Sage Contingent
19-1508 - Vol 03, Paskal, Kelsey	671	8	671	22	Counter to Gohde 344-354 Trial Tr.	Sage Contingent
19-1508 - Vol 03, Paskal, Kelsey	672	21	673	19	Counter to Gohde Trial Tr. at 344-354.	Sage Contingent
19-1508 - Vol 03, Paskal, Kelsey	673	21	674	7	Counter to Gohde Trial Tr. 344-354	Sage Contingent
19-1508 - Vol 03, Paskal, Kelsey	674	18	676	18	Counter to Gohde Trial Tr. 344-354	Sage Contingent
19-1508 - Vol 03, Paskal, Kelsey	676	19	676	21	Counter to Gohde Trial Tr. 344-354	Sage Contingent
19-1508 - Vol 03, Paskal, Kelsey	677	12	678	2	Counter to Gohde Trial Tr. 34-354	Sage Contingent
19-1508 - Vol 03, Paskal, Kelsey	678	3	678	6	Counter to Gohde 344-354	Sage Contingent
19-1508 - Vol 03, Paskal, Kelsey	678	15	679	3	Counter to Gohde Trial Tr. 344-354	Sage Contingent
19-1508 - Vol 03, Paskal, Kelsey	679	4	679	8	Counter to Gohde 344-354	Sage Contingent
19-1508 - Vol 03, Paskal, Kelsey	679	23	683	6	Counter to Gohde Trial Tr. 344-354	Sage Contingent
19-1508 - Vol 03, Paskal, Kelsey	693	21	695	9	pp. 691-693; Gohde Trial Testimony at pp. 344-354.	Sage Contingent

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Pawlik, Kate 2023-03-17	4	21	5	2	1, 17
Pawlik, Kate 2023-03-17	20	17	20	19	1, 17
Pawlik, Kate 2023-03-17	20	23	20	24	1, 17
Pawlik, Kate 2023-03-17	21	18	21	19	1, 17
Pawlik, Kate 2023-03-17	21	22	21	24	1, 17
Pawlik, Kate 2023-03-17	22	1	22	1	1, 17
Pawlik, Kate 2023-03-17	22	3	22	5	1, 17
Pawlik, Kate 2023-03-17	22	8	22	9	1, 17
Pawlik, Kate 2023-03-17	22	17	22	24	1, 3, 17
Pawlik, Kate 2023-03-17	46	6	46	8	1, 17
Pawlik, Kate 2023-03-17	46	12	46	13	1, 17
Pawlik, Kate 2023-03-17	225	7	225	14	1, 17
Pawlik, Kate 2023-03-17	225	15	225	18	1, 17
Pawlik, Kate 2023-03-17	225	22	225	23	1, 17

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Pawlik, Kate 2023-03-17	15	18	15	21	p. 46; **Many of Sage's counterdesignations are applicable to numerous PureWick designations across multiple witnesses and topic areas. Identification of page numbers are exemplary.	Sage Counter Designations
Pawlik, Kate 2023-03-17	19	12	19	13	p. 46	Sage Counter Designations
Pawlik, Kate 2023-03-17	19	16	19	18	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	19	21	19	22	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	20	8	20	14	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	21	2	21	3	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	21	16	21	16	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	23	17	23	20	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	26	12	26	17	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	26	24	27	2	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	29	6	29	14	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	29	19	30	1	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	30	2	30	8	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	30	11	30	18	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	30	19	30	21	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	31	1	31	3	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	31	14	31	17	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	31	20	31	21	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	31	23	32	1	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	32	24	33	4	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	33	17	33	19	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	33	23	33	24	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	36	16	36	17	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	36	21	36	23	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	37	1	37	5	e.g., pp. 20-22	Sage Counter Designations
	37	8	37	14	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	38	8	38	15	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	39	23	40	2	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	41	1	41	4	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	41	7	41	8	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	41	13	41	16	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	41	21	41	22	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	42	3	42	7	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	42	8	42	14	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	43	20	43	23	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	45	6	45	9	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	46	21	46	24	e.g., pp. 20-22, 46	Sage Counter Designations
Pawlik, Kate 2023-03-17	47	3	47	3	e.g., pp. 20-22, 46	Sage Counter Designations
Pawlik, Kate 2023-03-17	47	5	47	8	e.g., pp. 20-22, 46	Sage Counter Designations
Pawlik, Kate 2023-03-17	47	12	47	12	e.g., pp. 20-22, 46	Sage Counter Designations
Pawlik, Kate 2023-03-17	47	14	47	20	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	48	13	48	16	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	48	20	48	20	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	50	11	50	13	e.g., pp. 20-22	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Pawlik, Kate 2023-03-17	50	16	50	17	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	52	14	53	3	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	53	4	53	7	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	53	11	53	12	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	55	12	55	14	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	55	17	55	17	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	55	22	56	1	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	56	6	56	8	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	57	9	57	12	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	57	15	57	15	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	58	15	58	19	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	58	20	59	1	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	59	4	59	5	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	59	7	59	12	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	60	4	60	7	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	60	8	60	17	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	62	4	62	6	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	63	1	63	4	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	63	7	63	7	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	65	19	65	21	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	65	24	66	1	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	66	3	66	5	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	66	8	66	8	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	66	22	66	24	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	67	3	67	3	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	67	12	67	23	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	68	5	68	7	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	68	11	68	12	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	69	14	69	17	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	71	22	72	3	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	72	4	72	7	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	72	10	72	11	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	73	21	73	24	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	74	5	74	7	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	74	8	74	13	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	74	14	74	21	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	75	1	75	7	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	75	11	75	13	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	75	15	75	18	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	75	19	75	24	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	77	16	77	19	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	77	24	78	3	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	78	17	78	19	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	79	13	79	16	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	79	20	80	1	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	80	16	80	23	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	81	4	81	7	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	81	13	81	16	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	82	23	82	24	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	83	3	83	8	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	83	11	83	17	e.g., pp. 20-22	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Pawlik, Kate 2023-03-17	83	18	83	20	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	83	24	84	3	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	84	8	84	11	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	84	16	84	18	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	85	15	85	18	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	86	2	86	11	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	86	12	86	24	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	87	11	87	13	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	87	17	87	18	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	87	23	88	2	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	88	20	88	24	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	89	1	89	4	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	89	7	89	7	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	89	13	89	21	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	89	22	90	4	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	90	8	90	10	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	90	15	90	22	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	91	1	91	11	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	91	15	91	18	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	91	23	92	2	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	92	7	92	10	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	93	10	93	13	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	93	14	93	17	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	94	9	94	11	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	94	14	94	24	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	95	3	95	4	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	95	6	95	9	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	95	12	95	19	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	95	22	95	22	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	96	2	96	3	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	96	7	96	10	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	96	15	96	19	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	97	1	97	4	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	97	18	97	21	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	98	3	98	5	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	98	7	98	14	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	98	18	98	21	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	99	5	99	19	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	100	1	100	2	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	100	13	100	20	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	100	21	100	24	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	101	4	101	6	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	101	12	101	23	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	103	10	103	10	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	103	14	103	17	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	104	6	104	9	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	104	14	104	16	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	105	4	105	7	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	105	23	106	2	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	106	3	106	7	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	108	12	108	14	e.g., pp. 20-22	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Pawlik, Kate 2023-03-17	108	18	108	19	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	108	23	109	1	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	109	4	109	5	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	109	7	109	11	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	110	9	110	12	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	110	23	111	3	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	111	4	111	5	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	111	8	111	9	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	111	13	111	16	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	112	15	112	17	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	112	18	112	21	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	112	24	113	1	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	113	3	113	4	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	113	7	113	8	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	113	13	113	24	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	114	9	114	13	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	114	16	114	23	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	115	4	115	7	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	115	12	115	15	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	117	8	117	11	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	117	16	117	19	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	117	22	118	4	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	118	22	118	23	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	119	3	119	4	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	120	7	120	10	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	121	3	121	5	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	121	12	121	13	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	121	22	122	4	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	122	10	122	12	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	122	15	122	16	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	122	18	123	3	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	123	7	123	15	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	123	16	123	20	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	125	3	125	5	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	125	9	125	11	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	126	20	126	21	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	127	1	127	3	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	127	5	127	8	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	127	17	127	20	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	128	5	128	13	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	128	14	128	19	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	128	22	129	6	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	129	9	129	15	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	129	16	129	18	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	129	22	130	6	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	130	17	130	20	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	130	24	131	6	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	131	9	131	10	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	131	15	131	21	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	131	23	131	24	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	132	4	132	5	e.g., pp. 20-22	Sage Counter Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Pawlik, Kate 2023-03-17	133	6	133	8	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	133	11	133	12	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	133	16	133	18	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	133	22	133	22	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	133	24	134	6	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	134	10	134	13	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	134	16	134	18	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	135	5	135	6	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	135	9	135	10	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	135	13	135	16	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	135	18	135	19	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	135	22	135	23	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	136	9	136	10	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	136	13	136	20	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	136	21	136	22	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	137	1	137	3	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	137	6	137	7	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	137	10	137	13	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	137	18	137	19	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	137	22	138	1	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	138	21	138	22	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	140	7	140	9	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	140	13	140	15	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	140	21	140	21	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	141	1	141	3	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	147	11	147	14	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	147	18	147	20	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	147	21	148	2	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	148	6	148	9	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	148	10	148	22	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	149	7	149	9	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	149	12	149	12	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	149	20	149	22	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	154	8	154	11	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	154	14	154	14	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	154	16	154	19	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	154	22	154	22	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	156	10	156	11	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	156	15	156	15	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	157	16	157	20	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	158	5	158	9	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	159	2	159	5	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	159	21	160	2	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	167	22	168	6	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	168	19	168	22	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	168	24	169	3	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	169	24	170	4	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	171	5	171	6	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	171	9	171	9	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	173	11	173	14	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	173	19	173	21	e.g., pp. 20-22	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Pawlik, Kate 2023-03-17	174	2	174	2	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	174	8	174	11	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	175	1	175	4	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	175	7	175	19	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	175	22	176	6	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	176	10	176	10	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	176	14	176	17	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	176	19	176	23	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	177	12	177	19	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	177	23	177	24	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	178	2	178	4	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	178	7	178	11	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	179	5	179	9	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	179	12	179	13	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	179	18	179	23	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	179	24	180	2	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	180	5	180	5	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	180	21	180	24	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	181	5	181	13	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	181	21	182	1	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	182	4	182	5	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	183	22	183	23	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	184	3	184	6	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	184	10	184	13	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	184	17	185	1	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	185	4	185	7	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	185	11	185	13	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	185	19	186	6	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	186	10	186	13	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	186	15	186	17	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	187	2	187	12	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	187	18	187	22	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	188	5	188	10	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	188	14	188	17	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	189	6	189	12	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	189	15	189	17	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	191	5	191	12	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	191	16	191	18	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	192	9	192	11	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	192	15	192	22	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	193	2	193	2	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	194	17	194	23	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	195	4	195	8	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	195	13	195	16	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	196	8	196	11	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	196	16	196	17	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	197	2	197	5	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	197	8	197	9	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	198	7	198	10	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	198	12	198	15	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	198	19	198	21	e.g., pp. 20-22	Sage Counter Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Pawlik, Kate 2023-03-17	198	24	199	3	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	199	8	199	11	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	199	15	199	18	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	199	20	199	23	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	200	4	200	13	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	200	16	200	24	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	201	1	201	7	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	202	2	202	6	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	202	9	202	10	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	203	3	203	4	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	203	8	203	11	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	204	5	204	16	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	204	19	205	3	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	205	15	205	19	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	206	7	206	10	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	206	14	206	16	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	207	20	207	23	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	208	1	208	6	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	208	15	208	18	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	210	2	210	5	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	210	13	210	15	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	210	18	210	19	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	211	1	211	4	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	211	5	211	14	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	211	18	211	21	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	211	23	212	1	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	213	9	213	13	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	213	14	213	18	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	214	13	214	16	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	214	22	214	24	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	215	10	215	12	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	215	13	215	20	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	215	21	216	11	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	218	7	218	10	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	218	13	218	16	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	219	2	219	7	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	219	12	219	17	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	220	4	220	7	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	220	8	220	15	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	220	19	220	21	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	221	5	221	10	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	221	16	222	1	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	222	16	222	20	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	222	23	222	23	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	224	14	225	2	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	225	3	225	6	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	226	1	226	4	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	226	12	226	13	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	226	15	226	17	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	227	22	228	1	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	229	12	229	15	e.g., pp. 20-22	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Pawlik, Kate 2023-03-17	229	23	230	3	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	230	4	230	9	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	231	11	231	16	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	232	1	232	2	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	232	6	232	6	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	235	17	236	2	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	236	3	236	4	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	236	8	236	17	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	236	21	237	2	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	237	7	237	9	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	237	15	237	17	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	237	23	237	24	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	238	4	238	8	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	240	5	240	7	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	240	12	240	15	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	240	24	241	2	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	241	8	241	8	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	242	5	242	8	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	242	13	242	16	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	242	18	243	1	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	243	17	243	21	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	243	23	244	11	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	244	15	244	17	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	245	3	245	5	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	245	9	245	9	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	245	14	245	17	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	246	5	246	8	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	246	13	246	15	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	247	16	247	22	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	248	5	248	9	e.g., pp. 20-22, 46	Sage Counter Designations
Pawlik, Kate 2023-03-17	249	1	249	3	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	250	17	250	20	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	250	24	251	5	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	252	12	252	15	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	253	3	253	7	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	253	20	254	4	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	255	6	255	9	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	255	11	255	18	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	255	21	255	23	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	256	2	256	5	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	256	7	256	9	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	256	15	256	20	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	257	4	257	4	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	257	9	257	12	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	257	20	257	23	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	258	1	258	4	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	258	7	258	10	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	258	12	258	19	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	258	23	259	8	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	259	12	259	15	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	259	17	259	20	e.g., pp. 20-22	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Pawlik, Kate 2023-03-17	260	1	260	3	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	260	22	260	24	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	261	5	261	6	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	261	23	262	2	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	262	4	262	8	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	262	11	262	12	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	262	24	263	3	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	263	5	263	13	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	263	17	263	20	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	263	22	264	5	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	264	6	264	7	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	264	10	264	11	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	264	24	265	3	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	265	12	265	17	e.g., pp. 20-22	Sage Counter Designations
Pawlik, Kate 2023-03-17	266	9	266	12	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	266	14	266	18	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	266	22	266	24	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	267	3	267	4	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	268	18	269	3	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	269	6	269	9	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	269	13	269	20	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	269	23	270	1	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	270	5	270	17	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	270	20	271	1	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	271	2	271	12	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	271	18	272	3	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	272	19	272	22	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	272	24	273	4	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	274	5	274	11	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	274	17	274	23	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	275	2	275	4	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	275	6	275	9	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	275	13	275	17	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	275	22	275	24	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	276	11	276	19	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	276	20	277	7	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	277	8	277	15	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	277	16	277	17	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	277	21	277	23	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	278	1	278	2	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	283	15	283	18	e.g., pp. 20-22, 225	Sage Counter Designations
Pawlik, Kate 2023-03-17	283	20	284	8	e.g., pp. 20-22, 225	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Polanco, Patricia 2023-01-27	7	8	7	10	
Polanco, Patricia 2023-01-27	21	15	21	24	1, 5, 17
Polanco, Patricia 2023-01-27	22	2	22	3	
Polanco, Patricia 2023-01-27	23	15	25	14	1, 2, 3, 5, 17
Polanco, Patricia 2023-01-27	33	5	33	19	1, 17
Polanco, Patricia 2023-01-27	38	4	38	16	1, 4, 5, 17, MIL1
Polanco, Patricia 2023-01-27	38	18	38	22	cont
Polanco, Patricia 2023-01-27	56	17	56	18	1, 5, 17
Polanco, Patricia 2023-01-27	56	20	56	21	continued
Polanco, Patricia 2023-01-27	58	23	59	3	1, 5, 17
Polanco, Patricia 2023-01-27	59	12	59	18	1, 5, 17
Polanco, Patricia 2023-01-27	59	24	60	4	1, 5, 17
Polanco, Patricia 2023-01-27	61	6	61	14	1, 17
Polanco, Patricia 2023-01-27	65	18	66	16	
Polanco, Patricia 2023-01-27	66	22	67	2	
Polanco, Patricia 2023-01-27	70	4	70	16	
Polanco, Patricia 2023-01-27	78	18	79	12	
Polanco, Patricia 2023-01-27	79	15	79	18	

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Polanco, Patricia 2023-01-27	13	5	13	8	7	Sage Counter Designations
Polanco, Patricia 2023-01-27	14	16	14	18	7	Sage Counter Designations
Polanco, Patricia 2023-01-27	17	15	17	19	7, 17	Sage Counter Designations
Polanco, Patricia 2023-01-27	20	12	20	14	17-18	Sage Counter Designations
Polanco, Patricia 2023-01-27	20	16	20	23	17-18	Sage Counter Designations
Polanco, Patricia 2023-01-27	27	7	27	11	23-25	Sage Counter Designations
Polanco, Patricia 2023-01-27	29	6	29	16	23-25	Sage Counter Designations
Polanco, Patricia 2023-01-27	29	18	29	20	23-25	Sage Counter Designations
Polanco, Patricia 2023-01-27	30	16	30	24	23-25	Sage Counter Designations
Polanco, Patricia 2023-01-27	30	25	31	7	23-25	Sage Counter Designations
Polanco, Patricia 2023-01-27	32	7	32	12		Sage Contingent
Polanco, Patricia 2023-01-27	34	11	34	11	33	Sage Counter Designations
Polanco, Patricia 2023-01-27	34	14	34	17	33	Sage Counter Designations
Polanco, Patricia 2023-01-27	34	18	34	19	33	Sage Counter Designations
Polanco, Patricia 2023-01-27	35	2	35	9	33	Sage Counter Designations
Polanco, Patricia 2023-01-27	37	13	37	14	33, 38	Sage Counter Designations
Polanco, Patricia 2023-01-27	37	17	37	23	33, 38	Sage Counter Designations
Polanco, Patricia 2023-01-27	38	23	38	25	38	Sage Counter Designations
Polanco, Patricia 2023-01-27	39	2	39	4	38	Sage Counter Designations
Polanco, Patricia 2023-01-27	40	2	40	4	33, 38	Sage Counter Designations
Polanco, Patricia 2023-01-27	40	6	40	17	33, 38	Sage Counter Designations
Polanco, Patricia 2023-01-27	43	18	43	20	33, 38	Sage Counter Designations
Polanco, Patricia 2023-01-27	43	23	44	4	33, 38	Sage Counter Designations
Polanco, Patricia 2023-01-27	56	10	56	13	56	Sage Counter Designations
Polanco, Patricia 2023-01-27	59	19	59	23	59-60	Sage Counter Designations
	62	11	62	15	61-62	Sage Counter Designations
Polanco, Patricia 2023-01-27	62	16	62	17	continued	Sage Counter Designations
Polanco, Patricia 2023-01-27	62	20	62	23	continued	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Sanchez, Robert 2021-04-21	9	3	9	6	1, 17, MIL3
Sanchez, Robert 2021-04-21	17	24	17	25	1, 17, MIL3
Sanchez, Robert 2021-04-21	18	1	18	10	1, 17, MIL3
Sanchez, Robert 2021-04-21	18	19	19	25	1, 17, MIL3
Sanchez, Robert 2021-04-21	22	23	23	4	1,17, MIL3
Sanchez, Robert 2021-04-21	26	2	26	7	1,17, MIL3
Sanchez, Robert 2021-04-21	26	10	26	16	1,17, MIL3
Sanchez, Robert 2021-04-21	26	18	26	25	1,17, MIL3
Sanchez, Robert 2021-04-21	27	1	27	12	1,17, MIL3
Sanchez, Robert 2021-04-21	27	15	27	17	1,17, MIL3
Sanchez, Robert 2021-04-21	39	2	39	12	1,17, MIL3
Sanchez, Robert 2021-04-21	116	6	116	9	1,17, MIL3
Sanchez, Robert 2021-04-21	116	12	116	18	1,17, MIL3
Sanchez, Robert 2021-04-21	116	20	116	21	1,17, MIL3
Sanchez, Robert 2021-04-21	117	25	118	3	1,17, MIL3
Sanchez, Robert 2021-04-21	118	5	118	6	1,17, MIL3
Sanchez, Robert 2021-04-21	148	4	148	16	1,17, MIL3
Sanchez, Robert 2021-04-21	153	7	153	8	1,17, MIL3
Sanchez, Robert 2021-04-21	153	10	153	24	1,17, MIL3
Sanchez, Robert 2021-04-21	154	1	154	9	1,17, MIL3
Sanchez, Robert 2021-04-21	154	11	154	19	1,17, MIL3
Sanchez, Robert 2021-04-21	154	21	154	25	1,17, MIL3
Sanchez, Robert 2021-04-21	155	2	155	16	1,17, MIL3
Sanchez, Robert 2021-04-21	155	18	155	25	1,17, MIL3
Sanchez, Robert 2021-04-21	156	1	156	1	1,17, MIL3



Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Sanchez, Robert 2021-04-21	12	12	12	16	9:3-6	Sage Contingent
Sanchez, Robert 2021-04-21	16	17	16	20	9:3-6	Sage Contingent
Sanchez, Robert 2021-04-21	16	23	16	24	9:3-6	Sage Contingent
Sanchez, Robert 2021-04-21	17	2	17	5	9:3-6	Sage Contingent
Sanchez, Robert 2021-04-21	21	4	21	8	17:24-18:10, 18:19-19:25, 26:2-27:17	Sage Contingent
Sanchez, Robert 2021-04-21	21	12	21	14	17:24-18:10, 18:19-19:25, 26:2-27:17	Sage Contingent
Sanchez, Robert 2021-04-21	21	21	21	23	17:24-18:10, 18:19-19:25, 26:2-27:17	Sage Contingent
Sanchez, Robert 2021-04-21	38	1	38	3	148:4-16, 116:6-118:6	Sage Contingent
Sanchez, Robert 2021-04-21	38	5	38	5	148:4-16, 116:6-118:6	Sage Contingent
Sanchez, Robert 2021-04-21	40	15	40	16	39:2-12	Sage Contingent
Sanchez, Robert 2021-04-21	40	18	40	19	39:2-12	Sage Contingent
Sanchez, Robert 2021-04-21	41	5	41	8	39:2-12	Sage Contingent
Sanchez, Robert 2021-04-21	41	17	41	19	39:2-12	Sage Contingent
Sanchez, Robert 2021-04-21	41	22	42	10	39:2-12	Sage Contingent
Sanchez, Robert 2021-04-21	44	6	44	9	39:2-12	Sage Contingent
Sanchez, Robert 2021-04-21	68	4	68	6	26:2-27:17; 116:6-118:6	Sage Contingent
Sanchez, Robert 2021-04-21	68	8	68	8	26:2-27:17; 116:6-118:6	Sage Contingent
Sanchez, Robert 2021-04-21	68	10	68	23	26:2-27:17; 116:6-118:6	Sage Contingent
Sanchez, Robert 2021-04-21	69	7	69	18	26:2-27:17; 116:6-118:6	Sage Contingent
Sanchez, Robert 2021-04-21	70	9	70	14	26:2-27:17; 116:6-118:6	Sage Contingent
Sanchez, Robert 2021-04-21	77	14	77	17	26:2-27:17; 116:6-118:6	Sage Contingent
Sanchez, Robert 2021-04-21	77	21	77	23	26:2-27:17; 116:6-118:6	Sage Contingent
Sanchez, Robert 2021-04-21	78	1	78	1	26:2-27:17; 116:6-118:6	Sage Contingent
Sanchez, Robert 2021-04-21	78	12	78	15	26:2-27:17; 116:6-118:6	Sage Contingent
Sanchez, Robert 2021-04-21	78	20	78	22	22:23-23:4; 153:7-156:1; 26:2-27:17; 116:6-118:6	Sage Contingent
	78	25	78	25	22:23-23:4; 153:7-156:1; 26:2-27:17; 116:6-118:6	Sage Contingent
Sanchez, Robert 2021-04-21	79	2	79	4	22:23-23:4; 153:7-156:1; 26:2-27:17; 116:6-118:6	Sage Contingent
Sanchez, Robert 2021-04-21	94	10	94	16	e.g., pp. 26-27	Sage Counter Designations
Sanchez, Robert 2021-04-21	95	5	95	7	e.g., pp. 26-27	Sage Counter Designations
Sanchez, Robert 2021-04-21	96	4	96	5	e.g., pp. 26-27	Sage Counter Designations
Sanchez, Robert 2021-04-21	96	8	96	9	e.g., pp. 26-27	Sage Counter Designations
Sanchez, Robert 2021-04-21	96	11	96	14	e.g., pp. 26-27	Sage Counter Designations
Sanchez, Robert 2021-04-21	121	4	121	6	e.g., 116:6-118:6; 26:2-27:17	Sage Counter Designations
Sanchez, Robert 2021-04-21	121	8	121	13	e.g., 116:6-118:6; 26:2-27:17	Sage Counter Designations
Sanchez, Robert 2021-04-21	124	19	124	22	e.g., 26:2-27:17; 116:6-118:6; 148:4-16	Sage Counter Designations
Sanchez, Robert 2021-04-21	125	4	125	7	e.g., 26:2-27:17; 116:6-118:6; 148:4-16	Sage Counter Designations
Sanchez, Robert 2021-04-21	125	14	126	6	e.g., 26:2-27:17; 116:6-118:6; 148:4-16	Sage Counter Designations
Sanchez, Robert 2021-04-21	126	7	126	9	e.g., 26:2-27:17; 116:6-118:6; 148:4-16	Sage Counter Designations
Sanchez, Robert 2021-04-21	126	21	126	23	e.g., 26:2-27:17; 116:6-118:6; 148:4-16	Sage Counter Designations
Sanchez, Robert 2021-04-21	140	10	140	12	e.g., 116:6-118:6; 26:2-27:17	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Sanchez, Robert 2021-04-21	143	22	143	25	26:2-27:17; 116:6-118:6; 148:4-16	Sage Contingent
Sanchez, Robert 2021-04-21	144	1	144	9	26:2-27:17; 116:6-118:6; 148:4-16	Sage Contingent
Sanchez, Robert 2021-04-21	148	17	148	19	148:4-16; 153:7-156:1	Sage Contingent
Sanchez, Robert 2021-04-21	148	24	149	2	148:4-16; 153:7-156:1	Sage Contingent
Sanchez, Robert 2021-04-21	149	18	149	24	148:4-16; 153:7-156:1	Sage Contingent
Sanchez, Robert 2021-04-21	156	25	157	3	e.g., 148:4-16	Sage Counter Designations
Sanchez, Robert 2021-04-21	157	5	157	5	e.g., 148:4-16	Sage Counter Designations
Sanchez, Robert 2021-04-21	157	7	157	7	e.g., 148:4-16	Sage Counter Designations
Sanchez, Robert 2021-04-21	157	9	157	17	e.g., 26:2-27:17; 116:6-118:6; 148:4-16	Sage Counter Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Sexton, Kristin 2021-03-12	6	17	6	25	Entirety of transcript to the extent it is being used inconsistently with Sage's MILs/DAUB
Sexton, Kristin 2021-03-12	7	2	7	9	1
Sexton, Kristin 2021-03-12	15	20	15	25	1
Sexton, Kristin 2021-03-12	16	2	16	6	1
Sexton, Kristin 2021-03-12	18	16	18	24	1
Sexton, Kristin 2021-03-12	25	14	25	17	1, 5, 13, 17, 23, MIL1
Sexton, Kristin 2021-03-12	25	24	25	25	1, 5, 17, 18, 23, MIL1
Sexton, Kristin 2021-03-12	26	3	26	4	1, 5, 17, 18, 23, MIL1
Sexton, Kristin 2021-03-12	26	11	26	16	1, 3, 5, 17, 18, 23, MIL1
Sexton, Kristin 2021-03-12	27	3	27	7	1, 5, 17, 18, 23, MIL1
Sexton, Kristin 2021-03-12	96	22	96	25	1, 5, 17, 18, MIL2
Sexton, Kristin 2021-03-12	97	2	97	10	1, 3, 5, 15, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	97	12	97	13	1, 3, 5, 15, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	98	12	98	13	1, 3, 5, 15, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	98	18	98	22	1, 3, 5, 15, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	99	7	99	19	1, 3, 5, 15, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	102	17	102	25	1, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	103	2	103	4	1, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	104	14	104	25	1, 5, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	105	2	105	23	1, 5, 15, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	106	2	106	8	1, 5, 15, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	108	5	108	6	1, 3, 5, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	108	10	108	22	1, 3, 5, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	110	10	110	18	1, 5, 13, 15, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	110	22	110	25	1, 5, 13, 15, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	113	19	113	25	1, 5, 13, 15, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	114	2	114	4	1, 5, 13, 15, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	114	8	114	25	1, 5, 13, 15, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	115	2	115	2	1, 5, 13, 15, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	115	6	115	16	1, 5, 13, 15, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	115	20	115	21	1, 5, 13, 15, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	117	8	117	18	1, 3, 5, 13, 15, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	117	21	117	22	1, 3, 5, 13, 15, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	118	7	118	11	1, 3, 5, 13, 15, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	119	2	119	7	1, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	119	14	119	20	1, 3, 5, 13, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	120	3	120	6	1, 3, 5, 6, 13, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	120	9	120	21	1, 3, 5, 6, 13, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	120	25	120	25	1, 3, 5, 12, 13, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	121	2	121	2	1, 3, 5, 12, 13, 17, 18, 24, MIL2
Sexton, Kristin 2021-03-12	156	11	156	25	1, 2, 3, 17, 18, 23, MIL1
Sexton, Kristin 2021-03-12	157	2	157	18	1, 2, 3, 5, 17, 18, 23, MIL1
Sexton, Kristin 2021-03-12	184	23	184	25	1, 5, 17, 18, 23, MIL1
Sexton, Kristin 2021-03-12	185	4	185	25	1, 5, 17, 18, 23, MIL1
Sexton, Kristin 2021-03-12	186	5	186	16	1, 5, 13, 17, 23, MIL1
Sexton, Kristin 2021-03-12	186	19	186	21	1, 5, 13, 17, 23, MIL1
Sexton, Kristin 2021-03-12	209	19	209	23	1, 17, 18, 23, 24, MIL1
Sexton, Kristin 2021-03-12	210	4	210	21	1, 5, 13, 17, 18, 23, 24, MIL1
Sexton, Kristin 2021-03-12	211	24	211	25	1, 3, 5, 13, 17, 18, 23, 24, MIL1
Sexton, Kristin 2021-03-12	212	2	212	21	1, 2, 3, 5, 13, 17, 18, 23, 24, MIL1

Sexton, Kristin 2021-03-12	213	10	213	10	1, 2, 3, 5, 13, 17, 18, 23, 24, MIL1
Sexton, Kristin 2021-03-12	213	14	213	15	1, 2, 3, 5, 13, 17, 18, 23, 24, MIL1
Sexton, Kristin 2021-03-12	235	4	235	5	1, 2, 3, 5, 17, 18, 23, MIL1
Sexton, Kristin 2021-03-12	235	9	235	15	1, 2, 3, 5, 15, 17, 18, 23, MIL1
Sexton, Kristin 2021-03-12	235	20	235	23	1, 2, 3, 5, 15, 17, 18, 23, MIL1
Sexton, Kristin 2021-03-12	239	7	239	8	1, 2, 5, 15, 17, 18, 23, MIL1
Sexton, Kristin 2021-03-12	239	11	239	17	1, 2, 5, 6, 15, 17, 18, 23, MIL1
Sexton, Kristin 2021-03-12	239	20	239	21	1, 2, 5, 6, 15, 17, 18, 23, MIL1
Sexton, Kristin 2021-03-12	245	4	245	8	1, 2, 17, 18, 23, MIL1
Sexton, Kristin 2021-03-12	246	25	246	25	1, 2, 3, 5, 12, 17, 18, 23, MIL1
Sexton, Kristin 2021-03-12	247	2	247	19	1, 2, 3, 5, 12, 17, 18, 23, MIL1
Sexton, Kristin 2021-03-12	247	24	247	25	1, 2, 3, 5, 12, 17, 18, 23, MIL1
Sexton, Kristin 2021-03-12	248	7	248	10	1, 2, 3, 5, 12, 17, 18, 23, MIL1
Sexton, Kristin 2021-03-12	248	14	248	25	1, 2, 3, 5, 12, 17, 18, 23, MIL1
Sexton, Kristin 2021-03-12	249	2	249	6	1, 2, 3, 5, 12, 17, 18, 23, MIL1
Sexton, Kristin 2021-03-12	249	10	249	12	1, 2, 3, 5, 12, 17, 18, 23, MIL1
Sexton, Kristin 2021-03-12	249	15	249	25	1, 2, 23, MIL1
Sexton, Kristin 2021-03-12	250	2	250	12	1, 2, 3, 13, 17, 18, 23, MIL1
Sexton, Kristin 2021-03-12	250	16	250	25	1, 2, 3, 5, 13, 17, 18, 23, MIL1
Sexton, Kristin 2021-03-12	251	2	251	12	1, 2, 3, 5, 12, 13, 17, 18, 23, MIL1
Sexton, Kristin 2021-03-12	251	17	251	21	1, 2, 3, 5, 12, 13, 17, 18, 23, MIL1
Sexton, Kristin 2021-03-12	252	3	252	6	1, 2, 3, 5, 12, 13, 17, 18, 23, MIL1
Sexton, Kristin 2021-03-12	252	7	252	8	1, 2, 3, 5, 12, 13, 17, 18
Sexton, Kristin 2021-03-12	252	11	252	13	1, 2, 3, 5, 12, 13, 17, 18
Sexton, Kristin 2021-03-12	252	16	252	16	1, 2, 3, 5, 12, 13, 17, 18
Sexton, Kristin 2021-03-12	252	19	252	20	1, 2, 3, 5, 12, 13, 17, 18
Sexton, Kristin 2021-03-12	252	23	252	23	1, 2, 3, 5, 12, 13, 17, 18
Sexton, Kristin 2021-03-12	252	24	252	25	1, 2, 3, 5, 12, 13, 17, 18
Sexton, Kristin 2021-03-12	253	4	253	5	1, 2, 3, 5, 12, 13, 17, 18
Sexton, Kristin 2021-03-12	253	14	253	15	1, 2, 3, 5, 12, 13, 17, 18
Sexton, Kristin 2021-03-12	253	19	254	9	1, 2, 3, 5, 12, 13, 17, 18
Sexton, Kristin 2021-03-12	254	17	254	18	1, 2, 3, 5, 12, 13, 17, 18
Sexton, Kristin 2021-03-12	254	22	254	22	1, 2, 3, 5, 12, 13, 17, 18
Sexton, Kristin 2021-03-12	256	15	256	16	1, 2, 3, 5, 12, 13, 17, 18
Sexton, Kristin 2021-03-12	256	19	257	2	1, 2, 3, 5, 12, 13, 17, 18
Sexton, Kristin 2021-03-12	257	3	257	20	1, 2, 3, 5, 12, 13, 17, 18
Sexton, Kristin 2021-03-12	263	6	263	9	1, 2, 3, 5, 9, 13, 17, 18
Sexton, Kristin 2021-03-12	263	24	264	2	1, 2, 3, 5, 9, 13, 17, 18
Sexton, Kristin 2021-03-12	267	19	267	20	1, 2, 3, 5, 13, 17, 18
Sexton, Kristin 2021-03-12	267	23	267	25	1, 2, 3, 5, 13, 17, 18
Sexton, Kristin 2021-03-12	268	2	268	6	1, 2, 3, 5, 13, 17, 18
Sexton, Kristin 2021-03-12	269	16	269	20	1, 13, 17, 18
Sexton, Kristin 2021-03-12	269	25	270	7	1, 2, 13, 17, 18
Sexton, Kristin 2021-03-12	270	16	270	18	1, 2, 3, 5, 13, 17, 18
Sexton, Kristin 2021-03-12	270	23	270	24	1, 2, 3, 5, 13, 17, 18
Sexton, Kristin 2021-03-12	276	18	276	25	1, 2, 5, 13, 17, 18
Sexton, Kristin 2021-03-12	278	7	278	14	1, 2, 3, 13, 17, 18
Sexton, Kristin 2021-03-12	279	9	279	11	1, 2, 3, 5, 13, 17, 18
Sexton, Kristin 2021-03-12	279	14	279	15	1, 2, 3, 5, 13, 17, 18
Sexton, Kristin 2021-03-12	296	2	296	3	1, 2, 5, 13, 17, 18, 19, MIL1

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Sexton, Kristin 2021-03-12	13	11	13	16	6:17-25; 7:2-9	Sage Counter Designations
Sexton, Kristin 2021-03-12	14	20	15	4	6:17-25; 7:2-9	Sage Counter Designations
Sexton, Kristin 2021-03-12	16	25	17	4	15:20-16:6; 18:16-24	Sage Counter Designations
Sexton, Kristin 2021-03-12	17	7	17	21	15:20-16:6; 18:16-24	Sage Counter Designations
Sexton, Kristin 2021-03-12	19	20	20	8	15:20-16:6; 18:16-24	Sage Counter Designations
Sexton, Kristin 2021-03-12	20	11	20	17	15:20-16:6; 18:16-24	Sage Counter Designations
Sexton, Kristin 2021-03-12	27	8	27	12	25:14-17; 25:24-26:16	Sage Counter Designations
Sexton, Kristin 2021-03-12	35	10	35	15	25:14-17; 25:24-26:16	Sage Counter Designations
Sexton, Kristin 2021-03-12	36	23	37	22	25:14-17; 25:24-26:16	Sage Counter Designations
Sexton, Kristin 2021-03-12	37	25	38	3	25:14-17; 25:24-26:16	Sage Counter Designations
Sexton, Kristin 2021-03-12	48	17	48	19	25:14-17; 25:24-26:16	Sage Counter Designations
Sexton, Kristin 2021-03-12	48	22	49	7	25:14-17; 25:24-26:16	Sage Counter Designations
Sexton, Kristin 2021-03-12	87	14	87	15	96:22-25; 97:2-13	Sage Counter Designations
Sexton, Kristin 2021-03-12	87	21	87	23	96:22-25; 97:2-13	Sage Counter Designations
Sexton, Kristin 2021-03-12	88	3	88	5	96:22-25; 97:2-13	Sage Counter Designations
Sexton, Kristin 2021-03-12	88	8	88	9	96:22-25; 97:2-13	Sage Counter Designations
Sexton, Kristin 2021-03-12	94	3	94	6	96:22-25; 97:2-13	Sage Counter Designations
Sexton, Kristin 2021-03-12	96	3	96	11	96:22-25; 97:2-13	Sage Counter Designations
Sexton, Kristin 2021-03-12	96	14	96	21	96:22-25; 97:2-13	Sage Counter Designations
Sexton, Kristin 2021-03-12	97	21	98	2	96:22-25; 97:2-13	Sage Counter Designations
Sexton, Kristin 2021-03-12	98	23	99	6	99:7-9	Sage Counter Designations
Sexton, Kristin 2021-03-12	99	20	100	17	99:7-19	Sage Counter Designations
Sexton, Kristin 2021-03-12	100	20	101	13	99:7-19	Sage Counter Designations
Sexton, Kristin 2021-03-12	101	16	101	22	99:7-19	Sage Counter Designations
Sexton, Kristin 2021-03-12	111	2	111	4	110:10-25	Sage Counter Designations
	111	7	111	13	110:10-25	Sage Counter Designations
Sexton, Kristin 2021-03-12	111	14	111	17	102:12-103:4; 104:14-16:8; 108:5-22; 110:10-25; 113:19- 115:21; 117:8-118:11; 119:2- 121:2	Sage Contingent; Sage Counter Designations
Sexton, Kristin 2021-03-12	111	21	112	5	102:12-103:4; 104:14-16:8; 108:5-22; 110:10-25; 113:19- 115:21; 117:8-118:11; 119:2- 121:2	Sage Contingent; Sage Counter Designations
Sexton, Kristin 2021-03-12	112	6	112	9	102:12-103:4; 104:14-16:8; 108:5-22; 110:10-25; 113:19- 115:21; 117:8-118:11; 119:2- 121:2	Sage Contingent; Sage Counter Designations
Sexton, Kristin 2021-03-12	112	13	112	20	102:12-103:4; 104:14-16:8; 108:5-22; 110:10-25; 113:19- 115:21; 117:8-118:11; 119:2- 121:2	Sage Contingent; Sage Counter Designations
Sexton, Kristin 2021-03-12	138	25	139	7	96:22-25; 97:2-13	Sage Counter Designations
Sexton, Kristin 2021-03-12	237	13	237	15	235:4-23; 239:15-21; 245:4-8; 246:25-252:6	Sage Counter Designations
Sexton, Kristin 2021-03-12	237	20	238	8	235:4-23; 239:15-21; 245:4-8; 246:25-252:6	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Ulreich, Daniel 2021-04-08	5	13	5	19	
Ulreich, Daniel 2021-04-08	20	13	20	19	
Ulreich, Daniel 2021-04-08	20	22	20	22	
Ulreich, Daniel 2021-04-08	22	20	22	24	1, 2, 3, 5, 17
Ulreich, Daniel 2021-04-08	23	8	23	10	1, 2, 3, 5, 12, 17
Ulreich, Daniel 2021-04-08	23	13	23	25	1, 2, 3, 5, 12, 17
Ulreich, Daniel 2021-04-08	24	6	24	10	1, 2, 3, 5, 12, 17
Ulreich, Daniel 2021-04-08	24	13	24	25	1, 2, 3, 5, 12, 17
Ulreich, Daniel 2021-04-08	25	4	25	6	1, 2, 3, 5, 17
Ulreich, Daniel 2021-04-08	25	7	25	10	1, 17, 19
Ulreich, Daniel 2021-04-08	26	11	26	20	
Ulreich, Daniel 2021-04-08	26	23	26	24	
Ulreich, Daniel 2021-04-08	27	10	27	17	1, 5, 17
Ulreich, Daniel 2021-04-08	27	18	27	22	1, 5, 15, 17
Ulreich, Daniel 2021-04-08	27	25	28	5	1, 5, 15, 17
Ulreich, Daniel 2021-04-08	28	8	28	9	1, 5, 15, 17
Ulreich, Daniel 2021-04-08	29	24	30	17	1, 17
Ulreich, Daniel 2021-04-08	30	20	30	21	1, 17
Ulreich, Daniel 2021-04-08	30	25	31	9	1, 17
Ulreich, Daniel 2021-04-08	31	19	31	25	1, 17
Ulreich, Daniel 2021-04-08	32	4	32	7	1, 17
Ulreich, Daniel 2021-04-08	33	8	33	21	1, 5, 17
Ulreich, Daniel 2021-04-08	33	24	34	5	1, 17
Ulreich, Daniel 2021-04-08	34	8	34	12	1, 17
Ulreich, Daniel 2021-04-08	35	25	36	12	1, 17
Ulreich, Daniel 2021-04-08	36	15	36	17	1, 17
Ulreich, Daniel 2021-04-08	37	3	37	9	1, 17
Ulreich, Daniel 2021-04-08	40	5	40	18	1, 5, 17
Ulreich, Daniel 2021-04-08	42	24	43	13	
Ulreich, Daniel 2021-04-08	43	16	43	25	
Ulreich, Daniel 2021-04-08	44	18	45	3	
Ulreich, Daniel 2021-04-08	45	6	45	8	
Ulreich, Daniel 2021-04-08	46	18	47	6	1, 2, 3, 5, 15, 17
Ulreich, Daniel 2021-04-08	47	20	48	8	1, 3, 5, 12, 15, 17
Ulreich, Daniel 2021-04-08	48	11	48	22	1, 3, 5, 12, 15, 17
Ulreich, Daniel 2021-04-08	51	17	51	21	1, 3, 5, 15, 17
Ulreich, Daniel 2021-04-08	51	22	52	11	1, 3, 5, 15, 17
Ulreich, Daniel 2021-04-08	52	14	52	23	1, 3, 5, 15, 17
Ulreich, Daniel 2021-04-08	53	2	53	4	1, 3, 5, 15, 17
Ulreich, Daniel 2021-04-08	55	15	55	20	1, 3, 5, 15, 17
Ulreich, Daniel 2021-04-08	55	24	56	6	1, 3, 5, 15, 17
Ulreich, Daniel 2021-04-08	56	9	56	11	1, 3, 5, 15, 17
Ulreich, Daniel 2021-04-08	57	9	57	14	1, 3, 5, 15, 17
Ulreich, Daniel 2021-04-08	57	17	58	10	1, 3, 5, 15, 17
Ulreich, Daniel 2021-04-08	58	14	58	22	1, 3, 5, 15, 17
Ulreich, Daniel 2021-04-08	59	2	59	3	1, 3, 5, 15, 17
Ulreich, Daniel 2021-04-08	59	19	60	6	1, 3, 5, 15, 17, 23, MIL1
Ulreich, Daniel 2021-04-08	60	9	60	14	1, 3, 5, 15, 17, 23, MIL1
Ulreich, Daniel 2021-04-08	60	18	60	19	1, 3, 5, 15, 17, 23, MIL1
Ulreich, Daniel 2021-04-08	62	5	62	10	1, 17
Ulreich, Daniel 2021-04-08	62	14	62	16	1, 17
Ulreich, Daniel 2021-04-08	64	2	64	7	1, 3, 5, 12, 15, 17

Ulreich, Daniel 2021-04-08	64	24	65	10	1, 3, 5, 15, 17
Ulreich, Daniel 2021-04-08	65	21	65	25	1, 3, 5, 15, 17, incomplete
Ulreich, Daniel 2021-04-08	66	5	66	9	1, 3, 5, 15, 17,
Ulreich, Daniel 2021-04-08	69	8	69	24	1, 17
Ulreich, Daniel 2021-04-08	71	16	71	23	1, 5, 15, 17
Ulreich, Daniel 2021-04-08	72	8	72	14	1, 5, 15, 17
Ulreich, Daniel 2021-04-08	72	17	72	25	1, 5, 15, 17
Ulreich, Daniel 2021-04-08	73	25	74	8	1, 5, 8, 15, 17
Ulreich, Daniel 2021-04-08	74	12	74	15	1, 5, 8, 15, 17
Ulreich, Daniel 2021-04-08	74	24	75	6	1, 17
Ulreich, Daniel 2021-04-08	75	9	75	19	1, 3, 17
Ulreich, Daniel 2021-04-08	75	22	76	5	1, 17
Ulreich, Daniel 2021-04-08	76	8	76	9	
Ulreich, Daniel 2021-04-08	79	17	79	19	1, 5, 17
Ulreich, Daniel 2021-04-08	79	22	79	23	1, 5, 17
Ulreich, Daniel 2021-04-08	80	25	81	5	1, 3, 5, 12, 15, 17
Ulreich, Daniel 2021-04-08	81	9	81	24	1, 3, 5, 12, 15, 17
Ulreich, Daniel 2021-04-08	82	3	82	11	1, 5, 17
Ulreich, Daniel 2021-04-08	82	20	82	24	1, 5, 17
Ulreich, Daniel 2021-04-08	83	3	83	9	1, 5, 17
Ulreich, Daniel 2021-04-08	83	12	83	13	
Ulreich, Daniel 2021-04-08	83	19	83	22	1, 5, 6, 17
Ulreich, Daniel 2021-04-08	83	25	84	6	1, 5, 12, 15, 17
Ulreich, Daniel 2021-04-08	84	10	84	20	1, 5, 6, 12, 15, 17
Ulreich, Daniel 2021-04-08	85	7	85	12	
Ulreich, Daniel 2021-04-08	86	18	86	25	1, 17
Ulreich, Daniel 2021-04-08	87	2	87	6	1, 5, 17
Ulreich, Daniel 2021-04-08	87	9	87	15	1, 5, 17
Ulreich, Daniel 2021-04-08	87	19	88	3	1, 5, 12, 15, 17
Ulreich, Daniel 2021-04-08	88	7	88	10	
Ulreich, Daniel 2021-04-08	89	17	89	21	1, 5, 12, 17
Ulreich, Daniel 2021-04-08	89	24	90	8	1, 5, 12, 17
Ulreich, Daniel 2021-04-08	90	11	90	16	
Ulreich, Daniel 2021-04-08	92	10	93	9	1, 17
Ulreich, Daniel 2021-04-08	93	15	93	17	1, 15, 17
Ulreich, Daniel 2021-04-08	93	20	93	25	1, 5, 17
Ulreich, Daniel 2021-04-08	100	20	100	23	1, 6, 17
Ulreich, Daniel 2021-04-08	101	3	101	10	1, 6, 17
Ulreich, Daniel 2021-04-08	101	14	101	20	1, 5, 17
Ulreich, Daniel 2021-04-08	101	24	102	4	1, 6, 17
Ulreich, Daniel 2021-04-08	102	7	102	12	1, 6, 17
Ulreich, Daniel 2021-04-08	102	15	102	19	1, 6, 17
Ulreich, Daniel 2021-04-08	102	22	103	4	1, 6, 17
Ulreich, Daniel 2021-04-08	103	7	103	15	1, 6, 17
Ulreich, Daniel 2021-04-08	103	18	104	2	1, 6, 17
Ulreich, Daniel 2021-04-08	106	14	106	20	1, 5, 15, 17
Ulreich, Daniel 2021-04-08	106	23	107	9	1, 5, 15, 17
Ulreich, Daniel 2021-04-08	107	12	107	21	1, 5, 15, 17
Ulreich, Daniel 2021-04-08	107	24	108	4	1, 5, 15, 17
Ulreich, Daniel 2021-04-08	108	7	108	8	1, 5, 15, 17
Ulreich, Daniel 2021-04-08	108	11	108	23	1, 5, 15, 17
Ulreich, Daniel 2021-04-08	109	2	109	4	1, 5, 15, 17
Ulreich, Daniel 2021-04-08	109	13	109	16	1, 5, 15, 17

Ulreich, Daniel 2021-04-08	109	19	109	22	
Ulreich, Daniel 2021-04-08	111	6	111	8	1, 5, 17
Ulreich, Daniel 2021-04-08	111	11	111	12	
Ulreich, Daniel 2021-04-08	111	20	111	24	1, 5, 17
Ulreich, Daniel 2021-04-08	112	3	112	6	
Ulreich, Daniel 2021-04-08	112	14	112	16	1, 5, 17
Ulreich, Daniel 2021-04-08	112	19	112	24	1, 5, 17
Ulreich, Daniel 2021-04-08	113	3	113	4	
Ulreich, Daniel 2021-04-08	115	12	116	2	1, 17
Ulreich, Daniel 2021-04-08	118	5	118	12	1, 5, 12, 15, 17
Ulreich, Daniel 2021-04-08	118	15	118	19	1, 5, 17
Ulreich, Daniel 2021-04-08	118	22	119	5	1, 5, 17
Ulreich, Daniel 2021-04-08	119	8	119	13	1, 5, 17
Ulreich, Daniel 2021-04-08	119	16	119	22	1, 5, 17
Ulreich, Daniel 2021-04-08	119	25	120	15	1, 2, 3, 5, 17
Ulreich, Daniel 2021-04-08	120	18	120	20	
Ulreich, Daniel 2021-04-08	121	16	121	20	1, 5, 6, 17
Ulreich, Daniel 2021-04-08	121	23	122	11	1, 5, 6, 17
Ulreich, Daniel 2021-04-08	122	22	123	4	1, 2, 4, 5, 12, 13, 15, 19; Object as this representation by Counsel is factually incorrect
Ulreich, Daniel 2021-04-08	123	20	124	6	1, 17
Ulreich, Daniel 2021-04-08	132	13	132	17	1, 5, 17
Ulreich, Daniel 2021-04-08	132	22	133	4	
Ulreich, Daniel 2021-04-08	133	7	133	20	
Ulreich, Daniel 2021-04-08	133	23	134	2	
Ulreich, Daniel 2021-04-08	134	20	134	24	
Ulreich, Daniel 2021-04-08	135	3	135	25	
Ulreich, Daniel 2021-04-08	136	5	136	15	
Ulreich, Daniel 2021-04-08	137	24	138	12	
Ulreich, Daniel 2021-04-08	140	11	140	15	1, 12, 17
Ulreich, Daniel 2021-04-08	140	18	140	24	1, 12, 17
Ulreich, Daniel 2021-04-08	141	3	141	8	1, 12, 15, 17
Ulreich, Daniel 2021-04-08	141	11	141	14	1, 12, 17
Ulreich, Daniel 2021-04-08	141	17	141	23	
Ulreich, Daniel 2021-04-08	142	2	142	10	
Ulreich, Daniel 2021-04-08	142	18	142	21	
Ulreich, Daniel 2021-04-08	142	24	143	8	1, 12, 17
Ulreich, Daniel 2021-04-08	143	20	143	23	
Ulreich, Daniel 2021-04-08	144	2	144	8	
Ulreich, Daniel 2021-04-08	144	11	144	14	
Ulreich, Daniel 2021-04-08	144	17	144	17	
Ulreich, Daniel 2021-04-08	145	3	145	9	
Ulreich, Daniel 2021-04-08	145	12	145	14	
Ulreich, Daniel 2021-04-08	145	18	145	21	
Ulreich, Daniel 2021-04-08	145	24	146	6	
Ulreich, Daniel 2021-04-08	146	10	146	13	
Ulreich, Daniel 2021-04-08	146	24	147	5	1, 5, 12, 17, 23, MIL1
Ulreich, Daniel 2021-04-08	147	9	147	14	1, 5, 12, 17, 23, MIL1
Ulreich, Daniel 2021-04-08	147	18	147	18	
Ulreich, Daniel 2021-04-08	148	5	148	10	
Ulreich, Daniel 2021-04-08	148	13	148	22	1, 5, 17
Ulreich, Daniel 2021-04-08	155	14	155	21	1, 5, 17

Ulreich, Daniel 2021-04-08	155	24	156	2	
Ulreich, Daniel 2021-04-08	157	11	157	15	
Ulreich, Daniel 2021-04-08	157	19	157	22	
Ulreich, Daniel 2021-04-08	159	7	159	15	1, 5, 12, 15, 17
Ulreich, Daniel 2021-04-08	160	4	160	8	
Ulreich, Daniel 2021-04-08	160	11	160	16	
Ulreich, Daniel 2021-04-08	160	19	160	25	
Ulreich, Daniel 2021-04-08	161	6	161	14	1, 3, 17, 20
Ulreich, Daniel 2021-04-08	161	18	161	21	1, 3, 17, 20
Ulreich, Daniel 2021-04-08	161	25	162	2	1, 3, 17, 20
Ulreich, Daniel 2021-04-08	162	11	162	14	
Ulreich, Daniel 2021-04-08	162	16	162	21	
Ulreich, Daniel 2021-04-08	162	25	163	11	
Ulreich, Daniel 2021-04-08	163	22	164	2	1, 3, 17, 20
Ulreich, Daniel 2021-04-08	164	7	164	14	1, 3, 17, 20
Ulreich, Daniel 2021-04-08	164	19	164	23	
Ulreich, Daniel 2021-04-08	165	12	165	15	1, 5, 12, 15, 17
Ulreich, Daniel 2021-04-08	165	18	165	19	
Ulreich, Daniel 2021-04-08	166	15	166	22	
Ulreich, Daniel 2021-04-08	167	4	167	14	
Ulreich, Daniel 2021-04-08	167	19	167	21	
Ulreich, Daniel 2021-04-08	170	20	170	22	19
Ulreich, Daniel 2021-04-08	174	2	174	6	1, 5, 17
Ulreich, Daniel 2021-04-08	174	9	174	10	
Ulreich, Daniel 2021-04-08	175	4	175	6	1, 2, 3, 5, 15, 17
Ulreich, Daniel 2021-04-08	175	9	175	11	
Ulreich, Daniel 2021-04-08	175	22	176	2	1, 2, 3, 5, 12, 17
Ulreich, Daniel 2021-04-08	176	6	176	8	1, 2, 3, 5, 12, 17
Ulreich, Daniel 2021-04-08	176	17	177	10	1, 17
Ulreich, Daniel 2021-04-08	181	18	181	22	
Ulreich, Daniel 2021-04-08	182	2	182	3	
Ulreich, Daniel 2021-04-08	182	13	182	18	
Ulreich, Daniel 2021-04-08	182	22	182	23	
Ulreich, Daniel 2021-04-08	183	7	183	8	
Ulreich, Daniel 2021-04-08	183	11	183	24	1, 3, 5, 17
Ulreich, Daniel 2021-04-08	184	3	184	7	1, 2, 3, 5, 6, 17, 20
Ulreich, Daniel 2021-04-08	184	10	184	11	1, 2, 3, 5, 6, 17, 20
Ulreich, Daniel 2021-04-08	184	16	184	19	1, 5, 17
Ulreich, Daniel 2021-04-08	184	22	184	24	
Ulreich, Daniel 2021-04-08	185	13	185	17	1, 5, 17, 20
Ulreich, Daniel 2021-04-08	185	21	186	2	1, 5, 17, 20
Ulreich, Daniel 2021-04-08	186	6	186	7	
Ulreich, Daniel 2021-04-08	188	10	188	12	1, 5, 17, 23, MIL1, DAUB
Ulreich, Daniel 2021-04-08	188	15	189	3	1, 5, 17, 23, MIL1, DAUB
Ulreich, Daniel 2021-04-08	189	6	189	16	1, 5, 17, 23, MIL1, DAUB
Ulreich, Daniel 2021-04-08	189	19	189	23	1, 5, 17, 23, MIL1, DAUB
Ulreich, Daniel 2021-04-08	190	2	190	4	1, 5, 17, 23, MIL1, DAUB
Ulreich, Daniel 2021-04-08	192	20	193	5	1, 5, 12, 17
Ulreich, Daniel 2021-04-08	193	8	193	9	
Ulreich, Daniel 2021-04-08	194	9	194	13	1, 5, 17
Ulreich, Daniel 2021-04-08	194	16	194	18	
Ulreich, Daniel 2021-04-08	195	3	195	7	1, 5, 17
Ulreich, Daniel 2021-04-08	195	11	195	15	1, 5, 17



Ulreich, Daniel 2021-04-08	195	19	195	24	1, 5, 17
Ulreich, Daniel 2021-04-08	196	4	196	9	1, 5, 17
Ulreich, Daniel 2021-04-08	196	13	196	24	1, 5, 17
Ulreich, Daniel 2021-04-08	197	3	197	4	
Ulreich, Daniel 2021-04-08	197	13	197	19	1, 5, 17
Ulreich, Daniel 2021-04-08	197	23	197	25	
Ulreich, Daniel 2021-04-08	198	12	198	17	1, 2, 3, 5, 17, 23, MIL1
Ulreich, Daniel 2021-04-08	198	20	199	2	1, 2, 3, 5, 17, 23, MIL1
Ulreich, Daniel 2021-04-08	199	5	199	10	1, 2, 3, 5, 17, 23, MIL1
Ulreich, Daniel 2021-04-08	199	14	199	16	
Ulreich, Daniel 2021-04-08	199	19	199	21	1, 2, 3, 5, 17, 23, MIL1
Ulreich, Daniel 2021-04-08	199	25	200	7	1, 2, 3, 5, 17, 23, MIL1
Ulreich, Daniel 2021-04-08	200	11	200	12	
Ulreich, Daniel 2021-04-08	201	15	201	22	
Ulreich, Daniel 2021-04-08	201	25	202	7	1, 17
Ulreich, Daniel 2021-04-08	202	10	202	21	1, 17
Ulreich, Daniel 2021-04-08	202	24	203	3	
Ulreich, Daniel 2021-04-08	203	6	203	9	
Ulreich, Daniel 2021-04-08	203	12	203	12	
Ulreich, Daniel 2021-04-08	204	25	205	11	1, 17
Ulreich, Daniel 2021-04-08	205	14	205	22	1, 17
Ulreich, Daniel 2021-04-08	208	20	209	9	1, 2, 3, 5, 17
Ulreich, Daniel 2021-04-08	209	12	209	19	1, 2, 3, 5, 17
Ulreich, Daniel 2021-04-08	210	3	210	5	1, 2, 3, 5, 17
Ulreich, Daniel 2021-04-08	210	8	210	15	1, 2, 3, 5, 17
Ulreich, Daniel 2021-04-08	210	18	211	5	1, 2, 3, 5, 17
Ulreich, Daniel 2021-04-08	211	8	211	10	1, 2, 3, 5, 17
Ulreich, Daniel 2021-04-08	213	2	213	6	1, 2, 3, 5, 17
Ulreich, Daniel 2021-04-08	213	10	213	12	
Ulreich, Daniel 2021-04-08	213	16	213	19	1, 2, 3, 5, 17
Ulreich, Daniel 2021-04-08	213	23	214	7	1, 2, 3, 5, 17
Ulreich, Daniel 2021-04-08	221	5	221	14	1, 17
Ulreich, Daniel 2021-04-08	221	17	221	21	
Ulreich, Daniel 2021-04-08	225	2	225	5	1, 5, 17
Ulreich, Daniel 2021-04-08	225	10	225	18	1, 5, 17
Ulreich, Daniel 2021-04-08	225	21	225	21	
Ulreich, Daniel 2021-04-08	226	4	226	6	1, 17
Ulreich, Daniel 2021-04-08	226	9	226	10	
Ulreich, Daniel 2021-04-08	227	14	227	20	1, 17
Ulreich, Daniel 2021-04-08	227	23	228	7	1, 5, 12, 17
Ulreich, Daniel 2021-04-08	228	10	228	10	



Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Ulreich, Daniel 2021-04-08	5	20	5	22	5:13-19	Sage Counter Designations
Ulreich, Daniel 2021-04-08	8	12	8	19	e.g., 10:3-7; 16:22-25; 20:13-22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	8	20	8	23	e.g., 8:12-19; 10:3-7; 16:22-25; 20:13-22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	10	3	10	7	e.g., 8:12-19; 16:22-25; 20:13-22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	16	22	16	25	e.g., 8:12-19; 10:3-7; 16:22-25; 20:13-22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	17	12	17	16	e.g., 8:12-19; 10:3-7; 16:22-25; 20:13-22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	18	4	18	16	e.g., 8:12-19; 10:3-7; 16:22-25; 20:13-22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	18	19	18	20	e.g., 8:12-19; 10:3-7; 16:22-25; 20:13-22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	19	7	19	14	e.g., 8:12-19; 10:3-7; 16:22-25; 18:4-16; 20:13-22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	21	7	21	20	20:13-22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	22	3	22	8	20:13-22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	22	20	22	24	1, 2, 3, 5, 17	Sage Counter Designations
Ulreich, Daniel 2021-04-08	22	25	23	7	22:20-24; 23:8-15	Sage Counter Designations
Ulreich, Daniel 2021-04-08	24	2	24	5	22:20-24; 23:8-25	Sage Counter Designations
Ulreich, Daniel 2021-04-08	26	25	27	4	26:11-24; 27:10-28:1	Sage Counter Designations
Ulreich, Daniel 2021-04-08	27	7	27	9	26:11-24; 27:10-28:1	Sage Counter Designations
Ulreich, Daniel 2021-04-08	28	18	28	25	27:10-28:9	Sage Counter Designations
Ulreich, Daniel 2021-04-08	29	2	29	6	27:10-28:9	Sage Counter Designations
Ulreich, Daniel 2021-04-08	31	10	31	12	e.g., 29:24-31:9; 31:19-32:7; 33:8-34:5	Sage Counter Designations
Ulreich, Daniel 2021-04-08	31	15	31	18	e.g., 29:24-31:9; 31:19-32:7; 33:8-34:5	Sage Counter Designations
Ulreich, Daniel 2021-04-08	32	20	32	22	e.g., 29:24-31:9; 31:19-32:7; 33:8-34:5	Sage Counter Designations
Ulreich, Daniel 2021-04-08	32	25	33	3	e.g., 29:24-31:9; 31:19-32:7; 33:8-34:5	Sage Counter Designations
Ulreich, Daniel 2021-04-08	34	23	35	3	e.g., 29:24-31:9; 31:19-32:7; 33:8-34:5	Sage Counter Designations
Ulreich, Daniel 2021-04-08	35	6	35	9	e.g., 29:24-31:9; 31:19-32:7; 33:8-34:5	Sage Counter Designations
Ulreich, Daniel 2021-04-08	37	14	37	18	44:18-45:8	Sage Counter Designations
	38	4	38	5	e.g., 29:24-31:9; 31:19-32:7; 33:8-34:5	Sage Counter Designations
Ulreich, Daniel 2021-04-08	38	8	38	10	e.g., 29:24-31:9; 31:19-32:7; 33:8-34:5	Sage Counter Designations
Ulreich, Daniel 2021-04-08	41	3	41	9	40:5-18	Sage Counter Designations
Ulreich, Daniel 2021-04-08	41	12	41	14	40:5-18	Sage Counter Designations
Ulreich, Daniel 2021-04-08	45	18	45	20	44:18-45:8	Sage Counter Designations
Ulreich, Daniel 2021-04-08	45	23	45	25	44:18-45:8	Sage Counter Designations
Ulreich, Daniel 2021-04-08	46	2	46	3	44:18-45:8	Sage Counter Designations
Ulreich, Daniel 2021-04-08	46	6	46	8	44:18-45:8	Sage Counter Designations
Ulreich, Daniel 2021-04-08	46	9	46	12	46:18-47:6	Sage Contingent
Ulreich, Daniel 2021-04-08	46	16	46	17	46:18-47:6	Sage Contingent

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Ulreich, Daniel 2021-04-08	50	6	50	9	e.g., 8:12-19; 10:3-7; 16:22-25; 18:4-20; 20:13-22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	50	12	50	13	e.g., 8:12-19; 10:3-7; 16:22-25; 18:4-20; 20:13-22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	50	14	50	18	e.g., 8:12-19; 10:3-7; 16:22-25; 18:4-20; 20:13-22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	50	22	50	25	e.g., 8:12-19; 10:3-7; 16:22-25; 18:4-20; 20:13-22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	51	11	51	14	51:17-52:18	Sage Counter Designations
Ulreich, Daniel 2021-04-08	56	21	56	25	58:9-59:3	Sage Counter Designations
Ulreich, Daniel 2021-04-08	57	5	57	8	58:9-59:3	Sage Counter Designations
Ulreich, Daniel 2021-04-08	61	2	61	5	59:19-60:19	Sage Contingent
Ulreich, Daniel 2021-04-08	61	8	61	9	59:19-60:19	Sage Contingent
Ulreich, Daniel 2021-04-08	61	18	61	22	59:19-60:19	Sage Contingent
Ulreich, Daniel 2021-04-08	62	2	62	4	59:19-60:19	Sage Contingent
Ulreich, Daniel 2021-04-08	64	17	64	19	64:2-7	Sage Counter Designations
Ulreich, Daniel 2021-04-08	64	22	64	23	64:2-7	Sage Contingent
Ulreich, Daniel 2021-04-08	65	19	65	20	65:21-25	Sage Contingent
Ulreich, Daniel 2021-04-08	66	10	66	13	65:21-66:9	Sage Contingent
Ulreich, Daniel 2021-04-08	66	16	66	18	65:21-66:9	Sage Contingent
Ulreich, Daniel 2021-04-08	67	17	67	20	65:21-66:9	Sage Contingent
Ulreich, Daniel 2021-04-08	67	24	67	25	65:21-66:9	Sage Contingent
Ulreich, Daniel 2021-04-08	68	20	68	23	e.g., 8:12-19; 10:3-7; 16:22-25; 18:4-20; 20:13-22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	69	3	69	7	e.g., 8:12-19; 10:3-7; 16:22-25; 18:4-20; 20:13-22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	70	17	70	21	71:16-72:25	Sage Counter Designations
Ulreich, Daniel 2021-04-08	70	25	71	1	71:16-72:25	Sage Counter Designations
Ulreich, Daniel 2021-04-08	71	24	71	25	71:16-23	Sage Counter Designations
Ulreich, Daniel 2021-04-08	72	2	72	6	71:16-23	Sage Counter Designations
Ulreich, Daniel 2021-04-08	76	10	76	23	74:24-76:9	Sage Counter Designations
Ulreich, Daniel 2021-04-08	77	2	77	3	74:24-76:9	Sage Counter Designations
Ulreich, Daniel 2021-04-08	79	9	79	11	74:24-76:9	Sage Counter Designations
Ulreich, Daniel 2021-04-08	79	14	79	16	74:24-76:9	Sage Counter Designations
Ulreich, Daniel 2021-04-08	80	10	80	13	74:24-76:9	Sage Counter Designations
Ulreich, Daniel 2021-04-08	80	16	80	21	74:24-76:9	Sage Counter Designations
Ulreich, Daniel 2021-04-08	80	24	80	24	74:24-76:9	Sage Counter Designations
Ulreich, Daniel 2021-04-08	94	15	94	25	92:10-93:25	Sage Counter Designations
Ulreich, Daniel 2021-04-08	95	2	95	2	92:10-93:25	Sage Counter Designations
Ulreich, Daniel 2021-04-08	98	19	98	25		Sage Counter Designations
Ulreich, Daniel 2021-04-08	99	2	99	2		Sage Counter Designations
Ulreich, Daniel 2021-04-08	99	5	99	10		Sage Counter Designations
Ulreich, Daniel 2021-04-08	99	14	99	21		Sage Counter Designations
Ulreich, Daniel 2021-04-08	100	12	100	14	100:20-104:2	Sage Counter Designations
Ulreich, Daniel 2021-04-08	100	17	100	19	100:20-104:2	Sage Counter Designations
Ulreich, Daniel 2021-04-08	105	14	105	18	103:12-104:2	Sage Counter Designations
Ulreich, Daniel 2021-04-08	105	22	105	25	103:12-104:2	Sage Counter Designations
Ulreich, Daniel 2021-04-08	106	4	106	8	103:12-104:2	Sage Counter Designations
Ulreich, Daniel 2021-04-08	106	9	106	13	103:12-104:2	Sage Counter Designations
Ulreich, Daniel 2021-04-08	113	5	113	7	e.g., 111:6-113:4	Sage Counter Designations
Ulreich, Daniel 2021-04-08	113	10	113	14	e.g., 111:6-113:4	Sage Counter Designations
Ulreich, Daniel 2021-04-08	113	17	113	17	e.g., 111:6-113:4	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Ulreich, Daniel 2021-04-08	117	9	117	12	e.g., 115:12-116:2	Sage Counter Designations
Ulreich, Daniel 2021-04-08	124	16	124	24	e.g., 122:22-123:4; 123:20-124:6	Sage Counter Designations
Ulreich, Daniel 2021-04-08	125	3	125	7	e.g., 122:22-123:4; 123:20-124:6	Sage Counter Designations
Ulreich, Daniel 2021-04-08	125	10	125	20	e.g., 122:22-123:4; 123:20-124:6	Sage Counter Designations
Ulreich, Daniel 2021-04-08	125	23	125	24	e.g., 122:22-123:4; 123:20-124:6	Sage Counter Designations
Ulreich, Daniel 2021-04-08	127	6	127	12	e.g., 122:22-123:4; 123:20-124:6	Sage Counter Designations
Ulreich, Daniel 2021-04-08	127	15	127	16	e.g., 122:22-123:4; 123:20-124:6	Sage Counter Designations
Ulreich, Daniel 2021-04-08	128	3	128	9		Sage Counter Designations
Ulreich, Daniel 2021-04-08	138	13	138	17	e.g., 132:13-134:2; 134:20-136:15; 137:24-138:12	Sage Counter Designations
Ulreich, Daniel 2021-04-08	138	23	138	25	e.g., 132:13-134:2; 134:20-136:15; 137:24-138:12	Sage Counter Designations
Ulreich, Daniel 2021-04-08	139	2	139	11	e.g., 132:13-134:2; 134:20-136:15; 137:24-138:12	Sage Counter Designations
Ulreich, Daniel 2021-04-08	139	12	139	13	e.g., 132:13-134:2; 134:20-136:15; 137:24-138:12	Sage Counter Designations
Ulreich, Daniel 2021-04-08	139	16	139	18	e.g., 132:13-134:2; 134:20-136:15; 137:24-138:12	Sage Counter Designations
Ulreich, Daniel 2021-04-08	139	19	139	23	e.g., 132:13-134:2; 134:20-136:15; 137:24-138:12	Sage Counter Designations
Ulreich, Daniel 2021-04-08	143	9	143	19		Sage Counter Designations
Ulreich, Daniel 2021-04-08	145	15	145	17	145:3-13	Sage Counter Designations
Ulreich, Daniel 2021-04-08	149	9	149	11	148:13-22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	149	15	149	17	148:13-22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	156	17	156	20	e.g., 132:13-134:2; 134:20-136:15; 137:24-138:12; 140:11-142:10; 142:18-144:17; 145:3-146:13; 146:24-147:18; 148:5-148:22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	156	24	156	25	e.g., 132:13-134:2; 134:20-136:15; 137:24-138:12; 140:11-142:10; 142:18-144:17; 145:3-146:13; 146:24-147:18; 148:5-148:22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	157	2	157	6	e.g., 132:13-134:2; 134:20-136:15; 137:24-138:12; 140:11-142:10; 142:18-144:17; 145:3-146:13; 146:24-147:18; 148:5-148:22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	157	10	157	10	e.g., 132:13-134:2; 134:20-136:15; 137:24-138:12; 140:11-142:10; 142:18-144:17; 145:3-146:13; 146:24-147:18; 148:5-148:22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	157	23	158	2	157:11-22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	158	6	158	7	157:11-22	Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Ulreich, Daniel 2021-04-08	158	8	158	13	157:11-22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	158	18	158	19	157:11-22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	161	4	161	5		Sage Counter Designations
Ulreich, Daniel 2021-04-08	172	20	173	2	174:2-10	Sage Counter Designations
Ulreich, Daniel 2021-04-08	173	5	173	9	174:2-10	Sage Counter Designations
Ulreich, Daniel 2021-04-08	173	12	173	17	174:2-10	Sage Counter Designations
Ulreich, Daniel 2021-04-08	177	11	177	14	176:17-177:10	Sage Counter Designations
Ulreich, Daniel 2021-04-08	179	5	179	10		Sage Counter Designations
Ulreich, Daniel 2021-04-08	179	13	179	14		Sage Counter Designations
Ulreich, Daniel 2021-04-08	186	8	186	12	e.g., 185:13-186:7	Sage Counter Designations
Ulreich, Daniel 2021-04-08	186	17	186	17	e.g., 185:13-186:7	Sage Counter Designations
Ulreich, Daniel 2021-04-08	186	25	186	25	e.g., 185:13-186:7	Sage Counter Designations
Ulreich, Daniel 2021-04-08	187	2	187	4	e.g., 185:13-186:7	Sage Counter Designations
Ulreich, Daniel 2021-04-08	187	8	187	10	e.g., 185:13-186:7	Sage Counter Designations
Ulreich, Daniel 2021-04-08	190	13	190	15	188:10-190:4	Sage Contingent
Ulreich, Daniel 2021-04-08	190	18	190	19	188:10-190:4	Sage Contingent
Ulreich, Daniel 2021-04-08	190	20	190	25	188:10-190:4	Sage Contingent
Ulreich, Daniel 2021-04-08	191	6	191	8	188:10-190:4	Sage Contingent
Ulreich, Daniel 2021-04-08	191	22	192	3	188:10-190:4	Sage Contingent
Ulreich, Daniel 2021-04-08	192	8	192	14	188:10-190:4	Sage Contingent
Ulreich, Daniel 2021-04-08	193	22	193	25	194:9-13	Sage Counter Designations
Ulreich, Daniel 2021-04-08	194	4	194	6	194:9-13	Sage Counter Designations
Ulreich, Daniel 2021-04-08	194	7	194	8	194:9-13	Sage Counter Designations
Ulreich, Daniel 2021-04-08	194	19	194	21		Sage Counter Designations
Ulreich, Daniel 2021-04-08	194	25	195	2		Sage Counter Designations
Ulreich, Daniel 2021-04-08	206	6	206	9	e.g., 204:25-205:22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	206	13	206	14	e.g., 204:25-205:22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	207	8	207	13	e.g., 204:25-205:22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	207	16	207	18	e.g., 204:25-205:22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	207	19	207	23	e.g., 204:25-205:22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	209	20	209	25		Sage Counter Designations
Ulreich, Daniel 2021-04-08	211	11	211	12		Sage Counter Designations
Ulreich, Daniel 2021-04-08	211	15	211	18		Sage Counter Designations
Ulreich, Daniel 2021-04-08	211	19	211	21		Sage Counter Designations
Ulreich, Daniel 2021-04-08	211	25	212	3		Sage Counter Designations
Ulreich, Daniel 2021-04-08	219	16	219	19	e.g., 132:13-134:2; 134:20-136:15; 137:24-138:12; 140:11-142:10; 142:18-144:17; 145:3-146:13; 146:24-147:18; 148:5-148:22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	219	22	219	24	e.g., 132:13-134:2; 134:20-136:15; 137:24-138:12; 140:11-142:10; 142:18-144:17; 145:3-146:13; 146:24-147:18; 148:5-148:22	Sage Counter Designations
Ulreich, Daniel 2021-04-08	230	8	230	11		Sage Counter Designations
Ulreich, Daniel 2021-04-08	230	14	230	14		Sage Counter Designations
Ulreich, Daniel 2021-04-08	231	5	231	8		Sage Counter Designations
Ulreich, Daniel 2021-04-08	231	11	231	12		Sage Counter Designations
Ulreich, Daniel 2021-04-08	231	21	231	23		Sage Counter Designations
Ulreich, Daniel 2021-04-08	232	2	232	3		Sage Counter Designations
Ulreich, Daniel 2021-04-08	232	7	232	8		Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Ulreich, Daniel 2021-04-08	233	9	233	13		Sage Counter Designations
Ulreich, Daniel 2021-04-08	233	16	233	20		Sage Counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Ulreich, Daniel 2023-04-13	5	3	5	7	
Ulreich, Daniel 2023-04-13	9	3	9	5	1, 5, 17
Ulreich, Daniel 2023-04-13	9	11	9	12	
Ulreich, Daniel 2023-04-13	10	5	10	8	
Ulreich, Daniel 2023-04-13	10	23	10	24	1, 5, 17, MIL1, DAUB
Ulreich, Daniel 2023-04-13	11	3	11	6	
Ulreich, Daniel 2023-04-13	11	8	11	10	1, 5, 17, MIL1, DAUB
Ulreich, Daniel 2023-04-13	11	13	11	14	
Ulreich, Daniel 2023-04-13	11	16	11	24	1, 5, 17, MIL1, DAUB
Ulreich, Daniel 2023-04-13	14	15	14	17	1, 5, 17, MIL1, DAUB
Ulreich, Daniel 2023-04-13	14	21	14	23	1, 5, 17, MIL1, DAUB
Ulreich, Daniel 2023-04-13	15	1	15	5	1, 5, 17, MIL1, DAUB
Ulreich, Daniel 2023-04-13	15	8	15	10	1, 5, 17, MIL1, DAUB
Ulreich, Daniel 2023-04-13	15	12	15	14	1, 5, 17, MIL1, DAUB
Ulreich, Daniel 2023-04-13	15	18	15	18	1, 5, 17, MIL1, DAUB
Ulreich, Daniel 2023-04-13	15	20	15	23	
Ulreich, Daniel 2023-04-13	16	13	16	16	1, 17, 25
Ulreich, Daniel 2023-04-13	18	15	18	18	
Ulreich, Daniel 2023-04-13	19	9	19	10	
Ulreich, Daniel 2023-04-13	19	13	19	15	
Ulreich, Daniel 2023-04-13	19	17	19	22	
Ulreich, Daniel 2023-04-13	23	4	23	10	1, 17, 25
Ulreich, Daniel 2023-04-13	26	8	26	11	1, 17
Ulreich, Daniel 2023-04-13	26	14	26	16	
Ulreich, Daniel 2023-04-13	29	11	29	13	
Ulreich, Daniel 2023-04-13	29	18	29	21	1, 2, 17
Ulreich, Daniel 2023-04-13	30	8	30	10	
Ulreich, Daniel 2023-04-13	30	12	30	14	1, 2, 17
Ulreich, Daniel 2023-04-13	30	17	30	17	
Ulreich, Daniel 2023-04-13	30	19	31	4	1, 2, 17
Ulreich, Daniel 2023-04-13	37	12	37	16	1, 17, 25
Ulreich, Daniel 2023-04-13	47	19	47	23	1, 17, 25
Ulreich, Daniel 2023-04-13	47	24	48	1	1, 17, 25
Ulreich, Daniel 2023-04-13	48	4	48	5	
Ulreich, Daniel 2023-04-13	48	7	48	8	1, 17, 25
Ulreich, Daniel 2023-04-13	50	12	50	14	1, 17
Ulreich, Daniel 2023-04-13	50	19	50	19	
Ulreich, Daniel 2023-04-13	50	21	50	24	
Ulreich, Daniel 2023-04-13	51	4	51	4	
Ulreich, Daniel 2023-04-13	51	6	51	9	
Ulreich, Daniel 2023-04-13	60	24	61	5	
Ulreich, Daniel 2023-04-13	61	10	61	10	
Ulreich, Daniel 2023-04-13	61	21	61	24	
Ulreich, Daniel 2023-04-13	62	4	62	5	
Ulreich, Daniel 2023-04-13	62	7	62	11	1, 17
Ulreich, Daniel 2023-04-13	62	22	63	5	1, 17, 19
Ulreich, Daniel 2023-04-13	63	10	63	15	1, 17
Ulreich, Daniel 2023-04-13	63	16	63	18	1, 5, 17
Ulreich, Daniel 2023-04-13	63	21	63	22	
Ulreich, Daniel 2023-04-13	63	24	64	7	1, 5, 17
Ulreich, Daniel 2023-04-13	64	14	64	18	1, 17, 25

Ulreich, Daniel 2023-04-13	80	8	80	11	
Ulreich, Daniel 2023-04-13	80	19	80	20	1, 17
Ulreich, Daniel 2023-04-13	80	24	80	24	
Ulreich, Daniel 2023-04-13	81	2	81	9	1, 17
Ulreich, Daniel 2023-04-13	81	10	81	13	
Ulreich, Daniel 2023-04-13	82	9	82	18	1, 17
Ulreich, Daniel 2023-04-13	97	21	98	1	
Ulreich, Daniel 2023-04-13	98	16	98	22	1, 5, 12, 15, 17, 19, Incorrect representation by Counsel
Ulreich, Daniel 2023-04-13	99	2	99	2	
Ulreich, Daniel 2023-04-13	99	4	99	9	
Ulreich, Daniel 2023-04-13	105	8	105	13	
Ulreich, Daniel 2023-04-13	105	22	106	12	1, 12, 17, MIL1, DAUB
Ulreich, Daniel 2023-04-13	112	18	112	24	
Ulreich, Daniel 2023-04-13	113	11	113	21	1, 17
Ulreich, Daniel 2023-04-13	114	9	114	10	
Ulreich, Daniel 2023-04-13	114	12	115	3	1, 5, 17
Ulreich, Daniel 2023-04-13	125	10	125	12	
Ulreich, Daniel 2023-04-13	125	17	125	21	
Ulreich, Daniel 2023-04-13	126	3	126	6	1, 17
Ulreich, Daniel 2023-04-13	126	16	127	3	1, 5, 17
Ulreich, Daniel 2023-04-13	127	7	127	9	
Ulreich, Daniel 2023-04-13	127	11	127	20	
Ulreich, Daniel 2023-04-13	128	3	128	16	1, 17
Ulreich, Daniel 2023-04-13	128	19	128	23	
Ulreich, Daniel 2023-04-13	129	1	129	7	1, 17
Ulreich, Daniel 2023-04-13	129	8	129	11	1, 17
Ulreich, Daniel 2023-04-13	129	14	129	16	
Ulreich, Daniel 2023-04-13	129	18	129	20	1, 5, 17
Ulreich, Daniel 2023-04-13	129	23	129	24	
Ulreich, Daniel 2023-04-13	130	2	130	5	1, 5, 17
Ulreich, Daniel 2023-04-13	130	8	130	12	
Ulreich, Daniel 2023-04-13	131	5	131	6	
Ulreich, Daniel 2023-04-13	131	11	131	14	
Ulreich, Daniel 2023-04-13	131	20	132	18	1, 17
Ulreich, Daniel 2023-04-13	132	21	132	23	
Ulreich, Daniel 2023-04-13	133	1	133	3	1, 5, 17
Ulreich, Daniel 2023-04-13	133	6	133	7	
Ulreich, Daniel 2023-04-13	133	9	133	13	1, 5, 17
Ulreich, Daniel 2023-04-13	133	16	133	18	
Ulreich, Daniel 2023-04-13	133	20	134	4	1, 17
Ulreich, Daniel 2023-04-13	134	5	134	10	
Ulreich, Daniel 2023-04-13	134	11	134	14	1, 17
Ulreich, Daniel 2023-04-13	134	18	134	21	
Ulreich, Daniel 2023-04-13	134	23	135	3	1, 17
Ulreich, Daniel 2023-04-13	135	7	135	9	
Ulreich, Daniel 2023-04-13	135	11	135	15	1, 5, 12, 17
Ulreich, Daniel 2023-04-13	135	18	135	21	
Ulreich, Daniel 2023-04-13	135	23	136	6	1, 5, 12, 17
Ulreich, Daniel 2023-04-13	136	11	136	14	
Ulreich, Daniel 2023-04-13	142	23	143	4	
Ulreich, Daniel 2023-04-13	143	7	143	12	1, 17



Ulreich, Daniel 2023-04-13	143	18	144	1	1, 2, 5, 12, 17
Ulreich, Daniel 2023-04-13	144	4	144	6	
Ulreich, Daniel 2023-04-13	144	8	144	10	1, 2, 5, 12, 17
Ulreich, Daniel 2023-04-13	144	13	144	14	
Ulreich, Daniel 2023-04-13	144	16	144	22	
Ulreich, Daniel 2023-04-13	145	4	145	9	1, 12, 17
Ulreich, Daniel 2023-04-13	145	12	145	13	
Ulreich, Daniel 2023-04-13	145	15	146	1	1, 17
Ulreich, Daniel 2023-04-13	146	4	146	12	1, 12, 15, 17
Ulreich, Daniel 2023-04-13	146	15	146	16	
Ulreich, Daniel 2023-04-13	146	18	147	7	1, 15, 17
Ulreich, Daniel 2023-04-13	147	10	147	12	
Ulreich, Daniel 2023-04-13	147	14	147	15	1, 5, 12, 15, 17
Ulreich, Daniel 2023-04-13	147	19	147	21	
Ulreich, Daniel 2023-04-13	147	23	148	6	
Ulreich, Daniel 2023-04-13	148	23	148	24	1, 17
Ulreich, Daniel 2023-04-13	149	4	149	6	
Ulreich, Daniel 2023-04-13	149	8	149	15	1, 17
Ulreich, Daniel 2023-04-13	149	19	150	1	1, 17
Ulreich, Daniel 2023-04-13	150	5	150	6	
Ulreich, Daniel 2023-04-13	150	8	150	13	1, 17
Ulreich, Daniel 2023-04-13	150	17	150	19	
Ulreich, Daniel 2023-04-13	150	21	151	7	1, 5, 17
Ulreich, Daniel 2023-04-13	151	10	151	11	
Ulreich, Daniel 2023-04-13	151	13	151	18	1, 5, 17
Ulreich, Daniel 2023-04-13	151	21	151	23	
Ulreich, Daniel 2023-04-13	152	1	152	3	1, 5, 17
Ulreich, Daniel 2023-04-13	152	6	152	7	
Ulreich, Daniel 2023-04-13	152	9	152	11	
Ulreich, Daniel 2023-04-13	152	15	152	17	
Ulreich, Daniel 2023-04-13	152	19	152	20	1, 5, 17
Ulreich, Daniel 2023-04-13	152	23	152	24	
Ulreich, Daniel 2023-04-13	153	2	153	9	1, 5, 17
Ulreich, Daniel 2023-04-13	153	13	153	15	
Ulreich, Daniel 2023-04-13	153	17	153	19	1, 5, 17
Ulreich, Daniel 2023-04-13	153	22	153	23	
Ulreich, Daniel 2023-04-13	154	1	154	3	1, 5, 12, 15, 17
Ulreich, Daniel 2023-04-13	154	7	154	9	
Ulreich, Daniel 2023-04-13	154	11	154	13	1, 5, 12, 17
Ulreich, Daniel 2023-04-13	154	17	154	17	
Ulreich, Daniel 2023-04-13	154	20	154	20	
Ulreich, Daniel 2023-04-13	154	22	154	24	
Ulreich, Daniel 2023-04-13	155	5	155	9	1, 17
Ulreich, Daniel 2023-04-13	155	14	155	15	
Ulreich, Daniel 2023-04-13	155	17	155	23	1, 17
Ulreich, Daniel 2023-04-13	156	5	156	7	1, 17
Ulreich, Daniel 2023-04-13	156	11	156	13	
Ulreich, Daniel 2023-04-13	156	23	157	3	1, 17
Ulreich, Daniel 2023-04-13	157	6	157	7	
Ulreich, Daniel 2023-04-13	157	9	157	11	1, 12, 15, 17
Ulreich, Daniel 2023-04-13	157	15	157	18	
Ulreich, Daniel 2023-04-13	160	4	160	7	



Ulreich, Daniel 2023-04-13	160	12	160	18	
Ulreich, Daniel 2023-04-13	160	23	161	2	
Ulreich, Daniel 2023-04-13	161	11	161	15	1, 5, 12, 15, 17
Ulreich, Daniel 2023-04-13	161	18	161	20	
Ulreich, Daniel 2023-04-13	162	5	162	8	1, 17
Ulreich, Daniel 2023-04-13	162	11	162	13	
Ulreich, Daniel 2023-04-13	162	15	162	18	1, 5, 12, 15, 17
Ulreich, Daniel 2023-04-13	162	22	163	6	1, 5, 12, 15, 17
Ulreich, Daniel 2023-04-13	163	9	163	12	
Ulreich, Daniel 2023-04-13	166	20	166	24	
Ulreich, Daniel 2023-04-13	167	5	167	9	1, 5, 12, 17
Ulreich, Daniel 2023-04-13	167	12	167	14	
Ulreich, Daniel 2023-04-13	167	16	167	24	1, 17
Ulreich, Daniel 2023-04-13	168	4	168	5	
Ulreich, Daniel 2023-04-13	169	1	169	4	1, 17
Ulreich, Daniel 2023-04-13	169	8	169	10	
Ulreich, Daniel 2023-04-13	169	12	169	15	1, 17
Ulreich, Daniel 2023-04-13	169	18	169	18	
Ulreich, Daniel 2023-04-13	170	16	170	21	1, 17
Ulreich, Daniel 2023-04-13	171	1	171	4	
Ulreich, Daniel 2023-04-13	171	6	171	7	1, 17
Ulreich, Daniel 2023-04-13	171	11	171	15	
Ulreich, Daniel 2023-04-13	172	2	172	7	1, 2, 3, 5, 12, 15, 17
Ulreich, Daniel 2023-04-13	172	11	172	14	
Ulreich, Daniel 2023-04-13	175	24	176	3	1, 2, 5, 12, 15, 17, MIL1, DAUB
Ulreich, Daniel 2023-04-13	176	7	176	10	
Ulreich, Daniel 2023-04-13	182	12	182	14	1, 17
Ulreich, Daniel 2023-04-13	182	18	182	19	
Ulreich, Daniel 2023-04-13	182	21	182	24	1, 17

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Ulreich, Daniel 2023-04-13	14	2	14	5	10:23-11:24	Sage Contingent
Ulreich, Daniel 2023-04-13	16	17	16	17	e.g., 10-5-8; 16:13-16	Sage Counter Designations
Ulreich, Daniel 2023-04-13	16	20	16	22	e.g., 10-5-8; 16:13-16	Sage Counter Designations
Ulreich, Daniel 2023-04-13	16	24	17	1	e.g., 10-5-8; 16:13-16	Sage Counter Designations
Ulreich, Daniel 2023-04-13	17	5	17	8	e.g., 10-5-8; 16:13-16	Sage Counter Designations
Ulreich, Daniel 2023-04-13	17	10	17	17	e.g., 10-5-8; 16:13-16	Sage Counter Designations
Ulreich, Daniel 2023-04-13	20	4	20	18	e.g., 16:13-16; 19:9-22	Sage Counter Designations
Ulreich, Daniel 2023-04-13	21	23	21	24	e.g., 9:9-22	Sage Counter Designations
Ulreich, Daniel 2023-04-13	22	3	22	5	e.g., 9:9-22	Sage Counter Designations
Ulreich, Daniel 2023-04-13	22	7	22	10	e.g., 9:9-22	Sage Counter Designations
Ulreich, Daniel 2023-04-13	22	16	22	23	e.g., 16:13-16; 19:9-22	Sage Counter Designations
Ulreich, Daniel 2023-04-13	22	24	23	3	e.g., 16:13-16; 19:9-22	Sage Counter Designations
Ulreich, Daniel 2023-04-13	23	11	23	14	e.g., 23:4-10	Sage Counter Designations
Ulreich, Daniel 2023-04-13	24	7	24	13	e.g., 23:4-10	Sage Counter Designations
Ulreich, Daniel 2023-04-13	25	2	25	3	e.g., 16:13-16; 19:9-22	Sage Contingent
Ulreich, Daniel 2023-04-13	25	6	25	7	e.g., 16:13-16; 19:9-22	Sage Contingent
Ulreich, Daniel 2023-04-13	25	11	25	13	e.g., 16:13-16; 19:9-22	Sage Contingent
Ulreich, Daniel 2023-04-13	25	16	25	19	e.g., 16:13-16; 19:9-22	Sage Contingent
Ulreich, Daniel 2023-04-13	27	18	27	21	e.g., 16:13-16; 19:9-22; 26:8-16	Sage Contingent
Ulreich, Daniel 2023-04-13	27	24	28	1	e.g., 16:13-16; 19:9-22; 26:8-16	Sage Contingent
Ulreich, Daniel 2023-04-13	31	13	31	14	30:8-31:4	Sage Contingent
Ulreich, Daniel 2023-04-13	31	17	31	19	30:8-31:4	Sage Counter Designations
Ulreich, Daniel 2023-04-13	31	21	31	23	30:8-31:4	Sage Counter Designations
Ulreich, Daniel 2023-04-13	32	2	32	4	30:8-31:4	Sage Counter Designations
Ulreich, Daniel 2023-04-13	34	23	35	3	30:8-31:4	Sage Counter Designations
	35	7	35	10	30:8-31:4	Sage Counter Designations
Ulreich, Daniel 2023-04-13	36	9	36	12	30:8-31:4	Sage Counter Designations
Ulreich, Daniel 2023-04-13	38	10	38	12	e.g., 16:13-16; 19:9-22; 26:8-16; 30:8-31:4	Sage Contingent
Ulreich, Daniel 2023-04-13	38	16	38	18	e.g., 16:13-16; 19:9-22; 26:8-16; 30:8-31:4	Sage Contingent
Ulreich, Daniel 2023-04-13	38	20	38	22	e.g., 16:13-16; 19:9-22; 26:8-16; 30:8-31:4	Sage Contingent
Ulreich, Daniel 2023-04-13	39	2	39	4	e.g., 16:13-16; 19:9-22; 26:8-16; 30:8-31:4	Sage Contingent
Ulreich, Daniel 2023-04-13	39	6	39	7	e.g., 16:13-16; 19:9-22; 26:8-16; 30:8-31:4	Sage Contingent
Ulreich, Daniel 2023-04-13	39	11	39	12	e.g., 16:13-16; 19:9-22; 26:8-16; 30:8-31:4	Sage Contingent
Ulreich, Daniel 2023-04-13	39	22	39	24	e.g., 16:13-16; 19:9-22; 26:8-16; 30:8-31:4	Sage Contingent
Ulreich, Daniel 2023-04-13	40	4	40	7	e.g., 16:13-16; 19:9-22; 26:8-16; 30:8-31:4	Sage Contingent
Ulreich, Daniel 2023-04-13	40	9	40	11	e.g., 16:13-16; 19:9-22; 26:8-16; 30:8-31:4	Sage Contingent
Ulreich, Daniel 2023-04-13	40	14	40	16	e.g., 16:13-16; 19:9-22; 26:8-16; 30:8-31:4	Sage Contingent
Ulreich, Daniel 2023-04-13	40	20	40	23	e.g., 16:13-16; 19:9-22; 26:8-16; 30:8-31:4	Sage Contingent

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Ulreich, Daniel 2023-04-13	41	2	41	5	e.g., 16:13-16; 19:9-22; 26:8-16; 30:8-31:4	Sage Contingent
Ulreich, Daniel 2023-04-13	41	7	41	10	e.g., 16:13-16; 19:9-22; 26:8-16; 30:8-31:4	Sage Contingent
Ulreich, Daniel 2023-04-13	41	14	41	18	e.g., 16:13-16; 19:9-22; 26:8-16; 30:8-31:4	Sage Contingent
Ulreich, Daniel 2023-04-13	41	23	42	1	e.g., 16:13-16; 19:9-22; 26:8-16; 30:8-31:4	Sage Contingent
Ulreich, Daniel 2023-04-13	42	4	42	6	e.g., 16:13-16; 19:9-22; 26:8-16; 30:8-31:4	Sage Contingent
Ulreich, Daniel 2023-04-13	44	11	44	13	e.g., 16:13-16; 19:9-22; 26:8-16; 30:8-31:4	Sage Contingent
Ulreich, Daniel 2023-04-13	44	18	44	22	e.g., 16:13-16; 19:9-22; 26:8-16; 30:8-31:4	Sage Contingent
Ulreich, Daniel 2023-04-13	45	5	45	8	e.g., 16:13-16; 19:9-22; 26:8-16; 30:8-31:4	Sage Contingent
Ulreich, Daniel 2023-04-13	45	9	45	12	e.g., 16:13-16; 19:9-22; 26:8-16; 30:8-31:4	Sage Contingent
Ulreich, Daniel 2023-04-13	45	13	45	15	e.g., 16:13-16; 19:9-22; 26:8-16; 30:8-31:4	Sage Contingent
Ulreich, Daniel 2023-04-13	47	4	47	6	e.g., 16:13-16; 19:9-22; 26:8-16; 30:8-31:4	Sage Contingent
Ulreich, Daniel 2023-04-13	47	9	47	11	e.g., 16:13-16; 19:9-22; 26:8-16; 30:8-31:4	Sage Contingent
Ulreich, Daniel 2023-04-13	52	1	52	3	50:19-51:9	Sage Counter Designations
Ulreich, Daniel 2023-04-13	56	9	56	11	50:19-51:9	Sage Counter Designations
Ulreich, Daniel 2023-04-13	56	14	56	16	50:19-51:9	Sage Counter Designations
Ulreich, Daniel 2023-04-13	59	3	59	7		Sage Contingent
Ulreich, Daniel 2023-04-13	59	8	59	13		Sage Contingent
Ulreich, Daniel 2023-04-13	64	19	65	1	63:24-64:18	Sage Counter Designations
Ulreich, Daniel 2023-04-13	65	6	65	14	63:24-64:18	Sage Counter Designations
Ulreich, Daniel 2023-04-13	65	15	66	2	63:24-64:18	Sage Counter Designations
Ulreich, Daniel 2023-04-13	66	3	66	8	63:24-64:18	Sage Counter Designations
Ulreich, Daniel 2023-04-13	66	11	66	13	63:24-64:18	Sage Counter Designations
Ulreich, Daniel 2023-04-13	67	20	67	24	63:24-64:18	Sage Counter Designations
Ulreich, Daniel 2023-04-13	68	3	68	4	63:24-64:18	Sage Counter Designations
Ulreich, Daniel 2023-04-13	68	12	68	15	63:24-64:18	Sage Counter Designations
Ulreich, Daniel 2023-04-13	68	19	68	21	63:24-64:18	Sage Counter Designations
Ulreich, Daniel 2023-04-13	68	23	68	24	63:24-64:18	Sage Counter Designations
Ulreich, Daniel 2023-04-13	73	24	74	2	e.g., 16:13-16; 19:9-22; 26:8-16; 30:8-31:4; 63:24-64:18	Sage Contingent
Ulreich, Daniel 2023-04-13	74	6	74	9	e.g., 16:13-16; 19:9-22; 26:8-16; 30:8-31:4; 63:24-64:18	Sage Contingent
Ulreich, Daniel 2023-04-13	78	4	78	7	e.g., 16:13-16; 19:9-22; 26:8-16; 30:8-31:4; 63:24-64:18	Sage Contingent
Ulreich, Daniel 2023-04-13	78	11	78	15	e.g., 16:13-16; 19:9-22; 26:8-16; 30:8-31:4; 63:24-64:18	Sage Contingent
Ulreich, Daniel 2023-04-13	104	13	104	17	99:2-9	Sage Counter Designations
Ulreich, Daniel 2023-04-13	104	21	104	24	99:2-9	Sage Counter Designations
Ulreich, Daniel 2023-04-13	106	17	107	3	105:22-106:12	Sage Contingent
Ulreich, Daniel 2023-04-13	112	6	112	9	105:22-106:12	Sage Contingent
Ulreich, Daniel 2023-04-13	112	12	112	16	105:22-106:12	Sage Contingent

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Initials	Issues
Ulreich, Daniel 2023-04-13	114	1	114	5		Sage Contingent
Ulreich, Daniel 2023-04-13	115	4	115	5	114:9-115:3	Sage Contingent
Ulreich, Daniel 2023-04-13	115	9	115	13	114:9-115:3	Sage Contingent
Ulreich, Daniel 2023-04-13	119	21	120	2	e.g., 114:9-115:3	Sage Counter Designations
Ulreich, Daniel 2023-04-13	120	22	121	1	e.g., 114:9-115:3	Sage Counter Designations
Ulreich, Daniel 2023-04-13	121	7	121	9	e.g., 114:9-115:3	Sage Counter Designations
Ulreich, Daniel 2023-04-13	121	11	121	13	e.g., 114:9-115:3	Sage Counter Designations
Ulreich, Daniel 2023-04-13	121	17	121	20	e.g., 114:9-115:3	Sage Counter Designations
Ulreich, Daniel 2023-04-13	121	22	122	1	e.g., 114:9-115:3	Sage Counter Designations
Ulreich, Daniel 2023-04-13	122	4	122	6	e.g., 114:9-115:3	Sage Counter Designations
Ulreich, Daniel 2023-04-13	122	8	122	11	e.g., 114:9-115:3	Sage Counter Designations
Ulreich, Daniel 2023-04-13	122	12	122	19	e.g., 114:9-115:3	Sage Counter Designations
Ulreich, Daniel 2023-04-13	126	9	126	15	126:3-6	Sage Counter Designations
Ulreich, Daniel 2023-04-13	130	14	130	19	126:3-130:12	Sage Counter Designations
Ulreich, Daniel 2023-04-13	130	23	131	3	126:3-130:12	Sage Counter Designations
Ulreich, Daniel 2023-04-13	148	7	148	15	e.g., 142:22-148:6	Sage Counter Designations
Ulreich, Daniel 2023-04-13	148	19	148	21	e.g., 142:22-148:6	Sage Counter Designations
Ulreich, Daniel 2023-04-13	163	14	163	17	e.g., 162:5-163:12	Sage Counter Designations
Ulreich, Daniel 2023-04-13	163	21	164	1	e.g., 162:5-163:12	Sage Counter Designations
Ulreich, Daniel 2023-04-13	164	13	164	15	e.g., 162:5-163:12	Sage Counter Designations
Ulreich, Daniel 2023-04-13	164	19	164	23	e.g., 162:5-163:12	Sage Counter Designations
Ulreich, Daniel 2023-04-13	173	3	173	11	e.g., 169:1-18, 170:16-15; 172:2-14	Sage Counter Designations
Ulreich, Daniel 2023-04-13	183	18	184	3	e.g., 10:23-11:24, 16:13-16	Sage Counter Designations

# SCHEDULE E2c

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

PUREWICK CORPORATION,

Plaintiff,

v.

SAGE PRODUCTS, LLC,

Defendant.

)  
)  
)  
)  
)  
)  
)  
)  
)  
)  
)

C.A. No. 22-102-MN

**CONFIDENTIAL –  
FILED UNDER SEAL**

**PUREWICK CORPORATION’S OBJECTIONS AND COUNTER-  
COUNTER DESIGNATIONS TO SAGE PRODUCTS, LLC’S COUNTER-  
DESIGNATIONS AND COUNTER-CONTINGENT DESIGNATIONS**

DESCRIPTION	OBJECTIONS
FEDERAL RULES OF EVIDENCE 401/402 (IRRELEVANT)	402
FEDERAL RULE OF EVIDENCE 403 (UNDULY PREJUDICIAL, CONFUSING, MISLEADING, DELAY, AND/OR WASTE OF TIME)	403
FEDERAL RULE OF EVIDENCE 408 (COMPROMISE OFFERS AND NEGOTIATIONS)	408
FEDERAL RULE OF EVIDENCE 501 (PRIVILEGE)	P
FEDERAL RULE OF EVIDENCE 602 (LACK OF PERSONAL KNOWLEDGE OR COMPETENCY)	602
FEDERAL RULE OF EVIDENCE 611(C) (LEADING)	611
IMPROPER LAY OPINION / IMPROPER EXPERT TESTIMONY BY NON-EXPERT	701
IMPROPER TESTIMONY BY EXPERT WITNESS	702/703
FEDERAL RULE OF EVIDENCE 802 (HEARSAY)	H
LACKS FOUNDATION	F
CALLS FOR SPECULATION	Spec
FEDERAL RULE OF EVIDENCE 611(B) (BEYOND SCOPE OF DESIGNATIONS)	BSD
NOT TESTIMONY – INCLUDES ATTORNEY OBJECTIONS AND/OR DISCUSSIONS BETWEEN ATTORNEYS	NT
DESIGNATION INCOMPLETE / INCOMPREHENSIBLE / INCOMPLETE QUESTION / ANSWER	I
BEYOND SCOPE OF 30(B)(6) NOTICE / QUESTIONS	S
VAGUE AND AMBIGUOUS	V
ARGUMENTATIVE	Arg
IMPROPER / INCOMPLETE HYPOTHETICAL	Hyp
COMPOUND	C
MISCHARACTERIZATION	M
CALLS FOR LEGAL CONCLUSION	LC
ASSUMES FACTS NOT IN EVIDENCE	AF
NON-RESPONSIVE	NR
NARRATIVE	Nar
FOREIGN LANGUAGE	LANG
NOT EVIDENCE	NE
LATE DISCLOSED	LATE DISCLOSED
DUPLICATE	DUP
UNAVAILABILITY OF DEPONENT NOT ESTABLISHED	UNE

**PureWick's Designation of Deposition Testimony of Arun Alakhramsing, January 31, 2023**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
37:4-37:5	402, F, V
38:5-38:7	402, F, V
38:11-38:13	402, F, V
61:8-61:10	402, F, V, 602
61:13-61:14	402, F, V, 602
103:9-103:11	
103:14-103:17	
197:12-197:15	402, F, V
197:19-197:21	402, F, V
249:9-249:10	402, F, V
249:13-249:15	402, F, V
249:16-249:18	402, F, V



**PureWick's Designation of Deposition Testimony of Nick Alexander, April 13, 2021**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
27:5-27:9	
57:23-58:4	402, F, V, S, 602
60:19-61:8	402
63:18-63:20	402
83:17-83:19	402, 602
86:22-87:7	
89:14-89:16	
90:3-90:13	402, F, V
91:13-91:20	402, F, V, 602
96:9-96:13	402, F, V, H
96:19-96:25	402, F, V, H
97:10-97:15	402, F, V
100:7-100:8	402, F, V, H, 602
100:13-100:13	402, F, V, H
101:4-101:19	
101:20-101:24	
106:5-106:8	402, F, V, H
106:11-107:14	402, F, V, H
131:22-131:24	402, F, V, H, 602
132:13-132:17	402, F, V, H, 602
135:23-136:8	402, V, 602
167:9-167:23	402, F, V, H, counter-counter 167:24-25
217:15-217:17	
217:21-218:7	

**PureWick's Designation of Deposition Testimony of Jennifer Allen, February 1, 2023**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
11:9-11:18	
11:24-12:2	
20:6-20:11	
21:23-22:3	
22:12-22:18	
23:8-23:19	
29:8-29:12	
31:19-32:7	
32:11-32:15	
32:24-33:6	I
39:24-40:2	
50:24-51:2	F, 402, 403, H
54:22-55:4	
55:5-55:10	F, 402, 403, H
59:9-59:12	F, 402, 403, H, S
59:13-59:20	
67:14-67:22	F, 402, 403, H

**PureWick's Designation of Deposition Testimony of Brett Blabas, February 23, 2021**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
27:13-27:21	402
28:23-29:11	402
29:21-30:10	402
31:14-31:18	402
33:18-33:22	402, 403
34:23-35:3	402, 403
41:16-41:24	BSD, 402, 403
49:24-50:21	
50:25-51:7	602, 402, 403
57:22-57:25	402, 403
58:4-58:5	402, 403
68:3-68:13	BSD
68:25-69:12	BSD
73:22-74:7	
75:3-75:8	
75:9-75:20	
76:22-77:6	
77:7-78:5	BSD, 402, 403
80:22-81:3	BSD, 402, 403
86:2-86:8	BSD, 402, 403
88:6-88:22	BSD, 402, 403
91:19-92:2	
92:3-92:5	
92:10-92:17	
92:18-92:19	
92:23-93:4	
112:9-112:19	BSD, 402, 403, H
113:12-113:18	BSD, 402, 403, H
114:18-115:5	BSD, 402, 403, H, 602
119:21-120:23	BSD, 402, 403
127:13-127:21	BSD, 402, 403, H
128:21-129:2	
137:23-138:7	402, 403
138:17-138:24	402, 403
148:3-148:11	402, 403
148:21-149:7	BSD, 402, 403
149:8-149:12	BSD, 402, 403
149:18-149:25	BSD, 402, 403
150:2-150:14	BSD, 402, 403
157:6-157:14	
175:15-175:18	

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
179:21-181:11	BSD, 402, 403
182:9-182:13	
183:6-183:20	BSD, 402, 403
184:10-184:17	BSD, 402, 403
185:17-185:25	BSD, 402, 403
186:2-186:15	BSD, 402, 403
187:17-187:20	
188:2-188:9	BSD, 402, 403
190:12-190:16	
192:12-192:22	BSD, 402, 403
194:3-194:14	BSD, 402, 403
197:5-197:9	
197:21-198:6	BSD, 402, 403
201:17-202:11	BSD, 402, 403
205:8-205:21	BSD, 402, 403
206:19-207:17	BSD, 402, 403
209:2-209:6	
209:16-209:25	BSD, 402, 403
212:19-212:23	
215:11-215:20	BSD, 402, 403
216:15-216:25	BSD, 402, 403
217:20-217:24	
218:5-218:16	BSD, 402, 403
219:10-219:21	
220:17-220:23	
222:23-223:15	BSD, 402, 403
224:4-224:13	BSD, 402, 403
225:8-225:10	
226:2-226:13	BSD, 402, 403
226:20-227:6	BSD, 402, 403
231:8-231:21	BSD, 402, 403
232:8-232:12	
233:18-233:22	
234:21-235:7	BSD, 402, 403
237:8-237:16	BSD, 402, 403
238:21-238:23	
239:22-240:7	
240:8-240:16	
240:17-240:25	
241:15-241:17	
241:21-242:6	BSD, 402, 403
243:18-243:22	
244:17-244:25	

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
261:3-261:9	
261:10-261:20	
262:17-262:20	
262:23-263:6	
267:12-268:4	BSD, 402, 403, NT
276:23-277:9	
283:14-284:9	BSD, 402, 403
284:10-284:17	
292:7-292:14	NT
293:15-293:20	
294:19-295:2	602, 402, 403
295:18-296:2	BSD, 402, 403
296:17-297:5	BSD, 402, 403
299:22-300:9	BSD, 402, 403
303:4-303:10	
304:17-304:22	602, 402, 403
305:13-305:24	BSD, 402, 403
312:12-312:17	BSD, 402, 403
314:7-314:13	BSD, 602, 402, 403
320:8-320:18	
321:3-321:19	NT, 602, 402, 403

**PureWick's Designation of Deposition Testimony of Brett Blabas, August 31, 2023**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
20:16-20:21	602, 402, 403
24:10-24:12	602, 402, 403
29:16-29:23	BSD, 402, 403
29:24-29:24	BSD, 402, 403
30:6-30:7	BSD, 402, 403
31:4-31:9	BSD, 402, 403, NT
31:16-32:4	BSD, 402, 403
35:9-35:11	
35:18-35:22	
42:5-42:12	BSD, 402, 403
42:14-42:19	BSD, 402, 403
53:5-53:9	
56:3-56:13	BSD, 402, 403
86:18-86:23	BSD, 402, 403, H
87:14-87:22	BSD, 402, 403, H
87:23-88:2	BSD, 402, 403, H
89:17-89:22	BSD, 402, 403, H
94:18-95:3	BSD, 402, 403, H
102:10-102:18	BSD, 402, 403, H, NT
106:5-106:10	BSD, 402, 403, H
106:18-106:21	BSD, 402, 403, 602, H
107:5-107:14	BSD, 402, 403, 602, H
153:3-153:7	BSD, 402, 403, H
154:23-155:7	BSD, 402, 403
170:17-171:4	BSD, 402, 403
173:17-173:24	BSD, 402, 403, 602, NT
174:20-174:23	
175:23-176:5	BSD, 402, 403
177:14-177:18	BSD, 402, 403, 602
180:1-180:6	BSD, 402, 403, 602
180:17-180:24	BSD, 402, 403, 602
181:13-182:4	BSD, 402, 403, 602
184:17-184:20	
187:13-187:15	
188:17-188:21	BSD, 402, 403
188:24-188:24	BSD, 402, 403
190:12-191:7	BSD, 402, 403
191:14-191:19	BSD, 402, 403
193:16-194:4	BSD, 402, 403
196:9-196:10	
196:14-196:16	

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
196:18-196:23	NT
200:21-200:22	
202:9-202:16	BSD, 402, 403, NT
203:9-203:15	BSD, 402, 403, NT
205:15-205:22	
210:7-210:13	602, 402, 403, NT
211:9-211:17	BSD, 402, 403
211:22-211:23	BSD, 402, 403
212:1-212:11	BSD, 402, 403, NT
214:20-215:6	BSD, 602, 402, 403, NT
215:8-215:15	BSD, 402, 403, NT
222:18-222:24	BSD, 402, 403
228:21-229:11	BSD, 602, 402, 403, NT
231:3-231:4	
231:11-231:15	
232:15-232:20	BSD, 602, 402, 403
273:23-274:13	BSD, 402, 403, H
274:16-275:3	BSD, 402, 403, H
275:4-275:7	BSD, 402, 403, H
275:11-275:17	BSD, 402, 403, H
275:19-276:7	BSD, 402, 403, H
276:11-276:18	BSD, 402, 403, H
276:20-276:21	BSD, 402, 403, H, 611
276:24-277:3	BSD, 402, 403, H, 611
277:6-277:15	BSD, 402, 403, H, 611
279:18-279:22	BSD, 402, 403, H
280:2-280:16	BSD, 402, 403, H, Nar
280:21-280:24	BSD, 402, 403, H
281:5-281:11	BSD, 402, 403, H
281:15-281:22	BSD, 402, 403, H
282:1-282:2	BSD, 402, 403, H
282:4-282:8	BSD, 402, 403, H
282:11-282:13	BSD, 402, 403, H, Nar
282:16-284:8	BSD, 402, 403, H, Nar
284:10-284:12	BSD, 402, 403, H, 611, Nar
284:16-285:22	BSD, 402, 403, H, Nar
286:17-287:15	BSD, 402, 403, H, 611
287:23-288:1	BSD, 402, 403, H, 611
288:5-288:10	BSD, 402, 403, H
288:12-289:19	BSD, 402, 403, H, Nar
289:23-290:19	BSD, 402, 403, H, Nar
291:1-291:4	BSD, 402, 403, H, 611
291:8-291:9	BSD, 402, 403, H, 611

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
291:17-292:12	BSD, 402, 403, H
292:15-292:22	BSD, 402, 403, H
292:24-293:1	BSD, 402, 403, H, 611
293:11-293:20	BSD, 402, 403, H, 611
294:15-295:1	BSD, 402, 403, H
295:13-296:10	BSD, 402, 403, H
296:14-296:23	BSD, 602, 402, 403, H
297:1-297:8	BSD, 402, 403, H
297:12-297:17	BSD, 402, 403, H
297:20-297:24	BSD, 402, 403, H, 611
298:4-298:13	BSD, 402, 403, H
298:16-298:19	BSD, 402, 403, H, 611
298:22-299:2	BSD, 402, 403, H
300:14-300:17	BSD, 402, 403, H, 611
302:1-302:3	BSD, 402, 403, H
302:20-302:23	BSD, 402, 403, H
303:13-303:17	BSD, 402, 403, H, 611
303:20-303:20	BSD, 402, 403, H
304:1-304:3	BSD, 402, 403, H, 611
304:6-304:6	BSD, 402, 403, H
304:11-304:14	BSD, 402, 403, H
304:17-304:19	BSD, 402, 403, H
304:23-304:24	BSD, 602, 402, 403, H
305:2-305:5	BSD, 602, 402, 403, H
305:8-305:14	BSD, 602, 402, 403, H
305:17-305:18	BSD, 402, 403, H
305:21-306:1	BSD, 602, 402, 403, H
306:4-306:7	BSD, 402, 403, H, 611
306:11-306:16	BSD, 402, 403, H
306:24-307:5	BSD, 402, 403, H, 611
307:10-307:13	BSD, 602, 402, 403, H, 611
307:16-307:19	BSD, 402, 403, H, 611
307:22-308:1	BSD, 402, 403, H, 611
309:4-309:7	BSD, 402, 403, H, 611
309:23-310:10	BSD, 402, 403, H
310:16-310:18	BSD, 402, 403, H
310:22-311:10	BSD, 402, 403, H, 611
311:18-311:20	BSD, 402, 403, H, 611
311:24-312:8	BSD, 402, 403, H
312:10-312:19	BSD, 402, 403, H
312:23-313:23	BSD, 402, 403, H
314:6-314:9	BSD, 402, 403, H
314:16-314:19	BSD, 402, 403, H, 611



<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
314:23-315:2	BSD, 402, 403, H
315:15-315:16	BSD, 402, 403, H
315:24-316:1	BSD, 402, 403, H
316:14-316:24	BSD, 402, 403, H
317:12-317:15	BSD, 402, 403, H
317:19-318:5	BSD, 402, 403, H
318:9-319:4	BSD, 402, 403, H
319:18-319:19	BSD, 402, 403, H, 611
319:23-320:11	BSD, 402, 403, H, 611
320:14-320:17	BSD, 402, 403, H, 611
320:20-321:6	BSD, 402, 403, H, 611
321:9-321:12	BSD, 402, 403, H, 611
321:15-321:23	BSD, 402, 403, H, 611
322:1-322:3	BSD, 402, 403, H, F
323:3-323:18	BSD, 402, 403, H
324:2-324:7	BSD, 402, 403, H
324:10-324:11	BSD, 402, 403, H, 611
324:14-324:14	BSD, 402, 403, H
324:18-324:20	BSD, 402, 403, H, 611
324:23-325:4	BSD, 402, 403, H, 611
325:7-325:7	BSD, 402, 403, H
325:22-326:1	BSD, 402, 403, H, 611
326:4-326:14	BSD, 402, 403, H, 611
326:19-327:1	BSD, 402, 403, H
327:4-327:6	BSD, 402, 403, H
327:9-327:9	BSD, 402, 403, H
328:8-328:10	BSD, 402, 403, H, 611
328:13-328:16	BSD, 402, 403, H
329:23-329:24	BSD, 402, 403, H
330:3-330:4	BSD, 402, 403, H
330:6-330:7	BSD, 402, 403, H, 611
330:10-330:14	BSD, 402, 403, H, 611
330:17-330:20	BSD, 402, 403, H
330:23-331:3	BSD, 402, 403, H
331:6-331:6	BSD, 402, 403, H
331:14-331:16	BSD, 402, 403, H, 611
331:19-331:23	BSD, 402, 403, H
334:5-334:8	BSD, 402, 403, H
335:4-335:12	BSD, 402, 403, H
336:14-336:17	BSD, 402, 403, H
336:21-336:24	BSD, 402, 403, H
337:20-337:21	BSD, 402, 403, H
337:24-338:14	BSD, 402, 403, H, 611

**PureWick's Designation of Deposition Testimony of Jason Bobay, April 23, 2021**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
14:22-15:25	
17:9-17:25	
18:2-18:25	
20:2-21:11	402
21:21-21:25	402
22:2-22:8	
32:10-32:13	
32:19-32:21	H
48:22-49:7	402, F, S, 403
49:8-49:19	402, F, S, 403
75:4-75:12	402, F, S, 403, 602
76:14-76:16	I, counter-counter 76:10-13
76:19-77:6	402, V, S
81:14-82:12	402, F, S, 403, H
82:21-82:23	
83:3-83:14	402, F, S, 403, H
86:9-86:25	402, H
87:2-87:2	
90:3-90:8	402
90:17-90:19	402
92:20-92:22	
94:5-94:8	
94:12-94:25	402, H, F
95:2-95:25	402, H, F
96:2-96:25	402, H, F
100:17-100:25	I, 402, H, F
101:2-101:25	402, H, F
102:2-102:11	402, H, F
109:8-109:11	
109:14-109:15	BSD, 602, 402
112:3-112:7	
128:16-128:20	
130:2-130:4	
131:11-131:19	
132:9-132:11	
132:15-132:25	402
133:2-133:25	402
134:2-134:20	402
148:2-148:12	I, H, 402
152:23-153:3	H, 402, F, S
153:5-153:6	

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
154:19-154:25	
155:2-155:25	H, 402, F, S, 602
156:2-156:6	H, 402, F, S, 602
156:15-156:18	
161:9-161:25	402
162:2-162:14	402
163:17-163:20	
164:18-164:22	
164:25-164:25	
165:2-165:11	H, 402
165:16-165:25	H, 402, S
166:3-166:12	H, 402, S
167:6-167:12	H
167:16-167:17	
170:13-170:18	I, H, 402
171:25-172:7	402
176:23-177:8	I, 402
180:4-180:11	402
182:16-182:25	
183:2-183:25	402, F
184:2-184:25	402, F
185:2-185:5	402, F

**PureWick's Designation of Deposition Testimony of Adam Cole, February 8, 2023**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
30:8-30:9	
30:11-30:17	
36:17-36:19	
36:22-36:25	
37:3-37:15	
38:23-38:24	
39:5-39:9	
39:19-39:20	
40:2-40:15	
41:17-41:24	
42:1-42:7	
46:22-47:2	
51:10-51:12	
52:9-52:16	
52:25-53:4	
53:6-53:7	
53:9-53:17	
53:25-54:2	
54:4-55:3	BSD, 402, 403
55:4-55:17	BSD, 402, 403
55:20-56:2	BSD, 402, 403
56:7-56:8	BSD, 402, 403
56:11-56:22	BSD, 402, 403
68:9-68:11	
68:14-68:22	
74:22-74:24	
75:3-75:7	
80:21-80:23	
81:2-81:7	
83:21-83:21	
83:24-83:25	
84:3-84:5	
84:9-84:15	
85:19-85:21	
85:25-86:6	
91:9-91:12	
91:15-91:21	
96:18-96:21	
96:23-97:4	
99:16-99:19	
99:23-100:3	

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
100:4-100:5	
100:8-100:9	
100:11-100:12	
100:16-100:21	
107:6-107:8	
107:10-107:15	
108:4-108:5	
108:7-108:11	
108:13-108:16	
108:19-108:25	
111:7-111:8	
111:11-111:14	
117:3-117:4	
117:6-117:10	
118:8-118:10	
118:17-118:18	
125:19-125:21	BSD, 402, 403
126:1-126:12	BSD, 402, 403
134:25-135:1	I
140:7-140:22	BSD, 402, 403
140:23-140:25	BSD, 402, 403
141:3-141:9	BSD, 402, 403
141:17-141:21	BSD, 402, 403, I
143:21-143:22	
144:2-144:4	
149:11-149:16	
156:20-157:5	BSD, 402, 403
157:14-157:15	BSD, 402, 403
157:17-157:24	BSD, 402, 403
158:3-158:4	BSD, 402, 403
158:6-158:11	BSD, 402, 403
158:13-158:15	BSD, 402, 403
159:2-159:3	BSD, 402, 403, I
160:3-160:7	BSD, 402, 403
160:10-160:15	BSD, 402, 403
162:3-162:5	
162:7-162:8	
162:10-162:12	
162:14-162:20	
162:22-162:24	
163:3-163:5	
163:8-163:10	
191:4-191:5	

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
191:8-191:13	
191:21-191:22	
191:25-192:6	
194:10-194:12	
194:14-194:17	
198:10-198:14	
198:20-199:5	
209:4-209:5	
209:8-209:10	
210:5-211:5	BSD, 402, 403
211:6-211:10	BSD, 402, 403
212:16-212:18	
212:20-213:5	
221:20-221:25	
226:18-227:2	
227:11-227:16	
248:5-248:7	BSD, 402, 403
248:10-248:12	BSD, 402, 403
248:14-248:14	BSD, 402, 403
248:17-248:20	BSD, 402, 403
248:21-248:23	BSD, 402, 403
248:25-249:9	BSD, 402, 403
249:19-249:21	
249:24-250:9	BSD, 402, 403
250:18-250:19	BSD, 402, 403
250:23-250:23	BSD, 402, 403
250:25-251:4	BSD, 402, 403
251:14-251:23	
251:25-252:3	
255:10-255:12	
255:15-255:19	
257:7-257:9	
261:12-261:15	
264:21-264:25	
265:2-265:4	
265:9-265:10	
265:13-265:15	
268:24-268:25	BSD, 402, 403
269:3-269:6	BSD, 402, 403
269:8-269:16	BSD, 402, 403
269:18-269:20	BSD, 402, 403
269:24-270:8	BSD, 402, 403
271:13-272:4	BSD, 402, 403, NR

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
274:24-275:2	
275:4-275:11	
275:21-276:4	
279:3-279:4	BSD, 402, 403
279:7-279:10	BSD, 402, 403
279:12-279:14	BSD, 402, 403
279:17-279:19	BSD, 402, 403
281:23-281:25	
284:12-284:13	
284:16-284:20	
284:22-284:24	
285:3-285:7	
288:3-288:5	BSD, 402, 403, NR
288:9-288:14	BSD, 402, 403, NR

**PureWick's Designation of Deposition Testimony of Lorena Eckert, March 14, 2023**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
16:8-16:11	
18:3-18:13	402, 403, V
18:15-18:22	
19:11-19:19	I
19:23-20:2	402, 403
20:9-20:18	402, 403
21:8-21:22	402, 403
25:24-26:2	402
26:13-26:22	402
27:10-27:20	402
28:12-29:4	V
29:7-29:10	
29:12-29:16	V
29:20-29:24	V
31:19-31:22	
31:24-32:7	
35:21-35:24	
36:1-36:3	I
40:3-41:2	
41:15-42:4	
43:1-43:13	
55:10-55:13	
55:19-56:6	H, 402, 403
56:21-57:4	H, 402, 403
57:20-57:22	
58:14-58:20	H, 402, 403
60:20-60:22	V, I
61:6-61:8	V, I
62:15-62:21	402, 403, H, V
62:22-63:3	402, 403, H, V
63:9-63:14	
63:21-64:12	402, 403, V
64:15-64:16	
65:4-65:10	H, 402, 403
72:14-72:18	
72:21-72:22	402, 403, V, CS
73:5-73:8	I, 402, 403
75:12-75:18	H, 402, 403
76:2-76:5	402, 403
84:5-84:8	402, 403, V
100:18-100:19	



<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
101:1-101:9	402, 403
101:21-102:1	402, 403
102:7-102:21	402, 403, V
103:1-103:2	F
103:4-103:5	402, 403, V
103:8-103:13	
103:15-103:18	
103:22-103:22	
113:24-114:6	402, 403
118:2-118:12	402, 403
120:1-120:6	
120:23-121:11	402, 403, V
121:14-121:18	
121:20-122:3	402
122:6-122:12	402, 403, V
122:16-122:21	
125:10-125:20	402, 403, V
127:3-127:10	V, H
127:13-127:14	F
127:16-127:19	F, V
127:23-128:2	
128:5-128:5	
128:7-128:23	402, 403, 602, F, H
129:2-129:7	602, F
129:9-129:13	602, F
129:15-129:18	402, 403, F, H
129:22-130:2	602, F
130:4-130:11	402, 403, 602, H, F
135:1-135:15	
136:4-136:7	
144:19-144:23	
145:10-145:12	H
147:6-147:8	
147:20-147:23	H
150:18-151:6	V
151:19-151:19	
151:21-151:21	
151:24-153:3	402, 403, V, H, I
153:5-153:14	402, 403, H
153:17-153:17	
153:20-153:23	

**PureWick's Designation of Deposition Testimony of Eric Farrell, February 2, 2023**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
44:3-44:10	402, V, Spec
62:8-62:9	402, F
62:14-62:21	402, F
62:24-63:5	402, F
104:25-105:3	
105:5-105:7	
111:10-111:12	
111:14-111:18	402
197:11-197:19	402
197:22-198:3	402
239:6-239:14	F, Spec, V, 602

**PureWick's Designation of Deposition Testimony of Sameer Jirafe, February 10, 2023**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
22:23-22:24	
23:2-23:2	
23:4-23:8	NT
23:10-23:15	NT
24:10-24:13	NT
25:2-25:14	NT
31:4-31:11	NT
31:13-31:14	
31:17-31:20	
32:16-33:9	NT
39:3-39:8	NT
40:8-40:11	NT
40:19-41:9	NT
41:11-41:14	NT
41:15-41:20	NT
43:7-43:13	NT
84:6-84:13	NT, 402, 403
88:22-89:6	NT, 402, 403
134:13-135:8	NT, 402, 403
142:23-143:4	NT, DUP
146:4-147:17	NT, 402, 403
189:15-189:22	NT
210:5-210:22	NT

**PureWick's Designation of Deposition Testimony of Richard Morgan, February 10, 2023**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
10:9-10:14	BSD
13:3-13:14	BSD, 402, 403
13:20-13:24	BSD, 402, 403
16:1-17:4	BSD
20:10-20:23	BSD, 402, 403
22:16-22:19	BSD, 402, 403
22:21-22:22	BSD, 402, 403
27:20-27:23	BSD, 402, 403, F, H
28:2-28:13	BSD, 402, 403, F, H
30:2-30:12	BSD, Counter-designation: 30:13-17
30:18-31:1	BSD
31:19-32:4	BSD
32:7-32:22	BSD
35:5-35:13	BSD, 402, 403, F, H, CS, V, I, Counter-designation: 35:17-19; 35:20-38:1
35:15-35:16	BSD, 402, 403, H
38:2-38:5	BSD, 402, 403, H
38:8-38:20	BSD, 402, 403, H
39:6-39:9	BSD, 402, 403, H
40:15-41:1	BSD, 402, 403, H, CS, V, Exp
41:4-41:7	BSD, 402, 403, H, CS, V, Exp
41:9-41:11	BSD, 402, 403, H, CS, V, Exp
41:13-41:13	BSD, 402, 403, H, CS, V, Exp
41:20-42:10	BSD, 402, 403, H, CS, V, Exp
42:12-42:12	BSD, 402, 403, H, CS, V, Exp, I, Counter-designation: 42:13
42:21-43:3	BSD, 402, 403, H, CS, V, Exp
43:6-43:11	BSD, 402, 403, H, CS, V, Exp
43:13-43:16	BSD, 402, 403, H, CS, V, Exp
43:19-43:22	BSD, 402, 403, H, CS, V, Exp
44:5-44:12	BSD, 402, 403, H, CS, V, Exp
44:15-44:16	BSD, 402, 403, H, CS, V, Exp
45:13-45:21	BSD, 402, 403, H, CS, V, Exp
45:24-46:2	BSD, 402, 403, H, CS, V, Exp
46:4-46:5	BSD, 402, 403, H, CS, V, Exp
46:7-46:15	BSD, 402, 403, H, CS, V, Exp
46:20-46:21	BSD, 402, 403, H, CS, V, Exp, I, Counter-designation: 46:18- 19, 22-24

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
48:20-49:3	BSD, 402, 403, H
49:5-49:14	BSD, 402, 403, H, CS, V, Exp
50:5-50:11	BSD, 402, 403, H, CS, V, Exp, I, Counter-designation: 50:12
51:11-52:2	BSD, 402, 403, H, CS, V, Exp
52:6-53:3	BSD, 402, 403, H, CS, V, Exp
53:11-53:15	BSD, 402, 403, H, CS, V, Exp, I, Counter-designation: 53:6-10
68:14-68:21	BSD, 402, 403, H, F
93:15-94:1	BSD, 402, 403, H, CS, V
94:12-94:24	BSD, 402, 403, H, CS, V
95:3-95:16	BSD, 402, 403, H, CS, V
95:19-95:20	BSD, 402, 403, H, CS, V
96:19-96:21	BSD, 402, 403, H, CS, V
96:24-97:2	BSD, 402, 403, H, CS, V
102:2-102:18	BSD, 402, 403, H, CS, V
102:19-103:18	BSD, 402, 403, H, CS, V
104:8-104:22	BSD, 402, 403, H, CS, V
105:1-105:5	BSD, 402, 403, H, CS, V
105:18-106:11	BSD, 402, 403, H, CS, V
106:15-106:19	BSD, 402, 403, H, CS, V
106:21-108:6	BSD, 402, 403, H, CS, V
113:13-114:18	BSD, 402, 403, H, CS, V
116:6-116:15	BSD
116:18-116:18	BSD
117:14-117:22	BSD, 402, 403, H, CS, V, F
118:1-118:3	BSD, 402, 403, H, CS, V, F
118:5-118:7	BSD, 402, 403, H, CS, V, F
118:10-118:10	BSD, 402, 403, H, CS, V, F
118:12-118:14	BSD, 402, 403, H, CS, V, F
118:17-118:18	BSD, 402, 403, H, CS, V, F
119:3-119:21	BSD, 402, 403, H, F
119:24-120:3	BSD, 402, 403, H, F
120:5-121:12	BSD, 402, 403, H, F
121:15-121:20	BSD, 402, 403, H, F
122:18-123:6	BSD, 402, 403, H, F
123:9-123:12	BSD, 402, 403, H, F
124:9-124:11	BSD, 402, 403, H, F
124:14-124:22	BSD, 402, 403, H, F
125:3-126:5	BSD, 402, 403, H, F
131:8-131:16	BSD, 402, 403, H, F
131:19-131:20	BSD, 402, 403, H, F

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
133:1-133:3	BSD, 402, 403, H, F, I, Counter-designation: 133:4-10
133:24-134:10	BSD, 402, 403, H, F, I, Counter-designation: 134:13-15
135:12-136:16	BSD, 402, 403, H, F
140:23-141:1	BSD, 402, 403, H, F
142:5-142:6	BSD, 402, 403, H, F
143:9-143:11	BSD, 402, 403, H, F, CS, V
143:18-143:19	BSD, 402, 403, H, F, CS, V
143:21-144:1	BSD, 402, 403, H, F, CS, V
144:5-144:6	BSD, 402, 403, H, F, CS, V
144:11-144:12	BSD, 402, 403, H, F, CS, V
144:18-144:21	BSD, 402, 403, H, F, CS, V
145:5-145:9	BSD, 402, 403, H, F, CS, V
146:10-147:14	BSD
148:3-148:15	BSD

**PureWick's Designation of Deposition Testimony of Kate Pawlik, March 17, 2023**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
15:18-15:21	BSD, V, 402, 403
19:12-19:13	BSD, F
19:16-19:18	BSD, F, V
19:21-19:22	BSD, F
20:8-20:14	BSD, V
21:2-21:3	BSD, V, Arg
21:16-21:16	BSD, V, Arg
23:17-23:20	BSD, F, V, CS
26:12-26:17	BSD, F, 402, 403
26:24-27:2	BSD, F, 402, 403
29:6-29:14	BSD, I, NT, 402, 403
29:19-30:1	BSD, 402, 403
30:2-30:8	BSD, CS, F, 402, 403
30:11-30:18	BSD, CS, F, 402, 403
30:19-30:21	BSD, CS, F, 402, 403
31:1-31:3	BSD, CS, F, 402, 403
31:14-31:17	BSD, 402, 403, V
31:20-31:21	BSD, 402, 403
31:23-32:1	BSD, 402, 403
32:24-33:4	BSD, 402, 403, 611
33:17-33:19	BSD, F, V, 402, 403
33:23-33:24	BSD, F, V, CS, 402, 403
36:16-36:17	BSD, F, V, CS, 402, 403
36:21-36:23	BSD, F, V, CS, 402, 403
37:1-37:5	BSD, F, V, 402, 403
37:8-37:14	BSD, F, V, 402, 403
38:8-38:15	BSD, 402, 403
39:23-40:2	BSD, 402, 403
41:1-41:4	BSD, F, V, 402, 403
41:7-41:8	BSD, F, V, 402, 403
41:13-41:16	BSD, I, NT, 402, 403
41:21-41:22	BSD, 402, 403
42:3-42:7	BSD, 402, 403
42:8-42:14	BSD, 402, 403
43:20-43:23	BSD, 402, 403
45:6-45:9	BSD, F, 402, 403
46:21-46:24	BSD, F, Spec, V, 402, 403
47:3-47:3	BSD, F, Spec, V, 402, 403
47:5-47:8	BSD, F, Spec, V, 402, 403
47:12-47:12	BSD, F, Spec, V, 402, 403
47:14-47:20	BSD, 402, 403

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
48:13-48:16	BSD, F, V, M, 611, 402, 403
48:20-48:20	BSD, F, V, M, 611, 402, 403
50:11-50:13	BSD, F, V, 402, 403
50:16-50:17	BSD, F, V, 402, 403
52:14-53:3	BSD, F, V, M, 611, 402, 403
53:4-53:7	BSD, F, V, M, 402, 403
53:11-53:12	BSD, F, V, M, 402, 403
55:12-55:14	BSD, V, CS, M, 402, 403
55:17-55:17	BSD, V, CS, M, 402, 403
55:22-56:1	BSD, I, NT, 402, 403
56:6-56:8	BSD, 402, 403
57:9-57:12	BSD, F, V, 402, 403
57:15-57:15	BSD, F, V, 402, 403
58:15-58:19	BSD, 402, 403
58:20-59:1	BSD, V, M, 611, 402, 403
59:4-59:5	BSD, V, M, 611, 402, 403
59:7-59:12	BSD, 611, 402, 403
60:4-60:7	BSD, 402, 403
60:8-60:17	BSD, 402, 403
62:4-62:6	BSD, F, V, 611, 402, 403
63:1-63:4	BSD, F, M, 402, 403
63:7-63:7	BSD, F, M, 402, 403
65:19-65:21	BSD, F, V, 402, 403
65:24-66:1	BSD, F, V, 402, 403
66:3-66:5	BSD, F, V, 402, 403
66:8-66:8	BSD, F, V, 402, 403
66:22-66:24	BSD, F, V, 402, 403
67:3-67:3	BSD, F, V, 402, 403
67:12-67:23	BSD, 402, 403
68:5-68:7	BSD, F, V, 402, 403
68:11-68:12	BSD, F, V, 402, 403
69:14-69:17	BSD, V, 402, 403
71:22-72:3	BSD, 402, 403
72:4-72:7	BSD, V, 402, 403
72:10-72:11	BSD, V, 402, 403
73:21-73:24	BSD, I, NT, 402, 403
74:5-74:7	BSD, 402, 403
74:8-74:13	BSD, 402, 403
74:14-74:21	BSD, V, M, 402, 403
75:1-75:7	BSD, V, M, 402, 403
75:11-75:13	BSD, V, M, 402, 403
75:15-75:18	BSD, 611, 402, 403
75:19-75:24	BSD, F, 402, 403



<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
77:16-77:19	BSD, I, NT, 402, 403
77:24-78:3	BSD, 402, 403
78:17-78:19	BSD, 402, 403
79:13-79:16	BSD, I, NT, 402, 403
79:20-80:1	BSD, 402, 403
80:16-80:23	BSD, M, 402, 403
81:4-81:7	BSD, I, NT, 402, 403
81:13-81:16	BSD, 402, 403
82:23-82:24	BSD, F, V, 402, 403
83:3-83:8	BSD, F, V, 402, 403
83:11-83:17	BSD, 402, 403
83:18-83:20	BSD, V, CS, C, 402, 403
83:24-84:3	BSD, V, CS, C, 402, 403
84:8-84:11	BSD, I, NT, 402, 403
84:16-84:18	BSD, 402, 403
85:15-85:18	BSD, I, NT, 402, 403
86:2-86:11	BSD, 402, 403
86:12-86:24	BSD, 402, 403
87:11-87:13	BSD, V, AF, M, 402, 403
87:17-87:18	BSD, V, AF, M, 402, 403
87:23-88:2	BSD, I, NT, 402, 403
88:20-88:24	BSD, 402, 403
89:1-89:4	BSD, 402, 403
89:7-89:7	BSD, 402, 403
89:13-89:21	BSD, I, NT, 402, 403
89:22-90:4	BSD, V, AF, M, 402, 403
90:8-90:10	BSD, V, AF, M, 402, 403
90:15-90:22	BSD, I, NT, CS, 402, 403
91:1-91:11	BSD, CS, 402, 403
91:15-91:18	BSD, CS, 402, 403
91:23-92:2	BSD, I, NT, 402, 403
92:7-92:10	BSD, 402, 403
93:10-93:13	BSD, F, 402, 403
93:14-93:17	BSD, F, 402, 403
94:9-94:11	BSD, F, V, 402, 403
94:14-94:24	BSD, F, V, 402, 403
95:3-95:4	BSD, F, V, 402, 403
95:6-95:9	BSD, V, C, 402, 403
95:12-95:19	BSD, V, AF, 402, 403
95:22-95:22	BSD, V, AF, 402, 403
96:2-96:3	BSD, V, AF, 402, 403
96:7-96:10	BSD, I, NT, 402, 403
96:15-96:19	BSD, 402, 403

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
97:1-97:4	BSD, I, NT, 402, 403
97:18-97:21	BSD, V, CS, 402, 403
98:3-98:5	BSD, V, CS, 402, 403
98:7-98:14	BSD, 402, 403
98:18-98:21	BSD, I, NT, 402, 403
99:5-99:19	BSD, V, CS, 402, 403
100:1-100:2	BSD, V, CS, 402, 403
100:13-100:20	BSD, 402, 403
100:21-100:24	BSD, 402, 403
101:4-101:6	BSD, 402, 403
101:12-101:23	BSD, 611, M, 402, 403
103:10-103:10	BSD, F, V, CS, 402, 403
103:14-103:17	BSD, F, V, CS, 402, 403
104:6-104:9	BSD, I, NT, 402, 403
104:14-104:16	BSD, 402, 403
105:4-105:7	BSD, I, NT, 402, 403
105:23-106:2	BSD, 402, 403
106:3-106:7	BSD, 402, 403
108:12-108:14	BSD, V, M, 402, 403
108:18-108:19	BSD, V, M, 402, 403
108:23-109:1	BSD, I, F, V, 402, 403
109:4-109:5	BSD, F, V, 402, 403
109:7-109:11	BSD
110:9-110:12	BSD, I, NT, 402, 403
110:23-111:3	BSD, V, 402, 403
111:4-111:5	402, 403
111:8-111:9	BSD, 402, 403
111:13-111:16	BSD, I, NT, 402, 403
112:15-112:17	BSD, I, 611, 402, 403
112:18-112:21	BSD, V, 402, 403
112:24-113:1	BSD, V, 402, 403
113:3-113:4	BSD, F, V, CS, 402, 403
113:7-113:8	BSD, F, V, CS, 402, 403
113:13-113:24	BSD, 402, 403
114:9-114:13	BSD, M, AF
114:16-114:23	BSD, M, AF
115:4-115:7	BSD, I, NT, 402, 403
115:12-115:15	BSD, 402, 403
117:8-117:11	BSD, I, NT, 402, 403
117:16-117:19	BSD, V, CS, 402, 403
117:22-118:4	BSD, 402, 403
118:22-118:23	BSD, F, V, M, 402, 403
119:3-119:4	BSD, F, V, M, 402, 403

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
120:7-120:10	BSD, I, NT, 402, 403
121:3-121:5	BSD, 402, 403
121:12-121:13	BSD, 402, 403
121:22-122:4	BSD, 402, 403
122:10-122:12	BSD, F, V, CS, 402, 403
122:15-122:16	BSD, F, V, CS, 402, 403
122:18-123:3	BSD, F, V, AF, 402, 403
123:7-123:15	BSD, F, V, AF, 402, 403
123:16-123:20	BSD, F, V, AF, 402, 403
125:3-125:5	BSD, V, AF, 402, 403
125:9-125:11	BSD, V, AF, 402, 403
126:20-126:21	BSD, I, V, 402, 403
127:1-127:3	BSD, I, V, 402, 403
127:5-127:8	BSD, C, 402, 403
127:17-127:20	BSD, 402, 403
128:5-128:13	BSD, F, V, 402, 403
128:14-128:19	BSD, V, C, 402, 403
128:22-129:6	BSD, V, 402, 403
129:9-129:15	BSD, V, 402, 403
129:16-129:18	BSD, F, V, AF, CS, 402, 403
129:22-130:6	BSD, F, V, AF, CS, 402, 403
130:17-130:20	BSD, 402, 403
130:24-131:6	BSD, V, CS, 402, 403
131:9-131:10	BSD, V, CS, 402, 403
131:15-131:21	BSD, 402, 403
131:23-131:24	BSD, I, V, AF, CS, 402, 403
132:4-132:5	BSD, I, V, AF, CS, 402, 403
133:6-133:8	BSD, V, 402, 403
133:11-133:12	BSD, V, 402, 403
133:16-133:18	BSD, I, V, 402, 403
133:22-133:22	BSD, V, 402, 403
133:24-134:6	BSD, F, V, 402, 403
134:10-134:13	BSD, F, V, 402, 403
134:16-134:18	BSD, F, V, 402, 403
135:5-135:6	BSD, I, F, V, 402, 403
135:9-135:10	BSD, F, V, 402, 403
135:13-135:16	BSD, I, F, V, 402, 403
135:18-135:19	BSD, I, F, V, 402, 403
135:22-135:23	BSD, F, V, 402, 403
136:9-136:10	BSD, F, V, 402, 403
136:13-136:20	BSD, F, V, 402, 403
136:21-136:22	BSD, F, V, 402, 403
137:1-137:3	BSD, F, V, 402, 403

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
137:6-137:7	BSD, I, F, V, 402, 403
137:10-137:13	BSD, F, V, 402, 403
137:18-137:19	BSD, F, V, 402, 403
137:22-138:1	BSD, F, V, 402, 403
138:21-138:22	BSD, I, 402, 403
140:7-140:9	BSD, F, V, AF, 402, 403
140:13-140:15	BSD, F, V, AF, 402, 403
140:21-140:21	BSD, F, CS, 402, 403
141:1-141:3	BSD, F, CS, 402, 403
147:11-147:14	BSD, I, NT, 402, 403
147:18-147:20	BSD, 402, 403
147:21-148:2	BSD, 402, 403
148:6-148:9	BSD, 402, 403
148:10-148:22	BSD, 402, 403
149:7-149:9	BSD, F, CS, 402, 403
149:12-149:12	BSD, F, CS, 402, 403
149:20-149:22	BSD, 402, 403
154:8-154:11	BSD, I, F, C, CS, 402, 403
154:14-154:14	BSD, F, C, CS, 402, 403
154:16-154:19	BSD, F, C, CS, 402, 403
154:22-154:22	BSD, F, C, CS, 402, 403
156:10-156:11	BSD, F, M, CS, 402, 403
156:15-156:15	BSD, F, M, CS, 402, 403
157:16-157:20	BSD, F, V, 402, 403
158:5-158:9	BSD, F, V, 402, 403
159:2-159:5	BSD, F, 402, 403
159:21-160:2	BSD, F, 402, 403
167:22-168:6	BSD, F, 402, 403
168:19-168:22	BSD, I, NT, 402, 403
168:24-169:3	BSD, 402, 403
169:24-170:4	BSD, 402, 403
171:5-171:6	BSD, 402, 403
171:9-171:9	BSD, 402, 403
173:11-173:14	BSD, I, NT, 402, 403
173:19-173:21	BSD, 402, 403
174:2-174:2	BSD, 402, 403
174:8-174:11	BSD, F, 402, 403
175:1-175:4	BSD, I, 402, 403
175:7-175:19	BSD, V, 402, 403
175:22-176:6	BSD, V, 402, 403
176:10-176:10	BSD, V, 402, 403
176:14-176:17	I, NT, 402, 403
176:19-176:23	BSD, 402, 403

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
177:12-177:19	BSD, 402, 403
177:23-177:24	BSD, F, CS, 402, 403
178:2-178:4	BSD, F, CS, 402, 403
178:7-178:11	BSD, F, CS, 402, 403
179:5-179:9	BSD, F, CS, 402, 403
179:12-179:13	BSD, F, CS, 402, 403
179:18-179:23	BSD, 402, 403
179:24-180:2	BSD, 402, 403
180:5-180:5	BSD, I, NT, 402, 403
180:21-180:24	BSD, 402, 403
181:5-181:13	BSD, 402, 403
181:21-182:1	BSD, F, V, 402, 403
182:4-182:5	BSD, F, V, 402, 403
183:22-183:23	BSD, F, V, 402, 403
184:3-184:6	BSD, F, V, 402, 403
184:10-184:13	BSD, I, NT, 402, 403
184:17-185:1	BSD, 402, 403
185:4-185:7	BSD, I, NT, 402, 403
185:11-185:13	BSD, 402, 403
185:19-186:6	BSD, 402, 403
186:10-186:13	BSD, I, NT, 402, 403
186:15-186:17	BSD, 402, 403
187:2-187:12	BSD, I, NT, 402, 403
187:18-187:22	BSD, 402, 403
188:5-188:10	BSD, 402, 403
188:14-188:17	BSD, I, NT, 402, 403
189:6-189:12	BSD, F, V, 402, 403
189:15-189:17	BSD, F, V, 402, 403
191:5-191:12	BSD, F, V, M, CS, 402, 403
191:16-191:18	BSD, F, V, M, CS, 402, 403
192:9-192:11	BSD, V, CS, 402, 403
192:15-192:22	BSD, V, CS, 402, 403
193:2-193:2	BSD, V, CS, 402, 403
194:17-194:23	BSD, 402, 403
195:4-195:8	BSD, 402, 403
195:13-195:16	BSD, I, NT, 402, 403
196:8-196:11	BSD, 402, 403
196:16-196:17	BSD, 402, 403
197:2-197:5	BSD, F, V, 402, 403
197:8-197:9	BSD, F, V, 402, 403
198:7-198:10	BSD, I, NT, 402, 403
198:12-198:15	BSD, 402, 403
198:19-198:21	BSD, V, 402, 403

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
198:24-199:3	BSD, V, 402, 403
199:8-199:11	BSD, 402, 403
199:15-199:18	BSD, I, NT, 402, 403
199:20-199:23	BSD, 402, 403
200:4-200:13	BSD, 402, 403
200:16-200:24	BSD, I, NT, 402, 403
201:1-201:7	BSD, 402, 403
202:2-202:6	I, V, 402, 403
202:9-202:10	BSD, V, 402, 403
203:3-203:4	BSD, F, V, CS, 402, 403
203:8-203:11	BSD, F, V, CS, 402, 403
204:5-204:16	BSD, I, NT, 402, 403
204:19-205:3	BSD, I, NT, 402, 403
205:15-205:19	BSD, V, C, 402, 403
206:7-206:10	BSD, V, AF, CS, 402, 403
206:14-206:16	BSD, V, AF, CS, 402, 403
207:20-207:23	BSD, I, NT, 402, 403
208:1-208:6	BSD, CS, 402, 403
208:15-208:18	BSD, I, 402, 403
210:2-210:5	BSD, I, NT, 402, 403
210:13-210:15	BSD, V, 402, 403
210:18-210:19	BSD, V, 402, 403
211:1-211:4	BSD, 611, 402, 403
211:5-211:14	BSD, F, CS, 402, 403
211:18-211:21	BSD, F, CS, 402, 403
211:23-212:1	BSD, 402, 403
213:9-213:13	BSD, I, CS, 402, 403
213:14-213:18	BSD, 402, 403
214:13-214:16	BSD, I, NT, 402, 403
214:22-214:24	BSD, 402, 403
215:10-215:12	BSD, 402, 403
215:13-215:20	BSD, 611, 402, 403
215:21-216:11	BSD, 402, 403
218:7-218:10	BSD, CS, M, 402, 403
218:13-218:16	BSD, CS, M, 402, 403
219:2-219:7	BSD, CS, 402, 403
219:12-219:17	BSD, CS, 402, 403
220:4-220:7	BSD, 402, 403
220:8-220:15	BSD, V, C, CS, 402, 403
220:19-220:21	BSD, V, C, CS, 402, 403
221:5-221:10	BSD, I, CS, 402, 403
221:16-222:1	BSD, I, NT, 402, 403
222:16-222:20	BSD, V, CS, 402, 403

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
222:23-222:23	BSD, V, CS, 402, 403
224:14-225:2	BSD, I, NT, 402, 403
225:3-225:6	BSD, 402, 403
226:1-226:4	BSD, M, AF, Spec, 402, 403
226:12-226:13	BSD, M, AF, Spec, 402, 403
226:15-226:17	BSD, 402, 403
227:22-228:1	BSD, 402, 403
229:12-229:15	BSD, I, NT, 402, 403
229:23-230:3	BSD, 402, 403
230:4-230:9	BSD, 402, 403
231:11-231:16	BSD, I, CS, 402, 403
232:1-232:2	BSD, F, CS, AF, 402, 403
232:6-232:6	BSD, F, CS, AF, 402, 403
235:17-236:2	BSD, I, 402, 403
236:3-236:4	BSD, CS, AF, 402, 403
236:8-236:17	BSD, CS, AF, 402, 403
236:21-237:2	BSD, CS, AF, 402, 403
237:7-237:9	BSD, CS, AF, 402, 403
237:15-237:17	BSD, 402, 403
237:23-237:24	BSD, Arg, AF, 402, 403
238:4-238:8	BSD, Arg, AF, 402, 403
240:5-240:7	BSD, F, V, CS, AF, 402, 403
240:12-240:15	BSD, F, V, CS, AF, 402, 403
240:24-241:2	BSD, I, V, CS, 402, 403
241:8-241:8	BSD, I, V, CS, 402, 403
242:5-242:8	BSD, 402, 403
242:13-242:16	BSD, I, NT, 402, 403
242:18-243:1	BSD, 402, 403
243:17-243:21	BSD, 402, 403
243:23-244:11	BSD, I, 402, 403
244:15-244:17	BSD, 402, 403
245:3-245:5	BSD, CS, M, 402, 403
245:9-245:9	BSD, CS, M, 402, 403
245:14-245:17	BSD, I, NT, 402, 403
246:5-246:8	BSD, 402, 403
246:13-246:15	BSD, 402, 403
247:16-247:22	BSD, F, 402, 403
248:5-248:9	BSD, F, 402, 403
249:1-249:3	BSD, 402, 403
250:17-250:20	BSD, I, NT, 402, 403
250:24-251:5	BSD, 402, 403
252:12-252:15	BSD, I, NT, 402, 403
253:3-253:7	BSD, 402, 403

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
253:20-254:4	BSD, 402, 403
255:6-255:9	BSD, I, NT, 402, 403
255:11-255:18	BSD, 402, 403
255:21-255:23	BSD, 402, 403
256:2-256:5	BSD, I, NT, 402, 403
256:7-256:9	BSD, V, 402, 403
256:15-256:20	BSD, F, V, CS, AF, 402, 403
257:4-257:4	BSD, F, V, CS, AF, 402, 403
257:9-257:12	BSD, F, V, CS, AF, 402, 403
257:20-257:23	BSD, I, NT, 402, 403
258:1-258:4	BSD, 402, 403
258:7-258:10	BSD, I, NT, 402, 403
258:12-258:19	BSD, F, V, AF, 402, 403
258:23-259:8	BSD, F, V, AF, 402, 403
259:12-259:15	BSD, I, NT, 402, 403
259:17-259:20	BSD, F, V, CS, AF, 402, 403
260:1-260:3	BSD, F, V, CS, AF, 402, 403
260:22-260:24	BSD, I, 402, 403
261:5-261:6	BSD, F, I, 402, 403
261:23-262:2	BSD, I, 402, 403
262:4-262:8	BSD, F, C, V, CS, 402, 403
262:11-262:12	BSD, F, C, V, CS, 402, 403
262:24-263:3	BSD, I, NT, 402, 403
263:5-263:13	BSD, 402, 403
263:17-263:20	BSD, I, NT, 402, 403
263:22-264:5	BSD, CS, 402, 403
264:6-264:7	BSD, CS, C, V, 402, 403
264:10-264:11	BSD, CS, C, V, 402, 403
264:24-265:3	BSD, F, 402, 403
265:12-265:17	BSD, 402, 403
266:9-266:12	BSD, I, NT, 402, 403
266:14-266:18	BSD, 402, 403
266:22-266:24	BSD, CS, V, 402, 403
267:3-267:4	BSD, CS, V, 402, 403
268:18-269:3	BSD, I, NT, 402, 403
269:6-269:9	BSD, 402, 403
269:13-269:20	BSD, I, NT, V, 402, 403
269:23-270:1	BSD, V, 402, 403
270:5-270:17	BSD, I, NT, CS, V, 402, 403
270:20-271:1	BSD, CS, V, 402, 403
271:2-271:12	BSD, V, 402, 403
271:18-272:3	BSD, I, CS, V, 402, 403
272:19-272:22	BSD, I, NT, 402, 403



<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
272:24-273:4	BSD, 402, 403
274:5-274:11	BSD, V, 402, 403
274:17-274:23	BSD, CS, V, 402, 403
275:2-275:4	BSD, CS, V, 402, 403
275:6-275:9	BSD, F, CS, V, 402, 403
275:13-275:17	BSD, F, CS, V, AF, 402, 403
275:22-275:24	BSD, F, CS, V, AF, 402, 403
276:11-276:19	BSD, F, 402, 403
276:20-277:7	BSD, F, 402, 403
277:8-277:15	BSD, 611, M, CS, V, 402, 403
277:16-277:17	BSD, M, 402, 403
277:21-277:23	BSD, M, 402, 403
278:1-278:2	BSD, CS, V, 402, 403
283:15-283:18	BSD, I, NT, 402, 403
283:20-284:8	BSD, 611, M, 402, 403

**PureWick's Designation of Deposition Testimony of Patricia Polanco, January 27, 2023**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
13:5-13:8	
14:16-14:18	
17:15-17:19	
20:12-20:14	
20:16-20:23	
27:7-27:11	
29:6-29:16	
29:18-29:20	F, 402, 403, H, Spec, 602
30:16-30:24	F, 402, 403, H, Spec, 602
30:25-31:7	F, 402, 403, H, Spec, 602
32:7-32:12	F, 402, 403, H, Spec, 602
34:11-34:11	
34:14-34:17	
34:18-34:19	
35:2-35:9	
37:13-37:14	NR, F, 402, 403, H, Spec, 602
37:17-37:23	NR, F, 402, 403, H, Spec, 602
38:23-38:25	
39:2-39:4	
40:2-40:4	NR, F, 402, 403, H, Spec, 602
40:6-40:17	NR, F, 402, 403, H, Spec, 602
43:18-43:20	NR, F, 402, 403, H, Spec, 602
43:23-44:4	NR, F, 402, 403, H, Spec, 602
56:10-56:13	
59:19-59:23	
62:11-62:15	
62:16-62:17	
62:20-62:23	

**PureWick's Designation of Deposition Testimony of Robert Sanchez, April 21, 2021**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
12:12-12:16	BSD, 402, 403
16:17-16:20	BSD, 402, 403
16:23-16:24	BSD, 402, 403
17:2-17:5	BSD, 402, 403
21:4-21:8	
21:12-21:14	
21:21-21:23	
38:1-38:3	BSD, 402, 403
38:5-38:5	BSD, 402, 403
40:15-40:16	
40:18-40:19	
41:5-41:8	
41:17-41:19	
41:22-42:10	
44:6-44:9	
68:4-68:6	BSD, 402, 403
68:8-68:8	BSD, 402, 403
68:10-68:23	BSD, 402, 403, NT
69:7-69:18	BSD, 402, 403
70:9-70:14	BSD, 402, 403 counter-designate 150:23-152:2, 152:5-11
77:14-77:17	BSD, 402, 403, H
77:21-77:23	BSD, 402, 403, H
78:1-78:1	BSD, 402, 403, H
78:12-78:15	BSD, 402, 403, H
78:20-78:22	BSD, 402, 403, H
78:25-78:25	BSD, 402, 403, H
79:2-79:4	BSD, 402, 403, H
94:10-94:16	BSD, 402, 403, H
95:5-95:7	BSD, 402, 403, H
96:4-96:5	BSD, 402, 403, H
96:8-96:9	BSD, 402, 403, H
96:11-96:14	BSD, 402, 403, H
121:4-121:6	BSD, 402, 403
121:8-121:13	BSD, 402, 403
124:19-124:22	BSD, 402, 403
125:4-125:7	BSD, 402, 403
125:14-126:9	BSD, 402, 403
126:21-126:23	BSD, 402, 403
140:10-140:12	BSD, 402, 403

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
143:22-144:9	BSD, 402, 403
148:17-148:19	
148:24-149:2	
149:18-149:24	
156:25-157:3	BSD, 402, 403, F
157:5-157:5	BSD, 402, 403, F
157:7-157:7	BSD, 402, 403
157:9-157:17	BSD, 402, 403

**PureWick's Designation of Deposition Testimony of Kristin Sexton, March 12, 2021**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
13:11-13:16	
14:20-15:4	
16:25-17:4	
17:7-17:21	
19:20-20:8	
20:11-20:17	
27:8-27:12	
35:10-35:15	BSD, 402, 403
36:23-37:22	BSD, 402, 403, H
37:25-38:3	BSD, 402, 403, H
48:17-48:19	BSD, 402, 403, H
48:22-49:7	BSD, 402, 403, H
87:14-87:15	BSD, 402, 403, H
87:21-87:23	BSD, 402, 403, H
88:3-88:5	BSD, 402, 403, H
88:8-88:9	BSD, 402, 403, H
94:3-94:6	BSD, 402, 403, H
96:3-96:11	BSD, 402, 403, H
96:14-96:21	BSD, 402, 403, H
97:21-98:2	BSD, 402, 403, H
98:23-99:6	
99:20-100:17	BSD, 402, 403, H
100:20-101:13	BSD, 402, 403, H
101:16-101:22	BSD, 402, 403, H
111:2-111:4	
111:7-111:13	
111:14-111:17	
111:21-112:5	
112:6-112:9	
112:13-112:20	
138:25-139:7	BSD, 402, 403, H
237:13-237:15	BSD, 402, 403, H
237:20-238:8	BSD, 402, 403, H

**PureWick's Designation of Deposition Testimony of Dan Ulreich April 8, 2021**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
5:20-5:22	
8:12-8:19	
8:20-8:23	
10:3-10:7	
16:22-16:25	BSD, 402
17:12-17:16	
18:4-18:16	
18:19-18:20	
19:7-19:14	
21:7-21:20	
22:3-22:8	
22:20-22:24	
22:25-23:7	
24:2-24:5	
26:25-27:4	
27:7-27:9	
28:18-28:25	
29:2-29:6	Incom
31:10-31:12	
31:15-31:18	
32:20-32:22	BSD, 402, 403
32:25-33:3	BSD, Incom, 402, 403 counter-counter 33:3-4
34:23-35:3	BSD, 402, 403
35:6-35:9	BSD, 402, 403
37:14-37:18	BSD, 402, 403, Incom
38:4-38:5	BSD, 402, 403
38:8-38:10	BSD, 402, 403
41:3-41:9	BSD, 402, 403
41:12-41:14	BSD, 402, 403,
45:18-45:20	
45:23-45:25	
46:2-46:3	
46:6-46:8	
46:9-46:12	BSD, 402, 403
46:16-46:17	BSD, 402, 403
50:6-50:9	
50:12-50:13	
50:14-50:18	
50:22-50:25	NR, 402, 403
51:11-51:14	

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
56:21-56:25	BSD, 402, 403
57:5-57:8	BSD, 402, 403
61:2-61:5	
61:8-61:9	
61:18-61:22	
62:2-62:4	
64:17-64:19	
64:22-64:23	
65:19-65:20	Incom, BSD
66:10-66:13	BSD, 402, 403
66:16-66:18	BSD, 402, 403
67:17-67:20	BSD, 402, 403
67:24-67:25	Incom, BSD, 402, 403
68:20-68:23	BSD, 402, 403
69:3-69:7	BSD, 402, 403
70:17-70:21	BSD, 402, 403
70:25-71:1	BSD, 402, 403
71:24-71:25	BSD, 402, 403, H
72:2-72:6	BSD, 402, 403
76:10-76:23	BSD, 402, 403
77:2-77:3	BSD, 402, 403
79:9-79:11	BSD, 402, 403
79:14-79:16	BSD, 402, 403
80:10-80:13	BSD, 402, 403
80:16-80:21	BSD, 402, 403
80:24-80:24	BSD, 402, 403
94:15-94:25	
95:2-95:2	
98:19-98:25	BSD, 402, 403
99:2-99:2	BSD, 402, 403
99:5-99:10	BSD, 402, 403
99:14-99:21	
100:12-100:14	BSD, 402, 403
100:17-100:19	BSD, 402, 403
105:14-105:18	BSD, 402, 403
105:22-105:25	BSD, 402, 403
106:4-106:8	BSD, 402, 403
106:9-106:13	BSD, 402, 403
113:5-113:7	
113:10-113:14	
113:17-113:17	
117:9-117:12	
124:16-124:24	BSD, 402, 403

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
125:3-125:7	BSD, 402, 403
125:10-125:20	BSD, 402, 403
125:23-125:24	BSD, 402, 403
127:6-127:12	BSD, 402, 403
127:15-127:16	BSD, 402, 403
128:3-128:9	
138:13-138:17	BSD, 402, 403
138:23-138:25	BSD, 402, 403
139:2-139:11	BSD, 402, 403
139:12-139:13	BSD, 402, 403
139:16-139:18	BSD, 402, 403
139:19-139:23	BSD, 402, 403
143:9-143:19	
145:15-145:17	
149:9-149:11	
149:15-149:17	
156:17-156:20	
156:24-156:25	
157:2-157:6	
157:10-157:10	
157:23-158:2	
158:6-158:7	
158:8-158:13	
158:18-158:19	
161:4-161:5	
172:20-173:2	
173:5-173:9	
173:12-173:17	
177:11-177:14	
179:5-179:10	
179:13-179:14	
186:8-186:12	
186:17-186:17	
186:25-186:25	
187:2-187:4	
187:8-187:10	NR, 402, 403
190:13-190:15	
190:18-190:19	
190:20-190:25	
191:6-191:8	
191:22-192:3	
192:8-192:14	
193:22-193:25	



<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
194:4-194:6	
194:7-194:8	Incom
194:19-194:21	
194:25-195:2	
206:6-206:9	BSD, 402, 403
206:13-206:14	BSD, 402, 403
207:8-207:13	
207:16-207:18	
207:19-207:23	Incom
209:20-209:25	BSD, 402, 403, Incom
211:11-211:12	
211:15-211:18	
211:19-211:21	
211:25-212:3	
219:16-219:19	
219:22-219:24	
230:8-230:11	BSD, 402, 403
230:14-230:14	BSD, 402, 403
231:5-231:8	
231:11-231:12	
231:21-231:23	
232:2-232:3	Incom, 402, 403
232:7-232:8	
233:9-233:13	
233:16-233:20	NR, 402, 403

**PureWick's Designation of Deposition Testimony of Dan Ulreich, April 13, 2023**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
14:2-14:5	
16:17-16:17	
16:20-16:22	
16:24-17:1	BSD, 402, 403
17:5-17:8	BSD, 402, 403
17:10-17:17	BSD, 402, 403
20:4-20:18	
21:23-21:24	BSD, 402, 403, H
22:3-22:5	BSD, 402, 403, H
22:7-22:10	BSD, 402, 403, H
22:16-23:3	BSD, 402, 403, H
23:11-23:14	
24:7-24:13	BSD, 402, 403, H
25:2-25:3	BSD, 402, 403, H
25:6-25:7	BSD, 402, 403, H
25:11-25:13	BSD, 402, 403, H
25:16-25:19	BSD, 402, 403, H
27:18-27:21	BSD, 402, 403, H
27:24-28:1	BSD, 402, 403, H
31:13-31:14	
31:17-31:19	
31:21-31:23	
32:2-32:4	
34:23-35:3	BSD, 402, 403, H
35:7-35:10	BSD, 402, 403, H
36:9-36:12	BSD, 402, 403, H
38:10-38:12	BSD, 402, 403, H
38:16-38:18	BSD, 402, 403, H
38:20-38:22	BSD, 402, 403, H
39:2-39:4	BSD, 402, 403, H
39:6-39:7	BSD, 402, 403, H
39:11-39:12	BSD, 402, 403, H
39:22-39:24	BSD, 402, 403, H
40:4-40:7	BSD, 402, 403, H
40:9-40:11	BSD, 402, 403, H
40:14-40:16	BSD, 402, 403, H
40:20-40:23	BSD, 402, 403, H
41:2-41:5	BSD, 402, 403, H
41:7-41:10	BSD, 402, 403, H
41:14-41:18	BSD, 402, 403, H
41:23-42:1	BSD, 402, 403, H

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
42:4-42:6	BSD, 402, 403, H
44:11-44:13	BSD, 402, 403, H
44:18-44:22	BSD, 402, 403, H
45:5-45:15	BSD, 402, 403, H
47:4-47:6	BSD, 402, 403, H
47:9-47:11	BSD, 402, 403, H
52:1-52:3	
56:9-56:11	BSD, 402, 403, H
56:14-56:16	BSD, 402, 403, H
59:3-59:13	BSD, 402, 403, H
64:19-65:1	
65:6-66:8	BSD, 402, 403, H
66:11-66:13	BSD, 402, 403, H
67:20-67:24	BSD, 402, 403, H
68:3-68:4	BSD, 402, 403, H
68:12-68:15	BSD, 402, 403, H
68:19-68:21	BSD, 402, 403, H
68:23-68:24	BSD, 402, 403, H
73:24-74:2	BSD, 402, 403, H
74:6-74:9	BSD, 402, 403, H
78:4-78:7	BSD, 402, 403, H
78:11-78:15	BSD, 402, 403, H
104:13-104:17	BSD, 402, 403, H
104:21-104:24	BSD, 402, 403, H
106:17-107:3	BSD, 402, 403, H; counter-designate 107:11-14, 107:18-19, 109:4-7, 109:11, 109:14-16
112:6-112:9	BSD, 402, 403, H
112:12-112:16	BSD, 402, 403, H
114:1-114:5	
115:4-115:5	
115:9-115:13	
119:21-120:2	BSD, 402, 403, H, F, 602
120:22-121:1	BSD, 402, 403, H, F, 602
121:7-121:9	BSD, 402, 403, H, F, 602
121:11-121:13	BSD, 402, 403, H, F, 602
121:17-121:20	BSD, 402, 403, H, F, 602
121:22-122:1	BSD, 402, 403, H, F, 602
122:4-122:6	BSD, 402, 403, H, F, 602
122:8-122:19	BSD, 402, 403, H, F, 602
126:9-126:15	
130:14-130:19	
130:23-131:3	

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
148:7-148:15	
148:19-148:21	
163:14-163:17	BSD, 402, 403, H
163:21-164:1	BSD, 402, 403, H, 602
164:13-164:15	BSD, 402, 403, H
164:19-164:23	BSD, 402, 403, H, 602
173:3-173:11	BSD, 402, 403, H, 602
183:18-184:3	BSD, 402, 403, H

**PureWick's Designation of Trial Testimony of Camille Newton, March 28, 2022**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
185:15-185:22	
186:5-186:16	
188:14-190:4	
190:10-190:16	
224:24-225:8	
225:15-225:19	
226:2-226:25	BSD, 402, 403
227:1-227:20	BSD, 402, 403
229:20-229:24	Incom, BSD, 402, 403
229:25-230:7	BSD, 402, 403
230:8-230:8	BSD, 402, 403
230:15-231:8	BSD, 402, 403
231:20-232:5	402, 403
232:9-232:25	402, 403
233:1-233:14	
234:20-235:12	H, Arg, 402, 403
235:23-236:12	Arg, 402, 403
236:13-237:7	Arg, 402, 403
238:12-238:14	BSD, 402, 403
238:17-239:7	BSD, 402, 403
239:25-240:7	BSD, 402, 403
240:24-241:6	BSD, 402, 403
241:7-241:11	BSD, 402, 403
241:15-241:20	BSD, 402, 403
241:21-242:14	BSD, 402, 403
242:18-243:6	BSD, 402, 403
243:7-243:10	BSD, 402, 403
243:18-243:24	BSD, 402, 403
244:15-244:21	BSD, 402, 403
244:22-245:1	BSD, 402, 403
245:17-246:5	
246:6-246:19	
246:20-247:4	
247:12-247:16	BSD, 402, 403
247:20-247:22	
248:8-248:12	
248:17-248:18	
248:20-249:5	BSD, 402, 403
249:6-249:14	BSD, 402, 403
249:15-249:20	BSD, 402, 403

**PureWick's Designation of Trial Testimony of Camille Newton, March 29, 2022**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
258:10-258:13	
258:14-259:12	BSD, 402, 403
260:1-261:2	BSD, 402, 403
261:5-261:9	
261:21-262:2	BSD, 402, 403
262:3-262:19	BSD, 402, 403
263:14-263:25	
264:12-264:16	
266:25-267:16	BSD
267:17-268:1	BSD
268:2-268:18	BSD

**PureWick's Designation of Deposition Yestimony of Camille Newton, April 15, 2021**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
10:14-10:16	BSD
15:25-16:9	BSD
16:10-16:18	BSD
16:21-17:2	BSD
17:3-17:16	BSD
17:17-17:22	BSD
18:8-18:14	BSD
26:18-26:25	BSD
27:5-27:17	BSD
29:2-29:19	BSD
30:2-30:11	BSD, 402, 403, 602
31:5-31:8	BSD, I, Counter-designation: 31:4
31:24-32:7	BSD
33:19-33:24	BSD
33:25-34:7	BSD
34:15-34:23	H, F
35:1-35:1	BSD
40:11-40:14	BSD, H, F, 403
40:17-40:18	BSD, H, F, 403, 402
48:1-48:7	BSD
51:13-51:17	BSD, 402, 403, F, Counter-designation: 51:9-12, 51:25-52:10
52:11-52:13	BSD, 402, 403, 602, F
52:15-52:16	BSD, 402, 403, 602, F
55:13-55:15	BSD, 402, 403, 602, F, H
55:18-55:21	BSD, 402, 403, 602, F, H
65:18-66:4	BSD, F, 402, 403, Counter-designation: 66:8-10, 66:12-13, 66:15-24
66:6-66:6	BSD
66:25-67:10	BSD, F, 402, 403
67:13-67:21	BSD, F, 402, 403, Counter-designation: 67:22-68:4
68:14-68:18	BSD, H, F, 402, 403, V
68:20-68:21	BSD, H, F, 402, 403
70:13-70:15	BSD, 402, 403, V, F
70:22-70:22	BSD
70:24-70:25	BSD, 402, 403, V, Counter-designation: 71:9, 71:11-15

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
71:2-71:7	BSD, 402, 403
72:14-72:18	BSD, 402, 403
74:24-75:1	BSD, F, V, 402, 403
75:3-75:10	BSD, F, V, 402, 403
75:11-75:11	BSD, V, F
75:13-75:13	BSD
75:15-75:21	BSD
75:23-76:4	BSD, 402, 403, H
77:3-77:12	BSD, F, H
77:22-77:24	BSD
78:1-78:17	BSD
78:18-79:3	BSD, V
79:5-79:15	BSD
79:17-79:24	BSD, H, 402, 403
81:1-81:13	BSD, H, 402, 403, CS
81:25-82:4	BSD, 402, 403, V
83:7-83:10	BSD, 402, 403, V
83:12-83:13	BSD
97:16-97:17	BSD, F, H, 402, 403, I, Counter-designation: 97:14-15
101:18-101:25	BSD, 402, 403, F, H
102:1-102:1	BSD
102:3-102:7	BSD, 402, 403
103:4-103:11	BSD, 402, 403, F
103:13-103:15	BSD, 402, 403, F, V
103:25-104:2	BSD, 402, 403, F, V
104:5-104:6	BSD
104:12-104:14	BSD, 402, 403, F, V
106:7-106:16	BSD, 402, 403
107:13-107:14	BSD, 402, 403, V
107:16-107:16	BSD, 402, 403, V
108:5-108:15	BSD, 402, 403, V
108:16-108:18	BSD, 402, 403, V
108:19-108:22	BSD, 402, 403, V
109:10-109:12	BSD
109:14-109:16	402, 403, V, C, Counter- designation: 110:1-13
109:19-109:24	BSD
110:14-111:1	BSD, 402, 403
112:9-112:18	BSD, 402, 403, V, F
112:24-112:24	BSD, 402, 403, V, F
113:4-113:6	BSD, 402, 403, H, F, I
113:19-113:21	BSD, 402, 403, H, F



<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
113:24-114:4	BSD, 402, 403, H, F
114:5-114:6	BSD, 402, 403, H, F
114:9-114:10	BSD, 402, 403, H, F
114:17-114:19	BSD
115:13-115:15	BSD, 402, 403, F, Exp, Counter-designation: 114:20-21, 114:24-115:1, 115:3-4, 115:7-10
115:19-115:24	BSD
116:24-117:2	BSD, Counter-designation: 118:9-18, 118:22-24, 119:2-8
117:5-117:10	BSD, Counter-designation: 118:9-18, 118:22-24, 119:2-8
117:13-117:14	BSD
117:16-117:19	BSD
117:22-118:1	BSD
118:3-118:5	BSD, Counter-designation: 118:9-18, 118:22-24, 119:2-8
121:2-121:2	BSD, 402, 403, F, H
121:3-121:9	BSD, 402, 403, F, H
121:12-121:13	BSD, 402, 403, F, H
121:25-122:1	BSD, 402, 403, 602
122:4-122:4	BSD, 402, 403, 602
122:19-122:22	BSD, 402, 403, 602, H
122:24-123:4	BSD, 402, 403, 602, H
123:5-123:7	BSD, 402, 403, 602, H
123:9-123:9	BSD, 402, 403, 602
123:11-123:13	BSD, 402, 403, 602, F, H
123:15-123:16	BSD, 402, 403, 602, F, H
132:19-133:13	BSD, 402, 403
133:15-133:15	BSD, 402, 403
134:10-134:18	BSD, 402, 403
135:9-135:14	BSD, 402, 403, V
135:16-135:16	BSD, 402, 403
135:18-135:20	BSD, 402, 403, C, V
137:4-137:9	BSD, 402, 403
137:19-138:4	BSD, 402, 403, Counter-designation: 138:5-19
138:22-138:24	BSD, 402, 403, F, V
139:2-139:4	BSD, 402, 403, F
139:10-140:3	BSD, 402, 403, F
140:4-140:18	BSD, 402, 403, F

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
144:21-145:1	BSD, 402, 403, F, Counter-designation: 144:8-20, 145:2-7
145:11-145:13	BSD
145:21-145:23	BSD, 402, 403, F
146:4-146:14	BSD, 402, 403
146:15-147:2	BSD, 402, 403, Counter-designation: 147:3-14
147:15-147:24	BSD, 402, 403
148:12-148:21	BSD, 402, 403, Counter-designation: 148:22-149:7
149:8-149:11	BSD, 402, 403, Counter-designation: 149:12-14
149:15-149:17	BSD, 402, 403, V
149:20-149:24	BSD, 402, 403
156:13-157:2	BSD, 402, 403, H, F, V
157:7-157:9	BSD, 402, 403, F, V
157:11-157:25	BSD, 402, 403, PRIV
159:14-159:16	BSD, 402, 403, V
160:11-160:11	BSD, I, Counter-designation: 160:8-10
160:25-161:2	BSD, 402, 403, H, F, Counter-designation: 160:13-24
161:5-161:5	BSD
161:7-161:9	BSD, 402, 403, H, F, C
161:12-161:17	BSD, 402, 403, H, F
161:20-162:2	BSD, 402, 403, H, F
163:8-163:14	BSD, 402, 403, V
163:16-163:18	BSD, 402, 403
163:20-163:21	BSD, 402, 403, H, V
164:6-164:17	BSD, 402, 403
165:1-165:3	BSD
165:6-165:13	BSD
165:15-165:17	BSD
165:20-165:20	BSD
165:25-166:11	BSD, 402, 403
166:16-166:18	BSD, 402, 403
167:7-167:10	BSD, 402, 403
167:13-167:14	BSD, 402, 403
167:16-167:16	BSD, 402, 403
167:20-167:24	BSD, 402, 403
168:2-168:7	BSD, 402, 403
170:10-170:12	BSD, 402, 403
170:15-171:5	BSD, 402, 403, F, H

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
172:6-172:8	BSD, 402, 403, F, H
172:11-172:14	BSD, 402, 403, F, H
172:17-173:1	BSD, 402, 403, F, H
173:14-173:17	BSD, 402, 403, I, F, V, Counter-designation: 173:12-13
173:20-173:24	BSD, F
174:4-174:6	BSD, I, H
174:7-174:8	BSD, I, H
174:16-174:21	BSD
174:22-175:6	BSD, V, 403, Counter-designation: 175:16-18, 175:21-176:1
175:7-175:10	BSD, V, 403, I
175:13-175:14	BSD, F
177:24-177:25	BSD, I, H
178:15-178:19	BSD, 402, 403, V, Counter-designation: 176:7-10, 176:12-17
178:20-178:22	BSD, 402, 403, V
178:24-178:25	BSD, 402, 403, V
179:10-179:12	BSD, 402, 403, V
179:14-179:15	BSD, 402, 403, V
179:17-179:21	BSD, 402, 403, V
179:23-180:1	BSD, F, Counter-designation: 180:2-5
180:12-181:4	BSD, 402, 403, V
181:5-181:14	BSD, 402, 403, V
183:25-184:15	BSD, 402, 403, F, H
184:16-184:18	BSD, 402, 403, F, H
184:22-184:25	BSD, 402, 403, F, H
185:12-185:13	BSD, 402, 403, V
185:16-185:19	
185:24-186:4	BSD, 402, 403, Counter-designation: 186:16-19, 186:23-187:3
188:9-188:11	BSD
188:13-188:14	BSD, 402, 403, V, F, Counter-designation: 189:4-6, 189:14-15, 189:17-18
190:5-190:13	BSD
190:14-190:16	BSD
190:19-190:20	BSD

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
191:16-191:18	BSD, 402, 403, H, V
191:21-191:21	BSD
192:14-192:19	BSD, 402, 403
192:20-192:21	BSD, 402, 403
192:23-192:24	BSD, 402, 403
193:14-193:14	BSD
194:5-194:7	402, 403, F, H
194:10-194:14	BSD, 402, 403, F, H, Counter-designation: 194:16-18, 194:21-195:6
195:8-195:10	BSD, 402, 403, F, H
195:15-195:24	BSD, 402, 403, F, H
196:1-196:7	BSD, 402, 403
196:9-196:10	BSD, 402, 403
196:12-197:3	BSD, 402, 403, F, H
197:20-198:1	BSD, 402, 403, F, H
198:9-198:14	BSD, 402, 403, F, H
200:12-200:22	BSD
200:25-201:2	BSD
201:10-201:25	BSD
202:3-202:8	BSD, 402, 403, V
202:8-202:13	BSD, 402, 403, V
202:16-202:18	BSD, 402, 403, V
203:10-203:12	BSD, 402, 403, V, F

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
203:25-204:3	BSD
205:21-206:7	BSD, 402, 403, V, Counter-designation: 209:21-23
206:9-206:19	BSD, 402, 403, V, Counter-designation: 209:21-23
207:8-207:13	BSD, 402, 403, V, Counter-designation: 209:21-23
207:14-207:17	BSD, 402, 403, V, Counter-designation: 209:21-23
207:22-208:5	BSD, 402, 403, V, H, Counter-designations: 207:21, 209:21-23
208:9-208:19	BSD, 402, 403, V, Counter-designation: 209:5-15
208:25-209:4	BSD, 402, 403, V
211:3-211:7	BSD
212:12-212:12	BSD
212:19-213:11	BSD, 402, 403
213:12-213:20	BSD, 402, 403
213:22-214:5	BSD, 402, 403, V, F
214:7-214:13	BSD, 402, 403, V, F
214:15-214:16	BSD, 402, 403, V, F
215:2-215:3	BSD, 402, 403, V
215:8-215:12	BSD, 402, 403, V
215:22-216:1	BSD, 402, 403, V
216:2-216:4	BSD, 402, 403, V
216:6-216:6	BSD, 402, 403, V
216:8-216:10	BSD, 402, 403, V
216:16-216:19	BSD, 402, 403, V
216:21-217:6	BSD, 402, 403, V
217:7-217:8	BSD, 402, 403, V
217:10-217:10	BSD, 402, 403, V
217:12-217:13	BSD, 402, 403, V
217:15-217:16	BSD, 402, 403, V
217:18-217:21	BSD, 402, 403, V
217:24-218:11	BSD, 402, 403, V
218:13-218:18	BSD, 402, 403, V
218:20-218:20	BSD, 402, 403, V, I, F, H
218:21-218:24	BSD, 402, 403, V, I, F, H
219:19-220:9	BSD, 402, 403, F, H, 602
220:10-220:15	BSD, 402, 403, F, H, 602

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
220:18-220:25	BSD, 402, 403, F, H, 602
221:2-221:13	BSD
221:14-222:3	BSD
222:4-222:10	BSD
222:22-222:25	BSD
223:2-223:3	BSD
224:16-224:22	BSD, 402, 403
224:25-225:6	BSD, 402, 403
225:8-225:16	BSD, 402, 403, F, H
225:25-226:3	BSD, 402, 403, F, H
226:5-226:6	BSD, 402, 403, F, H
226:9-226:14	BSD, 402, 403, F, H
226:17-226:23	BSD, 402, 403, F, H
227:1-227:8	BSD, 402, 403, F, H
227:11-227:13	BSD, 402, 403, F, H
227:24-228:2	BSD, 402, 403
228:5-228:6	BSD, 402, 403
228:23-228:25	BSD, 402, 403
229:3-229:7	BSD, 402, 403, Counter-designation: 229:9-23
229:24-230:1	
234:9-234:19	BSD, 402, 403, F
234:22-234:23	BSD, 402, 403, F, H
236:21-236:23	BSD, 402, 403, H
236:25-236:25	BSD, 402, 403, H, Counter-designation: 237:2, 237:8-238:9
239:8-239:10	BSD, 402, 403, H, Counter-designation: 238:11-15, 238:17-239:6
239:13-239:17	BSD, 402, 403, H
239:19-239:21	BSD, 402, 403, H, F
242:16-242:24	H
243:2-243:9	BSD
243:13-243:20	BSD, I
248:11-248:12	BSD, 402, 403, H
248:13-248:13	BSD, 402, 403, H
249:10-249:12	BSD
249:15-249:16	BSD
250:8-250:11	BSD
250:14-250:15	BSD
260:11-260:15	BSD
260:18-261:1	BSD

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
261:4-261:7	BSD
261:10-261:13	BSD
261:15-261:16	BSD
275:20-276:2	BSD
276:22-277:1	BSD
278:11-278:13	BSD
278:15-278:16	BSD
279:7-279:11	BSD, Counter-designation: 279:12-280:13, 280:14-19
281:9-281:24	BSD
282:11-282:17	BSD
283:3-283:9	BSD
283:19-283:20	BSD
283:22-283:22	BSD
285:10-285:15	BSD
285:21-286:10	BSD
286:15-286:20	BSD
292:16-292:23	BSD, 402, 403, F, 602
292:24-292:25	BSD, 402, 403, V
293:2-293:3	BSD
296:15-296:18	BSD, 402, 403, I, H, F
297:20-297:24	BSD, 402, 403
298:3-298:8	BSD, 402, 403, Counter-designation: 298:9-16
298:17-298:22	BSD, 402, 403
298:24-298:25	BSD, 402, 403

**PureWick's Designation of Trial Testimony of Camille Newton, April 6, 2023**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
4:16-4:20	UNE, BSD
11:24-12:5	UNE, BSD
13:17-14:4	UNE, BSD
14:5-14:15	UNE, BSD
14:22-14:22	UNE, BSD
15:1-15:13	UNE, BSD
15:16-15:16	UNE, BSD
15:18-16:1	UNE, BSD
16:4-16:4	UNE, BSD
16:9-16:18	UNE, BSD
16:21-16:21	UNE, BSD
17:1-17:8	UNE, BSD
17:11-17:11	UNE, BSD
18:22-19:4	UNE, BSD
19:7-19:7	UNE, BSD
20:15-20:16	UNE, BSD
21:20-21:23	UNE, BSD
30:6-30:10	UNE, BSD
31:17-31:21	UNE, BSD
32:13-32:16	402, 403, F, UNE, BSD
33:16-33:18	402, 403, H, UNE, BSD
33:21-33:21	UNE, BSD
34:6-34:10	402, 403, F, H, UNE, BSD
34:17-34:19	402, 403, F, H, UNE, BSD
34:20-34:23	402, 403, F, UNE, BSD
35:2-35:2	UNE, BSD
36:22-37:1	402, 403, UNE, BSD
37:5-37:8	UNE, BSD
37:16-37:19	402, 403, F, H, UNE, BSD
38:11-38:15	402, 403, UNE, BSD
38:19-38:22	UNE, BSD
40:2-40:6	402, 403, F, H, 602, UNE, BSD
40:12-40:18	402, 403, F, H, 602, UNE, BSD
40:19-40:19	UNE, BSD
41:4-41:6	402, 403, F, H, 602, CS, LC, V, UNE, BSD
42:1-42:4	UNE, BSD
43:8-43:11	402, 403, H, UNE, BSD



<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
44:23-45:1	402, 403, F, V, LC, UNE, BSD
45:5-45:5	UNE, BSD
45:10-45:13	UNE, BSD
46:1-46:5	402, 403, H, UNE, BSD
48:16-48:19	UNE, BSD
50:8-50:12	402, 403, F, H, UNE, BSD
51:23-52:2	UNE, BSD
52:9-52:15	402, 403, H, F, 602, V, LC, CS, UNE, BSD
52:16-52:20	402, 403, H, F, 602, V, LC, CS, UNE, BSD
52:24-52:24	UNE, BSD
56:19-56:20	UNE, BSD
57:4-57:4	402, 403, PRIV, UNE, BSD
63:4-63:7	UNE, BSD
63:23-64:1	402, 403, H, UNE, BSD
67:14-67:17	UNE, BSD
68:8-68:11	402, 403, H, UNE, BSD
69:15-69:20	402, 403, H, UNE, BSD
69:21-69:22	402, 403, H, LC, UNE, BSD
70:3-70:3	UNE, BSD
71:22-72:1	402, 403, H, F, 602, UNE, BSD
72:5-72:8	UNE, BSD
72:22-73:1	402, 403, H, UNE, BSD
73:19-73:24	402, 403, H, UNE, BSD
74:1-74:2	402, 403, H, UNE, BSD
74:5-74:7	402, 403, CS, 602, F, UNE, BSD
76:20-76:22	402, 403, CS, 602, V, F, UNE, BSD
77:2-77:4	UNE, BSD
77:6-77:7	UNE, BSD
77:21-77:24	UNE, BSD
78:11-78:14	402, 403, H, UNE, BSD
78:15-78:24	402, 403, H, UNE, BSD
81:12-81:15	UNE, BSD
81:19-81:22	402, 403, H, UNE, BSD
83:4-83:7	PRIV, UNE, BSD
83:13-83:13	PRIV, UNE, BSD
84:4-84:5	PRIV, UNE, BSD
84:18-84:18	UNE, BSD
84:20-84:21	PRIV, UNE, BSD

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
86:13-86:13	UNE, BSD
88:15-88:18	UNE, BSD
89:21-89:22	402, 403, H, UNE, BSD
90:1-90:3	H, UNE, BSD
90:20-90:23	UNE, BSD
91:14-91:17	402, 403, H, UNE, BSD
92:1-92:2	402, 403, V, C, UNE, BSD
92:5-92:11	UNE, BSD
92:18-92:21	402, 403, PRIV, UNE, BSD
93:4-93:4	UNE, BSD
96:9-96:12	UNE, BSD
96:16-96:19	402, 403, H, F, UNE, BSD
99:5-99:8	UNE, BSD
99:12-99:20	402, 403, H, F, UNE, BSD
101:8-101:11	UNE, BSD
101:15-101:23	402, 403, H, LC, 602, UNE, BSD
101:24-102:2	UNE, BSD
102:9-102:10	602, CS, UNE, BSD
102:12-102:13	402, 403, 602, CS, V, UNE, BSD
102:17-102:19	UNE, BSD
102:21-102:22	402, 403, 602, CS, V, UNE, BSD
103:1-103:1	UNE, BSD
103:4-103:7	402, 403, 602, CS, V, UNE, BSD
104:1-104:4	402, 403, F, V, UNE, BSD
104:5-104:7	UNE, BSD
104:11-104:15	402, 403, V, F, UNE, BSD
104:19-104:21	UNE, BSD
105:7-105:9	402, 403, V, F, UNE, BSD
105:12-105:14	F, 602, UNE, BSD
105:16-105:18	402, 403, V, CS, 602, UNE, BSD
105:22-106:2	I, UNE, BSD
109:5-109:9	402, 403, F, V, Arg, LC, CS, Hyp, H, UNE, BSD
109:13-109:18	402, 403, F, Arg, H, LC, UNE, BSD
109:19-109:21	402, 403, UNE, BSD
110:9-110:11	402, 403, F, CS, 602, UNE, BSD

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
110:21-111:4	H, UNE, BSD
111:8-111:11	UNE, BSD
111:16-111:19	402, 403, H, UNE, BSD
111:20-111:24	402, 403, H, UNE, BSD
112:5-112:8	UNE, BSD
113:6-113:12	UNE, BSD
113:13-113:17	UNE, BSD
113:18-113:24	UNE, BSD
114:24-115:2	402, 403, F, 602, AF, UNE, BSD
115:6-115:9	UNE, BSD
115:13-115:17	H, UNE, BSD
115:21-115:24	H, 402, 403, UNE, BSD
116:11-116:12	402, 403, V, UNE, BSD
116:15-116:15	UNE, BSD
117:1-117:5	UNE, BSD
118:3-118:7	402, UNE, BSD
125:14-125:15	402, 403, V, UNE, BSD
125:18-125:19	UNE, BSD
126:22-127:2	402, 403, UNE, BSD
127:6-127:10	402, 403, UNE, BSD
128:9-128:12	UNE, BSD
128:16-128:19	H, UNE, BSD
129:3-129:7	402, 403, H, UNE, BSD
129:10-129:13	H, UNE, BSD
130:18-131:2	H, F, UNE, BSD
131:24-132:6	402, 403, V, LC, UNE, BSD
132:22-132:23	402, 403, V, LC, UNE, BSD
133:3-133:4	UNE, BSD
133:24-134:2	402, 403, V, LC, UNE, BSD
134:5-134:5	UNE, BSD
134:8-134:22	UNE, BSD
134:23-135:1	402, 403, V, LC, UNE, BSD
135:4-135:5	UNE, BSD
136:15-136:23	402, 403, V, F, H, UNE, BSD
137:3-137:7	UNE, BSD
137:11-137:18	402, 403, H, F, UNE, BSD
138:1-138:6	402, 403, H, F, UNE, BSD
141:16-141:22	402, 403, LC, V, F, UNE, BSD
142:1-142:1	UNE, BSD
144:4-144:11	UNE, BSD
144:12-144:14	PRIV, H, UNE, BSD
144:20-144:22	UNE, BSD

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
144:24-145:2	PRIV, H, UNE, BSD
145:8-145:13	PRIV, H, UNE, BSD
145:16-145:18	UNE, BSD
145:20-145:22	PRIV, H, UNE, BSD
146:2-146:7	PRIV, H, UNE, BSD
146:12-146:12	UNE, BSD
147:8-147:13	402, 403, V, UNE, BSD
147:18-147:24	402, 403, V, UNE, BSD

**PureWick's Designation of Trial Testimony of John Gohde, March 29, 2022**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
359:13-359:20	
369:16-371:19	F, H, 402, 403, 901, counter-designate: 379:11-380:4
371:23-373:24	F, H, 402, 403, 901, counter-designate: 379:11-380:4
374:3-375:19	F, H, 402, 403, 901, counter-designate: 379:11-380:4
375:24-376:10	F, H, 402, 403, 901, counter-designate: 379:11-380:4
376:14-377:4	F, H, 402, 403, 901, counter-designate: 379:11-380:4
377:8-378:11	F, H, 402, 403, 901, counter-designate: 379:11-380:4
378:15-379:4	F, H, 402, 403, 901, counter-designate: 379:11-380:4

**PureWick's Designation of Deposition Testimony of John Gohde, March 26, 2021**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
4:11-4:14	BSD
32:20-33:1	BSD, F, H, 602
33:23-34:1	BSD, F, H, 602
34:5-34:6	BSD, F, H, 602
35:12-35:15	BSD, F, H, 602
35:18-35:18	BSD, F, H, 602
35:20-35:22	BSD, 403, F, H, 602, I, Arg, Counter-designation: 36:1-2, 36:12-13, 36:16, 36:20, 36:22- 37:2
36:4-36:11	BSD
37:9-37:17	BSD
38:24-39:6	BSD, 403, F, H, 602, Arg.
39:10-39:19	BSD, 403, F, H, 602, Arg.
41:3-41:8	BSD
41:10-41:13	BSD
42:2-42:2	BSD, Counter-designation: 42:3-6
43:11-43:21	BSD
43:22-44:2	BSD
45:24-46:9	BSD
46:12-46:13	BSD
46:20-47:8	BSD
47:17-47:19	BSD, Counter-designation: 47:20-22
51:12-51:17	BSD
58:3-58:18	BSD, 402, 403, Counter- designation: 58:19-21
60:14-60:19	BSD
60:24-60:24	BSD
61:7-61:21	BSD
61:22-62:10	BSD
62:14-62:14	BSD
63:17-63:19	BSD, Counter-designation: 63:2-4, 63:7-13
63:23-64:1	BSD
64:22-65:10	BSD
68:23-68:24	BSD, 402, 403, H, Arg
70:6-70:9	BSD
70:10-70:14	BSD
71:12-72:13	BSD

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
73:15-73:21	BSD
73:24-74:16	BSD
107:20-108:7	BSD
141:22-142:3	BSD, 402, 403, H, F, 602
142:5-142:9	BSD, 402, 403, H, F, 602
142:10-142:14	BSD, 402, 403, H, F, 602
142:15-142:20	BSD, 402, 403, H, F, 602
142:21-143:2	BSD, 402, 403, H, F, 602
143:4-143:16	BSD, 402, 403, H, F, 602
143:17-143:24	BSD, 402, 403, H, F, 602
144:1-144:13	BSD, 402, 403, H, F, 602
144:17-144:19	BSD, 402, 403, H, F, 602
145:1-145:6	BSD, 402, 403, H
145:7-145:23	BSD, 402, 403, H
146:7-146:12	BSD, 402, 403, H
146:16-146:22	BSD, 402, 403, H
147:3-148:1	BSD
148:19-148:24	BSD
149:1-149:5	BSD
150:13-150:18	BSD
151:1-151:7	BSD
151:11-151:21	BSD, 402, 403, H, F, 602
153:12-153:17	BSD, 402, 403, H
153:19-154:12	BSD, 402, 403, H
154:13-154:21	BSD, 402, 403, H
155:11-156:1	BSD, 402, 403
156:4-156:5	BSD, 402, 403, F
156:9-156:14	BSD, 402, 403
163:8-163:13	BSD, 402, 403, H, F
164:5-164:16	BSD, 402, 403, H, F, 602
167:2-167:19	BSD, 402, 403, H, F, 602
167:20-168:9	BSD, 402, 403, H, F, 602
168:22-169:4	BSD, 402, 403, H, F, 602
175:10-175:14	BSD, H, 602
175:17-175:20	BSD, H, 602
175:22-177:3	BSD, H, 602, F, 402, 403
177:4-177:18	BSD, H, 602, F, 402, 403
177:20-178:2	BSD, H, 602, F, 402, 403
178:5-178:6	BSD, 402, 403, F
178:18-179:17	BSD, 402, 403, F, 602
179:18-179:23	BSD, 402, 403, F, 602
180:2-180:6	BSD, 402, 403, F, 602
180:8-180:10	BSD, 402, 403, F, 602

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
180:18-181:6	BSD, Counter-designation: 181:7-11
181:12-181:22	BSD
183:23-184:16	BSD, 402, 403, H, F
184:17-185:1	BSD, 402, 403, H, F
185:2-185:7	BSD, 402, 403, H, F
185:10-185:16	BSD, 402, 403, H, F
185:17-186:3	BSD, 402, 403, H, F
186:16-186:24	BSD
187:12-187:15	BSD, 402, 403, H, F
187:18-187:21	BSD, 402, 403, H, F
189:14-189:20	BSD, 402, 403, H, F
190:11-190:15	BSD, 402, 403, H, F
190:16-190:22	BSD, 402, 403, H, F
191:21-192:1	BSD, 402, 403, H, F
193:7-193:10	BSD, 402, 403, H, F
193:13-193:16	BSD, 402, 403, H, F
194:4-194:5	BSD, 402, 403, H, F
194:7-194:13	BSD, 402, 403, H, F
194:16-194:24	BSD, 402, 403, H, F
195:3-195:12	BSD, 402, 403, H, F
196:13-197:6	BSD, Counter-designation: 196:6-12
197:9-197:12	BSD
207:16-207:21	BSD, Counter-designation: 208:3-9
210:11-210:15	BSD
210:17-210:22	BSD, 403, H, F, 602
210:23-210:24	BSD, 403, H, F, 602
211:10-211:14	BSD, 403, H, F, 602
214:7-214:10	BSD, 402, 403, F, Arg, CLC
214:12-214:14	BSD, 402, 403, F, Arg, CLC
215:20-215:23	BSD, 402, 403, F, Arg, CLC
216:3-216:11	BSD, 402, 403, F, Arg, CLC
216:14-216:14	BSD, 402, 403, F, Arg, CLC



**PureWick's Designation of Trial Testimony of Raymond Newton, March 29, 2022**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
288:17-289:2	BSD, 402, 403
309:7-310:7	BSD, 402, 403
310:16-311:22	BSD, 402, 403
311:23-312:14	BSD, 402, 403
312:15-312:20	BSD, 402, 403
313:3-314:23	BSD, 402, 403
315:13-315:16	BSD, 402, 403
317:8-317:10	BSD, 402, 403 319:3-19
317:11-317:15	BSD, 402, 403 319:3-19
317:18-317:20	BSD, 402, 403 319:3-19
319:20-319:22	BSD, 402, 403
320:12-320:20	BSD, 402, 403
321:1-321:15	BSD, 402, 403 321:19-22
322:10-322:16	BSD, 402, 403 322:17-22
323:11-323:15	BSD, 402, 403 323:5-10

**PureWick's Designation of Trial Testimony of Raymond Newton, April 13, 2021**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
9:15-9:18	
21:4-21:11	
35:19-35:20	BSD, 402, 403, 701, LC 34:18-19, 34:21-23
35:22-36:3	BSD, 402, 403, 701, LC 34:18-19, 34:21-23
36:10-36:18	BSD, 402, 403
37:12-38:6	BSD, 402, 403
38:8-38:14	BSD, 402, 403
38:17-38:23	BSD, 402, 403
38:25-39:4	BSD, 402, 403
39:14-40:14	BSD, 402, 403
43:5-43:13	BSD, 402, 403
43:15-44:12	BSD, 402, 403
44:15-44:23	BSD, 402, 403
44:25-45:2	BSD, 402, 403
45:4-45:11	BSD, 402, 403
45:22-45:23	BSD, 402, 403
45:25-46:7	BSD, 402, 403
46:10-46:11	BSD, 402, 403
46:21-46:22	BSD, 402, 403, I
46:25-47:13	BSD, 402, 403
91:24-96:1	BSD, 402, 403 96:2-4
96:5-97:16	BSD, 402, 403 96:2-4
97:23-98:1	BSD, 402, 403 97:17-22
98:5-98:17	BSD, 402, 403
98:24-99:10	BSD, 402, 403
101:1-101:3	BSD, 402, 403
105:20-106:19	BSD, 402, 403
109:6-110:10	BSD, 402, 403 110:11-17
148:15-148:17	
153:22-154:7	BSD, 402, 403, 701, LC
154:10-155:10	BSD, 402, 403, 701, LC
155:13-155:16	BSD, 402, 403, 701, LC 156:11-13, 156:16-25, 157:3-4, 157:7-12
160:12-160:16	BSD, 402, 403

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
160:19-160:23	BSD, 402, 403
161:18-161:25	BSD, 402, 403
162:3-162:4	BSD, 402, 403
162:7-162:9	BSD, 402, 403
162:12-162:15	BSD, 402, 403
162:17-162:19	BSD, 402, 403
163:2-163:11	BSD, 402, 403
163:12-163:14	BSD, 402, 403
163:17-163:21	BSD, 402, 403
163:23-163:24	BSD, 402, 403
164:1-164:3	BSD, 402, 403
164:5-164:8	BSD, 402, 403
164:12-164:14	BSD, 402, 403
164:25-165:11	BSD, 402, 403
165:13-165:13	BSD, 402, 403
165:16-165:21	BSD, 402, 403
165:22-166:5	BSD, 402, 403 166:20-167:1
167:4-168:8	BSD, 402, 403, I
168:10-168:17	BSD, 402, 403
168:21-168:23	BSD, 402, 403
169:3-169:4	BSD, 402, 403
169:7-169:9	BSD, 402, 403 169:11-14, 169:17-21, 170:3-11, 170:14-18
199:6-199:9	BSD, 402, 403
199:12-199:19	BSD, 402, 403
199:23-199:25	BSD, 402, 403
200:2-200:4	BSD, 402, 403
200:7-200:11	BSD, 402, 403
200:14-200:21	BSD, 402, 403
201:15-201:18	BSD, 402, 403
201:21-201:25	BSD, 402, 403
202:3-202:3	BSD, 402, 403
202:16-202:18	BSD, 402, 403
202:22-202:23	BSD, 402, 403
203:1-203:5	BSD, 402, 403
203:11-203:13	BSD, 402, 403
203:16-203:23	BSD, 402, 403
204:1-204:1	BSD, 402, 403
204:3-204:5	BSD, 402, 403
204:7-204:7	BSD, 402, 403
204:9-204:11	BSD, 402, 403

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
204:14-204:17	BSD, 402, 403
204:19-204:22	BSD, 402, 403
204:25-205:4	BSD, 402, 403
205:7-205:8	BSD, 402, 403
205:10-205:11	BSD, 402, 403
205:14-205:20	BSD, 402, 403 205:21-22, 205:25-206:1, 206:21-23, 207:1-6, 207:8-9, 207, 12-15
207:17-207:19	BSD, 402, 403
207:22-207:23	BSD, 402, 403
208:3-208:10	BSD, 402, 403
208:12-208:13	BSD, 402, 403
209:11-209:12	BSD, 402, 403
209:15-209:20	BSD, 402, 403
209:22-210:1	BSD, 402, 403
210:21-210:23	BSD, 402, 403
211:1-211:6	BSD, 402, 403
211:9-211:9	BSD, 402, 403
212:23-213:4	BSD, 402, 403
213:7-213:7	BSD, 402, 403
213:17-213:18	BSD, 402, 403
213:21-213:25	BSD, 402, 403
214:3-214:4	BSD, 402, 403 214:15-16, 214:19-22, 214:25- 215:1
218:5-218:7	BSD, 402, 403
218:10-218:10	BSD, 402, 403
218:12-218:15	BSD, 402, 403, I 218:17-23, 219:1-6, 219:8-9, 219:12-17
219:19-219:20	BSD, 402, 403 219:8-9, 219:12-17
219:23-219:24	BSD, 402, 403 219:8-9, 219:12-17
220:2-220:3	BSD, 402, 403 219:8-9, 219:12-17
220:5-220:10	BSD, 402, 403 219:8-9, 219:12-17
220:12-220:13	BSD, 402, 403 219:8-9, 219:12-17
220:17-220:18	BSD, 402, 403 219:8-9, 219:12-17

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
220:21-220:23	BSD, 402, 403 219:8-9, 219:12-17
248:4-248:5	BSD, 402, 403
248:8-248:12	BSD, 402, 403
248:15-248:19	BSD, 402, 403
251:4-251:11	BSD, 402, 403 252:21-23, 253:1-6
251:16-252:2	BSD, 402, 403 252:21-23, 253:1-6
252:6-252:7	BSD, 402, 403 252:21-23, 253:1-6
252:10-252:14	BSD, 402, 403 252:21-23, 253:1-6
252:17-252:19	BSD, 402, 403 252:21-23, 253:1-6
254:1-254:3	BSD, 402, 403
254:6-254:10	BSD, 402, 403
254:13-254:13	BSD, 402, 403 254:15-17, 254:20-24, 255:2, 255:11-13, 255:16-18
256:23-257:3	BSD, 402, 403
257:13-257:19	BSD, 402, 403
259:16-259:17	BSD, 402, 403
259:19-260:24	BSD, 402, 403 260:25-261:5
261:3-261:5	BSD, 402, 403 260:25-261:5
262:7-262:25	BSD, 402, 403 263:23-264:7
263:19-263:22	BSD, 402, 403 263:23-264:7
264:8-264:24	BSD, 402, 403 263:23-264:7
265:1-265:2	BSD, 402, 403 263:23-264:7

**PureWick's Designation of Trial Testimony of Raymond Newton, May 3, 2023**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
4:19-4:22	
62:4-62:21	BSD, 402, 403
64:22-65:1	BSD, 402, 403
65:7-65:13	BSD, 402, 403
65:21-66:13	BSD, 402, 403
66:18-66:23	BSD, 402, 403
67:3-67:7	BSD, 402, 403
67:16-67:18	BSD, 402, 403
67:21-67:22	BSD, 402, 403
68:1-68:4	BSD, 402, 403
68:7-68:9	BSD, 402, 403
68:13-68:14	BSD, 402, 403
69:21-69:23	BSD, 402, 403
70:3-70:3	BSD, 402, 403
70:5-70:8	BSD, 402, 403
70:11-70:11	BSD, 402, 403
95:3-95:5	BSD, 402, 403
95:12-95:16	BSD, 402, 403
95:19-95:22	BSD, 402, 403
96:2-96:8	BSD, 402, 403
97:7-97:11	BSD, 402, 403 97:16-18, 97:22-98:2
97:14-97:14	BSD, 402, 403 97:16-18, 97:22-98:2
98:4-98:5	BSD, 402, 403
98:10-98:13	BSD, 402, 403
100:9-100:10	BSD, 402, 403
100:14-100:14	BSD, 402, 403
100:16-100:18	BSD, 402, 403
100:23-100:24	BSD, 402, 403
101:1-101:3	BSD, 402, 403, I 101:7-12
101:13-102:4	BSD, 402, 403 102:5-8, 102:11-18
103:18-103:22	BSD, 402, 403
105:3-105:5	BSD, 402, 403
105:9-105:11	BSD, 402, 403
106:2-106:7	BSD, 402, 403
106:12-106:13	BSD, 402, 403
106:15-106:17	BSD, 402, 403
106:20-106:23	BSD, 402, 403

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
107:14-107:23	BSD, 402, 403
108:1-108:3	BSD, 402, 403
108:6-108:7	BSD, 402, 403
108:10-108:10	BSD, 402, 403
108:12-108:13	BSD, 402, 403
108:16-108:16	BSD, 402, 403
108:18-108:18	BSD, 402, 403
108:22-108:23	BSD, 402, 403
109:19-109:20	BSD, 402, 403
110:1-111:15	BSD, 402, 403, I
112:8-112:11	BSD, 402, 403
112:14-112:15	BSD, 402, 403
112:17-112:20	BSD, 402, 403
113:21-113:23	BSD, 402, 403
114:2-114:5	BSD, 402, 403
115:12-115:15	BSD, 402, 403
115:18-115:18	BSD, 402, 403
115:20-115:21	BSD, 402, 403
115:24-116:1	BSD, 402, 403
116:3-116:9	BSD, 402, 403
121:22-121:24	BSD, 402, 403
122:5-122:8	BSD, 402, 403 122:9-23
123:1-123:3	BSD, 402, 403
123:6-123:6	BSD, 402, 403
123:8-123:9	BSD, 402, 403
123:12-123:13	BSD, 402, 403
123:15-123:18	BSD, 402, 403, F 123:23-124:5
124:15-124:17	BSD, 402, 403
124:21-124:23	BSD, 402, 403
132:22-132:24	BSD, 402, 403
133:5-133:8	BSD, 402, 403
133:11-133:12	BSD, 402, 403
133:18-133:23	BSD, 402, 403
134:7-134:8	BSD, 402, 403
134:12-134:15	BSD, 402, 403 134:17-22
134:23-134:24	BSD, 402, 403 134:17-22
135:5-135:6	BSD, 402, 403
135:11-135:14	BSD, 402, 403
135:17-135:19	BSD, 402, 403

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
135:23-135:23	BSD, 402, 403
136:1-136:3	BSD, 402, 403
136:8-136:10	BSD, 402, 403
136:14-136:16	BSD, 402, 403
137:2-137:3	BSD, 402, 403
137:10-137:11	BSD, 402, 403
137:14-137:16	BSD, 402, 403
138:10-138:12	BSD, 402, 403
138:16-138:16	BSD, 402, 403 138:18-20, 138:23-24
146:3-146:3	BSD, 402, 403
146:5-146:6	BSD, 402, 403
146:11-146:14	BSD, 402, 403
146:21-146:22	BSD, 402, 403
147:2-147:2	BSD, 402, 403
147:11-147:12	BSD, 402, 403
147:16-147:17	BSD, 402, 403
160:2-160:3	BSD, 402, 403
160:8-160:13	BSD, 402, 403
160:22-160:22	BSD, 402, 403
161:1-161:2	BSD, 402, 403
161:21-161:24	BSD, 402, 403
162:24-163:3	BSD, 402, 403
163:6-163:7	BSD, 402, 403
163:19-164:4	BSD, 402, 403
164:7-164:7	BSD, 402, 403
164:17-164:19	BSD, 402, 403
164:22-164:22	BSD, 402, 403
164:24-165:2	BSD, 402, 403
165:5-165:5	BSD, 402, 403
168:17-168:19	BSD, 402, 403
168:23-168:24	BSD, 402, 403
170:3-170:9	BSD, 402, 403 170:10-12
170:17-170:20	BSD, 402, 403
171:2-171:7	BSD, 402, 403
171:11-171:14	BSD, 402, 403
171:16-171:21	BSD, 402, 403
174:16-174:21	BSD, 402, 403
175:1-175:2	BSD, 402, 403
176:5-176:7	BSD, 402, 403
176:12-176:20	BSD, 402, 403, S
177:1-177:2	BSD, 402, 403, S



<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
177:16-177:21	BSD, 402, 403 178:2-3
178:4-178:6	BSD, 402, 403, S
178:10-178:11	BSD, 402, 403, S
178:16-178:16	BSD, 402, 403, S
178:18-178:21	BSD, 402, 403, S
179:1-179:2	BSD, 402, 403, S
179:9-179:12	BSD, 402, 403, S
179:16-179:23	BSD, 402, 403, S
180:3-180:8	BSD, 402, 403, S
180:12-180:12	BSD, 402, 403, S
180:14-180:17	BSD, 402, 403
181:1-181:4	BSD, 402, 403
182:6-182:9	BSD, 402, 403
184:4-184:7	BSD, 402, 403
185:14-185:17	BSD, 402, 403
186:23-187:10	BSD, 402, 403
187:15-187:18	BSD, 402, 403
193:2-193:3	BSD, 402, 403, F 193:8-9
193:13-193:18	BSD, 402, 403
194:7-194:9	BSD, 402, 403
194:13-194:14	BSD, 402, 403
198:3-198:9	BSD, 402, 403 196:16-20, 197:16-19, 197:23- 198:1, 198:10-11
205:12-205:14	BSD, 402, 403, S
205:19-205:22	BSD, 402, 403, S
205:23-206:2	BSD, 402, 403, S
206:7-206:7	BSD, 402, 403, S
206:15-206:23	BSD, 402, 403, S
207:2-207:4	BSD, 402, 403, S
207:9-207:9	BSD, 402, 403, S
207:11-207:11	BSD, 402, 403, S
207:13-207:15	BSD, 402, 403, S
207:18-207:18	BSD, 402, 403, S
207:20-207:21	BSD, 402, 403, S
207:24-208:1	BSD, 402, 403, S, I 208:3-4
208:5-208:9	BSD, 402, 403, S
208:11-208:13	BSD, 402, 403, S
208:16-208:16	BSD, 402, 403, S
208:18-208:21	BSD, 402, 403, S

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
208:24-208:24	BSD, 402, 403, S
209:9-209:10	BSD, 402, 403
209:15-209:22	BSD, 402, 403
209:23-210:2	BSD, 402, 403
210:6-210:7	BSD, 402, 403
210:9-210:11	BSD, 402, 403
210:14-210:14	BSD, 402, 403
221:9-221:11	BSD, 402, 403
221:16-221:18	BSD, 402, 403, 701

**PureWick's Designation of Trial Testimony of Brett Blabas, March 30, 2022**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
581:4-582:2	BSD, 402, 403, H
582:6-582:13	BSD, 402, 403, H
583:2-583:7	BSD, 402, 403, H
583:10-583:25	BSD, 402, 403, H
584:12-584:19	
584:25-587:2	BSD, 402, 403, H
587:10-587:14	
588:20-589:21	
590:23-592:1	BSD, 402, 403, H
592:3-592:11	BSD, 402, 403, H
592:14-592:22	
592:23-593:24	BSD, 402, 403, H
594:1-594:17	BSD, 402, 403, H
594:24-595:12	BSD, 402, 403, H
595:14-596:13	BSD, 402, 403, H
597:7-597:15	BSD, 402, 403, H, F
597:22-599:16	BSD, 402, 403, H
600:6-601:7	BSD, 402, 403, H
603:4-603:24	BSD, 402, 403, H
604:7-604:17	BSD, 402, 403, H
605:10-607:20	BSD, 402, 403, H, 701
607:24-608:13	BSD, 402, 403, H
608:25-609:2	BSD, 402, 403, H
609:5-609:9	
609:19-610:6	BSD, 402, 403, H
610:10-610:19	BSD, 402, 403, H
613:7-613:10	
614:4-614:7	
616:10-616:14	BSD, 402, 403, H
618:8-618:9	
620:1-620:3	
622:20-623:1	
624:23-625:2	BSD, 402, 403, H
626:18-626:24	BSD, 402, 403, H
633:18-6334:23	BSD, 402, 403, H
635:11-635:13	BSD, 402, 403, H

**PureWick's Designation of Trial Testimony of Kelsey Paskal, March 30, 2022**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
669:2-669:24	402, 403
670:1-670:23	BSD, I, 402, 403
671:8-671:22	BSD, 402, 403
672:21-673:19	BSD, I, 402, 403
673:21-674:7	BSD, I, 402, 403
674:18-676:18	BSD, I, 402, 403
676:19-676:21	BSD, 402, 403
677:12-678:2	BSD, F, 402, 403
678:3-678:6	BSD, 402, 403
678:15-679:3	BSD, 402, 403
679:4-679:8	BSD, 402, 403
679:23-683:6	BSD, I, 402, 403
693:21-695:9	BSD, 402, 403

**PureWick's Designation of Deposition Testimony of Kelsey Paskal, March 10, 2021**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
27:20-27:23	F, V
28:2-28:4	F, V
28:5-28:9	
36:12-36:18	
43:4-43:6	V, 402, 403
43:9-43:15	V, 402, 403
44:9-44:12	F, V, 402, 403
44:16-45:5	F, V, 402, 403
49:25-50:3	M, 402, 403
50:6-50:18	M, 402, 403
50:21-50:22	M, 402, 403
54:24-55:3	V, 402, 403
55:6-55:11	V, 402, 403
62:13-62:17	S, Spec, 402, 403
62:20-62:22	S, Spec, 402, 403
64:23-65:3	F, M, V, Spec, 402, 403
65:9-65:15	F, M, V, Spec, 402, 403
65:18-65:21	F, M, V, Spec, 402, 403
66:16-66:20	V, 402, 403
66:23-67:3	V, 402, 403
67:12-67:13	V, 402, 403
67:16-67:21	V, 402, 403
91:22-91:25	402, 403
92:4-92:6	402, 403
92:14-92:16	402, 403
92:20-92:23	402, 403
99:5-99:7	F, Spec, C, M, V, 402, 403
99:11-99:19	F, Spec, C, M, V, 402, 403
101:2-101:21	402, 403
164:19-164:19	402, 403
164:23-164:24	402, 403
165:18-165:19	F, 402, 403
165:23-166:2	F, 402, 403
166:14-166:20	402, 403
166:24-166:25	402, 403
227:4-227:7	402, 403
228:18-228:21	F, 402, 403
228:25-229:3	F, 402, 403

**PureWick's Designation of Trial Testimony of Nick Alexander, March 31, 2022**

<b>Sage's Counter-Designations</b>	<b>PureWick's Objection(s)</b>
879:10-881:15	402, F, H
882:7-883:23	402, F, H
884:2-886:19	402, F, H

**Schedule E2D: Sage's Objections to PureWick's Counter-Counter Designations**(See **Schedule E2b** for key to Sage objections)**Robert Sanchez, April 21, 2021**

<b>PureWick's Counter-Counter Desig</b>	<b>Sage Objection</b>
150:23-152:2, 152:5-11	1, 2, 3, 4, 10, 15, 17, 19, MIL3

**Ray Newton, April 13, 2021**

<b>PureWick's Counter-Counter Desig</b>	<b>Sage Objection</b>
110:11-17	1, 4, 17
169:11-14, 169:17-21	1, 4, 17
205:21-22, 205:25-206:1	1, 4, 17
206:21-23, 207:1-9	1, 4, 17
207:12-15	1, 4, 17
219:8-9, 219:12-17	1, 4, 17
252:21-23, 253:1-6	1, 2, 4, 16, 17
254:15-17, 254:20-24,	1, 4, 17
255:2, 255:11-13, 255:16-18	1, 4, 17
260:25-261:5	1, 4, 17
263:23-264:7	4

**Ray Newton, March 29, 2022**

<b>PureWick's Counter-Counter Desig</b>	<b>Sage Objection</b>
319:3-19	1, 4, 3, 5, 17
321:19-22	1, 4, 3, 5, 17
322:17-22	
323:5-10	

**Ray Newton, May 3, 2023**

<b>PureWick's Counter-Counter Desig</b>	<b>Sage Objection</b>
97:16-18	1, 4, 17
97:22-98:2	1, 4, 17
101:7-12	4
102:5-8	4
102:11-18	4
122:9-23	1, 4, 17
123:23-124:5	1, 4
134:17-22	4

138:18-20	4
138:23-24	4
170:10-12	4
178:2-3	
193:8-9	1, 4, 18
196:16-20	4
197:16-19	1, 4, 17
197:23-198:1	1, 4, 17
198:10-11	1, 4, 17
208:3-4	4

**Richard Morgan, February 10, 2023**

<b>PureWick's Counter-Counter Desig</b>	<b>Sage Objection</b>
30:13-17	1, 5
35:17-19	1, 19
35:20-38:1	4, 2, 3, 5
42:13	
46:18-19, 22-24	1, 3, 17, 19
50:12	1, 17, 19
53:6-10	1, 3, 5, 17, 19
133:4-10	1, 17, 19
134:13-15	1, 3, 5, 17

**John Gohde, March 26, 2021**

<b>PureWick's Counter-Counter Desig</b>	<b>Sage Objection</b>
36:1-2	1, 3, 17
36:12-13	1, 3, 17, 20
36:16	1, 3, 17, 20
36:20	1, 3, 17, 20
36:22-37:2	1, 3, 17, 20
42:3-6	1, 17
47:20-22	1, 17
58:19-21	1, 17
63:2-4	1, 17
63:7-13	1, 17
181:7-11	1, 17
196:6-12	1, 17
208:3-9	1, 17

**Dan Ulreich, April 13, 2023**

<b>PureWick's Counter-Counter Desig</b>	<b>Sage Objection</b>
---	-----------------------



107:11-14, 107:18-19, 109:4-7, 109:11, 109:14-16	1, 2, 3, 5, 17
---	----------------

**Camille Newton, April 15, 2021**

<b>PureWick's Counter-Counter Desig</b>	<b>Sage Objection</b>
31:4	1, 4, 17, 19
51:9-12, 51:25-52:10	1, 4, 17, 19
66:8-10, 66:12-13, 66:15-24	1, 4, 17
67:22-68:4	1, 4, 17
71:9, 71:11-15	4
97:14-15	1, 17
110:1-13	1, 4, 17
114:20-21, 114:24-115:1, 115:3-4, 115:7-10	4
118:9-18, 118:22-24, 119:2-8	1, 4, 17
138:5-19	4
144:8-20, 145:2-7	4
147:3-14	4
148:22-149:7	4
149:12-14	4
160:8-10	4
160:13-24	1, 4, 16, 17
173:12-13	
175:16-18, 175:21-176:1	1, 4, 16, 17
176:7-10, 176:12-17	1, 4, 17
180:2-5	4
186:16-19, 186:23-187:3	1, 4, 16, 17
189:4-6, 189:14-15, 189:17-18	1, 4, 16, 17
194:16-18, 194:21-195:6	1, 4, 16, 17
209:21-23	1, 4, 16, 17
207:21	1, 4, 16, 17
209:5-15	1, 4, 16, 17
229:9-23	1, 4, 16, 17, MIL2
237:2, 237:8-238:9	1, 4, 16, 17, MIL2, 24
238:11-15, 238:17-239:6	1, 4, 16, 17, MIL2, 24
279:12-280:13, 280:14-19	1, 4, 16, 17

**John Gohde, March 29, 2022**

<b>PureWick's Counter-Counter Desig</b>	<b>Sage Objection</b>
379:11-380:4	1, 3, 13, 17, 20, 22

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

PUREWICK CORPORATION,	)	
	)	
Plaintiff,	)	
	)	C.A. No. 22-102-MN
v.	)	
	)	
SAGE PRODUCTS, LLC,	)	
	)	
Defendant.	)	
	)	

**DEFENDANT’S TRIAL WITNESS LIST**

Below is an identification of the witnesses whose testimony Defendant may present at trial. The inclusion of a witness on this list does not require Defendant to call that witness to testify, and does not imply or establish that the party has the power to compel the live testimony of that witness or make that witness available to the opposing party.

Defendant expressly reserves the right to call any witness identified by the Plaintiff at any point before or during trial, whether or not listed on the lists below, live or by deposition or trial designations. Sage also expressly reserves the right to call any witness live or by deposition or trial designations (or to offer additional deposition designations from witnesses identified herein) for purposes of rebuttal, impeachment, or authentication of a document or as required by any of the Court’s pretrial or trial rulings as well as the use of Sage’s initial designations for a particular witness as counter-designations to PureWick designations. Sage also reserve the right to change or modify these lists as permitted by the Federal Rules of Civil Procedure, Local Rules, or Orders of the Court, including in view of events at trial or based on circumstances that may evolve prior to the commencement of trial, such as but not limited to, evidentiary rulings or other rulings by the Court. Deposition and/or trial designations are also attached to the pretrial order including for witnesses that Plaintiff has not indicated will be live at trial.

Sage expects to call the following witness to testify live or by deposition at trial: Adam Cole (expected to be live), Dr. Yadin David (live), Eric Farrell (expected to be live), Diane Newman (live), and Vince Thomas (live).

Sage further expects to call the following witnesses that have been represented by Plaintiff to testify live or by deposition at trial: Brian Burn (live or by deposition), John Gohde (live or by deposition/transcript), Robin Hanson (live or by deposition), Gregory Mann (live or by deposition), Richard Morgan (live or by deposition), Camille Newton (live per plaintiff; designations also provided), Ray Newton (live or by deposition/transcript), and Paul Zani (live or by deposition).

Sage may call the following witnesses to testify live or by deposition at trial: Arun Alakhramsing (live or by deposition), Nick Alexander (live or by deposition/transcript), Jen Allen (live or by deposition), Jason Bobay (live or by deposition), Ruby Dy (by deposition), Lorena Eckert (by deposition), Joseph Forehand (by deposition), Mark Harvie (expected by deposition), Ben Jackson (by deposition), Michael Jackson (by deposition), Sameer Jirafe (live or by deposition), Matthew Karlovsky (live), Edward Callan (by deposition), Kate Pawlik (by deposition), Patricia Polanco (live or by deposition), Robert Sanchez (by deposition), Laura Shaw (by deposition), Marcus Simon (expected by deposition), Sarah Skelton (live or by deposition), and Dan Ulreich (live or by deposition).

## **SCHEDULE E4a**

### **Sage's Initial Designations**

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Bobay, Jason 2021-04-23	7	3	7	9	Sage Initial Designations
Bobay, Jason 2021-04-23	14	7	14	12	Sage Initial Designations
Bobay, Jason 2021-04-23	14	22	15	25	Sage Initial Designations
Bobay, Jason 2021-04-23	16	2	16	2	Sage Initial Designations
Bobay, Jason 2021-04-23	17	9	17	25	Sage Initial Designations
Bobay, Jason 2021-04-23	18	2	18	25	Sage Initial Designations
Bobay, Jason 2021-04-23	20	2	21	11	Sage Initial Designations
Bobay, Jason 2021-04-23	21	21	21	25	Sage Initial Designations
Bobay, Jason 2021-04-23	22	2	22	8	Sage Initial Designations
Bobay, Jason 2021-04-23	82	21	82	23	Sage Initial Designations
Bobay, Jason 2021-04-23	83	3	83	14	Sage Initial Designations
Bobay, Jason 2021-04-23	86	9	86	25	Sage Initial Designations
Bobay, Jason 2021-04-23	87	2	87	2	Sage Initial Designations
Bobay, Jason 2021-04-23	92	20	92	22	Sage Initial Designations
Bobay, Jason 2021-04-23	94	5	94	8	Sage Initial Designations
Bobay, Jason 2021-04-23	94	12	94	25	Sage Initial Designations
Bobay, Jason 2021-04-23	95	2	95	25	Sage Initial Designations
Bobay, Jason 2021-04-23	96	2	96	25	Sage Initial Designations
Bobay, Jason 2021-04-23	100	17	100	25	Sage Initial Designations
Bobay, Jason 2021-04-23	101	2	101	25	Sage Initial Designations
Bobay, Jason 2021-04-23	102	2	102	11	Sage Initial Designations
Bobay, Jason 2021-04-23	130	2	130	4	Sage Initial Designations
Bobay, Jason 2021-04-23	131	11	131	19	Sage Initial Designations
Bobay, Jason 2021-04-23	132	9	132	11	Sage Initial Designations
Bobay, Jason 2021-04-23	132	15	132	25	Sage Initial Designations
Bobay, Jason 2021-04-23	133	2	133	25	Sage Initial Designations
Bobay, Jason 2021-04-23	134	2	134	20	Sage Initial Designations
Bobay, Jason 2021-04-23	146	8	146	10	Sage Initial Designations
Bobay, Jason 2021-04-23	147	3	147	6	Sage Initial Designations
Bobay, Jason 2021-04-23	148	2	148	12	Sage Initial Designations
Bobay, Jason 2021-04-23	152	23	153	3	Sage Initial Designations
Bobay, Jason 2021-04-23	153	5	153	6	Sage Initial Designations
Bobay, Jason 2021-04-23	154	19	154	25	Sage Initial Designations
Bobay, Jason 2021-04-23	155	2	155	25	Sage Initial Designations
Bobay, Jason 2021-04-23	156	2	156	6	Sage Initial Designations
Bobay, Jason 2021-04-23	156	15	156	18	Sage Initial Designations
Bobay, Jason 2021-04-23	157	8	157	13	Sage Initial Designations
Bobay, Jason 2021-04-23	161	9	161	25	Sage Initial Designations
Bobay, Jason 2021-04-23	162	2	162	14	Sage Initial Designations
Bobay, Jason 2021-04-23	163	17	163	20	Sage Initial Designations
Bobay, Jason 2021-04-23	164	18	164	22	Sage Initial Designations
Bobay, Jason 2021-04-23	164	25	164	25	Sage Initial Designations
Bobay, Jason 2021-04-23	165	2	165	11	Sage Initial Designations
Bobay, Jason 2021-04-23	165	16	165	25	Sage Initial Designations
Bobay, Jason 2021-04-23	166	2	166	2	Sage Initial Designations
Bobay, Jason 2021-04-23	166	3	166	12	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Bobay, Jason 2021-04-23	167	6	167	12	Sage Initial Designations
Bobay, Jason 2021-04-23	167	16	167	17	Sage Initial Designations
Bobay, Jason 2021-04-23	182	16	182	25	Sage Initial Designations
Bobay, Jason 2021-04-23	183	2	183	25	Sage Initial Designations
Bobay, Jason 2021-04-23	184	2	184	25	Sage Initial Designations
Bobay, Jason 2021-04-23	185	2	185	5	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Burn, Brian 2021-04-02	4	18	4	20	Sage Initial Designations
Burn, Brian 2021-04-02	10	9	10	23	Sage Initial Designations
Burn, Brian 2021-04-02	14	22	14	24	Sage Initial Designations
Burn, Brian 2021-04-02	21	6	21	10	Sage Initial Designations
Burn, Brian 2021-04-02	21	17	21	22	Sage Initial Designations
Burn, Brian 2021-04-02	23	7	23	9	Sage Initial Designations
Burn, Brian 2021-04-02	23	10	23	13	Sage Initial Designations
Burn, Brian 2021-04-02	28	12	28	14	Sage Initial Designations
Burn, Brian 2021-04-02	28	21	28	22	Sage Initial Designations
Burn, Brian 2021-04-02	29	1	29	2	Sage Initial Designations
Burn, Brian 2021-04-02	32	9	32	11	Sage Initial Designations
Burn, Brian 2021-04-02	37	4	37	7	Sage Initial Designations
Burn, Brian 2021-04-02	38	11	38	13	Sage Initial Designations
Burn, Brian 2021-04-02	39	4	42	20	Sage Initial Designations
Burn, Brian 2021-04-02	45	21	45	24	Sage Initial Designations
Burn, Brian 2021-04-02	46	1	46	4	Sage Initial Designations
Burn, Brian 2021-04-02	46	9	46	12	Sage Initial Designations
Burn, Brian 2021-04-02	46	13	46	16	Sage Initial Designations
Burn, Brian 2021-04-02	46	17	46	19	Sage Initial Designations
Burn, Brian 2021-04-02	46	20	46	22	Sage Initial Designations
Burn, Brian 2021-04-02	47	8	47	10	Sage Initial Designations
Burn, Brian 2021-04-02	50	21	51	1	Sage Initial Designations
Burn, Brian 2021-04-02	51	9	51	11	Sage Initial Designations
Burn, Brian 2021-04-02	51	12	51	16	Sage Initial Designations
Burn, Brian 2021-04-02	51	17	51	18	Sage Initial Designations
Burn, Brian 2021-04-02	51	23	51	23	Sage Initial Designations
Burn, Brian 2021-04-02	52	11	52	17	Sage Initial Designations
Burn, Brian 2021-04-02	53	13	53	24	Sage Initial Designations
Burn, Brian 2021-04-02	54	1	54	23	Sage Initial Designations
Burn, Brian 2021-04-02	54	24	55	4	Sage Initial Designations
Burn, Brian 2021-04-02	55	7	55	10	Sage Initial Designations
Burn, Brian 2021-04-02	55	13	56	5	Sage Initial Designations
Burn, Brian 2021-04-02	56	14	56	18	Sage Initial Designations
Burn, Brian 2021-04-02	56	20	56	22	Sage Initial Designations
Burn, Brian 2021-04-02	57	13	57	16	Sage Initial Designations
Burn, Brian 2021-04-02	57	17	57	24	Sage Initial Designations
Burn, Brian 2021-04-02	58	1	58	4	Sage Initial Designations
Burn, Brian 2021-04-02	58	15	58	18	Sage Initial Designations
Burn, Brian 2021-04-02	59	1	59	14	Sage Initial Designations
Burn, Brian 2021-04-02	59	17	59	21	Sage Initial Designations
Burn, Brian 2021-04-02	59	23	60	1	Sage Initial Designations
Burn, Brian 2021-04-02	60	23	61	9	Sage Initial Designations
Burn, Brian 2021-04-02	62	10	62	14	Sage Initial Designations
Burn, Brian 2021-04-02	62	16	62	17	Sage Initial Designations
Burn, Brian 2021-04-02	63	3	63	5	Sage Initial Designations
Burn, Brian 2021-04-02	63	7	64	3	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Burn, Brian 2021-04-02	64	7	64	12	Sage Initial Designations
Burn, Brian 2021-04-02	64	22	64	24	Sage Initial Designations
Burn, Brian 2021-04-02	65	5	65	6	Sage Initial Designations
Burn, Brian 2021-04-02	65	9	65	10	Sage Initial Designations
Burn, Brian 2021-04-02	65	14	65	16	Sage Initial Designations
Burn, Brian 2021-04-02	65	19	65	21	Sage Initial Designations
Burn, Brian 2021-04-02	66	11	66	12	Sage Initial Designations
Burn, Brian 2021-04-02	66	16	66	17	Sage Initial Designations
Burn, Brian 2021-04-02	66	19	66	21	Sage Initial Designations
Burn, Brian 2021-04-02	66	24	67	1	Sage Initial Designations
Burn, Brian 2021-04-02	69	4	69	18	Sage Initial Designations
Burn, Brian 2021-04-02	69	24	70	7	Sage Initial Designations
Burn, Brian 2021-04-02	72	19	72	21	Sage Initial Designations
Burn, Brian 2021-04-02	72	24	73	1	Sage Initial Designations
Burn, Brian 2021-04-02	73	10	73	12	Sage Initial Designations
Burn, Brian 2021-04-02	76	21	76	24	Sage Initial Designations
Burn, Brian 2021-04-02	79	11	79	12	Sage Initial Designations
Burn, Brian 2021-04-02	79	15	79	15	Sage Initial Designations
Burn, Brian 2021-04-02	79	17	79	17	Sage Initial Designations
Burn, Brian 2021-04-02	79	24	80	1	Sage Initial Designations
Burn, Brian 2021-04-02	80	3	80	5	Sage Initial Designations
Burn, Brian 2021-04-02	82	6	82	8	Sage Initial Designations
Burn, Brian 2021-04-02	82	12	82	12	Sage Initial Designations
Burn, Brian 2021-04-02	82	14	82	16	Sage Initial Designations
Burn, Brian 2021-04-02	82	23	82	24	Sage Initial Designations
Burn, Brian 2021-04-02	83	1	83	1	Sage Initial Designations
Burn, Brian 2021-04-02	83	7	83	17	Sage Initial Designations
Burn, Brian 2021-04-02	84	9	84	11	Sage Initial Designations
Burn, Brian 2021-04-02	84	19	84	22	Sage Initial Designations
Burn, Brian 2021-04-02	85	6	85	11	Sage Initial Designations
Burn, Brian 2021-04-02	85	14	85	14	Sage Initial Designations
Burn, Brian 2021-04-02	85	17	85	17	Sage Initial Designations
Burn, Brian 2021-04-02	86	4	86	8	Sage Initial Designations
Burn, Brian 2021-04-02	86	12	86	17	Sage Initial Designations
Burn, Brian 2021-04-02	86	20	86	20	Sage Initial Designations
Burn, Brian 2021-04-02	86	22	86	24	Sage Initial Designations
Burn, Brian 2021-04-02	87	7	87	8	Sage Initial Designations
Burn, Brian 2021-04-02	88	1	88	6	Sage Initial Designations
Burn, Brian 2021-04-02	90	22	90	24	Sage Initial Designations
Burn, Brian 2021-04-02	91	4	91	7	Sage Initial Designations
Burn, Brian 2021-04-02	92	1	92	3	Sage Initial Designations
Burn, Brian 2021-04-02	92	6	92	7	Sage Initial Designations
Burn, Brian 2021-04-02	92	9	92	9	Sage Initial Designations
Burn, Brian 2021-04-02	92	11	92	15	Sage Initial Designations
Burn, Brian 2021-04-02	92	17	92	20	Sage Initial Designations
Burn, Brian 2021-04-02	93	5	93	12	Sage Initial Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Burn, Brian 2021-04-02	93	15	93	17	Sage Initial Designations
Burn, Brian 2021-04-02	93	24	94	8	Sage Initial Designations
Burn, Brian 2021-04-02	94	10	94	11	Sage Initial Designations
Burn, Brian 2021-04-02	94	19	94	21	Sage Initial Designations
Burn, Brian 2021-04-02	95	1	95	1	Sage Initial Designations
Burn, Brian 2021-04-02	95	10	95	13	Sage Initial Designations
Burn, Brian 2021-04-02	95	16	95	17	Sage Initial Designations
Burn, Brian 2021-04-02	95	24	96	3	Sage Initial Designations
Burn, Brian 2021-04-02	96	20	96	23	Sage Initial Designations
Burn, Brian 2021-04-02	97	2	97	3	Sage Initial Designations
Burn, Brian 2021-04-02	97	5	97	7	Sage Initial Designations
Burn, Brian 2021-04-02	97	10	97	13	Sage Initial Designations
Burn, Brian 2021-04-02	98	19	98	22	Sage Initial Designations
Burn, Brian 2021-04-02	98	24	99	1	Sage Initial Designations
Burn, Brian 2021-04-02	100	1	100	5	Sage Initial Designations
Burn, Brian 2021-04-02	100	7	100	7	Sage Initial Designations
Burn, Brian 2021-04-02	100	10	100	15	Sage Initial Designations
Burn, Brian 2021-04-02	100	19	100	20	Sage Initial Designations
Burn, Brian 2021-04-02	100	22	100	23	Sage Initial Designations
Burn, Brian 2021-04-02	101	22	102	3	Sage Initial Designations
Burn, Brian 2021-04-02	102	5	102	6	Sage Initial Designations
Burn, Brian 2021-04-02	103	13	103	16	Sage Initial Designations
Burn, Brian 2021-04-02	103	19	103	23	Sage Initial Designations
Burn, Brian 2021-04-02	104	10	104	13	Sage Initial Designations
Burn, Brian 2021-04-02	104	16	104	17	Sage Initial Designations
Burn, Brian 2021-04-02	105	1	105	4	Sage Initial Designations
Burn, Brian 2021-04-02	105	6	105	7	Sage Initial Designations
Burn, Brian 2021-04-02	106	14	108	3	Sage Initial Designations
Burn, Brian 2021-04-02	111	12	112	5	Sage Initial Designations
Burn, Brian 2021-04-02	115	14	115	16	Sage Initial Designations
Burn, Brian 2021-04-02	116	23	117	6	Sage Initial Designations
Burn, Brian 2021-04-02	117	7	117	16	Sage Initial Designations
Burn, Brian 2021-04-02	119	15	119	17	Sage Initial Designations
Burn, Brian 2021-04-02	119	19	119	21	Sage Initial Designations
Burn, Brian 2021-04-02	120	2	120	4	Sage Initial Designations
Burn, Brian 2021-04-02	120	14	120	24	Sage Initial Designations
Burn, Brian 2021-04-02	121	3	121	4	Sage Initial Designations
Burn, Brian 2021-04-02	121	6	121	9	Sage Initial Designations
Burn, Brian 2021-04-02	121	13	121	13	Sage Initial Designations
Burn, Brian 2021-04-02	121	15	121	18	Sage Initial Designations
Burn, Brian 2021-04-02	121	21	122	1	Sage Initial Designations
Burn, Brian 2021-04-02	122	3	122	11	Sage Initial Designations
Burn, Brian 2021-04-02	122	12	122	16	Sage Initial Designations
Burn, Brian 2021-04-02	127	23	128	1	Sage Initial Designations
Burn, Brian 2021-04-02	128	17	129	10	Sage Initial Designations
Burn, Brian 2021-04-02	130	8	130	15	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Burn, Brian 2021-04-02	130	18	130	19	Sage Initial Designations
Burn, Brian 2021-04-02	134	21	135	13	Sage Initial Designations
Burn, Brian 2021-04-02	137	1	137	6	Sage Initial Designations
Burn, Brian 2021-04-02	138	20	139	9	Sage Initial Designations
Burn, Brian 2021-04-02	139	10	139	16	Sage Initial Designations
Burn, Brian 2021-04-02	139	20	140	4	Sage Initial Designations
Burn, Brian 2021-04-02	140	5	140	20	Sage Initial Designations
Burn, Brian 2021-04-02	141	2	141	9	Sage Initial Designations
Burn, Brian 2021-04-02	142	1	142	7	Sage Initial Designations
Burn, Brian 2021-04-02	142	14	142	23	Sage Initial Designations
Burn, Brian 2021-04-02	143	8	143	11	Sage Initial Designations
Burn, Brian 2021-04-02	151	22	152	4	Sage Initial Designations
Burn, Brian 2021-04-02	154	24	155	2	Sage Initial Designations
Burn, Brian 2021-04-02	155	4	155	7	Sage Initial Designations
Burn, Brian 2021-04-02	155	10	155	17	Sage Initial Designations
Burn, Brian 2021-04-02	159	17	159	19	Sage Initial Designations
Burn, Brian 2021-04-02	160	2	160	5	Sage Initial Designations
Burn, Brian 2021-04-02	160	8	160	13	Sage Initial Designations
Burn, Brian 2021-04-02	160	22	162	2	Sage Initial Designations
Burn, Brian 2021-04-02	162	5	162	8	Sage Initial Designations
Burn, Brian 2021-04-02	162	10	162	17	Sage Initial Designations
Burn, Brian 2021-04-02	162	20	163	8	Sage Initial Designations
Burn, Brian 2021-04-02	163	11	163	21	Sage Initial Designations
Burn, Brian 2021-04-02	163	22	164	2	Sage Initial Designations
Burn, Brian 2021-04-02	164	4	164	17	Sage Initial Designations
Burn, Brian 2021-04-02	164	19	164	22	Sage Initial Designations
Burn, Brian 2021-04-02	169	9	169	11	Sage Initial Designations
Burn, Brian 2021-04-02	169	13	169	15	Sage Initial Designations
Burn, Brian 2021-04-02	170	14	171	16	Sage Initial Designations
Burn, Brian 2021-04-02	171	18	171	23	Sage Initial Designations
Burn, Brian 2021-04-02	172	1	172	3	Sage Initial Designations
Burn, Brian 2021-04-02	172	21	172	23	Sage Initial Designations
Burn, Brian 2021-04-02	173	1	173	11	Sage Initial Designations
Burn, Brian 2021-04-02	176	24	177	22	Sage Initial Designations
Burn, Brian 2021-04-02	177	23	178	1	Sage Initial Designations
Burn, Brian 2021-04-02	178	3	178	6	Sage Initial Designations
Burn, Brian 2021-04-02	178	8	178	9	Sage Initial Designations
Burn, Brian 2021-04-02	178	11	178	14	Sage Initial Designations
Burn, Brian 2021-04-02	178	16	178	17	Sage Initial Designations
Burn, Brian 2021-04-02	178	19	179	2	Sage Initial Designations
Burn, Brian 2021-04-02	179	3	179	6	Sage Initial Designations
Burn, Brian 2021-04-02	179	9	179	10	Sage Initial Designations
Burn, Brian 2021-04-02	187	12	187	14	Sage Initial Designations
Burn, Brian 2021-04-02	187	16	188	6	Sage Initial Designations
Burn, Brian 2021-04-02	188	9	188	12	Sage Initial Designations
Burn, Brian 2021-04-02	188	14	188	17	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Burn, Brian 2021-04-02	188	20	189	19	Sage Initial Designations
Burn, Brian 2021-04-02	189	24	190	10	Sage Initial Designations
Burn, Brian 2021-04-02	191	3	191	5	Sage Initial Designations
Burn, Brian 2021-04-02	191	7	191	11	Sage Initial Designations
Burn, Brian 2021-04-02	191	18	192	4	Sage Initial Designations
Burn, Brian 2021-04-02	192	21	193	1	Sage Initial Designations
Burn, Brian 2021-04-02	195	15	195	18	Sage Initial Designations
Burn, Brian 2021-04-02	196	2	196	4	Sage Initial Designations
Burn, Brian 2021-04-02	196	6	196	7	Sage Initial Designations
Burn, Brian 2021-04-02	199	13	199	17	Sage Initial Designations
Burn, Brian 2021-04-02	202	5	202	7	Sage Initial Designations
Burn, Brian 2021-04-02	202	9	202	12	Sage Initial Designations
Burn, Brian 2021-04-02	202	15	202	20	Sage Initial Designations
Burn, Brian 2021-04-02	203	4	203	19	Sage Initial Designations
Burn, Brian 2021-04-02	203	23	203	24	Sage Initial Designations
Burn, Brian 2021-04-02	204	4	204	5	Sage Initial Designations
Burn, Brian 2021-04-02	204	7	204	12	Sage Initial Designations
Burn, Brian 2021-04-02	204	23	205	4	Sage Initial Designations
Burn, Brian 2021-04-02	205	8	205	14	Sage Initial Designations
Burn, Brian 2021-04-02	211	11	211	14	Sage Initial Designations
Burn, Brian 2021-04-02	211	15	211	21	Sage Initial Designations
Burn, Brian 2021-04-02	211	23	212	1	Sage Initial Designations
Burn, Brian 2021-04-02	212	3	212	4	Sage Initial Designations
Burn, Brian 2021-04-02	212	18	212	23	Sage Initial Designations
Burn, Brian 2021-04-02	213	3	213	10	Sage Initial Designations
Burn, Brian 2021-04-02	213	12	213	13	Sage Initial Designations
Burn, Brian 2021-04-02	218	11	218	16	Sage Initial Designations
Burn, Brian 2021-04-02	220	11	220	22	Sage Initial Designations
Burn, Brian 2021-04-02	221	4	221	7	Sage Initial Designations
Burn, Brian 2021-04-02	221	17	221	19	Sage Initial Designations
Burn, Brian 2021-04-02	222	9	222	24	Sage Initial Designations
Burn, Brian 2021-04-02	223	5	223	8	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Burn, Brian 2023-03-23	4	14	4	16	Sage Initial Designations
Burn, Brian 2023-03-23	18	22	19	1	Sage Initial Designations
Burn, Brian 2023-03-23	19	8	19	11	Sage Initial Designations
Burn, Brian 2023-03-23	22	14	22	16	Sage Initial Designations
Burn, Brian 2023-03-23	24	17	24	20	Sage Initial Designations
Burn, Brian 2023-03-23	24	24	25	3	Sage Initial Designations
Burn, Brian 2023-03-23	25	20	25	22	Sage Initial Designations
Burn, Brian 2023-03-23	26	2	26	3	Sage Initial Designations
Burn, Brian 2023-03-23	26	7	26	9	Sage Initial Designations
Burn, Brian 2023-03-23	29	6	29	18	Sage Initial Designations
Burn, Brian 2023-03-23	30	16	30	19	Sage Initial Designations
Burn, Brian 2023-03-23	30	23	31	5	Sage Initial Designations
Burn, Brian 2023-03-23	32	13	32	16	Sage Initial Designations
Burn, Brian 2023-03-23	33	13	33	16	Sage Initial Designations
Burn, Brian 2023-03-23	33	21	33	23	Sage Initial Designations
Burn, Brian 2023-03-23	34	4	34	7	Sage Initial Designations
Burn, Brian 2023-03-23	43	14	43	17	Sage Initial Designations
Burn, Brian 2023-03-23	44	9	44	11	Sage Initial Designations
Burn, Brian 2023-03-23	45	7	45	10	Sage Initial Designations
Burn, Brian 2023-03-23	49	1	49	4	Sage Initial Designations
Burn, Brian 2023-03-23	49	6	49	12	Sage Initial Designations
Burn, Brian 2023-03-23	51	7	51	19	Sage Initial Designations
Burn, Brian 2023-03-23	52	7	52	15	Sage Initial Designations
Burn, Brian 2023-03-23	56	13	57	12	Sage Initial Designations
Burn, Brian 2023-03-23	58	3	58	24	Sage Initial Designations
Burn, Brian 2023-03-23	59	4	59	10	Sage Initial Designations
Burn, Brian 2023-03-23	59	13	59	13	Sage Initial Designations
Burn, Brian 2023-03-23	59	18	60	18	Sage Initial Designations
Burn, Brian 2023-03-23	65	19	65	21	Sage Initial Designations
Burn, Brian 2023-03-23	66	1	66	1	Sage Initial Designations
Burn, Brian 2023-03-23	66	3	66	17	Sage Initial Designations
Burn, Brian 2023-03-23	67	2	67	4	Sage Initial Designations
Burn, Brian 2023-03-23	67	13	67	14	Sage Initial Designations
Burn, Brian 2023-03-23	67	17	67	18	Sage Initial Designations
Burn, Brian 2023-03-23	67	23	68	2	Sage Initial Designations
Burn, Brian 2023-03-23	68	14	68	20	Sage Initial Designations
Burn, Brian 2023-03-23	69	24	70	6	Sage Initial Designations
Burn, Brian 2023-03-23	70	11	70	16	Sage Initial Designations
Burn, Brian 2023-03-23	70	20	70	22	Sage Initial Designations
Burn, Brian 2023-03-23	71	14	72	2	Sage Initial Designations
Burn, Brian 2023-03-23	72	11	72	14	Sage Initial Designations
Burn, Brian 2023-03-23	72	18	72	18	Sage Initial Designations
Burn, Brian 2023-03-23	72	23	73	3	Sage Initial Designations
Burn, Brian 2023-03-23	74	2	74	5	Sage Initial Designations
Burn, Brian 2023-03-23	75	10	75	13	Sage Initial Designations
Burn, Brian 2023-03-23	75	17	75	17	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Burn, Brian 2023-03-23	75	19	75	20	Sage Initial Designations
Burn, Brian 2023-03-23	75	23	75	23	Sage Initial Designations
Burn, Brian 2023-03-23	76	1	76	7	Sage Initial Designations
Burn, Brian 2023-03-23	76	24	77	3	Sage Initial Designations
Burn, Brian 2023-03-23	77	7	77	7	Sage Initial Designations
Burn, Brian 2023-03-23	77	17	78	7	Sage Initial Designations
Burn, Brian 2023-03-23	78	22	79	2	Sage Initial Designations
Burn, Brian 2023-03-23	79	5	79	10	Sage Initial Designations
Burn, Brian 2023-03-23	79	19	79	24	Sage Initial Designations
Burn, Brian 2023-03-23	81	17	81	20	Sage Initial Designations
Burn, Brian 2023-03-23	82	10	82	13	Sage Initial Designations
Burn, Brian 2023-03-23	82	18	83	8	Sage Initial Designations
Burn, Brian 2023-03-23	83	22	84	1	Sage Initial Designations
Burn, Brian 2023-03-23	84	11	84	13	Sage Initial Designations
Burn, Brian 2023-03-23	84	16	84	17	Sage Initial Designations
Burn, Brian 2023-03-23	85	2	85	6	Sage Initial Designations
Burn, Brian 2023-03-23	86	22	87	10	Sage Initial Designations
Burn, Brian 2023-03-23	88	10	88	15	Sage Initial Designations
Burn, Brian 2023-03-23	91	9	91	15	Sage Initial Designations
Burn, Brian 2023-03-23	92	9	92	10	Sage Initial Designations
Burn, Brian 2023-03-23	92	13	92	18	Sage Initial Designations
Burn, Brian 2023-03-23	92	21	92	21	Sage Initial Designations
Burn, Brian 2023-03-23	94	3	94	6	Sage Initial Designations
Burn, Brian 2023-03-23	96	21	97	7	Sage Initial Designations
Burn, Brian 2023-03-23	97	16	97	24	Sage Initial Designations
Burn, Brian 2023-03-23	98	11	98	13	Sage Initial Designations
Burn, Brian 2023-03-23	101	1	101	3	Sage Initial Designations
Burn, Brian 2023-03-23	101	7	101	9	Sage Initial Designations
Burn, Brian 2023-03-23	101	11	101	14	Sage Initial Designations
Burn, Brian 2023-03-23	101	18	101	21	Sage Initial Designations
Burn, Brian 2023-03-23	104	6	104	8	Sage Initial Designations
Burn, Brian 2023-03-23	104	14	104	14	Sage Initial Designations
Burn, Brian 2023-03-23	110	5	110	18	Sage Initial Designations
Burn, Brian 2023-03-23	111	12	111	17	Sage Initial Designations
Burn, Brian 2023-03-23	112	6	112	9	Sage Initial Designations
Burn, Brian 2023-03-23	112	14	112	16	Sage Initial Designations
Burn, Brian 2023-03-23	112	19	112	21	Sage Initial Designations
Burn, Brian 2023-03-23	113	5	113	8	Sage Initial Designations
Burn, Brian 2023-03-23	114	24	115	3	Sage Initial Designations
Burn, Brian 2023-03-23	115	15	115	16	Sage Initial Designations
Burn, Brian 2023-03-23	115	22	115	23	Sage Initial Designations
Burn, Brian 2023-03-23	116	5	116	7	Sage Initial Designations
Burn, Brian 2023-03-23	116	18	116	20	Sage Initial Designations
Burn, Brian 2023-03-23	116	24	117	3	Sage Initial Designations
Burn, Brian 2023-03-23	117	12	117	15	Sage Initial Designations
Burn, Brian 2023-03-23	117	21	118	1	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Burn, Brian 2023-03-23	118	5	118	20	Sage Initial Designations
Burn, Brian 2023-03-23	119	5	119	14	Sage Initial Designations
Burn, Brian 2023-03-23	119	17	119	23	Sage Initial Designations
Burn, Brian 2023-03-23	120	12	120	14	Sage Initial Designations
Burn, Brian 2023-03-23	120	20	120	23	Sage Initial Designations
Burn, Brian 2023-03-23	121	6	121	7	Sage Initial Designations
Burn, Brian 2023-03-23	121	10	121	13	Sage Initial Designations
Burn, Brian 2023-03-23	121	20	122	3	Sage Initial Designations
Burn, Brian 2023-03-23	122	14	122	16	Sage Initial Designations
Burn, Brian 2023-03-23	122	22	123	3	Sage Initial Designations
Burn, Brian 2023-03-23	123	5	123	9	Sage Initial Designations
Burn, Brian 2023-03-23	123	19	124	1	Sage Initial Designations
Burn, Brian 2023-03-23	128	20	128	23	Sage Initial Designations
Burn, Brian 2023-03-23	129	4	129	6	Sage Initial Designations
Burn, Brian 2023-03-23	129	9	129	12	Sage Initial Designations
Burn, Brian 2023-03-23	131	2	131	4	Sage Initial Designations
Burn, Brian 2023-03-23	131	7	131	7	Sage Initial Designations
Burn, Brian 2023-03-23	132	16	132	17	Sage Initial Designations
Burn, Brian 2023-03-23	132	23	132	23	Sage Initial Designations
Burn, Brian 2023-03-23	133	3	133	6	Sage Initial Designations
Burn, Brian 2023-03-23	133	19	134	1	Sage Initial Designations
Burn, Brian 2023-03-23	134	7	134	19	Sage Initial Designations
Burn, Brian 2023-03-23	136	11	136	23	Sage Initial Designations
Burn, Brian 2023-03-23	138	8	138	11	Sage Initial Designations
Burn, Brian 2023-03-23	139	10	139	20	Sage Initial Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Dy, Ruby 2021-04-14	6	20	7	8	Sage Initial Designations
Dy, Ruby 2021-04-14	13	22	13	22	Sage Initial Designations
Dy, Ruby 2021-04-14	14	15	14	22	Sage Initial Designations
Dy, Ruby 2021-04-14	17	16	17	18	Sage Initial Designations
Dy, Ruby 2021-04-14	17	21	18	2	Sage Initial Designations
Dy, Ruby 2021-04-14	18	9	18	10	Sage Initial Designations
Dy, Ruby 2021-04-14	18	12	18	13	Sage Initial Designations
Dy, Ruby 2021-04-14	20	9	20	11	Sage Initial Designations
Dy, Ruby 2021-04-14	22	24	23	2	Sage Initial Designations
Dy, Ruby 2021-04-14	28	6	28	8	Sage Initial Designations
Dy, Ruby 2021-04-14	31	14	31	23	Sage Initial Designations
Dy, Ruby 2021-04-14	34	8	34	19	Sage Initial Designations
Dy, Ruby 2021-04-14	35	10	35	13	Sage Initial Designations
Dy, Ruby 2021-04-14	35	15	35	17	Sage Initial Designations
Dy, Ruby 2021-04-14	35	19	35	23	Sage Initial Designations
Dy, Ruby 2021-04-14	36	20	36	22	Sage Initial Designations
Dy, Ruby 2021-04-14	36	24	36	25	Sage Initial Designations
Dy, Ruby 2021-04-14	37	3	37	11	Sage Initial Designations
Dy, Ruby 2021-04-14	40	3	40	5	Sage Initial Designations
Dy, Ruby 2021-04-14	40	7	40	7	Sage Initial Designations
Dy, Ruby 2021-04-14	40	9	40	10	Sage Initial Designations
Dy, Ruby 2021-04-14	40	13	40	17	Sage Initial Designations
Dy, Ruby 2021-04-14	41	6	41	9	Sage Initial Designations
Dy, Ruby 2021-04-14	41	17	41	20	Sage Initial Designations
Dy, Ruby 2021-04-14	43	18	43	23	Sage Initial Designations
Dy, Ruby 2021-04-14	44	25	45	1	Sage Initial Designations
Dy, Ruby 2021-04-14	45	3	45	8	Sage Initial Designations
Dy, Ruby 2021-04-14	45	11	45	20	Sage Initial Designations
Dy, Ruby 2021-04-14	45	22	45	23	Sage Initial Designations
Dy, Ruby 2021-04-14	46	1	46	9	Sage Initial Designations
Dy, Ruby 2021-04-14	47	13	47	14	Sage Initial Designations
Dy, Ruby 2021-04-14	47	18	47	20	Sage Initial Designations
Dy, Ruby 2021-04-14	48	16	48	24	Sage Initial Designations
Dy, Ruby 2021-04-14	49	2	49	3	Sage Initial Designations
Dy, Ruby 2021-04-14	49	7	49	13	Sage Initial Designations
Dy, Ruby 2021-04-14	49	16	49	22	Sage Initial Designations
Dy, Ruby 2021-04-14	50	15	50	25	Sage Initial Designations
Dy, Ruby 2021-04-14	51	3	51	4	Sage Initial Designations
Dy, Ruby 2021-04-14	53	21	53	23	Sage Initial Designations
Dy, Ruby 2021-04-14	55	8	55	12	Sage Initial Designations
Dy, Ruby 2021-04-14	55	14	55	14	Sage Initial Designations
Dy, Ruby 2021-04-14	55	25	56	4	Sage Initial Designations
Dy, Ruby 2021-04-14	56	9	56	13	Sage Initial Designations
Dy, Ruby 2021-04-14	57	7	57	7	Sage Initial Designations
Dy, Ruby 2021-04-14	57	9	57	9	Sage Initial Designations
Dy, Ruby 2021-04-14	57	13	57	15	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Dy, Ruby 2021-04-14	58	1	58	13	Sage Initial Designations
Dy, Ruby 2021-04-14	61	11	61	13	Sage Initial Designations
Dy, Ruby 2021-04-14	61	16	61	17	Sage Initial Designations
Dy, Ruby 2021-04-14	62	11	62	13	Sage Initial Designations
Dy, Ruby 2021-04-14	62	24	63	1	Sage Initial Designations
Dy, Ruby 2021-04-14	64	15	64	17	Sage Initial Designations
Dy, Ruby 2021-04-14	64	20	64	21	Sage Initial Designations
Dy, Ruby 2021-04-14	64	25	65	3	Sage Initial Designations
Dy, Ruby 2021-04-14	65	6	65	8	Sage Initial Designations
Dy, Ruby 2021-04-14	66	4	66	7	Sage Initial Designations
Dy, Ruby 2021-04-14	66	20	66	22	Sage Initial Designations
Dy, Ruby 2021-04-14	66	25	67	2	Sage Initial Designations
Dy, Ruby 2021-04-14	67	23	67	24	Sage Initial Designations
Dy, Ruby 2021-04-14	68	2	68	5	Sage Initial Designations
Dy, Ruby 2021-04-14	68	20	68	21	Sage Initial Designations
Dy, Ruby 2021-04-14	69	17	69	23	Sage Initial Designations
Dy, Ruby 2021-04-14	70	18	70	18	Sage Initial Designations
Dy, Ruby 2021-04-14	70	21	70	22	Sage Initial Designations
Dy, Ruby 2021-04-14	71	14	71	16	Sage Initial Designations
Dy, Ruby 2021-04-14	81	24	81	24	Sage Initial Designations
Dy, Ruby 2021-04-14	82	2	82	14	Sage Initial Designations
Dy, Ruby 2021-04-14	83	2	83	4	Sage Initial Designations
Dy, Ruby 2021-04-14	83	24	84	1	Sage Initial Designations
Dy, Ruby 2021-04-14	84	4	84	6	Sage Initial Designations
Dy, Ruby 2021-04-14	84	9	84	11	Sage Initial Designations
Dy, Ruby 2021-04-14	88	2	88	5	Sage Initial Designations
Dy, Ruby 2021-04-14	88	7	88	13	Sage Initial Designations
Dy, Ruby 2021-04-14	88	21	88	22	Sage Initial Designations
Dy, Ruby 2021-04-14	88	25	89	1	Sage Initial Designations
Dy, Ruby 2021-04-14	89	23	89	24	Sage Initial Designations
Dy, Ruby 2021-04-14	90	3	90	5	Sage Initial Designations
Dy, Ruby 2021-04-14	90	19	90	21	Sage Initial Designations
Dy, Ruby 2021-04-14	90	24	90	25	Sage Initial Designations
Dy, Ruby 2021-04-14	91	14	91	16	Sage Initial Designations
Dy, Ruby 2021-04-14	91	20	91	22	Sage Initial Designations
Dy, Ruby 2021-04-14	91	24	92	2	Sage Initial Designations
Dy, Ruby 2021-04-14	92	5	92	12	Sage Initial Designations
Dy, Ruby 2021-04-14	92	16	92	19	Sage Initial Designations
Dy, Ruby 2021-04-14	92	24	93	4	Sage Initial Designations
Dy, Ruby 2021-04-14	93	14	93	18	Sage Initial Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Eckert, Lorena 2023-03-14	4	9	4	13	Sage Initial Designations
Eckert, Lorena 2023-03-14	16	8	16	11	Sage Initial Designations
Eckert, Lorena 2023-03-14	18	3	18	13	Sage Initial Designations
Eckert, Lorena 2023-03-14	18	15	18	22	Sage Initial Designations
Eckert, Lorena 2023-03-14	19	11	19	19	Sage Initial Designations
Eckert, Lorena 2023-03-14	19	23	20	2	Sage Initial Designations
Eckert, Lorena 2023-03-14	20	9	20	18	Sage Initial Designations
Eckert, Lorena 2023-03-14	21	8	21	22	Sage Initial Designations
Eckert, Lorena 2023-03-14	25	24	26	2	Sage Initial Designations
Eckert, Lorena 2023-03-14	26	13	26	22	Sage Initial Designations
Eckert, Lorena 2023-03-14	27	10	27	20	Sage Initial Designations
Eckert, Lorena 2023-03-14	28	12	29	4	Sage Initial Designations
Eckert, Lorena 2023-03-14	29	7	29	10	Sage Initial Designations
Eckert, Lorena 2023-03-14	29	12	29	16	Sage Initial Designations
Eckert, Lorena 2023-03-14	29	20	29	24	Sage Initial Designations
Eckert, Lorena 2023-03-14	31	19	31	22	Sage Initial Designations
Eckert, Lorena 2023-03-14	31	24	32	7	Sage Initial Designations
Eckert, Lorena 2023-03-14	35	21	35	24	Sage Initial Designations
Eckert, Lorena 2023-03-14	36	1	36	3	Sage Initial Designations
Eckert, Lorena 2023-03-14	40	3	41	2	Sage Initial Designations
Eckert, Lorena 2023-03-14	41	15	42	4	Sage Initial Designations
Eckert, Lorena 2023-03-14	43	1	43	13	Sage Initial Designations
Eckert, Lorena 2023-03-14	55	10	55	13	Sage Initial Designations
Eckert, Lorena 2023-03-14	55	19	56	6	Sage Initial Designations
Eckert, Lorena 2023-03-14	56	21	57	4	Sage Initial Designations
Eckert, Lorena 2023-03-14	57	20	57	22	Sage Initial Designations
Eckert, Lorena 2023-03-14	58	14	58	20	Sage Initial Designations
Eckert, Lorena 2023-03-14	62	22	63	3	Sage Initial Designations
Eckert, Lorena 2023-03-14	63	9	63	14	Sage Initial Designations
Eckert, Lorena 2023-03-14	63	21	64	12	Sage Initial Designations
Eckert, Lorena 2023-03-14	64	15	64	16	Sage Initial Designations
Eckert, Lorena 2023-03-14	65	4	65	10	Sage Initial Designations
Eckert, Lorena 2023-03-14	72	14	72	18	Sage Initial Designations
Eckert, Lorena 2023-03-14	72	21	72	22	Sage Initial Designations
Eckert, Lorena 2023-03-14	73	5	73	8	Sage Initial Designations
Eckert, Lorena 2023-03-14	75	12	75	18	Sage Initial Designations
Eckert, Lorena 2023-03-14	76	2	76	5	Sage Initial Designations
Eckert, Lorena 2023-03-14	84	5	84	8	Sage Initial Designations
Eckert, Lorena 2023-03-14	100	18	100	19	Sage Initial Designations
Eckert, Lorena 2023-03-14	101	1	101	9	Sage Initial Designations
Eckert, Lorena 2023-03-14	101	21	102	1	Sage Initial Designations
Eckert, Lorena 2023-03-14	102	7	102	21	Sage Initial Designations
Eckert, Lorena 2023-03-14	103	1	103	2	Sage Initial Designations
Eckert, Lorena 2023-03-14	103	4	103	5	Sage Initial Designations
Eckert, Lorena 2023-03-14	103	8	103	13	Sage Initial Designations
Eckert, Lorena 2023-03-14	103	15	103	18	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Eckert, Lorena 2023-03-14	103	22	103	22	Sage Initial Designations
Eckert, Lorena 2023-03-14	113	24	114	6	Sage Initial Designations
Eckert, Lorena 2023-03-14	118	2	118	12	Sage Initial Designations
Eckert, Lorena 2023-03-14	120	1	120	6	Sage Initial Designations
Eckert, Lorena 2023-03-14	120	23	121	11	Sage Initial Designations
Eckert, Lorena 2023-03-14	121	14	121	18	Sage Initial Designations
Eckert, Lorena 2023-03-14	121	20	122	3	Sage Initial Designations
Eckert, Lorena 2023-03-14	122	6	122	12	Sage Initial Designations
Eckert, Lorena 2023-03-14	122	16	122	21	Sage Initial Designations
Eckert, Lorena 2023-03-14	125	10	125	20	Sage Initial Designations
Eckert, Lorena 2023-03-14	127	3	127	10	Sage Initial Designations
Eckert, Lorena 2023-03-14	127	13	127	14	Sage Initial Designations
Eckert, Lorena 2023-03-14	127	16	127	19	Sage Initial Designations
Eckert, Lorena 2023-03-14	127	23	128	2	Sage Initial Designations
Eckert, Lorena 2023-03-14	128	5	128	5	Sage Initial Designations
Eckert, Lorena 2023-03-14	128	7	128	23	Sage Initial Designations
Eckert, Lorena 2023-03-14	129	2	129	7	Sage Initial Designations
Eckert, Lorena 2023-03-14	129	9	129	13	Sage Initial Designations
Eckert, Lorena 2023-03-14	129	15	129	18	Sage Initial Designations
Eckert, Lorena 2023-03-14	129	22	130	2	Sage Initial Designations
Eckert, Lorena 2023-03-14	130	4	130	11	Sage Initial Designations
Eckert, Lorena 2023-03-14	135	1	135	15	Sage Initial Designations
Eckert, Lorena 2023-03-14	136	4	136	7	Sage Initial Designations
Eckert, Lorena 2023-03-14	144	19	144	23	Sage Initial Designations
Eckert, Lorena 2023-03-14	145	10	145	12	Sage Initial Designations
Eckert, Lorena 2023-03-14	147	6	147	8	Sage Initial Designations
Eckert, Lorena 2023-03-14	147	20	147	23	Sage Initial Designations
Eckert, Lorena 2023-03-14	150	18	150	24	Sage Initial Designations
Eckert, Lorena 2023-03-14	151	1	151	6	Sage Initial Designations
Eckert, Lorena 2023-03-14	151	19	151	19	Sage Initial Designations
Eckert, Lorena 2023-03-14	151	21	151	21	Sage Initial Designations
Eckert, Lorena 2023-03-14	151	24	153	3	Sage Initial Designations
Eckert, Lorena 2023-03-14	153	5	153	14	Sage Initial Designations
Eckert, Lorena 2023-03-14	153	17	153	17	Sage Initial Designations
Eckert, Lorena 2023-03-14	153	20	153	23	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Forehand, Joseph 3-24-2021	7	15	7	17	Sage Initial Designations
Forehand, Joseph 3-24-2021	14	4	14	5	Sage Initial Designations
Forehand, Joseph 3-24-2021	14	15	14	17	Sage Initial Designations
Forehand, Joseph 3-24-2021	17	8	17	15	Sage Initial Designations
Forehand, Joseph 3-24-2021	18	6	18	21	Sage Initial Designations
Forehand, Joseph 3-24-2021	19	4	19	7	Sage Initial Designations
Forehand, Joseph 3-24-2021	19	16	19	24	Sage Initial Designations
Forehand, Joseph 3-24-2021	20	2	20	3	Sage Initial Designations
Forehand, Joseph 3-24-2021	20	5	20	5	Sage Initial Designations
Forehand, Joseph 3-24-2021	20	7	20	10	Sage Initial Designations
Forehand, Joseph 3-24-2021	20	15	21	2	Sage Initial Designations
Forehand, Joseph 3-24-2021	21	4	21	6	Sage Initial Designations
Forehand, Joseph 3-24-2021	28	3	28	11	Sage Initial Designations
Forehand, Joseph 3-24-2021	28	13	29	1	Sage Initial Designations
Forehand, Joseph 3-24-2021	29	5	29	8	Sage Initial Designations
Forehand, Joseph 3-24-2021	30	3	30	5	Sage Initial Designations
Forehand, Joseph 3-24-2021	30	7	30	11	Sage Initial Designations
Forehand, Joseph 3-24-2021	31	20	31	23	Sage Initial Designations
Forehand, Joseph 3-24-2021	32	7	32	10	Sage Initial Designations
Forehand, Joseph 3-24-2021	33	14	33	14	Sage Initial Designations
Forehand, Joseph 3-24-2021	34	13	34	15	Sage Initial Designations
Forehand, Joseph 3-24-2021	34	23	35	5	Sage Initial Designations
Forehand, Joseph 3-24-2021	36	6	36	9	Sage Initial Designations
Forehand, Joseph 3-24-2021	38	6	38	7	Sage Initial Designations
Forehand, Joseph 3-24-2021	38	12	38	12	Sage Initial Designations
Forehand, Joseph 3-24-2021	39	8	39	10	Sage Initial Designations
Forehand, Joseph 3-24-2021	39	13	39	18	Sage Initial Designations
Forehand, Joseph 3-24-2021	39	23	40	4	Sage Initial Designations
Forehand, Joseph 3-24-2021	55	14	55	17	Sage Initial Designations
Forehand, Joseph 3-24-2021	55	21	55	23	Sage Initial Designations
Forehand, Joseph 3-24-2021	56	3	56	4	Sage Initial Designations
Forehand, Joseph 3-24-2021	56	7	56	7	Sage Initial Designations
Forehand, Joseph 3-24-2021	61	7	61	13	Sage Initial Designations
Forehand, Joseph 3-24-2021	69	16	69	22	Sage Initial Designations
Forehand, Joseph 3-24-2021	70	21	71	1	Sage Initial Designations
Forehand, Joseph 3-24-2021	71	12	71	17	Sage Initial Designations
Forehand, Joseph 3-24-2021	73	1	73	18	Sage Initial Designations
Forehand, Joseph 3-24-2021	74	6	74	7	Sage Initial Designations
Forehand, Joseph 3-24-2021	74	9	74	9	Sage Initial Designations
Forehand, Joseph 3-24-2021	74	14	74	14	Sage Initial Designations
Forehand, Joseph 3-24-2021	74	20	74	23	Sage Initial Designations
Forehand, Joseph 3-24-2021	74	25	75	5	Sage Initial Designations
Forehand, Joseph 3-24-2021	75	7	75	8	Sage Initial Designations
Forehand, Joseph 3-24-2021	75	13	75	15	Sage Initial Designations
Forehand, Joseph 3-24-2021	76	12	76	15	Sage Initial Designations
Forehand, Joseph 3-24-2021	76	17	77	20	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Forehand, Joseph 3-24-2021	77	24	78	10	Sage Initial Designations
Forehand, Joseph 3-24-2021	78	25	79	3	Sage Initial Designations
Forehand, Joseph 3-24-2021	80	5	80	9	Sage Initial Designations
Forehand, Joseph 3-24-2021	80	21	80	24	Sage Initial Designations
Forehand, Joseph 3-24-2021	81	6	81	8	Sage Initial Designations
Forehand, Joseph 3-24-2021	81	20	81	22	Sage Initial Designations
Forehand, Joseph 3-24-2021	81	25	82	1	Sage Initial Designations
Forehand, Joseph 3-24-2021	82	3	82	5	Sage Initial Designations
Forehand, Joseph 3-24-2021	82	12	82	14	Sage Initial Designations
Forehand, Joseph 3-24-2021	83	19	83	21	Sage Initial Designations
Forehand, Joseph 3-24-2021	83	23	83	23	Sage Initial Designations
Forehand, Joseph 3-24-2021	84	1	84	3	Sage Initial Designations
Forehand, Joseph 3-24-2021	84	18	84	21	Sage Initial Designations
Forehand, Joseph 3-24-2021	85	2	85	13	Sage Initial Designations
Forehand, Joseph 3-24-2021	85	21	86	3	Sage Initial Designations
Forehand, Joseph 3-24-2021	86	7	86	11	Sage Initial Designations
Forehand, Joseph 3-24-2021	86	13	86	22	Sage Initial Designations
Forehand, Joseph 3-24-2021	87	8	87	16	Sage Initial Designations
Forehand, Joseph 3-24-2021	87	20	87	24	Sage Initial Designations
Forehand, Joseph 3-24-2021	88	7	88	16	Sage Initial Designations
Forehand, Joseph 3-24-2021	88	20	88	22	Sage Initial Designations
Forehand, Joseph 3-24-2021	89	1	89	1	Sage Initial Designations
Forehand, Joseph 3-24-2021	89	9	89	18	Sage Initial Designations
Forehand, Joseph 3-24-2021	90	16	90	19	Sage Initial Designations
Forehand, Joseph 3-24-2021	91	14	91	24	Sage Initial Designations
Forehand, Joseph 3-24-2021	92	1	92	2	Sage Initial Designations
Forehand, Joseph 3-24-2021	92	11	92	17	Sage Initial Designations
Forehand, Joseph 3-24-2021	96	15	96	20	Sage Initial Designations
Forehand, Joseph 3-24-2021	97	3	97	7	Sage Initial Designations
Forehand, Joseph 3-24-2021	99	4	99	7	Sage Initial Designations
Forehand, Joseph 3-24-2021	100	4	100	6	Sage Initial Designations
Forehand, Joseph 3-24-2021	103	4	103	9	Sage Initial Designations
Forehand, Joseph 3-24-2021	104	20	105	2	Sage Initial Designations
Forehand, Joseph 3-24-2021	105	10	105	13	Sage Initial Designations
Forehand, Joseph 3-24-2021	105	18	105	24	Sage Initial Designations
Forehand, Joseph 3-24-2021	106	5	106	6	Sage Initial Designations
Forehand, Joseph 3-24-2021	106	8	106	8	Sage Initial Designations
Forehand, Joseph 3-24-2021	106	16	106	18	Sage Initial Designations
Forehand, Joseph 3-24-2021	106	21	107	15	Sage Initial Designations
Forehand, Joseph 3-24-2021	107	18	107	18	Sage Initial Designations
Forehand, Joseph 3-24-2021	107	20	107	22	Sage Initial Designations
Forehand, Joseph 3-24-2021	108	1	108	4	Sage Initial Designations
Forehand, Joseph 3-24-2021	108	14	108	20	Sage Initial Designations
Forehand, Joseph 3-24-2021	108	23	109	7	Sage Initial Designations
Forehand, Joseph 3-24-2021	109	14	109	15	Sage Initial Designations
Forehand, Joseph 3-24-2021	109	17	109	17	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Forehand, Joseph 3-24-2021	115	3	115	7	Sage Initial Designations
Forehand, Joseph 3-24-2021	115	15	115	16	Sage Initial Designations
Forehand, Joseph 3-24-2021	115	23	116	3	Sage Initial Designations
Forehand, Joseph 3-24-2021	116	7	116	10	Sage Initial Designations
Forehand, Joseph 3-24-2021	116	12	116	22	Sage Initial Designations
Forehand, Joseph 3-24-2021	117	2	117	3	Sage Initial Designations
Forehand, Joseph 3-24-2021	117	20	118	10	Sage Initial Designations
Forehand, Joseph 3-24-2021	118	16	118	23	Sage Initial Designations
Forehand, Joseph 3-24-2021	119	18	119	23	Sage Initial Designations
Forehand, Joseph 3-24-2021	120	24	121	13	Sage Initial Designations
Forehand, Joseph 3-24-2021	122	2	122	3	Sage Initial Designations
Forehand, Joseph 3-24-2021	122	6	122	7	Sage Initial Designations
Forehand, Joseph 3-24-2021	122	9	122	10	Sage Initial Designations
Forehand, Joseph 3-24-2021	122	12	122	16	Sage Initial Designations
Forehand, Joseph 3-24-2021	123	4	123	7	Sage Initial Designations
Forehand, Joseph 3-24-2021	123	11	123	18	Sage Initial Designations
Forehand, Joseph 3-24-2021	124	1	124	10	Sage Initial Designations
Forehand, Joseph 3-24-2021	124	17	124	20	Sage Initial Designations
Forehand, Joseph 3-24-2021	126	20	126	25	Sage Initial Designations
Forehand, Joseph 3-24-2021	127	4	127	7	Sage Initial Designations
Forehand, Joseph 3-24-2021	127	21	127	23	Sage Initial Designations
Forehand, Joseph 3-24-2021	127	25	127	25	Sage Initial Designations
Forehand, Joseph 3-24-2021	134	19	135	12	Sage Initial Designations
Forehand, Joseph 3-24-2021	147	12	148	4	Sage Initial Designations
Forehand, Joseph 3-24-2021	148	25	149	3	Sage Initial Designations
Forehand, Joseph 3-24-2021	150	25	151	17	Sage Initial Designations
Forehand, Joseph 3-24-2021	152	13	152	21	Sage Initial Designations
Forehand, Joseph 3-24-2021	153	23	154	4	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Gohde, John 2023-02-08	4	10	4	13	Sage Initial Designations
Gohde, John 2023-02-08	4	13	4	14	Sage Initial Designations
Gohde, John 2023-02-08	7	20	8	6	Sage Initial Designations
Gohde, John 2023-02-08	8	17	8	21	Sage Initial Designations
Gohde, John 2023-02-08	8	22	8	24	Sage Initial Designations
Gohde, John 2023-02-08	9	13	9	16	Sage Initial Designations
Gohde, John 2023-02-08	10	14	10	21	Sage Initial Designations
Gohde, John 2023-02-08	12	8	12	14	Sage Initial Designations
Gohde, John 2023-02-08	12	15	12	24	Sage Initial Designations
Gohde, John 2023-02-08	16	16	16	23	Sage Initial Designations
Gohde, John 2023-02-08	18	7	18	14	Sage Initial Designations
Gohde, John 2023-02-08	20	5	20	13	Sage Initial Designations
Gohde, John 2023-02-08	21	5	21	20	Sage Initial Designations
Gohde, John 2023-02-08	23	14	24	1	Sage Initial Designations
Gohde, John 2023-02-08	28	22	29	3	Sage Initial Designations
Gohde, John 2023-02-08	30	1	30	11	Sage Initial Designations
Gohde, John 2023-02-08	30	21	30	23	Sage Initial Designations
Gohde, John 2023-02-08	31	6	31	7	Sage Initial Designations
Gohde, John 2023-02-08	31	10	31	11	Sage Initial Designations
Gohde, John 2023-02-08	35	6	35	10	Sage Initial Designations
Gohde, John 2023-02-08	35	11	35	19	Sage Initial Designations
Gohde, John 2023-02-08	36	18	36	23	Sage Initial Designations
Gohde, John 2023-02-08	37	9	37	12	Sage Initial Designations
Gohde, John 2023-02-08	37	15	37	15	Sage Initial Designations
Gohde, John 2023-02-08	37	17	38	1	Sage Initial Designations
Gohde, John 2023-02-08	38	11	38	24	Sage Initial Designations
Gohde, John 2023-02-08	49	16	49	19	Sage Initial Designations
Gohde, John 2023-02-08	49	24	50	4	Sage Initial Designations
Gohde, John 2023-02-08	51	11	51	17	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
19-1508 - Vol 02, J. Gohde	359	13	359	20	Sage Initial Designations
19-1508 - Vol 02, J. Gohde	369	16	371	19	Sage Initial Designations
19-1508 - Vol 02, J. Gohde	371	23	373	24	Sage Initial Designations
19-1508 - Vol 02, J. Gohde	374	3	375	19	Sage Initial Designations
19-1508 - Vol 02, J. Gohde	375	24	376	10	Sage Initial Designations
19-1508 - Vol 02, J. Gohde	376	14	377	4	Sage Initial Designations
19-1508 - Vol 02, J. Gohde	377	8	378	11	Sage Initial Designations
19-1508 - Vol 02, J. Gohde	378	15	379	4	Sage Initial Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Gohde, John 2021-03-26	4	11	4	14	Sage Initial Designations
Gohde, John 2021-03-26	8	15	8	20	Sage Initial Designations
Gohde, John 2021-03-26	8	21	8	24	Sage Initial Designations
Gohde, John 2021-03-26	9	9	9	11	Sage Initial Designations
Gohde, John 2021-03-26	17	8	17	12	Sage Initial Designations
Gohde, John 2021-03-26	17	18	17	23	Sage Initial Designations
Gohde, John 2021-03-26	18	8	18	20	Sage Initial Designations
Gohde, John 2021-03-26	20	9	20	15	Sage Initial Designations
Gohde, John 2021-03-26	20	19	21	11	Sage Initial Designations
Gohde, John 2021-03-26	21	15	22	1	Sage Initial Designations
Gohde, John 2021-03-26	22	7	23	5	Sage Initial Designations
Gohde, John 2021-03-26	23	9	24	3	Sage Initial Designations
Gohde, John 2021-03-26	24	7	24	16	Sage Initial Designations
Gohde, John 2021-03-26	31	8	31	11	Sage Initial Designations
Gohde, John 2021-03-26	31	15	31	17	Sage Initial Designations
Gohde, John 2021-03-26	32	20	33	1	Sage Initial Designations
Gohde, John 2021-03-26	33	23	34	1	Sage Initial Designations
Gohde, John 2021-03-26	34	5	34	6	Sage Initial Designations
Gohde, John 2021-03-26	35	12	35	15	Sage Initial Designations
Gohde, John 2021-03-26	35	18	35	18	Sage Initial Designations
Gohde, John 2021-03-26	35	20	35	22	Sage Initial Designations
Gohde, John 2021-03-26	36	4	36	11	Sage Initial Designations
Gohde, John 2021-03-26	37	9	37	17	Sage Initial Designations
Gohde, John 2021-03-26	38	24	39	6	Sage Initial Designations
Gohde, John 2021-03-26	39	10	39	19	Sage Initial Designations
Gohde, John 2021-03-26	41	3	41	8	Sage Initial Designations
Gohde, John 2021-03-26	41	10	41	13	Sage Initial Designations
Gohde, John 2021-03-26	42	2	42	2	Sage Initial Designations
Gohde, John 2021-03-26	43	11	43	21	Sage Initial Designations
Gohde, John 2021-03-26	43	22	44	2	Sage Initial Designations
Gohde, John 2021-03-26	45	24	46	9	Sage Initial Designations
Gohde, John 2021-03-26	46	12	46	13	Sage Initial Designations
Gohde, John 2021-03-26	46	20	47	8	Sage Initial Designations
Gohde, John 2021-03-26	47	17	47	19	Sage Initial Designations
Gohde, John 2021-03-26	51	12	51	17	Sage Initial Designations
Gohde, John 2021-03-26	58	3	58	18	Sage Initial Designations
Gohde, John 2021-03-26	60	14	60	19	Sage Initial Designations
Gohde, John 2021-03-26	60	24	60	24	Sage Initial Designations
Gohde, John 2021-03-26	61	7	61	21	Sage Initial Designations
Gohde, John 2021-03-26	61	22	62	10	Sage Initial Designations
Gohde, John 2021-03-26	62	14	62	14	Sage Initial Designations
Gohde, John 2021-03-26	63	17	63	19	Sage Initial Designations
Gohde, John 2021-03-26	63	23	64	1	Sage Initial Designations
Gohde, John 2021-03-26	64	22	65	10	Sage Initial Designations
Gohde, John 2021-03-26	68	23	68	24	Sage Initial Designations
Gohde, John 2021-03-26	70	6	70	9	Sage Initial Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Gohde, John 2021-03-26	70	10	70	14	Sage Initial Designations
Gohde, John 2021-03-26	71	12	72	13	Sage Initial Designations
Gohde, John 2021-03-26	73	15	73	21	Sage Initial Designations
Gohde, John 2021-03-26	73	24	74	16	Sage Initial Designations
Gohde, John 2021-03-26	107	20	108	7	Sage Initial Designations
Gohde, John 2021-03-26	141	22	142	3	Sage Initial Designations
Gohde, John 2021-03-26	142	5	142	9	Sage Initial Designations
Gohde, John 2021-03-26	142	10	142	14	Sage Initial Designations
Gohde, John 2021-03-26	142	15	142	20	Sage Initial Designations
Gohde, John 2021-03-26	142	21	143	2	Sage Initial Designations
Gohde, John 2021-03-26	143	4	143	16	Sage Initial Designations
Gohde, John 2021-03-26	143	17	143	24	Sage Initial Designations
Gohde, John 2021-03-26	144	1	144	13	Sage Initial Designations
Gohde, John 2021-03-26	144	17	144	19	Sage Initial Designations
Gohde, John 2021-03-26	145	1	145	6	Sage Initial Designations
Gohde, John 2021-03-26	145	7	145	23	Sage Initial Designations
Gohde, John 2021-03-26	146	7	146	12	Sage Initial Designations
Gohde, John 2021-03-26	146	16	146	22	Sage Initial Designations
Gohde, John 2021-03-26	147	3	148	1	Sage Initial Designations
Gohde, John 2021-03-26	148	19	148	24	Sage Initial Designations
Gohde, John 2021-03-26	149	1	149	5	Sage Initial Designations
Gohde, John 2021-03-26	150	13	150	18	Sage Initial Designations
Gohde, John 2021-03-26	151	1	151	7	Sage Initial Designations
Gohde, John 2021-03-26	151	11	151	21	Sage Initial Designations
Gohde, John 2021-03-26	153	12	153	17	Sage Initial Designations
Gohde, John 2021-03-26	153	19	154	12	Sage Initial Designations
Gohde, John 2021-03-26	154	13	154	21	Sage Initial Designations
Gohde, John 2021-03-26	155	11	156	1	Sage Initial Designations
Gohde, John 2021-03-26	156	4	156	5	Sage Initial Designations
Gohde, John 2021-03-26	156	9	156	14	Sage Initial Designations
Gohde, John 2021-03-26	163	8	163	13	Sage Initial Designations
Gohde, John 2021-03-26	164	5	164	16	Sage Initial Designations
Gohde, John 2021-03-26	167	2	167	19	Sage Initial Designations
Gohde, John 2021-03-26	167	20	168	9	Sage Initial Designations
Gohde, John 2021-03-26	168	22	169	4	Sage Initial Designations
Gohde, John 2021-03-26	175	10	175	14	Sage Initial Designations
Gohde, John 2021-03-26	175	17	175	20	Sage Initial Designations
Gohde, John 2021-03-26	175	22	177	3	Sage Initial Designations
Gohde, John 2021-03-26	177	4	177	18	Sage Initial Designations
Gohde, John 2021-03-26	177	20	178	2	Sage Initial Designations
Gohde, John 2021-03-26	178	5	178	6	Sage Initial Designations
Gohde, John 2021-03-26	178	18	179	17	Sage Initial Designations
Gohde, John 2021-03-26	179	18	179	23	Sage Initial Designations
Gohde, John 2021-03-26	180	2	180	6	Sage Initial Designations
Gohde, John 2021-03-26	180	8	180	10	Sage Initial Designations
Gohde, John 2021-03-26	180	18	181	6	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Gohde, John 2021-03-26	181	12	181	22	Sage Initial Designations
Gohde, John 2021-03-26	183	23	184	16	Sage Initial Designations
Gohde, John 2021-03-26	184	17	185	1	Sage Initial Designations
Gohde, John 2021-03-26	185	2	185	7	Sage Initial Designations
Gohde, John 2021-03-26	185	10	185	16	Sage Initial Designations
Gohde, John 2021-03-26	185	17	186	3	Sage Initial Designations
Gohde, John 2021-03-26	186	16	186	24	Sage Initial Designations
Gohde, John 2021-03-26	187	12	187	15	Sage Initial Designations
Gohde, John 2021-03-26	187	18	187	21	Sage Initial Designations
Gohde, John 2021-03-26	189	14	189	20	Sage Initial Designations
Gohde, John 2021-03-26	190	11	190	15	Sage Initial Designations
Gohde, John 2021-03-26	190	16	190	22	Sage Initial Designations
Gohde, John 2021-03-26	191	21	192	1	Sage Initial Designations
Gohde, John 2021-03-26	193	7	193	10	Sage Initial Designations
Gohde, John 2021-03-26	193	13	193	16	Sage Initial Designations
Gohde, John 2021-03-26	193	17	194	1	Sage Initial Designations
Gohde, John 2021-03-26	194	4	194	5	Sage Initial Designations
Gohde, John 2021-03-26	194	7	194	13	Sage Initial Designations
Gohde, John 2021-03-26	194	16	194	24	Sage Initial Designations
Gohde, John 2021-03-26	195	3	195	12	Sage Initial Designations
Gohde, John 2021-03-26	196	13	197	6	Sage Initial Designations
Gohde, John 2021-03-26	197	9	197	12	Sage Initial Designations
Gohde, John 2021-03-26	207	16	207	21	Sage Initial Designations
Gohde, John 2021-03-26	210	11	210	15	Sage Initial Designations
Gohde, John 2021-03-26	210	17	210	22	Sage Initial Designations
Gohde, John 2021-03-26	210	23	210	24	Sage Initial Designations
Gohde, John 2021-03-26	211	10	211	14	Sage Initial Designations
Gohde, John 2021-03-26	214	7	214	10	Sage Initial Designations
Gohde, John 2021-03-26	214	12	214	14	Sage Initial Designations
Gohde, John 2021-03-26	215	20	215	23	Sage Initial Designations
Gohde, John 2021-03-26	216	3	216	11	Sage Initial Designations
Gohde, John 2021-03-26	216	14	216	14	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Notes	Issues
Hanson, Robin 2023-11-06	7	22	7	24		Sage Initial Designations
Hanson, Robin 2023-11-06	13	8	13	11		Sage Initial Designations
Hanson, Robin 2023-11-06	13	12	13	16		Sage Initial Designations
Hanson, Robin 2023-11-06	13	17	14	2		Sage Initial Designations
Hanson, Robin 2023-11-06	14	3	14	18		Sage Initial Designations
Hanson, Robin 2023-11-06	14	25	15	3		Sage Initial Designations
Hanson, Robin 2023-11-06	15	6	15	13		Sage Initial Designations
Hanson, Robin 2023-11-06	15	16	15	20		Sage Initial Designations
Hanson, Robin 2023-11-06	16	2	16	3		Sage Initial Designations
Hanson, Robin 2023-11-06	16	7	16	10		Sage Initial Designations
Hanson, Robin 2023-11-06	16	23	17	4		Sage Initial Designations
Hanson, Robin 2023-11-06	17	9	17	11		Sage Initial Designations
Hanson, Robin 2023-11-06	17	17	17	24		Sage Initial Designations
Hanson, Robin 2023-11-06	19	1	19	5		Sage Initial Designations
Hanson, Robin 2023-11-06	19	14	19	16		Sage Initial Designations
Hanson, Robin 2023-11-06	19	18	19	18		Sage Initial Designations
Hanson, Robin 2023-11-06	20	6	20	11		Sage Initial Designations
Hanson, Robin 2023-11-06	20	19	20	21		Sage Initial Designations
Hanson, Robin 2023-11-06	21	15	22	1		Sage Initial Designations
Hanson, Robin 2023-11-06	22	6	22	6		Sage Initial Designations
Hanson, Robin 2023-11-06	23	2	23	19		Sage Initial Designations
Hanson, Robin 2023-11-06	30	23	31	14		Sage Initial Designations
Hanson, Robin 2023-11-06	31	24	32	1		Sage Initial Designations
Hanson, Robin 2023-11-06	32	6	32	7		Sage Initial Designations
Hanson, Robin 2023-11-06	32	9	32	14		Sage Initial Designations
Hanson, Robin 2023-11-06	33	22	33	25		Sage Initial Designations
Hanson, Robin 2023-11-06	34	2	34	5		Sage Initial Designations
Hanson, Robin 2023-11-06	34	13	35	9		Sage Initial Designations
Hanson, Robin 2023-11-06	35	17	35	19		Sage Initial Designations
Hanson, Robin 2023-11-06	35	21	35	24		Sage Initial Designations
Hanson, Robin 2023-11-06	36	24	37	10		Sage Initial Designations
Hanson, Robin 2023-11-06	37	12	37	12		Sage Initial Designations
Hanson, Robin 2023-11-06	37	23	37	25		Sage Initial Designations
Hanson, Robin 2023-11-06	38	3	38	21		Sage Initial Designations
Hanson, Robin 2023-11-06	39	8	39	19		Sage Initial Designations
Hanson, Robin 2023-11-06	39	22	40	1		Sage Initial Designations
Hanson, Robin 2023-11-06	40	11	40	13		Sage Initial Designations
Hanson, Robin 2023-11-06	40	16	40	17		Sage Initial Designations
Hanson, Robin 2023-11-06	41	21	42	1		Sage Initial Designations
Hanson, Robin 2023-11-06	42	4	42	8		Sage Initial Designations
Hanson, Robin 2023-11-06	42	10	42	11		Sage Initial Designations
Hanson, Robin 2023-11-06	42	13	42	19		Sage Initial Designations
Hanson, Robin 2023-11-06	43	3	43	17		Sage Initial Designations
Hanson, Robin 2023-11-06	43	18	43	21		Sage Initial Designations
Hanson, Robin 2023-11-06	43	23	43	24		Sage Initial Designations
Hanson, Robin 2023-11-06	44	10	44	13		Sage Initial Designations
Hanson, Robin 2023-11-06	45	15	45	24		Sage Initial Designations
Hanson, Robin 2023-11-06	46	14	46	17		Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Notes	Issues
Hanson, Robin 2023-11-06	47	4	47	15		Sage Initial Designations
Hanson, Robin 2023-11-06	47	16	48	6		Sage Initial Designations
Hanson, Robin 2023-11-06	48	18	49	8		Sage Initial Designations
Hanson, Robin 2023-11-06	49	9	49	15		Sage Initial Designations
Hanson, Robin 2023-11-06	49	18	49	24		Sage Initial Designations
Hanson, Robin 2023-11-06	51	13	51	20		Sage Initial Designations
Hanson, Robin 2023-11-06	51	24	52	4		Sage Initial Designations
Hanson, Robin 2023-11-06	52	7	52	13		Sage Initial Designations
Hanson, Robin 2023-11-06	52	14	52	15		Sage Initial Designations
Hanson, Robin 2023-11-06	52	17	52	23		Sage Initial Designations
Hanson, Robin 2023-11-06	53	7	53	8		Sage Initial Designations
Hanson, Robin 2023-11-06	53	19	54	1		Sage Initial Designations
Hanson, Robin 2023-11-06	54	4	54	13		Sage Initial Designations
Hanson, Robin 2023-11-06	54	15	55	4		Sage Initial Designations
Hanson, Robin 2023-11-06	55	5	55	12		Sage Initial Designations
Hanson, Robin 2023-11-06	55	17	55	22		Sage Initial Designations
Hanson, Robin 2023-11-06	56	22	57	5		Sage Initial Designations
Hanson, Robin 2023-11-06	57	7	57	15		Sage Initial Designations
Hanson, Robin 2023-11-06	58	3	58	8		Sage Initial Designations
Hanson, Robin 2023-11-06	58	14	58	15		Sage Initial Designations
Hanson, Robin 2023-11-06	58	18	58	22		Sage Initial Designations
Hanson, Robin 2023-11-06	59	5	59	9		Sage Initial Designations
Hanson, Robin 2023-11-06	59	12	59	12		Sage Initial Designations
Hanson, Robin 2023-11-06	59	14	60	4		Sage Initial Designations
Hanson, Robin 2023-11-06	60	5	60	12		Sage Initial Designations
Hanson, Robin 2023-11-06	60	15	60	20		Sage Initial Designations
Hanson, Robin 2023-11-06	60	24	61	4		Sage Initial Designations
Hanson, Robin 2023-11-06	61	16	61	17		Sage Initial Designations
Hanson, Robin 2023-11-06	62	1	62	4		Sage Initial Designations
Hanson, Robin 2023-11-06	62	15	62	17		Sage Initial Designations
Hanson, Robin 2023-11-06	62	20	62	21		Sage Initial Designations
Hanson, Robin 2023-11-06	62	23	63	3		Sage Initial Designations
Hanson, Robin 2023-11-06	63	5	63	7		Sage Initial Designations
Hanson, Robin 2023-11-06	63	9	63	11		Sage Initial Designations
Hanson, Robin 2023-11-06	63	12	63	14		Sage Initial Designations
Hanson, Robin 2023-11-06	63	20	64	2		Sage Initial Designations
Hanson, Robin 2023-11-06	64	7	64	12		Sage Initial Designations
Hanson, Robin 2023-11-06	64	16	64	18		Sage Initial Designations
Hanson, Robin 2023-11-06	64	19	64	22		Sage Initial Designations
Hanson, Robin 2023-11-06	65	3	65	11		Sage Initial Designations
Hanson, Robin 2023-11-06	65	21	66	6		Sage Initial Designations
Hanson, Robin 2023-11-06	66	10	66	12		Sage Initial Designations
Hanson, Robin 2023-11-06	66	14	66	15		Sage Initial Designations
Hanson, Robin 2023-11-06	66	18	66	19		Sage Initial Designations
Hanson, Robin 2023-11-06	66	21	67	1		Sage Initial Designations
Hanson, Robin 2023-11-06	67	2	67	10		Sage Initial Designations
Hanson, Robin 2023-11-06	67	17	67	21		Sage Initial Designations
Hanson, Robin 2023-11-06	68	1	68	6		Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Notes	Issues
Hanson, Robin 2023-11-06	68	9	68	15		Sage Initial Designations
Hanson, Robin 2023-11-06	68	17	68	18		Sage Initial Designations
Hanson, Robin 2023-11-06	69	4	69	7		Sage Initial Designations
Hanson, Robin 2023-11-06	69	9	69	9		Sage Initial Designations
Hanson, Robin 2023-11-06	73	6	73	8		Sage Initial Designations
Hanson, Robin 2023-11-06	73	13	73	18		Sage Initial Designations
Hanson, Robin 2023-11-06	73	19	74	3		Sage Initial Designations
Hanson, Robin 2023-11-06	74	4	74	6		Sage Initial Designations
Hanson, Robin 2023-11-06	74	9	74	12		Sage Initial Designations
Hanson, Robin 2023-11-06	74	14	74	22		Sage Initial Designations
Hanson, Robin 2023-11-06	75	1	75	3		Sage Initial Designations
Hanson, Robin 2023-11-06	75	5	75	6		Sage Initial Designations
Hanson, Robin 2023-11-06	75	8	75	12		Sage Initial Designations
Hanson, Robin 2023-11-06	75	24	76	1		Sage Initial Designations
Hanson, Robin 2023-11-06	76	4	76	18		Sage Initial Designations
Hanson, Robin 2023-11-06	76	21	76	25		Sage Initial Designations
Hanson, Robin 2023-11-06	77	15	77	16		Sage Initial Designations
Hanson, Robin 2023-11-06	77	20	77	23		Sage Initial Designations
Hanson, Robin 2023-11-06	78	6	78	13		Sage Initial Designations
Hanson, Robin 2023-11-06	78	14	78	17		Sage Initial Designations
Hanson, Robin 2023-11-06	78	18	79	3		Sage Initial Designations
Hanson, Robin 2023-11-06	79	6	79	7		Sage Initial Designations
Hanson, Robin 2023-11-06	79	9	79	12		Sage Initial Designations
Hanson, Robin 2023-11-06	79	15	79	19		Sage Initial Designations
Hanson, Robin 2023-11-06	79	21	79	23		Sage Initial Designations
Hanson, Robin 2023-11-06	80	1	80	2		Sage Initial Designations
Hanson, Robin 2023-11-06	84	25	85	9		Sage Initial Designations
Hanson, Robin 2023-11-06	85	15	85	18		Sage Initial Designations
Hanson, Robin 2023-11-06	85	22	86	3		Sage Initial Designations
Hanson, Robin 2023-11-06	87	6	87	13		Sage Initial Designations
Hanson, Robin 2023-11-06	87	16	87	23		Sage Initial Designations
Hanson, Robin 2023-11-06	87	25	88	3		Sage Initial Designations
Hanson, Robin 2023-11-06	88	6	88	11		Sage Initial Designations
Hanson, Robin 2023-11-06	89	5	89	18		Sage Initial Designations
Hanson, Robin 2023-11-06	89	19	90	2		Sage Initial Designations
Hanson, Robin 2023-11-06	92	7	92	10		Sage Initial Designations
Hanson, Robin 2023-11-06	92	13	92	17		Sage Initial Designations
Hanson, Robin 2023-11-06	92	19	92	22		Sage Initial Designations
Hanson, Robin 2023-11-06	98	24	99	15		Sage Initial Designations
Hanson, Robin 2023-11-06	100	4	100	6		Sage Initial Designations
Hanson, Robin 2023-11-06	100	9	100	14		Sage Initial Designations
Hanson, Robin 2023-11-06	100	18	100	23		Sage Initial Designations
Hanson, Robin 2023-11-06	101	2	101	7		Sage Initial Designations
Hanson, Robin 2023-11-06	101	11	101	22		Sage Initial Designations
Hanson, Robin 2023-11-06	101	23	101	24		Sage Initial Designations
Hanson, Robin 2023-11-06	102	4	102	15		Sage Initial Designations
Hanson, Robin 2023-11-06	102	20	103	6		Sage Initial Designations
Hanson, Robin 2023-11-06	103	9	103	13		Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Notes	Issues
Hanson, Robin 2023-11-06	104	2	104	15		Sage Initial Designations
Hanson, Robin 2023-11-06	104	19	104	20		Sage Initial Designations
Hanson, Robin 2023-11-06	104	23	104	25		Sage Initial Designations
Hanson, Robin 2023-11-06	108	13	109	2		Sage Initial Designations
Hanson, Robin 2023-11-06	109	5	109	11		Sage Initial Designations
Hanson, Robin 2023-11-06	109	15	109	23		Sage Initial Designations
Hanson, Robin 2023-11-06	109	25	110	4		Sage Initial Designations
Hanson, Robin 2023-11-06	110	8	111	7		Sage Initial Designations
Hanson, Robin 2023-11-06	111	10	111	19		Sage Initial Designations
Hanson, Robin 2023-11-06	111	22	112	2		Sage Initial Designations
Hanson, Robin 2023-11-06	113	1	113	6		Sage Initial Designations
Hanson, Robin 2023-11-06	113	9	113	21		Sage Initial Designations
Hanson, Robin 2023-11-06	114	12	114	13		Sage Initial Designations
Hanson, Robin 2023-11-06	114	16	114	20		Sage Initial Designations
Hanson, Robin 2023-11-06	115	21	116	4		Sage Initial Designations
Hanson, Robin 2023-11-06	116	8	116	13		Sage Initial Designations
Hanson, Robin 2023-11-06	116	17	116	22		Sage Initial Designations
Hanson, Robin 2023-11-06	116	23	116	25		Sage Initial Designations
Hanson, Robin 2023-11-06	117	2	118	2		Sage Initial Designations
Hanson, Robin 2023-11-06	120	2	120	7		Sage Initial Designations
Hanson, Robin 2023-11-06	120	11	120	16		Sage Initial Designations
Hanson, Robin 2023-11-06	120	20	121	3		Sage Initial Designations
Hanson, Robin 2023-11-06	121	7	121	13		Sage Initial Designations
Hanson, Robin 2023-11-06	121	17	121	22		Sage Initial Designations
Hanson, Robin 2023-11-06	122	2	122	14		Sage Initial Designations
Hanson, Robin 2023-11-06	122	17	123	5		Sage Initial Designations
Hanson, Robin 2023-11-06	123	6	123	12		Sage Initial Designations
Hanson, Robin 2023-11-06	124	2	124	7		Sage Initial Designations
Hanson, Robin 2023-11-06	124	11	124	16		Sage Initial Designations
Hanson, Robin 2023-11-06	126	2	126	17		Sage Initial Designations
Hanson, Robin 2023-11-06	126	18	126	18		Sage Initial Designations
Hanson, Robin 2023-11-06	127	4	127	20		Sage Initial Designations
Hanson, Robin 2023-11-06	128	6	128	17		Sage Initial Designations
Hanson, Robin 2023-11-06	128	20	128	24		Sage Initial Designations
Hanson, Robin 2023-11-06	129	2	129	5		Sage Initial Designations
Hanson, Robin 2023-11-06	129	21	130	22		Sage Initial Designations
Hanson, Robin 2023-11-06	131	4	131	8		Sage Initial Designations
Hanson, Robin 2023-11-06	131	13	131	17		Sage Initial Designations
Hanson, Robin 2023-11-06	132	13	132	17		Sage Initial Designations
Hanson, Robin 2023-11-06	132	21	134	6		Sage Initial Designations
Hanson, Robin 2023-11-06	134	21	135	11		Sage Initial Designations
Hanson, Robin 2023-11-06	135	16	135	24		Sage Initial Designations
Hanson, Robin 2023-11-06	136	2	136	4		Sage Initial Designations
Hanson, Robin 2023-11-06	138	2	139	2		Sage Initial Designations
Hanson, Robin 2023-11-06	139	4	139	14		Sage Initial Designations
Hanson, Robin 2023-11-06	139	16	139	20		Sage Initial Designations
Hanson, Robin 2023-11-06	139	23	140	12		Sage Initial Designations
Hanson, Robin 2023-11-06	140	14	140	22		Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Notes	Issues
Hanson, Robin 2023-11-06	141	2	141	9		Sage Initial Designations
Hanson, Robin 2023-11-06	142	11	142	22		Sage Initial Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Harvie, Mark 2021-04-19	4	20	4	24	Sage Initial Designations
Harvie, Mark 2021-04-19	7	5	7	7	Sage Initial Designations
Harvie, Mark 2021-04-19	7	17	7	24	Sage Initial Designations
Harvie, Mark 2021-04-19	8	16	8	24	Sage Initial Designations
Harvie, Mark 2021-04-19	9	2	9	4	Sage Initial Designations
Harvie, Mark 2021-04-19	9	7	9	12	Sage Initial Designations
Harvie, Mark 2021-04-19	9	16	10	10	Sage Initial Designations
Harvie, Mark 2021-04-19	10	23	12	10	Sage Initial Designations
Harvie, Mark 2021-04-19	12	20	12	24	Sage Initial Designations
Harvie, Mark 2021-04-19	13	3	13	8	Sage Initial Designations
Harvie, Mark 2021-04-19	13	12	13	23	Sage Initial Designations
Harvie, Mark 2021-04-19	14	1	14	22	Sage Initial Designations
Harvie, Mark 2021-04-19	15	7	16	4	Sage Initial Designations
Harvie, Mark 2021-04-19	16	7	16	7	Sage Initial Designations
Harvie, Mark 2021-04-19	16	13	16	16	Sage Initial Designations
Harvie, Mark 2021-04-19	16	19	16	22	Sage Initial Designations
Harvie, Mark 2021-04-19	17	3	17	7	Sage Initial Designations
Harvie, Mark 2021-04-19	17	11	18	3	Sage Initial Designations
Harvie, Mark 2021-04-19	18	5	18	22	Sage Initial Designations
Harvie, Mark 2021-04-19	19	5	19	14	Sage Initial Designations
Harvie, Mark 2021-04-19	19	23	20	7	Sage Initial Designations
Harvie, Mark 2021-04-19	20	10	20	14	Sage Initial Designations
Harvie, Mark 2021-04-19	20	16	22	12	Sage Initial Designations
Harvie, Mark 2021-04-19	22	15	23	22	Sage Initial Designations
Harvie, Mark 2021-04-19	24	3	24	7	Sage Initial Designations
Harvie, Mark 2021-04-19	24	9	24	11	Sage Initial Designations
Harvie, Mark 2021-04-19	24	14	24	19	Sage Initial Designations
Harvie, Mark 2021-04-19	25	1	25	2	Sage Initial Designations
Harvie, Mark 2021-04-19	25	4	25	23	Sage Initial Designations
Harvie, Mark 2021-04-19	26	4	26	19	Sage Initial Designations
Harvie, Mark 2021-04-19	26	22	27	10	Sage Initial Designations
Harvie, Mark 2021-04-19	27	13	27	13	Sage Initial Designations
Harvie, Mark 2021-04-19	27	19	29	8	Sage Initial Designations
Harvie, Mark 2021-04-19	29	11	29	12	Sage Initial Designations
Harvie, Mark 2021-04-19	29	14	29	19	Sage Initial Designations
Harvie, Mark 2021-04-19	29	22	29	22	Sage Initial Designations
Harvie, Mark 2021-04-19	30	1	30	2	Sage Initial Designations
Harvie, Mark 2021-04-19	30	4	31	22	Sage Initial Designations
Harvie, Mark 2021-04-19	32	1	32	3	Sage Initial Designations
Harvie, Mark 2021-04-19	32	5	32	8	Sage Initial Designations
Harvie, Mark 2021-04-19	32	11	32	13	Sage Initial Designations
Harvie, Mark 2021-04-19	32	15	32	18	Sage Initial Designations
Harvie, Mark 2021-04-19	32	22	33	12	Sage Initial Designations
Harvie, Mark 2021-04-19	33	15	33	17	Sage Initial Designations
Harvie, Mark 2021-04-19	33	20	35	7	Sage Initial Designations
Harvie, Mark 2021-04-19	35	22	35	24	Sage Initial Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Harvie, Mark 2021-04-19	36	5	36	7	Sage Initial Designations
Harvie, Mark 2021-04-19	36	10	36	10	Sage Initial Designations
Harvie, Mark 2021-04-19	36	12	36	13	Sage Initial Designations
Harvie, Mark 2021-04-19	36	17	36	17	Sage Initial Designations
Harvie, Mark 2021-04-19	36	19	36	21	Sage Initial Designations
Harvie, Mark 2021-04-19	37	1	37	10	Sage Initial Designations
Harvie, Mark 2021-04-19	37	12	37	15	Sage Initial Designations
Harvie, Mark 2021-04-19	37	18	37	19	Sage Initial Designations
Harvie, Mark 2021-04-19	37	21	38	4	Sage Initial Designations
Harvie, Mark 2021-04-19	38	22	38	24	Sage Initial Designations
Harvie, Mark 2021-04-19	39	4	39	4	Sage Initial Designations
Harvie, Mark 2021-04-19	40	13	40	19	Sage Initial Designations
Harvie, Mark 2021-04-19	40	23	41	24	Sage Initial Designations
Harvie, Mark 2021-04-19	43	16	43	24	Sage Initial Designations
Harvie, Mark 2021-04-19	44	8	44	10	Sage Initial Designations
Harvie, Mark 2021-04-19	44	12	44	15	Sage Initial Designations
Harvie, Mark 2021-04-19	44	21	46	3	Sage Initial Designations
Harvie, Mark 2021-04-19	47	8	47	15	Sage Initial Designations
Harvie, Mark 2021-04-19	47	18	47	20	Sage Initial Designations
Harvie, Mark 2021-04-19	47	22	48	1	Sage Initial Designations
Harvie, Mark 2021-04-19	48	14	48	17	Sage Initial Designations
Harvie, Mark 2021-04-19	48	22	48	24	Sage Initial Designations
Harvie, Mark 2021-04-19	49	4	49	5	Sage Initial Designations
Harvie, Mark 2021-04-19	49	7	49	9	Sage Initial Designations
Harvie, Mark 2021-04-19	49	13	49	15	Sage Initial Designations
Harvie, Mark 2021-04-19	49	17	49	18	Sage Initial Designations
Harvie, Mark 2021-04-19	49	22	49	23	Sage Initial Designations
Harvie, Mark 2021-04-19	50	1	50	4	Sage Initial Designations
Harvie, Mark 2021-04-19	50	7	50	8	Sage Initial Designations
Harvie, Mark 2021-04-19	50	12	52	1	Sage Initial Designations
Harvie, Mark 2021-04-19	52	8	53	20	Sage Initial Designations
Harvie, Mark 2021-04-19	54	1	54	2	Sage Initial Designations
Harvie, Mark 2021-04-19	54	5	54	7	Sage Initial Designations
Harvie, Mark 2021-04-19	54	18	54	19	Sage Initial Designations
Harvie, Mark 2021-04-19	54	22	54	23	Sage Initial Designations
Harvie, Mark 2021-04-19	55	17	56	24	Sage Initial Designations
Harvie, Mark 2021-04-19	56	2	57	1	Sage Initial Designations
Harvie, Mark 2021-04-19	57	2	57	2	Sage Initial Designations
Harvie, Mark 2021-04-19	57	3	58	12	Sage Initial Designations
Harvie, Mark 2021-04-19	58	15	58	15	Sage Initial Designations
Harvie, Mark 2021-04-19	58	19	58	20	Sage Initial Designations
Harvie, Mark 2021-04-19	58	23	59	4	Sage Initial Designations
Harvie, Mark 2021-04-19	59	9	62	6	Sage Initial Designations
Harvie, Mark 2021-04-19	62	10	63	6	Sage Initial Designations
Harvie, Mark 2021-04-19	63	9	63	14	Sage Initial Designations
Harvie, Mark 2021-04-19	63	17	63	22	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Harvie, Mark 2021-04-19	64	1	64	1	Sage Initial Designations
Harvie, Mark 2021-04-19	64	2	66	19	Sage Initial Designations
Harvie, Mark 2021-04-19	67	1	67	4	Sage Initial Designations
Harvie, Mark 2021-04-19	67	7	67	7	Sage Initial Designations
Harvie, Mark 2021-04-19	67	9	69	5	Sage Initial Designations
Harvie, Mark 2021-04-19	69	1	69	5	Sage Initial Designations
Harvie, Mark 2021-04-19	69	8	69	12	Sage Initial Designations
Harvie, Mark 2021-04-19	69	16	69	16	Sage Initial Designations
Harvie, Mark 2021-04-19	69	20	70	11	Sage Initial Designations
Harvie, Mark 2021-04-19	71	5	71	11	Sage Initial Designations
Harvie, Mark 2021-04-19	72	6	72	10	Sage Initial Designations
Harvie, Mark 2021-04-19	72	14	72	22	Sage Initial Designations
Harvie, Mark 2021-04-19	73	2	73	5	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Jackson, Benjamin 2023-03-02	5	6	5	8	Sage Initial Designations
Jackson, Benjamin 2023-03-02	7	21	7	24	Sage Initial Designations
Jackson, Benjamin 2023-03-02	8	5	8	12	Sage Initial Designations
Jackson, Benjamin 2023-03-02	22	3	22	4	Sage Initial Designations
Jackson, Benjamin 2023-03-02	22	7	22	9	Sage Initial Designations
Jackson, Benjamin 2023-03-02	44	13	44	14	Sage Initial Designations
Jackson, Benjamin 2023-03-02	44	17	44	21	Sage Initial Designations
Jackson, Benjamin 2023-03-02	44	23	45	2	Sage Initial Designations
Jackson, Benjamin 2023-03-02	45	11	45	12	Sage Initial Designations
Jackson, Benjamin 2023-03-02	45	15	45	15	Sage Initial Designations
Jackson, Benjamin 2023-03-02	45	17	45	19	Sage Initial Designations
Jackson, Benjamin 2023-03-02	60	10	60	16	Sage Initial Designations
Jackson, Benjamin 2023-03-02	60	19	60	19	Sage Initial Designations
Jackson, Benjamin 2023-03-02	60	21	61	8	Sage Initial Designations
Jackson, Benjamin 2023-03-02	64	5	64	8	Sage Initial Designations
Jackson, Benjamin 2023-03-02	64	12	64	12	Sage Initial Designations
Jackson, Benjamin 2023-03-02	64	17	65	2	Sage Initial Designations
Jackson, Benjamin 2023-03-02	65	5	65	7	Sage Initial Designations
Jackson, Benjamin 2023-03-02	65	9	65	11	Sage Initial Designations
Jackson, Benjamin 2023-03-02	66	13	66	15	Sage Initial Designations
Jackson, Benjamin 2023-03-02	67	7	67	9	Sage Initial Designations
Jackson, Benjamin 2023-03-02	68	12	68	14	Sage Initial Designations
Jackson, Benjamin 2023-03-02	68	17	68	23	Sage Initial Designations
Jackson, Benjamin 2023-03-02	69	1	69	3	Sage Initial Designations
Jackson, Benjamin 2023-03-02	69	12	69	12	Sage Initial Designations
Jackson, Benjamin 2023-03-02	69	15	69	16	Sage Initial Designations
Jackson, Benjamin 2023-03-02	71	2	71	3	Sage Initial Designations
Jackson, Benjamin 2023-03-02	71	6	71	9	Sage Initial Designations
Jackson, Benjamin 2023-03-02	73	21	73	24	Sage Initial Designations
Jackson, Benjamin 2023-03-02	74	21	74	24	Sage Initial Designations
Jackson, Benjamin 2023-03-02	76	3	76	6	Sage Initial Designations
Jackson, Benjamin 2023-03-02	76	12	76	15	Sage Initial Designations
Jackson, Benjamin 2023-03-02	76	17	76	19	Sage Initial Designations
Jackson, Benjamin 2023-03-02	76	22	76	22	Sage Initial Designations
Jackson, Benjamin 2023-03-02	76	24	77	4	Sage Initial Designations
Jackson, Benjamin 2023-03-02	77	7	77	8	Sage Initial Designations
Jackson, Benjamin 2023-03-02	77	10	77	11	Sage Initial Designations
Jackson, Benjamin 2023-03-02	77	14	77	21	Sage Initial Designations
Jackson, Benjamin 2023-03-02	77	23	77	24	Sage Initial Designations
Jackson, Benjamin 2023-03-02	78	6	78	7	Sage Initial Designations
Jackson, Benjamin 2023-03-02	78	10	78	11	Sage Initial Designations
Jackson, Benjamin 2023-03-02	78	15	78	20	Sage Initial Designations
Jackson, Benjamin 2023-03-02	88	21	88	23	Sage Initial Designations
Jackson, Benjamin 2023-03-02	90	1	90	1	Sage Initial Designations
Jackson, Benjamin 2023-03-02	90	4	90	5	Sage Initial Designations
Jackson, Benjamin 2023-03-02	90	7	90	7	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Jackson, Benjamin 2023-03-02	90	10	90	13	Sage Initial Designations
Jackson, Benjamin 2023-03-02	91	13	92	7	Sage Initial Designations
Jackson, Benjamin 2023-03-02	92	11	92	21	Sage Initial Designations
Jackson, Benjamin 2023-03-02	92	23	93	2	Sage Initial Designations
Jackson, Benjamin 2023-03-02	93	6	93	11	Sage Initial Designations
Jackson, Benjamin 2023-03-02	93	13	93	16	Sage Initial Designations
Jackson, Benjamin 2023-03-02	93	20	93	20	Sage Initial Designations
Jackson, Benjamin 2023-03-02	94	11	94	14	Sage Initial Designations
Jackson, Benjamin 2023-03-02	94	18	94	20	Sage Initial Designations
Jackson, Benjamin 2023-03-02	95	4	95	17	Sage Initial Designations
Jackson, Benjamin 2023-03-02	95	20	95	22	Sage Initial Designations
Jackson, Benjamin 2023-03-02	97	10	97	12	Sage Initial Designations
Jackson, Benjamin 2023-03-02	98	2	98	7	Sage Initial Designations
Jackson, Benjamin 2023-03-02	98	13	98	13	Sage Initial Designations
Jackson, Benjamin 2023-03-02	98	16	98	24	Sage Initial Designations
Jackson, Benjamin 2023-03-02	99	2	99	4	Sage Initial Designations
Jackson, Benjamin 2023-03-02	99	8	99	8	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Jackson, Michael 2023-03-16	9	15	9	19	Sage Initial Designations
Jackson, Michael 2023-03-16	14	11	14	24	Sage Initial Designations
Jackson, Michael 2023-03-16	15	11	15	12	Sage Initial Designations
Jackson, Michael 2023-03-16	17	20	17	22	Sage Initial Designations
Jackson, Michael 2023-03-16	20	10	20	15	Sage Initial Designations
Jackson, Michael 2023-03-16	20	18	21	6	Sage Initial Designations
Jackson, Michael 2023-03-16	21	8	21	10	Sage Initial Designations
Jackson, Michael 2023-03-16	21	12	21	21	Sage Initial Designations
Jackson, Michael 2023-03-16	28	11	28	12	Sage Initial Designations
Jackson, Michael 2023-03-16	28	14	28	17	Sage Initial Designations
Jackson, Michael 2023-03-16	28	19	28	19	Sage Initial Designations
Jackson, Michael 2023-03-16	41	3	41	4	Sage Initial Designations
Jackson, Michael 2023-03-16	41	6	41	11	Sage Initial Designations
Jackson, Michael 2023-03-16	41	14	41	20	Sage Initial Designations
Jackson, Michael 2023-03-16	42	2	42	10	Sage Initial Designations
Jackson, Michael 2023-03-16	42	12	42	15	Sage Initial Designations
Jackson, Michael 2023-03-16	42	18	42	19	Sage Initial Designations
Jackson, Michael 2023-03-16	42	21	42	25	Sage Initial Designations
Jackson, Michael 2023-03-16	45	24	45	25	Sage Initial Designations
Jackson, Michael 2023-03-16	46	2	46	2	Sage Initial Designations
Jackson, Michael 2023-03-16	47	23	48	15	Sage Initial Designations
Jackson, Michael 2023-03-16	48	17	48	23	Sage Initial Designations
Jackson, Michael 2023-03-16	49	1	49	4	Sage Initial Designations
Jackson, Michael 2023-03-16	49	7	49	7	Sage Initial Designations
Jackson, Michael 2023-03-16	51	6	51	21	Sage Initial Designations
Jackson, Michael 2023-03-16	51	23	52	2	Sage Initial Designations
Jackson, Michael 2023-03-16	52	4	52	8	Sage Initial Designations
Jackson, Michael 2023-03-16	52	10	52	11	Sage Initial Designations
Jackson, Michael 2023-03-16	53	2	53	7	Sage Initial Designations
Jackson, Michael 2023-03-16	53	9	53	10	Sage Initial Designations
Jackson, Michael 2023-03-16	54	24	55	9	Sage Initial Designations
Jackson, Michael 2023-03-16	55	11	55	13	Sage Initial Designations
Jackson, Michael 2023-03-16	57	12	57	22	Sage Initial Designations
Jackson, Michael 2023-03-16	58	2	58	3	Sage Initial Designations
Jackson, Michael 2023-03-16	58	5	58	5	Sage Initial Designations
Jackson, Michael 2023-03-16	59	4	59	17	Sage Initial Designations
Jackson, Michael 2023-03-16	59	19	60	1	Sage Initial Designations
Jackson, Michael 2023-03-16	60	20	61	2	Sage Initial Designations
Jackson, Michael 2023-03-16	61	19	61	22	Sage Initial Designations
Jackson, Michael 2023-03-16	61	24	61	25	Sage Initial Designations
Jackson, Michael 2023-03-16	66	21	67	9	Sage Initial Designations
Jackson, Michael 2023-03-16	67	12	67	16	Sage Initial Designations
Jackson, Michael 2023-03-16	67	18	67	18	Sage Initial Designations
Jackson, Michael 2023-03-16	67	20	67	21	Sage Initial Designations
Jackson, Michael 2023-03-16	68	6	68	7	Sage Initial Designations
Jackson, Michael 2023-03-16	68	9	68	9	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Jackson, Michael 2023-03-16	68	11	68	16	Sage Initial Designations
Jackson, Michael 2023-03-16	70	13	70	21	Sage Initial Designations
Jackson, Michael 2023-03-16	71	4	71	10	Sage Initial Designations
Jackson, Michael 2023-03-16	71	13	71	16	Sage Initial Designations
Jackson, Michael 2023-03-16	71	20	71	21	Sage Initial Designations
Jackson, Michael 2023-03-16	71	23	71	24	Sage Initial Designations
Jackson, Michael 2023-03-16	72	2	72	4	Sage Initial Designations
Jackson, Michael 2023-03-16	72	5	72	14	Sage Initial Designations
Jackson, Michael 2023-03-16	72	16	73	4	Sage Initial Designations
Jackson, Michael 2023-03-16	73	7	73	8	Sage Initial Designations
Jackson, Michael 2023-03-16	79	14	79	25	Sage Initial Designations
Jackson, Michael 2023-03-16	80	2	80	21	Sage Initial Designations
Jackson, Michael 2023-03-16	80	23	81	4	Sage Initial Designations
Jackson, Michael 2023-03-16	81	6	81	7	Sage Initial Designations
Jackson, Michael 2023-03-16	81	9	81	12	Sage Initial Designations
Jackson, Michael 2023-03-16	81	14	81	18	Sage Initial Designations
Jackson, Michael 2023-03-16	81	23	82	7	Sage Initial Designations
Jackson, Michael 2023-03-16	86	21	87	6	Sage Initial Designations
Jackson, Michael 2023-03-16	99	12	99	13	Sage Initial Designations
Jackson, Michael 2023-03-16	99	15	99	15	Sage Initial Designations
Jackson, Michael 2023-03-16	99	17	99	20	Sage Initial Designations
Jackson, Michael 2023-03-16	99	23	99	25	Sage Initial Designations
Jackson, Michael 2023-03-16	109	14	109	23	Sage Initial Designations
Jackson, Michael 2023-03-16	109	25	110	15	Sage Initial Designations
Jackson, Michael 2023-03-16	110	17	110	18	Sage Initial Designations
Jackson, Michael 2023-03-16	110	20	110	21	Sage Initial Designations
Jackson, Michael 2023-03-16	110	23	110	23	Sage Initial Designations
Jackson, Michael 2023-03-16	112	17	112	19	Sage Initial Designations
Jackson, Michael 2023-03-16	112	21	112	21	Sage Initial Designations
Jackson, Michael 2023-03-16	112	23	113	1	Sage Initial Designations
Jackson, Michael 2023-03-16	113	22	113	22	Sage Initial Designations
Jackson, Michael 2023-03-16	113	24	113	24	Sage Initial Designations
Jackson, Michael 2023-03-16	116	2	116	4	Sage Initial Designations
Jackson, Michael 2023-03-16	116	7	116	8	Sage Initial Designations
Jackson, Michael 2023-03-16	116	10	116	15	Sage Initial Designations
Jackson, Michael 2023-03-16	116	17	116	17	Sage Initial Designations
Jackson, Michael 2023-03-16	127	4	127	6	Sage Initial Designations
Jackson, Michael 2023-03-16	127	10	127	18	Sage Initial Designations
Jackson, Michael 2023-03-16	127	21	128	10	Sage Initial Designations
Jackson, Michael 2023-03-16	128	12	128	19	Sage Initial Designations
Jackson, Michael 2023-03-16	128	21	129	1	Sage Initial Designations
Jackson, Michael 2023-03-16	129	11	129	15	Sage Initial Designations
Jackson, Michael 2023-03-16	129	17	129	23	Sage Initial Designations
Jackson, Michael 2023-03-16	130	1	130	3	Sage Initial Designations
Jackson, Michael 2023-03-16	130	5	130	5	Sage Initial Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Mann, Gregory 2021-03-31	4	12	4	15	Sage Initial Designations
Mann, Gregory 2021-03-31	8	14	8	22	Sage Initial Designations
Mann, Gregory 2021-03-31	9	7	9	11	Sage Initial Designations
Mann, Gregory 2021-03-31	9	20	9	23	Sage Initial Designations
Mann, Gregory 2021-03-31	17	2	17	7	Sage Initial Designations
Mann, Gregory 2021-03-31	18	21	19	4	Sage Initial Designations
Mann, Gregory 2021-03-31	19	7	19	7	Sage Initial Designations
Mann, Gregory 2021-03-31	19	9	20	4	Sage Initial Designations
Mann, Gregory 2021-03-31	20	8	20	14	Sage Initial Designations
Mann, Gregory 2021-03-31	20	19	20	20	Sage Initial Designations
Mann, Gregory 2021-03-31	20	23	20	23	Sage Initial Designations
Mann, Gregory 2021-03-31	21	4	21	8	Sage Initial Designations
Mann, Gregory 2021-03-31	21	11	21	11	Sage Initial Designations
Mann, Gregory 2021-03-31	21	20	22	3	Sage Initial Designations
Mann, Gregory 2021-03-31	22	6	22	6	Sage Initial Designations
Mann, Gregory 2021-03-31	140	14	141	6	Sage Initial Designations
Mann, Gregory 2021-03-31	142	7	143	5	Sage Initial Designations
Mann, Gregory 2021-03-31	143	15	143	19	Sage Initial Designations
Mann, Gregory 2021-03-31	144	1	144	5	Sage Initial Designations
Mann, Gregory 2021-03-31	144	11	145	10	Sage Initial Designations
Mann, Gregory 2021-03-31	145	22	146	8	Sage Initial Designations
Mann, Gregory 2021-03-31	146	14	147	8	Sage Initial Designations
Mann, Gregory 2021-03-31	147	16	147	18	Sage Initial Designations
Mann, Gregory 2021-03-31	147	23	150	8	Sage Initial Designations
Mann, Gregory 2021-03-31	150	12	151	12	Sage Initial Designations
Mann, Gregory 2021-03-31	151	16	151	19	Sage Initial Designations
Mann, Gregory 2021-03-31	152	3	152	6	Sage Initial Designations
Mann, Gregory 2021-03-31	152	11	152	12	Sage Initial Designations
Mann, Gregory 2021-03-31	152	15	152	15	Sage Initial Designations
Mann, Gregory 2021-03-31	153	23	154	1	Sage Initial Designations
Mann, Gregory 2021-03-31	154	4	154	4	Sage Initial Designations
Mann, Gregory 2021-03-31	154	6	155	3	Sage Initial Designations
Mann, Gregory 2021-03-31	155	6	155	7	Sage Initial Designations
Mann, Gregory 2021-03-31	156	7	156	24	Sage Initial Designations
Mann, Gregory 2021-03-31	158	19	159	12	Sage Initial Designations
Mann, Gregory 2021-03-31	160	17	160	22	Sage Initial Designations
Mann, Gregory 2021-03-31	161	9	161	16	Sage Initial Designations
Mann, Gregory 2021-03-31	164	13	164	15	Sage Initial Designations
Mann, Gregory 2021-03-31	164	24	165	5	Sage Initial Designations
Mann, Gregory 2021-03-31	165	9	165	16	Sage Initial Designations
Mann, Gregory 2021-03-31	165	19	165	24	Sage Initial Designations
Mann, Gregory 2021-03-31	166	2	166	4	Sage Initial Designations
Mann, Gregory 2021-03-31	166	8	166	9	Sage Initial Designations
Mann, Gregory 2021-03-31	167	24	168	7	Sage Initial Designations
Mann, Gregory 2021-03-31	169	12	169	17	Sage Initial Designations
Mann, Gregory 2021-03-31	170	4	170	6	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Mann, Gregory 2021-03-31	170	23	171	5	Sage Initial Designations
Mann, Gregory 2021-03-31	171	16	172	4	Sage Initial Designations
Mann, Gregory 2021-03-31	172	19	172	24	Sage Initial Designations
Mann, Gregory 2021-03-31	173	2	173	9	Sage Initial Designations
Mann, Gregory 2021-03-31	173	22	174	1	Sage Initial Designations
Mann, Gregory 2021-03-31	174	9	174	13	Sage Initial Designations
Mann, Gregory 2021-03-31	183	1	183	5	Sage Initial Designations
Mann, Gregory 2021-03-31	183	12	183	19	Sage Initial Designations
Mann, Gregory 2021-03-31	184	24	185	10	Sage Initial Designations
Mann, Gregory 2021-03-31	185	13	186	2	Sage Initial Designations
Mann, Gregory 2021-03-31	187	1	187	13	Sage Initial Designations
Mann, Gregory 2021-03-31	187	18	188	8	Sage Initial Designations
Mann, Gregory 2021-03-31	189	8	189	19	Sage Initial Designations
Mann, Gregory 2021-03-31	192	19	192	24	Sage Initial Designations
Mann, Gregory 2021-03-31	195	9	195	11	Sage Initial Designations
Mann, Gregory 2021-03-31	195	24	196	6	Sage Initial Designations
Mann, Gregory 2021-03-31	196	12	197	2	Sage Initial Designations
Mann, Gregory 2021-03-31	198	5	198	17	Sage Initial Designations
Mann, Gregory 2021-03-31	201	5	201	8	Sage Initial Designations
Mann, Gregory 2021-03-31	201	20	202	21	Sage Initial Designations
Mann, Gregory 2021-03-31	204	1	204	12	Sage Initial Designations
Mann, Gregory 2021-03-31	206	16	206	21	Sage Initial Designations
Mann, Gregory 2021-03-31	218	14	218	24	Sage Initial Designations
Mann, Gregory 2021-03-31	221	11	221	20	Sage Initial Designations
Mann, Gregory 2021-03-31	229	5	229	7	Sage Initial Designations
Mann, Gregory 2021-03-31	229	15	229	16	Sage Initial Designations
Mann, Gregory 2021-03-31	232	9	232	16	Sage Initial Designations
Mann, Gregory 2021-03-31	232	19	232	24	Sage Initial Designations
Mann, Gregory 2021-03-31	233	4	233	6	Sage Initial Designations
Mann, Gregory 2021-03-31	237	8	237	11	Sage Initial Designations
Mann, Gregory 2021-03-31	240	11	240	14	Sage Initial Designations
Mann, Gregory 2021-03-31	241	11	241	23	Sage Initial Designations
Mann, Gregory 2021-03-31	242	8	243	10	Sage Initial Designations
Mann, Gregory 2021-03-31	244	17	245	5	Sage Initial Designations
Mann, Gregory 2021-03-31	247	5	247	10	Sage Initial Designations
Mann, Gregory 2021-03-31	247	12	248	9	Sage Initial Designations
Mann, Gregory 2021-03-31	250	9	250	21	Sage Initial Designations
Mann, Gregory 2021-03-31	251	23	252	5	Sage Initial Designations
Mann, Gregory 2021-03-31	252	10	252	15	Sage Initial Designations
Mann, Gregory 2021-03-31	253	2	253	6	Sage Initial Designations
Mann, Gregory 2021-03-31	254	17	254	22	Sage Initial Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Mann, Gregory 2023-02-16	5	5	5	8	Sage Initial Designations
Mann, Gregory 2023-02-16	12	5	12	7	Sage Initial Designations
Mann, Gregory 2023-02-16	14	10	14	12	Sage Initial Designations
Mann, Gregory 2023-02-16	15	1	15	3	Sage Initial Designations
Mann, Gregory 2023-02-16	19	24	20	7	Sage Initial Designations
Mann, Gregory 2023-02-16	20	11	20	11	Sage Initial Designations
Mann, Gregory 2023-02-16	23	18	23	20	Sage Initial Designations
Mann, Gregory 2023-02-16	23	24	23	24	Sage Initial Designations
Mann, Gregory 2023-02-16	24	2	24	5	Sage Initial Designations
Mann, Gregory 2023-02-16	28	9	28	11	Sage Initial Designations
Mann, Gregory 2023-02-16	30	18	30	19	Sage Initial Designations
Mann, Gregory 2023-02-16	30	21	30	21	Sage Initial Designations
Mann, Gregory 2023-02-16	31	15	31	16	Sage Initial Designations
Mann, Gregory 2023-02-16	31	18	31	18	Sage Initial Designations
Mann, Gregory 2023-02-16	37	6	37	7	Sage Initial Designations
Mann, Gregory 2023-02-16	37	9	37	9	Sage Initial Designations
Mann, Gregory 2023-02-16	64	14	64	17	Sage Initial Designations
Mann, Gregory 2023-02-16	64	21	64	22	Sage Initial Designations
Mann, Gregory 2023-02-16	64	24	65	3	Sage Initial Designations
Mann, Gregory 2023-02-16	65	5	65	5	Sage Initial Designations
Mann, Gregory 2023-02-16	65	7	65	8	Sage Initial Designations
Mann, Gregory 2023-02-16	65	11	65	11	Sage Initial Designations
Mann, Gregory 2023-02-16	65	13	65	15	Sage Initial Designations
Mann, Gregory 2023-02-16	65	18	65	18	Sage Initial Designations
Mann, Gregory 2023-02-16	66	9	66	10	Sage Initial Designations
Mann, Gregory 2023-02-16	66	13	66	13	Sage Initial Designations
Mann, Gregory 2023-02-16	67	20	67	22	Sage Initial Designations
Mann, Gregory 2023-02-16	68	1	68	1	Sage Initial Designations
Mann, Gregory 2023-02-16	70	2	70	3	Sage Initial Designations
Mann, Gregory 2023-02-16	70	5	70	5	Sage Initial Designations
Mann, Gregory 2023-02-16	73	5	73	6	Sage Initial Designations
Mann, Gregory 2023-02-16	73	8	73	10	Sage Initial Designations
Mann, Gregory 2023-02-16	74	3	74	5	Sage Initial Designations
Mann, Gregory 2023-02-16	76	15	76	16	Sage Initial Designations
Mann, Gregory 2023-02-16	76	18	76	22	Sage Initial Designations
Mann, Gregory 2023-02-16	77	15	77	16	Sage Initial Designations
Mann, Gregory 2023-02-16	77	18	77	18	Sage Initial Designations
Mann, Gregory 2023-02-16	86	23	86	24	Sage Initial Designations
Mann, Gregory 2023-02-16	87	3	87	5	Sage Initial Designations
Mann, Gregory 2023-02-16	87	8	87	10	Sage Initial Designations
Mann, Gregory 2023-02-16	87	14	87	17	Sage Initial Designations
Mann, Gregory 2023-02-16	87	20	87	20	Sage Initial Designations
Mann, Gregory 2023-02-16	90	17	90	24	Sage Initial Designations
Mann, Gregory 2023-02-16	91	3	91	8	Sage Initial Designations
Mann, Gregory 2023-02-16	91	12	91	12	Sage Initial Designations
Mann, Gregory 2023-02-16	97	11	97	16	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Mann, Gregory 2023-02-16	97	20	97	21	Sage Initial Designations
Mann, Gregory 2023-02-16	97	24	98	2	Sage Initial Designations
Mann, Gregory 2023-02-16	98	19	98	20	Sage Initial Designations
Mann, Gregory 2023-02-16	98	23	98	23	Sage Initial Designations
Mann, Gregory 2023-02-16	99	7	99	7	Sage Initial Designations
Mann, Gregory 2023-02-16	99	10	99	10	Sage Initial Designations
Mann, Gregory 2023-02-16	99	12	99	13	Sage Initial Designations
Mann, Gregory 2023-02-16	99	16	99	17	Sage Initial Designations
Mann, Gregory 2023-02-16	100	10	100	10	Sage Initial Designations
Mann, Gregory 2023-02-16	100	13	100	13	Sage Initial Designations
Mann, Gregory 2023-02-16	101	14	101	15	Sage Initial Designations
Mann, Gregory 2023-02-16	101	18	101	18	Sage Initial Designations
Mann, Gregory 2023-02-16	101	20	101	20	Sage Initial Designations
Mann, Gregory 2023-02-16	101	23	102	4	Sage Initial Designations
Mann, Gregory 2023-02-16	102	7	102	11	Sage Initial Designations
Mann, Gregory 2023-02-16	103	22	103	24	Sage Initial Designations
Mann, Gregory 2023-02-16	104	3	104	5	Sage Initial Designations
Mann, Gregory 2023-02-16	104	15	104	16	Sage Initial Designations
Mann, Gregory 2023-02-16	104	19	104	22	Sage Initial Designations
Mann, Gregory 2023-02-16	105	1	105	1	Sage Initial Designations
Mann, Gregory 2023-02-16	105	11	105	13	Sage Initial Designations
Mann, Gregory 2023-02-16	105	17	105	21	Sage Initial Designations
Mann, Gregory 2023-02-16	105	24	106	3	Sage Initial Designations
Mann, Gregory 2023-02-16	106	5	106	7	Sage Initial Designations
Mann, Gregory 2023-02-16	106	10	106	14	Sage Initial Designations
Mann, Gregory 2023-02-16	106	17	106	23	Sage Initial Designations
Mann, Gregory 2023-02-16	107	2	107	2	Sage Initial Designations
Mann, Gregory 2023-02-16	113	19	113	20	Sage Initial Designations
Mann, Gregory 2023-02-16	113	23	113	23	Sage Initial Designations
Mann, Gregory 2023-02-16	116	6	116	8	Sage Initial Designations
Mann, Gregory 2023-02-16	116	10	116	10	Sage Initial Designations
Mann, Gregory 2023-02-16	116	12	116	14	Sage Initial Designations
Mann, Gregory 2023-02-16	116	16	116	16	Sage Initial Designations
Mann, Gregory 2023-02-16	116	18	116	19	Sage Initial Designations
Mann, Gregory 2023-02-16	116	21	116	23	Sage Initial Designations
Mann, Gregory 2023-02-16	118	17	118	18	Sage Initial Designations
Mann, Gregory 2023-02-16	118	23	118	24	Sage Initial Designations
Mann, Gregory 2023-02-16	145	20	145	22	Sage Initial Designations
Mann, Gregory 2023-02-16	146	1	146	4	Sage Initial Designations
Mann, Gregory 2023-02-16	146	7	146	8	Sage Initial Designations
Mann, Gregory 2023-02-16	149	13	149	15	Sage Initial Designations
Mann, Gregory 2023-02-16	149	18	149	20	Sage Initial Designations
Mann, Gregory 2023-02-16	149	22	149	23	Sage Initial Designations
Mann, Gregory 2023-02-16	150	2	150	4	Sage Initial Designations
Mann, Gregory 2023-02-16	150	6	150	7	Sage Initial Designations
Mann, Gregory 2023-02-16	150	10	150	10	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Mann, Gregory 2023-02-16	150	20	150	22	Sage Initial Designations
Mann, Gregory 2023-02-16	151	1	151	7	Sage Initial Designations
Mann, Gregory 2023-02-16	153	12	153	13	Sage Initial Designations
Mann, Gregory 2023-02-16	153	16	153	19	Sage Initial Designations
Mann, Gregory 2023-02-16	154	10	154	12	Sage Initial Designations
Mann, Gregory 2023-02-16	154	15	154	15	Sage Initial Designations
Mann, Gregory 2023-02-16	158	10	158	13	Sage Initial Designations
Mann, Gregory 2023-02-16	158	16	158	16	Sage Initial Designations
Mann, Gregory 2023-02-16	163	23	164	3	Sage Initial Designations
Mann, Gregory 2023-02-16	173	21	174	3	Sage Initial Designations
Mann, Gregory 2023-02-16	174	6	174	6	Sage Initial Designations
Mann, Gregory 2023-02-16	175	2	175	4	Sage Initial Designations
Mann, Gregory 2023-02-16	175	7	175	9	Sage Initial Designations
Mann, Gregory 2023-02-16	177	21	177	22	Sage Initial Designations
Mann, Gregory 2023-02-16	177	24	178	2	Sage Initial Designations
Mann, Gregory 2023-02-16	179	1	179	2	Sage Initial Designations
Mann, Gregory 2023-02-16	179	5	179	11	Sage Initial Designations
Mann, Gregory 2023-02-16	179	23	180	2	Sage Initial Designations
Mann, Gregory 2023-02-16	180	11	180	15	Sage Initial Designations
Mann, Gregory 2023-02-16	180	18	180	24	Sage Initial Designations
Mann, Gregory 2023-02-16	181	3	181	4	Sage Initial Designations
Mann, Gregory 2023-02-16	183	7	183	11	Sage Initial Designations
Mann, Gregory 2023-02-16	183	12	183	16	Sage Initial Designations
Mann, Gregory 2023-02-16	183	19	183	19	Sage Initial Designations
Mann, Gregory 2023-02-16	190	10	190	11	Sage Initial Designations
Mann, Gregory 2023-02-16	190	15	190	18	Sage Initial Designations
Mann, Gregory 2023-02-16	190	20	190	20	Sage Initial Designations
Mann, Gregory 2023-02-16	191	21	191	22	Sage Initial Designations
Mann, Gregory 2023-02-16	192	1	192	2	Sage Initial Designations
Mann, Gregory 2023-02-16	192	5	192	5	Sage Initial Designations
Mann, Gregory 2023-02-16	192	7	192	8	Sage Initial Designations
Mann, Gregory 2023-02-16	192	11	192	11	Sage Initial Designations
Mann, Gregory 2023-02-16	192	18	192	20	Sage Initial Designations
Mann, Gregory 2023-02-16	192	24	192	24	Sage Initial Designations
Mann, Gregory 2023-02-16	194	4	194	6	Sage Initial Designations
Mann, Gregory 2023-02-16	194	10	194	11	Sage Initial Designations
Mann, Gregory 2023-02-16	194	24	195	1	Sage Initial Designations
Mann, Gregory 2023-02-16	195	5	195	6	Sage Initial Designations
Mann, Gregory 2023-02-16	195	9	195	9	Sage Initial Designations
Mann, Gregory 2023-02-16	195	15	195	17	Sage Initial Designations
Mann, Gregory 2023-02-16	195	20	195	22	Sage Initial Designations
Mann, Gregory 2023-02-16	196	6	196	7	Sage Initial Designations
Mann, Gregory 2023-02-16	196	10	196	10	Sage Initial Designations
Mann, Gregory 2023-02-16	198	16	198	17	Sage Initial Designations
Mann, Gregory 2023-02-16	199	3	199	5	Sage Initial Designations
Mann, Gregory 2023-02-16	199	7	199	7	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Mann, Gregory 2023-02-16	199	9	199	10	Sage Initial Designations
Mann, Gregory 2023-02-16	199	14	199	14	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Morgan, Richard 2023-02-10	4	23	5	1	Sage Initial Designations
Morgan, Richard 2023-02-10	8	7	9	2	Sage Initial Designations
Morgan, Richard 2023-02-10	10	9	10	14	Sage Initial Designations
Morgan, Richard 2023-02-10	13	3	13	14	Sage Initial Designations
Morgan, Richard 2023-02-10	13	20	13	24	Sage Initial Designations
Morgan, Richard 2023-02-10	16	1	16	1	Sage Initial Designations
Morgan, Richard 2023-02-10	16	1	17	4	Sage Initial Designations
Morgan, Richard 2023-02-10	17	18	17	23	Sage Initial Designations
Morgan, Richard 2023-02-10	20	10	20	23	Sage Initial Designations
Morgan, Richard 2023-02-10	22	16	22	19	Sage Initial Designations
Morgan, Richard 2023-02-10	22	21	22	22	Sage Initial Designations
Morgan, Richard 2023-02-10	23	5	23	21	Sage Initial Designations
Morgan, Richard 2023-02-10	24	6	24	11	Sage Initial Designations
Morgan, Richard 2023-02-10	24	13	24	17	Sage Initial Designations
Morgan, Richard 2023-02-10	27	20	27	23	Sage Initial Designations
Morgan, Richard 2023-02-10	28	2	28	13	Sage Initial Designations
Morgan, Richard 2023-02-10	30	2	30	12	Sage Initial Designations
Morgan, Richard 2023-02-10	30	18	31	1	Sage Initial Designations
Morgan, Richard 2023-02-10	31	19	32	4	Sage Initial Designations
Morgan, Richard 2023-02-10	32	7	33	1	Sage Initial Designations
Morgan, Richard 2023-02-10	33	4	33	5	Sage Initial Designations
Morgan, Richard 2023-02-10	34	7	34	21	Sage Initial Designations
Morgan, Richard 2023-02-10	35	5	35	13	Sage Initial Designations
Morgan, Richard 2023-02-10	35	15	35	16	Sage Initial Designations
Morgan, Richard 2023-02-10	38	2	38	5	Sage Initial Designations
Morgan, Richard 2023-02-10	38	8	38	20	Sage Initial Designations
Morgan, Richard 2023-02-10	39	6	39	9	Sage Initial Designations
Morgan, Richard 2023-02-10	40	15	41	1	Sage Initial Designations
Morgan, Richard 2023-02-10	41	4	41	7	Sage Initial Designations
Morgan, Richard 2023-02-10	41	9	41	11	Sage Initial Designations
Morgan, Richard 2023-02-10	41	13	41	13	Sage Initial Designations
Morgan, Richard 2023-02-10	41	20	41	24	Sage Initial Designations
Morgan, Richard 2023-02-10	42	1	42	10	Sage Initial Designations
Morgan, Richard 2023-02-10	42	12	42	12	Sage Initial Designations
Morgan, Richard 2023-02-10	42	21	43	3	Sage Initial Designations
Morgan, Richard 2023-02-10	43	6	43	11	Sage Initial Designations
Morgan, Richard 2023-02-10	43	13	43	16	Sage Initial Designations
Morgan, Richard 2023-02-10	43	19	43	22	Sage Initial Designations
Morgan, Richard 2023-02-10	44	5	44	12	Sage Initial Designations
Morgan, Richard 2023-02-10	44	15	44	16	Sage Initial Designations
Morgan, Richard 2023-02-10	45	13	45	21	Sage Initial Designations
Morgan, Richard 2023-02-10	45	24	46	2	Sage Initial Designations
Morgan, Richard 2023-02-10	46	4	46	5	Sage Initial Designations
Morgan, Richard 2023-02-10	46	7	46	15	Sage Initial Designations
Morgan, Richard 2023-02-10	46	20	46	21	Sage Initial Designations
Morgan, Richard 2023-02-10	48	20	49	3	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Morgan, Richard 2023-02-10	49	5	49	14	Sage Initial Designations
Morgan, Richard 2023-02-10	50	5	50	11	Sage Initial Designations
Morgan, Richard 2023-02-10	51	11	52	2	Sage Initial Designations
Morgan, Richard 2023-02-10	52	6	52	9	Sage Initial Designations
Morgan, Richard 2023-02-10	52	11	53	3	Sage Initial Designations
Morgan, Richard 2023-02-10	53	11	53	15	Sage Initial Designations
Morgan, Richard 2023-02-10	68	14	68	21	Sage Initial Designations
Morgan, Richard 2023-02-10	73	15	73	17	Sage Initial Designations
Morgan, Richard 2023-02-10	73	19	73	21	Sage Initial Designations
Morgan, Richard 2023-02-10	73	23	73	24	Sage Initial Designations
Morgan, Richard 2023-02-10	74	3	74	4	Sage Initial Designations
Morgan, Richard 2023-02-10	75	8	75	24	Sage Initial Designations
Morgan, Richard 2023-02-10	77	12	77	14	Sage Initial Designations
Morgan, Richard 2023-02-10	77	16	77	17	Sage Initial Designations
Morgan, Richard 2023-02-10	78	21	78	22	Sage Initial Designations
Morgan, Richard 2023-02-10	78	24	79	1	Sage Initial Designations
Morgan, Richard 2023-02-10	80	4	80	15	Sage Initial Designations
Morgan, Richard 2023-02-10	80	20	80	21	Sage Initial Designations
Morgan, Richard 2023-02-10	93	15	94	1	Sage Initial Designations
Morgan, Richard 2023-02-10	94	12	94	24	Sage Initial Designations
Morgan, Richard 2023-02-10	95	3	95	13	Sage Initial Designations
Morgan, Richard 2023-02-10	95	14	95	16	Sage Initial Designations
Morgan, Richard 2023-02-10	95	19	95	20	Sage Initial Designations
Morgan, Richard 2023-02-10	96	19	96	21	Sage Initial Designations
Morgan, Richard 2023-02-10	96	24	97	2	Sage Initial Designations
Morgan, Richard 2023-02-10	102	2	102	18	Sage Initial Designations
Morgan, Richard 2023-02-10	102	19	102	24	Sage Initial Designations
Morgan, Richard 2023-02-10	103	1	103	18	Sage Initial Designations
Morgan, Richard 2023-02-10	104	8	104	22	Sage Initial Designations
Morgan, Richard 2023-02-10	105	1	105	5	Sage Initial Designations
Morgan, Richard 2023-02-10	105	18	106	11	Sage Initial Designations
Morgan, Richard 2023-02-10	106	15	106	19	Sage Initial Designations
Morgan, Richard 2023-02-10	106	21	108	6	Sage Initial Designations
Morgan, Richard 2023-02-10	113	13	114	10	Sage Initial Designations
Morgan, Richard 2023-02-10	114	11	114	24	Sage Initial Designations
Morgan, Richard 2023-02-10	115	3	115	5	Sage Initial Designations
Morgan, Richard 2023-02-10	115	23	116	1	Sage Initial Designations
Morgan, Richard 2023-02-10	116	3	116	4	Sage Initial Designations
Morgan, Richard 2023-02-10	116	6	116	15	Sage Initial Designations
Morgan, Richard 2023-02-10	116	18	116	18	Sage Initial Designations
Morgan, Richard 2023-02-10	117	14	117	22	Sage Initial Designations
Morgan, Richard 2023-02-10	118	1	118	3	Sage Initial Designations
Morgan, Richard 2023-02-10	118	5	118	7	Sage Initial Designations
Morgan, Richard 2023-02-10	118	10	118	10	Sage Initial Designations
Morgan, Richard 2023-02-10	118	12	118	14	Sage Initial Designations
Morgan, Richard 2023-02-10	118	17	118	18	Sage Initial Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Morgan, Richard 2023-02-10	119	3	119	12	Sage Initial Designations
Morgan, Richard 2023-02-10	119	13	119	21	Sage Initial Designations
Morgan, Richard 2023-02-10	119	24	120	3	Sage Initial Designations
Morgan, Richard 2023-02-10	120	5	121	12	Sage Initial Designations
Morgan, Richard 2023-02-10	121	15	121	20	Sage Initial Designations
Morgan, Richard 2023-02-10	122	18	123	6	Sage Initial Designations
Morgan, Richard 2023-02-10	123	9	123	12	Sage Initial Designations
Morgan, Richard 2023-02-10	124	9	124	11	Sage Initial Designations
Morgan, Richard 2023-02-10	124	14	124	22	Sage Initial Designations
Morgan, Richard 2023-02-10	125	3	125	24	Sage Initial Designations
Morgan, Richard 2023-02-10	126	1	126	5	Sage Initial Designations
Morgan, Richard 2023-02-10	131	8	131	16	Sage Initial Designations
Morgan, Richard 2023-02-10	131	19	131	20	Sage Initial Designations
Morgan, Richard 2023-02-10	133	1	133	3	Sage Initial Designations
Morgan, Richard 2023-02-10	133	24	134	8	Sage Initial Designations
Morgan, Richard 2023-02-10	134	9	134	10	Sage Initial Designations
Morgan, Richard 2023-02-10	135	12	135	17	Sage Initial Designations
Morgan, Richard 2023-02-10	135	18	135	18	Sage Initial Designations
Morgan, Richard 2023-02-10	135	19	136	16	Sage Initial Designations
Morgan, Richard 2023-02-10	140	23	141	1	Sage Initial Designations
Morgan, Richard 2023-02-10	142	5	142	6	Sage Initial Designations
Morgan, Richard 2023-02-10	143	9	143	11	Sage Initial Designations
Morgan, Richard 2023-02-10	143	18	143	19	Sage Initial Designations
Morgan, Richard 2023-02-10	143	21	144	1	Sage Initial Designations
Morgan, Richard 2023-02-10	144	5	144	6	Sage Initial Designations
Morgan, Richard 2023-02-10	144	11	144	12	Sage Initial Designations
Morgan, Richard 2023-02-10	144	18	144	21	Sage Initial Designations
Morgan, Richard 2023-02-10	145	5	145	7	Sage Initial Designations
Morgan, Richard 2023-02-10	145	8	145	8	Sage Initial Designations
Morgan, Richard 2023-02-10	145	11	145	24	Sage Initial Designations
Morgan, Richard 2023-02-10	146	10	146	24	Sage Initial Designations
Morgan, Richard 2023-02-10	147	1	147	14	Sage Initial Designations
Morgan, Richard 2023-02-10	148	3	148	16	Sage Initial Designations
Morgan, Richard 2023-02-10	148	17	149	21	Sage Initial Designations
Morgan, Richard 2023-02-10	149	22	149	22	Sage Initial Designations
Morgan, Richard 2023-02-10	150	8	150	23	Sage Initial Designations
Morgan, Richard 2023-02-10	150	24	152	6	Sage Initial Designations
Morgan, Richard 2023-02-10	152	7	153	5	Sage Initial Designations
Morgan, Richard 2023-02-10	154	8	154	24	Sage Initial Designations
Morgan, Richard 2023-02-10	155	1	155	7	Sage Initial Designations
Morgan, Richard 2023-02-10	155	17	156	11	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
19-1508 - Vol 01, Newton, Camille	224	24	225	8	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	225	15	225	19	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	226	2	226	25	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	227	1	227	20	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	229	20	229	24	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	229	25	230	7	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	230	8	230	8	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	230	15	231	8	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	231	20	232	5	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	232	9	232	25	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	233	1	233	14	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	234	20	235	12	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	235	23	236	12	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	236	13	237	7	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	238	12	238	14	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	238	17	239	7	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	239	25	240	7	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	240	24	241	6	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	241	7	241	11	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	241	21	242	14	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	242	18	243	6	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	243	7	243	10	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	243	18	243	24	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	244	15	244	21	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	244	22	245	1	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	245	17	246	5	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	246	6	246	19	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	246	20	247	4	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	247	12	247	16	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	247	20	247	22	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	248	8	248	12	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	248	17	248	18	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	248	20	249	5	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	249	6	249	14	Sage Initial Designations
19-1508 - Vol 01, Newton, Camille	249	15	249	20	Sage Initial Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
19-1508 - Vol 02, Newton, Camille	258	14	259	12	Sage Initial Designations
19-1508 - Vol 02, Newton, Camille	260	1	261	2	Sage Initial Designations
19-1508 - Vol 02, Newton, Camille	261	5	261	9	Sage Initial Designations
19-1508 - Vol 02, Newton, Camille	261	21	262	2	Sage Initial Designations
19-1508 - Vol 02, Newton, Camille	262	3	262	19	Sage Initial Designations
19-1508 - Vol 02, Newton, Camille	263	14	263	25	Sage Initial Designations
19-1508 - Vol 02, Newton, Camille	264	12	264	16	Sage Initial Designations
19-1508 - Vol 02, Newton, Camille	266	25	267	16	Sage Initial Designations
19-1508 - Vol 02, Newton, Camille	267	17	268	1	Sage Initial Designations
19-1508 - Vol 02, Newton, Camille	268	2	268	18	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Newton, Camille 2021-04-15	10	14	10	16	Sage Initial Designations
Newton, Camille 2021-04-15	15	25	16	9	Sage Initial Designations
Newton, Camille 2021-04-15	16	10	16	18	Sage Initial Designations
Newton, Camille 2021-04-15	16	21	17	2	Sage Initial Designations
Newton, Camille 2021-04-15	17	3	17	16	Sage Initial Designations
Newton, Camille 2021-04-15	17	17	17	22	Sage Initial Designations
Newton, Camille 2021-04-15	18	8	18	14	Sage Initial Designations
Newton, Camille 2021-04-15	19	6	19	8	Sage Initial Designations
Newton, Camille 2021-04-15	26	18	26	25	Sage Initial Designations
Newton, Camille 2021-04-15	27	5	27	17	Sage Initial Designations
Newton, Camille 2021-04-15	29	2	29	19	Sage Initial Designations
Newton, Camille 2021-04-15	30	2	30	11	Sage Initial Designations
Newton, Camille 2021-04-15	31	5	31	8	Sage Initial Designations
Newton, Camille 2021-04-15	31	24	32	7	Sage Initial Designations
Newton, Camille 2021-04-15	33	19	33	24	Sage Initial Designations
Newton, Camille 2021-04-15	33	25	34	7	Sage Initial Designations
Newton, Camille 2021-04-15	34	15	34	23	Sage Initial Designations
Newton, Camille 2021-04-15	35	1	35	1	Sage Initial Designations
Newton, Camille 2021-04-15	40	11	40	14	Sage Initial Designations
Newton, Camille 2021-04-15	40	17	40	18	Sage Initial Designations
Newton, Camille 2021-04-15	48	1	48	7	Sage Initial Designations
Newton, Camille 2021-04-15	51	13	51	17	Sage Initial Designations
Newton, Camille 2021-04-15	52	11	52	13	Sage Initial Designations
Newton, Camille 2021-04-15	52	15	52	16	Sage Initial Designations
Newton, Camille 2021-04-15	53	6	53	8	Sage Initial Designations
Newton, Camille 2021-04-15	53	9	53	9	Sage Initial Designations
Newton, Camille 2021-04-15	53	24	54	2	Sage Initial Designations
Newton, Camille 2021-04-15	55	13	55	15	Sage Initial Designations
Newton, Camille 2021-04-15	55	18	55	21	Sage Initial Designations
Newton, Camille 2021-04-15	55	25	56	3	Sage Initial Designations
Newton, Camille 2021-04-15	56	6	56	6	Sage Initial Designations
Newton, Camille 2021-04-15	60	9	60	10	Sage Initial Designations
Newton, Camille 2021-04-15	60	13	60	19	Sage Initial Designations
Newton, Camille 2021-04-15	60	25	61	6	Sage Initial Designations
Newton, Camille 2021-04-15	65	18	66	4	Sage Initial Designations
Newton, Camille 2021-04-15	66	6	66	6	Sage Initial Designations
Newton, Camille 2021-04-15	66	25	67	10	Sage Initial Designations
Newton, Camille 2021-04-15	67	13	67	21	Sage Initial Designations
Newton, Camille 2021-04-15	68	14	68	18	Sage Initial Designations
Newton, Camille 2021-04-15	68	20	68	21	Sage Initial Designations
Newton, Camille 2021-04-15	70	13	70	15	Sage Initial Designations
Newton, Camille 2021-04-15	70	22	70	22	Sage Initial Designations
Newton, Camille 2021-04-15	70	24	70	25	Sage Initial Designations
Newton, Camille 2021-04-15	71	2	71	7	Sage Initial Designations
Newton, Camille 2021-04-15	72	14	72	18	Sage Initial Designations
Newton, Camille 2021-04-15	74	24	75	1	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Newton, Camille 2021-04-15	75	3	75	10	Sage Initial Designations
Newton, Camille 2021-04-15	75	11	75	11	Sage Initial Designations
Newton, Camille 2021-04-15	75	13	75	13	Sage Initial Designations
Newton, Camille 2021-04-15	75	15	75	21	Sage Initial Designations
Newton, Camille 2021-04-15	75	23	76	4	Sage Initial Designations
Newton, Camille 2021-04-15	77	3	77	12	Sage Initial Designations
Newton, Camille 2021-04-15	77	22	77	24	Sage Initial Designations
Newton, Camille 2021-04-15	78	1	78	17	Sage Initial Designations
Newton, Camille 2021-04-15	78	18	79	3	Sage Initial Designations
Newton, Camille 2021-04-15	79	5	79	15	Sage Initial Designations
Newton, Camille 2021-04-15	79	17	79	24	Sage Initial Designations
Newton, Camille 2021-04-15	81	1	81	13	Sage Initial Designations
Newton, Camille 2021-04-15	83	7	83	10	Sage Initial Designations
Newton, Camille 2021-04-15	83	12	83	13	Sage Initial Designations
Newton, Camille 2021-04-15	85	4	85	7	Sage Initial Designations
Newton, Camille 2021-04-15	86	15	86	18	Sage Initial Designations
Newton, Camille 2021-04-15	88	11	89	5	Sage Initial Designations
Newton, Camille 2021-04-15	97	16	97	17	Sage Initial Designations
Newton, Camille 2021-04-15	97	22	97	25	Sage Initial Designations
Newton, Camille 2021-04-15	99	12	99	19	Sage Initial Designations
Newton, Camille 2021-04-15	99	22	99	23	Sage Initial Designations
Newton, Camille 2021-04-15	100	6	100	8	Sage Initial Designations
Newton, Camille 2021-04-15	101	1	101	9	Sage Initial Designations
Newton, Camille 2021-04-15	101	15	101	17	Sage Initial Designations
Newton, Camille 2021-04-15	101	18	101	25	Sage Initial Designations
Newton, Camille 2021-04-15	102	1	102	1	Sage Initial Designations
Newton, Camille 2021-04-15	102	3	102	7	Sage Initial Designations
Newton, Camille 2021-04-15	103	4	103	11	Sage Initial Designations
Newton, Camille 2021-04-15	103	13	103	15	Sage Initial Designations
Newton, Camille 2021-04-15	103	25	104	2	Sage Initial Designations
Newton, Camille 2021-04-15	104	5	104	6	Sage Initial Designations
Newton, Camille 2021-04-15	104	12	104	14	Sage Initial Designations
Newton, Camille 2021-04-15	106	7	106	16	Sage Initial Designations
Newton, Camille 2021-04-15	107	13	107	14	Sage Initial Designations
Newton, Camille 2021-04-15	107	16	107	16	Sage Initial Designations
Newton, Camille 2021-04-15	108	5	108	15	Sage Initial Designations
Newton, Camille 2021-04-15	108	16	108	18	Sage Initial Designations
Newton, Camille 2021-04-15	108	19	108	22	Sage Initial Designations
Newton, Camille 2021-04-15	109	10	109	12	Sage Initial Designations
Newton, Camille 2021-04-15	109	14	109	16	Sage Initial Designations
Newton, Camille 2021-04-15	109	19	109	24	Sage Initial Designations
Newton, Camille 2021-04-15	110	14	111	1	Sage Initial Designations
Newton, Camille 2021-04-15	112	9	112	18	Sage Initial Designations
Newton, Camille 2021-04-15	112	24	112	24	Sage Initial Designations
Newton, Camille 2021-04-15	113	4	113	6	Sage Initial Designations
Newton, Camille 2021-04-15	113	19	113	21	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Newton, Camille 2021-04-15	113	24	114	4	Sage Initial Designations
Newton, Camille 2021-04-15	114	5	114	6	Sage Initial Designations
Newton, Camille 2021-04-15	114	9	114	10	Sage Initial Designations
Newton, Camille 2021-04-15	114	17	114	19	Sage Initial Designations
Newton, Camille 2021-04-15	115	13	115	15	Sage Initial Designations
Newton, Camille 2021-04-15	115	19	115	24	Sage Initial Designations
Newton, Camille 2021-04-15	116	24	117	2	Sage Initial Designations
Newton, Camille 2021-04-15	117	5	117	10	Sage Initial Designations
Newton, Camille 2021-04-15	117	13	117	14	Sage Initial Designations
Newton, Camille 2021-04-15	117	16	117	19	Sage Initial Designations
Newton, Camille 2021-04-15	117	22	118	1	Sage Initial Designations
Newton, Camille 2021-04-15	118	3	118	5	Sage Initial Designations
Newton, Camille 2021-04-15	121	2	121	2	Sage Initial Designations
Newton, Camille 2021-04-15	121	3	121	9	Sage Initial Designations
Newton, Camille 2021-04-15	121	12	121	13	Sage Initial Designations
Newton, Camille 2021-04-15	121	25	122	1	Sage Initial Designations
Newton, Camille 2021-04-15	122	4	122	4	Sage Initial Designations
Newton, Camille 2021-04-15	122	19	122	22	Sage Initial Designations
Newton, Camille 2021-04-15	122	24	123	4	Sage Initial Designations
Newton, Camille 2021-04-15	123	5	123	7	Sage Initial Designations
Newton, Camille 2021-04-15	123	9	123	9	Sage Initial Designations
Newton, Camille 2021-04-15	123	11	123	13	Sage Initial Designations
Newton, Camille 2021-04-15	123	15	123	16	Sage Initial Designations
Newton, Camille 2021-04-15	129	14	129	17	Sage Initial Designations
Newton, Camille 2021-04-15	129	20	129	23	Sage Initial Designations
Newton, Camille 2021-04-15	129	25	130	7	Sage Initial Designations
Newton, Camille 2021-04-15	132	19	133	13	Sage Initial Designations
Newton, Camille 2021-04-15	133	15	133	15	Sage Initial Designations
Newton, Camille 2021-04-15	134	10	134	18	Sage Initial Designations
Newton, Camille 2021-04-15	135	9	135	14	Sage Initial Designations
Newton, Camille 2021-04-15	135	16	135	16	Sage Initial Designations
Newton, Camille 2021-04-15	135	18	135	20	Sage Initial Designations
Newton, Camille 2021-04-15	135	23	136	9	Sage Initial Designations
Newton, Camille 2021-04-15	136	18	136	20	Sage Initial Designations
Newton, Camille 2021-04-15	137	4	137	9	Sage Initial Designations
Newton, Camille 2021-04-15	137	19	138	4	Sage Initial Designations
Newton, Camille 2021-04-15	138	22	138	24	Sage Initial Designations
Newton, Camille 2021-04-15	139	2	139	4	Sage Initial Designations
Newton, Camille 2021-04-15	139	10	140	3	Sage Initial Designations
Newton, Camille 2021-04-15	140	4	140	18	Sage Initial Designations
Newton, Camille 2021-04-15	142	5	142	18	Sage Initial Designations
Newton, Camille 2021-04-15	144	21	145	1	Sage Initial Designations
Newton, Camille 2021-04-15	145	11	145	13	Sage Initial Designations
Newton, Camille 2021-04-15	145	21	145	23	Sage Initial Designations
Newton, Camille 2021-04-15	146	4	146	14	Sage Initial Designations
Newton, Camille 2021-04-15	146	15	147	2	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Newton, Camille 2021-04-15	147	15	147	24	Sage Initial Designations
Newton, Camille 2021-04-15	148	12	148	21	Sage Initial Designations
Newton, Camille 2021-04-15	149	8	149	11	Sage Initial Designations
Newton, Camille 2021-04-15	149	15	149	17	Sage Initial Designations
Newton, Camille 2021-04-15	149	20	149	24	Sage Initial Designations
Newton, Camille 2021-04-15	150	16	151	2	Sage Initial Designations
Newton, Camille 2021-04-15	152	17	152	20	Sage Initial Designations
Newton, Camille 2021-04-15	154	15	155	7	Sage Initial Designations
Newton, Camille 2021-04-15	155	9	155	10	Sage Initial Designations
Newton, Camille 2021-04-15	155	12	155	15	Sage Initial Designations
Newton, Camille 2021-04-15	155	23	156	9	Sage Initial Designations
Newton, Camille 2021-04-15	156	13	157	2	Sage Initial Designations
Newton, Camille 2021-04-15	157	7	157	9	Sage Initial Designations
Newton, Camille 2021-04-15	157	11	157	25	Sage Initial Designations
Newton, Camille 2021-04-15	159	14	159	16	Sage Initial Designations
Newton, Camille 2021-04-15	160	11	160	11	Sage Initial Designations
Newton, Camille 2021-04-15	160	25	161	2	Sage Initial Designations
Newton, Camille 2021-04-15	161	5	161	5	Sage Initial Designations
Newton, Camille 2021-04-15	161	7	161	9	Sage Initial Designations
Newton, Camille 2021-04-15	161	12	161	17	Sage Initial Designations
Newton, Camille 2021-04-15	161	20	162	2	Sage Initial Designations
Newton, Camille 2021-04-15	163	8	163	14	Sage Initial Designations
Newton, Camille 2021-04-15	163	16	163	18	Sage Initial Designations
Newton, Camille 2021-04-15	163	20	163	21	Sage Initial Designations
Newton, Camille 2021-04-15	164	4	164	5	Sage Initial Designations
Newton, Camille 2021-04-15	164	6	164	17	Sage Initial Designations
Newton, Camille 2021-04-15	165	1	165	3	Sage Initial Designations
Newton, Camille 2021-04-15	165	6	165	13	Sage Initial Designations
Newton, Camille 2021-04-15	165	15	165	17	Sage Initial Designations
Newton, Camille 2021-04-15	165	20	165	20	Sage Initial Designations
Newton, Camille 2021-04-15	165	25	166	11	Sage Initial Designations
Newton, Camille 2021-04-15	166	16	166	18	Sage Initial Designations
Newton, Camille 2021-04-15	166	21	166	22	Sage Initial Designations
Newton, Camille 2021-04-15	167	7	167	10	Sage Initial Designations
Newton, Camille 2021-04-15	167	13	167	14	Sage Initial Designations
Newton, Camille 2021-04-15	167	16	167	16	Sage Initial Designations
Newton, Camille 2021-04-15	167	20	167	24	Sage Initial Designations
Newton, Camille 2021-04-15	168	2	168	7	Sage Initial Designations
Newton, Camille 2021-04-15	170	7	170	9	Sage Initial Designations
Newton, Camille 2021-04-15	170	10	170	12	Sage Initial Designations
Newton, Camille 2021-04-15	170	15	171	5	Sage Initial Designations
Newton, Camille 2021-04-15	172	6	172	8	Sage Initial Designations
Newton, Camille 2021-04-15	172	11	172	14	Sage Initial Designations
Newton, Camille 2021-04-15	172	17	173	1	Sage Initial Designations
Newton, Camille 2021-04-15	173	8	173	11	Sage Initial Designations
Newton, Camille 2021-04-15	173	12	173	13	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Newton, Camille 2021-04-15	173	14	173	17	Sage Initial Designations
Newton, Camille 2021-04-15	173	20	173	24	Sage Initial Designations
Newton, Camille 2021-04-15	174	4	174	6	Sage Initial Designations
Newton, Camille 2021-04-15	174	7	174	8	Sage Initial Designations
Newton, Camille 2021-04-15	174	16	174	21	Sage Initial Designations
Newton, Camille 2021-04-15	174	22	175	6	Sage Initial Designations
Newton, Camille 2021-04-15	175	7	175	10	Sage Initial Designations
Newton, Camille 2021-04-15	175	13	175	14	Sage Initial Designations
Newton, Camille 2021-04-15	177	24	177	25	Sage Initial Designations
Newton, Camille 2021-04-15	178	15	178	19	Sage Initial Designations
Newton, Camille 2021-04-15	178	20	178	22	Sage Initial Designations
Newton, Camille 2021-04-15	178	24	178	25	Sage Initial Designations
Newton, Camille 2021-04-15	179	10	179	12	Sage Initial Designations
Newton, Camille 2021-04-15	179	14	179	15	Sage Initial Designations
Newton, Camille 2021-04-15	179	17	179	21	Sage Initial Designations
Newton, Camille 2021-04-15	179	23	180	1	Sage Initial Designations
Newton, Camille 2021-04-15	180	12	181	4	Sage Initial Designations
Newton, Camille 2021-04-15	181	5	181	14	Sage Initial Designations
Newton, Camille 2021-04-15	182	15	182	15	Sage Initial Designations
Newton, Camille 2021-04-15	183	25	184	15	Sage Initial Designations
Newton, Camille 2021-04-15	184	16	184	18	Sage Initial Designations
Newton, Camille 2021-04-15	184	22	184	25	Sage Initial Designations
Newton, Camille 2021-04-15	185	12	185	13	Sage Initial Designations
Newton, Camille 2021-04-15	185	16	185	19	Sage Initial Designations
Newton, Camille 2021-04-15	185	24	186	4	Sage Initial Designations
Newton, Camille 2021-04-15	188	9	188	11	Sage Initial Designations
Newton, Camille 2021-04-15	188	13	188	14	Sage Initial Designations
Newton, Camille 2021-04-15	190	5	190	13	Sage Initial Designations
Newton, Camille 2021-04-15	190	14	190	16	Sage Initial Designations
Newton, Camille 2021-04-15	190	19	190	20	Sage Initial Designations
Newton, Camille 2021-04-15	191	16	191	18	Sage Initial Designations
Newton, Camille 2021-04-15	191	21	191	21	Sage Initial Designations
Newton, Camille 2021-04-15	192	14	192	19	Sage Initial Designations
Newton, Camille 2021-04-15	192	20	192	21	Sage Initial Designations
Newton, Camille 2021-04-15	192	23	192	24	Sage Initial Designations
Newton, Camille 2021-04-15	193	14	193	14	Sage Initial Designations
Newton, Camille 2021-04-15	194	5	194	7	Sage Initial Designations
Newton, Camille 2021-04-15	194	10	194	14	Sage Initial Designations
Newton, Camille 2021-04-15	195	8	195	10	Sage Initial Designations
Newton, Camille 2021-04-15	195	15	195	24	Sage Initial Designations
Newton, Camille 2021-04-15	196	1	196	7	Sage Initial Designations
Newton, Camille 2021-04-15	196	9	196	10	Sage Initial Designations
Newton, Camille 2021-04-15	196	12	197	3	Sage Initial Designations
Newton, Camille 2021-04-15	197	20	198	1	Sage Initial Designations
Newton, Camille 2021-04-15	198	9	198	14	Sage Initial Designations
Newton, Camille 2021-04-15	200	12	200	22	Sage Initial Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Newton, Camille 2021-04-15	200	25	201	2	Sage Initial Designations
Newton, Camille 2021-04-15	201	10	201	25	Sage Initial Designations
Newton, Camille 2021-04-15	202	3	202	8	Sage Initial Designations
Newton, Camille 2021-04-15	202	8	202	13	Sage Initial Designations
Newton, Camille 2021-04-15	202	16	202	18	Sage Initial Designations
Newton, Camille 2021-04-15	203	10	203	12	Sage Initial Designations
Newton, Camille 2021-04-15	203	14	203	19	Sage Initial Designations
Newton, Camille 2021-04-15	203	25	204	3	Sage Initial Designations
Newton, Camille 2021-04-15	205	21	206	7	Sage Initial Designations
Newton, Camille 2021-04-15	206	9	206	19	Sage Initial Designations
Newton, Camille 2021-04-15	207	8	207	13	Sage Initial Designations
Newton, Camille 2021-04-15	207	14	207	17	Sage Initial Designations
Newton, Camille 2021-04-15	207	22	208	5	Sage Initial Designations
Newton, Camille 2021-04-15	208	9	208	19	Sage Initial Designations
Newton, Camille 2021-04-15	208	25	209	4	Sage Initial Designations
Newton, Camille 2021-04-15	211	3	211	7	Sage Initial Designations
Newton, Camille 2021-04-15	212	12	212	12	Sage Initial Designations
Newton, Camille 2021-04-15	212	19	213	11	Sage Initial Designations
Newton, Camille 2021-04-15	213	12	213	20	Sage Initial Designations
Newton, Camille 2021-04-15	213	22	214	5	Sage Initial Designations
Newton, Camille 2021-04-15	214	7	214	13	Sage Initial Designations
Newton, Camille 2021-04-15	214	15	214	16	Sage Initial Designations
Newton, Camille 2021-04-15	215	2	215	3	Sage Initial Designations
Newton, Camille 2021-04-15	215	8	215	12	Sage Initial Designations
Newton, Camille 2021-04-15	215	22	216	1	Sage Initial Designations
Newton, Camille 2021-04-15	216	2	216	4	Sage Initial Designations
Newton, Camille 2021-04-15	216	6	216	6	Sage Initial Designations
Newton, Camille 2021-04-15	216	8	216	10	Sage Initial Designations
Newton, Camille 2021-04-15	216	16	216	19	Sage Initial Designations
Newton, Camille 2021-04-15	216	21	217	6	Sage Initial Designations
Newton, Camille 2021-04-15	217	7	217	8	Sage Initial Designations
Newton, Camille 2021-04-15	217	10	217	10	Sage Initial Designations
Newton, Camille 2021-04-15	217	12	217	13	Sage Initial Designations
Newton, Camille 2021-04-15	217	15	217	16	Sage Initial Designations
Newton, Camille 2021-04-15	217	18	217	21	Sage Initial Designations
Newton, Camille 2021-04-15	217	24	218	11	Sage Initial Designations
Newton, Camille 2021-04-15	218	13	218	18	Sage Initial Designations
Newton, Camille 2021-04-15	218	20	218	20	Sage Initial Designations
Newton, Camille 2021-04-15	218	21	218	24	Sage Initial Designations
Newton, Camille 2021-04-15	219	19	220	9	Sage Initial Designations
Newton, Camille 2021-04-15	220	10	220	15	Sage Initial Designations
Newton, Camille 2021-04-15	220	18	220	25	Sage Initial Designations
Newton, Camille 2021-04-15	221	2	221	13	Sage Initial Designations
Newton, Camille 2021-04-15	221	14	222	3	Sage Initial Designations
Newton, Camille 2021-04-15	222	4	222	10	Sage Initial Designations
Newton, Camille 2021-04-15	222	22	222	25	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Newton, Camille 2021-04-15	223	2	223	3	Sage Initial Designations
Newton, Camille 2021-04-15	224	16	224	22	Sage Initial Designations
Newton, Camille 2021-04-15	224	25	225	6	Sage Initial Designations
Newton, Camille 2021-04-15	225	8	225	16	Sage Initial Designations
Newton, Camille 2021-04-15	225	25	226	3	Sage Initial Designations
Newton, Camille 2021-04-15	226	5	226	6	Sage Initial Designations
Newton, Camille 2021-04-15	226	9	226	14	Sage Initial Designations
Newton, Camille 2021-04-15	226	17	226	23	Sage Initial Designations
Newton, Camille 2021-04-15	227	1	227	8	Sage Initial Designations
Newton, Camille 2021-04-15	227	11	227	13	Sage Initial Designations
Newton, Camille 2021-04-15	227	24	228	2	Sage Initial Designations
Newton, Camille 2021-04-15	228	5	228	6	Sage Initial Designations
Newton, Camille 2021-04-15	228	23	228	25	Sage Initial Designations
Newton, Camille 2021-04-15	229	3	229	7	Sage Initial Designations
Newton, Camille 2021-04-15	229	24	230	1	Sage Initial Designations
Newton, Camille 2021-04-15	234	9	234	19	Sage Initial Designations
Newton, Camille 2021-04-15	234	22	234	23	Sage Initial Designations
Newton, Camille 2021-04-15	236	21	236	23	Sage Initial Designations
Newton, Camille 2021-04-15	236	25	236	25	Sage Initial Designations
Newton, Camille 2021-04-15	239	8	239	10	Sage Initial Designations
Newton, Camille 2021-04-15	239	13	239	17	Sage Initial Designations
Newton, Camille 2021-04-15	239	19	239	21	Sage Initial Designations
Newton, Camille 2021-04-15	242	16	242	24	Sage Initial Designations
Newton, Camille 2021-04-15	243	2	243	9	Sage Initial Designations
Newton, Camille 2021-04-15	243	13	243	20	Sage Initial Designations
Newton, Camille 2021-04-15	248	11	248	12	Sage Initial Designations
Newton, Camille 2021-04-15	248	13	248	13	Sage Initial Designations
Newton, Camille 2021-04-15	249	10	249	12	Sage Initial Designations
Newton, Camille 2021-04-15	249	15	249	16	Sage Initial Designations
Newton, Camille 2021-04-15	250	8	250	11	Sage Initial Designations
Newton, Camille 2021-04-15	250	14	250	15	Sage Initial Designations
Newton, Camille 2021-04-15	260	11	260	15	Sage Initial Designations
Newton, Camille 2021-04-15	260	18	261	1	Sage Initial Designations
Newton, Camille 2021-04-15	261	4	261	7	Sage Initial Designations
Newton, Camille 2021-04-15	261	10	261	13	Sage Initial Designations
Newton, Camille 2021-04-15	261	15	261	16	Sage Initial Designations
Newton, Camille 2021-04-15	275	20	276	2	Sage Initial Designations
Newton, Camille 2021-04-15	276	22	277	1	Sage Initial Designations
Newton, Camille 2021-04-15	278	11	278	13	Sage Initial Designations
Newton, Camille 2021-04-15	278	15	278	16	Sage Initial Designations
Newton, Camille 2021-04-15	279	7	279	11	Sage Initial Designations
Newton, Camille 2021-04-15	281	9	281	24	Sage Initial Designations
Newton, Camille 2021-04-15	282	11	282	17	Sage Initial Designations
Newton, Camille 2021-04-15	283	3	283	9	Sage Initial Designations
Newton, Camille 2021-04-15	283	19	283	20	Sage Initial Designations
Newton, Camille 2021-04-15	283	22	283	22	Sage Initial Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Newton, Camille 2021-04-15	285	10	285	15	Sage Initial Designations
Newton, Camille 2021-04-15	285	21	286	10	Sage Initial Designations
Newton, Camille 2021-04-15	286	15	286	20	Sage Initial Designations
Newton, Camille 2021-04-15	292	16	292	23	Sage Initial Designations
Newton, Camille 2021-04-15	292	24	292	25	Sage Initial Designations
Newton, Camille 2021-04-15	293	2	293	3	Sage Initial Designations
Newton, Camille 2021-04-15	296	15	296	18	Sage Initial Designations
Newton, Camille 2021-04-15	297	20	297	24	Sage Initial Designations
Newton, Camille 2021-04-15	298	3	298	8	Sage Initial Designations
Newton, Camille 2021-04-15	298	17	298	22	Sage Initial Designations
Newton, Camille 2021-04-15	298	24	298	25	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Newton, Camille 2023-04-06	4	16	4	20	Sage Initial Designations
Newton, Camille 2023-04-06	11	24	12	5	Sage Initial Designations
Newton, Camille 2023-04-06	13	17	14	4	Sage Initial Designations
Newton, Camille 2023-04-06	14	5	14	15	Sage Initial Designations
Newton, Camille 2023-04-06	14	22	14	22	Sage Initial Designations
Newton, Camille 2023-04-06	15	1	15	13	Sage Initial Designations
Newton, Camille 2023-04-06	15	16	15	16	Sage Initial Designations
Newton, Camille 2023-04-06	15	18	16	1	Sage Initial Designations
Newton, Camille 2023-04-06	16	4	16	4	Sage Initial Designations
Newton, Camille 2023-04-06	16	9	16	18	Sage Initial Designations
Newton, Camille 2023-04-06	16	21	16	21	Sage Initial Designations
Newton, Camille 2023-04-06	17	1	17	8	Sage Initial Designations
Newton, Camille 2023-04-06	17	11	17	11	Sage Initial Designations
Newton, Camille 2023-04-06	18	22	19	4	Sage Initial Designations
Newton, Camille 2023-04-06	19	7	19	7	Sage Initial Designations
Newton, Camille 2023-04-06	20	15	20	16	Sage Initial Designations
Newton, Camille 2023-04-06	21	20	21	23	Sage Initial Designations
Newton, Camille 2023-04-06	22	9	22	11	Sage Initial Designations
Newton, Camille 2023-04-06	22	18	22	18	Sage Initial Designations
Newton, Camille 2023-04-06	24	13	24	15	Sage Initial Designations
Newton, Camille 2023-04-06	24	19	24	19	Sage Initial Designations
Newton, Camille 2023-04-06	24	21	24	24	Sage Initial Designations
Newton, Camille 2023-04-06	26	17	26	19	Sage Initial Designations
Newton, Camille 2023-04-06	26	24	26	24	Sage Initial Designations
Newton, Camille 2023-04-06	27	2	27	4	Sage Initial Designations
Newton, Camille 2023-04-06	27	10	27	10	Sage Initial Designations
Newton, Camille 2023-04-06	30	6	30	10	Sage Initial Designations
Newton, Camille 2023-04-06	31	17	31	21	Sage Initial Designations
Newton, Camille 2023-04-06	32	13	32	16	Sage Initial Designations
Newton, Camille 2023-04-06	33	16	33	18	Sage Initial Designations
Newton, Camille 2023-04-06	33	21	33	21	Sage Initial Designations
Newton, Camille 2023-04-06	34	6	34	10	Sage Initial Designations
Newton, Camille 2023-04-06	34	17	34	19	Sage Initial Designations
Newton, Camille 2023-04-06	34	20	34	23	Sage Initial Designations
Newton, Camille 2023-04-06	35	2	35	2	Sage Initial Designations
Newton, Camille 2023-04-06	36	22	37	1	Sage Initial Designations
Newton, Camille 2023-04-06	37	5	37	8	Sage Initial Designations
Newton, Camille 2023-04-06	37	16	37	19	Sage Initial Designations
Newton, Camille 2023-04-06	38	11	38	15	Sage Initial Designations
Newton, Camille 2023-04-06	38	19	38	22	Sage Initial Designations
Newton, Camille 2023-04-06	40	2	40	6	Sage Initial Designations
Newton, Camille 2023-04-06	40	12	40	18	Sage Initial Designations
Newton, Camille 2023-04-06	40	19	40	19	Sage Initial Designations
Newton, Camille 2023-04-06	41	4	41	6	Sage Initial Designations
Newton, Camille 2023-04-06	42	1	42	4	Sage Initial Designations
Newton, Camille 2023-04-06	43	8	43	11	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Newton, Camille 2023-04-06	44	23	45	1	Sage Initial Designations
Newton, Camille 2023-04-06	45	5	45	5	Sage Initial Designations
Newton, Camille 2023-04-06	45	10	45	13	Sage Initial Designations
Newton, Camille 2023-04-06	46	1	46	5	Sage Initial Designations
Newton, Camille 2023-04-06	48	16	48	19	Sage Initial Designations
Newton, Camille 2023-04-06	50	8	50	12	Sage Initial Designations
Newton, Camille 2023-04-06	51	23	52	2	Sage Initial Designations
Newton, Camille 2023-04-06	52	9	52	15	Sage Initial Designations
Newton, Camille 2023-04-06	52	16	52	20	Sage Initial Designations
Newton, Camille 2023-04-06	52	24	52	24	Sage Initial Designations
Newton, Camille 2023-04-06	56	19	56	20	Sage Initial Designations
Newton, Camille 2023-04-06	57	4	57	4	Sage Initial Designations
Newton, Camille 2023-04-06	63	4	63	7	Sage Initial Designations
Newton, Camille 2023-04-06	63	23	64	1	Sage Initial Designations
Newton, Camille 2023-04-06	67	14	67	17	Sage Initial Designations
Newton, Camille 2023-04-06	68	8	68	11	Sage Initial Designations
Newton, Camille 2023-04-06	69	15	69	20	Sage Initial Designations
Newton, Camille 2023-04-06	69	21	69	22	Sage Initial Designations
Newton, Camille 2023-04-06	70	3	70	3	Sage Initial Designations
Newton, Camille 2023-04-06	71	22	72	1	Sage Initial Designations
Newton, Camille 2023-04-06	72	5	72	8	Sage Initial Designations
Newton, Camille 2023-04-06	72	22	73	1	Sage Initial Designations
Newton, Camille 2023-04-06	73	19	73	24	Sage Initial Designations
Newton, Camille 2023-04-06	74	1	74	2	Sage Initial Designations
Newton, Camille 2023-04-06	74	5	74	7	Sage Initial Designations
Newton, Camille 2023-04-06	76	20	76	22	Sage Initial Designations
Newton, Camille 2023-04-06	77	2	77	4	Sage Initial Designations
Newton, Camille 2023-04-06	77	6	77	7	Sage Initial Designations
Newton, Camille 2023-04-06	77	21	77	24	Sage Initial Designations
Newton, Camille 2023-04-06	78	11	78	14	Sage Initial Designations
Newton, Camille 2023-04-06	78	15	78	24	Sage Initial Designations
Newton, Camille 2023-04-06	81	12	81	15	Sage Initial Designations
Newton, Camille 2023-04-06	81	19	81	22	Sage Initial Designations
Newton, Camille 2023-04-06	83	4	83	7	Sage Initial Designations
Newton, Camille 2023-04-06	83	13	83	13	Sage Initial Designations
Newton, Camille 2023-04-06	84	4	84	5	Sage Initial Designations
Newton, Camille 2023-04-06	84	18	84	18	Sage Initial Designations
Newton, Camille 2023-04-06	84	20	84	21	Sage Initial Designations
Newton, Camille 2023-04-06	86	13	86	13	Sage Initial Designations
Newton, Camille 2023-04-06	88	15	88	18	Sage Initial Designations
Newton, Camille 2023-04-06	89	21	89	22	Sage Initial Designations
Newton, Camille 2023-04-06	90	1	90	3	Sage Initial Designations
Newton, Camille 2023-04-06	90	20	90	23	Sage Initial Designations
Newton, Camille 2023-04-06	91	14	91	17	Sage Initial Designations
Newton, Camille 2023-04-06	92	1	92	2	Sage Initial Designations
Newton, Camille 2023-04-06	92	5	92	11	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Newton, Camille 2023-04-06	92	18	92	21	Sage Initial Designations
Newton, Camille 2023-04-06	93	4	93	4	Sage Initial Designations
Newton, Camille 2023-04-06	96	9	96	12	Sage Initial Designations
Newton, Camille 2023-04-06	96	16	96	19	Sage Initial Designations
Newton, Camille 2023-04-06	99	5	99	8	Sage Initial Designations
Newton, Camille 2023-04-06	99	12	99	20	Sage Initial Designations
Newton, Camille 2023-04-06	101	8	101	11	Sage Initial Designations
Newton, Camille 2023-04-06	101	15	101	23	Sage Initial Designations
Newton, Camille 2023-04-06	101	24	102	2	Sage Initial Designations
Newton, Camille 2023-04-06	102	9	102	10	Sage Initial Designations
Newton, Camille 2023-04-06	102	12	102	13	Sage Initial Designations
Newton, Camille 2023-04-06	102	17	102	19	Sage Initial Designations
Newton, Camille 2023-04-06	102	21	102	22	Sage Initial Designations
Newton, Camille 2023-04-06	103	1	103	1	Sage Initial Designations
Newton, Camille 2023-04-06	103	4	103	7	Sage Initial Designations
Newton, Camille 2023-04-06	104	1	104	4	Sage Initial Designations
Newton, Camille 2023-04-06	104	5	104	7	Sage Initial Designations
Newton, Camille 2023-04-06	104	11	104	15	Sage Initial Designations
Newton, Camille 2023-04-06	104	19	104	21	Sage Initial Designations
Newton, Camille 2023-04-06	105	7	105	9	Sage Initial Designations
Newton, Camille 2023-04-06	105	12	105	14	Sage Initial Designations
Newton, Camille 2023-04-06	105	16	105	18	Sage Initial Designations
Newton, Camille 2023-04-06	105	22	106	2	Sage Initial Designations
Newton, Camille 2023-04-06	109	5	109	9	Sage Initial Designations
Newton, Camille 2023-04-06	109	13	109	18	Sage Initial Designations
Newton, Camille 2023-04-06	109	19	109	21	Sage Initial Designations
Newton, Camille 2023-04-06	110	9	110	11	Sage Initial Designations
Newton, Camille 2023-04-06	110	21	111	4	Sage Initial Designations
Newton, Camille 2023-04-06	111	8	111	11	Sage Initial Designations
Newton, Camille 2023-04-06	111	16	111	19	Sage Initial Designations
Newton, Camille 2023-04-06	111	20	111	24	Sage Initial Designations
Newton, Camille 2023-04-06	112	5	112	8	Sage Initial Designations
Newton, Camille 2023-04-06	113	6	113	12	Sage Initial Designations
Newton, Camille 2023-04-06	113	13	113	17	Sage Initial Designations
Newton, Camille 2023-04-06	113	18	113	24	Sage Initial Designations
Newton, Camille 2023-04-06	114	24	115	2	Sage Initial Designations
Newton, Camille 2023-04-06	115	6	115	9	Sage Initial Designations
Newton, Camille 2023-04-06	115	13	115	17	Sage Initial Designations
Newton, Camille 2023-04-06	115	21	115	24	Sage Initial Designations
Newton, Camille 2023-04-06	116	11	116	12	Sage Initial Designations
Newton, Camille 2023-04-06	116	15	116	15	Sage Initial Designations
Newton, Camille 2023-04-06	117	1	117	5	Sage Initial Designations
Newton, Camille 2023-04-06	118	3	118	7	Sage Initial Designations
Newton, Camille 2023-04-06	125	14	125	15	Sage Initial Designations
Newton, Camille 2023-04-06	125	18	125	19	Sage Initial Designations
Newton, Camille 2023-04-06	126	22	127	2	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Newton, Camille 2023-04-06	127	6	127	10	Sage Initial Designations
Newton, Camille 2023-04-06	128	9	128	12	Sage Initial Designations
Newton, Camille 2023-04-06	128	16	128	19	Sage Initial Designations
Newton, Camille 2023-04-06	129	3	129	7	Sage Initial Designations
Newton, Camille 2023-04-06	129	10	129	13	Sage Initial Designations
Newton, Camille 2023-04-06	130	18	131	2	Sage Initial Designations
Newton, Camille 2023-04-06	131	24	132	6	Sage Initial Designations
Newton, Camille 2023-04-06	132	22	132	23	Sage Initial Designations
Newton, Camille 2023-04-06	133	3	133	4	Sage Initial Designations
Newton, Camille 2023-04-06	133	24	134	2	Sage Initial Designations
Newton, Camille 2023-04-06	134	5	134	5	Sage Initial Designations
Newton, Camille 2023-04-06	134	8	134	22	Sage Initial Designations
Newton, Camille 2023-04-06	134	23	135	1	Sage Initial Designations
Newton, Camille 2023-04-06	135	4	135	5	Sage Initial Designations
Newton, Camille 2023-04-06	136	15	136	23	Sage Initial Designations
Newton, Camille 2023-04-06	137	3	137	7	Sage Initial Designations
Newton, Camille 2023-04-06	137	11	137	18	Sage Initial Designations
Newton, Camille 2023-04-06	138	1	138	6	Sage Initial Designations
Newton, Camille 2023-04-06	141	16	141	22	Sage Initial Designations
Newton, Camille 2023-04-06	142	1	142	1	Sage Initial Designations
Newton, Camille 2023-04-06	144	4	144	11	Sage Initial Designations
Newton, Camille 2023-04-06	144	12	144	14	Sage Initial Designations
Newton, Camille 2023-04-06	144	20	144	22	Sage Initial Designations
Newton, Camille 2023-04-06	144	24	145	2	Sage Initial Designations
Newton, Camille 2023-04-06	145	8	145	13	Sage Initial Designations
Newton, Camille 2023-04-06	145	16	145	18	Sage Initial Designations
Newton, Camille 2023-04-06	145	20	145	22	Sage Initial Designations
Newton, Camille 2023-04-06	146	2	146	7	Sage Initial Designations
Newton, Camille 2023-04-06	146	12	146	12	Sage Initial Designations
Newton, Camille 2023-04-06	147	8	147	13	Sage Initial Designations
Newton, Camille 2023-04-06	147	18	147	24	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
19-1508 - Vol 02, Newton, Raymond	291	12	291	17	Sage Initial Designations
19-1508 - Vol 02, Newton, Raymond	292	3	293	18	Sage Initial Designations
19-1508 - Vol 02, Newton, Raymond	293	23	295	2	Sage Initial Designations
19-1508 - Vol 02, Newton, Raymond	295	10	297	7	Sage Initial Designations
19-1508 - Vol 02, Newton, Raymond	297	18	297	20	Sage Initial Designations
19-1508 - Vol 02, Newton, Raymond	300	16	300	21	Sage Initial Designations
19-1508 - Vol 02, Newton, Raymond	301	2	301	10	Sage Initial Designations
19-1508 - Vol 02, Newton, Raymond	302	2	302	6	Sage Initial Designations
19-1508 - Vol 02, Newton, Raymond	309	7	310	7	Sage Initial Designations
19-1508 - Vol 02, Newton, Raymond	317	11	317	15	Sage Initial Designations
19-1508 - Vol 02, Newton, Raymond	317	18	317	20	Sage Initial Designations
19-1508 - Vol 02, Newton, Raymond	321	1	321	15	Sage Initial Designations
19-1508 - Vol 02, Newton, Raymond	322	10	322	16	Sage Initial Designations
19-1508 - Vol 02, Newton, Raymond	323	11	323	15	Sage Initial Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Newton, Ray 2021-04-13	9	15	9	18	Sage Initial Designations
Newton, Ray 2021-04-13	17	10	17	13	Sage Initial Designations
Newton, Ray 2021-04-13	18	2	18	5	Sage Initial Designations
Newton, Ray 2021-04-13	18	25	19	9	Sage Initial Designations
Newton, Ray 2021-04-13	21	4	21	11	Sage Initial Designations
Newton, Ray 2021-04-13	21	21	22	7	Sage Initial Designations
Newton, Ray 2021-04-13	29	12	29	15	Sage Initial Designations
Newton, Ray 2021-04-13	33	17	33	25	Sage Initial Designations
Newton, Ray 2021-04-13	34	2	34	5	Sage Initial Designations
Newton, Ray 2021-04-13	35	19	35	20	Sage Initial Designations
Newton, Ray 2021-04-13	35	22	36	3	Sage Initial Designations
Newton, Ray 2021-04-13	36	10	36	18	Sage Initial Designations
Newton, Ray 2021-04-13	37	12	38	6	Sage Initial Designations
Newton, Ray 2021-04-13	38	8	38	14	Sage Initial Designations
Newton, Ray 2021-04-13	38	17	38	23	Sage Initial Designations
Newton, Ray 2021-04-13	38	25	39	4	Sage Initial Designations
Newton, Ray 2021-04-13	39	14	40	14	Sage Initial Designations
Newton, Ray 2021-04-13	43	5	43	13	Sage Initial Designations
Newton, Ray 2021-04-13	43	15	44	12	Sage Initial Designations
Newton, Ray 2021-04-13	44	15	44	23	Sage Initial Designations
Newton, Ray 2021-04-13	44	25	45	2	Sage Initial Designations
Newton, Ray 2021-04-13	45	4	45	11	Sage Initial Designations
Newton, Ray 2021-04-13	45	22	45	23	Sage Initial Designations
Newton, Ray 2021-04-13	45	25	46	7	Sage Initial Designations
Newton, Ray 2021-04-13	46	10	46	11	Sage Initial Designations
Newton, Ray 2021-04-13	46	21	46	22	Sage Initial Designations
Newton, Ray 2021-04-13	46	25	47	13	Sage Initial Designations
Newton, Ray 2021-04-13	47	15	47	17	Sage Initial Designations
Newton, Ray 2021-04-13	47	19	47	22	Sage Initial Designations
Newton, Ray 2021-04-13	48	5	48	8	Sage Initial Designations
Newton, Ray 2021-04-13	48	11	48	14	Sage Initial Designations
Newton, Ray 2021-04-13	48	16	48	16	Sage Initial Designations
Newton, Ray 2021-04-13	48	18	49	1	Sage Initial Designations
Newton, Ray 2021-04-13	49	5	49	6	Sage Initial Designations
Newton, Ray 2021-04-13	49	8	49	10	Sage Initial Designations
Newton, Ray 2021-04-13	49	22	49	23	Sage Initial Designations
Newton, Ray 2021-04-13	49	25	49	25	Sage Initial Designations
Newton, Ray 2021-04-13	50	7	50	10	Sage Initial Designations
Newton, Ray 2021-04-13	50	12	51	2	Sage Initial Designations
Newton, Ray 2021-04-13	52	1	52	20	Sage Initial Designations
Newton, Ray 2021-04-13	52	22	53	19	Sage Initial Designations
Newton, Ray 2021-04-13	56	3	56	21	Sage Initial Designations
Newton, Ray 2021-04-13	57	4	57	15	Sage Initial Designations
Newton, Ray 2021-04-13	57	18	57	23	Sage Initial Designations
Newton, Ray 2021-04-13	58	14	59	5	Sage Initial Designations
Newton, Ray 2021-04-13	60	2	60	11	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Newton, Ray 2021-04-13	71	7	71	24	Sage Initial Designations
Newton, Ray 2021-04-13	76	2	76	7	Sage Initial Designations
Newton, Ray 2021-04-13	76	9	76	10	Sage Initial Designations
Newton, Ray 2021-04-13	76	22	77	4	Sage Initial Designations
Newton, Ray 2021-04-13	77	12	77	16	Sage Initial Designations
Newton, Ray 2021-04-13	77	19	77	20	Sage Initial Designations
Newton, Ray 2021-04-13	77	23	78	11	Sage Initial Designations
Newton, Ray 2021-04-13	78	14	78	16	Sage Initial Designations
Newton, Ray 2021-04-13	78	18	78	25	Sage Initial Designations
Newton, Ray 2021-04-13	79	1	79	9	Sage Initial Designations
Newton, Ray 2021-04-13	79	10	79	11	Sage Initial Designations
Newton, Ray 2021-04-13	79	13	79	13	Sage Initial Designations
Newton, Ray 2021-04-13	81	8	81	13	Sage Initial Designations
Newton, Ray 2021-04-13	81	23	82	4	Sage Initial Designations
Newton, Ray 2021-04-13	84	14	85	7	Sage Initial Designations
Newton, Ray 2021-04-13	85	22	85	25	Sage Initial Designations
Newton, Ray 2021-04-13	87	14	88	4	Sage Initial Designations
Newton, Ray 2021-04-13	91	24	92	2	Sage Initial Designations
Newton, Ray 2021-04-13	96	5	97	16	Sage Initial Designations
Newton, Ray 2021-04-13	97	23	98	1	Sage Initial Designations
Newton, Ray 2021-04-13	98	5	98	8	Sage Initial Designations
Newton, Ray 2021-04-13	104	2	104	13	Sage Initial Designations
Newton, Ray 2021-04-13	104	18	104	25	Sage Initial Designations
Newton, Ray 2021-04-13	107	11	108	25	Sage Initial Designations
Newton, Ray 2021-04-13	109	6	109	16	Sage Initial Designations
Newton, Ray 2021-04-13	110	1	110	10	Sage Initial Designations
Newton, Ray 2021-04-13	111	3	111	11	Sage Initial Designations
Newton, Ray 2021-04-13	112	22	112	25	Sage Initial Designations
Newton, Ray 2021-04-13	113	2	113	5	Sage Initial Designations
Newton, Ray 2021-04-13	115	23	116	1	Sage Initial Designations
Newton, Ray 2021-04-13	117	5	117	7	Sage Initial Designations
Newton, Ray 2021-04-13	117	18	117	22	Sage Initial Designations
Newton, Ray 2021-04-13	117	24	117	24	Sage Initial Designations
Newton, Ray 2021-04-13	118	15	118	19	Sage Initial Designations
Newton, Ray 2021-04-13	118	21	118	25	Sage Initial Designations
Newton, Ray 2021-04-13	119	2	119	3	Sage Initial Designations
Newton, Ray 2021-04-13	119	22	120	4	Sage Initial Designations
Newton, Ray 2021-04-13	120	13	120	14	Sage Initial Designations
Newton, Ray 2021-04-13	120	16	120	22	Sage Initial Designations
Newton, Ray 2021-04-13	120	24	120	24	Sage Initial Designations
Newton, Ray 2021-04-13	121	2	121	4	Sage Initial Designations
Newton, Ray 2021-04-13	121	7	121	9	Sage Initial Designations
Newton, Ray 2021-04-13	121	11	121	21	Sage Initial Designations
Newton, Ray 2021-04-13	125	11	126	3	Sage Initial Designations
Newton, Ray 2021-04-13	126	6	126	8	Sage Initial Designations
Newton, Ray 2021-04-13	126	10	126	13	Sage Initial Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Newton, Ray 2021-04-13	127	23	127	25	Sage Initial Designations
Newton, Ray 2021-04-13	128	3	128	4	Sage Initial Designations
Newton, Ray 2021-04-13	128	8	128	10	Sage Initial Designations
Newton, Ray 2021-04-13	128	13	129	3	Sage Initial Designations
Newton, Ray 2021-04-13	129	5	129	12	Sage Initial Designations
Newton, Ray 2021-04-13	129	14	129	15	Sage Initial Designations
Newton, Ray 2021-04-13	129	17	129	19	Sage Initial Designations
Newton, Ray 2021-04-13	132	13	133	2	Sage Initial Designations
Newton, Ray 2021-04-13	133	5	133	13	Sage Initial Designations
Newton, Ray 2021-04-13	133	19	133	23	Sage Initial Designations
Newton, Ray 2021-04-13	134	1	134	2	Sage Initial Designations
Newton, Ray 2021-04-13	134	11	134	14	Sage Initial Designations
Newton, Ray 2021-04-13	134	16	135	1	Sage Initial Designations
Newton, Ray 2021-04-13	136	10	136	25	Sage Initial Designations
Newton, Ray 2021-04-13	139	12	139	20	Sage Initial Designations
Newton, Ray 2021-04-13	139	25	140	2	Sage Initial Designations
Newton, Ray 2021-04-13	140	4	140	7	Sage Initial Designations
Newton, Ray 2021-04-13	141	12	142	5	Sage Initial Designations
Newton, Ray 2021-04-13	142	8	142	14	Sage Initial Designations
Newton, Ray 2021-04-13	142	20	143	1	Sage Initial Designations
Newton, Ray 2021-04-13	144	2	144	7	Sage Initial Designations
Newton, Ray 2021-04-13	144	9	144	10	Sage Initial Designations
Newton, Ray 2021-04-13	144	12	145	10	Sage Initial Designations
Newton, Ray 2021-04-13	145	22	145	24	Sage Initial Designations
Newton, Ray 2021-04-13	146	3	146	6	Sage Initial Designations
Newton, Ray 2021-04-13	146	8	146	14	Sage Initial Designations
Newton, Ray 2021-04-13	146	16	146	17	Sage Initial Designations
Newton, Ray 2021-04-13	146	19	146	25	Sage Initial Designations
Newton, Ray 2021-04-13	148	15	148	17	Sage Initial Designations
Newton, Ray 2021-04-13	153	9	153	12	Sage Initial Designations
Newton, Ray 2021-04-13	153	22	154	7	Sage Initial Designations
Newton, Ray 2021-04-13	154	10	155	10	Sage Initial Designations
Newton, Ray 2021-04-13	155	13	155	16	Sage Initial Designations
Newton, Ray 2021-04-13	156	11	156	13	Sage Initial Designations
Newton, Ray 2021-04-13	156	16	156	25	Sage Initial Designations
Newton, Ray 2021-04-13	157	3	157	4	Sage Initial Designations
Newton, Ray 2021-04-13	157	7	157	9	Sage Initial Designations
Newton, Ray 2021-04-13	157	14	157	20	Sage Initial Designations
Newton, Ray 2021-04-13	158	2	158	5	Sage Initial Designations
Newton, Ray 2021-04-13	160	12	160	16	Sage Initial Designations
Newton, Ray 2021-04-13	160	19	160	23	Sage Initial Designations
Newton, Ray 2021-04-13	163	2	163	11	Sage Initial Designations
Newton, Ray 2021-04-13	163	23	163	24	Sage Initial Designations
Newton, Ray 2021-04-13	164	1	164	3	Sage Initial Designations
Newton, Ray 2021-04-13	164	5	164	8	Sage Initial Designations
Newton, Ray 2021-04-13	164	12	164	14	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Newton, Ray 2021-04-13	164	25	165	11	Sage Initial Designations
Newton, Ray 2021-04-13	165	13	165	13	Sage Initial Designations
Newton, Ray 2021-04-13	165	16	165	21	Sage Initial Designations
Newton, Ray 2021-04-13	166	6	166	19	Sage Initial Designations
Newton, Ray 2021-04-13	167	4	168	8	Sage Initial Designations
Newton, Ray 2021-04-13	168	10	168	17	Sage Initial Designations
Newton, Ray 2021-04-13	168	21	168	23	Sage Initial Designations
Newton, Ray 2021-04-13	169	3	169	4	Sage Initial Designations
Newton, Ray 2021-04-13	169	7	169	9	Sage Initial Designations
Newton, Ray 2021-04-13	170	3	170	11	Sage Initial Designations
Newton, Ray 2021-04-13	170	14	170	18	Sage Initial Designations
Newton, Ray 2021-04-13	171	9	171	16	Sage Initial Designations
Newton, Ray 2021-04-13	171	19	171	25	Sage Initial Designations
Newton, Ray 2021-04-13	172	2	172	6	Sage Initial Designations
Newton, Ray 2021-04-13	172	9	173	10	Sage Initial Designations
Newton, Ray 2021-04-13	173	12	173	20	Sage Initial Designations
Newton, Ray 2021-04-13	174	13	174	15	Sage Initial Designations
Newton, Ray 2021-04-13	174	18	174	19	Sage Initial Designations
Newton, Ray 2021-04-13	175	22	175	25	Sage Initial Designations
Newton, Ray 2021-04-13	176	21	176	24	Sage Initial Designations
Newton, Ray 2021-04-13	177	2	177	4	Sage Initial Designations
Newton, Ray 2021-04-13	179	1	179	11	Sage Initial Designations
Newton, Ray 2021-04-13	179	13	179	14	Sage Initial Designations
Newton, Ray 2021-04-13	179	17	179	22	Sage Initial Designations
Newton, Ray 2021-04-13	180	20	181	4	Sage Initial Designations
Newton, Ray 2021-04-13	181	13	181	15	Sage Initial Designations
Newton, Ray 2021-04-13	181	18	181	19	Sage Initial Designations
Newton, Ray 2021-04-13	182	2	182	5	Sage Initial Designations
Newton, Ray 2021-04-13	182	8	182	9	Sage Initial Designations
Newton, Ray 2021-04-13	182	12	182	13	Sage Initial Designations
Newton, Ray 2021-04-13	182	15	182	18	Sage Initial Designations
Newton, Ray 2021-04-13	182	21	182	25	Sage Initial Designations
Newton, Ray 2021-04-13	183	4	183	13	Sage Initial Designations
Newton, Ray 2021-04-13	185	1	185	9	Sage Initial Designations
Newton, Ray 2021-04-13	185	12	185	12	Sage Initial Designations
Newton, Ray 2021-04-13	186	12	186	20	Sage Initial Designations
Newton, Ray 2021-04-13	186	23	186	24	Sage Initial Designations
Newton, Ray 2021-04-13	187	2	187	3	Sage Initial Designations
Newton, Ray 2021-04-13	187	6	187	10	Sage Initial Designations
Newton, Ray 2021-04-13	187	14	187	17	Sage Initial Designations
Newton, Ray 2021-04-13	187	19	187	23	Sage Initial Designations
Newton, Ray 2021-04-13	188	17	188	18	Sage Initial Designations
Newton, Ray 2021-04-13	188	20	189	5	Sage Initial Designations
Newton, Ray 2021-04-13	189	8	190	2	Sage Initial Designations
Newton, Ray 2021-04-13	190	5	190	6	Sage Initial Designations
Newton, Ray 2021-04-13	190	8	190	9	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Newton, Ray 2021-04-13	191	4	191	7	Sage Initial Designations
Newton, Ray 2021-04-13	191	11	191	19	Sage Initial Designations
Newton, Ray 2021-04-13	191	24	191	25	Sage Initial Designations
Newton, Ray 2021-04-13	192	3	192	6	Sage Initial Designations
Newton, Ray 2021-04-13	192	8	192	11	Sage Initial Designations
Newton, Ray 2021-04-13	192	13	192	16	Sage Initial Designations
Newton, Ray 2021-04-13	192	19	192	20	Sage Initial Designations
Newton, Ray 2021-04-13	193	8	193	16	Sage Initial Designations
Newton, Ray 2021-04-13	193	19	193	19	Sage Initial Designations
Newton, Ray 2021-04-13	193	21	193	25	Sage Initial Designations
Newton, Ray 2021-04-13	194	3	194	3	Sage Initial Designations
Newton, Ray 2021-04-13	194	5	194	6	Sage Initial Designations
Newton, Ray 2021-04-13	194	8	194	12	Sage Initial Designations
Newton, Ray 2021-04-13	194	15	194	19	Sage Initial Designations
Newton, Ray 2021-04-13	194	21	194	21	Sage Initial Designations
Newton, Ray 2021-04-13	195	3	195	9	Sage Initial Designations
Newton, Ray 2021-04-13	195	12	195	18	Sage Initial Designations
Newton, Ray 2021-04-13	195	23	196	1	Sage Initial Designations
Newton, Ray 2021-04-13	196	5	196	11	Sage Initial Designations
Newton, Ray 2021-04-13	197	22	198	3	Sage Initial Designations
Newton, Ray 2021-04-13	198	6	198	13	Sage Initial Designations
Newton, Ray 2021-04-13	199	6	199	9	Sage Initial Designations
Newton, Ray 2021-04-13	199	12	199	19	Sage Initial Designations
Newton, Ray 2021-04-13	199	23	199	25	Sage Initial Designations
Newton, Ray 2021-04-13	200	2	200	4	Sage Initial Designations
Newton, Ray 2021-04-13	200	7	200	11	Sage Initial Designations
Newton, Ray 2021-04-13	200	14	200	21	Sage Initial Designations
Newton, Ray 2021-04-13	201	15	201	18	Sage Initial Designations
Newton, Ray 2021-04-13	201	21	201	25	Sage Initial Designations
Newton, Ray 2021-04-13	202	3	202	3	Sage Initial Designations
Newton, Ray 2021-04-13	202	16	202	18	Sage Initial Designations
Newton, Ray 2021-04-13	202	22	202	23	Sage Initial Designations
Newton, Ray 2021-04-13	203	1	203	5	Sage Initial Designations
Newton, Ray 2021-04-13	203	11	203	13	Sage Initial Designations
Newton, Ray 2021-04-13	203	16	203	23	Sage Initial Designations
Newton, Ray 2021-04-13	204	1	204	1	Sage Initial Designations
Newton, Ray 2021-04-13	204	3	204	5	Sage Initial Designations
Newton, Ray 2021-04-13	204	7	204	7	Sage Initial Designations
Newton, Ray 2021-04-13	204	9	204	11	Sage Initial Designations
Newton, Ray 2021-04-13	204	14	204	17	Sage Initial Designations
Newton, Ray 2021-04-13	204	19	204	22	Sage Initial Designations
Newton, Ray 2021-04-13	204	25	205	4	Sage Initial Designations
Newton, Ray 2021-04-13	205	7	205	8	Sage Initial Designations
Newton, Ray 2021-04-13	205	10	205	11	Sage Initial Designations
Newton, Ray 2021-04-13	205	14	205	20	Sage Initial Designations
Newton, Ray 2021-04-13	208	3	208	10	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Newton, Ray 2021-04-13	208	12	208	13	Sage Initial Designations
Newton, Ray 2021-04-13	208	23	208	24	Sage Initial Designations
Newton, Ray 2021-04-13	209	1	209	1	Sage Initial Designations
Newton, Ray 2021-04-13	209	11	209	12	Sage Initial Designations
Newton, Ray 2021-04-13	209	15	209	20	Sage Initial Designations
Newton, Ray 2021-04-13	209	22	210	1	Sage Initial Designations
Newton, Ray 2021-04-13	210	21	210	23	Sage Initial Designations
Newton, Ray 2021-04-13	211	1	211	6	Sage Initial Designations
Newton, Ray 2021-04-13	211	9	211	9	Sage Initial Designations
Newton, Ray 2021-04-13	212	23	213	4	Sage Initial Designations
Newton, Ray 2021-04-13	213	7	213	7	Sage Initial Designations
Newton, Ray 2021-04-13	213	17	213	18	Sage Initial Designations
Newton, Ray 2021-04-13	213	21	213	25	Sage Initial Designations
Newton, Ray 2021-04-13	214	3	214	4	Sage Initial Designations
Newton, Ray 2021-04-13	214	15	214	16	Sage Initial Designations
Newton, Ray 2021-04-13	214	19	214	22	Sage Initial Designations
Newton, Ray 2021-04-13	214	25	215	1	Sage Initial Designations
Newton, Ray 2021-04-13	215	15	215	17	Sage Initial Designations
Newton, Ray 2021-04-13	215	20	215	25	Sage Initial Designations
Newton, Ray 2021-04-13	218	5	218	7	Sage Initial Designations
Newton, Ray 2021-04-13	218	10	218	10	Sage Initial Designations
Newton, Ray 2021-04-13	218	12	218	15	Sage Initial Designations
Newton, Ray 2021-04-13	218	17	218	23	Sage Initial Designations
Newton, Ray 2021-04-13	219	1	219	6	Sage Initial Designations
Newton, Ray 2021-04-13	219	19	219	20	Sage Initial Designations
Newton, Ray 2021-04-13	219	23	219	24	Sage Initial Designations
Newton, Ray 2021-04-13	220	2	220	3	Sage Initial Designations
Newton, Ray 2021-04-13	220	5	220	10	Sage Initial Designations
Newton, Ray 2021-04-13	220	12	220	13	Sage Initial Designations
Newton, Ray 2021-04-13	220	17	220	18	Sage Initial Designations
Newton, Ray 2021-04-13	220	21	220	23	Sage Initial Designations
Newton, Ray 2021-04-13	222	14	222	17	Sage Initial Designations
Newton, Ray 2021-04-13	222	21	222	22	Sage Initial Designations
Newton, Ray 2021-04-13	224	21	224	25	Sage Initial Designations
Newton, Ray 2021-04-13	225	11	225	14	Sage Initial Designations
Newton, Ray 2021-04-13	227	15	227	17	Sage Initial Designations
Newton, Ray 2021-04-13	229	1	229	3	Sage Initial Designations
Newton, Ray 2021-04-13	236	21	236	23	Sage Initial Designations
Newton, Ray 2021-04-13	236	25	236	25	Sage Initial Designations
Newton, Ray 2021-04-13	238	2	238	11	Sage Initial Designations
Newton, Ray 2021-04-13	238	13	238	17	Sage Initial Designations
Newton, Ray 2021-04-13	240	8	240	9	Sage Initial Designations
Newton, Ray 2021-04-13	240	12	241	1	Sage Initial Designations
Newton, Ray 2021-04-13	241	4	241	8	Sage Initial Designations
Newton, Ray 2021-04-13	241	20	241	23	Sage Initial Designations
Newton, Ray 2021-04-13	241	25	242	8	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Newton, Ray 2021-04-13	242	11	242	24	Sage Initial Designations
Newton, Ray 2021-04-13	243	2	243	9	Sage Initial Designations
Newton, Ray 2021-04-13	244	19	245	17	Sage Initial Designations
Newton, Ray 2021-04-13	246	15	246	20	Sage Initial Designations
Newton, Ray 2021-04-13	246	23	247	13	Sage Initial Designations
Newton, Ray 2021-04-13	248	8	248	12	Sage Initial Designations
Newton, Ray 2021-04-13	248	15	248	19	Sage Initial Designations
Newton, Ray 2021-04-13	251	4	251	11	Sage Initial Designations
Newton, Ray 2021-04-13	251	16	252	2	Sage Initial Designations
Newton, Ray 2021-04-13	252	6	252	7	Sage Initial Designations
Newton, Ray 2021-04-13	252	10	252	14	Sage Initial Designations
Newton, Ray 2021-04-13	252	17	252	19	Sage Initial Designations
Newton, Ray 2021-04-13	254	1	254	3	Sage Initial Designations
Newton, Ray 2021-04-13	254	6	254	10	Sage Initial Designations
Newton, Ray 2021-04-13	254	13	254	13	Sage Initial Designations
Newton, Ray 2021-04-13	256	23	257	3	Sage Initial Designations
Newton, Ray 2021-04-13	257	13	257	19	Sage Initial Designations
Newton, Ray 2021-04-13	258	22	258	25	Sage Initial Designations
Newton, Ray 2021-04-13	259	16	259	17	Sage Initial Designations
Newton, Ray 2021-04-13	259	19	260	24	Sage Initial Designations
Newton, Ray 2021-04-13	261	3	261	5	Sage Initial Designations
Newton, Ray 2021-04-13	262	7	262	25	Sage Initial Designations
Newton, Ray 2021-04-13	263	19	263	22	Sage Initial Designations
Newton, Ray 2021-04-13	264	8	264	24	Sage Initial Designations
Newton, Ray 2021-04-13	265	1	265	2	Sage Initial Designations
Newton, Ray 2021-04-13	265	9	265	15	Sage Initial Designations
Newton, Ray 2021-04-13	265	18	265	19	Sage Initial Designations
Newton, Ray 2021-04-13	267	24	268	16	Sage Initial Designations
Newton, Ray 2021-04-13	269	3	269	9	Sage Initial Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Newton, Ray 2023-05-03	4	19	4	22	Sage Initial Designations
Newton, Ray 2023-05-03	16	19	16	24	Sage Initial Designations
Newton, Ray 2023-05-03	17	13	17	16	Sage Initial Designations
Newton, Ray 2023-05-03	21	5	21	6	Sage Initial Designations
Newton, Ray 2023-05-03	21	9	21	11	Sage Initial Designations
Newton, Ray 2023-05-03	21	13	21	16	Sage Initial Designations
Newton, Ray 2023-05-03	25	7	25	8	Sage Initial Designations
Newton, Ray 2023-05-03	25	11	25	13	Sage Initial Designations
Newton, Ray 2023-05-03	25	17	25	18	Sage Initial Designations
Newton, Ray 2023-05-03	25	20	25	22	Sage Initial Designations
Newton, Ray 2023-05-03	26	15	26	16	Sage Initial Designations
Newton, Ray 2023-05-03	26	21	26	23	Sage Initial Designations
Newton, Ray 2023-05-03	27	4	27	7	Sage Initial Designations
Newton, Ray 2023-05-03	27	10	27	10	Sage Initial Designations
Newton, Ray 2023-05-03	27	12	27	16	Sage Initial Designations
Newton, Ray 2023-05-03	27	22	27	24	Sage Initial Designations
Newton, Ray 2023-05-03	28	7	28	16	Sage Initial Designations
Newton, Ray 2023-05-03	28	22	28	24	Sage Initial Designations
Newton, Ray 2023-05-03	29	4	29	6	Sage Initial Designations
Newton, Ray 2023-05-03	29	8	29	9	Sage Initial Designations
Newton, Ray 2023-05-03	29	14	29	22	Sage Initial Designations
Newton, Ray 2023-05-03	30	3	30	5	Sage Initial Designations
Newton, Ray 2023-05-03	30	8	30	8	Sage Initial Designations
Newton, Ray 2023-05-03	30	10	30	11	Sage Initial Designations
Newton, Ray 2023-05-03	30	16	30	21	Sage Initial Designations
Newton, Ray 2023-05-03	32	1	32	4	Sage Initial Designations
Newton, Ray 2023-05-03	32	9	32	11	Sage Initial Designations
Newton, Ray 2023-05-03	32	15	32	16	Sage Initial Designations
Newton, Ray 2023-05-03	32	21	32	24	Sage Initial Designations
Newton, Ray 2023-05-03	34	4	34	8	Sage Initial Designations
Newton, Ray 2023-05-03	34	11	34	11	Sage Initial Designations
Newton, Ray 2023-05-03	34	22	34	23	Sage Initial Designations
Newton, Ray 2023-05-03	35	2	35	2	Sage Initial Designations
Newton, Ray 2023-05-03	39	1	39	8	Sage Initial Designations
Newton, Ray 2023-05-03	39	12	39	12	Sage Initial Designations
Newton, Ray 2023-05-03	40	8	40	10	Sage Initial Designations
Newton, Ray 2023-05-03	40	15	40	18	Sage Initial Designations
Newton, Ray 2023-05-03	42	12	42	13	Sage Initial Designations
Newton, Ray 2023-05-03	42	18	42	21	Sage Initial Designations
Newton, Ray 2023-05-03	42	24	42	24	Sage Initial Designations
Newton, Ray 2023-05-03	43	1	43	4	Sage Initial Designations
Newton, Ray 2023-05-03	43	12	43	14	Sage Initial Designations
Newton, Ray 2023-05-03	43	17	43	19	Sage Initial Designations
Newton, Ray 2023-05-03	43	24	44	2	Sage Initial Designations
Newton, Ray 2023-05-03	44	22	44	24	Sage Initial Designations
Newton, Ray 2023-05-03	45	1	45	5	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Newton, Ray 2023-05-03	45	16	45	19	Sage Initial Designations
Newton, Ray 2023-05-03	46	4	46	6	Sage Initial Designations
Newton, Ray 2023-05-03	46	14	46	16	Sage Initial Designations
Newton, Ray 2023-05-03	46	19	46	20	Sage Initial Designations
Newton, Ray 2023-05-03	47	1	47	7	Sage Initial Designations
Newton, Ray 2023-05-03	47	11	47	13	Sage Initial Designations
Newton, Ray 2023-05-03	47	17	47	19	Sage Initial Designations
Newton, Ray 2023-05-03	47	21	47	24	Sage Initial Designations
Newton, Ray 2023-05-03	48	1	48	1	Sage Initial Designations
Newton, Ray 2023-05-03	49	12	49	14	Sage Initial Designations
Newton, Ray 2023-05-03	49	19	49	24	Sage Initial Designations
Newton, Ray 2023-05-03	50	1	50	1	Sage Initial Designations
Newton, Ray 2023-05-03	50	17	50	24	Sage Initial Designations
Newton, Ray 2023-05-03	51	1	51	5	Sage Initial Designations
Newton, Ray 2023-05-03	51	8	51	9	Sage Initial Designations
Newton, Ray 2023-05-03	51	11	51	13	Sage Initial Designations
Newton, Ray 2023-05-03	51	17	51	17	Sage Initial Designations
Newton, Ray 2023-05-03	51	19	51	20	Sage Initial Designations
Newton, Ray 2023-05-03	52	4	52	6	Sage Initial Designations
Newton, Ray 2023-05-03	52	20	52	21	Sage Initial Designations
Newton, Ray 2023-05-03	53	1	53	1	Sage Initial Designations
Newton, Ray 2023-05-03	53	5	53	6	Sage Initial Designations
Newton, Ray 2023-05-03	53	9	53	10	Sage Initial Designations
Newton, Ray 2023-05-03	53	14	53	16	Sage Initial Designations
Newton, Ray 2023-05-03	53	19	53	19	Sage Initial Designations
Newton, Ray 2023-05-03	53	21	53	22	Sage Initial Designations
Newton, Ray 2023-05-03	54	2	54	4	Sage Initial Designations
Newton, Ray 2023-05-03	55	4	55	6	Sage Initial Designations
Newton, Ray 2023-05-03	55	16	55	18	Sage Initial Designations
Newton, Ray 2023-05-03	56	5	56	16	Sage Initial Designations
Newton, Ray 2023-05-03	56	19	56	19	Sage Initial Designations
Newton, Ray 2023-05-03	56	21	56	24	Sage Initial Designations
Newton, Ray 2023-05-03	57	3	57	6	Sage Initial Designations
Newton, Ray 2023-05-03	57	9	57	10	Sage Initial Designations
Newton, Ray 2023-05-03	57	12	57	14	Sage Initial Designations
Newton, Ray 2023-05-03	57	17	57	17	Sage Initial Designations
Newton, Ray 2023-05-03	58	23	59	7	Sage Initial Designations
Newton, Ray 2023-05-03	59	12	59	12	Sage Initial Designations
Newton, Ray 2023-05-03	60	4	60	7	Sage Initial Designations
Newton, Ray 2023-05-03	60	10	60	12	Sage Initial Designations
Newton, Ray 2023-05-03	61	22	61	23	Sage Initial Designations
Newton, Ray 2023-05-03	62	4	62	21	Sage Initial Designations
Newton, Ray 2023-05-03	64	22	65	1	Sage Initial Designations
Newton, Ray 2023-05-03	65	7	65	13	Sage Initial Designations
Newton, Ray 2023-05-03	65	21	66	13	Sage Initial Designations
Newton, Ray 2023-05-03	66	18	66	23	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Newton, Ray 2023-05-03	67	3	67	7	Sage Initial Designations
Newton, Ray 2023-05-03	67	16	67	18	Sage Initial Designations
Newton, Ray 2023-05-03	67	21	67	22	Sage Initial Designations
Newton, Ray 2023-05-03	68	1	68	4	Sage Initial Designations
Newton, Ray 2023-05-03	68	7	68	9	Sage Initial Designations
Newton, Ray 2023-05-03	68	13	68	14	Sage Initial Designations
Newton, Ray 2023-05-03	69	21	69	23	Sage Initial Designations
Newton, Ray 2023-05-03	70	3	70	3	Sage Initial Designations
Newton, Ray 2023-05-03	70	5	70	8	Sage Initial Designations
Newton, Ray 2023-05-03	70	11	70	11	Sage Initial Designations
Newton, Ray 2023-05-03	75	21	75	22	Sage Initial Designations
Newton, Ray 2023-05-03	76	3	76	6	Sage Initial Designations
Newton, Ray 2023-05-03	76	22	76	24	Sage Initial Designations
Newton, Ray 2023-05-03	77	1	77	1	Sage Initial Designations
Newton, Ray 2023-05-03	77	13	77	15	Sage Initial Designations
Newton, Ray 2023-05-03	77	18	77	21	Sage Initial Designations
Newton, Ray 2023-05-03	83	22	83	24	Sage Initial Designations
Newton, Ray 2023-05-03	84	4	84	20	Sage Initial Designations
Newton, Ray 2023-05-03	84	24	85	5	Sage Initial Designations
Newton, Ray 2023-05-03	87	4	87	5	Sage Initial Designations
Newton, Ray 2023-05-03	87	22	88	1	Sage Initial Designations
Newton, Ray 2023-05-03	88	5	88	7	Sage Initial Designations
Newton, Ray 2023-05-03	88	10	88	11	Sage Initial Designations
Newton, Ray 2023-05-03	88	13	88	14	Sage Initial Designations
Newton, Ray 2023-05-03	88	22	89	8	Sage Initial Designations
Newton, Ray 2023-05-03	89	12	89	12	Sage Initial Designations
Newton, Ray 2023-05-03	89	14	89	15	Sage Initial Designations
Newton, Ray 2023-05-03	89	20	89	22	Sage Initial Designations
Newton, Ray 2023-05-03	94	1	94	5	Sage Initial Designations
Newton, Ray 2023-05-03	94	8	94	9	Sage Initial Designations
Newton, Ray 2023-05-03	94	12	94	20	Sage Initial Designations
Newton, Ray 2023-05-03	94	24	95	1	Sage Initial Designations
Newton, Ray 2023-05-03	95	3	95	5	Sage Initial Designations
Newton, Ray 2023-05-03	95	12	95	16	Sage Initial Designations
Newton, Ray 2023-05-03	95	19	95	22	Sage Initial Designations
Newton, Ray 2023-05-03	96	2	96	8	Sage Initial Designations
Newton, Ray 2023-05-03	97	7	97	11	Sage Initial Designations
Newton, Ray 2023-05-03	97	14	97	14	Sage Initial Designations
Newton, Ray 2023-05-03	98	4	98	5	Sage Initial Designations
Newton, Ray 2023-05-03	98	10	98	13	Sage Initial Designations
Newton, Ray 2023-05-03	98	16	98	16	Sage Initial Designations
Newton, Ray 2023-05-03	100	9	100	10	Sage Initial Designations
Newton, Ray 2023-05-03	100	14	100	14	Sage Initial Designations
Newton, Ray 2023-05-03	100	16	100	18	Sage Initial Designations
Newton, Ray 2023-05-03	100	23	100	24	Sage Initial Designations
Newton, Ray 2023-05-03	101	1	101	3	Sage Initial Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Newton, Ray 2023-05-03	101	13	102	4	Sage Initial Designations
Newton, Ray 2023-05-03	103	18	103	22	Sage Initial Designations
Newton, Ray 2023-05-03	105	3	105	5	Sage Initial Designations
Newton, Ray 2023-05-03	105	9	105	11	Sage Initial Designations
Newton, Ray 2023-05-03	106	2	106	7	Sage Initial Designations
Newton, Ray 2023-05-03	106	12	106	13	Sage Initial Designations
Newton, Ray 2023-05-03	106	15	106	17	Sage Initial Designations
Newton, Ray 2023-05-03	106	20	106	23	Sage Initial Designations
Newton, Ray 2023-05-03	107	14	107	23	Sage Initial Designations
Newton, Ray 2023-05-03	108	1	108	3	Sage Initial Designations
Newton, Ray 2023-05-03	108	6	108	7	Sage Initial Designations
Newton, Ray 2023-05-03	108	10	108	10	Sage Initial Designations
Newton, Ray 2023-05-03	108	12	108	13	Sage Initial Designations
Newton, Ray 2023-05-03	108	16	108	16	Sage Initial Designations
Newton, Ray 2023-05-03	108	18	108	18	Sage Initial Designations
Newton, Ray 2023-05-03	108	22	108	23	Sage Initial Designations
Newton, Ray 2023-05-03	109	19	109	20	Sage Initial Designations
Newton, Ray 2023-05-03	110	1	111	15	Sage Initial Designations
Newton, Ray 2023-05-03	112	8	112	11	Sage Initial Designations
Newton, Ray 2023-05-03	112	14	112	15	Sage Initial Designations
Newton, Ray 2023-05-03	112	17	112	20	Sage Initial Designations
Newton, Ray 2023-05-03	113	21	113	23	Sage Initial Designations
Newton, Ray 2023-05-03	114	2	114	5	Sage Initial Designations
Newton, Ray 2023-05-03	115	12	115	15	Sage Initial Designations
Newton, Ray 2023-05-03	115	18	115	18	Sage Initial Designations
Newton, Ray 2023-05-03	115	20	115	21	Sage Initial Designations
Newton, Ray 2023-05-03	115	24	116	1	Sage Initial Designations
Newton, Ray 2023-05-03	116	3	116	9	Sage Initial Designations
Newton, Ray 2023-05-03	121	22	121	24	Sage Initial Designations
Newton, Ray 2023-05-03	122	5	122	8	Sage Initial Designations
Newton, Ray 2023-05-03	123	1	123	3	Sage Initial Designations
Newton, Ray 2023-05-03	123	6	123	6	Sage Initial Designations
Newton, Ray 2023-05-03	123	8	123	9	Sage Initial Designations
Newton, Ray 2023-05-03	123	12	123	13	Sage Initial Designations
Newton, Ray 2023-05-03	123	15	123	18	Sage Initial Designations
Newton, Ray 2023-05-03	124	15	124	17	Sage Initial Designations
Newton, Ray 2023-05-03	124	21	124	23	Sage Initial Designations
Newton, Ray 2023-05-03	132	22	132	24	Sage Initial Designations
Newton, Ray 2023-05-03	133	5	133	8	Sage Initial Designations
Newton, Ray 2023-05-03	133	11	133	12	Sage Initial Designations
Newton, Ray 2023-05-03	133	18	133	23	Sage Initial Designations
Newton, Ray 2023-05-03	134	7	134	8	Sage Initial Designations
Newton, Ray 2023-05-03	134	12	134	15	Sage Initial Designations
Newton, Ray 2023-05-03	134	23	134	24	Sage Initial Designations
Newton, Ray 2023-05-03	135	5	135	6	Sage Initial Designations
Newton, Ray 2023-05-03	135	11	135	14	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Newton, Ray 2023-05-03	135	17	135	19	Sage Initial Designations
Newton, Ray 2023-05-03	135	23	135	23	Sage Initial Designations
Newton, Ray 2023-05-03	136	1	136	3	Sage Initial Designations
Newton, Ray 2023-05-03	136	8	136	10	Sage Initial Designations
Newton, Ray 2023-05-03	136	14	136	16	Sage Initial Designations
Newton, Ray 2023-05-03	137	2	137	3	Sage Initial Designations
Newton, Ray 2023-05-03	137	10	137	11	Sage Initial Designations
Newton, Ray 2023-05-03	137	14	137	16	Sage Initial Designations
Newton, Ray 2023-05-03	138	10	138	12	Sage Initial Designations
Newton, Ray 2023-05-03	138	16	138	16	Sage Initial Designations
Newton, Ray 2023-05-03	139	2	139	3	Sage Initial Designations
Newton, Ray 2023-05-03	139	8	139	11	Sage Initial Designations
Newton, Ray 2023-05-03	141	9	141	22	Sage Initial Designations
Newton, Ray 2023-05-03	142	1	142	1	Sage Initial Designations
Newton, Ray 2023-05-03	142	17	143	5	Sage Initial Designations
Newton, Ray 2023-05-03	143	8	143	9	Sage Initial Designations
Newton, Ray 2023-05-03	143	11	143	15	Sage Initial Designations
Newton, Ray 2023-05-03	144	14	144	16	Sage Initial Designations
Newton, Ray 2023-05-03	144	23	144	24	Sage Initial Designations
Newton, Ray 2023-05-03	145	3	145	3	Sage Initial Designations
Newton, Ray 2023-05-03	145	6	145	6	Sage Initial Designations
Newton, Ray 2023-05-03	145	13	145	16	Sage Initial Designations
Newton, Ray 2023-05-03	145	20	145	20	Sage Initial Designations
Newton, Ray 2023-05-03	145	22	145	24	Sage Initial Designations
Newton, Ray 2023-05-03	146	3	146	3	Sage Initial Designations
Newton, Ray 2023-05-03	146	5	146	6	Sage Initial Designations
Newton, Ray 2023-05-03	146	11	146	14	Sage Initial Designations
Newton, Ray 2023-05-03	146	21	146	22	Sage Initial Designations
Newton, Ray 2023-05-03	147	2	147	2	Sage Initial Designations
Newton, Ray 2023-05-03	147	11	147	12	Sage Initial Designations
Newton, Ray 2023-05-03	147	16	147	17	Sage Initial Designations
Newton, Ray 2023-05-03	147	19	147	20	Sage Initial Designations
Newton, Ray 2023-05-03	149	12	149	13	Sage Initial Designations
Newton, Ray 2023-05-03	149	20	149	21	Sage Initial Designations
Newton, Ray 2023-05-03	149	24	150	1	Sage Initial Designations
Newton, Ray 2023-05-03	150	22	151	3	Sage Initial Designations
Newton, Ray 2023-05-03	151	8	151	22	Sage Initial Designations
Newton, Ray 2023-05-03	152	5	152	6	Sage Initial Designations
Newton, Ray 2023-05-03	152	8	152	13	Sage Initial Designations
Newton, Ray 2023-05-03	152	16	152	16	Sage Initial Designations
Newton, Ray 2023-05-03	152	18	152	19	Sage Initial Designations
Newton, Ray 2023-05-03	153	1	153	6	Sage Initial Designations
Newton, Ray 2023-05-03	153	10	153	11	Sage Initial Designations
Newton, Ray 2023-05-03	160	2	160	3	Sage Initial Designations
Newton, Ray 2023-05-03	160	8	160	13	Sage Initial Designations
Newton, Ray 2023-05-03	160	22	160	22	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Newton, Ray 2023-05-03	161	1	161	2	Sage Initial Designations
Newton, Ray 2023-05-03	161	21	161	24	Sage Initial Designations
Newton, Ray 2023-05-03	162	24	163	3	Sage Initial Designations
Newton, Ray 2023-05-03	163	6	163	7	Sage Initial Designations
Newton, Ray 2023-05-03	163	19	164	4	Sage Initial Designations
Newton, Ray 2023-05-03	164	7	164	7	Sage Initial Designations
Newton, Ray 2023-05-03	164	17	164	19	Sage Initial Designations
Newton, Ray 2023-05-03	164	22	164	22	Sage Initial Designations
Newton, Ray 2023-05-03	164	24	165	2	Sage Initial Designations
Newton, Ray 2023-05-03	165	5	165	5	Sage Initial Designations
Newton, Ray 2023-05-03	168	17	168	19	Sage Initial Designations
Newton, Ray 2023-05-03	168	23	168	24	Sage Initial Designations
Newton, Ray 2023-05-03	170	3	170	9	Sage Initial Designations
Newton, Ray 2023-05-03	170	17	170	20	Sage Initial Designations
Newton, Ray 2023-05-03	171	2	171	7	Sage Initial Designations
Newton, Ray 2023-05-03	171	11	171	14	Sage Initial Designations
Newton, Ray 2023-05-03	171	16	171	21	Sage Initial Designations
Newton, Ray 2023-05-03	174	16	174	21	Sage Initial Designations
Newton, Ray 2023-05-03	175	1	175	2	Sage Initial Designations
Newton, Ray 2023-05-03	176	5	176	7	Sage Initial Designations
Newton, Ray 2023-05-03	176	12	176	20	Sage Initial Designations
Newton, Ray 2023-05-03	177	1	177	2	Sage Initial Designations
Newton, Ray 2023-05-03	177	16	177	21	Sage Initial Designations
Newton, Ray 2023-05-03	178	4	178	6	Sage Initial Designations
Newton, Ray 2023-05-03	178	10	178	11	Sage Initial Designations
Newton, Ray 2023-05-03	178	16	178	16	Sage Initial Designations
Newton, Ray 2023-05-03	178	18	178	21	Sage Initial Designations
Newton, Ray 2023-05-03	179	1	179	2	Sage Initial Designations
Newton, Ray 2023-05-03	179	9	179	12	Sage Initial Designations
Newton, Ray 2023-05-03	179	16	179	23	Sage Initial Designations
Newton, Ray 2023-05-03	180	3	180	8	Sage Initial Designations
Newton, Ray 2023-05-03	180	12	180	12	Sage Initial Designations
Newton, Ray 2023-05-03	180	14	180	17	Sage Initial Designations
Newton, Ray 2023-05-03	181	1	181	4	Sage Initial Designations
Newton, Ray 2023-05-03	182	6	182	9	Sage Initial Designations
Newton, Ray 2023-05-03	184	4	184	7	Sage Initial Designations
Newton, Ray 2023-05-03	185	14	185	17	Sage Initial Designations
Newton, Ray 2023-05-03	186	23	187	10	Sage Initial Designations
Newton, Ray 2023-05-03	187	15	187	18	Sage Initial Designations
Newton, Ray 2023-05-03	193	2	193	3	Sage Initial Designations
Newton, Ray 2023-05-03	193	13	193	18	Sage Initial Designations
Newton, Ray 2023-05-03	194	16	194	17	Sage Initial Designations
Newton, Ray 2023-05-03	194	22	194	22	Sage Initial Designations
Newton, Ray 2023-05-03	196	8	196	10	Sage Initial Designations
Newton, Ray 2023-05-03	196	14	196	14	Sage Initial Designations
Newton, Ray 2023-05-03	196	21	196	23	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Newton, Ray 2023-05-03	197	3	197	5	Sage Initial Designations
Newton, Ray 2023-05-03	197	7	197	15	Sage Initial Designations
Newton, Ray 2023-05-03	198	3	198	9	Sage Initial Designations
Newton, Ray 2023-05-03	198	12	198	18	Sage Initial Designations
Newton, Ray 2023-05-03	200	10	200	20	Sage Initial Designations
Newton, Ray 2023-05-03	200	23	201	1	Sage Initial Designations
Newton, Ray 2023-05-03	205	12	205	14	Sage Initial Designations
Newton, Ray 2023-05-03	205	19	205	22	Sage Initial Designations
Newton, Ray 2023-05-03	206	15	206	23	Sage Initial Designations
Newton, Ray 2023-05-03	207	2	207	4	Sage Initial Designations
Newton, Ray 2023-05-03	207	9	207	9	Sage Initial Designations
Newton, Ray 2023-05-03	207	11	207	11	Sage Initial Designations
Newton, Ray 2023-05-03	207	13	207	15	Sage Initial Designations
Newton, Ray 2023-05-03	207	18	207	18	Sage Initial Designations
Newton, Ray 2023-05-03	207	20	207	21	Sage Initial Designations
Newton, Ray 2023-05-03	207	24	208	1	Sage Initial Designations
Newton, Ray 2023-05-03	208	5	208	9	Sage Initial Designations
Newton, Ray 2023-05-03	208	11	208	13	Sage Initial Designations
Newton, Ray 2023-05-03	208	16	208	16	Sage Initial Designations
Newton, Ray 2023-05-03	208	18	208	21	Sage Initial Designations
Newton, Ray 2023-05-03	208	24	208	24	Sage Initial Designations
Newton, Ray 2023-05-03	209	9	209	10	Sage Initial Designations
Newton, Ray 2023-05-03	209	15	209	22	Sage Initial Designations
Newton, Ray 2023-05-03	221	9	221	11	Sage Initial Designations
Newton, Ray 2023-05-03	221	16	221	18	Sage Initial Designations
Newton, Ray 2023-05-03	224	21	224	24	Sage Initial Designations
Newton, Ray 2023-05-03	225	3	225	3	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Pawlik, Kate 2023-03-17	4	21	5	2	Sage Initial Designations
Pawlik, Kate 2023-03-17	14	15	14	19	Sage Initial Designations
Pawlik, Kate 2023-03-17	15	18	15	21	Sage Initial Designations
Pawlik, Kate 2023-03-17	19	12	19	13	Sage Initial Designations
Pawlik, Kate 2023-03-17	19	16	19	18	Sage Initial Designations
Pawlik, Kate 2023-03-17	19	21	19	22	Sage Initial Designations
Pawlik, Kate 2023-03-17	20	8	20	14	Sage Initial Designations
Pawlik, Kate 2023-03-17	20	17	20	19	Sage Initial Designations
Pawlik, Kate 2023-03-17	20	23	20	24	Sage Initial Designations
Pawlik, Kate 2023-03-17	21	2	21	3	Sage Initial Designations
Pawlik, Kate 2023-03-17	21	16	21	16	Sage Initial Designations
Pawlik, Kate 2023-03-17	22	3	22	5	Sage Initial Designations
Pawlik, Kate 2023-03-17	22	8	22	9	Sage Initial Designations
Pawlik, Kate 2023-03-17	23	17	23	20	Sage Initial Designations
Pawlik, Kate 2023-03-17	26	12	26	17	Sage Initial Designations
Pawlik, Kate 2023-03-17	26	24	27	2	Sage Initial Designations
Pawlik, Kate 2023-03-17	29	6	29	14	Sage Initial Designations
Pawlik, Kate 2023-03-17	29	19	30	1	Sage Initial Designations
Pawlik, Kate 2023-03-17	30	2	30	8	Sage Initial Designations
Pawlik, Kate 2023-03-17	30	11	30	18	Sage Initial Designations
Pawlik, Kate 2023-03-17	30	19	30	21	Sage Initial Designations
Pawlik, Kate 2023-03-17	31	1	31	3	Sage Initial Designations
Pawlik, Kate 2023-03-17	31	14	31	17	Sage Initial Designations
Pawlik, Kate 2023-03-17	31	20	31	21	Sage Initial Designations
Pawlik, Kate 2023-03-17	31	23	32	1	Sage Initial Designations
Pawlik, Kate 2023-03-17	32	24	33	4	Sage Initial Designations
Pawlik, Kate 2023-03-17	33	17	33	19	Sage Initial Designations
Pawlik, Kate 2023-03-17	33	23	33	24	Sage Initial Designations
Pawlik, Kate 2023-03-17	36	16	36	17	Sage Initial Designations
Pawlik, Kate 2023-03-17	36	21	36	23	Sage Initial Designations
Pawlik, Kate 2023-03-17	37	1	37	5	Sage Initial Designations
Pawlik, Kate 2023-03-17	37	8	37	14	Sage Initial Designations
Pawlik, Kate 2023-03-17	38	8	38	15	Sage Initial Designations
Pawlik, Kate 2023-03-17	39	23	40	2	Sage Initial Designations
Pawlik, Kate 2023-03-17	41	1	41	4	Sage Initial Designations
Pawlik, Kate 2023-03-17	41	7	41	8	Sage Initial Designations
Pawlik, Kate 2023-03-17	41	13	41	16	Sage Initial Designations
Pawlik, Kate 2023-03-17	41	21	41	22	Sage Initial Designations
Pawlik, Kate 2023-03-17	42	3	42	7	Sage Initial Designations
Pawlik, Kate 2023-03-17	42	8	42	14	Sage Initial Designations
Pawlik, Kate 2023-03-17	43	20	43	23	Sage Initial Designations
Pawlik, Kate 2023-03-17	45	6	45	9	Sage Initial Designations
Pawlik, Kate 2023-03-17	47	14	47	20	Sage Initial Designations
Pawlik, Kate 2023-03-17	48	13	48	16	Sage Initial Designations
Pawlik, Kate 2023-03-17	48	20	48	20	Sage Initial Designations
Pawlik, Kate 2023-03-17	50	11	50	13	Sage Initial Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Pawlik, Kate 2023-03-17	50	16	50	17	Sage Initial Designations
Pawlik, Kate 2023-03-17	52	14	53	3	Sage Initial Designations
Pawlik, Kate 2023-03-17	53	4	53	7	Sage Initial Designations
Pawlik, Kate 2023-03-17	53	11	53	12	Sage Initial Designations
Pawlik, Kate 2023-03-17	55	12	55	14	Sage Initial Designations
Pawlik, Kate 2023-03-17	55	17	55	17	Sage Initial Designations
Pawlik, Kate 2023-03-17	55	22	56	1	Sage Initial Designations
Pawlik, Kate 2023-03-17	56	6	56	8	Sage Initial Designations
Pawlik, Kate 2023-03-17	57	9	57	12	Sage Initial Designations
Pawlik, Kate 2023-03-17	57	15	57	15	Sage Initial Designations
Pawlik, Kate 2023-03-17	58	15	58	19	Sage Initial Designations
Pawlik, Kate 2023-03-17	58	20	59	1	Sage Initial Designations
Pawlik, Kate 2023-03-17	59	4	59	5	Sage Initial Designations
Pawlik, Kate 2023-03-17	59	7	59	12	Sage Initial Designations
Pawlik, Kate 2023-03-17	60	4	60	7	Sage Initial Designations
Pawlik, Kate 2023-03-17	60	8	60	17	Sage Initial Designations
Pawlik, Kate 2023-03-17	62	4	62	6	Sage Initial Designations
Pawlik, Kate 2023-03-17	63	1	63	4	Sage Initial Designations
Pawlik, Kate 2023-03-17	63	7	63	7	Sage Initial Designations
Pawlik, Kate 2023-03-17	65	19	65	21	Sage Initial Designations
Pawlik, Kate 2023-03-17	65	24	66	1	Sage Initial Designations
Pawlik, Kate 2023-03-17	66	3	66	5	Sage Initial Designations
Pawlik, Kate 2023-03-17	66	8	66	8	Sage Initial Designations
Pawlik, Kate 2023-03-17	66	22	66	24	Sage Initial Designations
Pawlik, Kate 2023-03-17	67	3	67	3	Sage Initial Designations
Pawlik, Kate 2023-03-17	67	12	67	23	Sage Initial Designations
Pawlik, Kate 2023-03-17	68	5	68	7	Sage Initial Designations
Pawlik, Kate 2023-03-17	68	11	68	12	Sage Initial Designations
Pawlik, Kate 2023-03-17	69	14	69	17	Sage Initial Designations
Pawlik, Kate 2023-03-17	71	22	72	3	Sage Initial Designations
Pawlik, Kate 2023-03-17	72	4	72	7	Sage Initial Designations
Pawlik, Kate 2023-03-17	72	10	72	11	Sage Initial Designations
Pawlik, Kate 2023-03-17	73	21	73	24	Sage Initial Designations
Pawlik, Kate 2023-03-17	74	5	74	7	Sage Initial Designations
Pawlik, Kate 2023-03-17	74	8	74	13	Sage Initial Designations
Pawlik, Kate 2023-03-17	74	14	74	21	Sage Initial Designations
Pawlik, Kate 2023-03-17	75	1	75	7	Sage Initial Designations
Pawlik, Kate 2023-03-17	75	11	75	13	Sage Initial Designations
Pawlik, Kate 2023-03-17	75	15	75	18	Sage Initial Designations
Pawlik, Kate 2023-03-17	75	19	75	24	Sage Initial Designations
Pawlik, Kate 2023-03-17	77	16	77	19	Sage Initial Designations
Pawlik, Kate 2023-03-17	77	24	78	3	Sage Initial Designations
Pawlik, Kate 2023-03-17	78	17	78	19	Sage Initial Designations
Pawlik, Kate 2023-03-17	79	13	79	16	Sage Initial Designations
Pawlik, Kate 2023-03-17	79	20	80	1	Sage Initial Designations
Pawlik, Kate 2023-03-17	80	16	80	23	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Pawlik, Kate 2023-03-17	81	4	81	7	Sage Initial Designations
Pawlik, Kate 2023-03-17	81	13	81	16	Sage Initial Designations
Pawlik, Kate 2023-03-17	82	23	82	24	Sage Initial Designations
Pawlik, Kate 2023-03-17	83	3	83	8	Sage Initial Designations
Pawlik, Kate 2023-03-17	83	11	83	17	Sage Initial Designations
Pawlik, Kate 2023-03-17	83	18	83	20	Sage Initial Designations
Pawlik, Kate 2023-03-17	83	24	84	3	Sage Initial Designations
Pawlik, Kate 2023-03-17	84	8	84	11	Sage Initial Designations
Pawlik, Kate 2023-03-17	84	16	84	18	Sage Initial Designations
Pawlik, Kate 2023-03-17	85	15	85	18	Sage Initial Designations
Pawlik, Kate 2023-03-17	86	2	86	11	Sage Initial Designations
Pawlik, Kate 2023-03-17	86	12	86	24	Sage Initial Designations
Pawlik, Kate 2023-03-17	87	11	87	13	Sage Initial Designations
Pawlik, Kate 2023-03-17	87	17	87	18	Sage Initial Designations
Pawlik, Kate 2023-03-17	87	23	88	2	Sage Initial Designations
Pawlik, Kate 2023-03-17	88	20	88	24	Sage Initial Designations
Pawlik, Kate 2023-03-17	89	1	89	4	Sage Initial Designations
Pawlik, Kate 2023-03-17	89	7	89	7	Sage Initial Designations
Pawlik, Kate 2023-03-17	89	13	89	21	Sage Initial Designations
Pawlik, Kate 2023-03-17	89	22	90	4	Sage Initial Designations
Pawlik, Kate 2023-03-17	90	8	90	10	Sage Initial Designations
Pawlik, Kate 2023-03-17	90	15	90	22	Sage Initial Designations
Pawlik, Kate 2023-03-17	91	1	91	11	Sage Initial Designations
Pawlik, Kate 2023-03-17	91	15	91	18	Sage Initial Designations
Pawlik, Kate 2023-03-17	91	23	92	2	Sage Initial Designations
Pawlik, Kate 2023-03-17	92	7	92	10	Sage Initial Designations
Pawlik, Kate 2023-03-17	93	10	93	13	Sage Initial Designations
Pawlik, Kate 2023-03-17	93	14	93	17	Sage Initial Designations
Pawlik, Kate 2023-03-17	94	9	94	11	Sage Initial Designations
Pawlik, Kate 2023-03-17	94	14	94	24	Sage Initial Designations
Pawlik, Kate 2023-03-17	95	3	95	4	Sage Initial Designations
Pawlik, Kate 2023-03-17	95	6	95	9	Sage Initial Designations
Pawlik, Kate 2023-03-17	95	12	95	19	Sage Initial Designations
Pawlik, Kate 2023-03-17	95	22	95	22	Sage Initial Designations
Pawlik, Kate 2023-03-17	96	2	96	3	Sage Initial Designations
Pawlik, Kate 2023-03-17	96	7	96	10	Sage Initial Designations
Pawlik, Kate 2023-03-17	96	15	96	19	Sage Initial Designations
Pawlik, Kate 2023-03-17	97	1	97	4	Sage Initial Designations
Pawlik, Kate 2023-03-17	97	18	97	21	Sage Initial Designations
Pawlik, Kate 2023-03-17	98	3	98	5	Sage Initial Designations
Pawlik, Kate 2023-03-17	98	7	98	14	Sage Initial Designations
Pawlik, Kate 2023-03-17	98	18	98	21	Sage Initial Designations
Pawlik, Kate 2023-03-17	99	5	99	19	Sage Initial Designations
Pawlik, Kate 2023-03-17	100	1	100	2	Sage Initial Designations
Pawlik, Kate 2023-03-17	100	13	100	20	Sage Initial Designations
Pawlik, Kate 2023-03-17	100	21	100	24	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Pawlik, Kate 2023-03-17	101	4	101	6	Sage Initial Designations
Pawlik, Kate 2023-03-17	101	12	101	23	Sage Initial Designations
Pawlik, Kate 2023-03-17	103	10	103	10	Sage Initial Designations
Pawlik, Kate 2023-03-17	103	14	103	17	Sage Initial Designations
Pawlik, Kate 2023-03-17	104	6	104	9	Sage Initial Designations
Pawlik, Kate 2023-03-17	104	14	104	16	Sage Initial Designations
Pawlik, Kate 2023-03-17	105	4	105	7	Sage Initial Designations
Pawlik, Kate 2023-03-17	105	23	106	2	Sage Initial Designations
Pawlik, Kate 2023-03-17	106	3	106	7	Sage Initial Designations
Pawlik, Kate 2023-03-17	108	12	108	14	Sage Initial Designations
Pawlik, Kate 2023-03-17	108	18	108	19	Sage Initial Designations
Pawlik, Kate 2023-03-17	108	23	109	1	Sage Initial Designations
Pawlik, Kate 2023-03-17	109	4	109	5	Sage Initial Designations
Pawlik, Kate 2023-03-17	109	7	109	11	Sage Initial Designations
Pawlik, Kate 2023-03-17	110	9	110	12	Sage Initial Designations
Pawlik, Kate 2023-03-17	110	23	111	3	Sage Initial Designations
Pawlik, Kate 2023-03-17	111	4	111	5	Sage Initial Designations
Pawlik, Kate 2023-03-17	111	8	111	9	Sage Initial Designations
Pawlik, Kate 2023-03-17	111	13	111	16	Sage Initial Designations
Pawlik, Kate 2023-03-17	112	15	112	17	Sage Initial Designations
Pawlik, Kate 2023-03-17	112	18	112	21	Sage Initial Designations
Pawlik, Kate 2023-03-17	112	24	113	1	Sage Initial Designations
Pawlik, Kate 2023-03-17	113	3	113	4	Sage Initial Designations
Pawlik, Kate 2023-03-17	113	7	113	8	Sage Initial Designations
Pawlik, Kate 2023-03-17	113	13	113	24	Sage Initial Designations
Pawlik, Kate 2023-03-17	114	9	114	13	Sage Initial Designations
Pawlik, Kate 2023-03-17	114	16	114	23	Sage Initial Designations
Pawlik, Kate 2023-03-17	115	4	115	7	Sage Initial Designations
Pawlik, Kate 2023-03-17	115	12	115	15	Sage Initial Designations
Pawlik, Kate 2023-03-17	117	8	117	11	Sage Initial Designations
Pawlik, Kate 2023-03-17	117	16	117	19	Sage Initial Designations
Pawlik, Kate 2023-03-17	117	22	118	4	Sage Initial Designations
Pawlik, Kate 2023-03-17	118	22	118	23	Sage Initial Designations
Pawlik, Kate 2023-03-17	119	3	119	4	Sage Initial Designations
Pawlik, Kate 2023-03-17	120	7	120	10	Sage Initial Designations
Pawlik, Kate 2023-03-17	121	3	121	5	Sage Initial Designations
Pawlik, Kate 2023-03-17	121	12	121	13	Sage Initial Designations
Pawlik, Kate 2023-03-17	121	22	122	4	Sage Initial Designations
Pawlik, Kate 2023-03-17	122	10	122	12	Sage Initial Designations
Pawlik, Kate 2023-03-17	122	15	122	16	Sage Initial Designations
Pawlik, Kate 2023-03-17	122	18	123	3	Sage Initial Designations
Pawlik, Kate 2023-03-17	123	7	123	15	Sage Initial Designations
Pawlik, Kate 2023-03-17	123	16	123	20	Sage Initial Designations
Pawlik, Kate 2023-03-17	125	3	125	5	Sage Initial Designations
Pawlik, Kate 2023-03-17	125	9	125	11	Sage Initial Designations
Pawlik, Kate 2023-03-17	126	20	126	21	Sage Initial Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Pawlik, Kate 2023-03-17	127	1	127	3	Sage Initial Designations
Pawlik, Kate 2023-03-17	127	5	127	8	Sage Initial Designations
Pawlik, Kate 2023-03-17	127	17	127	20	Sage Initial Designations
Pawlik, Kate 2023-03-17	128	5	128	13	Sage Initial Designations
Pawlik, Kate 2023-03-17	128	14	128	19	Sage Initial Designations
Pawlik, Kate 2023-03-17	128	22	129	6	Sage Initial Designations
Pawlik, Kate 2023-03-17	129	9	129	15	Sage Initial Designations
Pawlik, Kate 2023-03-17	129	16	129	18	Sage Initial Designations
Pawlik, Kate 2023-03-17	129	22	130	6	Sage Initial Designations
Pawlik, Kate 2023-03-17	130	17	130	20	Sage Initial Designations
Pawlik, Kate 2023-03-17	130	24	131	6	Sage Initial Designations
Pawlik, Kate 2023-03-17	131	9	131	10	Sage Initial Designations
Pawlik, Kate 2023-03-17	131	15	131	21	Sage Initial Designations
Pawlik, Kate 2023-03-17	131	23	131	24	Sage Initial Designations
Pawlik, Kate 2023-03-17	132	4	132	5	Sage Initial Designations
Pawlik, Kate 2023-03-17	133	6	133	8	Sage Initial Designations
Pawlik, Kate 2023-03-17	133	11	133	12	Sage Initial Designations
Pawlik, Kate 2023-03-17	133	16	133	18	Sage Initial Designations
Pawlik, Kate 2023-03-17	133	22	133	22	Sage Initial Designations
Pawlik, Kate 2023-03-17	133	24	134	6	Sage Initial Designations
Pawlik, Kate 2023-03-17	134	10	134	13	Sage Initial Designations
Pawlik, Kate 2023-03-17	134	16	134	18	Sage Initial Designations
Pawlik, Kate 2023-03-17	135	5	135	6	Sage Initial Designations
Pawlik, Kate 2023-03-17	135	9	135	10	Sage Initial Designations
Pawlik, Kate 2023-03-17	135	13	135	16	Sage Initial Designations
Pawlik, Kate 2023-03-17	135	18	135	19	Sage Initial Designations
Pawlik, Kate 2023-03-17	135	22	135	23	Sage Initial Designations
Pawlik, Kate 2023-03-17	136	9	136	10	Sage Initial Designations
Pawlik, Kate 2023-03-17	136	13	136	20	Sage Initial Designations
Pawlik, Kate 2023-03-17	136	21	136	22	Sage Initial Designations
Pawlik, Kate 2023-03-17	137	1	137	3	Sage Initial Designations
Pawlik, Kate 2023-03-17	137	6	137	7	Sage Initial Designations
Pawlik, Kate 2023-03-17	137	10	137	13	Sage Initial Designations
Pawlik, Kate 2023-03-17	137	18	137	19	Sage Initial Designations
Pawlik, Kate 2023-03-17	137	22	138	1	Sage Initial Designations
Pawlik, Kate 2023-03-17	138	21	138	22	Sage Initial Designations
Pawlik, Kate 2023-03-17	140	7	140	9	Sage Initial Designations
Pawlik, Kate 2023-03-17	140	13	140	15	Sage Initial Designations
Pawlik, Kate 2023-03-17	140	21	140	21	Sage Initial Designations
Pawlik, Kate 2023-03-17	141	1	141	3	Sage Initial Designations
Pawlik, Kate 2023-03-17	147	11	147	14	Sage Initial Designations
Pawlik, Kate 2023-03-17	147	18	147	20	Sage Initial Designations
Pawlik, Kate 2023-03-17	147	21	148	2	Sage Initial Designations
Pawlik, Kate 2023-03-17	148	6	148	9	Sage Initial Designations
Pawlik, Kate 2023-03-17	148	10	148	22	Sage Initial Designations
Pawlik, Kate 2023-03-17	149	7	149	9	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Pawlik, Kate 2023-03-17	149	12	149	12	Sage Initial Designations
Pawlik, Kate 2023-03-17	149	20	149	22	Sage Initial Designations
Pawlik, Kate 2023-03-17	154	8	154	11	Sage Initial Designations
Pawlik, Kate 2023-03-17	154	14	154	14	Sage Initial Designations
Pawlik, Kate 2023-03-17	154	16	154	19	Sage Initial Designations
Pawlik, Kate 2023-03-17	154	22	154	22	Sage Initial Designations
Pawlik, Kate 2023-03-17	156	10	156	11	Sage Initial Designations
Pawlik, Kate 2023-03-17	156	15	156	15	Sage Initial Designations
Pawlik, Kate 2023-03-17	157	16	157	20	Sage Initial Designations
Pawlik, Kate 2023-03-17	158	5	158	9	Sage Initial Designations
Pawlik, Kate 2023-03-17	159	2	159	5	Sage Initial Designations
Pawlik, Kate 2023-03-17	159	21	160	2	Sage Initial Designations
Pawlik, Kate 2023-03-17	167	22	168	6	Sage Initial Designations
Pawlik, Kate 2023-03-17	168	19	168	22	Sage Initial Designations
Pawlik, Kate 2023-03-17	168	24	169	3	Sage Initial Designations
Pawlik, Kate 2023-03-17	169	24	170	4	Sage Initial Designations
Pawlik, Kate 2023-03-17	171	5	171	6	Sage Initial Designations
Pawlik, Kate 2023-03-17	171	9	171	9	Sage Initial Designations
Pawlik, Kate 2023-03-17	173	11	173	14	Sage Initial Designations
Pawlik, Kate 2023-03-17	173	19	173	21	Sage Initial Designations
Pawlik, Kate 2023-03-17	174	2	174	2	Sage Initial Designations
Pawlik, Kate 2023-03-17	174	8	174	11	Sage Initial Designations
Pawlik, Kate 2023-03-17	175	1	175	4	Sage Initial Designations
Pawlik, Kate 2023-03-17	175	7	175	19	Sage Initial Designations
Pawlik, Kate 2023-03-17	175	22	176	6	Sage Initial Designations
Pawlik, Kate 2023-03-17	176	10	176	10	Sage Initial Designations
Pawlik, Kate 2023-03-17	176	14	176	17	Sage Initial Designations
Pawlik, Kate 2023-03-17	176	19	176	23	Sage Initial Designations
Pawlik, Kate 2023-03-17	177	12	177	19	Sage Initial Designations
Pawlik, Kate 2023-03-17	177	23	177	24	Sage Initial Designations
Pawlik, Kate 2023-03-17	178	2	178	4	Sage Initial Designations
Pawlik, Kate 2023-03-17	178	7	178	11	Sage Initial Designations
Pawlik, Kate 2023-03-17	179	5	179	9	Sage Initial Designations
Pawlik, Kate 2023-03-17	179	12	179	13	Sage Initial Designations
Pawlik, Kate 2023-03-17	179	18	179	23	Sage Initial Designations
Pawlik, Kate 2023-03-17	179	24	180	2	Sage Initial Designations
Pawlik, Kate 2023-03-17	180	5	180	5	Sage Initial Designations
Pawlik, Kate 2023-03-17	180	21	180	24	Sage Initial Designations
Pawlik, Kate 2023-03-17	181	5	181	13	Sage Initial Designations
Pawlik, Kate 2023-03-17	181	21	182	1	Sage Initial Designations
Pawlik, Kate 2023-03-17	182	4	182	5	Sage Initial Designations
Pawlik, Kate 2023-03-17	183	22	183	23	Sage Initial Designations
Pawlik, Kate 2023-03-17	184	3	184	6	Sage Initial Designations
Pawlik, Kate 2023-03-17	184	10	184	13	Sage Initial Designations
Pawlik, Kate 2023-03-17	184	17	185	1	Sage Initial Designations
Pawlik, Kate 2023-03-17	185	4	185	7	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Pawlik, Kate 2023-03-17	185	11	185	13	Sage Initial Designations
Pawlik, Kate 2023-03-17	185	19	186	6	Sage Initial Designations
Pawlik, Kate 2023-03-17	186	10	186	13	Sage Initial Designations
Pawlik, Kate 2023-03-17	186	15	186	17	Sage Initial Designations
Pawlik, Kate 2023-03-17	187	2	187	12	Sage Initial Designations
Pawlik, Kate 2023-03-17	187	18	187	22	Sage Initial Designations
Pawlik, Kate 2023-03-17	188	5	188	10	Sage Initial Designations
Pawlik, Kate 2023-03-17	188	14	188	17	Sage Initial Designations
Pawlik, Kate 2023-03-17	189	6	189	12	Sage Initial Designations
Pawlik, Kate 2023-03-17	189	15	189	17	Sage Initial Designations
Pawlik, Kate 2023-03-17	191	5	191	12	Sage Initial Designations
Pawlik, Kate 2023-03-17	191	16	191	18	Sage Initial Designations
Pawlik, Kate 2023-03-17	192	9	192	11	Sage Initial Designations
Pawlik, Kate 2023-03-17	192	15	192	22	Sage Initial Designations
Pawlik, Kate 2023-03-17	193	2	193	2	Sage Initial Designations
Pawlik, Kate 2023-03-17	194	17	194	23	Sage Initial Designations
Pawlik, Kate 2023-03-17	195	4	195	8	Sage Initial Designations
Pawlik, Kate 2023-03-17	195	13	195	16	Sage Initial Designations
Pawlik, Kate 2023-03-17	196	8	196	11	Sage Initial Designations
Pawlik, Kate 2023-03-17	196	16	196	17	Sage Initial Designations
Pawlik, Kate 2023-03-17	197	2	197	5	Sage Initial Designations
Pawlik, Kate 2023-03-17	197	8	197	9	Sage Initial Designations
Pawlik, Kate 2023-03-17	198	7	198	10	Sage Initial Designations
Pawlik, Kate 2023-03-17	198	12	198	15	Sage Initial Designations
Pawlik, Kate 2023-03-17	198	19	198	21	Sage Initial Designations
Pawlik, Kate 2023-03-17	198	24	199	3	Sage Initial Designations
Pawlik, Kate 2023-03-17	199	8	199	11	Sage Initial Designations
Pawlik, Kate 2023-03-17	199	15	199	18	Sage Initial Designations
Pawlik, Kate 2023-03-17	199	20	199	23	Sage Initial Designations
Pawlik, Kate 2023-03-17	200	4	200	13	Sage Initial Designations
Pawlik, Kate 2023-03-17	200	16	200	24	Sage Initial Designations
Pawlik, Kate 2023-03-17	201	1	201	7	Sage Initial Designations
Pawlik, Kate 2023-03-17	202	2	202	6	Sage Initial Designations
Pawlik, Kate 2023-03-17	202	9	202	10	Sage Initial Designations
Pawlik, Kate 2023-03-17	203	3	203	4	Sage Initial Designations
Pawlik, Kate 2023-03-17	203	8	203	11	Sage Initial Designations
Pawlik, Kate 2023-03-17	204	5	204	16	Sage Initial Designations
Pawlik, Kate 2023-03-17	204	19	205	3	Sage Initial Designations
Pawlik, Kate 2023-03-17	205	15	205	19	Sage Initial Designations
Pawlik, Kate 2023-03-17	206	7	206	10	Sage Initial Designations
Pawlik, Kate 2023-03-17	206	14	206	16	Sage Initial Designations
Pawlik, Kate 2023-03-17	207	20	207	23	Sage Initial Designations
Pawlik, Kate 2023-03-17	208	1	208	6	Sage Initial Designations
Pawlik, Kate 2023-03-17	208	15	208	18	Sage Initial Designations
Pawlik, Kate 2023-03-17	210	2	210	5	Sage Initial Designations
Pawlik, Kate 2023-03-17	210	13	210	15	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Pawlik, Kate 2023-03-17	210	18	210	19	Sage Initial Designations
Pawlik, Kate 2023-03-17	211	1	211	4	Sage Initial Designations
Pawlik, Kate 2023-03-17	211	5	211	14	Sage Initial Designations
Pawlik, Kate 2023-03-17	211	18	211	21	Sage Initial Designations
Pawlik, Kate 2023-03-17	211	23	212	1	Sage Initial Designations
Pawlik, Kate 2023-03-17	213	9	213	13	Sage Initial Designations
Pawlik, Kate 2023-03-17	213	14	213	18	Sage Initial Designations
Pawlik, Kate 2023-03-17	214	13	214	16	Sage Initial Designations
Pawlik, Kate 2023-03-17	214	22	214	24	Sage Initial Designations
Pawlik, Kate 2023-03-17	215	10	215	12	Sage Initial Designations
Pawlik, Kate 2023-03-17	215	13	215	20	Sage Initial Designations
Pawlik, Kate 2023-03-17	215	21	216	11	Sage Initial Designations
Pawlik, Kate 2023-03-17	218	7	218	10	Sage Initial Designations
Pawlik, Kate 2023-03-17	218	13	218	16	Sage Initial Designations
Pawlik, Kate 2023-03-17	219	2	219	7	Sage Initial Designations
Pawlik, Kate 2023-03-17	219	12	219	17	Sage Initial Designations
Pawlik, Kate 2023-03-17	220	4	220	7	Sage Initial Designations
Pawlik, Kate 2023-03-17	220	8	220	15	Sage Initial Designations
Pawlik, Kate 2023-03-17	220	19	220	21	Sage Initial Designations
Pawlik, Kate 2023-03-17	221	5	221	10	Sage Initial Designations
Pawlik, Kate 2023-03-17	221	16	222	1	Sage Initial Designations
Pawlik, Kate 2023-03-17	222	16	222	20	Sage Initial Designations
Pawlik, Kate 2023-03-17	222	23	222	23	Sage Initial Designations
Pawlik, Kate 2023-03-17	224	14	225	2	Sage Initial Designations
Pawlik, Kate 2023-03-17	225	3	225	9	Sage Initial Designations
Pawlik, Kate 2023-03-17	229	12	229	15	Sage Initial Designations
Pawlik, Kate 2023-03-17	229	23	230	3	Sage Initial Designations
Pawlik, Kate 2023-03-17	230	4	230	9	Sage Initial Designations
Pawlik, Kate 2023-03-17	231	11	231	16	Sage Initial Designations
Pawlik, Kate 2023-03-17	232	1	232	2	Sage Initial Designations
Pawlik, Kate 2023-03-17	232	6	232	6	Sage Initial Designations
Pawlik, Kate 2023-03-17	235	17	236	2	Sage Initial Designations
Pawlik, Kate 2023-03-17	236	3	236	4	Sage Initial Designations
Pawlik, Kate 2023-03-17	236	8	236	17	Sage Initial Designations
Pawlik, Kate 2023-03-17	236	21	237	2	Sage Initial Designations
Pawlik, Kate 2023-03-17	237	7	237	9	Sage Initial Designations
Pawlik, Kate 2023-03-17	237	15	237	17	Sage Initial Designations
Pawlik, Kate 2023-03-17	237	23	237	24	Sage Initial Designations
Pawlik, Kate 2023-03-17	238	4	238	8	Sage Initial Designations
Pawlik, Kate 2023-03-17	240	5	240	7	Sage Initial Designations
Pawlik, Kate 2023-03-17	240	12	240	15	Sage Initial Designations
Pawlik, Kate 2023-03-17	240	24	241	2	Sage Initial Designations
Pawlik, Kate 2023-03-17	241	8	241	8	Sage Initial Designations
Pawlik, Kate 2023-03-17	242	5	242	8	Sage Initial Designations
Pawlik, Kate 2023-03-17	242	13	242	16	Sage Initial Designations
Pawlik, Kate 2023-03-17	242	18	243	1	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Pawlik, Kate 2023-03-17	243	17	243	21	Sage Initial Designations
Pawlik, Kate 2023-03-17	243	23	244	11	Sage Initial Designations
Pawlik, Kate 2023-03-17	244	15	244	17	Sage Initial Designations
Pawlik, Kate 2023-03-17	245	3	245	5	Sage Initial Designations
Pawlik, Kate 2023-03-17	245	9	245	9	Sage Initial Designations
Pawlik, Kate 2023-03-17	245	14	245	17	Sage Initial Designations
Pawlik, Kate 2023-03-17	246	5	246	8	Sage Initial Designations
Pawlik, Kate 2023-03-17	246	13	246	15	Sage Initial Designations
Pawlik, Kate 2023-03-17	247	16	247	22	Sage Initial Designations
Pawlik, Kate 2023-03-17	248	5	248	9	Sage Initial Designations
Pawlik, Kate 2023-03-17	249	1	249	3	Sage Initial Designations
Pawlik, Kate 2023-03-17	250	17	250	20	Sage Initial Designations
Pawlik, Kate 2023-03-17	250	24	251	5	Sage Initial Designations
Pawlik, Kate 2023-03-17	252	12	252	15	Sage Initial Designations
Pawlik, Kate 2023-03-17	253	3	253	7	Sage Initial Designations
Pawlik, Kate 2023-03-17	253	20	254	4	Sage Initial Designations
Pawlik, Kate 2023-03-17	255	6	255	9	Sage Initial Designations
Pawlik, Kate 2023-03-17	255	11	255	18	Sage Initial Designations
Pawlik, Kate 2023-03-17	255	21	255	23	Sage Initial Designations
Pawlik, Kate 2023-03-17	256	2	256	5	Sage Initial Designations
Pawlik, Kate 2023-03-17	256	7	256	9	Sage Initial Designations
Pawlik, Kate 2023-03-17	256	15	256	20	Sage Initial Designations
Pawlik, Kate 2023-03-17	257	4	257	4	Sage Initial Designations
Pawlik, Kate 2023-03-17	257	9	257	12	Sage Initial Designations
Pawlik, Kate 2023-03-17	257	20	257	23	Sage Initial Designations
Pawlik, Kate 2023-03-17	258	1	258	4	Sage Initial Designations
Pawlik, Kate 2023-03-17	258	7	258	10	Sage Initial Designations
Pawlik, Kate 2023-03-17	258	12	258	19	Sage Initial Designations
Pawlik, Kate 2023-03-17	258	23	259	8	Sage Initial Designations
Pawlik, Kate 2023-03-17	259	12	259	15	Sage Initial Designations
Pawlik, Kate 2023-03-17	259	17	259	20	Sage Initial Designations
Pawlik, Kate 2023-03-17	260	1	260	3	Sage Initial Designations
Pawlik, Kate 2023-03-17	260	22	260	24	Sage Initial Designations
Pawlik, Kate 2023-03-17	261	5	261	6	Sage Initial Designations
Pawlik, Kate 2023-03-17	261	23	262	2	Sage Initial Designations
Pawlik, Kate 2023-03-17	262	4	262	8	Sage Initial Designations
Pawlik, Kate 2023-03-17	262	11	262	12	Sage Initial Designations
Pawlik, Kate 2023-03-17	262	24	263	3	Sage Initial Designations
Pawlik, Kate 2023-03-17	263	5	263	13	Sage Initial Designations
Pawlik, Kate 2023-03-17	263	17	263	20	Sage Initial Designations
Pawlik, Kate 2023-03-17	263	22	264	5	Sage Initial Designations
Pawlik, Kate 2023-03-17	264	6	264	7	Sage Initial Designations
Pawlik, Kate 2023-03-17	264	10	264	11	Sage Initial Designations
Pawlik, Kate 2023-03-17	264	24	265	3	Sage Initial Designations
Pawlik, Kate 2023-03-17	265	12	265	17	Sage Initial Designations
Pawlik, Kate 2023-03-17	266	9	266	12	Sage Initial Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Pawlik, Kate 2023-03-17	266	14	266	18	Sage Initial Designations
Pawlik, Kate 2023-03-17	266	22	266	24	Sage Initial Designations
Pawlik, Kate 2023-03-17	267	3	267	4	Sage Initial Designations
Pawlik, Kate 2023-03-17	268	18	269	3	Sage Initial Designations
Pawlik, Kate 2023-03-17	269	6	269	9	Sage Initial Designations
Pawlik, Kate 2023-03-17	269	13	269	20	Sage Initial Designations
Pawlik, Kate 2023-03-17	269	23	270	1	Sage Initial Designations
Pawlik, Kate 2023-03-17	270	5	270	17	Sage Initial Designations
Pawlik, Kate 2023-03-17	270	20	271	1	Sage Initial Designations
Pawlik, Kate 2023-03-17	271	2	271	12	Sage Initial Designations
Pawlik, Kate 2023-03-17	271	18	272	3	Sage Initial Designations
Pawlik, Kate 2023-03-17	272	19	272	22	Sage Initial Designations
Pawlik, Kate 2023-03-17	272	24	273	4	Sage Initial Designations
Pawlik, Kate 2023-03-17	274	5	274	11	Sage Initial Designations
Pawlik, Kate 2023-03-17	274	17	274	23	Sage Initial Designations
Pawlik, Kate 2023-03-17	275	2	275	4	Sage Initial Designations
Pawlik, Kate 2023-03-17	275	6	275	9	Sage Initial Designations
Pawlik, Kate 2023-03-17	275	13	275	17	Sage Initial Designations
Pawlik, Kate 2023-03-17	275	22	275	24	Sage Initial Designations
Pawlik, Kate 2023-03-17	276	11	276	19	Sage Initial Designations
Pawlik, Kate 2023-03-17	276	20	277	7	Sage Initial Designations
Pawlik, Kate 2023-03-17	277	8	277	15	Sage Initial Designations
Pawlik, Kate 2023-03-17	277	16	277	17	Sage Initial Designations
Pawlik, Kate 2023-03-17	277	21	277	23	Sage Initial Designations
Pawlik, Kate 2023-03-17	278	1	278	2	Sage Initial Designations
Pawlik, Kate 2023-03-17	283	15	283	18	Sage Initial Designations
Pawlik, Kate 2023-03-17	283	20	284	8	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Shaw, Laura 2021-04-13	9	13	9	15	Sage Initial Designations
Shaw, Laura 2021-04-13	12	18	13	1	Sage Initial Designations
Shaw, Laura 2021-04-13	13	22	13	23	Sage Initial Designations
Shaw, Laura 2021-04-13	14	11	14	21	Sage Initial Designations
Shaw, Laura 2021-04-13	14	23	15	3	Sage Initial Designations
Shaw, Laura 2021-04-13	15	10	15	14	Sage Initial Designations
Shaw, Laura 2021-04-13	15	23	16	22	Sage Initial Designations
Shaw, Laura 2021-04-13	17	2	17	9	Sage Initial Designations
Shaw, Laura 2021-04-13	17	23	18	23	Sage Initial Designations
Shaw, Laura 2021-04-13	20	9	20	10	Sage Initial Designations
Shaw, Laura 2021-04-13	20	13	20	14	Sage Initial Designations
Shaw, Laura 2021-04-13	20	16	21	2	Sage Initial Designations
Shaw, Laura 2021-04-13	21	15	21	16	Sage Initial Designations
Shaw, Laura 2021-04-13	21	19	21	19	Sage Initial Designations
Shaw, Laura 2021-04-13	23	19	23	21	Sage Initial Designations
Shaw, Laura 2021-04-13	24	3	24	21	Sage Initial Designations
Shaw, Laura 2021-04-13	24	24	24	24	Sage Initial Designations
Shaw, Laura 2021-04-13	25	2	25	4	Sage Initial Designations
Shaw, Laura 2021-04-13	25	7	25	7	Sage Initial Designations
Shaw, Laura 2021-04-13	25	10	25	22	Sage Initial Designations
Shaw, Laura 2021-04-13	26	6	26	7	Sage Initial Designations
Shaw, Laura 2021-04-13	26	10	26	10	Sage Initial Designations
Shaw, Laura 2021-04-13	26	13	27	6	Sage Initial Designations
Shaw, Laura 2021-04-13	27	9	28	3	Sage Initial Designations
Shaw, Laura 2021-04-13	28	6	28	23	Sage Initial Designations
Shaw, Laura 2021-04-13	29	1	29	4	Sage Initial Designations
Shaw, Laura 2021-04-13	29	7	29	19	Sage Initial Designations
Shaw, Laura 2021-04-13	30	5	30	8	Sage Initial Designations
Shaw, Laura 2021-04-13	30	10	30	10	Sage Initial Designations
Shaw, Laura 2021-04-13	30	12	30	13	Sage Initial Designations
Shaw, Laura 2021-04-13	30	16	30	21	Sage Initial Designations
Shaw, Laura 2021-04-13	30	23	30	25	Sage Initial Designations
Shaw, Laura 2021-04-13	31	17	31	18	Sage Initial Designations
Shaw, Laura 2021-04-13	31	21	32	1	Sage Initial Designations
Shaw, Laura 2021-04-13	32	3	32	5	Sage Initial Designations
Shaw, Laura 2021-04-13	32	22	32	23	Sage Initial Designations
Shaw, Laura 2021-04-13	33	1	33	6	Sage Initial Designations
Shaw, Laura 2021-04-13	33	8	33	10	Sage Initial Designations
Shaw, Laura 2021-04-13	34	7	34	8	Sage Initial Designations
Shaw, Laura 2021-04-13	34	11	34	20	Sage Initial Designations
Shaw, Laura 2021-04-13	35	13	35	14	Sage Initial Designations
Shaw, Laura 2021-04-13	35	17	35	22	Sage Initial Designations
Shaw, Laura 2021-04-13	35	24	36	1	Sage Initial Designations
Shaw, Laura 2021-04-13	36	17	36	18	Sage Initial Designations
Shaw, Laura 2021-04-13	36	21	37	1	Sage Initial Designations
Shaw, Laura 2021-04-13	37	3	37	10	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Shaw, Laura 2021-04-13	37	13	37	14	Sage Initial Designations
Shaw, Laura 2021-04-13	37	17	37	25	Sage Initial Designations
Shaw, Laura 2021-04-13	38	18	38	20	Sage Initial Designations
Shaw, Laura 2021-04-13	38	22	38	22	Sage Initial Designations
Shaw, Laura 2021-04-13	38	24	38	25	Sage Initial Designations
Shaw, Laura 2021-04-13	39	3	39	3	Sage Initial Designations
Shaw, Laura 2021-04-13	39	14	39	18	Sage Initial Designations
Shaw, Laura 2021-04-13	39	20	39	25	Sage Initial Designations
Shaw, Laura 2021-04-13	40	1	40	6	Sage Initial Designations
Shaw, Laura 2021-04-13	40	9	40	9	Sage Initial Designations
Shaw, Laura 2021-04-13	40	11	40	16	Sage Initial Designations
Shaw, Laura 2021-04-13	41	5	41	8	Sage Initial Designations
Shaw, Laura 2021-04-13	41	10	41	10	Sage Initial Designations
Shaw, Laura 2021-04-13	41	12	41	14	Sage Initial Designations
Shaw, Laura 2021-04-13	41	17	41	22	Sage Initial Designations
Shaw, Laura 2021-04-13	41	24	42	14	Sage Initial Designations
Shaw, Laura 2021-04-13	42	17	42	17	Sage Initial Designations
Shaw, Laura 2021-04-13	42	19	42	19	Sage Initial Designations
Shaw, Laura 2021-04-13	42	22	42	25	Sage Initial Designations
Shaw, Laura 2021-04-13	43	12	43	13	Sage Initial Designations
Shaw, Laura 2021-04-13	43	16	44	12	Sage Initial Designations
Shaw, Laura 2021-04-13	44	15	44	15	Sage Initial Designations
Shaw, Laura 2021-04-13	44	17	44	18	Sage Initial Designations
Shaw, Laura 2021-04-13	44	21	44	21	Sage Initial Designations
Shaw, Laura 2021-04-13	44	23	44	23	Sage Initial Designations
Shaw, Laura 2021-04-13	45	1	45	22	Sage Initial Designations
Shaw, Laura 2021-04-13	46	7	46	8	Sage Initial Designations
Shaw, Laura 2021-04-13	46	11	46	16	Sage Initial Designations
Shaw, Laura 2021-04-13	46	25	47	7	Sage Initial Designations
Shaw, Laura 2021-04-13	47	11	47	11	Sage Initial Designations
Shaw, Laura 2021-04-13	47	14	47	17	Sage Initial Designations
Shaw, Laura 2021-04-13	47	19	47	22	Sage Initial Designations
Shaw, Laura 2021-04-13	47	24	47	24	Sage Initial Designations
Shaw, Laura 2021-04-13	48	2	48	4	Sage Initial Designations
Shaw, Laura 2021-04-13	48	7	48	7	Sage Initial Designations
Shaw, Laura 2021-04-13	48	11	48	15	Sage Initial Designations
Shaw, Laura 2021-04-13	48	20	48	23	Sage Initial Designations
Shaw, Laura 2021-04-13	49	5	49	5	Sage Initial Designations
Shaw, Laura 2021-04-13	49	8	49	13	Sage Initial Designations
Shaw, Laura 2021-04-13	49	15	49	18	Sage Initial Designations
Shaw, Laura 2021-04-13	49	20	49	21	Sage Initial Designations
Shaw, Laura 2021-04-13	49	24	49	24	Sage Initial Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Simon, Marcus 2021-03-03	7	12	7	17	Sage Initial Designations
Simon, Marcus 2021-03-03	8	11	8	13	Sage Initial Designations
Simon, Marcus 2021-03-03	10	7	10	14	Sage Initial Designations
Simon, Marcus 2021-03-03	15	18	15	19	Sage Initial Designations
Simon, Marcus 2021-03-03	17	1	17	6	Sage Initial Designations
Simon, Marcus 2021-03-03	17	19	17	25	Sage Initial Designations
Simon, Marcus 2021-03-03	19	4	19	9	Sage Initial Designations
Simon, Marcus 2021-03-03	22	1	22	16	Sage Initial Designations
Simon, Marcus 2021-03-03	22	21	22	22	Sage Initial Designations
Simon, Marcus 2021-03-03	23	3	23	5	Sage Initial Designations
Simon, Marcus 2021-03-03	23	9	23	17	Sage Initial Designations
Simon, Marcus 2021-03-03	24	3	24	12	Sage Initial Designations
Simon, Marcus 2021-03-03	25	14	25	23	Sage Initial Designations
Simon, Marcus 2021-03-03	26	25	27	5	Sage Initial Designations
Simon, Marcus 2021-03-03	28	12	28	15	Sage Initial Designations
Simon, Marcus 2021-03-03	28	17	30	11	Sage Initial Designations
Simon, Marcus 2021-03-03	31	14	32	17	Sage Initial Designations
Simon, Marcus 2021-03-03	33	2	33	24	Sage Initial Designations
Simon, Marcus 2021-03-03	34	22	35	3	Sage Initial Designations
Simon, Marcus 2021-03-03	35	21	36	6	Sage Initial Designations
Simon, Marcus 2021-03-03	37	4	37	8	Sage Initial Designations
Simon, Marcus 2021-03-03	38	16	39	8	Sage Initial Designations
Simon, Marcus 2021-03-03	39	17	40	9	Sage Initial Designations
Simon, Marcus 2021-03-03	41	17	41	19	Sage Initial Designations
Simon, Marcus 2021-03-03	41	23	42	10	Sage Initial Designations
Simon, Marcus 2021-03-03	51	16	51	21	Sage Initial Designations
Simon, Marcus 2021-03-03	52	1	52	11	Sage Initial Designations
Simon, Marcus 2021-03-03	54	9	55	6	Sage Initial Designations
Simon, Marcus 2021-03-03	60	23	62	11	Sage Initial Designations
Simon, Marcus 2021-03-03	65	13	66	2	Sage Initial Designations
Simon, Marcus 2021-03-03	66	17	67	2	Sage Initial Designations
Simon, Marcus 2021-03-03	67	7	67	7	Sage Initial Designations
Simon, Marcus 2021-03-03	67	8	67	18	Sage Initial Designations
Simon, Marcus 2021-03-03	69	4	69	18	Sage Initial Designations
Simon, Marcus 2021-03-03	69	22	70	1	Sage Initial Designations
Simon, Marcus 2021-03-03	72	3	72	9	Sage Initial Designations
Simon, Marcus 2021-03-03	73	13	73	22	Sage Initial Designations
Simon, Marcus 2021-03-03	73	25	74	12	Sage Initial Designations
Simon, Marcus 2021-03-03	74	17	75	4	Sage Initial Designations
Simon, Marcus 2021-03-03	77	3	77	7	Sage Initial Designations
Simon, Marcus 2021-03-03	78	3	78	17	Sage Initial Designations
Simon, Marcus 2021-03-03	78	23	78	25	Sage Initial Designations
Simon, Marcus 2021-03-03	79	2	79	16	Sage Initial Designations
Simon, Marcus 2021-03-03	80	24	81	8	Sage Initial Designations
Simon, Marcus 2021-03-03	81	16	81	22	Sage Initial Designations
Simon, Marcus 2021-03-03	82	3	82	25	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Simon, Marcus 2021-03-03	83	1	83	1	Sage Initial Designations
Simon, Marcus 2021-03-03	83	2	84	3	Sage Initial Designations
Simon, Marcus 2021-03-03	84	11	84	20	Sage Initial Designations
Simon, Marcus 2021-03-03	85	14	85	24	Sage Initial Designations
Simon, Marcus 2021-03-03	86	16	88	20	Sage Initial Designations
Simon, Marcus 2021-03-03	88	24	89	3	Sage Initial Designations
Simon, Marcus 2021-03-03	89	8	89	10	Sage Initial Designations
Simon, Marcus 2021-03-03	90	1	90	7	Sage Initial Designations
Simon, Marcus 2021-03-03	92	12	92	12	Sage Initial Designations
Simon, Marcus 2021-03-03	92	13	92	18	Sage Initial Designations
Simon, Marcus 2021-03-03	92	25	94	4	Sage Initial Designations
Simon, Marcus 2021-03-03	94	5	94	5	Sage Initial Designations
Simon, Marcus 2021-03-03	94	6	94	11	Sage Initial Designations
Simon, Marcus 2021-03-03	94	22	94	25	Sage Initial Designations
Simon, Marcus 2021-03-03	95	10	95	13	Sage Initial Designations
Simon, Marcus 2021-03-03	95	24	96	9	Sage Initial Designations
Simon, Marcus 2021-03-03	97	17	97	21	Sage Initial Designations
Simon, Marcus 2021-03-03	107	6	108	8	Sage Initial Designations
Simon, Marcus 2021-03-03	109	14	110	1	Sage Initial Designations
Simon, Marcus 2021-03-03	110	11	112	16	Sage Initial Designations
Simon, Marcus 2021-03-03	114	20	114	23	Sage Initial Designations
Simon, Marcus 2021-03-03	115	7	117	3	Sage Initial Designations
Simon, Marcus 2021-03-03	118	12	118	20	Sage Initial Designations
Simon, Marcus 2021-03-03	119	5	120	25	Sage Initial Designations
Simon, Marcus 2021-03-03	121	4	121	4	Sage Initial Designations
Simon, Marcus 2021-03-03	121	5	122	11	Sage Initial Designations
Simon, Marcus 2021-03-03	123	1	123	25	Sage Initial Designations
Simon, Marcus 2021-03-03	124	19	124	25	Sage Initial Designations
Simon, Marcus 2021-03-03	125	9	126	2	Sage Initial Designations
Simon, Marcus 2021-03-03	127	10	127	21	Sage Initial Designations
Simon, Marcus 2021-03-03	128	7	128	15	Sage Initial Designations
Simon, Marcus 2021-03-03	130	23	130	23	Sage Initial Designations
Simon, Marcus 2021-03-03	130	24	131	8	Sage Initial Designations
Simon, Marcus 2021-03-03	131	16	132	25	Sage Initial Designations
Simon, Marcus 2021-03-03	133	5	134	19	Sage Initial Designations
Simon, Marcus 2021-03-03	135	1	135	5	Sage Initial Designations
Simon, Marcus 2021-03-03	135	22	136	1	Sage Initial Designations
Simon, Marcus 2021-03-03	136	9	136	17	Sage Initial Designations
Simon, Marcus 2021-03-03	137	1	138	11	Sage Initial Designations
Simon, Marcus 2021-03-03	139	2	139	6	Sage Initial Designations
Simon, Marcus 2021-03-03	139	21	140	1	Sage Initial Designations
Simon, Marcus 2021-03-03	142	13	142	20	Sage Initial Designations
Simon, Marcus 2021-03-03	143	4	143	11	Sage Initial Designations
Simon, Marcus 2021-03-03	144	1	144	15	Sage Initial Designations
Simon, Marcus 2021-03-03	144	25	145	7	Sage Initial Designations
Simon, Marcus 2021-03-03	145	1	145	7	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Simon, Marcus 2021-03-03	145	11	146	16	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Skelton, Sarah 2023-01-18	5	14	5	17	Sage Initial Designations
Skelton, Sarah 2023-01-18	8	18	8	24	Sage Initial Designations
Skelton, Sarah 2023-01-18	9	1	9	3	Sage Initial Designations
Skelton, Sarah 2023-01-18	10	4	10	13	Sage Initial Designations
Skelton, Sarah 2023-01-18	10	14	11	3	Sage Initial Designations
Skelton, Sarah 2023-01-18	11	10	12	13	Sage Initial Designations
Skelton, Sarah 2023-01-18	15	24	16	2	Sage Initial Designations
Skelton, Sarah 2023-01-18	16	8	16	13	Sage Initial Designations
Skelton, Sarah 2023-01-18	22	9	22	20	Sage Initial Designations
Skelton, Sarah 2023-01-18	24	1	24	3	Sage Initial Designations
Skelton, Sarah 2023-01-18	24	6	24	12	Sage Initial Designations
Skelton, Sarah 2023-01-18	28	10	28	14	Sage Initial Designations
Skelton, Sarah 2023-01-18	28	17	29	12	Sage Initial Designations
Skelton, Sarah 2023-01-18	31	1	31	24	Sage Initial Designations
Skelton, Sarah 2023-01-18	32	2	32	17	Sage Initial Designations
Skelton, Sarah 2023-01-18	32	19	33	12	Sage Initial Designations
Skelton, Sarah 2023-01-18	35	8	36	14	Sage Initial Designations
Skelton, Sarah 2023-01-18	36	15	37	11	Sage Initial Designations
Skelton, Sarah 2023-01-18	37	19	38	17	Sage Initial Designations
Skelton, Sarah 2023-01-18	38	20	38	24	Sage Initial Designations
Skelton, Sarah 2023-01-18	39	2	39	3	Sage Initial Designations
Skelton, Sarah 2023-01-18	39	6	39	7	Sage Initial Designations
Skelton, Sarah 2023-01-18	39	22	39	22	Sage Initial Designations
Skelton, Sarah 2023-01-18	40	16	40	21	Sage Initial Designations
Skelton, Sarah 2023-01-18	41	18	41	20	Sage Initial Designations
Skelton, Sarah 2023-01-18	41	23	42	4	Sage Initial Designations
Skelton, Sarah 2023-01-18	42	6	43	10	Sage Initial Designations
Skelton, Sarah 2023-01-18	43	21	43	24	Sage Initial Designations
Skelton, Sarah 2023-01-18	49	24	50	9	Sage Initial Designations
Skelton, Sarah 2023-01-18	52	1	53	6	Sage Initial Designations
Skelton, Sarah 2023-01-18	53	16	53	22	Sage Initial Designations
Skelton, Sarah 2023-01-18	55	18	56	16	Sage Initial Designations
Skelton, Sarah 2023-01-18	56	23	56	24	Sage Initial Designations
Skelton, Sarah 2023-01-18	57	2	57	2	Sage Initial Designations
Skelton, Sarah 2023-01-18	57	4	57	8	Sage Initial Designations
Skelton, Sarah 2023-01-18	67	2	68	21	Sage Initial Designations
Skelton, Sarah 2023-01-18	68	22	69	23	Sage Initial Designations
Skelton, Sarah 2023-01-18	76	19	77	2	Sage Initial Designations
Skelton, Sarah 2023-01-18	77	3	78	1	Sage Initial Designations
Skelton, Sarah 2023-01-18	78	3	78	7	Sage Initial Designations
Skelton, Sarah 2023-01-18	78	9	78	13	Sage Initial Designations
Skelton, Sarah 2023-01-18	78	15	78	20	Sage Initial Designations
Skelton, Sarah 2023-01-18	80	22	80	24	Sage Initial Designations
Skelton, Sarah 2023-01-18	81	2	81	4	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Zani, Paul 2021-03-23	9	9	9	11	Sage Initial Designations
Zani, Paul 2021-03-23	13	20	13	22	Sage Initial Designations
Zani, Paul 2021-03-23	14	16	15	18	Sage Initial Designations
Zani, Paul 2021-03-23	20	14	20	18	Sage Initial Designations
Zani, Paul 2021-03-23	21	2	21	8	Sage Initial Designations
Zani, Paul 2021-03-23	21	14	22	6	Sage Initial Designations
Zani, Paul 2021-03-23	22	21	24	24	Sage Initial Designations
Zani, Paul 2021-03-23	25	4	27	10	Sage Initial Designations
Zani, Paul 2021-03-23	27	20	27	24	Sage Initial Designations
Zani, Paul 2021-03-23	28	20	28	24	Sage Initial Designations
Zani, Paul 2021-03-23	29	7	29	22	Sage Initial Designations
Zani, Paul 2021-03-23	31	22	33	13	Sage Initial Designations
Zani, Paul 2021-03-23	36	9	36	13	Sage Initial Designations
Zani, Paul 2021-03-23	36	20	37	12	Sage Initial Designations
Zani, Paul 2021-03-23	38	4	38	7	Sage Initial Designations
Zani, Paul 2021-03-23	38	11	38	19	Sage Initial Designations
Zani, Paul 2021-03-23	47	8	47	17	Sage Initial Designations
Zani, Paul 2021-03-23	47	19	47	21	Sage Initial Designations
Zani, Paul 2021-03-23	49	3	49	8	Sage Initial Designations
Zani, Paul 2021-03-23	49	12	49	15	Sage Initial Designations
Zani, Paul 2021-03-23	50	18	50	23	Sage Initial Designations
Zani, Paul 2021-03-23	50	25	51	1	Sage Initial Designations
Zani, Paul 2021-03-23	56	4	56	10	Sage Initial Designations
Zani, Paul 2021-03-23	56	16	56	21	Sage Initial Designations
Zani, Paul 2021-03-23	58	14	58	16	Sage Initial Designations
Zani, Paul 2021-03-23	59	10	59	16	Sage Initial Designations
Zani, Paul 2021-03-23	65	14	65	18	Sage Initial Designations
Zani, Paul 2021-03-23	65	24	66	3	Sage Initial Designations
Zani, Paul 2021-03-23	66	21	66	23	Sage Initial Designations
Zani, Paul 2021-03-23	67	24	69	13	Sage Initial Designations
Zani, Paul 2021-03-23	71	9	71	11	Sage Initial Designations
Zani, Paul 2021-03-23	71	16	72	10	Sage Initial Designations
Zani, Paul 2021-03-23	72	12	72	16	Sage Initial Designations
Zani, Paul 2021-03-23	72	23	74	3	Sage Initial Designations
Zani, Paul 2021-03-23	75	1	75	9	Sage Initial Designations
Zani, Paul 2021-03-23	76	9	76	13	Sage Initial Designations
Zani, Paul 2021-03-23	77	12	77	19	Sage Initial Designations
Zani, Paul 2021-03-23	80	10	80	15	Sage Initial Designations
Zani, Paul 2021-03-23	80	23	81	4	Sage Initial Designations
Zani, Paul 2021-03-23	82	13	83	13	Sage Initial Designations
Zani, Paul 2021-03-23	86	12	87	7	Sage Initial Designations
Zani, Paul 2021-03-23	88	14	89	2	Sage Initial Designations
Zani, Paul 2021-03-23	89	20	90	22	Sage Initial Designations
Zani, Paul 2021-03-23	97	22	98	3	Sage Initial Designations
Zani, Paul 2021-03-23	98	16	98	20	Sage Initial Designations
Zani, Paul 2021-03-23	99	16	99	19	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Zani, Paul 2021-03-23	100	23	101	7	Sage Initial Designations
Zani, Paul 2021-03-23	101	25	102	13	Sage Initial Designations
Zani, Paul 2021-03-23	103	8	103	11	Sage Initial Designations
Zani, Paul 2021-03-23	103	13	103	20	Sage Initial Designations
Zani, Paul 2021-03-23	105	2	105	18	Sage Initial Designations
Zani, Paul 2021-03-23	105	22	105	23	Sage Initial Designations
Zani, Paul 2021-03-23	106	1	106	1	Sage Initial Designations
Zani, Paul 2021-03-23	106	13	106	22	Sage Initial Designations
Zani, Paul 2021-03-23	106	25	106	25	Sage Initial Designations
Zani, Paul 2021-03-23	107	2	107	5	Sage Initial Designations
Zani, Paul 2021-03-23	107	8	107	16	Sage Initial Designations
Zani, Paul 2021-03-23	108	4	108	14	Sage Initial Designations
Zani, Paul 2021-03-23	108	20	108	24	Sage Initial Designations
Zani, Paul 2021-03-23	109	1	110	1	Sage Initial Designations
Zani, Paul 2021-03-23	110	16	111	11	Sage Initial Designations
Zani, Paul 2021-03-23	112	5	112	17	Sage Initial Designations
Zani, Paul 2021-03-23	113	1	113	25	Sage Initial Designations
Zani, Paul 2021-03-23	114	9	114	12	Sage Initial Designations
Zani, Paul 2021-03-23	114	14	114	14	Sage Initial Designations
Zani, Paul 2021-03-23	114	17	114	21	Sage Initial Designations
Zani, Paul 2021-03-23	114	23	115	8	Sage Initial Designations
Zani, Paul 2021-03-23	115	13	115	17	Sage Initial Designations
Zani, Paul 2021-03-23	116	9	116	14	Sage Initial Designations
Zani, Paul 2021-03-23	117	24	118	8	Sage Initial Designations
Zani, Paul 2021-03-23	121	15	122	5	Sage Initial Designations
Zani, Paul 2021-03-23	131	16	131	20	Sage Initial Designations
Zani, Paul 2021-03-23	138	2	138	5	Sage Initial Designations
Zani, Paul 2021-03-23	138	7	138	9	Sage Initial Designations
Zani, Paul 2021-03-23	138	25	140	15	Sage Initial Designations
Zani, Paul 2021-03-23	141	1	141	9	Sage Initial Designations
Zani, Paul 2021-03-23	141	11	141	14	Sage Initial Designations
Zani, Paul 2021-03-23	141	19	141	20	Sage Initial Designations
Zani, Paul 2021-03-23	142	7	142	17	Sage Initial Designations
Zani, Paul 2021-03-23	142	23	143	1	Sage Initial Designations
Zani, Paul 2021-03-23	147	3	147	17	Sage Initial Designations
Zani, Paul 2021-03-23	148	1	148	5	Sage Initial Designations
Zani, Paul 2021-03-23	148	8	148	10	Sage Initial Designations
Zani, Paul 2021-03-23	148	18	148	21	Sage Initial Designations
Zani, Paul 2021-03-23	148	23	149	4	Sage Initial Designations
Zani, Paul 2021-03-23	149	10	149	15	Sage Initial Designations
Zani, Paul 2021-03-23	150	13	150	17	Sage Initial Designations
Zani, Paul 2021-03-23	150	20	150	21	Sage Initial Designations
Zani, Paul 2021-03-23	153	16	153	23	Sage Initial Designations
Zani, Paul 2021-03-23	153	25	154	5	Sage Initial Designations
Zani, Paul 2021-03-23	154	16	154	19	Sage Initial Designations
Zani, Paul 2021-03-23	155	1	155	4	Sage Initial Designations



Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Zani, Paul 2021-03-23	155	7	155	11	Sage Initial Designations
Zani, Paul 2021-03-23	157	23	158	1	Sage Initial Designations
Zani, Paul 2021-03-23	158	6	158	17	Sage Initial Designations
Zani, Paul 2021-03-23	158	21	158	24	Sage Initial Designations
Zani, Paul 2021-03-23	159	1	159	3	Sage Initial Designations
Zani, Paul 2021-03-23	160	15	160	24	Sage Initial Designations
Zani, Paul 2021-03-23	161	2	161	4	Sage Initial Designations
Zani, Paul 2021-03-23	162	12	163	2	Sage Initial Designations
Zani, Paul 2021-03-23	163	12	163	13	Sage Initial Designations
Zani, Paul 2021-03-23	163	16	163	18	Sage Initial Designations
Zani, Paul 2021-03-23	163	24	164	15	Sage Initial Designations
Zani, Paul 2021-03-23	164	18	164	19	Sage Initial Designations
Zani, Paul 2021-03-23	164	21	164	25	Sage Initial Designations
Zani, Paul 2021-03-23	165	3	165	4	Sage Initial Designations
Zani, Paul 2021-03-23	165	6	165	8	Sage Initial Designations
Zani, Paul 2021-03-23	177	24	178	2	Sage Initial Designations
Zani, Paul 2021-03-23	178	4	179	3	Sage Initial Designations
Zani, Paul 2021-03-23	179	18	180	3	Sage Initial Designations
Zani, Paul 2021-03-23	181	9	181	25	Sage Initial Designations
Zani, Paul 2021-03-23	183	2	183	5	Sage Initial Designations
Zani, Paul 2021-03-23	183	18	183	23	Sage Initial Designations
Zani, Paul 2021-03-23	183	25	184	12	Sage Initial Designations
Zani, Paul 2021-03-23	184	17	184	20	Sage Initial Designations
Zani, Paul 2021-03-23	185	4	185	17	Sage Initial Designations
Zani, Paul 2021-03-23	186	2	186	24	Sage Initial Designations
Zani, Paul 2021-03-23	199	11	199	14	Sage Initial Designations
Zani, Paul 2021-03-23	199	16	199	20	Sage Initial Designations
Zani, Paul 2021-03-23	201	1	201	6	Sage Initial Designations
Zani, Paul 2021-03-23	201	9	201	13	Sage Initial Designations
Zani, Paul 2021-03-23	203	19	204	21	Sage Initial Designations
Zani, Paul 2021-03-23	204	23	205	16	Sage Initial Designations
Zani, Paul 2021-03-23	205	18	205	19	Sage Initial Designations
Zani, Paul 2021-03-23	205	21	205	23	Sage Initial Designations
Zani, Paul 2021-03-23	206	23	207	18	Sage Initial Designations
Zani, Paul 2021-03-23	208	3	209	1	Sage Initial Designations
Zani, Paul 2021-03-23	211	12	212	5	Sage Initial Designations
Zani, Paul 2021-03-23	212	23	213	11	Sage Initial Designations
Zani, Paul 2021-03-23	213	13	213	19	Sage Initial Designations
Zani, Paul 2021-03-23	215	18	217	12	Sage Initial Designations
Zani, Paul 2021-03-23	217	15	217	16	Sage Initial Designations
Zani, Paul 2021-03-23	217	18	217	23	Sage Initial Designations
Zani, Paul 2021-03-23	217	25	218	10	Sage Initial Designations
Zani, Paul 2021-03-23	218	17	218	25	Sage Initial Designations
Zani, Paul 2021-03-23	219	10	219	15	Sage Initial Designations
Zani, Paul 2021-03-23	219	18	219	22	Sage Initial Designations
Zani, Paul 2021-03-23	220	4	221	4	Sage Initial Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	Issues
Zani, Paul 2021-03-23	221	5	221	24	Sage Initial Designations
Zani, Paul 2021-03-23	222	2	222	7	Sage Initial Designations
Zani, Paul 2021-03-23	222	9	223	1	Sage Initial Designations
Zani, Paul 2021-03-23	223	4	223	7	Sage Initial Designations
Zani, Paul 2021-03-23	223	10	223	18	Sage Initial Designations
Zani, Paul 2021-03-23	223	20	225	1	Sage Initial Designations
Zani, Paul 2021-03-23	225	8	225	20	Sage Initial Designations
Zani, Paul 2021-03-23	225	23	226	3	Sage Initial Designations
Zani, Paul 2021-03-23	226	5	227	2	Sage Initial Designations
Zani, Paul 2021-03-23	227	5	227	10	Sage Initial Designations
Zani, Paul 2021-03-23	227	12	227	17	Sage Initial Designations
Zani, Paul 2021-03-23	229	7	229	17	Sage Initial Designations
Zani, Paul 2021-03-23	229	20	229	21	Sage Initial Designations
Zani, Paul 2021-03-23	230	9	230	24	Sage Initial Designations
Zani, Paul 2021-03-23	243	17	244	23	Sage Initial Designations



# SCHEDULE E4b

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

PUREWICK CORPORATION,	)	
	)	
Plaintiff,	)	
	)	C.A. No. 22-102-MN
v.	)	
	)	<b>CONFIDENTIAL –</b>
SAGE PRODUCTS, LLC,	)	<b>FILED UNDER SEAL</b>
	)	
Defendant.	)	
	)	

**PUREWICK CORPORATION’S OBJECTIONS AND COUNTER-DESIGNATIONS TO  
SAGE PRODUCTS, LLC’S DEPOSITION DESIGNATIONS**

DESCRIPTION	OBJECTIONS
FEDERAL RULES OF EVIDENCE 401/402 (IRRELEVANT)	402
FEDERAL RULE OF EVIDENCE 403 (UNDULY PREJUDICIAL, CONFUSING, MISLEADING, DELAY, AND/OR WASTE OF TIME)	403
FEDERAL RULE OF EVIDENCE 408 (COMPROMISE OFFERS AND NEGOTIATIONS)	408
FEDERAL RULE OF EVIDENCE 501 (PRIVILEGE)	PRIV
FEDERAL RULE OF EVIDENCE 602 (LACK OF PERSONAL KNOWLEDGE OR COMPETENCY)	602
FEDERAL RULE OF EVIDENCE 611(C) (LEADING)	611
IMPROPER LAY OPINION / IMPROPER EXPERT TESTIMONY BY NON-EXPERT	701
IMPROPER TESTIMONY BY EXPERT WITNESS	702/703
FEDERAL RULE OF EVIDENCE 802 (HEARSAY)	H
LACKS FOUNDATION	F
CALLS FOR SPECULATION	CS
FEDERAL RULE OF EVIDENCE 611(B) (BEYOND SCOPE OF DESIGNATIONS)	BSD
NOT TESTIMONY – INCLUDES ATTORNEY OBJECTIONS AND/OR DISCUSSIONS BETWEEN ATTORNEYS	NT
DESIGNATION INCOMPLETE / INCOMPREHENSIBLE / INCOMPLETE QUESTION / ANSWER	I
BEYOND SCOPE OF 30(B)(6) NOTICE / TOPICS	S
VAGUE AND AMBIGUOUS	V
ARGUMENTATIVE	Arg
IMPROPER / INCOMPLETE HYPOTHETICAL	Hyp
COMPOUND	C
MISCHARACTERIZATION	M
CALLS FOR LEGAL CONCLUSION	LC
ASSUMES FACTS NOT IN EVIDENCE	AF
NON-RESPONSIVE	NR
NARRATIVE	Nar
FOREIGN LANGUAGE	LANG
NOT EVIDENCE	NE
LATE DISCLOSED	LATE DISCLOSED
DUPLICATE	DUP
BEST EVIDENCE RULE	1004
UNAVAILABILITY OF DEPONENT NOT ESTABLISHED	UNE

**Sage's Designation of Deposition Testimony of Jason Bobay, April 23, 2021**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter-Designations</b>	<b>Sage's Objection(s)</b>
7:3-7:9			
14:7-14:12			
14:22-15:25			
16:2-16:2			
17:9-17:25	402, 403		
18:2-18:25	402, 403		
20:2-21:11			
21:21-21:25			
22:2-22:8			
82:21-82:23			
83:3-83:14			
86:9-86:25		87:3-11	
87:2-87:2		87:3-11	
92:20-92:22	F, V, 402, 403, H, 602		
94:5-94:8	F, V, 402, 403, H, 602		
94:12-94:25	F, V, 402, 403, H, 602		
95:2-95:25	F, V, 402, 403, H, 602		
96:2-96:25	F, V, 402, 403, H, 602		
100:17-100:25			
101:2-101:25			
102:2-102:11			
130:2-130:4		130:5-8	
131:11-131:19			
132:9-132:11			
132:15-132:25			
133:2-133:25			
134:2-134:20	H	134:21-25	

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
146:8-146:10			
147:3-147:6			
148:2-148:12			
152:23-153:3			
153:5-153:6			
154:19-154:25	F, H, A, 402, 403	153:21-154:10	
155:2-155:25	F, H, A, 402, 403		
156:2-156:6	F, H, A, 402, 403		
156:15-156:18			
157:8-157:13			
161:9-161:25			
162:2-162:14	F, V	162:15-24	
163:17-163:20			
164:18-164:22		164:4-17	
164:25-164:25	F, V, H, 403		
165:2-165:11	F, V, H, 403		
165:16-165:25	F, V, H, 403		
166:2-166:2	F, V, H, 403		
166:3-166:12	F, V, H, 403		
167:6-167:12	F, V, H, 403	167:18-168:4	
167:16-167:17	F, V, H, 403	167:18-168:4	
182:16-182:25	H, F		
183:2-183:25	H, F		
184:2-184:25	H, F		
185:2-185:5	H, F		

**Sage's Designation of Deposition Testimony of Brian Burn, April 2, 2021**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter-Designations</b>	<b>Sage's Objection(s)</b>
4:18-4:20			
10:9-10:23			
14:22-14:24		15:1-10	
21:6-21:10		20:15-21:5	
21:17-21:22			
23:7-23:9	F, 403	22:23-23:6	
23:10-23:13	F, 403		
28:12-28:14			
28:21-28:22			
29:1-29:2			
32:9-32:11			
37:4-37:7		37:1-3	
38:11-38:13	NT		
39:4-42:20			
45:21-45:24	402		
46:1-46:4	402		
46:9-46:12	402		
46:13-46:16	402, Duplicate		
46:17-46:19	402		
46:20-46:22	402		
47:8-47:10	402, 403		
50:21-51:1			
51:9-51:11			
51:12-51:16			
51:17-51:18			
51:23-51:23			
52:11-52:17	402, 403		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
53:13-53:24	402, 403		
54:1-54:23	402, 403, 611		
54:24-55:4	402, 403, 611		
55:7-55:10	402, 403, CS		
55:13-56:5	402, 403, 611		
56:14-56:18	402, 403		
56:20-56:22	402, 403		
57:13-57:16	402, 403		
57:17-57:24	402, 403		
58:1-58:4	402, 403		
58:15-58:18	402, 403, 602, CS		
59:1-59:14	402, 403, CS, V		
59:17-59:21	F, 402, 403, CS		
59:23-60:1	402, 403		
60:23-61:9	402, 403		
62:10-62:14	402, 403		
62:16-62:17	402, 403		
63:3-63:5	402, 403		
63:7-64:3	402, 403, 602	64:4-6	
64:7-64:12	402, 403		
64:22-64:24			
65:5-65:6	402, 403, 602	65:11-13	
65:9-65:10	402, 403, 602		
65:14-65:16	402, 403		
65:19-65:21	402, 403		
66:11-66:12	I, F, 402, 403		
66:16-66:17	402, 403		
66:19-66:21	402, 403		
66:24-67:1	402, 403		

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter- Designations</b>	<b>Sage's Objection(s)</b>
69:4-69:18			
69:24-70:7			
72:19-72:21	V		
72:24-73:1			
73:10-73:12			
76:21-76:24	I		
79:11-79:12			
79:15-79:15			
79:17-79:17			
79:24-80:1			
80:3-80:5			
82:6-82:8	F, 402, 403		
82:12-82:12			
82:14-82:16	I, F, 402, 403	82:17-18	
82:23-82:24	402, 403		
83:1-83:1			
83:7-83:17	402, 403		
84:9-84:11			
84:19-84:22			
85:6-85:11	F, 602		
85:14-85:14	F, 602		
85:17-85:17			
86:4-86:8			
86:12-86:17	F, 402, 403, 602		
86:20-86:20			
86:22-86:24	F, 402, 403, 602		
87:7-87:8			
88:1-88:6	F		
90:22-90:24	402, 403		



Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
91:4-91:7			
92:1-92:3	402, 403		
92:6-92:7			
92:9-92:9	402, 403		
92:11-92:15	402, 403		
92:17-92:20			
93:5-93:12	402, 403	93:13-14	
93:15-93:17			
93:24-94:8	F, 602		
94:10-94:11			
94:19-94:21	F, 602	94:13-18	
95:1-95:1			
95:10-95:13	H, F, 402, 403		
95:16-95:17			
95:24-96:3			
96:20-96:23	H, F, 402, 403, 602	96:18-19	
97:2-97:3			
97:5-97:7	F, 402, 403		
97:10-97:13			
98:19-98:22			
98:24-99:1	F, 402, 403, 602	100:8-9	
100:1-100:5	F, 402, 403, 602		
100:7-100:7	Error		
100:10-100:15	F, 402, 403		
100:19-100:20	F, 402, 403		
100:22-100:23			
101:22-102:3	F, 602		
102:5-102:6			
103:13-103:16		103:17-18	

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
103:19-103:23			
104:10-104:13	CS, I, 402, 403		
104:16-104:17			
105:1-105:4	611, CS		
105:6-105:7			
106:14-108:3	402, 403, 602, 611		
111:12-112:5	H, 402, 403, 602, 611		
115:14-115:16			
116:23-117:6	602	117:17-20	
117:7-117:16			
119:15-119:17			
119:19-119:21	I		
120:2-120:4			
120:14-120:24	602, 611, V		
121:3-121:4			
121:6-121:9	V		
121:13-121:13	V		
121:15-121:18	V		
121:21-122:1			
122:3-122:11			
122:12-122:16			
127:23-128:1	F, 611		
128:17-129:10	F		
130:8-130:15	F		
130:18-130:19			
134:21-135:13	F, 402, 403		
137:1-137:6	I, F, 402, 403		
138:20-139:9	F, 402, 403		
139:10-139:16			

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
139:20-140:4			
140:5-140:20			
141:2-141:9	C, 611		
142:1-142:7			
142:14-142:23	611, CLC		
143:8-143:11			
151:22-152:4	F		
154:24-155:2			
155:4-155:7		155:8-9	
155:10-155:17			
159:17-159:19			
160:2-160:5			
160:8-160:13			
160:22-162:2	402, 403, 611, CLC, CS		
162:5-162:8	402, 403		
162:10-162:17	402, 403, CLC, CS		
162:20-163:8	402, 403, CLC, CS		
163:11-163:21	402, 403, CLC, CS		
163:22-164:2	402, 403, CLC, CS		
164:4-164:17	402, 403, CLC, CS		
164:19-164:22	Error		
169:9-169:11			
169:13-169:15			
170:14-171:16	402, 403, 611, V		
171:18-171:23	V, C		
172:1-172:3			
172:21-172:23			
173:1-173:11			
176:24-177:22	F		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
177:23-178:1	CLC, CS		
178:3-178:6			
178:8-178:9	CLC, CS, V		
178:11-178:14			
178:16-178:17	I		
178:19-179:2	CLC, CS		
179:3-179:6	CLC, CS		
179:9-179:10			
187:12-187:14			
187:16-188:6	Error		
188:9-188:12			
188:14-188:17	611, 402, 403		
188:20-189:19	611, 402, 403		
189:24-190:10	611, 402, 403		
191:3-191:5			
191:7-191:11			
191:18-192:4	NAR, C		
192:21-193:1			
195:15-195:18			
196:2-196:4	V, CS		
196:6-196:7			
199:13-199:17	F, V, CS, CLC		
202:5-202:7			
202:9-202:12			
202:15-202:20	H, 402, 403, 602		
203:4-203:19	H, 402, 403, 602		
203:23-203:24	402, 403, 602, CS		
204:4-204:5			
204:7-204:12	602		

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter- Designations</b>	<b>Sage's Objection(s)</b>
204:23-205:4	F, CS, 602		
205:8-205:14			
211:11-211:14	402, 403		
211:15-211:21	402, 403		
211:23-212:1			
212:3-212:4			
212:18-212:23	F, 611		
213:3-213:10			
213:12-213:13			
218:11-218:16	402		
220:11-220:22	F, CS		
221:4-221:7	403		
221:17-221:19	403		
222:9-222:24			
223:5-223:8	403		

**Sage's Designation of Deposition Testimony of Brian Burn, March 23, 2023**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter-Designations</b>	<b>Sage's Objection(s)</b>
4:14-4:16			
18:22-19:1			
19:8-19:11			
22:14-22:16	LC, 402		
24:17-24:20	LC, 402		
24:24-25:3			
25:20-25:22	H		
26:2-26:3			
26:7-26:9	402, PRIV		
29:6-29:18	I	29:5, 29:19-21, 30:1-3	
30:16-30:19			
30:23-31:5	H		
32:13-32:16	H, CS		
33:13-33:16			
33:21-33:23	H		
34:4-34:7	H		
43:14-43:17			
44:9-44:11			
45:7-45:10	H		
49:1-49:4			
49:6-49:12	H, F		
51:7-51:19	H		
52:7-52:15	H, F		
56:13-57:12	H, CS, 402, 403		
58:3-58:24	S, 402, 403		
59:4-59:10			
59:13-59:13			

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
59:18-60:18			
65:19-65:21	S, AF		
66:1-66:1			
66:3-66:17	402, 403		
67:2-67:4			
67:13-67:14	S, CS		
67:17-67:18			
67:23-68:2			
68:14-68:20	H, F		
69:24-70:6	H, F		
70:11-70:16	CS, S, 402, 403		
70:20-70:22			
71:14-72:2	CS, 402		
72:11-72:14	S, AF		
72:18-72:18			
72:23-73:3	402, 403		
74:2-74:5			
75:10-75:13	S, F, H, 402, 403		
75:17-75:17			
75:19-75:20	F		
75:23-75:23			
76:1-76:7			
76:24-77:3	S, AF		
77:7-77:7			
77:17-78:7	402, 403		
78:22-79:2	S, AF		
79:5-79:10			
79:19-79:24	402, 403, 701		
81:17-81:20			

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
82:10-82:13	H, F		
82:18-83:8	402, H		
83:22-84:1			
84:11-84:13	402		
84:16-84:17	402		
85:2-85:6	402		
86:22-87:10	402, 403		
88:10-88:15	402, 403		
91:9-91:15			
92:9-92:10	S		
92:13-92:18	S		
92:21-92:21			
94:3-94:6			
96:21-97:7			
97:16-97:24	S		
98:11-98:13			
101:1-101:3	S		
101:7-101:9			
101:11-101:14	402, 403, S, M		
101:18-101:21			
104:6-104:8	402, 403		
104:14-104:14			
110:5-110:18			
111:12-111:17	I	111:20	
112:6-112:9	S, F		
112:14-112:16	V, 402, 403		
112:19-112:21	402, 403		
113:5-113:8	402, 403		
114:24-115:3			



Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
115:15-115:16			
115:22-115:23			
116:5-116:7	402, 403, F		
116:18-116:20			
116:24-117:3			
117:12-117:15	402, 403, F		
117:21-118:1			
118:5-118:20	402, 403, F		
119:5-119:14	402, 403, F		
119:17-119:23	402, 403, H		
120:12-120:14	402, 403, H		
120:20-120:23	402, 403, H		
121:6-121:7	S		
121:10-121:13			
121:20-122:3	402, 403, H		
122:14-122:16	402, 403, H		
122:22-123:3	402, 403, H		
123:5-123:9	402, 403, F, I	123:4	
123:19-124:1	402, 403	125:6-8, 125:14-126:5	
128:20-128:23	402, 403, S, M		
129:4-129:6			
129:9-129:12			
131:2-131:4	Arg, 402, 403, S	130:19-24	
131:7-131:7			
132:16-132:17	S, F, CS	132:9-15	
132:23-132:23			
133:3-133:6			
133:19-134:1	H, F		
134:7-134:19	H, 402, 403, F		

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter- Designations</b>	<b>Sage's Objection(s)</b>
136:11-136:23			
138:8-138:11			
139:10-139:20	402, 403		

**Sage's Designation of Deposition Testimony of Ruby Dy, April 14, 2021**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter-Designations</b>	<b>Sage's Objection(s)</b>
6:20-7:8			
13:22-13:22			
14:15-14:22	402, 403		
17:16-17:18			
17:21-18:2			
18:9-18:10			
18:12-18:13			
20:9-20:11			
22:24-23:2			
28:6-28:8	402		
31:14-31:23			
34:8-34:19		34:23-35:8	
35:10-35:13			
35:15-35:17			
35:19-35:23			
36:20-36:22		36:12-19	
36:24-36:25			
37:3-37:11			
40:3-40:5			
40:7-40:7			
40:9-40:10			
40:13-40:17			
41:6-41:9			
41:17-41:20	402		
43:18-43:23	402		
44:25-45:1			
45:3-45:8			

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
45:11-45:20	I		
45:22-45:23			
46:1-46:9			
47:13-47:14	F, Nar		
47:18-47:20	F		
48:16-48:24	NT (48:24)		
49:2-49:3		49:4-6	
49:7-49:13			
49:16-49:22			
50:15-50:25	402, 403		
51:3-51:4	402, 403		
53:21-53:23	402, 403		
55:8-55:12	402, 403		
55:14-55:14	402, 403		
55:25-56:4			
56:9-56:13			
57:7-57:7			
57:9-57:9			
57:13-57:15			
58:1-58:13	402, 403		
61:11-61:13	402, 403		
61:16-61:17			
62:11-62:13	I	62:17-18	
62:24-63:1			
64:15-64:17	402, 403		
64:20-64:21	402, 403		
64:25-65:3			
65:6-65:8			
66:4-66:7			

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
66:20-66:22			
66:25-67:2			
67:23-67:24	H, F		
68:2-68:5	H, F		
68:20-68:21	I		
69:17-69:23			
70:18-70:18	402, 403		
70:21-70:22	402, 403		
71:14-71:16			
81:24-81:24			
82:2-82:14	402, 403		
83:2-83:4			
83:24-84:1	V, F, CS		
84:4-84:6	V, F, CS		
84:9-84:11	I		
88:2-88:5	CS		
88:7-88:13	CS		
88:21-88:22	402, 403		
88:25-89:1	402, 403		
89:23-89:24	I		
90:3-90:5			
90:19-90:21	CS		
90:24-90:25			
91:14-91:16	F, CS		
91:20-91:22			
91:24-92:2	402, 403		
92:5-92:12	402, 403		
92:16-92:19	402, 403		
92:24-93:4	I, 402, 403		

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter- Designations</b>	<b>Sage's Objection(s)</b>
93:14-93:18	402, 403		

**Sage's Designation of Deposition Testimony of Lorena Eckert, March 14, 2023**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter-Designations</b>	<b>Sage's Objection(s)</b>
4:9-4:13			
16:8-16:11			
18:3-18:13	402, 403, V		
18:15-18:22			
19:11-19:19	I	19:8-10	
19:23-20:2	402, 403		
20:9-20:18	402, 403		
21:8-21:22	402, 403		
25:24-26:2	402		
26:13-26:22	402		
27:10-27:20	402		
28:12-29:4	402, 403, V		
29:7-29:10			
29:12-29:16	V		
29:20-29:24			
31:19-31:22			
31:24-32:7		32:8-35:20	
35:21-35:24			
36:1-36:3			
40:3-41:2		37:5-40:2	
41:15-42:4			
43:1-43:13		43:14-21	
55:10-55:13			
55:19-56:6	H, 402, 403		
56:21-57:4	H, 402, 403	56:7-8, 56:11-12, 56:14-20	
57:20-57:22			
58:14-58:20	H, 402, 403		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
62:22-63:3	402, 403, H		
63:9-63:14			
63:21-64:12	402, 403, V		
64:15-64:16			
65:4-65:10	H, 402, 403		
72:14-72:18		72:3-6, 72:12-13	
72:21-72:22	402, 403, V, CS		
73:5-73:8	I, 402, 403	73:4, 73:10-15, 73:19, 73:21-74:3, 74:6	
75:12-75:18	H, 402, 403	75:19-23	
76:2-76:5	402, 403	76:6-8, 76:11-12	
84:5-84:8	402, 403, V	82:18-20, 82:23-83:8	
100:18-100:19			
101:1-101:9	402, 403		
101:21-102:1	402, 403		
102:7-102:21	402, 403, V		
103:1-103:2	F		
103:4-103:5	402, 403, V		
103:8-103:13			
103:15-103:18			
103:22-103:22			
113:24-114:6	402, 403		
118:2-118:12	402, 403		
120:1-120:6			
120:23-121:11	402, 403, V		
121:14-121:18			
121:20-122:3	402		
122:6-122:12	402, 403, V		
122:16-122:21			



Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
125:10-125:20	402, 403, V		
127:3-127:10	V, H		
127:13-127:14	F		
127:16-127:19	F, V		
127:23-128:2			
128:5-128:5			
128:7-128:23	402, 403, 602, F, H		
129:2-129:7	602, F		
129:9-129:13	602, F		
129:15-129:18	402, 403, F, H		
129:22-130:2	602, F		
130:4-130:11	402, 403, 602, H, F		
135:1-135:15			
136:4-136:7		135:22-136:3	
144:19-144:23			
145:10-145:12	H		
147:6-147:8			
147:20-147:23	H		
150:18-150:24			
151:1-151:6	V		
151:19-151:19			
151:21-151:21			
151:24-153:3	402, 403, V, H, I	151:11-17	
153:5-153:14	402, 403, H		
153:17-153:17			
153:20-153:23			

**Sage's Designation of Deposition Testimony of Joseph Forehand, March 24, 2021**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter-Designations</b>	<b>Sage's Objection(s)</b>
7:15-7:17			
14:4-14:5			
14:15-14:17			
17:8-17:15		16:20-17:7	
18:6-18:21	F, 602, Arg (for 18:18-21)		
19:4-19:7			
19:16-19:24	F, 602, Arg (for 19:22-24)		
20:2-20:3	F, 602, Arg		
20:5-20:5	F, 602, Arg		
20:7-20:10			
20:15-21:2	F, 602, CS		
21:4-21:6	F, 602, CS		
28:3-28:11			
28:13-29:1			
29:5-29:8		29:14-30:2	
30:3-30:5	V		
30:7-30:11			
31:20-31:23		30:20-31:17	
32:7-32:10			
33:14-33:14	F, I		
34:13-34:15			
34:23-35:5			
36:6-36:9	402, 403		
38:6-38:7			
38:12-38:12			
39:8-39:10	F		
39:13-39:18	F		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
39:23-40:4			
55:14-55:17			
55:21-55:23	F		
56:3-56:4	F		
56:7-56:7	F		
61:7-61:13			
69:16-69:22	I, 402, 403		
70:21-71:1			
71:12-71:17			
73:1-73:18			
74:6-74:7	F, CS		
74:9-74:9	F, CS		
74:14-74:14	F, CS		
74:20-74:23	F, CS		
74:25-75:5	F, CS		
75:7-75:8	F, CS		
75:13-75:15			
76:12-76:15	F, 602, CS		
76:17-77:20	F, 602, CS, H	77:22-23	
77:24-78:10	F, 602, CS, H		
78:25-79:3			
80:5-80:9		80:10-12	
80:21-80:24			
81:6-81:8		81:9-19	
81:20-81:22			
81:25-82:1			
82:3-82:5		82:7-9	
82:12-82:14			
83:19-83:21	F, CS		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
83:23-83:23	F, CS		
84:1-84:3	F, CS		
84:18-84:21			
85:2-85:13	CS, F, V, Arg		
85:21-86:3	CS, V		
86:7-86:11	CS, V		
86:13-86:22	CS, V		
87:8-87:16	H		
87:20-87:24			
88:7-88:16			
88:20-88:22			
89:1-89:1			
89:9-89:18			
90:16-90:19	402		
91:14-91:24	H, F		
92:1-92:2	H, F		
92:11-92:17		92:18-21	
96:15-96:20			
97:3-97:7	H, F		
99:4-99:7			
100:4-100:6			
103:4-103:9			
104:20-105:2	I, 402		
105:10-105:13	402, 403		
105:18-105:24	402, 403		
106:5-106:6	402, 403, V, F		
106:8-106:8	402, 403, V, F		
106:16-106:18	402, 403, V, F		
106:21-107:15	402, 403		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
107:18-107:18			
107:20-107:22			
108:1-108:4	F, V		
108:14-108:20	F, V		
108:23-109:7	F, V		
109:14-109:15	F, V		
109:17-109:17	F, V		
115:3-115:7	602, V, F 403		
115:15-115:16	F, 402, 403, I		
115:23-116:3			
116:7-116:10			
116:12-116:22			
117:2-117:3			
117:20-118:10			
118:16-118:23			
119:18-119:23			
120:24-121:13			
122:2-122:3	F, V		
122:6-122:7	F, V		
122:9-122:10	F, V		
122:12-122:16	F, V		
123:4-123:7	V, CS, 611		
123:11-123:18	V, CS, 611		
124:1-124:10			
124:17-124:20			
126:20-126:25	402, 403		
127:4-127:7	402, 403		
127:21-127:23	402, 403		
127:25-127:25	402, 403		

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter- Designations</b>	<b>Sage's Objection(s)</b>
134:19-135:12			
147:12-148:4			
148:25-149:3			
150:25-151:17			
152:13-152:21			
153:23-154:4			

**Sage's Designation of Deposition Testimony of John Gohde, February 8, 2023**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter-Designations</b>	<b>Sage's Objection(s)</b>
4:10-4:13			
4:13-4:14			
7:20-8:6			
8:17-8:21			
8:22-8:24			
9:13-9:16			
10:14-10:21			
12:8-12:14			
12:15-12:24			
16:16-16:23	C, CS.		
18:7-18:14			
20:5-20:13		20:14-15	
21:5-21:20			
23:14-24:1	C, M, 402, 403, F, H		
28:22-29:3	402, 403	28:18-21; 29:4-15	
30:1-30:11	C, 402, 403		
30:21-30:23	F, 402, 403		
31:6-31:7	402, 403		
31:10-31:11	402, 403		
35:6-35:10	F, H, 402, 403		
35:11-35:19	F, H, 402, 403		
36:18-36:23	F, H, 402, 403		
37:9-37:12	F, 402, 403		
37:15-37:15	F, 402, 403		
37:17-38:1	F, 402, 403		
38:11-38:24	402, 403, 602		
49:16-49:19	F, H, 402, 403, 602		

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter- Designations</b>	<b>Sage's Objection(s)</b>
49:24-50:4	F, H, 402, 403, 602		
51:11-51:17	F, 402, 403, 602		



**Sage's Designation of Trial Testimony of John Gohde, March 29, 2022**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter- Designations</b>	<b>Sage's Objection(s)</b>
359:13-359:20			
369:16-371:19	F, H, 402, 403, 901	379:11-380:4	
371:23-373:24	F, H, 402, 403, 901	379:11-380:4	
374:3-375:19	F, H, 402, 403, 901	379:11-380:4	
375:24-376:10	F, H, 402, 403, 901	379:11-380:4	
376:14-377:4	F, H, 402, 403, 901	379:11-380:4	
377:8-378:11	F, H, 402, 403, 901	379:11-380:4	
378:15-379:4	F, H, 402, 403, 901	379:11-380:4	

**Sage's Designation of Deposition Testimony of John Gohde, March 26, 2021**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter-Designations</b>	<b>Sage's Objection(s)</b>
4:11-4:14			
8:15-8:20			
8:21-8:24			
9:9-9:11		9:12-10:2	
17:8-17:12			
17:18-17:23			
18:8-18:20			
20:9-20:15			
20:19-21:11			
21:15-22:1			
22:7-23:5			
23:9-24:3			
24:7-24:16			
31:8-31:11	403, F, H, 602		
31:15-31:17	403, F, H, 602		
32:20-33:1	F, H, 602		
33:23-34:1	F, H, 602		
34:5-34:6	F, H, 602		
35:12-35:15	F, H, 602		
35:18-35:18	F, H, 602		
35:20-35:22	403, F, H, 602, I, Arg	36:1-2, 36:12-13, 36:16, 36:20, 36:22-37:2	
36:4-36:11			
37:9-37:17			
38:24-39:6	403, F, H, 602, Arg.		
39:10-39:19	403, F, H, 602, Arg.		
41:3-41:8			

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
41:10-41:13			
42:2-42:2		42:3-6	
43:11-43:21			
43:22-44:2			
45:24-46:9			
46:12-46:13			
46:20-47:8			
47:17-47:19		47:20-22	
51:12-51:17			
58:3-58:18	402, 403	58:19-21	
60:14-60:19			
60:24-60:24			
61:7-61:21			
61:22-62:10			
62:14-62:14			
63:17-63:19		63:2-4, 63:7-13	
63:23-64:1			
64:22-65:10			
68:23-68:24	402, 403, H, Arg		
70:6-70:9			
70:10-70:14			
71:12-72:13			
73:15-73:21			
73:24-74:16			
107:20-108:7			
141:22-142:3	402, 403, H, F, 602		
142:5-142:9	402, 403, H, F, 602		
142:10-142:14	402, 403, H, F, 602		
142:15-142:20	402, 403, H, F, 602		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
142:21-143:2	402, 403, H, F, 602		
143:4-143:16	402, 403, H, F, 602		
143:17-143:24	402, 403, H, F, 602		
144:1-144:13	402, 403, H, F, 602		
144:17-144:19	402, 403, H, F, 602		
145:1-145:6	402, 403, H		
145:7-145:23	402, 403, H		
146:7-146:12	402, 403, H		
146:16-146:22	402, 403, H		
147:3-148:1			
148:19-148:24			
149:1-149:5			
150:13-150:18			
151:1-151:7			
151:11-151:21	402, 403, H, F, 602		
153:12-153:17	402, 403, H		
153:19-154:12	402, 403, H		
154:13-154:21	402, 403, H		
155:11-156:1	402, 403		
156:4-156:5	402, 403, F		
156:9-156:14	402, 403		
163:8-163:13	402, 403, H, F		
164:5-164:16	402, 403, H, F, 602		
167:2-167:19	402, 403, H, F, 602		
167:20-168:9	402, 403, H, F, 602		
168:22-169:4	402, 403, H, F, 602		
175:10-175:14	H, 602		
175:17-175:20	H, 602		
175:22-177:3	H, 602, F, 402, 403		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
177:4-177:18	H, 602, F, 402, 403		
177:20-178:2	H, 602, F, 402, 403		
178:5-178:6	402, 403, F		
178:18-179:17	402, 403, F, 602		
179:18-179:23	402, 403, F, 602		
180:2-180:6	402, 403, F, 602		
180:8-180:10	402, 403, F, 602		
180:18-181:6		181:7-11	
181:12-181:22			
183:23-184:16	402, 403, H, F		
184:17-185:1	402, 403, H, F		
185:2-185:7	402, 403, H, F		
185:10-185:16	402, 403, H, F		
185:17-186:3	402, 403, H, F		
186:16-186:24			
187:12-187:15	402, 403, H, F		
187:18-187:21	402, 403, H, F		
189:14-189:20	402, 403, H, F		
190:11-190:15	402, 403, H, F		
190:16-190:22	402, 403, H, F		
191:21-192:1	402, 403, H, F		
193:7-193:10	402, 403, H, F		
193:13-193:16	402, 403, H, F		
193:17-194:1	402, 403, H, F		
194:4-194:5	402, 403, H, F		
194:7-194:13	402, 403, H, F		
194:16-194:24	402, 403, H, F		
195:3-195:12	402, 403, H, F		
196:13-197:6		196:6-12	

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter- Designations</b>	<b>Sage's Objection(s)</b>
197:9-197:12			
207:16-207:21		208:3-9	
210:11-210:15			
210:17-210:22	403, H, F, 602		
210:23-210:24	403, H, F, 602		
211:10-211:14	403, H, F, 602		
214:7-214:10	402, 403, F, Arg, CLC		
214:12-214:14	402, 403, F, Arg, CLC		
215:20-215:23	402, 403, F, Arg, CLC		
216:3-216:11	402, 403, F, Arg, CLC		
216:14-216:14	402, 403, F, Arg, CLC		

**Sage's Designation of Deposition Testimony of Robin Hanson, November 6, 2023**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter-Designations</b>	<b>Sage's Objection(s)</b>
7:22-7:24			
13:8-13:11			
13:12-13:16			
13:17-14:2			
14:3-14:18			
14:25-15:3			
15:6-15:13	I, 402, 403		
15:16-15:20	402, 403		
16:2-16:3	402, 403		
16:7-16:10	402, 403		
16:23-17:4	402, 403		
17:9-17:11	402, 403		
17:17-17:24	F, 402, 403		
19:1-19:5	402, 403		
19:14-19:16	402, 403		
19:18-19:18	402, 403		
20:6-20:11	402, 403		
20:19-20:21	402, 403		
21:15-22:1	CS, 402, 403		
22:6-22:6	402, 403		
23:2-23:19	402, 403		
30:23-31:14	402, 403		
31:24-32:1	402, 403		
32:6-32:7	402, 403		
32:9-32:14	402, 403		
33:22-33:25	402, 403		
34:2-34:5	I, 402, 403		

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter- Designations</b>	<b>Sage's Objection(s)</b>
34:13-35:9	F, 402, 403		
35:17-35:19	F, V, 402, 403		
35:21-35:24	F, V, 402, 403		
36:24-37:10	402, 403		
37:12-37:12	402, 403		
37:23-37:25	I, 402, 403		
38:3-38:21	402, 403		
39:8-39:19	F, CS, 402, 403		
39:22-40:1	F, CS, 402, 403		
40:11-40:13	I, 402, 403		
40:16-40:17	402, 403		
41:21-42:1	CS, 611, 402, 403		
42:4-42:8	CS, 611, 402, 403		
42:10-42:11	V, 402, 403		
42:13-42:19	V, 402, 403		
43:3-43:17	402, 403		
43:18-43:21	V, 402, 403		
43:23-43:24	V, 402, 403		
44:10-44:13	F, 611, 402, 403		
45:15-45:24	I, 611, 402, 403		
46:14-46:17	I, 611, 402, 403		
47:4-47:15	402, 403		
47:16-48:6	402, 403		
48:18-49:8	402, 403		
49:9-49:15	F, CS, 402, 403		
49:18-49:24	F, CS, 402, 403		
51:13-51:20	F, 402, 403		
51:24-52:4	F, CS, 402, 403		
52:7-52:23	F, CS, 402, 403		



Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
53:7-53:8	402, 403	53:12-13	
53:19-54:1	F, V, CS, 402, 403		
54:4-54:13	F, V, CS, 402, 403		
54:15-55:4	402, 403		
55:5-55:12	I, F, V, CS, 402, 403		
55:17-55:22	F, V, CS, 402, 403		
56:22-57:5	F, V, CS, 402, 403		
57:7-57:15	F, V, CS, 402, 403		
58:3-58:8	I, 402, 403		
58:14-58:15	F, V, 611, 402, 403		
58:18-58:22	F, V, 611, 402, 403		
59:5-59:9	F, V, 611, 402, 403		
59:12-59:12	F, V, 611, 402, 403		
59:14-60:4	611, 402, 403		
60:5-60:12	F, CS, 611, 402, 403		
60:15-60:20	F, CS, M, 611, 402, 403		
60:24-61:4	611, 402, 403		
61:16-61:17	402, 403		
62:1-62:4	611, 402, 403		
62:15-62:17	F, CS, 402, 403		
62:20-62:21	F, CS, 402, 403		
62:23-63:3	V, C, 402, 403		
63:5-63:7	V, C, 402, 403		
63:9-63:11	402, 403		
63:12-63:14	402, 403		
63:20-64:2	V, CS, 402, 403		
64:7-64:12	I, CS, 402, 403		
64:16-64:18	402, 403		
64:19-64:22	611, 402, 403		

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter- Designations</b>	<b>Sage's Objection(s)</b>
65:3-65:11	611, 402, 403		
65:21-66:6	402, 403		
66:10-66:12	I, 402, 403		
66:14-66:15	F, CS, 611, 402, 403		
66:18-66:19	F, CS, 611, 402, 403		
66:21-67:1	611, 402, 403		
67:2-67:10	F, CS, 611, 402, 403		
67:17-67:21	F, CS, 611, 402, 403		
68:1-68:6	F, V, CS, 402, 403		
68:9-68:15	F, V, CS, 402, 403		
68:17-68:18	F, V, CS, 402, 403		
69:4-69:7	V, C, 402, 403		
69:9-69:9	V, C, 402, 403		
73:6-73:8	I, 402, 403		
73:13-73:18	611, 402, 403		
73:19-74:3	402, 403		
74:4-74:6	V, CS, 402, 403		
74:9-74:12	V, CS, 402, 403		
74:14-74:22	F, AF, CS, 402, 403		
75:1-75:3	F, AF, CS, 402, 403		
75:5-75:6	F, AF, CS, 402, 403		
75:8-75:12	F, AF, CS, 402, 403		
75:24-76:1	I, 402, 403		
76:4-76:18	I, F, CS, 402, 403		
76:21-76:25	F, CS, 402, 403		
77:15-77:16	F, V, CS, 611, 402, 403		
77:20-77:23	F, V, CS, 611, 402, 403		
78:6-78:13	402, 403		
78:14-78:17	402, 403		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
78:18-79:3	F, AF, CS, 402, 403		
79:6-79:7	F, AF, CS, 402, 403		
79:9-79:12	F, V, CS, 402, 403		
79:15-79:19	F, V, CS, 402, 403		
79:21-79:23	F, V, Hyp, CS, 402, 403		
80:1-80:2	F, V, Hyp, CS, 402, 403	80:4-10	
84:25-85:9	, 402, 403		
85:15-85:18	F, M, 611, 402, 403		
85:22-86:3	F, M, 611, 402, 403		
87:6-87:13	V, M, CS, 402, 403		
87:16-87:23	V, M, CS, 402, 403		
87:25-88:3	V, M, CS, 402, 403		
88:6-88:11	V, M, CS, 402, 403	88:13-14, 88:17-18	
89:5-89:18	I, CS, 402, 403		
89:19-90:2	I, CS, 402, 403	90:3-4, 90:6-7	
92:7-92:10	F, V, M, 402, 403		
92:13-92:17	F, V, M, 402, 403		
92:19-92:22	V, CS, 402, 403	92:23-93:5	
98:24-99:15	F, 402, 403		
100:4-100:6	I, 402, 403		
100:9-100:14	611, 402, 403		
100:18-100:23	402, 403		
101:2-101:7	402, 403		
101:11-101:22	CS, 402, 403		
101:23-101:24	402, 403		
102:4-102:15	611, 402, 403		
102:20-103:6	F, CS, Arg, 611, 402, 403		
103:9-103:13	F, CS, Arg, 611, 402, 403		
104:2-104:15	F, I, CS, 611, 402, 403	105:2-5	

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
104:19-104:20	F, I, CS, 611, 402, 403	105:2-5	
104:23-104:25	F, I, CS, 611, 402, 403	105:2-5	
108:13-109:2	F, CS, 611, 402, 403		
109:5-109:11	F, CS, 611, 402, 403		
109:15-109:23	V, 611, 402, 403		
109:25-110:4	V, 611, 402, 403		
110:8-111:7	CS, 611, 402, 403		
111:10-111:19	CS, 611, 402, 403		
111:22-112:2	CS, 402, 403	112:3-7	
113:1-113:6	V, CS, 402, 403		
113:9-113:21	V, CS, 402, 403		
114:12-114:13	V, Hyp, CS, 402, 403		
114:16-114:20	V, Hyp, CS, 402, 403		
115:21-116:4	402, 403		
116:8-116:13	402, 403		
116:17-116:22	402, 403		
116:23-116:25	V, 402, 403		
117:2-118:2	V, 402, 403	118:3-5, 118:7-11	
120:2-120:7	402, 403		
120:11-120:16	402, 403		
120:20-121:3	402, 403		
121:7-121:13	402, 403		
121:17-121:22	402, 403		
122:2-122:14	CS, 402, 403		
122:17-123:5	I, CS, 402, 403		
123:6-123:12	I, CS, 402, 403		
124:2-124:7	402, 403		
124:11-124:16	402, 403		
126:2-126:17	F, CS, 402, 403		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
126:18-126:18	F, CS, 402, 403		
127:4-127:20	F, CS, 402, 403	127:21-128:5	
128:6-128:17	V, CS, 611, 402, 403		
128:20-128:24	V, CS, 611, 402, 403		
129:2-129:5	CS, 611, 402, 403	129:6-7	
129:21-130:22	M, CS, 402, 403		
131:4-131:8	611, 402, 403		
131:13-131:17	402, 403		
132:13-132:17	402, 403		
132:21-134:6	CS, 611, 402, 403		
134:21-135:11	611, 402, 403		
135:16-135:24	CS, 611, 402, 403		
136:2-136:4	CS, 611, 402, 403		
138:2-139:2	V, CS, 611, 402, 403		
139:4-139:14	V, CS, 611, 402, 403		
139:16-139:20	V, CS, 611, 402, 403		
139:23-140:12	V, CS, 611, 402, 403		
140:14-140:22	V, M, CS, 611, 402, 403		
141:2-141:9	H, CS, 602, 402, 403		
142:11-142:22	611, 402, 403		

**Sage's Designation of Deposition Testimony of Mark Harvie, April 19, 2021**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter-Designations</b>	<b>Sage's Objection(s)</b>
4:20-4:24			
7:5-7:7			
7:17-7:24			
8:16-8:24			
9:2-9:4			
9:7-9:12			
9:16-10:10			
10:23-12:10			
12:20-12:24			
13:3-13:8	F, 402, 403, H, 602, LC		
13:12-13:23			
14:1-14:22	F, 402, 403, H, 602, AF		
15:7-16:4	F, 402, 403, H, 602, CS		
16:7-16:7	F, 402, 403, H, 602, CS		
16:13-16:16	F, 402, 403, H, 602, CS		
16:19-16:22	F, 402, 403, H, 602, CS		
17:3-17:7		17:8-10	
17:11-18:3	F, 402, 403, H, 602, CS		
18:5-18:22	F, 402, 403, H, 602, AF	19:2-3	
19:5-19:14			
19:23-20:7	F, 402, 403, H, 602, V	19:15-22	
20:10-20:14			
20:16-22:12	F, 402, 403, H, 602, V		
22:15-23:22	I	23:23	
24:3-24:7			
24:9-24:11	F, 402, 403, H, 602, V		
24:14-24:19	F, 402, 403, H, 602, V		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
25:1-25:2			
25:4-25:23	611, F, Arg		
26:4-26:19	F, 402, 403, H, 602, AF		
26:22-27:10	F, 402, 403, H, 602, V, 611, Arg		
27:13-27:13	F, 402, 403, H, 602, V		
27:19-29:8	F, 402, 403, H, 602, V		
29:11-29:12			
29:14-29:19	F, 402, 403, H, 602, AF		
29:22-29:22	F, 402, 403, H, 602, AF		
30:1-30:2			
30:4-31:22	F, 402, 403, H, 602, V		
32:1-32:3			
32:5-32:8	F, 402, 403, H, 602, V		
32:11-32:13			
32:15-32:18			
32:22-33:12	F, 402, 403, H, 602, V		
33:15-33:17	F, 402, 403, H, 602, V, 611		
33:20-35:7	F, 402, 403, H, 602		
35:22-35:24	F, 402, 403, H, 602, V, 611		
36:5-36:7	F, 402, 403, H, 602, V		
36:10-36:10			
36:12-36:13	F, 402, 403, H, 602, LC		
36:17-36:17			
36:19-36:21	F, 402, 403, H, 602, V		
37:1-37:10	611, V, F, 403		
37:12-37:15	F, 402, 403, H, 602, V, 611		
37:18-37:19	611, V, F, 403		
37:21-38:4	F, 402, 403, H, 602, V		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
38:22-38:24			
39:4-39:4	611, F, Arg		
40:13-40:19	F, 402, 403, H, 602, AF		
40:23-41:24	F, 402, 403, H, 602, V, 611, Arg		
43:16-43:24	F, 402, 403, H, 602, V		
44:8-44:10	F, 402, 403, H, 602, V		
44:12-44:15			
44:21-46:3	F, 402, 403, H, 602, AF		
47:8-47:15	F, 402, 403, H, 602, AF		
47:18-47:20			
47:22-48:1	F, 402, 403, H, 602, V		
48:14-48:17			
48:22-48:24	F, 402, 403, H, 602, V		
49:4-49:5			
49:7-49:9			
49:13-49:15	F, 402, 403, H, 602, V		
49:17-49:18	F, 402, 403, H, 602, V, 611		
49:22-49:23	F, 402, 403, H, 602		
50:1-50:4	F, 402, 403, H, 602, V, 611		
50:7-50:8	F, 402, 403, H, 602, V		
50:12-52:1			
52:8-53:20	F, 402, 403, H, 602, LC		
54:1-54:2	F, 402, 403, H, 602, V, 611		
54:5-54:7	611, V, 403		
54:18-54:19	F, 402, 403, H, 602, V, AF, LC, 611		
54:22-54:23	F, 402, 403, H, 602, V, AF, LC, 611	55:1-3, 55:6-13	



Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
55:17-56:24			
56:2-57:1			
57:2-57:2			
57:3-58:12	F, 402, 403, H, 602, V, 611		
58:15-58:15	611, V, 403		
58:19-58:20	F, 402, 403, H, 602, V, 611		
58:23-59:4	611, V, 403		
59:9-62:6	F, 402, 403, H, 602, V		
62:10-63:6	F, 402, 403, H, 602, V		
63:9-63:14	F, 402, 403, H, 602, V		
63:17-63:22	F, 402, 403, H, 602, V		
64:1-64:1			
64:2-66:19	F, 402, 403, H, 602, V		
67:1-67:4	F, 402, 403, H, 602, V		
67:7-67:7			
67:9-69:5			
69:1-69:5	F, 402, 403, H, 602, V		
69:8-69:12			
69:16-69:16			
69:20-70:11		70:19-21, 70:24-71:1	
71:5-71:11	F, 402, 403, H, 602, V, 611		
72:6-72:10			
72:14-72:22	F, 402, 403, H, 602, V, AF, 611		
73:2-73:5			

**Sage's Designation of Deposition Testimony of Benjamin Jackson, March 2, 2023**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter-Designations</b>	<b>Sage's Objection(s)</b>
5:6-5:8			
7:21-7:24			
8:5-8:12			
22:3-22:4			
22:7-22:9			
44:13-44:14			
44:17-44:21			
44:23-45:2	402, 403, H		
45:11-45:12	402, 403, H		
45:15-45:15	402, 403, H		
45:17-45:19	402, 403, H		
60:10-60:16	402, 403, H, F, CS, V, 602		
60:19-60:19	402, 403, H, F, CS, V, 602		
60:21-61:8	402, 403, H, F, CS, V, 602		
64:5-64:8	402, 403, H, F, CS, V, 602		
64:12-64:12	402, 403, H, F, CS, V, 602		
64:17-65:2	402, 403, H, F, CS, V, 602		
65:5-65:7	402, 403, H, F, CS, V, 602		
65:9-65:11	402, 403, H, F, CS, V, 602		
66:13-66:15	H, F		
67:7-67:9	402, 403, H, F, CS, V, 602		
68:12-68:14	402, 403, H, F, CS, V, 602		
68:17-68:23	402, 403, H, F, CS, V, 602		
69:1-69:3	402, 403, H, F, CS, V, 602		
69:12-69:12	402, 403, H, F, CS, V, 602		
69:15-69:16	402, 403, H, F, CS, V, 602		
71:2-71:3	402, 403, H, F, CS, V		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
71:6-71:9	402, 403, H, F, CS, V		
73:21-73:24	402, 403, H, F, CS, V, 602		
74:21-74:24	402, 403, H, F, CS, V, 602		
76:3-76:6	402, 403, H, F, CS, V, 602		
76:12-76:15	402, 403, H, F, CS, V, 602		
76:17-76:19	402, 403, H, F, CS, V, 602		
76:22-76:22	402, 403, H, F, CS, V, 602		
76:24-77:4	402, 403, H, F, CS, V, 602		
77:7-77:8	402, 403, H, F, CS, V, 602		
77:10-77:11	402, 403, H, F, CS, V, 602		
77:14-77:21	402, 403, H, F, CS, V, 602		
77:23-77:24	402, 403, H, F, CS, V, 602		
78:6-78:7	402, 403, H, F, CS, V, 602		
78:10-78:11	402, 403, H, F, CS, V, 602		
78:15-78:20	402, 403, H, F, CS, V, 602		
88:21-88:23			
90:1-90:1			
90:4-90:5			
90:7-90:7			
90:10-90:13			
91:13-92:7	402, 403, H, F, CS, V		
92:11-92:21	402, 403, H, F, CS, V		
92:23-93:2	402, 403, H, F, CS, V		
93:6-93:11	402, 403, H, F, CS, V		
93:13-93:16	402, 403, H, F, CS, V		
93:20-93:20	402, 403, H, F, CS, V		
94:11-94:14	402, 403, H, F, CS, V		
94:18-94:20	402, 403, H, F, CS, V, I	94:21-95:2	
95:4-95:17	402, 403, H, F, CS, V		

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter- Designations</b>	<b>Sage's Objection(s)</b>
95:20-95:22	402, 403, H, F, CS, V		
97:10-97:12	402, 403, H		
98:2-98:7	402, 403, H		
98:13-98:13	402, 403, H		
98:16-98:24	402, 403, H		
99:2-99:4	402, 403, H		
99:8-99:8	402, 403, H		

**Sage's Designation of Deposition Testimony of Michael Jackson, March 16, 2023**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter-Designations</b>	<b>Sage's Objection(s)</b>
9:15-9:19			
14:11-14:24			
15:11-15:12	402, 403		
17:20-17:22	402, 403		
20:10-20:15			
20:18-21:6	402, 403		
21:8-21:10	402, 403		
21:12-21:21	402, 403	21:25-22:3, 22:5-7	
28:11-28:12	402, 403, F		
28:14-28:17	402, 403, F		
28:19-28:19	402, 403, F		
41:3-41:4	402, 403, F		
41:6-41:11	402, 403, F		
41:14-41:20	402, 403, F, I		
42:2-42:10	402, 403, F		
42:12-42:15	402, 403, F		
42:18-42:19	402, 403, F		
42:21-42:25	402, 403, F		
45:24-45:25	402, 403, F		
46:2-46:2	402, 403, F		
47:23-48:15	402, 403, F		
48:17-48:23	402, 403, F		
49:1-49:4	402, 403, F		
49:7-49:7	402, 403, F		
51:6-51:21	402, 403, F		
51:23-52:2			
52:4-52:8			

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
52:10-52:11			
53:2-53:7	402, 403		
53:9-53:10	402, 403		
54:24-55:9	402, 403, F		
55:11-55:13	402, 403, F		
57:12-57:22	402, 403, F, I		
58:2-58:3	402, 403, F		
58:5-58:5	402, 403, F		
59:4-59:17	402, 403		
59:19-60:1	402, 403, F, I		
60:20-61:2	402, 403, F, I		
61:19-61:22	402, 403, F		
61:24-61:25	402, 403, F		
66:21-67:9	402, 403, F		
67:12-67:16	402, 403, F		
67:18-67:18	402, 403, F		
67:20-67:21	402, 403, F, I		
68:6-68:7	F		
68:9-68:9	F		
68:11-68:16	402, 403, I		
70:13-70:21	402, 403, F		
71:4-71:10	V, F		
71:13-71:16	V, F, CS		
71:20-71:21	V, F, CS		
71:23-71:24	V, F, CS		
72:2-72:4	402, 403		
72:5-72:14			
72:16-73:4	V, F, CS		
73:7-73:8	V, F, CS		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
79:14-79:25	402, 403, F		
80:2-80:21	CS		
80:23-81:4	CS		
81:6-81:7	CS		
81:9-81:12	403, V, CS		
81:14-81:18	403, V, CS		
81:23-82:7	403, V, CS		
86:21-87:6	402, 403, I		
99:12-99:13	402, 403, F, V, CS		
99:15-99:15	402, 403, F, V, CS		
99:17-99:20	402, 403, F, V, CS		
99:23-99:25	402, 403, F, V, CS		
109:14-109:23	402, 403		
109:25-110:15	403, CS		
110:17-110:18	403, CS		
110:20-110:21	403, CS		
110:23-110:23	403, CS		
112:17-112:19	402, 403, F, V, CS		
112:21-112:21	402, 403, F, V, CS		
112:23-113:1	402, 403, F, V, CS		
113:22-113:22	402, 403, F, V, CS		
113:24-113:24	402, 403, F, V, CS	114:2-3, 114:6-7	
116:2-116:4	402, 403, F, V		
116:7-116:8	402, 403, F, V		
116:10-116:15	402, 403, F		
116:17-116:17	402, 403, F		
127:4-127:6	402, 403		
127:10-127:18			
127:21-128:10	402, 403		

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter- Designations</b>	<b>Sage's Objection(s)</b>
128:12-128:19	402, 403		
128:21-129:1	402, 403, I		
129:11-129:15	402, 403, CS		
129:17-129:23	402, 403, CS		
130:1-130:3	402, 403, CS		
130:5-130:5	402, 403, CS		



**Sage's Designation of Deposition Testimony of Gregory Mann, March 31, 2021**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter-Designations</b>	<b>Sage's Objection(s)</b>
4:12-4:15			
8:14-8:22			
9:7-9:11			
9:20-9:23	I	9:22-10:1	
17:2-17:7			
18:21-19:4			
19:7-19:7			
19:9-20:4			
20:8-20:14			
20:19-20:20			
20:23-20:23			
21:4-21:8			
21:11-21:11			
21:20-22:3			
22:6-22:6			
140:14-141:6	H, 402, 403, F, 602, V, CS		
142:7-143:5	H, 402, 403, F, 602, V, CS		
143:15-143:19	H, 402, 403, F, 602, V, CS		
144:1-144:5	H, 402, 403, F, 602, V, CS		
144:11-145:10	H, 402, 403, F, 602, V, CS		
145:22-146:8	H, 402, 403, F, 602, V, CS		
146:14-147:8	H, 402, 403, F, 602, V, CS		
147:16-147:18	H, 402, 403, F, 602, V, CS		
147:23-150:8	H, 402, 403, F, 602, V, CS		
150:12-151:12	H, 402, 403, F, 602, V, CS		
151:16-151:19	H, 402, 403, F, 602, V, CS		
152:3-152:6	H, 402, 403, F, 602, V, CS		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
152:11-152:12	H, 402, 403, F, 602, V, CS		
152:15-152:15	H, 402, 403, F, 602, V, CS, I	152:16-153:18	
153:23-154:1	H, 402, 403, F, 602, V, CS		
154:4-154:4	H, 402, 403, F, 602, V, CS		
154:6-155:3	H, 402, 403, F, 602, V, CS		
155:6-155:7	H, 402, 403, F, 602, V, CS		
156:7-156:24	H, 402, 403, F, 602, V, CS		
158:19-159:12	402, 403		
160:17-160:22			
161:9-161:16	H, 402, 403, F, 602, V, CS	162:3-5	
164:13-164:15	402, 403, F, 602		
164:24-165:5	402, 403, F, 602		
165:9-165:16	402, 403, F, 602		
165:19-165:24	402, 403, F, 602		
166:2-166:4	402, 403, F, 602		
166:8-166:9	402, 403, F, 602		
167:24-168:7	402, 403, F, 602		
169:12-169:17	402, 403, F, 602		
170:4-170:6	H, 402, 403, F, 602, V, CS		
170:23-171:5	H, 402, 403, F, 602, V, CS		
171:16-172:4	H, 402, 403, F, 602, V, CS		
172:19-172:24	H, 402, 403, F, 602, V, CS		
173:2-173:9			
173:22-174:1			
174:9-174:13			
183:1-183:5	H, 402, 403, F, 602, V, CS		
183:12-183:19	H, 402, 403, F, 602, V, CS		
184:24-185:10	H, 402, 403, F, 602, V, CS		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
185:13-186:2	H, 402, 403, F, 602, V, CS		
187:1-187:13	H, 402, 403, F, 602, V, CS		
187:18-188:8	H, 402, 403, F, 602, V, CS		
189:8-189:19	H, 402, 403, F, 602, V, CS		
192:19-192:24	H, 402, 403, F, 602		
195:9-195:11	H, 402, 403, F, 602		
195:24-196:6	H, 402, 403, F, 602		
196:12-197:2	H, 402, 403, F, 602		
198:5-198:17	H, 402, 403, F, 602		
201:5-201:8	H, 402, 403, F, 602		
201:20-202:21	H, 402, 403, F, 602		
204:1-204:12	H, 402, 403, F, 602	204:13-205:-9	
206:16-206:21	H, 402, 403, F, 602		
218:14-218:24	H, 402, 403, F, 602		
221:11-221:20	H, 402, 403, F, 602		
229:5-229:7	H, 402, 403, F, 602		
229:15-229:16	H, 402, 403, F, 602		
232:9-232:16	H, 402, 403, F, 602		
232:19-232:24	H, 402, 403, F, 602		
233:4-233:6			
237:8-237:11	H, 402, 403, F, 602		
240:11-240:14	H, 402, 403, F, 602		
241:11-241:23	H, 402, 403, F, 602		
242:8-243:10	H, 402, 403, F, 602		
244:17-245:5	H, 402, 403, F, 602		
247:5-247:10	H, 402, 403, F, 602		
247:12-248:9	H, 402, 403, F, 602		
250:9-250:21	H, 402, 403, F, 602		
251:23-252:5	H, 402, 403, F, 602		

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter- Designations</b>	<b>Sage's Objection(s)</b>
252:10-252:15	H, 402, 403, F, 602		
253:2-253:6	H, 402, 403, F, 602		
254:17-254:22	H, 402, 403, F, 602		

**Sage's Designation of Deposition Testimony of Gregory Mann, February 16, 2023**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter-Designations</b>	<b>Sage's Objection(s)</b>
5:5-5:8			
12:5-12:7			
14:10-14:12	402, 403		
15:1-15:3	402, 403, F, 602, H		
19:24-20:7	402, 403		
20:11-20:11	402, 403		
23:18-23:20	402, 403		
23:24-23:24	402, 403		
24:2-24:5	402, 403		
28:9-28:11	402, 403		
30:18-30:19			
30:21-30:21			
31:15-31:16			
31:18-31:18			
37:6-37:7	402, V, CS	40:17-18, 20; 42:22-43:1, 3	
37:9-37:9		46:15-17, 21; 47:3, 5-6, 8-12; 59:15-20, 22; 60:4-5, 7	
64:14-64:17	402, 403, F, H		
64:21-64:22	402, 403, F, H		
64:24-65:3	402, 403, F, H		
65:5-65:5	402, 403, F, H		
65:7-65:8	402, 403, F, H		
65:11-65:11	402, 403, F, H		
65:13-65:15	402, 403, F, H		
65:18-65:18	402, 403, F, H		
66:9-66:10	402, 403, F, H		
66:13-66:13	402, 403, F, H		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
67:20-67:22	402, 403, F, H		
68:1-68:1	402, 403, F, H		
70:2-70:3			
70:5-70:5	402, 403, F, H		
73:5-73:6	402, 403, F, H		
73:8-73:10	402, 403, F, H		
74:3-74:5	402, 403, F, H		
76:15-76:16	402, 403, F, H		
76:18-76:22	402, 403, F, H		
77:15-77:16			
77:18-77:18			
86:23-86:24	402, 403, F, H, S, CS		
87:3-87:5	402, 403, F, H, S, CS		
87:8-87:10	402, 403, F, H, S, CS		
87:14-87:17	402, 403, F, H, S, CS		
87:20-87:20	402, 403, F, H, S, CS		
90:17-90:24	402, 403, F, H		
91:3-91:8	402, 403, F, H		
91:12-91:12	402, 403, F, H	91:14-17, 19; 93:8-9, 11;	
97:11-97:16	402, 403, F, H		
97:20-97:21	402, 403, F, H		
97:24-98:2	402, 403, F, H		
98:19-98:20	402, 403, F, H		
98:23-98:23	402, 403, F, H		
99:7-99:7	402, 403, F, H, 602, S		
99:10-99:10	402, 403, F, H, 602, S		
99:12-99:13	402, 403, F, H, 602, S		
99:16-99:17	402, 403, F, H, 602, S		
100:10-100:10	402, 403, F, H, 602, S		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
100:13-100:13	402, 403, F, H, 602, S		
101:14-101:15	402, 403, F, H, 602, S		
101:18-101:18	402, 403, F, H, 602, S		
101:20-101:20	402, 403, F, H, 602, S		
101:23-102:4	402, 403, F, H, 602, S		
102:7-102:11	402, 403, F, H, 602, S		
103:22-103:24	402, 403, F, H, 602, S		
104:3-104:5	402, 403, F, H, 602, S		
104:15-104:16	402, 403, F, H, 602, S		
104:19-104:22	402, 403, F, H, 602, S		
105:1-105:1	402, 403, F, H, 602, S		
105:11-105:13	402, 403, F, H, 602, S		
105:17-105:21	402, 403, F, H, 602, S		
105:24-106:3	402, 403, F, H, 602, S		
106:5-106:7	402, 403, F, H, 602, S		
106:10-106:14	402, 403, F, H, 602, S		
106:17-106:23	402, 403, F, H, 602, S		
107:2-107:2	402, 403, F, H, 602, S		
113:19-113:20	402, 403, F, H		
113:23-113:23	402, 403, F, H		
116:6-116:8	402, 403, F, H		
116:10-116:10	402, 403, F, H		
116:12-116:14	402, 403, F, H		
116:16-116:16	402, 403, F, H		
116:18-116:19	402, 403, F, H		
116:21-116:23	402, 403, F, H		
118:17-118:18		120:17-19, 24; 121:1,	

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
118:23-118:24		122:15-17, 20, 22; 123:1-4, 6-9, 19-22, 24; 125:6-9, 11-15, 126:3-6, 8, 15-16, 18-19	
145:20-145:22	402, 403, F, H, 602, S		
146:1-146:4	402, 403, F, H, 602, S		
146:7-146:8	402, 403, F, H, 602, S		
149:13-149:15	402, 403, F, H, 602, S		
149:18-149:20	402, 403, F, H, 602, S		
149:22-149:23	402, 403, F, H, 602, S		
150:2-150:4	402, 403, F, H, 602, S		
150:6-150:7	402, 403, F, H, 602, S		
150:10-150:10	402, 403, F, H, 602, S		
150:20-150:22	402, 403, F, H, 602, S		
151:1-151:7	402, 403, F, H, 602, S		
153:12-153:13	402, 403, F, H, 602, S		
153:16-153:19	402, 403, F, H, 602, S		
154:10-154:12	402, 403, F, H, 602, S		
154:15-154:15	402, 403, F, H, 602, S		
158:10-158:13	402, 403, F, H, 602, S		
158:16-158:16	402, 403, F, H, 602, S		
163:23-164:3	402, 403, F, H, 602, S		
173:21-174:3	402, 403, F, H, 602, S		
174:6-174:6	402, 403, F, H, 602, S		
175:2-175:4	402, 403, F, H, 602, S		
175:7-175:9	402, 403, F, H, 602, S		
177:21-177:22	402, 403, F, H, 602, S		
177:24-178:2	402, 403, F, H, 602, S	178:8-14	
179:1-179:2	402, 403, F, H, 602, S		
179:5-179:11	402, 403, F, H, 602, S		



Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
179:23-180:2	402, 403, F, H, 602, S		
180:11-180:15	402, 403, F, H, 602, S		
180:18-180:24	402, 403, F, H, 602, S		
181:3-181:4	402, 403, F, H, 602, S		
183:7-183:11	402, 403, F, H, 602, S		
183:12-183:16	402, 403, F, H, 602, S		
183:19-183:19	402, 403, F, H, 602, S	183:21-23	
190:10-190:11	402, 403, F, H, 602, S		
190:15-190:18	402, 403, F, H, 602, S		
190:20-190:20	402, 403, F, H, 602, S		
191:21-191:22	402, 403, F, H, 602, S		
192:1-192:2	402, 403, F, H, 602, S		
192:5-192:5	402, 403, F, H, 602, S		
192:7-192:8	402, 403, F, H, 602, S		
192:11-192:11	402, 403, F, H, 602, S		
192:18-192:20	402, 403, F, H, 602, S		
192:24-192:24	402, 403, F, H, 602, S		
194:4-194:6	402, 403, F, H, 602, S		
194:10-194:11	402, 403, F, H, 602, S		
194:24-195:1	402, 403, F, H, 602, S		
195:5-195:6	402, 403, F, H, 602, S		
195:9-195:9	402, 403, F, H, 602, S		
195:15-195:17	402, 403, F, H, 602, S		
195:20-195:22	402, 403, F, H, 602, S		
196:6-196:7	402, 403, F, H, 602, S		
196:10-196:10	402, 403, F, H, 602, S		
198:16-198:17	402, 403, F, H, 602, S		
199:3-199:5	402, 403, F, H, 602, S		
199:7-199:7	402, 403, F, H, 602, S		

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter- Designations</b>	<b>Sage's Objection(s)</b>
199:9-199:10	402, 403, F, H, 602, S		
199:14-199:14	402, 403, F, H, 602, S		

**Sage's Designation of Deposition Testimony of Richard Morgan, February 2, 2023**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter-Designations</b>	<b>Sage's Objection(s)</b>
4:23-5:1			
8:7-9:2			
10:9-10:14			
13:3-13:14			
13:20-13:24			
16:1-16:1			
16:1-17:4			
17:18-17:23			
20:10-20:23			
22:16-22:19			
22:21-22:22			
23:5-23:21			
24:6-24:11			
24:13-24:17			
27:20-27:23	402, 403, F, H		
28:2-28:13	402, 403, F, H		
30:2-30:12	402, 403, F, H, I	30:13-17	
30:18-31:1			
31:19-32:4			
32:7-33:1			
33:4-33:5			
34:7-34:21			
35:5-35:13	402, 403, F, H, CS, V, I	35:17-19; 35:20-38:1	
35:15-35:16	402, 403, H		
38:2-38:5	402, 403, H		
38:8-38:20	402, 403, H		
39:6-39:9	402, 403, H		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
40:15-41:1	402, 403, H, CS, V, Exp		
41:4-41:7	402, 403, H, CS, V, Exp		
41:9-41:11	402, 403, H, CS, V, Exp		
41:13-41:13	402, 403, H, CS, V, Exp		
41:20-41:24	402, 403, H, CS, V, Exp		
42:1-42:10	402, 403, H, CS, V, Exp		
42:12-42:12	402, 403, H, CS, V, Exp, I	42:13	
42:21-43:3	402, 403, H, CS, V, Exp		
43:6-43:11	402, 403, H, CS, V, Exp		
43:13-43:16	402, 403, H, CS, V, Exp		
43:19-43:22	402, 403, H, CS, V, Exp		
44:5-44:12	402, 403, H, CS, V, Exp		
44:15-44:16	402, 403, H, CS, V, Exp		
45:13-45:21	402, 403, H, CS, V, Exp		
45:24-46:2	402, 403, H, CS, V, Exp		
46:4-46:5	402, 403, H, CS, V, Exp		
46:7-46:15	402, 403, H, CS, V, Exp		
46:20-46:21	402, 403, H, CS, V, Exp, I	46:18-19, 22-24	
48:20-49:3	402, 403, H		
49:5-49:14	402, 403, H, CS, V, Exp		
50:5-50:11	402, 403, H, CS, V, Exp, I	50:12	
51:11-52:2	402, 403, H, CS, V, Exp		
52:6-52:9	402, 403, H, CS, V, Exp		
52:11-53:3	402, 403, H, CS, V, Exp		
53:11-53:15	402, 403, H, CS, V, Exp, I	53:6-10	
68:14-68:21	402, 403, H, F		
73:15-73:17	H, F, 602		
73:19-73:21	H, F, 602		
73:23-73:24	H, F, 602		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
74:3-74:4	H, F, 602		
75:8-75:24	402, 403, H, CS, V		
77:12-77:14	402, 403, H, CS, V, I	77:6-11	
77:16-77:17	402, 403, H, CS, V		
78:21-78:22	402, 403, H, CS, V		
78:24-79:1	402, 403, H, CS, V		
80:4-80:15	402, 403, H, CS, V		
80:20-80:21	402, 403, H, CS, V		
93:15-94:1	402, 403, H, CS, V		
94:12-94:24	402, 403, H, CS, V		
95:3-95:13	402, 403, H, CS, V		
95:14-95:16	402, 403, H, CS, V		
95:19-95:20	402, 403, H, CS, V		
96:19-96:21	402, 403, H, CS, V		
96:24-97:2	402, 403, H, CS, V		
102:2-102:18	402, 403, H, CS, V		
102:19-102:24	402, 403, H, CS, V		
103:1-103:18	402, 403, H, CS, V		
104:8-104:22	402, 403, H, CS, V		
105:1-105:5	402, 403, H, CS, V		
105:18-106:11	402, 403, H, CS, V		
106:15-106:19	402, 403, H, CS, V		
106:21-108:6	402, 403, H, CS, V		
113:13-114:10	402, 403, H, CS, V		
114:11-114:24			
115:3-115:5			
115:23-116:1			
116:3-116:4			
116:6-116:15			

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
116:18-116:18			
117:14-117:22	402, 403, H, CS, V, F		
118:1-118:3	402, 403, H, CS, V, F		
118:5-118:7	402, 403, H, CS, V, F		
118:10-118:10	402, 403, H, CS, V, F		
118:12-118:14	402, 403, H, CS, V, F		
118:17-118:18	402, 403, H, CS, V, F		
119:3-119:12	402, 403, H, F		
119:13-119:21	402, 403, H, F		
119:24-120:3	402, 403, H, F		
120:5-121:12	402, 403, H, F		
121:15-121:20	402, 403, H, F		
122:18-123:6	402, 403, H, F		
123:9-123:12	402, 403, H, F		
124:9-124:11	402, 403, H, F		
124:14-124:22	402, 403, H, F		
125:3-125:24	402, 403, H, F		
126:1-126:5	402, 403, H, F		
131:8-131:16	402, 403, H, F		
131:19-131:20	402, 403, H, F		
133:1-133:3	402, 403, H, F, I	133:4-10	
133:24-134:8	402, 403, H, F, I	134:13-15	
134:9-134:10	402, 403, H, F		
135:12-135:17	402, 403, H, F		
135:18-135:18	402, 403, H, F		
135:19-136:16	402, 403, H, F		
140:23-141:1	402, 403, H, F		
142:5-142:6	402, 403, H, F		
143:9-143:11	402, 403, H, F, CS, V		

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter- Designations</b>	<b>Sage's Objection(s)</b>
143:18-143:19	402, 403, H, F, CS, V		
143:21-144:1	402, 403, H, F, CS, V		
144:5-144:6	402, 403, H, F, CS, V		
144:11-144:12	402, 403, H, F, CS, V		
144:18-144:21	402, 403, H, F, CS, V		
145:5-145:7	402, 403, H, F, CS, V		
145:8-145:8	402, 403, H, F, CS, V		
145:11-145:24			
146:10-146:24			
147:1-147:14			
148:3-148:16			
148:17-149:21			
149:22-149:22			
150:8-150:23			
150:24-152:6			
152:7-153:5			
154:8-154:24			
155:1-155:7			
155:17-156:11			

**Sage's Designation of Trial Testimony of Camille Newton, March 28, 2022**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter-Designations</b>	<b>Sage's Objection(s)</b>
224:24-225:8	I, 611, 402, 403, UNE	225:9-14	
225:15-225:19	402, 403, UNE		
226:2-226:25	F, 402, 403, 611, CS, UNE		
227:1-227:20	F, 402, 403, 611, CS, UNE		
229:20-229:24	I, 402, 403, 611, UNE		
229:25-230:7	402, 403, 611, CS, UNE		
230:8-230:8	402, 403, UNE		
230:15-231:8	402, 403, 611, CS, NT, UNE	231:9-16	
231:20-232:5	F, 402, 403, NT, UNE		
232:9-232:25	402, 403, 611, UNE		
233:1-233:14	402, 403, 611, UNE	233:15-20	
234:20-235:12	402, 403, 611, UNE	235:13-22	
235:23-236:12	402, 403, CS, 611, UNE		
236:13-237:7	I, 402, 403, CS, 611, UNE	237:8-17	
238:12-238:14	402, 403, 611, UNE	238:10-11, 238:15-16	
238:17-239:7	402, 403, CS, 611, UNE	238:10-11, 238:15-16, 239:8-18	
239:25-240:7	402, 403, 611, UNE		
240:24-241:6	402, 403, 611, UNE	240:15-23	
241:7-241:11	402, 403, 611, UNE		
241:21-242:14	402, 403, 611, UNE		
242:18-243:6	AF, CS, 402, 403, 611, UNE		
243:7-243:10	402, 403, UNE		
243:18-243:24	M, 402, 403, UNE	243:25-244:14	
244:15-244:21	402, 403, 611, UNE	243:25-244:14	
244:22-245:1	Nar, M, 402, 403, UNE	245:2-16	



<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter- Designations</b>	<b>Sage's Objection(s)</b>
245:17-246:5	M, 402, 403, UNE		
246:6-246:19	402, 403, 611, UNE		
246:20-247:4	402, 403, 611, UNE	247:5-11, 247:17-19	
247:12-247:16	402, 403, 611, UNE	247:5-11, 247:17-19	
247:20-247:22	402, 403, UNE	247:5-11, 247:17-19	
248:8-248:12	402, 403, UNE		
248:17-248:18	NT, 402, 403, UNE		
248:20-249:5	C, Nar, 402, 403, 611, UNE		
249:6-249:14	CS, 402, 403, UNE		
249:15-249:20	402, 403, UNE		

**Sage's Designation of Trial Testimony of Camille Newton, March 29, 2022**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter-Designations</b>	<b>Sage's Objection(s)</b>
258:14-259:12	NT, 402, 403, 611, UNE		
260:1-261:2	I, CS, 402, 403, UNE	261:3-4	
261:5-261:9	I, CS, 402, 403, UNE	261:10-20	
261:21-262:2	402, 403, 611, UNE		
262:3-262:19	M, 402, 403, 602, 611, UNE	262:20-263:13	
263:14-263:25	CS, 402, 403, UNE	264:1-11	
264:12-264:16	402, 403, UNE	264:1-11	
266:25-267:16	LC, 402, 403, 701, UNE		
267:17-268:1	LC, 402, 403, 611, 701, UNE		
268:2-268:18	CS, 402, 403, 611, UNE		

**Sage's Designation of Deposition Testimony of Camille Newton, April 5, 2021**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter-Designations</b>	<b>Sage's Objection(s)</b>
10:14-10:16	UNE		
15:25-16:9	UNE		
16:10-16:18	UNE		
16:21-17:2	UNE		
17:3-17:16	UNE		
17:17-17:22	UNE		
18:8-18:14	UNE		
19:6-19:8	402, 403, UNE	19:15-17	
26:18-26:25	UNE		
27:5-27:17	UNE		
29:2-29:19	UNE		
30:2-30:11	402, 403, 602, UNE		
31:5-31:8	I, UNE	31:4	
31:24-32:7	UNE		
33:19-33:24	UNE		
33:25-34:7	UNE		
34:15-34:23	H, F, UNE		
35:1-35:1	UNE		
40:11-40:14	H, F, 403, UNE		
40:17-40:18	H, F, 403, 402, UNE		
48:1-48:7	UNE		
51:13-51:17	402, 403, F, UNE	51:9-12, 51:25-52:10	
52:11-52:13	402, 403, 602, F, UNE		
52:15-52:16	402, 403, 602, F, UNE		
53:6-53:8	UNE		
53:9-53:9	UNE		
53:24-54:2	UNE	54:5-10	

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
55:13-55:15	402, 403, 602, F, H, UNE		
55:18-55:21	402, 403, 602, F, H, UNE		
55:25-56:3	402, 403, UNE		
56:6-56:6	402, 403, UNE		
60:9-60:10	F, 403, UNE	56:8-9, 56:12, 56:14-19, 56:22-25	
60:13-60:19	F, 403, UNE		
60:25-61:6	F, 402, 403, UNE		
65:18-66:4	F, 402, 403, UNE	66:8-10, 66:12-13, 66:15-24	
66:6-66:6	UNE		
66:25-67:10	F, 402, 403, UNE		
67:13-67:21	F, 402, 403, UNE	67:22-68:4	
68:14-68:18	H, F, 402, 403, V, UNE		
68:20-68:21	H, F, 402, 403, UNE		
70:13-70:15	402, 403, V, F, UNE		
70:22-70:22	UNE		
70:24-70:25	402, 403, V, UNE	71:9, 71:11-15	
71:2-71:7	402, 403, UNE		
72:14-72:18	402, 403, UNE		
74:24-75:1	F, V, 402, 403, UNE		
75:3-75:10	F, V, 402, 403, UNE		
75:11-75:11	V, F, UNE		
75:13-75:13	UNE		
75:15-75:21	UNE		
75:23-76:4	402, 403, H, UNE		
77:3-77:12	F, H, UNE		
77:22-77:24	UNE		
78:1-78:17	UNE		
78:18-79:3	V, UNE		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
79:5-79:15	UNE		
79:17-79:24	H, 402, 403, UNE		
81:1-81:13	H, 402, 403, CS, UNE		
83:7-83:10	402, 403, V, UNE		
83:12-83:13	UNE		
85:4-85:7	402, 403, UNE	85:8-9, 85:11-13, 86:15-16, 85:18-19	
86:15-86:18	UNE		
88:11-89:5	UNE		
97:16-97:17	F, H, 402, 403, I, UNE	97:14-15	
97:22-97:25	F, H, 402, 403, UNE		
99:12-99:19	H, F, V, 402, 403, I, UNE	99:11	
99:22-99:23	402, 403, 602, UNE		
100:6-100:8	402, 403, I, UNE	100:5	
101:1-101:9	402, 403, F, H, UNE		
101:15-101:17	402, 403, F, H, UNE		
101:18-101:25	402, 403, F, H, UNE		
102:1-102:1	UNE		
102:3-102:7	402, 403, UNE		
103:4-103:11	402, 403, F, UNE		
103:13-103:15	402, 403, F, V, UNE		
103:25-104:2	402, 403, F, V, UNE		
104:5-104:6	UNE		
104:12-104:14	402, 403, F, V, UNE		
106:7-106:16	402, 403, UNE		
107:13-107:14	402, 403, V, UNE		
107:16-107:16	402, 403, V, UNE		
108:5-108:15	402, 403, V, UNE		
108:16-108:18	402, 403, V, UNE		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
108:19-108:22	402, 403, V, UNE		
109:10-109:12	UNE		
109:14-109:16	402, 403, V, C, UNE		
109:19-109:24	UNE		
110:14-111:1	402, 403, UNE	110:1-13	
112:9-112:18	402, 403, V, F, UNE		
112:24-112:24	402, 403, V, F, UNE		
113:4-113:6	402, 403, H, F, I, UNE		
113:19-113:21	402, 403, H, F, UNE		
113:24-114:4	402, 403, H, F, UNE		
114:5-114:6	402, 403, H, F, UNE		
114:9-114:10	402, 403, H, F, UNE		
114:17-114:19	UNE		
115:13-115:15	402, 403, F, Exp, UNE	114:20-21, 114:24-115:1, 115:3-4, 115:7-10	
115:19-115:24	UNE		
116:24-117:2	UNE	118:9-18, 118:22-24, 119:2-8	
117:5-117:10	UNE	118:9-18, 118:22-24, 119:2-8	
117:13-117:14	UNE		
117:16-117:19	UNE		
117:22-118:1	UNE		
118:3-118:5	UNE	118:9-18, 118:22-24, 119:2-8	
121:2-121:2	402, 403, F, H, UNE		
121:3-121:9	402, 403, F, H, UNE		
121:12-121:13	402, 403, F, H, UNE		
121:25-122:1	402, 403, 602, UNE		
122:4-122:4	402, 403, 602, UNE		
122:19-122:22	402, 403, 602, H, UNE		
122:24-123:4	402, 403, 602, H, UNE		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
123:5-123:7	402, 403, 602, H, UNE		
123:9-123:9	402, 403, 602, UNE		
123:11-123:13	402, 403, 602, F, H, UNE		
123:15-123:16	402, 403, 602, F, H, UNE		
129:14-129:17	402, 403, ARG, UNE		
129:20-129:23	402, 403, ARG, UNE		
129:25-130:7	402, 403, UNE		
132:19-133:13	402, 403, UNE		
133:15-133:15	402, 403, UNE		
134:10-134:18	402, 403, UNE		
135:9-135:14	402, 403, V, UNE		
135:16-135:16	402, 403, UNE		
135:18-135:20	402, 403, C, V, UNE		
135:23-136:9	402, 403, H, F, UNE		
136:18-136:20	402, 403, V, UNE		
137:4-137:9	402, 403, UNE		
137:19-138:4	402, 403, UNE	138:5-19	
138:22-138:24	402, 403, F, V, UNE		
139:2-139:4	402, 403, F, UNE		
139:10-140:3	402, 403, F, UNE		
140:4-140:18	402, 403, F, UNE		
142:5-142:18	402, 403, F, UNE		
144:21-145:1	402, 403, F, UNE	144:8-20, 145:2-7	
145:11-145:13	UNE		
145:21-145:23	402, 403, F, UNE		
146:4-146:14	402, 403, UNE		
146:15-147:2	402, 403, UNE	147:3-14	
147:15-147:24	402, 403, UNE		
148:12-148:21	402, 403, UNE	148:22-149:7	

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
149:8-149:11	402, 403, UNE	149:12-14	
149:15-149:17	402, 403, V, UNE		
149:20-149:24	402, 403, UNE		
150:16-151:2	UNE		
152:17-152:20	402, 403, UNE		
154:15-155:7	402, 403, UNE		
155:9-155:10	402, 403, V, F, UNE		
155:12-155:15	402, 403, F, UNE	155:17, 155:19-22	
155:23-156:9	402, 403, H, F, UNE		
156:13-157:2	402, 403, H, F, V, UNE		
157:7-157:9	402, 403, F, V, UNE		
157:11-157:25	402, 403, PRIV, UNE		
159:14-159:16	402, 403, V, UNE		
160:11-160:11	I, UNE	160:8-10	
160:25-161:2	402, 403, H, F, UNE	160:13-24	
161:5-161:5	UNE		
161:7-161:9	402, 403, H, F, C, UNE		
161:12-161:17	402, 403, H, F, UNE		
161:20-162:2	402, 403, H, F, UNE		
163:8-163:14	402, 403, V, UNE		
163:16-163:18	402, 403, UNE		
163:20-163:21	402, 403, H, V, UNE		
164:4-164:5	UNE		
164:6-164:17	402, 403, UNE		
165:1-165:3	UNE		
165:6-165:13	UNE		
165:15-165:17	UNE		
165:20-165:20	UNE		
165:25-166:11	402, 403, UNE		



Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
166:16-166:18	402, 403, UNE		
166:21-166:22	402, 403, UNE		
167:7-167:10	402, 403, UNE		
167:13-167:14	402, 403, UNE		
167:16-167:16	402, 403, UNE		
167:20-167:24	402, 403, UNE		
168:2-168:7	402, 403, UNE		
170:7-170:9	402, 403, UNE		
170:10-170:12	402, 403, UNE		
170:15-171:5	402, 403, F, H, UNE		
172:6-172:8	402, 403, F, H, UNE		
172:11-172:14	402, 403, F, H, UNE		
172:17-173:1	402, 403, F, H, UNE		
173:8-173:11	402, 403, UNE		
173:12-173:13	402, 403, I, F, V, UNE		
173:14-173:17	4032, 403, I, F, V, UNE	173:12-13	
173:20-173:24	F, UNE		
174:4-174:6	I, H, UNE		
174:7-174:8	I, H, UNE		
174:16-174:21	UNE		
174:22-175:6	V, 403, UNE	175:16-18, 175:21-176:1	
175:7-175:10	V, 403, I, UNE		
175:13-175:14	F, UNE		
177:24-177:25	I, H, UNE		
178:15-178:19	402, 403, V, UNE	176:7-10, 176:12-17	
178:20-178:22	402, 403, V, UNE		
178:24-178:25	402, 403, V, UNE		
179:10-179:12	402, 403, V, UNE		
179:14-179:15	402, 403, V, UNE		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
179:17-179:21	402, 403, V, UNE		
179:23-180:1	F, UNE	180:2-5	
180:12-181:4	402, 403, V, UNE		
181:5-181:14	402, 403, V, UNE		
182:15-182:15	402, 403, V, UNE		
183:25-184:15	402, 403, F, H, UNE		
184:16-184:18	402, 403, F, H, UNE		
184:22-184:25	402, 403, F, H, UNE		
185:12-185:13	402, 403, V, UNE		
185:16-185:19	UNE		
185:24-186:4	402, 403, UNE	186:16-19, 186:23-187:3	
188:9-188:11	UNE		
188:13-188:14	402, 403, V, F, UNE	189:4-6, 189:14-15, 189:17-18	
190:5-190:13	UNE		
190:14-190:16	UNE		
190:19-190:20	UNE		
191:16-191:18	402, 403, H, V, UNE		
191:21-191:21	UNE		
192:14-192:19	402, 403, UNE		
192:20-192:21	402, 403, UNE		
192:23-192:24	402, 403, UNE		
193:14-193:14	UNE		
194:5-194:7	402, 403, F, H, UNE		
194:10-194:14	402, 403, F, H, UNE	194:16-18, 194:21-195:6	
195:8-195:10	402, 403, F, H, UNE		
195:15-195:24	402, 403, F, H		
196:1-196:7	402, 403, UNE		
196:9-196:10	402, 403, UNE		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
196:12-197:3	402, 403, F, H, UNE		
197:20-198:1	402, 403, F, H, UNE		
198:9-198:14	402, 403, F, H, UNE		
200:12-200:22	UNE		
200:25-201:2	UNE		
201:10-201:25	UNE		
202:3-202:8	402, 403, V, UNE		
202:8-202:13	402, 403, V, UNE		
202:16-202:18	402, 403, V, UNE		
203:10-203:12	402, 403, V, F, UNE		
203:14-203:19	UNE		
203:25-204:3	UNE		
205:21-206:7	402, 403, V, UNE	209:21-23	
206:9-206:19	402, 403, V, UNE	209:21-23	
207:8-207:13	402, 403, V, UNE	209:21-13	
207:14-207:17	402, 403, V, UNE	209:21-23	
207:22-208:5	402, 403, V, H, UNE	207:21, 209:21-23	
208:9-208:19	402, 403, V, UNE	209:5-15	
208:25-209:4	402, 403, V, UNE		
211:3-211:7	UNE		
212:12-212:12	UNE		
212:19-213:11	402, 403, UNE		
213:12-213:20	402, 403, UNE		
213:22-214:5	402, 403, V, F, UNE		
214:7-214:13	402, 403, V, F, UNE		
214:15-214:16	402, 403, V, F, UNE		
215:2-215:3	402, 403, V, UNE		
215:8-215:12	402, 403, V, UNE		
215:22-216:1	402, 403, V, UNE		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
216:2-216:4	402, 403, V, UNE		
216:6-216:6	402, 403, V, UNE		
216:8-216:10	402, 403, V, UNE		
216:16-216:19	402, 403, V, UNE		
216:21-217:6	402, 403, V, UNE		
217:7-217:8	402, 403, V, UNE		
217:10-217:10	402, 403, V, UNE		
217:12-217:13	402, 403, V, UNE		
217:15-217:16	402, 403, F, UNE		
217:18-217:21	402, 403, V, UNE		
217:24-218:11	402, 403, V, UNE		
218:13-218:18	402, 403, V, UNE		
218:20-218:20	402, 403, V, I, F, H, UNE		
218:21-218:24	402, 403, V, I, F, H, UNE		
219:19-220:9	402, 403, F, H, 602, UNE		
220:10-220:15	402, 403, F, H, 602, UNE		
220:18-220:25	402, 403, F, H, 602, UNE		
221:2-221:13	UNE		
221:14-222:3	UNE		
222:4-222:10	UNE		
222:22-222:25	UNE		
223:2-223:3	UNE		
224:16-224:22	402, 403, UNE		
224:25-225:6	402, 403, UNE		
225:8-225:16	402, 403, F, H, UNE		
225:25-226:3	402, 403, F, H, UNE		
226:5-226:6	402, 403, F, H, UNE		
226:9-226:14	402, 403, F, H, UNE		
226:17-226:23	402, 403, F, H, UNE		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
227:1-227:8	402, 403, F, H, UNE		
227:11-227:13	402, 403, F, H, UNE		
227:24-228:2	402, 403, UNE		
228:5-228:6	402, 403, UNE		
228:23-228:25	402, 403, UNE		
229:3-229:7	402, 403, UNE	229:9-23	
229:24-230:1	UNE		
234:9-234:19	402, 403, F, UNE		
234:22-234:23	402, 403, F, H, UNE		
236:21-236:23	402, 403, H, UNE		
236:25-236:25	402, 403, H, UNE	237:2, 237:8-238:9	
239:8-239:10	402, 403, H, UNE	238:11-15, 238:17-239:6	
239:13-239:17	402, 403, H, UNE		
239:19-239:21	402, 403, H, F, UNE		
242:16-242:24	H, UNE		
243:2-243:9	UNE		
243:13-243:20	I, UNE		
248:11-248:12	402, 403, H, UNE		
248:13-248:13	402, 403, H, UNE		
249:10-249:12	UNE		
249:15-249:16	UNE		
250:8-250:11	UNE		
250:14-250:15	UNE		
260:11-260:15	UNE		
260:18-261:1	UNE		
261:4-261:7	UNE		
261:10-261:13	UNE		
261:15-261:16	UNE		
275:20-276:2	UNE		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
276:22-277:1	UNE		
278:11-278:13	UNE		
278:15-278:16	UNE		
279:7-279:11	UNE	279:12-280:13, 280:14-19	
281:9-281:24	UNE		
282:11-282:17	UNE		
283:3-283:9	UNE		
283:19-283:20	UNE		
283:22-283:22	UNE		
285:10-285:15	UNE		
285:21-286:10	UNE		
286:15-286:20	UNE		
292:16-292:23	402, 403, F, 602, UNE		
292:24-292:25	402, 403, V, UNE		
293:2-293:3	UNE		
296:15-296:18	402, 403, I, H, F, UNE		
297:20-297:24	402, 403, UNE		
298:3-298:8	402, 403, UNE	298:9-16	
298:17-298:22	402, 403, UNE		
298:24-298:25	402, 403, UNE		

**Sage's Designation of Deposition Testimony of Camille Newton, April 6, 2023**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter-Designations</b>	<b>Sage's Objection(s)</b>
4:16-4:20	UNE		
11:24-12:5	UNE		
13:17-14:4	UNE		
14:5-14:15	UNE		
14:22-14:22	UNE		
15:1-15:13	UNE		
15:16-15:16	UNE		
15:18-16:1	UNE		
16:4-16:4	UNE		
16:9-16:18	UNE		
16:21-16:21	UNE		
17:1-17:8	UNE		
17:11-17:11	UNE		
18:22-19:4	UNE		
19:7-19:7	UNE		
20:15-20:16	UNE		
21:20-21:23	UNE		
22:9-22:11	402, 403, UNE		
22:18-22:18	UNE		
24:13-24:15	402, 403, UNE		
24:19-24:19	UNE		
24:21-24:24	402, 403, F, 602, UNE		
26:17-26:19	402, 403, UNE		
26:24-26:24	UNE		
27:2-27:4	402, 403, F, UNE		
27:10-27:10	UNE		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
30:6-30:10	UNE		
31:17-31:21	UNE		
32:13-32:16	402, 403, F, UNE		
33:16-33:18	402, 403, H, UNE		
33:21-33:21	UNE		
34:6-34:10	402, 403, F, H, UNE	34:5	
34:17-34:19	402, 403, F, H, UNE		
34:20-34:23	402, 403, F, UNE		
35:2-35:2	UNE		
36:22-37:1	402, 403, UNE		
37:5-37:8	UNE		
37:16-37:19	402, 403, F, H, UNE		
38:11-38:15	402, 403, UNE		
38:19-38:22	UNE		
40:2-40:6	402, 403, F, H, 602, UNE		
40:12-40:18	402, 403, F, H, 602, UNE		
40:19-40:19	UNE		
41:4-41:6	402, 403, F, H, 602, CS, LC, V, UNE		
42:1-42:4	UNE		
43:8-43:11	402, 403, H, UNE		
44:23-45:1	402, 403, F, V, LC, UNE		
45:5-45:5	UNE		
45:10-45:13	UNE		
46:1-46:5	402, 403, H, UNE	46:6-47:2, 47:6, 47:8-11, 47:15-20	
48:16-48:19	UNE		
50:8-50:12	402, 403, F, H, UNE		
51:23-52:2	UNE		



Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
52:9-52:15	402, 403, H, F, 602, V, LC, CS, UNE		
52:16-52:20	402, 403, H, F, 602, V, LC, CS, UNE		
52:24-52:24	UNE		
56:19-56:20	UNE		
57:4-57:4	402, 403, PRIV, UNE		
63:4-63:7	UNE		
63:23-64:1	402, 403, H, UNE		
67:14-67:17	UNE		
68:8-68:11	402, 403, H, UNE		
69:15-69:20	402, 403, H, UNE		
69:21-69:22	402, 403, H, LC, UNE		
70:3-70:3	UNE		
71:22-72:1	402, 403, H, F, 602, UNE		
72:5-72:8	UNE		
72:22-73:1	402, 403, H, UNE		
73:19-73:24	402, 403, H, UNE		
74:1-74:2	402, 403, H, UNE		
74:5-74:7	402, 403, CS, 602, F, UNE		
76:20-76:22	402, 403, CS, 602, V, F, UNE		
77:2-77:4	UNE		
77:6-77:7	UNE		
77:21-77:24	UNE		
78:11-78:14	402, 403, H, UNE		
78:15-78:24	402, 403, H, UNE		
81:12-81:15	UNE		
81:19-81:22	402, 403, H, UNE		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
83:4-83:7	PRIV, UNE		
83:13-83:13	PRIV, UNE		
84:4-84:5	PRIV, UNE		
84:18-84:18	UNE		
84:20-84:21	PRIV, UNE		
86:13-86:13	UNE		
88:15-88:18	UNE		
89:21-89:22	402, 403, H, UNE		
90:1-90:3	H, UNE		
90:20-90:23	UNE		
91:14-91:17	402, 403, H, UNE		
92:1-92:2	402, 403, V, C, UNE		
92:5-92:11	UNE		
92:18-92:21	402, 403, PRIV, UNE		
93:4-93:4	UNE		
96:9-96:12	UNE		
96:16-96:19	402, 403, H, F, UNE		
99:5-99:8	UNE		
99:12-99:20	402, 403, H, F, UNE		
101:8-101:11	UNE		
101:15-101:23	402, 403, H, LC, 602, UNE		
101:24-102:2	UNE		
102:9-102:10	602, CS, UNE		
102:12-102:13	402, 403, 602, CS, V, UNE		
102:17-102:19	UNE		
102:21-102:22	402, 403, 602, CS, V, UNE		
103:1-103:1	UNE		
103:4-103:7	402, 403, 602, CS, V, UNE		
104:1-104:4	402, 403, F, V, UNE		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
104:5-104:7	UNE		
104:11-104:15	402, 403, V, F, UNE		
104:19-104:21	UNE		
105:7-105:9	402, 403, V, F, UNE		
105:12-105:14	F, 602, UNE		
105:16-105:18	402, 403, V, CS, 602, UNE		
105:22-106:2	I, UNE	106:12-20	
109:5-109:9	402, 403, F, V, Arg, LC, CS, Hyp, H, UNE		
109:13-109:18	402, 403, F, Arg, H, LC, UNE		
109:19-109:21	402, 403, UNE		
110:9-110:11	402, 403, F, CS, 602, UNE		
110:21-111:4	H, UNE		
111:8-111:11	UNE		
111:16-111:19	402, 403, H, UNE		
111:20-111:24	402, 403, H, UNE		
112:5-112:8	UNE		
113:6-113:12	UNE		
113:13-113:17	UNE		
113:18-113:24	UNE		
114:24-115:2	402, 403, F, 602, AF, UNE		
115:6-115:9	UNE		
115:13-115:17	H, UNE		
115:21-115:24	H, 402, 403, UNE	116:1-3, 116:6-9	
116:11-116:12	402, 403, V, UNE		
116:15-116:15	UNE		
117:1-117:5	UNE		
118:3-118:7	402, UNE		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
125:14-125:15	402, 403, V, UNE		
125:18-125:19	UNE		
126:22-127:2	402, 403, UNE		
127:6-127:10	402, 403, UNE		
128:9-128:12	UNE		
128:16-128:19	H, UNE		
129:3-129:7	402, 403, H, UNE		
129:10-129:13	H, UNE		
130:18-131:2	H, F, UNE		
131:24-132:6	402, 403, V, LC, UNE		
132:22-132:23	402, 403, V, LC, UNE		
133:3-133:4	UNE		
133:24-134:2	402, 403, V, LC, UNE		
134:5-134:5	UNE		
134:8-134:22	UNE		
134:23-135:1	402, 403, V, LC, UNE		
135:4-135:5	UNE		
136:15-136:23	402, 403, V, F, H, UNE		
137:3-137:7	UNE		
137:11-137:18	402, 403, H, F, UNE		
138:1-138:6	402, 403, H, F, UNE		
141:16-141:22	402, 403, LC, V, F, UNE		
142:1-142:1	UNE		
144:4-144:11	UNE		
144:12-144:14	PRIV, H, UNE		
144:20-144:22	UNE		
144:24-145:2	PRIV, H, UNE		
145:8-145:13	PRIV, H, UNE		
145:16-145:18	UNE		

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter- Designations</b>	<b>Sage's Objection(s)</b>
145:20-145:22	PRIV, H, UNE		
146:2-146:7	PRIV, H, UNE		
146:12-146:12	UNE		
147:8-147:13	402, 403, V, UNE		
147:18-147:24	402, 403, V, UNE		

**Sage's Designation of Trial Testimony of Ray Newton, March 29, 2022**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter-Designations</b>	<b>Sage's Objection(s)</b>
291:12-291:17	402, 403	288:6-10, 289:21-290:1, 290:15-290:11	
292:3-293:18	402, 403	293:19-22	
293:23-295:2	402, 403		
295:10-297:7	402, 403	297:8-17	
297:18-297:20	402, 403, V	297:21-299:23	
300:16-300:21	402, 403		
301:2-301:10	402, 403		
302:2-302:6	402, 403	302:11-305:14	
309:7-310:7	402, 403		
317:11-317:15	402, 403		
317:18-317:20	402, 403	318:9-319:22	
321:1-321:15	402, 403	321:16-322:9	
322:10-322:16	402, 403, C, Arg		
323:11-323:15	402, 403	324:17-325:5	

**Sage's Designation of Deposition Testimony of Ray Newton, April 13, 2021**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter-Designations</b>	<b>Sage's Objection(s)</b>
9:15-9:18			
17:10-17:13	402, 403		
18:2-18:5	402, 403		
18:25-19:9	402, 403	19:10-11	
21:4-21:11	402, 403		
21:21-22:7	402, 403		
29:12-29:15	402, 403, V		
33:17-33:25	402, 403, V		
34:2-34:5	402, 403, V		
35:19-35:20	402, 403, V		
35:22-36:3	402, 403, V		
36:10-36:18	402, 403	36:19-23	
37:12-38:6	402, 403		
38:8-38:14	402, 403		
38:17-38:23	402, 403		
38:25-39:4	402, 403		
39:14-40:14	402, 403		
43:5-43:13	402, 403, V		
43:15-44:12	402, 403, V		
44:15-44:23	402, 403, V		
44:25-45:2	402, 403, V		
45:4-45:11	402, 403, V	45:12-21	
45:22-45:23	402, 403, V		
45:25-46:7	402, 403, V		
46:10-46:11	402, 403, V		
46:21-46:22	402, 403, V		
46:25-47:13	402, 403, V		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
47:15-47:17	402, 403, V		
47:19-47:22	402, 403, V		
48:5-48:8	402, 403, V		
48:11-48:14	402, 403, V		
48:16-48:16	402, 403, V		
48:18-49:1	402, 403, V		
49:5-49:6	402, 403, V		
49:8-49:10	402, 403, V		
49:22-49:23	402, 403, V		
49:25-49:25	402, 403, V	50:2-5	
50:7-50:10	402, 403, V		
50:12-51:2	402, 403, V		
52:1-52:20	402, 403, V		
52:22-53:19	402, 403, V		
56:3-56:21	402, 403, V		
57:4-57:15	402, 403, V		
57:18-57:23	402, 403, V		
58:14-59:5	402, 403, V	59:8-13	
60:2-60:11	402, 403, V		
71:7-71:24	402, 403, V	72:1-6, 72:8-25	
76:2-76:7	402, 403, V, Arg		
76:9-76:10	402, 403, V, Arg		
76:22-77:4	402, 403, V, Arg		
77:12-77:16	402, 403, V, Arg		
77:19-77:20	402, 403, V		
77:23-78:11	402, 403, V		
78:14-78:16	402, 403, V		
78:18-78:25	402, 403, V	79:15-17, 79:19-80:9, 80:12-20	



Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
79:1-79:9	402, 403, V	79:15-17, 79:19-80:9, 80:12-20	
79:10-79:11	402, 403, V	79:15-17, 79:19-80:9, 80:12-20	
79:13-79:13	402, 403, V	79:15-17, 79:19-80:9, 80:12-20	
81:8-81:13	402, 403, V	81:14-22	
81:23-82:4	402, 403, V		
84:14-85:7	402, 403, V		
85:22-85:25	402, 403, V		
87:14-88:4	402, 403		
91:24-92:2			
96:5-97:16	402, 403		
97:23-98:1			
98:5-98:8		98:10-17	
104:2-104:13	402, 403, H, F		
104:18-104:25	402, 403, H, F		
107:11-108:25	402, 403, V	98:24-99:20, 100:22-101:12	
109:6-109:16	402, 403	109:17-25	
110:1-110:10	402, 403		
111:3-111:11	402, 403		
112:22-112:25			
113:2-113:5		113:7-11, 113:14-25, 114:25-115:22	
115:23-116:1	402, 403, H, F		
117:5-117:7	402, 403		
117:18-117:22	402, 403		
117:24-117:24	402, 403		
118:15-118:19	402, 403, V		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
118:21-118:25	402, 403, V		
119:2-119:3	402, 403, V		
119:22-120:4	402, 403, V		
120:13-120:14	402, 403, V		
120:16-120:22	402, 403, V		
120:24-120:24	402, 403, V		
121:2-121:4	402, 403, V		
121:7-121:9	402, 403, V		
121:11-121:21	402, 403, V	121:22-122:1, 122:3-13	
125:11-126:3	402, 403, V		
126:6-126:8	402, 403, V		
126:10-126:13	402, 403, V	126:15-18	
127:23-127:25	402, 403		
128:3-128:4	402, 403		
128:8-128:10	402, 403, Arg		
128:13-129:3	402, 403		
129:5-129:12	402, 403, V		
129:14-129:15	402, 403, V		
129:17-129:19			
132:13-133:2	402, 403		
133:5-133:13	402, 403		
133:19-133:23	402, 403		
134:1-134:2	402, 403		
134:11-134:14	402, 403, 701		
134:16-135:1	402, 403, 701		
136:10-136:25	402, 403, V, 701		
139:12-139:20	402, 403, V, F	137:1-15, 138:23, 139:2, 139:5-10	
139:25-140:2	402, 403		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
140:4-140:7	402, 403	141:1-3, 141:6-10	
141:12-142:5			
142:8-142:14			
142:20-143:1			
144:2-144:7			
144:9-144:10	402, 403, V		
144:12-145:10	402, 403, V		
145:22-145:24			
146:3-146:6			
146:8-146:14			
146:16-146:17			
146:19-146:25		147:1-4	
148:15-148:17	402, 403, F		
153:9-153:12			
153:22-154:7	402, 403, V, LC		
154:10-155:10	402, 403, V, LC		
155:13-155:16	402, 403, V		
156:11-156:13	402, 403, V, LC		
156:16-156:25	402, 403, V		
157:3-157:4	402, 403, V, LC		
157:7-157:9	402, 403		
157:14-157:20	402, 403		
158:2-158:5	402, 403		
160:12-160:16	402, 403		
160:19-160:23	402, 403		
163:2-163:11	402, 403		
163:23-163:24	402, 403, V	162:22-23, 163:1	
164:1-164:3	402, 403, V, F		
164:5-164:8	402, 403, F		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
164:12-164:14	402, 403, F	164:15-16	
164:25-165:11	402, 403, V		
165:13-165:13	402, 403, V		
165:16-165:21	402, 403, V		
166:6-166:19	402, 403		
167:4-168:8	402, 403, I, V		
168:10-168:17	402, 403, V		
168:21-168:23	402, 403, V		
169:3-169:4	402, 403		
169:7-169:9	402, 403	169:11-14, 169:17-21	
170:3-170:11	402, 403		
170:14-170:18	402, 403		
171:9-171:16	402, 403, F		
171:19-171:25	402, 403, F		
172:2-172:6	402, 403, F		
172:9-173:10	402, 403, F, V, Arg		
173:12-173:20	402, 403		
174:13-174:15	402, 403		
174:18-174:19	402, 403		
175:22-175:25	402, 403, F		
176:21-176:24	402, 403, F		
177:2-177:4	402, 403, F		
179:1-179:11	402, 403		
179:13-179:14	402, 403		
179:17-179:22	402, 403, F, H		
180:20-181:4	402, 403		
181:13-181:15	402, 403		
181:18-181:19	402, 403		
182:2-182:5	402, 403		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
182:8-182:9	402, 403		
182:12-182:13	402, 403		
182:15-182:18	402, 403, V		
182:21-182:25	402, 403, V		
183:4-183:13	402, 403, V	184:2-14, 184:17-25	
185:1-185:9	402, 403		
185:12-185:12	402, 403		
186:12-186:20	402, 403, V	186:5-11	
186:23-186:24	402, 403, V		
187:2-187:3	402, 403, V		
187:6-187:10	402, 403		
187:14-187:17	402, 403, V		
187:19-187:23	402, 403		
188:17-188:18	402, 403, V		
188:20-189:5	402, 403, V		
189:8-190:2	402, 403, V		
190:5-190:6	402, 403, V		
190:8-190:9	402, 403		
191:4-191:7	402, 403, V		
191:11-191:19	402, 403		
191:24-191:25	402, 403		
192:3-192:6	402, 403		
192:8-192:11	402, 403, V, H		
192:13-192:16	402, 403, V		
192:19-192:20	402, 403, V		
193:8-193:16	402, 403		
193:19-193:19	402, 403		
193:21-193:25	402, 403, V		
194:3-194:3	402, 403		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
194:5-194:6	402, 403, V		
194:8-194:12	402, 403, F		
194:15-194:19	402, 403, V, F		
194:21-194:21	402, 403, V, F		
195:3-195:9	402, 403, V, I		
195:12-195:18	402, 403, V, I		
195:23-196:1	402, 403		
196:5-196:11	402, 403		
197:22-198:3	402, 403, V, F		
198:6-198:13	402, 403, V	199:3-5	
199:6-199:9	402, 403		
199:12-199:19	402, 403		
199:23-199:25	402, 403		
200:2-200:4	402, 403		
200:7-200:11	402, 403, F, 602		
200:14-200:21	402, 403, F, 602		
201:15-201:18	402, 403		
201:21-201:25	402, 403		
202:3-202:3	402, 403		
202:16-202:18	402, 403		
202:22-202:23	402, 403		
203:1-203:5	402, 403		
203:11-203:13	402, 403, V		
203:16-203:23	402, 403, V		
204:1-204:1	402, 403		
204:3-204:5	402, 403, V		
204:7-204:7	402, 403		
204:9-204:11	402, 403		
204:14-204:17	402, 403, V		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
204:19-204:22	402, 403, V		
204:25-205:4	402, 403	207:8-9, 207:12-15	
205:7-205:8	402, 403		
205:10-205:11	402, 403, V		
205:14-205:20	402, 403	205:21-22, 205:25-206:1, 206:21-23, 207:1-6, 207:8-9, 207:12-15	
208:3-208:10	402, 403, V		
208:12-208:13	402, 403, V		
208:23-208:24	402, 403, F		
209:1-209:1	402, 403, F		
209:11-209:12	402, 403, F		
209:15-209:20	402, 403, F		
209:22-210:1	402, 403		
210:21-210:23	402, 403, F		
211:1-211:6	402, 403, F		
211:9-211:9	402, 403		
212:23-213:4	402, 403, F		
213:7-213:7	402, 403		
213:17-213:18	402, 403, V		
213:21-213:25	402, 403, V		
214:3-214:4	402, 403		
214:15-214:16	402, 403		
214:19-214:22	402, 403, V		
214:25-215:1	402, 403		
215:15-215:17	402, 403, V, F		
215:20-215:25	402, 403		
218:5-218:7	402, 403, F, H		
218:10-218:10	402, 403, F, H		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
218:12-218:15	402, 403, H		
218:17-218:23	402, 403, H		
219:1-219:6	402, 403, H		
219:19-219:20	402, 403, V	219:8-9, 219:12-17	
219:23-219:24	402, 403		
220:2-220:3	402, 403, V		
220:5-220:10	402, 403, V		
220:12-220:13	402, 403		
220:17-220:18	402, 403, V		
220:21-220:23	402, 403		
222:14-222:17	402, 403		
222:21-222:22	402, 403		
224:21-224:25	402, 403		
225:11-225:14	402, 403, F		
227:15-227:17	402, 403, F		
229:1-229:3	402, 403, F		
236:21-236:23	402, 403		
236:25-236:25	402, 403		
238:2-238:11	402, 403, H		
238:13-238:17	402, 403, H		
240:8-240:9	402, 403, V, 602, F		
240:12-241:1	402, 403, V, 602, F		
241:4-241:8	402, 403, V, 602, F		
241:20-241:23	402, 403, H, F, I		
241:25-242:8	402, 403, H, F		
242:11-242:24	402, 403, H, 602	244:11-14	
243:2-243:9	402, 403, H, 602	244:11-14	
244:19-245:17	402, 403, H, 602, F	244:11-14	
246:15-246:20	402, 403, H, 602, F	244:11-14	



Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
246:23-247:13	402, 403, H, 602, F	244:11-14	
248:8-248:12	402, 403, H, F, I		
248:15-248:19	402, 403, H, F		
251:4-251:11	402, 403	252:21-23, 253:1-6	
251:16-252:2	402, 403	252:21-23, 253:1-6	
252:6-252:7	402, 403	252:21-23, 253:1-6	
252:10-252:14	402, 403	252:21-23, 253:1-6	
252:17-252:19	402, 403	252:21-23, 253:1-6	
254:1-254:3	402, 403, 1004	254:15-17, 254:20-24, 255:2, 255:11-13, 255:16-18	
254:6-254:10	402, 403, 1004	254:15-17, 254:20-24, 255:2, 255:11-13, 255:16-18	
254:13-254:13	402, 403, 1004	254:15-17, 254:20-24, 255:2, 255:11-13, 255:16-18	
256:23-257:3	402, 403		
257:13-257:19	402, 403		
258:22-258:25	402, 403, F, 602		
259:16-259:17	402, 403, V		
259:19-260:24	402, 403, V	260:25-261:2	
261:3-261:5	402, 403, F, H		
262:7-262:25	402, 403		
263:19-263:22	402, 403	263:23-264:7	
264:8-264:24	402, 403		
265:1-265:2	402, 403		
265:9-265:15	402, 403, F, 602		
265:18-265:19	402, 403, F, 602		
267:24-268:16	402, 403		
269:3-269:9	402, 403		

**Sage's Designation of Deposition Testimony of Ray Newton, May 3, 2023**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter-Designations</b>	<b>Sage's Objection(s)</b>
4:19-4:22			
16:19-16:24	402, 403, V		
17:13-17:16	402, 403, V		
21:5-21:6	402, 403, V		
21:9-21:11	402, 403, V		
21:13-21:16	402, 403, V		
25:7-25:8	402, 403, V		
25:11-25:13	402, 403, V		
25:17-25:18	402, 403, V		
25:20-25:22	402, 403, V	25:23-26:2 26:6-12	
26:15-26:16	402, 403, V		
26:21-26:23	402, 403, V		
27:4-27:7	402, 403, V		
27:10-27:10	402, 403, V		
27:12-27:16	402, 403, V		
27:22-27:24	402, 403, V		
28:7-28:16	402, 403		
28:22-28:24	402, 403, V		
29:4-29:6	402, 403, V		
29:8-29:9	402, 403, V		
29:14-29:22	402, 403		
30:3-30:5	402, 403, V		
30:8-30:8	402, 403, V		
30:10-30:11	402, 403, V		
30:16-30:21	402, 403, V	30:22-31:5 31:9-10	
32:1-32:4	402, 403		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
32:9-32:11	402, 403		
32:15-32:16	402, 403		
32:21-32:24	402, 403		
34:4-34:8	402, 403, V		
34:11-34:11	402, 403, V		
34:22-34:23	402, 403, V, I		
35:2-35:2	402, 403, V	35:4-5 35:9-15	
39:1-39:8	402, 403, V		
39:12-39:12	402, 403, V	39:14-16 39:22-23	
40:8-40:10	402, 403		
40:15-40:18	402, 403		
42:12-42:13	402, 403		
42:18-42:21	402, 403		
42:24-42:24	402, 403, V		
43:1-43:4	402, 403, V		
43:12-43:14	402, 403		
43:17-43:19	402, 403		
43:24-44:2	402, 403		
44:22-44:24	402, 403, V		
45:1-45:5	402, 403, V, I		
45:16-45:19	402, 403, V		
46:4-46:6	402, 403, V, I		
46:14-46:16	402, 403, V, I		
46:19-46:20	402, 403, V		
47:1-47:7	402, 403, V, NT		
47:11-47:13	402, 403, V, I		
47:17-47:19	402, 403, V		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
47:21-47:24	402, 403, V		
48:1-48:1	402, 403, V		
49:12-49:14	402, 403, V		
49:19-49:24	402, 403		
50:1-50:1	402, 403		
50:17-50:24	402, 403, V		
51:1-51:5	402, 403		
51:8-51:9	402, 403		
51:11-51:13	402, 403, V		
51:17-51:17	402, 403, V		
51:19-51:20	402, 403		
52:4-52:6	402, 403, V, I		
52:20-52:21	402, 403, V, I		
53:1-53:1	402, 403, V, I		
53:5-53:6	402, 403, V, I		
53:9-53:10	402, 403, V, I	53:12-13	
53:14-53:16	402, 403, V, CS, 701, LC		
53:19-53:19	402, 403, V, CS, 701, LC		
53:21-53:22	402, 403, V, CS, 701, LC		
54:2-54:4	402, 403, V, CS, 701, LC		
55:4-55:6	402, 403		
55:16-55:18	402, 403, V		
56:5-56:16	402, 403, V	55:19-20 55:23-56:3	
56:19-56:19	402, 403, V		
56:21-56:24	402, 403		
57:3-57:6	402, 403, V		
57:9-57:10	402, 403, V		
57:12-57:14	402, 403, V		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
57:17-57:17	402, 403, V		
58:23-59:7	402, 403, V		
59:12-59:12	402, 403, V		
60:4-60:7	402, 403, V		
60:10-60:12	402, 403, V		
61:22-61:23	402, 403		
62:4-62:21	402, 403, NT		
64:22-65:1	402, 403, V		
65:7-65:13	402, 403, I		
65:21-66:13	402, 403, CS		
66:18-66:23	402, 403		
67:3-67:7	402, 403		
67:16-67:18	402, 403, V		
67:21-67:22	402, 403, V		
68:1-68:4	402, 403, V		
68:7-68:9	402, 403, V		
68:13-68:14	402, 403, V		
69:21-69:23	402, 403	68:18-69:7 69:11-20	
70:3-70:3	402, 403		
70:5-70:8	402, 403		
70:11-70:11	402, 403		
75:21-75:22	402, 403		
76:3-76:6	402, 403		
76:22-76:24	402, 403		
77:1-77:1	402, 403, S		
77:13-77:15	402, 403, S		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
77:18-77:21	402, 403, S	77:23 78:3-11 78:15-16 80:16-18 89:22-81:13	
83:22-83:24	402, 403, F, AF		
84:4-84:20	402, 403, F, AF		
84:24-85:5	402, 403, F, AF		
87:4-87:5	402, 403		
87:22-88:1	402, 403		
88:5-88:7	402, 403		
88:10-88:11	402, 403		
88:13-88:14	402, 403		
88:22-89:8	402, 403, F, 602		
89:12-89:12	402, 403, F, 602		
89:14-89:15	402, 403		
89:20-89:22	402, 403		
94:1-94:5	402, 403		
94:8-94:9	402, 403		
94:12-94:20	402, 403		
94:24-95:1	402, 403		
95:3-95:5	402, 403		
95:12-95:16	402, 403, F		
95:19-95:22	402, 403		
96:2-96:8	402, 403		
97:7-97:11	402, 403, V	97:16-18 97:22-98:2	
97:14-97:14	402, 403		
98:4-98:5	402, 403		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
98:10-98:13	402, 403		
98:16-98:16	402, 403		
100:9-100:10	402, 403, V		
100:14-100:14	402, 403, V		
100:16-100:18	402, 403		
100:23-100:24	402, 403		
101:1-101:3	402, 403, I, CS	101:7-12	
101:13-102:4	402, 403, I	102:5-8 102:11-18	
103:18-103:22	402, 403		
105:3-105:5	402, 403, V		
105:9-105:11	402, 403, V		
106:2-106:7	402, 403		
106:12-106:13	402, 403		
106:15-106:17	402, 403		
106:20-106:23	402, 403		
107:14-107:23	402, 403		
108:1-108:3	402, 403, I		
108:6-108:7	402, 403		
108:10-108:10	402, 403		
108:12-108:13	402, 403		
108:16-108:16	402, 403		
108:18-108:18	402, 403		
108:22-108:23	402, 403		
109:19-109:20	402, 403, I		
110:1-111:15	402, 403, V, I		
112:8-112:11	402, 403		
112:14-112:15	402, 403		
112:17-112:20	402, 403		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
113:21-113:23	402, 403, I		
114:2-114:5	402, 403	114:7-11 114:15-17	
115:12-115:15	402, 403		
115:18-115:18	402, 403		
115:20-115:21	402, 403		
115:24-116:1	402, 403, V		
116:3-116:9	402, 403, V		
121:22-121:24	402, 403		
122:5-122:8	402, 403		
123:1-123:3	402, 403, V		
123:6-123:6	402, 403, V		
123:8-123:9	402, 403, V		
123:12-123:13	402, 403, V		
123:15-123:18	402, 403		
124:15-124:17	402, 403, V		
124:21-124:23	402, 403, V		
132:22-132:24	402, 403		
133:5-133:8	402, 403, AF, F		
133:11-133:12	402, 403		
133:18-133:23	402, 403, CS		
134:7-134:8	402, 403, I, AF, F		
134:12-134:15	402, 403	134:17-22	
134:23-134:24	402, 403, I		
135:5-135:6	402, 403		
135:11-135:14	402, 403, AF, F, I		
135:17-135:19	402, 403		
135:23-135:23	402, 403		
136:1-136:3	402, 403		



Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
136:8-136:10	402, 403		
136:14-136:16	402, 403		
137:2-137:3	402, 403		
137:10-137:11	402, 403, V		
137:14-137:16	402, 403, V		
138:10-138:12	402, 403		
138:16-138:16	402, 403	138:18-20 138:23-24	
139:2-139:3	402, 403		
139:8-139:11	402, 403		
141:9-141:22	402, 403		
142:1-142:1	402, 403		
142:17-143:5	402, 403		
143:8-143:9	402, 403	143:16-19 143:22-144:2	
143:11-143:15	402, 403	143:16-19 143:22-144:2	
144:14-144:16	402, 403		
144:23-144:24	402, 403		
145:3-145:3	402, 403		
145:6-145:6	402, 403		
145:13-145:16	402, 403		
145:20-145:20	402, 403		
145:22-145:24	402, 403		
146:3-146:3	402, 403		
146:5-146:6	402, 403		
146:11-146:14	402, 403		
146:21-146:22	402, 403		
147:2-147:2	402, 403		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
147:11-147:12	402, 403		
147:16-147:17	402, 403		
147:19-147:20	402, 403		
149:12-149:13	402, 403, F, 602		
149:20-149:21	402, 403, F, 602		
149:24-150:1	402, 403, F, 602	149:18-19	
150:22-151:3	402, 403		
151:8-151:22	402, 403, S		
152:5-152:6	402, 403, S		
152:8-152:13	402, 403, S		
152:16-152:16	402, 403, S		
152:18-152:19	402, 403, S		
153:1-153:6	402, 403, S		
153:10-153:11	402, 403, S	153:13-15 153:18-21 155:16-156:7	
160:2-160:3	402, 403		
160:8-160:13	402, 403		
160:22-160:22	402, 403		
161:1-161:2	402, 403		
161:21-161:24	402, 403		
162:24-163:3	402, 403		
163:6-163:7	402, 403		
163:19-164:4	402, 403		
164:7-164:7	402, 403		
164:17-164:19	402, 403		
164:22-164:22	402, 403		
164:24-165:2	402, 403		
165:5-165:5	402, 403		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
168:17-168:19	402, 403		
168:23-168:24	402, 403		
170:3-170:9	402, 403, I	170:10-12	
170:17-170:20	402, 403		
171:2-171:7	402, 403		
171:11-171:14	402, 403		
171:16-171:21	402, 403		
174:16-174:21	402, 403, CS		
175:1-175:2	402, 403, CS		
176:5-176:7	402, 403		
176:12-176:20	402, 403, S		
177:1-177:2	402, 403, S, CS		
177:16-177:21	402, 403	178:2-3	
178:4-178:6	402, 403, F, 602		
178:10-178:11	402, 403, F, S, 602, CS, AF		
178:16-178:16	402, 403, F, S, 602, CS, AF		
178:18-178:21	402, 403, F, S, 602, CS, AF		
179:1-179:2	402, 403, F, S, 602, CS, AF		
179:9-179:12	402, 403, F, S, 602, CS, AF		
179:16-179:23	402, 403, F, S, 602, CS, AF		
180:3-180:8	402, 403, F, S, 602, CS, AF		
180:12-180:12	402, 403, F, S, 602, CS, AF		
180:14-180:17	402, 403		
181:1-181:4	402, 403, I		
182:6-182:9	402, 403		
184:4-184:7	402, 403		
185:14-185:17	402, 403, F, S, 602, CS, AF		
186:23-187:10	402, 403, F, S, 602, CS, AF		
187:15-187:18	402, 403		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
193:2-193:3	402, 403	193:8-9	
193:13-193:18	402, 403, F, 602		
194:16-194:17	402, 403, F, 602, I		
194:22-194:22	402, 403, F, 602		
196:8-196:10	402, 403, F, 602	196:16-20	
196:14-196:14	402, 403, F, 602		
196:21-196:23	402, 403, F, 602		
197:3-197:5	402, 403, F, 602		
197:7-197:15	402, 403, F, 602	197:16-18 197:23-198:1	
198:3-198:9	402, 403, CS	198:10-11	
198:12-198:18	402, 403, CS		
200:10-200:20	402, 403		
200:23-201:1	402, 403		
205:12-205:14	402, 403		
205:19-205:22	402, 403		
206:15-206:23	402, 403, S		
207:2-207:4	402, 403, S		
207:9-207:9	402, 403, S		
207:11-207:11	402, 403, S		
207:13-207:15	402, 403, S		
207:18-207:18	402, 403, S		
207:20-207:21	402, 403, S		
207:24-208:1	402, 403, S	208:3-4	
208:5-208:9	402, 403, S		
208:11-208:13	402, 403, S		
208:16-208:16	402, 403, S		
208:18-208:21	402, 403, S		
208:24-208:24	402, 403, S		

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter- Designations</b>	<b>Sage's Objection(s)</b>
209:9-209:10	402, 403, S		
209:15-209:22	402, 403, S	209:23-210:2 210:6-7	
221:9-221:11	402, 403, S, 701, LC		
221:16-221:18	402, 403, S, 701, LC		
224:21-224:24	402, 403, S, 701, LC		
225:3-225:3	402, 403, S, 701, LC		

**Sage's Designation of Deposition Testimony of Kate Pawlik, March 17, 2023**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter-Designations</b>	<b>Sage's Objection(s)</b>
4:21-5:2			
14:15-14:19	V, 402, 403		
15:18-15:21	V, 402, 403		
19:12-19:13	F		
19:16-19:18	F, V		
19:21-19:22	F	19-24:20-3	
20:8-20:14	V		
20:17-20:19	V		
20:23-20:24	V		
21:2-21:3	V, Arg		
21:16-21:16	V, Arg		
22:3-22:5	V, 402, 403		
22:8-22:9	402, 403		
23:17-23:20	F, V, CS	23:10-12	
26:12-26:17	F, 402, 403		
26:24-27:2	F, 402, 403		
29:6-29:14	I, NT, 402, 403		
29:19-30:1	402, 403		
30:2-30:8	CS, F, 402, 403		
30:11-30:18	CS, F, 402, 403		
30:19-30:21	CS, F, 402, 403		
31:1-31:3	CS, F, 402, 403		
31:14-31:17	402, 403, V		
31:20-31:21	402, 403		
31:23-32:1	402, 403		
32:24-33:4	402, 403, 611		
33:17-33:19	F, V, 402, 403		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
33:23-33:24	F, V, CS, 402, 403		
36:16-36:17	F, V, CS, 402, 403	36:3-6, 36:10-14	
36:21-36:23	F, V, CS, 402, 403		
37:1-37:5	F, V, 402, 403		
37:8-37:14	F, V, 402, 403		
38:8-38:15	402, 403	37:20-38:2, 38:6	
39:23-40:2	402, 403		
41:1-41:4	F, V, 402, 403		
41:7-41:8	F, V, 402, 403		
41:13-41:16	I, NT, 402, 403		
41:21-41:22	402, 403	41:23	
42:3-42:7	402, 403		
42:8-42:14	402, 403		
43:20-43:23	402, 403		
45:6-45:9	F, 402, 403		
47:14-47:20	611, 402, 403		
48:13-48:16	F, V, M, 611, 402, 403		
48:20-48:20	F, V, M, 611, 402, 403		
50:11-50:13	F, V, 402, 403		
50:16-50:17	F, V, 402, 403		
52:14-53:3	F, V, M, 611, 402, 403		
53:4-53:7	F, V, M, 402, 403		
53:11-53:12	F, V, M, 402, 403		
55:12-55:14	V, CS, M, 402, 403		
55:17-55:17	V, CS, M, 402, 403		
55:22-56:1	I, NT, 402, 403		
56:6-56:8	402, 403		
57:9-57:12	F, V, 402, 403		
57:15-57:15	F, V, 402, 403		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
58:15-58:19	402, 403		
58:20-59:1	V, M, 611, 402, 403		
59:4-59:5	V, M, 611, 402, 403		
59:7-59:12	611, 402, 403		
60:4-60:7	402, 403		
60:8-60:17	402, 403		
62:4-62:6	F, V, 611, 402, 403	62:9-11	
63:1-63:4	F, M, 402, 403		
63:7-63:7	F, M, 402, 403		
65:19-65:21	F, V, 402, 403		
65:24-66:1	F, V, 402, 403		
66:3-66:5	F, V, 402, 403		
66:8-66:8	F, V, 402, 403		
66:22-66:24	F, V, 402, 403		
67:3-67:3	F, V, 402, 403		
67:12-67:23	402, 403		
68:5-68:7	F, V, 402, 403		
68:11-68:12	F, V, 402, 403	69:1-2	
69:14-69:17	V, 402, 403	70:3-4, 70:7-8	
71:22-72:3	402, 403	71:9-12, 71:19-20	
72:4-72:7	V, 402, 403		
72:10-72:11	V, 402, 403	72:13-15, 72:18, 73:13-17	
73:21-73:24	I, NT, 402, 403		
74:5-74:7	402, 403		
74:8-74:13	402, 403		
74:14-74:21	V, M, 402, 403		
75:1-75:7	V, M, 402, 403		
75:11-75:13	V, M, 402, 403		
75:15-75:18	611, 402, 403		



Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
75:19-75:24	F, 402, 403		
77:16-77:19	I, NT, 402, 403		
77:24-78:3	402, 403		
78:17-78:19	402, 403		
79:13-79:16	I, NT, 402, 403		
79:20-80:1	402, 403		
80:16-80:23	M, 402, 403		
81:4-81:7	I, NT, 402, 403		
81:13-81:16	402, 403	81:17-22	
82:23-82:24	F, V, 402, 403		
83:3-83:8	F, V, 402, 403		
83:11-83:17	402, 403		
83:18-83:20	V, CS, C, 402, 403		
83:24-84:3	V, CS, C, 402, 403		
84:8-84:11	I, NT, 402, 403		
84:16-84:18	402, 403		
85:15-85:18	I, NT, 402, 403		
86:2-86:11	402, 403		
86:12-86:24	402, 403		
87:11-87:13	V, AF, M, 402, 403		
87:17-87:18	V, AF, M, 402, 403		
87:23-88:2	I, NT, 402, 403		
88:20-88:24	402, 403		
89:1-89:4	402, 403		
89:7-89:7	402, 403		
89:13-89:21	I, NT, 402, 403		
89:22-90:4	V, AF, M, 402, 403		
90:8-90:10	V, AF, M, 402, 403		
90:15-90:22	I, NT, CS, 402, 403		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
91:1-91:11	CS, 402, 403		
91:15-91:18	CS, 402, 403		
91:23-92:2	I, NT, 402, 403		
92:7-92:10	402, 403		
93:10-93:13	F, 402, 403		
93:14-93:17	F, 402, 403		
94:9-94:11	F, V, 402, 403		
94:14-94:24	F, V, 402, 403		
95:3-95:4	F, V, 402, 403		
95:6-95:9	V, C, 402, 403		
95:12-95:19	V, AF, 402, 403		
95:22-95:22	V, AF, 402, 403		
96:2-96:3	V, AF, 402, 403		
96:7-96:10	I, NT, 402, 403		
96:15-96:19	402, 403		
97:1-97:4	I, NT, 402, 403		
97:18-97:21	V, CS, 402, 403		
98:3-98:5	V, CS, 402, 403		
98:7-98:14	402, 403		
98:18-98:21	I, NT, 402, 403		
99:5-99:19	V, CS, 402, 403		
100:1-100:2	V, CS, 402, 403		
100:13-100:20	402, 403		
100:21-100:24	402, 403		
101:4-101:6	402, 403		
101:12-101:23	611, M, 402, 403		
103:10-103:10	F, V, CS, 402, 403		
103:14-103:17	F, V, CS, 402, 403		
104:6-104:9	I, NT, 402, 403		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
104:14-104:16	402, 403		
105:4-105:7	I, NT, 402, 403		
105:23-106:2	402, 403		
106:3-106:7	402, 403		
108:12-108:14	V, M, 402, 403		
108:18-108:19	V, M, 402, 403		
108:23-109:1	I, F, V, 402, 403		
109:4-109:5	F, V, 402, 403		
109:7-109:11			
110:9-110:12	I, NT, 402, 403		
110:23-111:3	V, 402, 403		
111:4-111:5	402, 403		
111:8-111:9	402, 403		
111:13-111:16	I, NT, 402, 403		
112:15-112:17	I, 611, 402, 403		
112:18-112:21	V, 402, 403		
112:24-113:1	V, 402, 403		
113:3-113:4	F, V, CS, 402, 403		
113:7-113:8	F, V, CS, 402, 403		
113:13-113:24	402, 403		
114:9-114:13	M, AF		
114:16-114:23	M, AF		
115:4-115:7	I, NT, 402, 403		
115:12-115:15	402, 403		
117:8-117:11	I, NT, 402, 403		
117:16-117:19	V, CS, 402, 403		
117:22-118:4	402, 403	118:7-9, 118:12-13	
118:22-118:23	F, V, M, 402, 403		
119:3-119:4	F, V, M, 402, 403		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
120:7-120:10	I, NT, 402, 403		
121:3-121:5	402, 403		
121:12-121:13	402, 403		
121:22-122:4	402, 403		
122:10-122:12	F, V, CS, 402, 403		
122:15-122:16	F, V, CS, 402, 403		
122:18-123:3	F, V, AF, 402, 403		
123:7-123:15	F, V, AF, 402, 403		
123:16-123:20	F, V, AF, 402, 403	124:6-10, 124:13-16	
125:3-125:5	V, AF, 402, 403		
125:9-125:11	V, AF, 402, 403		
126:20-126:21	I, V, 402, 403		
127:1-127:3	I, V, 402, 403		
127:5-127:8	C, 402, 403		
127:17-127:20	402, 403	127:21-23, 128:3	
128:5-128:13	F, V, 402, 403		
128:14-128:19	V, C, 402, 403		
128:22-129:6	V, 402, 403		
129:9-129:15	V, 402, 403		
129:16-129:18	F, V, AF, CS, 402, 403		
129:22-130:6	F, V, AF, CS, 402, 403		
130:17-130:20	402, 403		
130:24-131:6	V, CS, 402, 403		
131:9-131:10	V, CS, 402, 403		
131:15-131:21	402, 403		
131:23-131:24	I, V, AF, CS, 402, 403		
132:4-132:5	I, V, AF, CS, 402, 403	132:18-19, 132:22	
133:6-133:8	V, 402, 403		
133:11-133:12	V, 402, 403		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
133:16-133:18	I, V, 402, 403		
133:22-133:22	V, 402, 403		
133:24-134:6	F, V, 402, 403		
134:10-134:13	F, V, 402, 403		
134:16-134:18	F, V, 402, 403		
135:5-135:6	I, F, V, 402, 403		
135:9-135:10	F, V, 402, 403		
135:13-135:16	I, F, V, 402, 403		
135:18-135:19	I, F, V, 402, 403		
135:22-135:23	F, V, 402, 403		
136:9-136:10	F, V, 402, 403		
136:13-136:20	F, V, 402, 403		
136:21-136:22	F, V, 402, 403		
137:1-137:3	F, V, 402, 403		
137:6-137:7	I, F, V, 402, 403		
137:10-137:13	F, V, 402, 403		
137:18-137:19	F, V, 402, 403		
137:22-138:1	F, V, 402, 403		
138:21-138:22	I, 402, 403		
140:7-140:9	F, V, AF, 402, 403	139:18-20, 139:24	
140:13-140:15	F, V, AF, 402, 403	140:17-20	
140:21-140:21	F, CS, 402, 403		
141:1-141:3	F, CS, 402, 403		
147:11-147:14	I, NT, 402, 403		
147:18-147:20	402, 403		
147:21-148:2	402, 403	148:3-5	
148:6-148:9	402, 403		
148:10-148:22	402, 403		
149:7-149:9	F, CS, 402, 403		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
149:12-149:12	F, CS, 402, 403		
149:20-149:22	402, 403		
154:8-154:11	I, F, C, CS, 402, 403		
154:14-154:14	F, C, CS, 402, 403		
154:16-154:19	F, C, CS, 402, 403		
154:22-154:22	F, C, CS, 402, 403		
156:10-156:11	F, M, CS, 402, 403		
156:15-156:15	F, M, CS, 402, 403		
157:16-157:20	F, V, 402, 403		
158:5-158:9	F, V, 402, 403	158:10-12, 158:16-18	
159:2-159:5	F, 402, 403		
159:21-160:2	F, 402, 403		
167:22-168:6	F, 402, 403		
168:19-168:22	I, NT, 402, 403		
168:24-169:3	402, 403		
169:24-170:4	402, 403		
171:5-171:6	402, 403		
171:9-171:9	402, 403		
173:11-173:14	I, NT, 402, 403		
173:19-173:21	402, 403		
174:2-174:2	402, 403		
174:8-174:11	F, 402, 403		
175:1-175:4	I, 402, 403		
175:7-175:19	V, 402, 403		
175:22-176:6	V, 402, 403		
176:10-176:10	V, 402, 403		
176:14-176:17	I, NT, 402, 403		
176:19-176:23	402, 403		
177:12-177:19	402, 403		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
177:23-177:24	F, CS, 402, 403		
178:2-178:4	F, CS, 402, 403		
178:7-178:11	F, CS, 402, 403		
179:5-179:9	F, CS, 402, 403		
179:12-179:13	F, CS, 402, 403		
179:18-179:23	402, 403		
179:24-180:2	402, 403		
180:5-180:5	I, NT, 402, 403		
180:21-180:24	402, 403		
181:5-181:13	402, 403		
181:21-182:1	F, V, 402, 403	181:16-20	
182:4-182:5	F, V, 402, 403		
183:22-183:23	F, V, 402, 403		
184:3-184:6	F, V, 402, 403		
184:10-184:13	I, NT, 402, 403		
184:17-185:1	402, 403		
185:4-185:7	I, NT, 402, 403		
185:11-185:13	402, 403	185:14-18	
185:19-186:6	402, 403		
186:10-186:13	I, NT, 402, 403		
186:15-186:17	402, 403	186:18-22	
187:2-187:12	I, NT, 402, 403		
187:18-187:22	402, 403		
188:5-188:10	402, 403		
188:14-188:17	I, NT, 402, 403		
189:6-189:12	F, V, 402, 403		
189:15-189:17	F, V, 402, 403		
191:5-191:12	F, V, M, CS, 402, 403		
191:16-191:18	F, V, M, CS, 402, 403		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
192:9-192:11	V, CS, 402, 403		
192:15-192:22	V, CS, 402, 403		
193:2-193:2	V, CS, 402, 403		
194:17-194:23	402, 403		
195:4-195:8	402, 403		
195:13-195:16	I, NT, 402, 403		
196:8-196:11	402, 403		
196:16-196:17	402, 403		
197:2-197:5	F, V, 402, 403		
197:8-197:9	F, V, 402, 403		
198:7-198:10	I, NT, 402, 403		
198:12-198:15	402, 403		
198:19-198:21	V, 402, 403		
198:24-199:3	V, 402, 403	199:5-7	
199:8-199:11	402, 403		
199:15-199:18	I, NT, 402, 403		
199:20-199:23	402, 403		
200:4-200:13	402, 403		
200:16-200:24	I, NT, 402, 403		
201:1-201:7	402, 403		
202:2-202:6	I, V, 402, 403		
202:9-202:10	V, 402, 403		
203:3-203:4	F, V, CS, 402, 403		
203:8-203:11	F, V, CS, 402, 403		
204:5-204:16	I, NT, 402, 403		
204:19-205:3	I, NT, 402, 403		
205:15-205:19	V, C, 402, 403		
206:7-206:10	V, AF, CS, 402, 403		
206:14-206:16	V, AF, CS, 402, 403		



Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
207:20-207:23	I, NT, 402, 403		
208:1-208:6	CS, 402, 403		
208:15-208:18	I, 402, 403		
210:2-210:5	I, NT, 402, 403		
210:13-210:15	V, 402, 403		
210:18-210:19	V, 402, 403		
211:1-211:4	611, 402, 403		
211:5-211:14	F, CS, 402, 403		
211:18-211:21	F, CS, 402, 403		
211:23-212:1	402, 403	212:2-4, 212:8-14	
213:9-213:13	I, CS, 402, 403		
213:14-213:18	402, 403		
214:13-214:16	I, NT, 402, 403		
214:22-214:24	402, 403		
215:10-215:12	402, 403		
215:13-215:20	611, 402, 403		
215:21-216:11	402, 403		
218:7-218:10	CS, M, 402, 403		
218:13-218:16	CS, M, 402, 403		
219:2-219:7	CS, 402, 403		
219:12-219:17	CS, 402, 403		
220:4-220:7	402, 403		
220:8-220:15	V, C, CS, 402, 403		
220:19-220:21	V, C, CS, 402, 403		
221:5-221:10	I, CS, 402, 403	221:11-13	
221:16-222:1	I, NT, 402, 403		
222:16-222:20	V, CS, 402, 403		
222:23-222:23	V, CS, 402, 403		
224:14-225:2	I, NT, 402, 403		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
225:3-225:9	402, 403	225:10-14	
229:12-229:15	I, NT, 402, 403		
229:23-230:3	402, 403		
230:4-230:9	402, 403		
231:11-231:16	I, CS, 402, 403		
232:1-232:2	F, CS, AF, 402, 403	232:8-10	
232:6-232:6	F, CS, AF, 402, 403	232:8-10	
235:17-236:2	I, 402, 403		
236:3-236:4	CS, AF, 402, 403		
236:8-236:17	CS, AF, 402, 403		
236:21-237:2	CS, AF, 402, 403		
237:7-237:9	CS, AF, 402, 403		
237:15-237:17	402, 403		
237:23-237:24	Arg, AF, 402, 403		
238:4-238:8	Arg, AF, 402, 403		
240:5-240:7	F, V, CS, AF, 402, 403		
240:12-240:15	F, V, CS, AF, 402, 403		
240:24-241:2	I, V, CS, 402, 403		
241:8-241:8	I, V, CS, 402, 403		
242:5-242:8	402, 403		
242:13-242:16	I, NT, 402, 403		
242:18-243:1	402, 403		
243:17-243:21	402, 403		
243:23-244:11	I, 402, 403		
244:15-244:17	402, 403		
245:3-245:5	CS, M, 402, 403		
245:9-245:9	CS, M, 402, 403		
245:14-245:17	I, NT, 402, 403		
246:5-246:8	402, 403		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
246:13-246:15	402, 403		
247:16-247:22	F, 402, 403	247:23-248:2	
248:5-248:9	F, 402, 403		
249:1-249:3	402, 403		
250:17-250:20	I, NT, 402, 403		
250:24-251:5	402, 403		
252:12-252:15	I, NT, 402, 403		
253:3-253:7	402, 403		
253:20-254:4	402, 403		
255:6-255:9	I, NT, 402, 403		
255:11-255:18	402, 403		
255:21-255:23	402, 403		
256:2-256:5	I, NT, 402, 403		
256:7-256:9	V, 402, 403		
256:15-256:20	F, V, CS, AF, 402, 403		
257:4-257:4	F, V, CS, AF, 402, 403		
257:9-257:12	F, V, CS, AF, 402, 403		
257:20-257:23	I, NT, 402, 403		
258:1-258:4	402, 403		
258:7-258:10	I, NT, 402, 403		
258:12-258:19	F, V, AF, 402, 403		
258:23-259:8	F, V, AF, 402, 403		
259:12-259:15	I, NT, 402, 403		
259:17-259:20	F, V, CS, AF, 402, 403		
260:1-260:3	F, V, CS, AF, 402, 403		
260:22-260:24	I, 402, 403		
261:5-261:6	F, I, 402, 403		
261:23-262:2	I, 402, 403		
262:4-262:8	F, C, V, CS, 402, 403		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
262:11-262:12	F, C, V, CS, 402, 403		
262:24-263:3	I, NT, 402, 403		
263:5-263:13	402, 403		
263:17-263:20	I, NT, 402, 403		
263:22-264:5	CS, 402, 403		
264:6-264:7	CS, C, V, 402, 403		
264:10-264:11	CS, C, V, 402, 403		
264:24-265:3	F, 402, 403	265:4-6, 265:10	
265:12-265:17	402, 403	265:18-22	
266:9-266:12	I, NT, 402, 403		
266:14-266:18	402, 403		
266:22-266:24	CS, V, 402, 403		
267:3-267:4	CS, V, 402, 403		
268:18-269:3	I, NT, 402, 403		
269:6-269:9	402, 403		
269:13-269:20	I, NT, V, 402, 403		
269:23-270:1	V, 402, 403		
270:5-270:17	I, NT, CS, V, 402, 403		
270:20-271:1	CS, V, 402, 403		
271:2-271:12	V, 402, 403		
271:18-272:3	I, CS, V, 402, 403		
272:19-272:22	I, NT, 402, 403		
272:24-273:4	402, 403		
274:5-274:11	V, 402, 403	274:12-14	
274:17-274:23	CS, V, 402, 403		
275:2-275:4	CS, V, 402, 403		
275:6-275:9	F, CS, V, 402, 403		
275:13-275:17	F, CS, V, AF, 402, 403		
275:22-275:24	F, CS, V, AF, 402, 403		

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter- Designations</b>	<b>Sage's Objection(s)</b>
276:11-276:19	F, 402, 403		
276:20-277:7	F, 402, 403		
277:8-277:15	611, M, CS, V, 402, 403		
277:16-277:17	M, 402, 403		
277:21-277:23	M, 402, 403		
278:1-278:2	CS, V, 402, 403		
283:15-283:18	I, NT, 402, 403		
283:20-284:8	611, M, 402, 403		

**Sage's Designation of Deposition Testimony of Laura Shaw, April 13, 2021**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter-Designations</b>	<b>Sage's Objection(s)</b>
9:13-9:15			
12:18-13:1			
13:22-13:23		13:24-14:1	
14:11-14:21			
14:23-15:3			
15:10-15:14	402, 403		
15:23-16:22	402, 403, 602, CS		
17:2-17:9	402, 403, 602	17:10-12	
17:23-18:23	H, 402, 403, 602		
20:9-20:10	H, 402, 403, 602, CS		
20:13-20:14	H, 402, 403, 602		
20:16-21:2	H, 402, 403, 602		
21:15-21:16	H, 402, 403		
21:19-21:19	H, 402, 403		
23:19-23:21	H, 402, 403, 602		
24:3-24:21			
24:24-24:24			
25:2-25:4	H, 402, 403, 602, CS		
25:7-25:7			
25:10-25:22	H, 402, 403, 602, CS		
26:6-26:7	H, 402, 403, 602, CS		
26:10-26:10	H, 402, 403, 602, CS		
26:13-27:6	H, 402, 403, 602, CS		
27:9-28:3	H, 402, 403, 602, CS		
28:6-28:23	H, 402, 403, 602, CS		
29:1-29:4	402, 403, 602, CS		
29:7-29:19	402, 403, 602, CS	29:25-30:3	

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
30:5-30:8	402, 403, 602, CS		
30:10-30:10	402, 403, 602, CS	31:1-8	
30:12-30:13			
30:16-30:21			
30:23-30:25	402, 403, 602, CS	31:1-8	
31:17-31:18	H, 402, 403, 602, CS		
31:21-32:1	H, 402, 403, 602, CS		
32:3-32:5			
32:22-32:23			
33:1-33:6	H, 402, 403, 602, CS		
33:8-33:10			
34:7-34:8	H, 402, 403, 602, CS		
34:11-34:20	H, 402, 403, 602, CS		
35:13-35:14	H, 402, 403, 602, CS		
35:17-35:22	H, 402, 403, 602, CS		
35:24-36:1	H, 402, 403, 602, CS		
36:17-36:18	H, 402, 403, 602, CS		
36:21-37:1			
37:3-37:10			
37:13-37:14			
37:17-37:25	H, 402, 403, 602, CS		
38:18-38:20	H, 402, 403, 602, CS, V		
38:22-38:22			
38:24-38:25			
39:3-39:3			
39:14-39:18	H, 402, 403, 602, CS		
39:20-39:25	H, 402, 403, 602, CS		
40:1-40:6	H, 402, 403, 602, CS		
40:9-40:9	CS		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
40:11-40:16	H, 402, 403, 602, CS	40:17-41:4	
41:5-41:8	H, 402, 403, 602, CS		
41:10-41:10	H, 402, 403, 602, CS		
41:12-41:14	H, 402, 403, 602, CS		
41:17-41:22			
41:24-42:14	H, 402, 403, 602, CS		
42:17-42:17	602, CS		
42:19-42:19			
42:22-42:25			
43:12-43:13	H, 402, 403, 602, CS		
43:16-44:12	H, 402, 403, 602, CS		
44:15-44:15			
44:17-44:18			
44:21-44:21			
44:23-44:23			
45:1-45:22	H, 402, 403, 602, CS		
46:7-46:8			
46:11-46:16	H, 402, 403, 602, CS		
46:25-47:7	H, 402, 403, 602, CS		
47:11-47:11	H, 402, 403, 602, CS		
47:14-47:17	H, 402, 403, 602, CS		
47:19-47:22	H, 402, 403, 602, CS		
47:24-47:24			
48:2-48:4	H, 402, 403, 602, CS		
48:7-48:7			
48:11-48:15	I		
48:20-48:23			
49:5-49:5			
49:8-49:13	H, 402, 403, 602, CS		



<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter- Designations</b>	<b>Sage's Objection(s)</b>
49:15-49:18			
49:20-49:21	H, 402, 403, 602, CS		
49:24-49:24			

**Sage's Designation of Deposition Testimony of Marcus Simon, March 3, 2021**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter-Designations</b>	<b>Sage's Objection(s)</b>
7:12-7:17			
8:11-8:13		7:1-3	
10:7-10:14	402, 403	10:2-6	
15:18-15:19			
17:1-17:6			
17:19-17:25	H, 402, 403, 602, CS		
19:4-19:9	H, 402, 403, 602, CS		
22:1-22:16			
22:21-22:22			
23:3-23:5			
23:9-23:17			
24:3-24:12	H, 402, 403, 602, CS		
25:14-25:23		25:24-26:19	
26:25-27:5			
28:12-28:15	H, 402, 403, 602, CS		
28:17-30:11	H, 402, 403, 602, CS		
31:14-32:17	H, 402, 403, 602, CS		
33:2-33:24			
34:22-35:3	402, 403, 602, CS, V, F		
35:21-36:6			
37:4-37:8		7:1-3	
38:16-39:8	402, 403	10:2-6	
39:17-40:9			
41:17-41:19			
41:23-42:10	H, 402, 403, 602, CS		
51:16-51:21	H, 402, 403, 602, CS		
52:1-52:11			

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
54:9-55:6			
60:23-62:11			
65:13-66:2			
66:17-67:2	H, 402, 403, 602, CS		
67:7-67:7		25:24-26:19	
67:8-67:18			
69:4-69:18	H, 402, 403, 602, CS		
69:22-70:1	H, 402, 403, 602, CS		
72:3-72:9	H, 402, 403, 602, CS		
73:13-73:22			
73:25-74:12	402, 403, 602, CS, V, F		
74:17-75:4			
77:3-77:7		7:1-3	
78:3-78:17	402, 403	10:2-6	
78:23-78:25			
79:2-79:16			
80:24-81:8	H, 402, 403, 602, CS		
81:16-81:22	H, 402, 403, 602, CS		
82:3-82:25	402, 403, 602, CS, V, F, I	83:1	
83:1-83:1			
83:2-84:3			
84:11-84:20			
85:14-85:24	402, 403, 602, CS, V, F		
86:16-88:20	402, 403, 602, CS, V, F		
88:24-89:3		89:4-7	
89:8-89:10	402, 403, 602, CS, V, F		
90:1-90:7	402, 403, 602, CS, V, F		
92:12-92:12			
92:13-92:18			

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter- Designations</b>	<b>Sage's Objection(s)</b>
92:25-94:4	402, 403, 602, CS, V, F		
94:5-94:5			
94:6-94:11			
94:22-94:25	402, 403, 602, CS, V, F		
95:10-95:13			
95:24-96:9			
97:17-97:21	402, 403, 602, CS, V, F		
107:6-108:8			
109:14-110:1			
110:11-112:16	402, 403, 602, CS, V, F		
114:20-114:23		114:24	
115:7-117:3	402, 403, 602, CS, V, F		
118:12-118:20	402, 403, 602, CS, V, F	118:5-11	
119:5-120:25	402, 403, 602, CS, V, F		
121:4-121:4			
121:5-122:11	402, 403, 602, CS, V, F		
123:1-123:25			
124:19-124:25		124:14-18	
125:9-126:2	402, 403, 602, CS, V, F		
127:10-127:21			
128:7-128:15	402, 403, 602, CS, V		
130:23-130:23			
130:24-131:8	402, 403, 602, CS, V		
131:16-132:25	402, 403, 602, CS, V, F		
133:5-134:19	402, 403, 602, CS, V, F		
135:1-135:5			
135:22-136:1	402, 403, 602, CS, V, F		
136:9-136:17	402, 403, 602, CS, V, F		
137:1-138:11	402, 403, 602, CS, V, F		

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter- Designations</b>	<b>Sage's Objection(s)</b>
139:2-139:6			
139:21-140:1			
142:13-142:20	402, 403, 602, CS, V, F		
143:4-143:11	402, 403, 602, CS, V, F		
144:1-144:15	402, 403, 602, CS, V, F		
144:25-145:7		144:16-24	
145:1-145:7			
145:11-146:16	402, 403, 602, CS, V, F		

**Sage's Designation of Deposition Testimony of Sarah Skelton, January 18, 2023**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter-Designations</b>	<b>Sage's Objection(s)</b>
5:14-5:17			
8:18-8:24		9:4-10	
9:1-9:3			
10:4-10:13			
10:14-11:3			
11:10-12:13			
15:24-16:2			
16:8-16:13			
22:9-22:20			
24:1-24:3	F, 402, 403, 602, CS		
24:6-24:12	F, 402, 403, 602, CS		
28:10-28:14			
28:17-29:12			
31:1-31:24	F, 402, 403, 602, V		
32:2-32:17	F, 402, 403, 602, V		
32:19-33:12	F, 402, 403, 602, V		
35:8-36:14			
36:15-37:11	F, 402, 403, 602	37:12-14	
37:19-38:17			
38:20-38:24	402, 403, M		
39:2-39:3	402, 403, M		
39:6-39:7	402,402, CS, F, 602	39:9-10, 39:13-20	
39:22-39:22			
40:16-40:21			
41:18-41:20	F, 402, 403, 602, AF		
41:23-42:4	F, 402, 403, 602, AF		
42:6-43:10	F, 402, 403, 602, V	43:12-20	

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
43:21-43:24	F, 402, 403, 602, V	43:12-20	
49:24-50:9			
52:1-53:6	F, 402, 403, 602, CS		
53:16-53:22			
55:18-56:16			
56:23-56:24			
57:2-57:2			
57:4-57:8			
67:2-68:21	F, 402, 403, 602, CS		
68:22-69:23			
76:19-77:2	F, 402, 403, 602, V		
77:3-78:1	F, 402, 403, 602, V		
78:3-78:7	F, 402, 403, 602, V		
78:9-78:13	F, 402, 403, 602, V		
78:15-78:20	F, 402, 403, 602, V		
80:22-80:24	F, 402, 403, Arg		
81:2-81:4	F, 402, 403, Arg	81:6-8, 81:10-16	

**Sage's Designation of Deposition Testimony of Paul Zani, March 23, 2021**

<b>Sage's Designated Testimony (Page/line)</b>	<b>PureWick's Objection(s)</b>	<b>PureWick's Counter-Designations</b>	<b>Sage's Objection(s)</b>
9:9-9:11			
13:20-13:22			
14:16-15:18			
20:14-20:18	H, 402, 403		
21:2-21:8	H, 402, 403		
21:14-22:6	H, 402, 403		
22:21-24:24	H, 402, 403		
25:4-27:10	H, 402, 403		
27:20-27:24	V		
28:20-28:24	V		
29:7-29:22	H, 402, 403, 602, CLC		
31:22-33:13	H, 402, 403, 602, CLC	30:13-31:21	
36:9-36:13	I, H, 402, 403, 602	36:6-8	
36:20-37:12	H, 402, 403, 602		
38:4-38:7	H, 402, 403, 602	38:20-39:3	
38:11-38:19			
47:8-47:17	H, 402, 403, 602		
47:19-47:21	H, 402, 403, 602		
49:3-49:8	H, 402, 403, 602	48:3-49:2	
49:12-49:15			
50:18-50:23	I	50:16-17	
50:25-51:1	H, 402, 403, 602		
56:4-56:10			
56:16-56:21	CS, V		
58:14-58:16	CS, V		
59:10-59:16	I, 602, CS, V	58:18-59:9	
65:14-65:18	602, CS	65:6-13	



Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
65:24-66:3			
66:21-66:23			
67:24-69:13	H, 402, 403, F		
71:9-71:11			
71:16-72:10	H, 402, 403, F		
72:12-72:16			
72:23-74:3	H, 402, 403, F, 602		
75:1-75:9	H, 402, 403, F, 602	75:10-15	
76:9-76:13	H, 402, 403, F		
77:12-77:19	H, 402, 403, F, 602, V, CS		
80:10-80:15		80:6-9	
80:23-81:4			
82:13-83:13	I, H, 402, 403, F, 602, CS, V	82:10-12	
86:12-87:7			
88:14-89:2	H, 402, 403, F, 602		
89:20-90:22			
97:22-98:3	H, 402, 403, F, 602		
98:16-98:20	I, H, 402, 403, F, 602	98:15	
99:16-99:19	F, 602	99:12-15	
100:23-101:7		101:8-24	
101:25-102:13			
103:8-103:11	F, V, CS		
103:13-103:20	H, 402, 403, F, 602, BSD, ARG		
105:2-105:18	H, 402, 403, F, 602		
105:22-105:23	H, 402, 403, F, 602		
106:1-106:1			
106:13-106:22	H, 402, 403, V, CS		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
106:25-106:25			
107:2-107:5	H, 402, 403, V, CS		
107:8-107:16	H, 402, 403, V, CS		
108:4-108:14	H, 402, 403, V, CS, F		
108:20-108:24			
109:1-110:1		108:25	
110:16-111:11	H, 402, 403, V, CS		
112:5-112:17			
113:1-113:25	H, 402, 403, F, 602		
114:9-114:12	H, 402, 403, F, 602		
114:14-114:14	H, 402, 403, F, 602		
114:17-114:21	H, 402, 403, F, 602		
114:23-115:8	H, 402, 403, F, 602		
115:13-115:17	H, 402, 403, F, 602		
116:9-116:14	H, 402, 403, F, 602		
117:24-118:8	H, 402, 403, F, 602		
121:15-122:5	H, 402, 403, F, 602		
131:16-131:20	H, 402, 403, F, 602, V, CS	131:21-132:6	
138:2-138:5	H, 402, 403, F, 602		
138:7-138:9			
138:25-140:15	H, 402, 403, F, 602		
141:1-141:9	H, 402, 403, F, 602, V, CS		
141:11-141:14	H, 402, 403, F, 602		
141:19-141:20	H, 402, 403, F, 602		
142:7-142:17	H, 402, 403, F, 602		
142:23-143:1	H, 402, 403, F, 602, V, CS		
147:3-147:17			
148:1-148:5	H, 402, 403, F, 602, V, CS,		
148:8-148:10	H, 402, 403, F, 602, V, CS,		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter-Designations	Sage's Objection(s)
148:18-148:21	I	148:17	
148:23-149:4			
149:10-149:15	H, 402, 403, F, 602, V, CS,	149:5-9	
150:13-150:17	H, 402, 403, F, 602, V, CS,		
150:20-150:21	H, 402, 403, F, 602, V, CS,		
153:16-153:23	H, 402, 403, F, 602, V, CS,		
153:25-154:5			
154:16-154:19		154:20-25	
155:1-155:4	H, 402, 403, F, 602, V, CS		
155:7-155:11	H, 402, 403, F, 602, V, CS		
157:23-158:1		158:3-5	
158:6-158:17	H, 402, 403, F, 602, V, CS		
158:21-158:24			
159:1-159:3			
160:15-160:24			
161:2-161:4			
162:12-163:2			
163:12-163:13	H, 402, 403, F, 602, V, CS		
163:16-163:18	H, 402, 403, F, 602, V, CS		
163:24-164:15	H, 402, 403, F, 602, V, CS		
164:18-164:19	H, 402, 403, F, 602, V, CS		
164:21-164:25	H, 402, 403, F, 602, V, CS		
165:3-165:4			
165:6-165:8			
177:24-178:2			
178:4-179:3	H, 402, 403, F, 602, V, CS		
179:18-180:3	H, 402, 403, F, 602, V, CS		
181:9-181:25	H, 402, 403, F, 602, V, CS		
183:2-183:5	H, 402, 403, F, 602, V, CS	182:1-183:1; 183:6-10	

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
183:18-183:23	H, 402, 403, F, 602, V, CS		
183:25-184:12			
184:17-184:20			
185:4-185:17	H, 402, 403, F, 602, V, CS		
186:2-186:24	H, 402, 403, F, 602, V, CS		
199:11-199:14			
199:16-199:20	H, 402, 403, F, 602, V, CS		
201:1-201:6	H, 402, 403, F, 602, V, CS		
201:9-201:13			
203:19-204:21	H, 402, 403, F, 602, V, CS		
204:23-205:16	H, 402, 403, F, 602, V, CS		
205:18-205:19			
205:21-205:23			
206:23-207:18	H, 402, 403, F, 602, V, CS		
208:3-209:1	H, 402, 403, F, 602, V, CS		
211:12-212:5			
212:23-213:11	H, 402, 403, F, 602, V, CS		
213:13-213:19			
215:18-217:12	H, 402, 403, F, 602, V, CS		
217:15-217:16			
217:18-217:23	H, 402, 403, F, 602, V, CS		
217:25-218:10	H, 402, 403, F, 602, V, CS		
218:17-218:25	H, 402, 403, F, 602, V, CS	219:1-9	
219:10-219:15			
219:18-219:22			
220:4-221:4	H, 402, 403, F, 602, V, CS		
221:5-221:24	H, 402, 403, F, 602, V, CS		
222:2-222:7			
222:9-223:1	H, 402, 403, F, 602, V, CS		

Sage's Designated Testimony (Page/line)	PureWick's Objection(s)	PureWick's Counter- Designations	Sage's Objection(s)
223:4-223:7			
223:10-223:18			
223:20-225:1			
225:8-225:20	H, 402, 403, F, 602, V, CS	225:2-7	
225:23-226:3	H, 402, 403, F, 602, V, CS		
226:5-227:2	H, 402, 403, F, 602, V, CS		
227:5-227:10	H, 402, 403, F, 602, V, CS		
227:12-227:17			
229:7-229:17	H, 402, 403, F, 602, V, CS		
229:20-229:21			
230:9-230:24	H, 402, 403, F, 602, V, CS		
243:17-244:23	H, 402, 403, F, 602, V, CS		

## **SCHEDULE E4c**

### **Sage's Objections to PureWick's Counter-Designations**

**Sage's Objections to PureWick's Designations**

<b><u>Number</u></b>	<b><u>Objection</u></b>
1	Irrelevant
2	Lacks foundation / lacks personal knowledge
3	Calls for Speculation
4	Hearsay
5	Vague and Ambiguous
6	Asked and Answered
7	Argumentative
8	Hypothetical
9	Privilege
10	Leading
11	Compound
12	Mischaracterization
13	Best Evidence
14	Calls for Legal Conclusion
15	Assumes facts not in evidence
16	Non-responsive
17	Rule 403
18	Outside scope of 30(b)(6)
19	Not testimony / Not responding to a question
20	Opinion / Expert opinion testimony by non-expert / Rule 701
21	Rule 702
22	Calls for a narrative
23	Improper and/or irrelevant reference to PrimaFit 1.0
24	Vague, improper, and/or irrelevant reference to a PureWick product
25	Violation of Court Order prohibiting duplicative testimony
MIL1	Objectionable as set forth in Sage's Motion in Limine No. 1
MIL2	Objectionable as set forth in Sage's Motion in Limine No. 2
MIL3	Objectionable as set forth in Sage's Motion in Limine No. 3
CONT	Testimony relates to contingent designations including designations subject to outstanding motions
DAUB	Addresses issues raised in Sage's <i>Daubert</i> motions/motions to strike
Outside Scope	Outside scope of designation

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Bobay, Jason 2021-04-23	87	3	87	11	1, 17, MIL2
Bobay, Jason 2021-04-23	130	5	130	8	1, 17, MIL2
Bobay, Jason 2021-04-23	134	21	134	25	1, 17, MIL1, MIL2
Bobay, Jason 2021-04-23	153	21	154	10	1, 4, 17, MIL2
Bobay, Jason 2021-04-23	162	15	162	24	1, 17, MIL2
Bobay, Jason 2021-04-23	164	4	164	17	1, 4, 17, MIL2
Bobay, Jason 2021-04-23	167	18	168	4	1, 17, MIL2



Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Burn, Brian 2021-04-02	15	1	15	10	1, 17
Burn, Brian 2021-04-02	20	15	21	5	1, 17
Burn, Brian 2021-04-02	22	23	23	6	1, 17
Burn, Brian 2021-04-02	37	1	37	3	
Burn, Brian 2021-04-02	46	23	47	4	15
Burn, Brian 2021-04-02	64	4	64	6	
Burn, Brian 2021-04-02	65	11	65	13	
Burn, Brian 2021-04-02	82	17	82	18	
Burn, Brian 2021-04-02	93	13	93	14	
Burn, Brian 2021-04-02	94	13	94	18	1, 17
Burn, Brian 2021-04-02	96	18	96	19	1, 17
Burn, Brian 2021-04-02	100	8	100	9	1, 17
Burn, Brian 2021-04-02	103	17	103	18	1, 17
Burn, Brian 2021-04-02	117	17	117	20	
Burn, Brian 2021-04-02	155	8	155	9	1, 17

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Burn, Brian 2023-03-23	29	5	29	5	
Burn, Brian 2023-03-23	29	19	29	21	1, 17
Burn, Brian 2023-03-23	30	1	30	3	1, 17
Burn, Brian 2023-03-23	111	20	111	20	
Burn, Brian 2023-03-23	123	4	123	4	
Burn, Brian 2023-03-23	125	6	125	8	1, 2, 4, 17
Burn, Brian 2023-03-23	125	14	126	5	1, 2, 4, 17
Burn, Brian 2023-03-23	130	19	130	24	1, 17, Fragment
Burn, Brian 2023-03-23	132	9	132	15	1, 2, 17

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Eckert, Lorena 2023-03-14	19	8	19	10	
Eckert, Lorena 2023-03-14	32	8	35	20	1, 16, 17
Eckert, Lorena 2023-03-14	37	5	40	2	1, 16, 17
Eckert, Lorena 2023-03-14	43	14	43	21	
Eckert, Lorena 2023-03-14	56	7	56	8	
Eckert, Lorena 2023-03-14	56	11	56	12	
Eckert, Lorena 2023-03-14	56	14	56	20	
Eckert, Lorena 2023-03-14	72	3	72	6	
Eckert, Lorena 2023-03-14	72	12	72	13	
Eckert, Lorena 2023-03-14	73	4	73	4	
Eckert, Lorena 2023-03-14	73	10	73	15	
Eckert, Lorena 2023-03-14	73	19	73	19	
Eckert, Lorena 2023-03-14	73	21	74	3	
Eckert, Lorena 2023-03-14	74	6	74	6	
Eckert, Lorena 2023-03-14	75	19	75	23	
Eckert, Lorena 2023-03-14	76	6	76	8	
Eckert, Lorena 2023-03-14	76	11	76	12	
Eckert, Lorena 2023-03-14	82	18	82	20	1, 17
Eckert, Lorena 2023-03-14	82	23	83	8	1, 17, outside scope
Eckert, Lorena 2023-03-14	135	22	136	3	
Eckert, Lorena 2023-03-14	151	11	151	17	

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Forehand, Joseph 2021-03-24	16	20	17	7	1, 17
Forehand, Joseph 2021-03-24	29	14	30	2	
Forehand, Joseph 2021-03-24	30	20	31	17	1, 17
Forehand, Joseph 2021-03-24	77	22	77	23	
Forehand, Joseph 2021-03-24	80	10	80	12	1, 17
Forehand, Joseph 2021-03-24	81	9	81	19	1, 17
Forehand, Joseph 2021-03-24	82	7	82	9	1, 17
Forehand, Joseph 2021-03-24	92	18	92	21	

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Gohde, John 2021-03-26	9	12	10	2	
Gohde, John 2021-03-26	36	1	36	2	1, 3, 17
Gohde, John 2021-03-26	36	12	36	13	1, 3, 17, 20
Gohde, John 2021-03-26	36	16	36	16	1, 3, 17, 20
Gohde, John 2021-03-26	36	20	36	20	1, 3, 17, 20
Gohde, John 2021-03-26	36	22	37	2	1, 3, 17, 20
Gohde, John 2021-03-26	42	3	42	6	1, 17
Gohde, John 2021-03-26	47	20	47	22	1, 17
Gohde, John 2021-03-26	58	19	58	21	1, 17
Gohde, John 2021-03-26	63	2	63	4	1, 17
Gohde, John 2021-03-26	63	7	63	13	1, 17
Gohde, John 2021-03-26	181	7	181	11	1, 17
Gohde, John 2021-03-26	196	6	196	12	1, 17
Gohde, John 2021-03-26	208	3	208	9	1, 17

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Gohde, John 2023-02-08	20	14	20	15	1, 13, 17
Gohde, John 2023-02-08	28	18	28	21	1, 3, 5, 13, 17
Gohde, John 2023-02-08	29	4	29	15	1, 3, 5, 13, 17

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Hanson, Robin 2023-11-06	53	12	53	13	1, 5, 17
Hanson, Robin 2023-11-06	80	4	80	10	1, 3, 5, 13, 15, 17
Hanson, Robin 2023-11-06	88	13	88	14	1, 5, 17, 19
Hanson, Robin 2023-11-06	88	17	88	18	1, 5, 17, 19
Hanson, Robin 2023-11-06	90	3	90	4	1, 2, 17
Hanson, Robin 2023-11-06	90	6	90	7	1, 2, 17
Hanson, Robin 2023-11-06	92	23	93	5	1, 13, 17
Hanson, Robin 2023-11-06	105	2	105	5	1, 3, 5, 17
Hanson, Robin 2023-11-06	112	3	112	7	1, 5, 13, 17
Hanson, Robin 2023-11-06	118	3	118	5	1, 17
Hanson, Robin 2023-11-06	118	7	118	11	1, 17
Hanson, Robin 2023-11-06	127	21	128	5	1, 3, 17
Hanson, Robin 2023-11-06	129	6	129	7	1, 3, 13

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Harvie, Mark 2021-04-19	17	8	17	10	
Harvie, Mark 2021-04-19	19	2	19	3	
Harvie, Mark 2021-04-19	19	15	19	22	1
Harvie, Mark 2021-04-19	40	12	40	12	
Harvie, Mark 2021-04-19	46	13	46	14	1
Harvie, Mark 2021-04-19	46	18	46	19	1
Harvie, Mark 2021-04-19	48	7	48	13	1
Harvie, Mark 2021-04-19	55	1	55	3	1
Harvie, Mark 2021-04-19	55	6	55	13	1
Harvie, Mark 2021-04-19	70	19	70	21	
Harvie, Mark 2021-04-19	70	24	71	1	
Harvie, Mark 2021-04-19	75	3	76	9	1, 17
Harvie, Mark 2021-04-19	76	13	76	17	1, 17



Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Jackson, Benjamin 2023-03-02	94	21	95	2	1, 17

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Jackson, Michael 2023-03-16	21	25	22	3	1, 3, 5, 17, 23
Jackson, Michael 2023-03-16	22	5	22	7	1, 3, 5, 17, 23
Jackson, Michael 2023-03-16	114	2	114	3	1, 3, 5, 17
Jackson, Michael 2023-03-16	114	6	114	7	1, 3, 5, 17

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Mann, Gregory 2021-03-31	9	24	10	1	
Mann, Gregory 2021-03-31	20	5	20	7	
Mann, Gregory 2021-03-31	34	22	35	1	1, 17, outside scope
Mann, Gregory 2021-03-31	143	20	143	24	
Mann, Gregory 2021-03-31	152	7	152	10	
Mann, Gregory 2021-03-31	152	16	152	24	1, 16, 17
Mann, Gregory 2021-03-31	153	2	153	18	
Mann, Gregory 2021-03-31	159	13	159	23	
Mann, Gregory 2021-03-31	161	20	162	17	
Mann, Gregory 2021-03-31	164	11	164	12	
Mann, Gregory 2021-03-31	164	21	164	23	
Mann, Gregory 2021-03-31	165	6	165	8	
Mann, Gregory 2021-03-31	166	10	167	1	
Mann, Gregory 2021-03-31	204	13	204	24	
Mann, Gregory 2021-03-31	205	1	205	9	

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Mann, Gregory 2023-02-16	40	17	40	18	1, 4, 17, outside scope
Mann, Gregory 2023-02-16	40	20	40	20	1,4 , 17, outside scope
Mann, Gregory 2023-02-16	42	22	43	1	1,4 , 17, outside scope
Mann, Gregory 2023-02-16	43	3	43	3	1,4 , 17, outside scope
Mann, Gregory 2023-02-16	46	15	46	17	1,4 , 17, outside scope
Mann, Gregory 2023-02-16	46	21	46	21	1,4 , 17, outside scope
Mann, Gregory 2023-02-16	47	3	47	3	1,4 , 17, outside scope
Mann, Gregory 2023-02-16	47	5	47	6	1,4 , 17, outside scope
Mann, Gregory 2023-02-16	47	8	47	12	1,4 , 17, outside scope
Mann, Gregory 2023-02-16	59	15	59	20	1,4 , 17, outside scope
Mann, Gregory 2023-02-16	59	22	59	22	1,4 , 17, outside scope
Mann, Gregory 2023-02-16	60	4	60	5	1,4 , 17, outside scope
Mann, Gregory 2023-02-16	60	7	60	7	1,4 , 17, outside scope
Mann, Gregory 2023-02-16	91	14	91	17	1, 4, 17, outside scope
Mann, Gregory 2023-02-16	91	19	91	19	1, 4, 17, outside scope
Mann, Gregory 2023-02-16	93	8	93	9	1, 3, 4, 17, outside scope
Mann, Gregory 2023-02-16	93	11	93	11	
Mann, Gregory 2023-02-16	120	17	120	19	1, 4, 17, outside scope
Mann, Gregory 2023-02-16	120	24	121	1	1, 4, 17, outside scope
Mann, Gregory 2023-02-16	122	15	122	17	1, 4, 17, outside scope
Mann, Gregory 2023-02-16	122	20	122	20	1, 4, 17, outside scope
Mann, Gregory 2023-02-16	122	22	122	23	1, 4, 17, outside scope
Mann, Gregory 2023-02-16	123	1	123	4	1, 4, 17, outside scope
Mann, Gregory 2023-02-16	123	6	123	9	1, 4, 17, outside scope
Mann, Gregory 2023-02-16	123	19	123	22	1, 4, 17, outside scope
Mann, Gregory 2023-02-16	123	24	123	24	1, 4, 17, outside scope
Mann, Gregory 2023-02-16	125	6	125	9	1, 4, 17, outside scope
Mann, Gregory 2023-02-16	125	11	125	15	1, 4, 17, outside scope
Mann, Gregory 2023-02-16	126	3	126	6	1, 4, 17, outside scope
Mann, Gregory 2023-02-16	126	8	126	8	1, 4, 17, outside scope
Mann, Gregory 2023-02-16	126	15	126	16	1, 4, 17, outside scope
Mann, Gregory 2023-02-16	126	18	126	19	1, 4, 17, outside scope
Mann, Gregory 2023-02-16	178	8	178	14	1, 4, 17
Mann, Gregory 2023-02-16	183	21	183	23	1, 17

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Morgan, Richard 2023-02-10	30	13	30	17	1, 5
Morgan, Richard 2023-02-10	46	18	46	19	1, 3, 17, 19
Morgan, Richard 2023-02-10	46	22	46	24	1,3, 17, 19
Morgan, Richard 2023-02-10	50	12	50	12	1, 17, 19
Morgan, Richard 2023-02-10	53	6	53	10	1, 3, 5, 17. 19
Morgan, Richard 2023-02-10	77	6	77	11	1, 3, 17, 19
Morgan, Richard 2023-02-10	133	4	133	10	1, 17. 19
Morgan, Richard 2023-02-10	134	13	134	15	1, 3, 5, 17

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
19-1508 - Vol 01, Newton, Camille	160	11	160	19	1, 4, 17
19-1508 - Vol 01, Newton, Camille	225	9	225	14	1, 4, 5, 17
19-1508 - Vol 01, Newton, Camille	231	9	231	16	1, 2, 4, 17
19-1508 - Vol 01, Newton, Camille	233	15	233	20	1, 4, 17
19-1508 - Vol 01, Newton, Camille	235	13	235	22	1, 4, 16, 17
19-1508 - Vol 01, Newton, Camille	237	8	237	17	1, 4, 17
19-1508 - Vol 01, Newton, Camille	238	10	238	11	1, 4, 17
19-1508 - Vol 01, Newton, Camille	238	15	238	16	1, 4, 17
19-1508 - Vol 01, Newton, Camille	239	8	239	18	1, 4, 16, 17
19-1508 - Vol 01, Newton, Camille	240	15	240	23	1, 4, 17
19-1508 - Vol 01, Newton, Camille	243	25	244	14	1, 4, 16, 17
19-1508 - Vol 01, Newton, Camille	245	2	245	16	1, 4, 16, 17
19-1508 - Vol 01, Newton, Camille	247	5	247	11	1, 4, 16, 17
19-1508 - Vol 01, Newton, Camille	247	17	247	19	1, 4, 16, 17

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
19-1508 - Vol 02, Newton, Camille	261	3	261	4	1, 4, 17
19-1508 - Vol 02, Newton, Camille	261	10	261	20	1, 4, 17
19-1508 - Vol 02, Newton, Camille	262	20	263	13	1, 4, 16, 17
19-1508 - Vol 02, Newton, Camille	264	1	264	11	1, 4, 16, 17
19-1508 - Vol 02, Newton, Camille	268	25	269	14	1, 4, 17, MIL3
19-1508 - Vol 02, Newton, Camille	269	15	269	19	1, 4, 17, MIL3
19-1508 - Vol 02, Newton, Camille	269	20	270	24	1, 4, 17, MIL3
19-1508 - Vol 02, Newton, Camille	271	2	272	20	1, 4, 17, 24, MIL3
19-1508 - Vol 02, Newton, Camille	272	22	273	9	1, 4, 17, 24
19-1508 - Vol 02, Newton, Camille	273	10	273	13	1, 4, 17
19-1508 - Vol 02, Newton, Camille	273	18	275	14	1, 4, 16, 17
19-1508 - Vol 02, Newton, Camille	275	16	275	20	1, 4, 17
19-1508 - Vol 02, Newton, Camille	275	24	276	8	1, 4, 17

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Newton, Camille 2021-04-15	19	15	19	17	1, 4, 17
Newton, Camille 2021-04-15	31	4	31	4	4
Newton, Camille 2021-04-15	48	8	48	9	1, 4, 17
Newton, Camille 2021-04-15	48	11	48	12	1, 4, 17
Newton, Camille 2021-04-15	51	9	51	12	1, 4, 17
Newton, Camille 2021-04-15	51	25	52	10	1, 4, 17, MIL3
Newton, Camille 2021-04-15	54	5	54	10	1, 4, 17
Newton, Camille 2021-04-15	56	8	56	9	1, 4, 17
Newton, Camille 2021-04-15	56	12	56	12	1, 4, 17
Newton, Camille 2021-04-15	56	14	56	19	1, 4, 17
Newton, Camille 2021-04-15	56	22	56	25	1, 4, 17
Newton, Camille 2021-04-15	66	8	66	10	1, 4, 17
Newton, Camille 2021-04-15	66	12	66	13	1, 4, 17
Newton, Camille 2021-04-15	66	15	66	24	1, 4, 17
Newton, Camille 2021-04-15	67	22	68	4	1, 4, 17
Newton, Camille 2021-04-15	71	9	71	9	4
Newton, Camille 2021-04-15	71	11	71	15	4
Newton, Camille 2021-04-15	85	8	85	9	4
Newton, Camille 2021-04-15	85	11	85	13	4
Newton, Camille 2021-04-15	85	15	85	16	4
Newton, Camille 2021-04-15	85	18	85	19	4
Newton, Camille 2021-04-15	97	14	97	15	1, 17
Newton, Camille 2021-04-15	99	11	99	11	1, 4, 17
Newton, Camille 2021-04-15	100	5	100	5	4
Newton, Camille 2021-04-15	110	2	110	13	1, 4, 17
Newton, Camille 2021-04-15	114	20	114	21	4
Newton, Camille 2021-04-15	114	24	115	1	4
Newton, Camille 2021-04-15	115	3	115	4	4
Newton, Camille 2021-04-15	115	7	115	10	4
Newton, Camille 2021-04-15	118	9	118	18	4, 16
Newton, Camille 2021-04-15	118	22	118	24	4
Newton, Camille 2021-04-15	119	2	119	8	4
Newton, Camille 2021-04-15	138	5	138	19	4
Newton, Camille 2021-04-15	144	8	144	20	4
Newton, Camille 2021-04-15	145	2	145	7	4
Newton, Camille 2021-04-15	147	3	147	14	4
Newton, Camille 2021-04-15	148	22	149	7	4
Newton, Camille 2021-04-15	149	12	149	14	4
Newton, Camille 2021-04-15	155	17	155	17	4
Newton, Camille 2021-04-15	155	19	155	22	4
Newton, Camille 2021-04-15	160	8	160	10	4
Newton, Camille 2021-04-15	160	13	160	24	1, 4, 16, 17
Newton, Camille 2021-04-15	175	16	175	18	1, 4, 16, 17
Newton, Camille 2021-04-15	175	21	176	1	1, 4, 16, 17
Newton, Camille 2021-04-15	180	2	180	5	4
Newton, Camille 2021-04-15	186	16	186	19	1, 4, 16, 17
Newton, Camille 2021-04-15	186	23	187	3	1, 4, 16, 17
Newton, Camille 2021-04-15	189	4	189	6	4
Newton, Camille 2021-04-15	189	14	189	15	1, 4, 16, 17
Newton, Camille 2021-04-15	189	17	189	18	1, 4, 16, 17
Newton, Camille 2021-04-15	194	16	194	18	1, 4, 16, 17



Newton, Camille 2021-04-15	194	21	195	6	1, 4, 16, 17
Newton, Camille 2021-04-15	207	21	207	21	4
Newton, Camille 2021-04-15	209	5	209	15	1, 4, 16, 17
Newton, Camille 2021-04-15	209	21	209	23	1, 4, 16, 17
Newton, Camille 2021-04-15	229	9	229	23	1, 4, 16, 17, MIL2
Newton, Camille 2021-04-15	237	2	237	2	1, 4, 16, 17, MIL2, 24
Newton, Camille 2021-04-15	237	8	237	21	1, 4, 16, 17, MIL2, 24
Newton, Camille 2021-04-15	237	22	238	9	1, 4, 16, 17, MIL2, 24
Newton, Camille 2021-04-15	238	11	238	15	1, 4, 16, 17, MIL2, 24
Newton, Camille 2021-04-15	238	17	239	6	1, 4, 16, 17, MIL2, 24
Newton, Camille 2021-04-15	279	12	280	13	1, 4, 16, 17
Newton, Camille 2021-04-15	280	14	280	19	1, 4, 16, 17
Newton, Camille 2021-04-15	298	9	298	16	1, 4, 16, 17

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Newton, Camille 2023-04-06	34	5	34	5	
Newton, Camille 2023-04-06	46	6	47	2	4
Newton, Camille 2023-04-06	47	6	47	6	4
Newton, Camille 2023-04-06	47	8	47	11	4
Newton, Camille 2023-04-06	47	15	47	20	4
Newton, Camille 2023-04-06	106	12	106	20	1, 4, 16, 17
Newton, Camille 2023-04-06	116	1	116	3	4
Newton, Camille 2023-04-06	116	6	116	9	4

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
19-1508 - Vol 02, Newton, Raymond	288	6	288	10	4
19-1508 - Vol 02, Newton, Raymond	289	21	290	1	1, 4, 3, 5, 17
19-1508 - Vol 02, Newton, Raymond	290	15	291	11	1, 4, 3, 5, 17
19-1508 - Vol 02, Newton, Raymond	293	19	293	22	1, 4, 3, 5, 17
19-1508 - Vol 02, Newton, Raymond	297	8	297	17	1, 4, 3, 5, 17
19-1508 - Vol 02, Newton, Raymond	297	21	299	23	1, 4, 3, 5, 17
19-1508 - Vol 02, Newton, Raymond	302	11	305	14	1, 4, 3, 5, 17
19-1508 - Vol 02, Newton, Raymond	318	9	319	22	1, 4, 3, 5, 17
19-1508 - Vol 02, Newton, Raymond	321	16	322	9	1, 4, 3, 5, 17
19-1508 - Vol 02, Newton, Raymond	324	17	325	5	1, 4, 3, 5, 17

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Newton, Ray 2021-04-13	19	10	19	11	1, 4, 17, 19
Newton, Ray 2021-04-13	36	19	36	23	1, 4, 16, 17
Newton, Ray 2021-04-13	45	12	45	21	1, 4, 17
Newton, Ray 2021-04-13	50	2	50	5	4
Newton, Ray 2021-04-13	59	8	59	13	4
Newton, Ray 2021-04-13	72	1	72	6	4
Newton, Ray 2021-04-13	72	8	72	25	4
Newton, Ray 2021-04-13	79	15	79	17	4
Newton, Ray 2021-04-13	79	19	80	9	4
Newton, Ray 2021-04-13	80	12	80	20	1, 4, 16, 17
Newton, Ray 2021-04-13	81	14	81	22	4
Newton, Ray 2021-04-13	98	10	98	17	1,4 , 17, MIL3
Newton, Ray 2021-04-13	98	24	99	20	1, 4, 17, MIL3
Newton, Ray 2021-04-13	100	22	101	12	1, 4, 17, MIL3
Newton, Ray 2021-04-13	109	17	109	25	1, 4, 17, MIL3
Newton, Ray 2021-04-13	113	7	113	11	1, 4, 17, MIL3
Newton, Ray 2021-04-13	113	14	113	25	1, 4, 17, MIL3
Newton, Ray 2021-04-13	114	25	115	22	1, 4, 17, MIL3
Newton, Ray 2021-04-13	121	22	122	1	4
Newton, Ray 2021-04-13	122	3	122	13	4
Newton, Ray 2021-04-13	126	15	126	18	4
Newton, Ray 2021-04-13	137	1	137	15	1, 4, 17
Newton, Ray 2021-04-13	138	23	138	23	1, 4, 17, MIL3
Newton, Ray 2021-04-13	139	2	139	2	1, 4, 17, MIL3
Newton, Ray 2021-04-13	139	5	139	10	1, 4, 17, MIL3
Newton, Ray 2021-04-13	141	1	141	3	4
Newton, Ray 2021-04-13	141	6	141	10	4
Newton, Ray 2021-04-13	147	1	147	4	4
Newton, Ray 2021-04-13	162	22	162	23	1, 4, 17
Newton, Ray 2021-04-13	163	1	163	1	1, 4, 17
Newton, Ray 2021-04-13	164	15	164	16	1, 4, 17
Newton, Ray 2021-04-13	169	11	169	14	1, 4, 17
Newton, Ray 2021-04-13	169	17	169	21	1, 4, 17
Newton, Ray 2021-04-13	184	2	184	14	1, 4, 16, 17
Newton, Ray 2021-04-13	184	17	184	25	1, 4, 16, 17
Newton, Ray 2021-04-13	186	5	186	11	4
Newton, Ray 2021-04-13	199	3	199	5	1, 4, 17
Newton, Ray 2021-04-13	205	21	205	22	1, 4, 17
Newton, Ray 2021-04-13	205	25	206	1	
Newton, Ray 2021-04-13	206	21	206	23	1, 4, 17
Newton, Ray 2021-04-13	207	1	207	6	1, 4, 17
Newton, Ray 2021-04-13	207	8	207	9	1, 4, 17
Newton, Ray 2021-04-13	207	12	207	15	1, 4, 17
Newton, Ray 2021-04-13	219	8	219	9	4
Newton, Ray 2021-04-13	219	12	219	17	4
Newton, Ray 2021-04-13	244	11	244	14	1, 4, 17, MIL3
Newton, Ray 2021-04-13	252	21	252	23	1, 2, 4, 16, 17
Newton, Ray 2021-04-13	253	1	253	6	1, 2, 4, 16, 17
Newton, Ray 2021-04-13	254	15	254	17	4
Newton, Ray 2021-04-13	254	20	254	24	4
Newton, Ray 2021-04-13	255	2	255	2	4
Newton, Ray 2021-04-13	255	11	255	13	4

Newton, Ray 2021-04-13	255	16	255	18	4
Newton, Ray 2021-04-13	260	25	261	2	4
Newton, Ray 2021-04-13	263	23	264	7	4

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Newton, Ray 2023-05-03	25	23	26	2	1, 4, 17
Newton, Ray 2023-05-03	26	6	26	12	1, 4, 17
Newton, Ray 2023-05-03	30	22	31	5	1, 4, 17
Newton, Ray 2023-05-03	31	9	31	10	1, 4, 17
Newton, Ray 2023-05-03	35	4	35	5	1, 4, 17
Newton, Ray 2023-05-03	35	9	35	15	1, 4, 17
Newton, Ray 2023-05-03	39	14	39	16	1, 4, 17
Newton, Ray 2023-05-03	39	22	39	23	1, 4, 17
Newton, Ray 2023-05-03	53	12	53	13	4
Newton, Ray 2023-05-03	55	19	55	20	4
Newton, Ray 2023-05-03	55	23	56	3	4
Newton, Ray 2023-05-03	68	18	69	7	4
Newton, Ray 2023-05-03	69	11	69	20	4
Newton, Ray 2023-05-03	77	23	77	23	1, 4, 17, 18
Newton, Ray 2023-05-03	78	3	78	11	1, 4, 16, 17, 18
Newton, Ray 2023-05-03	78	15	78	16	1, 4, 16, 17, 18
Newton, Ray 2023-05-03	80	16	80	18	1, 4, 16, 17, 18
Newton, Ray 2023-05-03	80	22	81	13	1, 4, 16, 17, 18
Newton, Ray 2023-05-03	97	16	97	18	1, 4, 17
Newton, Ray 2023-05-03	97	22	98	2	1, 4, 17
Newton, Ray 2023-05-03	101	7	101	12	4
Newton, Ray 2023-05-03	102	5	102	8	4
Newton, Ray 2023-05-03	102	11	102	18	4
Newton, Ray 2023-05-03	114	7	114	11	4
Newton, Ray 2023-05-03	114	15	114	17	4
Newton, Ray 2023-05-03	134	17	134	22	4
Newton, Ray 2023-05-03	138	18	138	20	4
Newton, Ray 2023-05-03	138	23	138	24	4
Newton, Ray 2023-05-03	143	16	143	19	4
Newton, Ray 2023-05-03	143	22	144	2	4
Newton, Ray 2023-05-03	149	18	149	19	4
Newton, Ray 2023-05-03	153	13	153	15	4
Newton, Ray 2023-05-03	153	18	153	21	4
Newton, Ray 2023-05-03	155	16	156	7	1, 4, 17
Newton, Ray 2023-05-03	170	10	170	12	4
Newton, Ray 2023-05-03	178	2	178	3	
Newton, Ray 2023-05-03	193	8	193	9	1, 4, 18
Newton, Ray 2023-05-03	196	16	196	20	4
Newton, Ray 2023-05-03	197	16	197	18	1, 4, 17
Newton, Ray 2023-05-03	197	23	198	1	1, 4, 17
Newton, Ray 2023-05-03	198	10	198	11	1, 4, 17
Newton, Ray 2023-05-03	208	3	208	4	4
Newton, Ray 2023-05-03	209	23	210	2	4
Newton, Ray 2023-05-03	210	6	210	7	4

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Pawlik, Kate 2023-03-17	19	24	20	3	
Pawlik, Kate 2023-03-17	23	10	23	12	
Pawlik, Kate 2023-03-17	36	3	36	6	
Pawlik, Kate 2023-03-17	36	10	36	14	
Pawlik, Kate 2023-03-17	37	20	38	2	
Pawlik, Kate 2023-03-17	38	6	38	6	
Pawlik, Kate 2023-03-17	41	23	41	23	
Pawlik, Kate 2023-03-17	62	9	62	11	
Pawlik, Kate 2023-03-17	69	1	69	2	
Pawlik, Kate 2023-03-17	70	3	70	4	
Pawlik, Kate 2023-03-17	70	7	70	8	
Pawlik, Kate 2023-03-17	71	9	71	12	
Pawlik, Kate 2023-03-17	71	19	71	20	
Pawlik, Kate 2023-03-17	72	13	72	15	1, 17
Pawlik, Kate 2023-03-17	72	18	72	18	1, 17
Pawlik, Kate 2023-03-17	73	13	73	17	1, 17
Pawlik, Kate 2023-03-17	81	17	81	22	
Pawlik, Kate 2023-03-17	118	7	118	9	
Pawlik, Kate 2023-03-17	118	12	118	13	
Pawlik, Kate 2023-03-17	124	6	124	10	1, 17
Pawlik, Kate 2023-03-17	124	13	124	16	1, 17
Pawlik, Kate 2023-03-17	127	21	127	23	
Pawlik, Kate 2023-03-17	128	3	128	3	
Pawlik, Kate 2023-03-17	132	18	132	19	1, 17
Pawlik, Kate 2023-03-17	132	22	132	22	1, 17
Pawlik, Kate 2023-03-17	139	18	139	20	
Pawlik, Kate 2023-03-17	139	24	139	24	
Pawlik, Kate 2023-03-17	140	17	140	20	
Pawlik, Kate 2023-03-17	148	3	148	5	
Pawlik, Kate 2023-03-17	158	10	158	12	
Pawlik, Kate 2023-03-17	158	16	158	18	
Pawlik, Kate 2023-03-17	181	16	181	20	
Pawlik, Kate 2023-03-17	185	14	185	18	
Pawlik, Kate 2023-03-17	186	18	186	22	
Pawlik, Kate 2023-03-17	199	5	199	7	
Pawlik, Kate 2023-03-17	212	2	212	4	1, 17
Pawlik, Kate 2023-03-17	212	8	212	14	1, 17
Pawlik, Kate 2023-03-17	221	11	221	13	
Pawlik, Kate 2023-03-17	225	10	225	14	1, 17
Pawlik, Kate 2023-03-17	232	8	232	10	
Pawlik, Kate 2023-03-17	247	23	248	2	
Pawlik, Kate 2023-03-17	265	4	265	6	
Pawlik, Kate 2023-03-17	265	10	265	10	
Pawlik, Kate 2023-03-17	265	18	265	22	1, 17
Pawlik, Kate 2023-03-17	274	12	274	14	

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Shaw, Laura 2021-04-13	13	24	14	1	
Shaw, Laura 2021-04-13	17	10	17	12	1, 17, fragment
Shaw, Laura 2021-04-13	29	25	30	3	1, 17, fragment
Shaw, Laura 2021-04-13	31	1	31	8	1, 17
Shaw, Laura 2021-04-13	40	17	41	4	1, 17



Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Simon, Marcus 2021-03-03	7	1	7	3	
Simon, Marcus 2021-03-03	10	2	10	6	
Simon, Marcus 2021-03-03	25	24	26	19	1
Simon, Marcus 2021-03-03	51	22	51	25	1
Simon, Marcus 2021-03-03	72	10	72	17	
Simon, Marcus 2021-03-03	73	11	73	12	
Simon, Marcus 2021-03-03	79	17	79	20	1
Simon, Marcus 2021-03-03	89	4	89	7	1, 19
Simon, Marcus 2021-03-03	114	24	114	24	
Simon, Marcus 2021-03-03	118	5	118	11	1
Simon, Marcus 2021-03-03	124	14	124	18	
Simon, Marcus 2021-03-03	144	16	144	24	1

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Skelton, Sarah 2023-01-18	9	4	9	10	1
Skelton, Sarah 2023-01-18	37	12	37	14	1, 19
Skelton, Sarah 2023-01-18	39	9	39	10	1, 19
Skelton, Sarah 2023-01-18	39	13	39	20	1, 19
Skelton, Sarah 2023-01-18	43	12	43	20	1, 19
Skelton, Sarah 2023-01-18	81	6	81	8	1, 17, 19
Skelton, Sarah 2023-01-18	81	10	81	16	

Transcript	PgFrom	LnFrom	PgTo	LnTo	Sage Preliminary Objections
Zani, Paul 2021-03-23	30	13	31	21	1, 5, 16, 17, 19
Zani, Paul 2021-03-23	36	6	36	8	1, 16, 19, 17
Zani, Paul 2021-03-23	38	20	39	3	1, 5
Zani, Paul 2021-03-23	48	3	49	2	1, 3, 5, 13
Zani, Paul 2021-03-23	50	16	50	17	1, 16, 17, 19
Zani, Paul 2021-03-23	58	18	59	9	1, 16, 17, 19
Zani, Paul 2021-03-23	65	6	65	13	1, 16, 17, 19
Zani, Paul 2021-03-23	75	10	75	15	1, 3, 13, 17
Zani, Paul 2021-03-23	80	6	80	9	1, 19
Zani, Paul 2021-03-23	82	10	82	12	1, 19
Zani, Paul 2021-03-23	98	15	98	15	1, 19
Zani, Paul 2021-03-23	99	12	99	15	1, 19
Zani, Paul 2021-03-23	101	8	101	24	1, 5, 13, 17, 19
Zani, Paul 2021-03-23	108	25	108	25	1, 19
Zani, Paul 2021-03-23	131	21	132	6	1, 3, 4, 17
Zani, Paul 2021-03-23	148	17	148	17	1, 19
Zani, Paul 2021-03-23	149	5	149	9	1, 17
Zani, Paul 2021-03-23	154	20	154	25	1, 3, 17
Zani, Paul 2021-03-23	158	3	158	5	1, 17
Zani, Paul 2021-03-23	182	1	183	1	1, 3, 17, 19
Zani, Paul 2021-03-23	183	6	183	10	1, 3, 17, 19
Zani, Paul 2021-03-23	219	1	219	9	1, 5, 16, 17, 19
Zani, Paul 2021-03-23	225	2	225	7	1, 3, 17, 20

## **SCHEDULE E4d**

### **Sage's Counter-Counter Designations**

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues
Bobay, Jason 2021-04-23	153	15	153	20	153-154, 168	Sage Counter-Counter

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues
Burn, Brian 2021-04-02	16	2	16	4	15	Sage Counter-Counter
Burn, Brian 2021-04-02	22	19	22	22	20	Sage Counter-Counter
Burn, Brian 2021-04-02	82	21	82	21	82	Sage Counter-Counter
Burn, Brian 2021-04-02	117	21	118	5	117	Sage Counter-Counter

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues
Burn, Brian 2023-03-23	126	14	126	18	125-126	Sage Counter-Counter
Burn, Brian 2023-03-23	126	19	127	6	125-126	Sage Counter-Counter
Burn, Brian 2023-03-23	127	7	127	11	125-126	Sage Counter-Counter

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues
Dy, Ruby 2021-04-14	34	20	34	21	p. 35	Sage Counter-Counter
Dy, Ruby 2021-04-14	35	24	36	2	p. 36	Sage Counter-Counter
Dy, Ruby 2021-04-14	36	5	36	10	p. 36	Sage Counter-Counter



Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues
Eckert, Lorena 2023-03-14	36	24	37	4	p. 37	Sage Counter-Counter
Eckert, Lorena 2023-03-14	43	22	44	1	p. 43	Sage Counter-Counter
Eckert, Lorena 2023-03-14	44	2	44	5	p. 37	Sage Counter-Counter
Eckert, Lorena 2023-03-14	44	9	46	9	p. 37	Sage Counter-Counter
Eckert, Lorena 2023-03-14	74	8	74	10		Sage Counter-Counter
Eckert, Lorena 2023-03-14	74	13	74	15		Sage Counter-Counter
Eckert, Lorena 2023-03-14	76	18	76	19	pp. 76-77	Sage Counter-Counter
Eckert, Lorena 2023-03-14	76	22	76	24	pp. 76-77	Sage Counter-Counter
Eckert, Lorena 2023-03-14	77	3	77	8	pp. 76-77	Sage Counter-Counter
Eckert, Lorena 2023-03-14	79	13	79	16	pp. 82-83	Sage Counter-Counter
Eckert, Lorena 2023-03-14	79	20	79	22	pp. 82-83	Sage Counter-Counter
Eckert, Lorena 2023-03-14	81	11	81	13	pp. 82-83	Sage Counter-Counter
Eckert, Lorena 2023-03-14	81	16	81	19	pp. 82-83	Sage Counter-Counter
Eckert, Lorena 2023-03-14	83	10	83	13	pp. 82-83	Sage Counter-Counter
Eckert, Lorena 2023-03-14	83	16	83	18	pp. 82-83	Sage Counter-Counter
Eckert, Lorena 2023-03-14	83	19	84	3	pp. 82-83	Sage Counter-Counter

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues
Forehand, Joseph 2021-03-24	82	10	82	11	82	Sage Counter-Counter

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues
Gohde, John 2021-03-26	37	18	38	9	36:1-37:2	Sage Counter-Counter
Gohde, John 2021-03-26	47	9	47	16	47:20-22	Sage Counter-Counter
Gohde, John 2021-03-26	62	15	63	1	63:2-13	Sage Counter-Counter

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues
Hanson, Robin 2023-11-06	53	14	53	18	53:12-13	Sage Counter-Counter
Hanson, Robin 2023-11-06	81	24	82	14	80:4-10	Sage Counter-Counter
Hanson, Robin 2023-11-06	88	19	88	20	88:13-18	Sage Counter-Counter
Hanson, Robin 2023-11-06	95	6	95	18	92:23-93:5	Sage Counter-Counter
Hanson, Robin 2023-11-06	129	8	129	17		Sage Counter-Counter

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues
Jackson, Michael 2023-03-16	22	9	22	11	21:25-22:7	Sage Counter-Counter
Jackson, Michael 2023-03-16	22	13	22	13	21:25-22:7	Sage Counter-Counter

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues
Mann, Gregory 2021-03-31	35	2	35	7	contingent	Sage Counter-Counter

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues
Mann, Gregory 2023-02-16	60	9	60	9	p. 60	Sage Counter-Counter
Mann, Gregory 2023-02-16	60	11	60	11	p. 60	Sage Counter-Counter

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues
Morgan, Richard 2023-02-10	46	20	46	20	46:18-19; 46:22-24	Sage Counter-Counter
Morgan, Richard 2023-02-10	50	11	50	11	5:12	Sage Counter-Counter
Morgan, Richard 2023-02-10	53	11	53	11	53:6-10	Sage Counter-Counter
Morgan, Richard 2023-02-10	76	10	76	22	77:6-11	Sage Counter-Counter
Morgan, Richard 2023-02-10	133	11	133	11	133:4-10	Sage Counter-Counter
Morgan, Richard 2023-02-10	134	17	134	18	134:13-15	Sage Counter-Counter
Morgan, Richard 2023-02-10	134	21	135	3	134:13-15	Sage Counter-Counter



Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues
19-1508 - Vol 01, Newton, Camille	225	20	226	1	e.g., p. 225	Sage Counter-Counter
19-1508 - Vol 01, Newton, Camille	228	4	228	10	e.g. p. 231	Sage Counter-Counter
19-1508 - Vol 01, Newton, Camille	229	4	229	9	e.g., p. 231	Sage Counter-Counter
19-1508 - Vol 01, Newton, Camille	231	17	231	19	p. 231	Sage Counter-Counter
19-1508 - Vol 01, Newton, Camille	233	21	234	19	p. 233	Sage Counter-Counter
19-1508 - Vol 01, Newton, Camille	237	18	238	9	p. 237-238	Sage Counter-Counter
19-1508 - Vol 01, Newton, Camille	239	19	239	24	p. 239	Sage Counter-Counter
19-1508 - Vol 01, Newton, Camille	241	12	241	20	p. 240	Sage Counter-Counter

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues
19-1508 - Vol 02, Newton, Camille	257	13	257	15	e.g., pp. 231, 237, 249, 261, 264; contingent	Sage Counter-Counter
19-1508 - Vol 02, Newton, Camille	257	16	257	19	e.g., pp. 231, 237, 249, 261, 264; contingent	Sage Counter-Counter
19-1508 - Vol 02, Newton, Camille	266	7	266	13	e.g., pp 268-269; Dep. Tr.; contingent	Sage Counter-Counter
19-1508 - Vol 02, Newton, Camille	266	14	266	24	e.g., pp 268-269; Dep. Tr.; contingent	Sage Counter-Counter

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues
Newton, Camille 2021-04-15	51	7	51	8	51:9-12	Sage Counter-Counter
Newton, Camille 2021-04-15	68	5	68	13	pp. 67-68	Sage Counter-Counter
Newton, Camille 2021-04-15	71	16	71	17	pp. 71	Sage Counter-Counter
Newton, Camille 2021-04-15	71	19	71	24	p. 71	Sage Counter-Counter
Newton, Camille 2021-04-15	72	2	72	3	p. 71	Sage Counter-Counter
Newton, Camille 2021-04-15	86	4	86	4	pp. 84-85	Sage Counter-Counter
Newton, Camille 2021-04-15	86	6	86	6	pp. 84-85	Sage Counter-Counter
Newton, Camille 2021-04-15	119	10	119	12	pp. 118-119	Sage Counter-Counter
Newton, Camille 2021-04-15	119	15	120	1	pp. 118-119	Sage Counter-Counter
Newton, Camille 2021-04-15	120	5	120	11	pp. 118-119	Sage Counter-Counter
Newton, Camille 2021-04-15	120	14	120	23	pp. 118-119	Sage Counter-Counter
Newton, Camille 2021-04-15	189	20	189	25	e.g., p. 189	Sage Counter-Counter
Newton, Camille 2021-04-15	209	16	209	18	p. 209 contingent	Sage Counter-Counter
Newton, Camille 2021-04-15	210	5	211	2	e.g., p. 209 contingent	Sage Counter-Counter

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues
19-1508 - Vol 02, Newton, Raymond	288	11	288	16	p. 288; **Many of Sage's counterdesignations are applicable to numerous PureWick designations across multiple witnesses and topic areas. Identification of page numbers are exemplary.	Sage Counter-Counter
19-1508 - Vol 02, Newton, Raymond	300	24	301	1	e.g., pp. 288-302	Sage Counter-Counter
19-1508 - Vol 02, Newton, Raymond	301	11	302	1	e.g., pp. 288-302	Sage Counter-Counter
19-1508 - Vol 02, Newton, Raymond	313	3	314	23	e.g., 319, 321-322; 288, 291, 293, 297-299, 302-304	Sage Counter-Counter
19-1508 - Vol 02, Newton, Raymond	314	24	315	12	e.g., pp. 288-302	Sage Counter-Counter
19-1508 - Vol 02, Newton, Raymond	315	13	315	16	e.g., pp. 289-299	Sage Counter-Counter
19-1508 - Vol 02, Newton, Raymond	319	23	320	11	e.g., pp. 319, 321-322	Sage Counter-Counter
19-1508 - Vol 02, Newton, Raymond	320	12	320	25	e.g., pp. 288, 291, 293, 297-299, 302-304; R. Newton Dep Counters	Sage Counter-Counter
19-1508 - Vol 02, Newton, Raymond	322	17	323	10	e.g., pp. 322-323; R. Newton Dep. Counters	Sage Counter-Counter
19-1508 - Vol 02, Newton, Raymond	323	16	324	9	e.g., pp. 288-302	Sage Counter-Counter

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues
Newton, Ray 2021-04-13	34	18	34	19	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207; **Many of Sage's counterdesignations are applicable to numerous PureWick designations across multiple witnesses and topic areas. Identification of page numbers are exemplary.	Sage Counter-Counter
Newton, Ray 2021-04-13	34	21	34	23	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter
Newton, Ray 2021-04-13	34	25	35	2	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter
Newton, Ray 2021-04-13	35	8	35	9	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter
Newton, Ray 2021-04-13	35	11	35	12	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter
Newton, Ray 2021-04-13	35	14	35	15	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter
Newton, Ray 2021-04-13	39	11	39	13	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter
Newton, Ray 2021-04-13	40	17	40	20	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter
Newton, Ray 2021-04-13	40	22	40	23	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter
Newton, Ray 2021-04-13	46	14	46	15	e.g., p. 45	Sage Counter-Counter
Newton, Ray 2021-04-13	54	1	54	2	e.g., p. 45	Sage Counter-Counter
Newton, Ray 2021-04-13	54	5	54	13	e.g., p. 45	Sage Counter-Counter
Newton, Ray 2021-04-13	54	16	54	21	e.g., p. 45	Sage Counter-Counter
Newton, Ray 2021-04-13	54	22	54	25	e.g., p. 45	Sage Counter-Counter
Newton, Ray 2021-04-13	60	12	60	25	e.g., pp. 59, 72	Sage Counter-Counter
Newton, Ray 2021-04-13	61	10	62	3	e.g., p. 72	Sage Counter-Counter
Newton, Ray 2021-04-13	62	7	62	19	e.g., p. 72	Sage Counter-Counter
Newton, Ray 2021-04-13	62	21	63	10	e.g., p. 72	Sage Counter-Counter
Newton, Ray 2021-04-13	63	20	63	21	e.g., p. 72	Sage Counter-Counter
Newton, Ray 2021-04-13	63	23	63	25	e.g., p. 72	Sage Counter-Counter
Newton, Ray 2021-04-13	64	2	64	10	e.g., p. 72	Sage Counter-Counter
Newton, Ray 2021-04-13	64	24	65	11	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter
Newton, Ray 2021-04-13	68	4	68	11	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter
Newton, Ray 2021-04-13	69	14	69	16	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter
Newton, Ray 2021-04-13	69	18	69	20	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter
Newton, Ray 2021-04-13	69	22	69	24	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter
Newton, Ray 2021-04-13	70	1	70	2	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter
Newton, Ray 2021-04-13	70	4	70	7	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter
Newton, Ray 2021-04-13	70	21	70	23	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter
Newton, Ray 2021-04-13	70	25	71	1	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter
Newton, Ray 2021-04-13	73	5	73	8	e.g., p. 72	Sage Counter-Counter
Newton, Ray 2021-04-13	75	10	75	17	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter
Newton, Ray 2021-04-13	76	14	76	21	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter
Newton, Ray 2021-04-13	77	5	77	11	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter

Newton, Ray 2021-04-13	77	17	77	18	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter
Newton, Ray 2021-04-13	80	22	80	23	e.g., pp. 79-80	Sage Counter-Counter
Newton, Ray 2021-04-13	80	25	81	6	e.g., pp. 79-80	Sage Counter-Counter
Newton, Ray 2021-04-13	82	15	82	17	e.g., pp. 80-81	Sage Counter-Counter
Newton, Ray 2021-04-13	82	21	82	23	e.g., pp. 80-81	Sage Counter-Counter
Newton, Ray 2021-04-13	82	25	83	20	e.g., pp. 80-81	Sage Counter-Counter
Newton, Ray 2021-04-13	83	21	84	1	e.g., pp. 80-81	Sage Counter-Counter
Newton, Ray 2021-04-13	92	3	96	1	e.g., pp. 98, 45, 50, 50, 72, 79-80, 122, 199, 205-207	Sage Counter-Counter
Newton, Ray 2021-04-13	119	5	119	9	e.g., pp. 98, 45, 50, 50, 72, 79-80, 122, 199, 205-207	Sage Counter-Counter
Newton, Ray 2021-04-13	119	10	119	13	e.g., pp. 98, 45, 50, 50, 72, 79-80, 122, 199, 205-207	Sage Counter-Counter
Newton, Ray 2021-04-13	119	16	119	20	e.g., pp. 98, 45, 50, 50, 72, 79-80, 122, 199, 205-207	Sage Counter-Counter
Newton, Ray 2021-04-13	120	7	120	12	e.g., p. 122	Sage Counter-Counter
Newton, Ray 2021-04-13	122	15	122	16	e.g., p. 122	Sage Counter-Counter
Newton, Ray 2021-04-13	122	19	122	22	e.g., p. 122	Sage Counter-Counter
Newton, Ray 2021-04-13	124	1	124	14	e.g., p. 122	Sage Counter-Counter
Newton, Ray 2021-04-13	137	16	137	18	e.g., p. 137	Sage Counter-Counter
Newton, Ray 2021-04-13	137	22	138	1	e.g., p. 137	Sage Counter-Counter
Newton, Ray 2021-04-13	138	3	138	4	e.g., pp. 138-139	Sage Counter-Counter
Newton, Ray 2021-04-13	138	7	138	8	e.g., pp. 137, 138-139	Sage Counter-Counter
Newton, Ray 2021-04-13	138	10	138	15	e.g., pp. 137, 138-139	Sage Counter-Counter
Newton, Ray 2021-04-13	138	18	138	21	e.g., pp. 137, 138-139	Sage Counter-Counter
Newton, Ray 2021-04-13	140	20	140	25	p. 141	Sage Counter-Counter
Newton, Ray 2021-04-13	159	1	159	18	e.g., p. 147; initial	Sage Counter-Counter
Newton, Ray 2021-04-13	161	2	161	6	e.g., p. 244, 250, 254, 255	Sage Counter-Counter
Newton, Ray 2021-04-13	162	3	162	4	e.g., pp. 162-164, 169, 186	Sage Counter-Counter
Newton, Ray 2021-04-13	162	7	162	9	e.g., pp. 162-164, 169, 186	Sage Counter-Counter
Newton, Ray 2021-04-13	162	12	162	15	e.g., pp. 162-164, 169, 186	Sage Counter-Counter
Newton, Ray 2021-04-13	162	17	162	19	e.g., pp. 162-164, 169, 186	Sage Counter-Counter
Newton, Ray 2021-04-13	163	12	163	14	e.g., pp. 162-164, 169, 186	Sage Counter-Counter
Newton, Ray 2021-04-13	163	17	163	21	e.g., pp. 162-164, 169, 186	Sage Counter-Counter
Newton, Ray 2021-04-13	164	17	164	24	e.g., pp. 162-164, 169, 186	Sage Counter-Counter
Newton, Ray 2021-04-13	165	22	166	5	e.g., pp. 162-164, 169, 186	Sage Counter-Counter
Newton, Ray 2021-04-13	166	20	167	3	e.g., pp. 162-164, 169, 186	Sage Counter-Counter
Newton, Ray 2021-04-13	169	23	169	24	e.g., pp. 162-164, 169, 186	Sage Counter-Counter
Newton, Ray 2021-04-13	170	1	170	1	e.g., pp. 162-164, 169, 186	Sage Counter-Counter
Newton, Ray 2021-04-13	170	22	170	23	e.g., pp. 162-164, 169, 186	Sage Counter-Counter
Newton, Ray 2021-04-13	170	25	170	25	e.g., pp. 162-164, 169, 186	Sage Counter-Counter
Newton, Ray 2021-04-13	171	3	171	7	e.g., pp. 162-164, 169, 186	Sage Counter-Counter
Newton, Ray 2021-04-13	185	23	185	25	e.g., pp. 162-164, 169	Sage Counter-Counter
Newton, Ray 2021-04-13	186	2	186	3	e.g., pp. 162-164, 169	Sage Counter-Counter
Newton, Ray 2021-04-13	188	6	188	8	e.g., pp. 162-164, 169	Sage Counter-Counter
Newton, Ray 2021-04-13	188	10	188	12	e.g., pp. 162-164, 169	Sage Counter-Counter
Newton, Ray 2021-04-13	190	11	190	12	e.g., pp. 184, 186	Sage Counter-Counter
Newton, Ray 2021-04-13	190	22	191	2	e.g., pp. 184, 186	Sage Counter-Counter
Newton, Ray 2021-04-13	206	3	206	3	pp. 205-206	Sage Counter-Counter
Newton, Ray 2021-04-13	206	5	206	7	pp. 205-206	Sage Counter-Counter
Newton, Ray 2021-04-13	206	9	206	12	pp. 205-206	Sage Counter-Counter
Newton, Ray 2021-04-13	206	13	206	14	pp. 205-206	Sage Counter-Counter
Newton, Ray 2021-04-13	206	16	206	19	pp. 205-206	Sage Counter-Counter
Newton, Ray 2021-04-13	243	11	243	13	p. 244	Sage Counter-Counter
Newton, Ray 2021-04-13	244	16	244	17	p. 244	Sage Counter-Counter
Newton, Ray 2021-04-13	249	18	249	20	e.g., 244, 250	Sage Counter-Counter
Newton, Ray 2021-04-13	249	23	249	24	e.g., 244, 250	Sage Counter-Counter
Newton, Ray 2021-04-13	253	8	253	9	pp. 252-253	Sage Counter-Counter
Newton, Ray 2021-04-13	253	11	253	13	pp. 252-253	Sage Counter-Counter
Newton, Ray 2021-04-13	253	15	253	17	pp. 252-253	Sage Counter-Counter
Newton, Ray 2021-04-13	256	8	256	9	pp. 254-256	Sage Counter-Counter

Newton, Ray 2021-04-13	256	12	256	12	pp. 254-256	Sage Counter-Counter
------------------------	-----	----	-----	----	-------------	----------------------

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues
Newton, Ray 2023-05-03	9	11	9	12	e.g., p. 208, 209-210, Trial Tr.; **Many of Sage's counterdesignations are applicable to numerous PureWick designations across multiple witnesses and topic areas. Identification of page numbers are exemplary.	Sage Counter-Counter
Newton, Ray 2023-05-03	14	18	15	5	e.g., 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter
Newton, Ray 2023-05-03	15	6	15	21	e.g., 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter
Newton, Ray 2023-05-03	17	1	17	7	e.g., 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter
Newton, Ray 2023-05-03	21	22	22	6	e.g., 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter
Newton, Ray 2023-05-03	26	24	27	3	e.g., 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter
Newton, Ray 2023-05-03	29	23	30	2	e.g., 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter
Newton, Ray 2023-05-03	32	12	32	14	e.g., 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter
Newton, Ray 2023-05-03	33	3	33	6	e.g., 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter
Newton, Ray 2023-05-03	37	2	37	5	e.g., 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter
Newton, Ray 2023-05-03	37	9	37	10	e.g., 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter
Newton, Ray 2023-05-03	40	1	40	7	pp. 39-40	Sage Counter-Counter
Newton, Ray 2023-05-03	41	4	41	7	pp. 39-40	Sage Counter-Counter
Newton, Ray 2023-05-03	41	8	41	9	pp. 39-40	Sage Counter-Counter
Newton, Ray 2023-05-03	41	13	41	15	pp. 39-40	Sage Counter-Counter
Newton, Ray 2023-05-03	44	3	44	7	e.g., pp. 39-40, 68-69, 138	Sage Counter-Counter
Newton, Ray 2023-05-03	45	6	45	7	e.g., pp. 49-40, 68-69, 138	Sage Counter-Counter
Newton, Ray 2023-05-03	45	8	45	11	e.g., pp. 49-40, 68-69, 138	Sage Counter-Counter
Newton, Ray 2023-05-03	45	12	45	13	e.g., pp. 49-40, 68-69, 138	Sage Counter-Counter
Newton, Ray 2023-05-03	46	11	46	13	e.g., pp. 49-40, 68-69, 138	Sage Counter-Counter
Newton, Ray 2023-05-03	48	7	48	12	e.g., pp. 49-40, 68-69, 138	Sage Counter-Counter
Newton, Ray 2023-05-03	50	2	50	6	e.g., pp. 49-40, 68-69, 138	Sage Counter-Counter
Newton, Ray 2023-05-03	52	1	52	3	e.g., p. 53	Sage Counter-Counter
Newton, Ray 2023-05-03	53	4	53	4	e.g., p. 53	Sage Counter-Counter
Newton, Ray 2023-05-03	54	6	54	8	e.g., p. 53, 55-56	Sage Counter-Counter
Newton, Ray 2023-05-03	54	11	54	12	e.g., p. 53, 55-56	Sage Counter-Counter
Newton, Ray 2023-05-03	54	14	54	17	e.g., p. 53, 55-56	Sage Counter-Counter
Newton, Ray 2023-05-03	54	18	54	20	e.g., p. 53, 55-56	Sage Counter-Counter
Newton, Ray 2023-05-03	54	23	55	2	e.g., p. 53, 55-56	Sage Counter-Counter
Newton, Ray 2023-05-03	65	18	65	20	e.g., pp. 53, 55-56, 153, 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	66	24	67	2	e.g., pp. 53, 55-56, 153, 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	67	8	67	11	e.g., pp. 53, 55-56, 153, 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	67	14	67	14	e.g., pp. 53, 55-56, 153, 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	71	1	71	3	e.g., pp. 68-69, 138	Sage Counter-Counter
Newton, Ray 2023-05-03	72	22	72	24	e.g., pp. 68-69, 138	Sage Counter-Counter
Newton, Ray 2023-05-03	73	5	73	5	e.g., pp. 68-69, 138	Sage Counter-Counter
Newton, Ray 2023-05-03	74	12	74	14	e.g., pp. 68-69, 138	Sage Counter-Counter



Newton, Ray 2023-05-03	74	17	74	17	e.g., pp. 68-69, 138	Sage Counter-Counter
Newton, Ray 2023-05-03	76	7	76	9	e.g., pp. 68-69, 138	Sage Counter-Counter
Newton, Ray 2023-05-03	81	15	82	3	pp. 80-81	Sage Counter-Counter
Newton, Ray 2023-05-03	82	4	82	6	pp. 80-81	Sage Counter-Counter
Newton, Ray 2023-05-03	82	10	82	16	pp. 80-81	Sage Counter-Counter
Newton, Ray 2023-05-03	82	18	82	21	pp. 80-81	Sage Counter-Counter
Newton, Ray 2023-05-03	83	1	83	18	pp. 80-81	Sage Counter-Counter
Newton, Ray 2023-05-03	88	19	88	21	e.g., pp. 80-81, 68-69, 138	Sage Counter-Counter
Newton, Ray 2023-05-03	89	23	90	1	e.g., pp. 80-81, 68-69, 138	Sage Counter-Counter
Newton, Ray 2023-05-03	98	22	99	1	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter
Newton, Ray 2023-05-03	99	5	99	5	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter
Newton, Ray 2023-05-03	104	3	104	12	e.g. pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter
Newton, Ray 2023-05-03	105	15	105	17	e.g. pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter
Newton, Ray 2023-05-03	105	22	105	24	e.g. pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter
Newton, Ray 2023-05-03	109	1	109	4	e.g. pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter
Newton, Ray 2023-05-03	109	12	109	16	e.g. pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter
Newton, Ray 2023-05-03	112	4	112	7	e.g. pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter
Newton, Ray 2023-05-03	112	21	112	23	e.g. pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter
Newton, Ray 2023-05-03	113	2	113	2	e.g. pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter
Newton, Ray 2023-05-03	113	9	113	17	e.g. pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter
Newton, Ray 2023-05-03	114	22	115	4	e.g., p. 114	Sage Counter-Counter
Newton, Ray 2023-05-03	115	8	115	10	e.g., p. 114	Sage Counter-Counter
Newton, Ray 2023-05-03	116	10	116	11	e.g. pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter
Newton, Ray 2023-05-03	116	15	116	20	e.g. pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter
Newton, Ray 2023-05-03	116	23	116	23	e.g. pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter
Newton, Ray 2023-05-03	117	2	117	2	e.g. pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter
Newton, Ray 2023-05-03	117	3	117	6	e.g. pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter
Newton, Ray 2023-05-03	117	9	117	9	e.g. pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter
Newton, Ray 2023-05-03	123	23	124	2	e.g., pp. 68-69, 138	Sage Counter-Counter
Newton, Ray 2023-05-03	124	6	124	7	e.g., pp. 68-69, 138	Sage Counter-Counter
Newton, Ray 2023-05-03	124	13	124	13	e.g., pp. 68-69, 138	Sage Counter-Counter
Newton, Ray 2023-05-03	125	1	125	5	e.g., pp. 68-69, 138	Sage Counter-Counter
Newton, Ray 2023-05-03	125	9	125	9	e.g., pp. 68-69, 138	Sage Counter-Counter
Newton, Ray 2023-05-03	126	1	126	3	e.g., pp. 68-69, 138	Sage Counter-Counter
Newton, Ray 2023-05-03	126	9	126	9	e.g., pp. 68-69, 138	Sage Counter-Counter
Newton, Ray 2023-05-03	128	20	128	24	e.g., pp. 68-69, 138	Sage Counter-Counter
Newton, Ray 2023-05-03	130	21	131	2	e.g., pp. 68-69, 138	Sage Counter-Counter
Newton, Ray 2023-05-03	134	4	134	6	e.g., p. 134	Sage Counter-Counter
Newton, Ray 2023-05-03	139	15	139	16	e.g., 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter
Newton, Ray 2023-05-03	139	19	139	20	e.g., 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter
Newton, Ray 2023-05-03	150	3	150	14	e.g., p. 149	Sage Counter-Counter

Newton, Ray 2023-05-03	150	15	150	16	e.g., p. 149	Sage Counter-Counter
Newton, Ray 2023-05-03	150	20	150	20	e.g., p. 149	Sage Counter-Counter
Newton, Ray 2023-05-03	162	1	162	6	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	162	10	162	11	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	162	13	162	18	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	162	22	162	22	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	163	9	163	10	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	163	13	163	18	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	164	11	164	12	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	164	15	164	15	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	167	5	167	12	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	167	16	167	17	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	167	23	168	1	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	168	5	168	5	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	169	1	169	4	incomplete	Sage Counter-Counter
Newton, Ray 2023-05-03	170	13	170	16	e.g., p. 170	Sage Counter-Counter
Newton, Ray 2023-05-03	170	21	171	1	e.g., p. 170	Sage Counter-Counter
Newton, Ray 2023-05-03	172	10	172	16	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	172	20	173	11	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	173	15	173	15	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	174	3	174	9	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	175	6	175	7	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	175	10	175	10	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	175	12	175	16	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	175	17	175	18	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	175	22	175	23	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	179	6	179	8	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	181	5	181	9	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	181	10	181	11	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	181	16	181	19	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	182	12	182	24	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	183	1	183	12	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	183	13	183	21	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	184	1	184	1	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	184	12	184	20	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	184	21	184	22	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	185	12	185	12	e.g., pp. 155-156, 170	Sage Counter-Counter
Newton, Ray 2023-05-03	187	19	188	2	e.g., pp. 155-156, 170, 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter
Newton, Ray 2023-05-03	188	7	188	8	e.g., pp. 155-156, 170, 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter
Newton, Ray 2023-05-03	188	12	188	13	e.g., pp. 155-156, 170, 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter
Newton, Ray 2023-05-03	189	1	189	3	e.g., pp. 155-156, 170, 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter
Newton, Ray 2023-05-03	190	7	190	12	e.g., pp. 155-156, 170, 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter
Newton, Ray 2023-05-03	190	16	190	17	e.g., pp. 155-156, 170, 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter
Newton, Ray 2023-05-03	195	21	195	22	e.g., p. 198	Sage Counter-Counter
Newton, Ray 2023-05-03	196	2	196	4	e.g., p. 198	Sage Counter-Counter
Newton, Ray 2023-05-03	196	6	196	7	e.g., p. 198	Sage Counter-Counter
Newton, Ray 2023-05-03	198	19	198	20	e.g., pp. 196-198	Sage Counter-Counter
Newton, Ray 2023-05-03	199	1	199	3	e.g., pp. 196-198	Sage Counter-Counter

Newton, Ray 2023-05-03	199	7	199	15	e.g., pp. 196-198	Sage Counter-Counter
Newton, Ray 2023-05-03	200	8	200	9	e.g., pp. 196-198	Sage Counter-Counter
Newton, Ray 2023-05-03	201	3	201	5	e.g., pp. 196-198	Sage Counter-Counter
Newton, Ray 2023-05-03	201	9	201	15	e.g., pp. 196-198	Sage Counter-Counter
Newton, Ray 2023-05-03	201	24	202	2	e.g., pp. 196-198	Sage Counter-Counter
Newton, Ray 2023-05-03	202	6	202	9	e.g., pp. 196-198	Sage Counter-Counter
Newton, Ray 2023-05-03	212	8	212	9	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter
Newton, Ray 2023-05-03	212	21	212	23	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter
Newton, Ray 2023-05-03	216	22	217	1	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter
Newton, Ray 2023-05-03	217	4	217	7	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter
Newton, Ray 2023-05-03	217	11	217	12	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter
Newton, Ray 2023-05-03	218	15	218	17	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter
Newton, Ray 2023-05-03	218	20	218	22	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter
Newton, Ray 2023-05-03	218	24	219	4	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter
Newton, Ray 2023-05-03	219	8	219	10	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter
Newton, Ray 2023-05-03	220	1	220	5	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter
Newton, Ray 2023-05-03	220	10	220	16	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter
Newton, Ray 2023-05-03	224	11	224	20	e.g., pp. 208, 209, 210	Sage Counter-Counter
Newton, Ray 2023-05-03	226	21	227	5	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter
Newton, Ray 2023-05-03	227	8	227	8	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues
Pawlik, Kate 2023-03-17	62	18	62	20	62:9-11	Sage Counter-Counter
Pawlik, Kate 2023-03-17	62	23	62	23	62:9-11	Sage Counter-Counter
Pawlik, Kate 2023-03-17	73	7	73	12	72-73	Sage Counter-Counter
Pawlik, Kate 2023-03-17	118	19	118	21	118	Sage Counter-Counter
Pawlik, Kate 2023-03-17	132	7	132	10	132	Sage Counter-Counter
Pawlik, Kate 2023-03-17	158	20	159	1	158	Sage Counter-Counter
Pawlik, Kate 2023-03-17	228	2	228	2		Sage Counter-Counter

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues
Shaw, Laura 2021-04-13	29	20	29	22		Sage Counter-Counter
Shaw, Laura 2021-04-13	31	10	31	11	31	Sage Counter-Counter
Shaw, Laura 2021-04-13	31	14	31	15	31	Sage Counter-Counter

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues
Simon, Marcus 2021-03-03	73	3	73	7	Counter-counter to p. 72	Sage Counter-Counter
Simon, Marcus 2021-03-03	73	9	73	10	Counter-counter to p. 72	Sage Counter-Counter

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues
Skelton, Sarah 2023-01-18	81	18	81	22	Counter-counter to p. 81	Sage Counter-Counter
Skelton, Sarah 2023-01-18	82	1	82	2	Counter-counter to p. 81	Sage Counter-Counter
Skelton, Sarah 2023-01-18	82	4	82	6	Counter-counter to p. 81	Sage Counter-Counter
Skelton, Sarah 2023-01-18	82	8	82	9	Counter-counter to p. 81	Sage Counter-Counter

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues
Zani, Paul 2021-03-23	39	4	39	14	38:20-39:3	Sage Counter-Counter
Zani, Paul 2021-03-23	49	9	49	11	48:3-49:2	Sage Counter-Counter
Zani, Paul 2021-03-23	49	20	49	24	50:16-17	Sage Counter-Counter
Zani, Paul 2021-03-23	75	16	75	23	75:10-15	Sage Counter-Counter
Zani, Paul 2021-03-23	132	7	132	9	131:21-132:6	Sage Counter-Counter
Zani, Paul 2021-03-23	132	12	132	13	131:21-132:6	Sage Counter-Counter
Zani, Paul 2021-03-23	183	11	183	13	182:1-183:1; 183:6-10	Sage Counter-Counter
Zani, Paul 2021-03-23	183	15	183	16	182:1-183:1; 183:6-10	Sage Counter-Counter



# **Schedule E4e**

PureWick's Objections to Sage's Counter-counter Designations

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
Bobay, Jason 2021-04-23	153	15	153	20	153-154, 168	Sage Counter-Counter	BSD, 402, 403, H, F

<b>Transcript</b>	<b>PgFrom</b>	<b>LnFrom</b>	<b>PgTo</b>	<b>LnTo</b>	<b>E.g., PureWick Counter</b>	<b>Issues</b>	<b>PureWick Objections</b>
Burn, Brian 2021-04-02	16	2	16	4	15	Sage Counter-Counter	BSD, 402, 403, H, F
Burn, Brian 2021-04-02	22	19	22	22	20	Sage Counter-Counter	BSD, 402, 403, H, F
Burn, Brian 2021-04-02	82	21	82	21	82	Sage Counter-Counter	BSD, 402, 403, H, F
Burn, Brian 2021-04-02	117	21	118	5	117	Sage Counter-Counter	BSD, 402, 403, H, F

<b>Transcript</b>	<b>PgFrom</b>	<b>LnFrom</b>	<b>PgTo</b>	<b>LnTo</b>	<b>E.g., PureWick Counter</b>	<b>Issues</b>	<b>PureWick Objections</b>
Burn, Brian 2023-03-23	126	14	126	18	125-126	Sage Counter-Counter	BSD, 402, 403, H, F
Burn, Brian 2023-03-23	126	19	127	6	125-126	Sage Counter-Counter	BSD, 402, 403, H, F
Burn, Brian 2023-03-23	127	7	127	11	125-126	Sage Counter-Counter	BSD, 402, 403, H, F

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
Dy, Ruby 2021-04-14	34	20	34	21	p. 35	Sage Counter-Counter	BSD, 402, 403, H, F
Dy, Ruby 2021-04-14	35	24	36	2	p. 36	Sage Counter-Counter	BSD, 402, 403, H, F
Dy, Ruby 2021-04-14	36	5	36	10	p. 36	Sage Counter-Counter	BSD, 402, 403, H, F

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
Eckert, Lorena 2023-03-14	36	24	37	4	p. 37	Sage Counter-Counter	BSD, 402, 403, H, F
Eckert, Lorena 2023-03-14	43	22	44	1	p. 43	Sage Counter-Counter	BSD, 402, 403, H, F
Eckert, Lorena 2023-03-14	44	2	44	5	p. 37	Sage Counter-Counter	BSD, 402, 403, H, F
Eckert, Lorena 2023-03-14	44	9	46	9	p. 37	Sage Counter-Counter	BSD, 402, 403, H, F
Eckert, Lorena 2023-03-14	74	8	74	10		Sage Counter-Counter	BSD, 402, 403, H, F
Eckert, Lorena 2023-03-14	74	13	74	15		Sage Counter-Counter	BSD, 402, 403, H, F
Eckert, Lorena 2023-03-14	76	18	76	19	pp. 76-77	Sage Counter-Counter	BSD, 402, 403, H, F
Eckert, Lorena 2023-03-14	76	22	76	24	pp. 76-77	Sage Counter-Counter	BSD, 402, 403, H, F
Eckert, Lorena 2023-03-14	77	3	77	8	pp. 76-77	Sage Counter-Counter	BSD, 402, 403, H, F
Eckert, Lorena 2023-03-14	79	13	79	16	pp. 82-83	Sage Counter-Counter	BSD, 402, 403, H, F
Eckert, Lorena 2023-03-14	79	20	79	22	pp. 82-83	Sage Counter-Counter	BSD, 402, 403, H, F
Eckert, Lorena 2023-03-14	81	11	81	13	pp. 82-83	Sage Counter-Counter	BSD, 402, 403, H, F
Eckert, Lorena 2023-03-14	81	16	81	19	pp. 82-83	Sage Counter-Counter	BSD, 402, 403, H, F
Eckert, Lorena 2023-03-14	83	10	83	13	pp. 82-83	Sage Counter-Counter	BSD, 402, 403, H, F
Eckert, Lorena 2023-03-14	83	16	83	18	pp. 82-83	Sage Counter-Counter	BSD, 402, 403, H, F
Eckert, Lorena 2023-03-14	83	19	84	3	pp. 82-83	Sage Counter-Counter	BSD, 402, 403, H, F

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
Forehand, Joseph 2021-03-24	82	10	82	11	82	Sage Counter-Counter	BSD, 402, 403, H, F

<b>Transcript</b>	<b>PgFrom</b>	<b>LnFrom</b>	<b>PgTo</b>	<b>LnTo</b>	<b>E.g., PureWick Counter</b>	<b>Issues</b>	<b>PureWick Objections</b>
Gohde, John 2021-03-26	37	18	38	9	36:1-37:2	Sage Counter-Counter	BSD, 402, 403, H, F
Gohde, John 2021-03-26	47	9	47	16	47:20-22	Sage Counter-Counter	BSD, 402, 403, H, F
Gohde, John 2021-03-26	62	15	63	1	63:2-13	Sage Counter-Counter	BSD, 402, 403, H, F



<b>Transcript</b>	<b>PgFrom</b>	<b>LnFrom</b>	<b>PgTo</b>	<b>LnTo</b>	<b>E.g., PureWick Counter</b>	<b>Issues</b>	<b>PureWick Objections</b>
Hanson, Robin 2023-11-06	53	14	53	18	53:12-13	Sage Counter-Counter	BSD, 402, 403, H, F
Hanson, Robin 2023-11-06	81	24	82	14	80:4-10	Sage Counter-Counter	BSD, 402, 403, H, F
Hanson, Robin 2023-11-06	88	19	88	20	88:13-18	Sage Counter-Counter	BSD, 402, 403, H, F
Hanson, Robin 2023-11-06	95	6	95	18	92:23-93:5	Sage Counter-Counter	BSD, 402, 403, H, F
Hanson, Robin 2023-11-06	129	8	129	17		Sage Counter-Counter	BSD, 402, 403, H, F

<b>Transcript</b>	<b>PgFrom</b>	<b>LnFrom</b>	<b>PgTo</b>	<b>LnTo</b>	<b>E.g., PureWick Counter</b>	<b>Issues</b>	<b>PureWick Objections</b>
Jackson, Michael 2023-03-16	22	9	22	11	21:25-22:7	Sage Counter-Counter	BSD, 402, 403, H, F
Jackson, Michael 2023-03-16	22	13	22	13	21:25-22:7	Sage Counter-Counter	BSD, 402, 403, H, F

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
Mann, Gregory 2021-03-31	35	2	35	7	contingent	Sage Counter-Counter	BSD, 402, 403, H, F

<b>Transcript</b>	<b>PgFrom</b>	<b>LnFrom</b>	<b>PgTo</b>	<b>LnTo</b>	<b>E.g., PureWick Counter</b>	<b>Issues</b>	<b>PureWick Objections</b>
Mann, Gregory 2023-02-16	60	9	60	9	p. 60	Sage Counter-Counter	BSD, 402, 403, H, F
Mann, Gregory 2023-02-16	60	11	60	11	p. 60	Sage Counter-Counter	BSD, 402, 403, H, F

<b>Transcript</b>	<b>PgFrom</b>	<b>LnFrom</b>	<b>PgTo</b>	<b>LnTo</b>	<b>E.g., PureWick Counter</b>	<b>Issues</b>	<b>PureWick Objections</b>
Morgan, Richard 2023-02-10	46	20	46	20	46:18-19; 46:22-24	Sage Counter-Counter	BSD, 402, 403, H, F
Morgan, Richard 2023-02-10	50	11	50	11	5:12	Sage Counter-Counter	BSD, 402, 403, H, F
Morgan, Richard 2023-02-10	53	11	53	11	53:6-10	Sage Counter-Counter	BSD, 402, 403, H, F
Morgan, Richard 2023-02-10	76	10	76	22	77:6-11	Sage Counter-Counter	BSD, 402, 403, H, F
Morgan, Richard 2023-02-10	133	11	133	11	133:4-10	Sage Counter-Counter	BSD, 402, 403, H, F
Morgan, Richard 2023-02-10	134	17	134	18	134:13-15	Sage Counter-Counter	BSD, 402, 403, H, F
Morgan, Richard 2023-02-10	134	21	135	3	134:13-15	Sage Counter-Counter	BSD, 402, 403, H, F

<b>Transcript</b>	<b>PgFrom</b>	<b>LnFrom</b>	<b>PgTo</b>	<b>LnTo</b>	<b>E.g., PureWick Counter</b>	<b>Issues</b>	<b>PureWick Objections</b>
19-1508 - Vol 01, Newton, Camille	225	20	226	1	e.g., p. 225	Sage Counter-Counter	BSD, 402, 403, H, F
19-1508 - Vol 01, Newton, Camille	228	4	228	10	e.g. p. 231	Sage Counter-Counter	BSD, 402, 403, H, F
19-1508 - Vol 01, Newton, Camille	229	4	229	9	e.g., p. 231	Sage Counter-Counter	BSD, 402, 403, H, F
19-1508 - Vol 01, Newton, Camille	231	17	231	19	p. 231	Sage Counter-Counter	BSD, 402, 403, H, F
19-1508 - Vol 01, Newton, Camille	233	21	234	19	p. 233	Sage Counter-Counter	BSD, 402, 403, H, F
19-1508 - Vol 01, Newton, Camille	237	18	238	9	p. 237-238	Sage Counter-Counter	BSD, 402, 403, H, F
19-1508 - Vol 01, Newton, Camille	239	19	239	24	p. 239	Sage Counter-Counter	BSD, 402, 403, H, F
19-1508 - Vol 01, Newton, Camille	241	12	241	20	p. 240	Sage Counter-Counter	BSD, 402, 403, H, F

<b>Transcript</b>	<b>PgFrom</b>	<b>LnFrom</b>	<b>PgTo</b>	<b>LnTo</b>	<b>E.g., PureWick Counter</b>	<b>Issues</b>	<b>PureWick Objections</b>
19-1508 - Vol 02, Newton, Camille	257	13	257	15	e.g., pp. 231, 237, 249, 261, 264; contingent	Sage Counter-Counter	BSD, 402, 403, H, F
19-1508 - Vol 02, Newton, Camille	257	16	257	19	e.g., pp. 231, 237, 249, 261, 264; contingent	Sage Counter-Counter	BSD, 402, 403, H, F
19-1508 - Vol 02, Newton, Camille	266	7	266	13	e.g., pp 268-269; Dep. Tr.; contingent	Sage Counter-Counter	BSD, 402, 403, H, F
19-1508 - Vol 02, Newton, Camille	266	14	266	24	e.g., pp 268-269; Dep. Tr.; contingent	Sage Counter-Counter	BSD, 402, 403, H, F

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
Newton, Camille 2021-04-15	51	7	51	8	51:9-12	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Camille 2021-04-15	68	5	68	13	pp. 67-68	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Camille 2021-04-15	71	16	71	17	pp. 71	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Camille 2021-04-15	71	19	71	24	p. 71	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Camille 2021-04-15	72	2	72	3	p. 71	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Camille 2021-04-15	86	4	86	4	pp. 84-85	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Camille 2021-04-15	86	6	86	6	pp. 84-85	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Camille 2021-04-15	119	10	119	12	pp. 118-119	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Camille 2021-04-15	119	15	120	1	pp. 118-119	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Camille 2021-04-15	120	5	120	11	pp. 118-119	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Camille 2021-04-15	120	14	120	23	pp. 118-119	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Camille 2021-04-15	189	20	189	25	e.g., p. 189	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Camille 2021-04-15	209	16	209	18	p. 209 contingent	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Camille 2021-04-15	210	5	211	2	e.g., p. 209 contingent	Sage Counter-Counter	BSD, 402, 403, H, F



Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
19-1508 - Vol 02, Newton, Raymond	288	11	288	16	p. 288; **Many of Sage's counterdesignations are applicable to numerous PureWick designations across multiple witnesses and topic areas. Identification of page numbers are exemplary.	Sage Counter-Counter	BSD, 402, 403, H, F
19-1508 - Vol 02, Newton, Raymond	300	24	301	1	e.g., pp. 288-302	Sage Counter-Counter	BSD, 402, 403, H, F
19-1508 - Vol 02, Newton, Raymond	301	11	302	1	e.g., pp. 288-302	Sage Counter-Counter	BSD, 402, 403, H, F
19-1508 - Vol 02, Newton, Raymond	313	3	314	23	e.g., 319, 321-322; 288, 291, 293, 297-299, 302-304	Sage Counter-Counter	BSD, 402, 403, H, F
19-1508 - Vol 02, Newton, Raymond	314	24	315	12	e.g., pp. 288-302	Sage Counter-Counter	BSD, 402, 403, H, F
19-1508 - Vol 02, Newton, Raymond	315	13	315	16	e.g., pp. 289-299	Sage Counter-Counter	BSD, 402, 403, H, F
19-1508 - Vol 02, Newton, Raymond	319	23	320	11	e.g., pp. 319, 321-322	Sage Counter-Counter	BSD, 402, 403, H, F

<b>Transcript</b>	<b>PgFrom</b>	<b>LnFrom</b>	<b>PgTo</b>	<b>LnTo</b>	<b>E.g., PureWick Counter</b>	<b>Issues</b>	<b>PureWick Objections</b>
19-1508 - Vol 02, Newton, Raymond	320	12	320	25	e.g., pp. 288, 291, 293, 297-299, 302-304; R. Newton Dep Counters	Sage Counter-Counter	BSD, 402, 403, H, F
19-1508 - Vol 02, Newton, Raymond	322	17	323	10	e.g., pp. 322-323; R. Newton Dep. Counters	Sage Counter-Counter	BSD, 402, 403, H, F
19-1508 - Vol 02, Newton, Raymond	323	16	324	9	e.g., pp. 288-302	Sage Counter-Counter	BSD, 402, 403, H, F

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
Newton, Ray 2021-04-13	34	18	34	19	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207; **Many of Sage's counterdesignations are applicable to numerous PureWick designations across multiple witnesses and topic areas. Identification of page numbers are exemplary.	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	34	21	34	23	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	34	25	35	2	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	35	8	35	9	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	35	11	35	12	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	35	14	35	15	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	39	11	39	13	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter	BSD, 402, 403, H, F

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
Newton, Ray 2021-04-13	40	17	40	20	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	40	22	40	23	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	46	14	46	15	e.g., p. 45	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	54	1	54	2	e.g., p. 45	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	54	5	54	13	e.g., p. 45	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	54	16	54	21	e.g., p. 45	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	54	22	54	25	e.g., p. 45	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	60	12	60	25	e.g., pp. 59, 72	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	61	10	62	3	e.g., p. 72	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	62	7	62	19	e.g., p. 72	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	62	21	63	10	e.g., p. 72	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	63	20	63	21	e.g., p. 72	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	63	23	63	25	e.g., p. 72	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	64	2	64	10	e.g., p. 72	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	64	24	65	11	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter	BSD, 402, 403, H, F

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
Newton, Ray 2021-04-13	68	4	68	11	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	69	14	69	16	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	69	18	69	20	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	69	22	69	24	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	70	1	70	2	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	70	4	70	7	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	70	21	70	23	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	70	25	71	1	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	73	5	73	8	e.g., p. 72	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	75	10	75	17	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	76	14	76	21	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	77	5	77	11	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter	BSD, 402, 403, H, F

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
Newton, Ray 2021-04-13	77	17	77	18	e.g., pp. 45, 50, 50, 72, 79-80, 199, 205-207	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	80	22	80	23	e.g., pp. 79-80	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	80	25	81	6	e.g., pp. 79-80	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	82	15	82	17	e.g., pp. 80-81	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	82	21	82	23	e.g., pp. 80-81	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	82	25	83	20	e.g., pp. 80-81	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	83	21	84	1	e.g., pp. 80-81	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	92	3	96	1	e.g., pp. 98, 45, 50, 50, 72, 79-80, 122, 199, 205-207	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	119	5	119	9	e.g., pp. 98, 45, 50, 50, 72, 79-80, 122, 199, 205-207	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	119	10	119	13	e.g., pp. 98, 45, 50, 50, 72, 79-80, 122, 199, 205-207	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	119	16	119	20	e.g., pp. 98, 45, 50, 50, 72, 79-80, 122, 199, 205-207	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	120	7	120	12	e.g., p. 122	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	122	15	122	16	e.g., p. 122	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	122	19	122	22	e.g., p. 122	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	124	1	124	14	e.g., p. 122	Sage Counter-Counter	BSD, 402, 403, H, F

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
Newton, Ray 2021-04-13	137	16	137	18	e.g., p. 137	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	137	22	138	1	e.g., p. 137	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	138	3	138	4	e.g., pp. 138-139	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	138	7	138	8	e.g., pp. 137, 138-139	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	138	10	138	15	e.g., pp. 137, 138-139	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	138	18	138	21	e.g., pp. 137, 138-139	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	140	20	140	25	p. 141	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	159	1	159	18	e.g., p. 147; initial	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	161	2	161	6	e.g., p. 244, 250, 254, 255	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	162	3	162	4	e.g., pp. 162-164, 169, 186	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	162	7	162	9	e.g., pp. 162-164, 169, 186	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	162	12	162	15	e.g., pp. 162-164, 169, 186	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	162	17	162	19	e.g., pp. 162-164, 169, 186	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	163	12	163	14	e.g., pp. 162-164, 169, 186	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	163	17	163	21	e.g., pp. 162-164, 169, 186	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	164	17	164	24	e.g., pp. 162-164, 169, 186	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	165	22	166	5	e.g., pp. 162-164, 169, 186	Sage Counter-Counter	BSD, 402, 403, H, F

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
Newton, Ray 2021-04-13	166	20	167	3	e.g., pp. 162-164, 169, 186	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	169	23	169	24	e.g., pp. 162-164, 169, 186	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	170	1	170	1	e.g., pp. 162-164, 169, 186	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	170	22	170	23	e.g., pp. 162-164, 169, 186	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	170	25	170	25	e.g., pp. 162-164, 169, 186	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	171	3	171	7	e.g., pp. 162-164, 169, 186	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	185	23	185	25	e.g., pp. 162-164, 169	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	186	2	186	3	e.g., pp. 162-164, 169	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	188	6	188	8	e.g., pp. 162-164, 169	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	188	10	188	12	e.g., pp. 162-164, 169	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	190	11	190	12	e.g., pp. 184, 186	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	190	22	191	2	e.g., pp. 184, 186	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	206	3	206	3	pp. 205-206	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	206	5	206	7	pp. 205-206	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	206	9	206	12	pp. 205-206	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	206	13	206	14	pp. 205-206	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	206	16	206	19	pp. 205-206	Sage Counter-Counter	BSD, 402, 403, H, F



<b>Transcript</b>	<b>PgFrom</b>	<b>LnFrom</b>	<b>PgTo</b>	<b>LnTo</b>	<b>E.g., PureWick Counter</b>	<b>Issues</b>	<b>PureWick Objections</b>
Newton, Ray 2021-04-13	243	11	243	13	p. 244	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	244	16	244	17	p. 244	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	249	18	249	20	e.g., 244, 250	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	249	23	249	24	e.g., 244, 250	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	253	8	253	9	pp. 252-253	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	253	11	253	13	pp. 252-253	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	253	15	253	17	pp. 252-253	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	256	8	256	9	pp. 254-256	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2021-04-13	256	12	256	12	pp. 254-256	Sage Counter-Counter	BSD, 402, 403, H, F

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
Newton, Ray 2023-05-03	9	11	9	12	e.g., p. 208, 209-210, Trial Tr.; **Many of Sage's counterdesignations are applicable to numerous PureWick designations across multiple witnesses and topic areas. Identification of page numbers are exemplary.	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	14	18	15	5	e.g., 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	15	6	15	21	e.g., 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	17	1	17	7	e.g., 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	21	22	22	6	e.g., 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	26	24	27	3	e.g., 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	29	23	30	2	e.g., 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter	BSD, 402, 403, H, F

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
Newton, Ray 2023-05-03	32	12	32	14	e.g., 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	33	3	33	6	e.g., 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	37	2	37	5	e.g., 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	37	9	37	10	e.g., 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	40	1	40	7	pp. 39-40	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	41	4	41	7	pp. 39-40	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	41	8	41	9	pp. 39-40	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	41	13	41	15	pp. 39-40	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	44	3	44	7	e.g., pp. 39-40, 68-69, 138	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	45	6	45	7	e.g., pp. 49-40, 68-69, 138	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	45	8	45	11	e.g., pp. 49-40, 68-69, 138	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	45	12	45	13	e.g., pp. 49-40, 68-69, 138	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	46	11	46	13	e.g., pp. 49-40, 68-69, 138	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	48	7	48	12	e.g., pp. 49-40, 68-69, 138	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	50	2	50	6	e.g., pp. 49-40, 68-69, 138	Sage Counter-Counter	BSD, 402, 403, H, F

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
Newton, Ray 2023-05-03	52	1	52	3	e.g., p. 53	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	53	4	53	4	e.g., p. 53	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	54	6	54	8	e.g., p. 53, 55-56	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	54	11	54	12	e.g., p. 53, 55-56	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	54	14	54	17	e.g., p. 53, 55-56	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	54	18	54	20	e.g., p. 53, 55-56	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	54	23	55	2	e.g., p. 53, 55-56	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	65	18	65	20	e.g., pp. 53, 55-56, 153, 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	66	24	67	2	e.g., pp. 53, 55-56, 153, 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	67	8	67	11	e.g., pp. 53, 55-56, 153, 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	67	14	67	14	e.g., pp. 53, 55-56, 153, 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	71	1	71	3	e.g., pp. 68-69, 138	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	72	22	72	24	e.g., pp. 68-69, 138	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	73	5	73	5	e.g., pp. 68-69, 138	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	74	12	74	14	e.g., pp. 68-69, 138	Sage Counter-Counter	BSD, 402, 403, H, F

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
Newton, Ray 2023-05-03	74	17	74	17	e.g., pp. 68-69, 138	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	76	7	76	9	e.g., pp. 68-69, 138	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	81	15	82	3	pp. 80-81	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	82	4	82	6	pp. 80-81	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	82	10	82	16	pp. 80-81	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	82	18	82	21	pp. 80-81	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	83	1	83	18	pp. 80-81	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	88	19	88	21	e.g., pp. 80-81, 68-69, 138	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	89	23	90	1	e.g., pp. 80-81, 68-69, 138	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	98	22	99	1	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	99	5	99	5	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	104	3	104	12	e.g., pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	105	15	105	17	e.g., pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	105	22	105	24	e.g., pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	109	1	109	4	e.g., pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter	BSD, 402, 403, H, F

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
Newton, Ray 2023-05-03	109	12	109	16	e.g. pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	112	4	112	7	e.g. pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	112	21	112	23	e.g. pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	113	2	113	2	e.g. pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	113	9	113	17	e.g. pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	114	22	115	4	e.g., p. 114	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	115	8	115	10	e.g., p. 114	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	116	10	116	11	e.g. pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	116	15	116	20	e.g. pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	116	23	116	23	e.g. pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	117	2	117	2	e.g. pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	117	3	117	6	e.g. pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter	BSD, 402, 403, H, F

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
Newton, Ray 2023-05-03	117	9	117	9	e.g., pp. 114, 80-81, 97-98, 101-102	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	123	23	124	2	e.g., pp. 68-69, 138	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	124	6	124	7	e.g., pp. 68-69, 138	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	124	13	124	13	e.g., pp. 68-69, 138	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	125	1	125	5	e.g., pp. 68-69, 138	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	125	9	125	9	e.g., pp. 68-69, 138	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	126	1	126	3	e.g., pp. 68-69, 138	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	126	9	126	9	e.g., pp. 68-69, 138	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	128	20	128	24	e.g., pp. 68-69, 138	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	130	21	131	2	e.g., pp. 68-69, 138	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	134	4	134	6	e.g., p. 134	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	139	15	139	16	e.g., 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	139	19	139	20	e.g., 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	150	3	150	14	e.g., p. 149	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	150	15	150	16	e.g., p. 149	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	150	20	150	20	e.g., p. 149	Sage Counter-Counter	BSD, 402, 403, H, F

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
Newton, Ray 2023-05-03	162	1	162	6	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	162	10	162	11	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	162	13	162	18	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	162	22	162	22	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	163	9	163	10	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	163	13	163	18	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	164	11	164	12	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	164	15	164	15	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	167	5	167	12	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	167	16	167	17	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	167	23	168	1	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	168	5	168	5	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	169	1	169	4	incomplete	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	170	13	170	16	e.g., p. 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	170	21	171	1	e.g., p. 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	172	10	172	16	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	172	20	173	11	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F



Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
Newton, Ray 2023-05-03	173	15	173	15	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	174	3	174	9	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	175	6	175	7	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	175	10	175	10	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	175	12	175	16	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	175	17	175	18	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	175	22	175	23	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	179	6	179	8	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	181	5	181	9	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	181	10	181	11	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	181	16	181	19	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	182	12	182	24	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	183	1	183	12	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	183	13	183	21	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	184	1	184	1	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	184	12	184	20	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	184	21	184	22	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
Newton, Ray 2023-05-03	185	12	185	12	e.g., pp. 155-156, 170	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	187	19	188	2	e.g., pp. 155-156, 170, 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	188	7	188	8	e.g., pp. 155-156, 170, 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	188	12	188	13	e.g., pp. 155-156, 170, 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	189	1	189	3	e.g., pp. 155-156, 170, 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	190	7	190	12	e.g., pp. 155-156, 170, 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	190	16	190	17	e.g., pp. 155-156, 170, 25-26, 30-31, 35, 39, 53, 55-56, 77-78, 80-81, 193	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	195	21	195	22	e.g., p. 198	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	196	2	196	4	e.g., p. 198	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	196	6	196	7	e.g., p. 198	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	198	19	198	20	e.g., pp. 196-198	Sage Counter-Counter	BSD, 402, 403, H, F

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
Newton, Ray 2023-05-03	199	1	199	3	e.g., pp. 196-198	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	199	7	199	15	e.g., pp. 196-198	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	200	8	200	9	e.g., pp. 196-198	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	201	3	201	5	e.g., pp. 196-198	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	201	9	201	15	e.g., pp. 196-198	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	201	24	202	2	e.g., pp. 196-198	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	202	6	202	9	e.g., pp. 196-198	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	212	8	212	9	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	212	21	212	23	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	216	22	217	1	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	217	4	217	7	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	217	11	217	12	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	218	15	218	17	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	218	20	218	22	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	218	24	219	4	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	219	8	219	10	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	220	1	220	5	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter	BSD, 402, 403, H, F

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
Newton, Ray 2023-05-03	220	10	220	16	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	224	11	224	20	e.g., pp. 208, 209, 210	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	226	21	227	5	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter	BSD, 402, 403, H, F
Newton, Ray 2023-05-03	227	8	227	8	e.g., pp. 80-81, 97-98, 101-102, 114	Sage Counter-Counter	BSD, 402, 403, H, F

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
Pawlik, Kate 2023-03-17	62	18	62	20	62:9-11	Sage Counter-Counter	BSD, 402, 403, H, F
Pawlik, Kate 2023-03-17	62	23	62	23	62:9-11	Sage Counter-Counter	BSD, 402, 403, H, F
Pawlik, Kate 2023-03-17	73	7	73	12	72-73	Sage Counter-Counter	BSD, 402, 403, H, F
Pawlik, Kate 2023-03-17	118	19	118	21	118	Sage Counter-Counter	BSD, 402, 403, H, F
Pawlik, Kate 2023-03-17	132	7	132	10	132	Sage Counter-Counter	BSD, 402, 403, H, F
Pawlik, Kate 2023-03-17	158	20	159	1	158	Sage Counter-Counter	BSD, 402, 403, H, F
Pawlik, Kate 2023-03-17	228	2	228	2		Sage Counter-Counter	BSD, 402, 403, H, F

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
Shaw, Laura 2021-04-13	29	20	29	22		Sage Counter-Counter	BSD, 402, 403, H, F
Shaw, Laura 2021-04-13	31	10	31	11	31	Sage Counter-Counter	BSD, 402, 403, H, F
Shaw, Laura 2021-04-13	31	14	31	15	31	Sage Counter-Counter	BSD, 402, 403, H, F

Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
Simon, Marcus 2021-03-03	73	3	73	7	Counter-counter to p. 72	Sage Counter-Counter	BSD, 402, 403, H, F
Simon, Marcus 2021-03-03	73	9	73	10	Counter-counter to p. 72	Sage Counter-Counter	BSD, 402, 403, H, F

<b>Transcript</b>	<b>PgFrom</b>	<b>LnFrom</b>	<b>PgTo</b>	<b>LnTo</b>	<b>E.g., PureWick Counter</b>	<b>Issues</b>	<b>PureWick Objections</b>
Skelton, Sarah 2023-01-18	81	18	81	22	Counter-counter to p. 81	Sage Counter-Counter	BSD, 402, 403, H, F
Skelton, Sarah 2023-01-18	82	1	82	2	Counter-counter to p. 81	Sage Counter-Counter	BSD, 402, 403, H, F
Skelton, Sarah 2023-01-18	82	4	82	6	Counter-counter to p. 81	Sage Counter-Counter	BSD, 402, 403, H, F
Skelton, Sarah 2023-01-18	82	8	82	9	Counter-counter to p. 81	Sage Counter-Counter	BSD, 402, 403, H, F



Transcript	PgFrom	LnFrom	PgTo	LnTo	E.g., PureWick Counter	Issues	PureWick Objections
Zani, Paul 2021-03-23	39	4	39	14	38:20-39:3	Sage Counter-Counter	BSD, 402, 403, H, F
Zani, Paul 2021-03-23	49	9	49	11	48:3-49:2	Sage Counter-Counter	BSD, 402, 403, H, F
Zani, Paul 2021-03-23	49	20	49	24	50:16-17	Sage Counter-Counter	BSD, 402, 403, H, F
Zani, Paul 2021-03-23	75	16	75	23	75:10-15	Sage Counter-Counter	BSD, 402, 403, H, F
Zani, Paul 2021-03-23	132	7	132	9	131:21-132:6	Sage Counter-Counter	BSD, 402, 403, H, F
Zani, Paul 2021-03-23	132	12	132	13	131:21-132:6	Sage Counter-Counter	BSD, 402, 403, H, F
Zani, Paul 2021-03-23	183	11	183	13	182:1-183:1; 183:6-10	Sage Counter-Counter	BSD, 402, 403, H, F
Zani, Paul 2021-03-23	183	15	183	16	182:1-183:1; 183:6-10	Sage Counter-Counter	BSD, 402, 403, H, F

# **SCHEDULE F1**

**PUREWICK MOTION *IN LIMINE* NO. 1 TO PRECLUDE SAGE FROM PRESENTING EVIDENCE OR ARGUMENT OF A GOOD FAITH BELIEF THAT PRIMAFIT 2.0 DOES NOT INFRINGE**

At the prior trial, Sage’s PrimaFit 1.0 (“1.0”) was held to willfully infringe U.S. Patents Nos. 10,226,376 and 10,390,989 (the “Asserted Patents”).<sup>1</sup> Shortly before that trial, Sage began to sell PrimaFit 2.0 (“2.0”). During the 1.0 case, Sage had argued that the design for 2.0 was an acceptable non-infringing alternative to 1.0. PureWick contended 2.0 also infringed and stood ready to establish that at the first trial, but Sage chose not to advance that assertion and dropped 2.0 as an alleged non-infringing alternative. After the jury’s verdict that 1.0 willfully infringed the Asserted Patents, Sage continued to make and sell 2.0 undeterred by the verdict and despite PureWick’s contention that 2.0 also infringed.

PureWick asserts that Sage’s sale of 2.0 is willful, especially after the first jury (and the Court) rejected Sage’s invalidity arguments and found 1.0 willfully infringed the Asserted Patents.<sup>2</sup> When PureWick sought discovery regarding Sage’s basis for alleging that its sale of 2.0 is not willful, Sage claimed that 2.0 contains certain new features and omits others that were present in 1.0 and, importantly, that Sage “has at all times since it developed the PrimaFit® 2.0 had a good faith belief that the PrimaFit® 2.0 is a bona-fide non-infringing redesign.” Ex. A at 20, 86; *see also id.* at 21-28. Sage, however, never provided a basis for this alleged good faith belief of non-infringement.<sup>3</sup> And when PureWick tried to take discovery of the basis for Sage’s conclusory assertion of its “good faith belief,” Sage repeatedly blocked that discovery as allegedly seeking privileged information. Sage did so despite the fact that its mental state clearly is relevant

---

<sup>1</sup> *PureWick, Corp. v. Sage Products, LLC*, C.A. No. 19-1508-MN (D. Del.), D.I. 381 at 1.

<sup>2</sup> PureWick also asserts that the differences between PrimaFit 1.0 and 2.0 [REDACTED] to infringement.

<sup>3</sup> Similarly, Sage’s technical expert on non-infringement has opined that “the PrimaFit 2.0 *was designed to be . . . a noninfringing alternative in the prior litigation*,” Ex. B ¶ 506 (emphasis added), but neither Sage nor its expert have explained how or why that is the case. And, of course, Sage declined to test that assertion “in the prior litigation.”

**PUREWICK MOTION *IN LIMINE* NO. 1 TO PRECLUDE SAGE FROM PRESENTING EVIDENCE OR ARGUMENT OF A GOOD FAITH BELIEF THAT PRIMAFIT 2.0 DOES NOT INFRINGE**

to assessing willfulness, and Sage put its mental state at issue by asserting that it has had, at all times, a good faith belief that 2.0 is non-infringing. Sage contends it had a good faith belief, but has consistently been unwilling to provide a basis for that belief claiming that such was privileged.

For those reasons, PureWick moves *in limine* to preclude Sage from arguing or introducing any evidence or testimony that Sage has a good faith basis for believing that the 2.0 does not infringe the Asserted Patents or that 2.0 was designed to avoid infringement. Of course, Sage is free, consistent with its interrogatory responses and expert reports, to identify [REDACTED] [REDACTED] that it contends renders 2.0 non-infringing. However, Sage should not be permitted to present evidence regarding its purported belief that any such differences render 2.0 non-infringing because it prevented PureWick from obtaining discovery regarding the basis for those purported beliefs.

For example, when PureWick questioned Sage's witnesses about Sage's mental state with respect to the design, development, and sale of 2.0, including in light of the prior litigation, Sage instructed its witnesses not to answer. *See* Ex. C at 174:10-179:20 ("Ms. Frantzen: Yeah, no, you literally are asking about changes due to a litigation which is like . . . -- in and of itself privileged."). And, Sage's Rule 30(b)(6) designee on 2.0's design and development was instructed not to answer when PureWick's counsel asked, "was any aspect of the PrimaFit 2.0 design motivated by an effort to avoid infringement of any patents." Ex. D at 239:15-240:2. The same occurred during numerous other depositions of Sage's 30(b)(6) designees. *See, e.g.*, Ex. E at 95:12-23 (instructing Sage's marketing designee not to answer PureWick's counsel's question, "Are you able to tell me, yes or no, whether litigation with Purewick influenced the development of the Primafit 2.0?"). And, on the basis of privilege, Sage refused to provide a witness to testify regarding PureWick's Rule 30(b)(6) Topic No. 6: "Sage's knowledge of the verdict in *PureWick, Corp. v. Sage Products*,

**PUREWICK MOTION *IN LIMINE* NO. 1 TO PRECLUDE SAGE FROM PRESENTING EVIDENCE OR ARGUMENT OF A GOOD FAITH BELIEF THAT PRIMAFIT 2.0 DOES NOT INFRINGE**

*LLC*, C.A. No. 19-1508-MN (D. Del.) and any actions taken with respect to the Accused Product in response to the verdict.” Ex. F at 1.

Not only did Sage refuse to allow PureWick to obtain discovery regarding Sage’s alleged “good faith belief” that it was not infringing, Sage also failed to provide any evidence showing that Sage actually had that alleged mental state. Sage and its experts have stated only that “[t]here are numerous differences between 1.0 and 2.0, including but not limited to the design, structure, material, and manufacturing.” Ex. A at 20; *see also* Ex. B ¶ 508. Sage has never provided any evidence that those alleged differences were relied on by the company to conclude that it had “a good faith belief” that the 2.0 does not infringe the Asserted Patents. Even if 2.0 differs from 1.0, that does not mean that those differences are meaningful or that Sage actually relied on such “differences” in its decision to sell 2.0 after 1.0 was found to willfully infringe. If Sage is right that 2.0 does not infringe, then this will not matter. But if wrong, then Sage’s bases for its belief will be at the center of the willfulness assessment.

Given Sage’s repeated refusal to allow discovery into Sage’s mental state regarding the design, development, and sale of 2.0, and Sage’s failure to provide discovery demonstrating the existence of that mental state, Sage should be precluded from presenting argument or evidence that 2.0 was designed to avoid infringement or that Sage has a good faith basis for believing that 2.0 does not infringe.<sup>4</sup>

---

<sup>4</sup> *See Ironburg Inventions Ltd. v. Valve Corp.*, 64 F.4th 1274, 1294 (Fed. Cir. 2023) (“The district court did not abuse its discretion in precluding Valve from presenting evidence at trial on a topic for which it did not provide discovery.”); *Energy Heating, LLC v. Heat On-The-Fly, LLC*, 889 F.3d 1291, 1303 (Fed. Cir. 2018) (holding that the district court did not abuse its discretion by excluding witness testimony at trial after the proponent of the testimony had prohibited the same witness from providing such testimony at his deposition, instead asserting privilege).

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

PUREWICK CORPORATION,

Plaintiff,

v.

SAGE PRODUCTS, LLC,

Defendant.

C.A. No. 22-102-MN

**CONFIDENTIAL  
FILED UNDER SEAL**

**SAGE'S RESPONSE TO PUREWICK'S MOTION IN LIMINE #1  
(TO PRECLUDE SAGE FROM PRESENTING EVIDENCE OR ARGUMENT OF A  
GOOD FAITH BELIEF THAT PRIMAFIT 2.0 DOES NOT INFRINGE)**

PureWick’s Motion in Limine seeks to effectively preclude Sage from introducing *any* evidence of non-willfulness and is a gross over-reach—effectively seeking summary judgment on the fact question of whether Sage had a good faith belief of noninfringement. The motion is based on numerous mischaracterizations and should be denied.

**First**, PureWick’s motion is based on the false premise that Sage did not “allow PureWick to obtain discovery regarding Sage’s alleged ‘good faith belief’ that it was not infringing.” (Br. at 1, 3.) PureWick’s claim, however, that Sage did not provide discovery on these topics is not credible as Sage provided ***extensive discovery*** including through interrogatory responses, 30(b)(6) testimony, and expert reports. (*See, e.g.*, Ex. 1 at 20-28, 9-18, 28-67, 68-75, 86-92; Ex. 2 at Topics 2-5; Ex. 3, Cole Tr. at 33, 138-142, 205-206, 235-236, 240; Ex. 4 at ¶¶416-453, 482-516; Ex. 5 at 125-146, 147-157.) This discovery details Sage’s good faith belief that it does not infringe any valid or enforceable claim including:

(a) Sage’s good faith belief that the PrimaFit 2.0 does not infringe—presented in this case and *PureWick I* (*e.g.*, Ex. 1 at 9-18; Ex. 4, ¶¶148-415, 416-516; *PureWick I*, D.I. 286-19);

(b) Sage’s detailed explanation regarding why it was not willful (*e.g.*, Ex. 1 at 20-28, 9-18, 28-67, 68-75, and 86-92);

(c) how the PrimaFit 2.0 as redesigned includes “features which PureWick represented are not covered by the claims of its patents” (*id.* at 22);

(d) how PureWick was aware of the PrimaFit 2.0 since 2020 and “knew that Sage contended it was a non-infringing alternative [“NIA”]...in PureWick I” but never claimed infringement in that case and how “PureWick’s actions and inactions led Sage to believe” PureWick did not believe the product was infringing (*id.* at 22-25);

(e) that PureWick’s infringement arguments “are contrary to the arguments it made in the PureWick I regarding prior art asserted there...” (*id.* at 25);

(f) “there is no evidence of copying (nor has PureWick identified any)” (*id.* at 28);

(g) Sage’s good faith belief that the patents are invalid (*id.* at 29, 32-37);

(h) Sage’s good belief that the patents are unenforceable for inequitable conduct (*id.* at 37, 43, 46-55); and

(i) numerous other good faith defenses (*id.* at 28-67).

Indeed, ***Sage felt so strongly about its noninfringing design that it requested*** that the Court allow

it to seek *summary judgment* on the issue. (D.I. 154).

*Second*, though PureWick broadly seeks to exclude *any* evidence of non-willfulness, PureWick focuses on the singular issue of design changes between the PrimaFit 1.0 and PrimaFit 2.0. That too was addressed extensively including, e.g., Sage’s good faith beliefs that:

(j) there are numerous differences between PrimaFit 1.0 and 2.0 (*id.* at 20-21, 68, 75, 85-92; Ex. 3 at 33, 138-142, 205-206, 235-236, 240) including that “virtually every document describing the 1.0 or the 2.0 documents the differences”;

(k) extensive discussion regarding the “design around” changes (*id.* at 86-92);

(l) expert testimony documenting how the 2.0 changed features relevant to PureWick’s claims of infringement (e.g., Ex. 4, ¶¶416-453); and

(m) witness testimony that the PrimaFit 2.0 removes “features that PureWick claims were infringing” as well as discussions regarding the differences between the products (e.g., Ex. 1 at 22; Ex. 3 at 138-142, 190-192, 210, 215-218, 231-233, 269).

PureWick’s real complaint seems to be that certain deposition testimony on design changes did not match its case theories. But numerous witnesses were made available (*see* Ex. 2), and PureWick fails to cite to where it *ever asked* witnesses about reasons for Sage’s belief in noninfringement, why the differences between the PrimaFit 1.0 and 2.0 were significant, or Sage’s reliance on PureWick’s untimeliness in asserting infringement, etc. Indeed, PureWick did address these topics. (E.g., Ex. 3 at 33, 138-42, 205-206, 235-36, 240; Ex. 7 at 97, 102-06, 115-18.)

Rather, PureWick’s cited questions are based on the false implicit assumptions that Sage believed that the 1.0 *infringed* and that this “belief” somehow infects the 2.0. But 1.0 and 2.0 are different products.<sup>1</sup> Moreover, the 2.0 was designed and launched before the *PrimaFit I* jury trial. (Ex. 1 at 9, 22-25.) The evidence reflects Sage removed numerous features in the 2.0 that *PureWick* alleged infringed in 1.0, presented the redesigned 2.0 to PureWick as an NIA in *PureWick I* and

---

<sup>1</sup> As Sage has explained, PureWick makes improper comparisons between the 1.0 and 2.0, but infringement is determined by comparing the 2.0 product to the claims—not the 1.0 device. (D.I. 157 at 5-8.)



PureWick never claimed it to be infringing through fact discovery, independently determined in good faith that PrimaFit 2.0 also does not infringe for many reasons, and maintained that good faith belief through the relevant time period. (Ex. 1 at 9-18, 19-28; *PureWick I*, D.I. 232 at 2-3.) And, despite PureWick's assertions, evidence shows that the 2.0 was [REDACTED] [REDACTED] (Ex. 9, STRSAGE21947; Ex. 3 at 138-139; Ex. 8 at 119-120; Ex. 4, ¶¶ 503, 508).<sup>2</sup>

**Third**, PureWick's focus on deposition questions seeking privileged communications is misguided. While Sage objected to questions that sought or were premised on attorney-client communications, that does not preclude Sage from introducing *non-privileged* evidence regarding its state of mind. *Sensormatic Electronics, LLC v. Genetec (USA) Inc.*, No. 20-760-GBW, 2022 WL 14760185 (D. Del. Oct. 20, 2022) (assertions of a party's state of mind are separate from privileged communications relied on); *Bosch v. Ball-Kell*, No. 03-1408, 2007 WL 601721 (C.D. Ill. Feb. 21, 2007) (defendant not precluded from presenting evidence of its good faith belief of non-infringement despite not waiving privilege). PureWick could have filed a motion to compel if it believed that Sage's privilege objections were improper or there was insufficient discovery on Sage's state of mind. PureWick never did. *Weber Metals, Inc. v. ACE Am. Ins. Co.*, No. 2:21-cv-05995-RGK-AS, 2022 WL 18397524, at \*1 (C.D. Cal. Apr. 1, 2022) ("Defendant has also failed to bring a motion to compel discovery on this issue. As such, the Court cannot find that Defendant is sufficiently prejudiced to warrant excluding evidence ..."). The motion should be denied.

---

<sup>2</sup> PureWick implicitly raises a fact dispute over the ultimate *merits* of Sage's good faith belief (again focusing on one of many issues). But that is not the proper subject of a motion in *limine*. *Nox Med. Ehf v. Natus Neurology Inc.*, No. 15-709-RGA, 2018 WL 6629704, \*1 (D. Del. Apr. 12, 2018) (denying MIL that was "really an untimely summary judgment motion").

Dated: January 26, 2024

YOUNG CONAWAY STARGATT &  
TAYLOR, LLP

Of Counsel:

Robert A. Surette  
Sandra A. Frantzen  
Christopher Scharff  
Ryan Pianetto  
McAndrews, Held & Malloy, Ltd  
500 West Madison Street  
Chicago, IL 60661  
(312) 775-8000

/s/ Anne Shea Gaza

Anne Shea Gaza (No. 4093)  
Samantha G. Wilson (No. 5816)  
Rodney Square  
1000 North King Street  
Wilmington, DE 19801  
(302) 571-6600  
agaza@ycst.com  
swilson@ycst.com

*Attorneys for Defendant Sage Products, LLC*

**PUREWICK'S REPLY IN SUPPORT OF MOTION *IN LIMINE* NO. 1**

The discovery responses, expert report, and deposition testimony Sage cites as purportedly evidencing Sage's "good faith belief" merely identify Sage's non-infringement and invalidity litigation contentions.<sup>1</sup> As already stated, PureWick does not contend that Sage may not assert that 1.0 allegedly is different than 2.0. Likewise, Sage can argue that it does not infringe or that the patents are invalid.<sup>2</sup> But advancing these litigation defenses is not the same as offering evidence that Sage had a subjective belief when it developed and sold 2.0 that it would not infringe or that the asserted patents are invalid. *See, e.g., Power Integrations, Inc. v. Fairchild Semi. Int'l*, No. 08-309, 2018 WL 5631531, at \*1 (D. Del. Oct. 31, 2018) ("General knowledge of the status of [the defenses in litigation], and even of the positions being advocated in them, does not equate to actual, subjective belief."). Sage can do the former, but should not be permitted to do the latter because Sage did not provide evidence of any such subjective belief and maintained during discovery that, to the extent it existed, it was privileged.<sup>3</sup> *See, e.g., Ex. D at 239:15-240:2.*

Sage made a tactical decision to claim privilege on communications regarding whether 2.0 infringed.<sup>4</sup> As a result, Sage should not be able to argue that it relied on such communications or had a subjective good faith belief in invalidity and/or noninfringement. *Power Integrations*, 2018 WL 5631531, at \*1 (granting motion *in limine* to preclude reliance on advice of counsel that was withheld as privileged during discovery).

---

<sup>1</sup> Sage's assertion that the PrimaFit 2.0 was intended to [REDACTED] [REDACTED] is not responsive. "Differentiation" did not refer to making the product non-infringing; it referred to market differentiation. *See, e.g., Sage Ex. 3 at 140:7-22.*

<sup>2</sup> To the extent such arguments are permitted by the Court's collateral estoppel Order. D.I. 134.

<sup>3</sup> Sage's position is interesting given its insistence that the jury not hear that 1.0 is infringing or that its prior art invalidity defenses failed.

<sup>4</sup> Sage's argument that PureWick should have moved to compel "if it believed that Sage's privilege objections were improper or there was insufficient discovery on Sage's state of mind" is not well taken. Sage represented that there were no such non-privileged communications. *See, e.g., Ex. F at 1.*

# **Index of Exhibits Referenced in PureWick MIL 1**

PureWick Opening Exhibits A-F

Sage Response Exhibits 1-9

# **PureWick**

## **EXHIBIT A**

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

PUREWICK CORPORATION,

Plaintiff,

v.

SAGE PRODUCTS, LLC,

Defendant.

C.A. No. 22-102-MN

**CONFIDENTIAL – SUBJECT TO  
PROTECTIVE ORDER**

**DEFENDANT’S SUPPLEMENTAL RESPONSES TO PLAINTIFF’S  
INTERROGATORIES TO DEFENDANT (NOS. 1-8)**

Pursuant to Rules 26 and 33 of the Federal Rules of Civil Procedure, Defendant Sage Products, LLC (“Sage”) hereby supplements its objections and responses to Plaintiff’s Interrogatories to Defendant (Nos. 1-8).

**GENERAL OBJECTIONS**

1. Sage objects to each of Plaintiff’s interrogatories, instructions, and definitions to the extent they attempt to impose any obligations on Sage beyond and/or inconsistent with those set forth in the Federal Rules of Civil Procedure, the District of Delaware Local Rules, the Default Standard for Discovery Including Discovery of ESI (“Default Standard”) including any modifications thereafter agreed upon by the parties, the Court’s July 7, 2022 Scheduling Order (D.I. 20) (“Case Scheduling Order”), the Court’s July 19, 2022 Stipulated Protective Order (D.I. 26) (“Protective Order”), or any Order of the Court. Sage further incorporates its objections and responses to PureWick’s document requests, interrogatories, and Rule 30(b)(6) Notices including definitions as they have evolved throughout the case. Sage objects to Plaintiff’s interrogatories to the extent they seek information protected from disclosure by the attorney-client privilege, the

performs the steps of “disposing ...a urine collection apparatus” and also performs the steps of “allowing the urine discharged...to be received [in the device]”, and “allowing the received urine to be withdrawn.” Under Plaintiff’s own allegations, various unrelated parties and actors that do not act in concert would perform such steps, and Sage does not direct or control others’ performance. This is also true for at least the steps of the “fluidically coupling the fluid discharge end of the tube [to vacuum]”, “allowing urine ....to be received in the fluid receptacle,” and “disposing in operative relationship . . . a second urine collecting apparatus.” For each claim, PureWick has failed to show that any single party performs all of these steps. Moreover, despite its burden, PureWick has provided no evidence of direct infringement whatsoever even with disparate parties. PureWick also cannot establish that Sage has or had the specific intent to induce infringement. Sage encourages hospitals to follow their own protocols for urine management infringe. Sage incorporates the testimony of Eric Farrell and Adam Cole. Sage also does not have and has never had knowledge of infringement as PureWick and its expert have never shown that the PrimaFit® 2.0 meets each limitation of any asserted claim of the patents-in-suit. PureWick has produced no evidence of knowledge of infringement. The PrimaFit® 2.0 is missing many limitations recited in each asserted claim of the patents-in-suit as discussed above. Sage further incorporates the expert reports of Don Sheldon regarding his opinions on PrimaFit 2.0.

Sage further states that discovery is ongoing and Sage will supplement its response to this interrogatory as necessary pursuant to Fed. R. Civ. P. 26(e) after further discovery has been conducted. Sage expressly reserves the right to supplement, modify, or amend its responses contained herein.

3. State the basis for any contention that any infringement of the Patents-in-Suit was not or will not be willful, including identifying all facts, literature, or other documents or evidence

that Defendant asserts support its contention, and identifying each person with knowledge of such facts.

### **THIRD SUPPLEMENTAL RESPONSE TO INTERROGATORY 3:**

In addition to the General Objections set forth above, Sage objects to this interrogatory as premature because it seeks information that is the subject of ongoing discovery and investigation, both of which are in the early stages. Discovery has just started in this case and there has been no deposition discovery. Plaintiff bears the burden of establishing willful infringement and Plaintiff has proffered no facts that indicate that Sage has willfully infringed any Patent-In-Suit. Responding to this interrogatory prior to any affirmative identification of evidence by Plaintiff is premature. Sage objects to this interrogatory to the extent it seeks information which is protected by any applicable privilege, including attorney-client privilege and/or work product immunity doctrine. Sage objects to this interrogatory as overly broad, unduly burdensome, and seeking information not relevant to the claims or defenses of any party or proportional to the needs of the case. For example, Sage objects to this interrogatory as overly broad and unduly burdensome in that it requests that Sage identify “all facts, literature, or other documents or evidence” rather than representative facts, literature, documents or other evidence sufficient to show the relevant information. Sage objects to this interrogatory as overly broad, unduly burdensome, and seeking information not relevant to the claims or defenses of any party or proportional to the needs of the case in requesting Sage identify “each person with knowledge of such facts.” Sage objects to this interrogatory because it contains multiple discrete parts, which should be counted as separate interrogatories pursuant to Fed. R. Civ. P. 33.

Subject to and without waiving any general or specific objections, Sage states that Plaintiff has not explained why it believes Defendant’s alleged infringement was willful despite being its burden. Sage further responds that it has not, does not, and will not willfully infringe any of the



Patents-In-Suit, at least because the accused PrimaFit® 2.0 product, and the use of the accused PrimaFit® 2.0 product, does not infringe any claim of the Patents-In-Suit and because the Patents-In-Suit are invalid and unenforceable.

In particular, Sage states that at all times since it developed the PrimaFit® 2.0 it has had a good-faith belief that the PrimaFit® 2.0 product does not infringe any asserted claim of the Patents-In-Suit, and incorporates its response to Interrogatory No. 2. Sage also incorporates by reference the factual and legal bases set forth in Sage's Answer and Defenses (D.I. 8) for its allegations that the accused PrimaFit® 2.0 product does not infringe any claim of the Patents-In-Suit, that the claims of the Patents-In-Suit are invalid for failure to meet one or more of the conditions of patentability as specified in Title 35 of the United States Code, including 35 U.S.C. §§ 102, 103, and/or 112, et seq., and unenforceable including for inequitable conduct, and that Plaintiff's claims are barred or otherwise limited under principles of equity, including waiver, estoppel including judicial estoppel and claim preclusion, unclean hands (including inequitable conduct), and/or acquiescence and render the patents-in-suit unenforceable. Further details have been and will be outlined in invalidity contentions and expert reports as well as Sage's response to Interrogatory Nos. 2 and 4 herein.

In addition, Sage states that it has not willfully infringed the Patents-in-Suit because it has at all times since it developed the PrimaFit® 2.0 had a good faith belief that the PrimaFit® 2.0 is a bona-fide non-infringing redesign. In particular, the PrimaFit 2.0 product is a completely different design and redevelopment of a urine management product. There are numerous differences between PrimaFit 1.0 and 2.0, including but not limited to the design, structure, material, and manufacturing. Nearly all of the components of the PrimaFit® 1.0 are not present in the PrimaFit® 2.0 including at least the "Fluid Reservoir, Cap," "Foam, Adhesive Strip, Bottom,"

"Absorbent Sleeve, Assembly," "Fabric, Absorbent," "Foam, Back," "Tubing, Suction," "Fabric Batting," "Suction Tubing Adapter," "Foam adhesive Strip, Top," and "Foam Tape, Square." Differences include but are not limited to: lack of a cap that PureWick asserted was the reservoir in PrimaFit 1.0, lack of the components that PureWick asserted were the casing in the original PrimaFit 1.0 including lack of a sewn seam and lack of foam-backed adhesives, lack of "batting" that PureWick asserted was the permeable support in the original PrimaFit 1.0, inclusion of a "Foam Backer," inclusion of thermoforming and ultrasonic welding processing and hot melt, inclusion of soft foam end, inclusion of a long flexible tube extending outside the device, redesigned end, inclusion of inner foam, inclusion of material extending the entire length of the device, inclusion of material with end to match the profile of the redesigned end of the device, newly designed suction connector, and redesigned patient-facing fabric. The entire shape, form, and dimensions of the PrimaFit® 2.0 are different, the device has different materials and includes new packaging and updated instructions. The PrimaFit® 2.0 has a new core design with entirely new components, which are described and depicted in the 2.0 specifications. PrimaFit® 2.0, compared to the PrimaFit® 1.0, was also designed to be manufactured using automation, e.g., to increase product margin and capacity. For the new design, Sage expended significant resources designing and building an advanced, automated assembly process that reduced labor resulting in cost savings and increased output. Virtually every document describing the 1.0 or the 2.0 documents the differences between the products as they are very different. However, differences between the products are shown, depicted, described, and may otherwise be ascertained from documents including, for example STRSAGE00000001-STRSAGE00000119. Changes including the examples listed further broadened differentiation with competing products. Sage further incorporates its response to PureWick Interrogatory Nos. 2, 4, 5, and 7.

As Mr. Cole testified, PrimaFit 2.0 is significantly different than the 1.0 product and remove several features that PureWick claims were infringing. Indeed, almost every component and feature is different. For example, these differences include no end cap, no batting, no bottom tape, no top tape, not bottom foam, no sewed seams, new suction connector, new soft foam end, new tubing – design and material, new foam backer made from new material, new bottom barrier, new inner foam, new method of securement for bowtie, new bowtie configuration, new hot melt for tubing, thermoform/seal, different configuration and attachment for fabric, and numerous manufacturing changes resulting in a structurally different product. Sage incorporates the testimony of Mr. Cole. Sage also incorporates its responses to Interrog. No. 5. The products as designed include the structure and features of the prior art including Kuntz and Mahnensmith, including features which PureWick represented are not covered by the claims of its patents. To the extent PureWick alleges infringement of the PrimaFit 2.0, the device practices the prior art and cannot infringe. Further, documents depicting and describing the PrimaFit 2.0 include STRSAGE000000001-STRSAGE00000119, and demonstrate that many limitations are missing from the device. Sage further incorporates technical documents discussed and marked during the deposition of Adam Cole.

Though PureWick has been aware of the PrimaFit 2.0 product since at least December 2020 including in February 2021 before the first deposition was taken by PureWick in the PureWick I case and knew that Sage contended it was a non-infringing alternative to the product at issue in PureWick I, PureWick never sought to add PrimaFit 2.0 as an infringing product to that case or claim infringement (and PureWick is estopped and precluded from doing so now). PureWick knew that Sage had designed, developed, and launched PrimaFit 2.0, which Sage

contended was a non-infringing alternative in the PureWick I litigation; however, PureWick never alleged infringement of PrimaFit 2.0 during that case.

In the PureWick I litigation, PureWick did not identify PrimaFit 2.0 as an infringing product and did not accuse the product of infringing (despite numerous interrogatories on the topic and PureWick bearing the burden of proving the lack of non-infringing alternatives to support its damages claims). The first time any allegation of infringement arose was in Reply expert reports when Sage had no chance to respond.

PureWick knew that Sage contended that the PrimaFit 2.0 product was a non-infringing alternative design to the PureWick product and PureWick took no action to allege that it was not, allowing Sage to continue on with full launch of that design alternative. In an interrogatory response relating to non-infringing alternatives, Sage identified numerous documents relating to the PrimaFit 2.0 design including, among other things, directions for use, pictures of the product, specifications and drawings, and a business plan relating to the development and release of the product. Sage also identified documents about PrimaFit 2.0 that PureWick had included in its own witness binders. PureWick questioned virtually every Sage fact witnesses about the PrimaFit 2.0 product during PureWick I. Sage even deposed a witness whose sole relevance to the PureWick I litigation was to discuss the structure and function of that product as a non-infringing alternative. Another Sage witness deposed in March 2021 testified that the PrimaFit 2.0 product had been launched in 2019. In March 2021, PureWick also inspected the PrimaFit 2.0 after having been provided detailed schematics. Yet, PureWick never brought a claim of infringement against Sage, again allowing Sage to move forward with the product. This further confirmed Sage's good faith belief of noninfringement.

Additional details regarding Sage's disclosures to PureWick regarding PrimaFit 2.0 are discussed in the following filings in the PureWick I litigation, which Sage incorporates by reference: Sage's Opening and Reply briefs on its motion to exclude and strike the testimony of John Collins (including, for example, D.I. 205 at 8-10 and D.I. 255 at 5); Sage's Opposition to PureWick's Motion to exclude the expert opinions of Donald Sheldon and Vincent Thomas (D.I. 232 at 1-4); and Sage's Opposition to PureWick's Motion In Limine No. 3 to Preclude Evidence or Argument that Sage's PrimaFit 2.0 Non-Infringing Alternative is Commercially Available (D.I. 308). 75. Yet despite the pending lawsuit on the 376 and 989 patents, PureWick never attempted to add an infringement claim relating to PrimaFit 2.0 to the PureWick I litigation. Nor did PureWick respond to Sage's interrogatory asking PureWick to identify why any asserted non-infringing alternatives (such as PrimaFit 2.0) were not infringing. Despite knowing about the PrimaFit 2.0, PureWick never raised any infringement or potential infringement issues relating to the PrimaFit 2.0 and the 989 or 376 patents in any correspondence between the parties, during any meet and confers between the parties, or during any conferences with the Court. That is because PureWick knew the design was not infringing just as Sage had repeatedly alleged. Discovery closed in April 2021 and PureWick never raised any infringement allegations with regard to that product.

After the close of fact discovery, the PureWick I litigation proceeded through the close of expert discovery and motions for summary judgment. Indeed, despite PureWick's burden of establishing the absence of non-infringing alternatives, PureWick's opening expert reports never attempted to prove that PrimaFit 2.0 was "infringing." It was not until its Reply expert report, filed months later, that PureWick unexpectedly asserted infringement and even then, PureWick did not seek to add the PrimaFit 2.0 into the case or raise cognizable claims of patent infringement.

Thus, in its correspondence and meetings with Sage and the Court throughout the PureWick I litigation, PureWick never accused the PrimaFit 2.0 of infringement and never referenced any issues related to infringement and the PrimaFit 2.0. PureWick's actions and inactions led Sage to believe that PureWick did not believe that the PrimaFit 2.0 infringed any PureWick patents. Indeed, PureWick did not even address PrimaFit 2.0 as a non-infringing alternative at trial to claim infringement despite its burden to do so. Instead of lodging new infringement allegations during the PureWick I litigation such that the cases could have been tried together or even addressing 2.0 as a purported non-infringing alternative, PureWick misleadingly allowed Sage to continue to move forward with the PrimaFit 2.0 product. In moving forward with the PrimaFit 2.0 product, Sage relied on PureWick's actions and inactions and the fact that Sage had not been accused of infringement or sued for infringement by PureWick.

More than a year after PureWick became aware of PrimaFit 2.0 product (and Sage's contention that it was a non-infringing alternative), PureWick changed course with the filing of this PureWick II lawsuit. PureWick's allegations of infringement by the PrimaFit 2.0 in PureWick II, however, are contrary to the arguments it made in the PureWick I lawsuit to overcome WO2007042823A2 ("Van Den Heuvel") as discussed above in response to Interrogatory No. 2.

In addition, as discussed above in Sage's response to Interrogatory No. 2, PureWick's allegations of infringement by the PrimaFit 2.0 in PureWick II are barred under the doctrine of estoppel including judicial estoppel and claim preclusion. With regard to the claims of both patents-in-suit, PureWick's current positions are in direct contradiction to its claim interpretation in PureWick I, upon which it has prevailed to date, including its positions regarding no invalidity based upon WO2007042823A2 ("Van Den Heuvel 823"). For example, in PureWick I, PureWick repeatedly contended that an area at the tapered end of a product between a permeable support and

a casing, such as that disclosed in Van Den Heuvel 823 (item 4), is not a “reservoir” because a reservoir must “aggregate urine.” For example, PureWick repeatedly contended that, unlike a product that had a cap (such as the product at issue in PureWick I), a product that had an area at the end (such as the product in Van Den Heuvel) was not a reservoir, because for example there is allegedly no evidence “that urine could accumulate in that space” and “no place for fluid to aggregate.” (Trial Tr. at 1174, 1162; D.I. 345, PureWick’s May 19, 2022 Opp. to Sage’s Post-Trial Motions at 14-15.)

Yet, now that Sage’s product has been modified to remove the cap as well as change numerous other features that PureWick claimed were infringing, PureWick now argues the opposite and asserts infringement against PrimaFit 2.0 even though it removes the very features that PureWick had alleged were infringing for, example, the reservoir in PureWick I (the cap), the components that PureWick claimed were the casing, and uses the prior art features that PureWick claimed were not covered by its patent (see also *infra*) or were not invalidating.

PureWick made no effort to establish that an alleged area at the tapered end of the PrimaFit 2.0 product is a “reservoir,” e.g., that it “aggregates urine,” as it previously asserted was required by that term. Nor has PureWick established that urine could accumulate during use in the area at the end of the PrimaFit 2.0 or that it is a place for fluid to aggregate. PureWick is legally estopped from taking such a position, including under the doctrine of judicial estoppel. PureWick is currently taking a position that is clearly inconsistent with its earlier position in PureWick I. PureWick’s earlier position was accepted by the prior tribunal in PureWick I as of this writing. And PureWick’s change in position creates an unfair advantage or detriment absent estoppel. Moreover, based on PureWick’s representations in the prior litigation as well as the prosecution

history (discussed *infra* in response to Interrogatory No. 4, which is incorporated by reference), the claims cannot be reasonably construed to cover the PrimaFit 2.0 product.

The Court recently construed “reservoir” or “fluid reservoir” at a first end of the device to be a place or a space where urine can collect. (*See* D.I. 131, March 30, 2023 Memorandum Order Regarding Claim Construction.) As discussed above in Interrogatory No. 2, PureWick has not provided any evidence that the PrimaFit 2.0 has a place or space where urine can collect nor is there such a space or place at a first end of the device as explained. Further, PureWick has not provided any evidence that the PrimaFit 2.0 is configured to receive urine into a space or place where urine can collect or to have the received urine withdrawn from the space or place where urine can collect as claimed in the asserted claims. PureWick also provided no evidence the PrimaFit 2.0 is used such that there is received urine or that urine is received into a space or place where urine can collect, or that urine is withdrawn from a space or place where urine can collect via a tube and out a fluid discharge end of the tube. There is no received urine.

In addition, to the extent that PureWick argues that any alleged willful infringement in the PureWick I litigation with respect to the original PrimaFit can be imputed to or applied to PrimaFit 2.0, Sage denies and disputes those allegations. First the products at issue in both cases are completely different and were, in fact, designed to be different with Sage specifically removing features that PureWick claimed were infringing and features that PureWick asserted were not covered by its patents (in prior art) at trial and throughout its contentions. Moreover, in any case, Sage has at all times since the verdict in PureWick I believed that the jury’s verdicts of infringement and willfulness in the PureWick I litigation were erroneous and should be overturned either by the District Court on Sage’s post-trial motions or by the Federal Circuit on appeal. Sage reiterates and incorporates by reference its briefing in the *PureWick I* litigation in support of its



Motions for renewed judgment as a matter of law and for a new trial, which explain that with respect to the original PrimaFit® product, PureWick offered no evidence of any post-issuance willfulness by Sage, that Sage's pre-issuance activity cannot as a matter of law establish willfulness, and that Sage did not copy any PureWick device, much less any patented device.

With regard to the presently-accused product there is no evidence of copying (nor has PureWick identified any); to the contrary, the evidence reflects that Sage made numerous changes to further distinguish the PrimaFit 2.0 from 1.0 and competitor products and remove features that were allegedly infringing as well as use known features in the prior art (including features that PureWick claimed were not covered by its patents). Sage proceeded in this litigation in good faith and advised PureWick about its redesigned product years ago. Sage's good-faith belief was confirmed, for example, by PureWick's conduct, as PureWick did not accuse the PrimaFit 2.0 of infringement in the PureWick I matter despite having amply opportunity to do so, and Sage incorporates its responses to Interrog. No. 4 in their entirety and the entirety of Sage's Answer and Defenses (D.I. 8). Sage's witnesses identified in its Rule 26 disclosures are knowledgeable about Sage's lack of willfulness. Sage further states that discovery is ongoing and Sage will supplement its response to this interrogatory as necessary pursuant to Fed. R. Civ. P. 26(e) after further discovery has been conducted. Sage expressly reserves the right to supplement, modify, or amend its responses contained herein.

4. Provide the complete factual and legal bases for each of Defendant's affirmative defenses raised in its Answer to Plaintiff's Complaint.

#### **THIRD SUPPLEMENTAL RESPONSE TO INTERROGATORY 4:**

In addition to the General Objections set forth above, Sage objects to this interrogatory as compound, overly broad and unduly burdensome in that it requests Sage identify "the complete

conducted including discovery from PureWick and third parties. Sage expressly reserves the right to supplement, modify, or amend its responses contained herein.

8. To the extent You have ever attempted to design around any of the Patents-in-Suit (at any time) or change an aspect of the PrimaFit 1.0 or PrimaFit 2.0 in response to any litigation, describe in detail these efforts, including identify all individuals involved, all documents relating to any such effort, and explain how the designs avoid infringing the Patents-in-Suit.

#### **SUPPLEMENTAL RESPONSE TO INTERROGATORY 8:**

In addition to the General Objections set forth above, Sage objects to this interrogatory as vague, overly broad, unduly burdensome, and seeking information not relevant to the claims or defenses of any party or proportional to the needs of the case including, for example, to the extent it seeks irrelevant information regarding unidentified “attempt[s] to design or re-design” or “change an aspect” of the PrimaFit 1.0 or 2.0 “in response to litigation.” Sage objects to this interrogatory to the extent it seeks information which is protected by any applicable privilege, including attorney-client privilege and/or work product immunity doctrine. Sage objects to this interrogatory as unduly burdensome and seeking information not relevant to the claims or defenses of any party or proportional to the needs of the case including to the extent it is directed to the “PrimaFit 1.0” or other products not accused of infringement in this case, as well as information related to “attempt[s] to design around any of the Patents-in-Suit.” Sage objects to this interrogatory as overly broad and unduly burdensome in that it requests that Sage identify “all” documents and “any” effort rather than representative facts, literature, documents or other evidence sufficient to show the relevant information. Sage also objects to this request as seeking irrelevant information not proportional to the needs of the case as it is unbounded in time, a purportedly seeks information from “any time.” Sage objects to this interrogatory to the extent it seeks expert testimony, legal conclusions, or analysis improperly and in contravention of the Scheduling Order. Sage further objects to this interrogatory to the extent it seeks information not

kept in the ordinary course of Sage's business or outside of Sage's possession, custody, or control. Sage objects to the extent that PureWick seeks information duplicative of information already provided in *PureWick I*. Sage objects to this interrogatory because it contains multiple discrete parts, which should be counted as separate interrogatories pursuant to Fed. R. Civ. P. 33. Sage further incorporates its response to Interrogatory Nos. 2-4, and 5. Sage further incorporates its analysis of the 2.0 product as a non-infringing alternative in PureWick as well as other non-infringing alternatives identified in PureWick I and throughout its responses to these interrogatories. Unless PureWick can clarify what additional information it seeks from this interrogatory, Sage is unable to further respond at this time.

However, Sage further states the PrimaFit® 2.0 product is a completely new design of the product at issue in the PureWick I litigation, offering new features as well as removing features that PureWick claimed were infringing. The PrimaFit® 2.0 was identified as a non-infringing alternative during the course of the PureWick I litigation. (PureWick I Litigation, D.I. 209, Ex. 24 at 174-184.) As Mr. Cole testified, PrimaFit 2.0 is significantly different than the 1.0 product and remove several features that PureWick claims were infringing. Indeed, almost every component and feature is different. For example, these differences include no end cap, no batting, no bottom tape, no top tape, not bottom foam, no sewed seams, new suction connector, new soft foam end, new tubing – design and material, new foam backer made from new material, new bottom barrier, new inner foam, new method of securement for bowtie, new bowtie configuration, new hot melt for tubing, thermoform/seal, different configuration and attachment for fabric, and numerous manufacturing changes resulting in a structurally different product. Sage incorporates the testimony of Mr. Cole. Sage also incorporates its responses to Interrog. No. 5. The products as designed include the structure and features of the prior art including Kuntz and Mahnensmith,

including features which PureWick represented are not covered by the claims of its patents. To the extent PureWick alleges infringement of the PrimaFit 2.0, the device practices the prior art and cannot infringe. Even though the PrimaFit® 2.0 product was publicly available in 2019 and PureWick obtained extensive discovery on it as a non-infringing alternative in the PureWick I litigation, PureWick never brought a claim asserting infringement of that design in the PureWick I litigation. PureWick is estopped and precluded from doing so now in a second lawsuit. With respect to the 376 patent, for example, the PrimaFit® 2.0 product does not include several elements of the claims of the 376 patent, including at least the claimed “apparatus” that includes “a fluid impermeable casing having a fluid reservoir at a first end, a fluid outlet at a second end,” “a fluid permeable casing . . . defining a longitudinally elongated opening between the fluid reservoir and the fluid outlet,” “a fluid permeable support disposed within the casing,” “a fluid permeable support . . . with a portion extending across the elongated opening,” “fluid reservoir,” “wherein the fluid permeable support is distinct from and at least proximate to the fluid reservoir,” “a fluid impermeable layer,” a “longitudinally elongated opening,” “a fluid permeable membrane disposed on the support . . . so that the membrane is supported on the support and disposed across the elongated opening,” and/or a “tube having a first end disposed in the reservoir” as required by asserted claim 1 of the 376 patent. This is at least because the PrimaFit® 2.0 product does not include at least a casing, much less an impermeable one or one that has or defines a fluid reservoir. The PrimaFit® 2.0 product does not have a fluid reservoir, much less one where the fluid permeable support is distinct from and at least proximate to the fluid reservoir. Nor does the PrimaFit® 2.0 have a tube having a first end disposed in the reservoir. The PrimaFit® 2.0 product also does not include a membrane supported on an inner support or the other elements enumerated above.

Moreover, based on PureWick’s representations in the prior litigation as well as the prosecution history (discussed *infra* in response to Interrogatory No. 4, which is incorporated by reference), the claims cannot be reasonably construed to cover the PrimaFit® 2.0 product.

As Sage explained in its September 22, 2022 Preliminary Identification of Claim Constructions, the claim elements have their plain and ordinary meaning (to the extent not indefinite) in view of the specifications, prosecution histories (including prosecution disclaimers), and the knowledge of the ordinarily skilled artisan. That ordinary meaning is also reflected by PureWick’s litigation statements that bear on the meaning of the term and likewise offer a preclusive effect. For example, based on PureWick’s own representations, a “reservoir” must “aggregate urine.” PureWick’s infringement contentions fail to support that any aspect of the PrimaFit® 2.0 has a structure that “aggregates urine,” much less the area at the end of the device as claimed. There is also no infringement for the reasons describe in Interrogatory No. 2.

Dated: March 31, 2023

*As to objections only,*

YOUNG CONAWAY STARGATT &  
TAYLOR, LLP

Of Counsel:

Robert A. Surrette  
Sandra A. Frantzen  
Christopher M. Scharff  
Ryan J. Pianetto  
McAndrews, Held & Malloy, Ltd  
500 West Madison Street  
Chicago, IL 60661  
(312) 775-8000  
bsurrette@mcandrews-ip.com  
sfrantzen@mcandrews-ip.com  
cscharff@mcandrews-ip.com  
rpianetto@mcandrews-ip.com

/s/ Samantha G. Wilson

Anne Shea Gaza (No. 4093)  
Samantha G. Wilson (No. 5816)  
Rodney Square  
1000 North King Street  
Wilmington, DE 19801  
(302) 571-6600  
agaza@ycst.com  
swilson@ycst.com

*Attorneys for Defendant Sage Products,  
LLC*

# **PureWick**

## **EXHIBIT B**

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

PUREWICK CORPORATION,

Plaintiff,

v.

SAGE PRODUCTS, LLC,

Defendant.

C. A. No. 22-102-MN

CONTAINS INFORMATION  
DESIGNATED CONFIDENTIAL UNDER  
THE PROTECTIVE ORDER

**RESPONSIVE EXPERT REPORT OF DR. YADIN B. DAVID REGARDING  
U.S. PATENT NOS. 10,226,376 AND 10,390,989**

point.) Dr. Collins appears to be incorrectly assuming that Ms. Blabas was involved with the PrimaFit 2.0 design simply because she was listed on a “Project Charter” document. (Collins Report ¶234 (citing STRSAGE00021947).) But, Dr. Collins ignores the evidence that both Mr. Cole and Mr. Ulreich testified that she was not involved in product design as discussed above. Ms. Sexton is a clinical nurse who is not involved in product engineering but provides feedback “from a voice [of] the customer feedback standpoint.” (Ulreich Dep. Tr., at 26.) Indeed, none of the documents cited by Dr. Collins show that Ms. Blabas or Ms. Sexton were involved in the design of the PrimaFit 2.0.

503. The actual designers of the PrimaFit 2.0 further testified that they developed the PrimaFit 2.0 to further distinguish the product from competitor products and no concepts or features were copied from the PureWick at all. (Ulreich Dep. Tr., at 119-120; 174 (“I’m really not familiar with the PureWick device), Cole Dep. Tr., at 277-278 (“Q. [REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]”).) Dr. Collins ignores this testimony and provides no evidence that any feature in Sage’s PrimaFit 2.0 is a copy of the PrimaFit 1.0.

504. In paragraph 234, Dr. Collins asserts that “the PrimaFit 2.0 is just a copy of a copy” and that “Brett Blabas, and other members of the PrimaFit 1.0 project team, such as Kristin Sexton, were also involved in the design and development of the PrimaFit 2.0.” (Collins Report ¶ 234.) For the reasons I just discussed, that is incorrect. Dr. Collins does not identify a single document from the 1.0 or 2.0 development that relates to PureWick or any “copying” whatsoever. Dr. Collins has no “expertise” to provide any opinion regarding what was in the heads of the PrimaFit 1.0 and 2.0 designers. Nor do his opinions add any technical knowledge—just his attempt to substitute his



own speculation in the place of the facts.

505. As I discussed above, the PrimaFit 2.0 contains numerous changes from the PrimaFit 1.0, and the PrimaFit 2.0 is a superior product with numerous differentiations from the flawed PureWick device, with the only commonalities being features that had long been in the prior art and which PureWick did not invent.

506. In paragraph 235, Dr. Collins assert that he has “seen no evidence that at any point during PrimaFit 2.0’s design and development, including after PureWick filed suit in PureWick I [i.e. August 2019], did Sage make changes to the device to avoid infringing the ‘376 and ‘989 patents.” (Collins Report ¶ 235.) As an initial matter, changes were made to the PrimaFit 2.0 since August 2019. (STRSAGE00000023; STRSAGE00000029; STRSAGE00000035; STRSAGE00025402.) In any case, Dr. Collins’ statement is nonsensical given the PrimaFit 2.0 was designed to be, and was identified as, a noninfringing alternative in the prior litigation, and Dr. Collins was aware of that. (3/16/21 Resp. to Interrog. No. 6 at 83.)


507. In contrast, as I mentioned, I understand that throughout the last litigation, Sage repeatedly provided to PureWick its good faith belief that PrimaFit 2.0 was not infringing. The PrimaFit 2.0 was repeatedly identified to PureWick as a noninfringing alternative and, notably, PureWick never accused the product of infringement in that lawsuit. (2/20/21 Resp. to Interrog. No. 6 at 48; 3/16/21 Resp. to Interrog. No. 6 at 83; 6/25/21 Sheldon Report at pp. 181-184; 4/8/21 Ulreich Dep. Tr., at pp. 18-35; Sexton Tr., at pp. 252-294.) Even Dr. Collins failed to explain how the device was infringing in his opening report on noninfringing alternatives, which he provided in May 2021. In my opinion, based on PureWick’s inactions with regard to that product and the fact that PureWick allowed Sage to continue with commercial launch and manufacture, it appears that PureWick agreed that it was noninfringing.

508. As I discussed above in Section VIII, the PrimaFit 2.0 product is a completely new design of the PrimaFit 1.0 product offering new features as well as removing many of the features that PureWick asserted were infringing including: removing the end cap, which PureWick asserted was a “reservoir;” removing the components that PureWick asserted were the “casing;” removing the batting that PureWick asserted was a “permeable support;” adjusting positioning of the tube within the new inner foam; and creating a sealed patient-facing end such that there could be no “opening.” Many other changes were made as well. Moreover, the PrimaFit 2.0 development documents show that the design was informed by, among other things, a desire to both improve the product and “broaden differentiation with competitor products.” (STRSAGE00021947.)

509. In paragraph 236, Dr. Collins again discusses the PrimaFit 1.0 device. He repeats his opinion that the “relatively short amount of time that it took for Sage to develop the PrimaFit 1.0 device, coupled with the similarities between the PureWick FEC and PrimaFit device . . . .further indicates that Sage copied PureWick’s product.” (Collins Report ¶236.) Again, the development of the 1.0 product and its alleged similarity to the PureWick product is immaterial. And again, I disagree that any “similarities between the PureWick FEC and PrimaFit device” support copying, regardless of whether Dr. Collins is referring to the PrimaFit 1.0 or 2.0.

510. At paragraphs 237-238, Dr. Collins asserts that “Sage has put forth no evidence that it made any substantive changes to the PrimaFit device as a result of the PureWick I litigation or as a result of the jury’s determination in PureWick I that the PrimaFit 1.0 device infringes the ‘376 and ‘989 patents” and that “Sage has put forth no evidence that it made any changes to the PrimaFit 2.0 to avoid infringing the ‘376 and ‘989 patents after the jury’s determination that the PrimaFit 1.0 infringes the ‘376 and ‘989 patents.” (Collins Report ¶¶ 237-238.) Dr. Collins did not explain why a determination about the differently-designed PrimaFit 1.0 product bears on a product that

June 16, 2023



---

Dr. Yadin David

# **PureWick**

## **EXHIBIT C**

<p style="text-align: right;">Page 1</p> <p>1           IN THE UNITED STATES DISTRICT COURT</p> <p>2                   FOR THE DISTRICT OF DELAWARE</p> <p>3</p> <p>4   PUREWICK CORPORATION,            )</p> <p>5                                   Plaintiff,    )</p> <p>6                                   vs.                ) NO. 22-102-MN</p> <p>7   SAGE PRODUCTS, LLC,            )</p> <p>8                                   Defendant.    )</p> <p>9</p> <p>10                   *** CONFIDENTIAL ***</p> <p>11                   PURSUANT TO PROTECTIVE ORDER</p> <p>12</p> <p>13                   The videotaped 30(b)(6) deposition of</p> <p>14   SAGE PRODUCTS, LLC through DANIEL ULREICH and</p> <p>15   DANIEL ULREICH, individually, called as a witness</p> <p>16   for examination, taken via videoteleconference</p> <p>17   pursuant to the Federal Rules of Civil Procedure of</p> <p>18   the United States District Courts pertaining to the</p> <p>19   taking of depositions, taken before VICTORIA C.</p> <p>20   CHRISTIANSSEN, a Certified Shorthand Reporter of the</p> <p>21   State of Illinois, CSR No. 84-3192, on the 13th day</p> <p>22   of April, A.D. 2023, at 9:05 a.m. CDT.</p> <p>23</p> <p>24</p>	<p style="text-align: right;">Page 3</p> <p>1       THE VIDEOGRAPHER: We are now on the record.</p> <p>2   The time is 9:05 a.m. Central time on April 13,</p> <p>3   2023.</p> <p>4       This begins Media 1 of the</p> <p>5   video-recorded deposition of Dan Ulreich taken in</p> <p>6   the matter of PureWick Corporation vs.</p> <p>7   Sage Products, LLC, in the United States District</p> <p>8   Court for the District of Delaware, Civil Action</p> <p>9   No. 22-102-MN.</p> <p>10       My name is Jonathan Popham, and I am</p> <p>11   your videographer today. The court reporter is</p> <p>12   Vicki Christiansen. We are representing Esquire</p> <p>13   Deposition Solutions.</p> <p>14       Counsel, would you please introduce</p> <p>15   yourselves and your affiliations.</p> <p>16       MS. FELICE: Nicola Felice of Quinn Emanuel on</p> <p>17   behalf of Plaintiff PureWick Corporation.</p> <p>18       MS. FRANTZEN: Sandra Frantzen, McAndrews,</p> <p>19   Held &amp; Malloy, on behalf of the defendant, Sage, as</p> <p>20   well as the witness.</p> <p>21       THE VIDEOGRAPHER: Okay. Will the court</p> <p>22   reporter please swear in the witness.</p> <p>23</p> <p>24</p>
<p style="text-align: right;">Page 2</p> <p>1   PRESENT:</p> <p>2       QUINN EMANUEL URQUHART &amp; SULLIVAN,</p> <p>3       (51 Madison Avenue, 22nd Floor,</p> <p>4       New York, New York 10010,</p> <p>5       212-849-7000), by:</p> <p>6       MS. NICOLA R. FELICE,</p> <p>7       nicolafelice@quinnemanuel.com,</p> <p>8       appeared via videoteleconference on</p> <p>9       behalf of the Plaintiff;</p> <p>10</p> <p>11       MCANDREWS, HELD &amp; MALLOY, LTD.,</p> <p>12       (500 West Madison Street, 34th Floor,</p> <p>13       Chicago, Illinois 60661,</p> <p>14       312-775-8000), by:</p> <p>15       MS. SANDRA A. FRANTZEN,</p> <p>16       sfrantzen@mcandrews-ip.com,</p> <p>17       appeared via videoteleconference on</p> <p>18       behalf of the Defendant.</p> <p>19</p> <p>20   VIDEOTAPED BY: JONATHAN POPHAM,</p> <p>21                                   Legal Videographer,</p> <p>22                                   Esquire Deposition Solutions;</p> <p>23   REPORTED BY: VICTORIA C. CHRISTIANSEN, RPR, CRR,</p> <p>24                                   Illinois CSR No. 84-3192.</p>	<p style="text-align: right;">Page 4</p> <p>1   THIS DEPOSITION IS BEING HELD VIA VIDEOCONFERENCING</p> <p>2   EQUIPMENT. THE WITNESS AND REPORTER ARE NOT IN THE</p> <p>3   SAME ROOM. THE WITNESS WILL BE SWORN IN REMOTELY</p> <p>4   PURSUANT TO AGREEMENT OF ALL PARTIES. THE PARTIES</p> <p>5   STIPULATE THAT THE TESTIMONY IS BEING GIVEN AS IF</p> <p>6   THE WITNESS WAS SWORN IN IN PERSON.</p> <p>7       (WHEREUPON, the witness was duly</p> <p>8       sworn.)</p> <p>9       DANIEL ULREICH,</p> <p>10   called as a witness herein, having been first duly</p> <p>11   sworn, was examined and testified as follows:</p> <p>12                   EXAMINATION</p> <p>13   BY MS. FELICE:</p> <p>14       Q. Great. Good morning, Mr. Ulreich. How</p> <p>15   are you today?</p> <p>16       A. Doing all right. How are you?</p> <p>17       Q. I'm good. I'm sure you have better</p> <p>18   things to be doing than this, and I know we've met</p> <p>19   before. I'm not sure if you -- if you remember.</p> <p>20   It was a little bit of time ago, but I -- I depose</p> <p>21   you in the previous case, so it's nice to see you</p> <p>22   again.</p> <p>23       So I -- I know that obviously you --</p> <p>24   you've done this already, but I want to go through</p>

Page 169

1 Q. [REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

5 MS. FRANTZEN: Object to the form, calls for  
6 speculation.  
7 BY THE WITNESS:  
8 A. [REDACTED]  
[REDACTED]  
[REDACTED].

11 BY MS. FELICE:  
12 Q. [REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

[REDACTED] FRANTZEN: Object to the form.  
17 BY THE WITNESS:  
18 A. To my knowledge, yes.  
19 BY MS. FELICE:  
20 Q. And the changes that -- that were made  
21 to -- so let me clarify first.  
22 [REDACTED]  
[REDACTED]  
[REDACTED]

Page 170

1 [REDACTED]  
2 MS. FRANTZEN: Objection to the form,  
3 mischaracterizes testimony.  
4 BY THE WITNESS:  
5 A. Can you repeat that for me?  
6 BY MS. FELICE:  
7 Q. [REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

13 MS. FRANTZEN: Object to the form.  
14 BY MS. FELICE:  
15 Q. [REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

22 MS. FRANTZEN: Object to the form, calls for  
23 speculation.  
24 BY THE WITNESS:

Page 171

1 [REDACTED]  
[REDACTED]  
[REDACTED]

4 since it's a draft.  
5 BY MS. FELICE:  
6 Q. And I understand that. I'm talking  
7 about the Rev. I that you know to be released.  
8 MS. FRANTZEN: Object to the form, calls for  
9 speculation, vague.  
10 BY THE WITNESS:  
11 A. [REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

16 BY MS. FELICE:  
17 Q. [REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

22 MS. FRANTZEN: Object to the form, vague.  
23 BY THE WITNESS:  
24 A. Can you repeat that again?

Page 172

1 BY MS. FELICE:  
2 Q. [REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

8 MS. FRANTZEN: Object to the form, vague,  
9 calls for speculation.  
10 BY THE WITNESS:  
11 A. [REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

15 BY MS. FELICE:  
16 Q. [REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

21 MS. FRANTZEN: Object to the form, lack of  
22 foundation, vague.  
23 BY THE WITNESS:  
24 A. I mean, I -- I am not really familiar

Page 173

1 with the PureWick product.

2 BY MS. FELICE:

3 Q. You know what the PureWick product is,

4 though, correct?

5 A. I would say I'm aware it exists, but I

6 am not familiar with the -- the product itself.

7 Q. You're not familiar with the features of

8 the product? Is that what you're saying?

9 A. Yes, I would say I'm not -- I'm not

10 really familiar with the -- the features of the

11 product.

12 Q. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

17 MS. FRANTZEN: Object to the form, vague.

18 BY THE WITNESS:

19 A. Could you be more specific on the term

20 "differentiate"?

21 BY MS. FELICE:

22 Q. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

5 foundation.

6 BY THE WITNESS:

7 A. Again, I'm really not familiar with the

8 PureWick device, so I can't really say.

9 BY MS. FELICE:

10 Q. [REDACTED]

[REDACTED]

[REDACTED]

13 MS. FRANTZEN: Object to the form, and I

14 instruct the witness not to answer to the extent it

15 would reveal any attorney/client communications.

16 So you should not answer that question

17 if it would reveal any attorney/client

18 communications.

19 MS. FELICE: And to be clear, I'm not asking

20 for -- for privileged information; I'm -- I'm

21 asking whether --

22 MS. FRANTZEN: You -- you are actually asking

23 for privileged information.

24 MS. FELICE: I mean, I -- I'm not if the

Page 175

1 witness says -- Mr. Ulreich still hasn't said

2 whether the only knowledge that he has would be

3 from an attorney on the question that I asked.

4 You're stating that, but --

5 MS. FRANTZEN: Yeah, no, I --

6 MS. FELICE: -- I haven't gotten that --

7 MS. FRANTZEN: -- said he should not to answer

8 the question if it would reveal any attorney/client

9 communications. That's what I instructed the

10 witness.

11 So I maintain my objection.

12 BY MS. FELICE:

13 Q. All right. So, Mr. Ulreich, are you

14 able to answer the -- the question without

15 revealing attorney/client communications?

16 MS. FRANTZEN: You -- you may need to repeat

17 the question at this point.

18 THE WITNESS: Yeah, I'm a little confused

19 here.

20 MS. FRANTZEN: Yeah.

21 BY MS. FELICE:

22 Q. So to your knowledge -- and let me just

23 back up.

24 Prior -- earlier today, much earlier

Page 176

1 today, you -- you stated that you were aware that

2 Sage lost the prior suit between PureWick and Sage.

3 Do you recall that testimony?

4 MS. FRANTZEN: Objection, mischaracterizes

5 prior testimony.

6 BY THE WITNESS:

7 A. I -- I believe that to be true. I mean,

8 I have minimal understanding of that situation, but

9 I -- my -- from what I understood that we had lost

10 that case.

11 BY MS. FELICE:

12 Q. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

17 MS. FRANTZEN: You should not answer that

18 question if it would reveal any attorney/client

19 communications or legal communications.

20 BY THE WITNESS:

21 A. I'm sorry. Can you repeat the question?

22 MS. FELICE: And, Ms. Frantzen --

23 BY MS. FELICE:

24 Q. Sure.



Page 177

1 MS. FELICE: And, Ms. Frantzen, I want to be  
 2 clear. I'm calling -- this question calls for a  
 3 yes or no answer, so I don't see how it would call  
 4 for attorney/client communications. I'm  
 5 specifically phrasing it as a yes or no instead of  
 6 asking --  
 7 MS. FRANTZEN: That's because you're asking --  
 8 no, you're asking for the substance of an  
 9 attorney/client communication, so you're --  
 10 MS. FELICE: I am asking --  
 11 MS. FRANTZEN: -- asking did -- if an attorney  
 12 communicated that information to him, that would  
 13 reveal the substance of a communication.  
 14 So I'm instructing the witness not to  
 15 answer if it would reveal an attorney/client  
 16 communication, and I maintain that instruction.  
 17 BY MS. FELICE:  
 18 Q. And I'm just trying to find my -- my  
 19 question, Mr. Ulreich. Hang on one second.  
 20 (WHEREUPON, there was a short  
 21 interruption.)  
 22 BY MS. FELICE:  
 23 Q. Right, and so my question is: Outside  
 24 of any information or discussions you got from an

Page 178

1 attorney, are you aware of whether any [REDACTED]  
 [REDACTED]  
 [REDACTED]  
 4 MS. FRANTZEN: I'm going to advise the witness  
 5 not to answer if he received legal communications  
 6 on that issue.  
 7 So you can answer whether you can  
 8 proceed with answering or not or if it would reveal  
 9 attorney/client communications or if you believe  
 10 it's privileged.  
 11 BY THE WITNESS:  
 12 A. I --  
 13 MS. FRANTZEN: You know, we can take a break  
 14 so I can see if there's a privilege issue, but  
 15 I'm -- we're not waiving privilege, so --  
 16 MS. FELICE: Yeah, I -- I understand that,  
 17 Ms. Frantzen. That's why --  
 18 MS. FRANTZEN: The question --  
 19 MS. FELICE: I'm only asking --  
 20 MS. FRANTZEN: The witness seems unable to  
 21 answer the question, so it suggests to me that  
 22 there's a privilege issue.  
 23 MS. FELICE: I mean, I -- I think it's  
 24 probably because you're -- I'm asking specifically

Page 179

1 for any information Mr. Ulreich got outside of  
 2 conversations with an attorney, but then you're  
 3 saying that he shouldn't reveal any conversations  
 4 with an attorney --  
 5 MS. FRANTZEN: You're asking about --  
 6 MS. FELICE: -- and that's not what I'm  
 7 asking.  
 8 MS. FRANTZEN [REDACTED]  
 [REDACTED]  
 [REDACTED]  
 11 MS. FELICE: I am not --  
 12 MS. FRANTZEN: -- in and of itself privileged.  
 13 Like you're literally asking for priv- --  
 14 privileged communications, so --  
 15 MS. FELICE: Well, it's --  
 16 MS. FRANTZEN: -- and so I've instructed the  
 17 witness not to answer on privileged communications  
 18 and we're not revealing privileged communications.  
 19 So I'm just going to instruct you not to  
 20 answer at this point.  
 21 MS. FELICE: I mean, Ms. Frantzen, I think  
 22 the -- the coaching of the witness that's occurring  
 23 on the record here is --  
 24 MS. FRANTZEN: If you can --

Page 180

1 MS. FELICE: -- a little bit ridiculous.  
 2 MS. FRANTZEN: That's not coaching, it's  
 3 called maintaining privilege, and I -- I really  
 4 think that's inappropriate, especially when you're  
 5 directly asking the witness to reveal privilege to  
 6 you.  
 7 So I --  
 8 MS. FELICE: I mean, this --  
 9 MS. FRANTZEN: -- I instruct the witness --  
 10 MS. FELICE: We're not going to fight on the  
 11 record, Ms. Frantzen.  
 12 MS. FRANTZEN: You can go to the next --  
 13 MS. FELICE: I'm specifically asking --  
 14 MS. FRANTZEN: You can go to the next  
 15 question, Ms. Felice, because we're not revealing  
 16 privileged information.  
 17 If you want, I can step out with the  
 18 witness to see if there's -- what the privilege  
 19 issue is, but we're not revealing privilege and we  
 20 are maintaining the objection, so --  
 21 BY MS. FELICE:  
 22 Q. So -- so --  
 23 MS. FRANTZEN: -- move on to the next  
 24 question.



Page 181

1 BY MS. FELICE:

2 Q. -- Mr. Ulreich, did -- did you have any

3 discussions with individuals at Sage that are not

4 attorneys about the results of the -- the

5 litigation between the parties?

6 MS. FRANTZEN: Objection to the form, asked

7 and answered. That question was asked and answered

8 this morning.

9 BY THE WITNESS:

10 A. [REDACTED]

11 [REDACTED]

12 [REDACTED].

13 BY MS. FELICE:

14 Q. [REDACTED]

15 [REDACTED]

16 [REDACTED]

17 [REDACTED]

18 MS. FRANTZEN: I guess you can confirm that

19 answer based on your past answer, but just don't

20 say anything more than confirming your prior

21 answer.

22 BY THE WITNESS:

23 A. If you could just repeat that one

24 more -- one more time for me.

Page 182

1 BY MS. FELICE:

2 Q. [REDACTED]

3 [REDACTED]

4 [REDACTED]

5 [REDACTED]

6 [REDACTED]

7 [REDACTED]

8 A. Correct.

9 Q. [REDACTED]

10 [REDACTED]

11 [REDACTED]

12 [REDACTED]

13 [REDACTED] 2.0 design that were made after April

14 2022?

15 MS. FRANTZEN: Objection to the form, asked and

16 answered.

17 BY THE WITNESS:

18 A. [REDACTED]

19 [REDACTED]

20 BY MS. FELICE:

21 Q. Yes.

22 A. Yeah, as -- I mean, as I've previously

23 answered, we have made some updates for

24 manufacturing clarity and quality.

Page 183

1 Q. And do you recall when the Revision I

2 design drawing for the PrimaFit 2.0 was released?

3 MS. FRANTZEN: Object to the form.

4 BY THE WITNESS:

5 A. Again, it's different than what's

6 depicted in this draft drawing, but I believe it

7 was sometime early this year.

8 BY MS. FELICE:

9 Q. Mr. Ulreich, in your role on the

10 PrimaFit 2.0 project, did you ever review patents

11 related to urine management devices?

12 MS. FRANTZEN: Object to the form, and do not

13 reveal any attorney/client communications if it

14 would re- -- you know, require that response.

15 BY THE WITNESS:

16 A. Can you repeat that again? Sorry.

17 BY MS. FELICE:

18 Q. Sure. In your role on the PrimaFit 2.0

19 project, did you ever review patents related to

20 urine management devices?

21 A. I typically do not review patents.

22 That's part of our IP team.

23 Q. And so when you say you typically don't

24 review patents, you -- you didn't review any

Page 184

1 patents while you were on the development team for

2 the PrimaFit 2.0?

3 A. No, not that I recall.

4 Q. Okay. So, Mr. Ulreich, do you remember

5 earlier today I -- we -- we briefly discussed what

6 you did to prepare for your deposition today?

7 A. It's been a -- been a long day, but --

8 Q. Yeah.

9 A. -- I think so.

10 Q. I understand. So -- and you had

11 mentioned that you met with Mr. Cole to prepare to

12 testify as a 30(b)(6) witness in this case.

13 Do you recall that?

14 MS. FRANTZEN: I am going to object to the

15 extent it mischaracterizes his prior testimony.

16 BY THE WITNESS:

17 A. I would say I did not meet with him.

18 We -- we had a phone call.

19 BY MS. FELICE:

20 Q. And that phone call was related to the

21 topic -- the 30(b)(6) topic on which you're

22 designated, right?

23 A. Yes. The Tier 2 Segue design, correct.

24 Q. And so you understand that you're --

# **PureWick**

## **EXHIBIT D**

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE

PUREWICK CORPORATION, )  
 )  
Plaintiff, )  
 )  
vs. ) C.A. No. 22-102-MN  
 )  
SAGE PRODUCTS, LLC, )  
 )  
Defendant. )

CONFIDENTIAL VIDEOTAPED DEPOSITION OF  
ADAM ROBERT COLE  
Conducted via Zoom  
Chicago, Illinois  
Wednesday, February 8th, 2023

REPORTED BY: GREG S. WEILAND, CSR, RMR, CRR  
JOB NO.: 221942

Page 234

1 A. Cole  
2 MS. FRANTZEN: Object to the form, outside  
3 the scope.

4 THE WITNESS: I don't recall whether we  
5 did that.

6 BY MR. NEWTON:

7 Q. [REDACTED]  
[REDACTED]

9 MS. FRANTZEN: Object to the form, vague.

10 THE WITNESS: Excuse me. Hold on a  
11 second.

12 I apologize. That almond went down wrong.  
13 I don't recall from the past few years  
14 [REDACTED]

15 BY MR. NEWTON:

16 Q. I understand. [REDACTED]  
[REDACTED]

19 MS. FRANTZEN: Object to the form, outside  
20 the scope.

21 THE WITNESS: I don't recall.

22 BY MR. NEWTON:

23 Q. You can put that document aside.

24 Do you need to take a break for a minute,  
25 or are you okay?

Page 236

1 A. Cole

2 [REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

7 THE WITNESS: Per my lawyer's objections,  
8 I'm prepared to talk about Number 5.

9 BY MR. NEWTON:

10 Q. [REDACTED]  
[REDACTED]  
[REDACTED]?

13 MS. FRANTZEN: I'm going to object to  
14 that. It's vague. It's outside the scope, and  
15 it seems to call for privileged information.

16 So I would ask you to rephrase your  
17 question because I think it seems to ask for  
18 privileged information.

19 MR. NEWTON: Are you instructing him not  
20 to answer as the question was posed?

21 MS. FRANTZEN: Yes.

22 BY MR. NEWTON:

23 Q. And Mr. --

24 MS. FRANTZEN: I mean, it seems to request  
25 a privileged question.

Page 235

1 A. Cole

2 A. I'm good.

3 MS. FRANTZEN: Thank you.

4 THE WITNESS: Thank you, though.

5 BY MR. NEWTON:

6 Q. Sure, sure. Just let me know. I've had  
7 it happen to me before.  
8 [REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

14 Do you see that? Do you see Topic 5,  
15 Mr. Cole?

16 A. I do see it.

17 Q. Are you prepared to provide 30(b)(6)  
18 testimony on behalf of Sage with respect to Topic 5?

19 MS. FRANTZEN: I'm going to state on this  
20 one in particular that that's going to be  
21 subject to our objections.

22 And specifically, we object to the fact of  
23 any allegation about infringement, and we've  
24 stated in our objections that we've agreed to  
25 designate a witness to testify on relevant and

Page 237

1 A. Cole

2 BY MR. NEWTON:

3 Q. Mr. Cole, are you going to follow your  
4 counsel's advice?

5 A. I don't want to disclose any privileged  
6 information, so if it's possible to reword, that  
7 would be preferred.

8 Q. Are you able to answer the question I  
9 posed without divulging privileged information?

10 MS. FRANTZEN: If you are able -- maybe  
11 you should repeat the question.

12 And if you are able to answer the question  
13 without revealing privileged information.

14 But maybe read it back again at this  
15 point.

16 It seemed implicit in the question that it  
17 would have to reveal privileged information if  
18 it was answered.

19 THE WITNESS: It would help if you read it  
20 back for me. Thank you.

21 BY MR. NEWTON:

22 Q. Was any aspect of the research,  
23 development, or design of the PrimaFit 2.0 based on  
24 litigation between Sage and PureWick?

25 MS. FRANTZEN: Yeah, that seems to request



Page 238

1 A. Cole  
 2 privileged information, [REDACTED]  
 [REDACTED]  
 [REDACTED]  
 [REDACTED]  
 [REDACTED] cally privileged. The reasons for  
 8 the --  
 9 MR. NEWTON: I just -- I want to know if  
 10 you're instructing him not to answer my  
 11 question as opposed.  
 12 MS. FRANTZEN: Yeah. As posed, I think  
 13 you're requesting privileged information. I  
 14 think there might be a way to answer it to get  
 15 the answer -- or ask it to get the answer that  
 16 you're looking for. [REDACTED]  
 [REDACTED]  
 [REDACTED]  
 19 MR. NEWTON: Right. I'm just going to try  
 20 to ask the question and please make a privilege  
 21 objection or don't. But I feel like we're kind  
 22 of going around in circles here.  
 23 BY MR. NEWTON:  
 24 Q. [REDACTED]  
 [REDACTED]

Page 240

1 A. Cole  
 2 A. I am.  
 3 MS. FRANTZEN: I will again state that you  
 4 can ask the witness the reasons for the  
 5 research and development, but you can't ask for  
 6 privileged information.  
 7 BY MR. NEWTON:  
 8 Q. You're familiar with PureWick, correct,  
 9 Mr. Cole?  
 10 A. I am familiar with -- vaguely with  
 11 PureWick.  
 12 Q. Okay. Are you familiar with Bard?  
 13 A. I am familiar that there is a company  
 14 named Bard.  
 15 Q. Do you understand that this litigation  
 16 involves the entity PureWick?  
 17 MS. FRANTZEN: This is -- objection to  
 18 outside the scope.  
 19 THE WITNESS: I understand that there is  
 20 litigation involving PureWick.  
 21 BY MR. NEWTON:  
 22 Q. [REDACTED]  
 [REDACTED]  
 [REDACTED]  
 25 MS. FRANTZEN: Objection, vague.

Page 239

1 A. Cole  
 2 [REDACTED]  
 3 MS. FRANTZEN: Yeah, I'm going to object  
 4 to the question as implicitly seeking a  
 5 question about attorney-client communications,  
 6 if any.  
 7 So --  
 8 MR. NEWTON: Are you instructing the  
 9 witness not to answer?  
 10 MS. FRANTZEN: I am.  
 11 BY MR. NEWTON:  
 12 Q. Mr. Cole, are you going to follow that  
 13 instruction?  
 14 A. I am.  
 15 Q. [REDACTED]  
 [REDACTED]  
 [REDACTED] ?  
 18 MS. FRANTZEN: I'm going to instruct the  
 19 witness not to answer that question, as it  
 20 clearly states privileged information, and it's  
 21 outside the scope of what we agreed to provide  
 22 a witness on.  
 23 BY MR. NEWTON:  
 24 Q. Mr. Cole, are you going to follow that  
 25 instruction?

Page 241

1 A. Cole  
 2 THE WITNESS: I can't speak to any actions  
 3 that PureWick has taken.  
 4 BY MR. NEWTON:  
 5 Q. [REDACTED]  
 [REDACTED]  
 [REDACTED] ?  
 8 MS. FRANTZEN: Objection to the form,  
 9 vague.  
 10 THE WITNESS: I would have no way of  
 11 knowing what actions or inactions a different  
 12 company such as PureWick would be taking.  
 13 BY MR. NEWTON:  
 14 Q. [REDACTED]  
 [REDACTED] luenced the design of the PrimaFit 2.0  
 16 device?  
 17 MS. FRANTZEN: Object to the form, vague.  
 18 THE WITNESS: Similar response. I can't  
 19 speak to what another company actions or  
 20 inactions are.  
 21 BY MR. NEWTON:  
 22 Q. [REDACTED]  
 [REDACTED]  
 [REDACTED]  
 25 MS. FRANTZEN: Object to the form, outside



# **PureWick**

## **EXHIBIT E**

ERIC FARRELL

IN THE UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF DELAWARE

\_\_\_\_\_)  
\_\_\_\_\_)  
PUREWICK CORPORATION, )  
\_\_\_\_\_)  
Plaintiff, )  
vs. ) Case No.  
\_\_\_\_\_) 22-102-MN  
SAGE PRODUCTS, LLC., )  
\_\_\_\_\_)  
Defendant. )  
\_\_\_\_\_)

\*\*\* CONFIDENTIAL \*\*\*

REMOTE DEPOSITION OF ERIC FARRELL

Thursday, February 2, 2023

Chicago, Illinois

Reported By: TRICIA J. LATHOURIS, CSR, RPR

JOB NO. 221941



Page 94

1 ERIC FARRELL

2 Q Right. But, again, I'm not asking you to  
3 interpret a specific sentence in a document --

4 A I felt like it --

5 Q Okay. Let's try not to talk over each  
6 other, first. Let me try again and just ask my  
7 question.

8 [REDACTED]

10 MR. SURRETTE: Objection. Form. Outside the  
11 scope.

12 A [REDACTED]

[REDACTED]

15 BY MR. NEWTON:

16 Q [REDACTED]

[REDACTED]

19 MR. SURRETTE: Objection. Foundation. Outside  
20 the scope.

21 A [REDACTED]

[REDACTED]

24 BY MR. NEWTON:

25 Q Did the -- did the litigation between Sage

Page 96

1 ERIC FARRELL

2 A Describe actions, please.

3 Q Anything that Bard or Purewick had done or  
4 said?

5 MR. SURRETTE: I still want to caution the  
6 witness -- I'm sorry, Mr. Newton. I thought you  
7 were done.

8 MR. NEWTON: I'll strike it and reask it. I  
9 apologize. I was a little delayed there.

10 BY MR. NEWTON:

11 Q Mr. Farrell, did any action that [REDACTED]

[REDACTED]

[REDACTED]

14 MR. SURRETTE: Objection. Foundation. Outside  
15 the scope. And also caution the witness in  
16 answering this question not to reveal the substance  
17 of any attorney-client communication.

18 A As far as I understand, Mr. Newton, [REDACTED]

[REDACTED]

[REDACTED] e

21 the patients and the customers that we deal with.

22 BY MR. NEWTON:

23 Q Did Bard influence that effort in any way?

24 MR. SURRETTE: Objection. Foundation. Outside  
25 the scope. Calls for speculation.

Page 95

1 ERIC FARRELL

2 [REDACTED]

[REDACTED]

4 the witness not to reveal the substance of any  
5 attorney-client communication in answering this  
6 question, if -- if it would be revealed.

7 Foundation. Outside the scope.

8 A [REDACTED]

[REDACTED]

[REDACTED]

11 BY MR. NEWTON:

12 Q Are you able to tell me, yes or no, whether  
13 litigation with [REDACTED]

[REDACTED]

15 MR. SURRETTE: I'm going to caution the witness

16 -- I'm actually going to instruct the witness not to

17 answer that question, because answering that

18 question would reveal the substance of an

19 attorney-client communication.

20 BY MR. NEWTON:

21 Q Are you going to follow your counsel's  
22 advice, Mr. Farrell?

23 A I will follow my counsel's advice.

24 Q Did any actions taken by [REDACTED]

[REDACTED]

Page 97

1 ERIC FARRELL

2 A [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

6 BY MR. NEWTON:

7 Q Did Bard influence those changes in any  
8 way?

9 MR. SURRETTE: Objection. Asked and answered.

10 Foundation. Outside the scope. Once again, I'll

11 caution the witness not to reveal the substance of

12 any attorney-client communication in answering that

13 question.

14 A [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

18 BY MR. NEWTON:

19 Q [REDACTED]

[REDACTED]

21 A Not that I can recall, and I don't know.

22 Q Okay. So why don't you take the time that

23 you need to look through Exhibit 37. Let me know

24 when you've had a chance to do that.

25 Have you had a chance to read Exhibit 37,

# **PureWick**

## **EXHIBIT F**

**quinn emanuel trial lawyers | newyork**

51 Madison Avenue, 22nd Floor, New York, New York 10010-1601 | TEL (212) 849-7000 FAX (212) 849-7100

WRITER'S DIRECT DIAL NO.  
**(312) 705-7450**

WRITER'S EMAIL ADDRESS  
**nicolafelice@quinnemanuel.com**

March 6, 2023

**CONFIDENTIAL**

**VIA E-MAIL**

**RPIANETTO@MCANDREWS-IP.COM**

Ryan Pianetto  
McAndrews, Held & Malloy, Ltd.  
500 W Madison St. # 3400  
Chicago, IL 60661

Re: *PureWick Corporation v. Sage Products, LLC*, Case No. 22-102-MN (D. Del.)

Dear Ryan:

I write to follow up regarding several deficiencies in Sage's discovery responses, including Sage's failure to provide a witness on PureWick's 30(b)(6) Topic No. 6, which seeks a witness to testify regarding "Sage's knowledge of the verdict in *PureWick, Corp. v. Sage Products, LLC*, C.A. No. 19-1508-MN (D. Del.) and any actions taken with respect to the Accused Product in response to the verdict," Sage's responses to RFA Nos. 18 and 19, and Sage's responses to Interrogatory Nos. 3 and 8.

When the parties previously discussed Sage's failure to designate a witness on PureWick's 30(b)(6) Topic No. 6 during the January 24th meet and confer, Sage's only response was that any such knowledge would be privileged. Sage's blanket assertion of privilege over this subject matter is improper.<sup>1</sup> Specifically, Sage's knowledge of the verdict is not privileged—the verdict is public information, and whether anyone at Sage has knowledge of it is a fact over which Sage cannot assert privilege. *See Illumina Inc. v. BGI Genomics Co.*, No. 20-cv-01465-WHO (TSH), 2020 U.S. Dist. LEXIS 224965, at \*10 (N.D. Cal. Dec. 1, 2020) ("[T]his type of discovery seeks to learn things the company has done or plans that it has made, and '[f]acts are not protected by the work product doctrine.'" (quoting *Shared Memory Graphics LLC v. Apple, Inc.*, 812 F. Supp. 2d 1022,

---

<sup>1</sup> Sage's counsel has also, on the alleged basis of privilege, instructed at least one of its witnesses not to answer questions regarding his knowledge of the *PureWick I* verdict, and any changes made to the PrimaFit 2.0 in response to the verdict. *See* A. Cole Dep. Tr. 236-239.

**quinn emanuel urquhart & sullivan, llp**

ATLANTA | AUSTIN | BOSTON | BRUSSELS | CHICAGO | DOHA | HAMBURG | HONG KONG | HOUSTON | LONDON | LOS ANGELES | MANNHEIM | MIAMI | MUNICH | NEUILLY-LA DEFENSE | NEW YORK | PARIS | PERTH | RIYADH | SALT LAKE CITY | SAN FRANCISCO | SEATTLE | SHANGHAI | SILICON VALLEY | STUTTGART | SYDNEY | TOKYO | WASHINGTON, DC | ZURICH

1026 n.4 (N.D. Cal. 2010)); *see also* *Thermos Co. v. Starbucks Corp.*, No. 96-3833, 1998 U.S. Dist. LEXIS 17753, 1998 WL 781120, at \*5 (N.D. Ill. Nov. 3, 1998) (“Information relating to redesign efforts are not immune from discovery simply because an attorney was involved in the process.”); *Illumina*, 2020 U.S. Dist. LEXIS 224965 at \*11 (“Any modifications Defendants have made to the accused products, or any plans Defendants have made to modify the accused products, to design around Illumina’s patents are not privileged or work product.”). Nor are the facts concerning any changes made to the PrimaFit in response to the verdict privileged, to the extent that any such changes were made. Indeed, courts routinely compel accused infringers to produce the type of information PureWick seeks by 30(b)(6) Topic No. 6. *See, e.g., Illumina*, 2020 U.S. Dist. LEXIS 224965 at \*11 (compelling accused infringer to respond to patentee’s interrogatory requiring the accused infringer to ‘set forth in detail each change and/or modification that You have made, or plan to make, to the design, operation, or use of the BGI Accused Products as a result of or in response to Your becoming aware of the Illumina Asserted Patents.’”); *Visteon Global Technologies, Inc. v. Garmin Intern., Inc.*, 2012 WL 4866351, \*7-\*8 (E.D. Mich. 2012) (compelling accused infringer to offer up its in-house counsel for a deposition regarding any design around efforts).

Sage’s failure to designate a witness regarding Topic No. 6 also appears to be part of a larger effort to withhold discovery on Sage’s actions in response to the *PureWick I* litigation and verdict, which are undoubtedly relevant to at least PureWick’s infringement claims, including, specifically, willful infringement, as well as damages. In response to PureWick’s RFA No. 19, requesting Sage to [REDACTED],” Sage denied that request, stating that “no Sage product infringes the patents-in-suit and Sage has identified multiple alternatives to the patents-in-suit including alternatives that remove features Plaintiff inaccurately alleges are infringing.” Sage’s answer is both factually incorrect, in that the jury in *PureWick I* found that Sage’s PrimaFit product infringes the patents asserted in this case, and non-responsive in that it discusses “alternatives to the patents-in-suit,” which have nothing to do with PureWick’s request.

The same can be said of Sage’s response to PureWick’s RFA No. 18, where PureWick asked Sage to “[REDACTED] in *PureWick Corp. v. Sage Products LLC*, C.A. No. 19-1508, finding that the PrimaFit 1.0 infringed the ’376 and ’989 patents.” Again, Sage’s response was at least non-responsive in that it states, “Sage has identified multiple design alternatives to the patents-in-suit,” which is not relevant to PureWick’s Request. The RFA does not ask Sage to admit whether there are design alternatives, it asks Sage to admit whether it made changes to the PrimaFit after the jury’s verdict in *PureWick I*. Moreover, the documents that Sage produced in this action seem to refute its denial of PureWick’s RFA No. 18. *See* STRSAGE00022026 (PrimaFit 2.0 design freeze as of February 21, 2020); STRSAGE00025340 (discussing commercial manufacture of PrimaFit 2.0 as of November 4, 2021). Sage does not explain this contradiction.

Sage’s responses to PureWick’s third and eighth interrogatories are also non-responsive and incomplete. PureWick’s third interrogatory asked Sage to “[s]tate the basis for any contention that any infringement of the Patents-in-Suit was not or will not be willful, including identifying all facts, literature, or other documents or evidence that Defendant asserts support its contention, and

identifying each person with knowledge of such facts.” The only even arguably responsive portion of Sage’s response stated that Sage “has not willfully infringed the Patents-in-Suit because it has at all times since it developed the PrimaFit® 2.0 had a good faith belief that the PrimaFit® 2.0 is a bona-fide non-infringing redesign. In particular, the PrimaFit 2.0 product is a completely different design and redevelopment of a urine management product.” Notably, Sage never explains how or why it has a good faith belief that the PrimaFit 2.0 is a non-infringing redesign, especially in light of the fact that the jury in *PureWick I* found that the PrimaFit infringed the same patents asserted here. Sage cannot both claim to have formed a good faith belief of non-infringement but withhold any information about the basis for that belief.

PureWick’s eighth interrogatory requested the following: “To the extent You have ever attempted to design around any of the Patents-in-Suit (at any time) or change an aspect of the PrimaFit 1.0 or PrimaFit 2.0 in response to any litigation, describe in detail these efforts, including identify all individuals involved, all documents relating to any such effort, and explain how the designs avoid infringing the Patents-in-Suit.” Sage’s response was to state only that “

PrimaFit® 2.0 was identified as a non-infringing alternative during the course of the PureWick I litigation.” That response does not state whether the alleged changes to the PrimaFit 2.0 product were made to design around the ’376 and ’989 patents, nor does it state whether the changes were made in response to any litigation. Based on Sage’s failure to admit PureWick RFA Nos. 18 and 19, discussed above, Sage appears to contend that it made changes to the structure and design of the PrimaFit 2.0 after the verdict in *PureWick I*, and that the PrimaFit 2.0 was designed in an effort to avoid infringement of the ’376 or ’989 patents. If that is the case, Sage must provide those facts and/or contentions in response to PureWick’s third and eighth interrogatories.

Please confirm that Sage will remedy the above identified deficiencies by amending its responses to RFA Nos. 18 and 19, supplementing its responses to Interrogatory Nos. 3 and 8, and providing a 30(b)(6) designee on Topic 6. To the extent that Sage is not willing or able to provide the above requested discovery, please provide us with Sage’s availability to meet and confer as soon as possible.

Very truly yours,

*Nicola Felice*

Nicola R. Felice

# **Sage Response Exhibits 1 – 9**

# **SAGE EXHIBIT 1**



**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

PUREWICK CORPORATION,

Plaintiff,

v.

SAGE PRODUCTS, LLC,

Defendant.

C.A. No. 22-102-MN

**CONFIDENTIAL – SUBJECT TO  
PROTECTIVE ORDER**

**DEFENDANT’S SUPPLEMENTAL RESPONSES TO PLAINTIFF’S  
INTERROGATORIES TO DEFENDANT (NOS. 1-8)**

Pursuant to Rules 26 and 33 of the Federal Rules of Civil Procedure, Defendant Sage Products, LLC (“Sage”) hereby supplements its objections and responses to Plaintiff’s Interrogatories to Defendant (Nos. 1-8).

**GENERAL OBJECTIONS**

1. Sage objects to each of Plaintiff’s interrogatories, instructions, and definitions to the extent they attempt to impose any obligations on Sage beyond and/or inconsistent with those set forth in the Federal Rules of Civil Procedure, the District of Delaware Local Rules, the Default Standard for Discovery Including Discovery of ESI (“Default Standard”) including any modifications thereafter agreed upon by the parties, the Court’s July 7, 2022 Scheduling Order (D.I. 20) (“Case Scheduling Order”), the Court’s July 19, 2022 Stipulated Protective Order (D.I. 26) (“Protective Order”), or any Order of the Court. Sage further incorporates its objections and responses to PureWick’s document requests, interrogatories, and Rule 30(b)(6) Notices including definitions as they have evolved throughout the case. Sage objects to Plaintiff’s interrogatories to the extent they seek information protected from disclosure by the attorney-client privilege, the



## **INTERROGATORIES**

1. For each month and year that the Accused Product has been sold or otherwise distributed by or for Defendant, identify on a monthly basis, by customer, the total number of units sold, gross revenues, net revenues, gross profits, net profits, and costs.

### **SECOND SUPPLEMENTAL RESPONSE TO INTERROGATORY 1:**

In addition to the General Objections set forth above, Sage objects to this interrogatory as vague, ambiguous, indefinite, overly broad and unduly burdensome and to the extent it seeks information that is not relevant to the claims or defenses of any party or not proportional to the needs of the case. Sage objects to this interrogatory as vague and indefinite, at least because the terms or phrases “gross revenues,” “net revenues,” “gross profits,” “net profits,” and “costs” have not been defined by Plaintiff and are not reasonably susceptible to precise definition in this context including without expert discovery. Similarly, Sage objects to this interrogatory as vague and indefinite to the extent that it seeks costs, profits, or other information “by customer.” Sage further objects to this interrogatory as unbounded in time and hereby incorporates General Objection No. 13. For example, this interrogatory is overly broad and unduly burdensome to the extent that Plaintiff seeks damages-related information regarding any accused product before providing notice of the Patents-In-Suit. Sage objects to this interrogatory as vague, overly broad, unduly burdensome, and seeking information not relevant to the claims or defenses of any party or proportional to the needs of the case to the extent the definition of “Accused Product” includes products other than Sage’s PrimaFit® 2.0 product identified in Plaintiff’s Complaint. In addition, Sage objects to the extent that customer-specific sales information is not relevant to the claims or defenses of any party or proportional to the needs of the case and will not provide such data until Plaintiff identifies its relevance, if any. Sage objects to this interrogatory as duplicative of other

discovery requests, such as Request for Production No. 40 and hereby incorporates its objections and response to Request for Production No. 40.

Subject to and without waiving any general or specific objections, pursuant to Federal Rule of Civil Procedure 33(d), Sage has produced documents reflecting cumulative sales data for the PrimaFit® 2.0 product identified in Plaintiff's Complaint. Sage preliminarily identifies the following: STRSAGE00000141 and STRSAGE00023164. Sage also incorporates any updated sales data produced by Sage by agreement of the parties in advance of the date for expert reports and/or trial. Sage further incorporates its response to PureWick Interrogatory Nos. 6, 7, and 9. Sage further states that discovery is ongoing and Sage will supplement its response to this interrogatory as necessary pursuant to Fed. R. Civ. P. 26(e). Sage expressly reserves the right to supplement, modify, or amend its responses contained herein.

2. For any asserted claim of the Patents-in-Suit that Defendant contends its Accused Product does not infringe, either directly, indirectly, literally, or under the doctrine of equivalents, provide the full bases for Defendant's contention, including by identifying each limitation in each claim that Defendant contends the Accused Product does not infringe, stating and explaining in full for each such limitation the entire legal and factual basis for the contention of non-infringement, identifying by production number all documents that support Defendant's contention, and identifying all persons (expert or otherwise) with knowledge regarding Defendant's contentions and/or upon whom Defendant intends to rely to support its contentions.

### **THIRD SUPPLEMENTAL RESPONSE TO INTERROGATORY 2:**

In addition to the General Objections set forth above, Sage objects to this interrogatory as a premature contention interrogatory that has been served before a substantial amount of discovery has been completed. Discovery has just started in this case and there has been no deposition discovery. Sage objects to this interrogatory as premature to the extent it seeks information that is the subject of expert discovery, which will be provided according to the Case Scheduling Order. Sage also objects to this interrogatory as premature because the parties have not yet proffered their

proposed constructions of the asserted claims, and the Court’s final claim constructions may affect Sage’s non-infringement contentions. Sage objects to this interrogatory as overly broad, unduly burdensome, and seeking information not relevant to the claims or defenses of any party or proportional to the needs of the case. For example, Sage objects to this interrogatory as vague, overly broad, unduly burdensome, and seeking information not relevant to the claims or defenses of any party or proportional to the needs of the case to the extent the definition of “Accused Product” includes products other than Sage’s PrimaFit® product identified in Plaintiff’s Complaint and its August 2022 infringement contentions. Sage also objects to this interrogatory as overly broad, unduly burdensome, and seeking information not relevant to the claims or defenses of any party or proportional to the needs of the case to the extent it requests Sage provide non-infringement bases for unasserted claims. Sage objects to this interrogatory as overly broad and unduly burdensome in that it requests Sage “stat[e] and explain[] in full for each such limitation the entire legal and factual basis for the contention of non-infringement.” Sage objects to this interrogatory because it contains multiple discrete parts, which should be counted as separate interrogatories pursuant to Fed. R. Civ. P. 33. The request that Sage identify “all documents” rather than representative documents or documents sufficient to show the relevant information is overly broad and unduly burdensome. That is particularly burdensome since all of Sage’s documents relating to the PrimaFit® product could potentially show why and how there is no infringement since many of the claim elements are missing.

Subject to and without waiving any general or specific objections, Sage incorporates the factual and legal bases for its allegations of non-infringement with respect to the PrimaFit® product identified in Sage’s Answer and Defenses (D.I. 8), and also incorporates by reference the factual and legal basis set forth in its July 1, 2022 Opposition to PureWick’s Motion for Judgment on the

Pleadings, as well as Sage's response to Interrogatory No. 4 (below). The PrimaFit® 2.0 product is a completely new design of the product at issue in the PureWick I litigation, offering new features as well as removing features that PureWick claimed were infringing. The PrimaFit® 2.0 was identified as a non-infringing alternative during the course of the PureWick I litigation. (PureWick I Litigation, D.I. 209, Ex. 24 at 174-184.) Even though the PrimaFit® 2.0 product was publicly available in 2019 and PureWick obtained extensive discovery on it as a non-infringing alternative in the PureWick I litigation, PureWick never brought a claim asserting infringement of that design in the PureWick I litigation. PureWick is estopped and precluded from doing so now in a second lawsuit. Sage further incorporates its response to PureWick Interrogatory No. 5.

PureWick asserts infringement of Claims 1, 5, 9 and 10 of the 376 Patent. With respect to the 376 patent, for example, the PrimaFit® 2.0 product does not include several elements of the claims of the 376 patent, including at least the claimed "apparatus" that includes "a fluid impermeable casing having a fluid reservoir at a first end, a fluid outlet at a second end," "casing having...a longitudinally extending fluid impermeable layer coupled to the fluid reservoir and the fluid outlet", "a fluid permeable casing . . . defining a longitudinally elongated opening between the fluid reservoir and the fluid outlet," "a fluid permeable support disposed within the casing," "a fluid permeable support . . . with a portion extending across the elongated opening," "fluid reservoir," "wherein the fluid permeable support is distinct from and at least proximate to the fluid reservoir," "a fluid impermeable layer," a "longitudinally elongated opening," "a fluid permeable membrane disposed on the support . . . so that the membrane is supported on the support and disposed across the elongated opening," "a fluid permeable membrane . . . covering at least the portion of the support that extends across the elongated opening," a "tube having a first end disposed in the reservoir," a "tube . . . extending behind at least the portion of the support and the

portion of the membrane disposed across the elongated opening and extending through the fluid outlet to a second, fluid discharge end,” and/or “the apparatus configured to be disposed with the opening adjacent to a urethral opening of a user, to receive urine discharged from the urethral opening through the opening of the fluid impermeable layer, the membrane, the support, and into the reservoir, and to have the received urine withdrawn from the reservoir via the tube and out of the fluid discharge end of the tube” as required by asserted claim 1 of the 376 patent. This is at least because the PrimaFit® 2.0 product does not include at least a casing, much less an impermeable one or one that has or defines a fluid reservoir . The PrimaFit® 2.0 product does not have a fluid reservoir (under any parties’ or the Court’s construction), much less one where the fluid permeable support is distinct from and at least proximate to the fluid reservoir. The Court recently construed “reservoir” or “fluid reservoir” at a first end of the device to be a place or a space where urine can collect. (*See* D.I. 131, March 30, 2023 Memorandum Order Regarding Claim Construction.) Sage continues to reserve all rights and defenses under its proffered constructions. PureWick has not provided any evidence that the PrimaFit 2.0 has a place or space where urine can collect nor is there such a space or place at a first end of the device as explained, for example, during the deposition of Mr. Cole. Further, PureWick has not provided any evidence that the PrimaFit 2.0 is configured to receive urine into a space or place where urine can collect or to have the received urine withdrawn from the space or place where urine can collect as claimed in the asserted claims. The PrimaFit® 2.0 does not have a place or a space where urine can collect or a structure that aggregates urine. There is no received urine. Nor does the PrimaFit® 2.0 have a tube having a first end disposed in the reservoir. The PrimaFit® 2.0 product also does not include a membrane supported on an inner support or the other elements enumerated above.

The PrimaFit® 2.0 also does not have a support and casing that are “substantially cylindrical” and the PrimaFit® 2.0 is not “configured to be: disposed with the elongated opening adjacent the urethral opening of a human female; oriented with the reservoir adjacent to the user's anus and the outlet disposed above the urethral opening; and arranged with a curved shape with the elongated opening disposed on the inside of the curve.” The PrimaFit® 2.0 does not have a fluid permeable membrane that “includes a wicking material.” The PrimaFit® 2.0 also does not have a reservoir that is “defined between the fluid impermeable casing and the fluid permeable support.”

PureWick asserts infringement of Claims 1-7 of the 989 Patent. With respect to the 989 patent, Sage incorporates its response regarding the 376 Patent including to the extent there is overlap in claim language. The PrimaFit® 2.0 product does not include several elements of the claims of the 989 patent, including at least the claimed “method” that includes “disposing in an operative relationship with the urethral opening of a female user a urine collecting apparatus” where the “urine collection apparatus” includes “a fluid impermeable casing having a fluid reservoir at a first end, a fluid outlet at a second end,” “a fluid impermeable casing . . . defining a longitudinally elongated opening between the fluid reservoir and the fluid outlet,” “elongated opening,” “a fluid impermeable casing having . . . a longitudinally extending fluid impermeable layer,” a “fluid impermeable layer,” “a fluid permeable support disposed within the fluid impermeable casing,” “a fluid permeable support . . . with a portion extending across the elongated opening,” “wherein the fluid permeable support is distinct from and at least proximate to the fluid reservoir,” “fluid permeable support” and “a fluid permeable membrane disposed on the fluid permeable support . . . so that the fluid permeable membrane is supported on the fluid permeable support and disposed across the longitudinally elongated opening,” “a fluid permeable

membrane . . . covering at least the portion of the fluid permeable support that extends across the longitudinally elongated opening,” “the operative relationship includes the longitudinally elongated opening being adjacent to the urethral opening,” “allowing urine discharged from the urethral opening to be received through the longitudinally elongated opening of the longitudinally extending fluid impermeable layer, the fluid permeable membrane, the fluid permeable support, and into the fluid reservoir, ” “allowing the received urine to be withdrawn from the fluid reservoir via the tube and out of the fluid discharge end of the tube,” a “tube having a first end disposed in the reservoir,” and/or a “tube . . . extending behind at least the portion of the fluid permeable support and the portion of the fluid permeable membrane disposed across the longitudinally elongated opening and extending through the fluid outlet to a second, fluid discharge end” as required by asserted claim 1 of the 989 patent. This is at least because the PrimaFit® 2.0 product does not include at least a casing, much less an impermeable one or one that has or defines a fluid reservoir. The PrimaFit® 2.0 product does not have a fluid reservoir, much less one where the fluid permeable support is distinct from and at least proximate to the fluid reservoir as discussed above. PureWick has not provided any evidence that any person or entity has allowed urine discharged to be received into a space or place where urine can collect in the PrimaFit 2.0 or allowing any received urine to be withdrawn from any reservoir including any space or place where urine can collect. There is no received urine as discussed. . Indeed, as discussed, PureWick has presented no evidence of use whatsoever despite repeated requests. Nor does the PrimaFit® 2.0 have a tube having a first end disposed in any reservoir. The PrimaFit® 2.0 product also does not include a membrane supported on an inner support. The use of the PrimaFit® 2.0 product therefore does not infringe any of the claims.

Use of the PrimaFit® 2.0 also does not include “fluidically coupling the fluid discharge end of the tube to a source of vacuum to assist in withdrawing the urine from the fluid reservoir via the tube,” “fluidically coupling the fluid discharge end of the tube to a fluid receptacle and allowing urine withdrawn from the fluid reservoir of the urine collecting apparatus via the tube to be received in the fluid receptacle,” or “removing the urine collecting apparatus from the operative relationship with the urethral opening of the user.” Use of the PrimaFit® 2.0 also does not include a urine collecting apparatus that is “a first urine collecting apparatus and further comprising disposing in operative relationship with the urethral opening of a female user a second urine collecting apparatus substantially similar to the first urine collecting apparatus.” Use of the PrimaFit® 2.0 also does not have a fluid permeable support and fluid impermeable casing that are “cylindrical and have a curved shape with the longitudinally elongated opening disposed on the inside of the curve, the disposing including disposing the urine collecting apparatus with the longitudinally elongated opening adjacent the urethral opening of the user and oriented with the fluid reservoir adjacent to the user's anus and the outlet disposed above the urethral opening.”

The PrimaFit® 2.0 also does not include the claimed “apparatus” that includes a “fluid permeable support disposed between a fluid permeable membrane and fluid reservoir,” “the fluid permeable support is distinct from and at least proximate to the fluid reservoir,” “a fluid outlet; “a fluid impermeable layer,” “a fluid impermeable layer disposed over at least a portion of the fluid permeable support and over at least a portion of the fluid permeable membrane, the fluid impermeable layer including the fluid reservoir at a first end thereof,” a fluid impermeable layer “defining a fluid impermeable casing,” a fluid permeable support that is “disposed within the fluid impermeable casing,” “the fluid impermeable layer defining a longitudinally elongated opening, the fluid permeable membrane extending across the longitudinally elongated opening,” “the




apparatus configured to be disposed with the longitudinally elongated opening, and a portion of the fluid permeable membrane, adjacent to a urethral opening of a user, to receive urine discharged from the urethral opening through the fluid permeable membrane, the fluid permeable support, and into the fluid reservoir, and to have the received urine withdrawn from the fluid reservoir via the fluid outlet,” and “the fluid impermeable layer including a vacuum relief opening therethrough spaced from the longitudinally elongated opening and arranged to provide a flow path for air in the event that the skin of the user occludes the longitudinally elongated opening” as recited by claim 7 of the 989 patent including for at least the reasons outlined above. For example, as discussed, the PrimaFit® 2.0 product does not have a fluid reservoir (under any parties’ or the Court’s construction), much less one where the fluid permeable support is distinct from and at least proximate to the fluid reservoir. PureWick has not provided any evidence that the PrimaFit 2.0 has a place or space where urine can collect nor is there such a space or place at a first end of the device as explained. Further, as discussed, PureWick has not provided any evidence that the PrimaFit 2.0 is configured to receive urine into any reservoir or to have any received urine withdrawn from any reservoir as claimed. The PrimaFit® 2.0 does not have a place or a space where urine can collect or a structure that aggregates urine and there is no received urine.

Sage further incorporates its response to Interrogatory No. 4, its Answer to PureWick’s Complaint detailing other areas of estoppel, as well as the expert reports of Donald Sheldon in the PureWick I litigation regarding noninfringement of the PrimaFit 2.0.

In addition, PureWick’s allegations of infringement by the PrimaFit 2.0 in PureWick II are barred under the doctrine of estoppel including judicial estoppel and claim preclusion. With regard to the claims of both patents-in-suit, PureWick’s current positions are in direct contradiction to its claim interpretation in PureWick I, upon which it has prevailed to date, including its positions

regarding no invalidity based upon WO2007042823A2 (“Van Den Heuvel 823”). For example, in PureWick I, PureWick repeatedly contended that an area at the tapered end of a product between a permeable support and a casing, such as that disclosed in Van Den Heuvel 823 (item 4), is not a “reservoir” because a reservoir must “aggregate urine.” For example, PureWick repeatedly contended that, unlike a product that had a cap (such as the product at issue in PureWick I), a product that had an area at the end (such as the product in Van Den Heuvel) was not a reservoir, because for example there is allegedly no evidence “that urine could accumulate in that space” and “no place for fluid to aggregate.” (Trial Tr. at 1174, 1162; D.I. 345, PureWick’s May 19, 2022 Opp. to Sage’s Post-Trial Motions at 14-15.)



Yet, now that Sage’s product has been modified to remove the cap (as well as numerous other features that PureWick asserted were infringing), PureWick now argues the opposite and asserts infringement against PrimaFit 2.0 even though it removes the very features that PureWick had alleged was the reservoir in PureWick I (the cap) and uses the prior art features that PureWick

claimed were not covered by its patent (see also *infra* including Interrogatory No. 4 and Sage's Answer to PureWick's Complaint) or were not invalidating. PureWick made no effort to establish that an alleged area at the tapered end of the PrimaFit 2.0 product is a "reservoir," e.g., that it "aggregates urine," as it previously asserted was required by that term. Nor has PureWick established that urine could accumulate during use in the area at the end of the PrimaFit 2.0 or that it is a place for fluid to aggregate. PureWick is legally estopped from taking such a position, including under the doctrine of judicial estoppel. PureWick is currently taking a position that is clearly inconsistent with its earlier position in PureWick I. PureWick's earlier position was accepted by the prior tribunal in PureWick I as of this writing. And PureWick's change in position creates an unfair advantage or detriment absent estoppel. Moreover, based on PureWick's representations in the prior litigation as well as the prosecution history (discussed *infra* in response to Interrogatory No. 4, which is incorporated by reference), the claims cannot be reasonably construed to cover the PrimaFit 2.0 product.

As Sage explained in its September 22, 2022 Preliminary Identification of Claim Constructions, the claim elements have their plain and ordinary meaning (to the extent not indefinite) in view of the specifications, prosecution histories (including prosecution disclaimers), and the knowledge of the ordinarily skilled artisan. That ordinary meaning is also reflected by PureWick's litigation statements that bear on the meaning of the term and likewise offer a preclusive effect. For example, based on PureWick's own representations, a "reservoir" must "aggregate urine." PureWick's infringement contentions fail to support that any aspect of the PrimaFit 2.0 has a structure that "aggregates urine," much less the area at the end of the device as claimed.

Further, documents depicting and describing the PrimaFit 2.0 including documents that were produced pursuant to Sage's core document productions that depict the structure, function, and operation, including STRSAGE00000001-STRSAGE00000119, demonstrate that many limitations are missing from the device. Nearly all documents describing the 2.0 product demonstrate the lack of infringement of the product. Sage further incorporates the testimony of Adam Cole, as well as technical documents discussed and marked during the deposition of Adam Cole, as well as the expert reports of Donald Sheldon in the PureWick I litigation describing the PrimaFit 2.0, and the documents relied on therein, and all trial exhibits or documents relied on by Mr. Sheldon showing, depicting, and/or describing the PrimaFit 2.0 devices. Sage also incorporates its responses to Interrog. Nos. 3, 4, and 5 served in this case.

PureWick is further estopped based on the factual findings made in the IPR decision rendered in Sage v. PureWick, which is hereby incorporated by reference, including findings relating to what was disclosed in the prior art at issue.

Sage has also not contributorily infringed or induced infringement of any valid and enforceable claim of the Patents-In-Suit. Sage does not have the requisite specific intent to infringe or knowledge of infringement of the Patents-In-Suit required for inducement of infringement or contributory infringement. Sage does not offer to sell or sell within the United States or import into the United States any component knowing that it is especially made or especially adapted for use in infringement of the Patents-In-Suit. Moreover, there is also no direct infringement because PureWick has not established that the PrimaFit® 2.0 meets the limitations of the asserted claims of the 376 or 989 Patents, and, as discussed above, many limitations are missing from the product. PureWick also has not established that there is any party that performs all of the steps of any claimed method claim. For example, PureWick has not established that there is any party that

performs the steps of “disposing ...a urine collection apparatus” and also performs the steps of “allowing the urine discharged...to be received [in the device]”, and “allowing the received urine to be withdrawn.” Under Plaintiff’s own allegations, various unrelated parties and actors that do not act in concert would perform such steps, and Sage does not direct or control others’ performance. This is also true for at least the steps of the “fluidically coupling the fluid discharge end of the tube [to vacuum]”, “allowing urine ....to be received in the fluid receptacle,” and “disposing in operative relationship . . . a second urine collecting apparatus.” For each claim, PureWick has failed to show that any single party performs all of these steps. Moreover, despite its burden, PureWick has provided no evidence of direct infringement whatsoever even with disparate parties. PureWick also cannot establish that Sage has or had the specific intent to induce infringement. Sage encourages hospitals to follow their own protocols for urine management infringe. Sage incorporates the testimony of Eric Farrell and Adam Cole. Sage also does not have and has never had knowledge of infringement as PureWick and its expert have never shown that the PrimaFit® 2.0 meets each limitation of any asserted claim of the patents-in-suit. PureWick has produced no evidence of knowledge of infringement. The PrimaFit® 2.0 is missing many limitations recited in each asserted claim of the patents-in-suit as discussed above. Sage further incorporates the expert reports of Don Sheldon regarding his opinions on PrimaFit 2.0.

Sage further states that discovery is ongoing and Sage will supplement its response to this interrogatory as necessary pursuant to Fed. R. Civ. P. 26(e) after further discovery has been conducted. Sage expressly reserves the right to supplement, modify, or amend its responses contained herein.

3. State the basis for any contention that any infringement of the Patents-in-Suit was not or will not be willful, including identifying all facts, literature, or other documents or evidence

that Defendant asserts support its contention, and identifying each person with knowledge of such facts.

### **THIRD SUPPLEMENTAL RESPONSE TO INTERROGATORY 3:**

In addition to the General Objections set forth above, Sage objects to this interrogatory as premature because it seeks information that is the subject of ongoing discovery and investigation, both of which are in the early stages. Discovery has just started in this case and there has been no deposition discovery. Plaintiff bears the burden of establishing willful infringement and Plaintiff has proffered no facts that indicate that Sage has willfully infringed any Patent-In-Suit. Responding to this interrogatory prior to any affirmative identification of evidence by Plaintiff is premature. Sage objects to this interrogatory to the extent it seeks information which is protected by any applicable privilege, including attorney-client privilege and/or work product immunity doctrine. Sage objects to this interrogatory as overly broad, unduly burdensome, and seeking information not relevant to the claims or defenses of any party or proportional to the needs of the case. For example, Sage objects to this interrogatory as overly broad and unduly burdensome in that it requests that Sage identify “all facts, literature, or other documents or evidence” rather than representative facts, literature, documents or other evidence sufficient to show the relevant information. Sage objects to this interrogatory as overly broad, unduly burdensome, and seeking information not relevant to the claims or defenses of any party or proportional to the needs of the case in requesting Sage identify “each person with knowledge of such facts.” Sage objects to this interrogatory because it contains multiple discrete parts, which should be counted as separate interrogatories pursuant to Fed. R. Civ. P. 33.

Subject to and without waiving any general or specific objections, Sage states that Plaintiff has not explained why it believes Defendant’s alleged infringement was willful despite being its burden. Sage further responds that it has not, does not, and will not willfully infringe any of the



Patents-In-Suit, at least because the accused PrimaFit® 2.0 product, and the use of the accused PrimaFit® 2.0 product, does not infringe any claim of the Patents-In-Suit and because the Patents-In-Suit are invalid and unenforceable.

In particular, Sage states that at all times since it developed the PrimaFit® 2.0 it has had a good-faith belief that the PrimaFit® 2.0 product does not infringe any asserted claim of the Patents-In-Suit, and incorporates its response to Interrogatory No. 2. Sage also incorporates by reference the factual and legal bases set forth in Sage's Answer and Defenses (D.I. 8) for its allegations that the accused PrimaFit® 2.0 product does not infringe any claim of the Patents-In-Suit, that the claims of the Patents-In-Suit are invalid for failure to meet one or more of the conditions of patentability as specified in Title 35 of the United States Code, including 35 U.S.C. §§ 102, 103, and/or 112, et seq., and unenforceable including for inequitable conduct, and that Plaintiff's claims are barred or otherwise limited under principles of equity, including waiver, estoppel including judicial estoppel and claim preclusion, unclean hands (including inequitable conduct), and/or acquiescence and render the patents-in-suit unenforceable. Further details have been and will be outlined in invalidity contentions and expert reports as well as Sage's response to Interrogatory Nos. 2 and 4 herein.

In addition, Sage states that it has not willfully infringed the Patents-in-Suit because it has at all times since it developed the PrimaFit® 2.0 had a good faith belief that the PrimaFit® 2.0 is a bona-fide non-infringing redesign. In particular, the PrimaFit 2.0 product is a completely different design and redevelopment of a urine management product. There are numerous differences between PrimaFit 1.0 and 2.0, including but not limited to the design, structure, material, and manufacturing. Nearly all of the components of the PrimaFit® 1.0 are not present in the PrimaFit® 2.0 including at least the "Fluid Reservoir, Cap," "Foam, Adhesive Strip, Bottom,"

"Absorbent Sleeve, Assembly," "Fabric, Absorbent," "Foam, Back," "Tubing, Suction," "Fabric Batting," "Suction Tubing Adapter," "Foam adhesive Strip, Top," and "Foam Tape, Square." Differences include but are not limited to: lack of a cap that PureWick asserted was the reservoir in PrimaFit 1.0, lack of the components that PureWick asserted were the casing in the original PrimaFit 1.0 including lack of a sewn seam and lack of foam-backed adhesives, lack of "batting" that PureWick asserted was the permeable support in the original PrimaFit 1.0, inclusion of a "Foam Backer," inclusion of thermoforming and ultrasonic welding processing and hot melt, inclusion of soft foam end, inclusion of a long flexible tube extending outside the device, redesigned end, inclusion of inner foam, inclusion of material extending the entire length of the device, inclusion of material with end to match the profile of the redesigned end of the device, newly designed suction connector, and redesigned patient-facing fabric. The entire shape, form, and dimensions of the PrimaFit® 2.0 are different, the device has different materials and includes new packaging and updated instructions. The PrimaFit® 2.0 has a new core design with entirely new components, which are described and depicted in the 2.0 specifications. PrimaFit® 2.0, compared to the [REDACTED]

[REDACTED] For the new design, Sage expended significant resources designing and building an advanced, automated assembly process that reduced labor resulting in cost savings and increased output. Virtually every document describing the 1.0 or the 2.0 documents the differences between the products as they are very different. However, differences between the products are shown, depicted, described, and may otherwise be ascertained from documents including, for example STRSAGE00000001-STRSAGE00000119. Changes including the examples listed further broadened differentiation with competing products. Sage further incorporates its response to PureWick Interrogatory Nos. 2, 4, 5, and 7.



As Mr. Cole testified, PrimaFit 2.0 is significantly different than the 1.0 product and remove several features that PureWick claims were infringing. Indeed, almost every component and feature is different. For example, these differences include no end cap, no batting, no bottom tape, no top tape, not bottom foam, no sewed seams, new suction connector, new soft foam end, new tubing – design and material, new foam backer made from new material, new bottom barrier, new inner foam, new method of securement for bowtie, new bowtie configuration, new hot melt for tubing, thermoform/seal, different configuration and attachment for fabric, and numerous manufacturing changes resulting in a structurally different product. Sage incorporates the testimony of Mr. Cole. Sage also incorporates its responses to Interrog. No. 5. The products as designed include the structure and features of the prior art including Kuntz and Mahnensmith, including features which PureWick represented are not covered by the claims of its patents. To the extent PureWick alleges infringement of the PrimaFit 2.0, the device practices the prior art and cannot infringe. Further, documents depicting and describing the PrimaFit 2.0 include STRSAGE000000001-STRSAGE00000119, and demonstrate that many limitations are missing from the device. Sage further incorporates technical documents discussed and marked during the deposition of Adam Cole.

Though PureWick has been aware of the PrimaFit 2.0 product since at least December 2020 including in February 2021 before the first deposition was taken by PureWick in the PureWick I case and knew that Sage contended it was a non-infringing alternative to the product at issue in PureWick I, PureWick never sought to add PrimaFit 2.0 as an infringing product to that case or claim infringement (and PureWick is estopped and precluded from doing so now). PureWick knew that Sage had designed, developed, and launched PrimaFit 2.0, which Sage

contended was a non-infringing alternative in the PureWick I litigation; however, PureWick never alleged infringement of PrimaFit 2.0 during that case.

In the PureWick I litigation, PureWick did not identify PrimaFit 2.0 as an infringing product and did not accuse the product of infringing (despite numerous interrogatories on the topic and PureWick bearing the burden of proving the lack of non-infringing alternatives to support its damages claims). The first time any allegation of infringement arose was in Reply expert reports when Sage had no chance to respond.

PureWick knew that Sage contended that the PrimaFit 2.0 product was a non-infringing alternative design to the PureWick product and PureWick took no action to allege that it was not, allowing Sage to continue on with full launch of that design alternative. In an interrogatory response relating to non-infringing alternatives, Sage identified numerous documents relating to the PrimaFit 2.0 design including, among other things, directions for use, pictures of the product, specifications and drawings, and a business plan relating to the development and release of the product. Sage also identified documents about PrimaFit 2.0 that PureWick had included in its own witness binders. PureWick questioned virtually every Sage fact witnesses about the PrimaFit 2.0 product during PureWick I. Sage even deposed a witness whose sole relevance to the PureWick I litigation was to discuss the structure and function of that product as a non-infringing alternative. Another Sage witness deposed in March 2021 testified that the PrimaFit 2.0 product had been launched in 2019. In March 2021, PureWick also inspected the PrimaFit 2.0 after having been provided detailed schematics. Yet, PureWick never brought a claim of infringement against Sage, again allowing Sage to move forward with the product. This further confirmed Sage's good faith belief of noninfringement.

Additional details regarding Sage's disclosures to PureWick regarding PrimaFit 2.0 are discussed in the following filings in the PureWick I litigation, which Sage incorporates by reference: Sage's Opening and Reply briefs on its motion to exclude and strike the testimony of John Collins (including, for example, D.I. 205 at 8-10 and D.I. 255 at 5); Sage's Opposition to PureWick's Motion to exclude the expert opinions of Donald Sheldon and Vincent Thomas (D.I. 232 at 1-4); and Sage's Opposition to PureWick's Motion In Limine No. 3 to Preclude Evidence or Argument that Sage's PrimaFit 2.0 Non-Infringing Alternative is Commercially Available (D.I. 308). 75. Yet despite the pending lawsuit on the 376 and 989 patents, PureWick never attempted to add an infringement claim relating to PrimaFit 2.0 to the PureWick I litigation. Nor did PureWick respond to Sage's interrogatory asking PureWick to identify why any asserted non-infringing alternatives (such as PrimaFit 2.0) were not infringing. Despite knowing about the PrimaFit 2.0, PureWick never raised any infringement or potential infringement issues relating to the PrimaFit 2.0 and the 989 or 376 patents in any correspondence between the parties, during any meet and confers between the parties, or during any conferences with the Court. That is because PureWick knew the design was not infringing just as Sage had repeatedly alleged. Discovery closed in April 2021 and PureWick never raised any infringement allegations with regard to that product.

After the close of fact discovery, the PureWick I litigation proceeded through the close of expert discovery and motions for summary judgment. Indeed, despite PureWick's burden of establishing the absence of non-infringing alternatives, PureWick's opening expert reports never attempted to prove that PrimaFit 2.0 was "infringing." It was not until its Reply expert report, filed months later, that PureWick unexpectedly asserted infringement and even then, PureWick did not seek to add the PrimaFit 2.0 into the case or raise cognizable claims of patent infringement.

Thus, in its correspondence and meetings with Sage and the Court throughout the PureWick I litigation, PureWick never accused the PrimaFit 2.0 of infringement and never referenced any issues related to infringement and the PrimaFit 2.0. PureWick's actions and inactions led Sage to believe that PureWick did not believe that the PrimaFit 2.0 infringed any PureWick patents. Indeed, PureWick did not even address PrimaFit 2.0 as a non-infringing alternative at trial to claim infringement despite its burden to do so. Instead of lodging new infringement allegations during the PureWick I litigation such that the cases could have been tried together or even addressing 2.0 as a purported non-infringing alternative, PureWick misleadingly allowed Sage to continue to move forward with the PrimaFit 2.0 product. In moving forward with the PrimaFit 2.0 product, Sage relied on PureWick's actions and inactions and the fact that Sage had not been accused of infringement or sued for infringement by PureWick.

More than a year after PureWick became aware of PrimaFit 2.0 product (and Sage's contention that it was a non-infringing alternative), PureWick changed course with the filing of this PureWick II lawsuit. PureWick's allegations of infringement by the PrimaFit 2.0 in PureWick II, however, are contrary to the arguments it made in the PureWick I lawsuit to overcome WO2007042823A2 ("Van Den Heuvel") as discussed above in response to Interrogatory No. 2.

In addition, as discussed above in Sage's response to Interrogatory No. 2, PureWick's allegations of infringement by the PrimaFit 2.0 in PureWick II are barred under the doctrine of estoppel including judicial estoppel and claim preclusion. With regard to the claims of both patents-in-suit, PureWick's current positions are in direct contradiction to its claim interpretation in PureWick I, upon which it has prevailed to date, including its positions regarding no invalidity based upon WO2007042823A2 ("Van Den Heuvel 823"). For example, in PureWick I, PureWick repeatedly contended that an area at the tapered end of a product between a permeable support and

a casing, such as that disclosed in Van Den Heuvel 823 (item 4), is not a “reservoir” because a reservoir must “aggregate urine.” For example, PureWick repeatedly contended that, unlike a product that had a cap (such as the product at issue in PureWick I), a product that had an area at the end (such as the product in Van Den Heuvel) was not a reservoir, because for example there is allegedly no evidence “that urine could accumulate in that space” and “no place for fluid to aggregate.” (Trial Tr. at 1174, 1162; D.I. 345, PureWick’s May 19, 2022 Opp. to Sage’s Post-Trial Motions at 14-15.)

Yet, now that Sage’s product has been modified to remove the cap as well as change numerous other features that PureWick claimed were infringing, PureWick now argues the opposite and asserts infringement against PrimaFit 2.0 even though it removes the very features that PureWick had alleged were infringing for, example, the reservoir in PureWick I (the cap), the components that PureWick claimed were the casing, and uses the prior art features that PureWick claimed were not covered by its patent (see also *infra*) or were not invalidating.

PureWick made no effort to establish that an alleged area at the tapered end of the PrimaFit 2.0 product is a “reservoir,” e.g., that it “aggregates urine,” as it previously asserted was required by that term. Nor has PureWick established that urine could accumulate during use in the area at the end of the PrimaFit 2.0 or that it is a place for fluid to aggregate. PureWick is legally estopped from taking such a position, including under the doctrine of judicial estoppel. PureWick is currently taking a position that is clearly inconsistent with its earlier position in PureWick I. PureWick’s earlier position was accepted by the prior tribunal in PureWick I as of this writing. And PureWick’s change in position creates an unfair advantage or detriment absent estoppel. Moreover, based on PureWick’s representations in the prior litigation as well as the prosecution

history (discussed *infra* in response to Interrogatory No. 4, which is incorporated by reference), the claims cannot be reasonably construed to cover the PrimaFit 2.0 product.

The Court recently construed “reservoir” or “fluid reservoir” at a first end of the device to be a place or a space where urine can collect. (*See* D.I. 131, March 30, 2023 Memorandum Order Regarding Claim Construction.) As discussed above in Interrogatory No. 2, PureWick has not provided any evidence that the PrimaFit 2.0 has a place or space where urine can collect nor is there such a space or place at a first end of the device as explained. Further, PureWick has not provided any evidence that the PrimaFit 2.0 is configured to receive urine into a space or place where urine can collect or to have the received urine withdrawn from the space or place where urine can collect as claimed in the asserted claims. PureWick also provided no evidence the PrimaFit 2.0 is used such that there is received urine or that urine is received into a space or place where urine can collect, or that urine is withdrawn from a space or place where urine can collect via a tube and out a fluid discharge end of the tube. There is no received urine.

In addition, to the extent that PureWick argues that any alleged willful infringement in the PureWick I litigation with respect to the original PrimaFit can be imputed to or applied to PrimaFit 2.0, Sage denies and disputes those allegations. First the products at issue in both cases are completely different and were, in fact, designed to be different with Sage specifically removing features that PureWick claimed were infringing and features that PureWick asserted were not covered by its patents (in prior art) at trial and throughout its contentions. Moreover, in any case, Sage has at all times since the verdict in PureWick I believed that the jury’s verdicts of infringement and willfulness in the PureWick I litigation were erroneous and should be overturned either by the District Court on Sage’s post-trial motions or by the Federal Circuit on appeal. Sage reiterates and incorporates by reference its briefing in the *PureWick I* litigation in support of its

Motions for renewed judgment as a matter of law and for a new trial, which explain that with respect to the original PrimaFit® product, PureWick offered no evidence of any post-issuance willfulness by Sage, that Sage's pre-issuance activity cannot as a matter of law establish willfulness, and that Sage did not copy any PureWick device, much less any patented device.

With regard to the presently-accused product there is no evidence of copying (nor has PureWick identified any); to the contrary, the evidence reflects that Sage made numerous changes to further distinguish the PrimaFit 2.0 from 1.0 and competitor products and remove features that were allegedly infringing as well as use known features in the prior art (including features that PureWick claimed were not covered by its patents). Sage proceeded in this litigation in good faith and advised PureWick about its redesigned product years ago. Sage's good-faith belief was confirmed, for example, by PureWick's conduct, as PureWick did not accuse the PrimaFit 2.0 of infringement in the PureWick I matter despite having ample opportunity to do so, and Sage incorporates its responses to Interrog. No. 4 in their entirety and the entirety of Sage's Answer and Defenses (D.I. 8). Sage's witnesses identified in its Rule 26 disclosures are knowledgeable about Sage's lack of willfulness. Sage further states that discovery is ongoing and Sage will supplement its response to this interrogatory as necessary pursuant to Fed. R. Civ. P. 26(e) after further discovery has been conducted. Sage expressly reserves the right to supplement, modify, or amend its responses contained herein.

4. Provide the complete factual and legal bases for each of Defendant's affirmative defenses raised in its Answer to Plaintiff's Complaint.

#### **THIRD SUPPLEMENTAL RESPONSE TO INTERROGATORY 4:**

In addition to the General Objections set forth above, Sage objects to this interrogatory as compound, overly broad and unduly burdensome in that it requests Sage identify "the complete

factual and legal bases for each of Defendant's affirmative defenses." Sage objects to this interrogatory because it contains multiple discrete parts, which should be counted as separate interrogatories pursuant to Fed. R. Civ. P. 33. Indeed, there are at least eleven enumerated affirmative defenses, many of which have sub defenses, including at least:

1. The Complaint fails to state a claim upon which relief can be granted, including, but not limited to, failing to adequately plead indirect or willful infringement and failing to plead infringement.
2. Sage has not engaged and is not engaging in any act that constitutes direct infringement, induced infringement, or contributory infringement, either literally or under the doctrine of equivalents, of any valid and enforceable claim of any of the patents-in-suit.
3. Sage has not engaged and is not engaging in any act that constitutes willful infringement of any valid and enforceable claim of any of the patents-in-suit.
4. The claims of the patents-in-suit are invalid for failure to meet one or more of the conditions of patentability as specified in Title 35 of the United States Code, including 35 U.S.C. §§ 102, 103, and/or 112, *et seq.* No claim of the patents-in-suit can be validly construed to cover any product or action of Sage.
5. Plaintiff's claims are barred in whole or in part by prosecution history estoppel.
6. Plaintiff's claims are barred or otherwise limited under principles of equity, including waiver, estoppel, unclean hands, and/or acquiescence and render the patents-in-suit unenforceable.
7. Plaintiff's right to seek damages is limited or barred, including, without limitation, by 35 U.S.C. § 287.



8. Plaintiff is barred by 35 U.S.C. § 288 from recovering any costs associated with this suit.
9. Plaintiff may not seek injunctive relief against Sage because the alleged damages are not immediate or irreparable.
10. Plaintiff has suffered no damages.
11. This is an exceptional case, and Sage is entitled to an award of attorneys' fees pursuant to 35 U.S.C. § 285.
12. The 376 and 989 patents are unenforceable as a result of inequitable conduct before the United States Patent and Trademark Office.

Thus, the interrogatory is unduly compound and improper under established law.

Sage further objects to this interrogatory as premature because it seeks information that is the subject of ongoing discovery and investigation, both of which are in the early stages. Discovery has just started in this case and there has been no deposition discovery. Sage objects to this interrogatory as premature to the extent it seeks information in advance of the timelines set forth in the Default Standard or the Case Scheduling Order, including the date for invalidity contentions. Sage objects to this interrogatory to the extent it seeks information which is protected by any applicable privilege, including attorney-client privilege and/or work product immunity doctrine. Sage objects to this interrogatory because it attempts to impose obligations on Sage beyond and/or inconsistent with those set forth in the Federal Rules of Civil Procedure, the District of Delaware Local Rules, the Default Standard, the Case Scheduling Order, the Protective Order, or any Order of the Court.

Subject to and without waiving any general or specific objections, Sage hereby incorporates Sage's Answer and Defenses (D.I. 8), which explain the basis of its defenses. Sage

also incorporates its responses to Interrogatories Nos. 1-3 and 5-8, which relate to at least some of its affirmative defenses, as well as its Invalidity Contentions, including its Initial Invalidity Contentions dated September 15, 2022 and Final Invalidity Contentions dated January 31, 2023. Further, Sage incorporates by reference its Fourth Supplemental Response to PureWick's Interrogatory No. 5 in PureWick I, which sought similar information as it related to that case.

For example, Sage has not engaged and is not engaging in any act that constitutes direct infringement, induced infringement, or contributory infringement, either literally or under the doctrine of equivalents, of any valid and enforceable claim of any of the patents-in-suit. Sage incorporates Sage's responses to Interrogatory No. 2 and Sage's Answer and Defenses (D.I. 8). In addition to there being no direct infringement, Sage does not have the requisite specific intent to infringe or knowledge of infringement of the '989 patent required for inducement of infringement or contributory infringement. Sage does not offer to sell or sell within the United States or import into the United States any component knowing that it is especially made or especially adapted for use in infringement of the '989 patent. No third party directly infringes the '989 patent via use of a PrimaFit<sup>®</sup> 2.0 product.

In addition, for example, Sage has not engaged and is not engaging in any act that constitutes willful infringement of any valid and enforceable claim of any of the patents-in-suit. It is PureWick's burden to establish willful infringement. Sage has not and cannot willfully infringe the 376 and 989 patents as explained previously in response to Interrogatory No. 3. Not only does PureWick fail to provide any evidence that would satisfy the requisite elements for willfulness, Sage cannot willfully infringe an invalid and/or not infringed patent. Sage also incorporates its responses to Interrog. No. 3.

The claims of the patents-in-suit are invalid for failure to meet one or more of the conditions of patentability as specified in Title 35 of the United States Code, including 35 U.S.C. §§ 102, 103, and/or 112, et seq. No claim of the patents-in-suit can be validly construed to cover any product or action of Sage. As a preliminary matter, in the PureWick I litigation, the priority date of the patents-in-suit were determined to be the filing dates (September 8, 2016, and June 1, 2017). The patents-in-suit are therefore invalid in view of admitted sales, offers for sales, and disclosures made by PureWick starting in fall 2015. Sage incorporates for example PureWick 0027004, 23811, which document sales of the PureWick well before the two priority dates. Sage further incorporates the expert reports of Mr. Sheldon and Dr. Newman. Recent discovery further confirms that there are numerous additional invalidating disclosures. Indeed, the recent document production of the Newtons as well as Kate Pawlik establish that PureWick repeatedly publicly demonstrated its product publicly without any obligation of confidentiality during the spring and summer of 2015, more than a year before the priority dates including to Kate Pawlik and others. These products embodied the claimed invention (every element) as discussed during the depositions and Ray and Camille Newton as well as Kate Pawlik or were obvious variants to the extent that each product did not include a reservoir as Mr. Newton testified at trial. As discussed herein, none of these products were disclosed to the Patent Office. Sage incorporates the Pawlik production and Pawlik deposition exhibits including at Pawlik\_004717-18, and new documents produced by the Newtons including at PWNewton\_0003719. As discussed in correspondence with PureWick, PureWick failed to produce evidence of these invalidating disclosures in the PureWick I matter despite numerous emails from the Newtons which should have been produced in PureWick I including agreed upon search terms. This withheld evidence is extremely prejudicial. Indeed, as discussed during the deposition of Kate Pawlik, in addition to providing free PureWick products to Kate

Pawlik prior to May 2015. PureWick offered to sell Ms. Pawlik invalidating PureWick products in May 2015. (See above and see deposition testimony of Ms. Pawlik.) Sage further incorporates the deposition testimony of the Newtons, both in PureWick I, the PureWick I trial, and any forthcoming deposition testimony.


Moreover, based at least in part on the claim constructions being presented by PureWick to allege infringement in the present litigation against PrimaFit 2.0 (which differ from the constructions offered by PureWick in the PureWick I litigation), the claims are also anticipated by and obvious in view of at least U.S. Patent Nos. 3,349,768, 4,747,166, 4,886,508, 4,886,509, 5,002,541, 5,678,564, 6,888,044, 7,220,250, 7,695,460, 7,749,205, and/or 8,287,508, U.S. Patent Publication Nos. 2004/0128749, 2005/00549981, 2006/0015080, 2009/0264840 and/or 2013/0006206, European Patent Publication Nos. EP0613355 and/or EP1504737, Japanese Patent Publication Nos. JP2003126242, JP11113946, British Patent Publication GB2148126, the OMNI AMXD/Dmax product, and/or International Publication and/or WO2000/057784, which disclose every element of the claims. Sage additionally hereby incorporates by reference its Invalidity Contentions, including its Initial Invalidity Contentions dated September 15, 2022 and its final invalidity contentions.

As Sage explained in its September 22, 2022 Preliminary Identification of Claim Constructions, the claim elements have their plain and ordinary meaning (to the extent not indefinite) in view of the specifications, prosecution histories (including prosecution disclaimers as discussed above), and the knowledge of the ordinarily skilled artisan. That ordinary meaning is also reflected by PureWick's litigation statements that bear on the meaning of the term and likewise offer a preclusive effect. For example, based on PureWick's own representations, a "reservoir" must "aggregate urine." PureWick's infringement contentions fail to support that any

aspect of the PrimaFit 2.0 has a structure that “aggregates urine,” much less the area at the end of the device as claimed. To the extent that an element is missing from any one of the foregoing references or references disclosed in Sage’s Invalidity Contentions, that element would have been obvious in view of other prior art or the knowledge of a person of ordinary skill in the art.

That is particularly true, here, where Plaintiff alleges that a product with no reservoir includes a fluid reservoir. Indeed, in the PureWick I litigation, PureWick took the position that a product with a reservoir at the end of the casing has no reservoir. For example, claims of the 376 and 989 Patents are anticipated by and obvious in view of at least Sanchez (U.S. Patent No. 8,287,508) and Kuntz (U.S. Patent No. 4,747,166), particularly as PureWick is now interpreting the claims. Plaintiff’s claims are barred in whole or in part by prosecution history estoppel as outlined herein and in Sage’s Answer to PureWick’s Complaint. After the claims were rejected by the Patent Office as anticipated by Kuntz, PureWick represented to the Patent Office that Kuntz did not include a reservoir at a first end because the support within the Kuntz casing extended to the end of the product (as it does in the accused PrimaFit 2.0) product. PureWick now takes a contrary position in this litigation alleging that a product with the configuration of Kuntz infringes. Later, the Patent Office rejected pending claims as obvious in view of Sanchez and Kuntz. The independent claims were then amended to require “wherein the fluid permeable support is distinct from and at least proximate to the fluid reservoir” to overcome this art and the Examiner subsequently allowed the claims. However, numerous prior art references disclosed a fluid permeable support that extended to the end of the casing as well as a fluid permeable support distinct from the fluid reservoir. PureWick is estopped by this prosecution history as explained throughout these interrogatory responses as well as Sage’s Answer to PureWick’s Complaint.

In addition, PureWick's allegations of infringement by the PrimaFit 2.0 in PureWick II are barred under the doctrine of estoppel including judicial estoppel and claim preclusion. With regard to the claims of both patents-in-suit, PureWick's current positions are in direct contradiction to its claim interpretation in PureWick I, upon which it has prevailed to date, including its positions regarding no invalidity based upon WO2007042823A2 ("Van Den Heuvel 823"). For example, in PureWick I, PureWick repeatedly contended that an area at the tapered end of a product between a permeable support and a casing, such as that disclosed in Van Den Heuvel 823 (item 4), is not a "reservoir" because a reservoir must "aggregate urine." For example, PureWick repeatedly contended that, unlike a product that had a cap (such as the product at issue in PureWick I), a product that had an area at the end (such as the product in Van Den Heuvel) was not a reservoir, because for example there is allegedly no evidence "that urine could accumulate in that space" and "no place for fluid to aggregate." (Trial Tr. at 1174, 1162; D.I. 345, PureWick's May 19, 2022 Opp. to Sage's Post-Trial Motions at 14-15.)



Yet, now that Sage's product has been modified to remove the cap, PureWick now argues the opposite and asserts infringement against PrimaFit 2.0 even though it removes the very features that PureWick had alleged was the reservoir in PureWick I (the cap) and uses the prior art features that PureWick claimed were not covered by its patent (see also *infra*) or were not invalidating. PureWick made no effort to establish that an alleged area at the tapered end of the PrimaFit 2.0 product is a "reservoir," e.g., that it "aggregates urine," as it previously asserted was required by that term. Nor has PureWick established that urine could accumulate during use in the area at the end of the PrimaFit 2.0 or that it is a place for fluid to aggregate. PureWick is legally estopped from taking such a position, including under the doctrine of judicial estoppel. PureWick is currently taking a position that is clearly inconsistent with its earlier position in PureWick I. PureWick's earlier position was accepted by the prior tribunal in PureWick I as of this writing. And PureWick's change in position creates an unfair advantage or detriment absent estoppel. Moreover, based on PureWick's representations in the prior litigation as well as the prosecution history (discussed *infra* and *supra*), the claims cannot be reasonably construed to cover the PrimaFit 2.0 product.

As Sage explained in its September 22, 2022 Preliminary Identification of Claim Constructions, the claim elements have their plain and ordinary meaning (to the extent not indefinite) in view of the specifications, prosecution histories (including prosecution disclaimers as discussed above), and the knowledge of the ordinarily skilled artisan. That ordinary meaning is also reflected by PureWick's litigation statements that bear on the meaning of the term and likewise offer a preclusive effect. For example, based on PureWick's own representations, a "reservoir" must "aggregate urine." PureWick's infringement contentions fail to support that any



aspect of the PrimaFit 2.0 has a structure that “aggregates urine,” much less the area at the end of the device as claimed.

As another example, the claims of the 376 and 989 patents are also invalid for being indefinite, lacking written description support, and/or lacking enablement under 35 U.S.C. § 112, particularly given PureWick’s current litigation positions. For example, at least the elements “casing,” “reservoir,” “fluid impermeable layer,” “wherein the fluid permeable support is distinct from and at least proximate to the fluid reservoir,” “tube having a first end disposed in the reservoir,” “substantially cylindrical,” and “cylindrical,” lack written description support, lack enablement, and are indefinite. PureWick’s shifting definitions of claim elements between the PureWick I and this litigation demonstrate the Section 112 problems with the claims. Claim 7 of the 989 patent is invalid for being indefinite, lacking written description support, and/or lacking enablement under 35 U.S.C. § 112, as the invention removes elements of the claimed invention that were essential to the invention, including the claimed tube, which was not described or enabled in the specification. Documents recently produced in this case by the Newtons demonstrate the applicants never conceived of such an embodiment at the time of the invention.

In addition, for example, Plaintiff’s claims are barred or otherwise limited under principles of equity, including waiver, estoppel including judicial estoppel and claim preclusion, unclean hands, and/or acquiescence and render the patents-in-suit unenforceable. [REDACTED]

[REDACTED] as discussed in Interrogatory No. 3 and Interrogatory No. 5, which are incorporated herein. As discussed in Interrogatory No. 2 and 3 (which are hereby incorporated by reference), though PureWick has been aware of the PrimaFit 2.0 product since at least December 2020 including February 2021 before the first deposition was taken by PureWick in the PureWick I case and knew that Sage



contended it was a non-infringing alternative to the product at issue in PureWick I, PureWick never sought to add PrimaFit 2.0 as an infringing product to that case or claim infringement. Indeed, PureWick was aware of the 2.0 as early as December 2020 when “2.0” was identified to PureWick as a term to be searched in email correspondence. *See, e.g.*, 2020 12 16 Scharff Email to Antons. Moreover, documents relating to the 2.0 were produced shortly thereafter in December 2020. PureWick knew that Sage had designed, developed, and launched PrimaFit 2.0, which Sage contended was a non-infringing alternative in the PureWick I litigation; however, PureWick never alleged infringement of PrimaFit 2.0 during that case but instead chose to bring this serial litigation. Sage also incorporates its discussions of PureWick’s knowledge of the PrimaFit 2.0 and failure to accuse the PrimaFit 2.0 in PureWick I from its prior filings, correspondence, and discovery responses, including in its answer (D.I. 8), and, from PureWick I, Sage’s Opposition to PureWick’s Post-Trial Motions (D.I. 344), Opening and Reply Briefs in Support of its Motions for Summary Judgment and To Exclude PureWick’s Experts (D.I. 204, 205, 255, 256), and Opposition to PureWick’s Motion to Exclude Expert Testimony of Donald Sheldon and Vincent Thomas (D.I. 232). Sage further incorporates the testimony of PureWick witnesses John Gohde, Rich Morgan, Sarah Skelton, Brian Burn, and Gregory Mann, including documents discussed during those depositions relating to PureWick’s knowledge of the 2.0 product.

In the PureWick I litigation, PureWick did not identify PrimaFit 2.0 as an infringing product and did not accuse the product of infringing (despite numerous interrogatories on the topic and PureWick bearing the burden of proving the lack of non-infringing alternatives to support its damages claims). The first time any allegation of infringement arose was in Reply expert reports when Sage had no chance to respond.

PureWick knew that Sage contended that the PrimaFit 2.0 product was a non-infringing alternative design to the PureWick product. In an interrogatory response relating to non-infringing alternatives, Sage identified numerous documents relating to the PrimaFit 2.0 design including, among other things, directions for use, pictures of the product, specifications and drawings, and a business plan relating to the development and release of the product. Sage also identified documents about PrimaFit 2.0 that PureWick had included in its own witness binders. PureWick questioned virtually every Sage fact witnesses about the PrimoFit 2.0 product. Sage even deposed a witness whose sole relevance to the PureWick I litigation was to discuss the structure and function of that product as a non-infringing alternative. Another Sage witness deposed in March 2021 testified that the PrimaFit 2.0 product had been launched in 2019. In March 2021, PureWick also inspected the PrimaFit 2.0 after having been provided detailed schematics. Yet, PureWick never brought a claim of infringement against Sage.

Additional details regarding Sage's disclosures to PureWick regarding PrimaFit 2.0 are discussed in the following filings in the PureWick I litigation, which Sage incorporates by reference including the documents cited and referenced therein: Sage's Opening and Reply briefs on its motion to exclude and strike the testimony of John Collins (including, for example, D.I. 205 at 8-10 and D.I. 255 at 5); Sage's Opposition to PureWick's Motion to exclude the expert opinions of Donald Sheldon and Vincent Thomas (D.I. 232 at 1-4); and Sage's Opposition to PureWick's Motion In Limine No. 3 to Preclude Evidence or Argument that Sage's PrimaFit 2.0 Non-Infringing Alternative is Commercially Available (D.I. 308). Yet despite the pending lawsuit on the 376 and 989 patents, PureWick never attempted to add an infringement claim relating to PrimaFit 2.0 to the PureWick I litigation. Nor did PureWick respond to Sage's interrogatory asking PureWick to identify why any asserted non-infringing alternatives (such as PrimaFit 2.0) were not

infringing. Despite knowing about the PrimaFit 2.0, PureWick never raised any infringement or potential infringement issues relating to the PrimaFit 2.0 and the 989 or 376 patents in any correspondence between the parties, during any meet and confers between the parties, or during any conferences with the Court. Discovery closed in April 2021 and PureWick never raised any infringement allegations with regard to that product.

After the close of fact discovery, the PureWick I litigation proceeded through the close of expert discovery and motions for summary judgment. Indeed, despite PureWick's burden of establishing the absence of non-infringing alternatives, PureWick's opening expert reports never asserted with any detail that PrimaFit 2.0 was "infringing." It was not until its Reply expert report, filed months later, that PureWick unexpectedly asserted infringement and even then, PureWick did not seek to add the PrimaFit 2.0 into the case or raise cognizable claims of patent infringement.


Thus, in its correspondence and meetings with Sage and the Court throughout the PureWick I litigation, PureWick never accused the PrimaFit 2.0 of infringement and never referenced any issues related to infringement and the PrimaFit 2.0. PureWick's actions and inactions led Sage to believe that PureWick did not believe that the PrimaFit 2.0 infringed any PureWick patents. Instead of lodging new infringement allegations during the PureWick I litigation such that the cases could have been tried together, PureWick misleadingly allowed Sage to continue to move forward with the PrimaFit 2.0 product. In moving forward with the PrimaFit 2.0 product, Sage relied on PureWick's actions and inactions and the fact that Sage had not been accused of infringement or sued for infringement by PureWick.

Almost a year after PureWick became aware of PrimaFit 2.0 product (and Sage's contention that it was a non-infringing alternative), PureWick changed course with the filing of this lawsuit. Sage has suffered prejudice as a result of PureWick's actions and inactions. Sage

would be materially prejudiced if PureWick was allowed to proceed with its charge of infringement of the 376 and 989 patents after never previously referencing any alleged rights in its dealings with Sage. Because PureWick misleadingly allowed Sage to improve and expand its product by investing in research and development, PureWick's deceptive conduct bears directly upon its allegations of infringement of the 376 and 989 patents. Moreover, as explained further below, PureWick further exacerbated the prejudice to Sage in this lawsuit by failing to preserve documents in anticipation of litigation (namely the PureWick email server). It now appears that, while PureWick initially represented that emails prior to its acquisition by C.R. Bard ("Bard") were misplaced, the extent of lost emails extends beyond that. This resulted in the loss of documents relating to Sage's invalidity defenses, among other things, including evidence of PureWick's invalidating sales and evidence supporting Sage's inequitable conduct claim and other equitable defenses.

Additionally, PureWick is barred by principles of estoppel from asserting infringement of the PrimaFit 2.0 product, as discussed above. Again, with regard to the claims of both patents-in-suit, PureWick's current positions are in direct contradiction to its claim interpretation in PureWick I, upon which it has prevailed to date, including its positions regarding no invalidity based upon WO2007042823A2 ("Van Den Heuvel 823"). For example, in PureWick I, PureWick repeatedly contended that an area at the tapered end of a product between a permeable support and a casing, such as that disclosed in Van Den Heuvel 823 (item 4), is not a "reservoir" because a reservoir must "aggregate urine." For example, PureWick repeatedly contended that, unlike a product that had a cap (such as the product at issue in PureWick I), a product that had an area at the end (such as the product in Van Den Heuvel) was not a reservoir, because for example there is allegedly no evidence "that urine could accumulate in that space" and "no place for fluid to aggregate." (Trial

Tr. at 1174, 1162; D.I. 345, PureWick's May 19, 2022 Opp. to Sage's Post-Trial Motions at 14-15.)



Yet, now that Sage's product has been modified to remove the cap, PureWick now argues the opposite and asserts infringement against PrimaFit 2.0 even though it removes the very features that PureWick had alleged was the reservoir in PureWick I (the cap) and uses the prior art features that PureWick claimed were not covered by its patent (see also *infra*) or were not invalidating. PureWick made no effort to establish that an alleged area at the tapered end of the PrimaFit 2.0 product is a "reservoir," e.g., that it "aggregates urine," as it previously asserted was required by that term. Nor has PureWick established that urine could accumulate during use in the area at the end of the PrimaFit 2.0 or that it is a place for fluid to aggregate. PureWick is legally estopped from taking such a position, including under the doctrine of judicial estoppel. PureWick is currently taking a position that is clearly inconsistent with its earlier position in PureWick I. PureWick's earlier position was accepted by the prior tribunal in PureWick I as of this writing.

And PureWick's change in position creates an unfair advantage or detriment absent estoppel. Moreover, based on PureWick's representations in the prior litigation as well as the prosecution history (discussed supra), the claims cannot be reasonably construed to cover the PrimaFit 2.0 product.

Further, there are additional grounds for unenforceability including unclean hands. In the current litigation, PureWick is asserting claim construction positions that are contrary to the positions that it took in the PureWick I litigation in advocating no invalidity and PureWick is estopped from doing so under principles of waiver, estoppel including judicial estoppel and claim preclusion, and acquiescence. In addition to its misleading statements, PureWick further acted inequitably with regard to the PrimaFit 2.0 including making false representations about PrimaFit 2.0 and about its purported lack of knowledge regarding that product and its launch in the PureWick I litigation. Additionally, during the course of the PureWick I litigation, PureWick representatives, Camille and Ray Newton, gave false testimony either during their depositions or at trial regarding sales of their female external catheter to the Connect Foundation, wasting significant resources litigating an issue, which they knew to be false.

An example of this testimony from Mr. Newton is reflected below:



Mr. Newton's Deposition Testimony	Mr. Newton's Trial Testimony
<p>Q. And did you indicate in the award submission that <u>the PureWick female external catheter</u> was sold on July 26th, 2015?</p> <p>THE WITNESS: <u>Yes</u>.</p> <p>Q. And were you honest in your submission that the product had been launched on July 23rd, 2015?</p> <p>THE WITNESS: <u>Yes</u>, we were honest.</p> <p>Q. Were you honest in your submission that the product was sold on July 26th, 2015?</p> <p>THE WITNESS: <u>Yes</u>.</p> <p>Q. Okay. And did you make a sale of the product on July 26th, 2015?</p> <p>THE WITNESS: Well, that's the date that we put on the form, <u>so I would say so</u>.</p> <p>(D.I. 211, Ex. 47 at 204:3-205:1.)</p>	<p>Q. And did you indicate in the award submission that the PureWick female external catheter was sold on July 26, 2015?</p> <p>A. Yes, the dry dock was sold, <u>we sold them a dry dock</u>.</p> <p>(Tr. at 319:22-25.)</p> <p>Q. But the female external catheter product, the dry dock is not an external natural catheter, female external catheter whatsoever, right?</p> <p>A. Well my undergo [sic] was a PureWick product had to be sold, so we sold the PureWick product at that time. Because <u>we didn't have any of the wicks ready for sales at that time</u>.</p> <p>(Tr. at 320:6-12.)</p>

An example of this testimony from Camille Newton is reflected below:

Dr. Newton's Deposition Testimony	Dr. Newton's Trial Testimony
<p>Q. In looking at the second page of the document, the last two lines of the second page, did PureWick indicate in the award submission that the <u>PureWick female external catheter</u> was launched on July 23rd, 2015?</p> <p>THE WITNESS: <u>That is what it says on here, yes.</u></p> <p>BY MS. FRANTZEN: Q. And did PureWick indicate in the award submission that the <u>PureWick female external catheter</u> was sold for -- the date of first sale was July 26th, 2015? ***</p> <p>THE WITNESS: <u>It does say that on there, yes.</u></p> <p>(D.I. 211, Ex. 46 at 214:1-8.)</p>	<p>Q. And if we go to the second page of the award, we talked about this earlier, you told CONNECT that you sold the product on July 26th, 2015?</p> <p>A. We sold it -- that was for the <u>dry dock</u> that we sold [REDACTED] -- DD and, or DD, that was for the dry dock that we sold her, and that was a component of our product.</p> <p>***</p> <p>Q. So when you applied in July 27th, 2015, and said you had a first sale on July 26th, 2015, you didn't say it was just for the dry dock, right?</p> <p>A. No, we did not.</p> <p>Q. And did PureWick indicate in the award submission that the PureWick female external catheter that the date of first sale was July 26th, 2015?</p> <p>A. We indicated that July 26th, 2015, was the date of our first sale in our application for the MIP product.</p> <p>Q. Did you indicate that it was for the PureWick female external catheter?</p> <p>A. We indicated that was the date of our first sale.</p> <p>Q. For the catheter?</p> <p>A. <u>For the dry dock.</u></p> <p>(232:10-233:9.)</p> <p>Q. So it's your testimony that you thought you had the most innovative product when you didn't even have a product and when you knew you had to generate sales to even apply?</p> <p>A. We were optimistic, yes.</p>

Other examples of PureWick's changed testimony are reflected in D.I. 312, pages 2 to 7, in the PureWick I litigation, which is hereby incorporated by reference. The misconduct outlined has an immediate and necessary relationship to the relief PureWick now seeks. Moreover, Mr. Newton



falsely testified at trial regarding when he conceived of a reservoir at the end of the device, and Sage incorporates the production of the Newtons.

Sage has recently discovered that the Newtons failed to produce numerous documents (emails) evidencing invalidity in the PureWick I case including documents that included search terms that the parties agreed to search as has been document in correspondence between counsel. These documents evince public disclosures and offers for sale that were never disclosed by PureWick either in documents or interrogatory response. PureWick's failure to produce requested emails and withholding them until the present action was improper, prejudicial, and has caused significant harm. Worse, the public disclosures and offers for sale should have been disclosed in interrogatory responses, but never were.

For example, the 376 and 989 patents are also unenforceable as a result of inequitable conduct before the United States Patent and Trademark Office. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Patent Office including inventors and prosecuting attorneys. Specifically, at least one of the individuals who owed a duty of candor and good faith to the Patent Office relating to the prosecution of the 376 and 989 patents, including Marcus Simon, an attorney who prosecuted the 376 and 989 patents, and Camille and Ray Newton, named inventors of the 376 and 989 patents, withheld material information from the U.S. Patent Office.

The 989 Patent was filed on September 8, 2016. The 989 Patent claims priority to several patent applications including a patent application filed in June 2016 ("the 968 application") as well as three provisional applications filed in March 2014 and November 2014 and their three follow-on utility applications. The 989 patent does not share a common specification with any of these seven applications and is identified as a continuation-in-part of these applications.

The 989 patent also claims priority to, and purports to be a continuation of, Application No. PCT/US2016/049274, which was filed on August 29, 2016 (“the August 2016 PCT Application”). The August 2016 PCT Application included material from the seven earlier applications but also added additional new matter. The 989 patent contains generally the same specification as the August 2016 PCT Application.

The 376 patent was filed on June 1, 2017. The 376 patent claims priority to, and purports to be a continuation-in-part of, the 989 patent. The 376 patent also claims priority to the several applications as well as the August 2016 PCT Application. The 376 patent also claims priority to two additional applications filed in October 2016 and April 2017. The 376 patent does not share a common specification with any of these applications and is identified as a continuation-in-part of the 989 patent. The established effective filing date of the 989 patent based on the PureWick I litigation is no earlier than September 8, 2016. The established effective filing date of the 376 patent based on the PureWick I litigation is no earlier than June 1, 2017.

Even though the Patent Office had repeatedly determined that claims of the '989 patent were not entitled to earlier priority date, these individuals withheld information about the public disclosure, use, offer for sale, and sale more than one year prior to the filing dates of PureWick products that embody the claimed inventions and obvious variations thereof from the Patent Office during the prosecution of those patents with the intent to deceive the Patent Office. At least Marcus Simon and/or Camille and Ray Newton, who each owed a duty of candor to the Patent Office, were aware of one or more of these public disclosures, uses, and offers for sale prior to September 8, 2015 and June 1, 2017. Yet, no one involved in the prosecution of the applications disclosed them to the Patent Office.

For example, in the trial of the PureWick I litigation, the Newtons testified that “hundreds and hundreds and hundreds” of products were made and tested, that they were preparing product advertisements for products by May 2015, that they were seeking marketing opportunities with the Connect Foundation for the products by July 2015, and had even submitted information to Connect about a product that they had claimed had been “launched” and “sold,” but which they later testified was falsely made so as to obtain an award. As discussed above, PureWick publicly disclosed, used, and offered for sale obvious variants of the PureWick device (if not anticipatory) in the spring and summer of 2015 including to Kate Pawlik and others (including an offer for sale in May 2015 previously not disclosed to Sage). These are documented in the Pawlik production as well as the Newton productions. Sage incorporates the deposition of Ms. Pawlik as well as depositions of the Newtons including exhibits. None of these highly material products were disclosed to the Patent Office despite the fact that the Newtons knew about them and knew of their obligation to disclose prior art products. PureWick knew of its obligation to disclose these prior art devices. (*See* Dorsey production; Camille Newton Dep. Tr., Ray Newton Dep. Tr., Burn Dep. Tr., Lorena Eckert Tr., and exhibits.)

Contrary to what was represented at trial, during their depositions, the Newtons testified that they were manufacturing and selling products by July 2015 (consistent with what was said to Connect). Indeed, the new evidence produced by Ms. Pawlik (and subsequently the Newtons) shows that PureWick was manufacturing and offering for sale products as early as May 2015 and exchanging such products for consideration. At trial, the Newtons said the opposite—that they were not making or selling products. The trial testimony, as well as the testimony of Ms. Pawlik, also shows that products were used and tested with no obligation of confidentiality. The “hundreds and hundreds” of undisclosed products that were used and tested with no obligation of

confidentiality and the marketing efforts were material to patentability. For example, evidence of products manufactured by PureWick that includes all the elements of the claimed inventions (or an obvious variant thereof including to the extent that PureWick claims that the devices did not have a reservoir) is depicted in PureWick22332-22333, rendering the claims both anticipated and obvious. But for the failure to disclose to the Patent Office that the PureWick products—which included all of the elements of the pending claims or obvious variations thereof—were publicly disclosed and used more than a year before the September 8, 2016, and June 1, 2017, filing dates of the 989 and 376 patents, the Patent Office would have rejected the claims of the 989 and 376 patent as anticipated or obvious in view of those products.

The most reasonable inference to be drawn from the evidence is that Simon and/or the Newtons, who each owed a duty of candor and good faith to the Patent Office, knew of the materiality of PureWick's products, yet failed to disclose any of them during the prosecution of the 376 and 989 patents and did so with the specific intent of deceiving the Patent Office and prevented the Patent Office from considering highly material publicly-available information. The Newtons testified at trial that they were involved in the prosecution of the patents-in-suit with Ray Newton testifying that he often distinguished prior art with his attorney. This intent is further evidenced by additional statements made about the lack of relevant references during this time period that were made during the prosecution of the 989 patent as discussed herein. At least this omission renders the claims of the 989 and 376 patents unenforceable.

Moreover, during the prosecution of the '989 patent, PureWick attorney Marcus Simon made repeated material false and misleading statements to the Patent Office suggesting that there was no relevant prior art between March 2014 (the earliest potential priority date) and August 29, 2016 (the effective priority date determined by the Patent Office). During the prosecution of

the '989 patent application, the Patent Office issued an Office Action on or about September 26, 2018, stated that pending claims 9-14 of the '989 Patent application (which correspond to issued claims 1-6 of the '989 Patent) were not supported by multiple earlier filed applications. The Patent Office thus concluded that "Claims 9-14 have an effective filing date of August 29, 2016," which was the filing date of the August 2016 PCT Application. The Patent Office stated in the September 2018 Office Action: "Should the applicant disagree with the examiner's conclusion, please kindly point out the specific passages in the parent application that provides support for the claims."

On or about December 20, 2018, PureWick attorney Marcus Simon responded to the September 2018 Office Action. Despite the Patent Office's request to "point out the specific passages in the parent application that provides" claim support, PureWick refused to do so in its response. Rather, PureWick represented that it need not provide the priority date information because relevant prior art references between the earliest potential priority date (March 2014) and the application's date of filing (September 2016) had not been identified. PureWick misleadingly did not advise the Patent Office of any of the "hundreds and hundreds and hundreds" of PureWick products that were being tested as well as PureWick's market efforts despite having knowledge of them and despite their high materiality to patentability.

Specifically, PureWick's attorney represented to the Patent Office:

Applicant will not "point out the specific passages in the parent application that provides support for the claims" at this time because the PTO should not have made a determination regarding the support for the claims. For example, the MPEP states that "[t]he only times during ex parte prosecution that the examiner considers the merits of an applicant's claim of priority is when a reference is found with an effective date between the data of the [reference's] filing and the [present application's] date of filing." MPEP § 216.

By making these statements, PureWick's attorney was representing to the Patent Office that there were no relevant references or public disclosures during the intervening period between

March 19, 2014 (the earliest potential priority date) and August 29, 2016 (the priority date identified by the Patent Office).

PureWick's statements to the Patent Office in the December 2018 PureWick Response were false and misleading. These statements were false and misleading given that PureWick's products were demonstrated, offered for sale, and purported to be sold between March 2014 and September 8, 2015 (as well as up to and including June 1, 2016). At the time PureWick's attorney made these statements, he was aware of public disclosures of PureWick's products described in the patent applications during the period between March 2014 and August 2016 including certain of the PureWick products. Moreover, the Newtons were also aware of public testing of their products as well as marketing efforts and disclosures to the Connect Foundation.

On or about February 14, 2019, the Patent Office issued another Office Action. The Patent Office again asserted that pending claims 9-14 were not supported by any of the earlier filed applications, and again concluded that "[c]laims 9-14 have an effective filing date of August 29, 2016." The Patent Office stated that it made this assessment of the priority date "for clarity of the record."

On or about May 13, 2019, PureWick submitted a response to the February 14, 2019 Office Action. In the May 2019 PureWick response, rather than disclosing any of the "hundreds and hundreds and hundreds" of PureWick products, any of its non-confidential testing, its marketing efforts, or advising the Patent Office about its public application to the Connect Foundation, PureWick's attorney again represented to the PTO that PureWick was not required to identify the specific passages in the parent applications that provided support for the claims because there were no relevant references or public disclosures between March 2014 (the earliest potential priority date) and August 29, 2016 (the priority date identified by the Patent Office).

Specifically, PureWick's attorney stated:

[The] PTO should not have made a determination regarding the support for the claims. For example, the MPEP states that "[t]he only times during ex parte prosecution that the examiner considers the merits of an applicant's claim of priority is when a reference is found with an effective date between the data of the [reference's] filing and the [present application's] date of filing." MPEP § 216.

By making this statement, PureWick's attorney again represented to the Patent Office that there were no relevant references or public disclosures during the intervening period even though numerous individuals were aware of relevant and highly material information. These statements were false and misleading given that PureWick's products were publicly used, demonstrated, offered for sale, and alleged to have been sold during that period and PureWick's representatives who owed a duty of candor and good faith to the Patent Office knew about those public disclosures. Immediately following those representations that there was no intervening prior art record, the Patent Office issued a notice of allowance allowing the patent claims without ever having the opportunity to assess the materiality of PureWick's products or its multiple public disclosures. These false and misleading representations were material. But for the false and misleading statements by PureWick's attorney and the Newtons, who owed a duty of candor and good faith to the Patent Office, the Patent Office would have rejected the pending claims of the '989 patent in view of the invalidating public disclosures given that the Patent Office had already determined that the priority date was August 29, 2016.

The most reasonable inference to draw from the evidence is that the false and misleading statements, which suggested that there were no relevant intervening prior art, were made with an intent to deceive the Patent Office into allowing the pending claims without evaluating relevant prior art and without forcing PureWick to adequately support any priority claim. That is particularly true because there clearly was intervening prior art, which PureWick, including Ray

and Camille Newton, knew about, and there was no reason to suggest that there was no such prior art other than to mislead the Patent Office and avoid a determination of the priority date. The false and misleading statements resulted in the Patent Office issuing a Notice of Allowance by wrongly misleading the Patent Office as to the relevance and existence of intervening public disclosures.

These representations and omissions were particularly egregious given that PureWick had applied for the Most Innovative New Product award allegedly for the claimed invention and relied on that award as evidence of secondary considerations of nonobviousness. The award application required that sales of the product be made and, in the award application, the Newtons represented that the product was launched and sold by July 23 and July 25, 2015, respectively. At trial in the PureWick I litigation, the Newtons testified that they told Connect about selling the female catheter and sold an unpatented vacuum pump, which was used with the catheters. Nevertheless, neither the Newtons nor Marcus Simon disclosed the information to the Patent Office. At least these false and misleading statements made during the prosecution of the 989 patent render the claims of the 989 patent unenforceable. Moreover, this inequitable conduct during the prosecution of the 989 patent also renders the 376 patent, which claims priority to the 989 patent, unenforceable including under the doctrine of infectious unenforceability.

This inequitable conduct during the prosecution of the 989 patent renders the 376 patent, which claims priority to the 989 patent, unenforceable. Neither Simon nor anyone involved in the prosecution of the 376 patent advised the Patent Office of the false and misleading statements during the prosecution of the 376 patent. Based on the foregoing, Sage is entitled to a judgment that the 376 patent is unenforceable due to this inequitable conduct committed during the prosecution of the 989 patent including under the doctrine of infectious unenforceability. In addition, PureWick advised Sage (after the parties had already exchanged and agreed upon search



procedures for electronic searching) that PureWick failed to preserve what PureWick described as a legacy PureWick server. As detailed in correspondence on this issue in PureWick I, including in an email from Ryan Pianetto dated February 12, 2021, this server contained critical information relating to Sage's defenses, including its prior art defense relating to the on-sale bar and information regarding the valuation of the patents. Sage understands that the server contained PureWick emails (including emails with inventors) from prior to PureWick's acquisition. Sage has also recently ascertained for the first time that it appears the "missing" or "lost" server actually also contained information post-dating the acquisition—a fact previously withheld from Sage. PureWick's email is highly germane to issues in this case. At least several of the identified PureWick custodians are legacy PureWick employees. The email server would contain historical communications and information related to development of the PureWick products and patents, invalidating disclosures to third parties, prior art, and other information regarding inventors, to name a few items, most or all of which would have been from a time period prior to the PureWick acquisition by Bard. For example, as discussed above, Camille Newton testified at trial that "hundreds and hundreds and hundreds" of products were made and tested, yet PureWick did not produce corresponding documentation. Also as discussed above, PureWick had submitted information to Connect about a product that they had claimed had been "launched" and "sold," but at trial in the PureWick I litigation, the Newtons changed their testimony and claimed the catheter was never sold at all. Information resolving this contradiction could also have been present on the missing server. Further yet, Camille Newton revealed for the first time at trial that PureWick had engaged in discussions with several third party companies (including First Quality, Molnlycke and Medline) regarding a potential acquisition of PureWick and its technology, yet despite Sage seeking discovery on this issue, PureWick never identified these entities as having relevant

knowledge and relevant documents may have been on the missing server. Indeed, one of the invalidity issues here revolved around PureWick's disclosures to third parties (including via email) prior to the priority date, which occurred before the acquisition. Moreover, recent discovery appears to suggest that documents well after the acquisition date are missing as well, which was withheld from Sage. PureWick never disputed that it was under the obligation to preserve PureWick email at the time the server was "shut down" in early to mid-2019, mere months before PureWick filed its Complaint in this case. PureWick indicated that it searched Bard employee email for correspondence with PureWick. Bard employees, however, would not have been privy to PureWick legacy correspondence. Particularly troubling is that Sage was unaware until late in PureWick I that PureWick emails were irrecoverable, when the parties were negotiating the email searching protocols for that case, because PureWick did not inform Sage that PureWick/Bard failed to preserve them at that time. Many of the search terms that Sage identified in PureWick I were prior art terms or terms relating to prior communications on invalidating disclosures. And, again, Sage has only recently learned that the loss of PureWick emails is likely more extensive than previously disclosed and may extend well after the PureWick acquisition as originally claimed. Sage has been significantly prejudiced in its ability to present its defenses due to PureWick's failure to preserve evidence. Moreover, PureWick has recently exacerbated this prejudice by refusing to adequately search for documents from its own inventors, which prompted a motion to compel, which was granted. PureWick also attempted to block all third party discovery by ten third parties despite its obvious relevance, which was denied by Magistrate Judge Hall. PureWick's conduct with regard to Kate Pawlik was especially inappropriate. For example, before PureWick's attorneys became involved, Pawlik had no objections, agreed to produce subpoenaed

documents (which she indicated was about 100 emails), and document collection was proceeding. (D.I. 62, Def. Ex. 15.)

Additionally, after stating that it was not withholding documents or information on the basis of estoppel, and after PureWick lost its motion for a protective order based on estoppel, PureWick inappropriately refuses to produce Rule 30(b)(6) witnesses based on estoppel. Moreover, PureWick continued to fail to produce relevant documents and information as documented by correspondence including in Sage's correspondence dated October 28, 2022, November 28, 2022, December 2, 2022, December 14, 2022, and December 30, 2022.

This is also an exceptional case, including for all of the reasons discussed above. The baseless allegations of patent infringement made by PureWick against Sage are causing irreparable damage to Sage. Since the conduct of PureWick renders this case to be "exceptional" under 35 U.S.C. § 285, Sage has a right to recover its reasonable costs, expenses and attorneys' fees. For example, PureWick's inequitable conduct in procuring the Asserted Patents, inconsistent claim construction, validity, and infringement positions between PureWick I and PureWick II despite being estopped, its conduct relating to the missing server, bad faith litigation, and the false statements of its witnesses at trial all render this case exceptional. Sage further reincorporates all of its statements above and its Answer and Defenses to Plaintiff's Complaint (D.I. 8), which explain the basis for Sage's affirmative defense that this is an exceptional case, and the basis for Sage's right to an award of attorneys' fees pursuant to 35 U.S.C. § 285. The other deficiencies have been discussed repeatedly in this case. Moreover, Plaintiff's litigation misconduct also warrants fees. For example, Plaintiff has resisted responding to interrogatories and requests for production on critical issues, most notably with regard to its own prior art products and other prior art in its possession, as explained in an October 28, 2022 letter from Ryan J. Pianetto to Nicola

Felice, a November 7, 2022 letter from Ryan J. Pianetto to Nicola Felice, and a November 28, 2022 email from Ryan J. Pianetto to Nicola Felice, which are hereby incorporated by reference (and many other pieces of correspondence). Indeed, PureWick produced little document production. PureWick also refused to search for responsive communications it held with the named inventors, forcing Sage to move to compel. PureWick also moved for a protective order in this case on behalf of subpoenaed third-parties in view of its motion for judgment on the pleadings related to issues of collateral estoppel and res judicata. PureWick, however, had already represented to Sage that it was not withholding documents from PureWick based on its motion for judgment on the pleadings, and offered no unique reason for moving for a protective order on behalf of third parties. PureWick moved on behalf of parties that its counsel did not represent, and also interfered with the production of at least one third-party, Kate Pawlik, who had already searched for responsive documents and agreed to produce them until counsel for PureWick contacted the third party and moved for a protective order. PureWick's motion was denied. Moreover, after PureWick's motion was denied, PureWick nonetheless continues to resist discovery based on its motion for judgment on the pleadings. For example, after its motion was denied, PureWick served objections to Sage's notices of deposition under Rule 30(b)(6) to PureWick Corporation dated January 13, 2023 where PureWick continues to object on the grounds that the discovery Sage seeks is "barred by collateral estoppel and/or res judicata," refusing to designate a witness to testify for nearly half of the topics requested by Sage.

Further, as discussed above, throughout this case (and the PureWick I case), PureWick and its counsel, who represents third parties including Camille Newton, Ray Newton, Kate Pawlik, Lorena Eckert, and Michael Jackson, continued to withhold relevant, non-privileged documents responsive to Sage's requests for production to PureWick and requests to the third parties served

pursuant to subpoena in November and December 2022, throughout the discovery period. As discussed, Sage was forced to move to compel PureWick and the third parties multiple times, and, further, Sage was forced to defend PureWick's baseless motion for protective order. The Court ordered production, yet PureWick and the third parties, via their counsel, continued to withhold documents for months, misrepresented that they had produced all responsive documents when they had not, undertook unreasonable, insufficient searches for responsive documents (withholding clearly relevant and responsive documents including failing to produce them in PureWick I), and delayed production until late in an extended discovery period including after many depositions had taken place. Counsel also withheld documents that were subject to requests and search terms allegedly utilized in the PureWick I case, only to eventually produce them after the Court ordered production and disclosure of search terms in PureWick II (including Pawlik\_004717-18 and PWNewton\_0003719-20, which was also held by Camille Newton, subject to keywords allegedly used to search Camille Newton's documents in PureWick I, yet not produced in the prior case). This was significantly prejudicial to Sage. Sage incorporates the correspondence between the counsel including Sage's 1/19/2023 Letter, Felice 3/10/23 Email; Sage's 3/23/2023 Letter, 3/3/23 Pianetto Email, 3/7/23 Pianetto Email; PureWick's 3/9/2023 Letter; PureWick's 3/28/2023 Letter; Emails between Counsel for Sage and PureWick in February and March, 2023; 3/24/2021 Antons email; 3/4/2021 Pianetto email.

Plaintiff's right to seek damages is limited or barred, including, without limitation, by 35 U.S.C. § 287. Despite its obligation to establish compliance with 35 U.S.C. 287, PureWick has failed to do so. PureWick failed to address compliance with Section 287 in response to Sage Interrogatory No. 4 related to PureWick's damages theories and has not asserted that the PureWick FEC products are marked with the patent numbers of the asserted patents. Thus, PureWick has not

adequately shown substantial compliance with the marking requirement with regard to the PureWick FEC. Additionally, Sage served Interrogatory No. 7 in PureWick I (which PureWick has not supplemented) which requests that PureWick “detail all facts and circumstances supporting or refuting whether any products, combination(s) of products, or system(s) were marked with any of the Asserted Patents (including any products, combination(s) of products, or system(s) referenced in Interrogatory No. 6) including all marking in compliance with 35 U.S.C. § 287, the products or materials that are so marked, the entire language used to identify the marking, where the marked products or materials can be found, the date when such marking began, and identification of all persons with knowledge of marking practices with respect to the Asserted Patents. Plaintiff’s response should include this information for each version or iteration of any marking on any product or material that refers to any of the Asserted Patents.” In its response to Interrog. No. 7 from PureWick I, PureWick admitted that its PureWick FEC product was not marked with the 376 Patent until after the PureWick I lawsuit was filed, and did not contend that any of its products are marked with the 989 patent. With regard to the 376 Patent, there is no evidence that the subsequent marking was proper and PureWick did not identify any evidence that any patent-in-suit (including the 376 Patent) actually appears on its products. Thus, PureWick has admitted that it sold unmarked products that are allegedly covered by the 376 Patent. Moreover, as discussed in PureWick I, PureWick failed to establish substantial compliance with regard to the 376 Patent. PureWick never alleged that it marked the PureWick FEC product with the patent number of the 989 Patent. Moreover, in this case, PureWick also failed to establish marking of the 989 patent and is not entitled to damages on that patent until the filing of the Complaint given its assertion of Claim 7 of the 989 Patent.

Plaintiff is also barred by 35 U.S.C. § 288 from recovering any costs associated with this suit. For example, Sage has set forth the factual and legal bases for its contention that the asserted claims of the Patents-In-Suit are invalid in its Invalidity Contentions. PureWick has not disclaimed these invalid claims and therefore is barred by 35 U.S.C. § 288 from recovering any costs associated with this suit.

Plaintiff may not seek injunctive relief against Sage because the alleged damages are not immediate or irreparable. A plaintiff seeking a permanent injunction must satisfy a four-factor test before a court may grant such relief. A plaintiff must demonstrate: (1) that it has suffered an irreparable injury; (2) that remedies available at law, such as monetary damages, are inadequate to compensate for that injury; (3) that, considering the balance of hardships between the plaintiff and defendant, a remedy in equity is warranted; and (4) that the public interest would not be disserved by a permanent injunction. *eBay Inc. v. MercExchange, L.L.C.*, 547 U.S. 388, 391, 126 S. Ct. 1837, 1839, 164 L. Ed. 2d 641 (2006). Here, an injunction would not be warranted for many of the same reasons set forth by Sage in its Opposition to PureWick's post-trial motions in PureWick I, which is incorporated by reference herein. In particular, public policy weighs against an injunction given that the PrimaFit 2.0 is superior in both efficacy and patient-safety to the PureWick device. Moreover, PureWick has not demonstrated that its alleged damages are immediate or irreparable, particularly given that PureWick waited approximately two years to sue Sage for infringement of any patent by the PrimaFit 1.0 in PureWick I and did not seek a preliminary injunction in PureWick I. PureWick also delayed in filing suit against the PrimaFit 2.0 and likewise did not seek a preliminary injunction. Again, as discussed above, PureWick knew about the 2.0 at least as early as February 2021 and knew that it had been launched in 2019. In March 2021, PureWick also inspected the PrimaFit 2.0 after having been provided detailed schematics. Additional details

regarding Sage's numerous disclosures to PureWick regarding PrimaFit 2.0 are discussed above. Moreover, PureWick was tracking Sage's products and also communicating internally about the PrimaFit 2.0 well before filing suit. Sage incorporates the deposition of Sarah Skelton and documents discussed therein. Yet, PureWick never brought a claim of infringement against Sage until January 26, 2022, showing that PureWick would not be irreparably harmed absent an injunction. Additionally, monetary damages are adequate to compensate for any injury and PureWick has not suffered any irreparable injury, for the same reasons set forth in Sage's Opposition brief to PureWick's post-trial motions in PureWick I.

Plaintiff has suffered no damages. For example, Sage has not engaged and is not engaging in any act that constitutes direct infringement, induced infringement, or contributory infringement, either literally or under the doctrine of equivalents, of any valid and enforceable claim of any of the patents-in-suit.

Additionally, "In patent cases, '[t]he burden of proving damages falls on the patentee,' . . . and '[t]he [patentee] must show his damages by evidence,' . . . Damages 'must not be left to conjecture by the jury. They must be proved, and not guessed at.'" *Promega Corp. v. Life Techs. Corp.*, 875 F.3d 651, 660 (Fed. Cir. 2017). PureWick has not proven that it has suffered any damages with any evidence. PureWick's damages model in PureWick Corporations Supplemental Identification of Accused Products, Asserted Patents and Damages Model, served on June 10, 2022, only states "PureWick identifies its initial damages model as lost profits caused by Sage's infringement and/or no less than a reasonable royalty. PureWick's damages model includes enhanced damages for Sage's willful infringement. And PureWick seeks a permanent injunction against future sales by Sage of the Accused PrimaFit® Product and Accused PrimoFit™ Product. PureWick's initial damages model is based upon information reasonably and presently available



to it. PureWick has not had the full benefit of discovery. Accordingly, PureWick reserves the right to amend and supplement its damages model, including its theory of damages and the applicable royalty base, in light of discovery and further investigation.” This provides no basis for its damages claim.

Further, Sage’s Interrogatory No. 4 asked PureWick to “[i]dentify the amount of damages that Plaintiff believes is the appropriate measure of damages should liability be established for Sage’s alleged infringement of the Asserted Patents, and describe in detail all formulas, evidence, documents, theories, calculations, and facts upon which the amount is based and describe any non-infringing alternatives and/or why such alternatives do not exist.” PureWick’s response has been inadequate as has been documented in correspondence between the parties including from Ryan Pianetto.

Nevertheless, to the extent that PureWick is entitled to a reasonable royalty, Sage states that each of the Georgia-Pacific factors supports Sage’s position that a reasonable royalty based on a hypothetical negotiation between the parties at the time of first alleged infringement would be minimal. Moreover, PureWick is not entitled to lost profits. PureWick cannot show the absence of noninfringing alternatives (nor has PureWick even attempted to despite its burden), demand for the patented product, or manufacturing and marketing capacity to make all of the sales that Sage has made of the PrimaFit 2.0 product. Sage incorporates its response to PureWick Interrogatory No. 7. Non-infringing alternatives to the 989 patent and the 376 patent include:

- a urine collection apparatus that does not include a casing
- a urine collection apparatus that does not include a reservoir including one where the alleged permeable support extends to the end of the alleged casing

- a urine collection apparatus that does not have a longitudinally elongated opening, for example a urine collection apparatus may include an array of openings
- a urine collection apparatus where the fluid permeable support is not distinct from and at least proximate to the fluid reservoir
- a urine collection apparatus where the fluid outlet is not at an end of the device opposite the reservoir
- a urine collection apparatus without a separate fluid permeable support and a fluid permeable membrane, such that the apparatus does not have a membrane supported on a support
- a urine collection apparatus where the fluid permeable membrane is only disposed across part of the elongated opening of the casing, which PureWick never disputed in the prior case.
- a urine collection device that does not have a membrane
- a urine collection device that does not have a tube with an end extending into a reservoir including one where the end of the tube is within the alleged permeable support
- a urine collection device that does not have a tube extending behind at least the portion of the support and the portion of the membrane disposed across the elongated opening, including one where any tube(s) extend only on the sides of the casing and not behind the elongated opening.

Many of the above variations are shown in the prior art of record and are standard features of the art in multiple prior art devices including, for example, as discussed in depth in Sage's Invalidity Contentions (see for example Mahnensmith 080, Mahnensmith 262, Keane 768,

Lawrence 564, Okabe 547, Lawrence 222, Cheng 133, Wolff 784, Wolff 066, Triunfol 675, Sweetser 793, Kuntz 166, Kuntz 355, Washington 508, Conkling 541, Van Den Heuvel 823, Van Den Heuvel 894, Sanchez 508 (with respect to the 376 and 989 patents), Suzuki 250, Chiku 946, Cottenden 126, Harvie 027, Hanifl 377, Ozenne 138, Bevan 395, Ishii 107, Cheng 321).

They are also modifications that can be made to the PrimaFit 2.0 device such as the ones discussed above. Sage identifies the Sage employees identified in its Rule 26 disclosures as knowledgeable on these topics.

Numerous non-infringing alternatives were on the market long before PureWick or Sage ever launched their products including: the Omni products as reflected in the production by Omni. See OMNI1-OMNI388 as well as the deposition testimony of Mark Harvie. Available Omni products which were available noninfringing alternatives included the Omni AMXDMax female product as well as the Omni UrinCare Advanced Bladder Management System. In addition to the Omni production already mentioned, these alternatives are also described, for example, in SAGE00021349-398, SAGE00040991-41277, SAGE00043339-456, and SAGE00033501-633 as well as the expert reports of Dr. Newman, which is incorporated by reference.

Another non-infringing alternative was the vacuum-assisted urine collection device described in Dr. Newman's 1997 book (see, e.g., IPR2020-01426 Exhibit 1014, The Urinary Incontinence Sourcebook, Newman, 1997, at p. 264; Newman Responsive Report Ex. G; DTX-523) and described repeatedly by Dr. Newman including in her IPR testimony, which is incorporated by reference. Other non-infringing alternative is the Van Den Heuvel device, which PureWick has claimed is publicly-available and not covered by the patents-in-suit. See SAGE00040893-40902. In addition, there are numerous other commercially-available noninfringing alternatives, including the Consure Qivi Female External Urine Management

System, the Boehringer CareDry® System, the Medline Versette female external catheter device, the Convatec female external urinary device, the Omni AMXD/DMax female product, the Brunel University Non-Invasive Continence Management System, the WellCare Smart External Urine Collection System. Patents relevant to one or more of these products include U.S. Patent No. 11,253,389 and U.S. Patent No. 8,303,554.

Additional non-infringing alternatives include: adult incontinence products such as Depends, adult urine pads such as Pee Pads, Dignity Super Duty Pads, and Sage Microclimate Body pad; urinary pouches such as the Hollister female pouch; catheters such as conventional catheters and Foley catheters; the vacuum-assist products referenced in the IPR for the 508 Patent; portable urinary containers and collection devices such as the Go Girl, Tinkle Belle, Sani Fem Freshette Feminine urinary director device, Carebag urinal bag, and Eloquest UriCap. Additionally, to the extent not anticipatory, earlier versions of the PureWick FEC device are also non-infringing alternative including the brown tape product that was presented to Connect and that won the 2015 Most Innovative New Product but PureWick claims was not covered by its patents in PureWick I. PureWick has still failed to provide discovery on most of these devices despite the Court's order and our requests, prejudicing Sage's ability to provide additional response on these issues. Documents relating to these products were previously identified in Sage's Invalidity Contentions, which are hereby incorporated by reference. Discovery from third parties on these devices is pending.

Information about these products is publicly available including on the internet and in PureWick's own records. Moreover, testimony and documents produced by Omni were provided in PureWick I. Sage hereby incorporates the expert reports of Dr. Diane Newman and Donald Sheldon from PureWick I on this art and on the issues of non-infringing alternatives.

In addition to the foregoing, Sage incorporates its response to PureWick Interrogatory No. 7 and Sage further identifies at least the following documents relevant to this interrogatory regarding non-infringing alternatives: STRSAGE00023017, STRSAGE00024739, STRSAGE00024736, STRSAGE00024736A-G, STRSAGE00024737, STRSAGE00024737A-E, STRSAGE00024738, STRSAGE00024739, STRSAGE00024740, STRSAGE00024741-42, STRSAGE00024743-44, STRSAGE00024745, STRSAGE00024746, STRSAGE00024747, STRSAGE00024748, STRSAGE00024749, STRSAGE00024750-51, Tricity0001-0025, FQE0000001-FQE0000913, BDPureWick\_00002132, BDPureWick\_00002071, STRSAGE00021235, STRSAGE00025166, and other documents referencing the alternatives in the parties' productions. Additional documents including physicals relevant to this interrogatory regarding non-infringing alternatives include: STRSAGE00024752, STRSAGE00024752A, STRSAGE00024752B, STRSAGE00024753, STRSAGE00024753A, STRSAGE00024753B, STRSAGE00024753C, as well as STRSAGE00024754. Sage also incorporates the production of Medline and additional documents cited in response to Interrog. No. 7. Further discovery is anticipated from third parties as well as experts who can speak to these issues. Sage further states that Sage witnesses are knowledgeable about this topic including the individuals identified in Sage's Rule 26 disclosures. Sage further states that discovery is ongoing and Sage will supplement its response to this interrogatory as necessary pursuant to Fed. R. Civ. P. 26(e) after further discovery has been conducted including discovery from PureWick and third parties. Sage expressly reserves the right to supplement, modify, or amend its responses contained herein.

Sage further states that PureWick has failed to establish that it sells any product covered by any of the patents-in-suit. Sage incorporates its responses and motions for judgment as a matter

of law in PureWick I regarding PureWick's failure to establish that its commercial product is covered.

Sage further states that discovery is ongoing and Sage will supplement its response to this interrogatory as necessary pursuant to Fed. R. Civ. P. 26(e) after further discovery has been conducted. Sage expressly reserves the right to supplement, modify, or amend its responses contained herein.

5. Identify and describe in detail any differences between the structure or operation of the PrimaFit 1.0 product and the structure or operation of the PrimaFit 2.0 product, explain why the differences in the PrimaFit 2.0 product were introduced by Sage, and identify all documents concerning the differences and the persons most knowledgeable about the differences.

#### **SUPPLEMENTAL RESPONSE TO INTERROGATORY 5:**

In addition to the General Objections set forth above, Sage objects to this topic as vague, overly broad, unduly burdensome, and seeking information not relevant to the claims or defenses of any party or proportional to the needs of the case including, for example, to the extent it seeks irrelevant information regarding "differences" between the PrimaFit® 2.0 and another unaccused device not at issue in this lawsuit and "why the differences . . . were introduced by Sage". Sage objects to this interrogatory to the extent it seeks information that is more properly obtained through other discovery methods, including PureWick's Request for Production Nos. 1-6, 11, and 14, and Sage hereby incorporates its objections and responses to those requests. Sage objects to this interrogatory to the extent it seeks information which is protected by any applicable privilege, including attorney-client privilege and/or work product immunity doctrine. Sage objects to this interrogatory to the extent it seeks expert testimony or analysis improperly and in contravention of the Scheduling Order. Sage objects to this interrogatory as overly broad and unduly burdensome in that it requests that Sage identify "any" differences and "all" documents rather than representative facts or differences sufficient to show the relevant information. Sage further objects

to this topic to the extent it seeks information not kept in the ordinary course of Sage's business or outside of Sage's possession, custody, or control. Sage objects to this interrogatory as duplicative to the extent that PureWick seeks information already provided in *PureWick I*.

Subject to and without waiving any general or specific objections including relevance, the PrimaFit® 2.0 product is a completely new design of the product at issue in the PureWick I litigation, offering new features as well as removing features that PureWick claimed were infringing. The PrimaFit® 2.0 was identified as a non-infringing alternative during the course of the PureWick I litigation and PureWick never accused it of infringement in that case despite knowing about it for over a year.

There are numerous differences between PrimaFit 1.0 and 2.0, including but not limited to the design, structure, material, and manufacturing. Nearly all of the components of the PrimaFit® 1.0 are not present in the PrimaFit® 2.0 including at least the "Fluid Reservoir, Cap," "Foam, Adhesive Strip, Bottom," "Absorbent Sleeve, Assembly," "Fabric, Absorbent," "Foam, Back," "Tubing, Suction," "Fabric Batting," "Suction Tubing Adapter," "Foam adhesive Strip, Top," and "Foam Tape, Square." Differences include but are not limited to: lack of a cap that PureWick asserted was the reservoir in PrimaFit 1.0, lack of the components that PureWick asserted were the casing in the original PrimaFit 1.0 including lack of a sewn seam and lack of foam-backed adhesives, lack of "batting" that PureWick asserted was the permeable support in the original PrimaFit 1.0, inclusion of a "Foam Backer," inclusion of thermoforming and ultrasonic welding processing and hot melt, inclusion of soft foam end, inclusion of a long flexible tube extending outside the device, redesigned end, inclusion of inner foam, inclusion of material extending the entire length of the device, inclusion of material with end to match the profile of the redesigned end of the device, newly designed suction connector, and redesigned patient-facing fabric. The

entire shape, form, and dimensions of the PrimaFit® 2.0 are different, the device has different materials and includes new packaging and updated instructions. The PrimaFit® 2.0 has a new core design with entirely new components, which are described and depicted in the 2.0 specifications.

PrimaFit® 2.0, compared to the [REDACTED]

[REDACTED]. For the new design, Sage expended significant resources designing and building an advanced, automated assembly process that reduced labor resulting in cost savings and increased output. Virtually every document describing the 1.0 or the 2.0 documents the differences between the products as they are very different. However, differences between the products are shown, depicted, described, and may otherwise be ascertained from documents including, for example STRSAGE00000001-STRSAGE00000119. Changes including the examples listed further broadened differentiation with competing products. Persons with relevant knowledge are identified in Sage's Rule 26 disclosures, which are incorporated herein. As Mr. Cole testified, PrimaFit 2.0 is significantly different than the 1.0 product and remove several features that PureWick claims were infringing. Indeed, almost every component and feature is different. For example, these differences include no end cap, no batting, no bottom tape, no top tape, not bottom foam, no sewed seams, new suction connector, new soft foam end, new tubing – design and material, new foam backer made from new material, new bottom barrier, new inner foam, new method of securement for bowtie, new bowtie configuration, new hot melt for tubing, thermoform/seal, different configuration and attachment for fabric, and numerous manufacturing changes resulting in a structurally different product. Sage incorporates the testimony of Mr. Cole. Sage also incorporates its responses to Interrog. No. 5. The products as designed include the structure and features of the prior art including Kuntz and Mahnensmith, including features which PureWick represented are not covered by the claims of its patents. To the



extent PureWick alleges infringement of the PrimaFit 2.0, the device practices the prior art and cannot infringe.

Sage incorporates the factual and legal bases for its allegations of non-infringement with respect to the PrimaFit® 2.0 product identified in Sage’s Answer and Defenses (D.I. 8) and its July 1, 2022 Opposition to PureWick’s Motion for Judgment on the Pleadings. Sage further incorporates its responses to PureWick interrogatory No. 2. Sage further incorporates responses to discovery it provided on the 2.0 including all pleadings relating to the 2.0 submitted by Sage in *PureWick I*. Even though the PrimaFit® 2.0 product was publicly available in 2019 and PureWick obtained extensive discovery on it as a non-infringing alternative in the PureWick I litigation, PureWick never brought a claim asserting infringement of that design in the PureWick I litigation. PureWick is estopped and precluded from doing so now in a second lawsuit. With respect to the 376 patent, for example, the PrimaFit® 2.0 product does not include several elements of the claims of the 376 patent, including at least the claimed “apparatus” that includes “a fluid impermeable casing having a fluid reservoir at a first end, a fluid outlet at a second end,” “a fluid permeable casing . . . defining a longitudinally elongated opening between the fluid reservoir and the fluid outlet,” “a fluid permeable support disposed within the casing,” “a fluid permeable support . . . with a portion extending across the elongated opening,” “fluid reservoir,” “wherein the fluid permeable support is distinct from and at least proximate to the fluid reservoir,” “a fluid impermeable layer,” a “longitudinally elongated opening,” “a fluid permeable membrane disposed on the support . . . so that the membrane is supported on the support and disposed across the elongated opening,” and/or a “tube having a first end disposed in the reservoir” as required by asserted claim 1 of the 376 patent. This is at least because the PrimaFit® 2.0 product does not include at least a casing, much less an impermeable one or one that has or defines a fluid reservoir.

The PrimaFit® 2.0 product does not have a fluid reservoir, much less one where the fluid permeable support is distinct from and at least proximate to the fluid reservoir. Nor does the PrimaFit® 2.0 have a tube having a first end disposed in the reservoir. The PrimaFit® 2.0 product also does not include a membrane supported on an inner support or the other elements enumerated above.

The PrimaFit® 2.0 also does not have a support and casing that are “substantially cylindrical,” and the PrimaFit® 2.0 is not “configured to be: disposed with the elongated opening adjacent the urethral opening of a human female; oriented with the reservoir adjacent to the user's anus and the outlet disposed above the urethral opening; and arranged with a curved shape with the elongated opening disposed on the inside of the curve.” The PrimaFit® 2.0 does not have a fluid permeable membrane that “includes a wicking material.” The PrimaFit® 2.0 also does not have a reservoir that is “defined between the fluid impermeable casing and the fluid permeable support.”

With respect to the 989 patent, the PrimaFit® 2.0 product does not include several elements of the claims of the 989 patent, including at least the claimed “method” that includes “disposing in an operative relationship with the urethral opening of a female user a urine collecting apparatus” where the “urine collection apparatus” includes “a fluid impermeable casing having a fluid reservoir at a first end, a fluid outlet at a second end,” “a fluid impermeable casing . . . defining a longitudinally elongated opening between the fluid reservoir and the fluid outlet,” “elongated opening,” “a fluid impermeable casing having . . . a longitudinally extending fluid impermeable layer,” a “fluid impermeable layer,” “a fluid permeable support disposed within the fluid impermeable casing,” “a fluid permeable support . . . with a portion extending across the elongated opening,” “wherein the fluid permeable support is distinct from and at least proximate to the fluid

reservoir,” “fluid permeable support” and “a fluid permeable membrane disposed on the fluid permeable support . . . so that the fluid permeable membrane is supported on the fluid permeable support and disposed across the longitudinally elongated opening,” “allowing urine discharged from the urethral opening to be received through the longitudinally elongated opening of the longitudinally extending fluid impermeable layer, the fluid permeable membrane, the fluid permeable support, and into the fluid reservoir, ” “allowing the received urine to be withdrawn from the fluid reservoir via the tube and out of the fluid discharge end of the tube,” and/or a “tube having a first end disposed in the reservoir” as required by asserted claim 1 of the 989 patent. This is at least because the PrimaFit® 2.0 product does not include at least a casing, much less an impermeable one or one that has or defines a fluid reservoir. The PrimaFit® 2.0 product does not have a fluid reservoir, much less one where the fluid permeable support is distinct from and at least proximate to the fluid reservoir. Nor does the PrimaFit® 2.0 have a tube having a first end disposed in the reservoir. The PrimaFit® 2.0 product also does not include a membrane supported on an inner support. The use of the PrimaFit® 2.0 product therefore does not infringe any of the claims.

Use of the PrimaFit® 2.0 also does not include “fluidically coupling the fluid discharge end of the tube to a source of vacuum to assist in withdrawing the urine from the fluid reservoir via the tube,” “fluidically coupling the fluid discharge end of the tube to a fluid receptacle and allowing urine withdrawn from the fluid reservoir of the urine collecting apparatus via the tube to be received in the fluid receptacle,” or “removing the urine collecting apparatus from the operative relationship with the urethral opening of the user.” Use of the PrimaFit® 2.0 also does not include a urine collecting apparatus that is “a first urine collecting apparatus and further comprising disposing in operative relationship with the urethral opening of a female user a second urine collecting apparatus substantially similar to the first urine collecting apparatus.” Use of the

PrimaFit® 2.0 also does not have a fluid permeable support and fluid impermeable casing that are “cylindrical and have a curved shape with the longitudinally elongated opening disposed on the inside of the curve, the disposing including disposing the urine collecting apparatus with the longitudinally elongated opening adjacent the urethral opening of the user and oriented with the fluid reservoir adjacent to the user's anus and the outlet disposed above the urethral opening.”

The PrimaFit® 2.0 also does not include the claimed “apparatus” that includes a “fluid permeable support disposed between a fluid permeable membrane and fluid reservoir,” “the fluid permeable support is distinct from and at least proximate to the fluid reservoir,” “a fluid outlet; “a fluid impermeable layer,” “a fluid impermeable layer disposed over at least a portion of the fluid permeable support and over at least a portion of the fluid permeable membrane, the fluid impermeable layer including the fluid reservoir at a first end thereof,” a fluid impermeable layer “defining a fluid impermeable casing,” a fluid permeable support that is “disposed within the fluid impermeable casing,” “the fluid impermeable layer defining a longitudinally elongated opening, the fluid permeable membrane extending across the longitudinally elongated opening,” “the apparatus configured to be disposed with the longitudinally elongated opening, and a portion of the fluid permeable membrane, adjacent to a urethral opening of a user, to receive urine discharged from the urethral opening through the fluid permeable membrane, the fluid permeable support, and into the fluid reservoir, and to have the received urine withdrawn from the fluid reservoir via the fluid outlet,” and “the fluid impermeable layer including a vacuum relief opening therethrough spaced from the longitudinally elongated opening and arranged to provide a flow path for air in the event that the skin of the user occludes the longitudinally elongated opening” as recited by claim 7 of the 989 patent including for at least the reasons outlined above.

Sage further incorporates its response to Interrogatory No. 4 as well as the expert reports of Donald Sheldon in the PureWick I litigation describing the PrimaFit 1.0 and 2.0 as well as the documents relied on therein, and all trial exhibits or documents relied on by Mr. Sheldon showing, depicting, and/or describing the PrimaFit 1.0 and 2.0 devices.

In addition, PureWick's allegations of infringement are barred under the doctrine of estoppel including judicial estoppel and claim preclusion. With regard to the claims of both patents-in-suit, PureWick's current positions are in direct contradiction to its claim interpretation in PureWick I, upon which it has prevailed to date, including its positions regarding no invalidity based upon WO2007042823A2 ("Van Den Heuvel 823"). For example, in PureWick I, PureWick repeatedly contended that an area at the tapered end of a product between a permeable support and a casing, such as that disclosed in Van Den Heuvel 823 (item 4), is not a "reservoir" because a reservoir must "aggregate urine." For example, PureWick repeatedly contended that, unlike a product that had a cap (such as the product at issue in PureWick I), a product that had an area at the end (such as the product in Van Den Heuvel) was not a reservoir, because for example there is allegedly no evidence "that urine could accumulate in that space" and "no place for fluid to aggregate." (Trial Tr. at 1174, 1162; D.I. 345, PureWick's May 19, 2022 Opp. to Sage's Post-Trial Motions at 14-15.) Yet, now that Sage's product has been modified to remove the cap, PureWick now argues the opposite and asserts infringement against PrimaFit® 2.0 even though it removes the very features that PureWick had alleged was the reservoir in PureWick I (the cap) and uses the prior art features that PureWick claimed were not covered by its patent or were not invalidating. PureWick made no effort to establish that an alleged area at the tapered end of the PrimaFit® 2.0 product is a "reservoir," e.g., that it "aggregates urine," as it previously asserted was required by that term. Nor has PureWick established that urine could accumulate during use in the area at the

end of the PrimaFit® 2.0 or that it is a place for fluid to aggregate. PureWick is legally estopped from taking such a position, including under the doctrine of judicial estoppel. PureWick is currently taking a position that is clearly inconsistent with its earlier position in PureWick I. PureWick's earlier position was accepted by the prior tribunal in PureWick I as of this writing. And PureWick's change in position creates an unfair advantage or detriment absent estoppel. Moreover, based on PureWick's representations in the prior litigation as well as the prosecution history (discussed *infra* in response to Interrogatory No. 4, which is incorporated by reference), the claims cannot be reasonably construed to cover the PrimaFit® 2.0 product.

As Sage explained in its September 22, 2022 Preliminary Identification of Claim Constructions, the claim elements have their plain and ordinary meaning (to the extent not indefinite) in view of the specifications, prosecution histories (including prosecution disclaimers), and the knowledge of the ordinarily skilled artisan. That ordinary meaning is also reflected by PureWick's litigation statements that bear on the meaning of the term and likewise offer a preclusive effect. For example, based on PureWick's own representations, a "reservoir" must "aggregate urine." PureWick's infringement contentions fail to support that any aspect of the PrimaFit® 2.0 has a structure that "aggregates urine," much less the area at the end of the device as claimed.

Sage further states that discovery is ongoing and Sage will supplement its response to this interrogatory as necessary pursuant to Fed. R. Civ. P. 26(e) after further discovery has been conducted. Sage expressly reserves the right to supplement, modify, or amend its responses contained herein.

conducted including discovery from PureWick and third parties. Sage expressly reserves the right to supplement, modify, or amend its responses contained herein.

8. To the extent You have ever attempted to design around any of the Patents-in-Suit (at any time) or change an aspect of the PrimaFit 1.0 or PrimaFit 2.0 in response to any litigation, describe in detail these efforts, including identify all individuals involved, all documents relating to any such effort, and explain how the designs avoid infringing the Patents-in-Suit.

#### **SUPPLEMENTAL RESPONSE TO INTERROGATORY 8:**

In addition to the General Objections set forth above, Sage objects to this interrogatory as vague, overly broad, unduly burdensome, and seeking information not relevant to the claims or defenses of any party or proportional to the needs of the case including, for example, to the extent it seeks irrelevant information regarding unidentified “attempt[s] to design or re-design” or “change an aspect” of the PrimaFit 1.0 or 2.0 “in response to litigation.” Sage objects to this interrogatory to the extent it seeks information which is protected by any applicable privilege, including attorney-client privilege and/or work product immunity doctrine. Sage objects to this interrogatory as unduly burdensome and seeking information not relevant to the claims or defenses of any party or proportional to the needs of the case including to the extent it is directed to the “PrimaFit 1.0” or other products not accused of infringement in this case, as well as information related to “attempt[s] to design around any of the Patents-in-Suit.” Sage objects to this interrogatory as overly broad and unduly burdensome in that it requests that Sage identify “all” documents and “any” effort rather than representative facts, literature, documents or other evidence sufficient to show the relevant information. Sage also objects to this request as seeking irrelevant information not proportional to the needs of the case as it is unbounded in time, a purportedly seeks information from “any time.” Sage objects to this interrogatory to the extent it seeks expert testimony, legal conclusions, or analysis improperly and in contravention of the Scheduling Order. Sage further objects to this interrogatory to the extent it seeks information not

kept in the ordinary course of Sage's business or outside of Sage's possession, custody, or control. Sage objects to the extent that PureWick seeks information duplicative of information already provided in *PureWick I*. Sage objects to this interrogatory because it contains multiple discrete parts, which should be counted as separate interrogatories pursuant to Fed. R. Civ. P. 33. Sage further incorporates its response to Interrogatory Nos. 2-4, and 5. Sage further incorporates its analysis of the 2.0 product as a non-infringing alternative in PureWick as well as other non-infringing alternatives identified in PureWick I and throughout its responses to these interrogatories. Unless PureWick can clarify what additional information it seeks from this interrogatory, Sage is unable to further respond at this time.

However, Sage further states the PrimaFit® 2.0 product is a completely new design of the product at issue in the PureWick I litigation, offering new features as well as removing features that PureWick claimed were infringing. The PrimaFit® 2.0 was identified as a non-infringing alternative during the course of the PureWick I litigation. (PureWick I Litigation, D.I. 209, Ex. 24 at 174-184.) As Mr. Cole testified, PrimaFit 2.0 is significantly different than the 1.0 product and remove several features that PureWick claims were infringing. Indeed, almost every component and feature is different. For example, these differences include no end cap, no batting, no bottom tape, no top tape, not bottom foam, no sewed seams, new suction connector, new soft foam end, new tubing – design and material, new foam backer made from new material, new bottom barrier, new inner foam, new method of securement for bowtie, new bowtie configuration, new hot melt for tubing, thermoform/seal, different configuration and attachment for fabric, and numerous manufacturing changes resulting in a structurally different product. Sage incorporates the testimony of Mr. Cole. Sage also incorporates its responses to Interrog. No. 5. The products as designed include the structure and features of the prior art including Kuntz and Mahnensmith,



including features which PureWick represented are not covered by the claims of its patents. To the extent PureWick alleges infringement of the PrimaFit 2.0, the device practices the prior art and cannot infringe. Even though the PrimaFit® 2.0 product was publicly available in 2019 and PureWick obtained extensive discovery on it as a non-infringing alternative in the PureWick I litigation, PureWick never brought a claim asserting infringement of that design in the PureWick I litigation. PureWick is estopped and precluded from doing so now in a second lawsuit. With respect to the 376 patent, for example, the PrimaFit® 2.0 product does not include several elements of the claims of the 376 patent, including at least the claimed “apparatus” that includes “a fluid impermeable casing having a fluid reservoir at a first end, a fluid outlet at a second end,” “a fluid permeable casing . . . defining a longitudinally elongated opening between the fluid reservoir and the fluid outlet,” “a fluid permeable support disposed within the casing,” “a fluid permeable support . . . with a portion extending across the elongated opening,” “fluid reservoir,” “wherein the fluid permeable support is distinct from and at least proximate to the fluid reservoir,” “a fluid impermeable layer,” a “longitudinally elongated opening,” “a fluid permeable membrane disposed on the support . . . so that the membrane is supported on the support and disposed across the elongated opening,” and/or a “tube having a first end disposed in the reservoir” as required by asserted claim 1 of the 376 patent. This is at least because the PrimaFit® 2.0 product does not include at least a casing, much less an impermeable one or one that has or defines a fluid reservoir. The PrimaFit® 2.0 product does not have a fluid reservoir, much less one where the fluid permeable support is distinct from and at least proximate to the fluid reservoir. Nor does the PrimaFit® 2.0 have a tube having a first end disposed in the reservoir. The PrimaFit® 2.0 product also does not include a membrane supported on an inner support or the other elements enumerated above.

PrimaFit® 2.0 also does not have a support and casing that are “substantially cylindrical,” and the PrimaFit® 2.0 is not “configured to be: disposed with the elongated opening adjacent the urethral opening of a human female; oriented with the reservoir adjacent to the user's anus and the outlet disposed above the urethral opening; and arranged with a curved shape with the elongated opening disposed on the inside of the curve.”. The PrimaFit® 2.0 does not have a fluid permeable membrane that “includes a wicking material.” The PrimaFit® 2.0 also does not have a reservoir that is “defined between the fluid impermeable casing and the fluid permeable support.”

With respect to the 989 patent, the PrimaFit® 2.0 product does not include several elements of the claims of the 989 patent, including at least the claimed “method” that includes “disposing in an operative relationship with the urethral opening of a female user a urine collecting apparatus” where the “urine collection apparatus” includes “a fluid impermeable casing having a fluid reservoir at a first end, a fluid outlet at a second end,” “a fluid impermeable casing . . . defining a longitudinally elongated opening between the fluid reservoir and the fluid outlet,” “elongated opening,” “a fluid impermeable casing having . . . a longitudinally extending fluid impermeable layer,” a “fluid impermeable layer,” “a fluid permeable support disposed within the fluid impermeable casing,” “a fluid permeable support . . . with a portion extending across the elongated opening,” “wherein the fluid permeable support is distinct from and at least proximate to the fluid reservoir,” “fluid permeable support” and “a fluid permeable membrane disposed on the fluid permeable support . . . so that the fluid permeable membrane is supported on the fluid permeable support and disposed across the longitudinally elongated opening,” “allowing urine discharged from the urethral opening to be received through the longitudinally elongated opening of the longitudinally extending fluid impermeable layer, the fluid permeable membrane, the fluid permeable support, and into the fluid reservoir, ” “allowing the received urine to be withdrawn

from the fluid reservoir via the tube and out of the fluid discharge end of the tube,” and/or a “tube having a first end disposed in the reservoir” as required by asserted claim 1 of the 989 patent. This is at least because the PrimaFit® 2.0 product does not include at least a casing, much less an impermeable one or one that has or defines a fluid reservoir. The PrimaFit® 2.0 product does not have a fluid reservoir, much less one where the fluid permeable support is distinct from and at least proximate to the fluid reservoir. Nor does the PrimaFit® 2.0 have a tube having a first end disposed in the reservoir. The PrimaFit® 2.0 product also does not include a membrane supported on an inner support. The use of the PrimaFit® 2.0 product therefore does not infringe any of the claims.

Use of the PrimaFit® 2.0 also does not include “fluidically coupling the fluid discharge end of the tube to a source of vacuum to assist in withdrawing the urine from the fluid reservoir via the tube,” “fluidically coupling the fluid discharge end of the tube to a fluid receptacle and allowing urine withdrawn from the fluid reservoir of the urine collecting apparatus via the tube to be received in the fluid receptacle,” or “removing the urine collecting apparatus from the operative relationship with the urethral opening of the user.” Use of the PrimaFit® 2.0 also does not include a urine collecting apparatus that is “a first urine collecting apparatus and further comprising disposing in operative relationship with the urethral opening of a female user a second urine collecting apparatus substantially similar to the first urine collecting apparatus.” Use of the PrimaFit® 2.0 also does not have a fluid permeable support and fluid impermeable casing that are “cylindrical and have a curved shape with the longitudinally elongated opening disposed on the inside of the curve, the disposing including disposing the urine collecting apparatus with the longitudinally elongated opening adjacent the urethral opening of the user and oriented with the fluid reservoir adjacent to the user's anus and the outlet disposed above the urethral opening.”

The PrimaFit® 2.0 also does not include the claimed “apparatus” that includes a “fluid permeable support disposed between a fluid permeable membrane and fluid reservoir,” “the fluid permeable support is distinct from and at least proximate to the fluid reservoir,” “a fluid outlet; “a fluid impermeable layer,” “a fluid impermeable layer disposed over at least a portion of the fluid permeable support and over at least a portion of the fluid permeable membrane, the fluid impermeable layer including the fluid reservoir at a first end thereof,” a fluid impermeable layer “defining a fluid impermeable casing,” a fluid permeable support that is “disposed within the fluid impermeable casing,” “the fluid impermeable layer defining a longitudinally elongated opening, the fluid permeable membrane extending across the longitudinally elongated opening,” “the apparatus configured to be disposed with the longitudinally elongated opening, and a portion of the fluid permeable membrane, adjacent to a urethral opening of a user, to receive urine discharged from the urethral opening through the fluid permeable membrane, the fluid permeable support, and into the fluid reservoir, and to have the received urine withdrawn from the fluid reservoir via the fluid outlet,” and “the fluid impermeable layer including a vacuum relief opening therethrough spaced from the longitudinally elongated opening and arranged to provide a flow path for air in the event that the skin of the user occludes the longitudinally elongated opening” as recited by claim 7 of the 989 patent including for at least the reasons outlined above.

Sage further incorporates its response to Interrogatory No. 4 as well as the expert reports of Donald Sheldon in the PureWick I litigation regarding noninfringement of the PrimaFit® 2.0.

In addition, PureWick’s allegations of infringement by the PrimaFit® 2.0 in PureWick II are barred under the doctrine of estoppel including judicial estoppel and claim preclusion. With regard to the claims of both patents-in-suit, PureWick’s current positions are in direct contradiction to its claim interpretation in PureWick I, upon which it has prevailed to date, including its positions

regarding no invalidity based upon WO2007042823A2 (“Van Den Heuvel 823”). For example, in PureWick I, PureWick repeatedly contended that an area at the tapered end of a product between a permeable support and a casing, such as that disclosed in Van Den Heuvel 823 (item 4), is not a “reservoir” because a reservoir must “aggregate urine.” For example, PureWick repeatedly contended that, unlike a product that had a cap (such as the product at issue in PureWick I), a product that had an area at the end (such as the product in Van Den Heuvel) was not a reservoir, because for example there is allegedly no evidence “that urine could accumulate in that space” and “no place for fluid to aggregate.” (Trial Tr. at 1174, 1162; D.I. 345, PureWick’s May 19, 2022 Opp. to Sage’s Post-Trial Motions at 14-15.)

Yet, now that Sage’s product has been modified to remove the cap as well as change numerous other features that PureWick claimed were infringing, PureWick now argues the opposite and asserts infringement against PrimaFit 2.0 even though it removes the very features that PureWick had alleged were infringing for, example, the reservoir in PureWick I (the cap), the components that PureWick claimed were the casing, and uses the prior art features that PureWick claimed were not covered by its patent (see also *infra*) or were not invalidating. For example, PureWick made no effort to establish that an alleged area at the tapered end of the PrimaFit® 2.0 product is a “reservoir,” e.g., that it “aggregates urine,” as it previously asserted was required by that term. Nor has PureWick established that urine could accumulate during use in the area at the end of the PrimaFit® 2.0 or that it is a place for fluid to aggregate. PureWick is legally estopped from taking such a position, including under the doctrine of judicial estoppel. PureWick is currently taking a position that is clearly inconsistent with its earlier position in PureWick I. PureWick’s earlier position was accepted by the prior tribunal in PureWick I as of this writing. And PureWick’s change in position creates an unfair advantage or detriment absent estoppel.

Moreover, based on PureWick’s representations in the prior litigation as well as the prosecution history (discussed *infra* in response to Interrogatory No. 4, which is incorporated by reference), the claims cannot be reasonably construed to cover the PrimaFit® 2.0 product.

As Sage explained in its September 22, 2022 Preliminary Identification of Claim Constructions, the claim elements have their plain and ordinary meaning (to the extent not indefinite) in view of the specifications, prosecution histories (including prosecution disclaimers), and the knowledge of the ordinarily skilled artisan. That ordinary meaning is also reflected by PureWick’s litigation statements that bear on the meaning of the term and likewise offer a preclusive effect. For example, based on PureWick’s own representations, a “reservoir” must “aggregate urine.” PureWick’s infringement contentions fail to support that any aspect of the PrimaFit® 2.0 has a structure that “aggregates urine,” much less the area at the end of the device as claimed. There is also no infringement for the reasons describe in Interrogatory No. 2.

Dated: March 31, 2023

*As to objections only,*

YOUNG CONAWAY STARGATT &  
TAYLOR, LLP

/s/ Samantha G. Wilson

Anne Shea Gaza (No. 4093)

Samantha G. Wilson (No. 5816)

Rodney Square

1000 North King Street

Wilmington, DE 19801

(302) 571-6600

agaza@ycst.com

swilson@ycst.com

*Attorneys for Defendant Sage Products,  
LLC*

Of Counsel:

Robert A. Surrette

Sandra A. Frantzen

Christopher M. Scharff

Ryan J. Pianetto

McAndrews, Held & Malloy, Ltd

500 West Madison Street

Chicago, IL 60661

(312) 775-8000

bsurrette@mcandrews-ip.com

sfrantzen@mcandrews-ip.com

cscharff@mcandrews-ip.com

rpianetto@mcandrews-ip.com

# **SAGE EXHIBIT 2**

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

PUREWICK CORPORATION,

Plaintiff,

v.

SAGE PRODUCTS, LLC,

Defendant.

C.A. No. 22-102-MN

**SAGE’S OBJECTIONS TO PLAINTIFF’S FIRST AND SECOND  
NOTICE OF RULE 30(B)(6) DEPOSITION OF SAGE PRODUCTS, LLC**

Defendant Sage Products, LLC (“Sage”) hereby makes the following objections and responses to Plaintiff PureWick Corporation’s (“PureWick”) Notice of Rule 30(b)(6) Deposition of Defendant Sage Products, LLC.

**GENERAL STATEMENT AND GENERAL OBJECTIONS**

Sage makes the following General Objections to the Definitions and Topics on Which Examination Is Requested set forth in Attachment A attached to PureWick’s First and Second Notices of Deposition. These General Objections are hereby incorporated by reference and are part of Sage’s response to each and every requested topic of examination. Sage’s failure to expressly repeat these General Objections in each response shall not be deemed a waiver thereof. Moreover, Sage’s specification of one or more objections to any given topic is not intended to preclude the applicability of any General Objections. Sage’s responses and objections do not waive Sage’s right to object to questions presented at the deposition, and Sage reserves the right to object as discussed herein or otherwise, during the deposition, if it takes place.

1. Sage hereby incorporates by reference its General and specific objections set forth



Scheduling Order. Sage further objects to this topic to the extent it seeks information not kept in the ordinary course of Sage's business or outside of Sage's possession, custody, or control. Sage objects to the extent that PureWick seeks testimony duplicative of information already provided in *PureWick I*. Subject to and without waiving any general or specific objections, and to the extent Sage understands this topic, Sage incorporates its response to Topic No. 2 and further agrees to designate a witness to testify on relevant and non-privileged aspects of the structure and use of the PrimaFit 2.0 product including representative and relevant user manuals, instructions for use, instructional guides, training manuals, and package inserts or labels, proportional to the needs of the case.

2. The design, structure, materials, and operation of the Accused Products.

**RESPONSE:**

In addition to the General Objections set forth above, Sage objects to this topic to the extent it seeks information that is more properly obtained through other discovery methods, including PureWick's Request for Production Nos. 1-3, 8, 10, and 14, and Sage hereby incorporates its objections and responses to those requests. Sage objects to this topic to the extent it seeks information which is protected by any applicable privilege, including attorney-client privilege and/or work product immunity doctrine. Sage objects to this topic as vague, overly broad, unduly burdensome, and seeking information not relevant to the claims or defenses of any party or proportional to the needs of the case including, for example, to the extent it seeks irrelevant information about the Accused Products. Sage incorporates its General Objection with respect to the term "Accused Products." Sage objects to this topic to the extent it seeks expert testimony or analysis improperly and in contravention of the Scheduling Order. Sage further objects to this topic

to the extent it seeks information not kept in the ordinary course of Sage's business or outside of Sage's possession, custody, or control. Sage objects to the extent that PureWick seeks testimony duplicative of information already provided in *PureWick I*. Subject to and without waiving any general or specific objections, and to the extent Sage understands this topic, Sage agrees to designate a witness to testify on relevant and non-privileged aspects of the design, structure, materials, and operation of the PrimaFit 2.0 product, proportional to the needs of the case.

3. All differences in design, structure, materials, and operations between PrimaFit 1.0 and PrimaFit 2.0, including but not limited to the reasons for all changes.

**RESPONSE:**

In addition to the General Objections set forth above, Sage objects to this topic as vague, overly broad, unduly burdensome, and seeking information not relevant to the claims or defenses of any party or proportional to the needs of the case including, for example, to the extent it seeks irrelevant information regarding "differences" and "reasons for all changes" between the PrimaFit 2.0 and another unaccused device not at issue in this lawsuit. Sage objects to this topic to the extent it seeks information that is more properly obtained through other discovery methods, including PureWick's Request for Production Nos. 1-6, 11, and 14, and Sage hereby incorporates its objections and responses to those requests. Sage objects to this topic to the extent it is duplicative of other topics including Topic Nos. 1-2. Sage objects to this topic to the extent it seeks information which is protected by any applicable privilege, including attorney-client privilege and/or work product immunity doctrine. Sage objects to this topic to the extent it seeks expert testimony or analysis improperly and in contravention of the Scheduling Order. Sage further objects to this topic to the extent it seeks information not kept in the ordinary course of Sage's business or outside of Sage's possession, custody, or control. Sage objects to the extent that PureWick seeks testimony

duplicative of information already provided in *PureWick I*. Subject to and without waiving any general or specific objections, and to the extent Sage understands this topic, Sage incorporates its responses to Topic Nos. 1 and 2 and agrees to designate a witness to testify on relevant and non-privileged aspects of the design, structure, materials, and operation of the PrimaFit 2.0 product including relevant changes made to the PrimaFit 2.0 product, proportional to the needs of the case.

4. Sage's research, design and development efforts relating to the Accused Products, specifically, including research, design, development, testing and evaluation of the Accused Products, prototypes, and competitor External Catheters, as well as modifications made during development.

**RESPONSE:**

In addition to the General Objections set forth above, Sage objects to this topic to the extent it seeks information that is more properly obtained through other discovery methods, including PureWick's Request for Production Nos. 1-5, 7-9 and 32, and Sage hereby incorporates its objections and responses to those requests. Sage objects to this topic to the extent it is duplicative of other topics, including Topic No. 8. Sage objects to this topic to the extent it seeks information which is protected by any applicable privilege, including attorney-client privilege and/or work product immunity doctrine. Sage objects to this topic as vague, overly broad, unduly burdensome, and seeking information not relevant to the claims or defenses of any party or proportional to the needs of the case. Sage incorporates its General Objection with respect to the terms "External Catheters" and "Accused Products." Sage objects to this topic as unbounded in time. For example, Sage objects to this topic as overly broad, unduly burdensome, and seek plainly irrelevant information as it seeks any and all information on research, design, and development of any "External Catheter" at any and all times. Sage further objects because "External Catheters," "competitor External Catheters" and "prototypes" are vague and indefinite and PureWick has not

clarified these terms nor explained any relevance to this case. As another example, Sage objects to this topic to the extent it seeks irrelevant information about the Accused Products or “competitor External Catheters” and the topic does not identify any particular features of the Accused Products or any competitor products and is unbounded in time. Sage objects to the definition of “Sage” to the extent that it includes any individual or corporate entity other than Sage Products, LLC. Sage further objects to this topic to the extent it seeks information not kept in the ordinary course of Sage’s business or outside of Sage’s possession, custody, or control. Sage objects to the extent that PureWick seeks testimony duplicative of information already provided in *PureWick I*. Subject to and without waiving any general or specific objections, and to the extent Sage understands this topic, Sage agrees to designate a witness to testify on relevant and non-privileged aspects of Sage’s research, design, and development of the PrimaFit 2.0 product and any relevant modifications, proportional to the needs of the case. Sage further incorporates its responses to Topic Nos. 8 and 11 regarding third-party products.

5. Sage’s attempts or plans to design or re-design, in whole or in part, the Accused Product or PrimaFit 1.0, or features thereof, so as to avoid infringing any claim of the Patents-in-suit.

**RESPONSE:**

In addition to the General Objections set forth above, Sage objects to this topic as vague, overly broad, unduly burdensome, and seeking information not relevant to the claims or defenses of any party or proportional to the needs of the case including, for example, to the extent it seeks irrelevant information regarding unidentified “attempts or plans to design or re-design” the PrimaFit 2.0 product as well as information relating to “PrimaFit 1.0,” which is not at issue in this lawsuit. Sage objects to this topic to the extent it seeks information that is more properly obtained

through other discovery methods, including PureWick’s Request for Production Nos. 1-6, 11, and 14, and Sage hereby incorporates its objections and responses to those requests. Sage objects to this topic to the extent it is duplicative of other topics, including Topic Nos. 1-3. Sage objects to this topic to the extent it seeks information which is protected by any applicable privilege, including attorney-client privilege and/or work product immunity doctrine. Sage incorporates its General Objection with respect to the term “Accused Products.” Sage objects to this topic to the extent it seeks expert testimony, legal conclusions, or analysis improperly and in contravention of the Scheduling Order. Sage further objects to this topic to the extent it seeks information not kept in the ordinary course of Sage’s business or outside of Sage’s possession, custody, or control. Sage objects to the extent that PureWick seeks testimony duplicative of information already provided in *PureWick I*. Subject to and without waiving any general or specific objections, and to the extent Sage understands this topic, Sage incorporates its responses to Topic Nos. 1-3 and agrees to designate a witness to testify on relevant and non-privileged aspects of the design, structure, materials, and operation of the PrimaFit 2.0 and relevant alternatives, proportional to the needs of the case.

6. Sage’s knowledge of the verdict in *PureWick, Corp. v. Sage Products, LLC*, C.A. No. 19-1508-MN (D. Del.) and any actions taken with respect to the Accused Product in response to the verdict.

**RESPONSE:**

In addition to the General Objections set forth above, Sage objects to this topic as vague, overly broad, unduly burdensome, and seeking information not relevant to the claims or defenses of any party or proportional to the needs of the case including, for example, to the extent it seeks irrelevant information regarding “knowledge” of a verdict of a lawsuit which did not involve the

# **SAGE EXHIBIT 3**

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE

PUREWICK CORPORATION, )  
 )  
Plaintiff, )  
 )  
vs. ) C.A. No. 22-102-MN  
 )  
SAGE PRODUCTS, LLC, )  
 )  
Defendant. )

CONFIDENTIAL VIDEOTAPED DEPOSITION OF  
ADAM ROBERT COLE  
Conducted via Zoom  
Chicago, Illinois  
Wednesday, February 8th, 2023

REPORTED BY: GREG S. WEILAND, CSR, RMR, CRR  
JOB NO.: 221942



DEPOSITION EXHIBITS (CONTINUED)			Page 6
NUMBER	DESCRIPTION	PAGE	
Exhibit 58	Biocompatibility Evaluation, PrimaFit 2.0, Bates labeled STRSAGE00023866 through 00023875	195	
Exhibit 59	Document titled PrimaFit 2.0, Limited Launch Testing, 05/07/2019, Bates labeled STRSAGE00021455	254	
Exhibit 60	Document titled PrimaFit 2.0 Weekly, 2019-05-09, Bates labeled STRSAGE00021457	256	
Exhibit 61	Document titled NPD to PE Knowledge Transfer Summary Report, Bates labeled SAGE00034173 through 00034183	281	
Exhibit 62	Emails, Bates labeled SAGE00027413 through 00027414	289	

Page 8

1 A. Cole

2 versus Sage Products LLC in the United States

3 District Court for the District of Delaware,

4 Case Number 22-102-MN.

5 This deposition is being held via

6 videoconference with participants appearing

7 remotely on Wednesday, February 8th, 2023, at

8 approximately 9:18 a.m.

9 My name is Audra Falk. I am the legal

10 video specialist from TSG Reporting,

11 Incorporated, headquartered at

12 228 East 45th Street, New York, New York.

13 The court reporter is Greg Weiland in

14 association with TSG.

15 Counsel, please introduce yourselves.

16 MR. NEWTON: Jared Newton from Quinn

17 Emanuel Urquhart & Sullivan on behalf of the

18 plaintiff, PureWick.

19 MS. FRANTZEN: Sandra Frantzen from

20 McAndrews, Held & Malloy on behalf of the

21 defendant, Sage, and the witness.

22 THE VIDEOGRAPHER: Will the reporter

23 please swear in the witness.

24 (Witness sworn.)

25

Page 7

1 A. Cole

2 THE VIDEOGRAPHER: Good morning,

3 counselors. My name is Audra Falk. I am a

4 legal videographer in association with

5 TSG Reporting, Incorporated.

6 Because this is a remote deposition, I

7 will not be in the same room with the witness.

8 Instead, I will record this videotaped

9 deposition remotely. The reporter,

10 Greg Weiland, also will not be in the same room

11 and will swear the witness remotely.

12 Do all parties stipulate to the validity

13 of this video recording and remote swearing and

14 that it will be admissible in the courtroom as

15 if it had been taken following Rule 30 of the

16 Federal Rules of Civil Procedures and the

17 state's rules where this case is pending?

18 MR. NEWTON: Yes, on behalf of the

19 plaintiff.

20 MS. FRANTZEN: Yes, subject to our regular

21 objections.

22 THE VIDEOGRAPHER: Thank you.

23 This is the start of media labeled

24 Number 1 of the video-recorded deposition of

25 Adam Cole in the matter PureWick Corporation

Page 9

1 A. Cole

2 ADAM ROBERT COLE

3 after being first duly sworn, testified as follows:

4 EXAMINATION

5 BY MR. NEWTON:

6 Q. Good morning, Mr. Cole. How are you?

7 A. I'm okay. Good morning, Mr. Newton.

8 Q. Would you please state your full name for

9 the record.

10 A. Adam Robert Cole.

11 Q. Would you please state your home address

12 as well?

13 [REDACTED]

14 Q. Have you ever had a deposition taken

15 before?

16 A. I have not.

17 Q. Have you ever testified in any type of

18 legal proceeding before?

19 A. I have not.

20 Q. Have you ever given any other kind of

21 written or oral sworn testimony?

22 A. No.

23 Q. I want to cover just a couple ground rules

24 for the deposition so that we're on the same page

25 with how this will work.



Confidential

<p style="text-align: right;">Page 10</p> <p>1 A. Cole</p> <p>2 The first one is if you need a break any</p> <p>3 time throughout the day, just let me know. I might</p> <p>4 wrap up a line of questioning, but I'm happy to</p> <p>5 accommodate any break time that you need.</p> <p>6 Does that make sense?</p> <p>7 A. Yes.</p> <p>8 Q. I'll ask you to do your best not to talk</p> <p>9 over me, and I'll try my best not to talk over you</p> <p>10 so that the court reporter can take down the</p> <p>11 questions and answers.</p> <p>12 Does that make?</p> <p>13 A. It does.</p> <p>14 Q. I'll ask you also to try to give verbal</p> <p>15 responses rather than shaking your head or nodding</p> <p>16 because that's more difficult to pick up for the</p> <p>17 court reporter.</p> <p>18 Understood?</p> <p>19 A. Understood.</p> <p>20 Q. If I ask a question that is confusing in</p> <p>21 any way or you don't understand it, can you let me</p> <p>22 know so that I can try to clarify it?</p> <p>23 A. Yes.</p> <p>24 Q. And do you understand that unless your</p> <p>25 counsel instructs you not to answer a question,</p>	<p style="text-align: right;">Page 11</p> <p>1 A. Cole</p> <p>2 you're required to give a complete and truthful</p> <p>3 answer?</p> <p>4 A. I do.</p> <p>5 Q. And I take it you understand that you're</p> <p>6 testifying under oath today?</p> <p>7 A. I do.</p> <p>8 Q. And is there any reason you can think of</p> <p>9 as to why you could not give truthful and accurate</p> <p>10 testimony?</p> <p>11 A. No.</p> <p>12 Q. And let me give you one other caution. I</p> <p>13 might ask some questions about your deposition</p> <p>14 preparation, and you should give your counsel time</p> <p>15 to object based on privilege grounds.</p> <p>16 I'm not trying to get after privileged</p> <p>17 information today, but I want to make sure I'm</p> <p>18 giving your lawyer the opportunity to make that</p> <p>19 objection.</p> <p>20 Does that make sense?</p> <p>21 A. It does.</p> <p>22 Q. So let me ask, what is your understanding</p> <p>23 of the litigation between PureWick and Sage?</p> <p>24 MS. FRANTZEN: I'll object to the form,</p> <p>25 vague.</p>
<p style="text-align: right;">Page 12</p> <p>1 A. Cole</p> <p>2 THE WITNESS: Could you clarify what you</p> <p>3 mean by "understanding"?</p> <p>4 BY MR. NEWTON:</p> <p>5 Q. What do you know about the case?</p> <p>6 MS. FRANTZEN: Objection, vague.</p> <p>7 And I caution the witness not to reveal</p> <p>8 any privileged information.</p> <p>9 THE WITNESS: I know there is a case.</p> <p>10 BY MR. NEWTON:</p> <p>11 Q. Do you know any details about it?</p> <p>12 A. No.</p> <p>13 MS. FRANTZEN: Object to the form.</p> <p>14 BY MR. NEWTON:</p> <p>15 Q. When did you first become aware that there</p> <p>16 was litigation between PureWick and Sage?</p> <p>17 MS. FRANTZEN: Object to the form.</p> <p>18 THE WITNESS: I don't recall specifically</p> <p>19 when I became aware. Sometime in the past</p> <p>20 couple of years, I suppose.</p> <p>21 BY MR. NEWTON:</p> <p>22 Q. Are you aware that there have been two</p> <p>23 litigation matters between PureWick and Sage?</p> <p>24 A. I -- I'm aware that there is litigation</p> <p>25 between the two companies. I'm not aware of</p>	<p style="text-align: right;">Page 13</p> <p>1 A. Cole</p> <p>2 quantity of litigation matters.</p> <p>3 Q. Are you aware that there was a jury trial</p> <p>4 and legal proceeding between PureWick and Sage last</p> <p>5 year?</p> <p>6 A. Yes, I'm aware.</p> <p>7 Q. When did you become aware of that jury</p> <p>8 trial?</p> <p>9 MS. FRANTZEN: Object to the form.</p> <p>10 THE WITNESS: I probably became aware</p> <p>11 shortly before the trial. I don't know exactly</p> <p>12 when it was, but sometime shortly before the</p> <p>13 actual trial took place.</p> <p>14 BY MR. NEWTON:</p> <p>15 Q. Did you play any role in the trial?</p> <p>16 A. No, I did not.</p> <p>17 Q. How did you learn about the trial?</p> <p>18 MS. FRANTZEN: I'm going to object to the</p> <p>19 form and caution the witness not to answer it</p> <p>20 in any -- reveal any attorney-client privilege,</p> <p>21 and if you can't answer the question, then you</p> <p>22 shouldn't answer it.</p> <p>23 THE WITNESS: The only thing I was aware</p> <p>24 of relative to the trial was that there would</p> <p>25 be people out of the office for a period of</p>

Page 30

1 A. Cole  
 2 generates the most revenue for Stryker?  
 3 MS. FRANTZEN: Objection, asked and  
 4 answered.  
 5 THE WITNESS: I cannot answer that  
 6 question confidently, no.  
 7 BY MR. NEWTON:  
 8 Q. What product that you're currently working  
 9 on takes up the most of your time?  
 10 MS. FRANTZEN: Object to the form.  
 11 THE WITNESS: That's an interesting  
 12 question.  
 13 I guess I would have to say it depends on  
 14 which week we're talking about. Various  
 15 products -- as I said earlier, there's a lot of  
 16 them. So on any given day or week, it varies  
 17 which one takes up my time.  
 18 BY MR. NEWTON:  
 19 Q. How about last week? Are you able to say  
 20 which product took up the most amount of time?  
 21 A. I don't specifically remember what amount  
 22 of time I spent on any given project or what  
 23 meetings were related to which project last week.  
 24 I would say there's probably two, three or  
 25 so products at any given time that are occupying my

Page 32

1 A. Cole  
 2 product?  
 3 MS. FRANTZEN: Object to the form.  
 4 THE WITNESS: It does vary quite a bit by  
 5 project. We will potentially, depending on the  
 6 project, move -- transfer responsibility or no  
 7 longer have responsibility, depending on the  
 8 project, after a period of time. But it is  
 9 highly variable.  
 10 BY MR. NEWTON:  
 11 Q. How long have you been with Stryker?  
 12 A. I've been with Stryker about six years.  
 13 Q. And prior to becoming director of new  
 14 product development, what was your title?  
 15 A. My previous title was senior manager of  
 16 new product development.  
 17 Q. Do you recall the approximate time frame  
 18 that you held that position?  
 19 A. I can't say specifically. Approximately  
 20 two years, perhaps.  
 21 Q. Do you have an engineering degree?  
 22 A. I do.  
 23 Q. What type of engineering?  
 24 A. My degree is in mechanical engineering.  
 25 Q. Is it right you received that from the

Page 31

1 A. Cole  
 2 day. I don't know that there's one that stands out  
 3 above the others.  
 4 Q. As director of new product development,  
 5 can you give me a sense of just -- let me strike  
 6 that.  
 7 Do you use the term "product life cycle"  
 8 in the context of your work?  
 9 A. The term "product life cycle" occasionally  
 10 is used as part of new product development.  
 11 Q. Do you and your team focus on a specific  
 12 part of the product life cycle?  
 13 MS. FRANTZEN: Object to the form.  
 14 THE WITNESS: Our team will handle a  
 15 variety of portions of the product life cycle,  
 16 including, you know, a fair amount of the new  
 17 product development, as our title suggests.  
 18 I don't know that there's a specific way  
 19 to say which cycle -- which part of the cycle  
 20 we do or do not get into.  
 21 BY MR. NEWTON:  
 22 Q. And that's what I was trying to get at is  
 23 that term "new product development," is there a  
 24 point where you kind of pass off a new product  
 25 because it's now an established or no longer a new

Page 33

1 A. Cole  
 2 University of Michigan?  
 3 A. I did.  
 4 Q. Are you familiar with the PrimaFit  
 5 product?  
 6 MS. FRANTZEN: Objection, vague as to the  
 7 term "PrimaFit."  
 8 THE WITNESS: I am familiar with the  
 9 PrimaFit 1.0 product and the PrimaFit 2.0  
 10 products.  
 11 BY MR. NEWTON:  
 12 Q. Do you consider the PrimaFit 1.0 and the  
 13 PrimaFit 2.0 different products?  
 14 MS. FRANTZEN: Object to the form.  
 15 THE WITNESS: [REDACTED]  
 16 [REDACTED]  
 17 [REDACTED]  
 18 BY MR. NEWTON:  
 19 Q. And they do have the same product code; is  
 20 that correct?  
 21 MS. FRANTZEN: Object to the form.  
 22 THE WITNESS: If you are referring to the  
 23 product SKU, that's not an area that  
 24 engineering directly handles. But I do believe  
 25 they have the same SKU.



Page 134

1 A. Cole  
 2 THE WITNESS: I don't know what  
 3 [REDACTED] refers to. It does not seem to  
 4 say here.  
 5 BY MR. NEWTON:  
 6 Q. I'm not asking you to --  
 7 A. I don't know if they're a customer. I  
 8 don't know if they're a hospital. I don't know what  
 9 that term specifically refers to.  
 10 Q. Do you see the last sentence of Colleen's  
 11 email to you where she says, "We still have to tell  
 12 them to follow the IFU, but sharing the testing  
 13 results"?  
 14 A. I see that this document says, "We still  
 15 have to tell them to follow the IFU."  
 16 Q. Do you understand Colleen to be saying  
 17 here that we, Sage, has to tell [REDACTED] to  
 18 follow the IFUs?  
 19 MS. FRANTZEN: Object to the form, outside  
 20 the scope.  
 21 THE WITNESS: I see in this document that  
 22 it appears to be an email from Colleen Olsen,  
 23 it says, "We still have to tell them to follow  
 24 the IFU."  
 25 I don't know who she is referring to other

Page 136

1 A. Cole  
 2 Q. Topic 2 says, "The design, structure,  
 3 materials, and operation of the Accused Product."  
 4 Do you see that?  
 5 A. I see that's what Topic 2 does say.  
 6 Q. Are you prepared to provide testimony on  
 7 behalf of Sage regarding the design, structure,  
 8 materials, and operation of the PrimaFit 2.0 device?  
 9 MS. FRANTZEN: Subject to our objections.  
 10 THE WITNESS: I am.  
 11 BY MR. NEWTON:  
 12 Q. Do you consider yourself knowledgeable  
 13 about the design, structure, materials, and  
 14 operation of the PrimaFit 2.0 device?  
 15 A. I do.  
 16 MR. NEWTON: I've marked Exhibit 55.  
 17 (Exhibit 55 was marked for  
 18 identification.)  
 19 MR. NEWTON: This is -- Exhibit 55 is a  
 20 native version of a document that was produced  
 21 at STRSAGE00022113.  
 22 BY MR. NEWTON:  
 23 Q. Do you see Exhibit 55, Mr. Cole?  
 24 A. I do.  
 25 Q. Do you see that the document on the first

Page 135

1 A. Cole  
 2 than what it says here in the email.  
 3 BY MR. NEWTON:  
 4 Q. Do you know if you corrected her when she  
 5 said this -- sent this email and said, "We don't  
 6 have to tell anyone to follow the IFUs"?  
 7 MS. FRANTZEN: Object to the form.  
 8 THE WITNESS: I have no recollection of  
 9 what I would have told Colleen.  
 10 BY MR. NEWTON:  
 11 Q. Are you aware of any emails where Sage  
 12 tells its customers that they don't have to follow  
 13 the IFUs?  
 14 A. I have -- I can't recall any email that  
 15 would say we tell them that.  
 16 Q. Are you aware of any documentation where  
 17 Sage tells its customers that they don't have to  
 18 follow the IFUs?  
 19 A. I'm not aware of any document that says  
 20 what you're implying.  
 21 Q. Let's go back to Exhibit 33, if you have  
 22 that available to you.  
 23 A. I do.  
 24 Q. If you go to Page 6.  
 25 A. Okay.

Page 137

1 A. Cole  
 2 page says "Project Overview, PrimaFit 2.0"?  
 3 MS. FRANTZEN: I need a moment because I  
 4 haven't had a chance to look at the document.  
 5 THE WITNESS: I see that is on the first  
 6 page. But can I have a moment to review this  
 7 document as well?  
 8 BY MR. NEWTON:  
 9 Q. Yes, please. Take a moment to review it.  
 10 A. I've looked through the device -- or the  
 11 document.  
 12 Q. Let's start on Page 1.  
 13 Do you see it says "Project Overview,  
 14 PrimaFit 2.0"?  
 15 A. I do see that on Page 1.  
 16 Q. Having reviewed the document, what do you  
 17 understand this document to be, referring to  
 18 Exhibit 55?  
 19 A. Per what it says on Slide 1, I presume  
 20 this is a project overview document.  
 21 Q. Have you seen the document marked as  
 22 Exhibit 55 before today?  
 23 A. I don't see a date on this document. I  
 24 don't know when this document was produced. I can't  
 25 say for certain if I've seen it before. I may have.



Page 138

1 A. Cole  
2 Q. Go to Slide 2. Do you see where it says,  
3 "Project Objective. Improve manufacturability and  
4 profitability while maintaining performance of  
5 current PrimaFit design"?

6 A. I see that phrase is stated on Slide 2.

7 Q. Was it an objective of the PrimaFit 2.0  
8 project to improve manufacturability and  
9 profitability?

10 A. As I stated earlier, there are many  
11 reasons why the PrimaFit 2.0 project was executed,  
12 including [REDACTED]  
13 [REDACTED]

14 This project objective doesn't  
15 specifically state any metrics there, but -- or if  
16 this document was associated with the limited launch  
17 in 2019 or the fully commercialized launch in 2020.  
18 But [REDACTED] were key --  
19 are often key drivers for our projects, including  
20 PrimaFit 2.0.

21 Q. In addition to [REDACTED]  
22 [REDACTED], what were the other reasons or  
23 objectives for the PrimaFit 2.0 project?

24 A. Another objective was to increase  
25 differentiation of our PrimaFit 2.0 product in the

Page 140

1 A. Cole  
2 further differentiation from other products in  
3 the market.

4 I don't recall any other reasons off -- as  
5 I sit here today, I don't recall other reasons.

6 BY MR. NEWTON:

7 Q. What do you mean "increase differentiation  
8 of your product"?

9 A. Sage is an innovation company. We're  
10 often trying to ensure we have the best-in-class  
11 product, the state-of-the-art products. And there  
12 are a number of different products on the market  
13 that are in the urine management space.

14 So, you know, we want to maintain -- we  
15 want to be innovative, as I said. And if we see an  
16 opportunity to do so and deliver an innovative  
17 solution to our customers -- you know, one example  
18 in PrimaFit 2.0's case is have a -- the long,  
19 extended tubing, which gives our customers the  
20 ability to place the device easily and differentiate  
21 our product from any number of other urine  
22 management products on the market.

23 Q. What other features specific to the  
24 PrimaFit 2.0 were intended to differentiate it from  
25 other products on the market?

Page 139

1 A. Cole

2 market.

3 Q. Please list all the reasons that you can  
4 recall, sitting here.

5 MS. FRANTZEN: Object to the form.

6 THE WITNESS: All the reasons I recall  
7 for -- can you clarify what you mean? All the  
8 reasons I recall for PrimaFit 2.0?

9 BY MR. NEWTON:

10 Q. Yes. You testified, and I'm reading from  
11 the rough transcript, but it says, "As I stated  
12 earlier, there were many reasons why the  
13 PrimaFit 2.0 project was executed, including more  
14 efficient manufacturing, lower cost opportunities."

15 Another reason you just mentioned was to  
16 increase differentiation.

17 My question is will you please list the  
18 other reasons that you are aware of, sitting here  
19 today.

20 MS. FRANTZEN: I'm going to object to the  
21 form.

22 THE WITNESS: As I sit here today, those  
23 are three reasons that I can recall for why we  
24 would -- why we did project PrimaFit 2.0; [REDACTED]  
25 [REDACTED], and

Page 141

1 A. Cole

2 MS. FRANTZEN: Object to the form.

3 THE WITNESS: You know, I think there's a  
4 few reasons.

5 Another reason is that the PrimaFit 2.0  
6 product has the soft, tapered end, and that is  
7 comfortable for patients when in use. And  
8 that's another benefit we feel in the market  
9 with competitive products.

10 BY MR. NEWTON:

11 Q. Any other differentiators that come to  
12 mind for the PrimaFit 2.0?

13 MS. FRANTZEN: I'm going to object to the  
14 questioning as outside the scope of this  
15 Rule 30(b)(6) deposition to the extent you're  
16 asking about market factors.

17 THE WITNESS: You know, I think by having  
18 a -- you know, the bowtie adhesive, which  
19 exists on PrimaFit 2.0, is a part of the design  
20 that is a benefit to the customers by helping  
21 to secure the device in place when in use.

22 BY MR. NEWTON:

23 Q. Any other differentiators for the  
24 PrimaFit 2.0 that you recall sitting here today?

25 MS. FRANTZEN: I'm going to again object

<p style="text-align: right;">Page 142</p> <p>1 A. Cole</p> <p>2 to this question as being outside the scope of</p> <p>3 this Rule 30(b) (6) deposition to the extent</p> <p>4 you're asking about market factors.</p> <p>5 THE WITNESS: Yeah, there may be other</p> <p>6 factors at play. I can't -- I'm not sure I'm,</p> <p>7 you know, able to recall others beyond the ones</p> <p>8 I've stated. And marketing may have their own</p> <p>9 list.</p> <p>10 But those are the ones I can think of at</p> <p>11 this time.</p> <p>12 BY MR. NEWTON:</p> <p>13 Q. On the Slide 2 of Exhibit 55 where it says</p> <p>14 Project Objective, do you see where it says "while</p> <p>15 maintaining performance of current PrimaFit design"?</p> <p>16 A. I see where that's stated in this slide.</p> <p>17 Q. Was it a design goal of the PrimaFit 2.0</p> <p>18 to maintain performance -- to maintain the same</p> <p>19 level of performance as the PrimaFit 1.0?</p> <p>20 A. I would say the objective, as it's stated</p> <p>21 here, is that it does include maintaining the</p> <p>22 performance.</p> <p>23 As I stated earlier, we're always looking</p> <p>24 for an innovative way to be best in class. And, you</p> <p>25 know, there's a lot of products that are in the</p>	<p style="text-align: right;">Page 143</p> <p>1 A. Cole</p> <p>2 urine management space, but, you know, we felt that</p> <p>3 the PrimaFit delivered -- was a best-in-class</p> <p>4 product.</p> <p>5 So as it states here, one of the project</p> <p>6 objectives was maintaining that performance.</p> <p>7 Q. This slide does not say "improve</p> <p>8 performance," correct?</p> <p>9 A. That's not stated on this slide, no.</p> <p>10 Q. If you'd go to Slide 4 of Exhibit 55</p> <p>11 titled Current Device.</p> <p>12 A. Okay.</p> <p>13 Q. And Slide 4, is it correct that that</p> <p>14 includes an illustration of the PrimaFit 1.0 device?</p> <p>15 MS. FRANTZEN: Object to the form, outside</p> <p>16 the scope, and lack of foundation.</p> <p>17 THE WITNESS: Slide 4 doesn't seem to say</p> <p>18 what device is depicted in that drawing. It</p> <p>19 does have a drawing of a device.</p> <p>20 BY MR. NEWTON:</p> <p>21 Q. Does that look like the PrimaFit 1.0 to</p> <p>22 you, Mr. Cole?</p> <p>23 MS. FRANTZEN: I'm going to object to the</p> <p>24 form, outside the scope, and lack of</p> <p>25 foundation.</p>
<p style="text-align: right;">Page 144</p> <p>1 A. Cole</p> <p>2 THE WITNESS: I can't say for sure where</p> <p>3 that image came from or what vintage of product</p> <p>4 it was.</p> <p>5 There are, you know, some references to a</p> <p>6 5400 drawing, but it doesn't say which vintage</p> <p>7 of product that is on this -- on this page.</p> <p>8 BY MR. NEWTON:</p> <p>9 Q. Go to Slide 5 titled Design Changes</p> <p>10 Overview.</p> <p>11 A. Okay.</p> <p>12 Q. Does the image on Slide 5 of Exhibit 55</p> <p>13 look like the PrimaFit 2.0 device?</p> <p>14 A. It does appear the image there has some</p> <p>15 resemblance to the PrimaFit 2.0 product.</p> <p>16 Q. And if you could go to Slide 6.</p> <p>17 A. Okay.</p> <p>18 Q. Slide 6 is titled Design Changes</p> <p>19 Components.</p> <p>20 Do you see that?</p> <p>21 A. I do.</p> <p>22 Q. And is the image in Slide 6 an exploded</p> <p>23 view of the PrimaFit 2.0 device?</p> <p>24 A. Again, similar to the previous reference,</p> <p>25 there's no specific statement here saying what this</p>	<p style="text-align: right;">Page 145</p> <p>1 A. Cole</p> <p>2 exploded view refers to, what version, what vintage,</p> <p>3 what revision or anything like that.</p> <p>4 This does seem to have some resemblance to</p> <p>5 a PrimaFit 2.0 device.</p> <p>6 Q. Do you consider that an accurate</p> <p>7 representation of the PrimaFit 2.0 device as it is</p> <p>8 currently sold?</p> <p>9 MS. FRANTZEN: Object to the form.</p> <p>10 THE WITNESS: I can't -- in the</p> <p>11 exploded-view form, it's not currently sold in</p> <p>12 that view, so I can't say without knowing</p> <p>13 revision or date or any history how it compares</p> <p>14 to what is currently sold.</p> <p>15 BY MR. NEWTON:</p> <p>16 Q. As an engineer who has worked on the</p> <p>17 PrimaFit 2.0 device, does the exploded view in</p> <p>18 Slide 6 of Exhibit 55 illustrate components of the</p> <p>19 PrimaFit 2.0 that are included in the version of the</p> <p>20 device that is currently sold to customers?</p> <p>21 MS. FRANTZEN: Object to the form, asked</p> <p>22 and answered.</p> <p>23 THE WITNESS: On Slide 6, I do see an</p> <p>24 exploded view of components. The components</p> <p>25 shown there are titled such things as Suction</p>



Page 190

1 A. Cole  
 2 3:01 p.m.  
 3 BY MR. NEWTON:  
 4 Q. Mr. Cole, could you go back to the exhibit  
 5 marked 33, please.  
 6 A. Did you say 33?  
 7 Q. Yes, 3-3. And I'll refer you to Page 6.  
 8 Let me know when you're there.  
 9 A. Okay. Hold on one second.  
 10 Okay. I'm on Page 6.  
 11 Q. Do you see Topic 3, "All differences in  
 12 design, structure, materials, and operation between  
 13 PrimaFit 1.0 and PrimaFit 2.0, including but not  
 14 limited to the reasons for all changes"?  
 15 A. I do see Number 3.  
 16 Q. Are you prepared to provide corporate  
 17 testimony on behalf of Sage with respect to Topic 3?  
 18 MS. FRANTZEN: Subject to our objections  
 19 and our statements in our objections.  
 20 THE WITNESS: I am.  
 21 BY MR. NEWTON:  
 22 Q. Was PrimaFit 1.0 used as a starting point  
 23 for the PrimaFit 2.0?  
 24 MS. FRANTZEN: Object to the form.  
 25 THE WITNESS: I don't know what you're

Page 192

1 A. Cole  
 2 PrimaFit 2.0 is its own unique product, and I  
 3 stated we're always looking to design  
 4 innovative products.  
 5 I don't know if I would use the term "from  
 6 scratch" for how we design products.  
 7 BY MR. NEWTON:  
 8 Q. PrimaFit 2.0 is considered a design  
 9 refresh of the PrimaFit 1.0?  
 10 MS. FRANTZEN: Object to the form, vague,  
 11 assumes facts not in evidence.  
 12 THE WITNESS: I'm not familiar with that  
 13 term. PrimaFit 2.0 is its own unique product.  
 14 BY MR. NEWTON:  
 15 Q. PrimaFit 2.0 is an upgrade of the  
 16 PrimaFit 1.0?  
 17 MS. FRANTZEN: Same objection.  
 18 THE WITNESS: As I said, PrimaFit 1.0 and  
 19 2.0 are unique products from each other.  
 20 BY MR. NEWTON:  
 21 Q. As an engineer who worked on these  
 22 products, do you consider PrimaFit 2.0 to be an  
 23 upgrade of the PrimaFit 1.0?  
 24 MS. FRANTZEN: I'm going to object to the  
 25 form and to the extent it mischaracterized past

Page 191

1 A. Cole  
 2 referring to with "starting point."  
 3 BY MR. NEWTON:  
 4 Q. In your own words, what is the  
 5 relationship between PrimaFit 1.0 and PrimaFit 2.0?  
 6 MS. FRANTZEN: Objection to the form,  
 7 vague.  
 8 THE WITNESS: PrimaFit 1.0 and  
 9 PrimaFit 2.0 are different products. [REDACTED]  
 10 [REDACTED]  
 11 [REDACTED]. They are unique in that way.  
 12 So they are urine management products, but  
 13 they're unique, independent products.  
 14 BY MR. NEWTON:  
 15 Q. Did Sage develop the PrimaFit 2.0 from  
 16 scratch?  
 17 MS. FRANTZEN: Object to the form, vague.  
 18 THE WITNESS: I don't know what you mean  
 19 by "from scratch."  
 20 BY MR. NEWTON:  
 21 Q. You don't know what it means to design  
 22 something from scratch?  
 23 MS. FRANTZEN: Same objection, and  
 24 argumentative.  
 25 THE WITNESS: I think, as I stated,

Page 193

1 A. Cole  
 2 testimony.  
 3 THE WITNESS: As I said, there were  
 4 various reasons for designing PrimaFit 2.0, and  
 5 I believe I've already captured that in  
 6 previous answers.  
 7 BY MR. NEWTON:  
 8 Q. I'm asking for your personal view as to  
 9 whether you consider the PrimaFit 2.0 to be an  
 10 upgrade of the PrimaFit 1.0 --  
 11 MS. FRANTZEN: Object to the form.  
 12 BY MR. NEWTON:  
 13 Q. -- to the extent you have such a view.  
 14 MS. FRANTZEN: Pardon me. Object to the  
 15 form, vague, asked and answered.  
 16 THE WITNESS: I believe PrimaFit 2.0 to be  
 17 a successful product. I don't know that I  
 18 would use the term "upgrade," as you've called  
 19 it.  
 20 BY MR. NEWTON:  
 21 Q. Would you use the term "design refresh" to  
 22 refer to the PrimaFit 2.0 relative to the  
 23 PrimaFit 1.0?  
 24 MS. FRANTZEN: Object to the form, asked  
 25 and answered.

<p style="text-align: right;">Page 202</p> <p>1 A. Cole</p> <p>2 backer, bottom barrier, and selective adhesive</p> <p>3 bowtie?</p> <p>4 MS. FRANTZEN: Object to the form,</p> <p>5 compound.</p> <p>6 THE WITNESS: I would want to confirm any</p> <p>7 material call-outs with the actual engineering</p> <p>8 specifications, and I do believe there are</p> <p>9 differences. But I believe that this table</p> <p>10 does state "Type EO Volara" and "Where used,"</p> <p>11 those parts are captured here, yes.</p> <p>12 BY MR. NEWTON:</p> <p>13 Q. Do you believe that this is an inaccurate</p> <p>14 description of the foam backer, the bottom barrier,</p> <p>15 and the selective adhesive bowtie in the</p> <p>16 PrimaFit 2.0?</p> <p>17 MS. FRANTZEN: Object to the form,</p> <p>18 mischaracterization.</p> <p>19 THE WITNESS: I didn't say that. I said</p> <p>20 that the actual material would be captured in</p> <p>21 the engineering specifications.</p> <p>22 I'm not familiar with this document</p> <p>23 specifically. I'm not aware of inaccuracies,</p> <p>24 but I can't say with confidence without looking</p> <p>25 at those specifications.</p>	<p style="text-align: right;">Page 203</p> <p>1 A. Cole</p> <p>2 BY MR. NEWTON:</p> <p>3 Q. Do you see the last column where it says</p> <p>4 "Used in PrimaFit 1.0"?</p> <p>5 A. I do see that column better.</p> <p>6 Q. Are you able to say whether Type EO Volara</p> <p>7 material was used in the PrimaFit 1.0?</p> <p>8 MS. FRANTZEN: I'm going to object to the</p> <p>9 form, and I'm going to object to outside the</p> <p>10 scope of the 30(b) (6) deposition.</p> <p>11 THE WITNESS: I can't say for certain.</p> <p>12 BY MR. NEWTON:</p> <p>13 Q. Can you go to the next page ending in 872.</p> <p>14 A. Okay.</p> <p>15 Q. The first entry towards the top of the</p> <p>16 document says, "TVF 103444 Dimple Mesh Polyester."</p> <p>17 Do you see that?</p> <p>18 A. I do see that entry.</p> <p>19 Q. Are you able to say whether that's a</p> <p>20 material used in the PrimaFit 2.0 device?</p> <p>21 MS. FRANTZEN: I'm going to object to the</p> <p>22 form.</p> <p>23 THE WITNESS: As I stated earlier, the</p> <p>24 actual engineering specifications would capture</p> <p>25 the material. I see that it's captured here in</p>
<p style="text-align: right;">Page 204</p> <p>1 A. Cole</p> <p>2 this table, in this document. The engineering</p> <p>3 specification would be the place I would like</p> <p>4 for it, but ...</p> <p>5 BY MR. NEWTON:</p> <p>6 Q. Sitting here looking at this document,</p> <p>7 you're not able to say for certain whether the</p> <p>8 wicking fabric in the PrimaFit 2.0 is made from</p> <p>9 TVF 103444 dimple mesh polyester?</p> <p>10 MS. FRANTZEN: I'm going to object to the</p> <p>11 form, asked and answered, and argumentative.</p> <p>12 THE WITNESS: Without knowing the origin</p> <p>13 of this document and without cross-referencing</p> <p>14 it against the engineering specifications, I</p> <p>15 can't say for certain.</p> <p>16 BY MR. NEWTON:</p> <p>17 Q. Are you able to say whether the</p> <p>18 PrimaFit 1.0 and the PrimaFit 2.0 use the same</p> <p>19 material for the wicking fabric?</p> <p>20 A. The fabric used on the two devices, as I</p> <p>21 understand it, has a different configuration and</p> <p>22 geometry between the two products.</p> <p>23 I believe -- without checking the</p> <p>24 specifications, I can't say for certain, but I</p> <p>25 believe they are -- the fabric is the same material;</p>	<p style="text-align: right;">Page 205</p> <p>1 A. Cole</p> <p>2 different configuration, different attachment,</p> <p>3 different shape.</p> <p>4 Q. Are you able to say whether the foam</p> <p>5 backer in the PrimaFit 1.0 and the PrimaFit 2.0 was</p> <p>6 made from the same material?</p> <p>7 MS. FRANTZEN: Object to the form,</p> <p>8 mischaracterization.</p> <p>9 THE WITNESS: I'm unable to say.</p> <p>10 BY MR. NEWTON:</p> <p>11 Q. You can put that document aside.</p> <p>12 Does the wicking fabric in the</p> <p>13 PrimaFit 2.0 have a larger surface area than that of</p> <p>14 the PrimaFit 1.0?</p> <p>15 MS. FRANTZEN: Object to the form.</p> <p>16 THE WITNESS: As I said, I know the shape</p> <p>17 and configuration and attachment of the fabric</p> <p>18 used in PrimaFit 1.0 and 2.0 are different. I</p> <p>19 can't speak to specific sizes.</p> <p>20 BY MR. NEWTON:</p> <p>21 Q. Go back to Exhibit 33 for me.</p> <p>22 A. Okay.</p> <p>23 Q. On Page 6 of Exhibit 33, do you see</p> <p>24 Topic 4?</p> <p>25 A. I do.</p>

<p style="text-align: right;">Page 206</p> <p>1 A. Cole</p> <p>2 Q. Topic 4 says "Sage's research, design, and</p> <p>3 development efforts relating to the Accused</p> <p>4 Product," which I'll stipulate is the PrimaFit 2.0,</p> <p>5 "specifically, including research, design,</p> <p>6 development, testing, and evaluation of the" --</p> <p>7 PrimaFit 2.0 -- "prototypes, and competitor external</p> <p>8 catheters as well as modifications made during</p> <p>9 development."</p> <p>10 Do you see that topic?</p> <p>11 A. I do.</p> <p>12 Q. Are you prepared to testify on behalf of</p> <p>13 Sage with respect to the subject matter of Topic 4?</p> <p>14 MS. FRANTZEN: As set forth in our</p> <p>15 response and objections to Topic 4, subject to</p> <p>16 our objections and our response as to the</p> <p>17 scope.</p> <p>18 THE WITNESS: I am.</p> <p>19 BY MR. NEWTON:</p> <p>20 Q. Did Sage evaluate competitor products as</p> <p>21 part of the research, design, and development of the</p> <p>22 PrimaFit 2.0?</p> <p>23 A. No, not that I'm aware.</p> <p>24 Q. Did Sage evaluate competitor products as</p> <p>25 part of the research, design, and development of the</p>	<p style="text-align: right;">Page 207</p> <p>1 A. Cole</p> <p>2 PrimaFit 1.0, to your knowledge?</p> <p>3 MS. FRANTZEN: Object to the form, outside</p> <p>4 the scope, lack of foundation.</p> <p>5 THE WITNESS: I wouldn't be able to answer</p> <p>6 that question. I have no idea.</p> <p>7 BY MR. NEWTON:</p> <p>8 Q. Earlier, we talked about the limited</p> <p>9 launch of the PrimaFit 2.0 in the fourth quarter of</p> <p>10 2019.</p> <p>11 Do you recall that discussion, generally?</p> <p>12 A. I do.</p> <p>13 Q. And is it your understanding that the</p> <p>14 first commercial sale of the PrimaFit 2.0 occurred</p> <p>15 in the fourth quarter of 2021?</p> <p>16 MS. FRANTZEN: Object to the form,</p> <p>17 mischaracterizes past testimony.</p> <p>18 THE WITNESS: As I believe I stated</p> <p>19 earlier, I don't know anything about commercial</p> <p>20 sales.</p> <p>21 BY MR. NEWTON:</p> <p>22 Q. What was the purpose of the limited launch</p> <p>23 in the fourth quarter of 2019 of the PrimaFit 2.0?</p> <p>24 MS. FRANTZEN: Object to the form, outside</p> <p>25 the scope.</p>
<p style="text-align: right;">Page 208</p> <p>1 A. Cole</p> <p>2 THE WITNESS: I can't speak to all</p> <p>3 potential reasons for a limited launch, but as</p> <p>4 the term states, it allows us to launch a</p> <p>5 product in a limited capacity to our customers.</p> <p>6 BY MR. NEWTON:</p> <p>7 Q. Do you know how many customers</p> <p>8 participated in the limited launch of the</p> <p>9 PrimaFit 2.0?</p> <p>10 A. No, I do not. I have no idea.</p> <p>11 MS. FRANTZEN: And I'm going to object to</p> <p>12 the form and outside the scope of the</p> <p>13 Rule 30(b)(6).</p> <p>14 BY MR. NEWTON:</p> <p>15 Q. Do you know how many samples of the</p> <p>16 PrimaFit 2.0 device were involved in the limited</p> <p>17 launch?</p> <p>18 MS. FRANTZEN: I'm going to object to the</p> <p>19 form and vague as to the word "samples."</p> <p>20 THE WITNESS: I'm not sure what you're</p> <p>21 referring to. I don't know.</p> <p>22 BY MR. NEWTON:</p> <p>23 Q. You don't know what I'm referring to with</p> <p>24 respect to --</p> <p>25 A. I'm sorry, the term "samples," I don't</p>	<p style="text-align: right;">Page 209</p> <p>1 A. Cole</p> <p>2 know what that means in your context, and nor do I</p> <p>3 know how many of any product was made.</p> <p>4 Q. Do you know how many PrimaFit 2.0 devices</p> <p>5 were part of the limited launch in Q4 2019?</p> <p>6 MS. FRANTZEN: Object to the form, outside</p> <p>7 the scope of the Rule 30(b)(6).</p> <p>8 THE WITNESS: There may be a document that</p> <p>9 summarizes that. I'm not sure, as we sit here,</p> <p>10 what that number would be.</p> <p>11 BY MR. NEWTON:</p> <p>12 Q. After the limited launch of the</p> <p>13 PrimaFit 2.0, did you and your team continue to make</p> <p>14 design changes to the device?</p> <p>15 MS. FRANTZEN: Object to the form.</p> <p>16 THE WITNESS: I don't recall specifically</p> <p>17 what design activities happened during or after</p> <p>18 limited launch.</p> <p>19 As I said earlier, we're always looking to</p> <p>20 improve our designs and continue to innovate.</p> <p>21 BY MR. NEWTON:</p> <p>22 Q. But with respect to the PrimaFit 2.0, you</p> <p>23 don't recall any specific design changes that were</p> <p>24 made after the limited launch?</p> <p>25 A. There may be documents that summarize</p>



Page 210

1 A. Cole

2 design changes. I can't speak to what specific

3 design changes may have occurred between the first

4 limited launch and subsequent years.

5 Q. Do you recall if there were any changes to

6 the manufacturing process of the PrimaFit 2.0 after

7 the limited launch?

8 A. As the term implies, "limited launch" is

9 limited. And when we would fully commercialize

10 product, we would often consider manufacturing

11 changes for that difference in those two types of

12 launches.

13 Q. Correct me if I'm wrong, but I believe you

14 said there are -- there were a number of differences

15 between the PrimaFit 1.0 and the PrimaFit 2.0?

16 A. You are correct; I did say that.

17 Q. Is it correct that one of those

18 differences involved removing an end cap from the

19 PrimaFit 1.0?

20 A. One of the many differences between the

21 unique PrimaFit 1.0 design and the unique

22 PrimaFit 2.0 product design is that the PrimaFit 2.0

23 does not have any sort of end cap.

24 Q. When Sage transitioned from the

25 PrimaFit 1.0 to the PrimaFit 2.0, is it correct that

Page 212

1 A. Cole

2 BY MR. NEWTON:

3 Q. Let me try a different way of asking this.

4 Do you agree that the differences between

5 the PrimaFit 2.0 and the PrimaFit 1.0 do not affect

6 the intended use of the devices?

7 MS. FRANTZEN: Object to the form, vague.

8 THE WITNESS: The intended use is probably

9 a better question for regulatory.

10 I can only say that the PrimaFit 2.0 is

11 unique and has numerous differences from 1.0

12 and is also a urine management product.

13 Intended use, specifically, I can't say

14 exactly.

15 BY MR. NEWTON:

16 Q. Did the PrimaFit 2.0 and the PrimaFit 1.0

17 have the same fundamental scientific technology in

18 terms of how they operate?

19 MS. FRANTZEN: Object to the form, vague.

20 THE WITNESS: I'm not sure what you mean

21 by "fundamental scientific technology."

22 Each unique product is made with unique

23 components, and as I said, there's no shortage

24 of differences between the two. From a

25 technology standpoint, there's quite a few

Page 211

1 A. Cole

2 it changed from a sewn to a heat-sealed device

3 design?

4 A. The design of PrimaFit 2.0 does not

5 include any sewn components.

6 Q. Is it correct that the PrimaFit 2.0 had

7 the addition of a flexible extension tube?

8 A. One of the components in the -- as we

9 discussed earlier, in the PrimaFit 2.0 design is a

10 flexible tube.

11 Q. It's correct that the PrimaFit 1.0 did not

12 have a flexible tube?

13 MS. FRANTZEN: Object to the form.

14 THE WITNESS: I can speak to that there's

15 a flexible tube in 2.0. I'm not familiar with

16 the terminology used for 1.0 that specifically.

17 BY MR. NEWTON:

18 Q. Do you agree that the modifications that

19 were made to the PrimaFit 2.0 device did not affect

20 the intended use or the fundamental scientific

21 technology of the device?

22 MS. FRANTZEN: Object to the form, vague.

23 THE WITNESS: Could you clarify what you

24 mean by "modifications"?

25

Page 213

1 A. Cole

2 differences in terms of the technology used to

3 make the products, used to make the components

4 within the products.

5 So I don't think I could say that.

6 MR. NEWTON: I'm going to mark as

7 Exhibit -- I'll show you what has previously

8 been marked as Exhibit 2, an email dated

9 January 31st, 2020. This was produced at

10 SAGE00037025.

11 (Exhibit 2 was identified.)

12 BY MR. NEWTON:

13 Q. Let me know when you're able to see

14 Exhibit 2. And if you need time to read it, please

15 do.

16 A. Yeah, I see it. Let me read through it

17 for a moment.

18 Q. Sure.

19 A. Okay. I've reviewed the document.

20 Q. Okay. Do you see that this is an email

21 from a Patricia Polanco?

22 A. This does appear to be an email from

23 Patricia.

24 Q. And she sent it to Dan Ulreich,

25 Kristin Sexton, Sameer Jirafe, as well as several

Page 214

1 A. Cole

2 others on the cc line?

3 A. I do see that.

4 Q. The subject of the email is "PrimaFit 2.0

5 New Product Code or Existing Product Code RA

6 perspective"?

7 MS. FRANTZEN: I'm going to object to the

8 form as -- and outside the scope, lack of

9 foundation.

10 THE WITNESS: I do see that subject listed

11 as "PrimaFit 2.0 New Product Code or Existing

12 Product Code RA perspective" in this email.

13 BY MR. NEWTON:

14 Q. In the first sentence of the email,

15 Ms. Polanco says, "Team, I know several of you have

16 asked Steve and me independently to provide the

17 Regulatory assessment on the PrimaFit 2.0 strategy

18 regarding creating a new product code or maintaining

19 the existing 5400 code."

20 MS. FRANTZEN: Object to the form, outside

21 the scope, lack of foundation.

22 THE WITNESS: I do see the first sentence

23 as you described it.

24 BY MR. NEWTON:

25 Q. Further down in the email Ms. Polanco

Page 216

1 A. Cole

2 MS. FRANTZEN: Object to the form,

3 compound.

4 THE WITNESS: I can't speak to what

5 Patricia was capturing here in this email, as

6 I'm not included on it, and it does appear to

7 be an RA topic.

8 There are probably about 20, nearly 20

9 differences between PrimaFit 1.0 and

10 PrimaFit 2.0. I don't know that I would have

11 listed four as she as done here. I can't speak

12 to why she chose to list those four.

13 BY MR. NEWTON:

14 Q. Do you agree that the four she listed are

15 design differences between the PrimaFit 1.0 and the

16 PrimaFit 2.0?

17 A. I think among the many design -- unique

18 design changes, or differences, to use that word

19 correctly, between PrimaFit 1.0 and 2.0 include

20 PrimaFit 2.0 does not have an end cap. PrimaFit 2.0

21 leverages a seam that does not include any sewing.

22 The manufacturing process used to attach

23 the materials in the PrimaFit 2.0 is unique. The --

24 there is no -- the PrimaFit 2.0 uses an inner foam

25 that is unique to PrimaFit 2.0. PrimaFit 2.0 does,

Page 215

1 A. Cole

2 says, "The proposed changes to this new version of

3 the PrimaFit - Female External Urine Device are as

4 follows."

5 Do you see that?

6 MS. FRANTZEN: I'm going to object to the

7 form, lack of foundation, outside the scope of

8 the Rule 30(b)(6) deposition.

9 THE WITNESS: I see that sentence in this

10 email.

11 BY MR. NEWTON:

12 Q. Do you see the four bullet points

13 underneath that sentence, "Removal of the cap;

14 Change from sewn to heat-sealed device design;

15 Addition of a flexible extension tube; Addition of a

16 foam in the new filler material"?

17 MS. FRANTZEN: Object to the form, outside

18 the scope of the Rule 30(b)(6), lack of

19 foundation.

20 THE WITNESS: I do see four bullets in

21 this email.

22 BY MR. NEWTON:

23 Q. In your view, are those four bullets

24 design differences between the PrimaFit 1.0 and the

25 PrimaFit 2.0?

Page 217

1 A. Cole

2 indeed, have an extension tube, which is a unique

3 feature of the product.

4 And, you know, there are numerous other

5 unique design features of PrimaFit 2.0, including a

6 unique suction connector, including the bottom

7 barrier, including the unique manufacturing process

8 used to make PrimaFit 2.0, including the attachment

9 and configuration of the fabric. There's a hot-melt

10 adhesive used on PrimaFit 2.0 unique to that

11 product, and numerous others.

12 Q. Why don't you go ahead and list them all.

13 A. Okay. Let's see if I can --

14 MS. FRANTZEN: I'm just going to object to

15 the extent it calls for a narrative.

16 THE WITNESS: I doubt I can list every

17 single change without reviewing documents, but

18 I can list --

19 BY MR. NEWTON:

20 Q. That's okay. I'll strike the question,

21 and I'll withdraw it.

22 A. Okay.

23 Q. The four proposed changes that Ms. Polanco

24 lists here in her email, do you agree that those

25 four changes do not affect the intended use of the

Page 218

1 A. Cole

2 PrimaFit 2.0 as compared to the PrimaFit 1.0?

3 MS. FRANTZEN: I object to the form, asked

4 and answered.

5 THE WITNESS: As I said earlier, intended

6 use is a better question for regulatory.

7 I can speak to the design differences.

8 You would have to ask someone in regulatory

9 about the intended use comparison of the

10 products.

11 BY MR. NEWTON:

12 Q. Is the intended use of the products

13 captured in the IFUs?

14 MS. FRANTZEN: Object to the form, outside

15 the scope.

16 THE WITNESS: I would want to confirm by

17 looking at the IFU how that is stated as an

18 instruction for use, which is what IFU stands

19 for. It may capture usage information.

20 BY MR. NEWTON:

21 Q. Do you agree that the fit and function of

22 the PrimaFit 2.0 remained the same as compared to

23 the PrimaFit 1.0?

24 MS. FRANTZEN: Object to the form --

25 pardon me. Object to the form.

Page 220

1 A. Cole

2 document. This is a document that was

3 previously marked as Exhibit 1.

4 (Exhibit 1 was identified.)

5 MR. NEWTON: And it was produced at

6 STRSAGE00021947.

7 BY MR. NEWTON:

8 Q. Let me know when you can see Exhibit 1,

9 Mr. Cole, and feel free to look through it if you

10 need to.

11 A. Okay. I've reviewed the document.

12 Q. Do you recognize the document marked as

13 Exhibit 1?

14 MS. FRANTZEN: I'm going to object to the

15 form.

16 THE WITNESS: I don't recognize the

17 specific content, but I recognize that I've

18 seen this document at some point in the past.

19 BY MR. NEWTON:

20 Q. What is a project charter --

21 MS. FRANTZEN: Object --

22 BY MR. NEWTON:

23 Q. -- in the context of your work at Sage?

24 MS. FRANTZEN: Sorry. Object to the form,

25 outside the scope of the Rule 30(b) (6).

Page 219

1 A. Cole

2 THE WITNESS: I don't think I can speak to

3 fit. I can speak that PrimaFit 2.0 diverts

4 urine away from the patient as part of its

5 function. I believe PrimaFit 1.0 also diverts

6 urine away from the patient. So that may be

7 something they have in common, but I can't

8 speak anymore specifically to fit or other

9 function.

10 BY MR. NEWTON:

11 Q. Having had the opportunity to read

12 Ms. Polanco's email here marked as Exhibit 2, do you

13 believe she's saying anything that you consider

14 inaccurate?

15 MS. FRANTZEN: Object to the form,

16 compound, lack of foundation, calls for

17 speculation.

18 THE WITNESS: I think that's a question

19 better for Patricia. That is a regulatory

20 discussion in this email, not an engineering

21 discussion, so I can't say that I have an

22 opinion otherwise.

23 BY MR. NEWTON:

24 Q. Understood.

25 MR. NEWTON: Why don't we go to another

Page 221

1 A. Cole

2 THE WITNESS: A project charter can be

3 used in many different ways. One way it may be

4 used is to summarize, you know, the overall

5 project in question.

6 BY MR. NEWTON:

7 Q. This is a project charter for the

8 PrimaFit 2.0; is that correct?

9 A. It does appear to be.

10 Q. Your name is listed in this document; is

11 that correct?

12 A. It does appear that I signed this

13 document.

14 Q. That's your signature on the page ending

15 in 21949?

16 A. It is.

17 Q. "NPD Engineering," is that new product

18 development engineering?

19 A. That is correct.

20 Q. What was the purpose of you signing off on

21 this document?

22 A. The -- one of the purposes of signing a

23 charter like this would be, to a degree, agree to

24 provide the resources requested to execute the

25 project.

Page 230

1 A. Cole

2 THE WITNESS: I can't speculate. I don't

3 know what that was referring to.

4 BY MR. NEWTON:

5 Q. A few bullet points down, it says, "No

6 dedicated reservoir cap to minimize material and

7 assembly costs."

8 Do you see that?

9 A. I do see that.

10 Q. Is it correct that the PrimaFit 1.0 had a

11 reservoir cap?

12 MS. FRANTZEN: Object to the form.

13 THE WITNESS: I -- I can't speak to

14 PrimaFit 1.0. I can speak to PrimaFit 2.0 does

15 not have any.

16 BY MR. NEWTON:

17 Q. Does not have a cap?

18 A. As I stated earlier, PrimaFit 2.0 has a

19 tapered end. There is no cap of any kind that I'm

20 aware of.

21 Q. Does the fact that the PrimaFit 2.0 does

22 not have a cap, was that design choice made to

23 minimize material and assembly costs?

24 MS. FRANTZEN: Object to the form.

25 THE WITNESS: The absence of a component

Page 232

1 A. Cole

2 all of the other features we've discussed.

3 It does not have features it doesn't have.

4 So ...

5 BY MR. NEWTON:

6 Q. Does the tapered tip in the PrimaFit 2.0

7 serve the same function as the cap in the

8 PrimaFit 1.0?

9 MS. FRANTZEN: Object to the form.

10 THE WITNESS: The tapered end in

11 PrimaFit 2.0 is intended to provide a soft

12 interface with the patient.

13 I can't speak to the PrimaFit 1.0 intent.

14 MS. FRANTZEN: I'm going to pause. I

15 haven't been able to get a word in. We've been

16 going well over an hour at this point, and so I

17 think it's time for a break.

18 MR. NEWTON: Let's go off the record.

19 THE VIDEOGRAPHER: We're off the record at

20 4:07 p.m.

21 (Whereupon, a recess was taken

22 from 4:07 p.m. to 4:21 p.m.)

23 THE VIDEOGRAPHER: We're on the record at

24 4:21 p.m.

25

Page 231

1 A. Cole

2 would certainly make it easier to assemble and

3 reduce costs. So any component that doesn't

4 exist would certainly be cheaper and easier.

5 BY MR. NEWTON:

6 Q. The PrimaFit 2.0, instead of having a cap,

7 it has the foam backer and the blocking barrier that

8 form the tapered end; is that correct?

9 MS. FRANTZEN: Object to the form,

10 mischaracterization.

11 THE WITNESS: PrimaFit 2.0 has a foam

12 backer, it does have a bottom barrier, and it

13 is described as having a tapered end.

14 BY MR. NEWTON:

15 Q. And the tapered end that includes the

16 blocking barrier and a portion of the foam backer,

17 was that designed to replace the cap of

18 PrimaFit 1.0?

19 MS. FRANTZEN: Object to form,

20 mischaracterization of testimony and

21 mischaracterization.

22 THE WITNESS: As I stated on multiple

23 occasions, PrimaFit 2.0 is a unique product.

24 It has numerous design differences. It

25 has a foam backer. It has a bottom barrier and

Page 233

1 A. Cole

2 BY MR. NEWTON:

3 Q. Mr. Cole, staying on the document marked

4 as Exhibit 1, the project charter, could you look at

5 Page 2 of the PDF ending in Number 21948.

6 A. Give me a second here.

7 Q. I believe it's the page we were on before

8 we took a break.

9 A. Yeah. I've got to get back to my spot

10 here.

11 Okay.

12 Q. Do you see the section of Page 21948

13 called Key Project Risks?

14 A. I do see a Key Project Risks section.

15 Q. Under the first risk listed, it says,

16 "Poor acceptance of new design by users."

17 Do you see that?

18 A. I do see where it says that.

19 Q. Next to that, for Mitigation, it says,

20 "In-house healthy subject testing."

21 Do you see that?

22 A. I see the document does include those

23 words.

24 Q. Do you recall any in-house healthy subject

25 testing for the PrimaFit 2.0 device?

Confidential

<p style="text-align: right;">Page 234</p> <p>1 A. Cole</p> <p>2 MS. FRANTZEN: Object to the form, outside</p> <p>3 the scope.</p> <p>4 THE WITNESS: I don't recall whether we</p> <p>5 did that.</p> <p>6 BY MR. NEWTON:</p> <p>7 Q. Do you know if Sage has performed any</p> <p>8 testing of the PrimaFit 2.0 device in humans?</p> <p>9 MS. FRANTZEN: Object to the form, vague.</p> <p>10 THE WITNESS: Excuse me. Hold on a</p> <p>11 second.</p> <p>12 I apologize. That almond went down wrong.</p> <p>13 I don't recall from the past few years</p> <p>14 what all the testing was we performed.</p> <p>15 BY MR. NEWTON:</p> <p>16 Q. I understand. Do you recall any specific</p> <p>17 testing that Sage performed of the PrimaFit 2.0</p> <p>18 device on a human patient?</p> <p>19 MS. FRANTZEN: Object to the form, outside</p> <p>20 the scope.</p> <p>21 THE WITNESS: I don't recall.</p> <p>22 BY MR. NEWTON:</p> <p>23 Q. You can put that document aside.</p> <p>24 Do you need to take a break for a minute,</p> <p>25 or are you okay?</p>	<p style="text-align: right;">Page 235</p> <p>1 A. Cole</p> <p>2 A. I'm good.</p> <p>3 MS. FRANTZEN: Thank you.</p> <p>4 THE WITNESS: Thank you, though.</p> <p>5 BY MR. NEWTON:</p> <p>6 Q. Sure, sure. Just let me know. I've had</p> <p>7 it happen to me before.</p> <p>8 Let's go back to Exhibit 33, please, and</p> <p>9 I'll direct your attention to Page 6, Topic 5, which</p> <p>10 is "Sage's attempts or plans to design or redesign,</p> <p>11 in whole or in part, the Accused Product or</p> <p>12 PrimaFit 1.0, or features thereof, so as to avoid</p> <p>13 infringing any claim of the Patents-in-Suit."</p> <p>14 Do you see that? Do you see Topic 5,</p> <p>15 Mr. Cole?</p> <p>16 A. I do see it.</p> <p>17 Q. Are you prepared to provide 30(b)(6)</p> <p>18 testimony on behalf of Sage with respect to Topic 5?</p> <p>19 MS. FRANTZEN: I'm going to state on this</p> <p>20 one in particular that that's going to be</p> <p>21 subject to our objections.</p> <p>22 And specifically, we object to the fact of</p> <p>23 any allegation about infringement, and we've</p> <p>24 stated in our objections that we've agreed to</p> <p>25 designate a witness to testify on relevant and</p>
<p style="text-align: right;">Page 236</p> <p>1 A. Cole</p> <p>2 nonprivileged aspects of the design structure,</p> <p>3 materials, and operation of the 2.0, and</p> <p>4 relevant alternatives proportional to the needs</p> <p>5 of the case. And so we maintain those</p> <p>6 objections, subject to those objections.</p> <p>7 THE WITNESS: Per my lawyer's objections,</p> <p>8 I'm prepared to talk about Number 5.</p> <p>9 BY MR. NEWTON:</p> <p>10 Q. Was any of the aspect of the research,</p> <p>11 development, design of the PrimaFit 2.0 based on</p> <p>12 litigation between Sage and PureWick?</p> <p>13 MS. FRANTZEN: I'm going to object to</p> <p>14 that. It's vague. It's outside the scope, and</p> <p>15 it seems to call for privileged information.</p> <p>16 So I would ask you to rephrase your</p> <p>17 question because I think it seems to ask for</p> <p>18 privileged information.</p> <p>19 MR. NEWTON: Are you instructing him not</p> <p>20 to answer as the question was posed?</p> <p>21 MS. FRANTZEN: Yes.</p> <p>22 BY MR. NEWTON:</p> <p>23 Q. And Mr. --</p> <p>24 MS. FRANTZEN: I mean, it seems to request</p> <p>25 a privileged question.</p>	<p style="text-align: right;">Page 237</p> <p>1 A. Cole</p> <p>2 BY MR. NEWTON:</p> <p>3 Q. Mr. Cole, are you going to follow your</p> <p>4 counsel's advice?</p> <p>5 A. I don't want to disclose any privileged</p> <p>6 information, so if it's possible to reword, that</p> <p>7 would be preferred.</p> <p>8 Q. Are you able to answer the question I</p> <p>9 posed without divulging privileged information?</p> <p>10 MS. FRANTZEN: If you are able -- maybe</p> <p>11 you should repeat the question.</p> <p>12 And if you are able to answer the question</p> <p>13 without revealing privileged information.</p> <p>14 But maybe read it back again at this</p> <p>15 point.</p> <p>16 It seemed implicit in the question that it</p> <p>17 would have to reveal privileged information if</p> <p>18 it was answered.</p> <p>19 THE WITNESS: It would help if you read it</p> <p>20 back for me. Thank you.</p> <p>21 BY MR. NEWTON:</p> <p>22 Q. Was any aspect of the research,</p> <p>23 development, or design of the PrimaFit 2.0 based on</p> <p>24 litigation between Sage and PureWick?</p> <p>25 MS. FRANTZEN: Yeah, that seems to request</p>

<p style="text-align: right;">Page 238</p> <p>1 A. Cole</p> <p>2 privileged information, so maybe you can ask</p> <p>3 for reasons for research, development, or</p> <p>4 design that don't request -- or that don't seek</p> <p>5 privileged information. Because you're saying</p> <p>6 it's "based on litigation," which is just</p> <p>7 specifically privileged. The reasons for</p> <p>8 the --</p> <p>9 MR. NEWTON: I just -- I want to know if</p> <p>10 you're instructing him not to answer my</p> <p>11 question as opposed.</p> <p>12 MS. FRANTZEN: Yeah. As posed, I think</p> <p>13 you're requesting privileged information. I</p> <p>14 think there might be a way to answer it to get</p> <p>15 the answer -- or ask it to get the answer that</p> <p>16 you're looking for. But you're specifically</p> <p>17 saying did you do something based on -- based</p> <p>18 on litigation, which implies counsel.</p> <p>19 MR. NEWTON: Right. I'm just going to try</p> <p>20 to ask the question and please make a privilege</p> <p>21 objection or don't. But I feel like we're kind</p> <p>22 of going around in circles here.</p> <p>23 BY MR. NEWTON:</p> <p>24 Q. Mr. Cole, was any aspect of the research,</p> <p>25 development, or design of the PrimaFit 2.0 based on</p>	<p style="text-align: right;">Page 239</p> <p>1 A. Cole</p> <p>2 litigation between Sage and PureWick?</p> <p>3 MS. FRANTZEN: Yeah, I'm going to object</p> <p>4 to the question as implicitly seeking a</p> <p>5 question about attorney-client communications,</p> <p>6 if any.</p> <p>7 So --</p> <p>8 MR. NEWTON: Are you instructing the</p> <p>9 witness not to answer?</p> <p>10 MS. FRANTZEN: I am.</p> <p>11 BY MR. NEWTON:</p> <p>12 Q. Mr. Cole, are you going to follow that</p> <p>13 instruction?</p> <p>14 A. I am.</p> <p>15 Q. Mr. Cole, was any aspect of the</p> <p>16 PrimaFit 2.0 design motivated by an effort to avoid</p> <p>17 infringement of any patents?</p> <p>18 MS. FRANTZEN: I'm going to instruct the</p> <p>19 witness not to answer that question, as it</p> <p>20 clearly states privileged information, and it's</p> <p>21 outside the scope of what we agreed to provide</p> <p>22 a witness on.</p> <p>23 BY MR. NEWTON:</p> <p>24 Q. Mr. Cole, are you going to follow that</p> <p>25 instruction?</p>
<p style="text-align: right;">Page 240</p> <p>1 A. Cole</p> <p>2 A. I am.</p> <p>3 MS. FRANTZEN: I will again state that you</p> <p>4 can ask the witness the reasons for the</p> <p>5 research and development, but you can't ask for</p> <p>6 privileged information.</p> <p>7 BY MR. NEWTON:</p> <p>8 Q. You're familiar with PureWick, correct,</p> <p>9 Mr. Cole?</p> <p>10 A. I am familiar with -- vaguely with</p> <p>11 PureWick.</p> <p>12 Q. Okay. Are you familiar with Bard?</p> <p>13 A. I am familiar that there is a company</p> <p>14 named Bard.</p> <p>15 Q. Do you understand that this litigation</p> <p>16 involves the entity PureWick?</p> <p>17 MS. FRANTZEN: This is -- objection to</p> <p>18 outside the scope.</p> <p>19 THE WITNESS: I understand that there is</p> <p>20 litigation involving PureWick.</p> <p>21 BY MR. NEWTON:</p> <p>22 Q. Was the design of the PrimaFit 2.0</p> <p>23 impacted in any way by actions that PureWick has</p> <p>24 taken?</p> <p>25 MS. FRANTZEN: Objection, vague.</p>	<p style="text-align: right;">Page 241</p> <p>1 A. Cole</p> <p>2 THE WITNESS: I can't speak to any actions</p> <p>3 that PureWick has taken.</p> <p>4 BY MR. NEWTON:</p> <p>5 Q. To your knowledge, has any action or</p> <p>6 inaction on the part of PureWick Corporation</p> <p>7 influenced the design of the PrimaFit 2.0?</p> <p>8 MS. FRANTZEN: Objection to the form,</p> <p>9 vague.</p> <p>10 THE WITNESS: I would have no way of</p> <p>11 knowing what actions or inactions a different</p> <p>12 company such as PureWick would be taking.</p> <p>13 BY MR. NEWTON:</p> <p>14 Q. Have any actions or inactions taken by</p> <p>15 Bard influenced the design of the PrimaFit 2.0</p> <p>16 device?</p> <p>17 MS. FRANTZEN: Object to the form, vague.</p> <p>18 THE WITNESS: Similar response. I can't</p> <p>19 speak to what another company actions or</p> <p>20 inactions are.</p> <p>21 BY MR. NEWTON:</p> <p>22 Q. Have any actions or inactions on the part</p> <p>23 of PureWick or Bard influenced the development of</p> <p>24 the PrimaFit 2.0 device?</p> <p>25 MS. FRANTZEN: Object to the form, outside</p>



Page 242

1 A. Cole  
 2 the scope of the 30(b)(6), and vague as to  
 3 "influenced the development."  
 4 THE WITNESS: As I said, I have no way of  
 5 commenting on actions or inactions taken by  
 6 other companies such as PureWick or Bard.  
 7 BY MR. NEWTON:  
 8 Q. You understand that PureWick Corporation  
 9 has asserted certain patents against Sage?  
 10 MS. FRANTZEN: I'm going to object as  
 11 outside the scope.  
 12 And you can answer that "yes" or "no," but  
 13 don't reveal any attorney-client  
 14 communications.  
 15 THE WITNESS: Yes.  
 16 BY MR. NEWTON:  
 17 Q. Have you analyzed any of PureWick's  
 18 patents?  
 19 A. No.  
 20 Q. Have you analyzed any of the defenses that  
 21 Sage has put forward in response to the infringement  
 22 allegations that PureWick Corporation has asserted?  
 23 MS. FRANTZEN: Object to the form, vague,  
 24 outside the scope.  
 25 THE WITNESS: Could you repeat the

Page 244

1 A. Cole  
 2 But the witness can answer whether Sage  
 3 has considered any alternative designs of the  
 4 PrimaFit 2.0.  
 5 And so I instruct you not to answer the  
 6 question as posed.  
 7 BY MR. NEWTON:  
 8 Q. Are you going to follow your counsel's  
 9 instruction?  
 10 A. I am.  
 11 Q. Are you able to tell me whether Sage has  
 12 considered any alternative designs for the  
 13 PrimaFit 2.0, outside of any information you may  
 14 have received from lawyers?  
 15 MS. FRANTZEN: I'm going to object to the  
 16 form of that question. The witness can answer  
 17 on whether he has considered any alternative  
 18 designs for the PrimaFit 2.0 without revealing  
 19 any privileged information.  
 20 THE WITNESS: As we discussed earlier, we  
 21 have -- we are always looking to innovate, and  
 22 we have considered several different design  
 23 options for PrimaFit 2.0 of -- associated with  
 24 several different aspects of the product.  
 25

Page 243

1 A. Cole  
 2 question, please?  
 3 BY MR. NEWTON:  
 4 Q. Are you familiar with any of Sage's  
 5 defenses in this litigation?  
 6 MS. FRANTZEN: Object to the form, vague  
 7 as to -- vague, and I'm going to actually  
 8 caution the witness not to reveal any  
 9 attorney-client communications.  
 10 THE WITNESS: I would not say I'm able to  
 11 comment on any actions or defenses. I don't  
 12 have any comment.  
 13 BY MR. NEWTON:  
 14 Q. Has Sage considered any alternative  
 15 designs for the PrimaFit 2.0 that would -- I'll  
 16 strike that.  
 17 Has Sage considered any alternative  
 18 designs of the PrimaFit 2.0 in order to avoid  
 19 alleged infringement of the PureWick Corporation  
 20 patents asserted in this case?  
 21 MS. FRANTZEN: I'm going to object to the  
 22 portion of the question that says "in order to  
 23 avoid alleged infringement of the PureWick  
 24 patents," and I think that seeks privileged  
 25 information.

Page 245

1 A. Cole  
 2 BY MR. NEWTON:  
 3 Q. As of today, is Sage planning to make any  
 4 design changes to the PrimaFit 2.0?  
 5 MS. FRANTZEN: Object to the form, vague,  
 6 outside the scope of the 30(b)(6).  
 7 THE WITNESS: I can't say what plans we  
 8 have over the course of the life or the future  
 9 of the product. We are considering a variety  
 10 of designs, but beyond that, I can't say.  
 11 BY MR. NEWTON:  
 12 Q. As of today, sitting here right now, are  
 13 you aware of any design changes that Sage plans to  
 14 make for the PrimaFit 2.0?  
 15 MS. FRANTZEN: Object to the form, vague,  
 16 asked and answered.  
 17 THE WITNESS: As of today, [REDACTED]  
 18 [REDACTED]. I can't speak to  
 19 if and when we would implement any of those  
 20 changes.  
 21 BY MR. NEWTON:  
 22 Q. What are the changes Sage is presently  
 23 considering for the PrimaFit 2.0 device?  
 24 MS. FRANTZEN: I'm going to object to the  
 25 extent it was asked and answered.



Page 246

1 A. Cole  
 2 THE WITNESS: [REDACTED]  
 3 There's -- as stated earlier, there are always  
 4 opportunities to make design changes or  
 5 improvements.  
 6 Some of the changes, you know, we may  
 7 consider would be to potentially change the  
 8 shape or location of the fabric or whether  
 9 there is -- you know, we continue to leverage  
 10 the fabric in the same way.  
 11 Other changes we've considered would be,  
 12 as discussed earlier, the bottom barrier and  
 13 potential other ways to achieve a similar  
 14 outcome with other design options.  
 15 We have considered the manufacturing  
 16 placement of the inner foam within the foam  
 17 backer.  
 18 We have considered the shape of the foam  
 19 backer itself.  
 20 We've considered the shape of the inner  
 21 foam itself, just to name a few.  
 22 Oh, we also considered or are considering  
 23 the tubing, its location within the product, or  
 24 whether there's more than one tube or where the  
 25 tubing resides.

Page 248

1 A. Cole  
 2 for future changes at this time, when or if  
 3 they would be implemented.  
 4 BY MR. NEWTON:  
 5 Q. For any of the potential changes that  
 6 you've listed, has Sage determined how much the  
 7 change would cost to implement?  
 8 MS. FRANTZEN: Object to the form, vague,  
 9 compound.  
 10 THE WITNESS: Can you be more specific  
 11 with what change you might be referring to with  
 12 cost?  
 13 BY MR. NEWTON:  
 14 Q. Any of them.  
 15 MS. FRANTZEN: Then, I'm going to object  
 16 to the form, vague, and compound.  
 17 THE WITNESS: Well, I guess I can give you  
 18 an example.  
 19 BY MR. NEWTON:  
 20 Q. No, I'll withdraw my question.  
 21 Has Sage determined how much it would cost  
 22 to change the shape or location of the fabric in the  
 23 PrimaFit 2.0 device?  
 24 MS. FRANTZEN: Object to the form.  
 25 THE WITNESS: I wouldn't be able to give

Page 247

1 A. Cole  
 2 So those are just to name a few of them.  
 3 BY MR. NEWTON:  
 4 Q. Let's start with the shape of the fabric.  
 5 Has -- is Sage currently planning to  
 6 change the shape of the fabric in the PrimaFit 2.0  
 7 device, yes or no?  
 8 MS. FRANTZEN: Object to the form, vague,  
 9 outside the scope.  
 10 THE WITNESS: [REDACTED]  
 11 [REDACTED]. I can't speak to Sage planning to  
 12 execute those designs at this time --  
 13 BY MR. NEWTON:  
 14 Q. Have any --  
 15 A. -- or at any time.  
 16 Q. I apologize.  
 17 Of any of the designs that you walked  
 18 through just now, is Sage currently planning to make  
 19 any of those design changes in the PrimaFit 2.0 as  
 20 of today?  
 21 MS. FRANTZEN: Object to the form, vague,  
 22 compound.  
 23 THE WITNESS: Design changes are always  
 24 being evaluated among the ones I listed and  
 25 beyond. I can't speak to decisions being made

Page 249

1 A. Cole  
 2 you a quote, but I would say that something of  
 3 that nature, from an engineering point of view,  
 4 would be fairly easy to do.  
 5 A simple modification to a fixture, you  
 6 know, I would say, you know, would cost no more  
 7 than [REDACTED]  
 8 [REDACTED] at most, probably less, and it could  
 9 be done quite quickly.  
 10 BY MR. NEWTON:  
 11 Q. Has Sage determined how the product would  
 12 perform if it were to change the shape or location  
 13 of the fabric in the PrimaFit 2.0 device?  
 14 A. I'm not sure exactly when you mean by  
 15 "perform." Any design change we would consider does  
 16 consider the impact to the device. I can't say for  
 17 sure if there's one performance metric you're  
 18 referring to.  
 19 Q. Has Sage analyzed how it would impact its  
 20 patients using the PrimaFit 2.0 if the device were  
 21 to have a different shape or location of the fabric?  
 22 MS. FRANTZEN: I'm going to object to the  
 23 form.  
 24 THE WITNESS: You know, as we talked  
 25 about, there are any number of changes



Page 266

1 A. Cole  
 2 Let's start with the PrimaFit 2.0. You're  
 3 familiar with the PrimaFit 2.0, correct?  
 4 A. I am.  
 5 Q. If I ask you about a product that is  
 6 different from the PrimaFit 2.0, are you able to  
 7 understand what I'm asking?  
 8 MS. FRANTZEN: I'm going to object to the  
 9 form.  
 10 THE WITNESS: I believe you to be asking  
 11 about other products beyond PrimaFit 2.0.  
 12 BY MR. NEWTON:  
 13 Q. Great. I think we were on the same page,  
 14 then.  
 15 If you go back to Exhibit 33, please.  
 16 A. Okay.  
 17 Q. On Page 6 -- I'm sorry, Page 7, do you see  
 18 Topic 10, "The manufacture of the Accused Product,  
 19 including the manufacturing process, facilities and  
 20 persons involved, and location(s) where the Accused  
 21 Product are manufactured"?  
 22 A. I do see Item 10.  
 23 Q. Are you prepared to provide 30(b) (6)  
 24 testimony with respect to that subject matter in the  
 25 PrimaFit 2.0 device?

Page 268

1 A. Cole  
 2 capacity, specifically.  
 3 MS. FRANTZEN: I'm going to object to the  
 4 question as vague.  
 5 BY MR. NEWTON:  
 6 Q. Are you able to say whether Sage currently  
 7 has manufacturing capacity to meet customer demand  
 8 for the PrimaFit 2.0?  
 9 MS. FRANTZEN: I'm going to object to the  
 10 form.  
 11 THE WITNESS: I'm not capable of speaking  
 12 to customer demand, therefore -- nor am I  
 13 capable to speaking to capacity, so I can't  
 14 answer that question.  
 15 BY MR. NEWTON:  
 16 Q. Is it correct that one reason for  
 17 developing the PrimaFit 2.0 was to have a [REDACTED]  
 18 [REDACTED]?  
 19 A. As stated earlier, there were several  
 20 reasons for developing the PrimaFit 2.0 process.  
 21 One of those reasons, as stated, was  
 22 [REDACTED], and that's how I would  
 23 answer that question.  
 24 Q. Do you consider the manufacturing process  
 25 for the PrimaFit 1.0 [REDACTED]?

Page 267

1 A. Cole  
 2 MS. FRANTZEN: That will be subject to  
 3 Sage's objections and responses in its 30(b) (6)  
 4 objections.  
 5 THE WITNESS: Do you want to clarify,  
 6 again, this "Accused Product" refers to  
 7 PrimaFit 2.0?  
 8 BY MR. NEWTON:  
 9 Q. I believe I did, but yes --  
 10 A. Okay. Then yes.  
 11 Q. -- when I used the word --  
 12 A. Yes, I'm sorry.  
 13 Q. -- "accused product."  
 14 A. Yes, I am.  
 15 Q. Where is the PrimaFit 2.0 currently  
 16 manufactured?  
 17 A. [REDACTED]  
 18 Q. What city?  
 19 A. [REDACTED].  
 20 Q. Are you familiar with the manufacturing  
 21 capacity that Sage has for the PrimaFit 2.0?  
 22 A. I can't speak to --  
 23 MS. FRANTZEN: I'm going to object to the  
 24 form and object as vague.  
 25 THE WITNESS: I can't speak to the

Page 269

1 A. Cole  
 2 MS. FRANTZEN: Object to the form.  
 3 THE WITNESS: It's my understanding that  
 4 the PrimaFit 2.0 product is -- [REDACTED]  
 5 [REDACTED] as part of its  
 6 manufacturing process.  
 7 BY MR. NEWTON:  
 8 Q. Was the [REDACTED] used for the  
 9 PrimaFit 2.0 also used for the PrimaFit 1.0?  
 10 MS. FRANTZEN: Object to the form.  
 11 THE WITNESS: As I have clarified earlier,  
 12 PrimaFit 2.0 is a unique product, different  
 13 than PrimaFit 1.0, and one of those unique  
 14 attributes, beyond all the other design  
 15 features, is the manufacturing process, which  
 16 is unique to PrimaFit 2.0.  
 17 BY MR. NEWTON:  
 18 Q. How is the manufacturing process for the  
 19 PrimaFit 2.0 different from the manufacturing  
 20 process for the PrimaFit 1.0?  
 21 MS. FRANTZEN: I'm going to object to the  
 22 form, outside the scope. I will object to the  
 23 extent that it's outside the scope.  
 24 THE WITNESS: I don't think, sitting here  
 25 today, I could speak at all to the

# **SAGE EXHIBIT 4**

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

PUREWICK CORPORATION,

Plaintiff,

v.

SAGE PRODUCTS, LLC,

Defendant.

C. A. No. 22-102-MN

CONTAINS INFORMATION  
DESIGNATED CONFIDENTIAL UNDER  
THE PROTECTIVE ORDER

**RESPONSIVE EXPERT REPORT OF DR. YADIN B. DAVID REGARDING  
U.S. PATENT NOS. 10,226,376 AND 10,390,989**

**TABLE OF CONTENTS**

I. INTRODUCTION ..... 1

II. PROFESSIONAL BACKGROUND AND OTHER INFORMATION ..... 2

    A. Qualifications ..... 2

    B. Prior Testimony In The Last Four Years ..... 11

    C. Materials Considered ..... 11

    D. Compensation ..... 11

III. SUMMARY OF OPINIONS ..... 12

IV. BASIC LEGAL PRINCIPLES ..... 13

    A. Person of Ordinary Skill In The Art ..... 13

    B. Patents and Patent Applications ..... 14

    C. Legal Standards for Infringement ..... 14

        1. Claim Construction ..... 15

        2. Infringement ..... 16

    D. Acceptable Noninfringing Alternatives ..... 17

V. BACKGROUND INFORMATION ..... 18

    A. Technology Background ..... 18

    B. The Asserted 989 and 376 Patents ..... 21

        1. The 989 Patent ..... 21

        2. The 376 Patent ..... 27

        3. PureWick’s Communications With The Patent Office  
            Regarding The 989 and 376 Patents ..... 31

        4. Alleged Benefits of the 376 and 989 Patents ..... 39

    D. Sage’s PrimaFit 2.0 ..... 44

VI.	SAGE’S PRIMAFIT DOES NOT DIRECTLY OR INDIRECTLY INFRINGE THE ASSERTED 376 AND 989 PATENTS.....	60
A.	Preliminary Statement Regarding Dr. Collins’ CT Scan .....	60
B.	376 Patent.....	68
1.	Claim 1 (376 Patent) .....	68
a.	“a fluid impermeable casing having a fluid reservoir at a first end, a fluid outlet at a second end” .....	69
b.	a fluid impermeable casing having “a longitudinally extending fluid impermeable layer coupled to the fluid reservoir and the fluid outlet” .....	93
c.	a fluid impermeable casing “defining a longitudinally elongated opening between the fluid reservoir and the fluid outlet” / “elongated opening” .....	97
d.	“a fluid permeable support disposed within the casing with a portion extending across the elongated opening” .....	101
e.	“wherein the fluid permeable support is distinct from and at least proximate to the fluid reservoir” .....	105
f.	“a fluid permeable support” and “a fluid permeable membrane disposed on the support . . . so that the membrane is supported on the support and disposed across the elongated opening” .....	113
g.	“a tube having a first end disposed in the reservoir” .....	116
h.	“the apparatus configured . . . to receive urine discharged from the urethral opening . . . into the reservoir, and to have the received urine withdrawn from the reservoir via the tube and out of the fluid discharge end of the tube.” .....	131
2.	Claim 5 (376 Patent) .....	135
3.	Claim 9 (376 Patent) .....	140
4.	Claim 10 (376 Patent) .....	141
C.	989 Patent.....	142
1.	Claim 1 (989 Patent) .....	143

a. “disposing in operative relationship with the urethral opening of a female user a urine collecting apparatus” ..... 146

i. “fluid impermeable casing having a fluid reservoir at a first end, a fluid outlet at a second end, and a longitudinally extending fluid impermeable layer coupled to the fluid reservoir and the fluid outlet and defining a longitudinally elongated opening between the fluid reservoir and the fluid outlet;” ..... 147

ii. “a fluid permeable support disposed within the fluid impermeable casing with a portion extending across the longitudinally elongated opening, wherein the fluid permeable support is distinct from and at least proximate to the fluid reservoir” ..... 147

iii. “a fluid permeable membrane disposed on the fluid permeable support and covering at least the portion of the fluid permeable support that extends across the longitudinally elongated opening, so that the fluid permeable membrane is supported on the fluid permeable support and disposed across the longitudinally elongated opening” ..... 148

iv. “a tube having a first end disposed in the fluid reservoir and extending behind at least the portion of the fluid permeable support and the portion of the fluid permeable membrane disposed across the longitudinally elongated opening and extending through the fluid outlet to a second, fluid discharge end” ..... 148

b. “allowing urine discharged from the urethral opening to be received through the longitudinally elongated opening of the longitudinally extending fluid impermeable layer, the fluid permeable membrane, the fluid permeable support, and into the fluid reservoir” ..... 149

c. “allowing the received urine to be withdrawn from the fluid reservoir via the tube and out of the fluid discharge end of the tube” ..... 151

2.	Claim 2 (989 Patent) .....	153
3.	Claim 3 (989 Patent) .....	156
4.	Claim 4 (989 Patent) .....	158
5.	Claim 5 (989 Patent) .....	159
6.	Claim 6 (989 Patent) .....	160
7.	Dr. Collins’ Failure To Identify Any Act Of Direct Infringement Of The 989 Patent .....	163
a.	Response to Dr. Collins’ Statement that Sage Directly Infringes The Methods of The 989 Patent .....	163
b.	Response to Dr. Collins’ Statement that Unidentified “Hospitals” Directly Infringe The Method Claims of The 989 Patent .....	166
VII.	RESPONSE TO DR. COLLINS’ GENERAL ALLEGATIONS OF INDIRECT INFRINGEMENT .....	167
VIII.	PRODUCT ENHANCEMENTS TO THE PRIMAFIT 2.0 PRODUCT AND RESPONSE TO DR. COLLINS’ COMPARISONS OF THE PRIMAFIT 1.0 AND 2.0 PRODUCTS .....	174
IX.	RESPONSE TO DR. COLLINS’ STATEMENTS REGARDING “BENEFITS PROVIDED BY THE PRIMAFIT DEVICE AND NEXUS TO THE INVENTIONS OF THE 376 AND 989 PATENTS” .....	191
X.	RESPONSE TO DR. COLLIN’S STATEMENT ABOUT WILLFULNESS .....	200
XI.	RESPONSE TO DR. COLLIN’S STATEMENT ON NONINFRINGEMENT ALTERNATIVES.....	214
1.	Manufacturing Change to Ensure Inner Foam Is Fully Seated Within The Foam Backer Of the PrimaFit 2.0 .....	217
2.	Blunt End Design.....	222
3.	Design Change to the Dimension of the Fabric .....	226
4.	Further Retraction Of The Vacuum Tube .....	229

XII. RESPONSE TO COLLINS’ STATEMENTS REGARDING  
PUREWICK’S DEVICE ..... 232

XIII. EXHIBITS ..... 238

XIV. SUPPLEMENTATION ..... 238



## I. INTRODUCTION

1. Defendant Sage Products LLC (“Sage”) asked that I provide opinions regarding the issues raised by Dr. John Collins in the Opening Expert Report of Dr. John Collins Regarding Infringement dated May 19, 2023 (“Collin’s Opening Report”), including whether the Sage PrimaFit 2.0 product accused of infringement in this case infringes the asserted claims of the asserted patents, opinions on noninfringing alternatives, and other additional related opinions provided in this report. Many of Dr. Collins’ opinions are also similar to opinions provided by Dr. Edward Yun, who also provided a report on May 19, 2023.

2. I understand that Plaintiff PureWick Corporation (“PureWick”) asserts in this case that Sage’s PrimaFit 2.0 device (the “Accused Product”) infringes U.S. Pat. No. 10,226, 376 (“376 Patent”) and U.S. Pat. No. 10,390,989 (“989 Patent,” and collectively the “Asserted Patents”). I understand that the claims that PureWick alleges infringe are Claims 1, 5, 9, and 10 of the 376 Patent and Claims 1-6 of the 989 Patent (“Asserted Claims”).<sup>1</sup>

3. I understand that another Sage expert, Dr. Diane Newman, provided an Opening Expert Report of Diane K. Newman, D.N.P., F.A.A.N Regarding U.S. Patent Nos. 10,226,376 and 10,390,989 dated May 19, 2023 (“Newman Opening Report”) regarding certain background information regarding the state of the art, invalidity, and relevance of certain publicly-disclosed information, among other things.

---

<sup>1</sup> Dr. Collins references these ten asserted claims in Paragraph 49 of his report (under “Asserted Claims”). There are a few places in Dr. Collins report, which appear to inadvertently reference Claim 7 of the 989 patent without any analysis (e.g., ¶24). Dr. Collins does not provide an infringement analysis for Claim 7 of the 989 patent (*see* Exhibit E), and I understand that the Court determined that Claim 7 was withdrawn from the case. (*See* D.I. 134 at n. 6.) Similarly, Dr. Collins appears to inadvertently reference eight asserted claims of the 376 patent, although there are only four asserted claims. (Collins Report ¶96.) I assume these are typographical errors.

4. I have formed the opinions expressed in this report through my independent evaluation and analysis. I reserve the right to amend or supplement my opinions if new information or documents come to light. I may also provide additional opinions to rebut any testimony, reports, or opinions offered by PureWick's witnesses (expert or otherwise).

## **II. PROFESSIONAL BACKGROUND AND OTHER INFORMATION**

### **A. Qualifications**

5. Below I briefly describe some of my professional qualifications including my formal education, certifications and registrations, employment history, awards and honors, and publications. Additional qualifications are found in my *Curriculum Vitae*, which is attached as Attachment A1, and includes further credentials.

6. I am an engineer, biomedical engineering instructor, and an engineering consultant that has worked in the field of medical devices for over 45 years, in research and development, consulting, and education. I have extensive experience designing, prototyping, testing, developing, servicing, performance assurance, and evaluating numerous types of medical devices including fluid handling devices and urine management products and catheters as well as problem-solving related to those products. I have developed, implemented, and conducted medical technology assessments, integration of healthcare technology, and life cycle technology management. I also have over 35 years of experience directing comprehensive biomedical engineering departments at research and academic medical centers. I specialize in medical devices, medical technology life cycle management, engineering incident investigation, clinical studies, regulatory compliance, and technical issues related to intellectual property such as patents. From my experience, I have a strong understanding of medical devices, including fluid handling medical devices, their construction, components, and materials, and use and testing of such products and devices.

7. In 1972, I earned a degree in Electrical Engineering Technology from the Technion - Israel Institute of Technology, a science and technology research university. In 1974 and 1975, I earned a Bachelor of Science in Electrical Engineering and a Master of Science in Electrical Engineering with a focus in Biomedical Engineering from West Virginia University. In 1983, I earned a Doctorate (Ed. D.) from an Inter-Disciplinary Doctorate Program at the School of Graduate Education Studies at West Virginia University.

8. I have a number of professional certifications and registrations. For example, in 1985, I became a Registered Professional Engineer in Biomedical Engineering (P.E.) in the State of Texas (Registration – Certificate No. 91626). From 1981-2008, I was an International Health Care Safety Professional (C.H.S.P.), Board Executive Level (Certificate No. 263). Since 1989, I have been a Certified Clinical Engineer (C.C.E.) – The International Certification Commission (Certificate No. 400). I have also been since 2004 certified in Clinical Engineering – Healthcare Technology Commission (HTC) (Certificate No. 118). Beginning in 2018, I was a Board Certified Diplomate in Forensic Engineering – The National Academy of Forensic Engineers (Certificate No. 1002S).

9. For over 25 years (1982-2008), I served as the Director of the Biomedical Engineering Department at Texas Children's Hospital, Houston, and during 14 of those years from 1982-1996, I was also the Director of Biomedical Engineering at St. Luke's Episcopal Hospital, Houston. Texas Children's is the largest children's hospital in the United States with over 950 beds and is consistently ranked as the best in Texas and among the best in the nation, and St. Luke's is an adult hospital with a focus on cardiac diseases and therapies.

10. As the Director of the Biomedical Engineering Departments for Texas Children's and St. Luke's, I was in a unique environment at the intersection of engineering and point of care,

where engineers, caregivers, and patients interact. There, I developed an understanding of a broad array of medical products used in hospitals. I was responsible for the management of the hospital medical/surgical technology life cycle from the innovation phase to the deployment phase as well as the retirement phase. I was responsible for a broad range of technologies in the hospital including, among other types, fluids control devices and systems such as dialysis machines, infusion pumps, water quality assurance systems, patient thermal regulation fluid systems, blood transfusion devices, urine pH analyzers, heart assist pumps, as well as other hospital technologies such as imaging systems (Computed Tomography (CT), radiographic imaging (x-ray), magnetic resonance imaging (MRI), nuclear cameras, and fluoroscopic devices), surgical and electrosurgical instruments, hospital beds and other patient support devices, warming/cooling devices, orthopedic devices, laboratory analyzers and equipment, sterilization equipment, surgical microscopes, physiological monitoring systems, and others.

11. As Director of Biomedical Engineering, my team and I participated in testing, observing, and evaluating of urine management products such as urinary catheters, and other urine management products which were commonplace in the hospitals including various diapers, pads, and bedpans. In my experience, these are ubiquitous products found in most if not all hospital systems, and understood readily by engineers and clinicians. My team and I designed testing protocols and oversaw testing related to the evaluation of urinary catheters and identified design and manufacturing improvements in the products, and we designed, developed, and tested other fluid management products including heart assist devices including implantable blood pumps, fluid catheters for monitoring blood attributes such as pH, infusion pumps, patient ventilators and breathing circuits, extracorporeal membrane oxygenation (ECMO) pumps, filters, fluid IV sets, and hospital operating room vacuum systems for anesthetic gases. My team also designed,

developed, and tested other medical devices such as newborn transport systems and improved pneumatic shock absorbers and vibration systems, and electromagnetic radiation reduction. The hospital received several patents on new inventions.

12. Since 1993, I have served on several advisory panels for the United States Food and Drug Administration (FDA). Between 1993 and 2016, I served as a consultant for the General Hospital and Personal Use Devices Panel, Center for Devices and Radiological Health (GHPUDP), Food and Drug Administration (FDA), Department of Health & Human Services (HHS), Rockville, Maryland. The GHPUDP, among other things, reviews and evaluates information related to the safety and effectiveness of marketed and investigational general hospital, infection control and personal use devices and makes appropriate recommendations to the Commissioner of the FDA. As a consultant, I was involved with the review and assessment of testing protocols and policies related to innovation and medical product compliance, including injectors, sterilizers, fluid handling products, and countless others.

13. Since 2014, I served on the Device Good Manufacturing Practice Advisory Committee (DGMPAC) for the FDA and become the Chairman of the committee in 2022. At the FDA, the DGMPAC views proposed regulations for good manufacturing practices governing the methods used in, and the facilities and controls used for, the manufacture, packing, storage, and installation of devices and makes recommendations on the feasibility and reasonableness of the proposed regulations. For example, the committee members utilize their industry experience in design, development, manufacturing, and deployment to make recommendations regarding the recommended practices for manufacturing medicals devices. In 2001, I received the FDA Commissioner's Special Citation for service performed on promoting public safety.

14. Since 2008, I have been a principal at Biomedical Engineering Consultants, LLC,

in Houston, Texas. Biomedical Engineering Consultants is a consulting firm that I launched, which focuses on the design and development of medical devices, optimization of the management of medical technology life cycles, including risk mitigation, patient safety, compliance validation and operational program efficiency issues. The company, among other things, advises clients in industry, health care delivery, hospitals, government agencies, and academic institutions on engineering issues and design, and other topics including technical support services. We provide services to start-up entities who seek to develop, validate, test, and commercialize new medical products.

15. During the course of my work at Biomedical Engineering Consultants, I have worked on the design, engineering, and consulting relating to different types of medical devices including catheters for delivery of therapies, telemedicine, patient tracking devices, systems, and information management, newborn delivery progress monitoring systems and sensors, and others. I also worked on conceptualization, as well as engineering design and development, prototyping, and testing of external urine capture devices and systems. The devices and systems included a non-invasive, external absorbent pad that managed urine and components to pattern and predict urination events, providing real-time and predictive alerts to a user or healthcare provider.

16. For approximately fifteen years (1984-1999), I taught as an adjunct Associate Professor at the University of Texas Health Sciences Center at Houston, Texas, within the anesthesiology department at the University's medical school that focuses on practice, education, and research. There, I taught seminars related to risk control of medical products and assisted in the instrumentation and monitoring of a research laboratory. I also designed and taught seminars related to methods I developed for monitoring bodily fluid parameters.

17. Between 1987 and 2010, I was an adjunct Assistant Professor at the Department of

Pediatrics, Baylor College of Medicine, Houston, Texas. The Department of Pediatrics at Baylor College of Medicine is one of the nation's largest, most diverse, and most successful programs, having comprehensive healthcare, research, and education programs. There, I taught medical students and medical residents about the principles and functions of bedside medical equipment including blood pressure monitoring, infusion pumps, drug administration, IV sets, point of care products including urine management products, and other common bedside medical equipment.

18. Between 2003 to 2012, I taught as an Adjunct Professor in the Biomedical Engineering Program, Health Sciences Division, Tecnológico De Monterrey School of Biotechnology and Health in Mexico. The Biomedical Engineering Program at the Tecnológico De Monterrey School of Biotechnology and Health is recognized as a top program in health promotion and prevention for professionals, particularly in genetics, epidemiology, and disease prevention. The private institute is based in Monterrey, Mexico, and has grown to include 35 campuses throughout Mexico and is highly regarded as a top university in Latin America. There, I taught classes related to design principles of point of care medical devices such as blood pressure monitoring, infusion pump, drug administration, IV sets, disposable point of care products including urine management products, and other common bedside medical equipment.

19. Between 2008 to 2021, I taught as an Assistant Professor at the University of Texas, School of Public Health in Houston, Texas. The School of Public Health at the University of Texas focuses on research, education, and solutions for imminent public health problems. There I assisted with workshops and projects related to medical devices and equipment, and more broadly related to hospitals and technology administration.

20. From 1976-1982, I was the Director of the Biomedical Engineering Section at West Virginia University Hospital, Morgantown, West Virginia where I supported deployment of

medical and surgical instrumentation and design their use for clinical trials at the medical center. Prior to that time period, from 1975-1976, I worked as a design engineer at Rockwell International where I was part of a team conducting design work for NASA related to navigation systems.

21. I also founded and am the current President Emeritus of the Healthcare Technology Foundation at the Global Clinical Engineering Alliance (GCEA), which is an international professional organization that focuses on advancing the field of clinical engineering and healthcare technology management. The GCEA aims to promote global collaboration, knowledge sharing, and best practices among clinical engineers and professionals involved in healthcare technology. The Healthcare Technology Foundations aims to improve healthcare delivery outcomes by promoting the development, application, and support of safe and effective healthcare technologies, and I have developed this Alliance through presentations and facilitated discussions with industry peers to bring focus to the intersection of engineering and point-of-care.

22. Between 2003 to 2014, I was the Chairman of the Biomedical Advisory Committee (BAC), a group of biomedical engineering experts in the US, Europe and Asia. I recruited colleagues practicing in hospitals to engage in sharing benchmarking data, methodologies, and best practices related to optimizing health technology life cycle management. I also set objectives for the organization to examine, selected topics to investigate, and guided the process leading to consensus buildup for the organization and its affiliate members.

23. Since 2017, I have also served as the Honorary Director of Capital Medical University School of Biomedical Engineering. Capital Medical University School of Biomedical Engineering is accepted a top university in Beijing founded by a renowned urologist and is comprised of nearly 20 associated hospitals having thousands of beds and nearly 40 teaching hospital partners. There, I guide the development of the applied clinical engineering program.



24. Since 1993, I advised the World Health Organization (WHO/PAHO) – Healthcare Infrastructure and Technology (HIT) in Geneva Switzerland and Washington, DC. HIT is aimed at strengthening healthcare systems and optimizing the use of technology in healthcare delivery by, among other things, providing input to enhance the physical infrastructure and support systems such as laboratories, supply chains, and information management within hospitals, clinics, and health centers. As an advisor, I have been involved with developing and delivering workshops and guidance documents to increase awareness and attract engineering talent to the medical field to advance innovation and design of point-of-care medical devices.

25. For approximately six years, I served as a judge for the Medical Device Design Excellence Award, UBM Canon (2004-2006, 2014-2017). The Medical Device Design Excellence Award honors innovative products whose contributions have had a demonstrable impact on technological, business, and cultural advancements in medical devices. Within these organizations, I generally served as a biomedical engineering expert with experience in medical products used at the point-of-care.

26. Over my professional career, I have received several awards and honors. In 1992, I was inducted as a Founding Fellow and the first clinical engineer to The American Institute of Medical and Biological Engineering (AIMBE). In 1999, I was awarded a Fellow status at the American College of Clinical Engineering. That same year, I became a Fellow at the American College of Forensic Examiners Institute. In 2008, I received the Robert L. Morris International Humanitarian Award from the American College of Clinical Engineering and Association for the Advancement of Medical Instrumentation (AAMI). In 2011, I received a Lifetime Achievement Award from the American College of Clinical Engineering and was inducted into their Hall of Fame in 2018. In 2017, I was inducted into the Academy of Chemical and Biomedical Engineering

at West Virginia University. In 2022, I received a fellowship recognition at the International Union for Physical and Engineering Sciences In Medicine (IUPESM).

27. As set forth further in my *Curriculum Vitae*, I have authored over 450 publications, many of which are peer reviewed, authored book chapters and excerpts, and given presentations related to medical devices, engineering, and regulatory standards for medical devices. Select examples include: David, A. Wald: “Codes, Standards, and Regulations”, Chapter in ‘Encyclopedia of Medical Devices and Instrumentation’, John G. Webster (editor), Wiley, Interscience, John Wiley & Sons, Inc., 1988; Y. David: “The Biomedical Engineering Handbook”, Clinical Engineering Section Editor, CRC Press, Inc., Boca Raton, Florida, 1995; Calderon, Y. David: “TRIAD Catheter System Engineering Delivery Solutions for Medical Applications”, IEEE/EMBS 1st Conference on Translational Engineering in Health & Medicine, Houston, Texas, USA, Nov. 2012; Y. David: “Regulation and Standards in Medical Device Management”, Clinical Engineering Advisory Council, Shanghai, China, Sept. 25, 2013 and Y. David: “Clinical Engineering” chapter in The Biomedical Engineering Handbook 4/e, CRC Press/Taylor & Francis Group, LLC, California, USA, 2017.

28. Over the years, I have also served as an editor for technical publications related to medical devices. For example, since 2018, I have been the Editor-in-Chief of the Global Clinical Engineering Journal (GCEJ). GCEJ publishes peer-reviewed manuscripts about the intersection of technology, engineering, and informatics related to health, wellness, disease management, and patient-care outcomes around the world. Since 2011, I have been an Editorial Board Member for the Journal on Health and Technology. The Journal of Health and Technology is jointly published by Springer and the International Union for Physical and Engineering Sciences in Medicine (IUPESM) in cooperation with the World Health Organization.

**B. Prior Testimony In The Last Four Years**

29. I have testified as an expert at deposition and/or trial in the past four years in the following cases: *Caroline Kubicki v. Medtronic, Inc.* No. 12-734-KBJ, (D. D.C), *Noto v. Zimmer, Inc.* and *Precision Orthopedics, Inc.* No. 17-6630, (Fla. Cir.), *Bereal v. Wesley Medical Center and R. Bajaj M.D.*, No. 11 CV4566 (Kan. Dist.), *Rivera v. Valley Hosp, Inc.*, No. CV 12-5704 (JLL) (N.J. Super.) *Bourdelaïs v. Frensinus Medical Care, et. al.*, No. 15-C-689 (Cir. Ct. W. Va), *Garrett v. Sorin Group USA, Inc., et. al.*, No. (E.D. Tex.), *Ascion, LLC v. Tempur Sealy Int'l, Inc.*, No. 17-403-JMH, (E.D. Ky.), *O'Haver v. Anesthesia Assocs. of Kan. City, P.C.*, No. 1816-CV30710 (Cir. Cr. Mo.), *Gu v. Retrovascular, Inc.*, No. RG19008006 (Cal. Super.). My *curriculum vitae* includes a case list (Attachment A1).

**C. Materials Considered**

30. I relied upon my knowledge, experience, training, education, and skills in my field of expertise in preparing my report. I considered also materials shown in Attachment B to my report as well as materials described throughout my report and the report of Dr. Collins and Dr. Yun. I reserve all rights to consider and rely upon additional documents and information provided to me in this case including information from or considered by PureWick's experts, including Dr. Collins and Dr. Yun, and I reserve the right to supplement as may be needed in view of additional information that is brought to my attention.

**D. Compensation**

31. I am an independent consultant being compensated in connection with this matter at a rate of \$475 per hour for analysis of information and documents and for preparing this report and any other report or declaration in connection with this matter. My compensation in connection with this matter is not dependent on the opinions or testimony I provide or the outcome of the

lawsuit. I am also reimbursed for reasonable expenses incurred related to my work on this case.

### **III. SUMMARY OF OPINIONS**

32. My opinions in this report are based upon my knowledge, experience, training, education, skills in my field of expertise, and review of the various materials and information referenced in my report (including in Attachment A2). My opinions regarding the 376 and 989 Patents and other related issues, as well bases and support for my opinions, are detailed throughout this report. I expect to testify concerning, among other things, what was understood and known to a person of ordinary skill in the art at the time of the alleged invention of the Asserted Patents and technical background information related to the issues in this case as set forth below. I further expect to testify regarding PureWick's products and Sage's products, including my opinions regarding Sage's alleged infringement of the Asserted Patents. I also expect to testify in this case regarding technical background information related to the issues in this case as set forth in my report, and other issues set forth in my report.

33. As set forth in detail below, I have concluded that Sage, and Sage's PrimaFit 2.0 product accused of infringement in this case, do not infringe the Asserted Claims of the 376 Patent and the 989 Patent.


34. I have responded to and provided opinions related to assertions of indirect infringement (i.e., no infringement by inducement and no contributory infringement) and certain statements made by Dr. Collins. In addition, I have responded to opinions set forth by Dr. Collins and provided opinions regarding Sage's lack of willfulness and have responded and provided opinions regarding the assertion that PureWick's product is covered by Asserted Claims of the 376 and 989 Patents. Further, I have concluded that certain alternative products are acceptable and noninfringing alternatives to PureWick's product. Other opinions are set forth in this report.

intervals including after larger voiding events in accordance with hospital protocols, use of diapers and pads will not result in IAD. That is why these products continue to be used in nearly every hospital system (and stocked in nearly every room or at least every floor) of those hospitals.


55. Other common urine management products include urinary catheters such as indwelling catheters and intermittent catheters. Both include tubes that are inserted into the urethra of a patient and into the patient's bladder to allow the bladder to be drained to a drainage bag. Catheters offer the same benefits as diapers, pads, urinals, and bedpans but also additional benefits. Although Dr. Collins asserts that these catheters are associated with urinary tract infections (e.g., paragraph 102), catheters are routinely selected for urine management during surgical and interventional procedures. Moreover, hospitals have succeeded in reducing instances of such infections over the years for numerous products due to improved techniques.

56. Vacuum-assist urine collection devices have also been known for decades. Two examples are U.S. Patent No. 4,747,166 to Kuntz ("Kuntz") and U.S. Patent No. 8, 287,508 to Sanchez ("Sanchez" or "508 Patent").

57. Kuntz describes a urine collecting apparatus for use with a female including a fluid impermeable casing ("lower backing layer 36a"), a fluid permeable support ("core 34"), a fluid permeable membrane (upper cover layer 28), a reservoir ("bore 22a"), and a tube (tube 18). Urine is withdrawn from the device via the tube by a "vacuum source 16" via a "tube 18" to a "remote receptacle" or urine collection vessel (14). (2:3-17, 3:35-57, 4:10-16, Fig. 2, 7, 8.) I note that the fluid permeable membrane can be a moisture-wicking article, as the Patent Office has found. (IPR2020-01426 (Final Written Decision) at 6, 52.) The Kuntz device is shown below, and discussed further in Section V.B.3 as the Patent Office determined that Kuntz had disclosed nearly every element of the claims of the 989 and 376 Patents:



58. Sanchez describes a urine collecting apparatus optionally with “a curved shape to enhance a close fit of the container 50 to the region surrounding the urethral region of a female body.” (6:1-3.) The device included a fluid permeable support (62), a fluid permeable membrane that included a “moisture-wicking article” (20a), a reservoir (64), and a tube (70) disposed in the reservoir and connected to vacuum to remove urine via the tube, out an outlet (68) at the other end of the device and into a suction canister (36). (5:3-9, 6:12-31; Figs. 1-3, 8.) Select figures from Sanchez are shown below.



59. I understand that figures from the Sanchez patent and some of its descriptions are included in the specifications of the 376 and 989 Patents and that the Sanchez patent was a PureWick patent. However, I note that Sanchez issued in 2012 and is prior art to the 376 and 989 patents, which were filed years later. I understand that the Patent Trial and Appeal Board found that claims of the Sanchez patent were invalid, as the elements claimed in the Sanchez patent were also already known. (IPR2020-01426 (Final Written Decision) at 63-64.)



60. I also understand that additional vacuum-assist urine collection devices have been known before the Asserted Patents including the Omni AMXD/AMXDMax devices, which are external devices with vacuum-assist used by the military, and the UrinCare which is a version for incontinence care. (OMNI\_0000210; OMNI\_0000215.) These devices are positioned external to the body and conform to the female anatomy. They rely on vacuum to draw urine away.

61. Other vacuum-assist products on the market today include the Versette by Medline, Qivi Female by Consure Medical, and CareDry by Boehringer.

## **B. The Asserted 989 and 376 Patents**

### **1. The 989 Patent**

62. The 989 Patent has the title “Apparatus And Methods For Receiving Discharged Urine” and was filed on September 8, 2016. The patent issued on August 27, 2019. The inventors listed on the cover are Camille Newton, Ray Newton, Robert Sanchez, and Joseph Forehand.

63. As shown on the cover and the first column, the 989 Patent states that it claims priority to a number of applications. The 989 Patent states that it is a continuation application of a PCT application (PCT/US2016/049274) filed just over a week earlier on August 29, 2016, which is a continuation-in-part application of US Patent Application 15/171,968 filed on Jun. 2, 2016. The 989 Patent also states that it is a continuation-in-part application of US Patent Application Number 14/947,759, filed Nov. 20, 2015, which claims priority to a US Provisional Application 62/082,279 filed on November 20, 2014. The 989 Patent application also states that it is a continuation-in-part application of US Patent Application 14/625,469 filed on February 18, 2015, which claims priority to US Provisional Application 61/955,537.

64. The 989 Patent generally relates to a “system suitable for collecting and transporting urine away from the body of a person or animal.” (Abstract.) The specification

Applicant stated Figure 32 is the preferred embodiment and that the placement of the device is such that the tube is near the user belly button. This method step is not currently claimed and could further differentiate from Kuntz.

Applicant argued that Kuntz fails to teach a reservoir "at a first end" of the apparatus because the Kuntz reference shows absorbent material between the reservoir and the distal tip of the impermeable membrane, pointing to FIG 32 to illustrate the claimed reservoir at the distal tip of the impermeable membrane. The Examiner argued that "at a first end" does not necessarily mean a distal tip, and that the reservoir illustrated by Kuntz is closer to "a first end" of the device, rather than in the middle or at a second end. Applicant argued that the "at a first end," when read in light of the Specification, is meant to mean at the distal tip of the impermeable membrane. The Examiner notes that since this argument is now of record in the case, it behooves the Applicant to include such clarifying language in the claim, which appears to overcome the Kuntz reference.

(PureWick\_0001449.)

105. PureWick subsequently amended the claims on **May 13, 2019**.

(PureWick\_0001462-1468.) PureWick also summarized the interview with the USPTO and explained that the bore 22a of Kuntz (the reservoir) was not at the "first end" of the Kuntz device.

(PureWick\_0001464.)

106. On **June 7, 2019**, the Patent Office ultimately allowed the claims, however, before doing so, the Patent Office entered an amendment to the claims to add the following limitation: **"wherein the fluid permeable support is distinct from and at least proximate to the fluid reservoir."** (PureWick\_0001826-1829.)

107. This feature was identified as the inventive feature. Specifically, the USPTO also indicated in the notice of allowability that "[t]he closest prior art of record is Kuntz US 4747166 and Sanchez US 8287508." (PureWick\_0001829.) The USPTO determined that "Kuntz and Sanchez teach a vacuum-assist urine collection device that has a casing, reservoir, support, and outlet. The reservoirs of Kuntz and Sanchez are found within the support. **"Kuntz and Sanchez fail to teach the reservoir is distinct from the fluid permeable support."** (PureWick\_0001829.) Thus, the Patent Office accepted PureWick's argument that the space where urine may collect in the device (as the Court construed the term "reservoir") must be separate and distinct from the



fluid permeable support.

108. The USPTO also considered the 376 Patent application around the same time period. The USPTO rejected independent claim 1 as anticipated by Kuntz, and subsequently as obvious over Sanchez in view of Kuntz. (PureWick\_0000442-453, PureWick\_0000520-532.). The USPTO allowed the claims, but only after the same amendment was made by adding the limitation “wherein the fluid permeable support is distinct from and at least proximate to the fluid reservoir.” (PureWick\_0000732-733.) The USPTO determined that “[t]he closest prior art of record are Sanchez (US 8,287,508) and Kuntz (US 4,747,166).” (PureWick\_0000736.) The USPTO also again asserted that both “fail[] to disclose or reasonably suggest alone or in combination, that the fluid permeable support is distinct from and at least proximate to the fluid reservoir.” (PureWick\_0000736-737.)

109. Thus, the prosecution of the patents showed that the inventive feature of the 376 and 989 patents was that the “fluid permeable support is distinct form and at least proximate to the fluid reservoir.”

#### **4. Alleged Benefits of the 376 and 989 Patents**

110. In paragraphs 100-111 and 192-210, Dr. Collins references certain “benefits” that he perceives were attributable to certain aspects of the 376 and 989 Patents. I disagree as set forth here.

111. As an initial matter, I note that Dr. Collins discusses “benefits” without regard to any actual apparent contribution of the 376 and 989 patents. However, as discussed above in the previous section, during the prosecution of the asserted patents, the Patent Office found all of the elements were known in the art in the combination claimed, and the claims were only allowed to issue as a patent after PureWick agreed to add the additional limitation “wherein the fluid

permeable support is distinct from and at least proximate to the fluid reservoir.” The benefits that Dr. Collins references are not at all tied to this claim element, which was recognized as the allegedly inventive aspect of the 376 and 989 patents.

112. Dr. Collins asserts that the inventions of the 376 and 989 Patents address problems resulting from incontinence associated dermatitis “with the use of a patient-facing wicking material or permeable layer and a vacuum to draw urine into and through the device and into an external collection canister, which helps the patient’s skin dry and reduces the risk of skin damage.” (Collins Report ¶104, 106.) Pads and diapers, however, also have a patient-facing permeable material that allows the urine to permeate quickly, removing urine from the source. In fact, these products have a significantly larger surface area of permeable material that work in conjunction with other portions or layers of the products to absorb urine away from the skin to keep it from returning or contacting the skin. Vacuum is thus not needed to keep patient skin dry. However, even traditional vacuum-assist products use permeable materials such as moisture-wicking articles that remove urine away from the skin as described in Kuntz and Sanchez. (Sanchez at 4:10–13; Kuntz at 4:35-39; IPR2020-01426 (Final Written Decision) at 6, 56.) Thus, this is not a new feature of the 376 and 989 patents.

113. Dr. Collins concludes that, as a result of the permeable membrane and vacuum, there is a reduction in IAD, but Dr. Collins provides no information to support that conclusion. (Collins Report ¶104, 106.) Dr. Collins cites two documents at PureWick\_0027822-32 and STRSAGE00000004. These documents show, however, that PureWick’s own product experiences issues with moisture in contact with the skin. For example, PureWick\_0027822-32 summarizes a trial for the PureWick device with 61 respondents where 26 users reported challenges including “3 users reported redness or skin damage” and “19 users reported leakage and maintaining

placement (particularly in mobile and obese patients).” (PureWick\_0027831.) The other document Dr. Collins cites is a Sage marketing document that states that the Sage PrimaFit 2.0 “keep[s] the skin dry,” which addresses a risk factor for IAD but that is true of any urine management product as I discuss.


114. In any event, as I mentioned, even if permeable membranes such as wicking materials in combination with vacuum provides certain benefits, those features were not inventive in the 376 and 989 patents. Indeed, prior vacuum-assist devices with patient-facing wicking materials were known before the 376 and 989 patents including in Sanchez and Kuntz as I discussed above.

115. In paragraphs 105 and 197, Dr. Collins asserts that keeping skin dry is “enhanced” by the “fluid impermeable casing with a fluid impermeable layer” of the 376 and 989 Patents. But impermeable casings and fluid impermeable layer were well known features in prior urine management products to keep the patient’s clothing or patient support surface such as a hospital bed dry. For example, diapers and pads typically include a layer of impermeable material on the non-patient facing side and often along the sides of the product to prevent urine from reaching other surfaces such as clothing and bedsheets. Similarly, prior vacuum-assist devices such as Kuntz also had an impermeable outer cover (“lower backing layer 36a”) that prevented urine leakage. (4:50.)

116. In paragraphs 106 and 198, Dr. Collins states that in the 989 and 376 Patents urine is “transported out of the device and in to a separate collection vessel”, which he states keeps the skin dry and “allows for the monitoring of the volume of urine expelled by the patient.” This too was not an inventive feature of the 376 and 989 patents. For example, bedpans divert urine away from the patient and may allow for the accurate measuring of volume. Diapers and pads too provide

these benefits, as they are disposable products and the urine is transported away when these products are removed from the patient and replaced. As PureWick's documents reflect, diapers and pads also allow for volume measurement, for example, by weighing these products after voiding. (*See, e.g.*, PureWick\_0025882.) In my own experience, this was common practice at the hospital, where nurses would weigh diapers to determine the amount discharged by a patient over time.

117. Of course, Kuntz and Sanchez also “transported out of the device and in to a separate collection vessel.” Each disclose vacuum-assisted urine management products where urine is suctioned through the device and collected in a typical suction canister as shown below:



118. In paragraph 107, Dr. Collins asserts that the “device and method [of the 376 and 989 patents] are easy to use, particularly as compared to traditional devices such as indwelling catheters, diapers and bed pads.” I disagree with this conclusion. PureWick's own documents state that catheters are “just easier” than the PureWick product. BDPurewick\_00002071 at 2093 (“why not BD PureWick . . . Perception – PureWick causes UTI's . . . improper placement leads to poor outcomes . . . Foleys are just easier”). Moreover, for example, nearly every nurse and medical practitioner are familiar with the use of traditional devices such as catheters, diapers, and bedpans, and they readily know how to place them. Indeed, most parents of a small child would know how

to use a diaper.

119. The same cannot be said about the PureWick device, which Dr. Collins states is covered by the patents. In fact, PureWick's founder and named inventor Dr. Camille Newton has repeatedly shown that the PureWick is difficult to use as she asserted that issues related to leaking and placement of the device are attributable to not being positioned correctly on a patient. (PureWick I Trial Tr., at 275 (“[I]t's very important that it's placed properly. A lot of times in the beginning people will just kind of stick it between the legs. It has to be well tucked. So there is a little bit of a learning curve in the beginning”).) Moreover, numerous documents including the PureWick instruction for use show the PureWick moves out of place when not positioned properly. (PureWick I Trial Tr., at 275; PureWick\_0014366 (“Improperly positioned or displaced wicks may cause urine to leak. . . .”) This has resulted in numerous problems with the product including leaking and improper fit, which I will discuss in this report.

120. Dr. Collins also asserts that indwelling catheters are more difficult to place but he provides no evidence for that theory. Based on my experience, medical staff are trained on how to use catheters and placement is routine. I have not seen any evidence that they present particular placement difficulties, especially compared to the PureWick product.

121. In paragraphs 108 and 198, Dr. Collins asserts that an “additional advantage relating to the transport of urine is provided by the permeable support claimed in the ‘376 and ‘989 Patents.” I disagree. The fact that urine flows through permeable materials in a urine management product is not an invention of the 376 and 989 patents. Of course, nearly every urine management product has permeability to allow urine to move away from the patient.

122. Dr. Collins cites to PureWick\_0028073-327, which references that a user can use the PureWick while lying on their back, side, or sitting. This makes my point, however, because

in these positions, urine entering the device flows towards the bottom of the device due to gravity, regardless of a permeable support. Indeed, Dr. Collins has not alleged that the support would allow flow of urine against gravity, for example, if the patient is lying in a prone position. The permeable support materials in diapers, likewise allow for permeation through the product while the user is lying on their back, side, or sitting. In any case, a permeable support was known well before the 376 and 989 Patents including in Kuntz (core 34) and Sanchez (container 62). (Kuntz at Fig. 2; Sanchez at Fig. 8.)

123. Thus, in my opinion, Dr. Collins has identified no elements of the 376 or 989 patents that result in features that are not already known in existing urine management products. Moreover, importantly, Dr. Collins identifies no benefits resulting from the purportedly inventive aspect of the patents – “wherein the fluid permeable support is distinct from and at least proximate to the fluid reservoir.”

#### **D. Sage’s PrimaFit 2.0**

124. In this case, PureWick alleges that Sage’s PrimaFit 2.0 infringes the Asserted Claims of the 376 and 989 Patents.

125. Sage’s PrimaFit 2.0 was launched in late 2019. (Cole Dep. Tr., at 77; Sage’s Response to Interrogatory No. 6.) Commercial sales began in December 2021 after investments were made in additional automation. (Farrell. Dep. Tr. at 90; Cole Tr., at 77; STRSAGE00023025.)

126. The PrimaFit 2.0 resulted from Sage’s continuous improvement processes for products. (Cole Dep. Tr., at 54, 138-140.) One of the project objectives for the PrimaFit 2.0 was to optimize “ [REDACTED] [REDACTED].” (SAGE00030464 at 2; Cole Dep Tr., at 138-140.) As part of the PrimaFit 2.0 project, Sage designed a [REDACTED] and processes to aid goals of

(STRSAGE000000004.)

**VI. SAGE’S PRIMAFIT DOES NOT DIRECTLY OR INDIRECTLY INFRINGE THE ASSERTED 376 AND 989 PATENTS**

148. Dr. Collins concluded that Sage infringes Claims 1, 5, 9, and 10 of the 376 Patent and claims 1-6 of the 989 Patent. (Collins Report ¶¶167-191, Exs. D and E.) I disagree. Sage does not infringe the Asserted Claims at least because Sage’s PrimaFit 2.0 and its use do not meet each and every limitation recited by the Asserted Claims either literally or under the doctrine of equivalents, including the limitations discussed below.

149. In developing my opinions, and as discussed elsewhere in my report, I reviewed numerous Sage documents and materials concerning the PrimaFit 2.0 device, including bills of material, engineering drawings and specifications, and other documents and materials including items mentioned throughout this report. Additionally, I examined PrimaFit 2.0 devices and disassembled certain of those samples to view the internal components of the device and to view the components individually. Photographs of the PrimaFit 2.0 are included as an attachment to my report (Attachment B). As discussed further below, I also directed that radiographic (x-ray) images be taken of devices to view the componentry, as well as computer tomography (CT) scans. The x-ray images I directed be taken are shown below and in Attachment C. 3D images from the CT scan are shown below and in Attachment D. Tomographic images in video form are in Attachment E. The photos, images, and video in these attachments support the opinions throughout my report.

**A. Preliminary Statement Regarding Dr. Collins’ CT Scan**

150. In paragraphs 190-191 of his report, Dr. Collins states that he directed “CT scans of the portion of the PrimaFit 2.0 device that [he] identified which include the reservoir.” Dr. Collins asserts that “[t]he purpose of the CT scans was to visualize the reservoir inside of an assembled PrimaFit 2.0” to support his opinions that the PrimaFit 2.0 meets the claim limitations


requiring a “reservoir,” “a fluid permeable support that is distinct from and at least proximate to the reservoir,” and “tube having a first end disposed in the fluid reservoir.” (Dr. Collins ¶191.)

151. Typically, during a CT scan, a narrow beam of x-ray is aimed at the target and a series of cross-sectional "slices" are captured. The slices are referred to as tomographic images. After many successive slices are taken, the images may be stacked together by software to generate three dimensional images of the target.

152. Dr. Collins conducted a CT scan but did not include many images or views. Instead, he included a select image from the scan in his report (Collins Report ¶191; Ex. D at 12; Ex. E at 14) and attached two additional images (Exhibit N) and a video (Exhibit O) constructed from the scan to his report. Dr. Collins does not explain what is specifically shown in the CT scan video and images in Exhibits N and O, or how they reflect the PrimaFit 2.0 device, other than to say that the image in the report and claims charts is “[o]ne of the CT images” generated and that “[a]dditional images and a video” are shown in Exhibits N and O.


153. As best may be understood, the video of Exhibit O is a “rotational video” (filename: “97116 Catheter Lower Portion Rotational Video.wmv”) that shows a sequence of tomographic images about a rotational plane(s). The video, like the images of Exhibit N, shows in each frame a tomographic image on the left and a 3D image of the device on the right with the graphical image plane as well as the axis of rotation, as shown in the labeled screenshot below.






154. From my review of these materials, in my opinion, Dr. Collins CT video and images cannot be relied upon to understand the components of interest in the PrimaFit 2.0.

155. Specifically, the video and images are not reliable to show the structures of the PrimaFit 2.0 device including the relative size, shape, and positioning of the components. For example, the PrimaFit 2.0 is not centered with respect to the axis of rotation. This is apparent by observing the 3D image of the device on the right side of the video, which shows that the rotational axis does not extend through the center of the device (or the center of the tube). Indeed, the axis shifts to various positions through the device in each frame. The PrimaFit 2.0 device itself (including the tube) is also angled with respect to the rotational axis of the video. Below I reproduce two screenshots of the video at different times (time 0:01 on left and 0:10 on right) that I labeled to illustrate the anomalies.




156. The components in the tomographic images also vary from frame to frame. To illustrate, below I reproduced tomographic images of the device that correspond to the planes shown above in the 3D images at times 0:01 and 0:10, where I labeled the components and their anomalies. In the images, the inner foam is shown as the speckled white/gray in the image, sides of the tube are the dark gray vertical line segments, and the black space is the alleged reservoir. As can be seen, the diameter of the same tube varies from frame to frame and the inner foam varies as well. Dr. Collins does not explain these discrepancies, which likely reflect his failure to ensure consistency or controls during the scanning procedure.



157. Further, as best may be understood, the CT images from the report, claim charts, and Exhibit N show a tomographic image slice taken across a plane (on the left side of the image), and a three-dimensional (3D) rendering of the device with a graphic to indicate the particular plane corresponding to the image (on the right side of the image). I label these below in the CT image from Exhibit N page 2:






158. Dr. Collins images are deceptive, as Dr. Collins relies on them to show infringement but they do not reliably show the inner foam, tube, and alleged reservoir in the PrimaFit 2.0 device to analyze infringement. Dr. Collins did not specify where from the CT scan the tomographic image from his report claim chart are derived from, but it is apparent that the image is not a cross section through the center of the device to show the components.

159. The misleading results can be demonstrated in one example. Below I reproduce an image from the CT rotational video at time 0:28 (left) and the CT image that Dr. Collins selected to analyze infringement in his report (right). As can be seen, unlike the select image used by Dr. Collins in his report, the image at time 0:28 of the video demonstrates the inner foam surrounding

the tube. But, in an attempt to suggest the tube is not retracted within the foam, Dr. Collins selected another image from an unidentified cross-section that is not a cross-section across a central plane to show all the components.




160. The CT images from Dr. Collins' report are also inconsistent with the actual photograph of a cut-open PrimaFit 2.0 from Dr. Collins' report which also confirms the foam around the tube:

**Image From Collins Report ¶176, Ex. D at 22, Ex. E at 24 (annotated)**

**Top view with wicking fabric  
and bottom barrier cut away**

**Fluid  
reservoir**



**Foam around tube**

161. As a result, the CT scan video and images are not reliable, including the images cited in his infringement claim charts. One may be misled to believe that the image reveals what the inside of the device looks like, for example, if the outer components were translucent and you could see to the inside, but they are not. But the image is an unspecified “slice” that does not show a cross-cross section of the device, as demonstrated by other images from the video. The image has no depth so it does not show any portion of the inner foam or tube beyond the particular slice in the image.

162. In contrast to Dr. Collins’ incoherent data, as I discuss further below, I conducted my own CT scan that does show a cross-section of the device including depth to fully reveal the



foam and tube components, which confirm how the tube is retracted within the foam.

## **B. 376 Patent**

163. Sage does not infringe Claims 1, 5, 9, and 10 of the 376 Patent at least because the PrimaFit 2.0 does not have all of the elements of any of these claims either literally or under the doctrine of equivalents. As a preliminary matter, and referenced below, I note that neither PureWick in its Final Infringement Contentions nor Dr. Collins have asserted that any limitation of the asserted claims of the 376 Patent is met under the doctrine of equivalents. Instead, PureWick and Dr. Collins assert only that each element of each asserted claim is found literally in the PrimaFit 2.0 device.

### **1. Claim 1 (376 Patent)**

164. Claim 1 of the 376 Patent recites:

1. An apparatus comprising:

a fluid impermeable casing having a fluid reservoir at a first end, a fluid outlet at a second end, and a longitudinally extending fluid impermeable layer coupled to the fluid reservoir and the fluid outlet and defining a longitudinally elongated opening between the fluid reservoir and the fluid outlet;

a fluid permeable support disposed within the casing with a portion extending across the elongated opening, wherein the fluid permeable support is distinct from and at least proximate to the fluid reservoir;

a fluid permeable membrane disposed on the support and covering at least the portion of the support that extends across the elongated opening, so that the membrane is supported on the support and disposed across the elongated opening;

a tube having a first end disposed in the reservoir and extending behind at least the portion of the support and the portion of the membrane disposed across the elongated opening and extending through the fluid outlet to a second, fluid discharge end,

the apparatus configured to be disposed with the opening adjacent to a urethral opening of a user, to receive urine discharged from the urethral opening through the opening of the fluid impermeable layer, the membrane, the support, and into the reservoir, and to have the received urine withdrawn from the reservoir via the tube and out of the fluid discharge end of the tube.

165. Sage's PrimaFit 2.0 does not infringe Claim 1 of the 376 Patent at least because the device does not include the following claim elements either literally or under the doctrine of equivalents:

- a. "a fluid impermeable casing having a fluid reservoir at a first end, a fluid outlet at a second end"
- b. a fluid impermeable casing having "a longitudinally extending fluid impermeable layer coupled to the fluid reservoir and the fluid outlet"
- c. a fluid impermeable casing "defining a longitudinally elongated opening between the fluid reservoir and the fluid outlet" / "elongated opening"
- d. "a fluid permeable support disposed within the casing with a portion extending across the elongated opening"
- e. "wherein the fluid permeable support is distinct from and at least proximate to the fluid reservoir"
- f. "a fluid permeable support" and "a fluid permeable membrane disposed on the support . . . so that the membrane is supported on the support and disposed across the elongated opening"
- g. "a tube having a first end disposed in the reservoir"
- h. "the apparatus configured . . . to receive urine discharged from the urethral opening . . . into the reservoir, and to have the received urine withdrawn from the reservoir via the tube and out of the fluid discharge end of the tube"

**a. "a fluid impermeable casing having a fluid reservoir at a first end, a fluid outlet at a second end"**

166. Dr. Collins states that the PrimaFit 2.0 includes "a fluid impermeable casing having a fluid reservoir at a first end, a fluid outlet at a second end" as recited in Claim 1. (*See, e.g.*, Collins Ex. D at 1-7.) I disagree as discussed below.


167. As I explain above, the Court has determined that the phrase "casing having a fluid reservoir at a first end [and] . . . , a fluid outlet at a second end . . ." means "an outer cover having . . . a fluid reservoir at a first end and a fluid outlet at a second end" (376 Patent, claims 1; 989 Patent, claim 1). The Court also determined that the phrase "fluid reservoir" in this limitation is a "space



where urine can collect.”

168. *First, the PrimaFit 2.0 does not have a “casing” or outer cover as recited by Claim 1.* Dr. Collins alleges that the PrimaFit 2.0 “includes a fluid impermeable casing (an outer cover) formed by the foam backer, bottom barrier and a portion of the adhesive bow-tie.” (Collins Ex. D at 1; Collins Report ¶167.) Dr. Collins does not provide further description of the purported casing, providing only the following image with a black boundary around various portions of the device that he labeled as a “casing:”


**Image from Collins Report p. 55 and Ex. D at 1**



169. As best as may be understood from Dr. Collins non-descript statement and annotated photograph, Dr. Collins selected the entire foam backer and bottom barrier, and a “portion” of the bowtie adhesive as shown as “forming” the casing. While he did not explain further what he specifically means by “portion of the adhesive bow-tie,” it appears the “portion” of the bowtie he considers part of the “casing” is the area shown in annotation in his photograph.


170. A person of ordinary skill in the art would not consider these components (including an unidentified portion of the bowtie adhesive) to be a casing or outer cover. The various, separate components do not form an assembly in the PrimaFit 2.0, there is no Sage part number for such an

assembly, and the components are not formed together independent from the other components of the device. Indeed, the foam backer and bottom barrier are non-contiguous, separated by the fabric (allegedly the “fluid permeable membrane”), as shown in the engineering drawing below. The fabric (not part of the casing) is placed on top of the foam backer and then the bottom barrier is placed on top of the fabric as can be represented in the BOM reproduced below.



(STRSAGE000000023 (annotated).)


171. This can also be seen in the photograph below of a PrimaFit 2.0 device with the bottom barrier and fabric cut away from the device.



(Attachment B.)

172. The bowtie adhesive is also an independent component of the device, structured separately from the foam backer, bottom barrier, and other components of the device, and is attached to the device with dabs of hot melt adhesive, as indicated in the engineering drawings below. The bowtie adhesive is not an outer cover to cover other components. It also does not perform the function of an outer cover of the device. Instead, the bowtie adhesive pad is simply an attached component that helps the product stay attached to the suprapubic region of a user with an adhesive. The mere fact that the bowtie adhesive is on an outer side of the device does not transform it into an outer cover for the device. One of skill would not consider the bowtie adhesive as serving structurally or functionally as an outer cover for other components and does not relate

to containing fluid.



(STRSAGE00025402 at 25406.)


173. Furthermore, that Dr. Collins arbitrarily selected only a portion of the bowtie adhesive pad to be included in what “forms” the casing also demonstrates that the component is not an outer cover as required by the claims. For example, the specifications of the 376 and 989 Patents do not include any description of a casing where a portion (much less an arbitrarily determined portion) of a component, but not the rest of it, is part of a casing (much less a casing that comprises different parts that are not even touching each other). To the contrary, each “casing”



described is a dedicated outer cover for the devices and is not separated by other permeable components. (*See, e.g.*, casing 1504, 1604, 1804, 2004, 2204, 2604 in the patents.)

174. A person of ordinary skill in the art would not understand how to determine what a “casing” is if one can arbitrarily pick and choose certain parts of components to form part of a “casing” while excluding others. For example, it is not clear to a person of ordinary skill in the art why Dr. Collins selected the portion he drew a black line around to constitute the “casing” and not the portion extending to the sides (i.e., either side of the bowtie that contains the adhesive to secure the device to the suprapubic region of a patient).

175. Dr. Collins also does not explain why he excluded from the alleged outer cover other components of the PrimaFit 2.0 that actually serve as an outer cover. For example, the foam backer (which allegedly forms part of the casing of PrimaFit 2.0) does not cover the fabric of the PrimaFit 2.0 (alleged to be the “fluid permeable membrane”). To the contrary, the fabric is positioned on top of and is an outer cover for the foam backer, as Dr. Collins acknowledged. (Collins Ex. D at 7 (“The opening in the casing is covered by the wicking material.”).)



176. The fact that the permeable fabric of the PrimaFit 2.0 covers the impermeable foam backer (the part that Dr. Collins says is the “casing”) suggests to one of skill in the art that the PrimaFit 2.0 does not have a “fluid impermeable casing” and that Dr. Collins incorrectly excluded

the fabric from his assessment of “casing.” Dr. Collins excludes the fabric even though it is the outer most component of a large portion of the device, covers other components including the inner foam, FlexLink, and tube, and, in fact helps contain those components within the device. If the fabric of PrimaFit 2.0 were cut away, the inner components would not be retained in the device. These observations illuminate the flaws in Dr. Collins’ assessment of casing, as he did not assess what components are an outer cover, and instead picked and chose components and portions of components to alleged they “form” a casing in a manner to argue infringement, not according to the understanding of one of skill in the art. Of course, when considering the fabric, that outer cover component of the product is permeable—not impermeable. If anything, then, the “outer cover” of PrimaFit 2.0 is not “impermeable” as required by the claim.

177. Moreover, no embodiment in the specifications of the asserted patents discusses such a configuration for the casing. Instead, consistent with the Court’s construction, the specifications of the asserted patents describe other components including the “fluid permeable membrane” as positioned in the casing, where the casing and not another permeable component is the outer cover. For example:

- “The permeable membrane 1530 and the permeable support 1540 can be positioned within the impermeable casing 1504 using any suitable method.” (376 Patent (22:62-64) and 989 Patent (21:56-60).)
- “The permeable membrane 1830 can be pulled over the permeable support 1840. The combination of the permeable membrane 1830 and the permeable support 1840 can then be inserted through the elongated opening 1804A of the impermeable casing 1804 and the impermeable casing 1804 can be stretched and/or otherwise maneuvered such that the impermeable casing 1804 surrounds the permeable membrane 1830 except in the area of the elongated opening 1804A.” (376 Patent (25:58-66) and 989 Patent (24:50-58).)
- “The permeable support 1540 in combination with the permeable membrane 1530 can be disposed within the interior of the impermeable casing 1504 such that the permeable support 1540 can maintain the permeable membrane 1530 against or near a source of moisture (e.g., a urethral opening) through the elongated opening 1504A.” (376 Patent 22:56-61) and 989 Patent (21:50-55).)


- Other examples are in the 376 Patent (22:37-39, 23:9-13, 23:46-49, 23:55-61) with similar disclosures in the 989 Patent.

178. Thus, the PrimaFit 2.0 does not have a fluid impermeable “casing” as recited by the claim.


179. **Second, the components Dr. Collins selected as the casing also do not form a “fluid impermeable” casing or outer cover.**

180. Notably, Dr. Collins fails to explain in his claim charts (Exhibits D and E) how the alleged casing is “fluid impermeable” as required by the claim. Elsewhere in his report, Dr. Collins states that “the components of the casing—the foam backer, bottom barrier, and bow-tie adhesive—are formed of fluid impermeable *material*.” (Collins Report ¶168 (emphasis added).) The claim does not require, however, that the *materials* forming the casing be fluid permeable, it requires the *casing* to be fluid impermeable. The flaw in Dr. Collins’ conclusion is realized by the fact that the casing collectively, and its components, are not impermeable, regardless of the composition of the components’ materials. Moreover, Dr. Collins ignores that his “casing” has his identified “permeable” membrane between two of the “impermeable” components.



181. For example, Dr. Collins provides no indication that the portion of the bowtie adhesive that he relies on is fluid impermeable or contains any liquid that enters the device because it does not. There are open gaps or spaces around the portion of the bowtie adhesive that Dr. Collins considers to form the casing, including between the bowtie adhesive and the flexible tube, between the bowtie adhesive and the fabric, and between each of the six dabs of hot melt that attaches the bowtie adhesive to the device. The gaps or spaces create pathways for fluid including urine to flow from the inside of the device to the outside of the device. The gaps or spaces are shown in the photographs below.



(STRSAGE00025402 at 25406.)










(Attachment B.)

182. In addition, the foam backer portion of the alleged “casing” is not fluid impermeable at least because it has two holes in the back through which urine can flow. The holes are shown in the engineering drawing with a diameter callout of 0.1 inches. The engineering drawing and a photograph of the holes is shown below:






(Attachment B.)



(STRSAGE00025402 at 25405.)

183. I confirmed Dr. Collins' "casing" is not fluid impermeable by pouring water into the device and observing that the water was able to readily escape through the holes and the gaps or spaces as shown, for example, in the photograph below. One of skill would understand that if water is able to flow through, then urine would also do so.






(Attachment B.)

184. Thus, the foam backer, bottom barrier, and portion of the bowtie adhesive do not form a “fluid impermeable” casing or outer cover as recited by the claim.

185. *Third, the alleged casing of the PrimaFit 2.0 is not a casing “having a fluid reservoir at a first end.”*


186. As discussed above, the Court determined that the “fluid reservoir” of the casing is a “space where urine can collect.” I note that, consistent with the Court’s construction, reservoirs depicted and described in the specifications of the asserted patents each include distinct reservoir spaces within the end of the casing where urine can collect:



187. Dr. Collins alleges that the “reservoir” of the PrimaFit 2.0 is “[t]he empty space between the bottom of the inner foam and the casing” which he alleges “provides a space where urine can collect.” (Collins Ex. D at 4.) Dr. Collins included the following annotated photograph with a red dotted line to visually depict his view of the claimed casing reservoir in the PrimaFit

2.0:

**Image From Collins' Report Ex. D at 4**



(Collins Ex. D at 4.)

188. More specifically, Dr. Collins states that “[t]he empty space between the bottom of the inner foam and the casing provides a space where urine can collect, as confirmed by the Fluid Path Visualization testing” (citing Exs. K to M). (Collins Ex. D at p. 4.) In Paragraphs 169 and 181 of his report, Dr. Collins similarly states that there is a reservoir, citing Exhibits K to O of his report.


189. However, nothing in Dr. Collins’ photograph above establishes that this area of the PrimaFit 2.0 is a “space where urine can collect” according to the Court’s claim construction. At most, it depicts inner foam not seated fully within the foam backer.

190. In contrast to the claimed reservoir, the PrimaFit 2.0 does not have a reservoir or “space where urine can collect.” Knowing that the photograph does not establish that the identified area is a “space where urine can collect.” Dr. Collins asserts that he has “show[n] how urine can



collect in the space [he] identified as the reservoir” via certain, non-standard testing he commissioned that he refers to as “Fluid Path Visualization” testing. (Collins Report ¶181, Ex. D at 4-5; see ¶¶180-189.) I do not agree that Dr. Collins’ testing establishes that the area he has identified as a “reservoir” is in fact a “space where urine can collect.”


191. Dr. Collins included the following screenshots in his report from an x-ray video recorded during his Fluid Path Visualization testing:



192. Dr. Collins’ testing is significantly flawed and the images and video he provided do not demonstrate that the PrimaFit 2.0 has a reservoir or “space where urine can collect.”

193. The procedure and model that Dr. Collins uses (depicted below) are not reliable and are not based on any scientific methodology that would show whether urine can collect in certain locations and does not simulate how the device is placed on a user. The model does not resemble a female user especially relating to the relevant female anatomy. Dr. Collins’ contraption and experimental conditions appear to have been artificially designed to funnel urine to the area he calls “the reservoir” rather than simulate the experience of a female user.

194. The directions for the PrimaFit 2.0 describes the positioning of the device on a user: "[a]lign tapered end with perineum and place device between the labia . . . ." (STRSAGE0000001 (step 7).) The Directions state to "[c]urve the device toward the patient's lower abdomen." (STRSAGE0000001 (step 8).) And, "[w]hile holding the device in place, remove the adhesive liner and adhere the adhesive pad over the suprapubic region." (STRSAGE0000001 (step 9).)



(BDPureWick\_EXP\_0000040 at time 1:15 (annotated).)

195. When positioning the device in the directed manner, the soft tapered end of the PrimaFit 2.0 fits snugly in the perineum and between the gluteal folds of the user. After placing the device, the user's legs and buttocks including gluteal folds are together. Thus, the soft tapered end of the PrimaFit 2.0, including the alleged "reservoir," is compressed between the gluteal folds due to its soft and conformable materials, as Sage engineer Adam Cole testified about the alleged "reservoir" area:

Q: Would that manufacturing variability that you just mentioned potentially result in a space, an empty space, between the bottom of the tapered tip and the end of the inner foam? [Objection]

A. As I stated, the manufacturing variability of placing the inner foam inside the foam backer, it may result in a variability of that fit. But ultimately, when in use, that area is compressed anyway.


Q. You mean when it's in use on a patient?

A. Yes. When in use on a patient, the bottom of the device is compressed.

(Cole Tr., at 166-167.)

196. Moreover, when the product is positioned on a user, the end of the device is not suspended vertically as depicted in Dr. Collins' images but rather curves inward with the patient in a horizontal direction toward the bottom of the user.


197. Though displayed with a different product, one can see how the anatomy turns inward at the gluteal folds in a user in PureWick's own images of its own product:



(BDPureWick\_00001037 at 1057; *see also* Dr. Edward Yun Opening Report dated May 29, 2023 at ¶23 (“The patient’s legs, gluteus muscles, and labia are separated and the soft patient-facing fabric is tucked between the separated gluteus and labia.”; PureWick\_0014365 (“snugly between labia and gluteus”; “tuck the end of the wick between the gluteus”).)

198. Below I reproduce an image depicting the anatomy of the vagina, perineum, buttocks including the gluteal folds, legs and lower torso.





199. For his experiment, however, Dr. Collins utilized equipment and employed a procedure in Exhibit K that does not position the PrimaFit 2.0 even remotely as intended and the testing has no relationship to how the product is used on a female. Thus the alleged reservoir “space” at the end of the device that Dr. Collins circles in the video screenshots do not reflect the device in real use and cannot establish that the alleged “reservoir” is a “space where urine can collect.”

200. Specifically, Dr. Collins directed that the PrimaFit 2.0 be positioned on “3B Scientific’s Catheterization Simulator BASIC, female” trainer. (Collins ¶¶181-189, Exhibit K.) The 3B Scientific catheterization trainer is intended for practicing application of indwelling catheters (i.e., Foley catheters) where access to other portions of the anatomy are unnecessary. (Attachment F (manual); [https://www.3bscientific.com/us/catheterization-simulator-basic-female-1020231-p93b-f-3b-scientific,p\\_1057\\_29185.html](https://www.3bscientific.com/us/catheterization-simulator-basic-female-1020231-p93b-f-3b-scientific,p_1057_29185.html).)

201. The 3B Scientific catheterization trainer includes a model of a portion of the female

anatomy on a relatively flat rectangular surface that is slightly curved. Importantly, the model lacks important anatomical features required to position a PrimaFit 2.0 device including lower torso and suprapubic region, perineal area, legs, and buttocks including the gluteal folds. The model is also suspended in the air by a white mounting bracket, which does not replicate how a patient is positioned in the supine position on a patient support surface such as a hospital bed. I represent these deficiencies in the annotated photograph of the catheterization trainer below.




(Attachment F.)

202. Dr. Collins states that "[i]n order to mimic the position and orientation of the


PrimaFit in use on a patient, 3B Scientific's Catheterization Simulator BASIC, female, depicted below, was used as the mounting apparatus." (Collins Report ¶185; *see* Collins Ex. K at 2 and 4.) Again, that is incorrect. Dr. Collins asserts that the PrimaFit 2.0 is used in practice in accordance with Sage's package Directions, yet he did not position the device according to the Directions for his experiment. (Collins Report ¶¶188, 219.) For the experiment, the PrimaFit 2.0 was not positioned with the soft tapered end of the PrimaFit 2.0 conforming with the user's anatomy (curving inward toward the perineum and between the gluteal folds) because the trainer lacks these anatomical features, and there is no patient support surface.

203. Instead of simulating real life conditions, Dr. Collins positioned the patient-facing surface of the PrimaFit 2.0 adjacent the urethra of the model. He then wrapped several pieces of tape around the bottom of the PrimaFit 2.0 and the model to secure it in place as shown below. At some point, Dr. Collins also wraps additional tape around the center device and the model, likely to further press and hold the device against the model's urethral area where water was being discharged. I have annotated the images to emphasize the inaccuracies in the placement. Again, the end of the PrimaFit 2.0 product is simply suspended vertically mid-air rather than being placed as intended with the end curving inward toward the gluteal folds. In this way, Dr. Collins set up his experiment artificially in an attempt to funnel urine to the area he asserts is the claimed reservoir.

**Image From Collins' Ex. L at 18; Report at ¶186 (annotated)**




**Image from Collins' Ex. L at 16 (annotated)**





**Image From Collins' Ex. L at 30 (annotated)**




204. Notably, Dr. Collins did not produce any images that show how the end of the product appears as it is obscured by blue tape.

205. Regarding the images depicted on page 67, the focal point of the x-ray imager that Dr. Collins employed is directed to the end of the device as shown in the x-ray screenshots reproduced again below. And, the tapered end of the PrimaFit 2.0 shown is not placed within the perineal space or between gluteal folds because the 3B Catheterization trainer lacks these features. Instead, as can be seen in the x-ray (but not the photographs), the tapered end is suspended vertically in the air away from the model, not in “the position and orientation of the PrimaFit in use on a patient” as Dr. Collins asserts. (Collins Report ¶185.) Again, the way Dr. Collins taped

the PrimaFit 2.0 in position, and with the end spaced from the model and suspended, demonstrates that the experiment was designed not to replicate a real-world application, but intended to create artificial conditions that funnel urine to the location he claims is a reservoir.

**Image From Collins' ¶189 and Ex. D at 5**



206. The purported fluid reservoir labeled in Dr. Collins' annotated video screenshots are not spaces "where fluid can collect" in real world conditions. As applied to the user, the end of the PrimaFit 2.0 (which includes Dr. Collins' alleged "reservoir") would not lie in a vertical plane pointing directly downward and away from the patient, but would instead curve horizontally inward. That urine flows to that area due to gravity due to Dr. Collins improperly-designed experiment is thus unremarkable and not conclusive on the issue of whether fluid "can collect" in the area he identified.

207. Moreover, the model certainly does not replicate how the end of the PrimaFit 2.0 product (where the alleged "reservoir" is) is compressed between the gluteal folds of the user since the model has no legs or buttocks or even a back side. This further demonstrates Dr. Collins lack of understanding of the PrimaFit 2.0 device and its operation. Notably, Dr. Collins does not address

this fact even though it is apparent from how the device designed to be positioned, and Mr. Cole identified it. (Cole Dep. Tr., at 167 (“When in use on a patient, the bottom of the device is compressed”).)

208. In Paragraphs 190 and 191, Dr. Collins also discusses an image from his CT scan, however, this CT image also do not demonstrate that the PrimaFit 2.0 has a “space where urine can collect.” Nothing in that image shows that urine can collect in the “space” that Dr. Collins identified. In any case, as I discuss in Section VI.A, the CT scans, which are provided with no description of perspective, are unreliable and do not reliably depict components within the device at least as they relate to each other.

209. I discuss the alleged reservoir further below in Sections VI.B.1.e and g.

210. Thus, Dr. Collins has not established that the area that he has identified as a “reservoir” is a space where urine can collect as required by the Court’s claim construction.

211. For at least these reasons, the PrimaFit 2.0 does not meet this limitation. PureWick and Dr. Collins did not allege this claim limitation is met under the doctrine of equivalents.

**b. a fluid impermeable casing having “a longitudinally extending fluid impermeable layer coupled to the fluid reservoir and the fluid outlet”**

212. Dr. Collins states that the PrimaFit 2.0 has a fluid impermeable casing or outer cover having “a longitudinally extending fluid impermeable layer coupled to the fluid reservoir and the fluid outlet” as recited in Claim 1. (e.g., Collins Ex. D at 1-7.) I disagree as discussed below.


213. As discussed above, the PrimaFit 2.0 does not include a “fluid impermeable casing” or a casing “having a fluid reservoir.” Thus, the PrimaFit 2.0 does not meet the limitation of a fluid impermeable casing having “a longitudinally extending fluid impermeable layer coupled to the



fluid reservoir and the fluid outlet,” as well as the requirement of a casing having an “impermeable layer” and an “outlet,” because the PrimaFit 2.0 lacks a casing and a fluid reservoir.

214. Even if the PrimaFit 2.0 is considered to have a casing and a casing having a fluid reservoir, the alleged “casing” of the PrimaFit 2.0 also does not include “a longitudinally extending fluid impermeable layer coupled to the fluid reservoir and the fluid outlet.”

215. As discussed above, Dr. Collins asserts that the alleged “casing” of the PrimaFit 2.0 is “formed” by the foam backer, bottom barrier, and the portion of the bowtie adhesive. Dr. Collins asserts, without further explanation, that the following image shows how the PrimaFit 2.0 has a casing having a longitudinally extending fluid impermeable layer coupled to the fluid reservoir and the fluid outlet”:





216. Besides the annotated photograph above, Dr. Collins provides no description of what component(s) of the PrimaFit 2.0 he believes are the “longitudinally extending fluid

impermeable layer” or how such a layer is “coupled” to the alleged fluid reservoir and outlet of the alleged casing. He also does not explain what component(s) comprises the claimed “fluid outlet.”

217. As best as may be understood from the photograph, he believes the foam backer is the fluid impermeable layer and that the alleged “fluid outlet” is some portion of component(s) near the end of the device where the PrimaFit 2.0 tube enters the device. Simply put, Dr. Collins appears to contend that the foam backer (the impermeable layer) forms empty spaces that he identifies as an outlet and as a “reservoir.”


218. First, one of skill of the art would not understand the foam backer as a “fluid impermeable layer” as claimed. The claim requires a fluid impermeable “layer,” but the foam backer is not a layer of material. The foam backer, as discussed above, is made from Volara type EO foam that is thermoformed and punched into an intricate shape shown, for example, in the engineering drawings shown below. It is not a “layer” of material.



**FOAM BACKER (R99732) THERMOFORM & PUNCH**

(STRSAGE00025402 at 25402, 25405.)

219. Second, the claim requires the fluid impermeable layer to be “coupled” to the fluid reservoir and outlet, and the foam backer does not have any componentry to “couple” it to the empty spaces that Dr. Collins identified as the fluid reservoir or fluid outlet. To the contrary, the foam backer forms those two elements, according to Dr. Collins. (Collins Ex. D at 4 (“The empty space between the bottom of the inner foam and the casing provides a space where urine can collect . . . .”); Collins Ex. D at 3.) Dr. Collins provides no explanation for how a layer of material is “coupled” to a “space” such as the fluid reservoir (or to the “fluid outlet”).



220. For at least these reasons, the PrimaFit 2.0 does not meet this limitation. PureWick and Dr. Collins did not allege this claim limitation is met under the doctrine of equivalents.

**c. a fluid impermeable casing “defining a longitudinally elongated opening between the fluid reservoir and the fluid outlet” / “elongated opening”**


221. Dr. Collins states that the PrimaFit 2.0 has a fluid impermeable casing or outer cover “defining a longitudinally elongated opening between the fluid reservoir and the fluid outlet” and has an “elongated opening” as recited in Claim 1. (e.g., Collins Ex. D at 1-7.) I disagree as discussed below.

222. As discussed above, the PrimaFit 2.0 does not include a “fluid impermeable casing” or a casing having a “fluid reservoir.” Thus, the PrimaFit 2.0 does not meet the limitation of a fluid impermeable casing “defining a longitudinally elongated opening between the fluid reservoir and the fluid outlet” because the PrimaFit 2.0 lacks a casing and reservoir.

223. Even if the PrimaFit 2.0 is considered to have a casing, the alleged “casing” of the PrimaFit 2.0 also does not “define a longitudinally elongated opening between the fluid reservoir and the fluid outlet.” As discussed above, Dr. Collins asserts that the alleged “casing” of the PrimaFit 2.0 is “formed” by the foam backer, bottom barrier, and a portion of the bowtie adhesive. Dr. Collins asserts, without further explanation, that the following image shows how the PrimaFit 2.0 has an elongated opening:




Image From Collins Ex. D at 7 and ¶171




224. The alleged casing components at the location of the brackets labeled as the “longitudinally elongated opening” in Dr. Collins’ figure above do not “defin[e] a longitudinally elongated opening” as required by claim 1. There is no opening in the PrimaFit 2.0 device at the location identified, much less one “defined” by those components.

225. As discussed above, the fabric of the PrimaFit 2.0 is placed on top of the foam backer and is welded to form a seam at the perimeter (below). The fabric covers and encloses the entire bracketed area that Dr. Collins designated as the “elongated opening.” There is no opening—much less one defined by the components Dr. Collins identified. With the fabric welded to the device and covering the components, no portion of the inside of the device is, for example, viewable or observable. An “opening” as the word implies, is open, and the PrimaFit 2.0 is welded

closed with permeable material. This fact is exemplified by Dr. Collins who had to cut the fabric off of the device to take photographs of the inside of the device. (Collins Ex. D at 8.) Dr. Collins ignores the welded fabric component as if it is not there.



(STRSAGE00025402 at 25405.)



(Attachment B.)

226. In contrast to the PrimaFit 2.0 device, the elongated openings of casings depicted and described in the asserted patents 376 and 989 are open, and inner components may be placed

through the actual opening. For example, “[t]he combination of the permeable membrane 1530 and the permeable support 1540 can then be inserted through the elongated opening 1504A of the impermeable casing 1504 and the impermeable casing 1504 can be stretched and/or otherwise maneuvered such that the impermeable casing 1504 surrounds the permeable membrane 1530 except in the area of the elongated opening 1504A.” (376 Patent, 22:64-23:6.) Moreover, “[t]he combination of the permeable membrane 1830 and the permeable support 1840 can then be inserted through the elongated opening 1804A . . . .” (376 Patent, 25:59-63.) These openings are also shown in the figures as shown below. In the bottom image the permeable membrane is depicted within the opening.





FIG. 35



(376 and 989 Patent Figures 34-35 (elongated opening 1804A, permeable membrane 1830 depicted within and not over the opening, permeable membrane is not described as an “opening”).)

227. I note that the opening in the PureWick device has caused a number of injuries because user's skin get trapped and pinched in the opening, causing e.g. skin tears. (BDPureWick\_001706, STRSAGE00024635, 24636, 24637; see Attachment H.) Not having an opening is one distinct advantage of the PrimaFit 2.0 product over PureWick's product.

228. For at least these reasons, the PrimaFit 2.0 does not meet this limitation. PureWick and Dr. Collins did not allege this claim limitation is met under the doctrine of equivalents.

**d. “a fluid permeable support disposed within the casing with a portion extending across the elongated opening”**

229. Dr. Collins asserts that the PrimaFit 2.0 includes “a fluid permeable support disposed within the casing with a portion extending across the elongated opening” as recited in Claim 1. (e.g., Collins Ex. D at 8-12, Report p. 59.) I disagree as discussed below.


230. As discussed above, the PrimaFit 2.0 does not include a casing or a casing “defining a longitudinally elongated opening between the fluid reservoir and the fluid outlet.” Thus, the PrimaFit 2.0 does not have “a fluid permeable support disposed within a casing with a portion extending across the elongated opening” because the PrimaFit 2.0 lacks a casing and an elongated opening.

231. Even if the PrimaFit 2.0 is considered to have a casing and elongated opening, the alleged “fluid permeable support” of the PrimaFit 2.0 (the inner foam, see Collins paragraph 51), does not have a portion “extending across the elongated opening.”


232. Again, Dr. Collins has stated the area bracketed below is the alleged elongated opening, extending from the edge of the bottom barrier to the edge of the bowtie adhesive pad.




Image From Collins Ex. D at 7 and P171



233. But the inner foam in the PrimaFit 2.0 does not extend across the alleged opening identified by Dr. Collins. Rather, the foam terminates before reaching the bowtie adhesive, as can be seen in the photographs below.



(Attachment B (annotated).)




(Attachment B.)

234. Importantly, the claim does not recite that the permeable support extends across only a *portion* of the elongated opening, it recites “a fluid permeable support . . . with a portion *extending across the elongated opening*.” One of skill in the art understands this means that the permeable support can have other portions at other locations, but it must have a portion that in fact “extend[s] across the elongated opening” as expressly recited in the claim. The PrimaFit 2.0 does

not satisfy the claim.

235. This understanding is confirmed by the specifications of the asserted patents, where the embodiments of a casing show portions of the permeable support (green) extending across the elongated opening (red). Other portions of the support are within the casing. For example:

FIG. 32



236. For at least these reasons, the PrimaFit 2.0 does not meet this limitation. PureWick and Dr. Collins did not allege this claim limitation is met under the doctrine of equivalents.

**e. “wherein the fluid permeable support is distinct from and at least proximate to the fluid reservoir”**


237. Dr. Collins asserts that the PrimaFit 2.0 product meets the limitation “wherein the fluid permeable support is distinct from and at least proximate to the fluid reservoir” as recited in Claim 1. (e.g., Collins Ex. D at 8-12.) I disagree as discussed below.

238. As discussed above, the PrimaFit 2.0 does not include casing having a “fluid reservoir.” Thus, the PrimaFit 2.0 does not meet the limitation of “wherein the fluid permeable support is distinct from and at least proximate to the fluid reservoir” because the PrimaFit 2.0 lacks the claimed reservoir.



239. Dr. Collins asserts that the inner foam of the PrimaFit 2.0 is the “fluid permeable support” and the “the empty space between the bottom of the inner foam and the casing provides a space where urine can collect.” (Collins Ex. D at 4.) Dr. Collins further asserts that the limitation “wherein the fluid permeable support is distinct from and at least proximate to the fluid reservoir” is met because, allegedly, “the inner foam is distinct from the empty space at the bottom of the casing that forms the fluid reservoir.” (Collins Ex. D at 10.)


240. Dr. Collins references the below photograph of a PrimaFit 2.0 cut open to reveal the inner foam (Collins Ex. D at 10), but does not further explain how the image demonstrates that this limitation is met. I reproduce the photograph below:



241. Dr. Collins also states in his claim chart that his CT images “confirm that, in a fully assembled PrimaFit 2.0, the inner foam is distinct from the empty space at the bottom of the casing that forms the fluid reservoir, and that the inner foam is proximate, or next to, the fluid reservoir.” (Collins Ex. D at 11-12.) A CT scan image annotated by Dr. Collins in his claim chart is reproduced

below. As discussed above in Section VI.A, the CT scans, which are provided with no description of perspective, are unreliable and do not reliably depict components within the device at least as they relate to each other.

**Image From Collins Ex. D at 12**




242. In any event, even if the Collins CT image were reliable, as can be seen from these images, Dr. Collins arbitrarily defines the “reservoir” as a parabolic area directly beneath the support. Thus, because Collins has arbitrarily defined the “reservoir” as the area below the support, he reaches the necessary conclusion that the support is separate and distinct from that reservoir. I do not agree with Dr. Collins’ analysis.

243. The Court held that the reservoir is the “space where fluid can collect.” But Dr. Collins’ own Fluid Path Visualization testing demonstrates that the space where urine can “collect” in the PrimaFit 2.0 extends throughout the device including in the very area that encompasses the inner foam, i.e., the alleged fluid permeable support. Thus, Dr. Collins’ testing has established that

there is no “fluid permeable support [] distinct from and at least proximate to the fluid reservoir.”


244. In the experiments, Dr. Collins asserts that the vacuum connected to the PrimaFit 2.0 was actuated, and the peristaltic pump connected to the 3B Scientific Catheterization trainer was operated to, purportedly, simulate a urine voiding event. (Collins Report ¶¶180-189 and Ex. K.) The radiographic videos recording the events (Collins Ex. M) show the PrimaFit 2.0 prior to the simulated urine voiding event, and subsequently, the PrimaFit 2.0 with the urine simulant flowing through the device.

245. As can be seen in the image from Dr. Collins’ report, a large portion of the device becomes black during the experiment, indicating that urine is throughout, including within the entirety of the inner foam and around the surfaces of the FlexLink. To the extent PrimaFit 2.0 is considered to have a “reservoir” or “space where urine can collect,” it would have to encompass the entire area where urine is shown according to Dr. Collins’ own experiment.

**Image From Collins Ex. D at 5 (annotated)****3) 25 Seconds in – Urine flowing**

246. Below I reproduce the x-ray image at time 0:25 from Dr. Collins report (Ex. D at 5) with the same screenshot having an overlay to further depict visually the inner foam (the alleged permeable support) of the PrimaFit 2.0 (shown in blue) and the urine simulant throughout the device (shown in yellow). This shows that, under Dr. Collins' own experiment, the alleged support is within the area where urine "can collect" (i.e., "the reservoir") is not "distinct from and at least proximate to the fluid reservoir."





247. Thus, it is clear that any "reservoir" in the PrimaFit 2.0 is not distinct from and proximate to the support as claimed, rather it includes the support. That is particularly true since, as I discussed above, the area that Dr. Collins has identified as the reservoir is compressed when in use; whereas the area identified above, which appears to collect fluid in his scans and video, is not.

248. Moreover, though the device was positioned to funnel fluid toward the bottom of the device (and thus not simulate real-life conditions), during Dr. Collins' testing, fluid rises from the bottom of the device into the inner foam, as can be seen in particular at time 0:25 shown above


(Collins Ex. D at 5) or, as another example, time 0:16 in video 1 of Collins Ex. M. This further demonstrates that the inner foam (alleged “support”) is not distinct from and proximate to the reservoir because fluid rises into the support.

249. As a result, though the PrimaFit 2.0 does not have casing having a reservoir or space where urine can collect as I discussed, to the extent the PrimaFit 2.0 is considered to have a one, the reservoir or space where urine can collect encompasses not only the arbitrarily-identified space at the bottom of the device as asserted by Dr. Collins but also a significant portion of the device that encompasses the inner foam (the asserted “fluid permeable support”).

250. Simply put, Dr. Collins’ experiments demonstrate that the PrimaFit 2.0 does not meet the limitation “wherein the fluid permeable support is distinct from and at least proximate to the fluid reservoir” because, to the extent the PrimaFit 2.0 has a reservoir or space where urine can collect, the inner foam (alleged “fluid permeable support”) is positioned within that reservoir as shown in the screenshots (e.g., at time 0:25).

251. Dr. Collins also states that “computed tomography (‘CT’) images also confirm that, in a fully assembled PrimaFit 2.0, the inner foam is distinct from the empty space at the bottom of the casing that forms the fluid reservoir, and that the inner foam is proximate, or next to, the fluid reservoir.” (Collins Ex. D at 11-12.) A CT scan image annotated by Dr. Collins in his claim chart is reproduced below:

## Image From Collins' Ex. D at 12



252. As discussed above in Section V.A, the CT image is not reliable because the location of the “reservoir” and inner foam is constantly shifting and adjusting due to the lack of controls applied during the experiment.

253. In any case, Dr. Collins’ analysis is flawed for an additional reason and does not show this limitation is met. In Dr. Collins’ CT scan and other drawings, Dr. Collins drew a red dotted line (above left) and arbitrarily shaded the parabolic area in yellow (above right) to denote the “reservoir.” To find infringement, Dr. Collins draws the parabolic shape only to exclude the inner foam of the PrimaFit 2.0. Indeed, he previously defined the reservoir as the “space between the bottom of the inner foam and the casing” such that the inner foam is not included by definition. (Collins Ex. D at 4.) This is flawed for a few reasons. First, the claim requires a “casing having a fluid reservoir.” And no part of the casing is shaped as a parabola (as traced along the bottom of foam) to form that “reservoir.” Second, nothing in Dr. Collins’ Fluid Path Visualization testing

demonstrates a parabolic reservoir appearing in the product. Indeed, the experiment shows that urine does not form that parabolic shape outlined in his CT scan.

254. For at least these reasons, the PrimaFit 2.0 does not meet this limitation. PureWick and Dr. Collins did not allege this claim limitation is met under the doctrine of equivalents.

**f. “a fluid permeable support” and “a fluid permeable membrane disposed on the support . . . so that the membrane is supported on the support and disposed across the elongated opening”**


255. Dr. Collins states that the PrimaFit includes “a fluid permeable membrane disposed on the support . . . so that the membrane is supported on the support and disposed across the elongated opening” as recited in Claim 1. (e.g., Collins Ex. D at 12-21.) I disagree as discussed below.

256. As discussed above, the PrimaFit 2.0 does not include a fluid impermeable casing or a fluid impermeable casing “defining a longitudinally elongated opening” between the fluid reservoir and the fluid outlet. Thus, the PrimaFit 2.0 does not have “a fluid permeable membrane disposed on the support . . . so that the membrane is supported on the support and disposed across the elongated opening” because the PrimaFit 2.0 lacks a casing and elongated opening. I also discussed the fluid permeable support element in Section V.B.1.d above.


257. Even if the PrimaFit 2.0 is considered to satisfy these other limitations, the PrimaFit 2.0 also does not meet the limitation “a fluid permeable membrane disposed on the support . . . so that the membrane is supported on the support and disposed across the elongated opening.”

258. As discussed, Dr. Collins alleges that the “casing” is the foam backer, bottom barrier, and a portion of the bowtie adhesive. As also discussed, the fabric of the PrimaFit 2.0 (alleged membrane) is placed on top of and welded to the foam backer.





(STRSAGE00025402 at 25405.)




259. With the fabric welded to the foam backer, it is supported by the foam backer, not the alleged support. The FlexLink can also contour the device to patient anatomy. Thus, the fabric is not “disposed on the support . . . so that the membrane is supported on the support . . . .”

260. Further, because the fabric is supported by the foam backer, independently from the inner foam (alleged support), the fabric is not “*disposed on the support . . . so that the membrane is . . . disposed across the elongated opening.*” The fabric being welded to the foam backer is the reason for its positioning with respect to the alleged elongated opening. It is not due to the fabric’s engagement with the inner foam.

261. To illustrate, below is a photograph of the PrimaFit 2.0 where the inner foam (the


alleged support) has been completely removed. As can be seen, the fabric is located in the same place as it is compared to when the foam is present in the device.



(Attachment B.)

262. This understanding is consistent with the specifications of the asserted patents. The specifications describe and depict casings with membranes that are positioned within and across the elongated opening, and supported on the support, for example:

FIG. 35



263. One of skill in the art would not conclude that the fabric of the PrimaFit 2.0, which is placed on top of the alleged foam backer “casing” component, and is located above the alleged

elongated opening, is disposed on the support so that the membrane is disposed across the elongated opening.


264. For at least these reasons, the PrimaFit 2.0 does not meet this limitation. PureWick and Dr. Collins did not allege this claim limitation is met under the doctrine of equivalents.

**g. “a tube having a first end disposed in the reservoir”**

265. Dr. Collins states that the PrimaFit 2.0 has “a tube having a first end disposed in the reservoir” as recited in Claim 1. (e.g., Collins Ex. D at 21-23.) I disagree as discussed below.

266. As discussed above, the PrimaFit 2.0 does not include a “fluid impermeable casing having a reservoir at a first end.” Thus, the PrimaFit 2.0 does not meet the limitation of a tube having a first end disposed in the “reservoir” because the PrimaFit 2.0 lacks a casing and reservoir as recited by the claim.


267. Even if the PrimaFit 2.0 is considered to have a reservoir or space where urine can collect, the PrimaFit 2.0 does not have “a tube having a first end disposed in the reservoir.” As discussed above in Section VI.B.1.a, Dr. Collins asserts that reservoir of the PrimaFit 2.0 is the “empty space between the bottom of the inner foam and the casing.” (Collins Ex. D at 4.) He also specifically opines that the “the inner foam is distinct from the empty space at the bottom of the casing that forms the fluid reservoir, and that the inner foam is proximate, or next to, the fluid reservoir.” (Collins Ex. D at 11.)



268. The end of the tube of the PrimaFit 2.0, however, is not disposed in that alleged reservoir as is evident from Collins’ own image disclosed above (and discussed further below). In fact, the product is specifically designed, as shown in the photograph on the left above, so that the tube is retracted within the inner foam, the very area that must be “distinct from” and “proximate to” the alleged reservoir.

269. Below I reproduce the engineering specification drawing for the PrimaFit 2.0 from the bill of materials. As shown, the specification includes a dimensional callout requiring the end of the tube to be retracted within the inner foam. During manufacturing, an [REDACTED] forms the inner foam around the tube and FlexLink with the tube fully retracted within the foam. (Attachment G, 0:47-0:53.) When the remainder of the product is assembled, the foam further compresses around the end of the tube at the tapered end (which has a smaller cross-section). The tube is not disposed in the “empty space between the bottom of the inner foam and the” and the alleged casing components (the foam backer and bottom barrier).





(STRSAGE00025402 at 25404.)


270. I also directed radiographic and CT imaging of the PrimaFit 2.0 to visualize the tapered end of the PrimaFit 2.0 including the alleged reservoir, tube, and inner foam. The imaging was commissioned under my order by Alloyweld Inspection Co. of Bensenville, IL, a leading non-destructive testing center for industries including aerospace, electronics, medical devices and forensics. (<https://www.alloyweldinspection.com/>). For 50 years, Alloyweld Inspection has provided accurate analysis of parts and products and is accredited by the National Aerospace & Defense Contractors Accreditation Program (NADCAP), certified in CR and DR digital radiographic inspection.

271. The Alloyweld technician that performed the imaging is fully certified (NAS 410 level 3, American Society of Destructive Testing, SNTC1) and utilized a Northstar Imaging (NSI) X View CT system. Images were taken with a 127 micron detector and a 225 kV fine focus with a 7 micron focus spot, and CT was shot with 1080 projections with a 3-frame average at 1.5 frames per second, 3 frame average and 1.5 frames per second at 180 kV.


272. I directed Alloyweld to take x-ray images and perform a CT scan of the PrimaFit 2.0. X-ray images are shown in my report and attached as Attachment C. CT scan images, described further below, are shown in my report and attached as Attachment D. As I mentioned previously, these exhibits support my conclusions throughout this report.

273. X-ray images are shown below. They depict two devices with front/back view (left)

and side view (right) (STRSAGE\_EXP\_000001 and STRSAGE\_EXP\_000002). The x-ray images further confirm that the end of the tube of the PrimaFit 2.0 is not disposed in the alleged reservoir, but is retracted within the inner foam. In the images, the tube is the translucent, cylindrical component extending generally vertically, the inner foam is the gray fibrous material, and the alleged reservoir is the “empty space between the bottom of the inner foam and the casing”, according to Dr. Collins. (Collins Ex. D, p. 4). As seen in the images, the tube is not disposed in the alleged reservoir; rather, the inner foam fully surrounds the end of the tube, which is retracted inward from the end of the inner foam.









(Attachment C.)

274. I also had x-rays performed on two additional devices that were left within their sealed, unopened packaging. (STRSAGE\_EXP\_000003 and STRSAGE\_EXP\_000004). These images also confirm the tube is within the alleged support and not within the “empty space” that Dr. Collins has identified as a “reservoir.”




275. Images from the CT scan are reproduced below as indicated. These images are from cross sectional views of the device as can be seen. The CT scan images also further confirm that the tube of the PrimaFit 2.0 is not disposed in the alleged reservoir, but rather in the inner foam (the alleged permeable support)—by definition the area that is not the “reservoir.” In the images, the tube is the translucent, cylindrical component extending generally vertically, the inner foam is the darker gray fibrous material, and the alleged reservoir is the area between the end of the inner foam and the foam backer/bottom barrier. As seen in the CT scan images, the inner foam surrounds the end of the tube, which is retracted inward from the end of the inner foam.



276. This is confirmed by own analysis of the device, for example, as shown in my own photographs shown below.





(Attachment B; *see also* Attachment G at 0:47-0:53.)

277. Dr. Collins, without further explanation, refers to six annotated figures that purportedly demonstrate that the PrimaFit 2.0 has a tube having a first end disposed in the


reservoir, but the figures demonstrate the opposite: that the end of the tube is not disposed within the alleged reservoir. (Collins Ex. D at 21-23.)

278. For example, Dr. Collins included the annotated photograph shown below to the left, purported to be a PrimaFit 2.0 device with the fabric and bottom barrier components cut away from the device to reveal the inner foam and tube. (Collins Ex. D at 22.) In any event, even in the disassembled state where the inner foam is not compacted toward the tube by the other product components, Dr. Collins' photograph shows that the tube is not disposed in the reservoir that Dr. Collins has identified; rather, the tube is retracted within the inner foam (the alleged permeable support), which Dr. Collins has stated is not part of the reservoir. Thus, Dr. Collins' photograph further demonstrates that the PrimaFit 2.0 tube is not disposed in the alleged reservoir.

**Image From Collins Report ¶176, Ex. D at 22, Ex. E at 24 (annotated)**

**Top view with wicking fabric  
and bottom barrier cut away**



**Fluid  
reservoir**




**No tube in  
alleged reservoir**

279. Dr. Collins also included an annotated drawing of a device from a Sage document (citing STRSAGE000000027), reproduced below. (Collins Ex. D at 4.) Dr. Collins labels “support” and “first end disposed in the reservoir,” but the inner foam is not even depicted in the figure, so this figure does not support his contention that the PrimaFit 2.0 has a “tube with a first end disposed in the fluid reservoir.” This drawing is not intended to be a dimensional drawing of where components exist in the product. Strangely, Dr. Collins ignores that the engineering specification that actually describes the tube’s location and requires the end of the tube to be fully retracted within the foam by a specific dimensional callout.



**Image From Collins Ex. D at 22 (annotated)****Specification Requires Tube to be Retracted**

(STRSAGE00025402 at 25404.)




(STRSAGE00000023.)

280. Dr. Collins also includes a series of photographs of the foam/tube/FlexLink of the PrimaFit 2.0 removed from the device, reproduced below. (Collins Ex. D at 22-23.) As an initial matter, I note that the photographs do not reflect the inside of the device as assembled. For example, as I mentioned, the foam backer, fabric, and bottom barrier have a tapered end with a

smaller cross-sectional area than the cross-sectional area of the end of the inner foam. As a result, in an assembled PrimaFit 2.0, the foam backer/fabric/bottom barrier compact the inner foam, pushing it around the tube at the end of the device. This can be seen in my CT and x-ray images above. The components align differently when the inner foam assembly has been removed from the PrimaFit 2.0. When removed, the inner foam expands at its end, changing the configuration of components.

281. Thus, the relative positioning of the tube and the inner foam were not preserved in the photographs that Dr. Collins provided, which I confirmed by disassembling PrimaFit 2.0 and taking my own photographs. One can see that the end of the foam around the tube flares outward in Dr. Collins' photographs rather than compresses within the tapered end of the PrimaFit 2.0. Worse, the photographs do not show the same inner foam/FlexLink/tube assembly, and, in the second and third images, the foam is flared outward even further, and the foam has been cut apart lengthwise, unlike how the assembled PrimaFit 2.0 is structured. In any event, one of skill in the art would recognize that, even in these photographs, with the foam seated within the device, the end of the foam would be positioned around the end of the tube.

**Image From Collins Ex. D at 22-23 (annotated)**




282. Dr. Collins does not reference his CT scan in his infringement claim charts for this limitation (Ex. D at 21-23; Ex. E at 23-25); however, in paragraph 191 he states that “the scans show that the PrimaFit 2.0’s flexible tubing has one end disposed in the reservoir.” I disagree.

283. As discussed above in Section VI.A, Dr. Collins CT video and images are unreliable and do not accurately show the components in the device. To the contrary, Dr. Collins selected a particular image that was likely not centered to show all the relevant components. This is apparent because other images in Dr. Collins’ CT video refute the image Dr. Collins provided




in his report (¶191) and show the true configuration in PrimaFit with the tube not extending into the alleged reservoir.

284. Below I reproduce an image from the CT rotational video at time 0:28 (left) and the CT image that Dr. Collins selected to analyze infringement in his report from paragraph 191 (right). As can be seen, unlike the select image used by Dr. Collins in his report, the image at time 0:28 of the video demonstrates the inner foam surrounding the tube and that the tube is not in the alleged “reservoir”. But, in an attempt to suggest the tube is not retracted within the foam, Dr. Collins selected another image from an unidentified cross-section that is not a cross-section across a central plane to show all the components. With the tube retracted, the PrimaFit 2.0 does not meet the limitation “a tube having a first end disposed in the fluid reservoir.”



285. Moreover, Dr. Collins' CT images are not cross-sectional or 3D views and do not

show depth, so they do not show all the inner foam that is present.<sup>7</sup> This is unlike the images that I have presented:




286. The CT images from Dr. Collins' report are also inconsistent with the actual photograph of a cut-open PrimaFit 2.0 from Dr. Collins' report which also confirms the foam around the tube:

---

<sup>7</sup> Compounding the unreliability, it is possible that for Dr. Collins' CT scan, whether knowingly or accidentally, Dr. Collins or perhaps the technician, handled the PrimaFit 2.0 in a way that did not preserve the integrity of the device or relationship of the components shown.

**Image From Collins Ex. D at 22 (annotated)**

**Top view with wicking fabric  
and bottom barrier cut away**



287. As a result, Dr. Collins’ unexplained CT scan video and images are not reliable, including the images cited in his infringement claim charts.

288. For at least these reasons, the PrimaFit 2.0 does not meet this limitation. PureWick and Dr. Collins did not allege this claim limitation is met under the doctrine of equivalents.

- h. “the apparatus configured . . . to receive urine discharged from the urethral opening . . . into the reservoir, and to have the received urine withdrawn from the reservoir via the tube and out of the fluid discharge end of the tube.”**

289. Dr. Collins states that the PrimaFit 2.0 satisfies the element “the apparatus configured to disposed with the opening adjacent to a urethral opening of a user, to receive urine



discharged from the urethral opening through the opening of the fluid impermeable layer, the membrane, the support, and into the reservoir, and to have the received urine withdrawn from the reservoir via the tube and out of the fluid discharge end of the tube” as recited in Claim 1. (e.g., Collins Ex. D at 23-27.) I disagree as discussed below

290. As discussed above, the PrimaFit 2.0 does not include the claimed “opening,” “fluid impermeable layer,” or casing having a “fluid reservoir.” Thus, the PrimaFit 2.0 does not meet the limitation of a fluid impermeable casing “the apparatus configured . . . to receive urine discharged from the urethral opening . . . into the reservoir, and to have the received urine withdrawn from the reservoir via the tube and out of the fluid discharge end of the tube” because the PrimaFit 2.0 lacks a casing, reservoir, or tube with an end disposed in the reservoir.

291. Even if the PrimaFit 2.0 is considered to have a “reservoir,” the PrimaFit 2.0 is not “configured . . . to receive urine discharged from the urethral opening . . . into the reservoir” or “configured . . . to have the received urine withdrawn from the reservoir via the tube and out of the fluid discharge end of the tube.” Notably, the claims do not require only that the device has a “casing having a fluid reservoir” and a tube having an end “disposed in the fluid reservoir,” they **additionally** require that the device be actually “**configured . . . to receive urine discharged from the urethral opening . . . into the reservoir, and to have the received urine withdrawn from the reservoir via the tube and out of the fluid discharge end of the tube.**” In my opinion, the 2.0 product is not configured in this manner.

292. As I have observed from my review of the device, as well as documents and testimony, the PrimaFit 2.0 is a urine management device that is configured to divert urine from the user, and I have seen no evidence that it is “**configured . . . to receive urine**”, much less to do so in the area that Dr. Collins has arbitrarily identified as the “reservoir.” (*See, e.g.,* Cole Dep. Tr.,

at 162 (“The PrimaFit 2.0 device diverts urine. It does not collect urine.”); Farrell Dep. Tr., at 84 (“The device in general diverts urine away from the patient.”).) There is no reservoir as I discussed above, but again even if that area were a “reservoir,” the product is not “configured to,” i.e. designed to, receive urine in that area.<sup>8</sup> I have also seen no evidence that the product is “configured . . . to have” “received urine” withdrawn from the alleged reservoir “via the tube.” To the contrary, the product is configured to divert urine so that there is no reservoir, much less “received urine” in a reservoir. Additionally, the tube is not in the reservoir as I have discussed.

293. In fact, as I discussed elsewhere in my report, rather than be configured to include a “reservoir,” the PrimaFit 2.0 designers specifically removed the “Fluid reservoir, cap” from the original PrimaFit product. Thus, this device is designed to or configured to have no reservoir and instead has a soft end design that compresses in the perineal space between the gluteal folds. (Cole Tr., at 166-167; STRSAGE00021947 (“No dedicated reservoir cap”).) Indeed, this was promoted as an improvement over prior devices that included areas for “received urine.” (STRSAGE00000004.)

294. Notably, Dr. Collins does not explain specifically how this limitation is met. He simply states, “[a]s shown in the following images from the PrimaFit brochure and training video,” the limitation is met and included a Sage marketing brochure image and a screenshot of a Sage marketing video. (Collins Ex. D at 25-27.) I reproduce those images below. (Collins Ex. D at 26 (citing STRSAGE000000004); Ex. D at 25 (citing <https://sageproducts.com/videos/primafit/training/> produced at BDPureWick\_EXP\_0000040).)

---

<sup>8</sup> I understand that “configured to” means the device is designed to perform the recited function, e.g., to receive urine. This is how a person of ordinary skill in the art would understand the phrase to be understood with regard to this particular claim element.



295. The marketing brochure image and the marketing video screenshot, as well as the marketing video from which the screenshot was taken, do not demonstrate that the PrimaFit 2.0 is an “apparatus configured . . . to receive urine discharged from the urethral opening . . . into the reservoir, and to have the received urine withdrawn from the reservoir via the tube and out of the fluid discharge end of the tube.” The brochure and video do not provide technical or scientific information about the PrimaFit 2.0 device, and do not depict the actual PrimaFit 2.0 device.

296. The marketing brochure image is a graphical representation of an animated user with a rendering of a PrimaFit 2.0. The animation’s right leg is translucent (see-through) in order to reveal the rendered PrimaFit 2.0 device, which would otherwise be blocked from view by a real user’s leg. Yellow graphical arrows and dashes are shown within the tube of the PrimaFit 2.0 and the suction tubing connected thereto to represent urine being diverted from the patient to a collection canister. Notably, the image does not depict any “received urine” in the alleged reservoir of the PrimaFit 2.0 rendering, much less that the product is “configured to receive urine...into the reservoir” or “configured to...have the received urine withdrawn from the reservoir via the tube....”. This image does not demonstrate the limitations and rather supports my opinion that the PrimaFit 2.0 is a urine diversion device.



297. Similarly, the marketing video and screenshot relied on by Dr. Collins shows a rendering of a PrimaFit 2.0 on an animated body. The video and screenshot do not depict urine in the alleged “reservoir” of the PrimaFit 2.0. In fact, in the video, consistent with my opinion, a narrator states that the PrimaFit 2.0 “diverts urine away from the patient's skin.” (Video at 1:57-2:01 (BDPureWick\_EXP\_0000040).) While Dr. Collins states that the video states that urine is

"suctioned from the tapered end," that statement does not describe the device being configured so that urine is "received" in any alleged "reservoir" or that "received urine" is withdrawn from that area, i.e., the particular area within the tapered end that Dr. Collins asserts is the claimed reservoir. The video and screenshot include yellow graphical arrows to represent urine being *diverted* to a suction canister—not a product that is configured to receive urine in any reservoir, much less have "received urine" withdrawn via a tube. The video and screenshot also do not demonstrate this limitation, and also further supports my discussion above about the PrimaFit 2.0 being a urine diversion device.



298. For at least these reasons, the PrimaFit 2.0 does not meet this limitation. PureWick and Dr. Collins did not allege this claim limitation is met under the doctrine of equivalents.


## 2. Claim 5 (376 Patent)

299. Claim 5 recites: "The apparatus of claim 1, wherein the support and casing are substantially cylindrical, the apparatus configured to be: disposed with the elongated opening adjacent the urethral opening of a human female; oriented with the reservoir adjacent to the user's anus and the outlet disposed above the urethral opening; and arranged with a curved shape with the elongated opening disposed on the inside of the curve." Dr. Collins asserts this


limitation is met. (e.g., Collins Ex. D at 27-33.) I disagree as set forth below.

300. The PrimaFit 2.0 does not meet the limitations of Claim 1 for the reasons discussed for Claim 1 above in Section VI.B.1, which I hereby incorporate by reference. As a result, the PrimaFit 2.0 does not infringe Claim 5 for this reason. In addition, as discussed above for Claim 1, the PrimaFit 2.0 does not meet the limitations “casing,” casing having a “fluid reservoir,” or a casing having an “elongated opening.” I incorporate herein my discussion of those elements from Sections VI.B.1.a and c.

301. The PrimaFit 2.0 also does not meet the additional limitations of Claim 5 “wherein the support and casing are substantially cylindrical” and “the apparatus configured to be . . . oriented with the reservoir adjacent to the user’s anus.” The alleged casing of the PrimaFit 2.0, which Dr. Collins asserts is “formed” by the foam backer, bottom barrier, and a portion of the bowtie adhesive, is not “substantially cylindrical” as required by Claim 5. This can be seen in the annotated engineering drawings of the alleged casing components and photographs reproduced below. A substantially cylindrical casing would have an almost circular cross section, not that which is shown in the photographs and drawings.





(STRSAGE00025402.)



302. As can be seen, the alleged casing components are not substantially cylindrical. For example, the foam backer is generally flat top, u-shaped on the bottom, and has irregularities on either end. The bowtie adhesive is also flat on top, the bottom barrier is also non-cylindrical.

303. Dr. Collins, without further explanation, states that the following two photographs

shows that the alleged casing is “substantially cylindrical.”




(Collins Ex. D at 31-32.)

304. Dr. Collins’ photographs show that the casing is not substantially cylindrical. Dr. Collins ignores the structures of the alleged casing I discussed above including foam backer having a flat top, u-shaped on the bottom, and has irregularities on either end, and the bowtie adhesive is also flat on top, the bottom barrier is also non-cylindrical, which are all visible in the photographs.

305. Moreover, the alleged “fluid permeable support” of the PrimaFit 2.0 (the inner foam) is also not “substantially cylindrical” as required by the claim. Below I reproduce an

engineering drawing and photograph of the component. As can be seen, the component has an irregularly shaped end with a taper (somewhat frustoconical), not a shape that is substantially cylindrical.




(STRSAGE00025402.)

306. My opinion about the alleged casing and support not being substantially cylindrical is also consistent with the specifications of the asserted patents. While the specifications do not describe what is specifically meant by “substantially” cylindrical, the specifications describe and depict casings and supports that are “cylindrical,” for example, “the permeable support 1540 can function as a hollow framework for the permeable membrane 1530 (e.g., a tubular or cylindrical shape as shown in FIG. 30).” (376 Patent, 23:13-17; 989 Patent, 22:23-22:31.) The cylindrical support is shown below from Fig. 30:



FIG. 30



307. One of skill in the art would understand that a support and casing that are “substantially cylindrical” are close in shape to the cylindrical supports and casings described and depicted in the asserted patents. The PrimaFit 2.0 is not. For at least these reasons, the PrimaFit 2.0 does not meet the limitations of claim 5. PureWick and Dr. Collins did not allege this claim limitation is met under the doctrine of equivalents.

### 3. Claim 9 (376 Patent)

308. Claim 9 recites: “The apparatus of claim 1, wherein the fluid permeable membrane includes a wicking material.” Dr. Collins asserts this limitation is met. (Collins Ex. D at 34-36.) I disagree as set forth below.

309. The PrimaFit 2.0 does not meet the limitations of Claim 1 for the reasons discussed for Claim 1 above in Section VI.B.1, which I hereby incorporate by reference. As a result, the PrimaFit 2.0 does not infringe Claim 9 either for this reason.

310. Additionally, as discussed above, the Court construed the phrase “wicking material” to mean: “an article that moves moisture by capillary action from one surface of the article to the other.”

311. Dr. Collins asserts that this limitation is met, without referencing the construction, by citing to several Sage documents that either refer to the PrimaFit 2.0 having a “wicking” material or that enumerate the material name (dimple polyester mesh) (e.g., STRSAGE00022113; SAGE00030464; STRSAGE00000011) as well as documents and testimony that refer to the original PrimaFit, not the PrimaFit 2.0. (SAGE00025099-100; SAGE00026372-415; Blabas Dep. Tr., at 274:19-278:13, 278:21-281:11; SAGE00026372-26415 at 26398-400, SAGE00025099-01, SAGE00024806-07).

312. Dr. Collins, however, has not explained how the fabric of the PrimaFit 2.0 is “an article that moves moisture by capillary action from one surface of the article to the other.” For example, he has not demonstrated moving moisture at all, let alone by “capillary action,” and he has not explained how moisture moves by capillary action from “one surface of the article to the other” or even what “one surface” and “the other” he believes are attributable to the alleged permeable membrane of the PrimaFit 2.0, the fabric.

313. In Paragraph ¶158, Dr. Collins attempts to rely on the finding of the material in the original PrimaFit product, but the materials in the two products are configured differently. (Cole Dep. Tr., at 204; STRSAGE000000005 (“14% more ultra-soft fabric”).) Thus, simple reference to the same fabric material does not establish that the article in PrimaFit 2.0 moves moisture by capillary action from one surface of that different article to another.

314. As a result, the PrimaFit 2.0 does not infringe Claim 9 either for this reason. PureWick and Dr. Collins did not allege this claim limitation is met under the doctrine of equivalents

#### **4. Claim 10 (376 Patent)**

315. Claim 10 recites: “The apparatus of claim 1, wherein the reservoir is defined



**between the fluid impermeable casing and the fluid permeable support.”** Dr. Collins asserts this limitation is met. (Collins Ex. D at 36-38.) I disagree as set forth below.

316. The PrimaFit 2.0 does not meet the limitations of Claim 1 for the reasons discussed for Claim 1 above in Section VI.B.1, which I hereby incorporate by reference. As a result, the PrimaFit 2.0 does not infringe Claim 10 either for this reason. In addition, as discussed above for Claim 1, the PrimaFit 2.0 does not meet the limitations “casing” or a casing having a “fluid reservoir.” I incorporate herein my discussion of those elements from Sections VI.B.1.a and e.

317. Indeed, as I discussed above in Section VI.B.1.e, which I incorporate by reference, even if the PrimaFit 2.0 were considered to have a space where urine can collect, at a minimum, it would have to encompass the entire area where fluid can collect according to Dr. Collins’ own testing, which showed the urine within the inner foam (the alleged “fluid permeable support”) including at a first end. Thus, Dr. Collins’ own evidence establishes the fluid reservoir is not “defined between the fluid impermeable casing and the fluid permeable support” as required by claim 10 as it is fully within the alleged fluid permeable support as well.

318. For at least these reasons, the PrimaFit 2.0 does not meet the limitations of claim 10. PureWick and Dr. Collins did not allege this claim limitation is met under the doctrine of equivalents.

### **C. 989 Patent**

319. The asserted 989 Patent is similar to the 376 patent in that it includes much of the same description and figures as the asserted 376 Patent, but there are differences. As discussed above, the 989 Patent does not contain Figures 41-51 or their associated descriptions as does the 376 Patent. Importantly here, the claims of the 989 Patent asserted in this case (claims 1-6) are directed to methods of using a urine collection device. Sage’s PrimaFit 2.0 does not infringe

Claims 1-6 of the asserted 989 Patent at least because the PrimaFit does not have all of the elements of these claims either literally or under the doctrine of equivalents, as discussed herein.

320. Sage does not infringe Claims 1-6 of the 989 Patent at least because the PrimaFit 2.0 and its use do not have all of the elements of any of these claims either literally or under the doctrine of equivalents. As a preliminary matter, and referenced below, I note that neither PureWick in its Final Infringement Contentions nor Dr. Collins have asserted that any limitation of the asserted claims of the 989 Patent is met under the doctrine of equivalents. Instead, PureWick and Dr. Collins assert only that each element of each asserted claim is found literally in the PrimaFit 2.0 device and its use. Dr. Collins has also not established the use of the device as claimed in the 989 patent claims, or that the use of the device infringes the 989 Patent.

#### **1. Claim 1 (989 Patent)**

Claim 1 recites:

1. A method comprising:

disposing in operative relationship with the urethral opening of a female user a urine collecting apparatus that includes:

a fluid impermeable casing having a fluid reservoir at a first end, a fluid outlet at a second end, and a longitudinally extending fluid impermeable layer coupled to the fluid reservoir and the fluid outlet and defining a longitudinally elongated opening between the fluid reservoir and the fluid outlet;

a fluid permeable support disposed within the fluid impermeable casing with a portion extending across the longitudinally elongated opening, wherein the fluid permeable support is distinct from and at least proximate to the fluid reservoir;

a fluid permeable membrane disposed on the fluid permeable support and covering at least the portion of the fluid permeable support that extends across the longitudinally elongated opening, so that the fluid permeable membrane is supported on the fluid permeable support and disposed across the longitudinally elongated opening;

a tube having a first end disposed in the fluid reservoir and extending behind at least the portion of the fluid permeable support and the portion of the fluid

permeable membrane disposed across the longitudinally elongated opening and extending through the fluid outlet to a second, fluid discharge end,

the operative relationship includes the longitudinally elongated opening being adjacent to the urethral opening;

allowing urine discharged from the urethral opening to be received through the longitudinally elongated opening of the longitudinally extending fluid impermeable layer, the fluid permeable membrane, the fluid permeable support, and into the fluid reservoir; and

allowing the received urine to be withdrawn from the fluid reservoir via the tube and out of the fluid discharge end of the tube.

321. Claim 1 of the 989 Patent includes many of the same claim limitations as Claims 1 of the 376 Patent as well as additional limitations that relate to methods of using the claimed urine collecting apparatus. I incorporate by reference my analyses from the 376 Patent above for any limitation in claim 1 of the 376 Patent that is also recited by claim 1 of the 989 Patent, as there is no infringement for the same reasons discussed above.

322. As an initial matter, and as I also explain in Sections V.I.C.7 below, Dr. Collins has not established “direct infringement” of any method steps of the asserted claims of the 989 Patent. Dr. Collins has not identified any person or entity that actually performed any (much less all) of the method steps recited by any asserted claim of the 989 Patent. For example, Dr. Collins has not identified a single person or entity who performed the steps recited in claim 1 of “**disposing** . . . a urine collection apparatus,” “**allowing** urine . . . to be received . . . ,” or “**allowing** the received urine to be withdrawn . . . .” For these reasons on their own, Sage does not infringe directly or indirectly independent claim 1, as well as dependent claims 2-6 which each depend from claim 1.

323. In addition, as I also explain in below, Dr. Collins has not established the additional requirements one must prove for indirect infringement. That includes the requirement that an accused infringer has knowledge of infringement. I discuss in detail how Dr. Collins has not demonstrated the knowledge requirement below in Section VII.

324. Sage's does not infringe claim 1 of the 989 Patent because, at a minimum, the PrimaFit 2.0 does not meet the following claim limitations, either literally or under the doctrine of equivalents. I again note for reference that PureWick and Dr. Collins have not asserted limitation is met under the doctrine of equivalents. The PrimaFit 2.0 does not meet at least the limitations listed below, including a "urine collecting apparatus that includes:"

- a. "a fluid impermeable casing having a fluid reservoir at a first end, a fluid outlet at a second end"
- b. fluid impermeable casing having "a longitudinally extending fluid impermeable layer coupled to the fluid reservoir and the fluid outlet"
- c. fluid impermeable casing "defining a longitudinally elongated opening between the fluid reservoir and the fluid outlet" / "elongated opening"
- d. "a fluid permeable support disposed within the fluid impermeable casing with a portion extending across the longitudinally elongated opening"
- e. "wherein the fluid permeable support is distinct from and at least proximate to the fluid reservoir"
- f. "a fluid permeable membrane disposed on the fluid permeable support . . . so that the fluid permeable membrane is supported on the fluid permeable support and disposed across the longitudinally elongated opening"
- g. "a tube having a first end disposed in the fluid reservoir"

325. In addition, for the method steps of claim 1 of the 989 Patent, PureWick and Dr. Collins have not established the following with regard to the use of the PrimaFit 2.0:

- a. "disposing in operative relationship with the urethral opening of a female user a urine collecting apparatus"
- b. "allowing urine discharged from the urethral opening to be received through the longitudinally elongated opening of the longitudinally extending fluid impermeable layer, the fluid permeable membrane, the fluid permeable support, and into the fluid reservoir"
- c. "allowing the received urine to be withdrawn from the fluid reservoir via the tube and out of the fluid discharge end of the tube"

**a. “disposing in operative relationship with the urethral opening of a female user a urine collecting apparatus”**

326. In my report above in this section, and in Section VII below, I provide a response regarding how Dr. Collins did not provide evidence of direct or indirect infringement of the method step of claim 1 requiring “disposing . . . a urine collection apparatus.” I also explain above in Section VI.B.1 for the 376 Patent, and below in this section for the 989 Patent, that the PrimaFit 2.0 does not meet the limitations for the claimed “urine collecting apparatus” recited in Claim 1 of the 989 Patent.

327. In his claim chart, Dr. Collins alleges that the method step of “disposing in operative relationship with the urethral opening of a female user a urine collecting apparatus” is met by citing to a single document, the Directions document for PrimaFit 2.0. (Collins Ex. E at 1-2.) But Dr. Collins does not refer to evidence that this step has been performed, and therefore has not shown that any specific instance of direct infringement has occurred. As an example, Dr. Collins has not demonstrated with any evidence that a specific individual or, perhaps, an entity, actually “dispos[ed]” a PrimaFit 2.0 “in operative relationship with the urethral opening of a female user a urine collecting apparatus” as recited in claim 1. Dr. Collins also does not state specifically the type of individual or entity that performed the specific method step recited. For example, he does not specify if a patient, or a medical practitioner such as a nurse, doctor, or other type of caregiver, performed the step. He generically states that “Use of the PrimaFit by, inter alia, health care providers and/or patients” meets the limitation. (Collins Ex. E at 30.)

328. For at least these reasons, infringement of this limitation has not been established and the limitation is not met by use of the PrimaFit 2.0. PureWick and Dr. Collins did not allege this claim limitation is met under the doctrine of equivalents.

- i. **“fluid impermeable casing having a fluid reservoir at a first end, a fluid outlet at a second end, and a longitudinally extending fluid impermeable layer coupled to the fluid reservoir and the fluid outlet and defining a longitudinally elongated opening between the fluid reservoir and the fluid outlet;”**

329. These limitations from claim 1 of the 989 Patent are identical to limitation from claim 1 of the 376 patent that I addressed above in Sections VI.B.1.a, b, and c which I incorporate by reference herein. On pages 3 to 9 of Exhibit E, Dr. Collins provides the same analysis for these limitations as he does for the same limitations in Claim 1 of the 376 patent (pages 1 to 7 of Exhibit D). My response is the same.

330. Thus, the PrimaFit 2.0 does not meet these limitations for the same reasons. PureWick and Dr. Collins did not allege this claim limitation is met under the doctrine of equivalents.

- ii. **“a fluid permeable support disposed within the fluid impermeable casing with a portion extending across the longitudinally elongated opening, wherein the fluid permeable support is distinct from and at least proximate to the fluid reservoir”**

331. These limitations from claim 1 of the 989 Patent are identical in all material aspects to a limitation from claim 1 of the 376 patent that I addressed above in Section VI.B.1.d and e,<sup>9</sup> which I incorporate by reference herein. On pages 10 to 14 of Exhibit E, Dr. Collins provides the same analysis for these limitations as he does for the same limitations in Claim 1 of the 376 patent (pages 8 to 12 of Exhibit D). My response is the same.

332. Thus, the PrimaFit 2.0 does not meet these limitations for the same reasons.

---

<sup>9</sup> Claim 1 of the 376 patent omits the words “fluid impermeable” and “longitudinally” before “the casing” and “the elongated opening,” respectively, as those terms are included in the prior clause of that claim (see above section).

PureWick and Dr. Collins did not allege this claim limitation is met under the doctrine of equivalents.

- iii. **“a fluid permeable membrane disposed on the fluid permeable support and covering at least the portion of the fluid permeable support that extends across the longitudinally elongated opening, so that the fluid permeable membrane is supported on the fluid permeable support and disposed across the longitudinally elongated opening”**

333. This limitation from claim 1 of the 989 Patent is identical in all material aspects to a limitation from claim 1 of the 376 that I addressed above in Section VI.B.1.f,<sup>10</sup> which I incorporate by reference herein. On pages 14 to 22 of Exhibit E, Dr. Collins provides the same analysis for these limitations as he does for the same limitations in Claim 1 of the 376 patent (pages 12 to 21 of Exhibit D). My response is the same.

334. Thus, the PrimaFit 2.0 does not meet these limitations for the same reasons. PureWick and Dr. Collins did not allege this claim limitation is met under the doctrine of equivalents.

- iv. **“a tube having a first end disposed in the fluid reservoir and extending behind at least the portion of the fluid permeable support and the portion of the fluid permeable membrane disposed across the longitudinally elongated opening and extending through the fluid outlet to a second, fluid discharge end”**

335. This limitation from claim 1 of the 989 Patent is identical in all material aspects to

---

<sup>10</sup> Claim 1 of the 376 patent omits the words “fluid” and “fluid permeable” before “reservoir” and “support,” respectively, as well as the words “fluid permeable” and “longitudinally” before “membrane and “elongated opening, respectively, as those terms are included in the prior clause of that claim (see above section).

a limitation from claim 1 of the 376 that I addressed above in Section VI.B.1.g,<sup>11</sup> which I incorporate by reference herein. On pages 23 to 25 of Exhibit E, Dr. Collins provides the same analysis for these limitations as he does for the same limitations in Claim 1 of the 376 patent (pages 21 to 23 of Exhibit D). My response is the same.

336. Thus, the PrimaFit 2.0 does not meet these limitations for the same reasons. PureWick and Dr. Collins did not allege this claim limitation is met under the doctrine of equivalents.

**b. “allowing urine discharged from the urethral opening to be received through the longitudinally elongated opening of the longitudinally extending fluid impermeable layer, the fluid permeable membrane, the fluid permeable support, and into the fluid reservoir”**

337. This limitation from claim 1 of the 989 Patent is similar to aspects of claim 1 of the 376 patent that I addressed above in Section VI.B.1.h, which I incorporate by reference herein. However, rather than the device being configured to receive urine, the method step requires urine to be received as a step in the method. On pages 28 to 30 of Exhibit E, Dr. Collins provides generally the same analysis for these limitations as he does for the same limitations in Claim 1 of the 376 patent (pages 23 to 27 of Exhibit D). My response is the same.

338. In addition, I further explained how the PrimaFit 2.0 does not include the recited “longitudinally elongated opening,” the “fluid impermeable layer,” “the fluid permeable support,” and the “fluid reservoir,” as explained above in Sections VI.B.1.a, b, and c, which I hereby incorporate by reference.

---

<sup>11</sup> Claim 1 of the 376 patent omits the words “fluid permeable” and “longitudinally” before “casing” and “elongated opening,” respectively, as those terms are included in the prior clause of that claim (see above section).



339. I further note that this claim element requires the “longitudinally elongated opening” to be “of the longitudinally extending fluid impermeable layer,” a point that Dr. Collins did not address.

340. As explained above in Section VI.C.7, Dr. Collins did not provide evidence of direct or indirect infringement of the method step of claim 1 requiring “allowing urine . . . to be received . . . .” In his claim chart, Dr. Collins alleges that the method step of “allowing urine discharged from the urethral opening to be received through the longitudinally elongated opening of the longitudinally extending fluid impermeable layer, the fluid permeable membrane, the fluid permeable support, and into the fluid reservoir” is met by citing to two documents, a marketing brochure and a screenshot from a Sage marketing video. (Collins Ex. E at 28-30 (citing STRSAGE000000004 and <https://sageproducts.com/videos/primafit/training/>.) These are the same two materials that I discussed above in Section VI.B.1.h, which I hereby incorporate by reference. My analysis applies.

341. Additionally, these marketing materials do not show or refer to any actual user or other entity using the PrimaFit 2.0 device as required by the method claims by “allowing urine discharged....to be received....” Instead, they are merely a graphical representation of the product, thus they cannot prove Dr. Collins’ point. Moreover, as I already explained, even if they did show or demonstrate use of the PrimaFit 2.0, the graphics do not even depict the urine being “received” as claimed. Indeed, no alleged elongated opening, support, membrane, or alleged reservoir are shown in the materials or video.

342. Dr. Collins does not refer to evidence that this step has been performed, and therefore has not shown that any specific instance of direct infringement has occurred. As an example, Dr. Collins has not demonstrated with evidence that a specific individual or, perhaps, an

entity, actually performed the step with a PrimaFit 2.0 of “allowing urine discharged from the urethral opening to be received through the longitudinally elongated opening of the longitudinally extending fluid impermeable layer, the fluid permeable membrane, the fluid permeable support, and into the fluid reservoir” as recited in claim 1. Dr. Collins also does not state specifically the type of individual or entity that performed the specific method step recited. For example, he does not specify if a patient, or a medical practitioner such as a nurse, doctor, or other type of caregiver, performed the step. He generically states that “Use of the PrimaFit” meets the limitation. (Collins Ex. E at 30.)

343. For at least these reasons, infringement of this limitation has not been established and the limitation is not met by use of the PrimaFit 2.0. PureWick and Dr. Collins did not allege this claim limitation is met under the doctrine of equivalents.

**c. “allowing the received urine to be withdrawn from the fluid reservoir via the tube and out of the fluid discharge end of the tube”**

344. This limitation from claim 1 of the 989 Patent is similar to aspects of claim 1 of the 376 patent that I addressed above in Section VI.B.1.h,<sup>12</sup> which I incorporate by reference herein. However, rather than the device being configured to allow received urine to be withdrawn, the method step requires “received urine” to be withdrawn as a step in the method. On pages 30 to 32 of Exhibit E, Dr. Collins provides the same general analysis for these limitations as he does for the same limitations in Claim 1 of the 376 patent (pages 23 to 27 of Exhibit D). My response is the same.

---

<sup>12</sup> Claim 1 of the 376 patent omits the words “fluid permeable” and “longitudinally” before “casing” and “elongated opening,” respectively, as those terms are included in the prior clause of that claim (see above section).

345. In addition, I further explained how the PrimaFit 2.0 does not include the recited “fluid reservoir,” as explained above in Section VI.B.1.a, which I hereby incorporate by reference.

346. I also incorporate my analysis from the previous section, Section VI.C.1.c, for the element “allowing urine . . . to be received . . .” As discussed, Dr. Collins has not demonstrated that limitation is met. Because the step of “allowing urine . . . to be received . . .” is not met, then neither can the element “allowing the received urine to be withdrawn . . .” There is no “received urine.”

347. As explained further in my report, Dr. Collins did not provide evidence of direct or indirect infringement of the method step of claim 1 requiring “allowing the received urine to be withdrawn from the fluid reservoir via the tube and out of the fluid discharge end of the tube.” In his claim chart, Dr. Collins alleges that the method step is met by citing to the same two documents as the prior claim element. My analysis is the same as in the prior section and above. As discussed above, these marketing materials do not show or refer to any actual patient or individual using the PrimaFit 2.0 device. Even if they did show or demonstrate use of the PrimaFit 2.0 by an actual patient or individual, the graphics do not even depict “received urine” being “withdrawn” from any “fluid reservoir via the tube and out of the fluid discharge end of the tube.” No alleged reservoir or tube is shown in the materials whatsoever.

348. Dr. Collins does not refer to evidence that this step has been performed, and therefore has not shown that any specific instance of direct infringement has occurred. As an example, Dr. Collins has not demonstrated with evidence that a specific individual or, perhaps, an entity, actually performed the step with a PrimaFit 2.0 of “allowing the received urine to be withdrawn from the fluid reservoir via the tube and out of the fluid discharge end of the tube” as recited in claim 1. Dr. Collins also does not state specifically the type of individual or entity that

performed the specific method step recited. For example, he does not specify if a patient, or a medical practitioner such as a nurse, doctor, or other type of caregiver, performed the step. He generically states that “Use of the PrimaFit” meets the limitation without identifying any uses. (Collins Ex. E at 30.)

349. For at least these reasons, infringement of this limitation has not been established and the limitation is not met by Sage or the PrimaFit 2.0. PureWick and Dr. Collins did not allege this claim limitation is met under the doctrine of equivalents.

## **2. Claim 2 (989 Patent)**

350. Claim 2 recites: **“The method of claim 1, further comprising fluidically coupling the fluid discharge end of the tube to a source of vacuum to assist in withdrawing the urine from the fluid reservoir via the tube.”**

351. Sage and the PrimaFit 2.0 do not infringe claim 1 for the reasons discussed for Claim 1 above. I incorporate by reference my analysis from claim 1. Thus, Sage and the PrimaFit 2.0 do not infringe claim 2 for this reason. In addition, I further explained how the PrimaFit 2.0 does not include the recited “fluid reservoir,” as explained above in Section VI.B.1.a, which I hereby incorporate by reference.

352. Moreover, as I discuss herein, Dr. Collins did not provide evidence of direct or indirect infringement of the any method step recited in the 989 patent including the step recited in claim 2. There is no evidence that any person or entity performed this claimed method step.

353. Sage and the PrimaFit also do not infringe claim 2 for additional reasons. Dr. Collins alleges this element is met by citing to the Directions that he annotated and that reference vacuum and a suction canister (Collins Ex. E at 32-35 (citing STRSAGE00000001)) and a marketing brochure that states urine is “suctioned into a collection canister.” (Collins Ex. E at 35-

36 (citing STRSAGE00000004).)

354. Notably, however, the instructions do not discuss coupling the end of the tube to a source of vacuum. Rather, it says to “[s]et up suction canister and tubing according to hospital protocol.” Dr. Collins does not cite or address any hospital protocol.

#### Placement

**Step 1** Set up suction canister and tubing according to hospital protocol. Replace tubing and empty and/or replace suction canister per hospital protocol.

**Step 2** Place patient in supine position and separate patient’s legs.

**Step 3** Clean, prep, and dry patient’s genital area from front to back, per hospital protocol and assess skin integrity.

**Step 4** Remove device from package.

**Step 5** Attach suction tubing to the device at the suction tubing adapter.

- Ensure connection of suction tubing to device is secure and connected at all times while the device is in use.
- Confirm there are no kinks in the tubing and that tubing does not run under the patient.

**Step 6** Position device vertically with tapered end facing downward and fabric facing patient’s labia.

**Step 7** Align tapered end with perineum and place device between the labia and against the urethral opening. Ensure fabric is covering the urethral meatus. If used on retracted male anatomy, use clinical judgment and hospital protocol.

**Step 8** Curve the device toward the patient’s lower abdomen.

**Step 9** While holding the device in place, remove the adhesive liner and adhere the adhesive pad over the suprapubic region.

**Step 10** Ensure suction tubing does not run under the patient. Secure tubing per hospital protocol.

- Ensure adequate length of suction tubing is available.

**Step 11** Set vacuum to low, continuous suction at a minimum of 60mmHG. Always use the minimum amount of suction necessary.

**Step 12** Return patient’s legs to naturally closed position and raise bed to comfortable position. Assess device periodically to ensure proper placement, particularly after turning or repositioning patient.

- Replace device every 12 hours, or if soiled with stool or bodily fluids other than urine. Dispose of device per hospital protocol and local regulations.

(Collins Ex. E at 34 (citing STRSAGE000000001).)

355. Moreover, as with the previous method steps discussed in claim 1, Dr. Collins does not refer to evidence that this step has been performed, and therefore has not shown that any specific instance of direct infringement has occurred. As an example, Dr. Collins has not demonstrated with evidence that a specific individual or, perhaps, an entity, actually performed the step with a PrimaFit 2.0 of “fluidically coupling the fluid discharge end of the tube to a source of vacuum to assist in withdrawing the urine from the fluid reservoir via the tube” as recited in claim 2. The Directions and marketing document do not show that the step was performed. Dr. Collins also does not state specifically the type of individual or entity that performed the specific method step recited. For example, he does not specify if a patient, or a medical practitioner such as a nurse, doctor, or other type of caregiver, performed the step. He generically states that “Use of the PrimaFit by, inter alia, health care providers and/or patients” meets the limitation. (Collins Ex. E at 32.)

356. Dr. Collins does not refer to any specific alleged “vacuum” that he believes was used, or how he believes Sage allegedly instructs users to such a vacuum. Dr. Collins does not refer to any specific alleged vacuum level or how the vacuum worked if at all, or the specific source of vacuum.

357. Moreover, unlike PureWick, Sage does not sell a vacuum pump for or with the PrimaFit 2.0 device.

358. For at least these reasons, infringement of this limitation has not been established and the limitation is not met by Sage or the PrimaFit 2.0. PureWick and Dr. Collins did not allege this claim limitation is met under the doctrine of equivalents.



### 3. Claim 3 (989 Patent)

359. Claim 3 recites: “The method of claim 1, further comprising fluidically coupling the fluid discharge end of the tube to a fluid receptacle and allowing urine withdrawn from the fluid reservoir of the urine collecting apparatus via the tube to be received in the fluid receptacle.”

360. Sage and the PrimaFit 2.0 do not infringe claim 1 for the reasons discussed for claim 1 above. I incorporate by reference my analysis from claim 1. Thus, Sage and the PrimaFit 2.0 do not infringe claim 3 for this reason. In addition, I further explained how the PrimaFit 2.0 does not include the recited “fluid reservoir,” as explained above in Section VI.B.1.a, which I hereby incorporate by reference.

361. This limitation from claim 3 of the 989 Patent is also similar to aspects of claim 1 of the 376 patent that I addressed above in Section VI.B.1.h, which I incorporate by reference herein. However, rather than the device being configured to allow received urine to be withdrawn, the method step requires urine to be withdrawn as a step in the method. On pages 36 to 39 of Exhibit E, Dr. Collins provides the same general analysis for these limitations as he does for Claim 1 of the 376 patent (pages 23 to 27 of Exhibit D) and claim 2 of the 989 Patent (pages 32-36 of Exhibit E). My response is the same.

362. Moreover, as I discuss herein, Dr. Collins did not provide evidence of direct or indirect infringement of the any method step recited in the 989 patent including the step recited in claim 3. There is no evidence that any person or entity performed this claimed method step.

363. Sage and the PrimaFit also do not infringe claim 3 for additional reasons. Dr. Collins alleges this element is met by citing to, as he did for claim 2, the Directions that he annotated and that reference vacuum and a suction canister, (Collins Ex. E at 36-37 (citing STRSAGE00000001) and a marketing brochure that states urine is “suctioned into a collection

canister.” Collins Ex. E at 38-39 (citing STRSAGE000000004).)

364. As I discussed above in claim 2, there is nothing in the Directions or marketing document that suggest “fluidically coupling the fluid discharge end of the tube to a fluid receptacle and allowing urine withdrawn from the fluid reservoir of the urine collecting apparatus via the tube to be received in the fluid receptacle.” Rather, again, the focus is on using the hospital protocol, which Dr. Collins has not identified or provided, as I discussed above in Claim 2.

365. Moreover, as with the previous method steps discussed above, Dr. Collins does not refer to evidence that this step has been performed, and therefore has not shown that any specific instance of direct infringement has occurred. As an example, Dr. Collins has not demonstrated with evidence that a specific individual or, perhaps, an entity, actually performed the step with a PrimaFit 2.0 of “fluidically coupling the fluid discharge end of the tube to a fluid receptacle and allowing urine withdrawn from the fluid reservoir of the urine collecting apparatus via the tube to be received in the fluid receptacle” as recited in claim 3. The Directions and marketing document do not show that the step was performed. Dr. Collins also does not state specifically the type of individual or entity that performed the specific method step recited. For example, he does not specify if a patient, or a medical practitioner such as a nurse, doctor, or other type of caregiver, performed the step. He generically states that “Use of the PrimaFit by, inter alia, health care providers and/or patients” meets the limitation. (Collins Ex. E at 36.)

366. Dr. Collins does refer to any specific alleged “fluid receptacle” that he believes was used, or how he believes Sage allegedly instructs users to couple such a fluid receptacle. He also does not state vacuum level was utilized or how the vacuum worked if at all.

367. Moreover, unlike PureWick, Sage does not sell a vacuum pump for or with the PrimaFit 2.0 device.



368. For at least these reasons, infringement of this limitation has not been established and claim 3 is not met by Sage or the PrimaFit 2.0. PureWick and Dr. Collins did not allege this claim limitation is met under the doctrine of equivalents.

#### **4. Claim 4 (989 Patent)**

Claim 4 recites: **“The method of claim 1, further comprising removing the urine collecting apparatus from the operative relationship with the urethral opening of the user.”**

369. Sage and the PrimaFit 2.0 do not infringe claim 1 for the reasons discussed for Claim 1 above. I incorporated by reference my analysis from claim 1. Thus, Sage and the PrimaFit 2.0 do not infringe claim 4 for this reason.

370. Moreover, as I discuss herein, Dr. Collins did not provide evidence of direct or indirect infringement of the any method step recited in the 989 patent including the step recited in claim 4. There is no evidence that any person or entity performed this claimed method step.

371. Sage and the PrimaFit also do not infringe claim 4 for additional reasons. Dr. Collins alleges this element is met by citing to the same Directions as claims 2 and 3, identifying the text that states “Separate the labia and remove the device.” (Collins Ex. E at 39-40 (citing STRSAGE00000001).) As with the previous method steps discussed in claim 1, Dr. Collins does not refer to evidence that this step has been performed, and therefore has not shown that any specific instance of direct infringement has occurred. As an example, Dr. Collins has not demonstrated with evidence that a specific individual or, perhaps, an entity, actually performed the step with a PrimaFit 2.0 of “removing the urine collecting apparatus from the operative relationship with the urethral opening of the user” as recited in claim 5. The Directions does not show that the step was performed. Dr. Collins also does not state specifically the type of individual or entity that performed the specific method step recited. For example, he does not specify if a

patient, or a medical practitioner such as a nurse, doctor, or other type of caregiver, performed the step. He generically states that “Use of the PrimaFit by, inter alia, health care providers and/or patients” meets the limitation. (Collins Ex. E at 39.) Dr. Collins does refer to any specific alleged device or when it was removed.

372. For at least these reasons, infringement of claim 4 has not been established and claim 4 is not met by Sage or the PrimaFit 2.0. PureWick and Dr. Collins did not allege this claim limitation is met under the doctrine of equivalents.

## **5. Claim 5 (989 Patent)**

Claim 5 recites: **“The method of claim 4, wherein the urine collecting apparatus is a first urine collecting apparatus and further comprising disposing in operative relationship with the urethral opening of a female user a second urine collecting apparatus substantially similar to the first urine collecting apparatus.”**

373. Sage and the PrimaFit 2.0 do not infringe claims 1 or 4 for the reasons discussed for Claims 1 and 4 above. I incorporate by reference my analysis from claims 1 and 4. Thus, Sage and the PrimaFit 2.0 do not infringe claim 5 for these reasons.

374. Moreover, as I discuss herein, Dr. Collins did not provide evidence of direct or indirect infringement of the any method step recited in the 989 patent including the step recited in claim 5.

375. Sage and the PrimaFit also do not infringe claim 5 for additional reasons. Dr. Collins alleges this element is met by citing to the same Directions as in prior claims, identifying text that states “Replace device every 12 hours, or if soiled with stool or bodily fluids other than urine. Dispose of device per hospital protocol and local regulations.” (Collins Ex. E at 39-40 (citing STRSAGE000000001).) As with the previous method steps, Dr. Collins does not provide evidence

an individual or entity performed the step of “disposing in operative relationship with the urethral opening of a female user a second urine collecting apparatus substantially similar to the first urine collecting apparatus” with a PrimaFit 2.0, or specifically with a “female user” as required by the claim. The Directions does not show that the step was performed. Dr. Collins again does not state specifically the type of individual or entity that performed the specific method step recited if at all. For example, he does not specify if a patient, or a medical practitioner such as a nurse, doctor, or other type of caregiver, performed the step. He generically states that “Use of the PrimaFit by, inter alia, health care providers and/or patients” meets the limitation. (Collins Ex. E at 30.) Dr. Collins also does not refer to any specific alleged second PrimaFit 2.0 device that was disposed (he does not even identify a first one).

376. For at least these reasons, infringement of claim 5 has not been established and claim 5 is not met by Sage or the PrimaFit 2.0. PureWick and Dr. Collins did not allege this claim limitation is met under the doctrine of equivalents.

## **6. Claim 6 (989 Patent)**

Claim 6 recites: “**6. The method of claim 1, wherein the fluid permeable support and fluid impermeable casing are cylindrical and have a curved shape with the longitudinally elongated opening disposed on the inside of the curve, the disposing including disposing the urine collecting apparatus with the longitudinally elongated opening adjacent the urethral opening of the user and oriented with the fluid reservoir adjacent to the user's anus and the outlet disposed above the urethral opening.**”

377. Sage and the PrimaFit 2.0 do not infringe claim 1 for the reasons discussed for Claim 1 above. I incorporate by reference my analysis from claim 1. Thus, Sage and the PrimaFit 2.0 do not infringe claim 6 for this reason. In addition, I further explained how the PrimaFit 2.0

does not include the recited “fluid permeable support,” “fluid impermeable casing,” “fluid reservoir,” and “longitudinally elongated opening,” as explained above in Sections VI.B.1.a, c, e, f, and g, which I hereby incorporate by reference.

378. This limitation from claim 6 of the 989 Patent is similar to aspects of claim 5 of the 376 Patent that I addressed above in Section VI.B.2, which I incorporate by reference herein. However, rather than the device having a support and casing that are “substantially cylindrical,” the method step requires the support and casing be “cylindrical.” On pages 41 to 49 of Exhibit E, Dr. Collins provides the same general analysis for these limitations as he does for the limitations in Claim 5 of the 376 Patent (pages 27 to 49 of Exhibit D), and Dr. Collins does not acknowledge the difference in the claim language. My response is the same, and since as I explained the alleged support and casing are not “substantially cylindrical” (376 Claim 5), so they certainly are not “cylindrical (989 claim 6).

379. This limitation from claim 6 of the 989 Patent is also similar to aspects of claim 1 of the 376 patent that I addressed above in Section VI.B.1.h, which I incorporate by reference herein. However, rather than the device being “configured to be: disposed with the elongated opening...adjacent to the user’s anus,” the method step requires actually “disposing the urine collecting apparatus with the longitudinally elongated opening adjacent the urethral opening of the user and oriented with the fluid reservoir adjacent to the user's anus and the outlet disposed above the urethral opening” as a step in the method. On pages 41 to 49 of Exhibit E, Dr. Collins provides the same general analysis for these limitations as he does for Claim 5 of the 376 patent (pages 27 to 34 of Exhibit D). My response is the same.

380. Moreover, as I discuss herein, Dr. Collins did not provide evidence of direct or indirect infringement of the any method step recited in the 989 patent including the method step

of claim 6. There is no evidence that any person or entity performed this claimed method step.

381. Sage and the PrimaFit also do not infringe claim 6 for additional reasons. Dr. Collins alleges this element is met by citing to the same Directions and marketing document as previous claims as well as an annotated screenshot from a video that shows the PrimaFit 2.0 device with a manikin. (Collins Ex. E, p. 47-49 (citing STRSAGE000000001, STRSAGE000000002-3, and <https://sageproducts.com/videos/primafit/training/> at 1:21.) Again, these are not users of the product.

382. Moreover, as with the previous method steps, Dr. Collins does not refer to evidence an individual or entity performed, and therefore has not shown that any specific instance of direct infringement has occurred. As an example, Dr. Collins has not demonstrated with evidence that a specific individual or, perhaps, an entity, actually performed the step with a PrimaFit 2.0 of “disposing including disposing the urine collecting apparatus with the longitudinally elongated opening adjacent the urethral opening of the user and oriented with the fluid reservoir adjacent to the user's anus and the outlet disposed above the urethral opening” with a PrimaFit 2.0, or specifically with a “female user” as required by claim 6. The Directions, marketing document, and marketing video do not show that the step was performed. Dr. Collins again does not state specifically the type of individual or entity that performed the specific method step recited if at all. For example, he does not specify if a patient, or a medical practitioner such as a nurse, doctor, or other type of caregiver, performed the step. He generically states that “Use of the PrimaFit by, inter alia, health care providers and/or patients” meets the limitation. (Collins Ex. E at 41.)

383. For at least these reasons, infringement of claim 6 has not been established and claim 6 is not met by Sage or the PrimaFit 2.0. PureWick and Dr. Collins did not allege this claim limitation is met under the doctrine of equivalents.

**7. Dr. Collins' Failure To Identify Any Act Of Direct Infringement Of The 989 Patent**

384. As a preliminary matter, there is no infringement of claims 1-6 of the 989 patent for at least the reasons discussed in Section VI.C of my report. Moreover, as I mentioned above, Dr. Collins has not identified any entity or person that practiced the method steps of the 989 patent including Sage or any third party. I understand, however, that direct infringement is required to show indirect infringement. Dr. Collins has identified no act of direct infringement of the claims of the 989 patent.

385. Dr. Collins appears to contend that Sage and "hospitals" directly infringe the 989 Patent without providing any specific details of how or when this was done or any relation to the claims of the 989 patent. I disagree as set forth below.

**a. Response to Dr. Collins' Statement that Sage Directly Infringes The Methods of The 989 Patent**

386. Dr. Collins' entire direct infringement theory that Sage has directly infringed the method claims of the 989 patents is a single statement in his report: "Sage has directly infringed claims 1-6 of the '989 patent by using the PrimaFit 2.0 product. For example, Sage, through its employees and/or agents, conducted in-service training on the PrimaFit 2.0 product where it placed the PrimaFit 2.0 product on patients in accordance with the PrimaFit 2.0 product's instructions for use." (Collins Report ¶146.) To support his conclusion, Dr. Collins cites to a single document, which he describes to be a document "reporting the results of a 5-day trial conducted from 6/13-6/17/22 where '108 staff members [were] educated via in person in-service.'" (Collins Report ¶146 (citing STRSAGE00021320).) I disagree with Dr. Collins' conclusion that this document shows any use of the product by Sage, much less Dr. Collins' entire direct infringement theory that Sage has directly infringed the method claims of the 989 patents by performing any of the numerous,

specific method steps recited in the claims.

387. Dr. Collins does not cite to the testimony of any Sage witness regarding the document, and I understand that no Sage witness was asked about the document. Thus, Dr. Collins rests his entire infringement opinion that Sage directly infringes six claims of the 989 Patent based on a single document without first learning what the document is, who drafted it, or whether or how the information accurately reflects any events that actually occurred. Moreover, Sage is a medical device manufacturer, not a hospital or medical care provider that provides medical care for patients. Dr. Collins has cited no testimony evidencing that Sage used a PrimaFit 2.0 on any patient, let alone in accordance with the asserted claims of the 989 Patent.

388. In any event, Dr. Collins conclusion is wrong because he assumes facts not found in the document. I reproduce the document Dr. Collins cited below (STRSAGE00021320). As can be seen, the document has the heading "Trial Result Summary - External Urine Management Systems for Males and Female Anatomy" and purports to be from "[REDACTED]". At the top left corner of the document is an image of two devices, including the Sage PrimoFit, which is a male device, and the original PrimaFit device that was accused of infringement in the prior lawsuit between the parties.

389. Moreover, regarding the passages quoted by Dr. Collins, nothing about the statement "108 staff members educated via in person in-service" provides any information about whether anyone (much less anyone from Sage) used the PrimaFit 2.0, let alone according to the method steps identified in the claims of the 989 patents. The document does not state who provided the "in-service" or how it was performed. Dr. Collins also vaguely asserts that the direct infringement is by Sage "employees and/or agents," but he identifies no "Sage employee and/or agents" because none is described in the document.





## Trial Result Summary - External Urine Management Systems for Male and Female Anatomy

### Background<sup>1</sup>

- Facility is evaluating external urine management systems for ongoing CAUTI reduction initiatives
- Current urinary management incontinence process involves indwelling catheters and other external devices for incontinent patients with male (incl. retracted) and female anatomy
- Per facility, issues with current products include competitor devices not staying in place and leaking which leads to perineal and labia pressure injuries<sup>1</sup>
- 2020 – 17 CAUTI, 2021 – 15 CAUTI, 2022 (through 6/17/22) – 2 CAUTI
- Cost to treat 1 CAUTI = \$13,793<sup>2</sup> (\$469k in CAUTI treatment costs since 2020)

#### • Staff survey of 46 nurses:

**Q: What products do you use to manage urinary incontinence?**

**A:** catheter (24%), external device (49%), briefs (6%), incontinence pads (21%; 63% stated 2-4 per day)

**Q: How often do you change the product?**

**A:** <2x/day (27%), 2x/day (11%), >2x/day (49%)

**Q: What is the biggest challenge of managing urinary incontinence?**

**A:** time (26%), skin breakdown from urine (36%), frequency of changing pads/briefs (38%)

**Q: 4. If you had a product that fit to the patient and staying in place, would you be more inclined to it?**

**A:** yes (89%), no answer (11%)

#### • Snapshot of incontinence standard of care (6/8/22)

ICU, ICUA, ICUC and PCU; 26 incontinent patients assessed; 65% male (17)/35% female (9)

##### 1. Products used to manage urinary incontinence

Indwelling catheter (57%), incontinence pad (22%), external device (13%), other (2%)

##### 2. Why is the catheter placed on the patient?

incontinence management (92%), acute urinary output (8%)

##### 3. Does the patient have IAD?

no (50%), unknown (40%), yes (10%)

### Trial

- A 5-day trial conducted from 6/13-6/17/22 on ICU (24 beds, ADC 25 patients) and PCU (26 beds, ADC 23 patients)
- 108 staff members educated via in person in-service

- No CAUTIs on patients with PrimaFit & PrimoFit during the trial

- 35 facility<sup>3</sup> hard copy PrimaFit evals collected:

**Q: "I would recommend use of this product."**

**A:** yes (89%, 31 responses), no (3%, 1), blank (8%, 3)

#### • Staff comments:

"The Stryker Sage PrimaFit is a good product for the patients. Keeps them dry and fits correctly onto the patient's labia."

"No leakage, looks great."

"Help place device, easy placement."

"The pad was completely dry in the morning."

"Better for the patient."

"Love the product, more secure on patient and it's flexible."

"Better than <competitor>."

"The new <product> helps keep my patients' skin from further breakdown."

"I received a detailed explanation of how to use this product. Very easy to use and place on patient."

"It seems to have a better seal than the <competitor>."

"For the first time using the product it was about as effective as <competitor> is on a moving patient."

"Once the patient made #2 (bowel) especially diarrhea it causes already the PrimaFit it leak everywhere."

(Collins Report ¶146 (citing STRSAGE00021320).)

390. In Paragraph 221, Dr. Collins states "Sage also conducted 'in-service' training on the PrimaFit 2.0 device, where they showed healthcare providers how to use the PrimaFit device in a way that infringes one or more claims of the '376 and '989 patents." But, again, nothing in the document references any instruction on how to use the product, much less any instructions by Sage. Dr. Collins makes similar statements in Paragraph 222 and 226 (e.g., Dr. Collins states: "Field evaluations of the PrimaFit 2.0 product took place in hospitals such as [REDACTED], where Sage employees trained hospital staff in person."), citing the same document. But, again, Dr. Collins provides no support for those conclusions whatsoever.

391. For at least these reasons, Sage does not directly infringe claims 1-6 of the 989 Patent and thus cannot indirectly infringe any claim.



**b. Response to Dr. Collins' Statement that Unidentified "Hospitals" Directly Infringe The Method Claims of The 989 Patent**

392. In Paragraph 147, Dr. Collins makes the following statement: Sage "sell[s] the PrimaFit 2.0 product to hospitals that have directly infringed the claims through their use of the PrimaFit 2.0 product with patients." (Collins Report ¶147.) Dr. Collins does not cite a single document to support that statement or any evidence of use by "hospitals" in accordance with the claims of the 989 patent whatsoever including any witness testimony.

393. In Paragraph 216, Dr. Collins asserts that "When hospitals use the PrimaFit 2.0 device the hospitals and/or their patients directly infringe the asserted claims of the '376 and '989 Patents." (Collins Report ¶216.) However, Dr. Collins identifies no evidence that the PrimaFit 2.0 was actually used in an infringing manner by any particular "hospital and/or patient." Dr. Collins cites to five documents to support this assertion, which do not support his conclusion:

- STRSAGE00022910 at 919-921, which is a marketing presentation with a slide discussing targeted "stakeholders" for Sage's products, which does not discuss use of any particular device including the PrimaFit 2.0;
- STRSAGE00021320, which refers to an alleged trial at [REDACTED] (discussed in Section VI.C.7.a above). As I explained, the document provides no detail about what any individual or entity did with the PrimaFit 2.0;
- STRSAGE00022999 and STRSAGE00023023, which are both the same document, do not describe any use, much less any particular use in accordance with the claims of the 989 patent. STRSAGE00023001 is a similar form that likewise provides no relevant information.
- A statement by Adam Cole which acknowledges that Sage "sell[s] the PrimaFit 2.0 to hospitals and hospital systems." (Cole Tr., at 58:13-14.)

394. Again, none of these documents actually show that the PrimaFit 2.0 was used, let alone by a specific individual or entity in the claimed manner. Dr. Collins has also not identified how any of these documents show direct infringement, meaning, that the specific limitations required by the claims were performed, nor has he identified which individuals or entities perform

which steps of the asserted method claims.

395. For example, Dr. Collins does not cite any documents that show any specific entity or individual performed any of the method steps required by the 989 patent (e.g., “disposing in operative relationship with the urethral opening of a female user a urine collecting apparatus that includes” and “allowing urine discharged from the urethral opening to be received through the longitudinally elongated opening of the longitudinally extending fluid impermeable layer, the fluid permeable membrane, the fluid permeable support, and into the fluid reservoir”). He also does not explain or establish how a single individual or entity performed all the steps of the claimed method, as opposed to more than one. For example, he has not shown that a medical practitioner performs all of the steps as opposed to a medical practitioner performing one or some of the steps, and the patient performing the other or others. Dr. Collins also did not provide evidence that Sage induced any individual or entity to perform the method steps.

396. Moreover, the asserted method claims of the 989 Patent (claims 1-6) expressly state that the claimed device must be used with a female (989 Patent claim 1: “disposing in operative relationship with the urethral opening of *a female user* a urine collecting apparatus”). Dr. Collins did not identify any direct infringement, and certainly offers no evidence that a particular use was by a female patient.

397. Thus, there is no evidence of any direct infringement of the method claims 1-6 of the 989 Patent and thus there can be no indirect infringement.

## **VII. RESPONSE TO DR. COLLINS’ GENERAL ALLEGATIONS OF INDIRECT INFRINGEMENT**

398. I explained above how the PrimaFit 2.0 does not meet the limitations of the asserted claims of the patents in suit including the “apparatus” claims of the 376 Patent and the “method” claims of the 989 Patent. In Paragraphs 211-227 of his report, Dr. Collins makes a number of

statements relating to alleged indirect infringement of the claims of the 376 and 989 including inducement and contributory infringement. In my opinion, Sage does not indirectly infringe under either theory.

399. As a preliminary matter, as I explained above in Section IV.C.2, it is my understanding that indirect infringement under a theory of inducement infringement or contributory infringement, requires evidence of at least one “direct” infringement. This means that one person or entity infringed the patent claims. In Section VI.B for the 376 Patent, and Section VI.C for the 989 Patent, I discussed how there was no direct infringement because the PrimaFit 2.0 does not meet the limitations of the asserted claims, and there is no evidence that any method steps were performed. Therefore, Sage does not and cannot indirectly infringe the asserted claims of the asserted patents whether by inducement infringement or contributory infringement.

400. Apparently recognizing that there is no evidence of an actual use or direct infringement of the PrimaFit 2.0, including according to the claimed method steps of the 989 Patent, Dr. Collins asserts in Paragraph 218 that “Sage instructs customers to use the PrimaFit 2.0 product in an infringing manner,” referencing the Directions for the product. I explained above why the Directions do not establish direct infringement and I incorporate that discussion here. Nevertheless, numerous Sage witnesses testified that hospitals use their own protocol for use of the product. (*See, e.g.*, Farrell Tr., at 149; Cole Dep. Tr., at 70.) In my roles throughout my career, including as Director of the Biomedical Engineering departments at Texas Children’s and St. Lukes hospitals, this is consistent with how hospitals use urine management products. And the Directions themselves repeatedly reference the use of the hospital’s own protocol. (STRSAGE000001.) Dr. Collins identifies no evidence that any individual or entity has followed the Directions as he suggests.

401. Having no evidence that any person or entity actually followed any particular directions, Dr. Collins asserts that he “understand[s] from Dr. Yun that hospitals typically follow the instructions for use for medical devices,” citing to the opening expert report of another PureWick expert, Dr. Edward Yun. (Collins Report ¶218 (citing Yun Report ¶43).) But I saw nothing in Dr. Yun’s report that indicates that he ever used a PrimaFit 2.0, much less that he knows how hospitals use them. As I mentioned, those familiar with the product state that hospitals use their own protocol.

402. In Paragraph 219, Dr. Collins also asserts that “Sage’s documents demonstrate that healthcare providers ask Sage for directions on how to use the PrimaFit 2.0 Device,” citing to a STRSAGE00025139 and STRSAGE00025143. (Collins Report ¶219.) Dr. Collins also states “Sage documents also show that Sage instructs hospitals to follow Sage’s Instructions for Use.” But the documents that Dr. Collins identify do not support his statement. The first document (STRSAGE00025139) is an internal email dated May 26, 2021, before Sage began commercial sales of the product, and there is no request for directions for using the device as Dr. Collins asserted. This document reflects discussions when the original PrimaFit product was being sold and that product is not accused of infringement in this case. The second document (STRSAGE00025143) is an incomplete, unsigned, draft letter also dated May 2021, which also does not appear to relate to the PrimaFit 2.0 as the document predates commercial sales of the product and thus does not support Dr. Collins assertion.

403. Dr. Collins also references the testimony of Mr. Cole, but Mr. Cole did not testify that Sage instructs hospitals to follow the package directions. But Mr. Cole testified that customers “use the product as [the customers] intend” (Cole Tr., at 70), and other Sage witnesses confirm that Sage intends for and hospitals to follow their own protocols. (Farrell Tr., at 149 (Q. Does Sage

intend for its customers to follow the instructions for use when it develops them? A. Sage encourages hospitals to follow their hospital protocol for management urinary-incontinent patients.”).)

404. In Paragraph 220, Dr. Collins states that “Sage also instructs customers and Healthcare providers to use the PrimaFit 2.0 device in a manner that infringes...through instructional training videos.” He cites a video at BDPureWick\_EXP\_40; however, he offers no explanation regarding how any aspect of that video satisfies any claim element.

405. Dr. Collins makes a number of other unsupported allegations relating to the PrimaFit 2.0 being allegedly used in an infringing way. (e.g., Collins Report ¶¶218-227.) None of the allegations are specific or demonstrate how, or if, the PrimaFit was used at all, let alone in the particular manner asserted by Dr. Collins so as to infringe the asserted patents. And as discussed above, the use of the PrimaFit 2.0 does not infringe the asserted claims.

406. As I also explained above in my legal section (Section IV.C.2), I understand induced infringement requires that the alleged indirect infringer must have known of the patent and have a specific intent to cause the acts that constitute direct infringement. A corresponding principle for contributory infringement is that the alleged indirect infringer must have had known that the component being sold is especially made or especially adapted for use in an infringing manner. The alleged infringer must know that the product was infringing. Dr. Collins has not shown that Sage specifically intended any other to infringe the asserted patents or that Sage knew that the PrimaFit 2.0 infringes or its use infringes any of the asserted patents. To the contrary, as I explain throughout this report, it is clear that the PrimaFit 2.0 was specifically identified as a “noninfringing alternative” in the prior lawsuit.

407. In Paragraphs 223 and 224, Dr. Collins concludes that Sage contributes to the

infringement of the two patents by selling the product to hospitals and states that the product is especially designed to infringe. In Paragraph 227, Dr. Collins states that “there are no substantial noninfringing uses for the PrimaFit 2.0 device” because “it was specifically designed to be used in a manner that infringes...” I disagree. The product is designed not to infringe, and Dr. Collins offers no explanation for how it is designed to. Moreover, more than one unrelated actor could have performed steps.

408. Regarding the knowledge of infringement requirement, Dr. Collins asserts that Sage had specific intent and knowledge of infringement based on his assumption that “Sage had knowledge of the ‘376 Patent at least as early as March 12, 2019, and knowledge of the ‘989 Patent at least as early as August 27, 2019.” (Collins Report ¶211.) However, I understand that knowledge of a patent is not sufficient to establish knowledge of *infringement*.

409. Dr. Collins also asserts that “Sage had knowledge of the application that led to the ‘989 patent at least as early as September 2016” and cited to SAGE00043475-51. (Collins Report ¶211.) The document cited at SAGE00043475-51, however, is an email that does not provide any patent application numbers at all and is not for the 989 Patent as Dr. Collins asserts. Dr. Collins does not explain how the email would lead to the knowledge of infringement as he purports. Indeed, at that time in 2016, the asserted claims were not even in the patent application. (See, e.g., PureWick\_000949-951 (claims as filed without all limitations of the issued patent).) In any event, I also incorporate my analysis from Section X regarding no willfulness, where I further discuss Sage’s lack of knowledge during this time and other issues regarding no knowledge of the asserted patents or infringement.

410. In Paragraph 212, Dr. Collins references “a Complaint against Sage” filed on August 12, 2019, alleging that Sage infringed the ‘376 patent and, therefore, Sage had knowledge

of its alleged infringement of both of those patents at least as of that date.” I understand that is a reference to the accusations against the original PrimaFit product, thus Dr. Collins appears to be confused in alleging “knowledge of infringement” of the product in this case. The PrimaFit 2.0 product was not launched by August 2019 and Sage could certainly not have known about any infringement before it was alleged to have happened.

411. In Paragraph 213, Dr. Collins asserts that he provided an expert report in the prior matter between the parties in July 2021 stating that the PrimaFit 2.0 product would infringe and was thus not a noninfringing alternative. (Collins Report ¶213.) However, I reviewed Mr. Sheldon’s response to Dr. Collins assertions (Sheldon Report, p. 183) and, in my opinion, Mr. Sheldon’s conclusions were sound. I note that, although PureWick bore the burden of establishing noninfringing alternatives, I understand that Dr. Collins did not present his infringement theories about the PrimaFit 2.0 at that trial. Moreover, even though Dr. Collins asserts that PureWick knew that Sage infringed in July 2021, PureWick never brought a lawsuit against that product during the original case. In my opinion, I disagree that Dr. Collin’s report would establish knowledge of infringement. To the contrary, it appears to establish Sage’s knowledge of noninfringement. I discuss many of these issues further in Section X below.

412. In Paragraphs 214, 215, and 217, Dr. Collins references the jury verdict on the original PrimaFit product. But Dr. Collins does not explain how the jury verdict on a different product has any bearing on whether the 2.0 product infringes. My understanding is that to determine infringement, claims of a patent should be compared to the patent—not another product. Moreover, it would seem that if PureWick believed that the 2.0 product infringed, it would have accused the 2.0 product of infringement in that case since Dr. Collins was clearly aware of it.

413. Moreover, as discussed more in Sections VIII and X, it is my understanding that

Sage has at all times since it developed the PrimaFit 2.0 had a good-faith belief that the PrimaFit 2.0 product does not infringe any asserted claim of the 376 and 989 Patents as reflected, for example, in my analysis above as well as the noninfringement analysis provided by Mr. Sheldon among other things. The PrimaFit 2.0 is a completely new design and identified as a noninfringing alternative, which PureWick never disputed throughout the case. These issues are discussed further in Sections VIII and X below.

414. Indeed, as I explain in Section X, Sage informed PureWick about the PrimaFit 2.0 product long ago and PureWick took no steps to stop continued commercial launch of the product. I understand that PureWick has been aware of the PrimaFit 2.0 product since at least December 2020 including in February 2021 before the first deposition was taken by PureWick in the other matter. PureWick knew that Sage contended it was a noninfringing alternative to the original PrimaFit product. Yet, PureWick never sought to add PrimaFit 2.0 as an infringing product to that case or claim infringement, leaving the impression PureWick also did not contend the PrimaFit 2.0 did not infringe. (*See, e.g.*, information from the prior matter including: Sage's Third Supplemental Response to Interrogatory No. 4 at 37-41; Sage's Response to Interrogatory No. 6 dated February 20, 2021 at 48 (PrimaFit 2.0 is a noninfringing alternative and citing SAGE00030399-SAGE00030408, SAGE00030410-30464, SAGE00036528-590); Sage's Response to Interrogatory No. 6 dated March 16, 2021 (citing SAGE00034065-34067, SAGE00040648, SAGE00040769-72, SAGE00040419, SAGE00040450-4062, SAGE00034065-34067, SAGE00037128-37136, SAGE00034755-34761, SAGE00034013, SAGE00034065, SAGE00034072, and others); PureWick's Response to Interrogatory No. 10 dated April 16, 2021 at 33.) I understand there was also briefing on it in the prior matter as well.

415. Thus, I disagree with Dr. Collins conclusions regarding Sage does not have the



requisite intent or knowledge of infringement required for inducement or contributory infringement and I address this further in Section X below.

#### **VIII. PRODUCT ENHANCEMENTS TO THE PRIMAFIT 2.0 PRODUCT AND RESPONSE TO DR. COLLINS' COMPARISONS OF THE PRIMAFIT 1.0 AND 2.0 PRODUCTS**

416. At paragraphs 151-179 (and primarily at paragraphs 151-166), Dr. Collins makes a number of comparisons between the original PrimaFit device (which he refers to as the “PrimaFit 1.0” device) and the PrimaFit 2.0. For example, he asserts that “the PrimaFit 1.0 and PrimaFit 2.0 devices are substantially similar, and that the minor differences between the two devices are insignificant when it comes to infringement of the ‘376 and ‘989 patents.” (Collins Report ¶152.) Similarly, he states “the PrimaFit 2.0 is not substantially different from Sage’s PrimaFit 1.0 product.” (¶148.) He further states that the differences between the PrimaFit 1.0 and PrimaFit 2.0 were to “improve manufacturability and profitability while maintaining the same function [as] the PrimaFit 1.0 design.” (¶151.) Dr. Collins then suggests that infringement can be shown by comparing the PrimaFit 1.0 to the PrimaFit 2.0 in view of the jury’s verdict in the prior litigation. I disagree.

417. In my opinion, the PrimaFit 2.0 has numerous substantive differences from the PrimaFit 1.0 and it is an entirely new product. Moreover, I understand that Dr. Collins is applying an incorrect legal analysis; as I explained in Section IV.C.2, my understanding is that infringement is determined by comparing the asserted claims against the accused product (i.e., the PrimaFit 2.0), not by comparing the accused product to another product. Moreover, my understanding is that “substantial similarity” to another product, “not substantially different” from another product, and

“same function” as another product is not the test for determining whether a product infringes.<sup>13</sup>



418. In my opinion, the PrimaFit 2.0 product is a new and different product than the one at issue in the prior litigation, offering new features and removing components that PureWick claimed were infringing. Indeed, as I mentioned Sage identified the PrimaFit 2.0 as a noninfringing design alternative in the prior PureWick litigation and discussed the launch of the product, and PureWick did not assert that it infringed in that case, as I explain further in this report. (*See* citations in Section VII above in last paragraph.)

419. Components of the original PrimaFit product are depicted below:

---

<sup>13</sup> In Paragraph 152, Dr. Collins purports to “incorporate” his Opening Report from the prior litigation including his description of the PrimaFit 1.0 device because “it is [his] opinion that the PrimaFit 1.0 and PrimaFit 2.0 devices are substantially similar...” I cannot ascertain what aspects of his Opening Report he is incorporating because his “substantial similarity” assessment seems to have no bearing on what must be assessed for infringement.

COMPONENTS BOM		
#	DESCRIPTION	QTY
1	FLUID RESERVOIR, CAP FOR 5400	1
2	FOAM, ADHESIVE STRIP, BOTTOM	1
3	ABSORBENT SLEEVE, ASSEMBLY	1
4	FABRIC BATTING, CONVERTED FOR 5400	1
5	TUBE PORT SUBASSEMBLY WITH FLEXLINK	1
6	PRIMAFIT GEN II TOP TAPE	1
7	BOW TIE, ASSEMBLY	1
8	PRINTED BAG	1



(See SAGE00000128; SAGE00000240; SAGE00000242; SAGE00000244.)

420. I have reviewed Sage documents describing the PrimaFit 2.0's development, and the PrimaFit 2.0 has numerous substantive differences from the PrimaFit 1.0 including ones that required extensive new testing to confirm that the device worked as intended and provided the desired performance parameters and results. Indeed, almost every component and feature is different. These differences include, among others:

- The PrimaFit 2.0 eliminates the relatively firm plastic end cap that PureWick asserted was the “reservoir” in the PrimaFit 1.0.
- The PrimaFit 2.0 eliminates the “batting” that PureWick asserted was the “permeable support” in the original PrimaFit 1.0.
- The PrimaFit 2.0 eliminates the components that PureWick asserted were the “casing” in the PrimaFit 1.0 including the bottom tape, top tape, and bottom foam.
- The PrimaFit 2.0 changed the dimensions and configuration of the fabric that PureWick contended was the “permeable material.”
- The PrimaFit 2.0 utilizes a welding process to weld the fabric material to the foam backer in the area that PureWick previously asserted was an “opening”.
- The PrimaFit 2.0 includes a new foam backer component, which is made from new, EO Volara material with a higher density and thickness.
- The PrimaFit 2.0 includes a new bottom barrier component.
- The PrimaFit 2.0 includes a new inner foam component that is designed to be seated within the foam backer and which is made from materials that were not utilized in the PrimaFit 1.0
- The PrimaFit 2.0 includes a new bowtie configuration and a new method of securement for the bowtie.

- The PrimaFit 2.0 includes a new suction connector.
- The PrimaFit 2.0 has a new soft tapered end.
- The PrimaFit 2.0 adds a long flexible tube extending outside the device.
- The PrimaFit 2.0 also is made by an entirely new [REDACTED] for the device and its assemblies, including a new thermoforming and ultrasonic welding processing and hot melt processing to make the device.

421. These differences are evident from a review of Dr. Collins infringement contentions in the 1.0 case, which he attached as Exhibit F and G to his report for this case (Exhibits E and F in report in prior case). (*See* STRSAGE00000001-STRSAGE00000119.) More examples are discussed in Mr. Cole's deposition as well as Sage's response to Interrogatory No. 8.


422. There are no components in the PrimaFit 1.0 that are now present in the PrimaFit 2.0 including the following components from the PrimaFit 1.0 that are not present in the PrimaFit 2.0 product: "Foam, Adhesive Strip, Bottom," "Foam, Back," "Foam, Adhesive Strip, Top," "Foam Tape, Square," "Absorbent Sleeve, Assembly," "Fabric, Absorbent," "Fabric, Batting," "Tubing, Suction," "Suction Tubing Adapter," and "Fluid Reservoir, Cap."

423. Indeed, the PrimaFit 2.0 was fundamentally a new design of the product, with all new and improved components and features:

- Suction Connector
- Flexible Tubing
- Fabric
- Foam Backer
- Bottom Barrier
- Inner Foam
- Selective Adhesive (bowtie)

- Hot Melt
- FlexLink

424. Of note, as I mentioned, the PrimaFit 2.0 eliminates the exact feature that PureWick previously asserted was the claimed “reservoir” in the PrimaFit 1.0, as shown below. Moreover, the placement of the suction tube within the device is also different, among other things.



425. Mr. Cole discussed many of the differences in his deposition. (See Cole Dep. Tr., at 33 (“Q. [REDACTED]”), 47-48 (“Q. Do you have an understanding of why Sage decided [REDACTED]? A: At Sage, in new product development, [REDACTED]”), 48 (“[REDACTED] . . . add some features and benefits . . .”).)

426. At Paragraph 151 of his report, Dr. Collins asserts that the PrimaFit 2.0 was developed [REDACTED]” (Collins Report ¶151.) As an initial matter, in my opinion, the

motivations behind the differences between the PrimaFit 2.0 and the PrimaFit 1.0 do not matter if they result in noninfringement of the 376 and 989 patents. But regardless, while [REDACTED] [REDACTED] may have been factors in the design of the PrimaFit 2.0, they were not the only factors. Rather, Sage's documents reflect that the motivations behind the development of the PrimaFit 2.0 also included "further improving the design" and "[b]roaden[ing] differentiation with competitor products." (*See* STRSAGE00021947; Sage's Supp. Resp. to Interrog. No. 3 at 21 ("Changes including the examples listed further broadened differentiation with competing products.").)

427. Indeed, Sage recognized that the new product would be perceived as different by users, recognizing that a risk would be "poor acceptance of new design by users" that could be mitigated by "in-house healthy subject testing." (STRSAGE00021948.) Therefore, Sage engaged in extensive clinical testing of the PrimaFit 2.0 prior to its release. (STRSAGE00022119 (detailing clinical testing of the PrimaFit 2.0 and clinical feedback); STRSAGE00023090 ("Clinicians like welded seam better . . . It is softer. . .").)

428. At Paragraph 152, Dr. Collins asserts that "the PrimaFit 1.0 and PrimaFit 2.0 devices are substantially similar" and "the minor differences between the two devices are insignificant when it comes to infringement of the '376 and '989 patents." (Collins Report ¶152.) He similarly asserts that the differences "do not impact the function or operation of the device, and do not impact infringement of the Patents-in-Suit." (Collins Report ¶152.) As I discuss below and elsewhere in this report, however, the differences between the two devices are in fact significant, both to users and, importantly, in establishing clear noninfringement of the patents. In any case, as I mentioned above, I understand the test for infringement is not "substantial similarity" to another product, but rather comparison of an accused product to the claims of the patents.




429. At Paragraph 157, Dr. Collins alleges that the PrimaFit 2.0 includes “many of the same components and/or materials used in the Prima Fit 1.0.” Yet, he identifies no *components* that are the same and identifies three *materials* that are allegedly the same (i.e., the silicone gel used for the adhesive for the bowtie, the dimple mesh polyester material used as the fabric, and the Volara type EO foam material used for certain components). Dr. Collins is incorrect in that analysis as I explain.

430. Dr. Collins over-simplifies or misunderstands the differences between the PrimaFit 1.0 and PrimaFit 2.0. As I discuss below with respect to individual features, there were numerous changes to the PrimaFit 2.0 device from the 1.0 device that impacted the function and operation of the device—they improved it. Among other things, the changes to the PrimaFit 2.0 device improve the fit, securement, and performance of the product, being more comfortable to patients and more user friendly including by further minimizing skin damage, reducing issues with tubing kinking, and enhancing securement. And regardless, the asserted claim of the 376 and 989 Patents do not claim the overall “function or operation” of the device. Rather, they claim a device having specific features, and the PrimaFit 2.0 device made several significant changes from the PrimaFit 1.0 device that result in noninfringement. The fact that both products are vacuum-assisted urine collection devices and thus have a common “function or operation” have no bearing on the inventions of the 376 and 989 Patents. Again, these are features are in the prior art including in Kuntz and Sanchez.

431. At Paragraph 158, Dr. Collins begins addressing specific components of the PrimaFit 2.0. (Collins Report ¶158.) He alleges that the PrimaFit 2.0 has the “same fabric used in the PrimaFit 1.0,” and that, “[i]n finding that the PrimaFit 1.0 infringed ‘376 claim 9 in the PureWick I case, the jury agreed with [his] opinion that this material is both a fluid permeable



membrane and a wicking material.” (Collins Report ¶158.) Dr. Collins is incorrect. First, the fabric in PrimaFit 2.0 is redesigned to make the device softer and have improved performance including by utilizing a different configuration. (STRSAGE000000005 (“14% more ultra-soft fabric”).)



(SAGE000000238; STRSAGE00022113.)

432. Moreover, to establish that the fabric in the PrimaFit 2.0 is a “wicking material,” Dr. Collins must establish that the fabric is “an article that moves moisture by capillary action from one surface of the article to the other” as discussed above in Section VI.B.3. Dr. Collins’ analysis, which failed to consider any changes to the fabric, is thus flawed.

433. Dr. Collins’ reference to the jury verdict in the prior lawsuit is irrelevant for purposes of the infringement analysis here because the jury never commented on or made any specific finding regarding the reconfigured fabric of the PrimaFit 2.0. Dr. Collins also cannot avoid performing an independent analysis or providing independent evidence that the fabric in the PrimaFit 2.0 is, for example, a wicking material. Again, infringement must be proven by comparing the asserted claims to the accused product (the PrimaFit 2.0) and not comparing one product to another product

434. At Paragraph 159, Dr. Collins concedes that PrimaFit 2.0 does not utilize the

“batting material used in the PrimaFit 1.0 device.” Dr. Collins nevertheless claims, however, that the “open cell foam” used in the PrimaFit 2.0 provides “the same function as the batting material of the PrimaFit 1.0 because it provides cushion against the flex ink assembly, allows urine to pass through the device, and provides fill to the device.” (Collins Report ¶159.) I disagree with his conclusion. One of the main reasons for utilizing the foam within the PrimaFit 2.0 device was to provide a softer, more cushioned feel for the user. (STRSAGE000000005; STRSAGAE00021948 (“Address Flex-Fit perception of hardness”).) This frustoconically-shaped component is also different in that it “extends throughout entire length of the device to maintain shape and maximize comfort to the patient” including to the tapered end (STRSAGE000021948; STRSAGE00022113). Thus, the documents that Dr. Collins relies on to establish the functions of the two products are the “same” actually prove the changes were made to provide a difference. In any case, whether one component in the PrimaFit 2.0 has the “same function” as a different component in the PrimaFit 1.0 is not the test for determining whether a product infringes the asserted claims.


435. At Paragraph 160, Dr. Collins concedes that the PrimaFit 2.0 does not utilize a “fluid reservoir cap, foam adhesive strips, and foam backing in the PrimaFit 1.0 device.” Dr. Collins then suggests these four components that are not present in the 2.0 (the end cap, top tape, bottom tape, and back layer) were “replaced” by other different components namely the “foam backer and bottom barrier.” Dr. Collins suggests that the “foam backer and bottom barrier” were added to allow the PrimaFit 2.0 “to be manufactured using [REDACTED]” and that they “perform the same function as the foam backing, adhesive strips, and fluid reservoir cap in the PrimaFit 2.0 device because the foam barrier and backing are impermeable to fluid and thus keep fluid inside the device.” I disagree with these assertions.

436. Sage’s documents reflect that a primary driver for eliminating the separate plastic

end cap was to make the product more comfortable to patients. (STRSAGE000000004 (touting “soft, tapered end gently fits in perineal area”); STRSAGE000000005 (“Redesigned tapered end”); STRSAGE00022119 (“PrimaFit 2.0 Design Overview. Clinical Benefit . . . Softer tapered end.”).) Likewise, the foam backer and bottom barrier are two new components, unlike any component in the PrimaFit 1.0, and have no relationship to each other as an independent unit as Dr. Collins appears to suggest. Moreover, the PrimaFit 2.0 does not utilize “the same type of foam” for the foam backer and bottom barrier. The Volara EO type foam material used is an improved denser and thicker material.

437. I also disagree with Dr. Collins’ conclusion that the jury “agreed with [his] opinion that this foam material covering the non-patient facing side of the [PrimaFit 1.0] device is a fluid impermeable layer” and that therefore the foam material in the PrimaFit 2.0 is as well. (Collins Report ¶160). Again, I understand the jury made no findings about the components of the 2.0 product. Moreover, infringement is determined by comparing the PrimaFit 2.0 product to the asserted claims—not to another product.

438. At paragraph 161, Dr. Collins concedes that the tubing in the PrimaFit 2.0 is a “longer and more flexible” tube than that used in the PrimaFit 1.0. He asserts, however, that “[l]ike the tubing in the PrimaFit 1.0, the tubing in the PrimaFit 2.0 extends from the end of the device covered by the bottom barrier, through the lumen in the inner foam, and out of the opposite end of the device, where it is connected to a vacuum source.” (Collins Report ¶161.) This assessment is wrong for a number of reasons. First, the PrimaFit 1.0 did not have a bottom barrier or an inner foam (much less an inner foam with a lumen). The placement of the tube within the device is also different as the tube in the 1.0 is exposed and extended into the reservoir cap, while the tube in the 2.0 is retracted within the inner foam.



439. Moreover, the other changes to the tubing were done for reasons unrelated to manufacturing ease or decreasing cost. This made the device more functional for patients and users, avoiding the concern that the tubing would inhibit the ability to properly place the product or would shift the product. (Cole Dep., p. 140-141.) Sage addressed that concern and improved the device by making that design change to the tubing. (*See id.*; STRSAGE00022119 (“PrimaFit 2.0 Clinical Update. Clinical Feedback: More comfortable with softer tube at the top. It absorbs much better. Doesn’t move around or shift because of the extra tubing. The extended tip is more comfortable for patients.”). Additionally, that was not the only change to the tubing in the PrimaFit 2.0. For example, I note that another change was including “three or more openings to prevent occlusion.” (STRSAGE00021948; STRSAGE00022113 (“Vented tubing allows fluid flow in the event the tube is occluded”).)

440. Dr. Collins repeated assertions that the tubing in the PrimaFit 2.0 “has the same relevant design and features” as well as similar “functions” of suctioning fluid as the 1.0 product misunderstand the relevant analysis. Again, whether one component in the PrimaFit 2.0 has the “same function” or “the same design” as a different component in the PrimaFit 1.0 is not the test



for determining whether a product infringes the asserted claims.

441. At Paragraph 164, Dr. Collins concedes that the “fabric is ultrasonically welded to the foam backer” in the PrimaFit 2.0, which is a new feature of the PrimaFit 2.0, a fact that Dr. Collins ignores. The fabric being welded to the foam backer results in a completely closed device, and there is no opening on the patient-facing side of the product. The weld of the PrimaFit 2.0 also provides a softer overall feel for the patient compared to the stitching of the PrimaFit 1.0, decreasing any discomfort felt by the user.

442. At Paragraph 165-166, citing to three documents (STRSAGE00023039, SAGE00037025, STRSAGE00023866), Dr. Collins concludes that “(1) removal of the end cap; (2) use of heat sealed, as opposed to sewn, device design; (3) addition of a flexible extension tube; and (4) addition of a foam as the filler material” were the only differences between the PrimaFit 1.0 and PrimaFit 2.0. (Collins Report ¶165.) He also concludes that “these modifications do not affect the intended use, the fundamental scientific technology of the device, and/or the fit or function of the device.” (Collins Report ¶165.) In fact, he goes so far as to incorrectly say “I agree with Sage’s documents that the modifications to the PrimaFit 2.0 do not affect the use, scientific technology, or function of the device” and that the modifications were only “for the purpose of automating the manufacturing process for the device.” (Collins Report ¶166.) These documents do not support Dr. Collins’ conclusion, and I disagree.

443. As a preliminary matter, as numerous witnesses testified, one of the documents that Dr. Collins cites to support his conclusions (Collins Report ¶165 (citing SAGE00037025)) is not a catalogue of changes to the product, but rather was an email regarding regulatory issues from regulatory personnel (not engineering). As Ms. Polanco, the regulatory affairs employee who drafted the email, explained: “Again, when I read the entire document . . . I say: From the

regulatory team perspective, I'm looking at all of this from a regulatory team perspective. So I'm not a design engineer. I'm assuming there are more features than the ones listed there.” (Polanco Dep. Tr., at 37.) The other documents he cites, including a testing document (STRSAGE00023866) and process document (STRSAGE00023039), likewise are not a catalogue of changes and simply refer to some new features.

444. Indeed, Mr. Cole, an engineer on the project and responsible for product design, explained “There are probably about 20, nearly 20 differences between PrimaFit 1.0 and PrimaFit 2.0. I don’t know that I would have listed four as she has done here.” (*See* Cole Dep. Tr., at 216.) Mr. Cole testified that, among the many differences are a “unique suction connector, including the bottom barrier, including the unique manufacturing process used to make PrimaFit 2.0, including the attachment and configuration of the fabric. There’s a hot melt adhesive used on PrimaFit 2.0 unique to that product, and numerous others.” (Cole Dep. Tr., at 217.) Mr. Cole also testified about other differences such as the fabric having “different configuration and geometry between the two products” as well as a “different attachment” (Cole Dep. Tr., at 204-205), the foam backer (231), “long, extended tubing” (140), “soft, tapered end” (141), and “inner foam” (146). Dr. Collins apparently chose to ignore that testimony. Another difference was the introduction of “selective adhesive to reduce amount of adhesive.” (STRSAGE00023090; STRSAGE00023106 (“Product Enhancements...Selective Adhesive Bow Tie”)). Dr. Collins ignored this as well.

445. Thus, the improvements to the PrimaFit 2.0 extended well beyond [REDACTED] [REDACTED] as they not only improved over Sage’s prior product design, but also “broaden[ed] differentiation with competitor products.” (STRSAGE00021947; STRSAGE00022119 (“PrimaFit 2.0 Design Overview. Clinical Benefit...Softer tapered end.”); STRSAGE00021947 (“Develop the 2.0 upgrade of the PrimaFit product that focuses on further

improving the design...Broaden differentiation with competitor products”); Sage’s Supp. Resp. to Interrog. No. 3 at 21 (“Changes including the examples listed further broadened differentiation with competing products.”).)

446. The new design features positively impacted the function of the device including the ease-of-use, clinical outcomes, and performance as I have already explained. (*See* STRSAGE00022119 (“PrimaFit 2.0 Clinical Update. Clinical Feedback: More comfortable with softer tube at the top. It absorbs much better. Doesn’t move around or shift because of the extra tubing. The extended tip is more comfortable for patients.”).) In fact, the one of the very documents that Dr. Collins cites (a Sage advertisement) touts the “longer, flexible suction tubing,” “14% more ultra-soft fabric,” and “redesigned tapered end” as distinct advantages over the PrimaFit 1.0. (STRSAGE000000005).

447. I also disagree with Dr. Collins’ statement that “Sage’s documents” state that the “modifications to the PrimaFit 2.0 do not affect the use, scientific technology, or function of the device.” (Collins Report ¶¶165-166, citing STRSAGE00023039, SAGE00037025, STRSAGE00023866.) As discussed above, Dr. Collins references documents relating to regulatory matters, but they were not written from a design engineering perspective and did not intend to include all of the changes to the product. They are also not relevant to whether the PrimaFit 2.0 product includes the elements of the asserted claims.

448. In Paragraphs 167-179, Dr. Collins identifies various elements of the 376 and 989 patent claims and asserts that, “[j]ust like the [component(s)] in the PrimaFit 1.0,” a different component(s) in the PrimaFit 2.0 infringes. (Collins Report ¶¶167-179.) For example, in Paragraph 172, Dr. Collins states “[j]ust like the fabric batting in the PrimaFit 1.0 [there is no fabric batting in the PrimaFit 1.0], the inner foam in the PrimaFit 2.0 is a fluid permeable support....” I again

note that this is not a correct infringement analysis. Infringement is determined by comparing the asserted claims to the accused PrimaFit 2.0 product, and not by comparing the PrimaFit 2.0 product to the PrimaFit 1.0 product.

449. Dr. Collins’ failed analysis is particularly problematic for certain claim limitations where Dr. Collins does not even cite to any documentation or analysis relating to the PrimaFit 2.0 at all, but only documents or analysis relating to the PrimaFit 1.0. For example, in Paragraph 175, Dr. Collins asserts that the fabric in the PrimaFit 2.0 is a “wicking fabric” that is “fluid permeable”—but he cites to documents relating to the PrimaFit 1.0, having made no independent evaluation as to whether the fabric as configured in the PrimaFit 2.0 actually “moves moisture by capillary action from one surface of the article to the” as required by the Court’s construction. (Collins Report ¶175.)

450. Similarly, in Paragraph 176, Dr. Collins states that the “tubing in PrimaFit 1.0 . . . has a first end disposed in the fluid reservoir” is “like” the tubing in the PrimaFit 2.0, showing pictures of the two products side by side.

451. Of course, as I explained, the PrimaFit 2.0, however, has a very different structure from the PrimaFit 1.0 in this regard as the PrimaFit 2.0 has no reservoir cap, much less one with a tube inside it. Indeed, I note that Dr. Collins very misleadingly uses different types of photographs inconsistently. For example, Dr. Collins uses the below photograph to assert that the tube in the PrimaFit 1.0 has a first end disposed in the fluid reservoir: